{
  "responseHeader":{
    "status":0,
    "QTime":51,
    "params":{
      "q":"(Doc_abstract: \"breast cancer\"^4 OR \"Breast Carcinoma\" OR Doc_title: \"breast cancer\"^4 OR \"Breast Carcinoma\") AND (Doc_abstract: \"ERBB2\"^4 OR \"NEU\" OR \"NGL\" OR \"HER2\" OR \"TKR1\" OR \"CD340\" OR \"HER-2\" OR \"MLN 19\" OR \"HER-2/neu\" OR Doc_title: \"ERBB2\"^4 OR \"NEU\" OR \"NGL\" OR \"HER2\" OR \"TKR1\" OR \"CD340\" OR \"HER-2\" OR \"MLN 19\" OR \"HER-2/neu\")"}},
  "response":{"numFound":6578,"start":0,"docs":[
      {
        "Doc_abstract":"Breast cancer is the second highest cause of carcinoma-related death caused by distant metastasis in women. Estrogen receptor (ER), human epidermal growth factor receptor 2, (HER2) and progesterone receptor (PR) are three classified makers of breast cancer, which are defined as ER+, HER2+, and the most serious ER-PR-HER2-â€‰(triple-negative). It is well known that ErbB2 (V-Erb-B2 avian erythroblastic leukemia viral oncogene homolog 2) plays an important part in breast cancer. However, the molecular mechanisms underlying ErbB2 action needs to be well studied. In this report, we discovered that the decreased expression levels of miR-34a were inversely correlated with the increased ErbB2 levels in breast cancer. A luciferase reporter assay was done to understand the potential correlation between ErbB2 and miR-34a. Over-expression of miR-34a reduces ErbB2 expression and suppresses breast cancer cell invasion and growth in vitro. What's more, reduced expression of ErbB2 inhibits breast Cancer cell proliferation and re-expression of ErbB2 reversed miR-34a-dependent tumor suppression. Meanwhile, miR-34a levels were correlated inversely with breast cancer malignancy. Our study demonstrates that miR-34a, like ErbB2, might be a diagnostic target in breast cancer.",
        "Doc_title":"MiR-34a modulates ErbB2 in breast cancer.",
        "Journal":"Cell biology international",
        "Do_id":"27813227",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605801027125116928},
      {
        "Doc_abstract":"Amplification of the epithelial growth factor receptor gene ERBB2 (HER2, NEU) in breast cancer is associated with a poor clinical prognosis. In mammary gland development, this receptor plays a role in ductal and lobuloalveolar differentiation. We conducted a systematic investigation of the role of genetic variation of the ERBB2 gene in breast cancer risk in a study of 842 histologically confirmed invasive breast cancer cases and 1,108 controls from the Shanghai Breast Cancer Study. We observed that the ERBB2 gene resides within a locus of high linkage disequilibrium, composed of three major ancestral haplotypes in the study population. These haplotypes are marked by simple tandem repeat and single nucleotide polymorphisms, including the missense variants I655V and P1170A. We observed a risk-modifying effect of a highly polymorphic simple tandem repeat within an evolutionarily conserved region, 4.4 kb upstream from the ERBB2 transcription start site. Under a dominant genetic model, the age-adjusted odds ratio was 1.74 (95% confidence interval, 1.27-2.37). Its association with breast cancer, and with breast cancer stratified by histology, by histologic grade, and by stage, remained significant after correction for multiple comparisons. In contrast, we observed no association of ERBB2 single nucleotide polymorphism haplotypes with breast cancer predisposition.",
        "Doc_title":"Heritable variation of ERBB2 and breast cancer risk.",
        "Journal":"Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology",
        "Do_id":"19336545",
        "Doc_ChemicalList":"Receptor, ErbB-2",
        "Doc_meshdescriptors":"Adenocarcinoma;Adult;Breast Neoplasms;Carcinoma, Ductal, Breast;Carcinoma, Lobular;Case-Control Studies;China;Female;Genetic Predisposition to Disease;Haplotypes;Humans;Linkage Disequilibrium;Middle Aged;Mutation, Missense;Polymorphism, Single Nucleotide;Prognosis;Receptor, ErbB-2;Risk Factors;Tandem Repeat Sequences",
        "Doc_meshqualifiers":"diagnosis;epidemiology;genetics;diagnosis;epidemiology;genetics;diagnosis;epidemiology;genetics;diagnosis;epidemiology;genetics;epidemiology;genetics;genetics;genetics;genetics;genetics",
        "_version_":1605908303339061248},
      {
        "Doc_abstract":"Gene amplification and protein overexpression of erbB2 (Her2/neu) has been observed in approximately 20-30% of breast cancers. ErbB2-positive breast cancer is tend to be more aggressive than other types of breast cancer and therefore further investigation on the signaling pathways of erbB2 is needed for the therapeutic target for breast cancer treatment. Here we report that microRNA-205 (miR-205), a molecule also reported to be associated with breast cancer, is negatively regulated by erbB2 overexpression. Breast epithelial cells exogenously overexpressed with erbB2 decreased the expression of miR-205, whereas increased the expression of cyclin D1, cyclin E, cyclin-dependent kinase 2 (CDK2), cyclin-dependent kinase 4 (CDK4), and cyclin-dependent kinase 6 (CDK6). The decreased expression of miR-205 slightly increased by the transfection of erbB2 siRNA into the erbB2-overexpressing breast cancer epithelial cells. Overexpression of erbB2 enabled breast epithelial cells to grow anchorage-independently in soft agar, and the transfection of the precursor of miR-205 into the cells leaded to the decrease in the ability to grow in soft agar. These results suggest that down-regulation of miR-205 in erbB2-overexpressing breast epithelial cells is essential for erbB2-induced tumorigenesis, and miR-205 may have the potential to be a novel important alternative therapeutic target for erbB2-positive breast cancer.",
        "Doc_title":"ErbB2 down-regulates microRNA-205 in breast cancer.",
        "Journal":"Biochemical and biophysical research communications",
        "Do_id":"21787752",
        "Doc_ChemicalList":"Cell Cycle Proteins;MIRN205 microRNA, human;MicroRNAs;Cyclin D1;ERBB2 protein, human;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Breast Neoplasms;Cell Cycle Proteins;Cell Line;Cell Transformation, Neoplastic;Cyclin D1;Female;Humans;MicroRNAs;Receptor, ErbB-2",
        "Doc_meshqualifiers":"genetics;metabolism;pathology;genetics;metabolism;genetics;metabolism;pathology;genetics;metabolism;metabolism;genetics;metabolism",
        "_version_":1605906985042051072},
      {
        "Doc_abstract":"Breast cancer displays significant intratumoral heterogeneity, which has been shown to have a substantial impact on both innate and acquired resistance to tyrosine kinase inhibitors. The heterogeneous expression of multiple receptor tyrosine kinases (RTK) in cancers supports tumor signaling robustness and plays a significant role in resistance to targeted inhibition. Recent studies have revealed interactions between the MET receptor and the ERBB receptor family in the therapeutic resistance of several cancers. In this study, the relationship between MET expression/activity and the expression/activity of the ERBB receptor family in human breast cancer was interrogated. Importantly, a significant percentage of ERBB2(+) tumors coexpressing MET and ERBB2 were observed and displayed significant heterogeneity with subpopulations of cells that are MET(-)/ERBB2(+), MET(+)/ERBB2(-), and MET(+)/ERBB2(+). In a MET(+)/ERBB2(+) breast cancer cell line, MET depletion resulted in increased ERBB2 activation, and conversely, ERBB2 depletion resulted in increased MET activation. Neither EGFR nor ERBB3 compensated for MET or ERBB2 knockdown. The loss of either MET or ERBB2 led to a decrease in PI3K/AKT signaling and increased dependency on MAPK. These data show that a subset of ERBB2(+) breast cancers express MET and contain MET(+)/ERBB2(+) subpopulations. Moreover, analysis of RTK activation during ERBB2 knockdown indicated that MET signaling is a compensatory pathway of resistance.;ERBB2(+) breast cancers with MET(+)/ERBB2(+) subpopulations may have an innate resistance to ERBB2 inhibition and may benefit from combined MET and ERBB2 inhibition.",
        "Doc_title":"MET and ERBB2 are coexpressed in ERBB2+ breast cancer and contribute to innate resistance.",
        "Journal":"Molecular cancer research : MCR",
        "Do_id":"23825050",
        "Doc_ChemicalList":"EGFR protein, human;ERBB2 protein, human;ERBB3 protein, human;MET protein, human;Proto-Oncogene Proteins c-met;Receptor, Epidermal Growth Factor;Receptor, ErbB-2;Receptor, ErbB-3;Proto-Oncogene Proteins c-akt",
        "Doc_meshdescriptors":"Breast Neoplasms;Cell Line, Tumor;Cell Proliferation;Drug Resistance, Neoplasm;Female;Gene Expression Regulation, Neoplastic;Gene Knockdown Techniques;Humans;MAP Kinase Signaling System;Proto-Oncogene Proteins c-akt;Proto-Oncogene Proteins c-met;Receptor, Epidermal Growth Factor;Receptor, ErbB-2;Receptor, ErbB-3",
        "Doc_meshqualifiers":"drug therapy;metabolism;pathology;metabolism;genetics;metabolism;metabolism;antagonists & inhibitors;genetics;metabolism;metabolism",
        "_version_":1605759206952009728},
      {
        "Doc_abstract":"Amplification and overexpression of the receptor tyrosine kinase ErbB2 occur in up to 30% of human breast cancers, and high ErbB2 levels are correlated with poor prognosis for breast cancer patients. In contrast to the epithelial growth factor receptor (ErbB1), ErbB2 is not downregulated by ligand-induced mechanisms. Here we show that flotillins are involved in the stabilization of ErbB2 at the plasma membrane. In SKBR3 breast cancer cells and breast cancer tissue, a positive correlation between flotillin and ErbB2 expression levels could be demonstrated. Moreover, the tissue microarray analyses of biopsies from 194 patients diagnosed with carcinomas of the breast showed that flotillin-2 emerged as a potential predictor of prognosis in breast cancer. Depletion of flotillin-1 and flotillin-2 leads to internalization and degradation of ErbB2. Furthermore, flotillin-1 and -2 were found to be in a molecular complex with ErbB2 and Hsp90. The depletion of one of these proteins results in disruption of this complex, followed by destabilization of ErbB2 at the membrane, and its internalization and degradation. As a consequence, ErbB2-triggered downstream signalling is inhibited. Our data demonstrate a novel mechanism for interfering with ErbB2 signalling, which potentially can have clinical impact. ",
        "Doc_title":"Flotillins as regulators of ErbB2 levels in breast cancer.",
        "Journal":"Oncogene",
        "Do_id":"22869152",
        "Doc_ChemicalList":"HSP90 Heat-Shock Proteins;Membrane Proteins;flotillins;ERBB2 protein, human;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Blotting, Western;Breast Neoplasms;Cell Line, Tumor;Female;Gene Expression Regulation, Neoplastic;HSP90 Heat-Shock Proteins;Humans;Immunohistochemistry;Immunoprecipitation;Membrane Proteins;Microscopy, Confocal;Receptor, ErbB-2;Signal Transduction;Tissue Array Analysis;Transfection",
        "Doc_meshqualifiers":"genetics;metabolism;physiology;genetics;metabolism;genetics;metabolism;genetics;metabolism;physiology",
        "_version_":1605742735188295680},
      {
        "Doc_abstract":"ErbB2 gene amplification occurs in 20%-25% of breast cancers, and its therapeutic targeting has markedly improved survival of patients with breast cancer in the adjuvant setting. However, resistance to these therapies can develop. Because epigenetic mechanisms can importantly influence oncogene expression and be druggable as well, we investigated histone modifications that influence ErbB2 overexpression, independent of gene amplification. We demonstrate here that ErbB2-overexpressing breast carcinomas acquire the H3K4me3 mark on the erbB2 promoter and that receptor-amplified tumors further acquire the H3K9ac mark, which is dependent on H3K4me3 mark acquisition. Targeting WD repeat domain 5 (Wdr5), which is absolutely required for H3K4me3 enrichment, decreased ErbB2 overexpression, associated with a decrease in the H3K4me3 mark on the erbB2 promoter. Of note, Wdr5 silencing cooperated with trastuzumab or chemotherapy in specifically inhibiting the growth of ErbB2-positive breast tumor cells. Thus, our studies illuminate epigenetic steps in the selection for ErbB2 activation. ",
        "Doc_title":"Chromatin modifications sequentially enhance ErbB2 expression in ErbB2-positive breast cancers.",
        "Journal":"Cell reports",
        "Do_id":"24120871",
        "Doc_ChemicalList":"Antibodies, Monoclonal, Humanized;Chromatin;Histones;RNA, Small Interfering;Transcription Factor AP-2;WDR5 protein, human;Histone-Lysine N-Methyltransferase;p300-CBP Transcription Factors;p300-CBP-associated factor;ERBB2 protein, human;Receptor, ErbB-2;Trastuzumab",
        "Doc_meshdescriptors":"Antibodies, Monoclonal, Humanized;Breast Neoplasms;Cell Line, Tumor;Cell Proliferation;Chromatin;Female;Histone-Lysine N-Methyltransferase;Histones;Humans;MCF-7 Cells;RNA Interference;RNA, Small Interfering;Receptor, ErbB-2;Transcription Factor AP-2;Trastuzumab;p300-CBP Transcription Factors",
        "Doc_meshqualifiers":"pharmacology;metabolism;pathology;drug effects;chemistry;metabolism;antagonists & inhibitors;genetics;metabolism;metabolism;metabolism;chemistry;genetics;metabolism;chemistry;metabolism;antagonists & inhibitors;genetics;metabolism",
        "_version_":1605837610243063808},
      {
        "Doc_abstract":"A recent in vitro study has suggested that overexpression of ERBB2 may mediate breast tumour progression and metastasis by inhibiting the transcription of the E-cadherin (E-CD) gene. To test this hypothesis in human breast cancer in vivo, we studied the relationship between the expression of both molecules in 247 breast carcinomas immunohistochemically. Five ductal carcinomas in situ overexpressed ERBB2 and showed preserved E-CD expression. Forty-four of 226 infiltrating ductal carcinomas (19.47%) showed ERBB2 overexpression, and a statistically significant relationship was found between ERBB2 overexpression and high histological grade. E-CD expression was preserved in 111 cases (49.1%) and correlated with the histological grade. However, no significant relationship was found between ERBB2 and E-CD expression. None of the 16 infiltrating lobular carcinomas expressed ERBB2 or E-CD. These observations in different histological types of breast carcinoma strongly argue against a role for ERBB2 as a transcriptional regulator of E-CD expression in most human breast carcinomas in vivo.",
        "Doc_title":"Relationship between ERBB2 and E-cadherin expression in human breast cancer.",
        "Journal":"Virchows Archiv : an international journal of pathology",
        "Do_id":"7496594",
        "Doc_ChemicalList":"Cadherins;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Breast Neoplasms;Cadherins;Carcinoma in Situ;Carcinoma, Ductal, Breast;Female;Humans;Immunohistochemistry;Receptor, ErbB-2",
        "Doc_meshqualifiers":"metabolism;metabolism;metabolism;metabolism;metabolism",
        "_version_":1605774222240514048},
      {
        "Doc_abstract":"Investigation of ErbB2 immunity in human breast cancer employing recombinant expression sources in immunoblot analysis revealed ErbB2-specific antibodies of the IgG isotype in sera of 14 of 71 cancer patients and 1 of 31 normal donors. Reactivity was confirmed on ErbB2-specific immunoprecipitates. Independent evidence of existing ErbB2 immunity was obtained after in vitro transformation of peripheral blood leukocytes from six positive patients. Furthermore, in vitro immortalization of B-lymphocytes unmasked existent ErbB2 immunity in 1 of 8 patients negative for ErbB2 serum antibodies. Determining shed ErbB2 extracellular domain as an indirect measure of tumor burden in ErbB2-positive malignancy, elevated serum levels were observed in 16 of 71 breast cancer and 1 of 31 normal donor sera. Strikingly, existing ErbB2 immunity correlated significantly with elevated shed ErbB2 ectodomain among the patients analyzed. Incidence of both ErbB2 immunity and elevated ErbB2 extracellular domain increased with a progressed disease stage and was significantly associated with metastatic breast cancer. These observations implicate soluble ErbB2 amounts in vivo in the development of ErbB2 immunity in breast cancer. They further project serum analysis of ErbB2 immunity and soluble ectodomain as potential markers of disease progression in ErbB2-positive malignancy.",
        "Doc_title":"ErbB2 immune response in breast cancer patients with soluble receptor ectodomain.",
        "Journal":"The American journal of pathology",
        "Do_id":"10751365",
        "Doc_ChemicalList":"Antibodies;Receptor, ErbB-2",
        "Doc_meshdescriptors":"3T3 Cells;Animals;Antibodies;Antibody Formation;B-Lymphocytes;Breast Neoplasms;Cell Line, Transformed;Female;Humans;Mice;Protein Structure, Tertiary;Receptor, ErbB-2;Solubility",
        "Doc_meshqualifiers":"blood;metabolism;blood;immunology;physiopathology;genetics;immunology;metabolism",
        "_version_":1605840889246121984},
      {
        "Doc_abstract":"The ERBB2 (HER-2/neu) protooncogene encodes a transmembrane protein with an intracellular tyrosine kinase activity. It is principally activated by gene amplification and its product, the erbB2 protein, becomes oncogenic when overexpressed. Quantitative PCR is both a simple and reliable method for the evaluation of ERBB2 activation, whereas immunoenzymatic methods allow quantitative determination of erbB2 protein in tissue and sera. ERBB2 amplification and/or surexpression is actually recognized as a prognostic factor in breast cancer and would be predictive in the therapeutic response. It might lead also to new therapeutic modalities using specific targeted drugs.",
        "Doc_title":"[Current aspects of the evaluation of ERBB2 activation in breast cancer. Therapeutic perspectives].",
        "Journal":"Annales de biologie clinique",
        "Do_id":"9499914",
        "Doc_ChemicalList":"Biomarkers, Tumor;Genetic Markers",
        "Doc_meshdescriptors":"Biomarkers, Tumor;Breast Neoplasms;Female;Forecasting;Gene Expression Regulation, Neoplastic;Genes, erbB-2;Genetic Markers;Humans;Polymerase Chain Reaction",
        "Doc_meshqualifiers":"genetics;metabolism;therapy;genetics",
        "_version_":1605800705991376896},
      {
        "Doc_abstract":"The erbB2 gene, which encodes a transmembrane growth factor receptor, is overexpressed in approximately 30% of breast cancers. Overexpressing this gene makes breast cancers resistant to certain chemotherapeutic agents. In this article, we review what is known about ErbB2-mediated chemoresistance and the controversies surrounding it. We also examine the antiapoptotic function of erbB2 as one of the molecular mechanisms of ErbB2-mediated Taxol resistance and describe several emerging strategies for overcoming intrinsic ErbB2-mediated chemoresistance. Finally, we discuss future avenues for studies of chemosensitivity in ErbB2-overexpressing breast cancers that may lead to the development of effective biology-based treatment strategies.",
        "Doc_title":"Role of erbB2 in breast cancer chemosensitivity.",
        "Journal":"BioEssays : news and reviews in molecular, cellular and developmental biology",
        "Do_id":"10878580",
        "Doc_ChemicalList":"Antibodies, Monoclonal;Antibodies, Monoclonal, Humanized;Antineoplastic Agents;Tretinoin;Trastuzumab;Paclitaxel",
        "Doc_meshdescriptors":"Antibodies, Monoclonal;Antibodies, Monoclonal, Humanized;Antineoplastic Agents;Breast Neoplasms;Drug Resistance;Female;Gene Expression;Genes, erbB-2;Humans;Paclitaxel;Trastuzumab;Tretinoin",
        "Doc_meshqualifiers":"therapeutic use;therapeutic use;drug therapy;genetics;therapy;genetics;therapeutic use;therapeutic use",
        "_version_":1605881253233426432},
      {
        "Doc_abstract":"Cytokines have been associated with symptoms and adverse outcomes in breast cancer. Overexpression of ERBB2 (c-erb-b2; formerly HER2/neu), which is a member of the epidermal growth receptor family, is associated with involvement of lymph nodes, large tumor size, high grade, steroid receptor negativity, aneuploidy, high proliferation rate, and low overall survival in breast cancer. The aim of the study was to examine whether ERBB2 amplification has any effect on circulating levels of tumor necrosis factor-alpha (TNF-alpha) and interleukin-2 (IL-2) in breast cancer patients.;Fifty patients with primary breast carcinoma, classified as either ERBB2 (+) or (-) by the fluorescence in situ hybridization (FISH) technique, were included in the study. Cytokines were studied by ELISA according to the procedure described in the commercial kit.;IL-2 levels were found significantly higher in ERBB2+ patients than in controls (p<0.05). A significant negative correlation existed between ERBB2 positivity and estrogen receptor status (p=0.004). Plasma TNF-alpha and IL-2 levels were positively correlated in ERBB2+ breast cancer patients (p<0.01).;The increase in IL-2 concentrations observed in our study suggests an activation of T cells by ERBB2 peptides.",
        "Doc_title":"Serum tumor necrosis factor-alpha and interleukin-2 concentrations in newly diagnosed ERBB2 (HER2/neu) positive breast cancer patients.",
        "Journal":"The International journal of biological markers",
        "Do_id":"19787624",
        "Doc_ChemicalList":"Cytokines;Interleukin-2;Tumor Necrosis Factor-alpha;ERBB2 protein, human;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Breast Neoplasms;Cytokines;Female;Humans;Interleukin-2;Neoplasm Staging;Receptor, ErbB-2;Tumor Necrosis Factor-alpha",
        "Doc_meshqualifiers":"blood;diagnosis;pathology;blood;blood;blood;blood",
        "_version_":1605746440162770946},
      {
        "Doc_abstract":"Analysis of a collection of human breast cancers (n = 150), enriched in ERBB2-positive cases (n = 57) and involving tumor genotyping relative to population-matched blood genotyping (n = 749) for a common ERBB2 single nucleotide polymorphism Ala(G)1170Pro(C), revealed that ERBB2 amplification in breast cancer is invariably monoallelic. Analysis of paired breast cancer and blood samples from informative (G1170C heterozygotic) ERBB2-positive (n = 12) and ERBB2-negative (n = 17) cases not only confirmed monoallelic amplification and ERBB2 transcriptional overexpression but also revealed that most low ERBB2 expressing breast cancers (12/17) exhibit unbalanced allelic transcription, showing 3-fold to nearly 5,000-fold preferential expression from one of two inherited alleles. To explore cis-acting transcriptional mechanisms potentially selected during ERBB2 amplification, levels of four different ERBB2 transcript variants (5.2, 4.7, 2.1, and 1.4 kb) were correlated with total (4.6 kb) ERBB2 mRNA levels in ERBB2-positive (n = 14) versus ERBB2-negative (n = 43) primary breast cancers. Relative expression of only the 2.1 kb extracellular domain-encoding splice variant and a 4.7 kb mRNA variant that uses an alternative start site were significantly increased in association with ERBB2-positivity, implicating altered promoter usage and selective transcript regulation within the ERBB2 amplicon. Altogether, these findings provide new mechanistic insights into the development of ERBB2-positive breast cancer and strong rationale for delineating candidate cis-acting regulatory elements that may link allele-specific ERBB2 transcription in premalignant breast epithelia with subsequent development of breast cancers bearing monoallelic ERBB2 amplicons.",
        "Doc_title":"Altered promoter usage characterizes monoallelic transcription arising with ERBB2 amplification in human breast cancers.",
        "Journal":"Genes, chromosomes & cancer",
        "Do_id":"16883574",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"Alleles;Alternative Splicing;Breast Neoplasms;Female;Gene Amplification;Gene Dosage;Gene Expression Regulation, Neoplastic;Genes, erbB-2;Genotype;Humans;Male;Neoplasm Invasiveness;Polymorphism, Single Nucleotide;Promoter Regions, Genetic;Transcription, Genetic",
        "Doc_meshqualifiers":"genetics;genetics;genetics;genetics;genetics",
        "_version_":1605923149813121024},
      {
        "Doc_abstract":"Ethanol is a tumor promoter. Both epidemiological and experimental studies suggest that ethanol may enhance the metastasis of breast cancer cells. We have previously demonstrated that ethanol increased the migration/invasion of breast cancer cells expressing high levels of ErbB2. Amplification of ErbB2 is found in 20-30% of breast cancer patients and is associated with poor prognosis. We sought to identify agents that can prevent or ameliorate ethanol-induced invasion of breast cancer cells. Cyanidin-3-glucoside (C3G), an anthocyanin present in many vegetables and fruits, is a potent natural antioxidant. Ethanol exposure causes the accumulation of intracellular reactive oxygen species (ROS). This study evaluated the effect of C3G on ethanol-induced breast cancer cell migration/invasion.;C3G attenuated ethanol-induced migration/invasion of breast cancer cells expressing high levels of ErbB2 (BT474, MDA-MB231 and MCF7(ErbB2)) in a concentration dependent manner. C3G decreased ethanol-mediated cell adhesion to the extracellular matrix (ECM) as well as the amount of focal adhesions and the formation of lamellipodial protrusion. It inhibited ethanol-stimulated phosphorylation of ErbB2, cSrc, FAK and p130(Cas), as well as interactions among these proteins. C3G abolished ethanol-mediated p130(Cas)/JNK interaction.;C3G blocks ethanol-induced activation of the ErbB2/cSrc/FAK pathway which is necessary for cell migration/invasion. C3G may be beneficial in preventing/reducing ethanol-induced breast cancer metastasis.",
        "Doc_title":"Cyanidin-3-glucoside inhibits ethanol-induced invasion of breast cancer cells overexpressing ErbB2.",
        "Journal":"Molecular cancer",
        "Do_id":"21034468",
        "Doc_ChemicalList":"Anthocyanins;Antineoplastic Agents;Glucosides;Reactive Oxygen Species;Ethanol;cyanidin 3-O-glucoside;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Anthocyanins;Antineoplastic Agents;Breast Neoplasms;Cell Adhesion;Cell Line, Tumor;Cell Movement;Ethanol;Glucosides;Humans;Immunoblotting;Immunoprecipitation;Microscopy, Fluorescence;Reactive Oxygen Species;Receptor, ErbB-2",
        "Doc_meshqualifiers":"pharmacology;pharmacology;metabolism;drug effects;drug effects;adverse effects;pharmacology;metabolism;metabolism",
        "_version_":1605755412868497408},
      {
        "Doc_abstract":"We illustrate the use of fluorescence in situ hybridization (FISH) for analysis of ERBB2 oncogene copy number, the level of amplification (here defined as the ratio of ERBB2 copy number to copy number of chromosome 17 centromeres), and the distribution of amplified genes in breast cancer cell lines and uncultured primary breast carcinomas. The relative ERBB2 copy number determined by FISH in 10 breast cancer cell lines correlated strongly with Southern blot results (r = 0.98) when probes for an identical reference locus were used in the two methods. Metaphase analysis of cell lines showed that amplified ERBB2 copies always occurred in intrachromosomal clusters but that the number and chromosomal location of these clusters varied among the cell lines. In interphase nuclei of primary tumors showing ERBB2 amplification (10/44), ERBB2 copies were seen as one to four clusters, also suggesting intrachromosomal localization. Regardless of the average level of amplification, all these tumors contained highly amplified cell subpopulations with at least 25, and sometimes more than 100, ERBB2 copies per cell. Tumors that did not show amplification by FISH (34/44) had an average of one to five ERBB2 copies scattered randomly in the nuclei and completely lacked cells with high copy levels. FISH results on primary tumors were concordant with slot blot results on amplification and with immunohistochemical detection of overexpression. Quantitative analysis of ERBB2 amplification by FISH may improve prognostic assessments based on the pattern of amplification and detection of heavily amplified tumor cell subpopulations.",
        "Doc_title":"ERBB2 amplification in breast cancer analyzed by fluorescence in situ hybridization.",
        "Journal":"Proceedings of the National Academy of Sciences of the United States of America",
        "Do_id":"1351679",
        "Doc_ChemicalList":"Oncogene Proteins, Viral;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Breast Neoplasms;Cell Line;Cell Nucleus;Female;Fluorescent Antibody Technique;Gene Amplification;Humans;Interphase;Metaphase;Nucleic Acid Hybridization;Oncogene Proteins, Viral;Oncogenes;Receptor, ErbB-2",
        "Doc_meshqualifiers":"genetics;physiology;ultrastructure;genetics",
        "_version_":1605831211069997056},
      {
        "Doc_abstract":"In the current genomic era, increasing evidence demonstrates that approximately 2% of HER2-negative breast cancers, by current standard testings, harbor activating mutations of ERBB2. However, whether patients with HER2-negative breast cancer with activating mutations of ERBB2 also experience response to anti-HER2 therapies remains unclear. This case report describes a patient with HER2-nonamplified heavily pretreated breast cancer who experienced prolonged response to trastuzumab in combination with pertuzumab and fulvestrant. Further molecular analysis demonstrated that her tumors had an elevated HER2 dimerization that corresponded to ERBB2 S310F mutation. Located in the extracellular domain of the HER2 protein, this mutation was reported to promote noncovalent dimerization that results in the activation of the downstream signaling pathways. This case highlights the fact that HER2-targeted therapy may be valuable in patients harboring an ERBB2 S310F mutation.",
        "Doc_title":"Prolonged Response to Trastuzumab in a Patient With HER2-Nonamplified Breast Cancer With Elevated HER2 Dimerization Harboring an ERBB2 S310F Mutation.",
        "Journal":"Journal of the National Comprehensive Cancer Network : JNCCN",
        "Do_id":"26358791",
        "Doc_ChemicalList":"Antibodies, Monoclonal, Humanized;Protein Kinase Inhibitors;fulvestrant;Estradiol;ERBB2 protein, human;Receptor, ErbB-2;pertuzumab;Trastuzumab",
        "Doc_meshdescriptors":"Antibodies, Monoclonal, Humanized;Antineoplastic Combined Chemotherapy Protocols;Breast Neoplasms;Carcinoma, Ductal, Breast;Estradiol;Female;Humans;Mastectomy, Segmental;Middle Aged;Protein Kinase Inhibitors;Protein Multimerization;Receptor, ErbB-2;Retreatment;Trastuzumab",
        "Doc_meshqualifiers":"administration & dosage;therapeutic use;chemistry;genetics;pathology;therapy;chemistry;genetics;secondary;therapy;administration & dosage;analogs & derivatives;therapeutic use;analysis;genetics;administration & dosage",
        "_version_":1605822071390076928},
      {
        "Doc_abstract":"Members of the Bcl-2 family act as master regulators of mitochondrial homeostasis and apoptosis. We analyzed whether ERBB2 influences the prognosis of breast cancer by influencing the proapoptotic versus antiapoptotic balance of Bcl-2 family members.;ERBB2-regulated Bcl-2 family members were identified by inducible expression of ERBB2 in MCF-7 breast cancer cells and by correlation analysis with ERBB2 expression in breast carcinomas. The prognostic relevance of ERBB2-regulated and all additional Bcl-2 family members was determined in 782 patients with untreated node-negative breast cancer. The biological relevance of ERBB2-induced inhibition of apoptosis was validated in a murine tumor model allowing conditional ERBB2 expression.;ERBB2 caused an antiapoptotic phenotype by upregulation of MCL-1, TEGT, BAG1, BNIP1, and BECN1 as well as downregulation of BAX, BMF, BNIPL, CLU, and BCL2L13. Upregulation of the antiapoptotic MCL-1 [P = 0.001, hazard ratio (HR) 1.5] and BNIP3 (P = 0.024; HR, 1.4) was associated with worse prognosis considering metastasis-free interval, whereas clusterin (P = 0.008; HR, 0.88) and the proapoptotic BCL2L13 (P = 0.019; HR, 0.45) were associated with better prognosis. This indicates that ERBB2 alters the expression of Bcl-2 family members in a way that leads to adverse prognosis. Analysis of apoptosis and tumor remission in a murine tumor model confirmed that the prototypic Bcl-2 family member Bcl-x(L) could partially substitute for ERBB2 to antagonize tumor remission.;Our results support the concept that ERBB2 influences the expression of Bcl-2 family members to induce an antiapoptotic phenotype. Antagonization of antiapoptotic Bcl-2 family members might improve breast cancer therapy, whereby MCL-1 and BNIP3 represent promising targets.",
        "Doc_title":"ERBB2 induces an antiapoptotic expression pattern of Bcl-2 family members in node-negative breast cancer.",
        "Journal":"Clinical cancer research : an official journal of the American Association for Cancer Research",
        "Do_id":"20068093",
        "Doc_ChemicalList":"Apoptosis Regulatory Proteins;ERBB2 protein, human;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Animals;Apoptosis;Apoptosis Regulatory Proteins;Breast Neoplasms;Carcinoma;Cohort Studies;Female;Gene Expression Profiling;Gene Expression Regulation, Neoplastic;Genes, bcl-2;Humans;Lymph Nodes;Mice;Models, Biological;Multigene Family;NIH 3T3 Cells;Oligonucleotide Array Sequence Analysis;Receptor, ErbB-2;Transplantation, Heterologous;Tumor Cells, Cultured",
        "Doc_meshqualifiers":"genetics;genetics;genetics;pathology;genetics;pathology;pathology;genetics;genetics;physiology",
        "_version_":1605853631235489792},
      {
        "Doc_abstract":"Amplification of the receptor tyrosine kinase ErbB2 is frequently observed in breast cancer. Amplification of erbB2 is also associated with multiple genomic gains and losses; however, the importance of these associated changes is largely unknown. We demonstrate that Brk, a cytoplasmic tyrosine kinase, is coamplified and coexpressed with ErbB2 in human breast cancers. ErbB2 interacts with Brk and increases its intrinsic kinase activity. Expression of Brk enhances the ErbB2-induced activation of Ras/MAPK signaling and cyclin E/cdk2 activity to induce cell proliferation of mammary 3-dimensional acini in culture. In a murine model of breast cancer, expression of Brk was found to shorten the latency of ErbB2-induced tumors by promoting cell proliferation, with no effect on protection from apoptosis. Furthermore, overexpression of Brk conferred resistance to the ability of Lapatinib, an ErbB2 kinase inhibitor, to inhibit ErbB2-induced proliferation. Thus, we identified Brk as a drug target for ErbB2-positive cancers.",
        "Doc_title":"Brk is coamplified with ErbB2 to promote proliferation in breast cancer.",
        "Journal":"Proceedings of the National Academy of Sciences of the United States of America",
        "Do_id":"18719096",
        "Doc_ChemicalList":"Neoplasm Proteins;Protein-Tyrosine Kinases;Receptor, ErbB-2;PTK6 protein, human;Ptk6 protein, mouse;src-Family Kinases;CDK2 protein, human;Cyclin-Dependent Kinase 2",
        "Doc_meshdescriptors":"Animals;Biopsy;Breast Neoplasms;Cell Line, Tumor;Cell Proliferation;Cyclin-Dependent Kinase 2;Female;Gene Amplification;Gene Expression Profiling;Humans;Mammary Neoplasms, Experimental;Mice;Neoplasm Proteins;Protein-Tyrosine Kinases;Receptor, ErbB-2;src-Family Kinases",
        "Doc_meshqualifiers":"etiology;genetics;pathology;analysis;metabolism;physiology;etiology;genetics;pathology;analysis;genetics;physiology;analysis;genetics;physiology;analysis;genetics;physiology;genetics;physiology",
        "_version_":1605851951785836544},
      {
        "Doc_abstract":"Overexpression of the ErbB2/HER2 receptor tyrosine kinase occurs in up to 20% of human breast cancers and correlates with aggressive disease. Several efficacious targeted therapies, including antibodies and kinase inhibitors, have been developed but the occurring of resistance to these agents is often observed. New therapeutic agents targeting the endocytic recycling and intracellular trafficking of membrane in tumor cells overexpressing ErbB2 are actually in clinical development. Nevertheless the mechanisms underlying ErbB2 downregulation are still obscure. We have previously demonstrated that the overexpression of the p130Cas adaptor protein in ErbB2 positive breast cancer, promotes tumor aggressiveness and progression. Here we demonstrate that lowering p130Cas expression in breast cancer cells is sufficient to induce ErbB2 degradation by autophagy. Conversely, p130Cas overexpression protects ErbB2 from degradation by autophagy. Furthermore, this autophagy-dependent preferential degradation of ErbB2 in absence of p130Cas is due to an increased ErbB2 ubiquitination. Indeed, the overexpression of p130Cas impairs ErbB2 ubiquitination by inhibiting the binding of Cbl and CHIP E3 ligases to ErbB2. Finally, our results indicate that p130Cas-dependent ErbB2 protection from degradation by autophagy may alter the sensitivity to the humanized monoclonal antibody trastuzumab. Consistently, in human ErbB2 positive breast cancers that develop resistance to trastuzumab, p130Cas expression is significantly increased suggesting that elevated levels of p130Cas can be involved in trastuzumab resistance.",
        "Doc_title":"p130Cas scaffold protein regulates ErbB2 stability by altering breast cancer cell sensitivity to autophagy.",
        "Journal":"Oncotarget",
        "Do_id":"26716506",
        "Doc_ChemicalList":"Antineoplastic Agents;Crk-Associated Substrate Protein;RNA, Messenger;ERBB2 protein, human;Receptor, ErbB-2;Trastuzumab",
        "Doc_meshdescriptors":"Antineoplastic Agents;Apoptosis;Autophagy;Blotting, Western;Breast Neoplasms;Carcinoma, Ductal, Breast;Carcinoma, Lobular;Cell Proliferation;Crk-Associated Substrate Protein;Drug Resistance, Neoplasm;Female;Humans;Immunoenzyme Techniques;Immunoprecipitation;Neoplasm Recurrence, Local;Neoplasm Staging;Prognosis;Protein Stability;RNA, Messenger;Real-Time Polymerase Chain Reaction;Receptor, ErbB-2;Reverse Transcriptase Polymerase Chain Reaction;Trastuzumab;Tumor Cells, Cultured",
        "Doc_meshqualifiers":"pharmacology;drug therapy;metabolism;pathology;drug therapy;metabolism;pathology;drug therapy;metabolism;pathology;genetics;metabolism;drug therapy;metabolism;pathology;genetics;chemistry;genetics;metabolism;pharmacology",
        "_version_":1605874443002839040},
      {
        "Doc_abstract":"Overexpression of the ERBB2 gene, linked to genomic and transcriptional amplifications, is a poor prognosis indicator in 25% to 30% of breast cancers. In contrast to some well-documented genomic amplifications, molecular mechanisms leading to ERBB2 transcriptional overexpression remain poorly characterized. Gene expression analyses of breast cancer have characterized distinct transcriptional signatures allowing a molecular classification of breast carcinoma. Coexpression of the ERBB2 and GATA4 genes was originally observed in tumors. Both genes are essential for cardiovascular development and GATA4 has been proposed to control the transcription of critical genes for the differentiation and the function of myocardium. We determined that ERBB2-targeted small interfering RNA repressed both ERBB2 and GATA4 genes, whereas GATA4-targeted small interfering RNA repressed GATA4 and activated ERBB2 transcription. Transfected GATA4-expressing construct repressed ERBB2 promoter. Phylogenetic foot printing revealed multiple putative GATA4 binding sites conserved in mammals within the ERBB2 promoter region. Chromatin immunoprecipitation showed that GATA4 binds specifically to several ERBB2 gene noncoding regions. Electrophoretic mobility shift assay revealed GATA4 binding to a well-conserved consensus motif. Site-directed mutagenesis confirmed the role of this new regulatory element for the activity of the ERBB2 gene enhancer. In agreement with a repressor role of GATA4 on ERBB2 gene expression balanced by ERBB2 activation of the GATA4 gene, a negative correlation between the relative levels of ERBB2 and GATA4 mRNA was observed in breast cancer cell lines and breast tumor samples. We propose that the negative feedback loop linking ERBB2 and GATA4 plays a role in the transcriptional dysregulation of ERBB2 gene expression in breast cancer.",
        "Doc_title":"A negative feedback regulatory loop associates the tyrosine kinase receptor ERBB2 and the transcription factor GATA4 in breast cancer cells.",
        "Journal":"Molecular cancer research : MCR",
        "Do_id":"19276186",
        "Doc_ChemicalList":"GATA4 Transcription Factor;GATA4 protein, human;RNA, Messenger;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Binding Sites;Breast Neoplasms;Cell Line, Tumor;Conserved Sequence;Feedback, Physiological;GATA4 Transcription Factor;Gene Expression Regulation, Neoplastic;Humans;Promoter Regions, Genetic;RNA, Messenger;Receptor, ErbB-2;Transcriptional Activation;Transfection",
        "Doc_meshqualifiers":"genetics;metabolism;biosynthesis;genetics;biosynthesis;genetics;biosynthesis;genetics",
        "_version_":1605754427549941760},
      {
        "Doc_abstract":"ErbB2 Receptor Tyrosine Kinase 2 (ErbB2, HER2/Neu) is amplified in breast cancer and associated with poor prognosis. Growing evidence suggests interplay between ErbB2 and insulin-like growth factor (IGF) signaling. For example, ErbB2 inhibitors can block IGF-induced signaling while, conversely, IGF1R inhibitors can inhibit ErbB2 action. ErbB receptors can bind and phosphorylate insulin receptor substrates (IRS) and this may be critical for ErbB-mediated anti-estrogen resistance in breast cancer. Herein, we examined crosstalk between ErbB2 and IRSs using cancer cell lines and transgenic mouse models.;MMTV-ErbB2 and MMTV-IRS2 transgenic mice were crossed to create hemizygous MMTV-ErbB2/MMTV-IRS2 bigenic mice. Signaling crosstalk between ErbB2 and IRSs was examined in vitro by knockdown or overexpression followed by western blot analysis for downstream signaling intermediates and growth assays.;A cross between MMTV-ErbB2 and MMTV-IRS2 mice demonstrated no enhancement of ErbB2 mediated mammary tumorigenesis or metastasis by elevated IRS2. Substantiating this, overexpression or knockdown of IRS1 or IRS2 in MMTV-ErbB2 mammary cancer cell lines had little effect upon ErbB2 signaling. Similar results were obtained in human mammary epithelial cells (MCF10A) and breast cancer cell lines.;Despite previous evidence suggesting that ErbB receptors can bind and activate IRSs, our findings indicate that ErbB2 does not cooperate with the IRS pathway in these models to promote mammary tumorigenesis.",
        "Doc_title":"Lack of interaction between ErbB2 and insulin receptor substrate signaling in breast cancer.",
        "Journal":"Cell communication and signaling : CCS",
        "Do_id":"27765041",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605792182799695872},
      {
        "Doc_abstract":"ErbB2 (HER-2) gene amplification and overexpression have been shown to predict a better outcome with doxorubicin-based chemotherapy as opposed to alkylator-based chemotherapy in early stage breast cancer. To understand the mechanism of differential response to these two regimens, we have evaluated the effect of signaling through the ErbB2 receptor on downstream enzymes that may affect drug response, using two different models. The first system employs breast cancer cells that have high levels of endogenous ErbB2 by gene amplification (BT-474 and SKBR3 cells). The second system allows us to isolate the effect of ErbB2 receptor-mediated intracellular signaling using an epidermal growth factor receptor-ErbB2 chimeric receptor activated by epidermal growth factor. Our experiments show that the cytotoxicity of doxorubicin is inhibited in ErbB2+ breast cancer cells by the anti-ErbB2 antibody, Herceptin. This is accompanied by a decrease in topoisomerase (topo) IIalpha protein and activity, suggesting that this is the mechanism of change in doxorubicin response. In addition, a 10-100-fold (1-2 log) decrease in the LD(50) of doxorubicin is seen after ErbB2 activation using the chimeric receptor model. Furthermore, we see a 100-fold decrease in the LD(50) of etoposide, another topo II inhibitor. This increase in doxorubicin sensitivity is associated with a 4.5-fold increase in the amount of topo IIalpha protein and an increase in topo II activity as measured by DNA decatenating and unknotting activities, as well as cleavable complex formation. In contradistinction to doxorubicin, we have observed an increased resistance to cyclophosphamide chemotherapy after chimeric receptor activation. We propose that the differential benefit seen with doxorubicin- versus alkylator-based chemotherapy in ErbB2+ breast cancer is due, in some cases, to ErbB2-mediated topo IIalpha activation. These data also suggest hypotheses for the optimal sequencing of Herceptin and chemotherapy agents in ErbB2+ breast cancer.",
        "Doc_title":"Induction of topoisomerase II activity after ErbB2 activation is associated with a differential response to breast cancer chemotherapy.",
        "Journal":"Clinical cancer research : an official journal of the American Association for Cancer Research",
        "Do_id":"11410482",
        "Doc_ChemicalList":"Antineoplastic Agents;Antineoplastic Agents, Alkylating;Nucleic Acid Synthesis Inhibitors;Epidermal Growth Factor;Etoposide;Doxorubicin;Cyclophosphamide;DNA;Receptor, ErbB-2;DNA Topoisomerases, Type II",
        "Doc_meshdescriptors":"3T3 Cells;Animals;Antineoplastic Agents;Antineoplastic Agents, Alkylating;Blotting, Western;Breast Neoplasms;Cell Cycle;Cell Nucleus;Cyclophosphamide;DNA;DNA Topoisomerases, Type II;Doxorubicin;Enzyme Activation;Epidermal Growth Factor;Etoposide;Female;Humans;Mice;Nucleic Acid Synthesis Inhibitors;Protein Binding;Receptor, ErbB-2;Signal Transduction;Time Factors;Transfection;Tumor Cells, Cultured",
        "Doc_meshqualifiers":"pharmacology;pharmacology;drug therapy;metabolism;pharmacology;drug effects;metabolism;pharmacology;metabolism;pharmacology;pharmacology;metabolism",
        "_version_":1605791089459986432},
      {
        "Doc_abstract":"Overexpression of the ERBB2 gene occurs in 30% of human breast cancers and is correlated with poor prognosis. The deregulation is the consequence of an increased transcription level and gene amplification. Several laboratories, including our own, have identified, in the proximal promoter, enhancers implicated in the gene overexpression. However, our previous studies of a 6-kb ERBB2 promoter fragment revealed the presence of repressing fragments, which were able to overcome the effect of the proximal enhancers. These repressing elements were functional in all cell lines, regardless of their endogenous ERBB2 expression level. Here, we show that a distal ERBB2 promoter region restores high transcription rates specifically in ERBB2 overexpressing breast cancer cells. This distal promoter region thus contains enhancers essential for the overexpression of the gene. By EMSA, performed with nuclear extract of cells overexpressing (BT-474) or not (MDA-MB-231) the ERBB2 gene, we show that at least two sequences of the distal promoter region are bound exclusively by BT-474 extract. Further experiments reveal that AP-2 transcription factors contribute to this differential binding activity, by binding recognition sequences located 4500 bp and 4000 bp upstream of the transcription start site. These sites are occupied by AP2 in vivo, as demonstrated by ChIP assay. Inactivation of AP-2 proteins in ERBB2 overexpressing cells reduces the distal promoter activity up to 70%, indicating the AP-2 factors are implicated in the strong distal enhancing effect. Moreover, we identified a 54-bp fragment that is bound specifically by BT-474 nuclear extract. Further experiments did not lead to the identification of the protein responsible for this binding. Our results thus highlight the importance of ERBB2 distal promoter region and further implicate AP-2 in ERBB2 overexpression in breast cancer cells.",
        "Doc_title":"Distal ERBB2 promoter fragment displays specific transcriptional and nuclear binding activities in ERBB2 overexpressing breast cancer cells.",
        "Journal":"DNA and cell biology",
        "Do_id":"16153159",
        "Doc_ChemicalList":"Oligonucleotides;Transcription Factor AP-2;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Base Sequence;Breast Neoplasms;Cell Line, Tumor;Chromatin Immunoprecipitation;Electrophoretic Mobility Shift Assay;Gene Expression Regulation, Neoplastic;Genes, erbB-2;Genetic Vectors;Humans;Molecular Sequence Data;Oligonucleotides;Promoter Regions, Genetic;Receptor, ErbB-2;Transcription Factor AP-2",
        "Doc_meshqualifiers":"genetics;metabolism;genetics;genetics;metabolism;metabolism",
        "_version_":1605879569189961728},
      {
        "Doc_abstract":"Receptor tyrosine kinase ErbB2/HER2 is frequently observed to be overexpressed in human cancers, leading to over activation of downstream signaling modules. HER2 positive is a major type of breast cancer for which ErbB2 targeting is already proving to be an effective therapeutic strategy. Apart from antibodies against ErbB2, the small molecule tyrosine kinase inhibitor lapatinib has had successful clinical outcomes, and other inhibitors such as neratinib are currently undergoing clinical investigations. In this study we report the effects of lapatinib and neratinib on the mRNA and protein levels of the ErbB2 receptor. We provide evidence that neratinib-induced down regulation of ErbB2 occurs through ubiquitin-mediated endocytic sorting and lysosomal degradation. At the mechanistic level, neratinib treatment leads to HSP90 release from ErbB2 and its subsequent ubiquitylation and endocytic degradation. Our findings provide novel insights into the mechanism of ErbB2 inhibition by neratinib.",
        "Doc_title":"Neratinib induces ErbB2 ubiquitylation and endocytic degradation via HSP90 dissociation in breast cancer cells.",
        "Journal":"Cancer letters",
        "Do_id":"27597738",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605760856318017536},
      {
        "Doc_abstract":"Heat shock protein 70 (HSP70) is known to be downstream of human epidermal growth factor receptor-2 (ERBB2), but little is known regarding the relationship between HSP70 and drug resistance mediated by ERBB2 in breast cancer.;After infecting breast cancer cells with lentivirus-mediated Lenti-ShHSP70 and Lenti-ShERBB2, we examined the expression of HSP70 and ERBB2 by real-time polymerase chain reaction and western blotting.;Compared to the control groups, mRNA expression of HSP70 was decreased in lentivirus-infected, and western blotting indicated a concordant reduction of HSP70 protein. On the other hand, ERBB2 was significantly down-regulated by HSP70 silencing in SK-BR-3 cells at both the mRNA and protein levels. Expression of HSP70 in transfected cells was also reduced by Lenti-ShERBB2. CCK8 viability assay indicated that inhibition of HSP70 increased the sensitivity of SK-BR-3 cells to fluorouracil treatment.;HSP70 affects ERBB2 and ERBB2-mediated drug-resistance in breast cancer cells.",
        "Doc_title":"Relationship Between HSP70 and ERBB2 Expression in Breast Cancer Cell Lines Regarding Drug Resistance.",
        "Journal":"Anticancer research",
        "Do_id":"26977021",
        "Doc_ChemicalList":"Antimetabolites, Antineoplastic;HSP70 Heat-Shock Proteins;RNA, Messenger;ERBB2 protein, human;Receptor, ErbB-2;Fluorouracil",
        "Doc_meshdescriptors":"Antimetabolites, Antineoplastic;Breast Neoplasms;Cell Line, Tumor;Cell Survival;Dose-Response Relationship, Drug;Drug Resistance, Neoplasm;Female;Fluorouracil;Gene Expression Regulation, Neoplastic;HSP70 Heat-Shock Proteins;Humans;RNA Interference;RNA, Messenger;Receptor, ErbB-2;Transfection",
        "Doc_meshqualifiers":"pharmacology;drug therapy;genetics;metabolism;pathology;drug effects;genetics;metabolism;genetics;metabolism;genetics;metabolism",
        "_version_":1605882930682396672},
      {
        "Doc_abstract":"ErbB2 is overexpressed in approximately 30% of breast cancer patients with a correlation to poor prognosis. ErbB2 has been identified as a useful receptor for molecular targeting. A cyclic 20 amino acid phage display random peptide library was constructed using the fUSE5 gene III system. The library was panned against 2 different purified forms of the external domain of ErbB2. This resulted in the identification of several ErbB2-binding phage clones with variable binding to different ErbB2 preparations. One clone (EC-1) bound all preparations of ErbB2 including live cells and fresh frozen human breast cancer specimens. The synthetic peptide based on the deduced sequence of the EC-1 clone and its biotin-conjugated form retained binding affinity for purified ErbB2 and ErbB2 overexpressing cell lysates. EC-1 peptide was able to effectively inhibit the phosphorylation of ErbB2 on residues Y1248 and Y877 in a dose- and time-dependent manner. Furthermore, EC-1 peptide selectively inhibits the proliferation of ErbB2 overexpressing breast cancer cells. The linear portion of the cyclic EC-1 peptide was shown to be essential for binding ErbB2. In addition, 4 biased phage libraries were constructed allowing 4 different regions of the EC-1 peptide to have random sequence. Screening these EC-1 biased libraries did not result in higher affinity peptides but did demonstrate the importance of amino acids at position 1-4 on the N-terminal flanking arm and 11-15 within the cyclic ring. Interestingly, EC-1 contains homologous motifs with known ErbB receptor family ligands. We have identified a small peptide that binds to the extracellular domain of ErbB2, inhibits ErbB2 autophosphorylation and inhibits the proliferation of ErbB2 overexpressing cells. This supports the notion that small peptides can bind to targets important in cancer therapy even if a target does not have a natural ligand. Continuing research with this peptide includes increasing its affinity to ErbB2, evaluation of pharmacokinetics and evaluation of anti-proliferative effects with conjugate anti-cancer agents.",
        "Doc_title":"Identification of a small peptide that inhibits the phosphorylation of ErbB2 and proliferation of ErbB2 overexpressing breast cancer cells.",
        "Journal":"International journal of cancer",
        "Do_id":"15300809",
        "Doc_ChemicalList":"Peptide Fragments;Peptide Library;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Amino Acid Sequence;Breast Neoplasms;Cloning, Molecular;Dose-Response Relationship, Drug;Enzyme-Linked Immunosorbent Assay;Female;Fluorescent Antibody Technique;Humans;Immunohistochemistry;Molecular Sequence Data;Peptide Fragments;Peptide Library;Phosphorylation;Prognosis;Receptor, ErbB-2",
        "Doc_meshqualifiers":"genetics;pathology;pharmacology;metabolism",
        "_version_":1605746465621147649},
      {
        "Doc_abstract":"Amplification and overexpression of the ERBB2 (HER-2/neu) oncogene has been implicated as contributing to the development of human breast cancer, and as a predictor of poor survival. In the present non-randomized study of 871 primary invasive breast tumours, ERBB2 activation was significantly correlated to a shorter disease-free and overall survival in the subgroup of patients receiving adjuvant tamoxifen therapy, but not in the untreated group. Further subcategorization demonstrated the relationship to poor prognosis to be confined to lymph node positive and steroid receptor-positive tumours. We suggest that steroid receptor and ERBB2-positive breast tumours are resistant to tamoxifen therapy and, supported by experimental evidence showing an oestrogen receptor dependent up-regulation of ERBB2 expression upon tamoxifen administration, possibly even growth stimulated by the drug.",
        "Doc_title":"ERBB2 amplification is associated with tamoxifen resistance in steroid-receptor positive breast cancer.",
        "Journal":"Cancer letters",
        "Do_id":"7912163",
        "Doc_ChemicalList":"Proto-Oncogene Proteins;Receptors, Estrogen;Receptors, Progesterone;Tamoxifen;Receptor, Epidermal Growth Factor;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Breast Neoplasms;Drug Resistance;Female;Gene Amplification;Humans;Proto-Oncogene Proteins;Proto-Oncogenes;Receptor, Epidermal Growth Factor;Receptor, ErbB-2;Receptors, Estrogen;Receptors, Progesterone;Tamoxifen",
        "Doc_meshqualifiers":"drug therapy;genetics;metabolism;genetics;genetics;analysis;analysis;therapeutic use",
        "_version_":1605902671330410496},
      {
        "Doc_abstract":"Gankyrin is a subunit of the 26S proteasome, and has been known to degrade p53 and retinoblastoma protein and promote the tumorigenicity and metastasis in some malignancies. However, the role of gankyrin in breast cancer has not been explored. In this study, we investigated the expression of gankyrin in breast cancer and evaluated its effect on breast cancer. Representative cancer tissues including normal breasts from 60 patients with breast cancer were stained immunohistochemically for gankyrin, estrogen receptor, progesterone receptor, and ErbB2. We evaluated the relationship between gankyrin expression and clinicopathologic parameters or prognostic markers. We also attempted to clarify the mechanism of gankyrin involved in breast carcinogenesis by using MCF7 breast cancer cells. Gankyrin was weakly expressed in normal breast epithelial cells, however, tumor regions of 37/60 (61.7%) cases showed an overexpression of gankyrin. Gankyrin overexpression was associated with extensive intraductal carcinoma (p=0.014) and ErbB2 positivity (p=0.031) in invasive ductal carcinoma. In MCF7 breast cancer cells, downregulation of gankyrin was associated with a reduction of cell proliferation and tumorigenicity. In conclusion, gankyrin was identified in normal breasts and overexpressed in invasive breast cancers. The overexpression of gankyrin was associated with extensive intraductal carcinoma and ErbB2 expression in breast cancer.",
        "Doc_title":"Gankyrin is frequently overexpressed in breast cancer and is associated with ErbB2 expression.",
        "Journal":"Experimental and molecular pathology",
        "Do_id":"23276718",
        "Doc_ChemicalList":"Biomarkers, Tumor;PSMD10 protein, human;Proto-Oncogene Proteins;Receptors, Estrogen;Receptors, Progesterone;ERBB2 protein, human;Receptor, ErbB-2;Proteasome Endopeptidase Complex",
        "Doc_meshdescriptors":"Adult;Aged;Aged, 80 and over;Biomarkers, Tumor;Breast;Breast Neoplasms;Carcinoma, Intraductal, Noninfiltrating;Cell Line, Tumor;Cell Proliferation;Female;Gene Expression Regulation, Neoplastic;Humans;MCF-7 Cells;Middle Aged;Proteasome Endopeptidase Complex;Proto-Oncogene Proteins;Receptor, ErbB-2;Receptors, Estrogen;Receptors, Progesterone;Up-Regulation;Young Adult",
        "Doc_meshqualifiers":"metabolism;metabolism;metabolism;metabolism;genetics;metabolism;genetics;metabolism;metabolism;metabolism;metabolism",
        "_version_":1605750468054614016},
      {
        "Doc_abstract":"The recent development of targeted therapies using monoclonal antibodies has added new dimensions to breast cancer treatment. Trastuzumab has been added to the regimens that contain chemotherapeutic agents, which has improved the clinical outcomes of patients in both the adjuvant and metastatic settings. However, trastuzumab resistance, both de novo and acquired, continues to be problematic. There have been scattered studies reporting ERBB2 gene mutation, but nothing is currently known about the ERBB2 binding site mutations. In the current study, we examined the ERBB2 juxtamembrane domain trastuzumab binding site for mutations in invasive breast cancers overexpressing ERBB2. Pure tumor cells of 54 breast cancer patients were procured using laser capture microdissection. Two polymerase chain reaction primer pairs were designed to amplify the trastuzumab binding site sequence. The polymerase chain reaction product was sequenced. Standard clinicopathological data were recorded. For the 54 patients, there was one (2%) case that showed missense point mutation in exon 17 (H559A). There were nine patients treated with trastuzumab in the metastatic setting, none of which had gene mutation. Therefore, we conclude that ERBB2 juxtamembrane domain (trastuzumab binding site) gene mutation is a rare event in breast cancer. Although it is unclear whether this substitution would result in trastuzumab target therapy resistance, this would not account for the relatively high frequency of this resistance encountered clinically.",
        "Doc_title":"ERBB2 juxtamembrane domain (trastuzumab binding site) gene mutation is a rare event in invasive breast cancers overexpressing the ERBB2 gene.",
        "Journal":"Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc",
        "Do_id":"21499233",
        "Doc_ChemicalList":"Antibodies, Monoclonal, Humanized;Antineoplastic Agents;ERBB2 protein, human;Receptor, ErbB-2;Trastuzumab",
        "Doc_meshdescriptors":"Adult;Aged;Aged, 80 and over;Antibodies, Monoclonal, Humanized;Antineoplastic Agents;Binding Sites;Breast Neoplasms;Drug Resistance, Neoplasm;Female;Humans;Lasers;Microdissection;Middle Aged;Mutation, Missense;Neoplasm Invasiveness;Receptor, ErbB-2;Trastuzumab",
        "Doc_meshqualifiers":"metabolism;therapeutic use;metabolism;therapeutic use;drug therapy;genetics;pathology;genetics;genetics",
        "_version_":1605909885433675776},
      {
        "Doc_abstract":"The erbB2 receptor is expressed at very high levels in nearly 30% of human breast cancer patients and plays an important role in the transformation and the prognosis of breast cancer. While evidence accumulates to support the relationship between erbB2 overexpression and poor overall survival in human breast cancer, understanding of the biological consequence(s) of erbB2 overexpression remains elusive. Our recent discovery, cloning, sequencing, and expression of the erbB2 ligand (gp30) has allowed us to identify a number of related but distinct biological endpoints which appear responsive to signal transduction through the erbB2 receptor. These endpoints of growth, invasiveness, and differentiation have clear implications for the emergence, maintenance, and/or control of malignancy, and represent established endpoints in the assessment of malignant progression in breast cancer. Studies in vitro have shown that gp30 induces a biphasic growth effect (induction of growth at low concentrations and inhibition of growth at high concentrations) on cells with erbB2 over-expression. Strikingly, we have recently observed that the erbB2 signalling pathway can be modulated by estrogen acting through the estrogen receptor (ER). Conversely, we observed that down regulation of erbB2 by estrogen can be blocked by gp30 acting through the erbB2 receptor. Clearly, mechanistic aspects of the erbB2/ligand interaction need to be understood from a therapeutic standpoint, and may furthermore provide additional insights into treatment synergy for particular patients. We think that these studies will facilitate the emergence of erbB2-targeted therapy.",
        "Doc_title":"William L. McGuire Memorial Symposium. The role of erbB2 signal transduction pathways in human breast cancer.",
        "Journal":"Breast cancer research and treatment",
        "Do_id":"7903175",
        "Doc_ChemicalList":"DNA Probes;DNA, Neoplasm;Proto-Oncogene Proteins;Receptors, Cell Surface;Estradiol;Receptor, Epidermal Growth Factor;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Base Sequence;Breast Neoplasms;Cell Division;Cell Line;DNA Probes;DNA, Neoplasm;Estradiol;Female;Humans;Molecular Sequence Data;Proto-Oncogene Proteins;Receptor, Epidermal Growth Factor;Receptor, ErbB-2;Receptors, Cell Surface;Signal Transduction;Tumor Cells, Cultured",
        "Doc_meshqualifiers":"genetics;metabolism;pathology;drug effects;analysis;pharmacology;genetics;metabolism;genetics;metabolism;metabolism",
        "_version_":1605763959141433344},
      {
        "Doc_abstract":"Resistance to anti-ErbB2 agents is a significant problem in the treatment of human ErbB2+ breast cancers. We show here that adhesion of human ErbB2+ breast cancer cells to basement membrane laminin-5 provides substantial resistance to trastuzumab and lapatinib, agents that respectively target the extracellular and kinase domains of ErbB2. Knockdown of laminin-binding integrins (alpha6beta4, alpha3beta1) or associated tetraspanin protein CD151 reversed laminin-5 resistance and sensitized ErbB2+ cells to trastuzumab and lapatinib. CD151 knockdown, together with trastuzumab treatment, inhibited ErbB2 activation and downstream signaling through Akt, Erk1/2, and focal adhesion kinase (FAK). Hence, ErbB2 function in mammary tumor cells is promoted by integrin-mediated adhesion to laminin-5, with strong support by CD151, leading to signaling through FAK. Consequently, removal or inhibition of any of these components (laminin-5, integrin, CD151, FAK) markedly sensitizes cells to anti-ErbB2 agents. These new insights should be useful when devising strategies for overcoming drug resistance in ErbB2+ cancers.",
        "Doc_title":"Disruption of laminin-integrin-CD151-focal adhesion kinase axis sensitizes breast cancer cells to ErbB2 antagonists.",
        "Journal":"Cancer research",
        "Do_id":"20197472",
        "Doc_ChemicalList":"Antibodies, Monoclonal;Antibodies, Monoclonal, Humanized;Antigens, CD;Antigens, CD151;Antineoplastic Agents;CD151 protein, human;Cell Adhesion Molecules;Integrin alpha3beta1;Integrin alpha6beta4;Protein Kinase Inhibitors;Quinazolines;kalinin;lapatinib;Receptor, ErbB-2;Focal Adhesion Protein-Tyrosine Kinases;Trastuzumab",
        "Doc_meshdescriptors":"Antibodies, Monoclonal;Antibodies, Monoclonal, Humanized;Antigens, CD;Antigens, CD151;Antineoplastic Agents;Breast Neoplasms;Cell Adhesion Molecules;Cell Line, Tumor;Drug Synergism;Enzyme Activation;Focal Adhesion Protein-Tyrosine Kinases;Humans;Integrin alpha3beta1;Integrin alpha6beta4;Protein Kinase Inhibitors;Quinazolines;Receptor, ErbB-2;Signal Transduction;Trastuzumab",
        "Doc_meshqualifiers":"pharmacology;metabolism;pharmacology;drug therapy;enzymology;metabolism;metabolism;metabolism;metabolism;metabolism;pharmacology;pharmacology;antagonists & inhibitors",
        "_version_":1605789255263584256},
      {
        "Doc_abstract":"This study examined the radiation-induced ERBB2 nuclear transport in the BT474 breast cancer cell line and the relationship between caveolin-1 and radiation-induced ERBB2 nuclear transport. The BT474 cells were treated with herceptin (200 nmol/L), PP2 (a caveolin-1 inhibitor, 100 nmol/L) and irradiation combined or alone. Confocal microscopy was used to observe the nuclear import of ERBB2 and caveolin-1 after irradiation. Western blotting was employed to detect the expression of ERBB2, caveolin-1 and DNA-PKcs after irradiation, and immunoprecipitation to identify the ERBB2 and caveolin-1 complex before perinuclear ERBB2 localization. Confocal microscopy showed the transport of ERBB2 and caveolin-1 from the cell membrane to the nucleus 15 min after irradiation and the proteins accumulated at the perinuclear region within 45 min. Western blotting revealed that the expression levels of ERBB2, caveolin-1 and DNA-PKcs were increased after irradiation and reached a peak 45 min later. Both herceptin and PP2 treatments were found to decrease ERBB2 expression. An immune complex composed of ERBB2 and caveolin-1 was found in the herceptin group after irradiation. It was concluded that after irradiation, ERBB2 may be transported from the cell membrane to the nucleus and activate DNA-PKcs to trigger DNA double-strand break (DSB) repair; caveolin-1 may participate in this process. Treatments involving the downregulation of caveolin-1 may increase the radiosensitization of breast cancer cells.",
        "Doc_title":"Caveolin-1 is involved in radiation-induced ERBB2 nuclear transport in breast cancer cells.",
        "Journal":"Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban",
        "Do_id":"23271292",
        "Doc_ChemicalList":"Caveolin 1;ERBB2 protein, human;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Active Transport, Cell Nucleus;Breast Neoplasms;Caveolin 1;Cell Line, Tumor;Female;Humans;Protein Transport;Radiation;Receptor, ErbB-2",
        "Doc_meshqualifiers":"physiology;metabolism;physiopathology;metabolism;physiology;metabolism",
        "_version_":1605759598467219456},
      {
        "Doc_abstract":"Molecular apocrine is a subtype of estrogen receptor-negative (ER.) breast cancer, which is characterized by a steroid-response gene signature that includes androgen receptor, FOXA1, and a high frequency of ErbB2 overexpression. In this study, we demonstrate that there is a strong association between the overexpression of FOXA1 and ErbB2 in ER- breast tumors. This has led us to identify a cross-regulation network between FOXA1 and ErbB2 signaling in ER- breast cancer. We present two mechanisms to explain the association between FOXA1 and ErbB2 overexpression in molecular apocrine cells. In one process, ErbB2 signaling genes CREB1 and c-Fos regulate FOXA1 transcription, and in another process, AP2Î± regulates the expression of both FOXA1 and ErbB2. Moreover, we demonstrate that FOXA1, in turn, regulates the transcription of ErbB2 signaling genes. This includes a core gene signature that is shared across two molecular apocrine cell lines. Importantly, the most upregulated (RELB) and downregulated (PAK1) genes in this signature are direct FOXA1 targets. Our data suggest that FOXA1 acts as a dual-function transcription factor and the repressive function of FOXA1 on RELB can be explained by the recruitment of its binding partner corepressor TLE3. It is notable that a group of FOXA1-regulated genes vary across molecular apocrine cell lines leading to the differences in the functional effects of FOXA1 on extracellular signal-regulated kinase phosphorylation and cell viability between these lines. This study demonstrates that there is a cross-regulation network between FOXA1 and ErbB2 signaling that connects FOXA1 to some of the key signaling pathways in ER-breast cancer.",
        "Doc_title":"Cross-regulation between FOXA1 and ErbB2 signaling in estrogen receptor-negative breast cancer.",
        "Journal":"Neoplasia (New York, N.Y.)",
        "Do_id":"22577344",
        "Doc_ChemicalList":"FOXA1 protein, human;Hepatocyte Nuclear Factor 3-alpha;Receptors, Estrogen;ERBB2 protein, human;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Blotting, Western;Breast Neoplasms;Cell Line, Tumor;Chromatin Immunoprecipitation;Female;Gene Expression Regulation, Neoplastic;Hepatocyte Nuclear Factor 3-alpha;Humans;Real-Time Polymerase Chain Reaction;Receptor, ErbB-2;Receptors, Estrogen;Signal Transduction;Tissue Array Analysis",
        "Doc_meshqualifiers":"genetics;metabolism;physiology;genetics;metabolism;genetics;metabolism;biosynthesis;physiology",
        "_version_":1605746800036151296},
      {
        "Doc_abstract":"ErbB2 is frequently highly expressed in premalignant breast cancers, including ductal carcinoma in situ (DCIS); however, little is known about the signals or pathways it contributes to progression into the invasive/malignant state. Radiotherapy is often used to treat early premalignant lesions regardless of ErbB2 status. Here, we show that clinically relevant doses of ionizing radiation (IR)-induce cellular invasion of ErbB2-expressing breast cancer cells, as well as MCF10A cells overexpressing ErbB2. ErbB2-negative breast cancer cells, such as MCF7 and T47D, do not invade following treatment with IR nor do MCF10A cells overexpressing epidermal growth factor receptor. ErbB2 becomes phosphorylated at tyrosine 877 in a dose- and time- dependent manner following exposure to X-rays, and activates downstream signaling cascades including PI3K/Akt. Inhibition of these pathways, as well as inhibition of reactive oxygen species (ROS) with antioxidants, prevents IR-induced invasion. Activation of ErbB2-dependent signaling results in upregulation of the forkhead family transcription factor, FoxM1, and its transcriptional targets, including matrix metalloproteinase 2 (MMP2). Inhibition of FoxM1 by RNA interference prevented induction of invasion by IR, and overexpression of FoxM1 in MCF10A cells was sufficient to promote IR-induced invasion. Moreover, we found that 14-3-3Î¶ is also upregulated by IR in cancer cells in a ROS-dependent manner, is required for IR-induced invasion in ErbB2-positive breast cancer cells and together with FoxM1 is sufficient for invasion in ErbB2-negative breast cancer cells. Thus, our data show that IR-mediated activation of ErbB2 and induction of 14-3-3Î¶ collaborate to regulate FoxM1 and promote invasion of breast cancer cells and furthermore, may serve as therapeutic targets to enhance radiosensitivity of breast cancers. ",
        "Doc_title":"ErbB2, FoxM1 and 14-3-3Î¶ prime breast cancer cells for invasion in response to ionizing radiation.",
        "Journal":"Oncogene",
        "Do_id":"23318431",
        "Doc_ChemicalList":"14-3-3 Proteins;FOXM1 protein, human;Forkhead Box Protein M1;Forkhead Transcription Factors;RNA, Small Interfering;Reactive Oxygen Species;YWHAZ protein, human;Phosphatidylinositol 3-Kinases;ERBB2 protein, human;Receptor, ErbB-2;Proto-Oncogene Proteins c-akt;MMP2 protein, human;Matrix Metalloproteinase 2",
        "Doc_meshdescriptors":"14-3-3 Proteins;Breast Neoplasms;Cell Line, Tumor;Cell Movement;Female;Forkhead Box Protein M1;Forkhead Transcription Factors;Humans;MCF-7 Cells;Matrix Metalloproteinase 2;Neoplasm Invasiveness;Phosphatidylinositol 3-Kinases;Phosphorylation;Proto-Oncogene Proteins c-akt;RNA Interference;RNA, Small Interfering;Radiation, Ionizing;Reactive Oxygen Species;Receptor, ErbB-2;Signal Transduction",
        "Doc_meshqualifiers":"genetics;metabolism;pathology;radiotherapy;genetics;biosynthesis;genetics;metabolism;biosynthesis;metabolism;radiation effects;metabolism;metabolism;metabolism;radiation effects",
        "_version_":1605795735873257472},
      {
        "Doc_abstract":"Overexpression of the ErbB2/Her2 receptor tyrosine kinase in breast cancers is associated with the most aggressive tumors. Experimental studies have revealed that ErbB2 shows many features of a therapeutic target: ErbB2 is able to confer many of the characteristics of a cancerous cell, including uncontrolled proliferation, resistance to apoptosis and increased motility; ErbB2 overexpression is specific to tumor cells; as a cell surface-associated protein, it is easily accessible to drugs and as a kinase it is amenable to targeted inhibition by small molecules. Recent clinical results demonstrate the efficacy of ErbB2-targeting therapy and promise an expanding use of ErbB2-targeting drugs for breast cancer treatment. However, as only a fraction of patients responds successfully to therapy and risks of recurrence are still high, further investigation is required for an improved understanding of the complex network of signaling pathways underlying ErbB2-driven cancer progression.",
        "Doc_title":"The ErbB2 signaling network as a target for breast cancer therapy.",
        "Journal":"Journal of mammary gland biology and neoplasia",
        "Do_id":"16947083",
        "Doc_ChemicalList":"Antibodies, Monoclonal;Antibodies, Monoclonal, Humanized;Antineoplastic Agents;Receptor, ErbB-2;Trastuzumab",
        "Doc_meshdescriptors":"Antibodies, Monoclonal;Antibodies, Monoclonal, Humanized;Antineoplastic Agents;Breast Neoplasms;Chemotherapy, Adjuvant;Female;Humans;Receptor, ErbB-2;Signal Transduction;Trastuzumab",
        "Doc_meshqualifiers":"pharmacology;therapeutic use;pharmacology;therapeutic use;drug therapy;metabolism;antagonists & inhibitors;metabolism",
        "_version_":1605910150827212800},
      {
        "Doc_abstract":"About two-thirds of the excess familial risk associated with breast cancer is still unaccounted for and may be explained by multiple weakly predisposing alleles. A gene thought to be involved in low-level predisposition to the disease is ERBB2 (HER2). This gene is involved in cell division, differentiation, and apoptosis and is frequently amplified in breast tumours. Its amplification correlates with poor prognosis. Moreover, the coding polymorphism I655V has previously been associated with an increased risk of breast cancer.;We aimed to determine if common polymorphisms (frequency >or= 5%) in ERBB2 were associated with breast cancer risk in a white British population. Five single-nucleotide polymorphisms (SNPs) were selected for study: SNP 1 near the promoter, SNP 2 in intron 1, SNP 3 in intron 4, SNP 4 in exon 17 (I655V), and SNP 5 in exon 27 (A1170P). We tested their association with breast cancer in a large case-control study (n = 2192 cases and 2257 controls).;There were no differences in genotype frequencies between cases and controls for any of the SNPs examined. To investigate the possibility that a common polymorphism not included in our study might be involved in breast cancer predisposition, we also constructed multilocus haplotypes. Our set of SNPs generated all existing (n = 6) common haplotypes and no differences were seen in haplotype frequencies between cases and controls (P = 0.44).;In our population, common ERBB2 polymorphisms are not involved in predisposition to breast cancer.",
        "Doc_title":"Common ERBB2 polymorphisms and risk of breast cancer in a white British population: a case-control study.",
        "Journal":"Breast cancer research : BCR",
        "Do_id":"15743501",
        "Doc_ChemicalList":"Receptor, ErbB-2",
        "Doc_meshdescriptors":"Adult;Aged;Aged, 80 and over;Case-Control Studies;England;European Continental Ancestry Group;Exons;Female;Genetic Predisposition to Disease;Genotype;Haplotypes;Humans;Introns;Middle Aged;Polymorphism, Single Nucleotide;Receptor, ErbB-2;Risk Factors",
        "Doc_meshqualifiers":"genetics;genetics;physiology",
        "_version_":1605746981890686976},
      {
        "Doc_abstract":"To develop a method for the detection of amplification of the erbB2 oncogene in breast cancer fine needle aspirates using fluorescence in situ hybridisation (FISH) and to compare amplification with immunohistochemical detection of the erbB2 protein.;A digoxigenin labelled probe to the erbB2 gene was hybridised to 15 aspirates prepared from operative breast cancer specimens. A chromosome 17 centromere probe was also hybridised to the aspirates either separately or in combination with the erbB2 probe. The aspirates were scored for erbB2 amplification and chromosome 17 centromere number. Subsequently, paraffin wax embedded sections of the tumours were stained with the antibody CB11 and scored for the presence of membrane staining.;Three of the 15 tumour aspirates showed high level amplification of erbB2 detected by FISH. These three tumours also showed chromosome 17 polysomy and diffuse membrane staining by immunohistochemistry.;FISH can be used to detect erbB2 amplification in fine needle aspirates and results correlate with conventional immunohistochemical staining. Difficulties were encountered in the visualisation of the signals in non-amplified cases without the use of specialised digital imaging.",
        "Doc_title":"Fluorescence in situ hybridisation detection of erbB2 amplification in breast cancer fine needle aspirates.",
        "Journal":"Molecular pathology : MP",
        "Do_id":"10474685",
        "Doc_ChemicalList":"Neoplasm Proteins;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Biopsy, Needle;Breast Neoplasms;Centromere;Chromosomes, Human, Pair 17;Female;Gene Amplification;Genes, erbB-2;Humans;Immunoenzyme Techniques;In Situ Hybridization, Fluorescence;Neoplasm Proteins;Pilot Projects;Receptor, ErbB-2",
        "Doc_meshqualifiers":"genetics;metabolism;methods;metabolism;metabolism",
        "_version_":1605741965741129728},
      {
        "Doc_abstract":"In 25-30% of breast cancer tumor cases amplification of chromosome fragment around the ERBB2 underlies the increased expression of genes adjacent to ERBB2. Increased expression of genes within ERBB2-containing am- plicons may have an impact not only on the growth and development of the tumor, but on the sensitivity of the tumor to different types of anti-cancer therapies. The initial cause of amplification and the exact borders of ERBB2-amplified chromosome fragment are still not completely characterized. No specific DNA sequences were found on the junction regions at intrachromosomal DNA amplification. We hypothesized that amplification borders can be specified by DNA structural peculiarities rather than the particular DNA sequence. This study focused on the mapping of ERBB2 amplification borders in breast cancer and the search for unusual structural features of DNA at the borders of the identified amplicons. The copy number of 10 genes adjacent to ERBB2 were evaluated by real time PCR in 162 breast cancer samples. Several ERBB2-containing amplicons of various lengths were revealed. In the majority of the analyzed samples, the borders of these amplicons were located within ZNFNIA3 and RARA genes. A bioinformatics analysis of the nucleotide sequence peculiarities around ERBB2 gene revealed the presence of AT-rich DNA regions with high degree of flexibility. These regions were able to form stable secondary structures. Positions of these sites strongly coincide with the positions of the ERBB2-containing amplicon borders found in real time PCR experiments. On the base of results obtained one can suppose that the structural features of DNA are involved in the formation of ERBB2-containing amplicon borders in breast cancer cells and the data are of importance for understanding the mechanisms of oncogene amplification.",
        "Doc_title":"[DNA structural features on the borders of ERBB2 amplicons in breast cancer].",
        "Journal":"Molekuliarnaia biologiia",
        "Do_id":"25509354",
        "Doc_ChemicalList":"DNA;ERBB2 protein, human;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Adult;Aged;Breast Neoplasms;Chromosomes, Human, Pair 17;DNA;Female;Gene Amplification;Humans;In Situ Hybridization, Fluorescence;Middle Aged;Nucleic Acid Conformation;Receptor, ErbB-2",
        "Doc_meshqualifiers":"genetics;pathology;genetics;chemistry;genetics;chemistry;genetics",
        "_version_":1605806355520684032},
      {
        "Doc_abstract":"The ERBB2 transmembrane tyrosine kinase receptor is both a prognostic marker and a therapeutic target in breast cancer. Accurate determination of ERBB2 status is a prerequisite for the establishment of prognostic significance and for the selection of ERBB2-overexpressing breast tumours for specific treatment. Unfortunately, there is no complete agreement on how this determination should be performed. This study has compared four methods of assessment of ERBB2 status. Two global, extraction-based methods using real-time quantitative PCR on DNA (Q-PCR) or RNA (RQ-PCR) and two non-global, tissue-based methods, ie fluorescence in situ hybridization (FISH) and immunohistochemistry (IHC), were used. The 94 breast cancers tested were enriched in cases scoring 2+ using the IHC scoring system currently in use and for which the actual ERBB2 status remains ill defined. To determine the best parameters and reagents for assessment, two protocols for FISH and five anti-ERBB2 antibodies were used, and both FISH and IHC were carried out on the same tissue microarrays (TMAs). It is shown that the combination of the two tissue-based methods gives the best results. The use of either PCR-based method did not improve the results significantly. A new combined IHC score based on the association of two selected anti-ERBB2 antibodies (HercepTest trade mark and TAB250) and a dual scale for improved assessment of ERBB2 protein expression, particularly in 2+ cases, are proposed.",
        "Doc_title":"Comparative multi-methodological measurement of ERBB2 status in breast cancer.",
        "Journal":"The Journal of pathology",
        "Do_id":"14991893",
        "Doc_ChemicalList":"Receptor, ErbB-2",
        "Doc_meshdescriptors":"Breast Neoplasms;Cell Line, Tumor;Female;Gene Amplification;Humans;Immunohistochemistry;In Situ Hybridization, Fluorescence;Predictive Value of Tests;Prognosis;Receptor, ErbB-2;Reverse Transcriptase Polymerase Chain Reaction;Sensitivity and Specificity",
        "Doc_meshqualifiers":"chemistry;methods;analysis",
        "_version_":1605798214128107520},
      {
        "Doc_abstract":"Overexpression of the proto-oncogene ERBB2 (HER2/NEU) has been observed in 20-30% of breast cancers involving poor prognosis. Genetic alterations within ERBB2 have been shown to induce carcinogenesis and metastasis. We investigated eight annotated single nucleotide polymorphisms for occurrence in familial breast cancer samples. The confirmed variants Ile654Val, Ile655Val and Ala1170Pro were analysed in subsequent epidemiological studies on familial breast cancer risk. While Ala1170Pro resides within a C-terminally located regulatory domain, the two adjacent polymorphisms Ile654Val and Ile655Val are part of the transmembrane domain. A case-control study analysing a cohort of 348 German familial breast cancer cases and 960 corresponding controls showed no significant association of either Ile655Val (OR = 1.05, 95% CI = 0.82-1.34, P = 0.728) or Ala1170Pro (OR = 0.94, 95% CI = 0.74-1.20, P = 0.632) with familial breast cancer risk. Differences in haplotype frequencies between cases and controls could also not be detected. The ERBB2 variant Ile654Val, however, revealed an increased risk for carriers of the heterozygous Val654 allele (OR = 2.56, 95% CI = 1.08-6.08, P = 0.028). The rare Val654 variant is linked with the more frequent Val655, resulting in two consecutive valine instead of two isoleucine residues within the transmembrane domain. Computational analyses suggest that the Val654-Val655 allele provokes receptor dimerization and activation, thus stimulating kinase activity and cell transformation. We hypothesize that ERBB2 Val654 represents an oncogenic variant which might, in addition, influence clinical outcome and predict a worse prognosis.",
        "Doc_title":"The rare ERBB2 variant Ile654Val is associated with an increased familial breast cancer risk.",
        "Journal":"Carcinogenesis",
        "Do_id":"15550452",
        "Doc_ChemicalList":"Isoleucine;Valine",
        "Doc_meshdescriptors":"Adult;Aged;Aged, 80 and over;Breast Neoplasms;Case-Control Studies;Female;Genes, erbB-2;Genetic Predisposition to Disease;Heterozygote Detection;Humans;Isoleucine;Middle Aged;Polymerase Chain Reaction;Risk Factors;Valine",
        "Doc_meshqualifiers":"genetics;genetics;genetics",
        "_version_":1605795816394457088},
      {
        "Doc_abstract":"Expression of MIR125A is diminished in breast tumors, however the reason for the hsa-mir-125a decrease in the cancer is not known. HER2 is encoded by ERBB2, a target for hsa-miR-125a which interacts with the 3'UTR of ERBB2 mRNA. The present study reveals that a polymorphism (rs12976445) within the pri-miR-125a sequence correlates with the amount of mature hsa-miR-125a in breast tumor samples. miRNA, RNA and DNA were extracted from breast cancer samples obtained from 26 patients. Following immunohistological evaluation of the samples, the ERBB2, PGR and ESR1 mRNA profiles were also analyzed using real-time PCR. Genomic DNA was sequenced using MIR125A flanking primers. PCR products were analyzed using a BaeGI restriction enzyme specific to the rs12976445 variant. The rs12976445 variant (C/T and C/C) correlated with a lower level of hsa-miR-125a in comparison with the T/T variant. The expression of HER2 mRNA was increased in tumors with the rs12976445 variant (C/T and C/C) compared with T/T. We conclude that rs12976445 may be a potential prognostic marker of HER2 expression in breast cancer. Its predictive value on the efficacy of trastuzumab treatment in patients with HER2-positive breast cancer warrants further study.",
        "Doc_title":"rs12976445 variant in the pri-miR-125a correlates with a lower level of hsa-miR-125a and ERBB2 overexpression in breast cancer patients.",
        "Journal":"Oncology letters",
        "Do_id":"23420759",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605821893441486848},
      {
        "Doc_abstract":"Topoisomerase II alpha (topo II alpha) is a key enzyme in DNA replication and a target for many anti-cancer drugs. High levels are associated with sensitivity to topoisomerase II inhibitors. Because its chromosome location is similar to erbB2 (17q21-22), which is frequently amplified in breast cancer, co-amplification of these genes was assessed. In 117 primary breast cancers, 25 were amplified for erbB2. Three of these cases showed co-amplification of topo II alpha. Topo II beta was not amplified. Four human breast cancer cell lines were assessed for erbB2 and topo II alpha co-amplification. They were also analysed for sensitivity to the topoisomerase inhibitors m-AMSA and mitoxantrone. The most sensitive cell line was SKBr3, which was the only one with erbB2 amplification. Topo II alpha was co-amplified to a similar extent as in tumours. This suggests that patients whose tumours show topo II alpha amplification should be assessed specifically for therapy with topoisomerase inhibitors.",
        "Doc_title":"Topoisomerase II alpha co-amplification with erbB2 in human primary breast cancer and breast cancer cell lines: relationship to m-AMSA and mitoxantrone sensitivity.",
        "Journal":"Oncogene",
        "Do_id":"8096076",
        "Doc_ChemicalList":"DNA, Neoplasm;Proto-Oncogene Proteins;Receptors, Estrogen;Amsacrine;Mitoxantrone;Receptor, Epidermal Growth Factor;Receptor, ErbB-2;DNA Topoisomerases, Type II",
        "Doc_meshdescriptors":"Adult;Aged;Amsacrine;Breast Neoplasms;DNA Topoisomerases, Type II;DNA, Neoplasm;Gene Amplification;Humans;In Vitro Techniques;Lymphatic Metastasis;Middle Aged;Mitoxantrone;Oncogenes;Proto-Oncogene Proteins;Receptor, Epidermal Growth Factor;Receptor, ErbB-2;Receptors, Estrogen;Tumor Cells, Cultured",
        "Doc_meshqualifiers":"pharmacology;drug therapy;genetics;pathology;genetics;genetics;pharmacology;genetics;metabolism;metabolism",
        "_version_":1605796757999976448},
      {
        "Doc_abstract":"ERBB2 is frequently amplified in breast tumours as part of a wide region of amplification on chromosome 17q21. This amplicon contains many candidate genes for breast cancer susceptibility. We used a genetic association study design to determine if common genetic variation (frequency>or=5%) in a 400-kb region surrounding ERBB2 and containing the PPARBP, CRK7, NEUROD2, PPP1R1B, STARD3, TCAP, PNMT, CAB2, ERBB2, C17ORF37, GRB7 and ZNFN1A3 genes, was associated with breast cancer risk. Sixteen tagging single-nucleotide polymorphisms (tSNPs) selected within blocks of linkage disequilibrium from the HapMap database, one HapMap singleton SNP, and six additional SNPs randomly selected from dbSNP were genotyped using Taqman in a large study set of British women (2275 cases, 2280 controls). We observed no association between any of the genotypes or associated haplotypes and disease risk. In order to simulate unidentified SNPs, we performed the leave-one-out cross-validation procedure on the HapMap data; over 90% of the common genetic variation was well represented by tagging polymorphisms. We are therefore likely to have tagged any common variants present in our population. In summary, we found no association between common genetic variation in the 17q21 ERBB2 amplicon and breast cancer risk in British women.",
        "Doc_title":"HapMap-based study of the 17q21 ERBB2 amplicon in susceptibility to breast cancer.",
        "Journal":"British journal of cancer",
        "Do_id":"17117180",
        "Doc_ChemicalList":"Receptor, ErbB-2",
        "Doc_meshdescriptors":"Adult;Aged;Aged, 80 and over;Breast Neoplasms;Case-Control Studies;Chromosomes, Human, Pair 17;Female;Gene Amplification;Genetic Predisposition to Disease;Genomics;Haplotypes;Humans;Middle Aged;Polymorphism, Single Nucleotide;Receptor, ErbB-2",
        "Doc_meshqualifiers":"genetics;genetics;genetics;genetics;metabolism",
        "_version_":1605842343884226560},
      {
        "Doc_abstract":"Breast cancer is one of the main causes of cancer death among South African women. Although several risk factors can be attributed to the observed high mortality rate, the biology of the tumors is not extensively investigated. Copy number gain of the DLX4 homeobox gene has been observed in breast cancer in association with poor prognosis and specific racial groups. Therefore, we aimed to assess the copy number and prognostic role of DLX4 in breast cancer from South African patients. Due to the co-location of ERBB2 and DLX4 in the 17q21 region, its copy number was also evaluated. Our results in the analysis of 66 cases demonstrated copy number gains of DLX4 and ERBB2 in 24.1 and 29.7% of the cases, respectively. Linear regression analysis showed no dependency between the copy number alterations in these genes. Although not significant, patients with DLX4 and ERBB2 gains presented a higher frequency of advanced-grade tumors. In addition, copy number alterations of these genes were not significantly differently observed in the 3 main racial groups of the Western Cape population: Colored, White, and Black. These findings indicate that gains of DLX4 and ERBB2 occur in South African breast cancer patients irrespectively of their race and factors known to influence prognosis. ",
        "Doc_title":"Copy Number Analysis of the DLX4 and ERBB2 Genes in South African Breast Cancer Patients.",
        "Journal":"Cytogenetic and genome research",
        "Do_id":"26524685",
        "Doc_ChemicalList":"DLX4 protein, human;Homeodomain Proteins;Transcription Factors",
        "Doc_meshdescriptors":"Adult;Aged;Breast Neoplasms;DNA Copy Number Variations;Female;Genes, erbB-2;Homeodomain Proteins;Humans;Middle Aged;Retrospective Studies;South Africa;Transcription Factors",
        "Doc_meshqualifiers":"ethnology;genetics;genetics;genetics",
        "_version_":1605824678594609152},
      {
        "Doc_abstract":"Because trastuzumab therapy is expected to be effective in a large fraction of erbB2 (HER-2/neu) overexpressing breast cancers, it is important to find the optimal method for evaluation of erbB2 positivity, and the patient group at greatest risk of dying without this therapy.;We evaluated erbB2 immunopositivity in breast cancer with the aim of finding a high-risk group for primary trastuzumab therapy.;Three hundred and seventeen samples were evaluated with an immunostaining index. Optimal cut point was systematically tested, and the effect of bcl-2 status on survival in the high-risk group was studied.;Among N+ patients the index value 1.5 reflected the biggest difference in survival. There was a significant correlation between erbB2 positivity and bcl-2 negativity. ErbB2 was a prognosticator among postmenopausal, N+, and postmenopausal N+ patients. In multivariate analysis, erbB2 was the best prognosticator among postmenopausal N+ patients. Six out of seven N+ patients with erbB2 index 1.5 or above died including all postmenopausal patients. Bcl-2 positivity was associated with longer survival in the erbB2 positive patient group.;The most obvious patients for primary trastuzumab therapy in breast cancer are N+ patients with high erbB2 immunostaining index (> 1.5) and bcl-2 negative immunostaining. In our material 2% of all breast cancer patients fell in this category. This patient group should be selected for testing trastuzumab in the primary treatment.",
        "Doc_title":"Quantitation of erbB2 positivity for evaluation of high-risk patients.",
        "Journal":"Annals of medicine",
        "Do_id":"12553494",
        "Doc_ChemicalList":"Antibodies, Monoclonal;Antibodies, Monoclonal, Humanized;Antineoplastic Agents;Proto-Oncogene Proteins c-bcl-2;Receptor, ErbB-2;Trastuzumab",
        "Doc_meshdescriptors":"Adult;Aged;Antibodies, Monoclonal;Antibodies, Monoclonal, Humanized;Antineoplastic Agents;Breast Neoplasms;Female;Follow-Up Studies;Humans;Immunohistochemistry;Middle Aged;Prognosis;Proportional Hazards Models;Proto-Oncogene Proteins c-bcl-2;Receptor, ErbB-2;Time Factors;Trastuzumab",
        "Doc_meshqualifiers":"therapeutic use;therapeutic use;drug therapy;genetics;mortality",
        "_version_":1605928991676432384},
      {
        "Doc_abstract":"Breast cancer cell lines display a wide variety of growth factor receptors, and considerable evidence implicates signaling from these receptors, especially ErbB2, in the important early stages of this disease, contributing to malignant progression. If this is true, then we would hypothesize that a useful prognostic indicator would be the level of activity of a second messenger protein used in common by these receptors. One such second messenger is the Shc adapter protein, which is activated when tyrosine phosphorylated by receptors. Therefore, one prediction from the hypothesis is that the level of tyrosine-phosphorylated Shc (PY-Shc) in breast cancer cell lines would correlate with total receptor tyrosine kinase activity. To begin to test this prediction, we examined Shc tyrosine phosphorylation in a diverse group of breast cancer cell lines that display varied levels of ErbB2. Using Shc immunoprecipitation and anti-phosphotyrosine immunoblotting analysis, we found a strong correlation between the level of ErbB2 overexpression (r = 0.91, p < 0.0002) and PY-ErbB2 levels (r = 0.89, p = 0.0005) compared with the level of tyrosine phosphorylation of the p52 and p46 Shc isoforms. Consistent with Shc tyrosine phosphorylation being driven by ErbB2, an ErbB2-specific tyrosine kinase inhibitor markedly reduced Shc tyrosine phosphorylation. Unexpectedly, although all cell lines had comparable total amounts of p52 and p46 Shc, the amount of an inhibitory Shc isoform, p66, was inversely related to the level of ErbB2 expression (r = -0.86, p = 0.0013). This suggests that reduced p66 Shc expression may play a role in ErbB2-positive breast cancer. In summary, these data are consistent with our prediction that the cellular level of PY-Shc would correlate with the levels of activated ErbB2 displayed by cell lines derived from breast cancers.",
        "Doc_title":"Constitutively tyrosine phosphorylated p52 Shc in breast cancer cells: correlation with ErbB2 and p66 Shc expression.",
        "Journal":"Breast cancer research and treatment",
        "Do_id":"9696394",
        "Doc_ChemicalList":"Adaptor Proteins, Signal Transducing;Adaptor Proteins, Vesicular Transport;Proteins;SHC1 protein, human;Shc Signaling Adaptor Proteins;Src Homology 2 Domain-Containing, Transforming Protein 1;Tyrosine;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Adaptor Proteins, Signal Transducing;Adaptor Proteins, Vesicular Transport;Breast Neoplasms;Female;Humans;Phosphorylation;Proteins;Receptor, ErbB-2;Shc Signaling Adaptor Proteins;Src Homology 2 Domain-Containing, Transforming Protein 1;Tumor Cells, Cultured;Tyrosine",
        "Doc_meshqualifiers":"metabolism;metabolism;metabolism;metabolism",
        "_version_":1605907143286849536},
      {
        "Doc_abstract":"Mutations in the p53 tumor suppressor gene are the most prevalent genetic events in human Her2-positive breast cancer and are associated with poor prognosis and survival. Human clinical data and our in vitro and in vivo studies strongly suggest potent oncogenic cooperation between mutant p53 and Her2 (ErbB2). Yet, the translational significance of mutant p53 in Her2 positive breast cancer, especially with respect to Her2-targeted therapies, has not been evaluated. Our previous work identified novel oncogenic activity of mutant p53 whereby mutp53 amplifies ErbB2 signaling via the mutp53-HSF1-ErbB2 feed-forward loop. Here we report that pharmacological interception of this circuit by ErbB2 inhibitor lapatinib downregulates mutant p53 in vitro and in vivo. We found that ErbB2 inhibition by lapatinib inhibits transcription factor HSF1, and its target Hsp90, followed by mutant p53 degradation in MDM2 dependent manner. Thus, our data suggest that mutant p53 sensitizes cancer cells to lapatinib via two complementary mechanisms: mutant p53 mediated amplification of ErbB2 signaling, and simultaneous annihilation of both potent oncogenic drivers, ErbB2 and mutant p53. Hence, our study could provide valuable information for the optimization of therapeutic protocols to achieve superior clinical effects in the treatment of Her2 positive breast cancer.",
        "Doc_title":"ErbB2 inhibition by lapatinib promotes degradation of mutant p53 protein in cancer cells.",
        "Journal":"Oncotarget",
        "Do_id":"27791982",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605801677284179968},
      {
        "Doc_abstract":"ErbB family of the receptor protein-tyrosine kinase plays an important role in the progression of human cancers including breast cancer. Finding protein-tyrosine phosphatase (PTPs) that can specifically regulate the function of ErbB should help design novel therapies for treatment. By performing a small interfering RNA screen against 43 human PTPs, we find that knockdown of protein-tyrosine phosphatase PTPN9 significantly increases ErbB2 tyrosyl phosphorylation in the SKBR3 breast cancer cell line. In addition, knockdown of PTPN9 expression also enhances tyrosyl phosphorylation of the ErbB1/epidermal growth factor receptor (EGFR) in the MDA-MB-231 breast cancer cell line. Conversely, increasing expression of PTPN9 wild type (WT) inhibits tyrosyl phosphorylation of ErbB2 and EGFR. To test whether ErbB2 and EGFR are substrates of PTPN9, PTPN9 WT, and a substrate trapping mutant (PTPN9 DA) are overexpressed in SKBR3 and MDA-MB-231 cells. Compared with vector control, expression of PTPN9 WT significantly inhibits whereas expression of PTPN9 DA dramatically enhances tyrosyl phosphorylation of ErbB2 and EGFR, respectively. In contrast, expression of PTPN9 WT or DA mutant does not affect tyrosyl phosphorylation of ErbB3 and Shc. Importantly, coimmunoprecipitation and glutathione S-transferase fusion protein pulldown experiments show that tyrosol-phosphorylated ErbB2 or EGFR is preferentially associated with PTPN9 DA compared with PTPN9 WT, indicating that ErbB2 and EGFR are substrates of PTPN9. Furthermore, PTPN9 WT expression specifically impairs EGF-induced STAT3 and STAT5 activation, and inhibits the cell growth in soft agar. Last, PTPN9 WT expression also reduces invasion and MMP2 expression of MDA-MB-231 cells. Our data suggest PTPN9 as a negative regulator of breast cancer cells by targeting ErbB2 and EGFR and inhibiting STAT activation.",
        "Doc_title":"Protein-tyrosine phosphatase PTPN9 negatively regulates ErbB2 and epidermal growth factor receptor signaling in breast cancer cells.",
        "Journal":"The Journal of biological chemistry",
        "Do_id":"20335174",
        "Doc_ChemicalList":"DNA Primers;ERBB2 protein, human;Receptor, Epidermal Growth Factor;Receptor, ErbB-2;PTPN9 protein, human;Protein Tyrosine Phosphatases, Non-Receptor",
        "Doc_meshdescriptors":"Base Sequence;Breast Neoplasms;Cell Division;Cell Line, Tumor;DNA Primers;Female;Humans;Neoplasm Invasiveness;Phosphorylation;Protein Tyrosine Phosphatases, Non-Receptor;Receptor, Epidermal Growth Factor;Receptor, ErbB-2;Signal Transduction;Substrate Specificity",
        "Doc_meshqualifiers":"enzymology;metabolism;pathology;physiology;metabolism;metabolism;physiology",
        "_version_":1605812307934314496},
      {
        "Doc_abstract":"Metastasis is the principal cause of death from breast cancer. ErbB2 (HER-2/neu) has been identified as an important regulator of metastatic potential of breast cancer. The present study investigated the molecular mechanism underlying the role of ErbB2 in malignant phenotypic conversion of MCF10A human breast epithelial cells which originally have 'normal' cell character. Here we report that ErbB2 induces invasion and migration of MCF10A cells though up-regulation of matrix metalloproteinase (MMP)-9. We also observed a marked reduction of an epithelial cell marker, E-cadherin, and an induction of vimentin in ErbB2-MCF10A cells, suggesting that epithelial-mesenchymal transition may play a role in the ErbB2-induced invasion and migration of MCF10A cells. Overexpression of ErbB2 significantly activated p38 MAPK and Akt, while Raf-1/MEK/ERK pathway was not activated by ErbB2. Using pharmacological inhibitors, we further show that p38 MAPK and Akt signaling pathways are crucial for the ErbB2-induced MMP-9 up-regulation, invasion and migration of MCF10A cells. Given that ErbB2 is one of the most important oncogenes in human breast cancer and thus is an attractive therapeutic target, our findings may provide a molecular basis for the promoting role of ErbB2 in breast cancer progression.",
        "Doc_title":"Overexpression of ErbB2 induces invasion of MCF10A human breast epithelial cells via MMP-9.",
        "Journal":"Cancer letters",
        "Do_id":"19022565",
        "Doc_ChemicalList":"DNA Primers;RNA, Small Interfering;Matrix Metalloproteinase 9",
        "Doc_meshdescriptors":"Base Sequence;Blotting, Western;Breast;Cell Line, Transformed;DNA Primers;Epithelial Cells;Gene Knockdown Techniques;Genes, erbB-2;Humans;MAP Kinase Signaling System;Matrix Metalloproteinase 9;Neoplasm Invasiveness;RNA, Small Interfering",
        "Doc_meshqualifiers":"enzymology;metabolism;pathology;enzymology;metabolism;metabolism",
        "_version_":1605884248653299712},
      {
        "Doc_abstract":"ErbB2 tyrosine kinase inhibitors (TKI) block tyrosine autophosphorylation and activation of the full-length transmembrane ErbB2 receptor (p185(ErbB2)). In addition to p185(ErbB2), truncated forms of ErbB2 exist in breast cancer cell lines and clinical tumors. The contribution of these truncated forms, specifically those expressed in tumor cell nuclei, to the development of therapeutic resistance to ErbB2 TKIs has not been previously shown. Here, we show that expression of a 95-kDa tyrosine phosphorylated form of ErbB2, herein referred to as p95L (lapatinib-induced p95) was increased in ErbB2(+) breast cancer cells treated with potent ErbB2 TKIs (lapatinib, GW2974). Expressed in tumor cell nuclei, tyrosine phosphorylation of p95L was resistant to inhibition by ErbB2 TKIs. Furthermore, the expression of p95L was increased in ErbB2(+) breast cancer models of acquired therapeutic resistance to lapatinib that mimic the clinical setting. Pretreatment with proteasome inhibitors blocked p95L induction in response to ErbB2 TKIs, implicating the role of the proteasome in the regulation of p95L expression. In addition, tyrosine phosphorylated C-terminal fragments of ErbB2, generated by alternate initiation of translation and similar in molecular weight to p95L, were expressed in tumor cell nuclei, where they too were resistant to inhibition by ErbB2 TKIs. When expressed in the nuclei of lapatinib-sensitive ErbB2(+) breast cancer cells, truncated ErbB2 rendered cells resistant to lapatinib-induced apoptosis. Elucidating the function of nuclear, truncated forms of ErbB2, and developing therapeutic strategies to block their expression and/or activation may enhance the clinical efficacy of ErbB2 TKIs.",
        "Doc_title":"Truncated ErbB2 expressed in tumor cell nuclei contributes to acquired therapeutic resistance to ErbB2 kinase inhibitors.",
        "Journal":"Molecular cancer therapeutics",
        "Do_id":"21673090",
        "Doc_ChemicalList":"Antineoplastic Agents;GTPase-Activating Proteins;Proteasome Inhibitors;Protein Kinase Inhibitors;Quinazolines;paxillin kinase linker protein, human;lapatinib;Receptor, ErbB-2;Proteasome Endopeptidase Complex",
        "Doc_meshdescriptors":"Animals;Antineoplastic Agents;Apoptosis;Breast Neoplasms;Cell Line, Tumor;Cell Nucleus;Drug Resistance, Neoplasm;Female;GTPase-Activating Proteins;Gene Expression Regulation, Neoplastic;Humans;Mice;Mice, Inbred NOD;Mice, SCID;Models, Biological;Phosphorylation;Proteasome Endopeptidase Complex;Proteasome Inhibitors;Protein Kinase Inhibitors;Quinazolines;Receptor, ErbB-2;Xenograft Model Antitumor Assays",
        "Doc_meshqualifiers":"pharmacology;genetics;genetics;metabolism;metabolism;genetics;metabolism;drug effects;drug effects;metabolism;pharmacology;pharmacology;antagonists & inhibitors;genetics",
        "_version_":1605746384959438851},
      {
        "Doc_abstract":"Increased breast cancer growth has been associated with increased expression of epidermal growth factor receptor (EGFR) and ErbB2 receptor tyrosine kinases (RTKs). Upon activation, RTKs may transmit their oncogenic signals by binding to the growth factor receptor bound protein-2 (Grb2), which in turn binds to SOS and activates the Ras/Raf/MEK/mitogen-activated protein (MAP) kinase pathway. Grb2 is important for the transformation of fibroblasts by EGFR and ErbB2; however, whether Grb2 is also important for the proliferation of breast cancer cells expressing these RTKs is unclear. We have used liposomes to deliver nuclease-resistant antisense oligodeoxynucleotides (oligos) specific for the GRB2 mRNA to breast cancer cells. Grb2 protein downregulation could inhibit breast cancer cell growth; the degree of growth inhibition was dependent upon the activation and/or endogenous levels of the RTKs. Grb2 inhibition led to MAP kinase inactivation in EGFR, but not in ErbB2, breast cancer cells, suggesting that different pathways might be used by EGFR and ErbB2 to regulate breast cancer growth.",
        "Doc_title":"Growth inhibition of breast cancer cells by Grb2 downregulation is correlated with inactivation of mitogen-activated protein kinase in EGFR, but not in ErbB2, cells.",
        "Journal":"Oncogene",
        "Do_id":"10022814",
        "Doc_ChemicalList":"Adaptor Proteins, Signal Transducing;GRB2 Adaptor Protein;GRB2 protein, human;Liposomes;Oligonucleotides, Antisense;Proteins;Epidermal Growth Factor;Receptor Protein-Tyrosine Kinases;Receptor, Epidermal Growth Factor;Receptor, ErbB-2;Calcium-Calmodulin-Dependent Protein Kinases",
        "Doc_meshdescriptors":"Adaptor Proteins, Signal Transducing;Breast Neoplasms;Calcium-Calmodulin-Dependent Protein Kinases;Cell Division;Down-Regulation;Epidermal Growth Factor;Female;GRB2 Adaptor Protein;Gene Expression Regulation, Neoplastic;Humans;Liposomes;Oligonucleotides, Antisense;Proteins;Receptor Protein-Tyrosine Kinases;Receptor, Epidermal Growth Factor;Receptor, ErbB-2;Signal Transduction;Tumor Cells, Cultured",
        "Doc_meshqualifiers":"metabolism;metabolism;drug effects;pharmacology;pharmacology;genetics;metabolism;metabolism",
        "_version_":1605763159019225088},
      {
        "Doc_abstract":"Cyclooxygenase 2 (HER-2) (Cox-2), an inducible form of Cox, is overexpressed in HER-2/neu-positive human breast cancers. The aim of this study was to determine whether celecoxib, a selective Cox-2 inhibitor, protected against HER-2/neu-induced experimental breast cancer. Cox-2 protein was detected in breast carcinomas from mouse mammary tumor virus (MMTV)/neu mice. Treatment with celecoxib (500 ppm) significantly reduced the incidence of mammary tumors in MMTV/neu mice (P = 0.003) and caused about a 50% reduction in mammary prostaglandin E2 (PGE2) levels. Because mammary glands from MMTV/neu mice expressed all four PGE2 receptor subtypes, we speculate that signaling through PGE2 receptors is important for mammary tumorigenesis. These results strengthen the rationale for developing clinical trials to determine whether selective Cox-2 inhibitors possess anticancer properties in humans at risk for breast cancer.",
        "Doc_title":"Celecoxib, a selective cyclooxygenase 2 inhibitor, protects against human epidermal growth factor receptor 2 (HER-2)/neu-induced breast cancer.",
        "Journal":"Cancer research",
        "Do_id":"12359744",
        "Doc_ChemicalList":"Anticarcinogenic Agents;Cyclooxygenase 2 Inhibitors;Cyclooxygenase Inhibitors;Isoenzymes;Membrane Proteins;Pyrazoles;Sulfonamides;Cyclooxygenase 2;PTGS2 protein, human;Prostaglandin-Endoperoxide Synthases;Receptor, ErbB-2;Celecoxib",
        "Doc_meshdescriptors":"Animals;Anticarcinogenic Agents;Celecoxib;Cyclooxygenase 2;Cyclooxygenase 2 Inhibitors;Cyclooxygenase Inhibitors;Female;Humans;Isoenzymes;Mammary Neoplasms, Experimental;Mammary Tumor Virus, Mouse;Membrane Proteins;Mice;Mice, Transgenic;Prostaglandin-Endoperoxide Synthases;Pyrazoles;Receptor, ErbB-2;Sulfonamides",
        "Doc_meshqualifiers":"pharmacology;pharmacology;antagonists & inhibitors;biosynthesis;enzymology;genetics;prevention & control;genetics;biosynthesis;antagonists & inhibitors;biosynthesis;genetics;pharmacology",
        "_version_":1605836842523951104},
      {
        "Doc_abstract":"Aim. Our aim the was to screen the commonly used Chinese herbs in order to detect changes in ERBB2 and ESR1 gene expression using MCF-7 cells. Methods. Using the MCF-7 human breast cancer cell line, cell cytotoxicity and proliferation were evaluated by MTT and trypan blue exclusion assays, respectively. A luciferase reporter assay was established by transient transfecting MCF-7 cells with plasmids containing either the ERBB2 or the ESR1 promoter region linked to the luciferase gene. Chinese herbal extracts were used to treat the cells at 24â€‰h after transfection, followed by measurement of their luciferase activity. The screening results were verified by Western blotting to measure HER2 and ER Î± protein expression. Results. At concentrations that induced little cytotoxicity, thirteen single herbal extracts and five compound recipes were found to increase either ERBB2 or ESR1 luciferase activity. By Western blotting, Si-Wu-Tang, Kuan-Shin-Yin, and Suan-Tsao-Ren-Tang were found to increase either HER2 or ER Î± protein expression. In addition, Ligusticum chuanxiong was shown to have a great effect on ERBB2 gene expression and synergistically with estrogen to stimulate MCF-7 cell growth. Conclusion. Our results provide important information that should affect clinical treatment strategies among breast cancer patients who are receiving hormonal or targeted therapies. ",
        "Doc_title":"Screening to Identify Commonly Used Chinese Herbs That Affect ERBB2 and ESR1 Gene Expression Using the Human Breast Cancer MCF-7 Cell Line.",
        "Journal":"Evidence-based complementary and alternative medicine : eCAM",
        "Do_id":"24987437",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605818719785713665},
      {
        "Doc_abstract":"Overexpression of ErbB2 is associated with poor prognosis in breast cancer. Targeting of ErbB2 is a very common therapeutic strategy in ErbB2-overexpressed breast cancer. Herceptin is the first approved and most widely used agent for ErbB2-targeting therapy in breast cancer. Even though the clinical application has been performed for more than 10 years, the exact mechanism underlying how Herceptin exhibits its effects has not been fully elucidated. In this study, we found that Herceptin could inhibit the expression of survivin in ErbB2-overexpressed cell lines. Overexpression of survivin could abrogate the inhibition of cell growth induced by Herceptin. Herceptin could reduce survivin expression at the transcriptional level. The beta-catenin/T-cell factor (TCF) pathway played a very crucial role in this cascade. We found that Herceptin could reduce tyrosine phosphorylation levels of ErbB2 and beta-catenin. Herceptin treatment induced degradation of beta-catenin protein, resulting in reduced binding affinity of beta-catenin/TCF4 to the promoter region of survivin. When we cross-mutated the TCF4 binding sites in the promoter region of survivin, the reduction of survivin promoter activity almost diminished. Taken together, we showed that Herceptin could inhibit survivin expression through the ErbB2-beta-catenin/TCF4-survivin pathway in ErbB2-overexpressed breast cancer cells. This indicates that there may be a new cascade axis from ErbB2 to survivin.",
        "Doc_title":"Inhibition of ErbB2 by Herceptin reduces survivin expression via the ErbB2-beta-catenin/TCF4-survivin pathway in ErbB2-overexpressed breast cancer cells.",
        "Journal":"Cancer science",
        "Do_id":"20331626",
        "Doc_ChemicalList":"Antibodies, Monoclonal;Antibodies, Monoclonal, Humanized;BIRC5 protein, human;Basic Helix-Loop-Helix Leucine Zipper Transcription Factors;Inhibitor of Apoptosis Proteins;Microtubule-Associated Proteins;TCF4 protein, human;Transcription Factors;beta Catenin;Phosphatidylinositol 3-Kinases;ERBB2 protein, human;Receptor, ErbB-2;Proto-Oncogene Proteins c-akt;Trastuzumab",
        "Doc_meshdescriptors":"Antibodies, Monoclonal;Antibodies, Monoclonal, Humanized;Basic Helix-Loop-Helix Leucine Zipper Transcription Factors;Breast Neoplasms;Cell Line, Tumor;Female;Humans;Inhibitor of Apoptosis Proteins;Microtubule-Associated Proteins;Phosphatidylinositol 3-Kinases;Proto-Oncogene Proteins c-akt;Receptor, ErbB-2;Transcription Factors;Trastuzumab;beta Catenin",
        "Doc_meshqualifiers":"pharmacology;physiology;pathology;antagonists & inhibitors;genetics;physiology;physiology;physiology;antagonists & inhibitors;physiology;physiology;physiology",
        "_version_":1605754254869397504},
      {
        "Doc_abstract":"The ErbB2 (Her2/neu epidermal growth receptor family) oncogene is overexpressed in 30% to 40% of human breast cancers. Cyclin D1 is the regulatory subunit of the holoenzyme that phosphorylates and inactivates the retinoblastoma (pRb) tumor suppressor and is an essential downstream target of ErbB2-induced tumor growth. Herein, we demonstrate that ErbB2 induces the activity of the Notch signaling pathway. ErbB2 induction of DNA synthesis, contact-independent growth, and mammosphere induction required Notch1. ErbB2-induced cyclin D1 and cyclin D1 expression was suficient to induce Notch1 activity, and conversely, genetic deletion of Notch1 in mammary epithelial cells using foxed Notch (Notch(fl/fl)) mice demonstrated that cyclin D1 is induced by Notch1. Genetic deletion of cyclin D1 or small interfering RNA (siRNA) to cyclin D1-reduced Notch1 activity and reintroduction of cyclin D1 into cyclin D1-deficient cells restored Notch1 activity through the inhibition of Numb, an endogenous inhibitor of Notch1 activity. Thus, cyclin D1 functions downstream as a genetic target of Notch1, amplifies Notch1 activity by repressing Numb, and identifies a novel pathway by which ErbB2 induces Notch1 activity via the induction of cyclin D1.",
        "Doc_title":"ErbB2 induces Notch1 activity and function in breast cancer cells.",
        "Journal":"Clinical and translational science",
        "Do_id":"20443831",
        "Doc_ChemicalList":"DNA, Neoplasm;Neuregulin-1;Receptor, Notch1;Cyclin D1;ERBB2 protein, human;Receptor, ErbB-2;Amyloid Precursor Protein Secretases",
        "Doc_meshdescriptors":"Amyloid Precursor Protein Secretases;Animals;Breast Neoplasms;Cell Line, Tumor;Cyclin D1;DNA, Neoplasm;Female;Humans;Mice;Neuregulin-1;Receptor, ErbB-2;Receptor, Notch1;Signal Transduction;Tumor Stem Cell Assay",
        "Doc_meshqualifiers":"metabolism;metabolism;pathology;metabolism;biosynthesis;metabolism;metabolism;metabolism",
        "_version_":1605741930432430081},
      {
        "Doc_abstract":"Breast cancers overexpressing the ErbB2 (HER2) receptor tyrosine kinase oncogene are treated with targeted therapies such as trastuzumab (Herceptin), an anti-ErbB2 antibody, and lapatinib (GW572016/Tykerb), a selective small molecule inhibitor of ErbB2 and epidermal growth factor receptor tyrosine kinases that was recently approved for ErbB2+ breast cancers that progressed on trastuzumab-based therapy. The efficacy of lapatinib as a monotherapy or in combination with chemotherapy, however, is limited by the development of therapeutic resistance that typically occurs within 12 months of starting therapy. In contrast to small molecule inhibitors targeting other receptor tyrosine kinases where resistance has been attributed to mutations within the targeted receptor, ErbB2 mutations have not been commonly found in breast tumors. Instead, acquired resistance to lapatinib seems to be mediated by redundant survival pathways that are activated as a consequence of marked inhibition of ErbB2 kinase activity. For example, inhibition of phosphatidylinositol3 kinase-Akt in lapatinib-treated cells leads to derepression of FOXO3A, a transcription factor that up-regulates estrogen receptor (ER) signaling, resulting in a switch in the regulation of survival factors (e.g., survivin) and cell survival from ErbB2 alone to ER and ErbB2 in resistant cells. In this review, we discuss the effects of lapatinib on signaling networks in ErbB2+ breast cancer cells to elucidate potential mechanisms of therapeutic resistance and strategies to overcome or prevent its development.",
        "Doc_title":"Acquired resistance to small molecule ErbB2 tyrosine kinase inhibitors.",
        "Journal":"Clinical cancer research : an official journal of the American Association for Cancer Research",
        "Do_id":"18980964",
        "Doc_ChemicalList":"Antineoplastic Agents;Protein Kinase Inhibitors;Quinazolines;lapatinib;ERBB2 protein, human;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Antineoplastic Agents;Antineoplastic Combined Chemotherapy Protocols;Breast Neoplasms;Drug Resistance, Neoplasm;Humans;Models, Biological;Protein Kinase Inhibitors;Quinazolines;Receptor, ErbB-2;Signal Transduction",
        "Doc_meshqualifiers":"therapeutic use;therapeutic use;drug therapy;metabolism;therapeutic use;therapeutic use;antagonists & inhibitors;metabolism;drug effects",
        "_version_":1605762686747934720},
      {
        "Doc_abstract":"The erbB2 gene is often found amplified and/or overexpressed in breast cancer in which it has clinical relevance as prognostic and predictive factor. It is involved in growth regulation and has a role in the initial phases of cell proliferation, while in vivo and in vitro studies have suggested an involvement also in cell invasion and metastases. It is not clear if these two roles are mutually exclusive and little is known about the mechanisms by which erbB2 may be involved in the control of these processes. Our previous data on patient series suggested that erbB2 might be regulated in different ways depending on the neoplastic status of the cells and that it might be involved in different regulatory pathways. To test this hypothesis we have measured the serum-dependent regulation of erbB2 as a function of the expression of the antimetastatic gene, nm23, in a panel of breast cancer cell lines. The experimental model consisted of three cell lines having different proliferative and invasive potentials: a non-metastatic estrogen receptor (ER) positive cell line, MCF-7; a highly metastatic ER negative cell line, MDA-MB435; and the MDA-MB435 cell line transfected with the nm23-H1 antimetastatic gene (clone H1-177) which has lost the ability to invade and metastasize. We first analysed the serum concentration dependence of invasion and proliferation after 3-4 days of serum deprivation confirming the proliferative and invasive potential of the three cell lines. Modulation of erbB2 expression by different concentrations of serum was then studied. ErbB2 expression in MCF-7 cells showed a complex pattern due to serum modulation, whereas, it was not longer regulated by serum in the MDA-MB435 cell line. In H1-177 cells the erbB2 response to serum was restored and it was very similar to that observed in MCF-7. These data showed a tight association between nm23 and the regulation of erbB2 expression by serum factors suggesting that the role of erbB2 in invasion might be dependent on nm23 expression.",
        "Doc_title":"ErbB2 and the antimetastatic nm23/NDP kinase in regulating serum induced breast cancer invasion.",
        "Journal":"International journal of molecular medicine",
        "Do_id":"12792823",
        "Doc_ChemicalList":"Antineoplastic Agents;NM23 Nucleoside Diphosphate Kinases;Proteins;Receptor, ErbB-2;NME1 protein, human;Nucleoside-Diphosphate Kinase",
        "Doc_meshdescriptors":"Antineoplastic Agents;Breast Neoplasms;Cell Division;Dose-Response Relationship, Drug;Female;Humans;NM23 Nucleoside Diphosphate Kinases;Neoplasm Invasiveness;Nucleoside-Diphosphate Kinase;Proteins;Receptor, ErbB-2",
        "Doc_meshqualifiers":"blood;pharmacology;metabolism;pathology;physiology;pathology;prevention & control;pharmacology;blood;metabolism",
        "_version_":1605896208520314880},
      {
        "Doc_abstract":"One of the most common genetic aberrations associated with breast cancer is the amplification and overexpression of the ERBB2 proto-oncogene located at chromosome 17, bands q12-21. The amplification/overexpression occurs in 25 to 30% of all breast cancers. In breast cancer, aneusomy of chromosome 17, either monosomy or polysomy, is frequently observed by conventional cytogenetics and fluorescence in situ hybridization (FISH). The aim of this study was to discover whether or not numerical aberrations on chromosome 17 have a correlation to the amplification or overexpression of the ERBB2 gene and to analyze their clinical implications in subgroups showing 2+ or 3+ positive scores by immunohistochemistry (IHC).;We used FISH on a series of 175 formalin-fixed paraffin-embedded breast carcinomas to detect ERBB2 amplification, using a dual-probe system for the simultaneous enumeration of the ERBB2 gene and the centromeric region of chromosome 17, as well as using IHC to detect overexpression. We analyzed clinical and pathological variables in a subgroup of patients with 2+ and 3+ IHC scores (147 patients), to describe any differences in clinicopathological characteristics between polysomic and non-polysomic cases with the use of the chi2 test.;We found 13% of cases presenting polysomy, and three cases presented monosomy 17 (2%). According to the status of the ERBB2 gene, instances of polysomy 17 were more frequently observed in non-amplified cases than in FISH-amplified cases, suggesting that the mechanism for ERBB2 amplification is independent of polysomy 17. Polysomy 17 was detected in patients with 2+ and 3+ IHC scores. We found that nodal involvement was more frequent in polysomic than in non-polysomic cases (P = 0.046).;The determination of the copy number of chromosome 17 should be incorporated into the assesment of ERBB2 status. It might also be helpful to differentiate a subgroup of breast cancer patients with polysomy of chromosome 17 and overexpression of ERBB2 protein that probably have genetic and clinical differences.",
        "Doc_title":"Polysomy of chromosome 17 in breast cancer tumors showing an overexpression of ERBB2: a study of 175 cases using fluorescence in situ hybridization and immunohistochemistry.",
        "Journal":"Breast cancer research : BCR",
        "Do_id":"15743507",
        "Doc_ChemicalList":"Receptor, ErbB-2",
        "Doc_meshdescriptors":"Breast Neoplasms;Chromosome Aberrations;Chromosomes, Human, Pair 18;Female;Gene Amplification;Gene Dosage;Gene Expression Profiling;Humans;Immunohistochemistry;In Situ Hybridization, Fluorescence;Prospective Studies;Receptor, ErbB-2;Up-Regulation",
        "Doc_meshqualifiers":"genetics;biosynthesis;genetics",
        "_version_":1605809071583133696},
      {
        "Doc_abstract":"Amplification of the ERBB2 oncogene at 17q12 has been well documented in breast cancer and has been shown to contribute to a poor clinical outcome. However, systematic surveys of copy number and expression levels of all genes within the 17q12 region have not been performed. Here, we used cDNA and comparative genomic hybridization microarray technologies to undertake a broad survey of genes involved in the 17q12 amplification in breast cancer. A chromosomal region-specific cDNA microarray containing 217 expressed sequence tag (EST) clones from 17q12 was constructed and used for parallel analysis of gene copy numbers and expression levels in seven breast cancer cell lines allowing direct identification of genes whose expression is elevated because of an increase in copy number in this chromosomal region. The copy number and expression survey identified 12 transcripts that showed a consistent pattern of increased copy number and expression in three or more of the 17q12-amplified cell lines. As expected, these included ERBB2 as well as the GRB7 and MLN64 genes previously shown to be coamplified with ERBB2. In addition, five other known genes and four uncharacterized ESTs were also found to be consistently activated by amplification in these breast cancer cell lines. Amplicon mapping by fluorescence in situ hybridization revealed a minimal common region of amplification containing four highly expressed genes, ERBB2, GRB7, MLN64, and an uncharacterized EST 48582. Furthermore, several other genes, although not located in the minimal common region of amplification, showed a correlated pattern of amplification and expression indicating that they might play a role in breast cancers with the 17q12 amplification. In conclusion, parallel analysis of gene copy number and expression levels by cDNA microarray can be used to directly identify candidate target genes involved in amplifications. Our results show that the 17q12 amplification in breast cancer leads to the simultaneous elevation of expression levels of several genes.",
        "Doc_title":"New amplified and highly expressed genes discovered in the ERBB2 amplicon in breast cancer by cDNA microarrays.",
        "Journal":"Cancer research",
        "Do_id":"11719455",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"Breast Neoplasms;Chromosomes, Human, Pair 17;Gene Amplification;Gene Dosage;Gene Expression;Genes, erbB-2;Genome, Human;Humans;In Situ Hybridization, Fluorescence;Oligonucleotide Array Sequence Analysis;Physical Chromosome Mapping;Tumor Cells, Cultured",
        "Doc_meshqualifiers":"genetics;genetics;genetics",
        "_version_":1605751319032758272},
      {
        "Doc_abstract":"All-trans retinoic acid (ATRA), the only clinically available cyto-differentiating agent, has potential for the therapy/chemoprevention of breast carcinoma. Given the heterogeneous nature of this tumor, a rational use of ATRA and derivatives (retinoids) in the clinic requires the identification of patients that would benefit from retinoid-based protocols. Here, we demonstrate that 23-32% of the human ERBB2(+) breast cancers show coamplification of retinoic acid receptor alpha (RARA), encoding the retinoic acid receptor, RARÎ±. This represents a novel subtype of breast cancer characterized by remarkable sensitivity to ATRA and RARÎ± agonists, regardless of positivity to the estrogen receptor, a known modulator of retinoid sensitivity. In estrogen-receptor-negative cellular models showing coamplification of ERBB2 and RARA, simultaneous targeting of the corresponding gene products with combinations of lapatinib and ATRA causes synergistic growth inhibition, cyto-differentiation and apoptosis. This provides proof-of-principle that coamplification of ERBB2 and RARA can be exploited for the stratified and targeted therapy of a novel subtype of breast cancer patients, with an approach characterized by tumor cell selectivity and low predicted toxicity. The available cellular models were exploited to define the molecular mechanisms underlying the antitumor activity of combinations between lapatinib and ATRA. Global gene expression and functional approaches provide evidence for three components of the antiproliferative/apoptotic responses triggered by lapatinib+ATRA. Induction of the retinoid-dependent RARRES3 protein by ATRA stabilizes the effect of lapatinib inhibiting ERBB2 phosphorylation. Upregulation and activation of the transcription factor FOXO3A integrates ATRA-dependent transcriptional and lapatinib-dependent posttranscriptional signals, controlling the levels of effector proteins like the antiapoptotic factor, BIRC5. Stimulation of the TGFÎ² pathway by ATRA mediates other components of the apoptotic process set in motion by simultaneous targeting of ERBB2 and RARÎ±.",
        "Doc_title":"Synergistic antitumor activity of lapatinib and retinoids on a novel subtype of breast cancer with coamplification of ERBB2 and RARA.",
        "Journal":"Oncogene",
        "Do_id":"22056878",
        "Doc_ChemicalList":"Antineoplastic Agents;FOXO3 protein, human;Forkhead Box Protein O3;Forkhead Transcription Factors;Quinazolines;RARA protein, human;Receptors, Retinoic Acid;Retinoic Acid Receptor alpha;Smad3 Protein;Transforming Growth Factor beta;lapatinib;Tretinoin;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Antineoplastic Agents;Breast Neoplasms;Cell Line, Tumor;Drug Synergism;Forkhead Box Protein O3;Forkhead Transcription Factors;Gene Amplification;Humans;Phosphorylation;Quinazolines;Receptor, ErbB-2;Receptors, Retinoic Acid;Retinoic Acid Receptor alpha;Smad3 Protein;Transcription, Genetic;Transcriptome;Transforming Growth Factor beta;Tretinoin",
        "Doc_meshqualifiers":"pharmacology;genetics;metabolism;metabolism;drug effects;drug effects;pharmacology;antagonists & inhibitors;genetics;metabolism;genetics;metabolism;metabolism;drug effects;drug effects;metabolism;pharmacology",
        "_version_":1605792020674117632},
      {
        "Doc_abstract":"ErbB2 receptor (HER2) tyrosine kinase was overexpressed in about 25% breast cancers, and was correlated with extremely aggressive phenotype and poor prognosis. Lapatinib, an oral, reversible inhibitor of both ErbB2 and EGFR tyrosine kinases, was approved in combination with capecitabine for treating advanced stage ErbB2 positive breast cancers. However, the clinical response of Lapatinib was seriously limited by the drug resistance. We established the Lapatinib resistant breast cancer cell lines and the preliminary data demonstrated the increased autophagosome formation in the stable resistant cells. The resistant cells were re-sensitized to Lapatinib after treated with autophagy inhibitor. According to our preliminary data and related reference, we hypothesized that autophagy could facilitate the ErbB2 positive breast cancer cells to be Lapatinib resistant and promoted the survival of the resistant cells. The abrogation of autophagy might restore the drug sensitivity. Autophagy might be one of the targets to overcome the Lapatinib resistance.",
        "Doc_title":"Autophagy facilitates the Lapatinib resistance of HER2 positive breast cancer cells.",
        "Journal":"Medical hypotheses",
        "Do_id":"21570197",
        "Doc_ChemicalList":"Antineoplastic Agents;Protein Kinase Inhibitors;Quinazolines;lapatinib;ERBB2 protein, human;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Antineoplastic Agents;Autophagy;Breast Neoplasms;Drug Resistance, Neoplasm;Female;Humans;Models, Biological;Protein Kinase Inhibitors;Quinazolines;Receptor, ErbB-2",
        "Doc_meshqualifiers":"metabolism;therapeutic use;physiology;drug therapy;physiology;metabolism;therapeutic use;metabolism;therapeutic use;metabolism",
        "_version_":1605804940674990081},
      {
        "Doc_abstract":"Multiple clinical trials in recent years have shown that breast cancer patients with primary tumors overexpressing ERBB2 can be effectively treated with specific forms of modern anti-ERBB2-targeted therapy. The aim of the present study was to analyze the expression of the ERBB2 (HER2) protein in uterine sarcomas, in order to investigate the possibility of applying this treatment modality in uterine sarcomas.;The expression of ERBB2 has been analyzed immunohistochemically in formalin-fixed paraffin-embedded primary uterine sarcomas (n = 11).;Using a semi-quantitative immunohistochemical score, we found that ERBB2 expression was very weak in the majority of tumors, with only three sarcomas showing moderate ERBB2 expression. Published studies evaluating the same issue in small numbers of uterine sarcomas reached similar findings.;Overall, ERBB2 expression appears to be weak in uterine sarcomas. However, targeted treatment might still be feasible in a subgroup of patients with uterine sarcomas overexpressing ERBB2.",
        "Doc_title":"ERBB2 (HER2) protein expression in uterine sarcomas.",
        "Journal":"European journal of gynaecological oncology",
        "Do_id":"19697624",
        "Doc_ChemicalList":"Receptor, ErbB-2",
        "Doc_meshdescriptors":"Adult;Aged;Female;Humans;Immunohistochemistry;Leiomyosarcoma;Middle Aged;Receptor, ErbB-2;Sarcoma;Uterine Neoplasms",
        "Doc_meshqualifiers":"metabolism;metabolism;drug therapy;metabolism;drug therapy;metabolism",
        "_version_":1605797572245454848},
      {
        "Doc_abstract":"Evaluating the chromatinized erbB2 gene in nuclei from breast cancer cells expressing varying levels of ErbB2 transcripts, we identified a nuclease-sensitive site within a 0.22 kb region of maximum enhancer activity centered over a conserved 28 bp polypurine(GGA)-polypyrimidine(TCC) mirror-repeat and an adjacent essential Ets binding site (EBS). Promoter footprinting with nuclear extracts reveals an intense Ets hypersensitivity site at the EBS whose degree of intensity correlates with the level of cellular ErbB2 expression. In vitro mapping assays show that the supercoiled erbB2 promoter forms an internal triplex structure (Hr-DNA) at the mirror-repeat element. Mutations preventing Hr-DNA formation can enhance erbB2 promoter activity in human breast cancer cells, a result consistent with previous demonstration that Ets-erbB2 promoter complexes cannot form when the mirror-repeat is engaged in triplex binding, and new results suggesting that Ets binding induces severe promoter bending that may restrict local triplex formation. In addition to previously described erbB2-regulating breast cancer Ets factors (PEA3, ESX/Elf-3), Elf-1 is now shown to be another endogenously expressed Ets candidate capable of binding to and upregulating the erbB2 promoter. Given current strategies to transcriptionally inhibit ErbB2 overexpression, including development of novel erbB2 promoter-targeted therapeutics, an EBS-targeted approach is presented using chimeric Ets proteins that strongly repress erbB2 promoter activity.",
        "Doc_title":"Ets regulation of the erbB2 promoter.",
        "Journal":"Oncogene",
        "Do_id":"11175365",
        "Doc_ChemicalList":"DNA, Superhelical;DNA-Binding Proteins;ELF3 protein, human;Macromolecular Substances;Neoplasm Proteins;Proto-Oncogene Proteins;Proto-Oncogene Proteins c-ets;Trans-Activators;Transcription Factors;proto-oncogene protein Spi-1",
        "Doc_meshdescriptors":"Adenocarcinoma;Binding Sites;Breast Neoplasms;DNA Footprinting;DNA, Superhelical;DNA-Binding Proteins;Enhancer Elements, Genetic;Female;Forecasting;Gene Expression Regulation, Neoplastic;Gene Silencing;Genes, erbB-2;Genetic Therapy;Humans;Macromolecular Substances;Multigene Family;Neoplasm Proteins;Nucleic Acid Conformation;Proto-Oncogene Proteins;Proto-Oncogene Proteins c-ets;Repetitive Sequences, Nucleic Acid;Trans-Activators;Transcription Factors;Transcription, Genetic;Transfection",
        "Doc_meshqualifiers":"genetics;metabolism;pathology;genetics;metabolism;pathology;genetics;metabolism;metabolism;genetics;metabolism;metabolism;metabolism;metabolism",
        "_version_":1605853656632000512},
      {
        "Doc_abstract":"Amplification and overexpression of erbB2 (Her-2/neu) proto-oncogene has been linked to human malignancies including tumors of the breast, ovary, and stomach. It has been implicated in tumor growth, sensitivity to standard chemotherapy, prognosis of patients, and disease-free survival. Although the clinical use of trastuzumab (Herceptin) has prolonged the survival of breast cancer patients with erbB2-overexpressing tumors, there is an urgent need for more potent and orally bioavailable small-molecule inhibitors. CP-724,714 is a potent inhibitor of erbB2 receptor autophosphorylation in intact cells and is currently undergoing phase I clinical trials. Here, we describe the effects of CP-724,714 in vitro and in vivo in human breast cancer models. CP-724,714 is selective for inhibiting growth of HER2-driven cell lines. In addition, we show that it induces G1 cell cycle block in erbB2-overexpressing BT-474 human breast carcinoma cells and inhibits erbB2 autophosphorylation in xenografts when administered p.o. to athymic mice. It induces a marked reduction of extracellular signal-regulated kinase and Akt phosphorylation, tumor cell apoptosis, and release of caspase-3. P.o. administration (q.d. or b.i.d.) of CP-724,714 inhibits the growth of erbB2-overexpressing tumors in athymic mice without overt adverse effects.",
        "Doc_title":"Discovery and pharmacologic characterization of CP-724,714, a selective ErbB2 tyrosine kinase inhibitor.",
        "Journal":"Cancer research",
        "Do_id":"17942920",
        "Doc_ChemicalList":"2-methoxy-N-(3-(4-((3-methyl-4-((6-methyl-3-pyridinyl)oxy)phenyl)amino)-6-quinazolinyl)-2-propenyl)acetamide;Protein Kinase Inhibitors;Quinazolines;Receptor, ErbB-2;Proto-Oncogene Proteins c-akt;Extracellular Signal-Regulated MAP Kinases",
        "Doc_meshdescriptors":"Animals;Apoptosis;Breast Neoplasms;Cell Cycle;Cell Growth Processes;Extracellular Signal-Regulated MAP Kinases;Female;Humans;Mice;Mice, Nude;NIH 3T3 Cells;Phosphorylation;Protein Kinase Inhibitors;Proto-Oncogene Proteins c-akt;Quinazolines;Receptor, ErbB-2;Xenograft Model Antitumor Assays",
        "Doc_meshqualifiers":"drug effects;drug therapy;metabolism;pathology;drug effects;drug effects;metabolism;drug effects;pharmacology;metabolism;pharmacology;antagonists & inhibitors;metabolism",
        "_version_":1605784475751415808},
      {
        "Doc_abstract":"An anti-ERBB2 antibody, trastuzumab, has been shown to be highly efficient in the treatment of metastatic breast cancers overexpressing the ERBB2 gene. It has been suggested that overexpression and even amplification of ERBB2 may play a role in the development of prostate cancer. Here, we have analyzed gene copy number and expression of the ERBB2 gene in both androgen-dependent primary and metastatic tumors, as well as recurrent hormone-refractory tumors. The expression levels were compared to the expression of ERBB2 in breast cancers with or without ERBB2 gene amplification. Of 126 prostate tumors, chromogenic in situ hybridization (CISH) revealed only 1 case containing borderline (six to eight copies) amplifications of ERBB2. This hormone-refractory tumor, however, did not express ERBB2 protein. Immunohistochemical staining of ERBB2 protein was negative (0 or 1+ intensity) in all prostate samples (n = 124) analyzed. To quantitate the level of ERBB2 mRNA expression in prostate tumors (n = 34) and cell lines (n = 3), as well as in breast tumors (n = 30) and cell lines (n = 16), real-time reverse transcriptase-polymerase chain reaction (LightCycler) methodology was used. The expression level was similar in all prostate tumor types and corresponded to the level of expression in breast carcinomas without ERBB2 amplification. Breast tumors with ERBB2 amplification expressed, on average, approximately 20 times (P < 0.001) higher mRNA levels than prostate tumors or breast carcinomas without the gene amplification. In conclusion, the expression of ERBB2 in prostate cancer is relatively low, and is not altered during disease progression. Thus, it is unlikely that treatment modalities relying on the overexpression of ERBB2 gene will be useful in treating prostate cancer.",
        "Doc_title":"Expression and gene copy number analysis of ERBB2 oncogene in prostate cancer.",
        "Journal":"The American journal of pathology",
        "Do_id":"11786427",
        "Doc_ChemicalList":"Receptor, ErbB-2",
        "Doc_meshdescriptors":"Breast Neoplasms;Female;Gene Amplification;Gene Dosage;Gene Expression;Genes, erbB-2;Humans;Immunohistochemistry;In Situ Hybridization;Male;Prostatic Neoplasms;Receptor, ErbB-2;Reverse Transcriptase Polymerase Chain Reaction;Tumor Cells, Cultured",
        "Doc_meshqualifiers":"genetics;metabolism;genetics;methods;genetics;metabolism;metabolism",
        "_version_":1605812260210475008},
      {
        "Doc_abstract":"The objective of this study was to assess the anti-tumor efficacy of rapamycin alone or in combination with herceptin in breast cancer. A total of 20 human breast cancer lines were examined for expression of various receptor tyrosine kinases and activation of their down stream signaling molecules, as well as for their invasion and colony forming ability. The ErbB2 and PI3 kinase pathway inhibitors were tested for the inhibition on breast cancer cell growth and tumor development. Seven of the 20 lines displayed an elevated level of ErbB2, others had varying level of EGF, IGF-1 or insulin receptor. Over 30% of the lines also had constitutive activation of Akt and MAP kinase. The lines displayed a wide range of colony forming and invasion ability. The PI3 kinase pathway inhibitors LY294002 and rapamycin inhibited the colony forming ability of all of the lines with the ErbB2 overexpressing lines having a higher sensitivity. A similar trend was observed for inhibition of invasion by LY294002. Rapamycin alone and additively together with herceptin inhibited the breast cancer cell growth especially in ErbB2 overexpressing cells. Rapamycin and herceptin synergistically inhibited tumor growth and endpoint tumor load in a xenograft model using a MCF-7 subline and in a MMTV-ErbB2 transgenic model. Rapamycin and herceptin significantly reduced the level of cyclin D1 and D3 and increased the cleavage of caspase 3 suggesting an increased apoptosis. Our results suggest that rapamycin together with herceptin has an enhanced anti-cancer effect and could be developed as an improved therapeutic regimen for breast cancer.",
        "Doc_title":"Rapamycin together with herceptin significantly increased anti-tumor efficacy compared to either alone in ErbB2 over expressing breast cancer cells.",
        "Journal":"International journal of cancer",
        "Do_id":"17304506",
        "Doc_ChemicalList":"Antineoplastic Agents;CCND3 protein, human;Ccnd3 protein, mouse;Cyclin D3;Cyclins;Intercellular Signaling Peptides and Proteins;herstatin;Cyclin D1;Phosphatidylinositol 3-Kinases;Receptor Protein-Tyrosine Kinases;Receptor, ErbB-2;Proto-Oncogene Proteins c-akt;Mitogen-Activated Protein Kinases;Caspase 3;Sirolimus",
        "Doc_meshdescriptors":"Animals;Antineoplastic Agents;Breast Neoplasms;Caspase 3;Cell Line, Tumor;Cell Proliferation;Cyclin D1;Cyclin D3;Cyclins;Female;Humans;Intercellular Signaling Peptides and Proteins;Mice;Mice, Inbred BALB C;Mitogen-Activated Protein Kinases;Neoplasm Invasiveness;Phosphatidylinositol 3-Kinases;Proto-Oncogene Proteins c-akt;Receptor Protein-Tyrosine Kinases;Receptor, ErbB-2;Signal Transduction;Sirolimus;Xenograft Model Antitumor Assays",
        "Doc_meshqualifiers":"pharmacology;metabolism;pathology;metabolism;drug effects;metabolism;metabolism;pharmacology;metabolism;pathology;metabolism;metabolism;metabolism;metabolism;drug effects;pharmacology",
        "_version_":1605791156779614208},
      {
        "Doc_abstract":"Activation of Src kinase plays important roles in the development of many neoplasias. Most of the previous Src studies focused on the deregulation of Src kinase activity. The deregulated Src protein synthesis and stability in mediating malignant phenotypes of cancer cells, however, have been neglected. While investigating the signal transduction pathways contributing to ErbB2-mediated metastasis, we found that ErbB2-activated breast cancer cells that had higher metastatic potentials also had increased Src activity compared with ErbB2 low-expressing cells. The increased Src activity in ErbB2-activated cells paralleled higher Src protein levels, whereas Src RNA levels were not significantly altered. Our studies revealed two novel mechanisms that are involved in Src protein up-regulation and activation by ErbB2: (a) ErbB2 increased Src translation through activation of the Akt/mammalian target of rapamycin/4E-BP1 pathway and (b) ErbB2 increased Src stability most likely through the inhibition of the calpain protease. Furthermore, inhibition of Src activity by a Src-specific inhibitor, PP2, or a Src dominant-negative mutant dramatically reduced ErbB2-mediated cancer cell invasion in vitro and metastasis in an experimental metastasis animal model. Together, activation of ErbB2 and downstream signaling pathways can lead to increased Src protein synthesis and decreased Src protein degradation resulting in Src up-regulation and activation, which play critical roles in ErbB2-mediated breast cancer invasion and metastasis.",
        "Doc_title":"ErbB2 promotes Src synthesis and stability: novel mechanisms of Src activation that confer breast cancer metastasis.",
        "Journal":"Cancer research",
        "Do_id":"15753384",
        "Doc_ChemicalList":"Adaptor Proteins, Signal Transducing;Carrier Proteins;EIF4EBP1 protein, human;Eif4ebp1 protein, mouse;Phosphoproteins;Proto-Oncogene Proteins;Protein Kinases;MTOR protein, human;TOR Serine-Threonine Kinases;mTOR protein, mouse;Receptor, ErbB-2;Proto-Oncogene Proteins pp60(c-src);AKT1 protein, human;Protein-Serine-Threonine Kinases;Proto-Oncogene Proteins c-akt;Phosphoprotein Phosphatases;Calpain",
        "Doc_meshdescriptors":"Adaptor Proteins, Signal Transducing;Animals;Breast Neoplasms;Calpain;Carrier Proteins;Enzyme Activation;Enzyme Stability;Female;Genes, Dominant;Humans;Lung Neoplasms;Mice;Mice, Inbred ICR;Mice, SCID;Neoplasm Invasiveness;Phosphoprotein Phosphatases;Phosphoproteins;Phosphorylation;Protein Biosynthesis;Protein Kinases;Protein-Serine-Threonine Kinases;Proto-Oncogene Proteins;Proto-Oncogene Proteins c-akt;Proto-Oncogene Proteins pp60(c-src);Receptor, ErbB-2;Signal Transduction;TOR Serine-Threonine Kinases;Tumor Cells, Cultured",
        "Doc_meshqualifiers":"metabolism;pathology;antagonists & inhibitors;metabolism;metabolism;secondary;pharmacology;metabolism;drug effects;metabolism;metabolism;metabolism;chemistry;genetics;metabolism;metabolism",
        "_version_":1605895642590216192},
      {
        "Doc_abstract":"Overexpression of the ERBB2 kinase is observed in about one-third of breast cancer patients and the dual ERBB1/ERBB2 kinase inhibitor lapatinib was recently approved for the treatment of advanced ERBB2-positive breast cancer. Mutations in the ERBB2 receptor have recently been reported in breast cancer at diagnosis and also in gastric, colorectal and lung cancer. These mutations may have an impact on the clinical responses achieved with lapatinib in breast cancer and may also have a potential impact on the use of lapatinib in other solid cancers. However, the sensitivity of lapatinib towards clinically observed ERBB2 mutations is not known.;We cloned a panel of 8 clinically observed ERBB2 mutations, established stable cell lines and characterized their sensitivity towards lapatinib and alternative ERBB2 inhibitors. Both lapatinib-sensitive and lapatinib-resistant ERBB2 mutations were observed. Interestingly, we were able to generate lapatinib resistance mutations in wt-ERBB2 cells incubated with lapatinib for prolonged periods of time. This indicates that these resistance mutations may also cause secondary resistance in lapatinib-treated patients. Lapatinib-resistant ERBB2 mutations were found to be highly resistant towards AEE788 treatment but remained sensitive towards the dual irreversible inhibitors CL-387785 and WZ-4002.;Patients harbouring certain ERBB2 kinase domain mutations at diagnosis may not benefit from lapatinib treatment. Moreover, secondary lapatinib resistance may develop due to kinase domain mutations. Irreversible ERBB2 inhibitors may offer alternative treatment options for breast cancer and other solid tumor patients harbouring lapatinib resistance mutations. In addition, these inhibitors may be of interest in the scenario of secondary lapatinib resistance.",
        "Doc_title":"Differential sensitivity of ERBB2 kinase domain mutations towards lapatinib.",
        "Journal":"PloS one",
        "Do_id":"22046346",
        "Doc_ChemicalList":"Antineoplastic Agents;Protein Kinase Inhibitors;Quinazolines;lapatinib;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Antineoplastic Agents;Breast Neoplasms;Cell Line, Tumor;Drug Resistance, Neoplasm;Female;Humans;Mutation;Protein Kinase Inhibitors;Quinazolines;Receptor, ErbB-2",
        "Doc_meshqualifiers":"drug therapy;genetics;pharmacology;genetics",
        "_version_":1605762639897559040},
      {
        "Doc_abstract":"The dog offers an increasingly important model for several human diseases, including cancer. Accordingly, the results of canine gene mapping studies will be of considerable significance. Herein, we have addressed the mapping of the canine gene ERBB2 (alias HER2, NEU). ERBB2 is a protooncogene encoding a tyrosine kinase receptor protein, the overexpression of which correlates with a more rapid progression and a worse prognosis in breast cancer. In addition, it apparently plays a role in the development of other tumors as well. By fluorescence in situ hybridization (FISH), we have mapped the canine ERBB2 to 1q13.1. Cytogenetic studies of canine tumors revealed that this region is very often affected by clonal chromosome aberrations in tumors of the dog.",
        "Doc_title":"The canine ERBB2 gene maps to a chromosome region frequently affected by aberrations in tumors of the dog (Canis familiaris).",
        "Journal":"Cytogenetics and cell genetics",
        "Do_id":"11856880",
        "Doc_ChemicalList":"Receptor, ErbB-2",
        "Doc_meshdescriptors":"Animals;Chromosome Aberrations;Chromosomes;Dog Diseases;Dogs;Humans;In Situ Hybridization, Fluorescence;Neoplasms;Physical Chromosome Mapping;Receptor, ErbB-2",
        "Doc_meshqualifiers":"genetics;genetics;genetics;genetics;veterinary;genetics",
        "_version_":1605880473282674688},
      {
        "Doc_abstract":"Crosstalk between the oestrogen receptor (ER) and ERBB2/HER-2 pathways has long been implicated in breast cancer aetiology and drug response, yet no direct connection at a transcriptional level has been shown. Here we show that oestrogen-ER and tamoxifen-ER complexes directly repress ERBB2 transcription by means of a cis-regulatory element within the ERBB2 gene in human cell lines. We implicate the paired box 2 gene product (PAX2), in a previously unrecognized role, as a crucial mediator of ER repression of ERBB2 by the anti-cancer drug tamoxifen. We show that PAX2 and the ER co-activator AIB-1/SRC-3 compete for binding and regulation of ERBB2 transcription, the outcome of which determines tamoxifen response in breast cancer cells. The repression of ERBB2 by ER-PAX2 links these two breast cancer subtypes and suggests that aggressive ERBB2-positive tumours can originate from ER-positive luminal tumours by circumventing this repressive mechanism. These data provide mechanistic insight into the molecular basis of endocrine resistance in breast cancer.",
        "Doc_title":"Regulation of ERBB2 by oestrogen receptor-PAX2 determines response to tamoxifen.",
        "Journal":"Nature",
        "Do_id":"19005469",
        "Doc_ChemicalList":"Estrogens;PAX2 Transcription Factor;Receptors, Estrogen;Repressor Proteins;Trans-Activators;Tamoxifen;Histone Acetyltransferases;NCOA3 protein, human;Nuclear Receptor Coactivator 3;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Breast Neoplasms;Cell Line;Cell Line, Tumor;Chromatin Immunoprecipitation;Drug Resistance, Neoplasm;Estrogens;Gene Expression Regulation, Neoplastic;Gene Silencing;Genes, erbB-2;Histone Acetyltransferases;Humans;Nuclear Receptor Coactivator 3;PAX2 Transcription Factor;Receptor, ErbB-2;Receptors, Estrogen;Regulatory Sequences, Nucleic Acid;Repressor Proteins;Tamoxifen;Trans-Activators",
        "Doc_meshqualifiers":"drug therapy;genetics;pathology;genetics;metabolism;drug effects;genetics;deficiency;genetics;metabolism;genetics;metabolism;genetics;metabolism;metabolism;pharmacology",
        "_version_":1605853710379909120},
      {
        "Doc_abstract":"Amplification of the ERBB2 oncogene at 17q12 is clinically the most relevant genetic aberration in breast cancer and several studies have linked ERBB2 activation to poor clinical outcome. The development of targeted antibody-based therapy for ERBB2-overexpressing tumors and the possible role of ERBB2 as a predictor of chemotherapy treatment response have further emphasized the essential role of ERBB2 in breast cancer. Here, we performed a detailed characterization of the molecular events occurring at the ERBB2 amplicon in primary breast tumors. Analysis of the amplicon structure in 330 breast tumors by fluorescence in situ hybridization to a tissue microarray revealed a 280-kb common region of amplification that contains 10 transcribed sequences, including eight known genes. The expression levels of these 10 transcripts were determined in 36 frozen samples of grade-matched ERBB2-amplified and -nonamplified (as determined by fluorescence in situ hybridization) primary breast tumors by using quantitativereal-time reverse transcriptase-polymerase chain reaction. A highly significant association between amplification and expression levels was observed for six of these genes, including ERBB2 and two uncharacterized hypothetical proteins, MGC9753 and MGC14832. These results support the recent findings on the influence of copy number on gene expression levels and highlight novel genes that might contribute to the clinical behavior of ERBB2-amplified breast tumors.",
        "Doc_title":"Amplification of a 280-kilobase core region at the ERBB2 locus leads to activation of two hypothetical proteins in breast cancer.",
        "Journal":"The American journal of pathology",
        "Do_id":"14578197",
        "Doc_ChemicalList":"PGAP3 protein, human;Receptors, Cell Surface",
        "Doc_meshdescriptors":"Breast Neoplasms;Gene Amplification;Gene Dosage;Gene Expression;Genes, erbB-2;Humans;In Situ Hybridization, Fluorescence;Protein Array Analysis;Receptors, Cell Surface;Reverse Transcriptase Polymerase Chain Reaction",
        "Doc_meshqualifiers":"genetics;metabolism",
        "_version_":1605820369498800128},
      {
        "Doc_abstract":"Well over a quarter of human breast cancers are ErbB2-driven and constitute a distinct subtype with substantially poorer prognosis. Yet, there are substantial gaps in our understanding of how ErbB2 tyrosine kinase activity unleashes a coordinated program of cellular and extracellular alterations that culminate in aggressive breast cancers. Cellular models that exhibit ErbB2 kinase dependency and can induce metastatic breast cancer in immune competent hosts are likely to help bridge this gap.;Here, we derived and characterized a cell line model obtained from a transgenic ErbB2/Neu-driven mouse mammary adenocarcinoma.;The MPPS1 cell line produces metastatic breast cancers when implanted in the mammary fat pads of immune-compromised as well as syngeneic immune-competent hosts. MPPS1 cells maintain high ErbB2 overexpression when propagated in DFCI-1 or related media, and their growth is ErbB2-dependent, as demonstrated by concentration-dependent inhibition of proliferation with the ErbB kinase inhibitor Lapatinib. When grown in 3-dimensional (3-D) culture on Matrigel, MPPS1 cells predominantly form large irregular cystic and solid structures. Remarkably, low concentrations of Lapatinib led to a switch to regular acinar growth on Matrigel. Immunofluorescence staining of control vs. Lapatinib-treated acini for markers of epithelial polarity revealed that inhibition of ErbB2 signaling led to rapid resumption of normal mammary epithelium-like cell polarity.;The strict dependence of the MPPS1 cell system on ErbB2 signals for proliferation and alterations in cell polarity should allow its use to dissect ErbB2 kinase-dependent signaling pathways that promote loss of cell polarity, a key component of the epithelial mesenchymal transition and aggressiveness of ErbB2-driven breast cancers.",
        "Doc_title":"Continuous requirement of ErbB2 kinase activity for loss of cell polarity and lumen formation in a novel ErbB2/Neu-driven murine cell line model of metastatic breast cancer.",
        "Journal":"Journal of carcinogenesis",
        "Do_id":"22190871",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605747010908979201},
      {
        "Doc_abstract":"HER2 (ErbB2) has been reported to be overexpressed in 20-30% of breast cancer and confers poor survival because of high proliferation and metastasis rates. MicroRNAs are small noncoding RNAs that are responsible for the post-transcriptional regulation of target genes. We found miR-199b-5p inhibited HER2 expression by direct targeting its 3'-untranslated region (3'UTR) in breast cancer cells. In addition, miR-199b-5p inhibited HER2 downstream signaling by ERK1/2 and AKT pathways in breast cancer cells. Besides, transwell migration, wound healing, and clonogenicity were obviously inhibited by overexpression of miR-199b-5p in HER2-positive breast cancer cells. We also found that miR-199b-5p could enhance the suppression of trastuzumab on cell migration and clonogenicity. These results suggest that miR-199b-5p may have the potential to be a novel important alternative therapeutic target for HER2-positive breast cancer.",
        "Doc_title":"MiR-199b-5p targets HER2 in breast cancer cells.",
        "Journal":"Journal of cellular biochemistry",
        "Do_id":"23296799",
        "Doc_ChemicalList":"3' Untranslated Regions;MicroRNAs;mirn199 microRNA, human;Receptor, ErbB-2",
        "Doc_meshdescriptors":"3' Untranslated Regions;Blotting, Western;Breast Neoplasms;Cell Line, Tumor;Cell Movement;Female;Humans;MicroRNAs;Receptor, ErbB-2;Reverse Transcriptase Polymerase Chain Reaction;Wound Healing",
        "Doc_meshqualifiers":"genetics;genetics;metabolism;genetics;physiology;genetics;metabolism;genetics;metabolism;genetics;physiology",
        "_version_":1605774569684074496},
      {
        "Doc_abstract":"Determining ErbB2/Her-2/neu status has become an essential part of breast cancer diagnosis and a prerequisite before considering a patient's eligibility for treatment with trastuzumab. Currently the most common techniques to assess ErbB2 status in routine practice are the identification of receptor overexpression by means of immunohistochemistry (IHC) and the analysis of gene amplification by means of dual color fluorescence in situ hybridisation (FISH). According to recent recommendations (\"ASCO/CAP Guidelines\" and German S3 guidelines for breast cancer) the choice of primary test procedure--IHC or ISH - is left to the individual institution. Both techniques are of equal predictive value provided that strict quality precautions have been taken: internal test validation by comparing IHC and (F)ISH, carrying out controls, and annual participation in round-robin tests. Equivocal IHC (score 2+) has to be checked by ISH for amplification. Borderline ISH (ratio 1.8-2.2 or gene copy number 4.0-6.0) should be retested by counting additional cells or performing IHC. In approximately 5% of cases these criteria give conflicting results and the gene copy number alone generates over 90% of the equivocal ISH cases, mostly due to chromosome 17 polysomy. These cases need to be tested by IHC since over-expression is very exceptional and only these tumors have the potential to be trastuzumab responders.",
        "Doc_title":"[ErbB2 diagnostics in breast cancer--an update].",
        "Journal":"Der Pathologe",
        "Do_id":"19214513",
        "Doc_ChemicalList":"Receptor, ErbB-2",
        "Doc_meshdescriptors":"Breast Neoplasms;Female;Genes, erbB-2;Humans;Immunohistochemistry;In Situ Hybridization;In Situ Hybridization, Fluorescence;Receptor, ErbB-2;Reproducibility of Results",
        "Doc_meshqualifiers":"diagnosis;genetics;pathology;genetics",
        "_version_":1605741984901758977},
      {
        "Doc_abstract":"A major challenge to broadening oncology applications for inhibitors of the ubiquitin-proteasome system (UPS) is the identification of UPS-dependent cancer pathways predictive of tumors responsive to peptidomimetic inhibitors of its 20S core protease activity. To inform clinical studies evaluating UPS inhibitors as breast cancer therapeutics, seven phenotypically diverse human breast cancer cell line models were characterized for their cellular and molecular responses to the clinically approved 20S inhibitor bortezomib (PS341; Velcade), focusing on those overexpressing estrogen receptor (ER) or ERBB2/HER2, because these oncogenic receptor pathways are constitutively activated in approximately 80% of all breast cancers. All models demonstrated dose-dependent bortezomib reduction in intracellular 20S activity correlating with cell growth inhibition, and bortezomib IC(50) values (concentrations producing 50% growth inhibition) varied directly with pretreatment 20S activities (r = 0.74; *, p < 0.05), suggesting that basal 20S activity may serve as a clinical predictor of tumor responsiveness to UPS inhibition. Reduction in 20S activity (> 60%) was associated with early (24 h) intracellular relocalization of ER (nucleus to cytoplasm) and ERBB2 (plasma membrane to perinuclear lysosomes), buildup of ubiquitinated and Hsp70-associated receptor, degradation and loss of ER and ERBB2 function, and induction of cellular apoptosis. These models were also used to screen a pharmacologic panel of pathway-targeted anticancer agents [4-hydroxy-3-methoxy-5-(benzothiazolylthiomethyl)benzylidenecyanoacetamide (AG825), 6-(4-bromo-2-chloro-phenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxy-ethoxy)-amide (AZD6244/ARRY142886), 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one hydrochloride (LY294002), 17-N-allylamino-17-demethoxy geldanamycin (17AAG), and (2E)-N-hydroxy-3-[4-[[(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino]methyl]phenyl]-2-propenamide (LAQ824)] for those capable of sensitizing to bortezomib. In keeping with the observation that 20S reduction has little effect on mitogen-activated protein kinase kinase 1/2 (MEK1/2) signaling in either ER-positive or ERBB2-positive models, only the MEK-1/2 inhibitor AZD6244 consistently improved the antitumor activity of bortezomib.",
        "Doc_title":"Proteasome-regulated ERBB2 and estrogen receptor pathways in breast cancer.",
        "Journal":"Molecular pharmacology",
        "Do_id":"17392524",
        "Doc_ChemicalList":"Antineoplastic Agents;Boronic Acids;Proteasome Inhibitors;Pyrazines;Receptors, Estrogen;Bortezomib;Receptor, ErbB-2;Proteasome Endopeptidase Complex",
        "Doc_meshdescriptors":"Antineoplastic Agents;Apoptosis;Boronic Acids;Bortezomib;Breast Neoplasms;Drug Therapy, Combination;Humans;Oxidation-Reduction;Proteasome Endopeptidase Complex;Proteasome Inhibitors;Pyrazines;Receptor, ErbB-2;Receptors, Estrogen;Transcription, Genetic",
        "Doc_meshqualifiers":"pharmacology;drug effects;pharmacology;drug therapy;metabolism;physiology;pharmacology;metabolism;metabolism;drug effects",
        "_version_":1605797605531451392},
      {
        "Doc_abstract":"Estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER-2) expression are crucial in the biology of breast carcinoma. HER-2/neu gene is amplified and overexpressed in 15-30% of invasive breast cancers. HER-2-positive breast cancers have worse prognosis than HER-2 negative tumors and possess distinctive clinical features. The aim of this study was to assess the expression of HER2 in cancer tissue of patients with invasive breast cancer in correlation with tumor type, histological grade, tumor size, lymph node status, and expression of estrogen receptor and progesterone receptor.;Formalin-fixed, paraffin-embedded tissues from 40 patients with invasive HER-2-positive breast cancer and from 191 patients with HER-2-negative breast cancer were used in this study. HER2 expression was determined using the test HerceptTestâ„¢ DAKO.;Among 231 cases of breast cancer, 18 invasive lobular carcinomas and 213 invasive ductal carcinomas were diagnosed. Sixty percent of HER-2-positive breast cancers were ER-positive compared with 77% in the HER-2-negative group (p = 0.002). The expression of PR was observed in 43% of HER-2-positive breast cancers and in 72% of HER2-negative tumors (p = 0.003). Excessive expression of HER2 protein was detected in 60% of patients positive for estrogen receptors, which may worsen prognosis in these patients.;Determination of HER2 overexpression in breast cancer patients, allows for a determination of a group of patients with a worse prognosis.",
        "Doc_title":"Immunohistochemical evaluation of human epidermal growth factor receptor 2 and estrogen and progesterone receptors in invasive breast cancer in women.",
        "Journal":"Archives of medical science : AMS",
        "Do_id":"23847668",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605902186529685504},
      {
        "Doc_abstract":"ERBB2 amplification and consecutive overexpression is a predictor for poor prognosis in breast cancer patients. In addition, incomplete resection of ERBB2-overexpressing tumors leads to increased proliferation of residual breast cancer cells. While the local release of cytokines is thought to be responsible for the malignant behavior of remaining tumor tissue, the exact mechanism is still unknown. We have analyzed epidermal growth factor receptor (EGFR), activated (p)EGFR, and activated (p)ERBB2 protein expression in ERBB2-overexpressing and in non-ERBB2-overexpressing tumors from patients who underwent breast surgery and consecutive re-excision for involved margins, and compared expression levels by immunohistochemistry. While overall ERBB2 protein expression in the initial and the re-excised sample were comparable, we observed an increase in pERBB2 in ductal carcinomas in situ in both, ERBB2-overexpressing (16/21 vs 24/24; P=0.018, chi(2) test) and non-ERBB2-overexpressing tumors (3/28 vs 5/12; P=0.025, chi(2) test). pERBB2 was not increased in invasive tumors, regardless on whether the samples had been taken from a ERBB2-overexpressing (9/25 vs 6/17; P=0.261, chi(2) test) or a non-ERBB2-overexpressing tumor (1/27 vs 0/8; P=0.581, chi(2) test). EGFR expression was only detected in 1/47 ERBB2-overexpressing primary tumors and 2/48 non-ERBB2-overexpressing tumors, and was undetectable in re-excised specimen. Taken together, we have demonstrated an increase in ERBB2 receptor activation in incompletely resected preinvasive breast cancer. We hypothesize that receptor phosphorylation is caused by growth factor stimulation in response to intraoperative tissue damage, and perioperative inhibition of specific cytokines could become a promising therapeutic strategy.",
        "Doc_title":"Incomplete surgical resection of ductal carcinomas in situ results in activation of ERBB2 in residual breast cancer cells.",
        "Journal":"Endocrine-related cancer",
        "Do_id":"18948375",
        "Doc_ChemicalList":"Neuregulin-1;ERBB2 protein, human;Receptor, Epidermal Growth Factor;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Adult;Aged;Aged, 80 and over;Breast Neoplasms;Carcinoma in Situ;Carcinoma, Ductal;Female;Humans;Immunohistochemistry;Middle Aged;Neoplasm, Residual;Neuregulin-1;Phosphorylation;Receptor, Epidermal Growth Factor;Receptor, ErbB-2",
        "Doc_meshqualifiers":"metabolism;pathology;surgery;metabolism;pathology;surgery;metabolism;pathology;surgery;metabolism;pathology;metabolism;physiology;metabolism;metabolism",
        "_version_":1605818583473979394},
      {
        "Doc_abstract":"Various members of the Ets multigene family exhibit diverse roles in development, cell differentiation, tissue-specific gene expression and human malignancy. In the search for Ets factors involved in mammary gland development and malignancy, ESX was found to be upregulated in a subset of breast tumours and cell lines. We report the transcriptional regulation of ESX in epithelial breast cancer cells. Transient reporter assays using the ESX promoter show that ESX transcription is regulated by ErbB receptor signalling. In cell lines and in 45 primary ductal breast cancers we show that ESX transcript expression significantly correlates with ErbB2 transcript levels. Moreover, expression of ErbB2 in cells upregulates ESX promoter activity while inhibition of ErbB2 or its downstream signaling pathways decrease both ESX promoter activity and endogenous ESX protein levels. These results indicate that the ESX promoter represents a transcriptional target of ErbB2, and ESX expression may represent a downstream mediator of ErbB2 signaling and ErbB2-induced gene expression.",
        "Doc_title":"ErbB2 activation of ESX gene expression.",
        "Journal":"Oncogene",
        "Do_id":"12032832",
        "Doc_ChemicalList":"DNA-Binding Proteins;ELF3 protein, human;Proto-Oncogene Proteins;Proto-Oncogene Proteins c-ets;Transcription Factors;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Animals;Blotting, Northern;DNA-Binding Proteins;Gene Expression Regulation, Neoplastic;Humans;Mice;Promoter Regions, Genetic;Proto-Oncogene Proteins;Proto-Oncogene Proteins c-ets;Receptor, ErbB-2;Reverse Transcriptase Polymerase Chain Reaction;Signal Transduction;Transcription Factors;Transcription, Genetic;Transfection;Tumor Cells, Cultured",
        "Doc_meshqualifiers":"biosynthesis;genetics;metabolism;biosynthesis;genetics",
        "_version_":1605830430676746240},
      {
        "Doc_abstract":"ErbB2 (HER2, Neu) and Ras play key roles in tumor invasion and metastasis. We identified a novel mechanism by which integrin alpha(6)beta(4) regulates ErbB2 expression, Ras activation, and the invasion of breast carcinoma cells. Here we show that integrin alpha(6)beta(4) regulates Ras activity especially in serum-depleted condition. Down-regulation of beta(4) integrin by beta(4) short hairpin RNA (shRNA) decreased Ras activity and carcinoma invasion whereas reexpression of this integrin restored Ras activity. ErbB2, a binding partner of epidermal growth factor receptor (EGFR), and EGFR modulated Ras activity, and integrin alpha(6)beta(4) regulated phospho-EGFR level without affecting EGFR expression. We also found that integrin alpha(6)beta(4) is involved in ErbB2 expression. Depletion of beta(4) by shRNA reduced ErbB2 protein level without affecting ErbB2 mRNA level and reexpression of beta(4) increased ErbB2 protein level. Reduction of eukaryotic initiation factor 4E, a rate-limiting factor for cap-dependent translation, decreased ErbB2 protein level, and beta(4) shRNA cells exhibited a shift in ErbB2 mRNA to light polysomes compared with control cells. These results show that integrin alpha(6)beta(4) regulates ErbB2 through translational control. In summary, we propose a novel mechanism for ErbB2 up-regulation and Ras activation in serum-depleted breast cancer cells; integrin alpha(6)beta(4) regulates the expression of ErbB2 and the subsequent phosphorylation of EGFR and activation of Ras. These findings provide a mechanism that substantiates the reported role of alpha(6)beta(4) in carcinoma invasion.",
        "Doc_title":"A novel mechanism for integrin-mediated ras activation in breast carcinoma cells: the alpha6beta4 integrin regulates ErbB2 translation and transactivates epidermal growth factor receptor/ErbB2 signaling.",
        "Journal":"Cancer research",
        "Do_id":"16510594",
        "Doc_ChemicalList":"Eukaryotic Initiation Factor-4E;Integrin alpha6beta4;Quinazolines;RNA, Small Interfering;Tyrphostins;tyrphostin AG 1478;Receptor, Epidermal Growth Factor;Receptor, ErbB-2;ras Proteins",
        "Doc_meshdescriptors":"Breast Neoplasms;Cell Line, Tumor;Eukaryotic Initiation Factor-4E;Humans;Integrin alpha6beta4;Neoplasm Invasiveness;Phosphorylation;Protein Biosynthesis;Quinazolines;RNA, Small Interfering;Receptor, Epidermal Growth Factor;Receptor, ErbB-2;Signal Transduction;Transcriptional Activation;Transfection;Tyrphostins;ras Proteins",
        "Doc_meshqualifiers":"genetics;metabolism;pathology;metabolism;biosynthesis;deficiency;genetics;physiology;genetics;antagonists & inhibitors;biosynthesis;genetics;metabolism;biosynthesis;genetics;metabolism;pharmacology;metabolism",
        "_version_":1605842326922461184},
      {
        "Doc_abstract":"The epidermal growth factor receptor (ERBB1) and related family member HER-2/neu (ERBB2) are often overexpressed in aggressive breast cancers and their overexpression is correlated with poor prognosis. Clinical studies using ERBB inhibitors have focused on tumor growth effects, but ERBBs can contribute to malignancy independent of their effects on tumor growth. Our studies were designed to evaluate the effect of ERBB inhibition on tumor cell motility and intravasation in vivo using clinically relevant small-molecule inhibitors.;Using in vivo mouse models of breast cancer, we test the effects of ERBB1 and ERBB2 inhibitors AC480 and lapatinib, ERBB1 inhibitor gefitinib, and ERBB2 inhibitor AG825 on in vivo tumor cell invasive properties in mammary fat pad tumors.;ERBB1 and ERBB2 inhibition rapidly (within 3 h) inhibits both tumor cell motility and intravasation. Using gefitinib, ERBB1 inhibition rapidly inhibits tumor cell motility and invasion but not intravasation, whereas ERBB2 inhibition by AG825 rapidly blocks intravasation.;ERBB1 and ERBB2 inhibition can rapidly block tumor cell invasive properties. In addition, we differentiate for the first time the contributions of ERBB1 and ERBB2 to the key metastatic properties of in vivo tumor cell invasion and intravasation. These experiments temporally and molecularly separate two key stages in tumor cell entry into blood vessels: invasion and intravasation. These results indicate that ERBB inhibition should be considered for blocking other tumor cell malignant properties besides growth.",
        "Doc_title":"ERBB1 and ERBB2 have distinct functions in tumor cell invasion and intravasation.",
        "Journal":"Clinical cancer research : an official journal of the American Association for Cancer Research",
        "Do_id":"19458057",
        "Doc_ChemicalList":"Benzothiazoles;Quinazolines;Tyrphostins;tyrphostin AG825;lapatinib;Receptor, Epidermal Growth Factor;Receptor, ErbB-2;gefitinib",
        "Doc_meshdescriptors":"Animals;Benzothiazoles;Cell Line, Tumor;Cell Movement;Female;Humans;Mammary Neoplasms, Experimental;Mice;Mice, SCID;Neoplasm Invasiveness;Neoplasm Metastasis;Phosphorylation;Quinazolines;Receptor, Epidermal Growth Factor;Receptor, ErbB-2;Tyrphostins;Xenograft Model Antitumor Assays",
        "Doc_meshqualifiers":"pharmacology;drug effects;drug therapy;metabolism;pathology;drug effects;pharmacology;antagonists & inhibitors;metabolism;physiology;antagonists & inhibitors;metabolism;physiology;pharmacology",
        "_version_":1605802160587538432},
      {
        "Doc_abstract":"The ERBB2 gene (HER2/neu) is overexpressed in many human breast cancers. It is an important therapeutic target and its product protein is a key biomarker for breast cancer. A 28-bp GGA repeat sequence (Pu28-mer) in the nuclease hypersensitive site of the ERBB2 promoter region may play an important role in the regulation of ERBB2 transcription, possibly involving the formation of a G-quadruplex. In order to investigate this possibility, an affinity MALDI-MS approach was used for in vitro protein capture from nuclear extracts from cultured MCF-7 and BT-474 cancer cells at Pu28-mer and control oligonucleotide-modified surfaces. Captured proteins from MCF-7 cells were analyzed by LC-MS/MS. Based on these results, Western blot was then used to interrogate captured proteins from both MCF-7 and the Her-2/neu-positive BT-474 cells. Results support the formation of a G-quadruplex by Pu28-mer, indicated by circular dichroism spectroscopy, that selectively captures transcription factors including Ku70, Ku80, PURA, nucleolin, and hnRNP K. Chromatin immunoprecipitation confirmed binding of Ku70, Ku80, PURA, and nucleolin to ERBB2 promoter in the live BT-474 cells. These findings may lead to a better understanding of the role of non-duplex DNA structures in gene regulation and provide a more complete picture of the regulation of ErbB2 expression in breast cancer. The results also provide a blueprint for development of \"genome-inspired\" aptamers based on the Pu28-mer sequence for in vitro and in vivo detection of proteins related to regulation of ERBB2 gene expression and breast cancer.",
        "Doc_title":"Capture and identification of proteins that bind to a GGA-rich sequence from the ERBB2 gene promoter region.",
        "Journal":"Analytical and bioanalytical chemistry",
        "Do_id":"22899247",
        "Doc_ChemicalList":"Transcription Factors;ERBB2 protein, human;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Base Sequence;Cell Line, Tumor;Gene Expression Regulation;Humans;Molecular Sequence Data;Nucleic Acid Conformation;Promoter Regions, Genetic;Protein Binding;Receptor, ErbB-2;Repetitive Sequences, Nucleic Acid;Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization;Transcription Factors",
        "Doc_meshqualifiers":"chemistry;genetics;metabolism;methods;metabolism",
        "_version_":1605742693351161858},
      {
        "Doc_abstract":"Ligands of the ErbB family of receptors and estrogens control the proliferation of breast cancer cells. Overexpression of human EGF receptor HER-2 (erbB2) leads to amplified heregulin (HRG) signaling, promoting more aggressive breast cancer that is nonresponsive to estrogen and the antiestrogenic drug tamoxifen. Herstatin (Hst), a secreted HER-2 gene product, binds to the HER-2 receptor ectodomain blocking receptor activation. The aim of this study was to investigate the impact of this HER-2 inhibitor on HRG-induced signaling, proliferation, and sensitivity to tamoxifen in breast cancer cells with and without HER-2 overexpression. The expression of Hst in MCF7 cells eliminated HRG signaling through both mitogen-activated protein kinase and Akt pathways and prevented HRG-mediated proliferation. The loss in signaling corresponded to downregulation of the HRG receptors, HER-3 and HER-4, whereas HER-2 overexpression strongly stimulated the levels of both HRG receptors. Although Hst blocked HRG signaling in both parental and HER-2 transfected cells, it enhanced sensitivity to tamoxifen only in the MCF7 cells that overexpressed HER-2. To evaluate further the efficacy of Hst as an anticancer agent, His-tagged Hst was expressed in transfected insect cells, purified, and added to the breast cancer cells. As in the transfected cells, purified Hst inhibited HER-3 levels and suppressed HRG-induced proliferation of MCF7 and BT474 breast cancer cells. In contrast, the HER-2 monoclonal antibody, herceptin, downregulated HER-2, but not HER-3. These results suggest the potential use of Hst against HRG-mediated growth of breast cancers with high and low levels of HER-2 and against tamoxifen resistance in HER-2 overexpressing breast cancer.",
        "Doc_title":"Herstatin inhibits heregulin-mediated breast cancer cell growth and overcomes tamoxifen resistance in breast cancer cells that overexpress HER-2.",
        "Journal":"Oncogene",
        "Do_id":"14603258",
        "Doc_ChemicalList":"Antineoplastic Agents, Hormonal;Carrier Proteins;Intercellular Signaling Peptides and Proteins;Neuregulin-1;herstatin;Tamoxifen;ERBB4 protein, human;Receptor, Epidermal Growth Factor;Receptor, ErbB-2;Receptor, ErbB-3;Receptor, ErbB-4",
        "Doc_meshdescriptors":"Antineoplastic Agents, Hormonal;Breast Neoplasms;Carrier Proteins;Drug Resistance, Neoplasm;Female;Humans;Intercellular Signaling Peptides and Proteins;Neuregulin-1;Receptor, Epidermal Growth Factor;Receptor, ErbB-2;Receptor, ErbB-3;Receptor, ErbB-4;Tamoxifen",
        "Doc_meshqualifiers":"pharmacology;enzymology;metabolism;metabolism;metabolism;metabolism;genetics;metabolism;metabolism;pharmacology",
        "_version_":1605762197151023104},
      {
        "Doc_abstract":"SUMMARY: Besides surgery, radiation, chemotherapy, and endocrine treatment, immunotherapy has become an established part of systemic therapy in treating metastatic breast cancer. One of the most interesting targets for the design of anticancer therapeutics is the HER2/ErbB2 receptor which is overexpressed in about 20-25% of breast cancers. Given the poor prognosis of women whose tumors express ErbB2 (HER2) at high levels, accurate determination of the ErbB2 status should be routinely performed in women with newly diagnosed invasive breast cancer. Efficacy and safety data of numerous trials led to the approval of the monoclonal antibody trastuzumab as the first ErbB2-targeting therapy in ErbB2-positive breast cancer. However, the majority of patients who achieve an initial response to trastuzumab-based regimens for metastatic disease develop resistance within 1 year. This underlines the need for alternative or additional anti-ErbB2-targeting strategies.",
        "Doc_title":"Targeted Therapy in Metastatic Breast Cancer: The HER2/neu Oncogene.",
        "Journal":"Breast care (Basel, Switzerland)",
        "Do_id":"20847829",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605891664048553984},
      {
        "Doc_abstract":"Data on Hormone Receptor and Her-2/neu expression in breast cancers from Saudi Arabia and Gulf Region is sparse. We undertook this study to describe the patterns of hormone receptor and Her-2/neu protein expression in breast carcinoma and compared them with the histological grade at a University Hospital in Riyadh.;We conducted a retrospective study on 164 invasive ductal carcinoma of breast between the year 2002 and 2008. Immunohistochemical analysis for Estrogen and Progesterone Receptor and Her-2/neu was done in all the cases. Fluorescent in situ hybridization for Her-2/neu gene amplification was performed in all 2+ cases and few equivocal 1+ and 3+cases by immunohistochemistry. Correlation between Estrogen and Progesterone Receptor and Her-2/ neu amplification and grade of tumor was calculated.;The expression of Estrogen Receptor, Progesterone Receptor were significantly correlated (p < 0.001). Also, there was a significant negative correlation between expression of hormone receptor and Her-2/neu amplification. The histologic grade of the tumor was significantly correlated to the expression of both Estrogen and Progesterone Receptor. However, the relationship between Her-2/ neu amplification and grade was not significant and many of the grade III tumor were Her-2/neu negative. In addition, Her-2/neu gene amplification by fluorescent in situ hybridization was observed in 84.6% of breast cancer that were 3+ and in 18.75 % cases that were 2+ by immunohistochemistry.;Prevalence of Estrogen and Progesterone Receptor expression and Her-2/neu amplification in breast cancer in the Saudi Arabian population is similar to that reported internationally. There is a negative correlation between hormone receptors expression and Her-2/neu amplification. However not all of the high-grade breast cancers showed Her-2/neu positive status.",
        "Doc_title":"Correlation of hormone receptors with Her-2 Neu protein expression and the histological grade in invasive breast cancers in a cohort of Saudi Arabia.",
        "Journal":"Turk patoloji dergisi",
        "Do_id":"22207430",
        "Doc_ChemicalList":"Biomarkers, Tumor;Receptors, Estrogen;Receptors, Progesterone;Receptors, Steroid;ERBB2 protein, human;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Biomarkers, Tumor;Breast Neoplasms;Carcinoma, Ductal, Breast;Cohort Studies;Female;Humans;In Situ Hybridization, Fluorescence;Neoplasm Grading;Prognosis;Receptor, ErbB-2;Receptors, Estrogen;Receptors, Progesterone;Receptors, Steroid;Retrospective Studies;Saudi Arabia",
        "Doc_meshqualifiers":"analysis;genetics;genetics;metabolism;pathology;genetics;metabolism;pathology;analysis;biosynthesis;genetics;analysis;biosynthesis;genetics;analysis;biosynthesis;genetics;biosynthesis;genetics",
        "_version_":1605742776709808128},
      {
        "Doc_abstract":"Lysyl oxidase-like 2 (LOXL2) is a matrix-remodeling enzyme that has been shown to play a key role in invasion and metastasis of breast carcinoma cells. However, very little is known about its role in normal tissue homeostasis. Here, we investigated the effects of LOXL2 expression in normal mammary epithelial cells to gain insight into how LOXL2 mediates cancer progression.;LOXL2 was expressed in MCF10A normal human mammary epithelial cells. The 3D acinar morphogenesis of these cells was assessed, as well as the ability of the cells to form branching structures on extracellular matrix (ECM)-coated surfaces. Transwell-invasion assays were used to assess the invasive properties of the cells. Clinically relevant inhibitors of ErbB2, lapatinib and Herceptin (traztuzumab), were used to investigate the role of ErbB2 signaling in this model. A retrospective study on a previously published breast cancer patient dataset was carried out by using Disease Specific Genomic Analysis (DSGA) to investigate the correlation of LOXL2 mRNA expression level with metastasis and survival of ErbB2-positive breast cancer patients.;Fluorescence staining of the acini revealed increased proliferation, decreased apoptosis, and disrupted polarity, leading to abnormal lumen formation in response to LOXL2 expression in MCF10A cells. When plated onto ECM, the LOXL2-expressing cells formed branching structures and displayed increased invasion. We noted that LOXL2 induced ErbB2 activation through reactive oxygen species (ROS) production, and ErbB2 inhibition by using Herceptin or lapatinib abrogated the effects of LOXL2 on MCF10A cells. Finally, we found LOXL2 expression to be correlated with decreased overall survival and metastasis-free survival in breast cancer patients with ErbB2-positive tumors.;These findings suggest that LOXL2 expression in normal epithelial cells can induce abnormal changes that resemble oncogenic transformation and cancer progression, and that these effects are driven by LOXL2-mediated activation of ErbB2. LOXL2 may also be a beneficial marker for breast cancer patients that could benefit most from anti-ErbB2 therapy.",
        "Doc_title":"LOXL2 induces aberrant acinar morphogenesis via ErbB2 signaling.",
        "Journal":"Breast cancer research : BCR",
        "Do_id":"23971878",
        "Doc_ChemicalList":"Quinazolines;Reactive Oxygen Species;lapatinib;Amino Acid Oxidoreductases;LOXL2 protein, human;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Acinar Cells;Amino Acid Oxidoreductases;Breast Neoplasms;Cell Line, Tumor;Cell Transformation, Neoplastic;Epithelial Cells;Epithelial-Mesenchymal Transition;Female;Gene Expression;Gene Expression Regulation, Neoplastic;Humans;Mammary Glands, Human;Morphogenesis;Neoplasm Metastasis;Phenotype;Prognosis;Quinazolines;Reactive Oxygen Species;Receptor, ErbB-2;Signal Transduction",
        "Doc_meshqualifiers":"drug effects;metabolism;pathology;genetics;metabolism;genetics;metabolism;mortality;pathology;genetics;metabolism;metabolism;drug effects;metabolism;pathology;genetics;pharmacology;metabolism;antagonists & inhibitors;metabolism;drug effects",
        "_version_":1605810465908195328},
      {
        "Doc_abstract":"The human ERBB2 gene is frequently amplified in breast tumors, and its high expression is associated with poor prognosis. We previously reported a significant inverse correlation between Myc promoter-binding protein-1 (MBP-1) and ERBB2 expression in primary breast invasive ductal carcinoma (IDC). MBP-1 is a transcriptional repressor of the c-MYC gene that acts by binding to the P2 promoter; only one other direct target of MBP-1, the COX2 gene, has been identified so far.;To gain new insights into the functional relationship linking MBP-1 and ERBB2 in breast cancer, we have investigated the effects of MBP-1 expression on endogenous ERBB2 transcript and protein levels, as well as on transcription promoter activity, by transient-transfection of SKBr3 cells. Reporter gene and chromatin immunoprecipitation assays were used to dissect the ERBB2 promoter and identify functional MBP-1 target sequences. We also investigated the relative expression of MBP-1 and HDAC1 in IDC and normal breast tissues by immunoblot analysis and immunohistochemistry.;Transfection experiments and chromatin immunoprecipitation assays in SKBr3 cells indicated that MBP-1 negatively regulates the ERBB2 gene by binding to a genomic region between nucleotide -514 and -262 of the proximal promoter; consistent with this, a concomitant recruitment of HDAC1 and loss of acetylated histone H4 was observed. In addition, we found high expression of MBP-1 and HDAC1 in normal tissues and a statistically significant inverse correlation with ErbB2 expression in the paired tumor samples.;Altogether, our in vitro and in vivo data indicate that the ERBB2 gene is a novel MBP-1 target, and immunohistochemistry analysis of primary tumors suggests that the concomitant high expression of MBP-1 and HDAC1 may be considered a diagnostic marker of cancer progression for breast IDC.",
        "Doc_title":"Negative transcriptional control of ERBB2 gene by MBP-1 and HDAC1: diagnostic implications in breast cancer.",
        "Journal":"BMC cancer",
        "Do_id":"23421821",
        "Doc_ChemicalList":"Biomarkers, Tumor;DENND4A protein, human;DNA-Binding Proteins;Neoplasm Proteins;ERBB2 protein, human;Receptor, ErbB-2;HDAC1 protein, human;Histone Deacetylase 1",
        "Doc_meshdescriptors":"Biomarkers, Tumor;Breast Neoplasms;Carcinoma, Ductal, Breast;DNA-Binding Proteins;Gene Expression Regulation, Neoplastic;Genes, erbB-2;Histone Deacetylase 1;Humans;Immunohistochemistry;Neoplasm Proteins;Promoter Regions, Genetic;Receptor, ErbB-2;Tumor Cells, Cultured",
        "Doc_meshqualifiers":"genetics;metabolism;genetics;metabolism;genetics;metabolism;genetics;metabolism;genetics;metabolism;metabolism",
        "_version_":1605876963952558080},
      {
        "Doc_abstract":"Breast cancer is the most common malignancy among women in both developed and developing countries. The burden is increasing in low-income and middle-income countries (LMCs) and threatens the public health of such societies. Introduction of expensive monoclonal antibodies to cancer treatment regimens poses a real challenge in the health systems of LMCs. Despite controversy of cost-effectiveness of bevacizumab in breast cancer, some studies indicate gain of patients from this drug. The present study aimed to propose a priority setting model for administration of anti-angiogenic agents in breast cancer via assessment of tumor angiogenesis by the microvessel density (MVD) method and associations with clinicopathological characteristics (including simultaneous mutations of TP53 and HER-2 genes).;Age, axillary lymph nodes status, tumor size, stage and grade, estrogen and progesterone receptors status, HER-2/neu status (by immunohistochemistry and FISH test), TP53 mutation, Ki-67 (for proliferation assay) and CD34 (for angiogenesis assay) were assessed in 111 breast cancer patients. The molecular subtype of each tumor was also determined and correlations of simultaneous mutations of HER-2 and p53 genes with angiogenesis and other clinicopathological characteristics were evaluated.;There were significant associations between simultaneous mutations of HER-2 and p53 genes and all other parameters except tumor size. The degree of angiogenesis in the ERBB2 subtype was greater than the others. Younger patients showed a higher angiogenesis rate rather those older than 50 years.;Our results demonstrated that patients with simultaneous mutations of HER-2 and p53 genes, those with ERBB2 molecular subtype and also younger women (often triple negative) seem more eligible for obtaining anti-angiogenic agents. These results suggest a model for priority setting of patients with breast cancer for treatment with anti-angiogenic drugs in LMCs.",
        "Doc_title":"Angiogenesis markers in breast cancer--potentially useful tools for priority setting of anti-angiogenic agents.",
        "Journal":"Asian Pacific journal of cancer prevention : APJCP",
        "Do_id":"24460348",
        "Doc_ChemicalList":"Angiogenesis Inhibitors;Biomarkers, Tumor;Receptors, Estrogen;Receptors, Progesterone;TP53 protein, human;Tumor Suppressor Protein p53;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Adult;Aged;Angiogenesis Inhibitors;Biomarkers, Tumor;Breast Neoplasms;Carcinoma, Ductal, Breast;Carcinoma, Lobular;Female;Follow-Up Studies;Humans;Immunoenzyme Techniques;Middle Aged;Mutation;Neoplasm Grading;Neoplasm Invasiveness;Neoplasm Staging;Neovascularization, Pathologic;Prognosis;Receptor, ErbB-2;Receptors, Estrogen;Receptors, Progesterone;Tumor Suppressor Protein p53",
        "Doc_meshqualifiers":"administration & dosage;analysis;blood supply;drug therapy;pathology;blood supply;drug therapy;pathology;blood supply;drug therapy;pathology;genetics;metabolism;metabolism;metabolism;genetics",
        "_version_":1605774693483151360},
      {
        "Doc_abstract":"The anti-ErbB2 antibodies trastuzumab and pertuzumab in combination have recently been approved for the treatment of patients with ErbB2-positive metastatic breast cancer. Pertuzumab, which binds to ErbB2 near the center of domain II, and trastuzumab, which binds to the juxtamembrane region of ErbB2 domain IV, directly interfere with domain II- and domain IV-mediated heterodimerization contacts, respectively. In this study, we report a novel anti-ErbB2 antibody, 3E10, which binds to an epitope in domain III that appears to be located opposite to the dimerization interfaces in domain II and domain IV of ErbB2. Our data show that the 3E10 antibody inhibits ErbB2 heterodimerization via a mechanism that strikingly differs from trastuzumab and pertuzumab. It could be speculated that the 3E10 antibody may affect ErbB2 heterodimerization by causing major conformational changes of ErbB2. Furthermore, 3E10 provides synergistic inhibition of ErbB2 heterodimerization and signaling in combination with either trastuzumab or pertuzumab. The combination of these three anti-ErbB2 antibodies that have complementary mechanisms of action appears to be an extremely potent ErbB2 heterodimerization blocker. Compared with trastuzumab plus pertuzumab, the combination of trastuzumab, pertuzumab and 3E10 provides a more potent blockade of ErbB2 signaling. Consistent with this, trastuzumab plus pertuzumab plus 3E10 results in greater in vitro and in vivo antitumor activity in ErbB2-overexpressing breast tumor models, suggesting its potential use for treating ErbB2-overexpressing breast cancer. ",
        "Doc_title":"A monoclonal antibody targeting ErbB2 domain III inhibits ErbB2 signaling and suppresses the growth of ErbB2-overexpressing breast tumors.",
        "Journal":"Oncogenesis",
        "Do_id":"26999718",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605897120484687872},
      {
        "Doc_abstract":"The expression of the erbB2 and p53 proteins was examined by immunohistochemistry in a series of 81 cases of primary breast carcinomas treated with an adjuvant chemotherapy with a median follow-up of 5 years. Expression of erbB2 was present in 19 cases (23%), 50% of them with more than 70% of positive tumoral cells. Expression of p53 was present in 32 cases (39%), 50% of them with more than 30% of positive tumoral cells; coexpression of erbB2 and p53 was observed in 11 cases (13.5%). Disease-free and overall survival of the patients were correlated with the number of positive lymph nodes (p = 0.08, p = 0.015). No significant trend was observed in response to adjuvant chemotherapy in correlation with erbB2 or p53 expression or both, whatever the level of expression.",
        "Doc_title":"Breast cancer response to adjuvant chemotherapy in correlation with erbB2 and p53 expression.",
        "Journal":"Anticancer research",
        "Do_id":"7872717",
        "Doc_ChemicalList":"Biomarkers, Tumor;Tumor Suppressor Protein p53;Tamoxifen;Mitoxantrone;Receptor, ErbB-2;Cisplatin;Fluorouracil;Methotrexate",
        "Doc_meshdescriptors":"Adult;Antineoplastic Combined Chemotherapy Protocols;Biomarkers, Tumor;Breast Neoplasms;Chemotherapy, Adjuvant;Cisplatin;Female;Fluorouracil;Gene Expression;Humans;Immunohistochemistry;Methotrexate;Middle Aged;Mitoxantrone;Ovariectomy;Predictive Value of Tests;Prognosis;Receptor, ErbB-2;Tamoxifen;Tumor Suppressor Protein p53",
        "Doc_meshqualifiers":"therapeutic use;analysis;drug therapy;metabolism;pathology;therapy;administration & dosage;administration & dosage;administration & dosage;therapeutic use;analysis;biosynthesis;therapeutic use;analysis;biosynthesis",
        "_version_":1605756035105030144},
      {
        "Doc_abstract":"The type I insulin-like growth factor receptor (IGF-IR) and ErbB2 (Her-2) are receptor tyrosine kinases implicated in human breast cancer. Both proteins are currently the subject of targeted therapeutics that are used in the treatment of breast cancer or which are in clinical trials. The focus of this study was to utilize our inducible model of IGF-IR overexpression to explore the interaction of these two potent oncogenes.;ErbB2 was overexpressed in our RM11A cell line, a murine tumor cell line that overexpresses human IGF-IR in an inducible manner. ErbB2 conferred an accelerated tumor onset and increased tumor incidence after injection of RM11A cells into the mammary glands of syngeneic wild type mice. This was associated with increased proliferation immediately after tumor cell colonization of the mammary gland; however, this effect was lost after tumor establishment. ErbB2 overexpression also impaired the regression of established RM11A tumors following IGF-IR downregulation and enhanced their metastatic potential.;This study has revealed that even in the presence of vast IGF-IR overexpression, a modest increase in ErbB2 can augment tumor establishment in vivo, mediate resistance to IGF-IR downregulation and facilitate metastasis. This supports the growing evidence suggesting a possible advantage of using IGF-IR and ErbB2-directed therapies concurrently in the treatment of breast cancer.",
        "Doc_title":"ErbB2 enhances mammary tumorigenesis, oncogene-independent recurrence and metastasis in a model of IGF-IR-mediated mammary tumorigenesis.",
        "Journal":"Molecular cancer",
        "Do_id":"20825649",
        "Doc_ChemicalList":"Receptor, ErbB-2;Receptor, IGF Type 1",
        "Doc_meshdescriptors":"Animals;Blotting, Western;Breast Neoplasms;Cell Line, Tumor;Cell Survival;Female;Fluorescent Antibody Technique;Gene Expression Regulation, Neoplastic;Humans;Immunohistochemistry;Mice;Neoplasm Metastasis;Rats;Receptor, ErbB-2;Receptor, IGF Type 1",
        "Doc_meshqualifiers":"genetics;metabolism;pathology;genetics;physiology;genetics;physiology;genetics;pathology;genetics;metabolism;genetics;metabolism",
        "_version_":1605789535384371200},
      {
        "Doc_abstract":"Glutamine metabolism is a central metabolic pathway in cancer. Recently, reductive carboxylation of glutamine for lipogenesis has been shown to constitute a key anabolic route in cancer cells. However, little is known regarding central regulators of the various glutamine metabolic pathways in cancer cells.;The impact of PGC-1Î± and ERRÎ± on glutamine enzyme expression was assessed in ERBB2+ breast cancer cell lines with quantitative RT-PCR, chromatin immunoprecipitation, and immunoblotting experiments. Glutamine flux was quantified using 13C-labeled glutamine and GC/MS analyses. Functional assays for lipogenesis were performed using 14C-labeled glutamine. The expression of glutamine metabolism genes in breast cancer patients was determined by bioinformatics analyses using The Cancer Genome Atlas.;We show that the transcriptional coactivator PGC-1Î±, along with the transcription factor ERRÎ±, is a positive regulator of the expression of glutamine metabolism genes in ERBB2+ breast cancer. Indeed, ERBB2+ breast cancer cells with increased expression of PGC-1Î± display elevated expression of glutamine metabolism genes. Furthermore, ERBB2+ breast cancer cells with reduced expression of PGC-1Î± or when treated with C29, a pharmacological inhibitor of ERRÎ±, exhibit diminished expression of glutamine metabolism genes. The biological relevance of the control of glutamine metabolism genes by the PGC-1Î±/ERRÎ± axis is demonstrated by consequent regulation of glutamine flux through the citric acid cycle. PGC-1Î± and ERRÎ± regulate both the canonical citric acid cycle (forward) and the reductive carboxylation (reverse) fluxes; the latter can be used to support de novo lipogenesis reactions, most notably in hypoxic conditions. Importantly, murine and human ERBB2+ cells lines display a significant dependence on glutamine availability for their growth. Finally, we show that PGC-1Î± expression is positively correlated with that of the glutamine pathway in ERBB2+ breast cancer patients, and high expression of this pathway is associated with reduced patient survival.;These data reveal that the PGC-1Î±/ERRÎ± axis is a central regulator of glutamine metabolism in ERBB2+ breast cancer. This novel regulatory link, as well as the marked reduction in patient survival time associated with increased glutamine pathway gene expression, suggests that targeting glutamine metabolism may have therapeutic potential in the treatment of ERBB2+ breast cancer.",
        "Doc_title":"PGC-1Î± supports glutamine metabolism in breast cancer.",
        "Journal":"Cancer & metabolism",
        "Do_id":"24304688",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605747077938151424},
      {
        "Doc_abstract":"SUMMARY: In women with estrogen receptor(ER)- and ErbB2 (HER2)-positive breast cancer, a vicious cycle is established between ER mechanisms of action and the growth factor receptor network, leading to enhanced cell proliferation and endocrine resistance. As such, co-targeting ErbB1 and ErbB2 with lapatinib in combination with hormonal therapy is an attractive approach to enhance the efficacy of either tamoxifen or estrogen deprivation. As demonstrated in the EGF30008 trial, a combined targeted strategy with letrozole and lapatinib significantly increased progression-free survival and clinical benefit rates in patients with metastatic breast cancer that co-expresses ER and ErbB2. Therefore, women who are not in an acutely life-threatening situation should be considered for upfront treatment with hormonal therapy (e.g. aromatase inhibitors) in combination with an anti-ErbB2 therapy.",
        "Doc_title":"Lapatinib in the Treatment of Hormone Receptor-Positive/ErbB2-Positive Breast Cancer.",
        "Journal":"Breast care (Basel, Switzerland)",
        "Do_id":"20847831",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605850860809617408},
      {
        "Doc_abstract":"High BCAR4 and ERBB2 mRNA levels in primary breast cancer associate with tamoxifen resistance and poor patient outcome. We determined whether BCAR4 expression sensitises breast cancer cells to lapatinib, and identifies a subgroup of patients who possibly may benefit from ERBB2-targeted therapies despite having tumours with low ERBB2 expression.;Proliferation assays were applied to determine the effect of BCAR4 expression on lapatinib treatment. Changes in cell signalling were quantified with reverse-phase protein microarrays. Quantitative reverse-transcriptase polymerase chain reaction (RT-PCR) of ERBB2 and BCAR4 was performed in 1418 primary breast cancers. Combined BCAR4 and ERBB2 mRNA levels were evaluated for association with progression-free survival (PFS) in 293 oestrogen receptor-Î± (ER)-positive patients receiving tamoxifen as first-line monotherapy for recurrent disease.;BCAR4 expression strongly sensitised ZR-75-1 and MCF7 breast cancer cells to the combination of lapatinib and antioestrogens. Lapatinib interfered with phosphorylation of ERBB2 and its downstream mediators AKT, FAK, SHC, STAT5, and STAT6. Reverse transcriptase-PCR analysis showed that 27.6% of the breast cancers were positive for BCAR4 and 22% expressed also low levels of ERBB2. The clinical significance of combining BCAR4 and ERBB2 mRNA status was underscored by the finding that the group of patients having BCAR4-positive/ERBB2-low-expressing cancers had a shorter PFS on tamoxifen treatment than the BCAR4-negative group.;This study shows that BCAR4 expression identifies a subgroup of ER-positive breast cancer patients without overexpression of ERBB2 who have a poor outcome and might benefit from combined ERBB2-targeted and antioestrogen therapy.",
        "Doc_title":"BCAR4 induces antioestrogen resistance but sensitises breast cancer to lapatinib.",
        "Journal":"British journal of cancer",
        "Do_id":"22892392",
        "Doc_ChemicalList":"Antineoplastic Agents;Antineoplastic Agents, Hormonal;BCAR4 non-coding RNA, human;Biomarkers, Tumor;Estrogen Receptor Modulators;Protein Kinase Inhibitors;Quinazolines;RNA, Long Noncoding;RNA, Messenger;RNA, Untranslated;Receptors, Estrogen;Tamoxifen;lapatinib;ERBB2 protein, human;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Adult;Aged;Antineoplastic Agents;Antineoplastic Agents, Hormonal;Biomarkers, Tumor;Breast Neoplasms;Cell Proliferation;Disease-Free Survival;Drug Resistance, Neoplasm;Estrogen Receptor Modulators;Female;Gene Expression Regulation, Neoplastic;Humans;Middle Aged;Molecular Targeted Therapy;Phosphorylation;Protein Kinase Inhibitors;Quinazolines;RNA, Long Noncoding;RNA, Messenger;RNA, Untranslated;Receptor, ErbB-2;Receptors, Estrogen;Reverse Transcriptase Polymerase Chain Reaction;Signal Transduction;Tamoxifen",
        "Doc_meshqualifiers":"pharmacology;therapeutic use;therapeutic use;analysis;drug therapy;metabolism;mortality;therapeutic use;drug effects;methods;drug effects;therapeutic use;pharmacology;therapeutic use;metabolism;drug effects;genetics;metabolism;drug effects;genetics;metabolism;analysis;drug effects;therapeutic use",
        "_version_":1605762732789858304},
      {
        "Doc_abstract":"The expression of the pS2 gene, which is induced by estrogen in the breast cancer cell line MCF-7, has been investigated in breast cancers by using pS2 mRNA determination in tumor specimens and immunocytochemistry to identify pS2 protein in paraffin-embedded sections. Using these assays we show that determination of pS2 gene expression allows the definition of subclasses of estrogen-receptor-containing breast cancers that may be used to more precisely identify estrogen-dependent tumors. Tumor specimens have also been analyzed for the presence of mRNAs for the estrogen receptor and for the ERBB2 oncogene. No evidence for the presence of truncated forms of estrogen-receptor mRNA has been found, and overexpression of the ERBB2 oncogene did not correlate with the steroid receptor status or pS2 gene expression.",
        "Doc_title":"Specific expression of the pS2 gene in subclasses of breast cancers in comparison with expression of the estrogen and progesterone receptors and the oncogene ERBB2.",
        "Journal":"Proceedings of the National Academy of Sciences of the United States of America",
        "Do_id":"3321071",
        "Doc_ChemicalList":"DNA, Neoplasm;Neoplasm Proteins;RNA, Messenger;RNA, Neoplasm;Receptors, Estrogen;Receptors, Progesterone",
        "Doc_meshdescriptors":"Breast Neoplasms;DNA, Neoplasm;Gene Expression Regulation;Humans;Immunoenzyme Techniques;Neoplasm Proteins;Oncogenes;RNA, Messenger;RNA, Neoplasm;Receptors, Estrogen;Receptors, Progesterone",
        "Doc_meshqualifiers":"genetics;genetics;genetics;genetics;genetics;genetics;genetics",
        "_version_":1605756582956630016},
      {
        "Doc_abstract":"Cyclin D1 is downstream of erbB2 and is required for erbB2 transformation. Here we report thatcyclin D1 functions are essential, rate limiting for erbB2 transformation, and reciprocally increase erbB2 levels. This interaction depends on three cyclin D1 activities: cyclin-dependent kinase 4-dependent kinase activity, titration of p27, and an intrinsic transcriptional activity of cyclin D1. Drugs active against erbB2 and cyclin D1 (Herceptin and flavopiridol) were synergistically cytotoxic against erbB2-positive breast cancer cell lines. Addition of flavopiridol to Herceptin synergistically lowered erbB2 levels in these cells. Our data suggest the potential use of combinations of cyclin-dependent kinase inhibitors and Herceptin in breast cancer.",
        "Doc_title":"Rate-limiting effects of Cyclin D1 in transformation by ErbB2 predicts synergy between herceptin and flavopiridol.",
        "Journal":"Cancer research",
        "Do_id":"11956082",
        "Doc_ChemicalList":"Antibodies, Monoclonal;Antibodies, Monoclonal, Humanized;Flavonoids;Piperidines;Proto-Oncogene Proteins;Cyclin D1;alvocidib;Receptor, ErbB-2;CDK4 protein, human;Cdk4 protein, mouse;Cyclin-Dependent Kinase 4;Cyclin-Dependent Kinases;Trastuzumab",
        "Doc_meshdescriptors":"3T3 Cells;Animals;Antibodies, Monoclonal;Antibodies, Monoclonal, Humanized;Antineoplastic Combined Chemotherapy Protocols;Breast Neoplasms;Cell Survival;Cell Transformation, Neoplastic;Cyclin D1;Cyclin-Dependent Kinase 4;Cyclin-Dependent Kinases;Drug Synergism;Flavonoids;Humans;Mice;Piperidines;Proto-Oncogene Proteins;Receptor, ErbB-2;Trastuzumab",
        "Doc_meshqualifiers":"administration & dosage;pharmacology;pharmacology;drug therapy;metabolism;drug effects;drug effects;metabolism;antagonists & inhibitors;metabolism;physiology;antagonists & inhibitors;metabolism;administration & dosage;pharmacology;administration & dosage;pharmacology;genetics;metabolism;physiology",
        "_version_":1605893042039947264},
      {
        "Doc_abstract":"Trastuzumab is widely used for advanced breast cancer patients with ERBB2-amplified tumors. Nevertheless, over half of these patients do not have an objective response. One reason may be altered expression of genes that might compensate for ERBB2 inhibition. We previously mapped the gene-rich region of chromosome 17 telomeric to ERBB2, and reported considerable variability in the telomeric extent of the ERBB2 amplicon. Here we examined whether the variable amplicon size may be associated with patient response to trastuzumab. In addition, we looked at associations between response and several signaling pathway-related genes unrelated to the ERBB2 amplicon, including AKT3, PTEN, PIK3CA, and PTGS2. In 35 patients with ERBB2-amplified metastatic breast cancer, with 40% overall response to trastuzumab, fluorescence in situ hybridization identified the telomeric extent of the ERBB2 amplicon and the status of the several pathway-related genes. Objective response strongly correlated with the telomeric amplicon size, with 62% of patients with shorter amplicons responding, compared with only 7% of patients with longer amplicons (P = 0.0015). Abnormal copy number of PTGS2 was marginally associated with objective response (P = 0.066), while abnormal copy numbers of two reference loci, 1q25 and the chromosome 10 centromere, were significantly associated with response. Pairwise combinations of copy number status of these loci and ERBB2 amplicon size provided stronger associations and identified a group of patients without responders. These results suggest that patient selection for trastuzumab may be improved by considering ERBB2 amplicon size and genomic status of the 1q25, PTGS2, and centromere 10 loci.",
        "Doc_title":"Effects of ERBB2 amplicon size and genomic alterations of chromosomes 1, 3, and 10 on patient response to trastuzumab in metastatic breast cancer.",
        "Journal":"Genes, chromosomes & cancer",
        "Do_id":"17243161",
        "Doc_ChemicalList":"Antibodies, Monoclonal;Antibodies, Monoclonal, Humanized;Antineoplastic Agents;Receptor, ErbB-2;Trastuzumab",
        "Doc_meshdescriptors":"Antibodies, Monoclonal;Antibodies, Monoclonal, Humanized;Antineoplastic Agents;Breast Neoplasms;Chromosomes, Human, Pair 1;Chromosomes, Human, Pair 10;Chromosomes, Human, Pair 3;Female;Humans;Neoplasm Metastasis;Receptor, ErbB-2;Trastuzumab",
        "Doc_meshqualifiers":"pharmacology;pharmacology;drug therapy;genetics;genetics;genetics;genetics;drug therapy;genetics;genetics",
        "_version_":1605819273682354176},
      {
        "Doc_abstract":"The tyrosine kinase receptor, HER2 is a crucial prognostic marker and therapeutic target for breast cancer; however, the downstream targets and biological effectors of HER2 remain unclear. We investigated the relationship between HER2 and the transcription factor FoxM1 in breast cancer. HER2 and FoxM1 expression levels were compared in breast carcinoma cell lines, paraffin-embedded breast cancer patient samples and at the mRNA level in purified breast epithelial cells. To further examine the relationship between HER2 and FoxM1 expression, we either overexpressed or siRNA-mediated depleted endogenous HER2 in breast cancer cell lines. Additionally, a mammary epithelium-targeted HER2 (neu) transgenic mouse model was also used to assess the effect of HER2 on FoxM1 levels. Furthermore, the effect of the HER2-tyrosine kinase inhibitor lapatinib on FoxM1 in HER2 positive breast cancer cells was investigated. HER2 protein levels directly correlated with FoxM1 expression in both breast carcinoma cell lines and paraffin-embedded breast cancer patient samples. Moreover, in purified breast epithelial cells, overexpression of HER2 was associated with high levels of FoxM1 mRNA, suggesting that the upregulation of FoxM1 expression is at least partially mediated transcriptionally. Furthermore, overexpression or ablation of endogenous HER2 resulted in parallel changes in FoxM1 expression. Critically, mammary epithelium-targeted HER2 mouse tumours also resulted in increased FoxM1 expression, suggesting that HER2 directed FoxM1 expression occurs in vivo and may be a critical downstream effector of HER2-targeting therapies. Indeed, treatment of breast cancer cells with lapatinib reduced FoxM1 expression at protein, mRNA and gene promoter levels. Moreover, analysis of normal and breast cancer patient samples revealed that elevated FoxM1 expression at protein and mRNA levels correlated with breast cancer development, but not significantly with cancer progression and survival. Our results indicate that the HER2 receptor regulates the expression of the FoxM1 transcription factor, which has a role in breast cancer development.",
        "Doc_title":"FoxM1 is a downstream target and marker of HER2 overexpression in breast cancer.",
        "Journal":"International journal of oncology",
        "Do_id":"19513552",
        "Doc_ChemicalList":"Antineoplastic Agents;FOXM1 protein, human;Forkhead Box Protein M1;Forkhead Transcription Factors;Foxm1 protein, mouse;Protein Kinase Inhibitors;Quinazolines;RNA, Messenger;lapatinib;ERBB2 protein, human;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Animals;Antineoplastic Agents;Breast Neoplasms;Cell Line, Tumor;Female;Forkhead Box Protein M1;Forkhead Transcription Factors;Gene Expression Regulation, Enzymologic;Gene Expression Regulation, Neoplastic;Humans;Mice;Mice, Transgenic;Middle Aged;Paraffin Embedding;Promoter Regions, Genetic;Protein Kinase Inhibitors;Quinazolines;RNA Interference;RNA, Messenger;Receptor, ErbB-2;Signal Transduction;Transcription, Genetic;Transfection;Up-Regulation",
        "Doc_meshqualifiers":"pharmacology;enzymology;genetics;pathology;genetics;metabolism;pharmacology;pharmacology;metabolism;antagonists & inhibitors;genetics;metabolism;drug effects;genetics",
        "_version_":1605746975340232705},
      {
        "Doc_abstract":"While in breast cancer the amplification and overexpression of the erbB2 gene has been reported in numerous studies and found to be correlated to poor prognosis, information about this oncogene with respect to ovarian cancer is still limited. A recent study reported that approximately 30% of tumor biopsies from ovarian cancer patients exhibited erbB2 amplification and overexpression and suggested that the overexpression of this oncogene is an indicator of bad prognosis in ovarian cancer. The purpose of our studies was to investigate amplification of the erbB2 gene, the levels of erbB2 m-RNA and the erbB2 product (p185) in ovarian cancer, and the correlation between these findings and the pathological and clinical features.;Amplification of the erbB2 gene was investigated by Southern blot analysis in 75 samples from 62 patients; mRNA levels were evaluated by Northern blot analysis in 58 samples from 48 patients; and p185 was determined by immunohistochemistry in 65 samples from 65 patients. The erbB2 gene was amplified in only one case (1.6%), and a marked increase in erbB2 mRNA was found only in the same case. Staining for p185 was positive in 12 cases (18.5%). The staining was always confined to the cytoplasm except in the case that showed amplification of erbB2 in which p185 was localized in the membrane. No correlation was found between p185 positivity and pathological and clinical features or response to chemotherapy. Western blot analysis showed that the molecular weight of p185 in positive ovarian cancer cells was approximately 10 KDa lower than in breast cancer.;In contrast to breast cancer, in ovarian cancer the amplification of erbB2 appears infrequent. The levels of p185 detected by immunohistochemistry were not related to the amplification of the gene or to the increase in mRNA, suggesting the possibility of a longer half-life of the protein in the positive cases. The finding that erbB2 product in ovarian cancer is mostly localised in cytoplasm and not in the membrane as in breast cancer and that it has a lower molecular weight than the p185 in breast cancer suggest that this oncogene plays a different biological role in these two neoplasms.",
        "Doc_title":"Overexpression of p185 is not related to erbB2 amplification in ovarian cancer.",
        "Journal":"Annals of oncology : official journal of the European Society for Medical Oncology",
        "Do_id":"7904177",
        "Doc_ChemicalList":"Proto-Oncogene Proteins;RNA, Messenger;Receptor, Epidermal Growth Factor;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Female;Gene Amplification;Gene Expression Regulation;Humans;Neoplasm Staging;Ovarian Neoplasms;Proto-Oncogene Proteins;Proto-Oncogenes;RNA, Messenger;Receptor, Epidermal Growth Factor;Receptor, ErbB-2",
        "Doc_meshqualifiers":"chemistry;genetics;pathology;analysis;genetics;analysis;analysis;genetics",
        "_version_":1605850843738800128},
      {
        "Doc_abstract":"The prognostic and predictive relevance of epidermal growth factor receptor 2 (ERBB2) and topoisomerase II alpha (TOP2A) have long been a matter of debate. However, the correlation of DNA amplification, RNA levels, and protein expression and their prognostic role and association with anthracycline responses in node-negative breast cancer have not yet been evaluated.;We first analyzed TOP2A and ERBB2 at the levels of gene amplification, and RNA and protein expression, and studied their correlations. Additionally, TOP2A and ERBB2 were analyzed in 782 node-negative breast carcinomas in patients who did not receive systemic therapy and in 80 patients treated with epirubicin and cyclophosphamide (EC) prior to surgery.;TOP2A gene amplification did not correlate with protein expression (P = 0.283) and showed an association with gene expression with only borderline significance (P = 0.047). By contrast, TOP2A RNA levels correlated with protein expression (P < 0.001). TOP2A gene expression was significantly associated with the metastasis-free interval (MFI; P < 0.001) and was associated with complete remission in patients treated with EC (P = 0.002). In contrast to TOP2A, ERBB2 gene amplification correlated with RNA level (P < 0.001) and protein expression (P < 0.001). ERBB2 gene expression was associated with the MFI only in estrogen receptor-positive carcinomas, whereas ERBB2 protein expression (P = 0.032) was associated with MFI in the entire cohort.;Overall, our study indicates that the TOP2A RNA level is a good prognostic marker and is also associated with a favorable response to anthracyclin-based therapy. By contrast, ESR1 was associated with poorer responses to anthracyclin-based therapy, whereas the association with ERBB2 RNA was not significant.",
        "Doc_title":"ERBB2 and TOP2A in breast cancer: a comprehensive analysis of gene amplification, RNA levels, and protein expression and their influence on prognosis and prediction.",
        "Journal":"Clinical cancer research : an official journal of the American Association for Cancer Research",
        "Do_id":"20371687",
        "Doc_ChemicalList":"Antigens, Neoplasm;Biomarkers, Tumor;DNA-Binding Proteins;Neoplasm Proteins;RNA, Neoplasm;Receptors, Estrogen;Epirubicin;Cyclophosphamide;ERBB2 protein, human;Receptor, ErbB-2;DNA Topoisomerases, Type II;DNA topoisomerase II alpha",
        "Doc_meshdescriptors":"Antigens, Neoplasm;Antineoplastic Combined Chemotherapy Protocols;Biomarkers, Tumor;Breast Neoplasms;Chemotherapy, Adjuvant;Cohort Studies;Cyclophosphamide;DNA Topoisomerases, Type II;DNA-Binding Proteins;Epirubicin;Female;Gene Amplification;Humans;Immunoenzyme Techniques;In Situ Hybridization, Fluorescence;Middle Aged;Neoadjuvant Therapy;Neoplasm Proteins;Neoplasm Staging;Pilot Projects;RNA, Neoplasm;Receptor, ErbB-2;Receptors, Estrogen;Survival Rate;Treatment Outcome",
        "Doc_meshqualifiers":"genetics;metabolism;therapeutic use;genetics;metabolism;drug therapy;genetics;metabolism;administration & dosage;genetics;metabolism;genetics;metabolism;administration & dosage;metabolism;genetics;genetics;metabolism;metabolism",
        "_version_":1605825648961519616},
      {
        "Doc_abstract":"Understanding breast cancer treatment options can help family physicians care for their patients during and after cancer treatment. This article reviews typical treatments based on stage, histology, and biomarkers. Lobular carcinoma in situ does not require treatment. Ductal carcinoma in situ can progress to invasive cancer and is treated with breast-conserving surgery and radiation therapy without further lymph node exploration or systemic therapy. Stages I and II breast cancers are usually treated with breast-conserving surgery and radiation therapy. Radiation therapy following breast-conserving surgery decreases mortality and recurrence. Sentinel lymph node biopsy is considered for most breast cancers with clinically negative axillary lymph nodes, and it does not have the adverse effects of arm swelling and pain that are associated with axillary lymph node dissection. Choice of adjuvant systemic therapy depends on lymph node involvement, hormone receptor status, ERBB2 (formerly HER2 or HER2/neu) overexpression, and patient age and menopausal status. In general, node-positive breast cancer is treated systemically with chemotherapy, endocrine therapy (for hormone receptor-positive cancer), and trastuzumab (for cancer overexpressing ERBB2). Anthracycline- and taxane-containing chemotherapeutic regimens are active against breast cancer. Stage III breast cancer typically requires induction chemotherapy to downsize the tumor to facilitate breast-conserving surgery. Inflammatory breast cancer, although considered stage III, is aggressive and requires induction chemotherapy followed by mastectomy, rather than breastconserving surgery, as well as axillary lymph node dissection and chest wall radiation. Prognosis is poor in women with recurrent or metastatic (stage IV) breast cancer, and treatment options must balance benefits in length of life and reduced pain against harms from treatment.",
        "Doc_title":"Treatment of breast cancer.",
        "Journal":"American family physician",
        "Do_id":"20521754",
        "Doc_ChemicalList":"Antineoplastic Agents",
        "Doc_meshdescriptors":"Antineoplastic Agents;Breast Neoplasms;Combined Modality Therapy;Female;Humans;Mastectomy;Neoplasm Staging;Sentinel Lymph Node Biopsy",
        "Doc_meshqualifiers":"therapeutic use;drug therapy;pathology;radiotherapy;surgery;therapy",
        "_version_":1605804778231693312},
      {
        "Doc_abstract":"Breast cancer (BC) and metastatic breast cancer (MBC) are significant causes of deaths amongst women worldwide, including developing countries. The cost of treatment in the latter is even more of an issue than in higher income countries. ErbB2 overexpression is a marker of poor prognosis and the goal for targeted therapy. This study was aimed at evaluating the cost-effectiveness in Colombia of ErbB2+ MBC treatment after progression on trastuzumab.;A decision analytic model was constructed for evaluating such treatment in a hypothetical cohort of ErbB2+MBC patients who progressed after a first scheme involving trastuzumab. The alternatives compared were lapatinib+capecitabine (L+C), and trastuzumab+a chemotherapy agent (capecitabine, vinorelbine or a taxane). Markov models were used for calculating progression-free time and the associated costs. Effectiveness estimators for such therapy were identified from primary studies; all direct medical costs based on national fees-guidelines were included. Sensitivity was analyzed and acceptability curves estimated. A 3 % discount rate and third-payer perspective were used within a 5-year horizon.;L+C dominated its comparators. Its cost-effectiveness ratio was COP $49,725,045 per progression-free year. The factors most influencing the results were the alternatives' hazard ratios and the cost of trastuzumab.;Lapatinib was cost-effective compared to its alternatives for treating MBC after progression on trastuzumab using a Colombian decision analytic model.",
        "Doc_title":"ErbB2+ metastatic breast cancer treatment after progression on trastuzumab: a cost-effectiveness analysis for a developing country.",
        "Journal":"Revista de salud publica (Bogota, Colombia)",
        "Do_id":"25383500",
        "Doc_ChemicalList":"Antimetabolites, Antineoplastic;Quinazolines;Taxoids;lapatinib;Vinblastine;Capecitabine;ERBB2 protein, human;Receptor, ErbB-2;Trastuzumab;vinorelbine",
        "Doc_meshdescriptors":"Adult;Aged;Antimetabolites, Antineoplastic;Antineoplastic Combined Chemotherapy Protocols;Breast Neoplasms;Capecitabine;Carcinoma, Ductal, Breast;Colombia;Cost-Benefit Analysis;Developing Countries;Disease Progression;Disease-Free Survival;Drug Resistance, Neoplasm;Female;Health Expenditures;Humans;Insurance, Health, Reimbursement;Markov Chains;Middle Aged;Prescription Fees;Quinazolines;Receptor, ErbB-2;Taxoids;Trastuzumab;Vinblastine",
        "Doc_meshqualifiers":"economics;therapeutic use;economics;therapeutic use;drug therapy;economics;administration & dosage;economics;therapeutic use;drug therapy;economics;administration & dosage;economics;analysis;antagonists & inhibitors;administration & dosage;economics;administration & dosage;administration & dosage;analogs & derivatives;economics",
        "_version_":1605824904991604736},
      {
        "Doc_abstract":"The transmembrane tyrosine kinase HER2 (ErbB2, neu) is a prototypical biomarker for breast cancers and a therapeutic target. Although anti-HER2 therapies are remarkably effective, HER2-positive tumors are heterogeneous and some subtypes do not respond or develop resistance to these therapies. Here we show that H2NTF, a novel N-terminal fragment of HER2, is expressed at variable levels in 60% of the breast cancer samples analyzed. Characterization of H2NTF shows that it is devoid of the tyrosine kinase domain but it readily interacts with full-length HER2 and other HER receptors. As a consequence, H2NTF acts as a dominant-negative, attenuating the signaling triggered by full-length HER receptors. Expression of H2NTF results in resistance to the treatment with low concentrations of trastuzumab in vitro. However, cells expressing H2NTF and non-expressing cells have similar sensitivity to trastuzumab in vivo, indicating that H2NTF/trastuzumab complexes trigger antibody-dependent cell-mediated cytotoxicity.",
        "Doc_title":"A dominant-negative N-terminal fragment of HER2 frequently expressed in breast cancers.",
        "Journal":"Oncogene",
        "Do_id":"22641219",
        "Doc_ChemicalList":"Protein Isoforms;ERBB2 protein, human;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Amino Acid Sequence;Animals;Breast Neoplasms;Carcinoma;Female;Gene Expression Regulation, Neoplastic;Gene Frequency;Genes, Dominant;HEK293 Cells;Humans;Mice;Mice, Inbred BALB C;Mice, Inbred NOD;Mice, Nude;Mice, SCID;Models, Biological;Molecular Sequence Data;Protein Isoforms;Protein Structure, Tertiary;Receptor, ErbB-2;Tumor Cells, Cultured",
        "Doc_meshqualifiers":"epidemiology;genetics;epidemiology;genetics;chemistry;genetics;genetics;physiology;chemistry;genetics;metabolism",
        "_version_":1605906700463767552},
      {
        "Doc_abstract":"Overexpression of ErbB2 has been found in approximately 25-30% of human breast cancers and has been shown to render the cancer cells more resistant to chemotherapy. However, it is not clear whether ErbB2 overexpression renders the cells more resistant to specific anti-cancer drugs or renders the cells more resistant to a broad range of anti-cancer drugs. It is not clear how the function of ErbB2 in drug resistance is related to expression and activation of the other ErbB receptors. In this communication, we showed that several breast cancer cell lines including BT20, BT474, MCF-7, MDA-MB-453, and SKBR-3 cells had a similar pattern of resistance to a broad range of anti-cancer drugs including 5-Fluorouracil, Cytoxan, Doxorubincin, Taxol, and Vinorelbin, suggesting a mechanism of multidrug resistance. High expression of P-glycoprotein and the ErbB receptors contribute to drug resistance of these breast cancer cells; however, overexpression of ErbB2 alone is not a major factor in determining drug resistance. To further determine the role of the ErbB receptors in drug resistance, we selected various NIH 3T3 cell lines that specifically expressed EGF receptor (EGFR), ErbB2, ErbB3, EGFR/ErbB2, EGFR/ErbB3, or ErbB2/ErbB3. A cytotoxicity assay showed that expression of ErbB2 alone did not significantly enhance drug resistance, whereas coexpression of either EGFR or ErbB3 with ErbB2 significantly enhanced drug resistance. Moreover, ErbB2 was highly phosphorylated in NIH 3T3 cells that coexpress ErbB2 with either EGFR or ErbB3, but not in NIH 3T3 cells that express ErbB2 alone. Together, our results suggest that coexpression of EGFR or ErbB3 with ErbB2 induces high phosphorylation of ErbB2 and renders the cells more resistant to various anti-cancer drugs.",
        "Doc_title":"Enhanced drug resistance in cells coexpressing ErbB2 with EGF receptor or ErbB3.",
        "Journal":"Biochemical and biophysical research communications",
        "Do_id":"11062025",
        "Doc_ChemicalList":"Antineoplastic Agents;P-Glycoprotein;Receptor, Epidermal Growth Factor;Receptor, ErbB-2;Receptor, ErbB-3",
        "Doc_meshdescriptors":"3T3 Cells;Animals;Antineoplastic Agents;Breast Neoplasms;Cell Survival;Drug Resistance, Neoplasm;Drug Screening Assays, Antitumor;Humans;Mice;P-Glycoprotein;Phosphorylation;Receptor, Epidermal Growth Factor;Receptor, ErbB-2;Receptor, ErbB-3;Transfection;Tumor Cells, Cultured",
        "Doc_meshqualifiers":"pharmacology;drug effects;physiology;biosynthesis;physiology;biosynthesis;physiology;biosynthesis;physiology;biosynthesis;physiology",
        "_version_":1605746431913623554},
      {
        "Doc_abstract":"Amplification and overexpression of ErbB2 (HER2/Neu) is one of the most common alterations associated with breast cancer. Activation of ErbB2 via homodimerization in a non-transformed human mammary epithelial cell line, MCF-10A, in basement membrane cultures leads to formation of proliferative structures that share properties with non-invasive early stage lesions. Recently, we have shown that activation of ErbB2 homodimers combined with expression of transforming growth factor (TGF)-beta induces invasive and migratory activity in MCF-10A cells. In this system, migration requires inputs from numerous cellular pathways. We discuss this data and a model for migration induced by ErbB2 and TGF-beta. Concurrent studies by other groups have also shown that ErbB2 and TGF-beta can cooperate to increase metastatic and invasive behavior in murine mammary tumors. Here we discuss these studies and the potential implications of this research on breast cancer therapeutics.",
        "Doc_title":"ErbB2 and TGF-beta: a cooperative role in mammary tumor progression?",
        "Journal":"Cell cycle (Georgetown, Tex.)",
        "Do_id":"15107620",
        "Doc_ChemicalList":"Transforming Growth Factor beta;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Animals;Breast Neoplasms;Cell Line;Cell Movement;Cell Transformation, Neoplastic;Female;Humans;Mice;Models, Biological;Neoplasm Metastasis;Receptor, ErbB-2;Transforming Growth Factor beta",
        "Doc_meshqualifiers":"metabolism;pathology;physiology;metabolism;metabolism",
        "_version_":1605875679511969792},
      {
        "Doc_abstract":"The erbB2 oncogene belongs to the type I trans-membrane tyrosine kinase family of receptors. Its medical importance stems from its widespread over-expression in breast cancer. This review will focus on the signal transduction through this protein, and explains how the overexpression of erbB2 may result in poor prognosis of breast cancer, and finally it will summerize our current understanding about the therapeutic potential of receptor-targeted therapy in breast cancer. ErbB2 does not have any known ligand which is able to bind to it with high affinity. However the kinase activity of erbB2 can be activated without any ligand, if it is overexpressed, and by heteroassociation with other members of the erbB family (erbB1 or epidermal growth factor receptor, erbB3 and erbB4). This interaction substantially increases the efficiency and diversity of signal transduction through these receptor complexes. In addition, erbB2 forms large scale receptor clusters containing hundreds of proteins. These receptor islands may take part in recruiting cytosolic factors which relay the signal towards the nucleus or the cytoplasm. Overexpression of erbB2 was linked to higher transforming activity, increased metastatic potential, angiogenesis and drug resistence of breast tumor in laboratory experiments. As a corollary of these properties, erbB2 amplification is generally thought to be associated with a poor prognosis in breast cancer patients. These early findings lead to the development of antibodies that down-regulate erbB2. Such a therapeutic approach has already been found effective in experimental tumor models and in clinical trials as well. Further understanding of the importance of erbB2 and growth factor receptors in the transformation of normal cells to malignant ones may once give us a chance to cure erbB2 over-expressing breast cancer.",
        "Doc_title":"Complexity of signal transduction mediated by ErbB2: clues to the potential of receptor-targeted cancer therapy.",
        "Journal":"Pathology oncology research : POR",
        "Do_id":"10607920",
        "Doc_ChemicalList":"Antibodies, Monoclonal;Antibodies, Monoclonal, Humanized;Antineoplastic Agents;Receptor, ErbB-2;Trastuzumab",
        "Doc_meshdescriptors":"Animals;Antibodies, Monoclonal;Antibodies, Monoclonal, Humanized;Antineoplastic Agents;Breast Neoplasms;Female;Genes, erbB-2;Genetic Therapy;Humans;Neoplasms;Receptor, ErbB-2;Signal Transduction;Trastuzumab",
        "Doc_meshqualifiers":"therapeutic use;therapeutic use;drug therapy;genetics;therapy;physiology",
        "_version_":1605891935534317568},
      {
        "Doc_abstract":"Increasing evidence suggests molecular interactions between erbB2 and other receptor tyrosine kinases, and estrogenic compounds and their cognate receptors. We have recently reported that downregulation of erbB3 abrogates erbB2-mediated tamoxifen resistance in breast cancer cells. On the basis of these data, we hypothesized that erbB3 may play a major role connecting these two sentinel pathways. Interactions were studied using mammary/breast cancer cell lines from wild-type rat c-neu gene transgenic mice and humans. Estradiol promoted cell proliferation and activated erbB2/neu tyrosine kinase, Akt, and mitogen-activated protein kinase signaling exclusively in mammary and breast epithelial cell lines with coexpression of both erbB2 and erbB3. Estradiol action was independent of the transgene promoter (MMTV-LTR) activity, both in vitro and in vivo, as well as c-neu transgene or endogenous erbB2 gene expression. Estrogen induction of cell growth promotion, erbB2/neu activation, and downstream signaling was abrogated by blockade of estrogen receptor (ER) with the pure ER antagonist ICI 182,780 or knockdown of erbB3 expression via specific siRNA. These data suggest that activation of both ER and erbB2/erbB3 signaling is requisite for estrogen-induced mitogenesis and erbB2/neu tyrosine kinase activation.",
        "Doc_title":"Estrogenic promotion of ErbB2 tyrosine kinase activity in mammary tumor cells requires activation of ErbB3 signaling.",
        "Journal":"Molecular cancer research : MCR",
        "Do_id":"19861407",
        "Doc_ChemicalList":"Estradiol;Receptor, ErbB-2;Receptor, ErbB-3",
        "Doc_meshdescriptors":"Animals;Breast Neoplasms;Cell Line, Tumor;Disease Models, Animal;Enzyme Activation;Estradiol;Female;Humans;Mammary Neoplasms, Experimental;Mice;Mice, Transgenic;Rats;Receptor, ErbB-2;Receptor, ErbB-3;Signal Transduction",
        "Doc_meshqualifiers":"enzymology;pathology;pharmacology;enzymology;pathology;genetics;metabolism;genetics;metabolism;drug effects",
        "_version_":1605893399341170688},
      {
        "Doc_abstract":"Mounting evidence suggests involvement of deregulated microRNA (miRNA) expression during the complex events of tumorigenesis. Among such deregulated miRNAs in cancer, miR-125b expression is reported to be consistently low in breast cancers. In this study, we screened a panel of breast cancer cell lines (BCCLs) for miR-125b expression and detected decreased expression in 14 of 19 BCCLs. Due to the heterogeneity of breast cancers, MCF7 cells were chosen as a model system for ERBB2 independent breast cancers to restore miR-125b expression (MCF7-125b) to investigate the phenotypical and related functional changes. Earlier, miR-125b was shown to regulate cell motility by targeting ERBB2 in ERBB2 overexpressing breast cancer cells. Here we showed decreased motility and migration in miR-125b expressing MCF7 cells, independent of ERBB2. MCF7-125b cells demonstrated profoundly decreased cytoplasmic protrusions detected by phalloidin staining of filamentous actin along with decreased motility and migration behaviors detected by in vitro wound closure and transwell migration assays compared to empty vector transfected cells (MCF7-EV). Among possible numerous targets of miR-125b, we showed ARID3B (AT-rich interactive domain 3B) to be a novel target with roles in cell motility in breast cancer cells. When ARID3B was transiently silenced, the decreased cell migration was also observed. In light of these findings, miR-125b continues to emerge as an interesting regulator of cancer related phenotypes.",
        "Doc_title":"miR-125b targets ARID3B in breast cancer cells.",
        "Journal":"Cell structure and function",
        "Do_id":"22307404",
        "Doc_ChemicalList":"3' Untranslated Regions;ARID3B protein, human;DNA-Binding Proteins;MIRN125 microRNA, human;MicroRNAs;Phalloidine;Luciferases, Renilla;ERBB2 protein, human;Receptor, ErbB-2;Extracellular Signal-Regulated MAP Kinases",
        "Doc_meshdescriptors":"3' Untranslated Regions;Breast Neoplasms;Cell Line, Tumor;Cell Movement;Cell Shape;DNA-Binding Proteins;Extracellular Signal-Regulated MAP Kinases;Female;Gene Expression;Gene Expression Regulation, Neoplastic;Genes, Reporter;Humans;Luciferases, Renilla;MicroRNAs;Phalloidine;Phosphorylation;RNA Interference;Real-Time Polymerase Chain Reaction;Receptor, ErbB-2",
        "Doc_meshqualifiers":"genetics;metabolism;metabolism;biosynthesis;genetics;genetics;metabolism;metabolism;metabolism",
        "_version_":1605840940246761472},
      {
        "Doc_abstract":"Inappropriate expression of Her-2/neu (ERBB2) gene has been associated with impaired breast cancer prognosis, suggesting a functional role in tumor progression. Herein we describe a quantitative method for analysis of Her-2/neu gene messenger RNA (mRNA), which employs reverse transcriptase polymerase chain reaction (RT-PCR) on a 10-microns cryostat section. The technique combines modified RNA extraction with complementary DNA (cDNA) synthesis to achieve a high level of sensitivity. Utilizing this PCR-based gene expression assay, we were able to quantitate variable amounts of Her-2/neu mRNA in cell lines with established levels of gene expression and in clinical human breast cancer specimens. In clinical samples, mRNA levels correlated with intensity of immunoperoxidase staining for corresponding oncoprotein. We conclude that PCR-based mRNA quantitation can be applied to quantitative analysis of Her-2/neu gene expression, and potentially many other genes, in samples of limited size.",
        "Doc_title":"Quantitative analysis of Her-2/neu (ERBB2) gene expression using reverse transcriptase polymerase chain reaction.",
        "Journal":"Diagnostic molecular pathology : the American journal of surgical pathology, part B",
        "Do_id":"7506983",
        "Doc_ChemicalList":"DNA, Neoplasm;Oncogene Proteins, Viral;RNA, Messenger;Receptor, ErbB-2;RNA-Directed DNA Polymerase",
        "Doc_meshdescriptors":"Base Sequence;Blotting, Southern;Breast Neoplasms;DNA, Neoplasm;Humans;Molecular Sequence Data;Oncogene Proteins, Viral;Polymerase Chain Reaction;RNA, Messenger;RNA-Directed DNA Polymerase;Receptor, ErbB-2;Tumor Cells, Cultured",
        "Doc_meshqualifiers":"genetics;biosynthesis;genetics;analysis",
        "_version_":1605798238286249984},
      {
        "Doc_abstract":"ErbB2 (HER2, Neu), a member of the epidermal growth factor (EGF) receptor tyrosine kinase family, is often overexpressed in breast cancer and other malignancies. ErbB2 homodimerizes but also presents as a common auxiliary subunit of the EGF and heregulin receptors (erbB1 or EGFR; and erbB3-4, respectively), with which it heteroassociates. ErbB2 is generally regarded as an orphan (ligand-less) receptor with a very potent kinase domain activated either via its associated partners or constitutively as a consequence of discrete mutations. It follows that the extent and regulation of its cell surface interactions are of central importance. We have studied the large-scale association pattern of erbB2 in quiescent and activated cells labeled with fluorescent anti-erbB2 monoclonal antibodies using scanning near-field optical microscopy (SNOM). ErbB2 was found to be concentrated in irregular membrane patches with a mean diameter of approx. 0.5 microm in nonactivated SKBR3 and MDA453 human breast tumor cells. The average number of erbB2 proteins in a single cluster on nonactivated SKBR3 cells was about 10(3). Activation of SKBR3 cells with EGF, heregulin as well as a partially agonistic anti-erbB2 monoclonal antibody led to an increase in the mean cluster diameter to 0.6-0.9 microm, irrespective of the ligand. The EGF-induced increase in the erbB2 cluster size was inhibited by the EGFR-specific tyrosine kinase inhibitor PD153035. The average size of erbB2 clusters on the erbB2-transfected line of CHO cells (CB2) was similar to that of activated SKBR3 cells, a finding correlated with the increased base-line tyrosine phosphorylation of erbB2 in cells expressing only erbB2. We conclude that an increase in cluster size may constitute a general phenomenon in the activation of erbB2.",
        "Doc_title":"Activation-dependent clustering of the erbB2 receptor tyrosine kinase detected by scanning near-field optical microscopy.",
        "Journal":"Journal of cell science",
        "Do_id":"10318765",
        "Doc_ChemicalList":"4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline;Enzyme Inhibitors;Quinazolines;Receptor Protein-Tyrosine Kinases;Receptor, Epidermal Growth Factor;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Animals;CHO Cells;Cricetinae;Enzyme Activation;Enzyme Inhibitors;Humans;Microscopy, Atomic Force;Microscopy, Confocal;Quinazolines;Receptor Protein-Tyrosine Kinases;Receptor, Epidermal Growth Factor;Receptor, ErbB-2;Tumor Cells, Cultured",
        "Doc_meshqualifiers":"pharmacology;methods;pharmacology;metabolism;antagonists & inhibitors;metabolism",
        "_version_":1605852342161244160},
      {
        "Doc_abstract":"Overexpression of the epidermal growth factor receptor (EGFR), ErbB2, and ErbB3 promotes growth and antiapoptotic signaling. Overexpression of ErbB2 in breast cancer is associated with poor clinical outcome, and ways of down-regulating ErbB2 are important as therapeutic approaches. In contrast to EGFR, ErbB2 has been shown to be endocytosis deficient. However, down-regulation of ErbB2 can be induced by incubation of cells with geldanamycin and geldanamycin derivatives, counteracting the stabilizing function of heat shock protein 90 on ErbB2. In the present study, we have made use of stably transfected isogenic cell lines expressing ErbB2 only or ErbB2 together with EGFR and/or ErbB3. We now show that whereas ErbB2 can be down-regulated by incubation with geldanamycin in cells expressing ErbB2 only, the rate of geldanamycin-induced down-regulation increases significantly when the cells additionally express EGFR and/or ErbB3. This increase does, however, not correlate with activation/phosphorylation of ErbB2. The potential of heterodimer formation in ErbB2-positive breast cancer cells could thus turn out to be prognostically predictive with respect to outcome of treatment with geldanamycin derivatives.",
        "Doc_title":"Expression of epidermal growth factor receptor or ErbB3 facilitates geldanamycin-induced down-regulation of ErbB2.",
        "Journal":"Molecular cancer research : MCR",
        "Do_id":"19208749",
        "Doc_ChemicalList":"Antibiotics, Antineoplastic;Benzoquinones;Cross-Linking Reagents;HSP90 Heat-Shock Proteins;Lactams, Macrocyclic;Epidermal Growth Factor;ERBB2 protein, human;Receptor, Epidermal Growth Factor;Receptor, ErbB-2;Receptor, ErbB-3;p38 Mitogen-Activated Protein Kinases;geldanamycin",
        "Doc_meshdescriptors":"Antibiotics, Antineoplastic;Apoptosis;Benzoquinones;Breast Neoplasms;Cell Proliferation;Cross-Linking Reagents;Dimerization;Down-Regulation;Epidermal Growth Factor;Flow Cytometry;Gene Expression Regulation, Neoplastic;HSP90 Heat-Shock Proteins;Humans;Immunoblotting;Immunoenzyme Techniques;Immunoprecipitation;Lactams, Macrocyclic;Phosphorylation;Receptor, Epidermal Growth Factor;Receptor, ErbB-2;Receptor, ErbB-3;Signal Transduction;Tumor Cells, Cultured;p38 Mitogen-Activated Protein Kinases",
        "Doc_meshqualifiers":"pharmacology;drug effects;pharmacology;drug therapy;metabolism;pathology;drug effects;pharmacology;metabolism;pharmacology;drug effects;genetics;metabolism;antagonists & inhibitors;genetics;metabolism;genetics;metabolism;drug effects;antagonists & inhibitors;metabolism",
        "_version_":1605784091339259904},
      {
        "Doc_abstract":"The ErbB2 oncogene is often overexpressed in breast tumors and associated with poor clinical outcome. p130Cas represents a nodal scaffold protein regulating cell survival, migration, and proliferation in normal and pathological cells. The functional role of p130Cas in ErbB2-dependent breast tumorigenesis was assessed by its silencing in breast cancer cells derived from mouse mammary tumors overexpressing ErbB2 (N202-1A cells), and by its reexpression in ErbB2-transformed p130Cas-null mouse embryonic fibroblasts. We demonstrate that p130Cas is necessary for ErbB2-dependent foci formation, anchorage-independent growth, and in vivo growth of orthotopic N202-1A tumors. Moreover, intranipple injection of p130Cas-stabilized siRNAs in the mammary gland of Balbc-NeuT mice decreases the growth of spontaneous tumors. In ErbB2-transformed cells, p130Cas is a crucial component of a functional molecular complex consisting of ErbB2, c-Src, and Fak. In human mammary cells, MCF10A.B2, the concomitant activation of ErbB2, and p130Cas overexpression sustain and strengthen signaling, leading to Rac1 activation and MMP9 secretion, thus providing invasive properties. Consistently, p130Cas drives N202-1A cell in vivo lung metastases colonization. These results demonstrate that p130Cas is an essential transducer in ErbB2 transformation and highlight its potential use as a novel therapeutic target in ErbB2 positive human breast cancers.",
        "Doc_title":"p130Cas is an essential transducer element in ErbB2 transformation.",
        "Journal":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology",
        "Do_id":"20505116",
        "Doc_ChemicalList":"Bcar1 protein, mouse;Crk-Associated Substrate Protein;RNA, Small Interfering",
        "Doc_meshdescriptors":"Animals;Cell Line, Tumor;Cell Transformation, Neoplastic;Crk-Associated Substrate Protein;Female;Gene Silencing;Genes, erbB-2;Humans;Mammary Neoplasms, Experimental;Mice;Mice, Inbred BALB C;NIH 3T3 Cells;RNA, Small Interfering;Signal Transduction",
        "Doc_meshqualifiers":"genetics;physiology;pathology",
        "_version_":1605902868724842496},
      {
        "Doc_abstract":"Overexpression of the human epidermal growth factor receptor-2 (HER2) in breast cancer strongly correlates with aggressive tumors and poor prognosis. Recently, a positive correlation between HER2 and MIF (macrophage migration inhibitory factor, a tumor-promoting protein and heat-shock protein 90 (HSP90) client) protein levels was shown in cancer cells. However, the underlying mechanistic link remained unknown. Here we show that overexpressed HER2 constitutively activates heat-shock factor 1 (HSF1), the master transcriptional regulator of the inducible proteotoxic stress response of heat-shock chaperones, including HSP90, and a crucial factor in initiation and maintenance of the malignant state. Inhibiting HER2 pharmacologically by Lapatinib (a dual HER2/epidermal growth factor receptor inhibitor) or CP724.714 (a specific HER2 inhibitor), or by knockdown via siRNA leads to inhibition of phosphoactivated Ser326 HSF1, and subsequently blocks the activity of the HSP90 chaperone machinery in HER2-overexpressing breast cancer lines. Consequently, HSP90 clients, including MIF, AKT, mutant p53 and HSF1 itself, become destabilized, which in turn inhibits tumor proliferation. Mechanistically, HER2 signals via the phosphoinositide-3-kinase (PI3K)-AKT- mammalian target of rapamycin (mTOR) axis to induce activated pSer326 HSF1. Heat-shock stress experiments confirm this functional link between HER2 and HSF1, as HER2 (and PI3K) inhibition attenuate the HSF1-mediated heat-shock response. Importantly, we confirmed this axis in vivo. In the mouse model of HER2-driven breast cancer, ErbB2 inhibition by Lapatinib strongly suppresses tumor progression, and this is associated with inactivation of the HSF1 pathway. Moreover, ErbB2-overexpressing cancer cells derived from a primary mouse ErbB2 tumor also show HSF1 inactivation and HSP90 client destabilization in response to ErbB2 inhibition. Furthermore, in HER2-positive human breast cancers HER2 levels strongly correlate with pSer326 HSF1 activity. Our results show for the first time that HER2/ErbB2 overexpression controls HSF1 activity, with subsequent stabilization of numerous tumor-promoting HSP90 clients such as MIF, AKT and HSF1 itself, thereby causing a robust promotion in tumor growth in HER2-positive breast cancer. ",
        "Doc_title":"HER2/ErbB2 activates HSF1 and thereby controls HSP90 clients including MIF in HER2-overexpressing breast cancer.",
        "Journal":"Cell death & disease",
        "Do_id":"24384723",
        "Doc_ChemicalList":"DNA-Binding Proteins;HSP90 Heat-Shock Proteins;Macrophage Migration-Inhibitory Factors;Transcription Factors;heat shock transcription factor;Phosphatidylinositol 3-Kinases;Receptor, ErbB-2;Intramolecular Oxidoreductases;MIF protein, human",
        "Doc_meshdescriptors":"Animals;Breast Neoplasms;Cell Line, Tumor;DNA-Binding Proteins;Female;HSP90 Heat-Shock Proteins;Humans;Intramolecular Oxidoreductases;Macrophage Migration-Inhibitory Factors;Mice;Mice, Knockout;Phosphatidylinositol 3-Kinases;Receptor, ErbB-2;Transcription Factors",
        "Doc_meshqualifiers":"genetics;metabolism;genetics;metabolism;genetics;metabolism;genetics;metabolism;genetics;metabolism;genetics;metabolism;genetics;metabolism;genetics;metabolism",
        "_version_":1605746308075749379},
      {
        "Doc_abstract":"We demonstrate here that the bioactive lipid sphingosine 1-phosphate (S1P) uses sphingosine 1-phosphate receptor 4 (S1P(4)) and human epidermal growth factor receptor 2 (HER2) to stimulate the extracellular signal regulated protein kinase 1/2 (ERK-1/2) pathway in MDA-MB-453 cells. This was based on several lines of evidence. First, the S1P stimulation of ERK-1/2 was abolished by JTE013, which we show here is an S1P(2/4) antagonist and reduced by siRNA knockdown of S1P(4). Second, the S1P-stimulated activation of ERK-1/2 was almost completely abolished by a HER2 inhibitor (ErbB2 inhibitor II) and reduced by siRNA knockdown of HER2 expression. Third, phyto-S1P, which is an S1P(4) agonist, stimulated ERK-1/2 activation in an S1P(4)- and HER2-dependent manner. Fourth, FTY720 phosphate, which is an agonist at S1P(1,3,4,5) but not S1P(2) stimulated activation of ERK-1/2. Fifth, S1P stimulated the tyrosine phosphorylation of HER2, which was reduced by JTE013. HER2 which is an orphan receptor tyrosine kinase is the preferred dimerization partner of the EGF receptor. However, EGF-stimulated activation of ERK-1/2 was not affected by siRNA knockdown of HER2 or by ErbB2 (epidermal growth factor receptor 2 (or HER2)) inhibitor II in MDA-MB-453 cells. Moreover, S1P-stimulated activation of ERK-1/2 does not require an EGF receptor. Thus, S1P and EGF function in a mutually exclusive manner. In conclusion, the magnitude of the signaling gain on the ERK-1/2 pathway produced in response to S1P can be increased by HER2 in MDA-MB-453 cells. The linkage of S1P with an oncogene suggests that S1P and specifically S1P(4) may have an important role in breast cancer progression.",
        "Doc_title":"Sphingosine 1-phosphate receptor 4 uses HER2 (ERBB2) to regulate extracellular signal regulated kinase-1/2 in MDA-MB-453 breast cancer cells.",
        "Journal":"The Journal of biological chemistry",
        "Do_id":"20837468",
        "Doc_ChemicalList":"JTE 013;Lysophospholipids;Propylene Glycols;Pyrazoles;Pyridines;Receptors, Lysosphingolipid;sphingosine 1-phosphate;Epidermal Growth Factor;Receptor, ErbB-2;MAPK1 protein, human;Mitogen-Activated Protein Kinase 1;Mitogen-Activated Protein Kinase 3;Fingolimod Hydrochloride;Sphingosine",
        "Doc_meshdescriptors":"Blotting, Western;Breast Neoplasms;Cell Line, Tumor;Dose-Response Relationship, Drug;Enzyme Activation;Epidermal Growth Factor;Female;Fingolimod Hydrochloride;HEK293 Cells;Humans;Lysophospholipids;Mitogen-Activated Protein Kinase 1;Mitogen-Activated Protein Kinase 3;Phosphorylation;Propylene Glycols;Pyrazoles;Pyridines;RNA Interference;Receptor, ErbB-2;Receptors, Lysosphingolipid;Reverse Transcriptase Polymerase Chain Reaction;Signal Transduction;Sphingosine",
        "Doc_meshqualifiers":"genetics;metabolism;pathology;drug effects;pharmacology;pharmacology;genetics;metabolism;genetics;metabolism;drug effects;pharmacology;pharmacology;pharmacology;genetics;metabolism;antagonists & inhibitors;genetics;metabolism;drug effects;analogs & derivatives;pharmacology",
        "_version_":1605742781670621184},
      {
        "Doc_abstract":"The human epidermal growth factor receptor-2 (HER-2)/neu is a proto-oncogene that is amplified in 10-30% of breast cancers. It is known to be associated with a poor overall survival. We studied the relationship between its amplification and different histological gradings of breast cancer.;We studied 196 patients diagnosed with breast cancer in 2005 at the Omid and Ghaem Training Hospital, Mashhad Medical University, Iran. The HER-2/neu oncoprotein was measured by immunohistochemistry and the histological gradings were carried out according to the Bloom-Richardson Grading system.;Sixty-seven (34.2%) cases were HER-2/neu positive and 129 (65.8%) cases were HER-2/neu negative. Overexpression of HER-2/neu was significantly higher in breast cancer patients <30 years (50% versus 33.3%, p=0.034). There was a non-significant statistical relationship between histological grading and overexpression of HER-2/neu oncogen (p=0.087). Twelve (17.5%) of HER-2/neu positive cases were metastatic and only 4 (3.1%) of HER-2/neu negative cases had metastasis (p=0.051).;HER-2/neu gene amplification or its overexpression is detected in approximately 34.2% of breast cancer cases. Patients with HER-2/neu positive breast cancer have higher stage and grade diseases. This may help to use a better treatment for patients.",
        "Doc_title":"Evaluation of the relationship between human epidermal growth factor receptor-2/neu (c-erbB-2) amplification and pathologic grading in patients with breast cancer.",
        "Journal":"Saudi medical journal",
        "Do_id":"17143354",
        "Doc_ChemicalList":"Receptor, ErbB-2",
        "Doc_meshdescriptors":"Adult;Aged;Aged, 80 and over;Breast Neoplasms;Female;Gene Amplification;Gene Expression Regulation, Neoplastic;Humans;Middle Aged;Receptor, ErbB-2",
        "Doc_meshqualifiers":"genetics;pathology;genetics;genetics",
        "_version_":1605884577679671296},
      {
        "Doc_abstract":"The ErbB2 receptor tyrosine kinase is overexpressed in approximately 30% of breast tumor cases and its overexpression correlates with an unfavorable prognosis. A major contributor for this course of the disease is the insensitivity of these tumors toward chemotherapy. Monoclonal antibodies, inhibiting the ligand-induced activation of the receptor and tyrosine kinase inhibitors acting on the intrinsic enzymatic activity of the intracellular domain, have been developed as targeted drugs. Both have been shown to be beneficial for breast cancer patients. We targeted a third aspect of receptor function: its association with intracellular signaling components. For this purpose, we selected peptide aptamers, which specifically interact with defined domains of the intracellular part of the receptor. The peptide aptamers were selected from a random peptide library using a yeast two-hybrid system with the intracellular tyrosine kinase domain of ErbB2 as a bait construct. The peptide aptamer AII-7 interacts with high specificity with the ErbB2 receptor in vitro and in vivo. The aptamers colocalized with the intracellular domain of ErbB2 within cells. We investigated the functional consequences of the aptamer interaction with the ErbB2 receptor within tumor cells. The aptamer sequences were either expressed intracellularly or introduced into the cells as recombinant aptamer proteins. The phosphorylation of p42/44 mitogen-activated protein kinase was nearly unaffected and the activation of signal transducers and activators of transcription-3 was only modestly reduced. In contrast, they strongly inhibited the induction of AKT kinase in MCF7 breast cancer cells treated with heregulin, whereas AKT activation downstream of insulin-like growth factor I or epidermal growth factor receptor was not or only slightly affected. High AKT activity is responsible for the enhanced resistance of ErbB2-overexpressing cancer cells toward chemotherapeutic agents. Peptide aptamer interference with AKT activation resulted in the restoration of regular sensitivity of breast cancer cells toward Taxol.",
        "Doc_title":"Peptide aptamers with binding specificity for the intracellular domain of the ErbB2 receptor interfere with AKT signaling and sensitize breast cancer cells to Taxol.",
        "Journal":"Molecular cancer research : MCR",
        "Do_id":"17189388",
        "Doc_ChemicalList":"Antineoplastic Agents;Aptamers, Peptide;Intercellular Signaling Peptides and Proteins;Peptide Library;herstatin;Receptor, ErbB-2;Proto-Oncogene Proteins c-akt;Paclitaxel",
        "Doc_meshdescriptors":"Amino Acid Motifs;Antineoplastic Agents;Aptamers, Peptide;Breast Neoplasms;Drug Interactions;Drug Screening Assays, Antitumor;Humans;Intercellular Signaling Peptides and Proteins;Paclitaxel;Peptide Library;Protein Conformation;Proto-Oncogene Proteins c-akt;Receptor, ErbB-2;Signal Transduction;Tumor Cells, Cultured",
        "Doc_meshqualifiers":"pharmacology;chemistry;pharmacology;pathology;pharmacology;pharmacology;physiology;drug effects;metabolism;drug effects;physiology",
        "_version_":1605774223134949376},
      {
        "Doc_abstract":"The aim of this work is to determine the possible relationship between the different profiles of molecular expression of hormone receptors and Her-2Ã·neu receptors to clinical and histopathological known prognostic variables for breast cancer.;A total of 110 breast carcinoma tumor samples were included. In this study 4 groups or immunohistochemical profiles were defined, based on expression of hormone receptors (estrogen andÃ·or progesterone) andÃ·or Her2Ã·neu (Luminal A, Luminal B, HER2 overexpressing profile, and triple-negative profile). We studied whether there were differences between them regarding clinical and histopathological variables with a known prognostic significance in addition to Nottingham Prognosis Index (NPI).;In this series, 65 cases corresponded to Luminal A (59.1%), 18 cases (16.4%) were Luminal B, in 14 cases (12.7%) HER2 was over-expressed, while 13 cases (11.8%) were of the triple negative subtype. It is worth noting the relationship between the triple negative and HER2 over-expressing immunophenotypes and the high NPI (>3.4) in comparison with the Luminal A and Luminal B immunophenotypes (p=.029). The association of the former two types with higher tumor grade was also observed, but such association did not reach statistical significance.;The subgroups without hormone receptor expression, with Her2Ã·neu overexpression or without (triple-negative group), have characteristics associated with variables of a poorer prognosis.;Breast cancer- Hormone receptors- Her2neu- Classification- Nottingham prognosis index.",
        "Doc_title":"Clinicopathologic significance of molecular classification of breast cancer: relation to nottingham prognosis index.",
        "Journal":"Journal of the Egyptian National Cancer Institute",
        "Do_id":"21863072",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605746335024152577},
      {
        "Doc_abstract":"Targeting non-oncogenic vulnerabilities may provide additional therapeutic approaches in tumors that are resistant to oncogene-targeted therapy. Using a computational pathway-based approach, we interrogated clinical breast cancer genomic data sets for candidate non-oncogenic vulnerabilities in breast cancers that have genomic amplification of ERBB2, which encodes human epidermal growth factor 2 (HER2). HER2-positive (HER2(+)) breast cancers showed increased expression of genes encoding proteins in the endoplasmic reticulum (ER)-associated degradation (ERAD) pathway. Genetic ablation or pharmacological inhibition of ERAD led to irrecoverable ER stress and selectively killed HER2(+) breast cancer cells. Cell death caused by ERAD inhibition partially depended on increased HER2-mTOR signaling, which imposed an increased proteotoxic burden on the ER. Cell death in response to ER stress required the IRE1Î±-JNK pathway, which was selectively suppressed in HER2(+) breast cancers by phosphatases that inactivate JNK. Accordingly, the cytotoxicity of inhibiting ERAD as well as JNK phosphatases was synergistic in HER2(+) but not in HER2-negative breast cancer cells. Therefore, our study suggests that reactivation of oncogene-induced stress by targeting stress-adaptive pathways may be a beneficial approach for therapy-resistant breast cancers.",
        "Doc_title":"HER2-mTOR signaling-driven breast cancer cells require ER-associated degradation to survive.",
        "Journal":"Science signaling",
        "Do_id":"26012635",
        "Doc_ChemicalList":"MTOR protein, human;TOR Serine-Threonine Kinases;ERBB2 protein, human;Receptor, ErbB-2;ERN1 protein, human;Protein-Serine-Threonine Kinases;MAP Kinase Kinase 4;Endoribonucleases",
        "Doc_meshdescriptors":"Breast Neoplasms;Cell Line, Tumor;Endoplasmic Reticulum;Endoplasmic Reticulum Stress;Endoribonucleases;Female;Humans;MAP Kinase Kinase 4;MAP Kinase Signaling System;Protein-Serine-Threonine Kinases;Proteolysis;Receptor, ErbB-2;TOR Serine-Threonine Kinases",
        "Doc_meshqualifiers":"genetics;metabolism;pathology;genetics;metabolism;pathology;genetics;genetics;metabolism;genetics;metabolism;genetics;metabolism;genetics;metabolism;genetics;metabolism",
        "_version_":1605832058977910784},
      {
        "Doc_abstract":"HER2 (or ErbB2), a member of ErbB receptor tyrosine kinases, is overexpressed in approximately 20% of human breast cancer, and the ErbB2 signaling pathway is a critical therapeutic target for ErbB2-overexpressing breast cancer. We investigated the inhibitory effects of the Gemini vitamin D analog BXL0124, the synthetic triterpenoid CDDO-Im and the combination on the tumorigenesis of ErbB2-overexpressing breast cancer. MMTV-ErbB2/neu transgenic mice were treated with BXL0124, CDDO-Im, or the combination from three months of age until the end of the experiment. Formation and growth of MMTV-ErbB2/neu mammary tumors were monitored every week, and all three treatments delayed the development of mammary tumors without significant toxicity. Decreased activation of ErbB2 as well as other ErbB receptors, ErbB1 and ErbB3, in MMTV-ErbB2/neu mammary tumors was shown by all treatments. Protein levels of downstream targets of the ErbB2 signaling pathway, including activated-Erk1/2, activated-Akt, c-Myc, CycD1, and Bcl2, were repressed by all three treatments, with the combination treatment exhibiting the strongest effects. To investigate therapeutic efficacy, the combination of BXL0124 and CDDO-Im was given to MMTV-ErbB2/neu mice after mammary tumors were established between 23 and 30 weeks of age. Short-term treatment with the combination did not show effects on tumor growth nor the ErbB2 signaling pathway. The present study shows BXL0124, CDDO-Im, and the combination as potential agents for prevention, but not treatment, against the tumorigenesis of ErbB2-overexpressing breast cancer.",
        "Doc_title":"Oral administration of a gemini vitamin D analog, a synthetic triterpenoid and the combination prevents mammary tumorigenesis driven by ErbB2 overexpression.",
        "Journal":"Cancer prevention research (Philadelphia, Pa.)",
        "Do_id":"23856074",
        "Doc_ChemicalList":"1,25-dihydroxy-21-(3-hydroxy-3-methyl-4,4,4-tributyl)-23-yne-26,27-hexafluorocholecalciferol;1-(2-cyano-3,12-dioxooleana-1,9-dien-28-oyl) imidazole;Imidazoles;RNA, Messenger;Oleanolic Acid;Receptor, ErbB-2;Calcitriol",
        "Doc_meshdescriptors":"Administration, Oral;Animals;Antineoplastic Combined Chemotherapy Protocols;Blotting, Western;Calcitriol;Cell Transformation, Neoplastic;Female;Humans;Imidazoles;Mammary Neoplasms, Animal;Mammary Tumor Virus, Mouse;Mice;Mice, Transgenic;Microscopy, Fluorescence;Oleanolic Acid;RNA, Messenger;Real-Time Polymerase Chain Reaction;Receptor, ErbB-2;Reverse Transcriptase Polymerase Chain Reaction;Signal Transduction",
        "Doc_meshqualifiers":"administration & dosage;analogs & derivatives;pharmacology;drug effects;pathology;administration & dosage;pharmacology;metabolism;pathology;prevention & control;genetics;administration & dosage;analogs & derivatives;pharmacology;genetics;physiology;drug effects",
        "_version_":1605825469523951616},
      {
        "Doc_abstract":"In an attempt to standardize the immunohistochemical detection of ERBB2, we evaluated six normal breast samples and 58 breast carcinomas for (1) the effect of four different fixatives (Bouin's fluid, buffered formalin, alcoholic formalin, and methacarn), and (2) the sensitivity and specificity of eight commercially available antibodies. ERBB2 gene copy numbers and RNA transcripts were measured by Southern and Northern blot analysis in all samples. The BT-474 and MCF7 cell lines were processed in the same way as the tissue samples and used a s references of activation or the normal state of the ERBB2 gene, respectively. Complete concordance between immunohistochemistry and molecular biology was observed in 43/58 cases (74 per cent). However, fixation and processing protocols significantly affected the reactivity of the antigenic determinants. The most consistent results were obtained with NCLCB11 on frozen sections and with Tab250 on paraffin-embedded sections. For prospective studies, the use of alcoholic formalin in association with a highly specific antibody (Tab250, 9G6, NCLCB11, or OA-11-854) gave the best results. Methacarn appears to be a reliable fixative, but was studied in only 28 cases. For retrospective studies, the most important parameter to take into account is the sensitivity of the antibody. Thus, with Bouin's fixation, 3B5 was the only reliable antibody, whereas with buffered formalin, Tab250 gave the most consistent results. This study will help inter-laboratory comparisons, and in determining the prognostic significance of ERBB2 expression in breast carcinomas using a standardized methodology.",
        "Doc_title":"Optimization of immunohistochemical detection of ERBB2 in human breast cancer: impact of fixation.",
        "Journal":"The Journal of pathology",
        "Do_id":"7931839",
        "Doc_ChemicalList":"Antibodies, Monoclonal;Biomarkers, Tumor;Fixatives;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Antibodies, Monoclonal;Biomarkers, Tumor;Blotting, Northern;Blotting, Southern;Breast Neoplasms;Female;Fixatives;Gene Amplification;Humans;Immunohistochemistry;Paraffin Embedding;Prognosis;Receptor, ErbB-2;Tissue Fixation;Tumor Cells, Cultured",
        "Doc_meshqualifiers":"chemistry;chemistry;genetics;methods;analysis;genetics",
        "_version_":1605751005503291392},
      {
        "Doc_abstract":"ErbB2 is a transmembrane tyrosine kinase whose surface overexpression is linked to tumorigenesis and poor prognosis in breast cancer patients. Two models have emerged that account for the high surface distribution of ErbB2. In one model, the surface pool is dynamic and governed by a balance between endocytosis and recycling, whereas in the other it is retained, static, and excluded from endocytosis. These models have contrasting implications for how ErbB2 exerts its biological function and how cancer therapies might down-regulate surface ErbB2, such as the antibody trastuzumab (Herceptin) or the Hsp90 inhibitor geldanamycin. Little is known, however, about how these treatments affect ErbB2 endocytic trafficking. To investigate this issue, we examined breast carcinoma cells by immunofluorescence and quantitative immunoelectron microscopy and developed imaging and trafficking kinetics assays using cell surface fluorescence quenching. Surprisingly, trastuzumab does not influence ErbB2 distribution but instead recycles passively with internalized ErbB2. By contrast, geldanamycin down-regulates surface ErbB2 through improved degradative sorting in endosomes exclusively rather than through increased endocytosis. These results reveal substantial dynamism in the surface ErbB2 pool and clearly demonstrate the significance of endosomal sorting in the maintenance of ErbB2 surface distribution, a critical feature of its biological function.",
        "Doc_title":"Endocytosis and sorting of ErbB2 and the site of action of cancer therapeutics trastuzumab and geldanamycin.",
        "Journal":"Molecular biology of the cell",
        "Do_id":"15385631",
        "Doc_ChemicalList":"Antibodies, Monoclonal;Antibodies, Monoclonal, Humanized;Benzoquinones;Lactams, Macrocyclic;Quinones;Receptor, ErbB-2;Trastuzumab;geldanamycin",
        "Doc_meshdescriptors":"Antibodies, Monoclonal;Antibodies, Monoclonal, Humanized;Benzoquinones;Biological Transport;Breast Neoplasms;Cell Line, Tumor;Down-Regulation;Endocytosis;Humans;Lactams, Macrocyclic;Lysosomes;Microscopy, Electron, Scanning;Microscopy, Fluorescence;Neoplasms;Quinones;Receptor, ErbB-2;Trastuzumab",
        "Doc_meshqualifiers":"immunology;metabolism;pharmacology;metabolism;pathology;ultrastructure;metabolism;drug therapy;immunology;metabolism;pathology;pharmacology;metabolism",
        "_version_":1605880404993114112},
      {
        "Doc_abstract":"Breast cancer subtyping and prognosis have been studied extensively by gene expression profiling, resulting in disparate signatures with little overlap in their constituent genes. Although a previous study demonstrated a prognostic concordance among gene expression signatures, it was limited to only one dataset and did not fully elucidate how the different genes were related to one another nor did it examine the contribution of well-known biological processes of breast cancer tumorigenesis to their prognostic performance.;To address the above issues and to further validate these initial findings, we performed the largest meta-analysis of publicly available breast cancer gene expression and clinical data, which are comprised of 2,833 breast tumors. Gene coexpression modules of three key biological processes in breast cancer (namely, proliferation, estrogen receptor [ER], and HER2 signaling) were used to dissect the role of constituent genes of nine prognostic signatures.;Using a meta-analytical approach, we consolidated the signatures associated with ER signaling, ERBB2 amplification, and proliferation. Previously published expression-based nomenclature of breast cancer 'intrinsic' subtypes can be mapped to the three modules, namely, the ER-/HER2- (basal-like), the HER2+ (HER2-like), and the low- and high-proliferation ER+/HER2- subtypes (luminal A and B). We showed that all nine prognostic signatures exhibited a similar prognostic performance in the entire dataset. Their prognostic abilities are due mostly to the detection of proliferation activity. Although ER- status (basal-like) and ERBB2+ expression status correspond to bad outcome, they seem to act through elevated expression of proliferation genes and thus contain only indirect information about prognosis. Clinical variables measuring the extent of tumor progression, such as tumor size and nodal status, still add independent prognostic information to proliferation genes.;This meta-analysis unifies various results of previous gene expression studies in breast cancer. It reveals connections between traditional prognostic factors, expression-based subtyping, and prognostic signatures, highlighting the important role of proliferation in breast cancer prognosis.",
        "Doc_title":"Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures.",
        "Journal":"Breast cancer research : BCR",
        "Do_id":"18662380",
        "Doc_ChemicalList":"Antineoplastic Agents;Receptors, Estrogen;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Antineoplastic Agents;Breast Neoplasms;Cell Proliferation;Cluster Analysis;Female;Gene Expression Profiling;Gene Expression Regulation, Neoplastic;Genes, erbB-2;Humans;Prognosis;Receptor, ErbB-2;Receptors, Estrogen;Signal Transduction",
        "Doc_meshqualifiers":"pharmacology;diagnosis;pathology;metabolism;metabolism",
        "_version_":1605756663289085952},
      {
        "Doc_abstract":"Ethanol is a tumor promoter and may enhance the metastasis of breast cancer. However, the underlying cellular/molecular mechanisms remain unknown. Amplification of ErbB2, a receptor tyrosine kinase, is found in 20-30% of breast cancer patients. Ethanol preferably stimulates invasion by breast cancer cells over-expressing ErbB2 in vitro. Over-expression of ErbB2 is positively associated with elevated levels of matrix metalloproteinase-2 (MMP-2) and MMP-9. Ethanol at physiologically relevant concentrations activates MMP-2 without altering its expression level in mammary epithelial cells over-expressing ErbB2, but not in cells expressing low levels of ErbB2. The activation is dependent on c-jun N-terminal kinases (JNK) and reactive oxygen species. Selective inhibitors of MMP-2 and anti-oxidants significantly inhibit ethanol-stimulated cell invasion. Similarly, knocking down MMP-2 by small interference RNA induces a partial blockage on ethanol-promoted cell invasion. Matrix metalloproteinase-2 is predominantly expressed in stromal fibroblasts; ethanol also activates fibroblastic MMP-2. The conditioned medium collected from ethanol-exposed fibroblasts dramatically stimulates the invasion of breast cancer cells. The role of MMP-2 in ethanol-induced tumor promotion is discussed.",
        "Doc_title":"Role of matrix metalloproteinase-2 in ethanol-induced invasion by breast cancer cells.",
        "Journal":"Journal of gastroenterology and hepatology",
        "Do_id":"16958676",
        "Doc_ChemicalList":"Reactive Oxygen Species;Ethanol;Phosphatidylinositol 3-Kinases;Receptor, ErbB-2;JNK Mitogen-Activated Protein Kinases;p38 Mitogen-Activated Protein Kinases;Matrix Metalloproteinase 2;Matrix Metalloproteinase 9",
        "Doc_meshdescriptors":"Epithelial Cells;Ethanol;Gene Expression Regulation;Genes, erbB-2;Humans;JNK Mitogen-Activated Protein Kinases;Mammary Glands, Human;Matrix Metalloproteinase 2;Matrix Metalloproteinase 9;Phosphatidylinositol 3-Kinases;Reactive Oxygen Species;Receptor, ErbB-2;Transcription, Genetic;Up-Regulation;p38 Mitogen-Activated Protein Kinases",
        "Doc_meshqualifiers":"enzymology;pharmacology;metabolism;cytology;enzymology;metabolism;metabolism;metabolism;metabolism;genetics;metabolism",
        "_version_":1605818723196731393},
      {
        "Doc_abstract":"AKT, a serine/threonine kinase that promotes cell survival, can be activated by overexpression of the receptor tyrosine kinase ErbB2. Conversely, down-regulation of ErbB2 inhibits AKT activation. Here, we identify PP1 as a serine/threonine phosphatase that associates with and dephosphorylates AKT in breast cancer cells, and we show that ErbB2 inhibits PP1-dependent dephosphorylation of AKT. Inhibition of ErbB2 by either the HSP (heat shock protein) 90 inhibitor geldanamycin or the ErbB inhibitor ZD1839 in SKBR3 cells, a human breast cancer cell line overexpressing ErbB2 protein, induces a rapid and dramatic decrease in AKT activity. Decreased AKT activity occurs many hours before the HSP90-dependent decline of AKT protein but is correlated with loss of AKT phosphorylation. Decreased AKT phosphorylation is not due to blockade of AKT activation or to preferential HSP90-mediated degradation of phosphorylated AKT. Instead, it is caused by increased AKT dephosphorylation. Sensitivity to a panel of phosphatase inhibitors suggests involvement of the phosphatase PP1 in this process. In vitro phosphatase assay (using PP1 immunoprecipitated from COS7 cells transiently transfected with the wild-type protein, as well as purified PP1) confirmed that AKT is a substrate of PP1. Furthermore, endogenous PP1 and AKT associate with each other in SKBR3. However, the phosphatase is phosphorylated and its activity is suppressed (determined by in vitro assay). In contrast, ErbB2 inhibition abrogates PP1 phosphorylation and restores its activity (measured by its ability to dephosphorylate AKT in vitro). Finally, transient overexpression of constitutively active PP1 in SKBR3 cells promotes marked dephosphorylation of endogenous AKT protein. These data indicate that ErbB2 acts to preserve the phosphorylation, and hence to prolong the activation, of AKT kinase by repressing the activity of the phosphatase PP1. ErbB2 thus functions to regulate AKT kinase by simultaneously promoting its activation while inhibiting its inactivation.",
        "Doc_title":"The heat shock protein 90 inhibitor geldanamycin and the ErbB inhibitor ZD1839 promote rapid PP1 phosphatase-dependent inactivation of AKT in ErbB2 overexpressing breast cancer cells.",
        "Journal":"Cancer research",
        "Do_id":"14633703",
        "Doc_ChemicalList":"Antibiotics, Antineoplastic;Benzoquinones;Enzyme Inhibitors;HSP90 Heat-Shock Proteins;Lactams, Macrocyclic;Proto-Oncogene Proteins;Quinazolines;Quinones;Receptor, ErbB-2;AKT1 protein, human;Protein-Serine-Threonine Kinases;Proto-Oncogene Proteins c-akt;Phosphoprotein Phosphatases;Protein Phosphatase 1;gefitinib;geldanamycin",
        "Doc_meshdescriptors":"Animals;Antibiotics, Antineoplastic;Benzoquinones;Breast Neoplasms;COS Cells;Cell Line, Tumor;Enzyme Activation;Enzyme Inhibitors;HSP90 Heat-Shock Proteins;Humans;Lactams, Macrocyclic;Phosphoprotein Phosphatases;Phosphorylation;Protein Phosphatase 1;Protein-Serine-Threonine Kinases;Proto-Oncogene Proteins;Proto-Oncogene Proteins c-akt;Quinazolines;Quinones;Receptor, ErbB-2",
        "Doc_meshqualifiers":"pharmacology;drug therapy;enzymology;metabolism;drug effects;pharmacology;antagonists & inhibitors;antagonists & inhibitors;metabolism;drug effects;antagonists & inhibitors;metabolism;pharmacology;pharmacology;antagonists & inhibitors;biosynthesis",
        "_version_":1605796376530124800},
      {
        "Doc_abstract":"Abnormalities of chromosome 17, recognised over two decades ago to be important in tumorigenesis, often occur in breast cancer. Changes of specific loci on chromosome 17 including ERBB2 amplification, P53 loss, BRCA1 loss, and TOP2A amplification or deletion are known to have important roles in breast-cancer pathophysiology. Numerical aberrations of chromosome 17 are linked to breast-cancer initiation and progression, and possibly to treatment response. However, the clinical importance of chromosome 17 anomalies, in particular the effect on ERBB2 protein expression, is unknown. Reports are conflicting regarding the association of copy gain of chromosome 17 (polysomy 17) with strong ERBB2 protein expression in the absence of true ERBB2 gene amplification. Copy-number anomalies in chromosome 17 seem to be common in tumours that show discrepant ERBB2 expression and in tumours with discordant ERBB2-protein and ERBB2 gene copy number measurements. The mechanisms of ERBB2 dosage changes-gene amplification versus chromosome gain and loss-probably differ in primary and metastatic disease; however, a correction for chromosome 17 copy-number is necessary to completely distinguish between these mechanisms. A better understanding of how polysomy 17 affects gene-copy number and protein expression will help to select patients who will respond to therapies targeting ERBB2 and other protein products of chromosome 17 loci.",
        "Doc_title":"Breast cancer and aneusomy 17: implications for carcinogenesis and therapeutic response.",
        "Journal":"The Lancet. Oncology",
        "Do_id":"19261255",
        "Doc_ChemicalList":"Antigens, Neoplasm;DNA-Binding Proteins;DNA Topoisomerases, Type II;DNA topoisomerase II alpha",
        "Doc_meshdescriptors":"Aneuploidy;Antigens, Neoplasm;Breast Neoplasms;Chromosome Aberrations;Chromosomes, Human, Pair 17;DNA Topoisomerases, Type II;DNA-Binding Proteins;Disease Progression;Female;Gene Amplification;Genes, erbB-2;Genes, p53;Humans;Prognosis",
        "Doc_meshqualifiers":"genetics;etiology;genetics;therapy;genetics;genetics",
        "_version_":1605891120638722048},
      {
        "Doc_abstract":"Breast cancer clinical outcome is affected by tumor molecular features, and the identification of subtype-specific prognostic biomarkers is relevant for breast cancer translational research. Gene expression signatures proved to be able to complement prognostic information provided by classical clinico-pathological features. Recently, microRNAs (miRNAs) have been causally linked to tumorigenesis and cancer progression and have been associated with patient outcome, also in breast cancer.;MicroRNAs associated with the development of distant metastasis were identified in a cohort of 92 ESR1+/ERBB2- lymph node-negative breast cancers from patients not receiving adjuvant treatment. Results were confirmed and further investigated in a total of 1246 miRNA and gene expression profiles of the Molecular Taxonomy of Breast Cancer International Consortium data set. Moderated t-test, univariable and multivariable Cox regression models were used for statistical analyses.;miR-30e* was identified as independent protective prognostic factor in lymph node-negative untreated patients with ESR1+/ERBB2- tumours and retained a significant association with a good prognosis in treated patients with the same tumor subtype as well as in the ERBB2+ subtype, but not in ESR1-/ERBB2- tumours.;We highlighted a relevant and subtype-specific role in breast cancer for miR-30e* and demonstrated that adding miRNA markers to gene signatures and clinico-pathological features can help for a better prognostication.",
        "Doc_title":"miR-30e* is an independent subtype-specific prognostic marker in breast cancer.",
        "Journal":"British journal of cancer",
        "Do_id":"26057454",
        "Doc_ChemicalList":"Estrogen Receptor alpha;MIRN30 microRNA, human;MicroRNAs;estrogen receptor alpha, human;ERBB2 protein, human;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Breast Neoplasms;Cell Line, Tumor;Estrogen Receptor alpha;Female;Humans;Lymphatic Metastasis;MicroRNAs;Prognosis;Proportional Hazards Models;Receptor, ErbB-2;Transcriptome",
        "Doc_meshqualifiers":"genetics;mortality;pathology;analysis;analysis;physiology;analysis",
        "_version_":1605818764437225473},
      {
        "Doc_abstract":"Amplification and elevated expression of the ErbB2 receptor tyrosine kinase occurs in 20% of human breast cancers and is associated with a poor prognosis. We have previously demonstrated that mammary tissue-specific expression of activated ErbB2 under the control of its endogenous promoter results in mammary tumor formation. Tumor development was associated with amplification and overexpression of ErbB2 at both the transcript and protein levels. Here we demonstrate that the EGR2/Krox20 transcription factor and its coactivator CITED1 are coordinately upregulated during ErbB2 tumor induction. We have identified an EGR2 binding site in the erbB2 promoter and demonstrated by chromatin immunoprecipitation assays that EGR2 and CITED1 associate specifically with this region of the promoter. EGR2 and CITED1 were shown to associate, and expression from an erbB2 promoter-reporter construct was stimulated by EGR2 and was further enhanced by CITED1 coexpression. Furthermore, expression of the 14-3-3sigma tumor suppressor led to downregulation of ErbB2 protein levels and relocalization of EGR2 from the nucleus to the cytoplasm. Taken together, these observations suggest that, in addition to an increased gene copy number and upregulation of EGR2 and CITED1, an elevated erbB2 transcript level involves the loss of 14-3-3sigma, which sequesters a key transcriptional regulator of the erbB2 promoter.",
        "Doc_title":"An EGR2/CITED1 transcription factor complex and the 14-3-3sigma tumor suppressor are involved in regulating ErbB2 expression in a transgenic-mouse model of human breast cancer.",
        "Journal":"Molecular and cellular biology",
        "Do_id":"17938205",
        "Doc_ChemicalList":"14-3-3 Proteins;Cited1 protein, mouse;Early Growth Response Protein 2;Nuclear Proteins;Sfn protein, mouse;Trans-Activators;Receptor, ErbB-2;Cre recombinase;Integrases",
        "Doc_meshdescriptors":"14-3-3 Proteins;Animals;Breast Neoplasms;Cell Line;Disease Models, Animal;Early Growth Response Protein 2;Female;Gene Expression Regulation, Neoplastic;Humans;Integrases;Mammary Tumor Virus, Mouse;Mice;Mice, Transgenic;Nuclear Proteins;Promoter Regions, Genetic;Protein Binding;Protein Transport;Receptor, ErbB-2;Subcellular Fractions;Trans-Activators;Transcriptional Activation;Up-Regulation",
        "Doc_meshqualifiers":"metabolism;genetics;pathology;genetics;metabolism;metabolism;genetics;metabolism;genetics;genetics;metabolism;metabolism;genetics;metabolism;genetics",
        "_version_":1605821198060486656},
      {
        "Doc_abstract":"HER-2/neu (ERBB2) gene amplification and/or overexpression is a major event in human breast tumorigenesis. HER-2/neu gene alterations have been the most frequently assessed prognostic factors during the last 10 years in breast cancer and have recently emerged as a management decision tool and a therapeutic target. There is still controversy over the best method to determine whether a tumor is HER-2/neu positive. Because of the increasing demand for HER-2/neu gene status determination in clinical practice, we compared HER-2/neu gene alterations at the DNA level (gene amplification) and the protein level (overexpression) in a panel of patients with lymph node-negative breast cancer who had received local radiotherapy alone, with no adjuvant therapy.;We tested 100 excised lymph node-negative breast tumors, using fluorescence in situ hybridization (FISH) with a biotinylated HER-2/neu DNA probe and immunohistochemical assays (IHC) with 2 different antibodies.;The FISH frequency of HER-2/neu gene amplification was 15%, and the IHC frequency of overexpression was 21%.;Although HER-2/neu amplification by FISH and HER-2/neu overexpression by IHC correlated well in this panel of lymph node-negative breast carcinomas, there were a number of discordant cases, pointing to the important need for determining HER-2/neu alteration for the future management of HER-2/neu-based clinical applications.",
        "Doc_title":"Fluorescence in situ hybridization and immunohistochemical assays for HER-2/neu status determination: application to node-negative breast cancer.",
        "Journal":"Archives of pathology & laboratory medicine",
        "Do_id":"11371225",
        "Doc_ChemicalList":"Receptor, ErbB-2",
        "Doc_meshdescriptors":"Adult;Aged;Aged, 80 and over;Breast Neoplasms;Female;Gene Amplification;Gene Expression;Genes, erbB-2;Humans;Immunohistochemistry;In Situ Hybridization, Fluorescence;Lymphatic Metastasis;Middle Aged;Neoplasm Recurrence, Local;Prognosis;Receptor, ErbB-2",
        "Doc_meshqualifiers":"genetics;metabolism;pathology;genetics;metabolism;pathology;metabolism",
        "_version_":1605902916404641792},
      {
        "Doc_abstract":"To investigate the expression of Rab5a and APPL1 in breast cancer and fibroma, and analyze their correlation with HER-2 expression, metastasis and development of breast cancer.;Rab5a and APPL1 in paraffin embedded tissues of 74 breast carcinomas and 40 breast fibromas were detected by immunohistochemistry. Their relationship with metastasis, pathological grade, and HER-2 expression in breast cancer was determined by statistical analysis.;There was no expression or low expression of Rab5a and APPL1 in the breast fibroma, but the positive expression rate of Rab5a and APPL1 in the breast carcinomas were 91.9% and 83.8%, respectively. No significant difference in expression of Rab5a and APPL1 was found between metastatic and non-metastatic groups, and pathological grade I/II and grade III groups. But Rab5a was overexpressed in HER-2-positive group compared with that in the HER-2-negative group.;Rab5a and APPL1 are overexpressed in breast cancer, and are positively correlated with the HER-2 expression. These proteins may influence the growth and proliferation of breast cancer cells by HER-2 signal transduction.",
        "Doc_title":"[Expression and significance of Rab5a and APPL1 in breast cancer].",
        "Journal":"Zhonghua zhong liu za zhi [Chinese journal of oncology]",
        "Do_id":"23291133",
        "Doc_ChemicalList":"APPL1 protein, human;Adaptor Proteins, Signal Transducing;ERBB2 protein, human;Receptor, ErbB-2;rab5 GTP-Binding Proteins",
        "Doc_meshdescriptors":"Adaptor Proteins, Signal Transducing;Adult;Aged;Aged, 80 and over;Breast Neoplasms;Carcinoma, Ductal, Breast;Carcinoma, Intraductal, Noninfiltrating;Carcinoma, Squamous Cell;Female;Fibroma;Humans;Immunohistochemistry;Lymphatic Metastasis;Middle Aged;Neoplasm Grading;Paraffin Embedding;Receptor, ErbB-2;Young Adult;rab5 GTP-Binding Proteins",
        "Doc_meshqualifiers":"metabolism;metabolism;pathology;metabolism;pathology;metabolism;pathology;metabolism;pathology;metabolism;pathology;metabolism;metabolism",
        "_version_":1605765513217048576},
      {
        "Doc_abstract":"HER-2/neu status of the primary breast cancer (PBC) is determined by immunohistochemistry and fluorescent in situ hybridization. Because of a variety of technical factors, however, the PBC may not accurately reflect the metastatic tumor in terms of HER-2/neu status. Recently published guidelines recommend that tumors be defined as HER-2/neu positive if 30% or more of the cells are 3+. Circulating levels of the HER-2 extracellular domain can be measured in serum using a test cleared by the US Food and Drug Administration, and increased serum HER-2/neu levels to above 15 ng/ml can reflect tumor progression. Studies comparing tissue HER-2/neu status of the PBC and HER-2/neu levels above 15 ng/ml in metastatic breast cancer patients are also reviewed.",
        "Doc_title":"HER-2/neu diagnostics in breast cancer.",
        "Journal":"Breast cancer research : BCR",
        "Do_id":"17561991",
        "Doc_ChemicalList":"Biomarkers, Tumor;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Biomarkers, Tumor;Breast Neoplasms;Female;Genetic Variation;Humans;In Situ Hybridization;In Situ Hybridization, Fluorescence;Neoplasm Metastasis;Receptor, ErbB-2",
        "Doc_meshqualifiers":"diagnosis;genetics;pathology;genetics;pathology;analysis;blood;genetics",
        "_version_":1605843469132103680},
      {
        "Doc_abstract":"The ErbB2 gene encodes a transmembrane growth factor receptor that belongs to the ErbB receptor tyrosine kinase subfamily. ErbB2 protein is overexpressed in approximately 30% of breast cancers. Although controversies exist, data from our laboratory and from clinical trials of trastuzumab indicate that ErbB2 overexpression confers chemoresistance to certain chemotherapeutic agents such as paclitaxel. One of the molecular mechanisms of ErbB2-mediated paclitaxel resistance is that overexpression of the ErbB2 receptor leads to deregulation of the G2/M cell cycle check-point that inhibits paclitaxel-induced apoptosis. Several promising ErbB2-targeting strategies have now been developed to conquer the adverse consequences of ErbB2 overexpression such as paclitaxel resistance. Among these, trastuzumab has brought great promise. We have recently shown that trastuzumab can effectively sensitize ErbB2-overexpressing breast cancer cells to paclitaxel by reversing the antiapoptotic function of ErbB2. Our studies provide additional support for chemotherapy combined with trastuzumab for ErbB2-overexpressing breast cancers, and it may bring insights into designing more effective and specific therapies that could offer great benefits to patients.",
        "Doc_title":"Mechanisms of ErbB2-mediated paclitaxel resistance and trastuzumab-mediated paclitaxel sensitization in ErbB2-overexpressing breast cancers.",
        "Journal":"Seminars in oncology",
        "Do_id":"11706391",
        "Doc_ChemicalList":"Antibodies, Monoclonal;Antibodies, Monoclonal, Humanized;Antineoplastic Agents;Receptor, ErbB-2;Trastuzumab;Paclitaxel",
        "Doc_meshdescriptors":"Animals;Antibodies, Monoclonal;Antibodies, Monoclonal, Humanized;Antineoplastic Agents;Apoptosis;Breast Neoplasms;Drug Resistance, Neoplasm;Gene Expression;Genes, erbB-2;Humans;Paclitaxel;Receptor, ErbB-2;Trastuzumab",
        "Doc_meshqualifiers":"pharmacology;pharmacology;drug therapy;genetics;metabolism;genetics;pharmacology",
        "_version_":1605826268756967424},
      {
        "Doc_abstract":"Cyclin E is a well-characterized cell cycle regulator and an amplified oncogene in breast cancer. Over-expression of cyclin E has generally been associated with poor survival. Recent studies have shown an interaction between HER-2 (ERBB2) and cyclin E, but the exact mechanism is unknown. Interestingly, cyclin E over-expression has been associated with trastuzumab resistance. We studied cyclin E over-expression, CCNE1 amplification, and relapse-free survival in HER-2-positive primary breast cancers treated with and without trastuzumab therapy. Formalin-fixed paraffin-embedded tissue samples from 202 HER-2-positive breast carcinomas were studied. Expression levels of cyclin E and proliferation marker Ki-67 were determined using immunohistochemistry. Chromogenic in situ hybridization (CISH) with a gene-specific bacterial artificial chromosome (BAC) probe was used to analyze presence of CCNE1 amplification. Majority of HER-2-positive breast carcinomas exhibited nuclear staining for cyclin E protein. Cyclin E was highly expressed (â‰¥50Â % cells) in 37Â % of cases. Incidence of CCNE1 amplification (â‰¥6 gene copies/cell or clusters) was 8Â %. Cyclin E amplification and over-expression were strongly associated with each other, grade, hormone receptors, and Ki-67. Neither high cyclin E expression nor CCNE1 amplification was associated with relapse-free survival (RFS) irrespective of short-term (9-week regimen) adjuvant trastuzumab therapy. These results confirm cyclin E and HER-2 gene co-amplification in a fraction of HER-2-positive breast cancers. Cyclin E is frequently over-expressed but appears to have limited value as a prognostic or predictive factor in HER-2-positive breast cancer regardless of trastuzumab therapy. ",
        "Doc_title":"Cyclin E amplification, over-expression, and relapse-free survival in HER-2-positive primary breast cancer.",
        "Journal":"Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine",
        "Do_id":"26810187",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605758260801961984},
      {
        "Doc_abstract":"The anti-diabetic drug metformin reduces human cancer incidence and improves the survival of cancer patients, including those with breast cancer. We studied the activity of metformin against diverse molecular subtypes of breast cancer cell lines in vitro. Metformin showed biological activity against all estrogen receptor (ER) positive and negative, erbB2 normal and abnormal breast cancer cell lines tested. It inhibited cellular proliferation, reduced colony formation and caused partial cell cycle arrest at the G(1) checkpoint. Metformin did not induce apoptosis (as measured by DNA fragmentation and PARP cleavage) in luminal A, B or erbB2 subtype breast cancer cell lines. At the molecular level, metformin treatment was associated with a reduction of cyclin D1 and E2F1 expression with no changes in p27(kip1) or p21(waf1). It inhibited mitogen activated protein kinase (MAPK) and Akt activity, as well as the mammalian target of rapamycin (mTOR) in both ER positive and negative, erbB2-overexpressing and erbB2-normal expressing breast cancer cells. In erbB2-overexpressing breast cancer cell lines, metformin reduced erbB2 expression at higher concentrations, and at lower concentrations within the therapeutic range, it inhibited erbB2 tyrosine kinase activity evidenced by a reduction of phosphorylated erbB2 (P-erbB2) at both auto- and Src- phosphorylation sites. These data suggest that metformin may have potential therapeutic utility against ER positive and negative, erbB2-overexpressing and erbB2-normal expressing breast cancer cells.",
        "Doc_title":"Metformin inhibits breast cancer cell growth, colony formation and induces cell cycle arrest in vitro.",
        "Journal":"Cell cycle (Georgetown, Tex.)",
        "Do_id":"19221498",
        "Doc_ChemicalList":"Hypoglycemic Agents;Receptors, Estrogen;Metformin;ERBB2 protein, human;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Apoptosis;Breast Neoplasms;Cell Cycle;Cell Line, Tumor;Cell Proliferation;Humans;Hypoglycemic Agents;Metformin;Receptor, ErbB-2;Receptors, Estrogen;Signal Transduction",
        "Doc_meshqualifiers":"metabolism;pathology;drug effects;physiology;drug effects;pharmacology;pharmacology;drug effects;metabolism;drug effects;metabolism",
        "_version_":1605844064676085760},
      {
        "Doc_abstract":"This past decade has witnessed the remarkable advances in the understanding of the role of the erbB2 gene in cancers and the stunning progress in developing targeted therapies for erbB2-overexpressing cancers. Activation of the ErbB2 receptor signaling pathways can enhance various metastasis-associated properties that lead to an increase of cancer metastasis. Additionally, ErbB2 overexpression confers therapeutic resistance via receptor-mediated antiapoptotic signals. To limit these disastrous effects of the overexpressed ErbB2, various ErbB2-blocking strategies have been developed in the laboratories and several have been tested in clinical trials or approved as therapies for ErbB2 overexpressing cancers. In this article, we will discuss the detrimental effects of the erbB2 gene in cancers, with a focus on breast cancer. We will also outline ErbB2-targeting strategies as potential therapies for ErbB2-overexpressing cancers. Progress in understanding the molecular biology of ErbB2 and in molecular-based treatment of ErbB2-overexpressing tumors will bring great benefits to cancer patients.",
        "Doc_title":"Overexpression of ErbB2 in cancer and ErbB2-targeting strategies.",
        "Journal":"Oncogene",
        "Do_id":"11156524",
        "Doc_ChemicalList":"Receptor, ErbB-2",
        "Doc_meshdescriptors":"Animals;Breast Neoplasms;Female;Humans;Neoplasm Metastasis;Receptor, ErbB-2",
        "Doc_meshqualifiers":"genetics;therapy;antagonists & inhibitors;genetics;immunology;metabolism",
        "_version_":1605742657629323264},
      {
        "Doc_abstract":"While most breast cancers are thought to arise from the luminal layer of the breast tissue, it remains unclear which specific cells in the luminal layer are the cells of origin of breast cancer. We have previously reported that WAP-positive luminal epithelial cells are at increased susceptibility to tumor initiation by ErbB2 compared to the bulk population, while the mammary cells with canonical Wnt signaling activity fail to evolve into tumors upon ErbB2 activation. Here, we used retrovirus to introduce ErbB2 into the Krt6a-positive mammary progenitor subset of the luminal epithelium and, for comparison, into the mammary luminal epithelium indiscriminately. Tumors developed from both groups of cells with a similar latency. These data indicate that the Krt6a-positive subset of mammary epithelial cells can be induced to form cancer by ErbB2 but it is not more susceptible to tumorigenesis initiated by ErbB2 than the bulk population of the luminal epithelium. ",
        "Doc_title":"Krt6a-positive mammary epithelial progenitors are not at increased vulnerability to tumorigenesis initiated by ErbB2.",
        "Journal":"PloS one",
        "Do_id":"25635772",
        "Doc_ChemicalList":"Keratin-6;STAT5 Transcription Factor;Erbb2 protein, mouse;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Animals;Apoptosis;Carcinogenesis;Cell Transformation, Neoplastic;Epithelial Cells;Female;Humans;Keratin-6;Mammary Glands, Animal;Mammary Tumor Virus, Mouse;Mice, Transgenic;Phosphorylation;Receptor, ErbB-2;Retroviridae;STAT5 Transcription Factor;Stem Cells;Virion;Virus Latency",
        "Doc_meshqualifiers":"metabolism;pathology;pathology;metabolism;pathology;metabolism;pathology;metabolism;metabolism;metabolism;metabolism;metabolism;pathology;metabolism",
        "_version_":1605746972496494593},
      {
        "Doc_abstract":"Treatment of ErbB2-overexpressing BT474 and MDA-MB-453 breast cancer cells with 1 to 10 Î¼mol/L betulinic acid inhibited cell growth, induced apoptosis, downregulated specificity protein (Sp) transcription factors Sp1, Sp3, and Sp4, and decreased expression of ErbB2. Individual or combined knockdown of Sp1, Sp3, Sp4 by RNA interference also decreased expression of ErbB2 and this response was because of repression of YY1, an Sp-regulated gene. Betulinic acid-dependent repression of Sp1, Sp3, Sp4, and Sp-regulated genes was due, in part, to induction of the Sp repressor ZBTB10 and downregulation of microRNA-27a (miR-27a), which constitutively inhibits ZBTB10 expression, and we show for the first time that the effects of betulinic acid on the miR-27a:ZBTB10-Sp transcription factor axis were cannabinoid 1 (CB1) and CB2 receptor-dependent, thus identifying a new cellular target for this anticancer agent.",
        "Doc_title":"Betulinic acid targets YY1 and ErbB2 through cannabinoid receptor-dependent disruption of microRNA-27a:ZBTB10 in breast cancer.",
        "Journal":"Molecular cancer therapeutics",
        "Do_id":"22553354",
        "Doc_ChemicalList":"Antineoplastic Agents, Phytogenic;MIRN27 microRNA, human;MicroRNAs;Receptors, Cannabinoid;Repressor Proteins;Sp Transcription Factors;Triterpenes;YY1 Transcription Factor;ZBTB10 protein, human;betulinic acid;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Animals;Antineoplastic Agents, Phytogenic;Apoptosis;Breast Neoplasms;Cell Line, Tumor;Cell Proliferation;Cricetinae;Female;Gene Expression Regulation, Neoplastic;Humans;Mice;Mice, Nude;MicroRNAs;Receptor, ErbB-2;Receptors, Cannabinoid;Repressor Proteins;Sp Transcription Factors;Triterpenes;YY1 Transcription Factor",
        "Doc_meshqualifiers":"pharmacology;drug effects;genetics;metabolism;drug effects;drug effects;genetics;antagonists & inhibitors;metabolism;genetics;genetics;metabolism;pharmacology;antagonists & inhibitors",
        "_version_":1605850553706872832},
      {
        "Doc_abstract":"Shedding of the extracellular domain of the ErbB2 tyrosine kinase receptor and expression of the remaining NH(2)-terminally truncated ErbB2 correlates with lymph node metastases and adverse outcome in human breast cancer. To study the possible signaling from such a truncated receptor, MCF-7 human breast cancer cells expressing NH(2)-terminally truncated ErbB2 (DeltaNErbB2) were compared with cells overexpressing wild-type ErbB2. Expression of DeltaNErbB2 in MCF-7 cells resulted in sustained activation of extracellular signal-regulated kinases (ERK) 1/2, extensive loss of the epithelial morphology, appearance of vesicles and long protrusions as well as pronounced scattering of the cells. Similar alterations were observed upon ErbB2 overexpression but at much lower levels. Employing cell clones with inducible expression of DeltaNErbB2, it was revealed that the morphological changes were fully reversible and depended on continuous expression of DeltaNErbB2 but not on the activation of the ERK1/2 pathway. Interestingly, the expression of DeltaNErbB2 resulted also in the increased expression and phosphorylation of ErbB1 as well as in the prolonged ligand-induced activation of the ErbB1 signaling pathway. In conclusion, constitutive signaling upon expression of the truncated ErbB2 receptor in human breast cancer cells promotes morphological changes indicative of a more motile and aggressive phenotype.",
        "Doc_title":"Truncated ErbB2 receptor enhances ErbB1 signaling and induces reversible, ERK-independent loss of epithelial morphology.",
        "Journal":"International journal of cancer",
        "Do_id":"11668496",
        "Doc_ChemicalList":"Epidermal Growth Factor;Receptor, Epidermal Growth Factor;Receptor, ErbB-2;Mitogen-Activated Protein Kinases",
        "Doc_meshdescriptors":"Breast Neoplasms;Enzyme Activation;Epidermal Growth Factor;Epithelial Cells;Female;Humans;Mitogen-Activated Protein Kinases;Receptor, Epidermal Growth Factor;Receptor, ErbB-2;Tumor Cells, Cultured",
        "Doc_meshqualifiers":"pathology;pharmacology;pathology;physiology;physiology;chemistry;physiology",
        "_version_":1605746453625438208},
      {
        "Doc_abstract":"Hormone therapy and anti-ErbB2 therapies are prescribed according to the hormone receptor [estrogen receptor Î± (ERÎ±)/progesterone receptor] and ErbB2 status of the initial tumor, but it appears that circulating tumor cells (CTCs) and, consequently, the metastatic cells may have a different receptor status. As an attempt to meet the crucial need for identification of the subpopulation of patients that will benefit from more individualized therapies, rapidly evolving therapies should allow a profiling of the tumors and/or of the CTCs. We established a triple fluorescence staining using eight cell lines to visualize the CTCs (cytokeratin detection) and then to define their individual ERÎ± and ErbB2 status. Afterward, we used this method for blood samples from 26 metastatic breast cancer patients. We identified major differences of ERÎ± levels between the cell lines and even within one cell line. For the metastatic patients, we detected and characterized CTCs in 38.5% of the patients with a total of 92 CTCs. We could demonstrate that at least 69.6% of the CTCs exhibit an ERÎ± and/or ErbB2 status different from the status of the primary tumor and that the CTCs from only 30% of the patients had no change of receptor status. Strikingly, heterogeneities of the status, aggregation, and size clearly appear within the CTCs. The data we generated outline the importance of a profiling not only of tumors but also of CTCs to establish individualized treatments. CTCs may then appear as new prognosis and treatment marker for both metastatic and adjuvant breast cancers.",
        "Doc_title":"Heterogeneity of ERÎ± and ErbB2 Status in Cell Lines and Circulating Tumor Cells of Metastatic Breast Cancer Patients.",
        "Journal":"Translational oncology",
        "Do_id":"23323159",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605818573239877634},
      {
        "Doc_abstract":"The receptor tyrosine kinase ErbB2 is overexpressed in up to a third of breast cancers, allowing targeted therapy with ErbB2-directed humanized antibodies such as Trastuzumab. Concurrent targeting of ErbB2 stability with HSP90 inhibitors is synergistic with Trastuzumab, suggesting that pharmacological agents that can inhibit HSP90 as well as signaling pathways activated by ErbB2 could be useful against ErbB2-overexpressing breast cancers. The triterpene natural product Celastrol inhibits HSP90 and several pathways relevant to ErbB2-dependent oncogenesis including the NFÎºB pathway and the proteasome, and has shown promising activity in other cancer models. Here, we demonstrate that Celastrol exhibits in vitro antitumor activity against a panel of human breast cancer cell lines with selectivity towards those overexpressing ErbB2. Celastrol strongly synergized with ErbB2-targeted therapeutics Trastuzumab and Lapatinib, producing higher cytotoxicity with substantially lower doses of Celastrol. Celastrol significantly retarded the rate of growth of ErbB2-overexpressing human breast cancer cells in a mouse xenograft model with only minor systemic toxicity. Mechanistically, Celastrol not only induced the expected ubiquitinylation and degradation of ErbB2 and other HSP90 client proteins, but it also increased the levels of reactive oxygen species (ROS). Our studies show that the Michael Acceptor functionality in Celastrol is important for its ability to destabilize ErbB2 and exert its bioactivity against ErbB2-overexpressing breast cancer cells. These studies suggest the potential use of Michael acceptor-containing molecules as novel therapeutic modalities against ErbB2-driven breast cancer by targeting multiple biological attributes of the driver oncogene.",
        "Doc_title":"Anticancer activity of Celastrol in combination with ErbB2-targeted therapeutics for treatment of ErbB2-overexpressing breast cancers.",
        "Journal":"Cancer biology & therapy",
        "Do_id":"21088503",
        "Doc_ChemicalList":"Antibodies, Monoclonal;Antibodies, Monoclonal, Humanized;Antineoplastic Agents;HSP90 Heat-Shock Proteins;Quinazolines;Triterpenes;lapatinib;Receptor, ErbB-2;tripterine;Trastuzumab",
        "Doc_meshdescriptors":"Animals;Antibodies, Monoclonal;Antibodies, Monoclonal, Humanized;Antineoplastic Agents;Antineoplastic Combined Chemotherapy Protocols;Breast Neoplasms;Cell Line, Tumor;Cell Survival;Dose-Response Relationship, Drug;Drug Evaluation, Preclinical;Drug Synergism;Female;HSP90 Heat-Shock Proteins;Humans;Inhibitory Concentration 50;Mice;Mice, SCID;Quinazolines;Receptor, ErbB-2;Signal Transduction;Trastuzumab;Triterpenes;Tumor Burden;Xenograft Model Antitumor Assays",
        "Doc_meshqualifiers":"pharmacology;therapeutic use;pharmacology;therapeutic use;pharmacology;therapeutic use;drug therapy;metabolism;pathology;drug effects;antagonists & inhibitors;metabolism;therapeutic use;pharmacology;therapeutic use;antagonists & inhibitors;metabolism;therapeutic use;administration & dosage;drug effects;methods",
        "_version_":1605800222942822400},
      {
        "Doc_abstract":"Chromosomal segment 17q11-q21 is a commonly amplified region in human breast carcinomas. Several lines of evidence suggest that ERBB2 is the gene responsible for the emergence of this amplicon, but four novel genes (called MLN 50, MLN 51, MLN 62, and MLN 64) in 17q11-q21 have recently been found to be amplified and overexpressed in breast cancer cell lines. We investigated 98 primary breast tumors for amplification of these five loci. Twenty-five tumors (25.5%) showed amplification of at least one of these markers, but most amplifications did not encompass all of the tested loci. The genes most frequently amplified were ERBB2 and MLN 64 (22 of 25 amplified cases). MLN 64 was always coamplified with ERBB2, and to a similar level. Amplification of these five genes always leads to overexpression of their mRNA; we observed no cases of overexpression without amplification in any of these genes. Our results suggest that: (a) an independent, amplified region defined by MLN 62 (also called CART1 or TRAF4) is located in 17q11-q12; (b) in addition to ERBB2, MLN 64 is a major target for the 17q12-q21 amplicon; and (c) these MLN genes could be of pathogenetic significance in breast cancer.",
        "Doc_title":"Two distinct amplified regions at 17q11-q21 involved in human primary breast cancer.",
        "Journal":"Cancer research",
        "Do_id":"8752152",
        "Doc_ChemicalList":"DNA, Neoplasm;Homeodomain Proteins;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Breast Neoplasms;Chromosome Mapping;Chromosomes, Human, Pair 17;DNA, Neoplasm;Gene Amplification;Gene Expression;Homeodomain Proteins;Humans;Leukocytes;Oncogenes;Receptor, ErbB-2",
        "Doc_meshqualifiers":"genetics;metabolism;analysis;genetics;biosynthesis;genetics;chemistry;biosynthesis;genetics",
        "_version_":1605748625161322496},
      {
        "Doc_abstract":"The introduction of trastuzumab for the treatment of tumors that overexpress ErbB2 (also known as HER2) has contributed significantly to recent improvements in systemic therapy for advanced breast cancer. The advances in systemic therapy have highlighted an increasing prevalence of central nervous system involvement in patients with ErbB2-positive breast cancer and a consequent need for new treatment options for brain metastases. Just as ErbB2-targeted systemic therapy has given rise to this challenge, so too could targeted therapy represent an opportunity to meet it. This Review considers the potential for targeted therapy to facilitate effective management of brain metastases in patients with ErbB2-positive breast cancer, and discusses in particular the data currently available in this setting for lapatinib, an orally available small-molecule tyrosine kinase inhibitor of ErbB1 and ErbB2.",
        "Doc_title":"New challenges and opportunities in the management of brain metastases in patients with ErbB2-positive metastatic breast cancer.",
        "Journal":"Nature clinical practice. Oncology",
        "Do_id":"18936791",
        "Doc_ChemicalList":"Antineoplastic Agents;Quinazolines;lapatinib;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Antineoplastic Agents;Brain Neoplasms;Breast Neoplasms;Clinical Trials as Topic;Female;Humans;Quinazolines;Receptor, ErbB-2",
        "Doc_meshqualifiers":"therapeutic use;drug therapy;metabolism;secondary;drug therapy;metabolism;pathology;therapeutic use;metabolism",
        "_version_":1605819938350563328},
      {
        "Doc_abstract":"In this study we selected three breast cancer cell lines (SKBR3, SUM149 and SUM190) with different oncogene expression levels involved in ERBB2 and EGFR signaling pathways as a model system for the evaluation of selective integration of subsets of transcriptomic and proteomic data. We assessed the oncogene status with reads per kilobase per million mapped reads (RPKM) values for ERBB2 (14.4, 400, and 300 for SUM149, SUM190, and SKBR3, respectively) and for EGFR (60.1, not detected, and 1.4 for the same 3 cell lines). We then used RNA-Seq data to identify those oncogenes with significant transcript levels in these cell lines (total 31) and interrogated the corresponding proteomics data sets for proteins with significant interaction values with these oncogenes. The number of observed interactors for each oncogene showed a significant range, e.g., 4.2% (JAK1) to 27.3% (MYC). The percentage is measured as a fraction of the total protein interactions in a given data set vs total interactors for that oncogene in STRING (Search Tool for the Retrieval of Interacting Genes/Proteins, version 9.0) and I2D (Interologous Interaction Database, version 1.95). This approach allowed us to focus on 4 main oncogenes, ERBB2, EGFR, MYC, and GRB2, for pathway analysis. We used bioinformatics sites GeneGo, PathwayCommons and NCI receptor signaling networks to identify pathways that contained the four main oncogenes and had good coverage in the transcriptomic and proteomic data sets as well as a significant number of oncogene interactors. The four pathways identified were ERBB signaling, EGFR1 signaling, integrin outside-in signaling, and validated targets of C-MYC transcriptional activation. The greater dynamic range of the RNA-Seq values allowed the use of transcript ratios to correlate observed protein values with the relative levels of the ERBB2 and EGFR transcripts in each of the four pathways. This provided us with potential proteomic signatures for the SUM149 and 190 cell lines, growth factor receptor-bound protein 7 (GRB7), Crk-like protein (CRKL) and Catenin delta-1 (CTNND1) for ERBB signaling; caveolin 1 (CAV1), plectin (PLEC) for EGFR signaling; filamin A (FLNA) and actinin alpha1 (ACTN1) (associated with high levels of EGFR transcript) for integrin signalings; branched chain amino-acid transaminase 1 (BCAT1), carbamoyl-phosphate synthetase (CAD), nucleolin (NCL) (high levels of EGFR transcript); transferrin receptor (TFRC), metadherin (MTDH) (high levels of ERBB2 transcript) for MYC signaling; S100-A2 protein (S100A2), caveolin 1 (CAV1), Serpin B5 (SERPINB5), stratifin (SFN), PYD and CARD domain containing (PYCARD), and EPH receptor A2 (EPHA2) for PI3K signaling, p53 subpathway. Future studies of inflammatory breast cancer (IBC), from which the cell lines were derived, will be used to explore the significance of these observations.",
        "Doc_title":"Genome wide proteomics of ERBB2 and EGFR and other oncogenic pathways in inflammatory breast cancer.",
        "Journal":"Journal of proteome research",
        "Do_id":"23647160",
        "Doc_ChemicalList":"Neoplasm Proteins;RNA, Messenger;EGFR protein, human;ERBB2 protein, human;Receptor, Epidermal Growth Factor;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Breast Neoplasms;Cell Line, Tumor;Female;Gene Expression Profiling;Gene Expression Regulation, Neoplastic;Genome-Wide Association Study;Humans;Inflammation;Molecular Sequence Annotation;Neoplasm Proteins;Proteomics;RNA, Messenger;Receptor, Epidermal Growth Factor;Receptor, ErbB-2;Signal Transduction",
        "Doc_meshqualifiers":"genetics;metabolism;pathology;genetics;metabolism;genetics;metabolism;genetics;metabolism;genetics;metabolism",
        "_version_":1605876671362105344},
      {
        "Doc_abstract":"Breast cancer cells that overexpress HER-2/neu are more resistant to chemotherapeutic agents such as paclitaxel (Taxol) and docetaxel (Taxotere) than those that do not overexpress HER-2/neu. In previous work, we showed that the adenovirus type 5 E1A can repress HER-2/neu expression at the transcriptional level. Here we first demonstrated that paclitaxel sensitivity correlates with HER-2/neu expression level in a panel of mouse fibroblasts expressing different levels of HER-2/ neu, and that downregulation of HER-2/neu expression by E1A sensitizes the cells to paclitaxel. To further test whether E1A can sensitize HER-2/neu-overexpressing human breast cancer cells to paclitaxel through E1A-mediated HER-2/neu repression, an adenoviral vector was used to transfer the E1A gene into two human breast cancer cell lines, MDA-MB-453 and MDA-MB-361, that overexpress HER-2/neu. After E1A delivery, we observed that HER-2/neu expression level was reduced, and cells were treated with paclitaxel. Cell proliferation assays showed a synergistic growth inhibition effect of E1A and paclitaxel. The synergistic effect was also confirmed by soft agar colony-formation assay. Breast cancer cell lines that express low levels of HER-2/neu, MDA-MB-435 and MDA-MB-231 cells showed no synergistic growth inhibition effect when treated on the same protocols. Thus, we concluded that the adenovirus type 5 E1A gene can sensitize paclitaxel-resistant HER-2/neu-overexpressing breast cancer cells to the drug by repressing HER-2/neu expression. This in turn may have important implications for the development of a novel therapy that combines chemotherapy and gene therapy.",
        "Doc_title":"Chemosensitization of HER-2/neu-overexpressing human breast cancer cells to paclitaxel (Taxol) by adenovirus type 5 E1A.",
        "Journal":"Oncogene",
        "Do_id":"9285690",
        "Doc_ChemicalList":"Adenovirus E1A Proteins;Antineoplastic Agents, Phytogenic;Paclitaxel",
        "Doc_meshdescriptors":"Adenovirus E1A Proteins;Animals;Antineoplastic Agents, Phytogenic;Breast Neoplasms;Cell Line;Down-Regulation;Drug Resistance;Gene Expression;Genes, erbB-2;Genetic Therapy;Genetic Vectors;Humans;Mice;Paclitaxel;Tumor Cells, Cultured",
        "Doc_meshqualifiers":"genetics;pharmacology;pharmacology;genetics;metabolism;therapy;pharmacology;drug effects",
        "_version_":1605792257697382400},
      {
        "Doc_abstract":"Evaluation of: Rasmussen BB, Regan MM, Lykkesfeldt AE et al.: Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomized trial. Lancet Oncol. 9, 23-28 (2008). This study analysed data after a median of 51 months follow-up from 4922 postmenopausal women with early hormone-sensitive breast cancer randomly assigned to 5 years of treatment with letrozole or tamoxifen. Tumors from 3650 (74%) patients were centrally assessed for estrogen receptor, progesterone receptor and ErbB2 status. By central assessment, 7% (257 of 3650) of tumors were classified as ErbB2-positive. Disease-free survival was significantly worse in patients with ErbB2-positive tumors (p < 0.0001). Letrozole improved disease-free survival compared with tamoxifen regardless of ErbB2 status.",
        "Doc_title":"Role of ErbB2 in selection for adjuvant tamoxifen or aromatase inhibitors.",
        "Journal":"Women's health (London, England)",
        "Do_id":"19072471",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605747020941754369},
      {
        "Doc_abstract":"It has long been hypothesized that body tissue uptake of aluminum may have biological implications in breast cancer. In vitro and in vivo studies have shown that aluminum may trigger genomic instability by interfering with DNA strands. The objective of this study was to examine the relationship between aluminum concentrations in the peripheral and central areas of breast tumors with the instability of three key genes in breast cancer, ERBB2, C-MYC, and CCND1 and aneuploidy of the chromosomes harboring these genes. Tissue samples of 118 women treated for breast cancer were obtained. Evaluation of aluminum content was carried out using graphite furnace atomic absorption spectrometry. A tissue microarray slide containing the tumor samples was used in FISH assays to assess ERBB2, C-MYC, and CCND1 expressions as well as the statuses of their respective chromosomes 17, 8, and 11. Clinicopathological data were obtained from patient's records. Aluminum levels of >2.0 mg/kg were found in 20.3 and 22.1% of the central and peripheral breast tumor areas, respectively. Amplification and/or aneuploid-positive statuses for ERBB2/CEP17, C-MYC/CEP8, and CCND1/CEP11 were detected in 24, 36.7, and 29.3% of the tumors, respectively. We found that aluminum concentration was not related to these altered gene statuses. Our findings suggest that aluminum concentration does not affect genomic stability in breast tissues. Tissue microenvironment modifications, due to the presence of aluminum compounds, seem more appealing as a possible target for future studies to determine the implications of aluminum in breast carcinogenesis.",
        "Doc_title":"Tissue aluminum concentration does not affect the genomic stability of ERBB2, C-MYC, and CCND1 genes in breast cancer.",
        "Journal":"Biological trace element research",
        "Do_id":"23861098",
        "Doc_ChemicalList":"CCND1 protein, human;MYC protein, human;Proto-Oncogene Proteins c-myc;Cyclin D1;Aluminum;ERBB2 protein, human;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Adult;Aluminum;Aneuploidy;Breast;Breast Neoplasms;Chromosomes, Human, Pair 11;Chromosomes, Human, Pair 17;Chromosomes, Human, Pair 8;Cyclin D1;Female;Genomic Instability;Humans;In Situ Hybridization, Fluorescence;Middle Aged;Proto-Oncogene Proteins c-myc;Receptor, ErbB-2;Spectrophotometry, Atomic",
        "Doc_meshqualifiers":"analysis;chemistry;metabolism;pathology;genetics;metabolism;pathology;genetics;genetics;genetics;genetics;genetics;genetics;methods",
        "_version_":1605775187682263040},
      {
        "Doc_abstract":"Defective autophagy has been implicated in mammary tumorigenesis, as the gene encoding the essential autophagy regulator BECN1 is deleted in human breast cancers and Becn1(+/-) mice develop mammary hyperplasias. In agreement with a recent study, which reports concurrent allelic BECN1 loss and ERBB2 amplification in a small number of human breast tumors, we found that low BECN1 mRNA correlates with ERBB2-overexpression in breast cancers, suggesting that BECN1 loss and ERBB2 overexpression may functionally interact in mammary tumorigenesis. We now report that ERBB2 overexpression suppressed autophagic response to stress in mouse mammary and human breast cancer cells. ERBB2-overexpressing Becn1(+/+) and Becn1(+/-) immortalized mouse mammary epithelial cells (iMMECs) formed mammary tumors in nude mice with similar kinetics, and monoallelic Becn1 loss did not alter ERBB2- and PyMT-driven mammary tumorigenesis. In human breast cancer databases, ERBB2-expressing tumors exhibit a low autophagy gene signature, independent of BECN1 mRNA expression, and have similar gene expression profiles with non-ERBB2-expressing breast tumors with low BECN1 levels. We also found that ERBB2-expressing BT474 breast cancer cells, despite being partially autophagy-deficient under stress, can be sensitized to the anti-ERBB2 antibody trastuzumab (tzb) by further pharmacological or genetic autophagy inhibition. Our results indicate that ERBB2-driven mammary tumorigenesis is associated with functional autophagy suppression and ERBB2-positive breast cancers are partially autophagy-deficient even in a wild-type BECN1 background. Furthermore and extending earlier findings using tzb-resistant cells, exogenously imposed autophagy inhibition increases the anticancer effect of trastuzumab on tzb-sensitive ERBB2-expressing breast tumor cells, indicating that pharmacological autophagy suppression has a wider role in the treatment of ERBB2-positive breast cancer. ",
        "Doc_title":"ERBB2 overexpression suppresses stress-induced autophagy and renders ERBB2-induced mammary tumorigenesis independent of monoallelic Becn1 loss.",
        "Journal":"Autophagy",
        "Do_id":"24492513",
        "Doc_ChemicalList":"Antibodies, Monoclonal, Humanized;Apoptosis Regulatory Proteins;BECN1 protein, human;Beclin-1;Becn1 protein, mouse;Membrane Proteins;Receptor, ErbB-2;Trastuzumab",
        "Doc_meshdescriptors":"Animals;Antibodies, Monoclonal, Humanized;Apoptosis Regulatory Proteins;Autophagy;Beclin-1;Breast Neoplasms;Cell Transformation, Neoplastic;Female;Humans;Mammary Glands, Animal;Membrane Proteins;Mice;Mice, Transgenic;Receptor, ErbB-2;Signal Transduction;Stress, Physiological;Trastuzumab",
        "Doc_meshqualifiers":"pharmacology;deficiency;drug effects;genetics;metabolism;pathology;metabolism;metabolism;deficiency;metabolism;drug effects;immunology;physiology",
        "_version_":1605741995001643008},
      {
        "Doc_abstract":"The heregulin/neu differentiation factor gene products were purified and cloned based on their ability to stimulate the phosphorylation of a 185-kDa protein in human breast carcinoma cell lines known to express erbB2. However, not all cells that express erbB2 respond to heregulin, indicating that other components besides erbB2 may be required for heregulin binding. Cells that are transfected with the closely related receptor, erbB3, display a single class of lower affinity heregulin binding sites than has been previously observed on breast carcinoma cell lines. Little or no stimulation of tyrosine phosphorylation in response to heregulin occurs in cells that are transfected with erbB3 alone. Transfection of cells with erbB3 and erbB2 reconstitutes a higher affinity binding receptor, which is also capable of generating a tyrosine phosphorylation signal in response to heregulin. A monoclonal antibody to erbB2 will inhibit heregulin activation of tyrosine phosphorylation and binding in cells transfected with both receptors but not with erbB3 alone. In cells expressing erbB2 and erbB3, both proteins become tyrosine-phosphorylated upon interaction with heregulin. Direct interaction between heregulin and the two proteins was demonstrated by chemical cross-linking experiments using 125I-heregulin followed by immunoprecipitation with antibodies specific for erbB2 or erbB3.",
        "Doc_title":"Coexpression of erbB2 and erbB3 proteins reconstitutes a high affinity receptor for heregulin.",
        "Journal":"The Journal of biological chemistry",
        "Do_id":"7514177",
        "Doc_ChemicalList":"Carrier Proteins;Cross-Linking Reagents;Glycoproteins;Iodine Radioisotopes;Neuregulin-1;Neuregulins;Proto-Oncogene Proteins;Recombinant Proteins;heregulin beta1;Phosphotyrosine;Tyrosine;Receptor, Epidermal Growth Factor;Receptor, ErbB-2;Receptor, ErbB-3",
        "Doc_meshdescriptors":"Animals;Carrier Proteins;Cell Line;Cercopithecus aethiops;Cross-Linking Reagents;Gene Expression;Glycoproteins;Humans;Iodine Radioisotopes;Kinetics;Neuregulin-1;Neuregulins;Phosphorylation;Phosphotyrosine;Proto-Oncogene Proteins;Proto-Oncogenes;Radioligand Assay;Receptor, Epidermal Growth Factor;Receptor, ErbB-2;Receptor, ErbB-3;Recombinant Proteins;Transfection;Tyrosine",
        "Doc_meshqualifiers":"biosynthesis;metabolism;biosynthesis;metabolism;analysis;biosynthesis;metabolism;analysis;biosynthesis;metabolism;analysis;biosynthesis;metabolism;analogs & derivatives;metabolism",
        "_version_":1605810868878049280},
      {
        "Doc_abstract":"Approximately 20% of breast cancer patients harbor tumors that overexpress human epidermal growth factor receptor 2 (HER2; also known as ErbB2), a receptor tyrosine kinase that belongs to the epidermal growth factor receptor family of receptor tyrosine kinases. HER2 amplification and hyperactivation drive the growth and survival of breast cancers through the aberrant activation of proto-oncogenic signaling systems, particularly the Ras/MAP kinase and PI3K/AKT pathways. Although HER2-positive (HER2(+)) breast cancer was originally considered to be a highly aggressive form of the disease, the clinical landscape of HER2(+) breast cancers has literally been transformed by the approval of anti-HER2 agents for adjuvant and neoadjuvant settings. Indeed, pertuzumab is a novel monoclonal antibody that functions as an anti-HER2 agent by targeting the extracellular dimerization domain of the HER2 receptor; it is also the first drug to receive an accelerated approval by the US Food and Drug Administration for use in neoadjuvant settings in early-stage HER2(+) breast cancer. Here, we review the molecular and cellular factors that contribute to the pathophysiology of HER2 in breast cancer, as well as summarize the landmark preclinical and clinical findings underlying the approval and use of pertuzumab in the neoadjuvant setting. Finally, the molecular mechanisms operant in mediating resistance to anti-HER2 agents, and perhaps to pertuzumab as well, will be discussed, as will the anticipated clinical impact and future directions of pertuzumab in breast cancer patients. ",
        "Doc_title":"Neoadjuvant therapy for early-stage breast cancer: the clinical utility of pertuzumab.",
        "Journal":"Cancer management and research",
        "Do_id":"26937204",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605826096629022720},
      {
        "Doc_abstract":"Biomechanical properties of tumor cells play an important role for the metastatic capacity of cancer. Cellular changes of viscoelastic features are prerequisite for cancer progression since they are essential for proliferation and metastasis. However, only little is known about the way how expression of oncogenes influences these biomechanical properties. To address this aspect we used a breast cancer cell line with inducible expression of an oncogenic version of ERBB2. ERBB2 is known to be correlated with bad prognosis in breast cancer. Cell elasticity was determined by the Optical Stretcher, where suspended cells are deformed by two slightly divergent laser beams. We found that induction of ERBB2 caused remarkable biomechanical alterations of the MCF-7 cells after 24 h: the cells actively contracted in response to mechanical stimuli, a phenomenon known as mechanoactivation. After this period, as the cells became senescent, the mechanoactivity returned to control levels. Time-resolved gene array analysis revealed that mechanoactivation was accompanied by temporal upregulation of 46 cytoskeletal genes. A possible role of these genes in tumor progression was investigated by expression analyses of 766 breast cancer patients. This showed an association of 12 out of these 46 genes with increased risk of metastasis. Our results demonstrate that overexpression of ERBB2 causes mechanoactivation of tumor cells, which may enhance tumor cell motility fostering distant metastasis.",
        "Doc_title":"ERBB2 overexpression triggers transient high mechanoactivity of breast tumor cells.",
        "Journal":"Cytoskeleton (Hoboken, N.J.)",
        "Do_id":"22407943",
        "Doc_ChemicalList":"Biomarkers, Tumor;RNA, Messenger;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Biomarkers, Tumor;Blotting, Western;Breast;Breast Neoplasms;Cell Adhesion;Cell Line, Tumor;Cell Movement;Cell Proliferation;Cohort Studies;Female;Gene Expression Profiling;Gene Expression Regulation, Neoplastic;Humans;Mechanotransduction, Cellular;Neoplasm Metastasis;Oligonucleotide Array Sequence Analysis;Prognosis;RNA, Messenger;Real-Time Polymerase Chain Reaction;Receptor, ErbB-2;Reverse Transcriptase Polymerase Chain Reaction;Signal Transduction;Survival Rate",
        "Doc_meshqualifiers":"genetics;metabolism;metabolism;pathology;metabolism;mortality;pathology;genetics;genetics;metabolism",
        "_version_":1605742070087024640},
      {
        "Doc_abstract":"Both fatty acid synthase (FASN) and ErbB2 have been shown to promote breast cancer cell migration. However, the underlying molecular mechanism remains poorly understood and there is no reported evidence that directly links glycolysis to breast cancer cell migration. In this study, we investigated the role of FASN, ErbB2-mediated glycolysis in breast cancer cell migration. First, we compared lactate dehydrogenase A (LDHA) protein levels, glycolysis and cell migration between FASN, ErbB2-overexpressing SK-BR-3 cells and FASN, ErbB2-low-expressing MCF7 cells. Then, SK-BR-3 cells were treated with cerulenin (Cer), an inhibitor of FASN, and ErbB2, LDHA protein levels, glycolysis, and cell migration were detected. Next, we transiently transfected ErbB2 plasmid into MCF7 cells and detected FASN, LDHA protein levels, glycolysis and cell migration. Heregulin-Î²1 (HRG-Î²1) is an activator of ErbB2 and 2-deoxyglucose (2-DG) and oxamate (OX) are inhibitors of glycolysis. MCF7 cells were treated with HRG-Î²1 alone, HRG-Î²1 plus 2-DG, OX or cerulenin and glycolysis, and cell migration were measured. We found that FASN, ErbB2-high-expressing SK-BR-3 cells displayed higher levels of glycolysis and migration than FASN, ErbB2-low-expressing MCF7 cells. Inhibition of FASN by cerulenin impaired glycolysis and migration in SK-BR-3 cells. Transient overexpression of ErbB2 in MCF7 cells promotes glycolysis and migration. Moreover, 2-deoxyglucose (2-DG), oxamate (OX), or cerulenin partially reverses heregulin-Î²1 (HRG-Î²1)-induced glycolysis and migration in MCF7 cells. In conclusion, this study demonstrates that FASN, ErbB2-mediated glycolysis is required for breast cancer cell migration. These novel findings indicate that targeting FASN, ErbB2-mediated glycolysis may be a new approach to reverse breast cancer cell migration.",
        "Doc_title":"FASN, ErbB2-mediated glycolysis is required for breast cancer cell migration.",
        "Journal":"Oncology reports",
        "Do_id":"26936618",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605852098375712768},
      {
        "Doc_abstract":"The coexpression of erbB3 and erbB2 is frequently observed in breast cancer; and erbB3 has a critical role in erbB2 promotion of breast cancer progression and anti-estrogen resistance. In this study, we determine the role of erbB3 in erbB2-mediated paclitaxel resistance in breast cancer cells. The overexpression of exogenous erbB3 via either stable or transient transfection in erbB2-overexpressing, but not epidermal growth factor receptor (EGFR)-expressing, breast cancer cells significantly decreases paclitaxel-induced growth inhibition and apoptosis. Consistently, knockdown of erbB3 expression with a specific short hairpin RNA (shRNA) in breast cancer cells with coexpression of both erbB2 and erbB3 enhances paclitaxel-induced apoptosis evidenced by increased DNA fragmentation, poly (ADP-ribose) polymerase (PARP) cleavage and activation of caspase-3 and -8. Furthermore, while forced overexpression of erbB3 increases, specific knockdown of erbB3 decreases the expression levels of Survivin only in the erbB2-overexpressing breast cancer cells. Targeting Survivin with specific shRNA overcomes paclitaxel resistance without effect on the expression levels of either erbB2 or erbB3. Mechanistic studies indicate that the specific phosphoinositide 3-kinase (PI-3K), Akt and mammalian target of rapamycin (mTOR) inhibitors, but not the mitogen-activated protein kinase kinase (MEK) inhibitor, not only abrogate erbB3-mediated upregulation of Survivin, but also reinforce the erbB2/erbB3-coexpressing breast cancer cells to paclitaxel-induced growth inhibition. These data demonstrate that heterodimerization of erbB2/erbB3 is a prerequisite for erbB2 tyrosine kinase activation; and elevated expression of erbB3 is required for erbB2-mediated paclitaxel resistance in breast cancer cells via PI-3K/Akt/mTOR signaling pathway-dependent upregulation of Survivin. Our studies suggest that new strategies targeting erbB3 or Survivin may enhance the efficacy of chemotherapeutic agents against erbB2-overexpressing breast cancer.",
        "Doc_title":"Elevated expression of erbB3 confers paclitaxel resistance in erbB2-overexpressing breast cancer cells via upregulation of Survivin.",
        "Journal":"Oncogene",
        "Do_id":"20498641",
        "Doc_ChemicalList":"Antineoplastic Agents, Phytogenic;BIRC5 protein, human;Inhibitor of Apoptosis Proteins;Intracellular Signaling Peptides and Proteins;Microtubule-Associated Proteins;Phosphatidylinositol 3-Kinases;MTOR protein, human;TOR Serine-Threonine Kinases;ERBB2 protein, human;Receptor, ErbB-2;Receptor, ErbB-3;Protein-Serine-Threonine Kinases;Proto-Oncogene Proteins c-akt;Paclitaxel",
        "Doc_meshdescriptors":"Antineoplastic Agents, Phytogenic;Apoptosis;Breast Neoplasms;Drug Resistance, Neoplasm;Female;Humans;Inhibitor of Apoptosis Proteins;Intracellular Signaling Peptides and Proteins;Microtubule-Associated Proteins;Paclitaxel;Phosphatidylinositol 3-Kinases;Protein-Serine-Threonine Kinases;Proto-Oncogene Proteins c-akt;Receptor, ErbB-2;Receptor, ErbB-3;TOR Serine-Threonine Kinases;Up-Regulation",
        "Doc_meshqualifiers":"pharmacology;drug effects;chemistry;drug therapy;physiology;genetics;pharmacology;physiology;physiology;physiology;analysis;physiology;analysis;physiology",
        "_version_":1605796132544315392},
      {
        "Doc_abstract":"The clinical use of trastuzumab (Herceptin), a humanized antibody against the HER2 growth factor receptor, has improved survival in patients with breast tumors with ERBB2 amplification and/or over-expression. However, most patients with advanced ERBB2 amplified breast cancers whose tumors initially respond to trastuzumab develop resistance to the drug, leading to tumor progression. To identify factors responsible for acquired resistance to trastuzumab, gene expression profiling was performed on subclones of an ERBB2 amplified breast cancer cell line, BT474, which had acquired resistance to trastuzumab. The most overexpressed gene in these subclones was PPP1R1B, encoding the DARPP-32 phosphatase inhibitor. Western analysis revealed that only the truncated isoform of the DARPP-32 protein, t-Darpp, was overexpressed in the trastuzumab resistant cells. Using gene silencing experiments, we confirmed that t-Darpp over-expression was required for trastuzumab resistance in these cells. Furthermore, transfecting t-Darpp in parental BT-474 cells conferred resistance to trastuzumab, suggesting that t-Darpp expression was sufficient for trastuzumab resistance. We also found that t-Darpp over-expression was associated with Akt activation and that the T75 residue in t-Darpp was required for both Akt activation and trastuzumab resistance. Finally, we found that full-length DARPP-32 and t-Darpp are expressed in a majority of primary breast tumors. Over-expression of full-length DARPP-32 can also confer resistance to trastuzumab and, moreover, is associated with a poor prognostic value in breast cancers. Thus, t-Darpp and DARPP-32 expression are novel prognostic and predictive biomarkers in breast cancer.",
        "Doc_title":"Both t-Darpp and DARPP-32 can cause resistance to trastuzumab in breast cancer cells and are frequently expressed in primary breast cancers.",
        "Journal":"Breast cancer research and treatment",
        "Do_id":"19301121",
        "Doc_ChemicalList":"Antibodies, Monoclonal;Antibodies, Monoclonal, Humanized;Antineoplastic Agents;Biomarkers, Tumor;Dopamine and cAMP-Regulated Phosphoprotein 32;Protein Isoforms;Proto-Oncogene Proteins c-akt;Trastuzumab",
        "Doc_meshdescriptors":"Antibodies, Monoclonal;Antibodies, Monoclonal, Humanized;Antineoplastic Agents;Biomarkers, Tumor;Blotting, Western;Breast Neoplasms;Comparative Genomic Hybridization;Dopamine and cAMP-Regulated Phosphoprotein 32;Drug Resistance, Neoplasm;Enzyme Activation;Female;Gene Expression Profiling;Genes, erbB-2;Humans;Immunohistochemistry;Prognosis;Protein Isoforms;Proto-Oncogene Proteins c-akt;Transfection;Trastuzumab",
        "Doc_meshqualifiers":"therapeutic use;therapeutic use;analysis;genetics;drug therapy;genetics;biosynthesis;genetics;genetics;genetics;genetics;biosynthesis;genetics;metabolism",
        "_version_":1605761056351715328},
      {
        "Doc_abstract":"About 9,500 new breast cancers are diagnosed in Belgium every year. Improvement of our knowledge of altered molecular events leading to the proliferation of tumor cells has resulted in the development of targeted therapies in subgroups of cancers. One of the first validation of targeted therapy is the anti-HER-2 monoclonal antibody trastuzumab (Herceptin) in patients with overexpression of human epidermal growth factor receptor type 2 (HER2) occurring in 20 to 25% of invasive breast carcinoma. Trastuzumab binds the extracellular juxtamembrane domain and is only active in tumor with HER2 gene amplification detected by fluorescence in situ hybridization (FISH). The results from randomized trials have rapidly lead to the approvement of the drug in the metastatic and then in the adjuvant setting. Another targeted therapy, also approved in the treatment of breast cancer, is the monoclonal antibody bevacizumab with an anti-VEGF (Vascular Endothelial Growth Factor) activity. We will review the benefit of these targeted therapies in breast cancer and their role in the treatment of breast cancer.",
        "Doc_title":"[Monoclonal antibodies and breast cancer. Current therapeutic progress].",
        "Journal":"Revue medicale de Liege",
        "Do_id":"19642459",
        "Doc_ChemicalList":"Antibodies, Monoclonal;Antibodies, Monoclonal, Humanized;Antineoplastic Agents;Vascular Endothelial Growth Factor A;Bevacizumab;Receptor, ErbB-2;Trastuzumab",
        "Doc_meshdescriptors":"Antibodies, Monoclonal;Antibodies, Monoclonal, Humanized;Antineoplastic Agents;Bevacizumab;Breast Neoplasms;Female;Humans;Receptor, ErbB-2;Trastuzumab;Vascular Endothelial Growth Factor A",
        "Doc_meshqualifiers":"therapeutic use;therapeutic use;drug therapy;metabolism;antagonists & inhibitors;antagonists & inhibitors",
        "_version_":1605756380435709952},
      {
        "Doc_abstract":"Breast cancer is the most common malignancy in women in the United States in the year 2000. The proto-oncogene Her-2/neu (c-erb-B2) has become an increasingly important prognostic and predictive factor in breast cancer. Overexpression/amplification of the Her-2/neu has been associated with a worse outcome in patients with breast cancer. Herceptin, a \"humanized\" murine monoclonal antibody directed against the extracellular domain of the Her-2/neu protein, is being used to treat breast cancer that overexpresses Her-2/neu. The status of Her-2/neu in the tumor has become a critical factor in the management strategy of a breast cancer patient. The objective of this article is to provide a comprehensive review of all aspects of Her-2/neu in breast cancer, including biology, prognostic and predictive value, targeted Herceptin therapy, and the laboratory testing of Her-2/neu.",
        "Doc_title":"Her-2/neu and breast cancer.",
        "Journal":"Diagnostic molecular pathology : the American journal of surgical pathology, part B",
        "Do_id":"11552716",
        "Doc_ChemicalList":"Antibodies, Monoclonal;Antibodies, Monoclonal, Humanized;Antineoplastic Agents;Receptor, ErbB-2;Trastuzumab",
        "Doc_meshdescriptors":"Adenocarcinoma;Antibodies, Monoclonal;Antibodies, Monoclonal, Humanized;Antineoplastic Agents;Breast Neoplasms;Female;Gene Amplification;Humans;Immunohistochemistry;In Situ Hybridization;Receptor, ErbB-2;Trastuzumab",
        "Doc_meshqualifiers":"drug therapy;metabolism;pathology;therapeutic use;therapeutic use;drug therapy;metabolism;pathology;immunology;metabolism",
        "_version_":1605896235600838656},
      {
        "Doc_abstract":"Although antiestrogen therapies targeting estrogen receptor (ER) Î± signaling prevent disease recurrence in the majority of patients with hormone-dependent breast cancer, a significant fraction of patients exhibit de novo or acquired resistance. Currently, the only accepted mechanism linked with endocrine resistance is amplification or overexpression of the ERBB2 (human epidermal growth factor receptor 2 [HER2]) proto-oncogene. Experimental and clinical evidence suggests that hyperactivation of the phosphatidylinositol 3-kinase (PI3K) pathway, the most frequently mutated pathway in breast cancer, promotes antiestrogen resistance. PI3K is a major signaling hub downstream of HER2 and other receptor tyrosine kinases. PI3K activates several molecules involved in cell-cycle progression and survival, and in ER-positive breast cancer cells, it promotes estrogen-dependent and -independent ER transcriptional activity. Preclinical tumor models of antiestrogen-resistant breast cancer often remain sensitive to estrogens and PI3K inhibition, suggesting that simultaneous targeting of the PI3K and ER pathways may be most effective. Herein, we review alterations in the PI3K pathway associated with resistance to endocrine therapy, the state of clinical development of PI3K inhibitors, and strategies for the clinical investigation of such drugs in hormone receptor-positive breast cancer.",
        "Doc_title":"Phosphatidylinositol 3-kinase and antiestrogen resistance in breast cancer.",
        "Journal":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
        "Do_id":"22010023",
        "Doc_ChemicalList":"Estrogen Receptor Modulators;Receptors, Estrogen;Phosphatidylinositol 3-Kinases",
        "Doc_meshdescriptors":"Breast Neoplasms;Clinical Trials as Topic;Drug Resistance, Neoplasm;Estrogen Receptor Modulators;Female;Humans;Phosphatidylinositol 3-Kinases;Receptors, Estrogen;Signal Transduction",
        "Doc_meshqualifiers":"chemistry;drug therapy;therapeutic use;antagonists & inhibitors;physiology;analysis;physiology;drug effects",
        "_version_":1605757731390619648},
      {
        "Doc_abstract":"Overexpression of ERBB2 and its neighboring genes on chromosome 17 occurs in approximately 25% of breast tumors and is associated with poor prognosis. While amplification of the 17q12-21 chromosomal region often correlates with an increase in the transcriptional rates of the locus, the molecular mechanisms and the factors involved in the coordinated expression of genes residing within the ERBB2 amplicon remain largely unknown. Here we demonstrate that estrogen-related receptor Î± (ERRÎ±, NR3B1) and its coregulator PGC-1Î² are key effectors in this process. Using a mouse model of ERBB2-initiated mammary tumorigenesis, we first show that ablation of ERRÎ± significantly delays ERBB2-induced tumor development and lowers the levels of amplicon transcripts. Chromosome 17q-wide binding site location analyses in human breast cancer cells show preferential recruitment of ERRÎ± to DNA segments associated with the ERBB2 amplicon. Furthermore, ERRÎ± directs the co-recruitment of the coactivator PGC-1Î² to segments in the 17q12 region and the recruitment of RNA polymerase II to the promoters of the ERBB2 and coamplified genes. ERRÎ± and PGC-1Î² also participate in the de-repression of ERBB2 expression through competitive genomic cross-talk with estrogen receptor Î± (ERÎ±) and, as a consequence, influence tamoxifen sensitivity in breast cancer cells. Taken together, our results suggest that ERRÎ± and PGC-1Î² are key players in the etiology of malignant breast cancer by coordinating the transcriptional regulation of genes located in the 17q12 region, a process that also involves interference with the repressive function of ERÎ± on ERBB2 expression.",
        "Doc_title":"Transcriptional control of the ERBB2 amplicon by ERRalpha and PGC-1beta promotes mammary gland tumorigenesis.",
        "Journal":"Cancer research",
        "Do_id":"20961995",
        "Doc_ChemicalList":"Carrier Proteins;ERRalpha estrogen-related receptor;GRB7 protein, human;PPARGC1B protein, human;Receptors, Estrogen;Tamoxifen;GRB7 Adaptor Protein;ERBB2 protein, human;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Animals;Breast Neoplasms;Carrier Proteins;Cell Line, Tumor;Cell Transformation, Neoplastic;Chromosomes, Human, Pair 17;Drug Resistance, Neoplasm;Female;GRB7 Adaptor Protein;Gene Amplification;Gene Expression Regulation, Neoplastic;Genes, erbB-2;Humans;Mammary Neoplasms, Experimental;Mice;Mice, Transgenic;Receptor, ErbB-2;Receptors, Estrogen;Tamoxifen",
        "Doc_meshqualifiers":"genetics;genetics;metabolism;genetics;metabolism;genetics;genetics;metabolism;biosynthesis;genetics;genetics;metabolism;pharmacology",
        "_version_":1605748375325507584},
      {
        "Doc_abstract":"HER2 (ErbB2), a member of the HER family of tyrosine kinase receptors (HER1-4), is a major driver of tumor growth in 20% of breast cancers. Treatment with the anti-HER2 monoclonal antibody trastuzumab has revolutionized the outcome of patients with this aggressive breast cancer subtype, but intrinsic and acquired resistance is common. Growing understanding of the biology and complexity of the HER2 signaling network and of potential resistance mechanisms has guided the development of new HER2-targeted agents. Combinations of these drugs to more completely inhibit the HER receptor layer, or combining HER2-targeted agents with agents that target downstream signaling, alternative pathways, or components of the host immune system, are being vigorously investigated in the preclinical and clinical settings. As a result, the list of more effective and well tolerated FDA-approved new regimens for patients with HER2+ tumors is constantly growing. ",
        "Doc_title":"Targeting HER2 for the treatment of breast cancer.",
        "Journal":"Annual review of medicine",
        "Do_id":"25587647",
        "Doc_ChemicalList":"Antibodies, Monoclonal, Humanized;Antineoplastic Agents;Aromatase Inhibitors;Nitriles;Quinazolines;Receptors, Estrogen;Triazoles;lapatinib;anastrozole;Receptor, ErbB-2;Trastuzumab",
        "Doc_meshdescriptors":"Antibodies, Monoclonal, Humanized;Antineoplastic Agents;Antineoplastic Combined Chemotherapy Protocols;Aromatase Inhibitors;Breast Neoplasms;Carcinoma;Female;Humans;Nitriles;Quinazolines;Receptor, ErbB-2;Receptors, Estrogen;Trastuzumab;Triazoles",
        "Doc_meshqualifiers":"therapeutic use;therapeutic use;therapeutic use;therapeutic use;drug therapy;metabolism;drug therapy;metabolism;therapeutic use;therapeutic use;antagonists & inhibitors;metabolism;metabolism;therapeutic use",
        "_version_":1605906794167664640},
      {
        "Doc_abstract":"Gene amplification is among the most common genetic abnormalities that cause cancer. One of the most clinically important gene amplifications in human cancer causes extensive reduplication of ERBB2. A variety of cancers also occasionally harbor somatic mutations in ERBB2. Gene amplification and activating mutations both have predictive value for clinical response to targeted inhibitors. Since the number of gene copies in an amplicon may exceed 100, and since amplicons may encompass multiple genes, high-resolution analysis of gene amplifications poses considerable technical challenges. We have overcome this obstacle by using emulsion-based resequencing to determine the sequence of many independently-amplified individual DNA molecules in parallel. We used this high throughput sequencing technology to analyze ERBB2 mutational status in five ERBB2 amplified cell lines (four breast, one ovarian) and two breast tumors. Genomic DNA was isolated and the 28 exons of ERBB2 were independently amplified. Amplicons were then pooled at equimolar ratios, subjected to emulsion PCR (emPCR) and finally to picotiter plate pyrosequencing. High-quality sequence data were obtained for all amplicons analyzed and no activating mutations within ERBB2 were identified. Although we did not find activating mutations within the multiple copies of ERBB2 in these samples, the results establish the utility of this technology as a feasible and cost-effective approach for high resolution analysis of amplified genes.",
        "Doc_title":"Direct resequencing of the complete ERBB2 coding sequence reveals an absence of activating mutations in ERBB2 amplified breast cancer.",
        "Journal":"Genes, chromosomes & cancer",
        "Do_id":"18418848",
        "Doc_ChemicalList":"DNA, Neoplasm;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Breast Neoplasms;DNA Mutational Analysis;DNA, Neoplasm;Female;Gene Amplification;Gene Expression Regulation, Neoplastic;Humans;Immunoprecipitation;Mutagenesis, Site-Directed;Mutation;Open Reading Frames;Polymerase Chain Reaction;Receptor, ErbB-2;Sequence Analysis, DNA;Transfection;Tumor Cells, Cultured",
        "Doc_meshqualifiers":"genetics;metabolism;genetics;metabolism;genetics;genetics;metabolism",
        "_version_":1605742069432713218},
      {
        "Doc_abstract":"The breast cancer-associated gene 1 (BRCA1) is the most frequently mutated tumor suppressor gene in familial breast cancers. Mutations in BRCA1 also predispose to other types of cancers, pointing to a fundamental role of this pathway in tumor suppression and emphasizing the need for effective chemoprevention in these high-risk patients. Because the methyl ester of the synthetic triterpenoid 2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oic acid (CDDO-Me) is a potent chemopreventive agent, we tested its efficacy in a highly relevant mouse model of BRCA1-mutated breast cancer. Beginning at 12 weeks of age, Brca1(Co/Co); MMTV-Cre;p53(+/-) mice were fed powdered control diet or diet containing CDDO-Me (50 mg/kg diet). CDDO-Me significantly (P < 0.05) delayed tumor development in the Brca1-mutated mice by an average of 5.2 weeks. We also observed that levels of ErbB2, p-ErbB2, and cyclin D1 increased in a time-dependent manner in the mammary glands in Brca1-deficient mice, and CDDO-Me inhibited the constitutive phosphorylation of ErbB2 in tumor tissues from these mice. In BRCA1-deficient cell lines, the triterpenoids directly interacted with ErbB2, decreased constitutive phosphorylation of ErbB2, inhibited proliferation, and induced G(0)-G(1) arrest. These results suggest that CDDO-Me has the potential to prevent BRCA1-mutated breast cancer.",
        "Doc_title":"CDDO-methyl ester delays breast cancer development in BRCA1-mutated mice.",
        "Journal":"Cancer prevention research (Philadelphia, Pa.)",
        "Do_id":"21933912",
        "Doc_ChemicalList":"Anticarcinogenic Agents;BRCA1 Protein;Oleanolic Acid;methyl 2-cyano-3,12-dioxoolean-1,9-dien-28-oate;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Animals;Anticarcinogenic Agents;BRCA1 Protein;Cell Cycle;Female;Genes, BRCA1;Genes, p53;Mammary Neoplasms, Animal;Mice;Mutation;Oleanolic Acid;Phosphorylation;Receptor, ErbB-2",
        "Doc_meshqualifiers":"pharmacology;genetics;genetics;prevention & control;analogs & derivatives;pharmacology;metabolism",
        "_version_":1605742744870846466},
      {
        "Doc_abstract":"Polysomy 17 is frequently found in breast cancer and may complicate the interpretation of HER-2 testing results. We investigated the impact of polysomy 17 on HER-2 testing and studied its clinicopathologic significance in relation to HER2 gene amplification.;In 226 patients with primary invasive breast carcinoma, HER2 gene and chromosome 17 copy numbers were determined by dual-color fluorescent in situ hybridization (FISH). The interpretation of FISH results was based on either absolute HER2 gene copy number or the ratio HER2/chromosome 17. Results were correlated with HER-2 protein expression on immunohistochemistry (IHC), HER2 mRNA expression by reverse transcriptase polymerase chain reaction (RT-PCR), and with various clinicopathologic parameters.;All cases with an equivocal HER-2 result by FISH, either by absolute HER2 copy number (44 of 226 patients; 19.5%) or by the ratio HER2/chromosome 17 (three of 226 patients; 1.3%), displayed polysomy 17. On its own, polysomy 17 was not associated with HER-2 overexpression on IHC or increased HER2 mRNA levels by RT-PCR. Moreover, and in contrast with HER2 gene amplification, polysomy 17 was not associated with high tumor grade, hormone receptor negativity, or reduced disease-free survival.;Polysomy 17 affects HER-2 testing in breast cancer and is a major cause of equivocal results by FISH. We show that tumors displaying polysomy 17 in the absence of HER2 gene amplification resemble more HER-2-negative than HER-2-positive tumors. These findings highlight the need for clinical trials to investigative whether polysomy 17 tumors benefit from HER-2-targeted therapy.",
        "Doc_title":"Polysomy 17 in breast cancer: clinicopathologic significance and impact on HER-2 testing.",
        "Journal":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
        "Do_id":"18794552",
        "Doc_ChemicalList":"Antibodies, Monoclonal;Antibodies, Monoclonal, Humanized;Antineoplastic Agents;ERBB2 protein, human;Receptor, ErbB-2;Trastuzumab",
        "Doc_meshdescriptors":"Aneuploidy;Antibodies, Monoclonal;Antibodies, Monoclonal, Humanized;Antineoplastic Agents;Breast Neoplasms;Chromosomes, Human, Pair 17;Disease-Free Survival;Female;Gene Amplification;Genes, erbB-2;Genetic Testing;Humans;In Situ Hybridization, Fluorescence;Lymphatic Metastasis;Receptor, ErbB-2;Trastuzumab",
        "Doc_meshqualifiers":"pharmacology;pharmacology;drug therapy;genetics;metabolism;pathology;genetics;genetics;methods;drug effects;genetics;metabolism",
        "_version_":1605893313573945344},
      {
        "Doc_abstract":"SUMMARY: Lapatinib is potentially an ideal therapy for the adjuvant and neoadjuvant treatment of women with breast cancer due to its convenience of use (oral, once-daily administration) and because it has shown activity in the first-line and refractory metastatic settings. Furthermore, the dual tyrosine kinase inhibitor appears to have a low incidence of cardiotoxicity, and may decrease the rate of later brain metastases. Therefore, several cooperative groups and academic centers have initiated trials investigating lapatinib in the treatment of early-stage ErbB2 (HER2)-overexpressing breast cancer.",
        "Doc_title":"Future Roles of Lapatinib in ErbB2-Positive Breast Cancer: Adjuvant and Neoadjuvant Trials.",
        "Journal":"Breast care (Basel, Switzerland)",
        "Do_id":"20847929",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605842110580260864},
      {
        "Doc_abstract":"One of the first consistent genetic alterations found in human breast tumors was amplification of the erbB-2 gene leading to overexpression of the protein. ErbB2 is a member of the ErbB/type I family of receptor tyrosine kinases which also includes epidermal growth factor receptor, ErbB3 and ErbB4. The role of ErbB2 in the biology of the mammary gland as well as in breast cancer development is under intense investigation. In clinical studies, the ErbB2 protein level has been examined for its utility in predicting patient prognosis and response to treatment. The ErbB2 receptor is also being tested as a target for tumor directed therapies.",
        "Doc_title":"ErbB2 activation and signal transduction in normal and malignant mammary cells.",
        "Journal":"Journal of mammary gland biology and neoplasia",
        "Do_id":"10887493",
        "Doc_ChemicalList":"Receptor, ErbB-2",
        "Doc_meshdescriptors":"Animals;Breast;Breast Neoplasms;Gene Expression Regulation, Neoplastic;Genes, erbB-2;Humans;Mammary Glands, Animal;Mammary Neoplasms, Experimental;Receptor, ErbB-2;Signal Transduction",
        "Doc_meshqualifiers":"metabolism;metabolism;metabolism;metabolism;genetics;metabolism",
        "_version_":1605742742025011202},
      {
        "Doc_abstract":"ERBB2 overexpression predicts a worse outcome for patients receiving high-dose chemotherapy (HDC). Trastuzumab improves response rate and survival in ERBB2 overexpressing metastatic breast cancer patients (MBC). We investigated the feasibility of combining high-dose alkylating agents with autologous hematopoietic stem cell (AHSC) support and trastuzumab in ERBB2 overexpressing MBC.;Eleven consecutive patients with pre-treated ERBB2 overexpressing MBC were enrolled. HDC regimen consisted of a single course of cyclophosphamide 120 mg/kg + melphalan 140 mg/m2 (CyMEL, n =8), a single course of Thiotepa 600 mg/m2 (TTP, n = 1) or a sequential combination of Thiotepa 600 mg/m2 followed on day 21 by BCNU 600 mg/m2 (TTP-BCNU, n =2). Trastuzumab (4mg/kg) was started 24 h after AHSC infusion and then administered weekly (2 mg/kg).;Median time to neutrophil and platelet recovery was 10 and 14.5 days, respectively. Three patients experienced febrile neutropenia and in 2 Herpes virus infections were documented. Five grade III/IV mucositis/oesophagitis were recorded. One patient experienced a reversible atrial arrhythmia on day 2 of trastuzumab, and another patients had a nonsymptomatic decrease in LVEF >10% on week 12 of trastuzumab. No toxic death was recorded. Median time to progression was 5 months (1 to 38 +).;Combining alkylating agent-based HDC and trastuzumab appears to be feasible in ERBB2 overexpressing MBC and warrants further investigation in a larger cohort.",
        "Doc_title":"High-dose alkylating agents with autologous hematopoietic stem cell support and trastuzumab in ERBB2 overexpressing metastatic breast cancer: a feasibility study.",
        "Journal":"Anticancer research",
        "Do_id":"15816643",
        "Doc_ChemicalList":"Antibodies, Monoclonal;Antibodies, Monoclonal, Humanized;Antineoplastic Agents;Antineoplastic Agents, Alkylating;Cyclophosphamide;Receptor, ErbB-2;Trastuzumab;Melphalan",
        "Doc_meshdescriptors":"Adult;Antibodies, Monoclonal;Antibodies, Monoclonal, Humanized;Antineoplastic Agents;Antineoplastic Agents, Alkylating;Blood Platelets;Breast Neoplasms;Combined Modality Therapy;Cyclophosphamide;Disease Progression;Disease-Free Survival;Feasibility Studies;Female;Heart;Humans;Melphalan;Middle Aged;Neoplasm Metastasis;Neutrophils;Receptor, ErbB-2;Risk;Stem Cell Transplantation;Time Factors;Trastuzumab",
        "Doc_meshqualifiers":"therapeutic use;therapeutic use;therapeutic use;metabolism;drug therapy;therapy;administration & dosage;drug effects;administration & dosage;metabolism;biosynthesis",
        "_version_":1605789189902696448},
      {
        "Doc_abstract":"The DNA topoisomerase enzymes are targets for the cytotoxic effects of a number of anticancer agents termed topoisomerase inhibitors. We have analysed breast cancer biopsy specimens for genetic alterations at and around topoisomerase loci in order to obtain molecular insight into factors which may determine how tumours respond to chemotherapy. We show that of 50 tumours examined, the topoisomerase II alpha locus is co-amplified in 3 cases out of 6 with erbB2 amplification and that amplification can be accompanied by high expression of topoisomerase II alpha. In our attempts to distinguish amplification from aneuploidy and define the limits of amplification, we also observed co-amplification of the retinoic acid-alpha receptor with erbB2 and topoisomerase II alpha in the same three samples. At the topoisomerase I locus on chromosome 20, we observed allelic loss in two out of 17 samples. Genetics abberations at topoisomerase loci, therefore, appear to be relatively common in breast cancer.",
        "Doc_title":"Co-amplification of erbB2, topoisomerase II alpha and retinoic acid receptor alpha genes in breast cancer and allelic loss at topoisomerase I on chromosome 20.",
        "Journal":"European journal of cancer (Oxford, England : 1990)",
        "Do_id":"8104440",
        "Doc_ChemicalList":"DNA, Neoplasm;Proto-Oncogene Proteins;Receptors, Retinoic Acid;Tretinoin;Receptor, Epidermal Growth Factor;Receptor, ErbB-2;DNA Topoisomerases, Type II",
        "Doc_meshdescriptors":"Aged;Aged, 80 and over;Alleles;Breast Neoplasms;Chromosomes, Human, Pair 17;DNA Topoisomerases, Type II;DNA, Neoplasm;Female;Gene Amplification;Humans;Middle Aged;Proto-Oncogene Proteins;Receptor, Epidermal Growth Factor;Receptor, ErbB-2;Receptors, Retinoic Acid;Tretinoin",
        "Doc_meshqualifiers":"genetics;biosynthesis;genetics;analysis;metabolism;metabolism;genetics;metabolism;metabolism",
        "_version_":1605818688135495681},
      {
        "Doc_abstract":"A large number of breast cancers are characterized by amplification and overexpression of the chromosome segment surrounding the HER2 (ERBB2) oncogene. As the HER2 amplicon at 17q12 contains multiple genes, we have systematically explored the role of the HER2 co-amplified genes in breast cancer cell growth and their relation to trastuzumab resistance. We integrated array comparative genomic hybridization (aCGH) data of the HER2 amplicon from 71 HER2 positive breast tumors and 10 cell lines with systematic functional RNA interference analysis of 23 core amplicon genes with several phenotypic endpoints in a panel of trastuzumab responding and non-responding HER2 positive breast cancer cells. In this Data in Brief we give a detailed description of the experimental procedures and the data analysis methods used in the study (1). ",
        "Doc_title":"The HER2 amplicon includes several genes required for the growth and survival of HER2 positive breast cancer cells - A data description.",
        "Journal":"Genomics data",
        "Do_id":"26484103",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605811861815558144},
      {
        "Doc_abstract":"Breast cancer is one of among all cancers with increased incidence, high mortality rate, and high economic and social costs. The the most common type of cancer among females worldwide, breast cancer is actually the uncontrolled proliferation of cells which attain malignancy. Recently it has shown that breast cancer contributes 11% among all types of cancer diagnosed globally on an annual basis and it is one of the leading causes of death among women. The human epidermal growth factor receptor 2 (HER-2) is a receptor tyrosine-protein kinase erbB-2 normally involved in the proliferation and division of breast cells. In some abnormal cases the HER2 gene does not work correctly and makes too many copies of itself. HER2-positive (HER2+) breast cancers constitute an aggressive type of breast cancer and tend to grow faster and are more likely to spread. However, therapies that specifically target HER2, such as HerceptinÂ® (traztuzumab), are very effective. HER2 targeted therapies, has significantly improved the therapeutic outcome for patients with HER2 positive breast cancer. ",
        "Doc_title":"HER-2 Positive Breast Cancer - a Mini-Review.",
        "Journal":"Asian Pacific journal of cancer prevention : APJCP",
        "Do_id":"27221828",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605754463214108672},
      {
        "Doc_abstract":"Overexpression of the HER2/Neu (ErbB2) proto-oncogene is associated with breast cancer progression and poor patient prognosis. Herceptin (trastuzumab) is a humanized IgG1 against the ectodomain of the HER2 receptor. In combination with chemotherapy, it induces regression of HER2-overexpressing metastatic breast tumors and prolongs patient survival. Single-agent Herceptin in patients with HER2-amplified breast tumors also induces a definite objective response and clinical benefit rates, and is well tolerated. These data suggest that Herceptin is an effective first-line single-agent therapy for a predictable cohort of metastatic breast cancers and can therefore be used as a platform for therapeutic discovery against tumors that overexpress HER2.",
        "Doc_title":"Trastuzumab, an appropriate first-line single-agent therapy for HER2-overexpressing metastatic breast cancer.",
        "Journal":"Breast cancer research : BCR",
        "Do_id":"12631388",
        "Doc_ChemicalList":"Antibodies, Monoclonal;Antibodies, Monoclonal, Humanized;Receptor, ErbB-2;Trastuzumab",
        "Doc_meshdescriptors":"Antibodies, Monoclonal;Antibodies, Monoclonal, Humanized;Breast Neoplasms;Female;Humans;Neoplasm Metastasis;Receptor, ErbB-2;Trastuzumab;Treatment Outcome",
        "Doc_meshqualifiers":"therapeutic use;drug therapy;metabolism;pathology;antagonists & inhibitors;metabolism",
        "_version_":1605790390320889856},
      {
        "Doc_abstract":"Gene expression microarrays are being used to develop new prognostic and predictive tests for breast cancer, and might be used at the same time to confirm oestrogen-receptor status and ERBB2 status. Our goal was to establish a new method to assign oestrogen receptor and ERBB2-receptor status to breast carcinoma based on mRNA expression measured using Affymetrix U133A gene-expression profiling.;We used gene expression data of 495 breast cancer samples to assess the correlation between oestrogen receptor (ESR1) and ERBB2 mRNA and clinical status of these genes (as established by immunohistochemical [IHC] or fluorescence in-situ hybridisation [FISH], or both). Data from 195 fine-needle aspiration (FNA) samples were used to define mRNA cutoff values that assign receptor status. We assessed the accuracy of these cutoffs in two independent datasets: 123 FNA samples and 177 tissue samples (ie, resected or core-needle biopsied tissues). Profiling was done at two institutions by use of the same platform (Affymetrix U133A GeneChip). All data were uniformly normalised with dCHIP software.;ESR1 and ERBB2 mRNA levels correlated closely with routine measurements for receptor status in all three datasets. Spearman's correlation coefficients ranged from 0.62 to 0.77. An ESR1 mRNA cutoff value of 500 identified oestrogen-receptor-positive status with an overall accuracy of 90% (training set), 88% (first validation set), and 96% (second validation set). An ERBB2 mRNA threshold of 1150 identified ERBB2-positive status with the overall accuracy of 93% (training set), 89% (first validation set), and 90% (second validation set). Reproducibility of mRNA measurements in 34 replicate experiments was high (correlation coefficient 0.975 for ESR1, 0.984 for ERBB2).;Amounts of ESR1 and ERBB2 mRNA as measured by the Affymetrix GeneChip reliably and reproducibly establish oestrogen-receptor status and ERBB2 status, respectively.",
        "Doc_title":"Determination of oestrogen-receptor status and ERBB2 status of breast carcinoma: a gene-expression profiling study.",
        "Journal":"The Lancet. Oncology",
        "Do_id":"17329190",
        "Doc_ChemicalList":"RNA, Messenger;Receptors, Estrogen",
        "Doc_meshdescriptors":"Breast Neoplasms;Gene Expression Profiling;Genes, erbB-2;Humans;RNA, Messenger;Receptors, Estrogen",
        "Doc_meshqualifiers":"genetics;genetics;analysis;biosynthesis;genetics",
        "_version_":1605810227464110080},
      {
        "Doc_abstract":"Inflammatory breast cancer (IBC) represents a rare but aggressive and lethal form of locally advanced breast cancer (LABC) and frequently with HER-2 neu overexpressed or amplified. We retrospectively identified 16 newly diagnosed HER-2 â„ neu-positive IBC patients who were treated with preoperative trastuzumab. We determined the pathological complete response rate (pCR) when trastuzumab was added to preoperative chemotherapy in patients with HER2â„ neupositive IBC. Furthermore, we assessed the expression of CXCR4 in metastatic recurrence sites. Ten patients (62.5%)achieved a pCR. Six patients (37.5%) achieved a partial response. Median follow-up of all patients was 24.2 months. Four(25%) patients have experienced a progression, of which three were in the brain. Two-year progression-free survival was 59.4% (95% CI 35â€“100). High expression of CXCR4 was detected in the brain metastases. We conclude that in spite of high pCR rates among women with HER-2 â„ neu-positive IBC treated with neoadjuvant trastuzumab-based regimens the outcome remains dismal and brain recurrences are frequent. CXCR4 may represent a novel therapeutic target.",
        "Doc_title":"Trastuzumab in Primary Inflammatory Breast Cancer  (IBC): High Pathological Response Rates and Improved  Outcome.",
        "Journal":"The breast journal",
        "Do_id":"20626396",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605895548350496768},
      {
        "Doc_abstract":"Breast cancer is a most common malignancy especially in Iraqi women accounting for high morbidity and mortality. Mutations in BRCA1 gene is one of the important genetic predisposing factors inbreast cancer. Similarly ERBB2 and TP53 are also key prognostic markers in breast cancer treatment.We were interested to explore the gene expression profiles of BRCA1, ERBB2 and TP53 in breast cancer women patients from Iraq so as to assess the potential of such markers in breast cancer treatment. The mRNA levels were significantly over-expressed in tumor tissues in comparison to normal ones with p values (p<0.005) observed between malignant BRCA1 and control tissue samples. Similarly significant difference (p<0.001) was observed between malignant ERBB2 in comparison to control, and malignant TP53 and benign tissue samples as well. However in blood samples, no considerable expression of these markers was observed. Out of three selected genes, ERBB2 expression was significantly expressed in comparison to BRCA1 and TP53 in cancer tissue. Mutation analysis of BRCA1, ERBB2 and TP53 has been made to find out the region most susceptible to mutations in these genes The BRCA1 exon 11, ERBB2 16 and TP53 exon 5 displayed increased chances of having mutations. We can conclude from the study that differential gene expression of BRCA1, ERBB2 and TP53 at mRNA levels may act as a diagnostic marker of circulating tumor cells having important prognostic value in breast cancer patients. ",
        "Doc_title":"Differential Gene Expression of BRCA1,ERBB2 and TP53 biomarkers between Human Breast Tissue and Peripheral Blood Samples of Breast Cancer.",
        "Journal":"Anti-cancer agents in medicinal chemistry",
        "Do_id":"26299666",
        "Doc_ChemicalList":"BRCA1 Protein;BRCA1 protein, human;Biomarkers, Tumor;RNA, Messenger;TP53 protein, human;Tumor Suppressor Protein p53;ERBB2 protein, human;Receptor, ErbB-2",
        "Doc_meshdescriptors":"BRCA1 Protein;Biomarkers, Tumor;Breast Neoplasms;Female;Gene Expression Profiling;Gene Expression Regulation, Neoplastic;Humans;RNA, Messenger;Real-Time Polymerase Chain Reaction;Receptor, ErbB-2;Tumor Suppressor Protein p53",
        "Doc_meshqualifiers":"blood;genetics;blood;genetics;blood;genetics;pathology;genetics;blood;genetics;blood;genetics",
        "_version_":1605907709529423872},
      {
        "Doc_abstract":"ErbB2 is an excellent target for cancer therapies. Unfortunately, the outcome of current therapies for ErbB2-positive breast cancers remains unsatisfying due to resistance and side effects. New therapies for ErbB2-overexpressing breast cancers continue to be in great need. Peptide therapy using cell-penetrating peptides (CPP) as peptide carriers is promising because the internalization is highly efficient, and the cargoes delivered can be bioactive. However, the major obstacle in using these powerful CPPs for therapy is their lack of specificity. Here, we sought to develop a peptide carrier that could introduce therapeutics specifically to ErbB2-overexpressing breast cancer cells. By modifying the HIV TAT-derived CPP and conjugating anti-HER-2/neu peptide mimetic (AHNP), we developed the peptide carrier (P3-AHNP) that specifically targeted ErbB2-overexpressing breast cancer cells in vitro and in vivo. A signal transducers and activators of transcription 3 (STAT3)-inhibiting peptide conjugated to this peptide carrier (P3-AHNP-STAT3BP) was delivered more efficiently into ErbB2-overexpressing than ErbB2 low-expressing cancer cells in vitro and successfully decreased STAT3 binding to STAT3-interacting DNA sequence. P3-AHNP-STAT3BP inhibited cell growth in vitro, with ErbB2-overexpressing 435.eB breast cancer cells being more sensitive to the treatment than the ErbB2 low-expressing MDA-MB-435 cells. Compared with ErbB2 low-expressing MDA-MB-435 xenografts, i.p. injected P3-AHNP-STAT3BP preferentially accumulated in 435.eB xenografts, which led to more reduction of proliferation and increased apoptosis and targeted inhibition of tumor growth. This novel peptide delivery system provided a sound basis for the future development of safe and effective new-generation therapeutics to cancer-specific molecular targets.",
        "Doc_title":"Selective inhibition of ErbB2-overexpressing breast cancer in vivo by a novel TAT-based ErbB2-targeting signal transducers and activators of transcription 3-blocking peptide.",
        "Journal":"Cancer research",
        "Do_id":"16585203",
        "Doc_ChemicalList":"Antibodies, Monoclonal;Gene Products, tat;Immunoconjugates;Peptide Fragments;STAT3 Transcription Factor;STAT3 protein, human;anti-HER2-neu peptide mimic, 1.5 kDa;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Amino Acid Sequence;Animals;Antibodies, Monoclonal;Breast Neoplasms;Drug Delivery Systems;Female;Gene Products, tat;Humans;Immunoconjugates;Mice;Mice, SCID;Molecular Sequence Data;NIH 3T3 Cells;Peptide Fragments;Receptor, ErbB-2;STAT3 Transcription Factor;Xenograft Model Antitumor Assays",
        "Doc_meshqualifiers":"pharmacokinetics;pharmacology;drug therapy;metabolism;pharmacokinetics;pharmacology;pharmacokinetics;pharmacology;pharmacokinetics;pharmacology;biosynthesis;metabolism;antagonists & inhibitors",
        "_version_":1605765398673752064},
      {
        "Doc_abstract":"Metastasis is the leading cause of death among breast cancer patients. Identifying key cellular factors controlling invasion and metastasis of breast cancer cells should pave the way to new therapeutic strategies efficiently interfering with the metastatic process. PAX2 (paired box 2) transcription factor is expressed by breast cancer cells in vivo and recently, it was shown to negatively regulate the expression of ERBB2 (erythroblastic leukemia viral oncogene homolog 2, HER-2/neu), a well-documented pro-invasive and pro-metastastic gene, in luminal/ERalpha-positive (ERÎ±+) breast cancer cells. The objective of the present study was to investigate a putative role for PAX2 in the control of luminal breast cancer cells invasion, and to begin to characterize its regulation.;PAX2 activity was higher in cell lines from luminal compared to non-luminal subtype, and activation of PAX2 by estradiol was selectively achieved in breast cancer cell lines of the luminal subtype. This process was blocked by ICI 182780 and could be antagonized by IGF-1. Knockdown of PAX2 in luminal MCF-7 cells completely abrogated estradiol-induced downregulation of ERBB2 and decrease of cell invasion, whereas overexpression of PAX2 in these cells enhanced estradiol effects on ERBB2 levels and cell invasion.;The study demonstrates that PAX2 activation by estradiol is selectively achieved in breast cancer cells of the luminal subtype, via ERÎ±, and identifies IGF-1 as a negative regulator of PAX2 activity in these cells. Further, it reveals a new role for PAX2 in the maintenance of a low invasive behavior in luminal breast cancer cells upon exposure to estradiol, and shows that overexpression and activation of PAX2 in these cells is sufficient to reduce their invasive ability.",
        "Doc_title":"PAX2 is activated by estradiol in breast cancer cells of the luminal subgroup selectively, to confer a low invasive phenotype.",
        "Journal":"Molecular cancer",
        "Do_id":"22168360",
        "Doc_ChemicalList":"Estrogens;PAX2 Transcription Factor;PAX2 protein, human;fulvestrant;Estradiol",
        "Doc_meshdescriptors":"Breast Neoplasms;Cell Line, Tumor;Cell Proliferation;Estradiol;Estrogens;Female;Humans;PAX2 Transcription Factor;Phenotype;Transfection",
        "Doc_meshqualifiers":"genetics;metabolism;analogs & derivatives;pharmacology;pharmacology;antagonists & inhibitors;genetics;metabolism",
        "_version_":1605919484602744832},
      {
        "Doc_abstract":"Studies have shown that antibodies targeting the intracellular (ICD) or extracellular domains (ECD) of human epidermal growth factor receptor 2 (HER2) are equivalent when traditional methods are used. We describe a new method to quantify ICD and ECD expression separately and assess the prognostic value of domain-specific HER2 results in patients who received adjuvant trastuzumab therapy.;We measured HER2 protein expression with quantitative immunofluorescence (QIF) in tissue microarrays (TMA) using two different antibodies targeting the ICD (CB11 and A0485) and ECD (SP3 and D8F12). We assessed the prognostic value of ICD and ECD expression in 180 patients from a clinical trial of adjuvant chemotherapy followed by trastuzumab (HeCOG 10/05). We performed an exploratory univariate domain-specific, disease-free survival (DFS) analysis and compared DFS functions with Kaplan-Meier estimates. All statistical tests were two-sided.;HER2 ICD expression by QIF showed slightly higher sensitivity to predict ERBB2 (HER2) gene amplification than ECD expression, which was more specific and had higher positive predictive value. In the HeCOG 10/05 trial specimens, 15% of cases showed discordant results for ICD and ECD expression. High ECD was statistically associated with longer DFS (log-rank P = .049, HR = 0.31, 95% CI = 0.144 to 0.997), while ICD status was not. Among patients with low ECD, there was no difference in DFS by ICD status. However, when ICD was high, high ECD was statistically associated with longer DFS (log-rank P = .027, HR = 0.23, 95% CI = 0.037 to 0.82) compared with low ECD.;Quantitative measurements of HER2 ICD and ECD expression in breast cancer suggest a subclassification of HER2-positive tumors. Trastuzumab-treated patients with high ECD showed better DFS than patients with low ECD. This suggests differential benefit from trastuzumab therapy based on HER2 ECD expression.",
        "Doc_title":"Measurement of Domain-Specific HER2 (ERBB2) Expression May Classify Benefit From Trastuzumab in Breast Cancer.",
        "Journal":"Journal of the National Cancer Institute",
        "Do_id":"25991002",
        "Doc_ChemicalList":"Antibodies, Monoclonal, Humanized;Antineoplastic Agents;Biomarkers, Tumor;ERBB2 protein, human;Receptor, ErbB-2;Trastuzumab",
        "Doc_meshdescriptors":"Adult;Aged;Antibodies, Monoclonal, Humanized;Antineoplastic Agents;Antineoplastic Combined Chemotherapy Protocols;Biomarkers, Tumor;Breast Neoplasms;Chemotherapy, Adjuvant;Clinical Trials as Topic;Disease-Free Survival;Extracellular Space;Female;Fluorescent Antibody Technique;Gene Expression Regulation, Neoplastic;Humans;Intracellular Space;Kaplan-Meier Estimate;Middle Aged;Predictive Value of Tests;Prognosis;Receptor, ErbB-2;Sensitivity and Specificity;Tissue Array Analysis;Trastuzumab;Treatment Outcome",
        "Doc_meshqualifiers":"administration & dosage;pharmacology;administration & dosage;pharmacology;therapeutic use;analysis;chemistry;drug therapy;mortality;chemistry;chemistry;analysis",
        "_version_":1605812689110564864},
      {
        "Doc_abstract":"The full extent of chromosomal alterations and their biological implications in early breast carcinogenesis has not been well examined. In this study, we aimed to identify chromosomal alterations associated with poor prognosis in early-stage breast cancers (EBC).;A total of 145 EBCs (stage I and II) were examined in this study. We analyzed copy number alterations in a discovery set of 48 EBCs using oligoarray-comparative genomic hybridization. In addition, the recurrently altered regions (RARs) associated with poor prognosis were validated using an independent set of 97 EBCs.;A total of 23 RARs were defined in the discovery set. Six were commonly detected in both stage I and II groups (> 50%), suggesting their connection with early breast tumorigenesis. There were gains on 1q21.2-q21.3, 8q24.13, 8q24.13-21, 8q24.3, and 8q24.3 and a loss on 8p23.1-p22. Among the 23 RARs, copy number gains on 16p11.2 (NUPR1) and 17q12 (ERBB2) showed a significant association with poor survival (P = 0.0186 and P = 0.0186, respectively). The patients simultaneously positive for both gains had a significantly worse prognosis (P = 0.0001). In the independent replication, the patients who were double-positive for NUPR1-ERBB2 gains also had a significantly poorer prognosis on multivariate analysis (HR = 7.31, 95% CI 2.65-20.15, P = 0.0001).;The simultaneous gain of NUPR1 and ERBB2 can be a significant predictor of poor prognosis in EBC. Our study will help to elucidate the molecular mechanisms underlying early-stage breast cancer tumorigenesis. This study also highlights the potential for using combinations of copy number alterations as prognosis predictors for EBC.",
        "Doc_title":"Simultaneous copy number gains of NUPR1 and ERBB2 predicting poor prognosis in early-stage breast cancer.",
        "Journal":"BMC cancer",
        "Do_id":"22938721",
        "Doc_ChemicalList":"Basic Helix-Loop-Helix Transcription Factors;Neoplasm Proteins;P8 protein, human;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Adult;Aged;Basic Helix-Loop-Helix Transcription Factors;Breast Neoplasms;Chromosome Aberrations;Comparative Genomic Hybridization;DNA Copy Number Variations;Female;Genome-Wide Association Study;Humans;Middle Aged;Multivariate Analysis;Neoplasm Proteins;Neoplasm Staging;Prognosis;Receptor, ErbB-2",
        "Doc_meshqualifiers":"genetics;genetics;mortality;pathology;genetics;genetics",
        "_version_":1605751764207796224},
      {
        "Doc_abstract":"ARID3B (AT-rich interaction domain 3) is a member of the family of ARID proteins, which constitutes evolutionarily conserved transcription factors implicated in normal development, differentiation, cell cycle regulation and chromatin remodeling. In addition, ARID3B has been linked to cellular immortalization, epithelial-mesenchymal transition (EMT) and tumorigenesis. Given the emerging role of ARID3B in tumor development, we examined its expression in primary patient-derived breast cancer samples and breast cancer-derived cell lines.;Immunohistochemistry (IHC) was used to detect ARID3B expression in 63 formalin-fixed paraffin-embedded (FFPE) invasive breast cancer samples. In addition, a panel of 6 (estrogen receptor-positive and -negative, ERBB2-positive and -negative) breast cancer-derived cell lines and immortalized non-tumorigenic epithelial breast cells were used for ARID3B expression analysis using RT-PCR. Specific primers and Western blotting were used to detect ARID3B isoforms.;Using IHC, nuclear, cytoplasmic and low levels of membranous ARID3B staining were detected in all 63 primary invasive breast tumors. Nuclear ARID3B staining positively correlated with estrogen receptor (ER) status and negatively correlated with tumor grade, mitotic index and ERBB2 status of the patients. Increased nuclear expression of ARID3B was confirmed in breast cancer-derived cell lines expressing ERÎ±. In addition, two out of three ERBB2-positive breast cancer cell lines were found to lack full length ARID3B. Three ARID3B isoforms were found to be present in normal breast epithelial cells as well as in breast cancer cells.;We report a positive correlation between ER positivity and nuclear ARID3B expression in primary breast cancers, along with a negative correlation with the ERBB2 status. Very similar correlations were noted in breast cancer-derived cell lines. Since in the recent past ARID3B expression has increasingly been related to cancer-associated proteins and microRNAs, knowledge on ARID3B expression and function may be instrumental for gaining further insight into potentially important cancer-related networks.",
        "Doc_title":"ARID3B expression in primary breast cancers and breast cancer-derived cell lines.",
        "Journal":"Cellular oncology (Dordrecht)",
        "Do_id":"25120063",
        "Doc_ChemicalList":"ARID3B protein, human;DNA-Binding Proteins",
        "Doc_meshdescriptors":"Adult;Aged;Aged, 80 and over;Blotting, Western;Breast Neoplasms;Cell Line, Tumor;DNA-Binding Proteins;Female;Humans;Immunohistochemistry;In Vitro Techniques;Middle Aged;Reverse Transcriptase Polymerase Chain Reaction",
        "Doc_meshqualifiers":"genetics;metabolism;genetics;metabolism",
        "_version_":1605747565939130368},
      {
        "Doc_abstract":"It was recently proposed that the molecular breast tumor subtypes are differently distributed in the elderly breast cancer patients, and also lack prognostic value. Given the limited number of elderly patients in previous studies, the aim of this study was to determine the prognostic effect of the molecular intrinsic subtypes in a large older breast cancer population.;Older breast cancer patients with invasive, non-metastatic breast cancer with tumor material available for immunohistochemical determination of Ki67, EGFR, CK5/6 and HER-2 were included. ER and PR expression was retrieved from the pathology report. Molecular subtypes were: Luminal A, Luminal B, ERBB2, Basal-like and Unclassified. Primary endpoint was Relapse Free Period (RFP), taking into account the competing risk of mortality, and adjusted for the most important patient, tumor and treatment characteristics. Secondary endpoint was Relative Survival (RS).;Overall, 1362 patients were included. Patients with a Luminal A subtype had the lowest risk of recurrence (11% at 5 yrs). Patients with a Basal (24% at 5yrs) or ERBB2 (34% at 5yrs) molecular breast tumor subtype had the highest risk of recurrence. The ERBB2 subtype had the worst prognosis in terms of RFP (SHR 2.07, 95% CI 1.35-3.20; p = 0.001). The worst RS was again observed for the ERBB2 subtype (48% at 10 yrs). In multivariable analyses, the relative excess risk of death for all molecular subtypes was significantly worse compared to the Luminal A subtype.;Molecular intrinsic breast tumor subtypes have significant prognostic value in the elderly population, even after taking competing mortality into account.",
        "Doc_title":"The clinical prognostic value of molecular intrinsic tumor subtypes in older breast cancer patients: A FOCUS study analysis.",
        "Journal":"Molecular oncology",
        "Do_id":"26706834",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605759713447772160},
      {
        "Doc_abstract":"In addition to repressing ERBB2 promoter function, histone deacetylase (HDAC) inhibitors induce the accelerated decay of mature ERBB2 transcripts; the mechanism mediating this transcript destabilization is unknown but depends on the 3' untranslated region (UTR) of ERBB2 mRNA. Using ERBB2-overexpressing human breast cancer cells (SKBR3), the mRNA stability factor HuR was shown to support ERBB2 transcript integrity, bind and endogenously associate with a conserved U-rich element within the ERBB2 transcript 3' UTR, coimmunoprecipitate with RNA-associated HDAC activity, and colocalize with HDAC6. HDAC6 also coimmunoprecipitates with HuR in an RNA-dependent manner and within 6 hours of exposure to a pan-HDAC inhibitor dose, that does not significantly alter cytosolic HuR levels or HuR binding to ERBB2 mRNA. Cellular ERBB2 transcript levels decline while remaining physically associated with HDAC6. Knockdown of HDAC6 protein by small interfering RNA partially suppressed the ERBB2 transcript decay induced by either pan-HDAC or HDAC6-selective enzymatic inhibitors. Three novel hydroxamates, ST71, ST17, and ST80 were synthesized and shown to inhibit HDAC6 with 14-fold to 31-fold greater selectivity over their binding and inhibition of HDAC1. Unlike more potent pan-HDAC inhibitors, these HDAC6-selective inhibitors produced dose-dependent growth arrest of ERBB2-overexpressing breast cancer cells by accelerating the decay of mature ERBB2 mRNA without repressing ERBB2 promoter function. In sum, these findings point to the therapeutic potential of HuR and HDAC6-selective inhibitors, contrasting ERBB2 stability effects induced by HDAC6 enzymatic inhibition and HDAC6 protein knockdown, and show that ERBB2 transcript stability mechanisms include exploitable targets for the development of novel anticancer therapies.",
        "Doc_title":"Destabilization of ERBB2 transcripts by targeting 3' untranslated region messenger RNA associated HuR and histone deacetylase-6.",
        "Journal":"Molecular cancer research : MCR",
        "Do_id":"18644987",
        "Doc_ChemicalList":"3' Untranslated Regions;ELAV Proteins;Enzyme Inhibitors;Hydroxamic Acids;RNA, Messenger;Niacinamide;ST 71;Receptor, ErbB-2;HDAC6 protein, human;Histone Deacetylases",
        "Doc_meshdescriptors":"3' Untranslated Regions;Base Sequence;Cell Line, Tumor;Cytosol;ELAV Proteins;Enzyme Inhibitors;Gene Expression Regulation, Neoplastic;Histone Deacetylases;Humans;Hydroxamic Acids;Molecular Sequence Data;Niacinamide;Promoter Regions, Genetic;Protein Transport;RNA Stability;RNA, Messenger;Receptor, ErbB-2",
        "Doc_meshqualifiers":"genetics;drug effects;metabolism;genetics;chemistry;pharmacology;drug effects;genetics;chemistry;pharmacology;analogs & derivatives;chemistry;pharmacology;genetics;drug effects;drug effects;genetics;metabolism;genetics;metabolism",
        "_version_":1605850570071998464},
      {
        "Doc_abstract":"ERBB2 (v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2) amplification is associated with invasive breast cancer. We discovered that TOM1L1 (target of myb1-like 1) and ERBB2 co-amplification defines a novel mechanism involved in breast cancer metastatic progression. Upregulation of the vesicular trafficking protein TOM1L1 enhances plasma membrane delivery of membrane-type 1 matrix metalloprotease (MT1-MMP) for efficient extracellular matrix degradation and tumor cell dissemination. ",
        "Doc_title":"Vesicular trafficking regulators are new players in breast cancer progression: Role of TOM1L1 in ERBB2-dependent invasion.",
        "Journal":"Molecular & cellular oncology",
        "Do_id":"27652326",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605874255043493888},
      {
        "Doc_abstract":"Human breast cancer cell line SKBR3 expresses high level of the ErbB2 molecule, which has been associated with poor prognosis of breast cancer. Elevated ErbB2 functions as a transactivating co-receptor and promotes the formation of ErbB2 containing heterodimers, which are more mitogenic and transforming, and have a higher ligand affinity and signaling potency by virtue of the potent latent kinase activity of ErbB2. Interestingly, SKBR3 cells are non-tumorigenic in nude mice. By ectopic overexpression of c-Jun in SKBR3 cells, involvement of c-Jun in invasiveness and metastasis in vivo was investigated in this study. The critical role of c-Jun in the tumorigenesis and metastasis is demonstrated in nude mice.",
        "Doc_title":"c-Jun, a crucial molecule in metastasis of breast cancer and potential target for biotherapy.",
        "Journal":"Oncology reports",
        "Do_id":"17914574",
        "Doc_ChemicalList":"Proto-Oncogene Proteins c-jun",
        "Doc_meshdescriptors":"Animals;Breast Neoplasms;Cell Line, Tumor;Cell Movement;Disease Models, Animal;Female;Humans;Liver Neoplasms;Mice;Mice, Inbred BALB C;Mice, Nude;Neoplasm Invasiveness;Phenotype;Proto-Oncogene Proteins c-jun;Transplantation, Heterologous",
        "Doc_meshqualifiers":"metabolism;pathology;genetics;secondary;genetics;pathology;metabolism",
        "_version_":1605790786643820544},
      {
        "Doc_abstract":"The erbB2 oncogene encodes a 185-kilodalton transmembrane protein whose sequence is similar to the epidermal growth factor receptor (EGFR). A 30-kilodalton factor (gp30) secreted from MDA-MB-231 human breast cancer cells was shown to be a ligand for p185erbB2. An antibody to EGFR abolished the tyrosine phosphorylation induced by EGF and transforming growth factor-alpha (TGF-alpha) but only partially blocked that produced by gp30 in SK-BR-3 breast cancer cells. In two cell lines that overexpress erbB2 but do not expresss EGFR (MDA-MB-453 breast cancer cells and a Chinese hamster ovary cell line that had been transfected with erbB2), phosphorylation of p185erbB2 was induced only by gp30. The gp30 specifically inhibited the growth of cells that overexpressed p185erbB2. An antibody to EGFR had no effect on the inhibition of SK-BR-3 cell colony formation obtained with gp30. Thus, it appeared that gp30 interacted directly with the EGFR and erbB2. Direct binding of gp30 to p185erbB2 was confirmed by binding competition experiments, where gp30 was found to displace the p185erbB2 binding of a specific antibody to p185erbB2. The evidence described here suggests that gp30 is a ligand for p185erbB2.",
        "Doc_title":"Direct interaction of a ligand for the erbB2 oncogene product with the EGF receptor and p185erbB2.",
        "Journal":"Science (New York, N.Y.)",
        "Do_id":"2218496",
        "Doc_ChemicalList":"Antibodies, Monoclonal;Ligands;Proto-Oncogene Proteins;Protein-Tyrosine Kinases;Receptor, Epidermal Growth Factor",
        "Doc_meshdescriptors":"Animals;Antibodies, Monoclonal;Binding, Competitive;Breast Neoplasms;Cell Line;Chromatography, Affinity;Female;Humans;Kinetics;Ligands;Molecular Weight;Phosphorylation;Protein-Tyrosine Kinases;Proto-Oncogene Proteins;Proto-Oncogenes;Receptor, Epidermal Growth Factor;Transfection",
        "Doc_meshqualifiers":"metabolism;genetics;immunology;metabolism;isolation & purification;metabolism",
        "_version_":1605902076461711360},
      {
        "Doc_abstract":"We have previously identified a set of breast cancer antiestrogen resistance (BCAR) genes causing estrogen independence and tamoxifen resistance in vitro using a functional genetic screen. Here, we explored whether these BCAR genes provide predictive value for tamoxifen resistance and prognostic information for tumor aggressiveness in breast cancer patients.;mRNA levels of 10 BCAR genes (AKT1, AKT2, BCAR1, BCAR3, EGFR, ERBB2, GRB7, SRC, TLE3, and TRERF1) were measured in estrogen receptor-positive breast tumors using quantitative reverse-transcriptase polymerase chain reaction. Normalized mRNA levels were evaluated for association with progression-free survival (PFS) in 242 patients receiving tamoxifen as first-line monotherapy for recurrent disease, and with distant metastasis-free survival (MFS) in 413 lymph node-negative (LNN) primary breast cancer patients who did not receive systemic adjuvant therapy.;Concerning tamoxifen resistance, BCAR3, ERBB2, GRB7, and TLE3 mRNA levels were predictive for PFS, independent of traditional predictive factors. By combining GRB7 (or ERBB2) and TLE3 mRNA levels, patients could be classified in three subgroups with distinct PFS. For the evaluation of tumor aggressiveness, AKT2, EGFR, and TRERF1 mRNA levels were all significantly associated with MFS, independent of traditional prognostic factors. Using the combined AKT2 and EGFR mRNA status, four prognostic groups were identified with different MFS outcomes.;The majority of BCAR genes, which were revealed to confer tamoxifen resistance and estrogen independence in vitro by functional screening, have clinical relevance, and associate with tamoxifen resistance and/or tumor aggressiveness in breast cancer patients.",
        "Doc_title":"Relevance of breast cancer antiestrogen resistance genes in human breast cancer progression and tamoxifen resistance.",
        "Journal":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
        "Do_id":"19075277",
        "Doc_ChemicalList":"Antineoplastic Agents, Hormonal;RNA, Messenger;Receptors, Estrogen;Tamoxifen",
        "Doc_meshdescriptors":"Adult;Aged;Antineoplastic Agents, Hormonal;Breast Neoplasms;Disease Progression;Drug Resistance, Neoplasm;Female;Humans;Middle Aged;RNA, Messenger;Receptors, Estrogen;Reverse Transcriptase Polymerase Chain Reaction;Survival Rate;Tamoxifen",
        "Doc_meshqualifiers":"therapeutic use;drug therapy;genetics;pathology;genetics;analysis;analysis;therapeutic use",
        "_version_":1605802146342633472},
      {
        "Doc_abstract":"The PPP1R1B-STARD3-TCAP-PNMT-MGC9753-ERBB2-MGC14832-GRB7 locus on human chromosome 17q12 is frequently amplified in human gastric and breast cancer. We have recently identified and characterized human MGC9753 (also known as wild-type CAB2) and mouse Mgc9753. Here, we identified and characterized mouse Erbb2 gene by using bioinformatics. BLAST programs revealed that mouse AK031099 cDNA was derived from mouse Erbb2 gene. Because AK031099 cDNA showed 806 C-->A nucleotide substitution compared with mouse genome draft sequences and mouse Erbb2 ESTs, the nucleotide sequence of mouse Erbb2 cDNA was determined in silico by correcting 806 A of AK031099 cDNA to C. Nucleotide position 48-3818 of mouse Erbb2 cDNA was the coding region. Mouse Erbb2 gene, consisting of 27 exons, was located within the Ppp1r1b-Grb7 locus on the mouse chromosome 11. Mouse Erbb2 protein (1256 aa) showed 87.5% total-amino-acid identity with human ERBB2 protein, and 95.2% total-amino-acid identity with rat Erbb2 protein. Mouse Ppp1r1b-Grb7 locus and human Ppp1r1b-Grb7 locus were evolutionarily conserved in the order and the orientation of genes therein. Nucleotide and amino-acid substitution rates of Neurod2 located centromeric to the Ppp1r1b-Grb7 locus were significantly lower than others within the Ppp1r1b-Grb7 locus. This is the first report on the complete coding sequence of mouse Erbb2 gene as well as on the comprehensive comparison of Ppp1r1b-Grb7 locus within the human and mouse genomes.",
        "Doc_title":"Identification and characterization of mouse Erbb2 gene in silico.",
        "Journal":"International journal of oncology",
        "Do_id":"12888924",
        "Doc_ChemicalList":"DNA, Complementary;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Amino Acid Sequence;Animals;Base Sequence;Chromosome Mapping;Computational Biology;Conserved Sequence;DNA Methylation;DNA, Complementary;Exons;Expressed Sequence Tags;Humans;Introns;Mice;Models, Genetic;Molecular Sequence Data;Receptor, ErbB-2;Sequence Homology, Amino Acid;Software",
        "Doc_meshqualifiers":"methods;metabolism;biosynthesis;genetics",
        "_version_":1605809067915214848},
      {
        "Doc_abstract":"Activation of the ERBB2 oncogene seems to be an early event in breast cancer progression and prevalent in in situ carcinomas. However, its prognosis value, albeit recognized for node-positive patients, remains controversial for those without apparent nodal involvement. One possible reason for this problem is likely to be the difficulty of defining threshold levels for ERBB2 protein overexpression. ERBB2 protein expression was therefore analyzed in primary invasive breast tumors. Quantification of the gene product by a commercial ELISA test was compared to results obtained by immunohistochemistry and western blotting, as well as to gene amplification status determined by Southern blotting. Correlations between results obtained by the different techniques were highly significant (P value < 10(-6)). Nevertheless, ELISA permitted us to determine three levels of protein expression corresponding to distinct tumor subsets. 1) Tumors with p185/ERBB2 expression levels exceeding 10 U/microgram exhibited in most cases amplification of the gene (83% of cases), DNA aneuploidy (81%) and absence of estrogen receptor (ER) (44%). Such high levels of protein expression were exclusively observed in invasive ductal carcinomas and were prevalent in those showing a significant in situ component. 2) \"Intermediate\" levels of expression (3-10 U/micrograms) were rarely observed in tumors exhibiting gene amplification (9%), but were preferentially found in cancers of more favorable prognosis (only 49% were aneuploid and 9% estrogen receptor negative). 3) Levels of p185/ERBB2 below 3 U/micrograms were detected in benign mastopathies and, thus, carcinomas presenting such levels were scored ERBB2 negative. Interestingly, invasive lobular carcinomas were rarely ERBB2 positive, and if so, only at intermediate levels. Moreover, our data show a complex interrelationship between p185/ERBB2 expression and ER levels. Indeed, tumors with more than 10 U/micrograms of p185 were prevalently ER, whereas those with p185 ranging from 3 to 10 U presented elevated levels of ER.",
        "Doc_title":"Quantification of ERBB2 protein expression in breast cancer: three levels of expression defined by their clinico-pathological correlations.",
        "Journal":"Oncology research",
        "Do_id":"7841539",
        "Doc_ChemicalList":"Receptor, ErbB-2",
        "Doc_meshdescriptors":"Aneuploidy;Breast Neoplasms;Enzyme-Linked Immunosorbent Assay;Female;Gene Amplification;Gene Expression;Gene Expression Regulation, Neoplastic;Humans;Immunohistochemistry;Receptor, ErbB-2",
        "Doc_meshqualifiers":"chemistry;genetics;analysis;genetics",
        "_version_":1605766034726322176},
      {
        "Doc_abstract":"The HER2 (ERBB2) oncogene encodes a transmembrane tyrosine kinase receptor that has evolved as a major biomarker of invasive breast cancer and target of therapy for the disease. HER2 gene amplification or protein overexpression is encountered in approximately 20% of newly diagnosed breast cancers and is a validated adverse prognostic factor with a mean relative risk for overall survival of 2.74. A series of quality assurance recommendations for the marketed slide-based HER2 testing approaches including immunohistochemistry (IHC), fluorescence in situ hybridization (FISH) and chromogenic in situ hybridization (CISH/SISH) has recently been published by the American Society of Clini- cal Oncology - College of American Pathologists (ASCO-CAP). Testing issues, such as the impact of chromosome 17 polysomy and local versus central HER2 testing and emerging novel HER2 testing techniques, including messenger RNA (mRNA)-based testing by real time polymerase chain reaction (RT-PCR) and DNA microarray methods, HER2 receptor dimerization, phosphorylated HER2 receptors and HER2 status in circulating tumor cells are of current interest in the management of breast cancer. Also of significant interest are the evolving lists of biomarkers proposed to predict resistance to the major anti-HER2 therapies, trastuzumab and lapatinib.",
        "Doc_title":"Breast cancer biomarkers and HER2 testing after 10 years of anti-HER2 therapy.",
        "Journal":"Drug news & perspectives",
        "Do_id":"19330168",
        "Doc_ChemicalList":"Antibodies, Monoclonal;Antibodies, Monoclonal, Humanized;Antineoplastic Agents;Biomarkers, Tumor;Quinazolines;lapatinib;ERBB2 protein, human;Receptor, ErbB-2;Trastuzumab",
        "Doc_meshdescriptors":"Animals;Antibodies, Monoclonal;Antibodies, Monoclonal, Humanized;Antineoplastic Agents;Biomarkers, Tumor;Breast Neoplasms;Cytological Techniques;Drug Resistance, Neoplasm;Female;Gene Amplification;Gene Expression;Genes, erbB-2;Genetic Techniques;Guidelines as Topic;Humans;Prognosis;Quinazolines;Receptor, ErbB-2;Trastuzumab",
        "Doc_meshqualifiers":"therapeutic use;therapeutic use;analysis;diagnosis;metabolism;drug effects;therapeutic use;analysis",
        "_version_":1605893309613473792},
      {
        "Doc_abstract":"Mutations in the ataxia-telangiectasia mutated (ATM) and checkpoint kinase 2 (CHEK2) genes and amplification of the v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2 (ERBB2) gene have been suggested to have an important role in breast cancer aetiology. However, whether common variation in these genes has a role in the development of breast cancer or breast cancer survival in humans is still not clear.;We performed a comprehensive haplotype analysis of the ATM, CHEK2 and ERBB2 genes in a Swedish population-based study, which included 1,579 breast cancer cases and 1,516 controls. We followed the cases for 8.5 years, on average, and retrieved information on the date and cause of death during that period from the nationwide Swedish causes of death registry. We selected seven haplotype-tagging SNPs (tagSNPs) in the ATM gene, six tagSNPs in the CHEK2 gene and seven tagSNPs in the ERBB2 gene that predicted both haplotypic and single locus variations in the respective genes with R2 values > or = 0.8. These tagSNPs were genotyped in the complete set of cases and controls. We computed expected haplotype dosages of the tagSNP haplotypes and included the dosages as explanatory variables in Cox proportional hazards or logistic regression models.;We found no association between any genetic variation in the ATM, CHEK2 or ERBB2 genes and breast cancer survival or the risk of developing tumours with certain characteristics.;Our results indicate that common variants in the ATM, CHEK2 or ERBB2 genes are not involved in modifying breast cancer survival or the risk of tumour-characteristic-defined breast cancer.",
        "Doc_title":"Comprehensive analysis of the ATM, CHEK2 and ERBB2 genes in relation to breast tumour characteristics and survival: a population-based case-control and follow-up study.",
        "Journal":"Breast cancer research : BCR",
        "Do_id":"17132159",
        "Doc_ChemicalList":"Cell Cycle Proteins;DNA-Binding Proteins;Tumor Suppressor Proteins;Checkpoint Kinase 2;ATM protein, human;Ataxia Telangiectasia Mutated Proteins;CHEK2 protein, human;Protein-Serine-Threonine Kinases",
        "Doc_meshdescriptors":"Aged;Ataxia Telangiectasia Mutated Proteins;Breast Neoplasms;Case-Control Studies;Cell Cycle Proteins;Checkpoint Kinase 2;DNA-Binding Proteins;Female;Follow-Up Studies;Genes, erbB-2;Genotype;Haplotypes;Humans;Linkage Disequilibrium;Middle Aged;Mutation;Polymorphism, Single Nucleotide;Protein-Serine-Threonine Kinases;Risk;Survival Analysis;Tumor Suppressor Proteins",
        "Doc_meshqualifiers":"genetics;genetics;genetics;genetics;genetics;genetics",
        "_version_":1605742125192839168},
      {
        "Doc_abstract":"The occurrence of large publically available repositories of human breast tumor gene expression profiles provides an important resource to discover new breast cancer biomarkers and therapeutic targets. For example, knowledge of the expression of the estrogen and progesterone hormone receptors (ER and PR), and that of the ERBB2 in breast tumor samples enables choice of therapies for the breast cancer patients that express these proteins. Identifying new biomarkers and therapeutic agents affecting the activity of signaling pathways regulated by the hormone receptors or ERBB2 might be accelerated by knowledge of their expression levels in large gene expression profiling data sets. Unfortunately, the status of these receptors is not invariably reported in public databases of breast tumor gene expression profiles. Attempts have been made to employ a single probe set to identify ER, PR and ERBB2 status, but the specificity or sensitivity of their prediction is low. We enquired whether estimation of ER, PR and ERBB2 status of profiled tumor samples could be improved by using multiple probe sets representing these three genes and others with related expression.We used 8 independent datasets of human breast tumor samples to define gene expression signatures comprising 24, 51 and 14 genes predictive of ER, PR and ERBB2 status respectively. These signatures, as demonstrated by sensitivity and specificity measures, reliably identified hormone receptor and ERBB2 expression in breast tumors that had been previously determined using protein and DNA based assays. Our findings demonstrate that gene signatures can be identified which reliably predict the expression status of the estrogen and progesterone hormone receptors and that of ERBB2 in publically available gene expression profiles of breast tumor samples. Using these signatures to query transcript profiles of breast tumor specimens may enable discovery of new biomarkers and therapeutic targets for particular subtypes of breast cancer.",
        "Doc_title":"Hormone receptor and ERBB2 status in gene expression profiles of human breast tumor samples.",
        "Journal":"PloS one",
        "Do_id":"22022496",
        "Doc_ChemicalList":"Receptors, Estrogen;Receptors, Progesterone;ERBB2 protein, human;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Algorithms;Breast Neoplasms;Female;Gene Expression Profiling;Gene Expression Regulation, Neoplastic;Genes, Neoplasm;Humans;Oligonucleotide Array Sequence Analysis;Receptor, ErbB-2;Receptors, Estrogen;Receptors, Progesterone;Sensitivity and Specificity",
        "Doc_meshqualifiers":"genetics;genetics;genetics;metabolism;metabolism;genetics;metabolism",
        "_version_":1605818792027357184},
      {
        "Doc_abstract":"Overexpression of the ErbB2 receptor tyrosine kinase is prevalent in approximately 30% of human breast cancers and confers Taxol resistance. Our previous work has shown that ErbB2 inhibits Taxol-induced apoptosis in breast cancer cells by transcriptionally up-regulating p21(Cip1). However, the mechanism of ErbB2-mediated p21(Cip1) up-regulation is unclear. Here, we show that ErbB2 up-regulates p21(Cip1) transcription through increased Src activity in ErbB2-overexpressing cells. Src activation further activated signal transducer and activator of transcription 3 (STAT3) that recognizes a SIE binding site on the p21(Cip1) promoter required for ErbB2-mediated p21(Cip1) transcriptional up-regulation. Both Src and STAT3 inhibitors restored Taxol sensitivity in resistant ErbB2-overexpressing breast cancer cells. Our data suggest that ErbB2 overexpression can activate STAT3 through Src leading to transcriptional up-regulation of p21(Cip1) that confers Taxol resistance of breast cancer cells. Our study suggests a potential clinical application of Src and STAT3 inhibitors in Taxol sensitization of ErbB2-overexpressing breast cancers.",
        "Doc_title":"ErbB2-mediated Src and signal transducer and activator of transcription 3 activation leads to transcriptional up-regulation of p21Cip1 and chemoresistance in breast cancer cells.",
        "Journal":"Molecular cancer research : MCR",
        "Do_id":"19372587",
        "Doc_ChemicalList":"Antineoplastic Agents, Phytogenic;CDKN1A protein, human;Cyclin-Dependent Kinase Inhibitor p21;STAT3 Transcription Factor;STAT3 protein, human;Luciferases;ERBB2 protein, human;Receptor, ErbB-2;Proto-Oncogene Proteins pp60(c-src);Paclitaxel",
        "Doc_meshdescriptors":"Antineoplastic Agents, Phytogenic;Blotting, Western;Breast Neoplasms;Cell Proliferation;Chromatin Immunoprecipitation;Cyclin-Dependent Kinase Inhibitor p21;Drug Resistance, Neoplasm;Electrophoretic Mobility Shift Assay;Female;Gene Expression Regulation, Neoplastic;Humans;Immunoprecipitation;Luciferases;Paclitaxel;Promoter Regions, Genetic;Proto-Oncogene Proteins pp60(c-src);Receptor, ErbB-2;STAT3 Transcription Factor;Transcription, Genetic;Tumor Cells, Cultured;Up-Regulation",
        "Doc_meshqualifiers":"pharmacology;drug therapy;genetics;pathology;drug effects;genetics;metabolism;physiology;metabolism;pharmacology;genetics;metabolism;genetics;metabolism;antagonists & inhibitors;genetics;metabolism",
        "_version_":1605764456200011776},
      {
        "Doc_abstract":"Amplification and overexpression of erbB2/neu proto-oncogene is observed in 20-30% human breast cancer and is inversely correlated with the survival of the patient. Despite this, somatic activating mutations within erbB2 in human breast cancers are rare. However, we have previously reported that a splice isoform of erbB2, containing an in-frame deletion of exon 16 (herein referred to as ErbB2Î”Ex16), results in oncogenic activation of erbB2 because of constitutive dimerization of the ErbB2 receptor. Here, we demonstrate that the ErbB2Î”Ex16 is a major oncogenic driver in breast cancer that constitutively signals from the cell surface. We further show that inducible expression of the ErbB2Î”Ex16 variant in mammary gland of transgenic mice results in the rapid development of metastatic multifocal mammary tumors. Genetic and biochemical characterization of the ErbB2Î”Ex16-derived mammary tumors exhibit several unique features that distinguish this model from the conventional ErbB2 ones expressing the erbB2 proto-oncogene in mammary epithelium. Unlike the wild-type ErbB2-derived tumors that express luminal keratins, ErbB2Î”Ex16-derived tumors exhibit high degree of intratumoral heterogeneity co-expressing both basal and luminal keratins. Consistent with these distinct pathological features, the ErbB2Î”Ex16 tumors exhibit distinct signaling and gene expression profiles that correlate with activation of number of key transcription factors implicated in breast cancer metastasis and cancer stem cell renewal.",
        "Doc_title":"The ErbB2Î”Ex16 splice variant is a major oncogenic driver in breast cancer that promotes a pro-metastatic tumor microenvironment.",
        "Journal":"Oncogene",
        "Do_id":"27157621",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605749740702531584},
      {
        "Doc_abstract":"The natural killer cell line NKâ€‘92 shows great cytotoxicity against various types of cancer. Several types of solid tumor cells, however, can effectively resist NK-mediated lysis by interaction of major histocompatibility complex (MHC) molecules with NK cell inhibitory receptors. To generate a eukaryotic expression vector encoding chimeric antigen receptor scFv anti-erbB2-CD28-Î¶ and to investigate the expression and action of this chimeric antigen receptor in cancer cells both in vitro and in vivo, NKâ€‘92 cells were genetically modified with an scFv anti-erbB2-CD28-Î¶ chimeric recep-tor by optimized electro-poration using the Amaxa Nucleofector system. The expression of the chimeric receptor was evaluated by RT-PCR and immunofluorescence. The ability of the genetically modified NKâ€‘92 cells to induce cell death in tumor targets was assessed in vitro and in vivo. The transduced NKâ€‘92-anti-erbB2 scFv-CD28-Î¶ cells expressing high levels of the fusion protein on the cell surface were analyzed by fluorescence-activated cell-sorting (FACS) analysis. These cells specifically enhanced the cell death of the erbB2â€‘expressing human breast cancer cell lines MDA-MB-453 and SKBr3. Furthermore, adoptive transfer of genetically modified NKâ€‘92 cells specifically reduced tumor size and lung metastasis of nude mice bearing established MDA-MB-453 cells, and significantly enhanced the survival period of these mice. The genetically modified NKâ€‘92 cells significantly enhanced the killing of erbB2â€‘expressing cancer and may be a novel therapeutic strategy for erbB2â€‘expressing cancer cells.",
        "Doc_title":"Specific growth inhibition of ErbB2â€‘expressing human breast cancer cells by genetically modified NKâ€‘92 cells.",
        "Journal":"Oncology reports",
        "Do_id":"25333815",
        "Doc_ChemicalList":"ERBB2 protein, human;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Adoptive Transfer;Animals;Antibody-Dependent Cell Cytotoxicity;Breast Neoplasms;Cell Line, Tumor;Female;Humans;Killer Cells, Natural;Mice, Inbred BALB C;Neoplasm Transplantation;Receptor, ErbB-2;Tumor Burden",
        "Doc_meshqualifiers":"metabolism;pathology;therapy;immunology;immunology;metabolism",
        "_version_":1605810892128124928},
      {
        "Doc_abstract":"The molecular classification of breast cancer mainly focuses on ER, PR, and HER2 status detected by immunohistochemistry (IHC) analysis. To explore the clinical value of breast cancer classification based on gene-based diagnosis of the triple markers, we measured ESR1, PGR, and ERBB2 mRNA levels in 294 breast cancer patients by reverse transcription quantitative polymerase chain reaction (RT-QPCR), and examined their correlation with ER, PR, and HER2 status detected by IHC. We observed a significant positive correlation between the mRNA levels of the triple markers and their protein status (ESR1 vs. ER, Spearman's Ï =Â 0.527, PÂ =Â 2.3Â Ã—Â 10(-22); PGR vs. PR, Spearman's Ï =Â 0.631, PÂ =Â 5.1Â Ã—Â 10(-34); ERBB2 vs. HER2, Spearman's Ï =Â 0.439, PÂ =Â 3.0Â Ã—Â 10(-15)). Furthermore, the subtypes determined by mRNA levels of the triple markers were significantly correlated to the subtypes determined based on their protein status (Spearman's Ï =Â 0.342, PÂ =Â 2.0Â Ã—Â 10(-8)). Kaplan-Meier analysis showed that the subtypes determined by mRNA levels of the triple-marker could predict the disease-free survival (DFS) in breast cancer patients. Multivariate analysis showed that the predictive value of DFS could be confirmed for the subtypes determined by mRNA levels of the triple markers (HRÂ =Â 2.285, PÂ =Â 0.008) but not for those determined by their protein status. Taken together, our results suggest that the detection of ESR1/PGR/ERBB2 mRNA levels by RT-QPCR is a better approach for subtyping breast cancer and predicting the prognosis.",
        "Doc_title":"The detection of ESR1/PGR/ERBB2 mRNA levels by RT-QPCR: a better approach for subtyping breast cancer and predicting prognosis.",
        "Journal":"Breast cancer research and treatment",
        "Do_id":"23397283",
        "Doc_ChemicalList":"Estrogen Receptor alpha;RNA, Messenger;Receptors, Progesterone;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Adult;Aged;Breast Neoplasms;Estrogen Receptor alpha;Female;Humans;Immunohistochemistry;Middle Aged;Neoplasm Grading;Neoplasm Metastasis;Neoplasm Staging;Prognosis;RNA, Messenger;Real-Time Polymerase Chain Reaction;Receptor, ErbB-2;Receptors, Progesterone;Reproducibility of Results;Reverse Transcriptase Polymerase Chain Reaction",
        "Doc_meshqualifiers":"diagnosis;genetics;metabolism;mortality;genetics;metabolism;genetics;genetics;metabolism;genetics;metabolism",
        "_version_":1605746451096272897},
      {
        "Doc_abstract":"Four different methods to measure in parallel the erbB2 protein expression (p185neu) were evaluated in order to: a) compare two enzyme immunoassays with the immunohistochemical assays (IHC) and western blotting (WB) and b) extrapolate eventual relationships between erbB2 and biological parameters. Tissue samples from 248 patients with primary breast cancer were consecutively assayed. We used two different cut-off levels for WB, ELISA, and EIA, defined as follows: 1) the highest level of expression of non malignant tissue was chosen as the discriminant threshold between 'low' and 'elevated' samples: 2) the elevated group was further subdivided into two subgroups: 'intermediate' and 'high', according to their median value. According to the first cut-off, the results were considered 'elevated' in about 52% of cases with the three biochemical methods, while using the second cut-off the percentage lowered to about 26%. Considering this cut-off, the concordance rates between the paired biochemical methods ranged between: 78.4% (WB vs EIA), 93% (ELISA vs EIA), and 82.6% (ELISA vs WB). The comparison between biochemical and immunohistochemical methods gave these concordance rates: 82% (WB vs IHC), 90.5% (ELISA vs IHC), and 85.5% (EIA vs. IHC). According to the first cut off level, 27.5% of tumor samples showed IHC detectable p185 levels, in agreement with other immunohistochemical studies. The relationship between high erbB2 and estrogen and progesterone receptors showed an inverse association. No relationship was found between erbB2 and axillary lymph node positivity or tumor size. In short, the results of the four methods seem generally well correlated; nevertheless, it appears that different methodological approaches of measuring p185neu are not completely equivalent, and there is a need for an authoritative standardization and quality control for clinical applications.",
        "Doc_title":"Determination of ErbB2 protein in breast cancer tissues by different methods. Relationships with other biological parameters.",
        "Journal":"Breast cancer research and treatment",
        "Do_id":"8825138",
        "Doc_ChemicalList":"Receptors, Estrogen;Receptors, Progesterone;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Blotting, Western;Breast Neoplasms;Female;Humans;Immunoenzyme Techniques;Immunohistochemistry;Receptor, ErbB-2;Receptors, Estrogen;Receptors, Progesterone",
        "Doc_meshqualifiers":"chemistry;pathology;analysis;analysis;analysis",
        "_version_":1605819776105447424},
      {
        "Doc_abstract":"The aggressive triple-negative phenotype of breast cancer (negative for estrogen and progesterone receptors and v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2 [ERBB2] [formerly human epidermal growth factor receptor 2 (HER2)]) is considered by some investigators to be a relative contraindication to breast-conserving therapy.;To compare outcomes of breast-conserving therapy for patients with triple-negative breast cancer (TNBC) with those of patients with the luminal A, luminal B, and ERBB2 subtypes.;Prospective database review at an academic tertiary medical center with a designated breast cancer center. We included 1851 consecutive patients ages 29 to 85 years with stages I to III invasive breast cancer who underwent breast-conserving therapy at a single institution from January 1, 2000, through May 30, 2012. Of these patients, 234 (12.6%) had TNBC; 1341 (72.4%), luminal A subtype; 212 (11.5%), luminal B subtype; and 64 (3.5%), ERBB2-enriched subtype.;Breast-conserving therapy.;The primary outcome measure was local recurrence (LR). Secondary outcome measures included regional recurrence, distant recurrence, and overall survival. RESULTS Triple-negative breast cancer was associated with younger age at diagnosis (56 vs 60 years; P =â€‰.001), larger tumors (2.1 vs 1.8 cm; P <â€‰.001), more stage II vs I cancer (42.1% vs 33.6%; P =â€‰.005), and more G3 tumors (86.4% vs 28.4%; P <â€‰.001) compared with the non-TNBC subtypes. Multivariable analysis showed that TNBC did not have a significantly increased risk of LR compared with the luminal A (hazard ratio, 1.4 [95% CI, 0.6-3.3]; P =â€‰.43), luminal B (1.6 [0.5-5.2]; P =â€‰.43), and ERBB2 (1.1 [0.2-5.2]; P =â€‰.87) subtypes. Only tumor size was a significant predictor of LR (hazard ratio, 4.7 [95% CI, 1.6-14.3]; P =â€‰.006). Predictors of worse overall survival included tumor size, grade, and stage and TNBC subtype.;Breast-conserving therapy for TNBC is not associated with increased LR compared with non-TNBC subtypes. However, the TNBC phenotype correlates with worse overall survival. Breast-conserving therapy is appropriate for patients with TNBC.",
        "Doc_title":"Breast-conserving therapy for triple-negative breast cancer.",
        "Journal":"JAMA surgery",
        "Do_id":"24382582",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"Adolescent;Adult;Aged;Aged, 80 and over;Female;Humans;Kaplan-Meier Estimate;Mastectomy, Segmental;Middle Aged;Neoplasm Grading;Neoplasm Recurrence, Local;Neoplasm Staging;Prognosis;Proportional Hazards Models;Retrospective Studies;Treatment Outcome;Triple Negative Breast Neoplasms;Young Adult",
        "Doc_meshqualifiers":"contraindications;epidemiology;mortality;pathology;surgery",
        "_version_":1605818744222777345},
      {
        "Doc_abstract":"Breast cancer is a heterogeneous disease with different morphologies, molecular profiles, clinical behaviour and response to therapy. The triple negative is a particular type of breast cancer defined by absence of oestrogen and progesterone receptor expression as well as absence of ERBB2 amplification. It is characterized by its biological aggressiveness, worse prognosis and lack of a therapeutic target in contrast with hormonal receptor positive and ERBB2+ breast cancers. Given these characteristics, triple-negative breast cancer is a challenge in today's clinical practice. A new breast cancer classification emerged recently in the scientific scene based in gene expression profiles. The new subgroups (luminal, ERBB2, normal breast and basal-like) have distinct gene expression patterns and phenotypical characteristics. Triple-negative breast cancer shares phenotypical features with basal-like breast cancer, which is in turn the most aggressive and with worse outcome. Since microarray gene-expression assays are only used in the research setting, clinicians use the triple-negative definition as a surrogate of basal-like breast cancer. The aim of this review, that focuses on triple-negative breast cancer, is to summarize the most relevant knowledge on this particular type of cancer in terms of molecular features, pathogenesis, clinical characteristics, current treatments and the new therapeutic options that include the use of platinum compounds, EGFR antagonists, antiangiogenics and PARP inhibitors. Advances in research are promising and new types of active drugs will become a reality in the near future, making possible a better outcome for this subgroup of breast cancer patients.",
        "Doc_title":"Triple-negative breast cancer: molecular features, pathogenesis, treatment and current lines of research.",
        "Journal":"Cancer treatment reviews",
        "Do_id":"20060649",
        "Doc_ChemicalList":"Receptors, Estrogen;Receptors, Progesterone;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Breast Neoplasms;Female;Humans;Receptor, ErbB-2;Receptors, Estrogen;Receptors, Progesterone",
        "Doc_meshqualifiers":"etiology;metabolism;pathology;therapy;metabolism;metabolism;metabolism",
        "_version_":1605750156919046144},
      {
        "Doc_abstract":"Although treatment with trastuzumab improves outcomes for women with ErbB2-positive breast cancer, many patients who achieve an initial response to trastuzumab subsequently acquire resistance within 1 year. Rac1, a Ras-like small GTPase, has been implicated in the control of cell growth and morphology and is believed to be associated with breast cancer progression and metastasis. Here, we show that when parental SKBR3 cells become resistant to trastuzumab, Rac1 activity is increased, leading to altered cell morphology, which is accompanied by significant cytoskeleton disorganization. Furthermore, both trastuzumab-mediated down-regulation of ErbB2 and epidermal growth factor-induced down-regulation of epidermal growth factor receptor are impaired in the trastuzumab-resistant SKBR3 cells, indicating that the endocytic down-regulation of ErbB receptors is compromised in the resistant cells. This results in an aberrant accumulation of ErbB2 on the cell surface and enhanced ErbB2 and extracellular signal-regulated kinase activity in trastuzumab-resistant SKBR3 cells. Additionally, overexpression of constitutively active Rac1G12V in parental SKBR3 cells reduces sensitivity to trastuzumab. After reduction of Rac1 activity by NSC23766, a specific Rac1 inhibitor, trastuzumab-resistant SKBR3 cells display a cellular morphology similar to parental SKBR3 cells. Moreover, we show that NSC23766 restores trastuzumab-mediated endocytic down-regulation of ErbB2 and reduces extracellular signal-regulated kinase activity in resistant SKBR3 cells. Our findings highlight an important role for Rac1 in trastuzumab resistance of human breast cancer cells and identify the impaired trastuzumab-mediated endocytic down-regulation of ErbB2 as a novel mechanism of trastuzumab resistance. The significant effects of NSC23766 on trastuzumab-resistant SKBR3 cells warrant further study of NSC23766 as a potential treatment of trastuzumab-resistant breast cancers.",
        "Doc_title":"Rac1 contributes to trastuzumab resistance of breast cancer cells: Rac1 as a potential therapeutic target for the treatment of trastuzumab-resistant breast cancer.",
        "Journal":"Molecular cancer therapeutics",
        "Do_id":"19509242",
        "Doc_ChemicalList":"Actins;Aminoquinolines;Antibodies, Monoclonal;Antibodies, Monoclonal, Humanized;Antineoplastic Agents;NSC 23766;Pyrimidines;RAC1 protein, human;Receptor, ErbB-2;Mitogen-Activated Protein Kinase 1;Mitogen-Activated Protein Kinase 3;Mitogen-Activated Protein Kinase 8;rac1 GTP-Binding Protein;Trastuzumab",
        "Doc_meshdescriptors":"Actins;Aminoquinolines;Antibodies, Monoclonal;Antibodies, Monoclonal, Humanized;Antineoplastic Agents;Blotting, Western;Breast Neoplasms;Cell Line, Tumor;Cell Proliferation;Cytoskeleton;Dose-Response Relationship, Drug;Down-Regulation;Drug Resistance, Neoplasm;Endocytosis;Humans;Microscopy, Confocal;Microscopy, Phase-Contrast;Mitogen-Activated Protein Kinase 1;Mitogen-Activated Protein Kinase 3;Mitogen-Activated Protein Kinase 8;Mutation;Pyrimidines;Receptor, ErbB-2;Trastuzumab;rac1 GTP-Binding Protein",
        "Doc_meshqualifiers":"metabolism;pharmacology;metabolism;pharmacology;pharmacology;genetics;metabolism;pathology;drug effects;metabolism;drug effects;drug effects;metabolism;metabolism;metabolism;pharmacology;metabolism;antagonists & inhibitors;genetics;metabolism",
        "_version_":1605742700767739904},
      {
        "Doc_abstract":"Trastuzumab is humanized monoclonal antibody targeting her 2 neu receptor, overexpressed in 20% of breast cancers and part of the complex of Epidermal Growth Factor Receptor.;To review new advances in the knowledge of the practical use of \"trastuzumab (Herceptin Â®)\" in breast cancer.;Review of literature using medical data bases (Medline, Science direct) with the following key words: breast cancer, targeted therapy, HER2 neu, transtuzumab/herceptine;Trastuzumab represent an important advance in breast cancer treatment with an improvement of median survival in metastatic setting and overall and disease-free survival in adjuvant setting in association with chemotherapy. Herceptin remain well tolerated with a low and rare risk of cardiac failure.;Trastuzumab is a new therapeutic tool very interesting to ameliorate prognosis of breast cancer.",
        "Doc_title":"[Trastuzumab (herceptin) for the medical treatment of breast cancer].",
        "Journal":"La Tunisie medicale",
        "Do_id":"22311450",
        "Doc_ChemicalList":"Antibodies, Monoclonal, Humanized;Antineoplastic Agents;Receptor, ErbB-2;Trastuzumab",
        "Doc_meshdescriptors":"Antibodies, Monoclonal, Humanized;Antineoplastic Agents;Breast Neoplasms;Female;Humans;Receptor, ErbB-2;Trastuzumab",
        "Doc_meshqualifiers":"pharmacology;therapeutic use;pharmacology;therapeutic use;drug therapy;antagonists & inhibitors",
        "_version_":1605791720393408512},
      {
        "Doc_abstract":"Mutations in the epidermal growth factor receptor gene (EGFR) in lung cancers predict for sensitivity to EGFR kinase inhibitors. HER2 (also known as NEU, EGFR2, or ERBB2) is a member of the EGFR family of receptor tyrosine kinases and plays important roles in the pathogenesis of certain human cancers, and mutations have recently been reported in lung cancers. We sequenced the full length of HER2 in 198 metastatic breast cancers (MBC) as well as 34 other epithelial cancers (bladder, prostate, and colorectal cancers) and compared the mutational status with clinic pathologic features and the presence of EGFR or KRAS mutations. HER2 mutations were present in 11.6Â % (23 of 198) of MBC and were absent in other types of cancers. HER2 mutations were located in exon 15 and the in-frame insertions in exon 20 with corresponding region as did EGFR insertions. HER2 mutations were significantly more frequent in patient after the administration of trastuzumab (34.8Â %, 8 of 23; Pâ€‰=â€‰0.02). Mutations in exon 15 and 20 were more potent than wild-type HER2 in associating with activating signal transducers and inducing survival, invasiveness, and tumorigenicity. ",
        "Doc_title":"Somatic mutations of the HER2 in metastatic breast cancer.",
        "Journal":"Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine",
        "Do_id":"25326805",
        "Doc_ChemicalList":"Antibodies, Monoclonal, Humanized;Antineoplastic Agents;KRAS protein, human;Proto-Oncogene Proteins;Receptor, Epidermal Growth Factor;Receptor, ErbB-2;Proto-Oncogene Proteins p21(ras);ras Proteins;Trastuzumab",
        "Doc_meshdescriptors":"Antibodies, Monoclonal, Humanized;Antineoplastic Agents;Breast Neoplasms;DNA Mutational Analysis;Exons;Female;Humans;Mutation;Neoplasm Metastasis;Proto-Oncogene Proteins;Proto-Oncogene Proteins p21(ras);Receptor, Epidermal Growth Factor;Receptor, ErbB-2;Trastuzumab;ras Proteins",
        "Doc_meshqualifiers":"therapeutic use;therapeutic use;drug therapy;genetics;pathology;genetics;genetics;genetics;genetics",
        "_version_":1605824530774753280},
      {
        "Doc_abstract":"Triple-negative breast cancer (TNBC) is an aggressive type of breast cancer that is clinically defined as lacking estrogen and progesterone receptors, as well as being ERBB2 (HER-2) negative. Without specific therapeutic targets, TNBC carries a worse prognosis than other types of breast cancer in the absence of therapy. Research has now further differentiated breast cancer into subtypes based on genetic expression patterns. One of these subtypes, basal-like, frequently overlaps with the clinical picture of TNBC. Additionally, both TNBC and basal-like breast cancer link to BRCA mutations. Recent pharmaceutical advances have created a class of drugs, poly(ADP-ribose) polymerase (PARP) inhibitors, which are showing potential to effectively treat these patients. The aim of this paper is to summarize the basis behind PARP inhibitors and update the current status of their development in clinical trials for the treatment of TNBC.",
        "Doc_title":"Current Status of Poly(ADP-ribose) Polymerase Inhibitors as Novel Therapeutic Agents for Triple-Negative Breast Cancer.",
        "Journal":"International journal of breast cancer",
        "Do_id":"22295252",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605906595044130816},
      {
        "Doc_abstract":"ErbB2 overexpression and/or gene amplification is present in 20% of all breast cancers and characterizes an aggressive form of this disease. Despite the availability of several active drugs that have yielded substantial survival improvements, most patients with ErbB2-positive metastatic disease will develop tumor progression, either because of primary or acquired resistance. Therefore, research has focused on drugs that can more efficiently interfere with ErbB2 and with other members of the epidermal growth factor receptor family.;This review focuses on those investigational drugs that inhibit ErbB2 tyrosine kinase activity (TKIs) for treating breast cancer.;ErbB-targeting TKIs show encouraging activity in patients with ErbB-positive tumors that are resistant to conventional ErbB-therapies (mostly trastuzumab), confirming pre-clinical observations. Efficient interference with the ErbB-network signaling implies also a potential use in ErbB2-normal tumors, where the phenotype is sustained by ErbB-aberrant signaling. Finally, early data suggests that ErbB-targeting TKIs could be active in treating patients with activating ErbB2 mutations. Ongoing and future research efforts should elucidate what is, according to the peculiarities of these compounds, their positioning in the treatment of women with breast cancer.",
        "Doc_title":"Investigational ErbB-2 tyrosine kinase inhibitors for the treatment of breast cancer.",
        "Journal":"Expert opinion on investigational drugs",
        "Do_id":"26863927",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605823770082148352},
      {
        "Doc_abstract":"Overexpression of the ERBB2 oncogene is observed in about 20% of human breast tumors and is the consequence of increased transcription rates frequently associated with gene amplification. Several studies have shown a link between activator protein 2 (AP-2) transcription factors and ERBB2 gene expression in breast cancer cell lines. Moreover, the Yin Yang 1 (YY1) transcription factor has been shown to stimulate AP-2 transcriptional activity on the ERBB2 promoter in vitro. In this report, we examined the relationships between ERBB2, AP-2alpha, and YY1 both in breast cancer tissue specimens and in a mammary cancer cell line.;ERBB2, AP-2alpha, and YY1 protein levels were analyzed by immunohistochemistry in a panel of 55 primary breast tumors. ERBB2 gene amplification status was determined by fluorescent in situ hybridization. Correlations were evaluated by a chi2 test at a p value of less than 0.05. The functional role of AP-2alpha and YY1 on ERBB2 gene expression was analyzed by small interfering RNA (siRNA) transfection in the BT-474 mammary cancer cell line followed by real-time reverse transcription-polymerase chain reaction and Western blotting.;We observed a statistically significant correlation between ERBB2 and AP-2alpha levels in the tumors (p < 0.01). Moreover, associations were found between ERBB2 protein level and the combined high expression of AP-2alpha and YY1 (p < 0.02) as well as between the expression of AP-2alpha and YY1 (p < 0.001). Furthermore, the levels of both AP-2alpha and YY1 proteins were inversely correlated to ERBB2 gene amplification status in the tumors (p < 0.01). Transfection of siRNAs targeting AP-2alpha and AP-2gamma mRNAs in the BT-474 breast cancer cell line repressed the expression of the endogenous ERBB2 gene at both the mRNA and protein levels. Moreover, the additional transfection of an siRNA directed against the YY1 transcript further reduced the ERBB2 protein level, suggesting that AP-2 and YY1 transcription factors cooperate to stimulate the transcription of the ERBB2 gene.;This study highlights the role of both AP-2alpha and YY1 transcription factors in ERBB2 oncogene overexpression in breast tumors. Our results also suggest that high ERBB2 expression may result either from gene amplification or from increased transcription factor levels.",
        "Doc_title":"The combined immunodetection of AP-2alpha and YY1 transcription factors is associated with ERBB2 gene overexpression in primary breast tumors.",
        "Journal":"Breast cancer research : BCR",
        "Do_id":"18218085",
        "Doc_ChemicalList":"Transcription Factor AP-2;YY1 Transcription Factor;YY1 protein, human",
        "Doc_meshdescriptors":"Adult;Aged;Aged, 80 and over;Breast Neoplasms;Cell Line, Tumor;Female;Genes, erbB-2;Humans;Immunohistochemistry;Middle Aged;Transcription Factor AP-2;YY1 Transcription Factor",
        "Doc_meshqualifiers":"genetics;metabolism;genetics;biosynthesis;genetics;biosynthesis;genetics",
        "_version_":1605825250783657984},
      {
        "Doc_abstract":"Activating, nonamplification ERBB2 mutations (ERBB2mut) are not detected by immunohistochemistry (IHC) or fluorescence in situ hybridization (FISH), but are detected by DNA sequencing and may predict clinical responses to human epidermal growth factor receptor (HER2)-targeted therapy. The authors queried 5605 advanced/metastatic breast cancers (mBC) to uncover the frequency of ERBB2mut genomic alterations. Clinical responses to anti-HER2 therapeutics were identified.;DNA was extracted from 40â€‰Âµm of formalin-fixed paraffin-embedded (FFPE) sections. Comprehensive genomic profiling (CGP) was used to evaluate up to 315 genes (592Ã— mean coverage depth). Results were analyzed for base substitutions, short indels, copy number changes, and selected rearrangements.;Of 5605 cases, 698 (12.5%) featured ERBB2 alterations, including 596 (10.6%) ERBB2 amplifications (ERBB2amp) and 138 (2.4%) ERBB2mut; 38 cases (0.7%) had co-occurring ERBB2amp and ERBB2mut. ERBB2mut predominantly affected the kinase (124 cases; 90%) or extracellular (15 cases; 11%) domains. Both primary BC (52 cases; 38%) and metastatic site biopsies (86 cases; 62%) were found to harbor ERBB2mut, which were distributed across carcinoma not otherwise specified (NOS) (69 cases; 50%), invasive ductal carcinoma (IDC) (40 cases; 29%), invasive lobular carcinoma (ILC) (27 cases; 20%), and mucinous mBC (2 cases; 1%). Genes commonly coaltered with ERBB2 were tumor protein 53 (TP53) (49%); phosphatidylinositol 3-kinase catalytic subunit alpha (PIK3CA) (42%); cadherin 1, type 1 (CDH1) (37%); MYC (17%); and cyclin D1 protein (CCND1) (16%). CDH1 mutations were enriched in ERBB2mut mBC (P<0.0006) and associated with recurrent mBC. Selected patients with ERBB2mut, without ERBB2amp, who responded to anti-HER2 targeted therapies are presented herein.;Within this large series, 1.8% of cases harbored ERBB2mut, which are undetectable by standard-of-care IHC or FISH tests. Metastatic BC driven by ERBB2mut respond to anti-HER2 targeted therapies, and expanding clinical trials designed to detect ERBB2mut by CGP and optimize targeted treatments are warranted. Cancer 2016. Â© 2016 American Cancer Society. Cancer 2016;122:2654-2662. Â© 2016 American Cancer Society.",
        "Doc_title":"Nonamplification ERBB2 genomic alterations in 5605 cases of recurrent and metastatic breast cancer: An emerging opportunity for anti-HER2 targeted therapies.",
        "Journal":"Cancer",
        "Do_id":"27284958",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605741972261175296},
      {
        "Doc_abstract":"ERBB2 (formerly HER2) is an important drug target in breast cancer, where anti-ERBB2 therapy has been shown to lead to improvements in disease recurrence and overall survival. ERBB2 status in head and neck squamous cell carcinoma (HNSCC) has not been well studied. Identification of ERBB2-positive tumors and characterization of response to ERBB2 therapy could lead to targeted treatment options in HNSCC.;To identify ERBB2 aberrations in HNSCCs and investigate the potential for ERBB2-targeted therapy in HNSCCs.;A retrospective case series of patients with laryngeal (42 tumor specimens) and oral cavity (94 tumor specimens) SCC enrolled in the University of Michigan Head and Neck Specialized Program of Research Excellence was conducted. Publicly available sequencing data (The Cancer Genome Atlas), as well as data from other studies, were reviewed to identify additional mutations and overexpression in ERBB2 in HNSCC. Established HNSCC cell lines were used for follow-up in vitro analysis. The study was conducted from October 1, 2014, to August 30, 2015.;With the use of targeted, amplicon-based sequencing with the Oncomine Cancer Panel, the copy number and mutation status of commonly altered genes in HNSCCs were assessed. Immunohistochemical staining was performed on tissue microarrays of HNSCCs to assess the expression of ERBB2. Western blotting for HNSCC cell line ERBB2 expression and cell survival assays after treatment with ERBB2 inhibitors were performed.;The prevalence of ERBB2 genetic aberrations and ERBB2 overexpression in laryngeal and oral cavity SCCs, prevalence of ERBB2 aberrations in HNSCC in The Cancer Genome Atlas, ERBB2 protein expression in HNSCC cell lines, and response of HNSCC cell lines to targeted ERBB2 inhibitors.;Of the 42 laryngeal SCC samples screened by targeted sequencing, 4 (10%) were positive for ERBB2 amplification. Two of these samples showed ERBB2 overexpression on immunohistochemistry. Two of the 94 oral cavity SCC samples (2%) were positive for ERBB2 on immunohistochemistry. Analysis of 288 patients from publicly available HNSCC sequencing data revealed 9 amplifications (3%) in ERBB2. Protein expression was variable across HNSCC cell lines, and a subset of these cell lines showed responsiveness to anti-ERBB2 therapy.;ERBB2 aberrations were identified in a subset of HNSCCs. These tumors may be responsive to targeted therapy against ERBB2. Screening for ERBB2 aberrations and applying targeted therapy in ERBB2-positive patients may be useful in personalized therapy trials, particularly in patients who are refractory to current treatment paradigms.",
        "Doc_title":"Identification of Targetable ERBB2 Aberrations in Head and Neck Squamous Cell Carcinoma.",
        "Journal":"JAMA otolaryngology-- head & neck surgery",
        "Do_id":"27077364",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605830497896759296},
      {
        "Doc_abstract":"Breast cancer is a leading cause of cancer-related deaths in women worldwide. Although tumorectomy, radiotherapy, chemotherapy and hormone replacement therapy have been used for the treatment of breast cancer, there is no effective therapy for patients with invasive and metastatic breast cancer. Immunotherapy may be proved effective in treating patients with advanced breast cancer. Breast cancer immunotherapy includes antibody based immunotherapy, cancer vaccine immunotherapy, adoptive T cell transfer immunotherapy and T cell receptor gene transfer immunotherapy. Antibody based immunotherapy such as the monoclonal antibody against HER-2/neu (trastuzumab) is successfully used in the treatment of breast cancer patients with over-expressed HER-2/neu, however, HER-2/neu is over-expressed only in 25-30% of breast cancer patients. Cancer vaccine immunotherapy is a promising method to treat cancer patients. Cancer vaccines can be used to induce specific anti-tumor immunity in breast cancer patients, but cannot induce objective tumor regression. Adoptive T cell transfer immunotherapy is an effective method in the treatment of melanoma patients. Recent advances in anti-tumor T cell generation ex vivo and limited clinical trial data have made the feasibility of adoptive T cell transfer immunotherapy in the treatment of breast cancer patients. T cell receptor gene transfer can redirect the specificity of T cells. Chimeric receptor, scFv(anti-HER-2/neu)/zeta receptor, was successfully used to redirect cytotoxic T lymphocyte hybridoma cells to obtain anti-HER-2/neu positive tumor cells, suggesting the feasibility of treatment of breast cancer patients with T cell receptor gene transfer immunotherapy. Clinical trials will approve that immunotherapy is an effective method to cure breast cancer disease in the near future.",
        "Doc_title":"Breast cancer immunotherapy.",
        "Journal":"Cellular & molecular immunology",
        "Do_id":"16225767",
        "Doc_ChemicalList":"Antineoplastic Agents;Cancer Vaccines;Receptors, Antigen, T-Cell",
        "Doc_meshdescriptors":"Adoptive Transfer;Animals;Antineoplastic Agents;Breast Neoplasms;Cancer Vaccines;Clinical Trials as Topic;Female;Humans;Immunotherapy;Immunotherapy, Adoptive;Receptors, Antigen, T-Cell;T-Lymphocytes;Tumor Cells, Cultured",
        "Doc_meshqualifiers":"therapeutic use;prevention & control;therapy;genetics;metabolism;cytology;physiology",
        "_version_":1605799721987735552},
      {
        "Doc_abstract":"The metastatic process requires changes in tumor cell adhesion properties, cell motility and remodeling of the extracellular matrix. The erbB2 proto-oncogene is overexpressed in approximately 30% of breast cancers and is a major prognostic parameter when present in invasive disease. A ligand for the erbB2 receptor has not yet been identified but it can be activated by heterodimerization with heregulin (HRG)-stimulated erbB3 and erbB4 receptors. The HRGs are a family of polypeptide growth factors that have been shown to play a role in embryogenesis, tumor formation, growth and differentiation of breast cancer cells. The erbB3 and erbB4 receptors are involved in transregulation of erbB2 signaling. The work presented here suggests biological roles for HRG including regulation of the actin cytoskeleton and induction of motility and invasion in breast cancer cells. HRG-expressing breast cancer cell lines are characterized by low erbB receptor levels and a high invasive and metastatic index, while those which overexpress erbB2 demonstrate minimal invasive potential in vitro and are non-tumorigenic in vivo. Treatment of the highly tumorigenic and metastatic HRG-expressing breast cancer cell line MDA-MB-231 with an HRG-neutralizing antibody significantly inhibited proliferation in culture and motility in the Boyden chamber assay. Addition of exogenous HRG to non-invasive erbB2 overexpressing cells (SKBr-3) at low concentrations induced formation of pseudopodia, enhanced phagocytic activity and increased chemomigration and invasion in the Boyden chamber assay. The specificity of the chemomigration response to HRG is demonstrated by inhibition with the anti-HRG neutralizing antibody. These results suggest that either HRG can act as an autocrine or paracrine ligand to promote the invasive behavior of breast cancer cells in vitro or thus may enhance the metastatic process in vivo.",
        "Doc_title":"Heregulin regulates the actin cytoskeleton and promotes invasive properties in breast cancer cell lines.",
        "Journal":"International journal of oncology",
        "Do_id":"10995872",
        "Doc_ChemicalList":"Actins;Antibodies, Monoclonal;Drug Combinations;Laminin;Neuregulin-1;Proteoglycans;RNA, Messenger;Recombinant Proteins;matrigel;Collagen",
        "Doc_meshdescriptors":"Actins;Animals;Antibodies, Monoclonal;Breast Neoplasms;Cell Differentiation;Cell Division;Cell Line;Cell Movement;Chemotaxis;Collagen;Cytoskeleton;Dose-Response Relationship, Drug;Drug Combinations;Gene Expression Regulation, Neoplastic;Humans;Laminin;Neoplasm Invasiveness;Neuregulin-1;Phagocytosis;Phenotype;Proteoglycans;Pseudopodia;RNA, Messenger;Recombinant Proteins;Tumor Cells, Cultured",
        "Doc_meshqualifiers":"drug effects;metabolism;immunology;pharmacology;genetics;pathology;drug effects;drug effects;drug effects;drug effects;drug effects;metabolism;genetics;pathology;genetics;immunology;pharmacology;drug effects;drug effects;genetics;metabolism;immunology;pharmacology;cytology;drug effects;metabolism",
        "_version_":1605836672764739584},
      {
        "Doc_abstract":"Genetic events underlying the pathogenesis of breast cancer have been studied extensively and several clinically significant markers have been identified. For example, amplification and overexpression of the ERBB2 oncogene is associated with poor prognosis in breast cancer and ERBB2 serves as a target for antibody-based therapy. Current knowledge on the pathogenesis of male breast cancer (MBC) is limited. The purpose of our study was to investigate the potential relevance of a series of genes known to be amplified in female breast cancer (FBC) in a the development and pathogenesis of MBC. To this end, we applied fluorescence in situ hybridization and immunohistochemistry to the analysis of 128 breast tumors from males. Amplification of ERBB2, MYC, PPM1D and ZNF217 was detected rarely (1-2% of tumors) indicating a considerably lower amplification frequency than in FBC. CCND1 amplification was observed in 12% of cases, being in good concordance with findings from FBC. In addition, CCND1 overexpression was detected in 63% of tumors and was associated with ER positivity (p < 0.0001). Our results indicate distinct differences in the genetic basis of MBC and FBC and suggest that marked differences exist in the pathogenesis of these diseases. The lack of ERBB2 involvement was especially unexpected and implies that ERBB2-targeted therapies are unlikely to be beneficial in MBC. Furthermore, the high frequency of hormone receptor positivity and the association between ER positivity and CCND1 overexpression supports the notion that hormonal regulation is likely to be essential for the development of MBC.",
        "Doc_title":"Frequent amplification and overexpression of CCND1 in male breast cancer.",
        "Journal":"International journal of cancer",
        "Do_id":"15300811",
        "Doc_ChemicalList":"Receptors, Estrogen;Cyclin D1",
        "Doc_meshdescriptors":"Breast Neoplasms, Male;Cyclin D1;Female;Gene Amplification;Gene Expression Profiling;Genes, erbB-2;Humans;Immunohistochemistry;In Situ Hybridization, Fluorescence;Male;Oligonucleotide Array Sequence Analysis;Receptors, Estrogen;Sex Factors;Up-Regulation",
        "Doc_meshqualifiers":"genetics;physiopathology;biosynthesis;physiology",
        "_version_":1605742794906796032},
      {
        "Doc_abstract":"Overexpression of the ERBB2 oncogene is observed in about 30% of breast cancers and is generally correlated with a poor prognosis. Previous results from our and other laboratories indicated that elevated transcriptional activity contributes significantly to the overexpression of ERBB2 mRNA in mammary adenocarcinoma cell lines. Activator protein 2 (AP-2) transcription factors account for this overexpression through two recognition sequences located 215 and 500 bp upstream from the transcription start site. Furthermore, AP-2 transcription factors are highly expressed in cancer cell lines overexpressing ERBB2. In this report, we examined the cooperative effect of Yin Yang 1 (YY1) on AP-2-induced activation of ERBB2 promoter activity. We detected high levels of YY1 transcription factor in mammary cancer cell lines. Notably, we showed that YY1 enhances AP-2alpha transcriptional activation of the ERBB2 promoter through an AP-2 site both in HepG2 and in HCT116 cells, whereas a carboxyl-terminal-truncated form of YY1 cannot. Moreover, we demonstrated the interaction between endogenous AP-2 and YY1 factors in the BT-474 mammary adenocarcinoma cell line. In addition, inhibition of endogenous YY1 protein by an antisense decreased the transcription of an AP-2-responsive ERBB2 reporter plasmid in BT-474 breast cancer cells. Finally, we detected in vivo AP-2 and YY1 occupancy of the ERBB2 proximal promoter in chromatin immunoprecipitation assays. Our data thus provide evidence that YY1 cooperates with AP-2 to stimulate ERBB2 promoter activity through the AP-2 binding sites.",
        "Doc_title":"Yin Yang 1 cooperates with activator protein 2 to stimulate ERBB2 gene expression in mammary cancer cells.",
        "Journal":"The Journal of biological chemistry",
        "Do_id":"15870067",
        "Doc_ChemicalList":"Chromatin;DNA-Binding Proteins;Erythroid-Specific DNA-Binding Factors;Oligonucleotides, Antisense;RNA, Messenger;TFAP2A protein, human;Transcription Factor AP-2;Transcription Factors;YY1 Transcription Factor;YY1 protein, human;Luciferases;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Binding Sites;Blotting, Western;Breast Neoplasms;Cell Line;Cell Line, Tumor;Cell Nucleus;Chromatin;Chromatin Immunoprecipitation;DNA-Binding Proteins;Erythroid-Specific DNA-Binding Factors;Gene Expression Regulation, Neoplastic;Genetic Vectors;Humans;Immunoprecipitation;Luciferases;Models, Genetic;Oligonucleotides, Antisense;Plasmids;Promoter Regions, Genetic;Protein Binding;RNA, Messenger;Receptor, ErbB-2;Transcription Factor AP-2;Transcription Factors;Transcription, Genetic;Transcriptional Activation;Transfection;YY1 Transcription Factor",
        "Doc_meshqualifiers":"metabolism;metabolism;chemistry;metabolism;physiology;metabolism;chemistry;metabolism;metabolism;biosynthesis;metabolism;physiology",
        "_version_":1605875984630808576},
      {
        "Doc_abstract":"Detection of selected predictive markers is currently included in the standard diagnostic algorithm of breast carcinoma specimens. Despite this fact we are facing several unresolved questions and issues. Probably the most frequently discussed predictive marker in breast carcinoma is HER-2/neu. The change of criteria of positivity in 2007 brought several confusions regarding the selection of patients eligible for anti-HER2 treatment. There is a deficiency of knowledge in tumors with the discordant phenotype (a discrepancy between the results of immunohistochemistry and in situ hybridization). Even in selected HER2 positive patients is the anti-HER2 treatment effective in only 30 % of cases. Thus, we evidently have to search for new markers which would help to more precisely select the optimal treatment for breast cancer patients.",
        "Doc_title":"[Predictive diagnosis of breast cancer].",
        "Journal":"Ceskoslovenska patologie",
        "Do_id":"22145211",
        "Doc_ChemicalList":"Biomarkers, Tumor;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Biomarkers, Tumor;Breast Neoplasms;Female;Humans;Prognosis;Receptor, ErbB-2",
        "Doc_meshqualifiers":"analysis;diagnosis;metabolism;therapy;metabolism",
        "_version_":1605903218958663680},
      {
        "Doc_abstract":"To exploit overexpression of erbB2 in human cancers, we constructed a single-chain immunotoxin (erb-38) that contains the Fv portion of monoclonal antibody e23 fused to a truncated form of Pseudomonas exotoxin A. In a Phase I study, five breast cancer patients and one esophageal cancer patient received three doses of erb-38 at 1.0 and 2.0 microg/kg. Hepatotoxicity was observed in all patients. Immunohistochemistry showed the presence of erbB2 on hepatocytes explaining the liver toxicity of erb-38. We suggest that targeting of tumors with antibodies to erbB2 armed with radioisotopes or other toxic agents may result in unexpected organ toxicities due to erbB2 on normal cells.",
        "Doc_title":"Hepatotoxicity in cancer patients receiving erb-38, a recombinant immunotoxin that targets the erbB2 receptor.",
        "Journal":"Clinical cancer research : an official journal of the American Association for Cancer Research",
        "Do_id":"10499598",
        "Doc_ChemicalList":"Antibodies, Monoclonal;Antibodies, Neoplasm;Bacterial Toxins;Exotoxins;Immunotoxins;Recombinant Proteins;Virulence Factors;ADP Ribose Transferases;toxA protein, Pseudomonas aeruginosa;Aspartate Aminotransferases;Alanine Transaminase;Receptor, ErbB-2",
        "Doc_meshdescriptors":"ADP Ribose Transferases;Adult;Alanine Transaminase;Antibodies, Monoclonal;Antibodies, Neoplasm;Aspartate Aminotransferases;Bacterial Toxins;Breast Neoplasms;Chemical and Drug Induced Liver Injury;Esophageal Neoplasms;Exotoxins;Female;Humans;Immunotoxins;Liver;Liver Diseases;Male;Middle Aged;Receptor, ErbB-2;Recombinant Proteins;Virulence Factors",
        "Doc_meshqualifiers":"metabolism;adverse effects;immunology;pharmacokinetics;therapeutic use;biosynthesis;metabolism;adverse effects;immunology;pharmacokinetics;therapeutic use;drug therapy;metabolism;drug therapy;metabolism;adverse effects;immunology;pharmacokinetics;therapeutic use;adverse effects;immunology;pharmacokinetics;therapeutic use;drug effects;metabolism;enzymology;metabolism;metabolism;adverse effects;immunology;pharmacokinetics;therapeutic use",
        "_version_":1605820640668942336},
      {
        "Doc_abstract":"Breast cancers are a biologically heterogeneous group of mammary tumors with distinct natural histories and varied responses to established therapies. They have long been divided into those that are hormone sensitive [as defined by expression of the estrogen receptor alpha (ERalpha) and/or the progesterone receptor (PR)] and those that are not. Notably, only those breast cancers that express ERalpha and/or PR typically respond to hormonal therapy with tamoxifen, aromatase inhibitors, or the newer agent fulvestrant. More recently, the transmembrane tyrosine kinase receptor HER-2/neu was identified as an oncogene overexpressed by about 30% of breast cancers. These HER-2/neu-overexpressing breast cancers define a subset of breast tumors that are characteristically more aggressive, and women who develop them have a shorter survival. Trastuzumab (Herceptin), a humanized monoclonal antibody specific for HER-2/neu, has revolutionized the management of metastatic HER-2/neu-overexpressing breast cancers. As a single agent, it produces response rates similar to those of many single-agent chemotherapeutic agents active in metastatic breast cancer and has limited toxicity. Combining trastuzumab with chemotherapy can result in synergistic antitumor activity. The clear efficacy of trastuzumab against HER-2/neu-overexpressing metastatic breast cancer has led to a keen interest in testing its role in the management of early breast cancer, and multiple large clinical trials are currently in progress. This review summarizes the available clinical data on the use of trastuzumab in HER-neu-overexpressing breast cancer and briefly highlights emerging opportunities for innovative, trastuzumab-based breast cancer therapies.",
        "Doc_title":"Trastuzumab: targeted therapy for the management of HER-2/neu-overexpressing metastatic breast cancer.",
        "Journal":"American journal of therapeutics",
        "Do_id":"15891269",
        "Doc_ChemicalList":"Antibodies, Monoclonal;Antibodies, Monoclonal, Humanized;Antineoplastic Agents;Receptor, ErbB-2;Trastuzumab",
        "Doc_meshdescriptors":"Animals;Antibodies, Monoclonal;Antibodies, Monoclonal, Humanized;Antineoplastic Agents;Antineoplastic Combined Chemotherapy Protocols;Breast Neoplasms;Chemotherapy, Adjuvant;Clinical Trials as Topic;Drug Administration Schedule;Drug Synergism;Female;Humans;Neoplasm Metastasis;Receptor, ErbB-2;Trastuzumab",
        "Doc_meshqualifiers":"adverse effects;pharmacology;therapeutic use;adverse effects;pharmacology;therapeutic use;therapeutic use;drug therapy;metabolism;pathology;biosynthesis;genetics;immunology",
        "_version_":1605746466189475841},
      {
        "Doc_abstract":"Human epidermal growth factor receptor 2 (HER2) is an important biomarker whose status plays a pivotal role in therapeutic decision-making for breast cancer patients and in determining their clinical outcomes. Ensuring the accuracy and reproducibility of HER2 assays by immunohistochemistry (IHC) and by fluorescence in situ hybridization (FISH) requires a reliable standard for monitoring assay sensitivity and specificity, and for assessing methodologic variation. A prior NIST workshop addressed this need by reaching a consensus to create cell lines as reference materials for HER2 testing.;Breast carcinoma cell lines SK-BR-3 and MCF-7 were characterized quantitatively by IHC with chicken anti-HER2 IgY antibody and by FISH with biotinylated bacterial artificial chromosome DNA probes; both assays used quantum dots as detectors. Formalin-fixed and paraffin-embedded (FFPE) cell blocks were prepared and tested for suitability as candidate reference materials by IHC and FISH with commercially available reagents. IHC and FISH results were also compared with those obtained by laser-scanning cytometry and real-time PCR, respectively.;MCF-7 cells had typical numbers of gene copies and very low production of HER2 protein, whereas SK-BR-3 cells contained approximately 10-fold more copies of the gene and exhibited approximately 15-fold higher amounts of HER2 protein than MCF-7 cells. FFPE SK-BR-3 cells showed results similar to those for fresh SK-BR-3 cells.;SK-BR-3 and MCF-7 are suitable as candidate reference materials in QC of HER2 testing. Coupled with the associated assay platforms, they provide valuable controls for quantitative measurement of HER2 amplification and production in breast cancer samples, irrespective of the antibody/probe or detector used.",
        "Doc_title":"Cell lines as candidate reference materials for quality control of ERBB2 amplification and expression assays in breast cancer.",
        "Journal":"Clinical chemistry",
        "Do_id":"19443566",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"Breast Neoplasms;Cell Line, Tumor;Gene Amplification;Genes, erbB-2;Humans;Immunohistochemistry;In Situ Hybridization, Fluorescence;Quality Control",
        "Doc_meshqualifiers":"genetics;pathology",
        "_version_":1605824465911939072},
      {
        "Doc_abstract":"ErbB2 can be activated by its own overexpression or be transactivated by the heregulin polypeptide growth factor. Activation of ErbB2 leads to breast cancer cell proliferation, presumably by inducing the activation of extracellular signal-regulated kinases 1,2 (Erk1,2) and Akt. We have previously reported that the growth factor receptor bound protein-2 (Grb2) is required for the proliferation of ErbB2-overexpressing breast cancer cells. We investigated here whether Grb2 protein plays a role in heregulin-stimulated proliferation. Grb2 protein inhibition led to growth inhibition of heregulin-stimulated breast cancer cells, but not Erk1,2 inactivation. These findings are similar to our earlier observations in ErbB2-overexpressing cells. Since Akt can also be activated by heregulin, the effects of Grb2 inhibition on Akt were examined. Akt was inactivated following Grb2 downregulation in heregulin-stimulated breast cancer cells. We then examined the effects of Grb2 downregulation on Akt in ErbB2-overexpressing cells in the absence of heregulin. Similar to heregulin-stimulated cells, Grb2 inhibition also led to Akt inactivation in ErbB2-overexpressing breast cancer cells. Our results indicate that the activation of ErbB2 by heregulin or by its overexpression requires Grb2 to stimulate the Akt pathway to propagate mitogenic signals.",
        "Doc_title":"Grb2 downregulation leads to Akt inactivation in heregulin-stimulated and ErbB2-overexpressing breast cancer cells.",
        "Journal":"Oncogene",
        "Do_id":"11175341",
        "Doc_ChemicalList":"Adaptor Proteins, Signal Transducing;GRB2 Adaptor Protein;GRB2 protein, human;Liposomes;Neuregulin-1;Oligodeoxyribonucleotides, Antisense;Proteins;Proto-Oncogene Proteins;Receptor, ErbB-2;AKT1 protein, human;Protein-Serine-Threonine Kinases;Proto-Oncogene Proteins c-akt",
        "Doc_meshdescriptors":"Adaptor Proteins, Signal Transducing;Breast Neoplasms;Cell Division;Down-Regulation;Female;GRB2 Adaptor Protein;Humans;Liposomes;Neuregulin-1;Oligodeoxyribonucleotides, Antisense;Protein-Serine-Threonine Kinases;Proteins;Proto-Oncogene Proteins;Proto-Oncogene Proteins c-akt;Receptor, ErbB-2;Transfection;Tumor Cells, Cultured",
        "Doc_meshqualifiers":"genetics;metabolism;pathology;drug effects;administration & dosage;genetics;pharmacology;pharmacology;genetics;metabolism;physiology;metabolism;genetics;metabolism",
        "_version_":1605741960183676930},
      {
        "Doc_abstract":"Understanding the signaling pathways that drive aggressive breast cancers is critical to the development of effective therapeutics. The oncogene MET is associated with decreased survival in breast cancer, yet the role that MET plays in the various breast cancer subtypes is unclear. We describe a knockin mouse with mutationally activated Met (Met(mut)) that develops a high incidence of diverse mammary tumors with basal characteristics, including metaplasia, absence of progesterone receptor and ERBB2 expression, and expression of cytokeratin 5. With gene expression and tissue microarray analysis, we show that high MET expression in human breast cancers significantly correlated with estrogen receptor negative/ERBB2 negative tumors and with basal breast cancers. Few treatment options exist for breast cancers of the basal or trastuzumab-resistant ERBB2 subtypes. We conclude from these studies that MET may play a critical role in the development of the most aggressive breast cancers and may be a rational therapeutic target.",
        "Doc_title":"Met induces diverse mammary carcinomas in mice and is associated with human basal breast cancer.",
        "Journal":"Proceedings of the National Academy of Sciences of the United States of America",
        "Do_id":"19567831",
        "Doc_ChemicalList":"Receptors, Progesterone;ERBB2 protein, human;Erbb2 protein, mouse;Proto-Oncogene Proteins c-met;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Adenocarcinoma;Animals;Breast Neoplasms;Female;Gene Amplification;Humans;Immunohistochemistry;Mammary Neoplasms, Experimental;Mice;Mice, Inbred C57BL;Proto-Oncogene Proteins c-met;Receptor, ErbB-2;Receptors, Progesterone;Signal Transduction",
        "Doc_meshqualifiers":"etiology;genetics;etiology;genetics;etiology;genetics;genetics;physiology;analysis;analysis",
        "_version_":1605748033374388224},
      {
        "Doc_abstract":"Previous studies demonstrated breast cancer tumor tissue samples could be classified into different subtypes based upon DNA microarray profiles. The most recent study presented evidence for the existence of five different subtypes: normal breast-like, basal, luminal A, luminal B, and ERBB2+.;Based upon the analysis of 599 microarrays (five separate cDNA microarray datasets) using a novel approach, we present evidence in support of the most consistently identifiable subtypes of breast cancer tumor tissue microarrays being: ESR1+/ERBB2-, ESR1-/ERBB2-, and ERBB2+ (collectively called the ESR1/ERBB2 subtypes). We validate all three subtypes statistically and show the subtype to which a sample belongs is a significant predictor of overall survival and distant-metastasis free probability.;As a consequence of the statistical validation procedure we have a set of centroids which can be applied to any microarray (indexed by UniGene Cluster ID) to classify it to one of the ESR1/ERBB2 subtypes. Moreover, the method used to define the ESR1/ERBB2 subtypes is not specific to the disease. The method can be used to identify subtypes in any disease for which there are at least two independent microarray datasets of disease samples.",
        "Doc_title":"Discovery and validation of breast cancer subtypes.",
        "Journal":"BMC genomics",
        "Do_id":"16965636",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"Algorithms;Breast Neoplasms;Female;Gene Expression Profiling;Humans;Multivariate Analysis;Oligonucleotide Array Sequence Analysis;Proportional Hazards Models;Risk Factors;Survival Analysis",
        "Doc_meshqualifiers":"classification;genetics;pathology;methods;statistics & numerical data;methods;statistics & numerical data",
        "_version_":1605840952289656832},
      {
        "Doc_abstract":"Overexpression of the epidermal growth factor receptor-related gene ErbB2 occurs in 18% to 25% of patients with breast cancer in Western countries and is associated with a poor prognosis. The prevalence of ErbB2-positive tumors in Asia is unclear, partly because data are limited. The objective of this review was to summarize the reported prevalence of ErbB2-positive tumors from a large sample of Asian patients and to examine ErbB2 assessment methods in Asia. From searches of MEDLINE, local language journals, and local and international conference proceedings as well as locoregional breast cancer experts' recommendations, the authors selected up to 5 studies each from India, Korea, Malaysia, the Philippines, Singapore, Taiwan, and Thailand that reported ErbB2 results based on assessment with immunohistochemistry (IHC) and/or fluorescence in situ hybridization (FISH). The reported prevalence of ErbB2-positive tumors in 22 studies on 24,671 patients, of whom 14,398 patients were assessed for ErbB2 status, varied widely (range, 6%-65%) as did the assessment methods used. Most studies (n=21) used IHC to assess ErbB2 status, but definitions for positivity varied. When robust assessment methods were used, the median prevalence was 19% based on strong IHC staining (IHC3+; n=9812 patients) and 25% based on FISH (n=681 patients). Data on the prevalence of ErbB2-positive breast cancer in Asia are limited. The current survey indicated that the prevalence in Asia may be similar to that in Western countries; thus, up to 1 in 4 Asian patients with breast cancer potentially could benefit from ErbB2-targeted treatment. A standard, reliable ErbB2 assessment method available to patients across Asia is urgently required.",
        "Doc_title":"The prevalence and assessment of ErbB2-positive breast cancer in Asia: a literature survey.",
        "Journal":"Cancer",
        "Do_id":"20715159",
        "Doc_ChemicalList":"Receptor, ErbB-2",
        "Doc_meshdescriptors":"Asia;Breast Neoplasms;Female;Humans;Immunohistochemistry;In Situ Hybridization, Fluorescence;Prevalence;Receptor, ErbB-2",
        "Doc_meshqualifiers":"epidemiology;genetics;genetics",
        "_version_":1605742750211244033},
      {
        "Doc_abstract":"Estrogen signaling is required for the proliferation of normal breast epithelial cells. However, prophylactic inhibition of estrogen signaling fails to prevent 56% of human breast cancer cases. The underlying mechanism is not well understood. Aberrant activation of growth factor signaling is known to provide alternative proliferation pathways in breast cells that are fully transformed, but it is not known whether activation of growth factor signaling can substitute for estrogen signaling in causing aberrant proliferation in the normal breast epithelium. Here, we report that in a retrovirus-based somatic mouse model (replication-competent ALV-LTR splice acceptor/tumor virus A) that closely mimics the evolution of sporadic human breast cancers, mammary epithelial cells harboring PyMT or activated ErbB2 evolve into tumors independent of estrogen or other ovarian functions in contrast to previous observations of estrogen-dependent cancer formation in germ line mouse models of ErbB2 activation. Importantly, ErbB2 activation in normal mammary cells causes estrogen-independent proliferation in both estrogen receptor (ER)-negative cells as well as in normally quiescent ER-positive cells. Therefore, aberrant activation of growth factor signaling contributes to estrogen-independent proliferation of both preneoplastic and cancerous mammary cells, and prophylactic therapy against both growth factor signaling and estrogen signaling may need to be considered in women with increased risk of breast cancer.",
        "Doc_title":"Somatic expression of PyMT or activated ErbB2 induces estrogen-independent mammary tumorigenesis.",
        "Journal":"Neoplasia (New York, N.Y.)",
        "Do_id":"20824048",
        "Doc_ChemicalList":"Antigens, Viral, Tumor;Estrogens;Erbb2 protein, mouse;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Animals;Antigens, Viral, Tumor;Carcinoma, Ductal, Breast;Cell Transformation, Neoplastic;Drug Resistance, Neoplasm;Enzyme Activation;Estrogens;Female;Gene Expression Regulation, Neoplastic;Genes, erbB-2;Mammary Neoplasms, Experimental;Mice;Mice, Transgenic;Polyomavirus;Receptor, ErbB-2;Transfection",
        "Doc_meshqualifiers":"genetics;metabolism;physiology;genetics;metabolism;pathology;genetics;metabolism;pathology;drug effects;physiology;pharmacology;genetics;genetics;metabolism;pathology;genetics;immunology;metabolism;genetics;metabolism;physiology",
        "_version_":1605818738750259202},
      {
        "Doc_abstract":"The oncogenic tyrosine kinase receptor ErbB2 is a prognostic factor and target for breast cancer therapeutics. In contrast with the other ErbB receptors, ErbB2 is hardly internalized by ligand induced mechanisms, indicating a prevalent surface expression. Elevated levels of ErbB2 in tumor cells are associated with its defective endocytosis and down regulation. Here we show that caveolin-1 expression in breast cancer derived SKBR-3 cells (SKBR-3/Cav-1) facilitates ligand induced ErbB2 endocytosis using an artificial peptide ligand EC-eGFP. Similarly, stimulation with humanized anti ErbB2 antibody Trastuzumab (Herceptin) was found to be internalized and co-localized with caveolin-1 in SKBR-3/Cav-1 cells. Internalized EC-eGFP and Trastuzumab in SKBR-3/Cav-1 cells were then delivered via caveolae to the caveolin-1 containing early endosomes. Consequently, attenuated Fc receptor mediated ADCC functions were observed when exposed to Trastuzumab and EC-Fc (EC-1 peptide conjugated to Fc part of human IgG). On the other hand, this caveolae dependent endocytic synergy was not observed in parental SKBR-3 cells. Therefore, caveolin-1 expression in breast cancer cells could be a predictive factor to estimate how cancer cells are likely to respond to Trastuzumab treatment. ",
        "Doc_title":"Identification of caveolin-1 as a potential causative factor in the generation of trastuzumab resistance in breast cancer cells.",
        "Journal":"Journal of Cancer",
        "Do_id":"23833684",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605763673375113216},
      {
        "Doc_abstract":"In order to analyze the clinicopathological features of Chinese triple negative tumors, we performed a retrospective study of 1993 female unilateral breast cancer patients undergoing surgery in Cancer Hospital of Fudan University, Shanghai, China. Survival curves were performed with Kaplan-Meier method and annual recurrence hazard was estimated by hazard function. We observed that the rate of larger tumors in triple negative patients was higher than that in HR+/ERBB2- women, but lower than that in ERBB2+ subgroup (P = 0.0001). In addition, 21.83% of triple negative patients had four or more axillary lymph nodes involved as compared to 27.40% of ERBB2+ women and 22.75% of HR+/ERBB2- subgroup (P = 0.0056). In the survival analysis, we found a statistical significance for recurrence-free survival (RFS) among the three subgroups (P = 0.0037), with the rate of 72.89% for ERBB2+ patients, 78.40% for HR+/ERBB2- ones and 75.76% for triple negative ones at the 11th year respectively. When it came to hazard peaks, discrepancies existed in different subgroups. Similar to HR+/ERBB2- patients, triple negative subgroup showed an early major recurrence surge peaking at approximately year 2.5 as opposed to ERBB2+ counterparts with a tapering sharp at the 1st year. Furthermore, the first peak of triple negative tumors was higher than that of HR+/ERBB2- patients, but lower than that of ERBB2+ ones. Therefore, our findings suggested biological characteristics and prognostic outlook of Chinese triple negative breast cancers might be more favorable and somewhat different from those in Western populations.",
        "Doc_title":"Clinicopathological features of the triple-negative tumors in Chinese breast cancer patients.",
        "Journal":"Breast cancer research and treatment",
        "Do_id":"18563552",
        "Doc_ChemicalList":"Receptors, Estrogen;Receptors, Progesterone;TP53 protein, human;Tumor Suppressor Protein p53;ERBB2 protein, human;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Adolescent;Adult;Aged;Aged, 80 and over;Asian Continental Ancestry Group;Breast Neoplasms;Disease-Free Survival;Female;Humans;Immunohistochemistry;Kaplan-Meier Estimate;Middle Aged;Neoplasm Recurrence, Local;Receptor, ErbB-2;Receptors, Estrogen;Receptors, Progesterone;Retrospective Studies;Tumor Suppressor Protein p53;Young Adult",
        "Doc_meshqualifiers":"genetics;metabolism;mortality;pathology;epidemiology;metabolism;pathology;metabolism;metabolism;metabolism;metabolism",
        "_version_":1605873590658400256},
      {
        "Doc_abstract":"Our recent studies using comparative genomic hybridization showed that gain or amplification at the 17q12-q21 region is very common in the intestinal type of gastric cancer. Here, we describe a fluorescence in situ hybridization study with gastrin (GAS)-specific and ERBB2-specific probes on ten specimens of gastric carcinoma that, by using comparative genomic hybridization, showed 1) DNA copy number gain or amplification at 17q12-q21, a region known to harbor the GAS and ERBB2 genes (four cases); 2) gain of the entire chromosome 17 (three cases); or 3) normal copy number of chromosome 17 (three cases). GAS and ERBB2 protein expression was studied by Western immunoblotting from gastric cancer cell lines with or without gain at 17q12-q21 as well as a breast cancer cell line with ERBB2 amplification. Our results showed that simultaneous amplification of both GAS and ERBB2 was four- to ninefold in the tumors with the 17q12-q21 amplification. Both genes were amplified in the same nuclei, and the hybridization signals were localized to the same region of the nucleus. Overexpression of GAS and ERBB2 was observed by Western immunoblotting only in the gastric cancer cell line with gain at 17q12-q21. The ERBB2 amplification is also a recurrent change in breast cancer. To investigate whether the GAS amplification is unique in gastric cancer, fluorescence in situ hybridization analysis was performed on 40 breast cancer cell lines. The ERBB2 amplification was observed in 11 cell lines, but none of the lines showed the GAS amplification. This indicates that the formation of an amplicon, in which both the GAS and the ERBB2 genes are amplified, might be unique in gastric cancer, especially in its intestinal type, and that simultaneous amplification of both genes is important to the tumorigenesis of intestinal gastric cancer. We demonstrate here for the first time that a gene of a physiological hormone is amplified in tumors that originate from cells that normally secrete the hormone.",
        "Doc_title":"Concomitant gastrin and ERBB2 gene amplifications at 17q12-q21 in the intestinal type of gastric cancer.",
        "Journal":"Genes, chromosomes & cancer",
        "Do_id":"9892105",
        "Doc_ChemicalList":"Gastrins;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Breast Neoplasms;Carcinoma;Chromosomes, Human, Pair 17;Gastrins;Gastrointestinal Neoplasms;Gene Amplification;Humans;In Situ Hybridization, Fluorescence;Receptor, ErbB-2;Tumor Cells, Cultured",
        "Doc_meshqualifiers":"genetics;genetics;genetics;genetics;genetics;genetics",
        "_version_":1605758484472659968},
      {
        "Doc_abstract":"Epidemiological evidence suggests that moderately elevated levels of circulating insulin-like growth factor-I (IGF-I) are associated with increased risk of breast cancer in women. How circulating IGF-I may promote breast cancer incidence is unknown, however, increased IGF-I signaling is linked to trastuzumab resistance in ErbB2 positive breast cancer. Few models have directly examined the effect of moderately high levels of circulating IGF-I on breast cancer initiation and progression. The purpose of this study was to assess the ability of circulating IGF-I to independently initiate mammary tumorigenesis and/or accelerate the progression of ErbB2 mediated mammary tumor growth.;We crossed heterozygous TTR-IGF-I mice with heterozygous MMTV-ErbB2 mice to generate 4 different genotypes: TTR-IGF-I/MMTV-ErbB2 (bigenic), TTR-IGF-I only, MMTV-ErbB2 only, and wild type (wt). Virgin females were palpated twice a week and harvested when tumors reached 1000 mm(3). For study of normal development, blood and tissue were harvested at 4, 6 and 9 weeks of age in TTR-IGF-I and wt mice.;TTR-IGF-I and TTR-IGF-I/ErbB2 bigenic mice showed a moderate 35% increase in circulating total IGF-I compared to ErbB2 and wt control mice. Elevation of circulating IGF-I had no effect upon pubertal mammary gland development. The transgenic increase in IGF-I alone wasn't sufficient to initiate mammary tumorigenesis. Elevated circulating IGF-I had no effect upon ErbB2-induced mammary tumorigenesis or metastasis, with median time to tumor formation being 30 wks and 33 wks in TTR-IGF-I/ErbB2 bigenic and ErbB2 mice respectively (p = 0.65). Levels of IGF-I in lysates from ErbB2/TTR-IGF-I tumors compared to ErbB2 was elevated in a similar manner to the circulating IGF-I, however, there was no effect on the rate of tumor growth (p = 0.23). There were no morphological differences in tumor type (solid adenocarcinomas) between bigenic and ErbB2 mammary glands.;Using the first transgenic animal model to elevate circulating levels of IGF-I to those comparable to women at increased risk of breast cancer, we showed that moderately high levels of systemic IGF-I have no effect on pubertal mammary gland development, initiating mammary tumorigenesis or promoting ErbB2 driven mammary carcinogenesis. Our work suggests that ErbB2-induced mammary tumorigenesis is independent of the normal variation in circulating levels of IGF-I.",
        "Doc_title":"A moderate elevation of circulating levels of IGF-I does not alter ErbB2 induced mammary tumorigenesis.",
        "Journal":"BMC cancer",
        "Do_id":"21867536",
        "Doc_ChemicalList":"Insulin-Like Growth Factor I;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Animals;Cell Transformation, Neoplastic;Female;Gene Expression Regulation;Insulin-Like Growth Factor I;Mammary Glands, Animal;Mammary Neoplasms, Experimental;Mice;Mice, Inbred C57BL;Mice, Transgenic;Receptor, ErbB-2;Signal Transduction;Transgenes",
        "Doc_meshqualifiers":"genetics;genetics;metabolism;metabolism;etiology;genetics;metabolism;genetics;metabolism",
        "_version_":1605746353012473857},
      {
        "Doc_abstract":"Members of the ErbB subfamily of receptor tyrosine kinases are important regulators of normal mammary gland physiology, and aberrations in their signaling have been associated with breast tumorigenesis. Therapeutics targeting epidermal growth factor receptor (EGFR = ErbB1) or ErbB2 in breast cancer have been approved for clinical use. In contrast, relatively little is known about the biological significance of ErbB4 signaling in breast cancer. This review focuses on recent advances in our understanding about the role of ErbB4 in breast carcinogenesis, as well as in the potential clinical relevance of ErbB4 in breast cancer prognostics and therapy.",
        "Doc_title":"Role of ErbB4 in breast cancer.",
        "Journal":"Journal of mammary gland biology and neoplasia",
        "Do_id":"18454307",
        "Doc_ChemicalList":"Biomarkers, Tumor;Neuregulins;ERBB4 protein, human;Receptor, Epidermal Growth Factor;Receptor, ErbB-4",
        "Doc_meshdescriptors":"Alternative Splicing;Biomarkers, Tumor;Breast Neoplasms;Drug Delivery Systems;Female;Gene Expression Profiling;Gene Expression Regulation, Neoplastic;Humans;Neuregulins;Prognosis;Receptor, Epidermal Growth Factor;Receptor, ErbB-4;Signal Transduction",
        "Doc_meshqualifiers":"genetics;metabolism;drug therapy;genetics;metabolism;pathology;metabolism;antagonists & inhibitors;genetics;metabolism",
        "_version_":1605876414295310336},
      {
        "Doc_abstract":"Taxol resistance remains a major obstacle to improve the benefit of breast cancer patients. Here, we studied whether overexpression of ErbB2 may lead to mitotic deregulation in breast cancer cells via up-regulation of survivin that confers Taxol resistance.;ErbB2-overexpressing and ErbB2-low-expressing breast cancer cell lines were used to compare their mitotic exit rate, survivin expression level, and apoptosis level in response to Taxol. Survivin was then down-regulated by antisense oligonucleotides to evaluate its contribution to mitotic exit and Taxol resistance in ErbB2-overexpressing breast cancer cells. At last, specific PI3K/Akt and Src inhibitors were used to investigate the involvement of these two pathways in ErbB2-mediated survivin up-regulation and Taxol resistance.;We found that ErbB2-overexpressing cells expressed higher levels of survivin in multiple breast cancer cell lines and patient samples. ErbB2-overexpressing cells exited M phase faster than ErbB2-low-expressing cells, which correlated with the increased resistance to Taxol-induced apoptosis. Down-regulation of survivin by antisense oligonucleotide delayed mitotic exit of ErbB2-overexpressing cells and also sensitized ErbB2-overexpressing cells to Taxol-induced apoptosis. Moreover, ErbB2 up-regulated survivin at translational level and PI3K/Akt and Src activation are involved. In addition, combination treatment of Taxol with PI3K/Akt and Src inhibitor led to increased apoptosis in ErbB2-overexpressing breast cancer cells than single treatment.;Survivin up-regulation by ErbB2 is a critical event in ErbB2-mediated faster mitotic exit and contributes to Taxol resistance.",
        "Doc_title":"Mitotic deregulation by survivin in ErbB2-overexpressing breast cancer cells contributes to Taxol resistance.",
        "Journal":"Clinical cancer research : an official journal of the American Association for Cancer Research",
        "Do_id":"19228734",
        "Doc_ChemicalList":"BIRC5 protein, human;Inhibitor of Apoptosis Proteins;Microtubule-Associated Proteins;Phosphatidylinositol 3-Kinases;ERBB2 protein, human;Receptor, ErbB-2;Proto-Oncogene Proteins c-akt;Paclitaxel",
        "Doc_meshdescriptors":"Apoptosis;Breast Neoplasms;Cell Line, Tumor;Drug Resistance, Neoplasm;Female;Humans;Inhibitor of Apoptosis Proteins;Microtubule-Associated Proteins;Mitosis;Paclitaxel;Phosphatidylinositol 3-Kinases;Proto-Oncogene Proteins c-akt;Receptor, ErbB-2",
        "Doc_meshqualifiers":"drug effects;drug therapy;pathology;antagonists & inhibitors;physiology;pharmacology;physiology;physiology;analysis",
        "_version_":1605897901992574976},
      {
        "Doc_abstract":"Previous studies have indicated that ErbB receptors for neuregulins play an important role in cardiac development and muscle spindle formation during embryogenesis; however, little is known about their functions in adulthood. Recent reports indicate that breast cancer therapy with humanized monoclonal ErbB2 antibody induces cardiomyopathy, suggesting that ErbB2 serves as a crucial signaling receptor, even in the adult heart. Here, we examine ErbB2 expression and localization in both cardiac and skeletal muscle of adult mice via immunoblot and immunohistochemistry. ErbB2 was detected as a band approximately 185 kD molecular mass in each cardiac and skeletal muscle extraction. Confocal images of double labeling showed that ErbB2 was colocalized with caveolin-3 in cardiac muscle and with dihydropyridine receptor in skeletal muscle, suggesting that ErbB2 was localized at the T-tubule. In addition, immunoelectron micrographs clearly demonstrated that ErbB2 was located at the T-tubule in both types of muscle. Taken together, the results of the present study suggest that neuregulin-ErbB2 signaling plays a role in the physiological function of cardiac and skeletal muscle, even in adulthood.",
        "Doc_title":"Neuregulin receptor ErbB2 localization at T-tubule in cardiac and skeletal muscle.",
        "Journal":"The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society",
        "Do_id":"15637341",
        "Doc_ChemicalList":"Neuregulins;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Animals;Immunoblotting;Immunohistochemistry;Mice;Microscopy, Immunoelectron;Muscle, Skeletal;Myocardium;Neuregulins;Receptor, ErbB-2;Sarcolemma",
        "Doc_meshqualifiers":"metabolism;ultrastructure;metabolism;ultrastructure;metabolism;metabolism;metabolism;ultrastructure",
        "_version_":1605841315709321216},
      {
        "Doc_abstract":"Immunohistochemistry (IHC) and fluorescent in situ hybridization (FISH) are reliable ways to identify overexpression or amplification of the HER-2/neu (HER2, symbol ERBB2) gene, but each technique requires a high-quality tissue sample, which may not be available. We investigated whether serum concentrations of the HER2 extracellular domain (ECD) can be used as an alternative to tissue HER2 status in metastatic breast cancer, and we defined an optimal decision-level concentration of serum HER2 for prediction of tissue HER2 status.;In 195 patients with metastatic breast cancer, we determined HER2 expression by IHC and performed FISH analysis on tumors for which IHC staining was graded as 2+. We measured serum HER2 by immunoassay and used ROC curve analysis to determine optimal serum HER2 ECD concentrations for differentiation between positive and negative HER2 status.;IHC results were 0/1+ for 30 (15%) of the patients, 2+ for 89 (46%), and 3+ for 76 (39%). FISH revealed HER2 amplification in 19 (21%) of the IHC 2+ tumors. Mean (SE) serum HER2 ECD was 22.2 (5.1) microg/L in the tissue HER2-negative group, significantly lower than the concentration of 363 (96) microg/L in the tissue HER2-positive group (P<0.0001). ROC curve analysis showed 95% specificity and 62% sensitivity for tissue HER2 positivity at 37 microg/L of serum HER2.;To use serum HER2 concentration as an alternative to direct determination of tissue HER2 status, we suggest 37 microg/L as a cutoff for predicting positive tissue HER2 with 95% specificity. Sensitivity, however, is low.",
        "Doc_title":"Predicting tissue HER2 status using serum HER2 levels in patients with metastatic breast cancer.",
        "Journal":"Clinical chemistry",
        "Do_id":"16777917",
        "Doc_ChemicalList":"Receptor, ErbB-2",
        "Doc_meshdescriptors":"Adult;Aged;Aged, 80 and over;Breast Neoplasms;Female;Humans;Middle Aged;Neoplasm Metastasis;Predictive Value of Tests;ROC Curve;Receptor, ErbB-2;Retrospective Studies",
        "Doc_meshqualifiers":"metabolism;pathology;blood;metabolism",
        "_version_":1605875706874560512},
      {
        "Doc_abstract":"To investigate whether overexpression of the neu protein in breast tumors differentiates risk factor patterns for breast cancer, neu protein overexpression was determined in 296 breast carcinomas of patients participating in an ongoing population-based case-control study. Risk factor information on these patients and 737 controls was obtained during home interviews. Most breast cancer risk factors showed similar associations with neu-positive and neu-negative tumors, but remarkable differences were found for breast-feeding and age at first full-term pregnancy. In contrast to the slightly protective effect of breast-feeding in the neu-negative group, the risk of neu-positive breast cancer was 4.2-fold increased in women who ever breast-fed. Increasing age at first full-term pregnancy was positively associated with both neu-positive and neu-negative breast cancer, but the association was about 2 times stronger for neu-positive tumors. We conclude that neu oncogene overexpression of the breast tumor seems to be associated with a distinct risk factor pattern.",
        "Doc_title":"Differences in breast cancer risk factors to neu (c-erbB-2) protein overexpression of the breast tumor.",
        "Journal":"Cancer research",
        "Do_id":"1348449",
        "Doc_ChemicalList":"Biomarkers, Tumor;Proto-Oncogene Proteins;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Adult;Biomarkers, Tumor;Breast Feeding;Breast Neoplasms;Female;Humans;Middle Aged;Proto-Oncogene Proteins;Receptor, ErbB-2;Risk Factors",
        "Doc_meshqualifiers":"genetics;genetics;genetics;metabolism",
        "_version_":1605746358480797696},
      {
        "Doc_abstract":"Fatty acid synthase (FASN) is a potential therapeutic target for treatment of cancer and obesity, and is highly elevated in 30% of HER2-overexpressing breast cancers. Considerable interest has developed in searching for novel FASN inhibitors as therapeutic agents in treatment of HER2-overexpressing breast cancers. Amentoflavone was found to be effective in suppressing FASN expression in HER2-positive SKBR3 cells. Pharmacological inhibition of FASN by amentoflavone specifically down-regulated HER2 protein and mRNA, and caused an up-regulation of PEA3, a transcriptional repressor of HER2. In addition, pharmacological blockade of FASN by amentoflavone preferentially decreased cell viability and induced cell death in SKBR3 cells. Palmitate reduced the cytotoxic effect of amentoflavone, as the percentage of viable cells was increased after the addition of exogenous palmitate. Amentoflavone-induced FASN inhibition inhibited the translocation of SREBP-1 in SKBR3 cells. Amentoflavone inhibited phosphorylation of AKT, mTOR, and JNK. The use of pharmacological inhibitors revealed that the modulation of AKT, mTOR, and JNK phosphorylation required synergistic amentoflavone-induced FASN inhibition and HER2 activation in SKBR3 cells. These results suggest that amentoflavone modulated FASN expression by regulation of HER2-pathways, and induced cell death to enhance chemopreventive or chemotherapeutic activity in HER2-positive breast cancers.",
        "Doc_title":"Fatty acid synthase inhibition by amentoflavone suppresses HER2/neu (erbB2) oncogene in SKBR3 human breast cancer cells.",
        "Journal":"Phytotherapy research : PTR",
        "Do_id":"22767439",
        "Doc_ChemicalList":"Antineoplastic Agents;Biflavonoids;amentoflavone;Fatty Acid Synthases;ERBB2 protein, human;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Antineoplastic Agents;Apoptosis;Biflavonoids;Breast Neoplasms;Cell Line, Tumor;Cell Survival;Fatty Acid Synthases;Female;Gene Expression Regulation, Neoplastic;Humans;Phosphorylation;Receptor, ErbB-2",
        "Doc_meshqualifiers":"pharmacology;drug effects;pharmacology;metabolism;antagonists & inhibitors;drug effects;genetics;metabolism",
        "_version_":1605836869435654144},
      {
        "Doc_abstract":"Many methodologies have been used in research to identify the \"intrinsic\" subtypes of breast cancer commonly known as Luminal A, Luminal B, HER2-Enriched (HER2-E) and Basal-like. The PAM50 gene set is often used for gene expression-based subtyping; however, surrogate subtyping using panels of immunohistochemical (IHC) markers are still widely used clinically. Discrepancies between these methods may lead to different treatment decisions.;We used the PAM50 RT-qPCR assay to expression profile 814 tumors from the GEICAM/9906 phase III clinical trial that enrolled women with locally advanced primary invasive breast cancer. All samples were scored at a single site by IHC for estrogen receptor (ER), progesterone receptor (PR), and Her2/neu (HER2) protein expression. Equivocal HER2 cases were confirmed by chromogenic in situ hybridization (CISH). Single gene scores by IHC/CISH were compared with RT-qPCR continuous gene expression values and \"intrinsic\" subtype assignment by the PAM50. High, medium, and low expression for ESR1, PGR, ERBB2, and proliferation were selected using quartile cut-points from the continuous RT-qPCR data across the PAM50 subtype assignments.;ESR1, PGR, and ERBB2 gene expression had high agreement with established binary IHC cut-points (area under the curve (AUC)â€‰â‰¥â€‰0.9). Estrogen receptor positivity by IHC was strongly associated with Luminal (A and B) subtypes (92%), but only 75% of ER negative tumors were classified into the HER2-E and Basal-like subtypes. Luminal A tumors more frequently expressed PR than Luminal B (94% vs 74%) and Luminal A tumors were less likely to have high proliferation (11% vs 77%). Seventy-seven percent (30/39) of ER-/HER2+ tumors by IHC were classified as the HER2-E subtype. Triple negative tumors were mainly comprised of Basal-like (57%) and HER2-E (30%) subtypes. Single gene scoring for ESR1, PGR, and ERBB2 was more prognostic than the corresponding IHC markers as shown in a multivariate analysis.;The standard immunohistochemical panel for breast cancer (ER, PR, and HER2) does not adequately identify the PAM50 gene expression subtypes. Although there is high agreement between biomarker scoring by protein immunohistochemistry and gene expression, the gene expression determinations for ESR1 and ERBB2 status was more prognostic.",
        "Doc_title":"PAM50 breast cancer subtyping by RT-qPCR and concordance with standard clinical molecular markers.",
        "Journal":"BMC medical genomics",
        "Do_id":"23035882",
        "Doc_ChemicalList":"Biomarkers, Tumor;Estrogen Receptor alpha;RNA, Messenger;estrogen receptor alpha, human;ERBB2 protein, human;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Biomarkers, Tumor;Breast;Breast Neoplasms;Cell Line, Tumor;Cell Proliferation;Clinical Trials as Topic;Cluster Analysis;Estrogen Receptor alpha;Female;Gene Expression Regulation, Neoplastic;Humans;Immunohistochemistry;Kaplan-Meier Estimate;Limit of Detection;Multivariate Analysis;Prognosis;RNA, Messenger;ROC Curve;Receptor, ErbB-2;Reference Standards;Reproducibility of Results;Reverse Transcriptase Polymerase Chain Reaction",
        "Doc_meshqualifiers":"genetics;metabolism;metabolism;pathology;classification;genetics;pathology;metabolism;genetics;metabolism;metabolism;methods",
        "_version_":1605875880663449600},
      {
        "Doc_abstract":"Type I receptor tyrosine kinases, including the epidermal growth factor receptor (EGFR) and erbB2, have been implicated in mammary carcinoma growth and metastasis. Recent evidence suggests that type I receptor signaling may be mediated by the CD44 family of transmembrane glycoproteins that also have been implicated in mammary tumor progression. Here, the authors tested whether CD44, EGFR, and erbB2 interacted and colocalized with one another in four mammary carcinoma cell lines (MCF-7, MDA-MB-231, MDA-MB-435, and MDA-MB-436) and in cytology samples obtained from patients with metastatic breast cancer. CD44 constitutively colocalized and coimmunoprecipitated with erbB2 and EGFR in all four mammary carcinoma cell lines. CD44 also colocalized with erbB2 and EGFR in all cytology samples expressing erbB2. CD44 colocalized with EGFR in cells from only 1 of 16 erbB2-negative cytology samples. These data indicate that CD44-EGFR-erbB2 protein complexes occur in a high proportion of metastatic mammary carcinomas and suggest that CD44-type I receptor colocalization may be a novel prognostic marker for aggressive mammary cancers.",
        "Doc_title":"CD44 associates with EGFR and erbB2 in metastasizing mammary carcinoma cells.",
        "Journal":"Applied immunohistochemistry & molecular morphology : AIMM",
        "Do_id":"11893033",
        "Doc_ChemicalList":"Antigens, CD44;Receptor, Epidermal Growth Factor;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Antigens, CD44;Blotting, Western;Breast Neoplasms;Humans;Immunohistochemistry;Microscopy, Confocal;Neoplasm Metastasis;Precipitin Tests;Protein Binding;Receptor, Epidermal Growth Factor;Receptor, ErbB-2;Tumor Cells, Cultured",
        "Doc_meshqualifiers":"metabolism;immunology;metabolism;pathology;metabolism;metabolism",
        "_version_":1605905473040547840},
      {
        "Doc_abstract":"The overexpression of the ErbB family of tyrosine kinase receptors is thought to be important in the development of many breast tumours. To date, most attention has focused on the ErbB2 receptor. Now, in a recent report, it has been shown that ErbB3 is a critical partner for the transforming activity of ErbB2 in breast cancer cells. Importantly, the proliferative signals from this transforming complex appear to act via the PI-3 kinase pathway.",
        "Doc_title":"Essential function for ErbB3 in breast cancer proliferation.",
        "Journal":"Breast cancer research : BCR",
        "Do_id":"15084235",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605906433759510528},
      {
        "Doc_abstract":"Approximately 20% of new diagnosed breast cancers overexpress the human epidermal growth factor receptor 2 (EGFR2), also known as erythroblastic leukemia viral oncogene homolog 2 (ERBB2) protein, as a consequence of ERBB2 gene amplification, resulting in a poor prognosis. Clinical outcome can be substantially improved by ERBB2-targeted therapy. Lapatinib is a potent, orally bioavailable small molecule that reversibly and selectively inhibits epidermal growth factor receptor (EGFR1 or ERBB1) and ERBB2 tyrosine kinases. Lapatinib binds the adenosine triphosphate-binding site of the receptor's intracellular domain to inhibit tumor cell growth. This review summarizes the pharmacology, pharmacokinetics, efficacy, and tolerability of lapatinib, and reviews both Food and Drug Administration-approved and investigational uses of lapatinib in breast cancer therapy. The drug is generally well tolerated in patients, with diarrhea and rashes being the most common (usually mild or moderate) adverse effects. Unlike trastuzumab, lapatinib has infrequent adverse effects on cardiac function. Lapatinib has substantial activity for advanced ERBB2-positive breast cancer, particularly in combination with capecitabine, following progression after anthracyclines, taxanes, and trastuzumab. Lapatinib combined with capecitabine yielded significant improvements in time to progression and response rate compared with capecitabine alone. This drug can also be combined with letrozole for the treatment of postmenopausal women with ERBB2-positive breast cancer, for whom hormonal therapy is indicated. Lapatinib has shown early promise in treatment of central nervous system metastasis and is being further evaluated in various clinical settings. ",
        "Doc_title":"Lapatinib: new opportunities for management of breast cancer.",
        "Journal":"Breast cancer (Dove Medical Press)",
        "Do_id":"24367169",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605742049573732353},
      {
        "Doc_abstract":"Specific abnormalities in cancers are the best molecular targets of therapeutics, which is exemplified by trastuzumab. ERBB2 amplification is present in 15-30% of invasive ductal carcinomas, and its overexpression was associated with poor prognosis. c-MYC amplification is present in 13-19%, but other forms of oncogene activation are rare. Germline mutations of BRCA1 and BRCA2 are responsible for familial breast cancers. Their somatic mutations in sporadic breast cancers are rare, but chromosomal losses are frequent. Inactivation of BRCA1 by its promoter methylation is also frequent. p53 mutations are present in 20-25% of sporadic breast cancers, and inactivation of its pathway is present in most of them. Further molecular analysis will reveal new targets for diagnosis and therapeutics.",
        "Doc_title":"[Genes involved in breast cancers].",
        "Journal":"Nihon rinsho. Japanese journal of clinical medicine",
        "Do_id":"16529032",
        "Doc_ChemicalList":"BRCA2 Protein",
        "Doc_meshdescriptors":"BRCA2 Protein;Breast Neoplasms;DNA Methylation;Gene Amplification;Genes, BRCA1;Genes, erbB-2;Genes, myc;Genes, p53;Humans;Mutation",
        "Doc_meshqualifiers":"genetics;genetics;genetics;genetics",
        "_version_":1605783811642097664},
      {
        "Doc_abstract":"This study was conducted as a part of the Chromosome-Centric Human Proteome Project (C-HPP) of the Human Proteome Organization. The United States team of C-HPP is focused on characterizing the protein-coding genes in chromosome 17. Despite its small size, chromosome 17 is rich in protein-coding genes; it contains many cancer-associated genes, including BRCA1, ERBB2, (Her2/neu), and TP53. The goal of this study was to examine the splice variants expressed in three ERBB2 expressed breast cancer cell-line models of hormone-receptor-negative breast cancers by integrating RNA-Seq and proteomic mass spectrometry data. The cell lines represent distinct phenotypic variations subtype: SKBR3 (ERBB2+ (overexpression)/ER-/PR-; adenocarcinoma), SUM190 (ERBB2+ (overexpression)/ER-/PR-; inflammatory breast cancer), and SUM149 (ERBB2 (low expression) ER-/PR-; inflammatory breast cancer). We identified more than one splice variant for 1167 genes expressed in at least one of the three cancer cell lines. We found multiple variants of genes that are in the signaling pathways downstream of ERBB2 along with variants specific to one cancer cell line compared with the other two cancer cell lines and with normal mammary cells. The overall transcript profiles based on read counts indicated more similarities between SKBR3 and SUM190. The top-ranking Gene Ontology and BioCarta pathways for the cell-line specific variants pointed to distinct key mechanisms including: amino sugar metabolism, caspase activity, and endocytosis in SKBR3; different aspects of metabolism, especially of lipids in SUM190; cell-to-cell adhesion, integrin, and ERK1/ERK2 signaling; and translational control in SUM149. The analyses indicated an enrichment in the electron transport chain processes in the ERBB2 overexpressed cell line models and an association of nucleotide binding, RNA splicing, and translation processes with the IBC models, SUM190 and SUM149. Detailed experimental studies on the distinct variants identified from each of these three breast cancer cell line models that may open opportunities for drug target discovery and help unveil their specific roles in cancer progression and metastasis. ",
        "Doc_title":"Distinct splice variants and pathway enrichment in the cell-line models of aggressive human breast cancer subtypes.",
        "Journal":"Journal of proteome research",
        "Do_id":"24111759",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"Breast Neoplasms;Cell Line, Tumor;Female;Humans;Mass Spectrometry;RNA Splicing",
        "Doc_meshqualifiers":"genetics;pathology",
        "_version_":1605819943278870528},
      {
        "Doc_abstract":"Both HER-2 and EGFR are expressed in breast cancer and are implicated in its development and progression. The discovery of the association between HER-2 gene amplification and poor prognosis in breast cancer led to the development of HER-2 targeted therapies. Trastuzumab, a monoclonal antibody to HER-2, has significantly improved the prognosis for HER-2-positive breast cancer patients. It is now approved for the treatment of both HER-2-positive metastatic breast cancer and early stage HER-2-positive breast cancer. Recent results from trials of the dual HER-2 and EGFR tyrosine kinase inhibitor, lapatinib, also show very promising results in HER-2-positive breast cancer. A number of EGFR inhibitors have been tested in breast cancer clinical trials, but with limited effect. This may be due to difficulty in selecting the appropriate patient population, caused by the lack of definitive predictive markers for response to EGFR inhibition.",
        "Doc_title":"EGFR and HER-2 antagonists in breast cancer.",
        "Journal":"Anticancer research",
        "Do_id":"17593621",
        "Doc_ChemicalList":"Antibodies, Monoclonal;Antibodies, Monoclonal, Humanized;Protein Kinase Inhibitors;Quinazolines;lapatinib;Receptor, Epidermal Growth Factor;Receptor, ErbB-2;Trastuzumab;Cetuximab;gefitinib",
        "Doc_meshdescriptors":"Antibodies, Monoclonal;Antibodies, Monoclonal, Humanized;Antineoplastic Combined Chemotherapy Protocols;Breast Neoplasms;Cetuximab;Humans;Protein Kinase Inhibitors;Quinazolines;Receptor, Epidermal Growth Factor;Receptor, ErbB-2;Trastuzumab",
        "Doc_meshqualifiers":"pharmacology;pharmacology;drug therapy;enzymology;pharmacology;pharmacology;antagonists & inhibitors;antagonists & inhibitors",
        "_version_":1605763987547357184},
      {
        "Doc_abstract":"ERBB2 is one of the most important oncogenes in breast cancer, and its disordered expression is commonly associated with gene amplification. Amplification of at least one gene near ERBB2, topoisomerase IIalpha (TOP2A), has been shown to be clinically significant, but the prevailing patterns of gene amplification in this region of chromosome arm 17q have not been studied systematically in clinical cases of breast cancer. For characterizing this region, a commercial ERBB2-containing contig probe and 7 probes prepared from single overlapping BAC and P1 clones lying telomeric to ERBB2 and including TOP2A were hybridized to 77 ERBB2-amplified archival breast tumor specimens from 75 patients. The 7 single-clone probes covered a region of approximately 650 kb starting 114 kb telomeric to ERBB2. Amplification of the ERBB2 contig target alone was found in 32% of the tumors, whereas all 8 probe targets were amplified in 12% of the tumors, based on an amplification criterion of there being more than or equal to 2 targets per chromosome 17 centromere. When one of the 7 overlapping probes encompassing TOP2A indicated amplification within a specimen, all probes telomeric to that probe usually showed amplification. Only 5 specimens had regions of normal or deleted targets separating 2 amplified targets. Also, tumors that showed deletion of TOP2A usually showed deletion of one or more contiguous targets. The observed patterns of amplification and deletion are consistent with the break-fusion-bridge model for gene amplification. TOP2A was amplified in 25% of all tumor specimens and was deleted in 24%, based on a deletion criterion of there being fewer than or equal to 0.75 targets per chromosome 17 centromere. Considering the relevance of the TOP2A gene product to anthracycline therapy and the wealth of other cancer-associated genes within the ERBB2/TOP2A region, the pattern of amplification and deletion near ERBB2 and TOP2A may have a dramatic effect on the malignant potential of breast carcinomas and their response to therapy.",
        "Doc_title":"Gene copy mapping of the ERBB2/TOP2A region in breast cancer.",
        "Journal":"Genes, chromosomes & cancer",
        "Do_id":"15034864",
        "Doc_ChemicalList":"Antigens, Neoplasm;DNA Probes;DNA, Neoplasm;DNA-Binding Proteins;Oncogene Proteins, Fusion;Receptor, ErbB-2;DNA Topoisomerases, Type II;DNA topoisomerase II alpha",
        "Doc_meshdescriptors":"Anaphase;Antigens, Neoplasm;Breast Neoplasms;Centromere;Chromosome Deletion;Chromosome Mapping;Chromosomes, Human, Pair 17;DNA Probes;DNA Topoisomerases, Type II;DNA, Neoplasm;DNA-Binding Proteins;Gene Amplification;Gene Dosage;Genes, erbB-2;Humans;Models, Genetic;Oncogene Proteins, Fusion;Paraffin Embedding;Receptor, ErbB-2;Recombination, Genetic",
        "Doc_meshqualifiers":"genetics;genetics;pathology;genetics;methods;genetics;genetics;genetics;genetics;genetics;genetics;genetics;genetics",
        "_version_":1605903055189966848},
      {
        "Doc_abstract":"The taxane docetaxel is currently the most effective chemotherapeutic drug for the treatment of advanced breast cancer. However, a considerable proportion of breast cancer patients do not respond positively to docetaxel. The mechanisms of docetaxel resistance are poorly understood. Overexpression of ERBB2 occurs in 15-30% of breast tumors and is associated with chemoresistance to a variety of anticancer drugs. In the present study, we sought to identify genes involved in ERBB2-mediated chemoresistance to docetaxel. We generated SAGE libraries from two human mammary cell lines expressing basal (HB4a) and high (C5.2) levels of ERBB2 before and after intensive exposure to docetaxel and identified potential ERBB2 target genes implicated in a variety of cellular processes including cell proliferation, cell adhesion, apoptosis and cytoskeleton organization. Comparison of the transcriptome of the cell lines before and after docetaxel exposure revealed substantially different expression patterns. Twenty-one differentially expressed genes between HB4a and C5.2 cell lines, before and after docetaxel treatment, were further analyzed by qPCR. The alterations in the expression patterns in HB4a and C5.2 cell lines in response to docetaxel treatment observed by SAGE analysis were confirmed by qPCR for the majority of the genes analyzed. Our study provides a comprehensive view of the expression changes induced in two human mammary cells expressing different levels of ERBB2 in response to docetaxel that could contribute to the elucidation of the mechanisms involved in ERBB2-mediated chemoresistance in breast cancer.",
        "Doc_title":"Transcriptome changes induced by docetaxel in human mammary cell lines expressing different levels of ERBB2.",
        "Journal":"International journal of molecular medicine",
        "Do_id":"19424599",
        "Doc_ChemicalList":"Antineoplastic Agents;Taxoids;docetaxel;ERBB2 protein, human;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Antineoplastic Agents;Blotting, Western;Breast Neoplasms;Cell Line, Tumor;Drug Resistance, Neoplasm;Electrophoresis, Polyacrylamide Gel;Gene Expression Regulation, Neoplastic;Humans;Polymerase Chain Reaction;Receptor, ErbB-2;Taxoids;Transcription, Genetic",
        "Doc_meshqualifiers":"pharmacology;drug therapy;metabolism;genetics;drug effects;genetics;metabolism;pharmacology;drug effects",
        "_version_":1605820041529393152},
      {
        "Doc_abstract":"Overexpression of the ErbB2 receptor is associated with the progression of breast cancer, and is a sign of a poor prognosis. Herceptin, a humanized antibody directed to the ErbB2 receptor, has been proven to be effective in the immunotherapy of breast cancer. However, it can result in cardiotoxicity, and a large fraction of breast cancer patients are resistant to Herceptin treatment. We have engineered three novel, fully human, anti-ErbB2 immunoagents: Erbicin, a human single-chain antibody fragment; ERB-hRNase, a human immunoRNase composed of Erbicin fused to a human RNase; ERB-hcAb, a human 'compact' antibody in which two Erbicin molecules are fused to the Fc fragment of a human IgG1. Both ERB-hRNase and ERB-hcAb strongly inhibit the growth of ErbB2-positive cells in vivo. The interactions of the Erbicin-derived immunoagents and Herceptin with the extracellular domain of ErbB2 (ErbB2-ECD) were investigated for the first time by three different methods. Erbicin-derived immunoagents bind soluble extracellular domain with a lower affinity than that measured for the native antigen on tumour cells. Herceptin, by contrast, shows a higher affinity for soluble ErbB2-ECD. Accordingly, ErbB2-ECD abolished the in vitro antitumour activity of Herceptin, with no effect on that of Erbicin-derived immunoagents. These results suggest that the fraction of immunoagent neutralized by free extracellular domain shed into the bloodstream is much higher for Herceptin than for Erbicin-derived immunoagents, which therefore may be used at lower therapeutic doses than those employed for Herceptin.",
        "Doc_title":"Differential binding of human immunoagents and Herceptin to the ErbB2 receptor.",
        "Journal":"The FEBS journal",
        "Do_id":"18795950",
        "Doc_ChemicalList":"Antibodies;Antibodies, Monoclonal;Antibodies, Monoclonal, Humanized;Antineoplastic Agents;Immunoglobulin Fragments;Recombinant Fusion Proteins;Receptor, ErbB-2;Trastuzumab",
        "Doc_meshdescriptors":"Antibodies;Antibodies, Monoclonal;Antibodies, Monoclonal, Humanized;Antineoplastic Agents;Breast Neoplasms;Female;Humans;Immunoglobulin Fragments;Immunotherapy;Protein Binding;Protein Engineering;Receptor, ErbB-2;Recombinant Fusion Proteins;Trastuzumab;Tumor Cells, Cultured",
        "Doc_meshqualifiers":"genetics;pharmacology;pharmacology;pharmacology;drug therapy;pathology;genetics;pharmacology;methods;methods;immunology;therapeutic use",
        "_version_":1605822853982191616},
      {
        "Doc_abstract":"HER2 and TOP2A gene status are assessed for diagnostic and research purposes in breast cancer with fluorescence in situ hybridization (FISH). However, FISH probes do not target only the annotated gene, while chromosome 17 (chr17) is among the most unstable chromosomes in breast cancer. Here we asked whether the status of specifically targeted genes on chr17 might help in refining prognosis of early high-risk breast cancer patients.;Copy numbers (CN) for 14 genes on chr17, 4 of which were within and 10 outside the core HER2 amplicon (HER2- and non-HER2-genes, respectively) were assessed with qPCR in 485 paraffin-embedded tumor tissue samples from breast cancer patients treated with adjuvant chemotherapy in the frame of two randomized phase III trials.;HER2-genes CN strongly correlated to each other (Spearman's rho >0.6) and were concordant with FISH HER2 status (Kappa 0.6697 for ERBB2 CN). TOP2A CN were not concordant with TOP2A FISH status (Kappa 0.1154). CN hierarchical clustering revealed distinct patterns of gains, losses and complex alterations in HER2- and non-HER2-genes associated with IHC4 breast cancer subtypes. Upon multivariate analysis, non-HER2-gene gains independently predicted for shorter disease-free survival (DFS) and overall survival (OS) in patients with triple-negative cancer, as compared to luminal and HER2-positive tumors (interaction p = 0.007 for DFS and p = 0.011 for OS). Similarly, non-HER2-gene gains were associated with worse prognosis in patients who had undergone breast-conserving surgery as compared to modified radical mastectomy (p = 0.004 for both DFS and OS). Non-HER2-gene losses were unfavorable prognosticators in patients with 1-3 metastatic nodes, as compared to those with 4 or more nodes (p = 0.017 for DFS and p = 0.001 for OS).;TOP2A FISH and qPCR may not identify the same pathology on chr17q. Non-HER2 chr17 CN patterns may further predict outcome in breast cancer patients with known favorable and unfavorable prognosis.",
        "Doc_title":"Adjusting breast cancer patient prognosis with non-HER2-gene patterns on chromosome 17.",
        "Journal":"PloS one",
        "Do_id":"25098819",
        "Doc_ChemicalList":"Antigens, Neoplasm;DNA-Binding Proteins;ERBB2 protein, human;Receptor, ErbB-2;DNA Topoisomerases, Type II;DNA topoisomerase II alpha",
        "Doc_meshdescriptors":"Adult;Antigens, Neoplasm;Breast Neoplasms;Chromosomal Instability;Chromosomes, Human, Pair 17;DNA Topoisomerases, Type II;DNA-Binding Proteins;Disease-Free Survival;Female;Humans;In Situ Hybridization, Fluorescence;Middle Aged;Receptor, ErbB-2;Survival Rate",
        "Doc_meshqualifiers":"genetics;genetics;metabolism;pathology;therapy;genetics;genetics;genetics;genetics",
        "_version_":1605906322156421120},
      {
        "Doc_abstract":"ErbB2 is a receptor tyrosine kinase whose activity in normal cells depends on dimerization with another ligand-binding ErbB receptor. In contrast, amplification of c-erbB2 in tumors results in dramatic overexpression and constitutive activation of the receptor. Breast cancer cells overexpressing ErbB2 depend on its activity for proliferation, because treatment of these cells with ErbB2-specific antagonistic antibodies or kinase inhibitors blocks tumor cells in the G1 phase of the cell cycle. Intriguingly, loss of ErbB2 signaling is accompanied by a decrease in the phosphotyrosine content of ErbB3. On the basis of these results, it has been proposed that ErbB3 might be a partner for ErbB2 in promoting cellular transformation. To test this hypothesis and directly examine the role of the \"kinase dead\" ErbB3, we specifically ablated its expression with a designer transcription factor (E3). By infection of ErbB2-overexpressing breast cancer cells with a retrovirus expressing E3, we show that ErbB3 is an essential partner in the transformation process. Loss of functional ErbB2 or ErbB3 has similar effects on cell proliferation and cell cycle regulators. Furthermore, expression of constitutively active protein kinase B rescues the proliferative block induced as a consequence of loss of ErbB2 or ErbB3 signaling. These results demonstrate that ErbB2 overexpression and activity alone are insufficient to promote breast tumor cell division. Furthermore, we identify ErbB3's role, which is to couple active ErbB2 to the phosphatidylinositol 3-kinase/protein kinase B pathway. Thus, the ErbB2/ErbB3 dimer functions as an oncogenic unit to drive breast tumor cell proliferation.",
        "Doc_title":"The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation.",
        "Journal":"Proceedings of the National Academy of Sciences of the United States of America",
        "Do_id":"12853564",
        "Doc_ChemicalList":"Proto-Oncogene Proteins;Transcription Factors;Phosphatidylinositol 3-Kinases;Receptor, ErbB-2;Receptor, ErbB-3;Protein-Serine-Threonine Kinases;Proto-Oncogene Proteins c-akt",
        "Doc_meshdescriptors":"Breast Neoplasms;Cell Division;Dimerization;Female;Gene Expression;Genes, erbB;Genes, erbB-2;Humans;Phosphatidylinositol 3-Kinases;Protein-Serine-Threonine Kinases;Proto-Oncogene Proteins;Proto-Oncogene Proteins c-akt;Receptor, ErbB-2;Receptor, ErbB-3;Signal Transduction;Transcription Factors;Transfection",
        "Doc_meshqualifiers":"enzymology;genetics;pathology;metabolism;metabolism;chemistry;genetics;metabolism;chemistry;genetics;metabolism;genetics;metabolism",
        "_version_":1605808621967376384},
      {
        "Doc_abstract":"Recently, expression profiling of breast carcinomas has revealed gene signatures that predict clinical outcome, and discerned prognostically relevant breast cancer subtypes. Measurement of the degree of genomic instability provides a very similar stratification of prognostic groups. We therefore hypothesized that these features are linked. We used gene expression profiling of 48 breast cancer specimens that profoundly differed in their degree of genomic instability and identified a set of 12 genes that defines the 2 groups. The biological and prognostic significance of this gene set was established through survival prediction in published datasets from patients with breast cancer. Of note, the gene expression signatures that define specific prognostic subtypes in other breast cancer datasets, such as luminal A and B, basal, normal-like, and ERBB2+, and prognostic signatures including MammaPrint and Oncotype DX, predicted genomic instability in our samples. This remarkable congruence suggests a biological interdependence of poor-prognosis gene signatures, breast cancer subtypes, genomic instability, and clinical outcome.",
        "Doc_title":"The gene expression signature of genomic instability in breast cancer is an independent predictor of clinical outcome.",
        "Journal":"International journal of cancer",
        "Do_id":"19101988",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"Adult;Aged;Aged, 80 and over;Breast Neoplasms;Disease-Free Survival;Female;Gene Expression Profiling;Genomic Instability;Humans;Immunohistochemistry;Middle Aged;Oligonucleotide Array Sequence Analysis;Prognosis",
        "Doc_meshqualifiers":"genetics;mortality;pathology",
        "_version_":1605792579192881152},
      {
        "Doc_abstract":"The invasive mammary cancer is the most frequent malignant tumor of women. Different inherited or acquired molecular genetic alterations have been identified in human breast cancers. A fraction of these cancers, as part of their development, undergoes gene amplification. Among the potential prognostic factors are included the biomarkers which measure or are associated with biological processes involved in tumor progression. Evaluation of HER-2 status is important in the management of patients with breast carcinoma, especially for the identification of those who are eligible for immunotherapy. The aim of our study was to evaluate HER-2 amplification status of human breast cancers by FISH and immunohistochemistry. From the total of 50 tumors included in the study, 17 (34%) presented different degrees of positivity; 33 (66%) did not express the oncoprotein HER-2. HER-2 gene and chromosome 17 status were tested in HER-2 2+ cases using FISH technique. FISH analysis may be useful to better evaluate HER-2 status in breast cancer in uncertain cases, where the immunohistochemistry score is 2+. HER-2 testing results have an important role in the clinical management of breast cancer patients. The identification of HER-2 positive tumors is certainly crucial in order to identify patient candidates for anti-HER-2 therapies.",
        "Doc_title":"Amplification of HER-2 gene in breast cancer: immunohistochemical and FISH assessment.",
        "Journal":"Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie",
        "Do_id":"20495751",
        "Doc_ChemicalList":"Receptor, ErbB-2",
        "Doc_meshdescriptors":"Adult;Aged;Aged, 80 and over;Breast Neoplasms;Female;Gene Amplification;Humans;Immunohistochemistry;In Situ Hybridization, Fluorescence;Middle Aged;Receptor, ErbB-2",
        "Doc_meshqualifiers":"enzymology;genetics;pathology;methods;biosynthesis;genetics",
        "_version_":1605746300368715776},
      {
        "Doc_abstract":"Medulloblastoma is frequently disseminated throughout the central nervous system by the time of diagnosis. Conventional therapeutic approaches have not reduced the high mortality associated with metastatic medulloblastoma and little is known regarding the molecular mechanisms that promote tumor invasion. Previously, we reported that overexpression of ERBB2 in medulloblastoma is associated with poor prognosis and metastasis. Here, we demonstrate that ERBB2 overexpression increases the migration of medulloblastoma cells across basement membranes in vitro. Furthermore, using microarray expression profiling, we show that ERBB2 up-regulates the expression of prometastatic genes in medulloblastoma cells. These include S100A4, which was previously shown to promote metastasis of breast cancer. We demonstrate that S100A4 is a direct target of ERBB2 signaling in medulloblastoma cells via a pathway involving phosphatidylinositol 3-kinase, AKT1, and extracellular signal-regulated kinase 1/2 and that levels of ERBB2 and S100A4 are tightly correlated in samples of primary medulloblastoma. Finally, we show that ERBB2-dependent medulloblastoma cell invasion in vitro and prometastatic gene expression in vivo can be blocked using the ERBB tyrosine kinase inhibitor OSI-774. These data identify an ERBB2 driven prometastatic pathway that may provide a novel target for therapeutic intervention in metastatic medulloblastoma.",
        "Doc_title":"ERBB2 up-regulates S100A4 and several other prometastatic genes in medulloblastoma.",
        "Journal":"Cancer research",
        "Do_id":"12517790",
        "Doc_ChemicalList":"Recombinant Proteins;S100 Calcium-Binding Protein A4;S100 Proteins;S100a4 protein, mouse;S100A4 protein, human;Luciferases;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Animals;Brain Stem Neoplasms;Child;Gene Expression Regulation, Neoplastic;Genes, Reporter;Genes, erbB-2;Humans;Luciferases;Medulloblastoma;Mice;Mice, Nude;Neoplasm Invasiveness;Neoplasm Metastasis;Oligonucleotide Array Sequence Analysis;Plasmids;Receptor, ErbB-2;Recombinant Proteins;S100 Calcium-Binding Protein A4;S100 Proteins;Transfection;Transplantation, Heterologous;Tumor Cells, Cultured",
        "Doc_meshqualifiers":"genetics;pathology;genetics;genetics;pathology;genetics;pathology;genetics;metabolism;genetics",
        "_version_":1605742115617243136},
      {
        "Doc_abstract":"Honokiol, an active component isolated and purified from Chinese traditional herb magnolia, was demonstrated to inhibit growth and induce apoptosis of different cancer cell lines such as human leukaemia, colon, and lung cancer cell lines; to attenuate the angiogenic activities of human endothelial cells in vitro; and to efficiently suppress the growth of angiosarcoma in nude mice. In this study, we have demonstrated that treatment of different human breast cancer cell lines with honokiol resulted in a time- and concentration-dependent growth inhibition in both estrogen receptor-positive and -negative breast cancer cell lines, as well as in drug-resistant breast cancer cell lines such as adriamycin-resistant and tamoxifen-resistant cell lines. The inhibition of growth was associated with a G1-phase cell cycle arrest and induction of caspase-dependent apoptosis. The effects of honokiol might be reversely related to the expression level of human epidermal growth receptor 2, (HER-2, also known as erbB2, c-erbB2) since knockdown of her-2 expression by siRNA significantly enhanced the sensitivity of the her-2 over-expressed BT-474 cells to the honokiol-induced apoptosis. Furthermore, inhibition of HER-2 signalling by specific human epidermal growth receptor 1/HER-2 (EGFR/HER-2) kinase inhibitor lapatinib synergistically enhanced the anti-cancer effects of honokiol in her-2 over-expressed breast cancer cells. Finally, we showed that honokiol was able to attenuate the PI3K/Akt/mTOR (Phosphoinositide 3-kinases/Akt/mammalian target of rapamycin) signalling by down-regulation of Akt phosphorylation and upregulation of PTEN (Phosphatase and Tensin homolog deleted on chromosome Ten) expression. Combination of honokiol with the mTOR inhibitor rapamycin presented synergistic effects on induction of apoptosis of breast cancer cells. In conclusion, honokiol, either alone or in combination with other therapeutics, could serve as a new, promising approach for breast cancer treatment.",
        "Doc_title":"Anti-tumor effect of honokiol alone and in combination with other anti-cancer agents in breast cancer.",
        "Journal":"European journal of pharmacology",
        "Do_id":"18588872",
        "Doc_ChemicalList":"Biphenyl Compounds;Lignans;Quinazolines;lapatinib;honokiol;Sirolimus",
        "Doc_meshdescriptors":"Animals;Antineoplastic Combined Chemotherapy Protocols;Apoptosis;Biphenyl Compounds;Breast Neoplasms;Cell Line, Tumor;Dose-Response Relationship, Drug;Drug Resistance, Neoplasm;Drug Screening Assays, Antitumor;Drug Synergism;Female;Gene Expression Regulation, Neoplastic;Humans;Lignans;Magnolia;Medicine, Chinese Traditional;Quinazolines;Signal Transduction;Sirolimus;Time Factors",
        "Doc_meshqualifiers":"administration & dosage;pharmacology;drug effects;administration & dosage;pharmacology;drug therapy;pathology;drug effects;administration & dosage;pharmacology;chemistry;administration & dosage;drug effects;administration & dosage",
        "_version_":1605906979716333568},
      {
        "Doc_abstract":"Amplification and resulting overexpression of the HER-2/ neu proto-oncogene is found in approximately 30% of human breast and 20% of human ovarian cancers. To better understand the molecular events associated with overexpression of this gene in human breast cancer cells, differential hybridization was used to identify genes whose expression levels are altered in cells overexpressing this receptor. Of 16 000 clones screened from an overexpression cell cDNA library, a total of 19 non-redundant clones were isolated including seven whose expression decreases (C clones) and 12 which increase (H clones) in association with HER-2/ neu overexpression. Of these, five C clones and 11 H clones have been confirmed to be differentially expressed by northern blot analysis. This group includes nine genes of known function, three previously sequenced genes of relatively uncharacterized function and four novel genes without a match in GenBank. Examination of the previously characterized genes indicates that they represent sequences known to be frequently associated with the malignant phenotype, suggesting that the subtraction cloning strategy used identified appropriate target genes. In addition, differential expression of 12 of 16 (75%) cDNAs identified in the breast cancer cell lines are also seen in HER-2/ neu -overexpressing ovarian cancer cells, indicating that they represent generic associations with HER-2/ neu overexpression. Finally, up-regulation of two of the identified cDNAs, one novel and one identified but as yet uncharacterized gene, was confirmed in human breast cancer specimens in association with HER-2/ neu overexpression. Further characterization of these genes may yield insight into the fundamental biology and pathogenetic effects of HER-2/ neu overexpression in human breast and ovarian cancer cells.",
        "Doc_title":"Identification of differentially expressed genes associated with HER-2/neu overexpression in human breast cancer cells.",
        "Journal":"Nucleic acids research",
        "Do_id":"10497265",
        "Doc_ChemicalList":"Receptor, ErbB-2",
        "Doc_meshdescriptors":"Amino Acid Sequence;Blotting, Northern;Breast Neoplasms;Female;Gene Amplification;Gene Expression Regulation, Neoplastic;Humans;Molecular Sequence Data;Ovarian Neoplasms;Phenotype;Receptor, ErbB-2;Tumor Cells, Cultured",
        "Doc_meshqualifiers":"genetics;metabolism;genetics;metabolism;biosynthesis;genetics",
        "_version_":1605796798113251328},
      {
        "Doc_abstract":"The molecular mechanisms governing breast tumor cellular self-renewal contribute to breast cancer progression and therapeutic resistance. The ErbB2 oncogene is overexpressed in approximately 30% of human breast cancers. c-Jun, the first cellular proto-oncogene, is overexpressed in human breast cancer. However, the role of endogenous c-Jun in mammary tumor progression is unknown. Herein, transgenic mice expressing the mammary gland-targeted ErbB2 oncogene were crossed with c-jun(f/f) transgenic mice to determine the role of endogenous c-Jun in mammary tumor invasion and stem cell function. The excision of c-jun by Cre recombinase reduced cellular migration, invasion, and mammosphere formation of ErbB2-induced mammary tumors. Proteomic analysis identified a subset of secreted proteins (stem cell factor (SCF) and CCL5) induced by ErbB2 expression that were dependent upon endogenous c-Jun expression. SCF and CCL5 were identified as transcriptionally induced by c-Jun. CCL5 rescued the c-Jun-deficient breast tumor cellular invasion phenotype. SCF rescued the c-Jun-deficient mammosphere production. Endogenous c-Jun thus contributes to ErbB2-induced mammary tumor cell invasion and self-renewal.",
        "Doc_title":"c-Jun induces mammary epithelial cellular invasion and breast cancer stem cell expansion.",
        "Journal":"The Journal of biological chemistry",
        "Do_id":"20053993",
        "Doc_ChemicalList":"CCL5 protein, human;Chemokine CCL5;Proto-Oncogene Proteins c-jun;Stem Cell Factor;ERBB2 protein, human;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Animals;Breast Neoplasms;Cell Division;Cell Line, Tumor;Cell Movement;Chemokine CCL5;Epithelial Cells;Female;Gene Expression Regulation, Neoplastic;Humans;Mice;Mice, Transgenic;Neoplasm Invasiveness;Phenotype;Proto-Oncogene Proteins c-jun;Receptor, ErbB-2;Stem Cell Factor",
        "Doc_meshqualifiers":"genetics;pathology;physiopathology;physiology;physiology;metabolism;pathology;physiology;pathology;physiopathology;genetics;metabolism;genetics;metabolism;metabolism",
        "_version_":1605898255721299968},
      {
        "Doc_abstract":"Human ERBB2 is a proto-oncogene that codes for the erbB-2 epithelial growth factor receptor. In human breast cancer (HBC), erbB-2 protein overexpression has been repeatedly correlated with poor prognosis. In more recent works, underexpression of this gene has been described in HBC. Moreover, it is also recognised that oncogenes that are commonly amplified or deleted encompass point mutations, and some of these are associated with HBC. In cat mammary lesions (CMLs), the overexpression of ERBB2 (27%-59.6%) has also been described, mostly at the protein level and although cat mammary neoplasias are considered to be a natural model of HBC, molecular information is still scarce. In the present work, a cat ERBB2 fragment, comprising exons 10 to 15 (ERBB2_10-15) was achieved for the first time. Allelic variants and genomic haplotype analyses were also performed, and differences between normal and CML populations were observed. Three amino acid changes, corresponding to 3 non-synonymous genomic sequence variants that were only detected in CMLs, were proposed to damage the 3D structure of the protein. We analysed the cat ERBB2 gene at the DNA (copy number determination), mRNA (expression levels assessment) and protein levels (in extra- and intra protein domains) in CML samples and correlated the last two evaluations with clinicopathological features. We found a positive correlation between the expression levels of the ERBB2 RNA and erbB-2 protein, corresponding to the intracellular region. Additionally, we detected a positive correlation between higher mRNA expression and better clinical outcome. Our results suggest that the ERBB2 gene is post-transcriptionally regulated and that proteins with truncations and single point mutations are present in cat mammary neoplastic lesions. We would like to emphasise that the recurrent occurrence of low erbB-2 expression levels in cat mammary tumours, suggests the cat mammary neoplasias as a valuable model for erbB-2 negative HBC. ",
        "Doc_title":"ERBB2 in cat mammary neoplasias disclosed a positive correlation between RNA and protein low expression levels: a model for erbB-2 negative human breast cancer.",
        "Journal":"PloS one",
        "Do_id":"24386251",
        "Doc_ChemicalList":"Proteins;RNA",
        "Doc_meshdescriptors":"Animals;Breast Neoplasms;Cats;Disease Models, Animal;Female;Gene Expression;Genes, erbB-2;Genetic Variation;Molecular Sequence Data;Proteins;RNA",
        "Doc_meshqualifiers":"genetics;metabolism;pathology;metabolism;genetics",
        "_version_":1605818726184124416},
      {
        "Doc_abstract":"Genomic studies have shown that large numbers of candidate targets are observed in breast cancer. Nevertheless, only a few of them are validated as relevant targets in clinical studies. Estrogen receptor (ER) and HER2 expressions could be associated with a level I evidence. Beyond ER and HER2, BRCA and PIK3CA mutations (when targeted with alpha-specific PI3K inhibitors) could be considered as promising targets in breast cancer since they have been associated with objective responses in phase I/II trials. In addition to these four molecular alterations, several others have shown promising results in preclinical studies and are being investigated in clinical trials. These genomic alterations include AKT1, ERBB2, and ESR1 mutations. These considerations highlight the lack of evidence for using multiplex technologies to individualize therapy in metastatic breast cancer. Sequencing multiple genes to treat metastatic breast cancer is very promising but should be done in the context of clinical trials, either to enrich phase I/II trials in patients with genomic alterations or to show medical usefulness of new biotechnologies like next-generation sequencing (NGS). Although most current approaches of precision medicine are aiming at targeting drivers, additional applications could be developed in the future. This includes the identification of DNA repair deficiencies, mechanisms of immune suppression, and identification of minority lethal subclones. Finally, one of the very promising applications of genomics for metastatic breast cancer is the identification of pathway activation or defects at the individual level. For example, gene expression and single nucleotide polymorphisms (SNP) signatures are being developed to detect kinase (such as mammalian target of rapamycin [mTOR]/CDK4) activations or DNA repair deficiencies. ",
        "Doc_title":"Precision medicine for metastatic breast cancer.",
        "Journal":"American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Meeting",
        "Do_id":"25993174",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"Breast Neoplasms;Female;Genomics;Humans;Neoplasm Metastasis;Precision Medicine",
        "Doc_meshqualifiers":"drug therapy;genetics;pathology",
        "_version_":1605752211655098368},
      {
        "Doc_abstract":"The recombinant humanized anti-ErbB2/HER2 monoclonal antibody Herceptin (Trastuzumab) has been shown to significantly enhance the tumoricidaleffects of antitumor drugs such as paclitaxel (Taxol) in patients with ErbB2-overexpressing breast cancers. Here, we investigated the molecular mechanisms by which Herceptin enhances the antitumor effects of Taxol. Because activation of p34(Cdc2) is required for Taxol-induced apoptosis and because overexpression of ErbB2 blocks Taxol-induced apoptosis by inhibiting p34(Cdc2) activation, we studied the effect of Herceptin treatment on p34(Cdc2) kinase activation and apoptosis in Taxol-treated human breast carcinoma cell lines MDA-MB-435, SKBr3, MDA-MB-453, and 435.eB, which is an ErbB2 transfectant of MDA-MB-435. Herceptin treatment down-regulated ErbB2, reduced the inhibitory phosphorylation of Cdc2 on Tyr-15, and down-regulated the expression of p21(Cip1), a Cdc2 inhibitor. Herceptin plus Taxol treatment led to higher levels of p34(Cdc2) kinase activity and apoptosis in ErbB2-overexpressing breast cancer cells, which is likely attributable to inhibition of Cdc2-Tyr-15 phosphorylation and p21(Cip1) expression. Because significant dephosphorylation of Cdc2-Tyr-15 and down-regulation of p21(Cip1) occur at least 24 h after Herceptin treatment, we investigated whether 24 h Herceptin pretreatment will render ErbB2-overexpressing breast cancer cells more sensitive to Taxol-induced apoptosis compared with the simultaneous treatment of Herceptin plus Taxol. Indeed, Herceptin pretreatment increased Taxol-induced apoptosis and cytotoxicity in vitro and more effectively inhibited the growth of tumor xenografts with enhanced in vivo apoptosis. Thus, Herceptin treatment of ErbB2-overexpressing cells can inhibit ErbB2-mediated Cdc2-Tyr-15 phosphorylation and p21(Cip1) up-regulation, which allows effective p34(Cdc2) activation and induction of apoptosis upon Taxol treatment. Herceptin pretreatment renders ErbB2-overexpressing breast cancers more susceptible to Taxol-induced cell death, which may have important clinical therapeutic implications.",
        "Doc_title":"Enhanced sensitization to taxol-induced apoptosis by herceptin pretreatment in ErbB2-overexpressing breast cancer cells.",
        "Journal":"Cancer research",
        "Do_id":"12384528",
        "Doc_ChemicalList":"Antibodies, Monoclonal;Antibodies, Monoclonal, Humanized;CDKN1A protein, human;Cdkn1a protein, mouse;Cyclin-Dependent Kinase Inhibitor p21;Cyclins;Receptor, ErbB-2;CDC2 Protein Kinase;Trastuzumab;Paclitaxel",
        "Doc_meshdescriptors":"Animals;Antibodies, Monoclonal;Antibodies, Monoclonal, Humanized;Antineoplastic Combined Chemotherapy Protocols;Apoptosis;Breast Neoplasms;CDC2 Protein Kinase;Cell Division;Cyclin-Dependent Kinase Inhibitor p21;Cyclins;Down-Regulation;Drug Synergism;Enzyme Activation;Female;Humans;Mice;Mice, Inbred ICR;Mice, SCID;Paclitaxel;Phosphorylation;Receptor, ErbB-2;Trastuzumab;Tumor Cells, Cultured;Xenograft Model Antitumor Assays",
        "Doc_meshqualifiers":"administration & dosage;pharmacology;drug effects;drug therapy;metabolism;pathology;metabolism;drug effects;antagonists & inhibitors;biosynthesis;drug effects;drug effects;administration & dosage;biosynthesis",
        "_version_":1605822531799875584},
      {
        "Doc_abstract":"Overexpression of the HER2/neu oncogene is a frequent molecular event in multiple human cancers. Being a cancer antigen, p185(erbB2) is an ideal target for immunotherapy. In order to decrease the immunogenicity of mouse anti-p185(erbB2) monoclonal antibody in human cancer therapy, we constructed the eukaryotic expression vector of anti-p185(erbB2) chimeric monoclonal antibody and verified expression of the chimeric antibody in CHO-dhfr(-) cell.;The variable regions of light chain and heavy chain were amplified with RT-PCR and inserted into the chimeric antibody vector pWSD2. After CHO-dhfr(-) cells were transfected with recombination plasmid by lipofectAMINE, the chimeric antibody expressing level was identified with RT-PCR, indirect-ELISA, and Western blot. The specificity of the anti-p185(erbB2) chimeric antibody was testified with ELISA assay and immunoprecipitation. Moreover, the effects of chimeric antibody on the proliferation of breast cancer cell line SKBR3, which is overexpressing p185(erbB2), were measured with MTT assay in vitro.;The anti-p185(erbB2) chimeric antibody eukaryotic expression vector was constructed successfully and the expression of the chimeric antibody in CHO-dhfr(-) was verified by RT-PCR, indirect-ELISA, and Western blot. ELISA assay showed that chimeric antibody reacted with cells overexpressing p185(erbB2) specifically, but did not react with that non-overexpressing p185(erbB2). Immunoprecipitation test confirmed that the chimeric antibody could bind to p185(erbB2) specifically. The MTT assay demonstrated that the chimeric antibody could inhibit the growth of SKBR3 cells overexpressing p185(erbB2) .;The anti-p185(erbB2) mouse/human chimeric antibody that was expressed in CHO-dhfr(-) cells can bind to p185(erbB2) specifically and inhibit proliferation of SKBR3 cells overexpressing p185(erbB2) . It has a potential application in biotherapy of cancer.",
        "Doc_title":"[Eukaryotic expression and biological activities of anti-p185 erbB2 mouse/human chimeric antibody].",
        "Journal":"Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences",
        "Do_id":"15489929",
        "Doc_ChemicalList":"Antibodies, Monoclonal;Recombinant Fusion Proteins;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Animals;Antibodies, Monoclonal;CHO Cells;Cricetinae;Cricetulus;Enzyme-Linked Immunosorbent Assay;Eukaryotic Cells;Humans;Immunoprecipitation;Mice;Receptor, ErbB-2;Recombinant Fusion Proteins;Reverse Transcriptase Polymerase Chain Reaction;Transfection",
        "Doc_meshqualifiers":"biosynthesis;genetics;metabolism;biosynthesis;genetics;immunology;biosynthesis;genetics;immunology;methods",
        "_version_":1605909371139653632},
      {
        "Doc_abstract":"Transcriptional activation by estrogen receptor (ER) is a key step to breast oncogenesis. Given previous findings that ADA3 is a critical component of HAT complexes that regulate ER function and evidence that overexpression of other ER coactivators such as SRC-3 is associated with clinical outcomes in breast cancer, the current study was designed to assess the potential significance of ADA3 expression/localization in human breast cancer patients. In this study, we analyzed ADA3 expression in breast cancer tissue specimens and assessed the correlation of ADA3 staining with cancer progression and patient outcome. Tissue microarrays prepared from large series of breast cancer patients with long-term follow-ups were stained with anti-ADA3 monoclonal antibody using immunohistochemistry. Samples were analyzed for ADA3 expression followed by correlation with various clinicopathological parameters and patients' outcomes. We report that breast cancer specimens show predominant nuclear, cytoplasmic, or mixed nuclearÂ +Â cytoplasmic ADA3 staining patterns. Predominant nuclear ADA3 staining correlated with ER+ status. While predominant cytoplasmic ADA3 staining negatively correlated with ER+ status, but positively correlated with ErbB2, EGFR, and Ki67. Furthermore, a positive correlation of cytoplasmic ADA3 was observed with higher histological grade, mitotic counts, Nottingham Prognostic Index, and positive vascular invasion. Patients with nuclear ADA3 and ER positivity have better breast cancer specific survival and distant metastasis free survival. Significantly, cytoplasmic expression of ADA3 showed a strong positive association with reduced BCSS and DMFS in ErbB2+/EGFR+ patients. Although in multivariate analyses ADA3 expression was not an independent marker of survival, predominant nuclear ADA3 staining in breast cancer tissues correlates with ER+ expression and together serves as a marker of good prognosis, whereas predominant cytoplasmic ADA3 expression correlates with ErbB2+/EGFR+ expression and together is a marker of poor prognosis. Thus, ADA3 cytoplasmic localization together with ErbB2+/EGFR+ status may serve as better prognostic marker than individual proteins to predict survival of patients.",
        "Doc_title":"Cytoplasmic localization of alteration/deficiency in activation 3 (ADA3) predicts poor clinical outcome in breast cancer patients.",
        "Journal":"Breast cancer research and treatment",
        "Do_id":"23288344",
        "Doc_ChemicalList":"Biomarkers, Tumor;TADA3 protein, human;Transcription Factors",
        "Doc_meshdescriptors":"Adolescent;Adult;Aged;Biomarkers, Tumor;Breast Neoplasms;Cell Nucleus;Cytoplasm;Female;Humans;Immunohistochemistry;Middle Aged;Neoplasm Staging;Prognosis;Protein Transport;Reproducibility of Results;Sensitivity and Specificity;Transcription Factors;Tumor Burden;Young Adult",
        "Doc_meshqualifiers":"metabolism;metabolism;mortality;pathology;metabolism;metabolism;metabolism",
        "_version_":1605903966355324928},
      {
        "Doc_abstract":"Administration of drugs targeting HER2 (official symbol ERBB2) is an important component of therapy for breast cancer patients with HER2 amplification/overexpression as determined by in situ hybridization (ISH) and immunohistochemistry (IHC). In approximately 5% of breast cancers, ISH assays fail. In these cases, HER2 protein expression is evaluated by IHC alone that may yield false negatives/positives for poor-quality samples. Therefore, we developed a method that was based on quantitative real-time PCR applicable for DNA from formalin-fixed, paraffin-embedded tissue samples. Its limit of detection was determined with breast cancer cell lines and validated with 223 breast cancer patient samples. On the basis of comparisons with fluorescent ISH (FISH) and IHC data, the sensitivity of the new method was 94.2% and 95.1%, its specificity was 100% and 99.1%, and overall concordance between results obtained with the quantitative real-time PCR method and FISH/IHC was 97.6% for both methods. The quantitative real-time PCR method was then used to evaluate the HER2 status of 198 of 3696 breast cancer tissues that yielded indeterminate FISH results. The HER2 copy number was successfully determined in 69.2% of these indeterminate samples. Thus, the DNA-based technique appears to be a specific, sensitive method for determining HER2 copy numbers when the FISH assay fails, which may complement IHC tests. ",
        "Doc_title":"Evaluation of HER2 Gene Status in Breast Cancer Samples with Indeterminate Fluorescence in Situ Hybridization by Quantitative Real-Time PCR.",
        "Journal":"The Journal of molecular diagnostics : JMD",
        "Do_id":"25956448",
        "Doc_ChemicalList":"Biomarkers, Tumor;Formaldehyde;ERBB2 protein, human;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Biomarkers, Tumor;Breast Neoplasms;Female;Formaldehyde;Gene Amplification;Gene Expression Regulation, Neoplastic;Humans;Immunoenzyme Techniques;In Situ Hybridization, Fluorescence;Paraffin Embedding;Real-Time Polymerase Chain Reaction;Receptor, ErbB-2;Retrospective Studies;Tumor Cells, Cultured",
        "Doc_meshqualifiers":"analysis;genetics;metabolism;pathology;chemistry;methods;methods;methods;genetics;metabolism",
        "_version_":1605836133364662272},
      {
        "Doc_abstract":"To investigate changes in gene expression associated with ERBB2, expression profiling of immortalized human mammary luminal epithelial cells and variants expressing a moderate and high level of ERBB2 has been carried out using cDNA microarrays corresponding to approximately 6000 unique genes/ESTs. A total of 61 significantly up- or downregulated (2.0-fold) genes were identified and further validated by RT-PCR analysis as well as microarray comparisons with a spontaneously ERBB2- overexpressing breast cancer cell line and ERBB2-positive primary breast tumors. The expression and clinical relevance of proteins predicted to be associated with ERBB2 overexpression in breast cancers were analysed together with their clinical relevance by antibody screening using a tissue array. Differentially regulated genes include those involved in cell-matrix interactions including proline 4-hydroxylase (P4HA2), galectin 1 (LGALS1) and galectin 3 (LGALS3), fibronectin 1 (FN1) and p-cadherin (CDH3), and cell proliferation (CRIP1, IGFBP3) and transformation (S100P, S100A4). A number of genes associated with MYC signalling were also differentially expressed, including NDRG1, USF2 and the epithelial membrane proteins 1 and 3 (EMP1, EMP3). These data represent profiles of the transcriptional changes associated with ERBB2-related pathways in the breast, and identify novel and potentially useful targets for prognosis and therapy.",
        "Doc_title":"cDNA microarray analysis of genes associated with ERBB2 (HER2/neu) overexpression in human mammary luminal epithelial cells.",
        "Journal":"Oncogene",
        "Do_id":"12730682",
        "Doc_ChemicalList":"Receptor, ErbB-2",
        "Doc_meshdescriptors":"Breast;Breast Neoplasms;Carcinoma;Epithelium;Female;Gene Expression Profiling;Humans;In Vitro Techniques;Oligonucleotide Array Sequence Analysis;Receptor, ErbB-2;Reverse Transcriptase Polymerase Chain Reaction;Tumor Cells, Cultured",
        "Doc_meshqualifiers":"metabolism;metabolism;metabolism;metabolism;biosynthesis;genetics",
        "_version_":1605813079545741312},
      {
        "Doc_abstract":"Cyclin D1 plays an important role in the regulation of the G1 phase in the cell cycle. In mammary epithelial cells the expression of cyclin D1 is regulated through the oestrogen receptor and via ErbB2 signalling. Here we investigated the prognostic significance of cyclin D1 among 230 breast cancer patients randomised for tamoxifen, CMF chemotherapy and radiotherapy. The importance of combined cyclin D1 and ErbB2 overexpression was also analysed. Immunohistochemical analysis of the cyclin D1 expression resulted in 69 (29.8%) weakly positive, 107 (46.5%) moderately positive and 54 (23.7%) strongly positive cases. The prognostic importance of ErbB2 was significantly greater for patients whose tumours overexpressed cyclin D1 than for other patients (p = 0.026). In the former group, ErbB2 overexpression was strongly associated with increased risk of recurrence (RR = 4.7; 95% CI, 2.1-10.4) and breast cancer death (RR = 5.4; 95% CI, 2.3-12.6). This result is in accordance with experimental studies demonstrating a link between cyclin D1 and ErbB2 in oncogenesis. Among oestrogen receptor positive patients, those with moderate cyclin D1 expression significantly did benefit from tamoxifen treatment (RR = 0.42; 95% CI, 0.21-0.82) whereas those with weak or strong expression did not. Therefore cyclin D1 might be a predictive marker for tamoxifen resistance.",
        "Doc_title":"Role of cyclin D1 in ErbB2-positive breast cancer and tamoxifen resistance.",
        "Journal":"Breast cancer research and treatment",
        "Do_id":"15868442",
        "Doc_ChemicalList":"Antineoplastic Agents, Hormonal;Biomarkers;Tamoxifen;Cyclin D1",
        "Doc_meshdescriptors":"Antineoplastic Agents, Hormonal;Biomarkers;Breast Neoplasms;Cyclin D1;Disease-Free Survival;Drug Resistance, Neoplasm;Female;Genes, erbB-2;Humans;Neoplasm Recurrence, Local;Prognosis;Proportional Hazards Models;Survival Rate;Sweden;Tamoxifen",
        "Doc_meshqualifiers":"pharmacology;drug therapy;epidemiology;mortality;physiopathology;metabolism;epidemiology;epidemiology;pharmacology",
        "_version_":1605764541130473472},
      {
        "Doc_abstract":"Statins are cholesterol-lowering drugs with pleiotropic activities including inhibition of isoprenylation reactions and reduction of signals driving cell proliferation and survival responses. The objectives of this study were to examine the effects of statins on breast cancer cells, both in vitro and in vivo, and to begin to determine their mechanism of action. We evaluated the effects of statins on breast cancer cell growth, phosphoprotein signaling intermediates, survival/apoptosis regulators, cell cycle regulators, and activated transcription factors. We also examined the in vivo effect of statin administration in a mouse ErbB2(+) breast cancer model. Only lipophilic statins had direct anticancer activity in vitro. Breast cancer cells with activated Ras or ErbB2 pathways seemed to be more sensitive than those overexpressing estrogen receptor, and this correlated with endogenous levels of activated nuclear factor kappaB (NF-kappaB). Key intermediates regulating cell survival by NF-kappaB activation, as well as cell proliferation by the mitogen activated protein kinase cascade, were among the earliest phosphoproteins influenced by statin treatment. These early effects were followed by declines in activator protein-1 and NF-kappaB activation and concordant changes in other mediators of proliferation and apoptosis. In vivo results showed that oral dosing of statins significantly inhibited the growth of a mouse mammary carcinoma. Lipophilic statins can exert direct anticancer activity in vitro by reducing proliferation and survival signals in susceptible breast cancer phenotypes. Tumor growth inhibition in vivo using a clinically relevant statin dose also seems to be associated with reduced tumor cell proliferation and survival. These findings provide supporting rationale for future statin trials in breast cancer patients.",
        "Doc_title":"Breast cancer growth prevention by statins.",
        "Journal":"Cancer research",
        "Do_id":"16951186",
        "Doc_ChemicalList":"Antineoplastic Agents;DNA, Neoplasm;Hydroxymethylglutaryl-CoA Reductase Inhibitors;NF-kappa B",
        "Doc_meshdescriptors":"Antineoplastic Agents;Breast Neoplasms;Cell Division;Cell Line, Tumor;DNA, Neoplasm;Female;Humans;Hydroxymethylglutaryl-CoA Reductase Inhibitors;NF-kappa B;Nucleic Acid Conformation",
        "Doc_meshqualifiers":"pharmacology;drug therapy;pathology;prevention & control;drug effects;chemistry;drug effects;pharmacology;metabolism",
        "_version_":1605765629019684864},
      {
        "Doc_abstract":"To retrospectively evaluate the mammographic imaging findings and pathologic changes of the so-called \"triple-negative\" breast cancer (ER(-)/PR(-)/HER-2(-) breast cancer), and to compare them with the ER(+)/PR(+)/HER-2(-) and ER(-)/PR(-)/HER-2(+) breast cancer patients.;Five hundred cases of breast cancer treated in Cancer Institute and Hospital of Tianjin University from January to June of 2010 were included in this study. There were 112 cases of triple-negative breast cancer, 310 cases of ER(+)/PR(+)/HER-2(-) breast cancer, and 78 cases of ER(-)/PR(-)/HER-2(+) breast cancer. Their pathological and mammographic data were reviewed and analyzed. The pathological and mammographic features of the three groups were compared.;Compared with the ER(+)/PR(+)/HER-2(-) breast cancer group, the triple-negative group had a higher histological grade (P < 0.001). Compared with the ER(+)/PR(+)/HER-2(-) and ER(-)/PR(-)/HER-2(+) groups, the triple-negative group was more likely to have a tumor mass (simple mass accounted for 58.0%, and tumor mass with calcification accounted for 19.6%). Moreover, compared with the ER(+)/PR(+)/HER-2(-) group (47.1% vs. 9.8%, P = 0.032)and the ER(-)/PR(-)/HER-2(+) group (47.1% vs. 0, P = 0.028), the tumor mass of triple-negative cancer was more likely to have a smooth margin. Triple-negative breast cancer seldom represented as calcification (simple calcification only accounted for 13.4%, and a mass with calcification accounted for 19.6%), and most of them were benign calcification (70.3%), significantly higher than that in the ER(+)/PR(+)/HER-2(-) group (23.1%, P = 0.002) and ER(-)/PR(-)/HER-2(+) group (10.2%, P < 0.001).;Different types of breast cancer have different biological characteristics and mammographic features. Analysis of the mammographic features may help us to predict the type of breast cancer and its prognosis, and to select an optimal treatment plan for patients with different types of breast cancer.",
        "Doc_title":"[Mammographic and pathological features of triple-negative breast cancer].",
        "Journal":"Zhonghua zhong liu za zhi [Chinese journal of oncology]",
        "Do_id":"22781043",
        "Doc_ChemicalList":"Receptors, Estrogen;Receptors, Progesterone;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Adult;Aged;Aged, 80 and over;Breast Neoplasms;Carcinoma, Ductal, Breast;Female;Humans;Lymphatic Metastasis;Mammography;Middle Aged;Neoplasm Grading;Receptor, ErbB-2;Receptors, Estrogen;Receptors, Progesterone;Retrospective Studies",
        "Doc_meshqualifiers":"diagnostic imaging;metabolism;pathology;diagnostic imaging;pathology;metabolism;metabolism;metabolism",
        "_version_":1605881188936843264},
      {
        "Doc_abstract":"Cancer cells induce a set of adaptive response pathways to survive in the face of stressors due to inadequate vascularization. One such adaptive pathway is the unfolded protein (UPR) or endoplasmic reticulum (ER) stress response mediated in part by the ER-localized transmembrane sensor IRE1 (ref. 2) and its substrate XBP1 (ref. 3). Previous studies report UPR activation in various human tumours, but the role of XBP1 in cancer progression in mammary epithelial cells is largely unknown. Triple-negative breast cancer (TNBC)--a form of breast cancer in which tumour cells do not express the genes for oestrogen receptor, progesterone receptor and HER2 (also called ERBB2 or NEU)--is a highly aggressive malignancy with limited treatment options. Here we report that XBP1 is activated in TNBC and has a pivotal role in the tumorigenicity and progression of this human breast cancer subtype. In breast cancer cell line models, depletion of XBP1 inhibited tumour growth and tumour relapse and reduced the CD44(high)CD24(low) population. Hypoxia-inducing factor 1Î± (HIF1Î±) is known to be hyperactivated in TNBCs. Genome-wide mapping of the XBP1 transcriptional regulatory network revealed that XBP1 drives TNBC tumorigenicity by assembling a transcriptional complex with HIF1Î± that regulates the expression of HIF1Î± targets via the recruitment of RNA polymerase II. Analysis of independent cohorts of patients with TNBC revealed a specific XBP1 gene expression signature that was highly correlated with HIF1Î± and hypoxia-driven signatures and that strongly associated with poor prognosis. Our findings reveal a key function for the XBP1 branch of the UPR in TNBC and indicate that targeting this pathway may offer alternative treatment strategies for this aggressive subtype of breast cancer.",
        "Doc_title":"XBP1 promotes triple-negative breast cancer by controlling the HIF1Î± pathway.",
        "Journal":"Nature",
        "Do_id":"24670641",
        "Doc_ChemicalList":"Antigens, CD24;Antigens, CD44;DNA-Binding Proteins;HIF1A protein, human;Hypoxia-Inducible Factor 1, alpha Subunit;Regulatory Factor X Transcription Factors;Transcription Factors;X-Box Binding Protein 1;XBP1 protein, human;Xbp1 protein, mouse;RNA Polymerase II",
        "Doc_meshdescriptors":"Animals;Antigens, CD24;Antigens, CD44;Cell Hypoxia;Cell Line, Tumor;Cell Proliferation;DNA-Binding Proteins;Disease Progression;Female;Gene Expression Regulation, Neoplastic;Gene Regulatory Networks;Gene Silencing;Humans;Hypoxia-Inducible Factor 1, alpha Subunit;Mice;Neoplasm Invasiveness;Neoplasm Recurrence, Local;Prognosis;RNA Polymerase II;Regulatory Factor X Transcription Factors;Transcription Factors;Transcription, Genetic;Triple Negative Breast Neoplasms;Unfolded Protein Response;X-Box Binding Protein 1",
        "Doc_meshqualifiers":"metabolism;metabolism;genetics;deficiency;genetics;metabolism;metabolism;metabolism;deficiency;genetics;metabolism;blood supply;genetics;metabolism;pathology",
        "_version_":1605852461946372096},
      {
        "Doc_abstract":"Breast cancer is a heterogeneous disease with molecular subtypes that have biological distinctness and different behavior. They are classified into luminal A, luminal B, Her-2 and triple negative/basal-like molecular subtypes. Most of breast cancers reported in Indonesia are already large size, with high grade or late stage but the clinicopathological features of different molecular subtypes are still unclear. They need to be better clarified to determine proper treatment and prognosis.;To elaborate the clinicopathological features of molecular subtypes of breast cancers in Indonesian women.;A retrospective cross-sectional study of 84 paraffin-embedded tissues of breast cancer samples from Dr. Sardjito General Hospital in Central Java, Indonesia was performed. Expression of ER, PR, Her-2 and Ki-67 was analyzed to classify molecular subtypes of breast cancer by immunohistochemistry. The relation of clinicopathological features of breast cancers with molecular subtypes of luminal A, luminal B, Her-2 and triple negative/basal-like were analyzed using Pearson's Chi-Square test. A p-value of <0.05 was considered statistically significant.;Case frequency of luminal A, Luminal B, Her-2+ and triple negative/basal-like subtypes were 38.1%, 16.7%, 20.2% and 25%, respectively. Significant difference was found in breast cancer molecular subtypes in regard to age, histological grade, lymph node status and staging. However it showed insignificant result in regard to tumor size. Luminal A subtype of breast cancer was commonly found in >50 years old women (p:0.028), low grade cancer (p:0.09), negative lymph node metastasis (p:0.034) and stage III (p:0.017). Eventhough the difference was insignificant, luminal A subtype breast cancer was mostly found in small size breast cancer (p:0.129). Her-2+ subtype breast cancer was more commonly diagnosed with large size, positive lymph node metastasis and poor grade. Triple negative/basal-like cancer was mostly diagnosed among <50 years old women.;This study suggests that immunohistochemistry-based subtyping is essential to classify breast carcinoma into subtypes that vary in clinicopathological features, implying different therapeutic options and prognosis for each subtype.",
        "Doc_title":"Clinicopathological features of indonesian breast cancers with different molecular subtypes.",
        "Journal":"Asian Pacific journal of cancer prevention : APJCP",
        "Do_id":"25124582",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605884407520952320},
      {
        "Doc_abstract":"Despite the ongoing \"war on cancer,\" cancer remains one of the major causes of human morbidity and mortality. A new paradigm of targeted therapies holds the most promise for the future, making identification of tumor-specific therapeutic targets of prime importance. ERBB2/HER2, best known for its role in breast cancer tumorigenesis, can be targeted by two types of pharmacological manipulation: antibody therapy against the extracellular receptor domain and small molecule compounds against the intracellular tyrosine kinase domain. Aberrant activation of ERBB2 by gene amplification has been shown to participate in the pathophysiology of breast, ovarian, gastric, colorectal, lung, brain, and head and neck tumors. However, the advent of next-generation sequencing technologies has enabled efficient identification of activating molecular alterations of ERBB2. In this review, we will focus on the functional role of these somatic mutations that cause ERBB2 receptor activation. We will additionally discuss the current preclinical and clinical therapeutic strategies for targeting mutationally activated ERBB2.",
        "Doc_title":"Activating Mutations in ERBB2 and Their Impact on Diagnostics and Treatment.",
        "Journal":"Frontiers in oncology",
        "Do_id":"23630663",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605746801129816064},
      {
        "Doc_abstract":"The ERBB2 gene is overexpressed in 30% of human breast cancers and this is correlated with poor prognosis. Overexpression of the ERBB2 gene is due to increased transcription and gene amplification. Our previous studies have identified a new cis element in the ERBB2 promoter which is involved in the gene's overexpression. This cis element, located 501 bp upstream from the main ERBB2 transcription initiation site, binds a transcription factor called HTF (HER2 transcription factor). We report here the identification of HTF as an AP-2 (activator protein-2) transcription factor. The new cis element is bound by AP-2 with high affinity, compared with a previously described AP-2 binding site located 284 bp downstream. Co-transfection of an AP-2alpha expression vector with a reporter vector containing the newly identified AP-2 binding site in front of a minimal ERBB2 promoter induced a dose-dependent increase in transcriptional activity. We examined the contribution of the new AP-2 binding site to ERBB2 overexpression. For this purpose we abolished the new and/or the previously described AP-2 binding sequence by site-directed mutagenesis. The results show that the two functional AP-2 sites in the first 700 bp of the ERBB2 promoter co-operate to achieve maximal transcriptional activity.",
        "Doc_title":"Identification of HTF (HER2 transcription factor) as an AP-2 (activator protein-2) transcription factor and contribution of the HTF binding site to ERBB2 gene overexpression.",
        "Journal":"The Biochemical journal",
        "Do_id":"12418962",
        "Doc_ChemicalList":"DNA Primers;DNA-Binding Proteins;TFAP2A protein, human;Transcription Factor AP-2;Transcription Factors;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Base Sequence;Binding Sites;DNA Primers;DNA-Binding Proteins;Humans;Mutagenesis, Site-Directed;Promoter Regions, Genetic;Receptor, ErbB-2;Sequence Homology, Nucleic Acid;Transcription Factor AP-2;Transcription Factors;Tumor Cells, Cultured",
        "Doc_meshqualifiers":"metabolism;genetics;metabolism;metabolism",
        "_version_":1605792239003369472},
      {
        "Doc_abstract":"The etiology of breast cancer involves a complex interplay of various factors, including genetic alterations. Many studies have been devoted to the identification and characterization of mutations that occur frequently during breast tumorigenesis. The major types of genetic abnormalities that are frequently observed in breast tumors are amplification of protooncogenes (MYC, ERBB2) and DNA from chromosome band 11q13; mutation of TP53; and loss of heterozygosity from chromosomes and chromosome arms 1, 3p, 6q, 7q, 8p, 11, 13q, 16q, 17, 18q, and 22q. The latter may correspond to losses or inactivations of tumor suppressor genes. Recently, linkage analyses of large families with a predisposition to breast cancer have been performed in order to map breast cancer susceptibility genes (TP53, BRCA1, BRCA2). The findings have thrown light on the molecular mechanisms of breast cancer and have enabled various genetic markers to be used in clinical oncology.",
        "Doc_title":"Genetic alterations in breast cancer.",
        "Journal":"Genes, chromosomes & cancer",
        "Do_id":"8605112",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"Breast Neoplasms;Carcinoma;Chromosome Aberrations;Chromosomes, Human;Female;Genes, Tumor Suppressor;Humans;Male;Models, Genetic;Mutation;Proto-Oncogenes",
        "Doc_meshqualifiers":"etiology;genetics;etiology;genetics",
        "_version_":1605818575877046272},
      {
        "Doc_abstract":"Amplification or overexpression of the HER-2/neu gene in breast cancers is associated with aggressive behavior and resistance to therapeutic regimens. The molecular mechanisms that contribute to therapeutic resistance/survival of HER-2/neu-overexpressing tumor cells have not been well defined. To determine if phosphatidylinositol 3-kinase/AKT signaling contributes to cell survival in HER-2/neu-positive breast cancers, we performed immunohistochemical analyses to evaluate expression of HER-2/neu and AKT in a series of 52 breast carcinomas. Elevated expression of HER-2/neu was found to correlate with overexpression of AKT2 protein and activation of AKT kinase. HER-2/neu-overexpressing breast cancer cell lines were resistant to apoptosis induced by UV treatment and hypoxia, which was suppressed in the presence of the phosphatidylinositol 3-kinase inhibitors LY294002 and wortmannin, indicating a link between AKT activation and stress resistance in HER-2/neu-overexpressing cells. These observations suggest that AKT signaling augments resistance to stress-induced apoptosis in breast cancer cells overexpressing HER-2/neu.",
        "Doc_title":"AKT2 is frequently upregulated in HER-2/neu-positive breast cancers and may contribute to tumor aggressiveness by enhancing cell survival.",
        "Journal":"Oncogene",
        "Do_id":"12032855",
        "Doc_ChemicalList":"Androstadienes;Chromones;Enzyme Inhibitors;Morpholines;Proto-Oncogene Proteins;2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one;Phosphatidylinositol 3-Kinases;Receptor, ErbB-2;AKT1 protein, human;AKT2 protein, human;Protein-Serine-Threonine Kinases;Proto-Oncogene Proteins c-akt;wortmannin",
        "Doc_meshdescriptors":"Androstadienes;Apoptosis;Breast Neoplasms;Carcinoma;Cell Hypoxia;Cell Survival;Chromones;Enzyme Inhibitors;Female;Humans;Morpholines;Phosphatidylinositol 3-Kinases;Protein-Serine-Threonine Kinases;Proto-Oncogene Proteins;Proto-Oncogene Proteins c-akt;Receptor, ErbB-2;Transfection;Tumor Cells, Cultured;Up-Regulation",
        "Doc_meshqualifiers":"pharmacology;enzymology;metabolism;pathology;enzymology;metabolism;pathology;pharmacology;pharmacology;pharmacology;antagonists & inhibitors;biosynthesis;metabolism;analysis;biosynthesis;genetics",
        "_version_":1605899194123419648},
      {
        "Doc_abstract":"In breast cancer, the predominant genetic mechanism for oncogene activation is through an amplification of a gene. The HER-2 (also known as ErbB2/c-erbB2/HER-2/neu) oncogene is the most frequently amplified oncogene in breast cancer, and its overexpression is associated with poor clinical outcome. In addition to its important role in breast cancer growth and progression, HER-2 is also a target for a new form of chemotherapy. Breast cancer patients have been treated with considerable success since 1998 with trastuzumab, a recombinant antibody designed to block signaling through HER-2 receptor. HER-2 has also been implicated in altering the chemosensitivity of breast cancer cells to different forms of conventional cytotoxic chemotherapy, particularly of topoII-inhibitors (e.g., anthracyclines). Topoisomerase IIalpha gene is located just by the HER-2 oncogene at the chromosome 17q12-q21 and is amplified or deleted in almost 90% of the HER-2 amplified primary breast tumors. Recent data suggests that amplification and deletion of topoisomerase IIalpha may account for both relative chemosensitivity and resistance to anthracycline therapy, depending on the specific genetic defect at the topoIIalpha locus. Expanding our understanding of HER-2 amplification also changes its role in the pathogenesis of breast cancer. HER-2 is an oncogene that clearly can drive tumor induction and growth and is also a target for a new kind of chemotherapy, but its function as a marker for chemoselection may be due to associated genetic changes, of which topoisomerase IIalpha is a good example. Moreover, despite potential evidence that genes other than HER-2, such as topoisomerase IIalpha, may be more important predictors of therapeutic response in breast cancer, HER-2 status still has a very significant role in therapeutic selection, mainly as the major criterion for administering trastuzumab in treating breast cancer. Thus, the clinical and therapeutic importance of the HER-2 and topoisomerase IIalpha status to breast cancer management should only increase in the next few years.",
        "Doc_title":"HER-2/neu and topoisomerase IIalpha in breast cancer.",
        "Journal":"Breast cancer research and treatment",
        "Do_id":"12755489",
        "Doc_ChemicalList":"Antibodies, Monoclonal;Antibodies, Monoclonal, Humanized;Antigens, Neoplasm;Antineoplastic Agents;DNA-Binding Proteins;Topoisomerase II Inhibitors;Receptor, ErbB-2;DNA Topoisomerases, Type II;DNA topoisomerase II alpha;Trastuzumab",
        "Doc_meshdescriptors":"Antibodies, Monoclonal;Antibodies, Monoclonal, Humanized;Antigens, Neoplasm;Antineoplastic Agents;Breast Neoplasms;DNA Topoisomerases, Type II;DNA-Binding Proteins;Female;Humans;Receptor, ErbB-2;Topoisomerase II Inhibitors;Trastuzumab",
        "Doc_meshqualifiers":"therapeutic use;therapeutic use;metabolism;physiology;antagonists & inhibitors;physiology",
        "_version_":1605905394534711296},
      {
        "Doc_abstract":"ErbB2, a member of the EGF receptor family of tyrosine kinases is overexpressed on many tumor cells of epithelial origin and is the molecular target of trastuzumab (Herceptin), the first humanized antibody used in the therapy of solid tumors. Trastuzumab, which is thought to act, at least in part, by downregulating ErbB2 expression is only effective in approximately 30-40% of ErbB2 positive breast tumors. Geldanamycin and its derivative 17-AAG are potential antitumor agents capable of downregulating client proteins of Hsp90, including ErbB2. To investigate the ability of 17-AAG to downregulate ErbB2 in trastuzumab resistant breast cancer cells and the possibility of 17-AAG and trastuzumab potentiating each other's effect, the recently established trastuzumab resistant breast cancer cell line, JIMT-1 was compared to the known trastuzumab sensitive SKBR-3 line. Baseline and stimulus-evoked dimerization and activation levels of ErbB2, and the effects of trastuzumab and 17-AAG alone and in combination on cell proliferation and apoptosis, as well as on ErbB2 expression and phosphorylation have been measured. Baseline activation and amenability to activation and downregulation by trastuzumab was much lower in the resistant line. However, 17-AAG enhanced ErbB2 homodimerization after 5-10 min of treatment in both cell lines, and decreased proliferation with an IC50 of 70 nM for SKBR-3 and 10nM for JIMT-1. Thus, 17-AAG may be a useful drug in trastuzumab resistant ErbB2 overexpressing tumors. The antiproliferative effect of 17-AAG was positively correlated with phosphorylation and downregulation of ErbB2 and was dominated by apoptosis, although, especially at higher doses, necrosis was also present. Interestingly, IC50 values for ErbB2 downregulation and phosphorylation, in the 30-40 nM range, were not significantly different for the two cell lines. This observation and the negative correlation between resting ErbB2 levels and the antiproliferative effect of 17-AAG may indicate that activation of ErbB2 to some extent could counteract the overall cytostatic effect, especially at higher levels of ErbB2 expression. The usual therapeutic dose of trastuzumab did not change the IC50 of 17-AAG on the proliferation of either cell line, but nevertheless decreased overall ErbB2 phosphorylation and at low doses of 17-AAG further decreased cell growth in the sensitive SKBR-3, thus trastuzumab may be a good combination partner to counteract undesired activating effects of 17-AAG.",
        "Doc_title":"Hsp90 inhibitor 17-AAG reduces ErbB2 levels and inhibits proliferation of the trastuzumab resistant breast tumor cell line JIMT-1.",
        "Journal":"Immunology letters",
        "Do_id":"16384610",
        "Doc_ChemicalList":"Antibodies, Monoclonal;Antibodies, Monoclonal, Humanized;Antineoplastic Agents;Benzoquinones;HSP90 Heat-Shock Proteins;Lactams, Macrocyclic;Protein Kinase Inhibitors;Rifabutin;tanespimycin;Receptor, ErbB-2;Trastuzumab",
        "Doc_meshdescriptors":"Antibodies, Monoclonal;Antibodies, Monoclonal, Humanized;Antineoplastic Agents;Benzoquinones;Breast Neoplasms;Cell Line, Tumor;Cell Proliferation;Dimerization;Drug Resistance, Neoplasm;HSP90 Heat-Shock Proteins;Humans;Lactams, Macrocyclic;Phosphorylation;Protein Kinase Inhibitors;Receptor, ErbB-2;Rifabutin;Trastuzumab",
        "Doc_meshqualifiers":"pharmacology;therapeutic use;pharmacology;therapeutic use;drug therapy;enzymology;drug effects;antagonists & inhibitors;pharmacology;therapeutic use;antagonists & inhibitors;metabolism;analogs & derivatives;pharmacology;therapeutic use",
        "_version_":1605905395664027648},
      {
        "Doc_abstract":"Distributions of ErbB receptors on membranes of SKBR3 breast cancer cells were mapped by immunoelectron microscopy. The most abundant receptor, ErbB2, is phosphorylated, clustered and active. Kinase inhibitors ablate ErbB2 phosphorylation without dispersing clusters. Modest co-clustering of ErbB2 and EGFR, even after EGF treatment, suggests that both are predominantly involved in homointeractions. Heregulin leads to dramatic clusters of ErbB3 that contain some ErbB2 and EGFR and abundant PI 3-kinase. Other docking proteins, such as Shc and STAT5, respond differently to receptor activation. Levels of Shc at the membrane increase two- to five-fold with EGF, whereas pre-associated STAT5 becomes strongly phosphorylated. These data suggest that the distinct topography of receptors and their docking partners modulates signaling activities.",
        "Doc_title":"Mapping ErbB receptors on breast cancer cell membranes during signal transduction.",
        "Journal":"Journal of cell science",
        "Do_id":"17652160",
        "Doc_ChemicalList":"Adaptor Proteins, Signal Transducing;Neuregulin-1;SHC1 protein, human;STAT5 Transcription Factor;Shc Signaling Adaptor Proteins;Src Homology 2 Domain-Containing, Transforming Protein 1;Phosphotyrosine;Epidermal Growth Factor;Phosphatidylinositol 3-Kinases;Receptor Protein-Tyrosine Kinases;Receptor, Epidermal Growth Factor;Receptor, ErbB-2;Receptor, ErbB-3",
        "Doc_meshdescriptors":"Adaptor Proteins, Signal Transducing;Animals;Breast Neoplasms;CHO Cells;Cell Membrane;Cricetinae;Cricetulus;Epidermal Growth Factor;Female;Humans;Neuregulin-1;Phosphatidylinositol 3-Kinases;Phosphotyrosine;Protein Transport;Receptor Protein-Tyrosine Kinases;Receptor, Epidermal Growth Factor;Receptor, ErbB-2;Receptor, ErbB-3;STAT5 Transcription Factor;Shc Signaling Adaptor Proteins;Signal Transduction;Src Homology 2 Domain-Containing, Transforming Protein 1;Transfection",
        "Doc_meshqualifiers":"metabolism;enzymology;ultrastructure;drug effects;enzymology;ultrastructure;pharmacology;pharmacology;metabolism;metabolism;drug effects;metabolism;metabolism;ultrastructure;metabolism;ultrastructure;metabolism;ultrastructure;metabolism;drug effects",
        "_version_":1605784957825843200},
      {
        "Doc_abstract":"The purpose of this work was to study the prognostic influence in breast cancer of thioredoxin reductase 1 (TXNRD1) and thioredoxin interacting protein (TXNIP), key players in oxidative stress control that are currently evaluated as possible therapeutic targets.;Analysis of the association of TXNRD1 and TXNIP RNA expression with the metastasis-free interval (MFI) was performed in 788 patients with node-negative breast cancer, consisting of three individual cohorts (Mainz, Rotterdam and Transbig). Correlation with metagenes and conventional clinical parameters (age, pT stage, grading, hormone and ERBB2 status) was explored. MCF-7 cells with a doxycycline-inducible expression of an oncogenic ERBB2 were used to investigate the influence of ERBB2 on TXNRD1 and TXNIP transcription.;TXNRD1 was associated with worse MFI in the combined cohort (hazard ratio = 1.955; P < 0.001) as well as in all three individual cohorts. In contrast, TXNIP was associated with better prognosis (hazard ratio = 0.642; P < 0.001) and similar results were obtained in all three subcohorts. Interestingly, patients with ERBB2-status-positive tumors expressed higher levels of TXNRD1. Induction of ERBB2 in MCF-7 cells caused not only an immediate increase in TXNRD1 but also a strong decrease in TXNIP. A subsequent upregulation of TXNIP as cells undergo senescence was accompanied by a strong increase in levels of reactive oxygen species.;TXNRD1 and TXNIP are associated with prognosis in breast cancer, and ERBB2 seems to be one of the factors shifting balances of both factors of the redox control system in a prognostic unfavorable manner.",
        "Doc_title":"Role of thioredoxin reductase 1 and thioredoxin interacting protein in prognosis of breast cancer.",
        "Journal":"Breast cancer research : BCR",
        "Do_id":"20584310",
        "Doc_ChemicalList":"Biomarkers, Tumor;Carrier Proteins;Reactive Oxygen Species;TXNIP protein, human;TXNRD1 protein, human;Thioredoxin Reductase 1;ERBB2 protein, human;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Biomarkers, Tumor;Breast Neoplasms;Carrier Proteins;Cohort Studies;Female;Follow-Up Studies;Gene Expression Profiling;Gene Expression Regulation, Neoplastic;Humans;Immunoblotting;Immunoenzyme Techniques;Middle Aged;Oligonucleotide Array Sequence Analysis;Prognosis;Reactive Oxygen Species;Receptor, ErbB-2;Survival Rate;Thioredoxin Reductase 1;Tissue Array Analysis;Tumor Cells, Cultured",
        "Doc_meshqualifiers":"genetics;metabolism;genetics;metabolism;pathology;genetics;metabolism;metabolism;metabolism;genetics;metabolism",
        "_version_":1605910357779415040},
      {
        "Doc_abstract":"DNA amplifications in breast cancer are frequent on chromosome 11q, in which multiple driver oncogenes likely reside in addition to cyclin D1 (CCND1). One such candidate, the scaffolding adapter protein, GRB2-associated binding protein 2 (GAB2), functions in ErbB signaling and was recently shown to enhance mammary epithelial cell proliferation, and metastasis of ERBB2 (HER2/neu)-driven murine breast cancer. However, the amplification status and function of GAB2 in the context of amplification remain undefined. In this study, by genomic profiling of 172 breast tumors, and fluorescence in situ hybridization validation in an independent set of 210 scorable cases, we observed focal amplification spanning GAB2 (11q14.1) independent of CCND1 (11q13.2) amplification, consistent with a driver role. Further, small interfering RNA (siRNA)-mediated knockdown of GAB2 in breast cancer lines (SUM52, SUM44PE and MDA468) with GAB2 amplification revealed a dependency on GAB2 for cell proliferation, cell-cycle progression, survival and invasion, likely mediated through altered phosphatidylinositol 3-kinase (PI3K) and mitogen-activated protein kinase (MAPK) signaling. GAB2 knockdown also reduced proliferation and survival in a cell line (BT474) with ERBB2 amplification, consistent with the possibility that GAB2 can function downstream of ERBB2. Our studies implicate focal amplification of GAB2 in breast carcinogenesis, and underscore an oncogenic role of scaffolding adapter proteins, and a potential new point of therapeutic intervention.",
        "Doc_title":"Focal amplification and oncogene dependency of GAB2 in breast cancer.",
        "Journal":"Oncogene",
        "Do_id":"19881546",
        "Doc_ChemicalList":"Adaptor Proteins, Signal Transducing;GAB2 protein, human",
        "Doc_meshdescriptors":"Adaptor Proteins, Signal Transducing;Breast Neoplasms;Cell Proliferation;Cell Survival;Comparative Genomic Hybridization;Female;Gene Amplification;Gene Expression Profiling;Humans;In Situ Hybridization, Fluorescence;Oligonucleotide Array Sequence Analysis;Oncogenes;Signal Transduction",
        "Doc_meshqualifiers":"genetics;genetics;physiology;physiology",
        "_version_":1605909403680112640},
      {
        "Doc_abstract":"The prognostic factors and expression of molecular markers in male breast carcinomas are similar to those in female breast cancers. The identification of distinct cytokeratin (CK) profiles (basal as opposed to luminal cells) helps to identify subsets of tumours with different clinical behaviour. The aim of this study was to investigate CK expression in male breast cancer.;Thirty-two cases of male breast cancer were studied. The panel of CKs studied by immunohistochemistry included: 5/6, 14, 17, 18 and 19. Pathological findings and CK expression were analysed in all cases. Histological patterns included ductal carcinoma in situ, invasive ductal carcinoma and mixed patterns. Four cases were positive for CK5/6 and CK14, identifying a basal-like phenotype. CK17 was negative in all but two cases. All cases expressing either CK5/6 or CK14 were invasive carcinomas of high nuclear and histological grade and were also larger compared with the tumours not expressing CK5/6 and CK14. All tumours except three (also negative for CK5/6) expressed CK18 and CK19. The four basal-like tumours were negative for Her-2 expression.;Male breast carcinomas have a basal-like phenotype that is similar in frequency to that of female breast carcinomas. The expression of CK5/6 and CK14 identifies a subset of pathologically aggressive male breast cancers.",
        "Doc_title":"Cytokeratin profiles of male breast cancers.",
        "Journal":"Histopathology",
        "Do_id":"16978199",
        "Doc_ChemicalList":"Biomarkers, Tumor;Keratins",
        "Doc_meshdescriptors":"Adult;Aged;Aged, 80 and over;Biomarkers, Tumor;Breast Neoplasms, Male;Carcinoma, Ductal, Breast;Humans;Immunohistochemistry;Keratins;Male;Middle Aged;Neoplasm Staging;Prognosis",
        "Doc_meshqualifiers":"analysis;metabolism;pathology;metabolism;pathology;biosynthesis",
        "_version_":1605747021988233216},
      {
        "Doc_abstract":"The adenoviral E1A-mediated sensitization to a variety of anti-cancer drug-induced apoptosis is a well-established phenomenon on different types of cell systems. However, the mechanisms underlying E1A-mediated chemosensitization are still not fully understood. Recent studies demonstrate that E1A-mediated sensitization to drug-induced apoptosis can occur via multiple pathways; some of which depend on the expression of functional p53 and/or p19ARF proteins, while some are not. In human breast cancer cells with Her-2/neu overexpression, which usually are more resistance to anti-cancer drugs than cells without Her-2/ neu overexpression, may be sensitized through E1A-mediated downregulation of Her-2/neu. Alternatively, E1A can induce sensitization to anticancer drugs in cancer cells or normal diploid fibroblast cells through upregulating the expression of caspase proenzymes, or downregulating the activity of a critical survival factor Akt and/or upregulating the activities of a pro-apoptotic kinase p38 and a protein phosphatase PP2A, etc. This review summarizes these progresses and proposes a plausible feed-forward model for E1A-mediated chemosensitization in human breast cancer cells.",
        "Doc_title":"Novel approaches for chemosensitization of breast cancer cells: the E1A story.",
        "Journal":"Advances in experimental medicine and biology",
        "Do_id":"17993239",
        "Doc_ChemicalList":"Adenovirus E1A Proteins;Neoplasm Proteins;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Adenovirus E1A Proteins;Apoptosis;Breast Neoplasms;Drug Resistance, Neoplasm;Female;Humans;Neoplasm Proteins;Receptor, ErbB-2",
        "Doc_meshqualifiers":"genetics;metabolism;genetics;drug therapy;genetics;metabolism;genetics;agonists;antagonists & inhibitors;metabolism;antagonists & inhibitors;metabolism",
        "_version_":1605903254417309696},
      {
        "Doc_abstract":"The introduction of trastuzumab for anti-HER2 therapy dramatically changed the clinical outcome for HER2 (ERBB2, neu) positive breast cancer patients. Today, patients eligible for trastuzumab are selected using HER2 expression/amplification status of the primary tumor. However, acquired and inherent resistance to anti-HER2 therapy in these patients poses a significant challenge, and better patient stratification will be needed to improve clinical response. Here, we provide a wide-ranging overview of potential biomarkers capable of stratifying patients regarding their response to trastuzumab. These include HER2 amplification, impaired access to the binding site (p95HER2, Î”16HER-2, MUC4), augmented signaling through other ERBB family receptors (HER1, HER3, HER4) and their ligands, activation of HER2 targets by alternate heterodimers (EphA2, IGF-1R, GDF15, MUC1*), signaling triggered by downstream members (PIK3CA, PTEN, SRC, mTOR), altered expression of cell cycle and apoptotic regulators (CDKs, p27(kip1), Bcl-2), hormone receptor status, resistance to antibody-dependent cellular cytotoxicity (FcÎ³R), and altered miRNA expression signatures. Multigenic molecular profile analyses have revealed further genes not directly associated with classical oncogenic pathways. Although numerous biomarkers have shown promise in pre-clinical studies, many have delivered controversial results when evaluated in clinical trials. One of the keys for targeting ERBB2 will be to consider the entire ERBB family and downstream associated pathways responsible for the malignant transformation. The heterogeneity of the disease is likely to represent a significant obstacle to accurately predicting the course of resistance. The future most probably involves the incorporation of multiple biomarkers into a unified predictor enabling selection of patients for superior targeted drug administration. ",
        "Doc_title":"A Comprehensive Outline of Trastuzumab Resistance Biomarkers in HER2 Overexpressing Breast Cancer.",
        "Journal":"Current cancer drug targets",
        "Do_id":"26452383",
        "Doc_ChemicalList":"Antineoplastic Agents;Biomarkers;ERBB2 protein, human;Receptor, ErbB-2;Trastuzumab",
        "Doc_meshdescriptors":"Antineoplastic Agents;Biomarkers;Breast Neoplasms;Drug Resistance, Neoplasm;Female;Humans;Receptor, ErbB-2;Trastuzumab",
        "Doc_meshqualifiers":"therapeutic use;analysis;drug therapy;genetics;metabolism;biosynthesis;genetics;therapeutic use",
        "_version_":1605907707308539904},
      {
        "Doc_abstract":"Human epidermal growth factor receptor 2-positive (HER2+) breast cancer is a subtype of breast cancer that is exhibited in approximately 20-30% of breast cancer cases. The overexpression of HER2 is typically associated with a more aggressive disease and poor prognosis. Currently, the therapeutic drugs trastuzumab and lapatinib are the most commonly used to combat HER2+ breast cancer. However, tumors can develop resistance to these drugs. A better understanding of the mechanism of how HER2+ breast cancer works will help aid the development for new therapeutic approaches which more closely target the source of the signaling dysfunction. This review summarizes four major points in the context of HER2 over-expressing breast cancer (i) HER2 as a molecular target in breast cancer therapy, (ii) current treatment options as well as ongoing clinical studies, (iii) animal and cellular models for the study of HER2 over-expressing breast cancer, and (iv) future therapies and chemopreventive agents used to target HER2+ breast cancer.",
        "Doc_title":"Targeting HER2 Positive Breast Cancer with Chemopreventive Agents.",
        "Journal":"Current pharmacology reports",
        "Do_id":"26442201",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605746290565578753},
      {
        "Doc_abstract":"To investigate the antitumor effect of a benzoquinone ansamycin antibiotic, geldanamycin (GA), against HER2 /neu tyrosine kinase-overexpressing human breast cancer cell line SKBr3.;To evaluate the antitumor activity of GA, the degradation of HER2 /neu tyrosine kinase in GA-treated SKBr3 cells was analyzed by Western blotting, their proliferation assessed using MTT assay, and the cell cycle distribution identified by flow cytometry. RT-PCR and Real-time PCR were employed to detect cyclin D1 mRNA expression and cell culture inserts model was used to evaluate the motility of the cells.;GA induced a dose- and time-dependent degradation of HER2 /neu tyrosine kinase and cell proliferation inhibition. GA treatment obviously decreased the survival rates of the cancer cells, leading also to a dose-dependent G(1) arrest. The antitumor effects of GA proved to be relevant with declined transcription of cyclin D1. The GA-treated cells also exhibited reduced motility.;GA can efficiently destabilize HER2 /neu tyrosine kinase and inhibit the proliferation and motility of human breast cancer cell line SKBr3 overexpressing HER2 /neu tyrosine kinase.",
        "Doc_title":"[Geldanamycin inhibits proliferation and motility of human HER2/neu-overexpressing breast cancer cell line SKBr3].",
        "Journal":"Nan fang yi ke da xue xue bao = Journal of Southern Medical University",
        "Do_id":"17959518",
        "Doc_ChemicalList":"Anti-Bacterial Agents;Benzoquinones;Lactams, Macrocyclic;Receptor, ErbB-2;geldanamycin",
        "Doc_meshdescriptors":"Anti-Bacterial Agents;Benzoquinones;Breast Neoplasms;Cell Line, Tumor;Cell Movement;Cell Proliferation;Down-Regulation;Female;Gene Expression;Humans;Lactams, Macrocyclic;Receptor, ErbB-2",
        "Doc_meshqualifiers":"pharmacology;pharmacology;genetics;metabolism;physiopathology;drug effects;drug effects;drug effects;pharmacology;genetics;metabolism",
        "_version_":1605750060904087552},
      {
        "Doc_abstract":"ErbB2 overexpressing breast tumors have a poor prognosis and a high risk to develop chemoresistance to therapeutic treatment. \"Chemoresistance\" is a response of cells to toxic stress, and, although it is a common phenomenon, it is still poorly defined. However, a detailed understanding is required to target desensitized pathways and mechanisms for successful reactivation as part of a tailored therapy. To gain insight, which malfunctions contribute to chemoresistance, two mechanisms relevant for tissue homeostasis, the regulation of the cell cycle and of apoptosis, were investigated. Maternal MCF-7- and ErbB2-overexpressing MCF-7(erbB2) breast cancer cells were long term pretreated with 2'-deoxy-5-fluorodeoxyuridine (5-FdUrd) or 1-beta-d-arabinofuranosylcytosine (AraC) and the acquisition of drug-insensitivity was analyzed. A phosphate-conjugated heterodinucleoside consisting of one 5-FdUrd- and one AraC-moiety (5-fluoro-2'-desoxyuridylyl-(3'-->5')-Arabinocytidine) was utilized as a tool to assess the type of acquired resistances. ErbB2-overexpression disrupted proper cell cycle regulation and furthermore facilitated the development of an apoptosis-refractory phenotype upon exposure to 5-FdUrd. Experiments with dimer 5-FdUrd-araC in ErbB2-overexpressing MCF-7(erbB2) cells, and also with nucleoside 5-FdUrd in maternal MCF-7 cells, evidenced that the phenotypes of resistance to cell cycle inhibition and to apoptosis induction were differently affected. The expression profile of cyclin D1 (but not that of p53, p21, or p27) correlated with the proliferative phenotypes and nuclear accumulation of apoptosis inducing factor (but not activation of caspase 7) with apoptotic phenotypes. Dimer 5-FdUrd-araC overrode acquired chemoresistances, whereas combined application of 5-FdUrd and AraC exhibited significantly less activity. Dimer 5-FdUrd-araC remained active in MCF-7 clones most likely by circumventing the prerequisite of first-step phosphorylation. The acquisition of chemoresistance encompassed the affection of apoptosis- and cell-cycle regulation to, respectively, different extents. Thus, drug-induced cell cycle arrest and apoptosis induction are independent of each other.",
        "Doc_title":"5-FdUrd-araC heterodinucleoside re-establishes sensitivity in 5-FdUrd- and AraC-resistant MCF-7 breast cancer cells overexpressing ErbB2.",
        "Journal":"Differentiation; research in biological diversity",
        "Do_id":"17177846",
        "Doc_ChemicalList":"5-fluoro-2'-deoxyuridylyl-(3'-5')-arabinocytidine;Antimetabolites, Antineoplastic;Floxuridine;Cytarabine;Cyclin D1;Receptor, ErbB-2;Caspase 7",
        "Doc_meshdescriptors":"Antimetabolites, Antineoplastic;Apoptosis;Breast Neoplasms;Caspase 7;Cell Cycle;Cell Proliferation;Cyclin D1;Cytarabine;Dimerization;Drug Resistance, Neoplasm;Female;Floxuridine;Humans;Receptor, ErbB-2;Tumor Cells, Cultured",
        "Doc_meshqualifiers":"chemistry;pharmacology;therapeutic use;drug therapy;metabolism;metabolism;drug effects;drug effects;antagonists & inhibitors;metabolism;analogs & derivatives;chemistry;pharmacology;therapeutic use;analogs & derivatives;chemistry;pharmacology;therapeutic use;metabolism",
        "_version_":1605774075347599360},
      {
        "Doc_abstract":"Recent reports revealed that the kinase domain of the ERBB2 gene is somatically mutated in lung adenocarcinoma, suggesting the mutated ERBB2 gene as an oncogene in human cancers. However, because previous reports focused the mutational search of ERBB2 primarily on lung cancers, the data on ERBB2 mutations in other types of human cancers have been largely unknown.;Here, we did a mutational analysis of the ERBB2 kinase domain by PCR single-strand conformational polymorphism assay in gastric, colorectal, and breast carcinoma tissues.;We detected the ERBB2 kinase domain mutations in 9 of 180 gastric carcinomas (5.0%), in 3 of 104 colorectal carcinomas (2.9%), and in 4 of 94 breast carcinomas (4.3%). All of the detected ERBB2 mutations except for one in-frame deletion mutation were missense mutations. Of the 16 ERBB2 mutations detected, 4 affected Val777 in the exon 20 site, and 3 affected Leu755 in the exon 19 site. We simultaneously analyzed the somatic mutations of EGFR, K-RAS, PIK3CA, and BRAF genes in the 16 samples with ERBB2 mutations, and found that all of the 3 colorectal carcinoma samples with ERBB2 mutations harbored K-RAS mutations.;This study showed that in addition to lung adenocarcinomas, ERBB2 kinase domain mutation occurs in other common human cancers such as gastric, breast, and colorectal cancers, and suggested that alterations of ERBB2-mediated signaling pathway by ERBB2 mutations alone or together with K-RAS mutations may contribute to the development of human cancers.",
        "Doc_title":"Somatic mutations of ERBB2 kinase domain in gastric, colorectal, and breast carcinomas.",
        "Journal":"Clinical cancer research : an official journal of the American Association for Cancer Research",
        "Do_id":"16397024",
        "Doc_ChemicalList":"Phosphatidylinositol 3-Kinases;PIK3CA protein, human;Receptor, Epidermal Growth Factor;BRAF protein, human;Proto-Oncogene Proteins B-raf",
        "Doc_meshdescriptors":"Aged;Breast Neoplasms;Colorectal Neoplasms;DNA Mutational Analysis;Female;Genes, erbB-2;Genes, ras;Humans;In Situ Hybridization, Fluorescence;Male;Middle Aged;Mutation;Phosphatidylinositol 3-Kinases;Polymerase Chain Reaction;Polymorphism, Single-Stranded Conformational;Proto-Oncogene Proteins B-raf;Receptor, Epidermal Growth Factor;Stomach Neoplasms",
        "Doc_meshqualifiers":"genetics;genetics;genetics;genetics;genetics;genetics;genetics;genetics",
        "_version_":1605841860873420800},
      {
        "Doc_abstract":"Breast cancer treatment trends are currently based on tailored therapies using tumor and patient biomarkers. Lapatinib is the first dual inhibitor of HER1 (EGFR, ErbB1) and HER2 (ErbB2, Neu) tyrosine kinases to be used in clinical practice. However, only HER2 is currently used for therapy indications and new predictors for the treatment with lapatinib are sought.;This minireview focuses on lapatinib and its role in breast cancer treatment. Preclinical and clinical studies as well as pharmacological characteristics are briefly reviewed while the focus is on efficacy assessment including predictive factors for therapy outcome.;Lapatinib (Tykerb/Tyverb) was Food and Drug Administration (FDA) approved in 2007 for use in combination with capecitabine for the treatment of HER2-positive advanced or metastatic breast cancer in patients who had received previous treatment (including anthracycline, taxane and trastuzumab containing regimens) and in 2010 for use in combination with letrozole for postmenopausal women with hormonal receptor positive and HER2- positive metastatic breast cancer. In contrast to trastuzumab (Herceptin), lapatinib is orally administered and it targets both HER2 and HER1 receptors. As a synthetic and oral tyrosine kinase inhibitor (TKI), it is convenient, cheaper and easier to produce than monoclonal antibodies. The recommended dosage is not dependent on body weight either. Lapatinib plasma level measurement could be an approach to tailored therapy for further optimizing the dose and prolonging this efficient therapy. New lapatinib response predictors are being evaluated. At this time, only HER2 amplification/overexpression is used to choose lapatinib therapy candidates. Further studies on concurrent HER1 fluorescent in situ hybridization (FISH)/immunohistochemistry (IHC) assessment and/or microarray analyses may produce new data on the predictive role of the HER1 (EGFR) gene/protein. PTEN loss and PIK3CA gene mutations are other markers that may predict lapatinib poor response.",
        "Doc_title":"Lapatinib in breast cancer - the predictive significance of HER1 (EGFR), HER2, PTEN and PIK3CA genes and lapatinib plasma level assessment.",
        "Journal":"Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia",
        "Do_id":"21293538",
        "Doc_ChemicalList":"Antineoplastic Agents;Protein Kinase Inhibitors;Quinazolines;lapatinib;Phosphatidylinositol 3-Kinases;PIK3CA protein, human;EGFR protein, human;Receptor, Epidermal Growth Factor;PTEN Phosphohydrolase;PTEN protein, human",
        "Doc_meshdescriptors":"Antineoplastic Agents;Breast Neoplasms;Female;Genes, erbB-2;Humans;PTEN Phosphohydrolase;Phosphatidylinositol 3-Kinases;Predictive Value of Tests;Protein Kinase Inhibitors;Quinazolines;Receptor, Epidermal Growth Factor;Treatment Outcome",
        "Doc_meshqualifiers":"blood;therapeutic use;blood;drug therapy;genetics;genetics;genetics;blood;therapeutic use;blood;therapeutic use;genetics",
        "_version_":1605875500314525696},
      {
        "Doc_abstract":"Cases of breast cancer showing human epidermal growth factor receptor-2 (HER-2) protein overexpression without corresponding gene amplification have been found in immunohistochemistry (IHC) and fluorescent in situ hybridization (FISH) results. We investigated the clinicopathological characteristics of cases showing HER-2 protein overexpression breast cancer without gene amplification (IHC3+/FISH-) and compared them to cases showing HER-2 protein overexpression breast cancer with gene amplification (IHC3+/FISH+). This study was conducted on 90 patients with HER-2 IHC3+ breast cancer. The clinicopathological factors analyzed included tumor size, histological grade, nuclear grade, nodal involvement, and hormone receptor status. HER-2 IHC3+/FISH- breast cancer was found in 14 of 84 tumors (16.7%) and showed a statistically significant lower histological and nuclear grade (P = .000) and higher expression of estrogen receptors (ERs) and progesterone receptors (PRs) (P = .006) than IHC3+/FISH+ breast cancer. In conclusion, HER-2 IHC3+/FISH- breast cancer could be a subgroup showing lower histological/nuclear grade and higher expression of ERs/PRs.",
        "Doc_title":"HER-2 protein overexpressing breast cancer without gene amplification shows higher hormone receptor expression than HER-2 protein overexpressing breast cancer with gene amplification.",
        "Journal":"International journal of surgical pathology",
        "Do_id":"19666946",
        "Doc_ChemicalList":"Biomarkers, Tumor;Receptors, Estrogen;Receptors, Progesterone;ERBB2 protein, human;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Biomarkers, Tumor;Breast Neoplasms;Carcinoma, Ductal, Breast;Chromosome Aberrations;Female;Gene Amplification;Gene Expression Profiling;Humans;Immunohistochemistry;In Situ Hybridization, Fluorescence;Neoplasm Grading;Neoplasm Staging;Receptor, ErbB-2;Receptors, Estrogen;Receptors, Progesterone",
        "Doc_meshqualifiers":"metabolism;genetics;metabolism;pathology;genetics;metabolism;secondary;genetics;metabolism;metabolism;metabolism",
        "_version_":1605791798349791232},
      {
        "Doc_abstract":"Human epidermal growth factor receptor 2 (HER2 or ErBb2) is a receptor tyrosine kinase overexpressed in 20-30% of breast cancers and associated with poor prognosis and outcome. Dysregulation of several microRNAs (miRNAs) plays a key role in breast cancer progression and metastasis. In this study, we screened and identified miRNAs dysregualted in HER2-positive breast cancer cells. Our molecular study demonstrated that miR-489 was specifically downregulated by the HER2-downstream signaling, especially through the MAPK pathway. Restoration or overexpression of miR-489 in HER2-positive breast cancer cells significantly inhibited cell growth in vitro and decreased the tumorigenecity and tumor growth in xenograft mice. Mechanistically, we found that overexpression of miR-489 led to the decreased levels of HER2 and SHP2 and thus attenuated HER2-downstream signaling. Furthermore, we for the first time demonstrated that HER2 is a direct target of miR-489 and therefore HER2-SHP2-MAPK and miR-489 signaling pathways form a mutually inhibitory loop. Using quantitative real-time PCR analysis and Fluorescent in situ hybridization technique (FISH), we found that miR-489 was expressed at significantly lower level in tumor tissues compared to the adjacent normal tissues. Downregulation of miR-489 in breast cancers was associated with aggressive tumor phenotypes. Overall, our results define a double-negative feedback loop involving miR-489 and the HER2-SHP2-MAPK signaling axis that can regulate breast cancer cell proliferation and tumor progression and might have therapeutic relevance for HER2-positive breast cancer. ",
        "Doc_title":"A novel double-negative feedback loop between miR-489 and the HER2-SHP2-MAPK signaling axis regulates breast cancer cell proliferation and tumor growth.",
        "Journal":"Oncotarget",
        "Do_id":"26918448",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605812777968992256},
      {
        "Doc_abstract":"Overexpression of the ErbB2 receptor tyrosine kinase is associated with most aggressive tumors in breast cancer patients and is thus one of the main investigated therapeutic targets. Human ErbB2 C-terminal domain is an unstructured anchor that recruits specific adaptors for signaling cascades resulting in cell growth, differentiation and migration. Herein, we report the presence of a SH3 binding motif in the proline rich unfolded ErbB2 C-terminal region. NMR analysis of this motif supports a PPII helix conformation and the binding to Fyn-SH3 domain. The interaction of a kinase of the Src family with ErbB2 C-terminal domain could contribute to synergistic intracellular signaling and enhanced oncogenesis.",
        "Doc_title":"Identification of a Src kinase SH3 binding site in the C-terminal domain of the human ErbB2 receptor tyrosine kinase.",
        "Journal":"FEBS letters",
        "Do_id":"24815698",
        "Doc_ChemicalList":"Peptides;polyproline;ERBB2 protein, human;Receptor, ErbB-2;src-Family Kinases",
        "Doc_meshdescriptors":"Amino Acid Motifs;Amino Acid Sequence;Binding Sites;Breast Neoplasms;Cell Line, Tumor;Humans;Magnetic Resonance Spectroscopy;Models, Molecular;Molecular Sequence Data;Peptides;Receptor, ErbB-2;src Homology Domains;src-Family Kinases",
        "Doc_meshqualifiers":"enzymology;pathology;chemistry;metabolism;chemistry;metabolism",
        "_version_":1605852323460939776},
      {
        "Doc_abstract":"Transmembrane receptor tyrosine kinases that bind to growth factors transmit signals that are essential to growth and differentiation. These receptors can be classified into groups based on their structure. One group implicated in the pathogenesis of breast cancer contains receptors belonging to the erbB family. This group includes the epidermal growth factor receptors, the HER-2/neu (erbB-2), HER-3, and HER-4. Despite the structural similarity of these receptors, HER-2/neu, HER-4, and HER-3 do not bind to any ligand of the epidermal growth factor receptor. However, a 44-kD glycoprotein called neu differentiation factor (neu differentiation factor/heregulin) has been isolated. This ligand phosphorylates the HER-2/neu receptor and binds directly to HER-4 and HER-3. The abundance of erbB receptors and their ligands in breast cancers points to their functional importance in the pathogenesis and biological behavior of breast cancers. Furthermore, these receptors and ligands may hold a promise for targeted therapy for breast cancer in the future.",
        "Doc_title":"Expression of the erbB-2 family of growth factor receptors and their ligands in breast cancers. Implication for tumor biology and clinical behavior.",
        "Journal":"American journal of clinical pathology",
        "Do_id":"7942609",
        "Doc_ChemicalList":"Glycoproteins;Ligands;Neuregulins;Receptors, Growth Factor;DNA",
        "Doc_meshdescriptors":"Breast Neoplasms;Cell Division;DNA;Gene Expression;Genes, Suppressor;Genes, erbB-2;Glycoproteins;Humans;Ligands;Multigene Family;Neuregulins;Oncogenes;Ploidies;Receptors, Growth Factor",
        "Doc_meshqualifiers":"genetics;metabolism;pathology;genetics;physiology;genetics;metabolism",
        "_version_":1605883483471740928},
      {
        "Doc_abstract":"The American Society of Clinical Oncology/College of American Pathologists ERBB2 testing guidelines address several pre-analytical variables known to affect ERBB2 testing accuracy. According to 2010 updated guidelines, the pre-analytical variable of time to tissue fixation (cold ischemia time) should be kept to <1â€‰h, however, little has been published about cold ischemia time and its significance in ERBB2 testing. To that end, this study evaluated ERBB2 status using two different FDA-approved in-situ hybridization methods and an FDA-approved immunohistochemistry (IHC) assay in the largest cohort to date (n=84) of invasive breast carcinomas with tracked cold ischemia time. Cold ischemia time was stratified into four groups (<1â€‰h (n=45), 1-2â€‰h (n=27), 2-3â€‰h (n=6), and >3â€‰h (n=6)) and ERBB2 status was evaluated in each group by IHC (4B5) and by in-situ hybridization methodologies (PathVysion(Â®) fluorescence in situ hybridization and the INFORM HER2(Â®) dual in situ DNA probe assay). Both in-situ hybridization methods were evaluated using three ERBB2 scoring criteria (dual-probe guidelines, single-probe guidelines, and the FDA package insert scoring instructions). Fluorescence in-situ hybridization (FISH) and INFORM HER2(Â®) demonstrated 100% concordance in the detection of ERBB2 amplification by all three scoring guidelines at all cold ischemia time points. Agreement between in-situ hybridization methodologies and IHC was superior using single-probe guidelines compared with dual probe or FDA scoring instructions. In addition, Inform HER2(Â®) in-situ hybridization signals were significantly more intense than FISH at all cold ischemia time points, however, no significant loss of either chromosome 17 or ERBB2 signal was detected by FISH or Inform HER2(Â®) in-situ hybridization in cold ischemia times up to 3â€‰h. On the basis of our findings, cold ischemia time up to 3â€‰h has no deleterious effect on the detection of ERBB2 via in-situ hybridization or IHC.",
        "Doc_title":"Delay to formalin fixation 'cold ischemia time': effect on ERBB2 detection by in-situ hybridization and immunohistochemistry.",
        "Journal":"Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc",
        "Do_id":"22899285",
        "Doc_ChemicalList":"Fixatives;Formaldehyde;ERBB2 protein, human;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Breast Neoplasms;Carcinoma, Ductal, Breast;Cold Ischemia;Cytodiagnosis;Female;Fixatives;Formaldehyde;Humans;Immunohistochemistry;In Situ Hybridization, Fluorescence;Receptor, ErbB-2;Reproducibility of Results;Time;Tissue Array Analysis;Tissue Fixation",
        "Doc_meshqualifiers":"genetics;metabolism;genetics;metabolism;methods;methods;standards;methods;analysis",
        "_version_":1605850671996731392},
      {
        "Doc_abstract":"Trastuzumab (Herceptin) is an effective targeted therapy in HER2-overexpressing human breast carcinoma. However, many HER2-positive patients initially or eventually become resistant to this treatment, so elucidating mechanisms of trastuzumab resistance that emerge in breast carcinoma cells is clinically important. Here, we show that autocrine motility factor (AMF) binds to HER2 and induces cleavage to the ectodomain-deleted and constitutively active form p95HER2. Mechanistic investigations indicated that interaction of AMF with HER2 triggers HER2 phosphorylation and metalloprotease-mediated ectodomain shedding, activating phosphoinositide-3-kinase (PI3K) and mitogen-activated protein kinase signaling and ablating the ability of trastuzumab to inhibit breast carcinoma cell growth. Furthermore, we found that HER2 expression and AMF secretion were inversely related in breast carcinoma cells. On the basis of this evidence that AMF may contribute to HER2-mediated breast cancer progression, our findings suggest that AMF-HER2 interaction might be a novel target for therapeutic management of patients with breast cancer, whose disease is resistant to trastuzumab.",
        "Doc_title":"Autocrine motility factor promotes HER2 cleavage and signaling in breast cancer cells.",
        "Journal":"Cancer research",
        "Do_id":"23248119",
        "Doc_ChemicalList":"Antibodies, Monoclonal, Humanized;Antineoplastic Agents;AMFR protein, human;Receptors, Autocrine Motility Factor;Phosphatidylinositol 3-Kinases;Receptor, ErbB-2;Mitogen-Activated Protein Kinases;Glucose-6-Phosphate Isomerase;Trastuzumab",
        "Doc_meshdescriptors":"Antibodies, Monoclonal, Humanized;Antineoplastic Agents;Blotting, Western;Breast Neoplasms;Cell Line, Tumor;Cell Movement;Cell Proliferation;Drug Resistance, Neoplasm;Enzyme Activation;Female;Glucose-6-Phosphate Isomerase;HEK293 Cells;Humans;Mitogen-Activated Protein Kinases;Phosphatidylinositol 3-Kinases;Phosphorylation;Protein Binding;RNA Interference;Receptor, ErbB-2;Receptors, Autocrine Motility Factor;Signal Transduction;Trastuzumab",
        "Doc_meshqualifiers":"pharmacology;pharmacology;genetics;metabolism;pathology;drug effects;drug effects;drug effects;genetics;metabolism;pharmacology;metabolism;metabolism;drug effects;genetics;metabolism;genetics;metabolism",
        "_version_":1605851340996608000},
      {
        "Doc_abstract":"Diagnosis of triple-negative breast cancer (ER-negative, PgR-negative, HER2-negative; TNBC) is performed by means of immunohistological staining. HER2-negative includes HER2(0) and HER2(1+), based on differences in the staining intensity, but there have been no reports on comparison of these two types in TNBC. Accordingly, this study was designed to investigate the possible differences in the biological characteristics of HER2(0) breast cancer and HER2(1+) breast cancer in TNBC.;Tissue specimens from 89 TNBC patients were immunohistochemically stained for CK5/6, EGFR, p53, Ki67, E-cadherin, TOP2A and Bcl-2. The expressions of these markers and the clinicopathological findings were compared between the HER2(0) patient group and the HER2(1+) patient group. When either CK5/6 or EGFR was positive, the specimen was judged to be the basal-like phenotype of breast cancer.;The percentages of CK5/6- and/or EGFR-positive specimens in the HER2(0) and HER2(1+) groups were 44.9 and 16.8%, respectively, showing that there was a significantly greater number of basal-like phenotype patients in the HER2(0) group (p < 0.01). The percentage of E-cadherin-positive specimens in the HER2(0) group was 66.6%, which was significantly greater than the 40.0% recorded in the HER2(1+) group (p < 0.05). The respective percentages of TOP2A-positive specimens in the HER2(0) and HER2(1+) groups were 55.0 and 30.0%, and the difference was statistically significant (p < 0.05).;In TNBC, HER2(0) breast cancer showed a strong tendency to include more of the basal-like phenotype compared with HER2(1+) breast cancer. The staining results indicated the possibility that HER2(0) breast cancer and HER2(1+) breast cancer have different characteristics.",
        "Doc_title":"Among triple-negative breast cancers, HER2(0) breast cancer shows a strong tendency to be basal-like compared with HER2(1+) breast cancer: preliminary results.",
        "Journal":"Breast cancer (Tokyo, Japan)",
        "Do_id":"21465226",
        "Doc_ChemicalList":"Antigens, Neoplasm;Biomarkers, Tumor;Cadherins;DNA-Binding Proteins;Ki-67 Antigen;Receptors, Estrogen;Receptors, Progesterone;TP53 protein, human;Tumor Suppressor Protein p53;EGFR protein, human;ERBB2 protein, human;Receptor, Epidermal Growth Factor;Receptor, ErbB-2;DNA Topoisomerases, Type II;DNA topoisomerase II alpha",
        "Doc_meshdescriptors":"Antigens, Neoplasm;Biomarkers, Tumor;Breast Neoplasms;Cadherins;DNA Topoisomerases, Type II;DNA-Binding Proteins;Female;Humans;Ki-67 Antigen;Middle Aged;Receptor, Epidermal Growth Factor;Receptor, ErbB-2;Receptors, Estrogen;Receptors, Progesterone;Tumor Suppressor Protein p53",
        "Doc_meshqualifiers":"metabolism;metabolism;metabolism;pathology;metabolism;metabolism;metabolism;metabolism;metabolism;metabolism;metabolism;metabolism;metabolism",
        "_version_":1605904939969675264},
      {
        "Doc_abstract":"Vesicular stomatitis virus (VSV) is a candidate for development for cancer therapy. We created a recombinant replicating VSV (rrVSV) with an altered surface protein that targeted preferentially to breast cancer cells. The rrVSV genome contained a single glycoprotein (gp) gene derived from Sindbis virus. This gene expressed a chimeric Sindbis E2 binding gp and the native Sindbis E1 fusion gp. The chimeric E2 binding gp, called Sindbis-SCA-erbb2, was modified to reduce its native binding function and to contain a single chain antibody (SCA) with specificity for the human epidermal growth factor receptor Her2/neu protein, erbb2. These viruses selectively infected, replicated in and killed cells expressing erbb2. The titer of rrVSV on SKBR3 cells, a human breast cancer cell line which highly expresses erbb2 was 3.1 x 10(7)/ml compared with a titer of 7.3 x 10(5)/ml on 143 cells, a human osteosarcoma cell line which does not express erbb2. The titer of rrVSV on D2F2/E2 cells, a mouse mammary cancer cell line stably transfected to express human erbb2 was 2.46 x 10(6)/ml compared with a titer of 5 x 10(4)/ml on the parent D2F2 cells which do not express erbb2. When titered on erbb2-negative cells, non-replicating pseudotype VSV coated with Sindbis-SCA-erbb2 had <3% the titer of pseudotype VSV coated with wild type Sindbis gp indicating that the chimeric Sindbis gp had severely impaired binding to the natural receptor. Analysis of the protein composition of the rrVSV found low expression of the modified Sindbis gp on the virus.",
        "Doc_title":"Preferential targeting of vesicular stomatitis virus to breast cancer cells.",
        "Journal":"Virology",
        "Do_id":"15527831",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"Breast Neoplasms;Cell Line, Tumor;Female;Genome, Viral;Humans;Vesicular stomatitis Indiana virus;Virus Replication",
        "Doc_meshqualifiers":"virology;genetics;isolation & purification;physiology",
        "_version_":1605928137495937024},
      {
        "Doc_abstract":"Tissue development and disease progression are multi-stage processes controlled by an evolving set of key regulatory factors, and identifying these factors necessitates a dynamic analysis spanning relevant time scales. Current omics approaches depend on incomplete biological databases to identify critical cellular processes. Herein, we present TRACER (TRanscriptional Activity CEll aRrays), which was employed to quantify the dynamic activity of numerous transcription factor (TFs) simultaneously in 3D and networks for TRACER (NTRACER), a computational algorithm that allows for cellular rewiring to establish dynamic regulatory networks based on activity of TF reporter constructs. We identified major hubs at various stages of culture associated with normal and abnormal tissue growth (i.e., ELK-1 and E2F1, respectively) and the mechanism of action for a targeted therapeutic, lapatinib, through GATA-1, which were confirmed in human ErbB2 positive breast cancer patients and human ErbB2 positive breast cancer cell lines that were either sensitive or resistant to lapatinib. ",
        "Doc_title":"Dynamic transcription factor activity and networks during ErbB2 breast oncogenesis and targeted therapy.",
        "Journal":"Integrative biology : quantitative biosciences from nano to macro",
        "Do_id":"25303361",
        "Doc_ChemicalList":"Adaptor Proteins, Signal Transducing;Antineoplastic Agents;ERBB2IP protein, human;Quinazolines;Transcription Factors;lapatinib",
        "Doc_meshdescriptors":"Adaptor Proteins, Signal Transducing;Antineoplastic Agents;Breast Neoplasms;Carcinogenesis;Cell Line, Tumor;Cell Survival;Computer Simulation;Female;Humans;Models, Biological;Molecular Targeted Therapy;Protein Array Analysis;Quinazolines;Transcription Factors;Transcriptional Activation",
        "Doc_meshqualifiers":"metabolism;administration & dosage;drug therapy;metabolism;drug effects;drug effects;methods;methods;therapeutic use;metabolism;drug effects",
        "_version_":1605851737499893760},
      {
        "Doc_abstract":"The ErbB2 (Neu) receptor tyrosine kinase is frequently overexpressed in human breast cancers, and this phenotype correlates with a poor clinical prognosis. We examined the effects of the mammalian target of rapamycin inhibitor, rapamycin, on mammary tumorigenesis in transgenic mice bearing an activated ErbB2 (NeuYD) transgene in the absence or presence of a second transgene encoding vascular endothelial growth factor (VEGF). Treatment of NeuYD or NeuYD x VEGF mice with rapamycin dramatically inhibited tumor growth accompanied by a marked decrease in tumor vascularization. Two key events that may underlie the antitumor activity of rapamycin were decreased expression of ErbB3 and inhibition of hypoxia-inducible factor-1-dependent responses to hypoxic stress. Rapamycin exposure caused only a modest inhibition of the proliferation of tumor-derived cell lines in standard monolayer cultures, but dramatically inhibited the growth of the same cells in three-dimensional cultures, due in part to the induction of apoptotic cell death. These studies underscore the therapeutic potential of mammalian target of rapamycin inhibitors in ErbB2-positive breast cancers and indicate that, relative to monolayer cultures, three-dimensional cell cultures are more predictive in vitro models for studies of the antitumor mechanisms of rapamycin and related compounds.",
        "Doc_title":"Antitumor activity of rapamycin in a transgenic mouse model of ErbB2-dependent human breast cancer.",
        "Journal":"Cancer research",
        "Do_id":"15958580",
        "Doc_ChemicalList":"DNA-Binding Proteins;HIF1A protein, human;Hif1a protein, mouse;Hypoxia-Inducible Factor 1;Hypoxia-Inducible Factor 1, alpha Subunit;Nuclear Proteins;Transcription Factors;Vascular Endothelial Growth Factor A;Protein Kinases;MTOR protein, human;TOR Serine-Threonine Kinases;mTOR protein, mouse;Receptor, ErbB-2;Receptor, ErbB-3;Sirolimus",
        "Doc_meshdescriptors":"Animals;Apoptosis;Breast Neoplasms;Cell Proliferation;DNA-Binding Proteins;Female;Humans;Hypoxia-Inducible Factor 1;Hypoxia-Inducible Factor 1, alpha Subunit;Male;Mammary Neoplasms, Experimental;Mice;Mice, Transgenic;Neovascularization, Pathologic;Nuclear Proteins;Phosphorylation;Protein Kinases;Receptor, ErbB-2;Receptor, ErbB-3;Sirolimus;Spheroids, Cellular;TOR Serine-Threonine Kinases;Transcription Factors;Vascular Endothelial Growth Factor A",
        "Doc_meshqualifiers":"drug effects;blood supply;drug therapy;genetics;drug effects;biosynthesis;blood supply;drug therapy;genetics;genetics;metabolism;biosynthesis;metabolism;biosynthesis;genetics;biosynthesis;pharmacology;biosynthesis;biosynthesis;genetics",
        "_version_":1605758670484799488},
      {
        "Doc_abstract":"To explore the hypothesis that aging not only increases breast cancer incidence but also alters breast cancer biology, we correlated patient age and diagnosis with tumor histology, stage and biomarkers independently determined from two different tumor archives: an American collection of approximately 800 paraffin-embedded and immunohistochemically analyzed primary breast cancers, and an European collection of approximately 3000 cryobanked primary breast cancers analyzed by ligand-binding and enzyme immunoassay (EIA). The prognostic biomarkers chosen for comparison represented surrogate measures of tumor: (i). proliferation, growth and genetic instability (mitotic and apoptotic indices, Ki-67/MIB-1-positivity, nuclear grade, p53-positivity), (ii). endocrine-dependence (estrogen receptor (ER), progesterone receptors (PR), pS2, Bcl2), (iii). growth factor receptor-dependence (ErbB2, EGFR/ErbB1), and (iv). angiogenic, invasive and proteolytic potential (uPA, PAI-1, Cathepsin D, VEGF). No biomarker reflecting tumor angiogenic, invasive or proteolytic potential showed a significant correlation with patient age at diagnosis. In contrast, significant inverse correlations (|r|>0.1; P< or =0.05) were observed for all measures of tumor growth and genetic instability as well as growth factor receptor overexpression (ErbB2 or EGFR positivity). Only one marker of endocrine-dependence, ER expression, showed a significant positive correlation with patient age at diagnosis. In summary, these findings support the hypothesis that breast cancer biology is significantly affected by patient age. In particular, breast tumors arising in older patients have slower growth rates, are more likely to be ER-positive, and are less likely to be p53-positive, EGFR-positive or ErbB2-positive.",
        "Doc_title":"Age-associated biomarker profiles of human breast cancer.",
        "Journal":"The international journal of biochemistry & cell biology",
        "Do_id":"12200028",
        "Doc_ChemicalList":"Biomarkers, Tumor;Endothelial Growth Factors;Intercellular Signaling Peptides and Proteins;Ki-67 Antigen;Lymphokines;Plasminogen Activator Inhibitor 1;Receptors, Estrogen;Tumor Suppressor Protein p53;Vascular Endothelial Growth Factor A;Vascular Endothelial Growth Factors;Receptor, Epidermal Growth Factor;Receptor, ErbB-2;Urokinase-Type Plasminogen Activator;Cathepsin D",
        "Doc_meshdescriptors":"Adult;Aged;Aged, 80 and over;Aging;Americas;Biomarkers, Tumor;Breast Neoplasms;Cathepsin D;Data Interpretation, Statistical;Endothelial Growth Factors;Europe;Female;Humans;Intercellular Signaling Peptides and Proteins;Ki-67 Antigen;Lymphokines;Middle Aged;Plasminogen Activator Inhibitor 1;Receptor, Epidermal Growth Factor;Receptor, ErbB-2;Receptors, Estrogen;Tumor Suppressor Protein p53;Urokinase-Type Plasminogen Activator;Vascular Endothelial Growth Factor A;Vascular Endothelial Growth Factors",
        "Doc_meshqualifiers":"analysis;chemistry;diagnosis;pathology;analysis;analysis;analysis;analysis;analysis;analysis;analysis;analysis;analysis;analysis;analysis",
        "_version_":1605880097370275840},
      {
        "Doc_abstract":"1) To evaluate the estrogen receptor(ER), progesterone receptor (PR) and Her-2 /neu expression in invasive breast carcinomas by immunohistochemistry and 2) to compare the pattern of expression with clinico-pathological parameters like patient's age, tumor size, mitotic index, histological type and grade and lymph node metastasis.;This is a retrospective study of 321 female invasive breast carcinomas diagnosed in the Department of Histopathology, Apollo Speciality Hospital, Chennai from January 2009 to June 2010.;The age of the patients ranged from 24 to 99 years, with a mean of 53.8, and the majority of the tumors were T2 (83.8% in range of 2-5 cms), predominantly histological grade 2 (57.3%), followed by grade 3 (33.3%). ER, PR and Her-2/neu expression was seen in 59, 51 and 27% of cases respectively. Triple-negative breast cancers constituted 25 % of our cases. We also found characteristic associations between hormonal receptor and Her-2/neu expression and various clinico-pathological parameters.;The hormonal receptor expression appears to be lower in the Indian population compared to the West. A significant proportion of tumors in our study with Her2/neu overexpression also showed ER and PR positivity. Triple-negative breast tumors were most commonly grade 3, in women aged more than 50 years.",
        "Doc_title":"Immunohistochemical profile of breast cancer patients at a tertiary care hospital in South India.",
        "Journal":"Asian Pacific journal of cancer prevention : APJCP",
        "Do_id":"21627355",
        "Doc_ChemicalList":"Biomarkers, Tumor;Receptors, Estrogen;Receptors, Progesterone;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Adult;Aged;Aged, 80 and over;Biomarkers, Tumor;Breast Neoplasms;Carcinoma, Ductal, Breast;Carcinoma, Lobular;Cohort Studies;Female;Humans;Immunoenzyme Techniques;India;Lymph Nodes;Lymphatic Metastasis;Middle Aged;Neoplasm Invasiveness;Neoplasm Staging;Prognosis;Receptor, ErbB-2;Receptors, Estrogen;Receptors, Progesterone;Retrospective Studies;Young Adult",
        "Doc_meshqualifiers":"metabolism;metabolism;pathology;metabolism;secondary;metabolism;secondary;metabolism;pathology;metabolism;metabolism;metabolism",
        "_version_":1605805934515322880},
      {
        "Doc_abstract":"ERBB3/HER3 is one of the four members of the epidermal growth factor receptor (ERBB) family. It is activated by binding to ligands Neuregulin-1 and Neuregulin-2. Since ERBB3 lacks intrinsic kinase activity, signal transduction occurs through formation of heterodimers with EGFR, ERBB2, and ERBB4. ERBB3 is a signaling specialist since it has six binding sites for the p85 SH2 adapter subunit of phosphoinositide 3' kinases. These lipid kinases coordinate regulation of metabolism, cell size, proliferation, survival, and angiogenesis. Not surprisingly, ERBB3 signaling has been linked to cancer etiology and progression. In breast cancer, the partnership of ERBB2 and ERBB3 may be crucial for the aggressive properties of cancers with ERBB2 amplification, and may contribute to pre-existing and acquired resistance to therapy. This partnership creates opportunities for improving efficacy of ERBB-targeted pharmaceuticals, by interfering with coupling of ERBB2 to ERBB3 through dimerization inhibitors, and by use of therapeutic compounds that target AKT-dependent pathways activated through ERBB3. Additional therapeutic opportunities may be identified through better understanding of how ERBBs are regulated and deployed in normal mammary gland processes. Work using mouse models has identified the main processes regulated by each of the four ERBBs, which has practical implications in understanding breast cancer etiology, and eventual development of better prognostic, predictive, and therapeutic tools.",
        "Doc_title":"ERBB3/HER3 and ERBB2/HER2 duet in mammary development and breast cancer.",
        "Journal":"Journal of mammary gland biology and neoplasia",
        "Do_id":"18454306",
        "Doc_ChemicalList":"Antineoplastic Agents;Phosphatidylinositol 3-Kinases;Receptor, ErbB-2;Receptor, ErbB-3",
        "Doc_meshdescriptors":"Animals;Antineoplastic Agents;Breast Neoplasms;Drug Resistance, Neoplasm;Female;Humans;Mammary Glands, Animal;Mammary Glands, Human;Mice;Phosphatidylinositol 3-Kinases;Receptor, ErbB-2;Receptor, ErbB-3;Signal Transduction",
        "Doc_meshqualifiers":"pharmacology;therapeutic use;drug therapy;genetics;metabolism;embryology;growth & development;metabolism;embryology;growth & development;metabolism;metabolism;antagonists & inhibitors;genetics;metabolism;antagonists & inhibitors;genetics;metabolism;drug effects",
        "_version_":1605746380565905408},
      {
        "Doc_abstract":"Overexpression of the ERBB2 gene in human breast cancer is associated with a poor prognosis and resistance to hormonal treatment and chemotherapy. Oestrogen receptor (ER) positive tumour-derived cell lines are known to express relatively low levels of ERBB2 protein under oestrogenic conditions, but markedly higher levels following withdrawal of oestrogens or administration of tamoxifen. Expression of the closely related ERBB3 gene, which co-operates with ERBB2 in cellular transformation, is now shown to respond to oestrogenic manipulation in a similar way, both responses being mediated largely by transcriptional changes. Six previously undescribed DNase I hypersensitive sites occur within the first intron of ERBB2 in cells that overexpress the gene. A 409 base pair DNA fragment containing one of these sites conferred ER dependent oestrogen inhibition on the ERBB2 promoter in two types of transient transfection assay. DNase I footprinting revealed four separate transcription factor binding sites within this fragment consistent with a role as a transcriptional enhancer. These findings implicate intron 1 sequences in the control of ERBB2 expression for the first time and demonstrate that one site within this region is involved in mediating the transcriptional response to oestrogens. Additionally, there is likely to be synergism between ERBB2 and ERBB3 signalling when both are overexpressed in response to oestrogen inhibition, thereby driving transformed cell behaviour.",
        "Doc_title":"An intron 1 enhancer element mediates oestrogen-induced suppression of ERBB2 expression.",
        "Journal":"Oncogene",
        "Do_id":"9242384",
        "Doc_ChemicalList":"RNA, Messenger;Receptors, Estrogen;Estradiol;Deoxyribonuclease I",
        "Doc_meshdescriptors":"Base Sequence;Deoxyribonuclease I;Enhancer Elements, Genetic;Estradiol;Genes, erbB;Genes, erbB-2;Humans;Introns;Molecular Sequence Data;Promoter Regions, Genetic;RNA, Messenger;Receptors, Estrogen",
        "Doc_meshqualifiers":"pharmacology;pharmacology;analysis;physiology",
        "_version_":1605765528879628288},
      {
        "Doc_abstract":"Breast carcinoma is the main malignant tumor occurring in patients with Cowden disease, a cancer-prone syndrome caused by germline mutation of the tumor suppressor gene PTEN characterized by the occurrence throughout life of hyperplastic, hamartomatous and malignant growths affecting various organs. The absence of known histological features for breast cancer arising in a PTEN-mutant background prompted us to explore them for potential new markers.;We first performed a microarray study of three tumors from patients with Cowden disease in the context of a transcriptomic study of 74 familial breast cancers. A subsequent histological and immunohistochemical study including 12 additional cases of Cowden disease breast carcinomas was performed to confirm the microarray data.;Unsupervised clustering of the 74 familial tumors followed the intrinsic gene classification of breast cancer except for a group of five tumors that included the three Cowden tumors. The gene expression profile of the Cowden tumors shows considerable overlap with that of a breast cancer subgroup known as molecular apocrine breast carcinoma, which is suspected to have increased androgenic signaling and shows frequent ERBB2 amplification in sporadic tumors. The histological and immunohistochemical study showed that several cases had apocrine histological features and expressed GGT1, which is a potential new marker for apocrine breast carcinoma.;These data suggest that activation of the ERBB2-PI3K-AKT pathway by loss of PTEN at early stages of tumorigenesis promotes the formation of breast tumors with apocrine features.",
        "Doc_title":"Molecular apocrine differentiation is a common feature of breast cancer in patients with germline PTEN mutations.",
        "Journal":"Breast cancer research : BCR",
        "Do_id":"20712882",
        "Doc_ChemicalList":"gamma-Glutamyltransferase;Phosphatidylinositol 3-Kinases;PIK3CA protein, human;ERBB2 protein, human;Receptor, ErbB-2;PTEN Phosphohydrolase;PTEN protein, human",
        "Doc_meshdescriptors":"Breast Neoplasms;Cluster Analysis;Comparative Genomic Hybridization;Gene Expression Profiling;Germ-Line Mutation;Hamartoma Syndrome, Multiple;Humans;Immunohistochemistry;Oligonucleotide Array Sequence Analysis;PTEN Phosphohydrolase;Phosphatidylinositol 3-Kinases;Principal Component Analysis;Receptor, ErbB-2;Signal Transduction;gamma-Glutamyltransferase",
        "Doc_meshqualifiers":"genetics;metabolism;pathology;genetics;metabolism;pathology;genetics;metabolism;genetics;metabolism;genetics;metabolism;metabolism",
        "_version_":1605742742406692865},
      {
        "Doc_abstract":"Estrogen receptor (ER)-negative breast cancer is heterogeneous, and the biology of this disease has remained poorly understood. Molecular apocrine is a subtype of ER-negative breast cancer that is characterized by the overexpression of steroid-response genes such as AR and a high rate of ErbB2 amplification. In this study, we have identified a positive feedback loop between the AR and extracellular signal-regulated kinase (ERK) signaling pathways in molecular apocrine breast cancer. In this process, AR regulates ERK phosphorylation and kinase activity. In addition, AR inhibition results in the down-regulation of ERK target proteins phospho-RSK1, phospho-Elk-1, and c-Fos using an in vivo molecular apocrine model. Furthermore, we show that AR-mediated induction of ERK requires ErbB2, and AR activity, in turn, regulates ErbB2 expression as an AR target gene. These findings suggest that ErbB2 is an upstream connector between the AR and ERK signaling pathways. Another feature of this feedback loop is an ERK-mediated regulation of AR. In this respect, the inhibition of ERK phosphorylation reduces AR expression and CREB1-mediated transcriptional regulation of AR acts as a downstream connector between the AR and ERK signaling pathways in molecular apocrine cells. Finally, we demonstrate that AR-positive staining is associated with the overexpression of ERK signaling targets phospho-Elk-1 and c-Fos in ER-negative breast tumors, which further supports a cross-regulation between the AR and ERK signaling pathways in molecular apocrine subtype. This study demonstrates an AR-ERK feedback loop in ER-negative breast cancer with significant biologic and therapeutic implications in this disease.",
        "Doc_title":"A feedback loop between androgen receptor and ERK signaling in estrogen receptor-negative breast cancer.",
        "Journal":"Neoplasia (New York, N.Y.)",
        "Do_id":"21403841",
        "Doc_ChemicalList":"Receptors, Androgen;Receptors, Estrogen;ERBB2 protein, human;Receptor, ErbB-2;Extracellular Signal-Regulated MAP Kinases",
        "Doc_meshdescriptors":"Animals;Breast Neoplasms;Cell Line, Tumor;Cell Proliferation;Extracellular Signal-Regulated MAP Kinases;Feedback, Physiological;Female;Gene Expression Regulation, Neoplastic;Humans;Mice;Phosphorylation;Receptor, ErbB-2;Receptors, Androgen;Receptors, Estrogen;Signal Transduction",
        "Doc_meshqualifiers":"genetics;metabolism;genetics;metabolism;genetics;metabolism;genetics;metabolism;genetics;metabolism",
        "_version_":1605891136979730432},
      {
        "Doc_abstract":"We have previously shown that neu oncogene-initiated rat mammary carcinomas uniquely over-express neu-related lipocalin (NRL), a member of the calycin protein superfamily. Here, we characterize the putative human homolog of NRL, neutrophil gelatinase-associated lipocalin (NGAL). ngal gene expression was found at moderate levels in only 2 of 17 human tissues examined, breast and lung. When breast cancers were examined for NGAL mRNA and protein levels, they were found to exhibit heterogeneous expression. NGAL levels varied in these tumors from undetectable to exceeding those in normal breast parenchyma. Immuno-histochemical analysis confirmed the presence of NGAL within breast carcinoma cells but detected only low levels of this protein in normal ductal epithelium. In contrast, large amounts of the protein were localized to the lumen of normal breast ducts in the vicinity of NGAL-expressing tumors. Interestingly, unlike NRL in rat mammary carcinomas, no significant association between NGAL expression and HER-2/neu activation was found in human breast tumors. In contrast, a significant correlation between NGAL expression in breast cancer was found with several other markers of poor prognosis, including estrogen and progesterone receptor-negative status and high proliferation (S-phase fraction). NGAL levels were stratified as high or low in breast cancers from a cohort of node-positive patients with known outcome. No significant association between NGAL expression and disease-free or overall survival was observed.",
        "Doc_title":"Heterogeneous expression of the lipocalin NGAL in primary breast cancers.",
        "Journal":"International journal of cancer",
        "Do_id":"9842963",
        "Doc_ChemicalList":"Acute-Phase Proteins;Carrier Proteins;LCN2 protein, human;Lipocalin-2;Lipocalins;Oncogene Proteins;Proto-Oncogene Proteins;Receptors, Estrogen;Receptors, Progesterone",
        "Doc_meshdescriptors":"Acute-Phase Proteins;Breast;Breast Neoplasms;Carrier Proteins;Cell Cycle;Gene Expression Regulation, Neoplastic;Genes, erbB-2;Humans;Immunohistochemistry;Lipocalin-2;Lipocalins;Neutrophils;Oncogene Proteins;Proto-Oncogene Proteins;Receptors, Estrogen;Receptors, Progesterone;Tumor Cells, Cultured",
        "Doc_meshqualifiers":"metabolism;metabolism;metabolism;metabolism;metabolism",
        "_version_":1605874703735455744},
      {
        "Doc_abstract":"We now recognize that all breast cancers are not the same. Different characteristics in gene expression profiles result in differential clinical behavior. With the use of gene microarrays, different subtypes of breast cancer have been characterized. The basal subtype is characterized by high expression of keratins 5 and 17, laminin, and fatty acid-binding protein 7. The ERBB2+ subtype is characterized by high expression of genes in the ERBB2 amplicon. The luminal A subtype is characterized by the highest expression of the ER alpha gene. The luminal B and C subtypes have a lower expression of the ER cluster. The importance of these different subtypes lies in the fact that they differ in clinical outcome, with the basal and ERBB2+ subtypes having the worse prognosis and the luminal A group having the best prognosis. Different strategies for evaluating tumors in a clinical setting have been developed. Two such strategies are the 21-gene assay (Oncotype DX; Genomic Health, Redwood City, CA), which is currently in commercial use in the United States, and the 70-gene assay, which has been developed by a group in the Netherlands. These assays have been shown to predict clinical outcome and response to therapy. However, to date these gene assays have not been studied in a prospective manner. Over the next year, prospective clinical trials will be initiated using these predictive tools in the treatment of breast cancer. In the near future, clinical decisions will most likely be dictated by the genetic characteristics of the tumor, with the clinical characteristics becoming less important. Tailoring our treatment based on individual tumor characteristics will help us develop better therapeutic strategies and save many patients from receiving unnecessary toxic therapy.",
        "Doc_title":"Gene expression in breast cancer.",
        "Journal":"Current treatment options in oncology",
        "Do_id":"16455023",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"Breast Neoplasms;Female;Gene Expression;Gene Expression Profiling;Genes, erbB-2;Humans;Oligonucleotide Array Sequence Analysis;Prognosis;Risk Assessment",
        "Doc_meshqualifiers":"genetics;therapy;physiology;methods",
        "_version_":1605810929781440512},
      {
        "Doc_abstract":"Breast cancer is currently regarded as a heterogeneous disease classified into various molecular subtypes using gene expression analysis. These molecular subtypes include: basal cell-like, Her-2/neu, luminal A, and luminal B.;To analyze the prevalence and clinicopathologic associations for molecular breast cancer subtypes in premenopausal and postmenopausal African-American women.;A retrospective analysis of all African-American women diagnosed with breast cancer from 1998 to 2005, who had assessable data for ER, PR, and Her-2/neu status. Molecular subtype classification was done based on immunohistochemical surrogates for ER, PR, and Her-2/neu status obtained from Howard University tumor registry for each patient. The molecular subtypes were defined as: luminal A (ER+ and/or PR+, HER2-), luminal B (ER+ and/or PR+, HER2+), basal-like (ER-, PR-, HER2-), and Her-2/neu (ER-, PR-, and HER2+).;We analyzed the prevalence of molecular breast cancer subtypes in a population of African-American women and determined their associations with patient demographics and clinicopathologic variables: node status, tumor size, histological grade, p53 mutation status, and breast cancer-specific survival.;The luminal A subtype was the most prevalent in our study sample (55.4%) compared with (11.8%) luminal B, (21.2%) basal cell-like, and (11.6%) Her-2/neu subtypes. The molecular subtypes did not differ by menopausal status. However, when stratified into age-specific groups, the basal cell-like subtype (57.1%) was the most prevalent in the age group <35 y compared with luminal A, luminal B, and Her-2/neu subtypes at 25.0%, 14.3%, and 3.6%, respectively. The basal cell-like subtype also showed an age-specific bimodal distribution with a peak in the <35 y and 51 to 65 y age groups. The basal cell-like and the Her-2/neu subtypes showed an increased association with clinicopathologic variables portending a more aggressive clinical course when compared with luminal A subtype. A paradoxical inverse relationship between the expression of p53 and Bcl-2 protooncoprotein was noted in the molecular subtypes. Breast cancer-specific survival differed significantly among the molecular subtypes (P < 0.04), with the basal cell-like and Her-2/neu subtypes having the poorest outcome.;The high prevalence of the basal cell-like subtype in the young premenopausal African-American women aged <35 y could be a contributory factor to the poorer prognosis of breast cancer observed in this cohort of patients.",
        "Doc_title":"Molecular breast cancer subtypes in premenopausal and postmenopausal African-American women: age-specific prevalence and survival.",
        "Journal":"The Journal of surgical research",
        "Do_id":"17950079",
        "Doc_ChemicalList":"Receptors, Estrogen;Receptors, Progesterone;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Adult;African Americans;Age Factors;Aged;Aged, 80 and over;Breast Neoplasms;Female;Gene Expression Regulation, Neoplastic;Humans;Kaplan-Meier Estimate;Middle Aged;Postmenopause;Premenopause;Prevalence;Prognosis;Receptor, ErbB-2;Receptors, Estrogen;Receptors, Progesterone;Retrospective Studies",
        "Doc_meshqualifiers":"ethnology;genetics;pathology;genetics;metabolism;genetics;metabolism;genetics;metabolism",
        "_version_":1605895484947300352},
      {
        "Doc_abstract":"Breast cancer is the most common female malignancy in many industrialized countries. Approximately one fourth of all women diagnosed with early breast cancer present with tumors that are characterized by erbB2 amplification. While the associated Her-2/neu receptor overexpression results in a high risk of relapse and poor prognosis, these tumors also represent a target for a selective monoclonal antibody therapy with trastuzumab (Herceptin). The combination of trastuzumab with chemotherapy has led to a considerable reduction of recurrences and to a significant reduction in breast cancer mortality both in the adjuvant and metastatic setting. Unfortunately, despite Her-2/neu overexpression, not all patients equally benefit from trastuzumab treatment, and almost all women with metastatic breast cancer eventually progress during antibody therapy. Moreover, trastuzumab is burdened with cardiotoxicity, thus increasing the risk of symptomatic congestive heart failure. In addition, the marginal costs for a 1 year therapy of trastuzumab-based therapy, which is currently considered to be the most effective treatment regimen in the adjuvant setting, may amount for up to US$ 40.000. Testing for erbB2 oncogene amplification by fluorescence in situ hybridization (FISH) and chromogenic in situ hybridization (CISH), respectively, and staining for Her-2/neu receptor overexpression by immunohistochemistry (IHC) represent the current standard for determining patient eligibility for trastuzumab-based therapy. However, while the negative predictive value of these assays for predicting the absence of benefit from trastuzumab-based therapy is sufficiently high, their positive predictive value remains insufficient, i.e. only a proportion of patients selected by these tests substantially benefit from trastuzumab-containing regimen. Accordingly, over the last years a number of biomarkers have been evaluated in their potential to predict response to trastuzumab-based therapies. These include markers auf activation of Her-2/neu (e.g., tyrosine phosphorylated Her-2/neu in tissue and cleaved Her-2/neu extracellular domain in serum) and its dimerization partners (e.g., EGFR), respectively, but also components of Her-2/neu-induced downstream signaling pathways that are crucial for the growth inhibitory effects of trastuzumab (e.g., PTEN and PI3K). Other parameters, such as topoisomerase-II alpha and c-myc co-amplifications, have also been identified as potentially useful predictors of response to trastuzumab-based chemotherapy regimen. While the benefit of these predictive biomarkers in the metastatic setting is currently explored, their usefulness in the adjuvant setting is still largely unknown. It is, however, undisputable that, within the group of Her-2/neu overexpressing tumors, further response predictors are needed in order to minimize trastuzumab-associated side effects, and to reduce the considerable societal costs that are associated with trastuzumab-based treatment regimen.",
        "Doc_title":"Predicting the efficacy of trastuzumab-based therapy in breast cancer: current standards and future strategies.",
        "Journal":"Biochimica et biophysica acta",
        "Do_id":"18375208",
        "Doc_ChemicalList":"Antibodies, Monoclonal;Antibodies, Monoclonal, Humanized;Biomarkers, Tumor;ERBB2 protein, human;Receptor, ErbB-2;Trastuzumab",
        "Doc_meshdescriptors":"Antibodies, Monoclonal;Antibodies, Monoclonal, Humanized;Antineoplastic Combined Chemotherapy Protocols;Biomarkers, Tumor;Breast Neoplasms;Chemotherapy, Adjuvant;Clinical Trials as Topic;Female;Forecasting;Gene Amplification;Genes, erbB-2;Humans;Models, Biological;Neoplasm Metastasis;Receptor, ErbB-2;Trastuzumab",
        "Doc_meshqualifiers":"economics;therapeutic use;therapeutic use;analysis;drug therapy;analysis",
        "_version_":1605903977216475136},
      {
        "Doc_abstract":"The amplified in breast cancer 1 (AIB1), steroid receptor co-activator family member, acts as an oestrogen receptor (ER) co-activator. Acting with HER-2, it is thought to play a role in endocrine resistance by facilitating ER-growth factor crosstalk. The aim was to analyse AIB1 expression by immunohistochemistry and study its correlations with other prognostic variables in breast cancer and its effect on survival.;A tissue microarray comprising tumours from 438 patients with 15.4 years' median follow-up was used. Interpretable AIB1 expression obtained in 395 patients was analysed along with other prognostic factors in breast cancer.;AIB1 expression scores ranged from 0 to 30; positive AIB1 expression (score > 14) was seen in 146/395 breast cancers; it correlated negatively with ER (P = 0.003) and progesterone receptor (PR) (P = 0.007), and positively with HER-2 (P = 0.005) and tumour grade (P = 0.014). It did not correlate with nodal status (P = 0.437). Among ER+ patients, AIB1 expression showed a trend towards loss of PR expression (29% versus 20%; P = 0.14). AIB1 did not predict survival on univariate or multivariate analysis.;AIB1 expression correlates with HER-2 expression in breast cancer and shows a trend of association with loss of PR expression in ER+ tumours. Our study supports the postulated role of AIB1 in ER-growth factor interactions.",
        "Doc_title":"Amplified in breast cancer 1 expression in breast cancer.",
        "Journal":"Histopathology",
        "Do_id":"19102007",
        "Doc_ChemicalList":"Trans-Activators;Histone Acetyltransferases;NCOA3 protein, human;Nuclear Receptor Coactivator 3",
        "Doc_meshdescriptors":"Adult;Aged;Aged, 80 and over;Breast Neoplasms;Female;Follow-Up Studies;Histone Acetyltransferases;Humans;Immunohistochemistry;Middle Aged;Nuclear Receptor Coactivator 3;Survival Analysis;Trans-Activators",
        "Doc_meshqualifiers":"metabolism;mortality;pathology;metabolism;metabolism",
        "_version_":1605839938874507264},
      {
        "Doc_abstract":"Triple negative (TN) and triple positive (TP) breast cancers both are aggressive types but TN generally has a shorter survival.;To compare the clinical characteristics and treatment outcomes for patients with TN versus TP breast cancer and to assess various prognostic factors affecting overall survival.;A retrospective audit of 85 breast cancer patients was conducted in the Department of Radiation Oncology and Medical Oncology on patients from 2006 to 2013 for whom IHC for ER, PgR and Her-2 neu were available. The patients were strati ed into: ER-, PR- and Her-2 neu- (Arm A, n=47) and ER+, PgR+ and Her-2 neu+ (Arm B, n=38).;TN subtype had higher numbers of premenopausal and advanced stage patients as compared to TP subtype. The locoregional recurrence (LRR) and distant metastatic rate was also higher in TN subtype but there was no de nite pattern in both the arms. Among the prognostic factors, patients with premenopausal status and advanced stage in TN breast cancer had inferior survival (P=0.07) whereas for those with postmenopausal status and early stage there was no survival difference between the two arms.;TN subtype tends to be more aggressive in terms of younger age and advanced stage at presentation, higher tumour grade, LRR and metastasis, suggesting need for future research efforts on providing aggressive treatment to these patients. We could attribute better outcome for TP subtype to receptor positivity enabling role of hormonal treatment and targeted therapy, although less number of patients received targeted therapy.",
        "Doc_title":"Survival of Triple Negative versus Triple Positive Breast Cancers: Comparison and Contrast.",
        "Journal":"Asian Pacific journal of cancer prevention : APJCP",
        "Do_id":"27644638",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605791866598457344},
      {
        "Doc_abstract":"In the present study, we evaluated expressions of estrogen receptor (ER), progestin receptor (PR), human epidermal growth factor receptor-2 (HER-2), cyclooxygenase-2 (COX-2), and vascular endothelial growth factor (VEGF) in primary and relapsed/metastatic breast cancers to elucidate the clinical significance of these markers. The markers were evaluated by immunohistochemistry in specimens of 50 patients with primary or metastatic breast cancer. Positive rates of ER were significantly (p = 0.002) higher in primary versus relapsed/metastatic breast cancer (70 vs. 38 %, respectively). The VEGF positive expression rates were also significantly higher in primary versus metastatic cancer (82 vs. 38 %, respectively; p < 0.001). By contrast, positive rates of HER-2 and COX-2 were not significantly different between different types of cancer. COX-2 correlated with HER-2 expression in both primary and relapsed/metastatic focuses of breast cancer. COX-2 also correlated with VEGF expression in primary breast cancer. Expressions of ER, PR, HER2, and COX-2 did not correlate between primary and relapsed/metastatic breast cancers, indicating that the treatment decision should be made according to the status of these markers in relapsed/metastatic focuses. The total change rates of ER, PR, HER-2, COX-2, and VEGF were 26, 18, 10, 30, and 58 %, respectively. In conclusion, HER-2 and COX-2, along with VEGF, appear to play a role in the development and progression of breast cancer. In addition, all of the studied markers may serve as indicators of prognosis.",
        "Doc_title":"Expressions of ER, PR, HER-2, COX-2, and VEGF in primary and relapsed/metastatic breast cancers.",
        "Journal":"Cell biochemistry and biophysics",
        "Do_id":"23955549",
        "Doc_ChemicalList":"Biomarkers, Tumor;Receptors, Estrogen;Receptors, Progesterone;Vascular Endothelial Growth Factor A;Cyclooxygenase 2;ERBB2 protein, human;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Adult;Biomarkers, Tumor;Breast Neoplasms;Cyclooxygenase 2;Female;Gene Expression Regulation, Neoplastic;Humans;Middle Aged;Neoplasm Metastasis;Receptor, ErbB-2;Receptors, Estrogen;Receptors, Progesterone;Recurrence;Vascular Endothelial Growth Factor A",
        "Doc_meshqualifiers":"metabolism;metabolism;pathology;metabolism;metabolism;metabolism;metabolism;metabolism",
        "_version_":1605903102880251904},
      {
        "Doc_abstract":"Overexpression of ErbB2, a receptor-like tyrosine kinase, is shared by several types of human carcinomas. In breast tumors the extent of overexpression has a prognostic value, thus identifying the oncoprotein as a target for therapeutic strategies. Already, antibodies to ErbB2 are used in combination with chemotherapy in the treatment of metastasizing breast cancer. The mechanisms underlying the oncogenic action of ErbB2 involve a complex network in which ErbB2 acts as a ligand-less signaling subunit of three other receptors that directly bind a large repertoire of stroma-derived growth factors. The major partners of ErbB2 in carcinomas are ErbB1 (also called EGFR) and ErbB3, a kinase-defective receptor whose potent mitogenic action is activated in the context of heterodimeric complexes. Why ErbB2-containing heterodimers are relatively oncopotent is a function of a number of processes. Apparently, these heterodimers evade normal inactivation processes, by decreasing the rate of ligand dissociation, internalizing relatively slowly and avoiding the degradative pathway by returning to the cell surface. On the other hand, the heterodimers strongly recruit survival and mitogenic pathways such as the mitogen-activated protein kinases and the phosphatidylinositol 3-kinase. Hyper-activated signaling through the ErbB-signaling network results in dysregulation of the cell cycle homeostatic machinery, with upregulation of active cyclin-D/CDK complexes. Recent data indicate that cell cycle regulators are also linked to chemoresistance in ErbB2-dependent breast carcinoma. Together with D-type cyclins, it seems that the CDK inhibitor p21waf1 plays an important role in evasion from apoptosis. These recent findings herald a preliminary understanding of the output layer which connects elevated ErbB-signaling to oncogenesis and chemoresistance.",
        "Doc_title":"Molecular mechanisms underlying ErbB2/HER2 action in breast cancer.",
        "Journal":"Oncogene",
        "Do_id":"11156523",
        "Doc_ChemicalList":"Receptors, Estrogen;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Amino Acid Sequence;Animals;Breast Neoplasms;Cell Cycle;Humans;Molecular Sequence Data;Receptor, ErbB-2;Receptors, Estrogen",
        "Doc_meshqualifiers":"immunology;metabolism;immunology;metabolism;physiology;metabolism",
        "_version_":1605783612273197056},
      {
        "Doc_abstract":"HER2 gene amplification and protein overexpression (HER2+) define a clinically challenging subgroup of breast cancer with variable prognosis and response to therapy. Although gene expression profiling has identified an ERBB2 molecular subtype of breast cancer, it is clear that HER2+ tumors reside in all molecular subtypes and represent a genomically and biologically heterogeneous group, needed to be further characterized in large sample sets.;Genome-wide DNA copy number profiling, using bacterial artificial chromosome (BAC) array comparative genomic hybridization (aCGH), and global gene expression profiling were performed on 200 and 87 HER2+ tumors, respectively. Genomic Identification of Significant Targets in Cancer (GISTIC) was used to identify significant copy number alterations (CNAs) in HER2+ tumors, which were related to a set of 554 non-HER2 amplified (HER2-) breast tumors. High-resolution oligonucleotide aCGH was used to delineate the 17q12-q21 region in high detail.;The HER2-amplicon was narrowed to an 85.92 kbp region including the TCAP, PNMT, PERLD1, HER2, C17orf37 and GRB7 genes, and higher HER2 copy numbers indicated worse prognosis. In 31% of HER2+ tumors the amplicon extended to TOP2A, defining a subgroup of HER2+ breast cancer associated with estrogen receptor-positive status and with a trend of better survival than HER2+ breast cancers with deleted (18%) or neutral TOP2A (51%). HER2+ tumors were clearly distinguished from HER2- tumors by the presence of recurrent high-level amplifications and firestorm patterns on chromosome 17q. While there was no significant difference between HER2+ and HER2- tumors regarding the incidence of other recurrent high-level amplifications, differences in the co-amplification pattern were observed, as shown by the almost mutually exclusive occurrence of 8p12, 11q13 and 20q13 amplification in HER2+ tumors. GISTIC analysis identified 117 significant CNAs across all autosomes. Supervised analyses revealed: (1) significant CNAs separating HER2+ tumors stratified by clinical variables, and (2) CNAs separating HER2+ from HER2- tumors.;We have performed a comprehensive survey of CNAs in HER2+ breast tumors, pinpointing significant genomic alterations including both known and potentially novel therapeutic targets. Our analysis sheds further light on the genomically complex and heterogeneous nature of HER2+ tumors in relation to other subgroups of breast cancer.",
        "Doc_title":"High-resolution genomic and expression analyses of copy number alterations in HER2-amplified breast cancer.",
        "Journal":"Breast cancer research : BCR",
        "Do_id":"20459607",
        "Doc_ChemicalList":"Biomarkers, Tumor;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Adult;Aged;Aged, 80 and over;Biomarkers, Tumor;Breast Neoplasms;Chromosomes, Artificial, Bacterial;Chromosomes, Human, Pair 17;Female;Gene Amplification;Gene Dosage;Gene Expression Profiling;Genome, Human;Humans;Middle Aged;Oligonucleotide Array Sequence Analysis;Prognosis;Receptor, ErbB-2;Survival Rate",
        "Doc_meshqualifiers":"genetics;genetics;pathology;genetics;genetics",
        "_version_":1605810175508217856},
      {
        "Doc_abstract":"Lobular inflammation (lobulitis) has been demonstrated in benign breast tissue adjacent to in situ and invasive breast cancers and, more recently, in nonneoplastic tissue from prophylactic mastectomy specimens for hereditary high-risk breast carcinoma. The aim of this study is to investigate the incidence of lobulitis in benign breast tissue of patients with breast cancer and associated clinicopathologic features. We reviewed nonneoplastic breast tissue sections from 334 patients with invasive breast carcinoma to study lobulitis in normal breast tissue and to correlate its presence with clinicopathologic features of the associated tumor. Clinical information (age, menopausal status, and follow-up), tumor characteristics (type, grade, size, lymph node status, stage, estrogen and progesterone receptor, HER2), and survival were recorded. Characteristics of women with and without lobulitis were cross-classified with categories of clinical, pathologic, and histologic characteristics, and differences in distributions were tested in univariate and multivariate analysis. Lobulitis was found in 26 (8%) of 334 patients. The lymphocytic infiltrate was predominantly T-cell type. In a multivariate model, lobulitis in patients with breast cancer was significantly associated with younger age, triple (estrogen receptor, progesterone receptor, HER2)-negative cancers, and medullary phenotypes. Lobulitis in nonneoplastic breast tissue, away from tumor, is associated with clinicopathologic features more commonly seen in hereditary breast cancer. ",
        "Doc_title":"Lobulitis in nonneoplastic breast tissue from breast cancer patients: association with phenotypes that are common in hereditary breast cancer.",
        "Journal":"Human pathology",
        "Do_id":"24157064",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"Adult;Age Distribution;Age Factors;Aged;Breast;Breast Neoplasms;Female;Humans;In Situ Hybridization, Fluorescence;Incidence;Inflammation;Middle Aged;Phenotype",
        "Doc_meshqualifiers":"pathology;congenital;pathology;epidemiology;pathology",
        "_version_":1605758359765516288},
      {
        "Doc_abstract":"Perturbations of oncogenes in breast carcinoma include amplifications of the HER-2/neu and PRAD1 genes, as well as p53 mutations. Some of these lesions frequently appear in early cancers such as ductal carcinoma in situ and are stable as the tumors become invasive and metastasize. Thus these findings suggest that oncogene mutations may define a point of origin for a given breast cancer, and are fixed lesions during tumor progression. Such germline abnormalities may occur at the BRCA1, H-RAS VNTR, and p53 loci. The rational use of genetics may be to identify women at high risk for the development of breast cancer so that they may be enrolled in future chemoprevention trials.",
        "Doc_title":"Oncogenes, breast cancer, and chemoprevention.",
        "Journal":"Journal of cellular biochemistry. Supplement",
        "Do_id":"8007694",
        "Doc_ChemicalList":"Biomarkers, Tumor",
        "Doc_meshdescriptors":"Biomarkers, Tumor;Breast Neoplasms;Female;Genetic Predisposition to Disease;Humans;Oncogenes",
        "Doc_meshqualifiers":"metabolism;genetics;metabolism;prevention & control",
        "_version_":1605790835190792192},
      {
        "Doc_abstract":"Cardiotoxicity is a common and potentially devastating side effect of antineoplastic drug therapy. This empiric observation is seen as paradoxical given that the cardiomyocyte is considered to be a terminally differentiated cell. Despite the fact that these cells do not divide after birth, adult cardiomyocytes may become \"innocent bystander\" targets of anticancer drugs designed to interfere with cell signaling pathways in rapidly proliferating cells. In breast cancer clinical trials, treatment with the erbB2 receptor antibody trastuzumab combined with anthracyclines has been associated with an increased risk for the development of cardiac pump failure. Trastuzumab/anthracycline cardiomyopathy may be the first clinically significant cardiotoxicity to emerge from signal transduction therapeutics. The erbB2 receptor tyrosine kinase is known to have a critical role in cardiac development. In addition, erbB2 is thought to participate in an important pathway for growth, repair, and survival of adult cardiomyocytes as part of a signaling network that involves neuregulins and the neuregulin receptor erbB4. However, erbB2 levels in the adult heart are low when compared with the levels found in erbB2-overexpressing breast cancer cells that are the intended targets of trastuzumab therapy. Thus, trastuzumab-associated cardiotoxicity must be explained by some alternative mechanism. After confirming that trastuzumab is capable of inducing tyrosine phosphorylation of the human cardiomyocyte erbB2 protein, a novel system for culturing human myocardium was developed in our laboratory. We used this system to study the effects of trastuzumab on human cardiomyocytes in vitro and observed trastuzumab-induced structural and functional changes in human cardiomyocytes that were at least partially reversible with the addition of recombinant neuregulins. The results obtained in these experiments support a direct action of trastuzumab on human cardiomyocytes. In addition, these data provide insight regarding potential molecular mechanisms. Most importantly, these data draw attention to the inherent risk of cardiotoxicity associated with a newly emerging class of antineoplastic drugs that interfere with signal transduction pathways.",
        "Doc_title":"Cardiotoxicity in signal transduction therapeutics: erbB2 antibodies and the heart.",
        "Journal":"Seminars in oncology",
        "Do_id":"11706392",
        "Doc_ChemicalList":"Antibiotics, Antineoplastic;Antibodies, Monoclonal;Antibodies, Monoclonal, Humanized;Antineoplastic Agents;Neuregulins;ERBB4 protein, human;Receptor, Epidermal Growth Factor;Receptor, ErbB-2;Receptor, ErbB-4;Trastuzumab",
        "Doc_meshdescriptors":"Animals;Antibiotics, Antineoplastic;Antibodies, Monoclonal;Antibodies, Monoclonal, Humanized;Antineoplastic Agents;Breast Neoplasms;Cell Cycle;Cells, Cultured;Heart;Heart Diseases;Humans;Myocardium;Neuregulins;Receptor, Epidermal Growth Factor;Receptor, ErbB-2;Receptor, ErbB-4;Signal Transduction;Trastuzumab",
        "Doc_meshqualifiers":"pharmacology;adverse effects;adverse effects;drug therapy;drug effects;drug effects;chemically induced;cytology;metabolism;metabolism;immunology;metabolism;drug effects",
        "_version_":1605903804406956032},
      {
        "Doc_abstract":"ERBB2 (HER2/Neu) gene amplification and overexpression is associated with increased risk of metastases and shorter survival in breast cancer. Tyrosine 1248 is a major phosphorylation site of ERBB2 and reflects the activation status of the receptor. The aim of this study was to investigate the relationships between quantitative levels of pY1248-ERBB2 (p-ERBB2) and the expression of epidermal growth factor receptor (EGFR)-family members, and whether p-ERBB2 could provide additional prognostic value compared with established prognostic markers. For this purpose we developed a highly sensitive chemiluminescence-linked immunoassay (CLISA) and detected p-ERBB2 levels in 70 primary breast cancer biopsies. Phosphorylated ERBB2 correlated with EGFR and ERBB2, and inversely with oestrogen receptor (ER), progesterone receptor (PgR) and ERBB4 expression levels. Additionally, p-ERBB2 was associated with poor clinical outcome in univariate and multivariate Cox regression analysis. Further studies are needed to evaluate the predictive value of p-ERBB2.",
        "Doc_title":"Phosphorylation of tyrosine 1248-ERBB2 measured by chemiluminescence-linked immunoassay is an independent predictor of poor prognosis in primary breast cancer patients.",
        "Journal":"European journal of cancer (Oxford, England : 1990)",
        "Do_id":"16414259",
        "Doc_ChemicalList":"Tyrosine;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Breast Neoplasms;Cell Line, Tumor;Disease-Free Survival;Female;Humans;Immunoassay;Luminescent Measurements;Phosphorylation;Prognosis;Receptor, ErbB-2;Tyrosine",
        "Doc_meshqualifiers":"metabolism;methods;methods;metabolism;metabolism",
        "_version_":1605882754452422656},
      {
        "Doc_abstract":"The expression of receptors belonging to the epidermal growth factor receptor subfamily has been largely studied these last years in epithelial cells mainly as involved in cell proliferation and malignant progression. Although much work has focused on the role of these growth factor receptors in the differentiation of a variety of tissues, there is little information in regards to normal stromal cells. We investigated erbB2 expression in the murine fibroblast cell line Swiss 3T3L1, which naturally or hormonally induced undergoes adipocyte differentiation. We found that the Swiss 3T3-L1 fibroblasts express erbB2, in addition to EGFR, and in a quantity comparable to or even greater than the breast cancer cell line T47D. Proliferating cells increased erbB2 and EGFR levels when reaching confluence up to 4- and 10-fold, respectively. This expression showed a significant decrease when growth-arrested cells were stimulated to differentiate with dexamethasone and isobutyl-methylxanthine. Differentiated cells presented a decreased expression of both erbB2 and EGFR regardless of whether the cells were hormonally or spontaneously differentiated. EGF stimulation of serum-starved cells increased erbB2 tyrosine phosphorylation and retarded erbB2 migration in SDS-PAGE, suggesting receptor association and activation. Heregulin-alpha1 and -beta1, two EGF related factors, had no effect on erbB2 or EGFR phosphorylation. Although 3T3-L1 cells expressed heregulin, its specific receptors, erbB3 and erbB4, were not found. This is the first time in which erbB2 is reported to be expressed in an adipocytic cell line which does not depend on non EGF family growth factors (thyroid hormone, growth hormone, etc.) to accomplish adipose differentiation. Since erbB2 and EGFR expression were downmodulated as differentiation progressed it is conceivable that a mechanism of switching from a mitogenic to a differentiating signaling pathway may be involved, through regulation of the expression of these growth factor receptors.",
        "Doc_title":"ErbB2 and EGFR are downmodulated during the differentiation of 3T3-L1 preadipocytes.",
        "Journal":"Journal of cellular biochemistry",
        "Do_id":"14523990",
        "Doc_ChemicalList":"Insulin;Neuregulin-1;heregulin alpha;heregulin beta1;Epidermal Growth Factor;Dexamethasone;Receptor, Epidermal Growth Factor;Receptor, ErbB-2",
        "Doc_meshdescriptors":"3T3-L1 Cells;Adipocytes;Animals;Cell Differentiation;Dexamethasone;Epidermal Growth Factor;Humans;Insulin;Mice;Neuregulin-1;Phosphorylation;Receptor, Epidermal Growth Factor;Receptor, ErbB-2;Tumor Cells, Cultured",
        "Doc_meshqualifiers":"metabolism;drug effects;physiology;pharmacology;metabolism;metabolism;metabolism;metabolism;metabolism",
        "_version_":1605819767424286720},
      {
        "Doc_abstract":"Phosphoinositide 3-kinase (PI3K)-activated signalling has a critical role in the evolution of aggressive tumourigenesis and is therefore a prime target for anticancer therapy. Previously we have shown that the beta galactoside binding protein (betaGBP) cytokine, an antiproliferative molecule, induces functional inhibition of class 1A and class 1B PI3K. Here, we have investigated whether, by targeting PI3K, betaGBP has therapeutic efficacy in aggressive breast cancer cells where strong mitogenic input is fuelled by overexpression of the ErbB2 (also known as HER/neu, for human epidermal growth factor receptor 2) oncoprotein receptor and have used immortalised ductal cells and non-aggressive mammary cancer cells, which express ErbB2 at low levels, as controls.;Aggressive BT474 and SKBR3 cancer cells where ErbB2 is overexpressed, MCF10A immortalised ductal cells and non-invasive MCF-7 cancer cells which express low levels of ErbB2, both in their naive state and when forced to mimic aggressive behaviour, were used. Class IA PI3K was immunoprecipitated and the conversion of phosphatidylinositol (4,5)-biphosphate (PIP2) to phosphatidylinositol (3,4,5)-trisphosphate (PIP3) assessed by ELISA. The consequences of PI3K inhibition by betaGBP were analysed at proliferation level, by extracellular signal-regulated kinase (ERK) activation, by akt gene expression and by apoptosis. Apoptosis was documented by changes in mitochondrial membrane potential, alteration of the plasma membrane, caspase 3 activation and DNA fragmentation. Phosphorylated and total ERK were measured by Western blot analysis and akt mRNA levels by Northern blot analysis. The results obtained with the BT474 and SKBR3 cells were validated in the MCF10A ductal cells and in non-invasive MCF-7 breast cancer cells forced into mimicking the in vitro behaviour of the BT474 and SKBR3 cells.;In aggressive breast cancer cells, where mitogenic signalling is enforced by the ErbB2 oncoprotein receptor, functional inhibition of the catalytic activity of PI3K by the betaGBP cytokine and loss of akt mRNA results in apoptotic death. A functional correlation between ERK and the kt gene was also found. The relationship between ERK, akt mRNA, PI3K and cell vulnerability to betaGBP challenge was sustained both in mammary ductal cells forced to mimic an aggressive behaviour and in non-aggressive breast cancer cells undergoing an enforced shift into an aggressive phenotype.;betaGBP, a newly discovered physiological inhibitor of PI3K, is a selective and potent inducer of apoptosis in aggressive breast cancer cells. Due to its physiological nature, which carries no chemotherapeutic disadvantages, betaGBP has the potential to be safely tested in clinical trials.",
        "Doc_title":"Phosphoinositide 3-kinase targeting by the beta galactoside binding protein cytokine negates akt gene expression and leads aggressive breast cancer cells to apoptotic death.",
        "Journal":"Breast cancer research : BCR",
        "Do_id":"19133120",
        "Doc_ChemicalList":"Galectins;Phosphatidylinositol 4,5-Diphosphate;Phosphatidylinositol Phosphates;RNA, Messenger;phosphatidylinositol 3,4,5-triphosphate;Phosphatidylinositol 3-Kinases;Receptor, ErbB-2;Proto-Oncogene Proteins c-akt;Mitogen-Activated Protein Kinase 1;Mitogen-Activated Protein Kinase 3",
        "Doc_meshdescriptors":"Apoptosis;Blotting, Northern;Blotting, Western;Breast Neoplasms;Enzyme-Linked Immunosorbent Assay;Female;Galectins;Gene Expression Regulation, Neoplastic;Humans;Mitogen-Activated Protein Kinase 1;Mitogen-Activated Protein Kinase 3;Phosphatidylinositol 3-Kinases;Phosphatidylinositol 4,5-Diphosphate;Phosphatidylinositol Phosphates;Phosphorylation;Proto-Oncogene Proteins c-akt;RNA, Messenger;Receptor, ErbB-2;Reverse Transcriptase Polymerase Chain Reaction;Tumor Cells, Cultured",
        "Doc_meshqualifiers":"drug effects;genetics;pathology;pharmacology;drug effects;metabolism;metabolism;antagonists & inhibitors;metabolism;metabolism;metabolism;antagonists & inhibitors;genetics;genetics;metabolism;genetics;metabolism",
        "_version_":1605754210694987776},
      {
        "Doc_abstract":"MYC and ERBB2 levels were measured in 38 benign breast diseases using a semiquantitative in situ hybridization technique. Mean levels of MYC and ERBB2 gene expression in benign tissues were similar to those measured in 15 breast cancers with no amplification at the loci concerned. Interestingly, MYC but not ERBB2 RNA levels were increased (t-test, P = 0.03) in benign mastopathies of patients with a first-degree (mother/sister) family history (FH) of breast cancer. Among patients without a first-degree FH, MYC RNA levels were significantly higher (t-test, P = 0.02) during the follicular (preovulatory) than the luteal (post-ovulatory) phase and also significantly higher than levels observed in patients with no menstrual cycle (peri- or postmenopausal) (P = 0.004), indicating an in vivo hormonal regulation of MYC. After exclusion of the first-degree FH patients a higher MYC expression was detected in atypia than in other histological types at the follicular but not at the luteal phase, suggesting an increased sensitivity of these high-risk lesions to estrogens. We propose that in addition to a family history and proliferative atypia, elevated MYC RNA levels during the post-ovulatory phase could potentially be used as a marker of the risk of developing breast cancer. The increase in MYC RNA in high-risk breast diseases also suggests that MYC deregulation might be involved in the early stages of mammary carcinogenesis.",
        "Doc_title":"Potential value of increased MYC but not ERBB2 RNA levels as a marker of high-risk mastopathies.",
        "Journal":"Oncogene",
        "Do_id":"8455947",
        "Doc_ChemicalList":"RNA, Messenger;RNA, Neoplasm;Receptors, Estrogen",
        "Doc_meshdescriptors":"Breast Diseases;Breast Neoplasms;Female;Gene Expression;Genes, myc;Humans;Hyperplasia;In Situ Hybridization;Menstruation;Pedigree;Proto-Oncogenes;RNA, Messenger;RNA, Neoplasm;Receptors, Estrogen;Risk Factors",
        "Doc_meshqualifiers":"genetics;genetics;genetics;genetics;genetics;genetics",
        "_version_":1605757919248252928},
      {
        "Doc_abstract":"Trastuzumab (Herceptin) has improved therapy of breast cancer. Only patients overexpressing ERBB2 are treated with trastuzumab, whereas its use in tumours without ERBB2 expression is useless. This led to the concept that the subgroup of trastuzumab-sensitive tumours is 'ERBB2-dependent', meaning that ERBB2 signalling is indispensable for growth of these tumours. We used a mouse model that allows anhydrotetracycline (ATc)-controlled downregulation of ERBB2 in tumour tissue. ERBB2 mRNA and protein expression were downregulated below detection limit leading to a macroscopically complete tumour remission within 14 days. Tumour remission was accompanied by a strong decrease in proliferation, a moderate increase in apoptosis, as well as dephosphorylation of ERK1/2 and AKT/PKB. These data clearly indicate ERBB2 dependence. Therefore, a high sensitivity to trastuzumab may be suspected. Surprisingly, trastuzumab caused a much weaker effect compared to ATc-induced ERBB2 downregulation, although a decrease in ERBB2 membrane localisation was induced. Only a slight decrease in proliferation and a weak transient increase in apoptosis were observed. Interestingly, tumours responded to trastuzumab by a sharp fivefold increase in phosphorylated AKT/PKB as well as a 3.5- and 5.3-fold increase in AKT1 and AKT2 mRNA levels, respectively. In conclusion, 'ERBB2 dependence' is not sufficient to define trastuzumab-responsive tumours. The suboptimal effect of trastuzumab compared to the maximally possible effect induced by ATc demonstrates a high potential for improved ERBB2 blocking therapies.",
        "Doc_title":"Trastuzumab therapy vs tetracycline controlled ERBB2 downregulation: influence on tumour development in an ERBB2-dependent mouse tumour model.",
        "Journal":"British journal of cancer",
        "Do_id":"18454161",
        "Doc_ChemicalList":"Antibodies, Monoclonal;Antibodies, Monoclonal, Humanized;Antineoplastic Agents;Ki-67 Antigen;RNA, Messenger;Tetracyclines;4-epianhydrotetracycline;Cytochromes c;Erbb2 protein, mouse;Receptor, ErbB-2;3-Phosphoinositide-Dependent Protein Kinases;Protein-Serine-Threonine Kinases;Proto-Oncogene Proteins c-akt;Mitogen-Activated Protein Kinase 3;Trastuzumab",
        "Doc_meshdescriptors":"3-Phosphoinositide-Dependent Protein Kinases;Animals;Antibodies, Monoclonal;Antibodies, Monoclonal, Humanized;Antineoplastic Agents;Apoptosis;Blotting, Western;Cell Proliferation;Cytochromes c;Down-Regulation;Drug Resistance, Neoplasm;Female;Gene Expression Regulation, Neoplastic;Immunohistochemistry;Ki-67 Antigen;Male;Mammary Neoplasms, Experimental;Mice;Mice, Nude;Mitogen-Activated Protein Kinase 3;Protein-Serine-Threonine Kinases;Proto-Oncogene Proteins c-akt;RNA, Messenger;Receptor, ErbB-2;Tetracyclines;Trastuzumab",
        "Doc_meshqualifiers":"pharmacology;pharmacology;drug effects;drug effects;metabolism;drug effects;drug effects;metabolism;drug therapy;metabolism;metabolism;metabolism;metabolism;metabolism;drug effects;genetics;metabolism;pharmacology",
        "_version_":1605842738134122496},
      {
        "Doc_abstract":"Around 20% of breast cancers (BC) show ERBB2 gene amplification and overexpression of the ERBB2 tyrosine kinase receptor. They are associated with a poor prognosis but can benefit from targeted therapy. A better knowledge of these BCs, genomically and biologically heterogeneous, may help understand their behavior and design new therapeutic strategies.;We defined the high resolution genome and gene expression profiles of 54 ERBB2-amplified BCs using 244K oligonucleotide array-comparative genomic hybridization and whole-genome DNA microarrays. Expression of ERBB2, phosphorylated ERBB2, EGFR, IGF1R and FOXA1 proteins was assessed by immunohistochemistry to evaluate the functional ERBB2 status and identify co-expressions.;First, we identified the ERBB2-C17orf37-GRB7 genomic segment as the minimal common 17q12-q21 amplicon, and CRKRS and IKZF3 as the most frequent centromeric and telomeric amplicon borders, respectively. Second, GISTIC analysis identified 17 other genome regions affected by copy number aberration (CNA) (amplifications, gains, losses). The expression of 37 genes of these regions was deregulated. Third, two types of heterogeneity were observed in ERBB2-amplified BCs. The genomic profiles of estrogen receptor-positive (ER+) and negative (ER-) ERBB2-amplified BCs were different. The WNT/Î²-catenin signaling pathway was involved in ER- ERBB2-amplified BCs, and PVT1 and TRPS1 were candidate oncogenes associated with ER+ ERBB2-amplified BCs. The size of the ERBB2 amplicon was different in inflammatory (IBC) and non-inflammatory BCs. ERBB2-amplified IBCs were characterized by the downregulated and upregulated mRNA expression of ten and two genes in proportion to CNA, respectively. IHC results showed (i) a linear relationship between ERBB2 gene amplification and its gene and protein expressions with a good correlation between ERBB2 expression and phosphorylation status; (ii) a potential signaling cross-talk between EGFR or IGF1R and ERBB2, which could influence response of ERBB2-positive BCs to inhibitors. FOXA1 was frequently coexpressed with ERBB2 but its expression did not impact on the outcome of patients with ERBB2-amplified tumors.;We have shown that ER+ and ER- ERBB2-amplified BCs are different, distinguished ERBB2 amplicons in IBC and non-IBC, and identified genomic features that may be useful in the design of alternative therapeutical strategies.",
        "Doc_title":"Genome profiling of ERBB2-amplified breast cancers.",
        "Journal":"BMC cancer",
        "Do_id":"20932292",
        "Doc_ChemicalList":"ERBB2 protein, human;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Adenocarcinoma;Breast Neoplasms;Cell Line, Tumor;Cohort Studies;Female;Gene Expression Profiling;Genome, Human;Humans;Immunohistochemistry;In Situ Hybridization, Fluorescence;Nucleic Acid Hybridization;Oligonucleotide Array Sequence Analysis;Phosphorylation;Receptor, ErbB-2;Treatment Outcome",
        "Doc_meshqualifiers":"metabolism;genetics;metabolism;methods;biosynthesis;genetics",
        "_version_":1605758941693739008},
      {
        "Doc_abstract":"erbB2/neu, an overexpressed oncogene product, has been proposed as a human cancer vaccine target. In the present study, transgenic (rat neuNT oncogene) FVB/neu mice, developing metastasizable mammary carcinoma, were immunized with a plasmid DNA encoding are not tolerant to the self antigen and sequences. We report that transgenic tumour-bearing mice, like some breast cancer patients erbB2 + X, develop anti-neu autoimmune responses, which can be boosted and skewed to a Th1 phenotype by DNA immunization. Intramuscular injections of neuNT plasmid drastically reduced (or even prevented in a small number of treated mice) the outgrowth of mammary neoplasms as well as their metastatic penetrance. Furthermore, DNA immunization caused haemorrhagic necrosis of established cancer nests, leaving a greatly reduced portion of the tumour burden for the host to cope with. The antitumour activities we obtained, in this very challenging model for cancer immunotherapy, lay the foundation for DNA-based immunization to control erbB2/neu-overexpressing neoplasms.",
        "Doc_title":"Genetic immunization against neu/erbB2 transgenic breast cancer.",
        "Journal":"Cancer immunology, immunotherapy : CII",
        "Do_id":"9875670",
        "Doc_ChemicalList":"Cancer Vaccines;DNA, Neoplasm;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Adenocarcinoma;Animals;Autoimmunity;Breast Neoplasms;Cancer Vaccines;DNA, Neoplasm;Disease Models, Animal;Female;Genes, erbB-2;Humans;Lung Neoplasms;Mice;Mice, Transgenic;Mutation;Neoplasm Transplantation;Rats;Receptor, ErbB-2",
        "Doc_meshqualifiers":"genetics;immunology;therapy;drug effects;immunology;genetics;immunology;therapy;genetics;immunology;pharmacology;administration & dosage;immunology;genetics;secondary;biosynthesis;genetics;immunology",
        "_version_":1605830689094107136},
      {
        "Doc_abstract":"The recent development of monoclonal antibodies targeting growth factor receptors in cancer treatment represents a milestone for both researchers and physicians. Advances in the understanding of key molecular pathways for tumour growth and survival have facilitated the development of these targeted therapies, in particular in breast cancer. This review focuses on the three most important recombinant humanised monoclonal antibodies that have shown activity in women with breast cancer: trastuzumab, pertuzumab and bevacizumab. Trastuzumab, an anti-erbB2 (human epidermal growth factor receptor) monoclonal antibody, is currently routinely used in both the metastatic and adjuvant settings for patients with erbB2-positive tumours. Pertuzumab, a monoclonal antibody binding to a different epitope on erbB2 than trastuzumab, is under early clinical evaluation. This drug has been developed for breast cancer patients, whether overexpressing erbB2 or not. Bevacizumab, a monoclonal antibody directed against vascular endothelial growth factor-A, is being evaluated in the metastatic setting for its antiangiogenic properties, and is showing promising results.",
        "Doc_title":"Monoclonal antibody-based targeted therapy in breast cancer: current status and future directions.",
        "Journal":"Drugs",
        "Do_id":"16956305",
        "Doc_ChemicalList":"Antibodies, Monoclonal;Antibodies, Monoclonal, Humanized;Antineoplastic Agents;Vascular Endothelial Growth Factors;Bevacizumab;Receptor, ErbB-2;pertuzumab;Trastuzumab",
        "Doc_meshdescriptors":"Antibodies, Monoclonal;Antibodies, Monoclonal, Humanized;Antineoplastic Agents;Bevacizumab;Breast Neoplasms;Clinical Trials as Topic;Female;Humans;Receptor, ErbB-2;Trastuzumab;Vascular Endothelial Growth Factors",
        "Doc_meshqualifiers":"metabolism;pharmacology;therapeutic use;metabolism;pharmacology;therapeutic use;drug therapy;drug effects;metabolism;antagonists & inhibitors",
        "_version_":1605749613135921152},
      {
        "Doc_abstract":"Identification of shared tumor-specific targets is useful in developing broadly applicable therapies. In a study designed to identify genes up-regulated in breast cancer, a cDNA clone corresponding to a novel gene C35 (C17orf37) was selected by representational difference analysis of tumor and normal human mammary cell lines. Abundant expression of C35 transcript in tumors was confirmed by Northern blot and real-time PCR. The C35 gene is located on chromosome 17q12, 505 nucleotides from the 3' end of the ERBB2 oncogene, the antigenic target for trastuzumab (Herceptin) therapy. The chromosomal arrangement of the genes encoding C35 and ERBB2 is tail to tail. An open reading frame encodes a 12-kDa protein of unknown function. Immunohistochemical analysis detected robust and frequent expression of C35 protein, including 32% of grade 1 and 66% of grades 2 and 3 infiltrating ductal carcinomas of the breast (in contrast to 20% overexpressing HER-2/neu), 38% of infiltrating lobular carcinoma (typically HER-2/neu negative), as well as tumors arising in other tissues. C35 was not detected in 38 different normal human tissues, except Leydig cells in the testes and trace levels in a small percentage of normal breast tissue samples. The distinct and favorable expression profile of C35 spanning early through late stages of disease, including high frequency of overexpression in various breast carcinoma, abundant expression in distant metastases, and either absence or low level expression in normal human tissues, warrants further investigation of the relevance of C35 as a biomarker and/or a target for development of broadly applicable cancer-specific therapies.",
        "Doc_title":"C35 (C17orf37) is a novel tumor biomarker abundantly expressed in breast cancer.",
        "Journal":"Molecular cancer therapeutics",
        "Do_id":"17121940",
        "Doc_ChemicalList":"Antigens, Neoplasm;Biomarkers, Tumor;DNA, Complementary;Intracellular Signaling Peptides and Proteins;MIEN1 protein, human;Neoplasm Proteins;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Amino Acid Sequence;Animals;Antigens, Neoplasm;Biomarkers, Tumor;Breast Neoplasms;DNA, Complementary;Female;Humans;Immunohistochemistry;Intracellular Signaling Peptides and Proteins;Molecular Sequence Data;Neoplasm Proteins;Receptor, ErbB-2;Tumor Cells, Cultured",
        "Doc_meshqualifiers":"genetics;metabolism;genetics;metabolism;genetics;metabolism;metabolism;genetics;metabolism;genetics;metabolism",
        "_version_":1605906334288445440},
      {
        "Doc_abstract":"A better understanding of how epidermal growth factor receptor family members (ErbBs) contribute to metastasis is important for evaluating ErbB-directed therapies. Activation of ErbB3/ErbB2 heterodimers can affect both proliferation and motility. We find that increasing ErbB3-dependent signaling in orthotopic injection models of breast cancer can enhance intravasation and lung metastasis with no effect on primary tumor growth or microvessel density. Enhanced metastatic ability due to increased expression of ErbB2 or ErbB3 correlated with stronger chemotaxis and invasion responses to heregulin beta1. Suppression of ErbB3 expression reduced both intravasation and metastasis. A human breast cancer tumor tissue microarray showed a significant association between ErbB3 and ErbB2 expression and metastasis independent of tumor size. These results indicate that ErbB3-dependent signaling through ErbB3/ErbB2 heterodimers can contribute to metastasis through enhancing tumor cell invasion and intravasation in vivo and that ErbB-directed therapies may be useful for the inhibition of invasion independent of effects on tumor growth.",
        "Doc_title":"ErbB3-dependent motility and intravasation in breast cancer metastasis.",
        "Journal":"Cancer research",
        "Do_id":"16452197",
        "Doc_ChemicalList":"Receptor, ErbB-2;Receptor, ErbB-3",
        "Doc_meshdescriptors":"Animals;Breast Neoplasms;Cell Line, Tumor;Cell Movement;Female;Humans;Lung Neoplasms;Mammary Neoplasms, Experimental;Mice;Mice, Inbred BALB C;Mice, SCID;Neoplastic Cells, Circulating;Rats;Receptor, ErbB-2;Receptor, ErbB-3",
        "Doc_meshqualifiers":"metabolism;pathology;physiology;secondary;metabolism;pathology;pathology;biosynthesis;biosynthesis",
        "_version_":1605761350136496128},
      {
        "Doc_abstract":"ERBB2/HER2 belongs to the EGFR-family of receptor tyrosine kinases and its overexpression can promote tumor progression. Breast cancer patients with ERBB2 amplifications are currently treated with lapatinib, a small-molecule kinase inhibitor that specifically blocks EGFR/ERBB2 signaling. Here, we show that hypoxia, via HIF-1, induces resistance to lapatinib-mediated effects in ERBB2-expressing mammary epithelial and ERBB2-positive breast cancer cells. Lapatinib-mediated growth inhibition and apoptosis in three-dimensional (3D) cultures are decreased under hypoxic conditions. Hypoxia can maintain activation of signaling pathways downstream from ERBB2 including AKT and ERK in the presence of lapatinib. HIF-1 is both required and sufficient to induce lapatinib resistance as overexpression of stable HIF-1 in ERBB2-expressing cells blocks lapatinib-mediated effects and maintains ERBB2-downstream signaling under normoxic conditions. Under hypoxia, activation of ERK signaling is required for lapatinib resistance as treatment with MEK inhibitor trametinib reverses hypoxia-mediated lapatinib resistance. HIF-1 can bypass the lapatinib-treated inhibition of the ERK pathway via inhibition of the dual-specificity phosphatase 2 (DUSP2). Indeed, overexpression of DUSP2 in ErbB2-positve breast cancer cells reverses hypoxia-mediated lapatinib resistance. Thus, our results provide rationale for therapeutic evaluation of the treatment of hypoxic ERBB2 expressing breast tumors with a combination of lapatinib and MEK inhibitors.",
        "Doc_title":"Hypoxia/HIF1Î± induces lapatinib resistance in ERBB2-positive breast cancer cells via regulation of DUSP2.",
        "Journal":"Oncotarget",
        "Do_id":"25596742",
        "Doc_ChemicalList":"HIF1A protein, human;Hypoxia-Inducible Factor 1, alpha Subunit;Protein Kinase Inhibitors;Pyridones;Pyrimidinones;Quinazolines;lapatinib;trametinib;ERBB2 protein, human;Receptor, ErbB-2;Proto-Oncogene Proteins c-akt;Extracellular Signal-Regulated MAP Kinases;DUSP2 protein, human;Dual Specificity Phosphatase 2",
        "Doc_meshdescriptors":"Apoptosis;Breast Neoplasms;Cell Hypoxia;Cell Line;Cell Line, Tumor;Cell Proliferation;Drug Resistance, Neoplasm;Dual Specificity Phosphatase 2;Extracellular Signal-Regulated MAP Kinases;Female;Gene Expression Regulation, Neoplastic;Humans;Hypoxia-Inducible Factor 1, alpha Subunit;Immunoblotting;Kaplan-Meier Estimate;Prognosis;Protein Kinase Inhibitors;Proto-Oncogene Proteins c-akt;Pyridones;Pyrimidinones;Quinazolines;RNA Interference;Receptor, ErbB-2;Reverse Transcriptase Polymerase Chain Reaction;Signal Transduction",
        "Doc_meshqualifiers":"drug effects;genetics;genetics;metabolism;pathology;drug effects;genetics;drug effects;genetics;genetics;metabolism;metabolism;drug effects;genetics;metabolism;pharmacology;metabolism;pharmacology;pharmacology;pharmacology;genetics;metabolism;drug effects;genetics",
        "_version_":1605755599295873024},
      {
        "Doc_abstract":"The study was performed to assess the status of immunohistochemical markers in primary and metastatic breast cancer and to determine the organ-specific characteristics of metastatic breast cancer.;Samples from 13 cases of paired primary and metastatic breast cancer and 34 cases of metastatic breast cancer were included.;In the analysis of 13 cases of paired primary and metastatic breast cancer, estrogen receptor and progesterone receptor loss were noted in 1 (7.7%) case each. Androgen receptor loss and gain was noted in 2 (15.4%) cases, respectively. HER-2 showed 100% concordance with primary and metastatic tumors. C-kit was demonstrated in only 2 (15.4%) cases of metastatic breast cancer. In the analysis of 34 cases of metastatic breast cancer, when classified into triple-negative type (ER-, PR-, and HER-2-), HER-2+ type, and ER+ or PR+/HER-2- type according to immunohistochemical stain results, HER-2 type (66.7%) in brain metastasis and ER+ or PR+/HER-2- type (75.0%) in liver metastasis were predominant. Bone metastasis was composed of triple negative type (44.4%) and ER+ or PR+/HER-2- type (55.6%), and lung metastasis showed all of three subtypes in similar proportions.;Metastatic breast cancer shows different immunohistochemical phenotypes according to metastatic site (P = 0.048).",
        "Doc_title":"Metastatic breast cancer shows different immunohistochemical phenotype according to metastatic site.",
        "Journal":"Tumori",
        "Do_id":"20845803",
        "Doc_ChemicalList":"Biomarkers, Tumor;Receptors, Estrogen;Receptors, Progesterone;ERBB2 protein, human;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Adult;Biomarkers, Tumor;Breast Neoplasms;Female;Humans;Immunohistochemistry;Kaplan-Meier Estimate;Middle Aged;Phenotype;Receptor, ErbB-2;Receptors, Estrogen;Receptors, Progesterone;Sampling Studies",
        "Doc_meshqualifiers":"analysis;chemistry;pathology;analysis;analysis;analysis",
        "_version_":1605747543908548608},
      {
        "Doc_abstract":"The WW domain containing E3 ubiquitin protein ligase 1 (WWP1) is a homologous to the E6-associated protein C terminus-type E3 ligase frequently overexpressed in human prostate and breast cancers due to gene amplification. Previous studies suggest that WWP1 promotes cell proliferation and survival; however, the mechanism of WWP1 action is still poorly understood. Here, we showed that WWP1 upregulates and maintains erythroblastic leukemia viral oncogene homolog 2 (ErbB2) and epithelial growth factor receptor (EGFR) in multiple cell lines. WWP1 depletion dramatically attenuates the EGF-induced ERK phosphorylation. WWP1 forms a protein complex with RING finger protein 11 (RNF11), a negative regulator of ErbB2 and EGFR. The protein-protein interaction is through the first and third WW domains of WWP1 and the PY motif of RNF11. Although WWP1 is able to ubiquitinate RNF11 in vitro and in vivo, WWP1 neither targets RNF11 for degradation nor changes RNF11's cellular localization. Importantly, inhibition of RNF11 can rescue WWP1 siRNA-induced ErbB2 and EGFR downregulation and growth arrest. Finally, we demonstrated that RNF11 is overexpressed in a panel of prostate and breast cancer cell lines with WWP1 expression. These findings suggest that WWP1 may promote cell proliferation and survival partially through suppressing RNF11-mediated ErbB2 and EGFR downregulation.",
        "Doc_title":"The WW domain containing E3 ubiquitin protein ligase 1 upregulates ErbB2 and EGFR through RING finger protein 11.",
        "Journal":"Oncogene",
        "Do_id":"18724389",
        "Doc_ChemicalList":"Carrier Proteins;RNF11 protein, human;Epidermal Growth Factor;WWP1 protein, human;Ubiquitin-Protein Ligases;ERBB2 protein, human;Receptor, Epidermal Growth Factor;Receptor, ErbB-2;Extracellular Signal-Regulated MAP Kinases",
        "Doc_meshdescriptors":"Breast Neoplasms;Carrier Proteins;Cell Division;Cell Line, Tumor;Cell Survival;Epidermal Growth Factor;Extracellular Signal-Regulated MAP Kinases;Female;Gene Amplification;Gene Deletion;Gene Expression Regulation, Neoplastic;Genes, erbB-2;Humans;Male;Phosphorylation;Prostatic Neoplasms;Receptor, Epidermal Growth Factor;Receptor, ErbB-2;Ubiquitin-Protein Ligases",
        "Doc_meshqualifiers":"genetics;pathology;genetics;physiology;physiology;metabolism;genetics;pathology;genetics;genetics;deficiency;genetics;metabolism",
        "_version_":1605807223165943808},
      {
        "Doc_abstract":"To determine whether the inferior outcome noted with triple-negative breast cancer (TNBC) reflects a higher risk population among patients with breast cancer liver metastases.;A total of 123 patients with breast cancer liver metastases diagnosed at Tianjin Medical University Cancer Hospital were included in this study. Breast cancer subtype was assigned using immunohistochemistry or fluorescence in situ hybridization: hormone receptor (HR) positive (+)/human epidermal growth factor receptor 2 (HER2) negative (-), HR+/HER2+, HR-/HER2+ and triple-negative subtype. Clinical features and survival were evaluated in different subtypes.;The median age at breast cancer diagnosis was 47 years (range, 23-67 years). Breast cancer subtype was confirmed in all patients (39.8% with HR+/HER2-, 24.4% with HR+/HER2+, 15.3% with HR-/HER2+ and 20.3% with TNBC). The median overall survival after liver metastases was 29 months (range, 4-89 months), and the overall 1-, 2- and 3-year survival rate was 68.3, 48.0 and 34.1%, respectively. Survival was found to be impacted by breast cancer subtype (P = 0.001), and was shortest for patients with TNBC. Time to liver metastases (TTLM) less than 24 months and liver metastasis lesions â‰¥3 were found to be important predictors of poor survival after liver metastases (P = 0.009 and 0.001, respectively).;The results indicate that clinical breast cancer subtype remains an independent prognostic predictor among patients with breast cancer liver metastases. Liver metastases arising from TNBC confers the worst prognosis, and novel agents capable of controlling intrahepatic and extrahepatic TNBC are needed.",
        "Doc_title":"The prognostic analysis of clinical breast cancer subtypes among patients with liver metastases from breast cancer.",
        "Journal":"International journal of clinical oncology",
        "Do_id":"22041927",
        "Doc_ChemicalList":"Receptors, Estrogen;Receptors, Progesterone;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Adult;Aged;Aged, 80 and over;Breast Neoplasms;Chemotherapy, Adjuvant;Disease-Free Survival;Female;Humans;In Situ Hybridization, Fluorescence;Liver Neoplasms;Middle Aged;Prognosis;Receptor, ErbB-2;Receptors, Estrogen;Receptors, Progesterone",
        "Doc_meshqualifiers":"classification;metabolism;pathology;pathology;secondary;metabolism;metabolism",
        "_version_":1605741982671437824},
      {
        "Doc_abstract":"Human carcinomas are generally considered to develop through the accumulation of various genetic abnormalities. The major types of genetic alterations that are frequently observed in breast cancer are amplification of protooncogenes (MYC, ERBB2); mutation of TP53; and loss of heterozygosity on chromosomes 1, 3p, 8p, 11p, 13q, 17q, 17, and 22q. The latter may correspond to losses or inactivations of tumor suppressor genes. Recently, two major distinct breast susptibility genes were isolated, namely BRCA1 and BRCA2. We performed PCR-SSCP analysis to determine the role of the BRCA1 gene in Japanese breast cancer and investigated how multiple genetic alterations contribute to tumor development and/or progression in primary breast cancer, using a large number of tumor materials.",
        "Doc_title":"[Genetic alterations and DNA-based diagnosis in breast cancer].",
        "Journal":"Nihon Geka Gakkai zasshi",
        "Do_id":"8709940",
        "Doc_ChemicalList":"BRCA1 Protein;BRCA2 Protein;DNA, Neoplasm;Neoplasm Proteins;Transcription Factors",
        "Doc_meshdescriptors":"BRCA1 Protein;BRCA2 Protein;Breast Neoplasms;DNA, Neoplasm;Family Health;Female;Humans;Neoplasm Proteins;Polymerase Chain Reaction;Polymorphism, Single-Stranded Conformational;Proto-Oncogenes;Transcription Factors",
        "Doc_meshqualifiers":"diagnosis;genetics;analysis;genetics;genetics",
        "_version_":1605907518400233472},
      {
        "Doc_abstract":"Her-2/neu (ErbB2) oncogene, the second member of the epidermal growth factor receptor (EGFR) family, encodes a transmembrane tyrosine kinase receptor in Her-2-positive tumors. Accumulating evidences demonstrate that signaling networks activated by EGFR and transcription factor NF-kappaB are associated with cell response to ionizing radiation (IR). The present study shows that overexpression of ErbB2 enhanced NF-kappaB activation induced by IR in human breast carcinoma MCF-7 cells transfected with ErbB2 genes (MCF-7/ErbB2). Stable transfection of dominant-negative mutant IkappaB (MCF-7/ErbB2/mIkappaB) or treatment with anti-ErbB2 antibody, Herceptin, inhibited NF-kappaB activation and radiosensitized MCF-7/ErbB2 cells. Consistent with NF-kappaB regulation, basal and IR-induced Akt, a kinase downstream of ErbB2, was activated in MCF-7/ErbB2 cells and inhibited by Herceptin. To identify specific genes affected by ErbB2-mediated NF-kappaB activation, a group of IR-responsive elements Cyclin B1, Cyclin D1, Bcl-2, Bcl/XL, BAD and BAX were evaluated. Basal levels of prosurvival elements Cyclin B1, Cyclin D1, Bcl-2 and Bcl/XL but not apoptotic BAD and BAX were upregulated in MCF-7/ErbB2 cells with striking enhancements in Bcl-2 and Bcl/XL. IR further induced Cyclin B1 and Cyclin D1 expression that was reduced by Herceptin. Bcl-2 kept a high steady level after Herceptin+IR treatment and, in contrast to control MCF-7/Vector cells, Bcl/XL was inhibited in MCF-7/ErbB2 cells by Herceptin+IR treatment. However, all four prosurvival proteins were downregulated by inhibition of NF-kappaB in MCF-7/ErbB2/mIkappaB cells. These results thus provide evidence suggesting that overexpression of ErbB2 is able to enhance NF-kappaB response to IR, and that a specific prosurvival network downstream of NF-kappaB is triggered by treatments using anti-ErbB2 antibody combined with radiation.",
        "Doc_title":"Expression of ErbB2 enhances radiation-induced NF-kappaB activation.",
        "Journal":"Oncogene",
        "Do_id":"14724581",
        "Doc_ChemicalList":"Antibodies, Monoclonal;Antibodies, Monoclonal, Humanized;BAD protein, human;BAX protein, human;BCL2L1 protein, human;CCNB1 protein, human;Carrier Proteins;Cyclin B;Cyclin B1;NF-kappa B;Proto-Oncogene Proteins;Proto-Oncogene Proteins c-bcl-2;bcl-2-Associated X Protein;bcl-Associated Death Protein;bcl-X Protein;Cyclin D1;Receptor, ErbB-2;AKT1 protein, human;Protein-Serine-Threonine Kinases;Proto-Oncogene Proteins c-akt;Trastuzumab",
        "Doc_meshdescriptors":"Antibodies, Monoclonal;Antibodies, Monoclonal, Humanized;Apoptosis;Carrier Proteins;Cell Line, Tumor;Cell Survival;Cyclin B;Cyclin B1;Cyclin D1;Enzyme Activation;Humans;NF-kappa B;Protein-Serine-Threonine Kinases;Proto-Oncogene Proteins;Proto-Oncogene Proteins c-akt;Proto-Oncogene Proteins c-bcl-2;Radiation, Ionizing;Receptor, ErbB-2;Trastuzumab;bcl-2-Associated X Protein;bcl-Associated Death Protein;bcl-X Protein",
        "Doc_meshqualifiers":"pharmacology;drug effects;radiation effects;metabolism;drug effects;radiation effects;metabolism;metabolism;drug effects;radiation effects;metabolism;metabolism;metabolism;genetics;metabolism",
        "_version_":1605742806883631104},
      {
        "Doc_abstract":"Trastuzumab treatment does not prevent intracranial seeding and is largely ineffective for established central nervous system metastasis in HER2 overexpressing breast cancer patients. Combination therapy of lapatinib and capecitabine may be an effective treatment option for brain metastasis of HER2-positive breast cancer. We report a patient with breast cancer overexpressing HER-2 where brain metastases were successfully treated with radiation and a combination of lapatinib and capecitabine. ",
        "Doc_title":"Nearly Complete Response of Brain Metastases from HER2 Overexpressing Breast Cancer with Lapatinib and Capecitabine after Whole Brain Irradiation.",
        "Journal":"Case reports in oncological medicine",
        "Do_id":"24191208",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605907056263430144},
      {
        "Doc_abstract":"BRCA1 associated tumours are found to express an oestrogen receptor negative \"basal epithelial-like\" phenotype. In contrast to ER negative tumours in general, such tumours rarely harbour amplification of the HER-2 gene. However, little is known about TOP2A gene amplification status in BRCA1-associated tumours. Such information may be of importance to therapy, as amplification of TOP2A has been associated with dose-dependent sensitivity to anthracycline therapy in breast cancer. We examined 40 breast carcinomas from BRCA1 mutation carriers and 40 sporadic breast carcinomas matched for age, tumour diameter and histological grade for HER-2 and TOP2A amplification status using fluorescence in situ hybridisation (FISH). Co-amplification of TOP2A and HER-2 was found in four of the mutation carriers and in three of the controls. While six tumours in the control group harboured HER-2 amplifications with normal TOP2A, this occurred in three of the BRCA1 associated tumours only. In contrast, three of the BRCA1-associated tumours but none of the controls harboured TOP2A amplification despite normal HER-2 status. Our findings have potential therapeutic implications. HER-2 assessment is routinely used to select breast cancer patients for trastuzumab but also dose-intensive anthracycline therapy. Our data suggest that BRCA1-associated breast cancers also need to be tested for TOP2A amplification.",
        "Doc_title":"Amplification of TOP2A and HER-2 genes in breast cancers occurring in patients harbouring BRCA1 germline mutations.",
        "Journal":"Acta oncologica (Stockholm, Sweden)",
        "Do_id":"17453369",
        "Doc_ChemicalList":"Antigens, Neoplasm;BRCA1 Protein;DNA, Neoplasm;DNA-Binding Proteins;DNA Topoisomerases, Type II;DNA topoisomerase II alpha",
        "Doc_meshdescriptors":"Antigens, Neoplasm;BRCA1 Protein;Breast Neoplasms;Carcinoma;DNA Topoisomerases, Type II;DNA, Neoplasm;DNA-Binding Proteins;Female;Gene Amplification;Genes, erbB-2;Germ-Line Mutation;Humans;In Situ Hybridization, Fluorescence",
        "Doc_meshqualifiers":"genetics;genetics;genetics;genetics;genetics;analysis;genetics;genetics",
        "_version_":1605818634902437889},
      {
        "Doc_abstract":"In Indian women with breast cancer, the HER-2/neu gene is amplified in 30% of cases. Elevated serum HER-2/neu levels have been shown to be associated with a poor clinical prognosis and decreased survival in early stage breast cancer patients, and testing for this may help to manage the disease. The present study was therefore to estimate serum HER-2/neu levels in breast cancer patients and associate these with other prognostic factors.;Serum HER-2/neu levels were studied in 207 patients with breast cancer, 15 with benign breast diseases, (BBD) and 175 age-matched healthy controls. Patients' age, menopausal status, node, and estrogen receptor (ER) and progesterone receptor (PgR) status were compared with serum HER-2/neu levels.;Serum HER-2/neu overexpression was associated with age, disease stage and positive nodal status but not with menopausal status. Serum HER-2/neu levels were negatively correlated with hormone receptor positivity.;HER-2/neu serum tests should be done more frequently in Indian women with breast cancer, irrespective of their ER and PgR hormone receptor status. ELISA is a reliable and economical tool to assess the HER-2/neu status in tumors, when breast tissue samples are not available.",
        "Doc_title":"Cancer biomarker HER-2/neu in breast cancer in Indian women.",
        "Journal":"Breast cancer (Dove Medical Press)",
        "Do_id":"24367173",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605875634388598784},
      {
        "Doc_abstract":"Trastuzumab is only effective in 25% to 30% of the administered breast cancer patients who overexpress the erbB2/Her-2 oncoprotein. PC cell-derived growth factor (PCDGF/GP88) is an 88-kDa glycoprotein growth factor overexpressed in 80% invasive ductal carcinomas. Our objective was to determine whether the increased levels of PCDGF/GP88 confers Trastuzumab resistance in erbB2-overexpressing breast cancer cells.;The ability of PCDGF to induce erbB2 phosphorylation and to confer Trastuzumab resistance was studied in erbB2-overexpressing MCF-7 and SKBR3 breast cancer cell lines.;PCDGF/GP88 added exogenously induced the phosphorylation of erbB2 in a dose-dependent and time-dependent manner in erbB2-overexpressing breast cancer cells. In addition, the overexpression of PCDGF/GP88 conferred Trastuzumab resistance in erbB2-overexpressing cells. Furthermore, overexpression of PCDGF/GP88 in erbB2-overexpressing cells provided a growth advantage over erbB2-overexpressing cells that do not have increased levels of PCDGF/GP88. Lastly, PCDGF/GP88 induced the phosphorylation of mitogen-activated protein kinase in a time-dependent manner in erbB2-overexpressing cells, and pretreatment with Trastuzumab was not able to attenuate the phosphorylation levels of mitogen-activated protein kinase induced by PCDGF/GP88.;These data suggest that PCDGF/GP88 confers Trastuzumab resistance in erbB2-overexpressing cells. Thus, the increase in PCDGF/GP88 levels may indicate Trastuzumab unresponsiveness in breast cancer patients.",
        "Doc_title":"PC cell-derived growth factor stimulates proliferation and confers Trastuzumab resistance to Her-2-overexpressing breast cancer cells.",
        "Journal":"Clinical cancer research : an official journal of the American Association for Cancer Research",
        "Do_id":"16857791",
        "Doc_ChemicalList":"Antibodies, Monoclonal;Antibodies, Monoclonal, Humanized;Antineoplastic Agents;GRN protein, human;Intercellular Signaling Peptides and Proteins;Receptor, ErbB-2;Trastuzumab",
        "Doc_meshdescriptors":"Animals;Antibodies, Monoclonal;Antibodies, Monoclonal, Humanized;Antineoplastic Agents;Breast Neoplasms;Cell Line, Tumor;Cell Proliferation;Dose-Response Relationship, Drug;Drug Resistance, Neoplasm;Female;Humans;Intercellular Signaling Peptides and Proteins;MAP Kinase Signaling System;Mice;Mice, Nude;Neoplasm Transplantation;Receptor, ErbB-2;Time Factors;Trastuzumab",
        "Doc_meshqualifiers":"pharmacology;pharmacology;drug therapy;pathology;biosynthesis;metabolism",
        "_version_":1605759266003615744},
      {
        "Doc_abstract":"This study is to investigate the binding capability of lidamycin apoprotein (LDP), an enediyne-associated apoprotein of the chromoprotein antitumor antibiotic family, to human breast cancer and normal tissues, the correlation of LDP binding capability to human breast cancer tissues and the expression of tumor therapeutic targets such as VEGF and HER2. In this study, the binding capability of LDP to human breast cancer tissues was detected with tissue microarray. The correlation study of LDP binding capability to human breast tumor tissues and relevant therapeutic targets was performed on breast cancer tissue microarrays. Immunocytochemical examination was used to detect the binding capability of LDP to human breast carcinoma MCF-7 cells. As a result, tissue microarray showed that LDP staining of 73.2% (30/41) of breast cancer tissues was positive, whereas that of 48.3% (15/31) of the adjacent normal breast specimens was positive. The difference between the tumor and normal samples was significant (Chi2 = 4.63, P < 0.05). LDP immunoreactivity in breast cancer correlated significantly with the overexpression of VEGF and HER2 (P < 0.001 and < 0.01, r = 0.389 and 0.287, respectively). Determined with confocal immunofluorescent analysis, LDP showed the binding capability to mammary carcinoma MCF-7 cells. It is demonstrated that LDP can bind to human breast cancer tissues and there is significant difference between the breast cancer tissues and the corresponding normal tissues. Notably, the binding reactivity shows positive correlation with the expression of VEGF and HER2 in breast carcinoma tissues. The results imply that LDP may have a potential use as targeting drug carrier in the research and development of new anticancer therapeutics. This study may provide reference for drug combination of LDM and other therapeutic agents.",
        "Doc_title":"[Binding capability of lidamycin apoprotein to human breast cancer detected by tissue microarrays].",
        "Journal":"Yao xue xue bao = Acta pharmaceutica Sinica",
        "Do_id":"20931759",
        "Doc_ChemicalList":"Aminoglycosides;Antibiotics, Antineoplastic;Apoproteins;Enediynes;Vascular Endothelial Growth Factor A;C 1027;ERBB2 protein, human;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Aminoglycosides;Antibiotics, Antineoplastic;Apoproteins;Breast Neoplasms;Cell Line, Tumor;Enediynes;Female;Humans;Protein Binding;Receptor, ErbB-2;Tissue Array Analysis;Vascular Endothelial Growth Factor A",
        "Doc_meshqualifiers":"metabolism;metabolism;metabolism;metabolism;pathology;metabolism;metabolism;methods;metabolism",
        "_version_":1605811898272448512},
      {
        "Doc_abstract":"The activation of receptor tyrosine kinases, particularly ErbB2, has been linked to the genesis and progression of breast cancer. Two of the central signaling pathways activated by ErbB2 are the Ras/Raf-1/Mek/Erk pathway, which plays an important role in tumor cell growth and migration, and the PI3K/Akt pathway, which plays an important role in cell survival. Recently, we and others have shown that signaling through the Ras-Erk pathway can be influenced by p21-activated kinase 1 (Pak1), an effector of the Rho family GTP ases Rac and Cdc42. Expression of activated forms of Rac promotes activation of Erk through mechanisms involving Pak1 phosphorylation of Raf-1 and Mek1. In addition, Pak1 has also been implicated in the activation of Akt. However, our understanding regarding the degree to which Rho GTPases, and their effectors such as Pak1, contribute to ErbB2-mediated signaling is very limited.Recent results from our laboratory indicate that ErbB2 expression correlates with Pak activation in estrogen receptor negative human breast tumor samples. Using a three-dimensional (3D) culture of human MCF-10A mammary epithelial cells, we found that activation of Rac-Pak pathway by ErbB2 induces growth factor independent proliferation and promotes disruption of acini-like structures through the activation of the Erk and Akt pathways. We also observed that blocking Pak1 activity by small molecule inhibitors impeded the ability of activated ErbB2 to transform these cells and to activate its associated downstream signaling targets. In addition, we found that suppressing Pak activity in ErbB2-amplified breast cancer cells delayed tumor formation and downregulated Erk and Akt signaling in vivo. These results support a model in which Pak, by activating Erk and Akt, cooperates with ErbB2 in transforming mammary epithelial cells.",
        "Doc_title":"p21-activated kinases in Erbb2-positive breast cancer: A new therapeutic target?",
        "Journal":"Small GTPases",
        "Do_id":"21686266",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605751560162246656},
      {
        "Doc_abstract":"Taxanes are effective in the treatment of metastatic breast cancer. Docetaxel has been shown to be more potent than paclitaxel in inducing bcl-2 phosphorylation and apoptosis and is clinically active in some paclitaxel-resistant breast tumors. HER-2/neu overexpression has been shown to correlate with resistance to hormonal therapy as well as chemotherapy. Using a HER-2/neu transfected MCF-7 human breast cancer cell line, we investigated the role of HER-2/neu overexpression on resistance to paclitaxel and docetaxel treatment. A control vector transfected MCF-7 human breast cancer cell line (MCF/neo) and a HER-2/neu transfected MCF-7 line (MCF/18) were treated with various concentrations of docetaxel or paclitaxel. Cell number was assessed using the MTT tetrazolium dye assay. In the control vector transfected MCF/neo cell line, paclitaxel and docetaxel gave similar dose-dependent growth inhibition ( p = 0.175). In HER-2/neu transfected MCF/18 cells, docetaxel treatment resulted in a dose-dependent inhibition similar to that seen in MCF/neo cells. Paclitaxel, however, gave significantly less growth inhibition than docetaxel in the HER-2/neu overexpressing MCF/18 cells (p = 0.0003). These data suggest that HER-2/neu overexpression may contribute to paclitaxel resistance. In contrast, the cytotoxic effects of docetaxel in these breast carcinoma cells are not affected by HER-2/neu expression. Therefore, docetaxel may be the preferred taxane therapy in HER-2/neu overexpressing breast tumors.",
        "Doc_title":"Decreased response to paclitaxel versus docetaxel in HER-2/neu transfected human breast cancer cells.",
        "Journal":"American journal of clinical oncology",
        "Do_id":"12576925",
        "Doc_ChemicalList":"Antineoplastic Agents, Phytogenic;Taxoids;docetaxel;Paclitaxel",
        "Doc_meshdescriptors":"Antineoplastic Agents, Phytogenic;Breast Neoplasms;Cell Division;Drug Resistance, Neoplasm;Drug Screening Assays, Antitumor;Gene Expression;Genes, erbB-2;Humans;Paclitaxel;Taxoids;Transfection;Tumor Cells, Cultured",
        "Doc_meshqualifiers":"pharmacology;drug therapy;genetics;drug effects;genetics;genetics;genetics;analogs & derivatives;pharmacology",
        "_version_":1605841077615460352},
      {
        "Doc_abstract":"Transferrin (Tf) conjugates of monomeric artemisinin (ART) and artemisinin dimer were synthesized. The two conjugates, ART-Tf and dimer-Tf, retained the original protein structure, and formed stable aggregates in aqueous buffer. ART-Tf induced declines in proteins involved in apoptosis (survivin), cell cycling (cyclin D1), oncogenesis (c-myelocytomatosis oncogene product (c-MYC)), and dysregulated WNT signaling (beta-catenin) in both the human prostate (DU145) and breast (MCF7) cancer cell lines. Both ART-Tf and dimer-Tf induced down-regulation of survivin, c-MYC and mutated human epidermal growth factor receptor-2 (ERBB2 or HER2) in the BT474 breast cancer cell line. To our knowledge, this is the first demonstration that an ART derivative can cause a decline of ERBB2 in a human cancer cell line. Potential mechanisms for the observed effects are presented. Both transferrin conjugates strongly inhibited the growth of BT474 cells in the same concentration range that the conjugates caused declines in the levels of ERBB2, survivin, and c-MYC, while showing essentially no toxicity towards MCF10A normal breast cells.",
        "Doc_title":"Effects of transferrin conjugates of artemisinin and artemisinin dimer on breast cancer cell lines.",
        "Journal":"Anticancer research",
        "Do_id":"23267137",
        "Doc_ChemicalList":"Artemisinins;BIRC5 protein, human;CCND1 protein, human;Inhibitor of Apoptosis Proteins;MYC protein, human;Proto-Oncogene Proteins c-myc;Transferrin;beta Catenin;Cyclin D1;artemisinine;ERBB2 protein, human;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Apoptosis;Artemisinins;Breast Neoplasms;Cell Line, Tumor;Cell Proliferation;Cyclin D1;Female;Humans;Inhibitor of Apoptosis Proteins;Male;Prostatic Neoplasms;Protein Multimerization;Proto-Oncogene Proteins c-myc;Receptor, ErbB-2;Transferrin;Wnt Signaling Pathway;beta Catenin",
        "Doc_meshqualifiers":"drug effects;administration & dosage;chemistry;drug therapy;genetics;metabolism;drug effects;metabolism;metabolism;drug therapy;genetics;metabolism;metabolism;metabolism;administration & dosage;chemistry;drug effects;metabolism",
        "_version_":1605912425799876608},
      {
        "Doc_abstract":"Breast cancer is a highly heterogeneous disease with distinct histologic subtypes. Targeted therapies such as endocrine therapy and growth factor receptor inhibitors have had a significant impact on the treatment of metastatic breast cancer patients. Unfortunately, resistance to these agents eventually occurs, and currently represents a significant clinical problem in the management of breast cancers. Inhibitors of histone deacetylases (HDACi) exhibit anticancer activity in a variety of tumor cell models and have been shown to target mechanisms of resistance to a number of targeted agents. It is unclear, however, if there are specific breast cancer subtypes for which an HDACi may be more or less effective. Here, we report that the class I isoform-selective HDACi entinostat (SNDX-275) preferentially inhibits cell proliferation/survival and inactivates downstream signaling in erbB2-overexpressing compared with basal breast cancer cells. SNDX-275 reduces the levels of both erbB2 and erbB3, as well as significantly decreases P-erbB2, P-erbB3, P-Akt, and P-MAPK in erbB2-overexpressing cells. Additionally, SNDX-275 promotes apoptosis and induces cell cycle arrest predominantly at G(1) phase in erbB2-overexpressing cells, whereas SNDX-275 mainly induces G(2)-M arrest in basal breast cancer cells. The cellular bias of SNDX-275 is shown to be related partly to the levels of erbB3 expression that directly impact the ability of SNDX-275 to inhibit proliferation/survival of the erbB2-overexpressing breast cancer cells. These findings show that SNDX-275 may be developed as a novel therapeutic agent to treat breast cancers with coexpression of both erbB2 and erbB3.",
        "Doc_title":"HDAC inhibitor SNDX-275 induces apoptosis in erbB2-overexpressing breast cancer cells via down-regulation of erbB3 expression.",
        "Journal":"Cancer research",
        "Do_id":"19826038",
        "Doc_ChemicalList":"Benzamides;Histone Deacetylase Inhibitors;Pyridines;RNA, Messenger;RNA, Small Interfering;entinostat;ERBB2 protein, human;Receptor, ErbB-2;Receptor, ErbB-3",
        "Doc_meshdescriptors":"Apoptosis;Benzamides;Blotting, Western;Breast Neoplasms;Cell Cycle;Cell Proliferation;Female;Flow Cytometry;Histone Deacetylase Inhibitors;Humans;Immunoblotting;Pyridines;RNA, Messenger;RNA, Small Interfering;Receptor, ErbB-2;Receptor, ErbB-3;Reverse Transcriptase Polymerase Chain Reaction;Tumor Cells, Cultured",
        "Doc_meshqualifiers":"drug effects;pharmacology;metabolism;pathology;drug effects;drug effects;pharmacology;genetics;metabolism;pharmacology;genetics;metabolism;antagonists & inhibitors;genetics;metabolism",
        "_version_":1605844153234620416},
      {
        "Doc_abstract":"Triple-negative breast cancers are defined by a lack of expression of oestrogen, progesterone, and ERBB2 receptors. This subgroup accounts for 15% of all types of breast cancer and for a higher percentage of breast cancer arising in African and African-American women who are premenopausal. Because of the absence of specific treatment guidelines for this subgroup, triple-negative breast cancers are managed with standard treatment; however, such treatment leaves them associated with a high rate of local and systemic relapse. Histologically, such cancers are poorly differentiated, and most fall into the basal subgroup of breast cancers, characterised by staining for basal markers (ie, cytokeratin 5/6). Analyses of microarray gene-expression profiling data show that they form a homogeneous group (or so-called cluster) in transcriptional terms and, increasingly, research studies are identifying basal cancers on the basis of exhibiting this distinctive transcriptional profile. Histologically and transcriptionally, triple-negative breast cancers have many similarities to BRCA1-associated breast cancers, which suggests that dysfunction in BRCA1 or related pathways occurs in this subset of sporadic cancers. In this review, we discuss the molecular features of triple-negative breast cancers and consider how the use of existing cytotoxic agents can be optimised for this patient group. We discuss the implications of a possible underlying BRCA1-pathway dysfunction in this subgroup in terms of treatment and we also investigate the predominant proliferative signals and the on-going research addressing the suitability of these signals as therapeutic targets.",
        "Doc_title":"Triple-negative breast cancer: therapeutic options.",
        "Journal":"The Lancet. Oncology",
        "Do_id":"17329194",
        "Doc_ChemicalList":"BRCA1 Protein;Receptors, Estrogen;Receptors, Progesterone;Receptor, ErbB-2",
        "Doc_meshdescriptors":"BRCA1 Protein;Breast Neoplasms;Female;Humans;Receptor, ErbB-2;Receptors, Estrogen;Receptors, Progesterone",
        "Doc_meshqualifiers":"biosynthesis;drug therapy;genetics;metabolism;pathology;biosynthesis;biosynthesis;biosynthesis",
        "_version_":1605792626823397376},
      {
        "Doc_abstract":"Triple-negative breast cancer accounts for less than 20% of breast cancers overall, but is the predominant subtype among carriers of mutations in BRCA1. However, few studies have assessed the association between breast cancer family history and risk of triple-negative breast cancer. We examined the relationship between having a family history of breast cancer in first-degree relatives and risk of triple-negative breast cancer, and risk of two other breast cancer subtypes defined by tumor marker expression. We evaluated data collected by the Breast Cancer Surveillance Consortium from 2,599,946 mammograms on 1,054,466 women, among whom 15% reported a first-degree family history of breast cancer. Using Cox regression in this cohort, we evaluated subtype-specific associations between family history and risk of triple-negative (N = 705), estrogen receptor-positive (ER+, N = 10,026), and hormone receptor-negative/HER2-expressing (ER-/PR-/HER2+, N = 308) breast cancer among women aged 40-84 years. First-degree family history was similarly and significantly associated with an increased risk of all the subtypes [hazard ratio (HR) = 1.73, 95% confidence interval (CI): 1.43-2.09, HR = 1.62, 95% CI: 1.54-1.70, and HR = 1.56, 95% CI: 1.15-2.13, for triple-negative, ER+, and ER-/PR-/HER2+, respectively]. Risk of all the subtypes was most pronounced among women with at least two affected first-degree relatives (versus women with no affected first-degree relatives, HR(triple-negative) = 2.66, 95% CI: 1.66-4.27, HR(ER+) = 2.05, 95% CI: 1.79-2.36, HR(ER)-(/PR)-(/HER2+) = 2.25, 95% CI: 0.99-5.08). Having a first-degree family history of breast cancer was associated with an increased risk of triple-negative breast cancer with a magnitude of association similar to that for the predominant ER+ subtype and ER-/PR-/HER2+ breast cancer.",
        "Doc_title":"Family history of breast cancer in first-degree relatives and triple-negative breast cancer risk.",
        "Journal":"Breast cancer research and treatment",
        "Do_id":"20814817",
        "Doc_ChemicalList":"Biomarkers, Tumor;Receptors, Estrogen;Receptors, Progesterone;ERBB2 protein, human;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Adult;Aged;Aged, 80 and over;Biomarkers, Tumor;Breast Neoplasms;Cohort Studies;Family Health;Female;Genetic Predisposition to Disease;Humans;Mammography;Middle Aged;Proportional Hazards Models;Receptor, ErbB-2;Receptors, Estrogen;Receptors, Progesterone;Risk",
        "Doc_meshqualifiers":"genetics;methods;biosynthesis;biosynthesis;genetics;biosynthesis;genetics",
        "_version_":1605766282743906304},
      {
        "Doc_abstract":"The human epidermal receptor-2/neu (HER-2/neu) oncogene encodes a transmembrane tyrosine kinase receptor. This molecule could have a diagnostic value since the extracellular domain of c-erbB-2 (HER-2) transmembrane is shed into the blood as a circulating antigen. The diagnostic value of serum HER-2/neu was calculated along with the conventional marker carbohydrate antigen 15-3 (CA15-3) and carcinoembryonic antigen (CEA) at 85th percentiles. Serum levels of breast carcinoma antigens HER-2/neu, CEA and CA15-3 were determined in 175 normal individuals and 268 malignant patients. The soluble form of serum HER-2/neu, CEA and CA15-3 was assayed by enzyme linked immunosorbent assay in control and breast cancer patients prior to treatment. Serum levels of the tested tumor markers HER-2/neu and CA15-3 and CEA were significantly higher in cancer patients compared to controls. At 85th percentile the sensitivity of HER-2/neu was 51.12Â %; the specificity was 86.29Â % and the overall accuracy was 64.56Â %. The sensitivity of CA15-3 was 73.13Â %; the specificity was 85.14Â % and the overall accuracy was 77.88Â %. The sensitivity of the combined testing was 82.84Â %; the specificity was 73.71Â % and the overall accuracy was 80.01Â %. The sensitivity and the overall accuracy of combined testing were higher than those of HER-2/neu and CA15-3 testing single. The combined testing of HER-2/neu and CA15-3 can increase the sensitivity and overall accuracy of breast cancer diagnosis. The results of this study suggest that the use of multiple tumor markers may be employed as combination and at 85th percentiles to assess the prognosis. ",
        "Doc_title":"Diagnostic Significance of CA15-3 with Combination of HER-2/neu Values at 85th Percentiles in Breast Cancer.",
        "Journal":"Indian journal of clinical biochemistry : IJCB",
        "Do_id":"24426198",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605766811705409536},
      {
        "Doc_abstract":"The receptor tyrosine kinase ErbB2 is an important prognostic marker and therapeutic target in breast cancer. The aim of this study was to investigate the correlation between ErbB2 gene amplification, mRNA and protein expression in a panel of >100 patient-derived nude mouse tumor xenografts of different histological origin.;Data were obtained using fluorescence in situ hybridization, GenChip expression analysis, immunohistochemistry and enzyme-linked immunosorbent assay (ELISA). Tumors included the following types: urinary bladder, breast, colon, stomach, kidney, liver, lung, melanoma, ovary, pancreas, prostate, uterus/cervix uteri and others.;All tumors with high-level ErbB2 gene amplification expressed ErbB2 mRNA at a level >10-fold above average and protein at a level >20-fold above average (ELISA). Correlation was found between ErbB2 mRNA and protein expression.;Based on expression data, cervical, gastric and adenocarcinomas of the lung emerged as new potential indications for ErbB2-directed cancer therapies.",
        "Doc_title":"Correlation of ErbB2 gene status, mRNA and protein expression in a panel of >100 human tumor xenografts of different origin.",
        "Journal":"Onkologie",
        "Do_id":"16770086",
        "Doc_ChemicalList":"Biomarkers, Tumor;Neoplasm Proteins;RNA, Messenger;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Biomarkers, Tumor;Gene Expression;Gene Expression Profiling;Genes, erbB-2;Humans;Neoplasm Proteins;Neoplasms;RNA, Messenger;Receptor, ErbB-2;Statistics as Topic;Transplantation, Heterologous;Tumor Cells, Cultured",
        "Doc_meshqualifiers":"genetics;metabolism;genetics;genetics;genetics;metabolism;diagnosis;genetics;metabolism;genetics;genetics;metabolism",
        "_version_":1605880426970218496},
      {
        "Doc_abstract":"ERBB2 (HER-2/neu) amplification and/or overexpression are associated with poor prognosis in node-positive breast carcinoma. Its prognostic value in node-negative cases and its predictive value for response to chemotherapy remain controversial. This may be related to the use of molecular methods, which are sensitive to dilution of tumor material by normal cells, or the use of nonstandardized immunohistochemistry (IHC) procedures, for the determination of the ERBB2 gene status. In addition, new therapeutic approaches that target the cells overexpressing ERBB2 are under development. These perspectives necessitate a reliable evaluation of the status of ERBB2 in individual tumors before the application of specific therapeutic strategies. Fluorescent in situ hybridization (FISH) and IHC allow the evaluation of the ERBB2 status specifically in tumor cells on archival material. We have analyzed a series of 100 invasive ductal breast carcinomas without lymph node invasion both by IHC, using the CB11 monoclonal antibody and a sensitive Auidin Biotin Complex (ABC) immunodetection system, and by FISH, using the Oncor Inform HER-21neu (ERBB2) gene amplification detection system as reference technique. Complete concordance between the results of FISH and IHC was seen in 98% of the cases. ERBB2 amplification (more than four signals per nucleus) was observed in 12 of the 100 cases, and all but one showed an overexpression of the protein (membrane staining) by IHC. Conversely, ERBB2 expression was present in one case without gene amplification. In conclusion, ERBB2 overexpression detected by IHC is highly correlated to gene amplification detected by FISH. Thus, under standardized conditions, IHC is a reliable and economical test to assess the ERBB2 status in tumors. The use of FISH could be limited to the verification of the status of tumors displaying a weak membrane immunostaining.",
        "Doc_title":"Strong correlation between results of fluorescent in situ hybridization and immunohistochemistry for the assessment of the ERBB2 (HER-2/neu) gene status in breast carcinoma.",
        "Journal":"Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc",
        "Do_id":"11106082",
        "Doc_ChemicalList":"DNA, Neoplasm;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Breast Neoplasms;Carcinoma, Ductal, Breast;DNA, Neoplasm;Female;Genes, erbB-2;Humans;Immunoenzyme Techniques;In Situ Hybridization, Fluorescence;Middle Aged;Receptor, ErbB-2;Reproducibility of Results;Sensitivity and Specificity",
        "Doc_meshqualifiers":"genetics;metabolism;pathology;genetics;metabolism;pathology;analysis;methods;methods;metabolism",
        "_version_":1605881570087927808},
      {
        "Doc_abstract":"The testing of newly diagnosed breast cancer specimens for HER-2/neu status has achieved \"standard of practice\" status for the management of breast cancer in the United States. The discussion as to the best method to determine HER-2/neu status in these samples continues, with the fluorescence in situ hybridization method gaining popularity owing to the recent evidence that it, in comparison with immunohistochemical analysis, might more accurately predict clinical responses to trastuzumab-based therapies. With trastuzumab achieving excellent results in the treatment of HER-2/neu-positive advanced disease and under extensive evaluation in major clinical trials for its potential efficacy when used at earlier clinical stages, the potential role(s) for HER-2/neu testing as a predictor of response to other therapies being resolved by large prospective clinical outcome studies, and the more convenient gene-based chromogenic in situ hybridization technique \"waiting in the wings,\" the saga of HER-2/neu testing in breast cancer will continue to unfold over the next several years.",
        "Doc_title":"HER-2/neu testing in breast cancer.",
        "Journal":"American journal of clinical pathology",
        "Do_id":"15298144",
        "Doc_ChemicalList":"Antibodies, Monoclonal;Antibodies, Monoclonal, Humanized;Receptor, ErbB-2;Trastuzumab",
        "Doc_meshdescriptors":"Antibodies, Monoclonal;Antibodies, Monoclonal, Humanized;Blotting, Southern;Breast;Breast Neoplasms;Female;Humans;Immunohistochemistry;In Situ Hybridization;Prognosis;Receptor, ErbB-2;Trastuzumab",
        "Doc_meshqualifiers":"therapeutic use;pathology;chemistry;drug therapy;pathology;analysis",
        "_version_":1605908025314377728},
      {
        "Doc_abstract":"To detect serum her-2/neu level in patients with breast cancer of different stages and its relationship with tissue her-2/neu overexpression as well as other factors.;A total of 120 women were alloted in this study, including 10 healthy volunteers, 31 breast benign disease patients, 53 primary breast cancer and 26 metastatic breast cancer patients. The level of serum her-2/neu was detected with enzyme-linked immunosorbent assay (ELISA).;Elevated serum her-2/neu levels were observed in 0/10 healthy volunteers, 0/31 patients with benign tumor and 10/53 (18.9%) operable breast cancer patients. Serum concentration of soluble her-2/neu was correlated with tumor size (P < 0.05), but not with axillary lymph nodes nor estrogen receptor status. In patients with metastatic disease, soluble her-2/neu serum level was elevated in 61.5% (16/26) of patients, which was not correlated with the site of metastasis (P > 0.05).;Serum her-2/neu level is correlated with tumor malignancy, stage and cancer load. It could be helpful in directing the treatment of recurrent or metastatic breast cancer.",
        "Doc_title":"[Serum her-2/neu level and related factors in patients with breast cancer].",
        "Journal":"Zhonghua zhong liu za zhi [Chinese journal of oncology]",
        "Do_id":"14690565",
        "Doc_ChemicalList":"Receptors, Estrogen;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Breast Neoplasms;Female;Humans;Lymphatic Metastasis;Middle Aged;Receptor, ErbB-2;Receptors, Estrogen",
        "Doc_meshqualifiers":"blood;pathology;blood;analysis",
        "_version_":1605818778635993089},
      {
        "Doc_abstract":"Amplification of the HER-2 gene occurs in approximately 25% of breast cancers, causing up-regulation of key signaling pathways which control cell growth and survival. In breast cancer patients, HER-2 overexpression correlates with an aggressive phenotype and poor prognosis. HER-2, therefore, has become the focus of many anti-cancer therapeutic approaches. Trastuzumab (Herceptin), a humanized monoclonal antibody directed against the extracellular domain of HER-2, was the first FDA-approved HER-2-targeted therapy for the treatment of metastatic breast cancer. However, not all HER-2-overexpressing patients respond to trastuzumab and most that initially respond develop resistance within one year of treatment. Trastuzumab resistance has been studied in cell line models of resistance and several mechanisms of resistance have been proposed. More recent anti-HER-2 strategies involve targeting its tyrosine kinase domain; for example, lapatinib (Tykerb) is a dual HER-2 and EGFR tyrosine kinase inhibitor and has shown efficacy as a single agent and in combination with other therapeutics. A number of novel HER-2 antagonists are currently in preclinical or clinical development, including both monoclonal antibodies and small molecule inhibitors. Increased understanding of HER-2 signaling in breast cancer, and of response and resistance to HER-2 antagonists, will aid the development of strategies to overcome resistance to HER-2 targeted therapies.",
        "Doc_title":"HER-2 signaling and inhibition in breast cancer.",
        "Journal":"Current cancer drug targets",
        "Do_id":"19442060",
        "Doc_ChemicalList":"Antibodies, Monoclonal;Antibodies, Monoclonal, Humanized;Antineoplastic Agents;ERBB2 protein, human;Receptor, ErbB-2;Trastuzumab",
        "Doc_meshdescriptors":"Antibodies, Monoclonal;Antibodies, Monoclonal, Humanized;Antineoplastic Agents;Breast Neoplasms;Cell Division;Cell Survival;Cell Transformation, Neoplastic;Clinical Trials as Topic;Drug Resistance, Neoplasm;Female;Gene Expression Regulation, Neoplastic;Humans;Receptor, ErbB-2;Signal Transduction;Trastuzumab;Up-Regulation",
        "Doc_meshqualifiers":"adverse effects;therapeutic use;therapeutic use;drug therapy;pathology;physiopathology;antagonists & inhibitors;genetics;physiology;physiology",
        "_version_":1605785255926562816},
      {
        "Doc_abstract":"To detect serum HER-2 oncoprotein levels in patients with operable and metastatic breast cancers, and to study the correlations between serum HER-2 level and lymph node status as well as other clinical parameters.;A total of 120 women were studied consisting of 10 healthy volunteers, 31 benign breast disease, 53 operable breast cancer, and 26 metastatic breast cancer patients. The levels of serum HER-2 were measured using an enzyme-liked immunosorbent assay (ELISA).;The mean serum HER-2 levels were 9.6 +/- 1.5 ng/mL in healthy volunteers, 11.9 +/- 1.6 ng/mL in benign breast disease, 13.2 +/- 4.2 ng/mL in operable breast cancer, and 30.5 +/- 30.8 ng/mL in metastatic breast cancer patients. The former is much lower than the latter three (P = 0.02, 0.001, 0.03, respectively). If using 15 ng/mL as a normal baseline, elevated serum HER-2 levels were observed in none of the healthy volunteers as well as patients with benign disease, but in 18.9% (10/53) operable breast cancer patients and 61.5% (16/26) metastatic patients. In patients with operable breast cancer, there was a positive correlation between serum concentrations of HER-2 and the size of primary tumor (P < 0.05), whereas there was no correlation between serum concentration and axillary lymph node or estrogen receptor status. In patients with metastatic disease, there was no correlation with site of metastases (P > 0.05).;Serum HER-2 level was strongly correlated with tumor loads and clinical stages, thus acting as a promising predictor of cancer recurrence in breast cancer patients.",
        "Doc_title":"Correlation between serum HER-2 oncoprotein and patients with breast cancer.",
        "Journal":"Chinese medical sciences journal = Chung-kuo i hsueh k'o hsueh tsa chih",
        "Do_id":"15506651",
        "Doc_ChemicalList":"Biomarkers, Tumor;Receptors, Estrogen;Receptors, Progesterone;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Biomarkers, Tumor;Breast Neoplasms;Female;Humans;Liver Neoplasms;Lung Neoplasms;Lymph Nodes;Neoplasm Recurrence, Local;Neoplasm Staging;Receptor, ErbB-2;Receptors, Estrogen;Receptors, Progesterone",
        "Doc_meshqualifiers":"blood;blood;pathology;chemistry;secondary;chemistry;secondary;pathology;blood;metabolism;metabolism",
        "_version_":1605810569726656512},
      {
        "Doc_abstract":"The ErbB/B2 (HER-2/neu) oncogene family plays a critical role in the development and metastatic spread of several tumor types including breast, ovarian and gastric cancer. In breast cancer, HER-2/neu is expressed in early disease development in a large percentage of DCIS lesions and its expression is associated with an increased risk of invasion and recurrence. Targeting HER-2 with antibodies such as trastuzumab or pertuzumab has improved survival, but patients with more extensive disease may develop resistance to therapy. Interestingly, response to HER-2 targeted therapies correlates with presence of immune response genes in the breast. Th1 cell production of the cytokines interferon gamma (IFNÎ³) and TNFÎ± can enhance MHC class I expression, PD-L1 expression, augment apoptosis and tumor senescence, and enhances growth inhibition of many anti-breast cancer agents, including anti-estrogens and HER-2 targeted therapies. Recently, we have identified that a loss of anti-HER-2 CD4 Th1 in peripheral blood occurs during breast tumorigenesis and is dramatically diminished, even in Stage I breast cancers. The loss of anti-HER-2 Th1 response is specific and not readily reversed by standard therapies. In fact, this loss of anti-HER-2 Th1 response in peripheral blood correlates with lack of complete response to neoadjuvant therapy and diminished disease-free survival. This defect can be restored with HER-2 vaccinations in both DCIS and IBC. Correcting the anti-HER-2 Th1 response may have significant impact in improving response to HER-2 targeted therapies. Development of immune monitoring systems for anti-HER-2 Th1 to identify patients at risk for recurrence could be critical to improving outcomes, since the anti-HER-2 Th1 response can be restored by vaccination. Correction of the cellular immune response against HER-2 may prevent recurrence in high-risk patients with DCIS and IBC at risk of developing new or recurrent breast cancer.",
        "Doc_title":"Restoring Lost Anti-HER-2 Th1 Immunity in Breast Cancer: A Crucial Role for Th1 Cytokines in Therapy and Prevention.",
        "Journal":"Frontiers in pharmacology",
        "Do_id":"27766079",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605852506016972800},
      {
        "Doc_abstract":"Activator protein 2 gamma (AP-2gamma) is a member of the transcription factor activator protein-2 (AP-2) family, which is developmentally regulated and plays a role in human neoplasia. AP-2gamma has been found to be overexpressed in most breast cancers, and have a dual role to inhibit tumor initiation and promote tumor progression afterwards during mammary tumorigensis.;To identify the gene targets that mediate its effects, we performed chromatin immunoprecipitation (ChIP) to isolate AP-2gamma binding sites on genomic DNA from human breast cancer cell line MDA-MB-453.;20 novel DNA fragments proximal to potential AP-2gamma targets were obtained. They are categorized into functional groups of carcinogenesis, metabolism and others. A combination of sequence analysis, reporter gene assays, quantitative real-time PCR, electrophoretic gel mobility shift assays and immunoblot analysis further confirmed the four AP-2gamma target genes in carcinogenesis group: ErbB2, CDH2, HPSE and IGSF11. Our results were consistent with the previous reports that ErbB2 was the target gene of AP-2gamma. Decreased expression and overexpression of AP-2gamma in human breast cancer cells significantly altered the expression of these four genes, indicating that AP-2gamma directly regulates them.;This suggested that AP-2gamma can coordinate the expression of a network of genes, involving in carcinogenesis, especially in breast cancer. They could serve as therapeutic targets against breast cancers in the future.",
        "Doc_title":"Identification of target genes of transcription factor activator protein 2 gamma in breast cancer cells.",
        "Journal":"BMC cancer",
        "Do_id":"19671168",
        "Doc_ChemicalList":"Antigens, CD;CDH2 protein, human;Cadherins;Cell Adhesion Molecules;IGSF11 protein, human;Immunoglobulins;Transcription Factor AP-2;ERBB2 protein, human;Receptor, ErbB-2;heparanase;Glucuronidase",
        "Doc_meshdescriptors":"Antigens, CD;Base Sequence;Binding Sites;Breast Neoplasms;Cadherins;Cell Adhesion Molecules;Cell Line, Tumor;Gene Expression Regulation;Glucuronidase;Humans;Immunoglobulins;Molecular Sequence Data;Protein Binding;Receptor, ErbB-2;Transcription Factor AP-2",
        "Doc_meshqualifiers":"chemistry;genetics;genetics;metabolism;chemistry;genetics;chemistry;genetics;chemistry;genetics;chemistry;genetics;chemistry;genetics;genetics;metabolism",
        "_version_":1605755956277280768},
      {
        "Doc_abstract":"The objective of this study was to determine the changes in peripheral blood circulating tumor cells in HER2-positive early breast cancer before and after Herceptin therapy, and to explore the effects of the HER2 gene and Herceptin on circulating tumor cells. CK19 mRNA expression in peripheral blood was evaluated by qRT-PCR as an index of circulating tumor cells in 15 cases of HER-2-positive breast cancer and 18 cases of HER2-negative breast cancer before, and after chemotherapy as well. Ten cases of HER2-positive breast cancer continued on Herceptin therapy for 3 months after chemotherapy, and their peripheral blood was again drawn and assayed for CK-19 mRNA expression. Preoperatively, all cases of HER2-positive cancer were positive for CK19 mRNA in peripheral blood, but 6 cases of HER2-negative breast cancer were positive (33.3%), where there was a substantial difference between the two groups. After 6 cycles of adjuvant chemotherapy, CK19 positive rates in cases of HER2-positive and -negative breast cancer reduced by 93.3 and 11.1%, respectively, with a significant difference still existing. After 3 months of Herceptin therapy, expression of CK19 mRNA declined considerably in 10 cases of HER2 positive breast cancer (113.66 Â± 88.65 vs 63.35 Â± 49.27, P = 0.025). HER-2 gene expression closely correlated with circulating tumor cells in peripheral blood of early breast cancer patients. Moreover, Herceptin, a monoclonal antibody for HER2, can reduce the number of circulating tumor cells, which can be an early predictive factor for Herceptin therapy effectiveness against breast cancer.",
        "Doc_title":"Effects of Herceptin on circulating tumor cells in HER2 positive early breast cancer.",
        "Journal":"Genetics and molecular research : GMR",
        "Do_id":"25867356",
        "Doc_ChemicalList":"Antineoplastic Agents;Biomarkers, Tumor;Keratin-19;ERBB2 protein, human;Receptor, ErbB-2;Trastuzumab",
        "Doc_meshdescriptors":"Antineoplastic Agents;Biomarkers, Tumor;Breast Neoplasms;Female;Genetic Association Studies;Humans;Keratin-19;Neoplastic Cells, Circulating;Prognosis;Receptor, ErbB-2;Trastuzumab",
        "Doc_meshqualifiers":"administration & dosage;pharmacology;blood;genetics;metabolism;blood;drug therapy;enzymology;surgery;biosynthesis;blood;genetics;drug effects;biosynthesis;genetics;administration & dosage;pharmacology",
        "_version_":1605760132865589248},
      {
        "Doc_abstract":"Despite patient selection based on ERBB2 overexpression, not all patients benefit from trastuzumab therapy. We have investigated whether a ERBB2 gene dosage effect might provoke increased biological aggressiveness and altered trastuzumab sensitivity. Absolute ERBB2 copy numbers (\"CN\") and ERBB2/centromer 17 ratios (\"R\") were measured by FISH analysis in tumors of 127 patients receiving trastuzumab-based treatment for Her-2/neu overexpressing metastatic breast cancer. CN and R were both significantly associated with shorter time to first metastasis (TTM) (CN: OR: 1.099, 95% CI: 1.042-1.159; R: OR: 1.211, 95% CI: 1.080-1.357) and longer PFS (CN: OR: 0.917, 95% CI: 0.867-0.969; R: OR: 0.840, 95% CI: 0.743-0.949) in a continuous variable Cox's regression model. Tumors with ERBB2/centromer 17 ratios of <2.2 had a significantly shorter TTM (pâ€‰=â€‰0.002) and significantly longer PFS (pâ€‰=â€‰0.003) than tumors with low-level (R: 2.2-6) and high-level amplification (R: >6). Interestingly, when ERBB2 copy numbers were analyzed, a significantly shorter TTM (pâ€‰=â€‰0.001) and longer PFS (pâ€‰=â€‰0.026) were observed in the group with high-level amplified CN (CN: >13), while no difference was observed between non- and low-level amplified CN. R, but not CN, was an independent predictor of complete (CR; OR: 1.685; 95% CI: 1.122-2.532) and partial (PR; OR: 1.704; 95% CI: 1.136-2.556) response in logistic regression analysis. CR (pâ€‰=â€‰0.016) rates were significantly higher in the high-level amplification group (Râ€‰>â€‰6), but no difference existed in response rates between non- and low-level amplified tumors in Chi-square tests. High-level ERBB2 amplification is associated with shorter TTM, but improved response to trastuzumab in metastatic breast cancer.",
        "Doc_title":"High-level ERBB2 gene amplification is associated with a particularly short time-to-metastasis, but results in a high rate of complete response once trastuzumab-based therapy is offered in the metastatic setting.",
        "Journal":"International journal of cancer",
        "Do_id":"24311197",
        "Doc_ChemicalList":"Antibodies, Monoclonal;Antibodies, Monoclonal, Humanized;ERBB2 protein, human;Receptor, ErbB-2;Trastuzumab",
        "Doc_meshdescriptors":"Adult;Aged;Antibodies, Monoclonal;Antibodies, Monoclonal, Humanized;Breast Neoplasms;Disease-Free Survival;Female;Gene Amplification;Gene Dosage;Humans;Middle Aged;Neoplasm Metastasis;Proportional Hazards Models;Receptor, ErbB-2;Trastuzumab",
        "Doc_meshqualifiers":"administration & dosage;administration & dosage;drug therapy;genetics;pathology;biosynthesis;genetics",
        "_version_":1605903463380680704},
      {
        "Doc_abstract":"The Src homology 2 (SH2) domain-containing protein Grb7 and the erbB2 receptor tyrosine kinase are overexpressed in a subset of human breast cancers. They also co-immunoprecipitate from cell lysates and associate directly in vitro. Whereas the Grb7 SH2 domain binds strongly to erbB2, the SH2 domain of Grb14, a protein closely related to Grb7, does not. We have investigated the preferred binding site of Grb7 within the erbB2 intracellular domain and the SH2 domain residues that determine the high affinity of Grb7 compared with Grb14 for this site. Phosphopeptide competition and site-directed mutagenesis revealed that Tyr-1139 of erbB2 is the major binding site for the Grb7 SH2 domain, indicating an overlap in binding specificity between the Grb7 and Grb2 SH2 domains. Substituting individual amino acids in the Grb14 SH2 domain with the corresponding residues from Grb7 demonstrated that a Gln to Leu change at the betaD6 position imparted high affinity erbB2 interaction, paralleled by a marked increase in affinity for the Tyr-1139 phosphopeptide. The reverse switch at the betaD6 position abrogated Grb7 binding to erbB2. This residue therefore represents an important determinant of SH2 domain specificity within the Grb7 family.",
        "Doc_title":"Structural determinants of the interaction between the erbB2 receptor and the Src homology 2 domain of Grb7.",
        "Journal":"The Journal of biological chemistry",
        "Do_id":"9079677",
        "Doc_ChemicalList":"Adaptor Proteins, Signal Transducing;GRB14 protein, human;GRB7 protein, human;Proteins;GRB7 Adaptor Protein;Tyrosine;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Adaptor Proteins, Signal Transducing;Amino Acid Sequence;Binding Sites;Binding, Competitive;Cells, Cultured;GRB7 Adaptor Protein;Humans;Models, Molecular;Molecular Sequence Data;Proteins;Receptor, ErbB-2;Sequence Alignment;Structure-Activity Relationship;Tyrosine;src Homology Domains",
        "Doc_meshqualifiers":"chemistry;metabolism;chemistry;metabolism;metabolism",
        "_version_":1605742088094220290},
      {
        "Doc_abstract":"The ligands of the epidermal growth factor family and their receptors, the ErbB proteins, have been linked to the development of different types of cancer. Particular attention has focused on ErbB2, whose activation may occur by receptor overexpression or by ligand-induced oligomerization with other ErbB receptors. Whether these two modes of ErbB2 activation cause the same biological responses is unknown. Here, we uncovered important differences in the signaling, proliferation rates, and the response to anti-ErbB2 antibodies when comparing MCF7 cells expressing the ligand neuregulin, to MCF7 cells overexpressing ErbB2. Expression of neuregulin caused higher proliferation than ErbB2 overexpression. Transmembrane neuregulin expression was accompanied by constitutive activation of ErbB2, ErbB3, and ErbB4 receptors. ErbB2 overexpression caused tyrosine phosphorylation of ErbB2, whereas ErbB3 and ErbB4 were only slightly tyrosine phosphorylated. Autocrine transmembrane neuregulin also caused constitutive activation of several signaling pathways, such as the Erk1/2, Erk5, and Akt routes, which have been linked to breast cancer cell proliferation. Interestingly, expression of neuregulin increased p21 levels and this was required for the proliferation of MCF7 cells. Treatment with the anti-ErbB2 receptor antibody Herceptin had an inhibitory effect on proliferation only in cells expressing neuregulin but not on cells overexpressing ErbB2, and its inhibitory activity was accompanied by a decrease in p21. These results suggest that Herceptin may also be of help in the treatment of tumors in which neuregulin feeds the tumoral tissue.",
        "Doc_title":"Activation of ErbB2 by overexpression or by transmembrane neuregulin results in differential signaling and sensitivity to herceptin.",
        "Journal":"Cancer research",
        "Do_id":"16061662",
        "Doc_ChemicalList":"Antibodies, Monoclonal;Antibodies, Monoclonal, Humanized;CDKN1A protein, human;Cell Cycle Proteins;Cyclin-Dependent Kinase Inhibitor p21;Neuregulins;Receptor, ErbB-2;Trastuzumab",
        "Doc_meshdescriptors":"Antibodies, Monoclonal;Antibodies, Monoclonal, Humanized;Breast Neoplasms;Cell Cycle Proteins;Cell Growth Processes;Cell Line, Tumor;Cyclin-Dependent Kinase Inhibitor p21;Down-Regulation;Enzyme Activation;Humans;Neuregulins;Phosphorylation;Receptor, ErbB-2;Signal Transduction;Transfection;Trastuzumab",
        "Doc_meshqualifiers":"immunology;pharmacology;drug therapy;genetics;metabolism;pathology;biosynthesis;genetics;physiology;biosynthesis;genetics;genetics;immunology;metabolism",
        "_version_":1605892166890029056},
      {
        "Doc_abstract":"Overexpression of Topoisomerase II alpha (TOP2A) has been implicated with gene amplification of the 17q21 amplicon and consecutively with ErbB2 overexpression and amplification. However, gene amplification does not necessarily correlate with RNA and protein expression. There is growing evidence that TOP2A protein expression is a strong prognostic and TOP2A gene amplification might be a predictive marker (particularly for the use of anthracyclines).;Large scale analysis was performed using Affymetrix microarray data from n = 1,681 breast cancer patients to evaluate TOP2A expression.;TOP2A expression showed a strong correlation with tumor size (chi(2)-test, P < 0.001), grading (P < 0.001), ErbB2 (P < 0.001) and Ki67 expression (P < 0.001) as well as nodal status (P = 0.042). Survival analysis revealed a significant prognostic value in ER positive (n = 994; log rank P < 0.001), but not in ER negative breast cancer patients (n = 369, P = 0.35). The prognostic impact of TOP2A expression was independent of Ki67 expression in ER positive tumors (P = 0.002 and P = 0.007 for high and low Ki67, respectively). Moreover a worse prognosis of high TOP2A expressing tumors was found in the subgroup of ErbB2 negative tumors (P < 0.001) and a trend among ErbB2 positive tumors (P = 0.11). The prognostic value of TOP2A was independent of whether the patients were untreated or had received adjuvant therapy. In multivariate Cox regression analysis including standard parameters TOP2A emerged to be the top prognostic marker (HR 2.40, 95% CI 1.68-3.43, P < 0.001).;TOP2A expression is an independent prognostic factor in ER positive breast cancer and could be helpful for risk assessment in ER positive breast cancer patients.",
        "Doc_title":"Gene expression of topoisomerase II alpha (TOP2A) by microarray analysis is highly prognostic in estrogen receptor (ER) positive breast cancer.",
        "Journal":"Breast cancer research and treatment",
        "Do_id":"18340528",
        "Doc_ChemicalList":"Antigens, Neoplasm;DNA-Binding Proteins;Receptors, Estrogen;DNA Topoisomerases, Type II;DNA topoisomerase II alpha",
        "Doc_meshdescriptors":"Antigens, Neoplasm;Breast Neoplasms;DNA Topoisomerases, Type II;DNA-Binding Proteins;Female;Gene Amplification;Gene Expression;Humans;Microarray Analysis;Middle Aged;Prognosis;Receptors, Estrogen;Survival Analysis",
        "Doc_meshqualifiers":"genetics;genetics;metabolism;genetics;genetics;metabolism",
        "_version_":1605893249879244800},
      {
        "Doc_abstract":"The HER-2/neu gene is altered in 15-20% of breast cancer patients. Immunohistochemistry (IHC) is considered to be the most cost-effective method for HER-2 detection in many countries. Approximately 8,000 new cases of breast cancer are observed annually in Iran. The aims of this study were to conduct a systematic review of the literature on the rate of HER-2-positive breast cancer diagnosed by IHC in Iran.;A systematic search of the medical literature using the Medline/PubMed, ISI and SID databases revealed articles published in the English and Persian languages evaluating HER-2-positive breast cancer in Iran.;From 22 studies, 3,033 patients were evaluated, of whom 1,350 were diagnosed as HER-2-positive by IHC HER-2 testing. The mean percentage of HER-2-positive patients was 44.5%, which is higher than that recorded in international statistics. Results of this meta-analysis showed a significant heterogeneity between ratios. There was a statistically significant difference between the results of pre- and post implementation of 2007 American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) guideline. IHC HER-2 testing has been performed in Iran for over 10 years. Similar to many other countries, before establishment of an infrastructure for IHC diagnostic tests, HER-2 testing was routinely performed in Iran. Our study showed that the statistics reported from Iran varied widely; for instance, the rate of HER-2-positive cases varied from 23.3% to 81.0%.;Our results demonstrate that the lack of standardization and harmonization of this test have led to marked variations in breast cancer diagnosis in Iran.",
        "Doc_title":"Prevalence of HER-2-positive invasive breast cancer: a systematic review from Iran.",
        "Journal":"Asian Pacific journal of cancer prevention : APJCP",
        "Do_id":"23317203",
        "Doc_ChemicalList":"Receptor, ErbB-2",
        "Doc_meshdescriptors":"Breast Neoplasms;Female;Humans;Iran;Prevalence;Receptor, ErbB-2",
        "Doc_meshqualifiers":"epidemiology;genetics;metabolism;epidemiology;genetics;metabolism",
        "_version_":1605764053730328576},
      {
        "Doc_abstract":"The proto-oncogene HER2/neu has been extensively studied in breast cancer patients. Serum levels of HER2/neu by ELISA in breast cancer patients were compared with tissue HER2/neu expression and with other clinicopathological parameters with the aim to investigate whether the serum assay could replace the established tests (IHC/FISH) for HER-2 status.;Blood and Tru-cut biopsy samples were collected for determining HER2/neu status in 64 breast cancer patients. The tissue specimens were processed routinely and immunohistochemistry (IHC) for HER2/ER/PR (oestrogen/progesterone receptors) performed. Fluorescence in-situ hybridization (FISH) was performed on all HER2/neu 2 positive cases. Sixty age matched healthy females and females with benign breast disease were taken as controls for ELISA.;Of the 64 breast cancer cases, 25 (39.1%) had elevated serum HER2/neu levels accompanied with increased tissue expression of HER2/neu receptors. On IHC, HER2/neu score was 3+ in 24 (37.5%) cases, 2+ in three (4.6%), 1+ in 18 (28.1%); while 19 cases (29.7%) showed no HER2/neu expression. o0 f the three 2+ cases on IHC, two showed amplification on FISH. Twenty one (32.8%) patients were ER positive and 17 (26.6%) were PR positive. There was a significant correlation (P<0.001) of serum HER2 concentration with tumour size, lymph node involvement, stage of disease and histological grade. Serum HER2/neu levels showed a negative correlation with ER status (P=0.047) but no correlation with PR status.;The results suggest that elevated serum HER2 level was associated with a clinicopathological aggressive phenotype of breast carcinoma and was related to tissue HER2 overexpression. Therefore, serum HER2 may be useful for monitoring the course of the disease and response to treatment.",
        "Doc_title":"Evaluation of HER2/neu oncoprotein in serum & tissue samples of women with breast cancer.",
        "Journal":"The Indian journal of medical research",
        "Do_id":"27748278",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605929177462079488},
      {
        "Doc_abstract":"Amplification of genomic DNA encoding oncogenes such as HER-2 (syn.c-erbB2/c-neu) may be substantially involved in the initiation and progression of breast cancer. In order to refine and facilitate the quantitative analysis of HER-2 amplification in breast cancer, differential polymerase chain reaction (PCR) was performed on DNA derived from single cryosections of tumor tissue. This technique is based on the simultaneous amplification of a potentially amplified oncogene (HER-2) and a reference gene (IFN-gamma). Differential PCR yielded reproducible results that were in agreement with gene copy quantification using the dot blot technique. Thus we suggest differential PCR to be a reliable and rapid method for determining relative gene dosage in a minute amount of tumour tissue.",
        "Doc_title":"Detection of HER-2 oncogene amplification in breast cancer by differential polymerase chain reaction from single cryosections.",
        "Journal":"Virchows Archiv. B, Cell pathology including molecular pathology",
        "Do_id":"7904515",
        "Doc_ChemicalList":"DNA, Neoplasm;Proto-Oncogene Proteins;Receptor, Epidermal Growth Factor;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Base Sequence;Breast Neoplasms;DNA, Neoplasm;Female;Frozen Sections;Gene Amplification;Humans;Molecular Sequence Data;Nucleic Acid Hybridization;Oncogenes;Polymerase Chain Reaction;Proto-Oncogene Proteins;Receptor, Epidermal Growth Factor;Receptor, ErbB-2",
        "Doc_meshqualifiers":"genetics;isolation & purification;genetics;genetics;genetics;genetics",
        "_version_":1605775169249345536},
      {
        "Doc_abstract":"Amplification of the HER-2/neu (ErbB2) gene is observed in approximately 30% of human breast cancers, correlating with a poor clinical prognosis. Src kinases are also involved in the etiology of breast cancer, and their activation was suggested to be necessary for Neu-induced oncogenesis. To address whether Src activity is essential for Neu-mediated tumorigenesis, we used a physiologic inhibitor of Src kinase activity, the Csk homologous kinase (CHK), expressed as a mammary tissue-specific transgene. Our data, using a physiologic inhibitor of Src activity (CHK), showed that blocking of Neu-induced Src activity without altering Src expression levels had no significant effects on Neu-mediated mammary tumorigenesis in vivo. This contradicts the current paradigm that activation of Src kinases is essential for Neu-induced oncogenesis. This study is the first to distinguish between the kinase-dependent and kinase-independent actions of Src and shows that its kinase-dependent properties are not requisite for Neu-induced tumorigenesis.",
        "Doc_title":"Role of SRC kinases in Neu-induced tumorigenesis: challenging the paradigm using Csk homologous kinase transgenic mice.",
        "Journal":"Cancer research",
        "Do_id":"16740714",
        "Doc_ChemicalList":"Membrane Proteins;Pag1 protein, mouse;Phosphoproteins;src-Family Kinases",
        "Doc_meshdescriptors":"Animals;Female;Genes, erbB-2;Mammary Glands, Animal;Mammary Neoplasms, Experimental;Mammary Tumor Virus, Mouse;Membrane Proteins;Mice;Phosphoproteins;Phosphorylation;src-Family Kinases",
        "Doc_meshqualifiers":"physiology;enzymology;growth & development;enzymology;genetics;genetics;antagonists & inhibitors;genetics;metabolism;antagonists & inhibitors;genetics;metabolism;antagonists & inhibitors;metabolism",
        "_version_":1605831481550176256},
      {
        "Doc_abstract":"The BRCA1 caretaker gene is associated with poor prognostic features in hereditary breast cancer and may also play a role in sporadic breast cancer (SBC). HER-1 and HER-2 overexpression is associated with adverse prognosis in SBC. We studied whether BRCA1 expression was associated with HER1, HER2 and other prognostic features in SBC.;Fifty newly-diagnosed SBC patients were studied for prognostic features and immunohistochemical expressions of BRCA1, HER-1 and HER-2.;Tumors were positive for BRCA1 in 26%, HER-1 in 32% and HER-2 in 20% of cases. Lack of BRCA1 expression was associated with node metastases and decreased estrogen receptor. HER-2 expression was associated with young age, HER-1, Ki67 and decreased hormone receptors. No correlation was observed between BRCA1 and HER-1 or HER-2.;In SBC, the lack of BRCA1 expression was associated with poor prognostic features, but unrelated to HER-1 and HER-2. HER2 and HER-1 were, however, highly correlated.",
        "Doc_title":"Expression of BRCA1, HER-1 (EGFR) and HER-2 in sporadic breast cancer and relationships to other clinicopathological prognostic features.",
        "Journal":"Anticancer research",
        "Do_id":"16334138",
        "Doc_ChemicalList":"BRCA1 Protein;Receptor, Epidermal Growth Factor;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Adult;Aged;Aged, 80 and over;BRCA1 Protein;Breast Neoplasms;Humans;Immunohistochemistry;Middle Aged;Prognosis;Receptor, Epidermal Growth Factor;Receptor, ErbB-2",
        "Doc_meshqualifiers":"biosynthesis;genetics;genetics;metabolism;pathology;biosynthesis;genetics;biosynthesis;genetics",
        "_version_":1605795136773554176},
      {
        "Doc_abstract":"Integrin and growth factor receptors play an important role in cell functions and their aberrant expressions are implicated in breast cancer malignancy. Recent studies have shown that integrins physically and functionally associate with growth factor receptors suggesting the cooperative regulation of these two signals. We studied the expression of integrin and erbB subunits by flow cytometer in human normal mammary epithelial (HME) cell, non-metastatic (MCF-7, ZR-75-1, MDA-MB453) and metastatic tumor cell lines (MDA-MB231, MDA-MB435). Compared with HME cells, all of non-metastatic and metastatic cell lines showed decreased expressions of alpha2 and beta4 integrin subunits. Two metastatic cell lines, but not three non-metastatic tumor cell lines, expressed alpha5 and alpha6 comparable to HME cells. There was no correlation of erbB2 expression with integrin expressions. We isolated MDA-MB435 subpopulations expressing lower amount of alpha6 integrin and found that alpha5, but not alpha2 and alphav integrins, was concomitantly decreased while erbB family was not affected. Then we transfected erbB2 gene into MDA-MB435 and found the induction of erbB3 expression but not erbB1 and erbB4. However, erbB2 transfection had no effect on the expression of alpha6 and beta4 integrin subunits. These data suggest that the expression of alpha5 and alpha6 integrins may contribute to metastasis, and that the regulation of erbB2 and alpha6 integrin expressions is independent in breast cancer cells.",
        "Doc_title":"Aberrant expression of integrin and erbB subunits in breast cancer cell lines.",
        "Journal":"International journal of oncology",
        "Do_id":"12370757",
        "Doc_ChemicalList":"Integrins;Protein Subunits;ERBB4 protein, human;Receptor, Epidermal Growth Factor;Receptor, ErbB-2;Receptor, ErbB-3;Receptor, ErbB-4",
        "Doc_meshdescriptors":"Breast Neoplasms;Female;Humans;Integrins;Neoplasm Metastasis;Protein Subunits;Receptor, Epidermal Growth Factor;Receptor, ErbB-2;Receptor, ErbB-3;Receptor, ErbB-4;Tumor Cells, Cultured",
        "Doc_meshqualifiers":"chemistry;pathology;analysis;physiology;analysis;analysis;analysis",
        "_version_":1605742787097001987},
      {
        "Doc_abstract":"We examined the involvement of BRCA1, which plays a major role in Western breast cancer families, in Japanese breast cancer families. Eleven families, in which at least three individuals within third degree relatives were affected by breast cancer, were collected. Five of them were early-onset breast cancer families, in which the average age at diagnosis was less than 45 years, and the other six were late-onset families. Ovarian cancer was observed in one patient in the early-onset families. Using seven polymorphic markers on chromosome 17q21, D17S250, ERBB2, THRA1, D17S579, D17S588, GIP and NME1, linkage to BRCA1 was analyzed. Linkage was not detected in any single family. Assuming homogeneity in an inherited component that confines the susceptibility to breast cancer in all families, we summed the LOD scores of all families. The cumulative LOD score obtained was -1.86 for D17S588 at theta = 0.001, indicating no linkage with BRCA1. Since the proportion of families linked to BRCA1 is larger in Western early-onset breast cancer families than in late-onset ones, we also summed the LOD scores of five early-onset families. However, again a negative LOD score was obtained. These results suggest that BRCA1 is not a major breast cancer susceptibility gene in Japanese familial breast cancer.",
        "Doc_title":"Linkage analysis of BRCA1 in Japanese breast cancer families.",
        "Journal":"Japanese journal of cancer research : Gann",
        "Do_id":"7852187",
        "Doc_ChemicalList":"BRCA1 Protein;DNA Primers;DNA, Neoplasm;Neoplasm Proteins;Transcription Factors",
        "Doc_meshdescriptors":"Adult;Age of Onset;BRCA1 Protein;Base Sequence;Breast Neoplasms;Chromosomes, Human, Pair 17;DNA Primers;DNA, Neoplasm;Female;Gene Frequency;Genes, Tumor Suppressor;Genetic Linkage;Humans;Japan;Lod Score;Middle Aged;Molecular Epidemiology;Molecular Sequence Data;Neoplasm Proteins;Neoplastic Syndromes, Hereditary;Pedigree;Polymorphism, Genetic;Transcription Factors",
        "Doc_meshqualifiers":"genetics;genetics;genetics;epidemiology;genetics;epidemiology;genetics",
        "_version_":1605759728382640128},
      {
        "Doc_abstract":"Changes in ER, PR and Her2 receptor status between primary and metastatic cancer tissue have been suggested in breast cancer. The frequencies of these changes are still not fully understood. The purpose of this study was to evaluate these changes in breast cancer population of Kuwait.;Changes in the biological features between primary and recurrent disease in 70 patients who presented between 2009 and 2012 was studied. Statistical comparisons between groups was done using chi square test while Kaplan Meier method was used to perform analysis of survival after relapse. All analysis was carried out using the IBM-SPSS statistical software.;There was a decrease in ER and PR positivity from 61.4% to 58.6% and 61.4% to 44.3% respectively. The overall change in ER and PR status was 28.5% and 25.7% respectively. There was an increase in the Her2 positivity as the tumor relapsed and overall changes were seen in 5.7% of cases.;Patients with breast cancer experience change in biological markers through the course of their disease. The changes are more with hormone receptors compared to Her2. Re-biopsy should be considered at relapse if feasible.;breast cancer, hormone receptors, Her2 neu, receptors, biological features, changes.",
        "Doc_title":"Changes in biologic features between primary and recurrent or relapsed breast cancers.",
        "Journal":"The Gulf journal of oncology",
        "Do_id":"24610284",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605822102500278272},
      {
        "Doc_abstract":"Identifying markers that have the potential to predict tumor behavior is important in breast cancer because of the variability in clinical disease progression. Genetic alterations in tumors may appear as changes in total DNA content, individual chromosomes, single genes, or gene expression. Alteration in DNA content is an imprecise but accessible measurement of the genome. Diploid tumors have been associated with a better clinical outcome, and increased ploidy correlates with other indicators of poor prognosis. Concurrent analysis of DNA content with markers of genetic expression is feasible (e.g., myc oncogene) and may increase its prognostic power. Chromosomal studies could provide a more precise tool for localizing genetic damage, but there is little cytogenetic information about primary breast cancers, no convincing evidence has emerged to target locations in the karyotype that appear specifically altered, and many primary and cultured breast cancers contain cells that appear chromosomally normal. Attempts to define molecular markers have used probes of different chromosomal sites, some chosen because of logical associations with hormonal activity, known oncogenes, or tumor-suppressor genes, and some by chance. Currently, to the authors' knowledge, none has shown uniform changes by mutation, loss, or overexpression in all breast cancers, although a remarkable number of loci are altered to some extent. These lesions must be associated with particular disease subsets or, retrospectively, with differential survival if they are to have prognostic value.;The authors examined several loci (ERBB2, INT2, MUC1) for gene amplification or loss of heterozygosity by Southern blotting and for gene expression by immunohistochemistry in breast tumors from patient groups selected by survival.;A retrospective series showed gene amplification at the erbB2 locus in 22% of rapidly recurrent (RR) tumors and 13% of tumors from long-term tumor-free survivors (LTS), but the difference was not statistically significant (P = 0.18). The erbB2 product was displayed histochemically with equal frequency between those with RR tumors and LTS patients. Moreover, the correlation was poor between different analytic measures on the same tumors. This result was tested using a prospective study of erbB2 to correlate DNA analysis with western blot findings and frozen and fixed histochemical results. Another oncogene, int2, showed significant correlation between amplification and recurrence; 16% of RR tumors showing genetic amplification (P = 0.02). Loci on other chromosomes, 1 (muc1) and 17 (cmm86), also are being investigated in groups selected for differences in survival.",
        "Doc_title":"Genetic markers as prognostic indicators in breast cancer.",
        "Journal":"Cancer",
        "Do_id":"1355402",
        "Doc_ChemicalList":"DNA, Neoplasm;FGF3 protein, human;Fibroblast Growth Factor 3;Genetic Markers;Membrane Glycoproteins;Mucin-1;Mucins;Neoplasm Proteins;Oncogene Proteins, Viral;Proto-Oncogene Proteins;Fibroblast Growth Factors;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Breast Neoplasms;Chromosome Aberrations;DNA, Neoplasm;Female;Fibroblast Growth Factor 3;Fibroblast Growth Factors;Gene Amplification;Genetic Markers;Humans;Male;Membrane Glycoproteins;Mucin-1;Mucins;Neoplasm Proteins;Oncogene Proteins, Viral;Ploidies;Prognosis;Proto-Oncogene Proteins;Receptor, ErbB-2",
        "Doc_meshqualifiers":"genetics;metabolism;analysis;analysis;analysis;analysis;analysis;analysis",
        "_version_":1605821725305470976},
      {
        "Doc_abstract":"The predictive and prognostic implication of oncogene amplification in breast cancer has received great attention in the past two decades. her-2/neu and c-myc are two oncogenes that are frequently amplified and overexpressed in breast carcinomas. Despite the extensive data on these oncogenes, their prognostic and predictive impact on breast cancer patients remains controversial. Schlotter and colleagues have recently suggested that c-myc, and not her-2/neu, could predict the recurrence and mortality of patients with node-negative breast carcinomas. Regardless of the promising results, caution should be exercised in the interpretation of data from studies assessing gene amplification without in situ analysis. We address the novelty, accuracy and clinical significance of the study by Schlotter and colleagues.",
        "Doc_title":"c-myc, not her-2/neu, can predict the prognosis of breast cancer patients: how novel, how accurate, and how significant?",
        "Journal":"Breast cancer research : BCR",
        "Do_id":"12817989",
        "Doc_ChemicalList":"DNA, Neoplasm;Proto-Oncogene Proteins c-myc;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Breast Neoplasms;DNA, Neoplasm;Female;Gene Expression Regulation, Neoplastic;Humans;Polymerase Chain Reaction;Predictive Value of Tests;Prognosis;Proto-Oncogene Proteins c-myc;Receptor, ErbB-2;Reproducibility of Results",
        "Doc_meshqualifiers":"genetics;pathology;genetics;methods;genetics;genetics",
        "_version_":1605882566346276864},
      {
        "Doc_abstract":"Trastuzumab is a recombinant humanized monoclonal antibody directed against the HER-2. HER-2 is overexpressed in 20-25% of invasive breast cancer and known as poor prognostic factor and its status of a tumor is related to response to trastuzumab. Combination therapy with trastuzumab and chemotherapy increases response rate, time to progression, and survival thus trastuzumab is perceived to be the first line treatment for HER-2 overexpressed metastatic breast cancer. The optimal duration and period of trastuzumab treatment are still unknown and result of large scale randomized trial will be expected.",
        "Doc_title":"[Trastuzumab treatment for breast cancer].",
        "Journal":"Nihon rinsho. Japanese journal of clinical medicine",
        "Do_id":"15283148",
        "Doc_ChemicalList":"Antibodies, Monoclonal;Antibodies, Monoclonal, Humanized;Antineoplastic Agents;Trastuzumab",
        "Doc_meshdescriptors":"Antibodies, Monoclonal;Antibodies, Monoclonal, Humanized;Antineoplastic Agents;Breast Neoplasms;Drug Delivery Systems;Genes, erbB-2;Humans;Trastuzumab",
        "Doc_meshqualifiers":"administration & dosage;administration & dosage;drug therapy;methods",
        "_version_":1605750171135639552},
      {
        "Doc_abstract":"The lipogenic enzyme fatty acid synthase (FAS) is differentially overexpressed and hyperactivated in a biologically aggressive subset of breast carcinomas and minimally in most normal adult tissues, rendering it an interesting target for antineoplastic therapy development. Recently, a molecular connection between the HER -2/ neu (c- erb B-2) oncogene and FAS has been described in human breast cancer cells. Here, we examined the relationship between breast cancer-associated FAS hyperactivity and HER -2/ neu -induced breast cancer chemoresistance to taxanes. Co-administration of docetaxel (Taxotere) and the mycotoxin cerulenin, a potent and non-competitive inhibitor of FAS activity, demonstrated strong synergism in HER -2/ neu -overexpressing and docetaxel-resistant SK-Br3 cells, modest synergism in moderately HER -2/ neu -expressing MCF-7 cells, and it showed additive effects in low HER -2/ neu -expressing and docetaxel-sensitive MDA-MB-231 cells. Sequential exposure to cerulenin followed by docetaxel again yielded strong synergism in SK-Br3 cells, whereas antagonistic and moderate synergistic interactions were observed in MCF-7 and MDA-MB-231 cells, respectively. Importantly, inhibition of FAS activity dramatically decreased the expression of HER -2/ neu oncogene in SK-Br3 breast cancer cells. To the best of our knowledge this is the first study demonstrating that FAS is playing an active role in HER -2/ neu -induced breast cancer chemotherapy resistance.",
        "Doc_title":"Inhibition of tumor-associated fatty acid synthase hyperactivity induces synergistic chemosensitization of HER -2/ neu -overexpressing human breast cancer cells to docetaxel (taxotere).",
        "Journal":"Breast cancer research and treatment",
        "Do_id":"14999148",
        "Doc_ChemicalList":"Antifungal Agents;Antineoplastic Agents, Phytogenic;Taxoids;docetaxel;Cerulenin;Fatty Acid Synthases",
        "Doc_meshdescriptors":"Antifungal Agents;Antineoplastic Agents, Phytogenic;Breast Neoplasms;Cell Division;Cell Line, Tumor;Cerulenin;Drug Resistance, Neoplasm;Fatty Acid Synthases;Female;Genes, erbB-2;Humans;Taxoids;Transfection",
        "Doc_meshqualifiers":"administration & dosage;administration & dosage;drug therapy;genetics;drug effects;administration & dosage;genetics;antagonists & inhibitors;genetics;administration & dosage",
        "_version_":1605804286141267968},
      {
        "Doc_abstract":"Genomic aberrations in the form of subchromosomal DNA copy number changes are a hallmark of epithelial cancers, including breast cancer. The goal of the present study was to analyze such aberrations in breast cancer at high resolution.;We employed high-resolution array comparative genomic hybridization with 4,134 bacterial artificial chromosomes that cover the genome at 0.9 megabase resolution to analyze 47 primary breast tumors and 18 breast cancer cell lines.;Common amplicons included 8q24.3 (amplified in 79% of tumors, with 5/47 exhibiting high level amplification), 1q32.1 and 16p13.3 (amplified in 66% and 57% of tumors, respectively). Moreover, we found several positive correlations between specific amplicons from different chromosomes, suggesting the existence of cooperating genetic loci. Queried by gene, the most frequently amplified kinase was PTK2 (79% of tumors), whereas the most frequently lost kinase was PTK2B (hemizygous loss in 34% of tumors). Amplification of ERBB2 as measured by comparative genomic hybridization (CGH) correlated closely with ERBB2 DNA and RNA levels measured by quantitative PCR as well as with ERBB2 protein levels. The overall frequency of recurrent losses was lower, with no region lost in more than 50% of tumors; the most frequently lost tumor suppressor gene was RB1 (hemizygous loss in 26% of tumors). Finally, we find that specific copy number changes in cell lines closely mimicked those in primary tumors, with an overall Pearson correlation coefficient of 0.843 for gains and 0.734 for losses.;High resolution CGH analysis of breast cancer reveals several regions where DNA copy number is commonly gained or lost, that non-random correlations between specific amplicons exist, and that specific genetic alterations are maintained in breast cancer cell lines despite repeat passage in tissue culture. These observations suggest that genes within these regions are critical to the malignant phenotype and may thus serve as future therapeutic targets.",
        "Doc_title":"High resolution genomic analysis of sporadic breast cancer using array-based comparative genomic hybridization.",
        "Journal":"Breast cancer research : BCR",
        "Do_id":"16457699",
        "Doc_ChemicalList":"DNA, Neoplasm;Receptor, ErbB-2;Focal Adhesion Kinase 1;PTK2 protein, human",
        "Doc_meshdescriptors":"Breast Neoplasms;Cell Line, Tumor;Chromosomes, Artificial, Bacterial;DNA, Neoplasm;Female;Focal Adhesion Kinase 1;Gene Dosage;Gene Expression Profiling;Humans;Nucleic Acid Hybridization;Oligonucleotide Array Sequence Analysis;Phenotype;Receptor, ErbB-2;Sensitivity and Specificity",
        "Doc_meshqualifiers":"genetics;genetics;genetics;genetics;genetics",
        "_version_":1605820572451733504},
      {
        "Doc_abstract":"We have reported that Erbin expression was down-regulated in the Jurkat leukaemia T lymphocytes treated with the recombinant soluble tumour necrosis factor-related apoptosis-inducing ligand (rsTRAIL). Herein, we studied the expression and the regulation of Erbin and its binding partner, ErbB2, in the MCF-7 breast cancer cell line. We showed that the expressions of Erbin and ErbB2 were modulated by PKCdelta inhibitor, rottlerin, in the TRAIL-resistant MCF-7 cell line. The affinity of Erbin-ErbB2 interaction was reduced by ErbB2 phosphorylation. Inhibiting the expression of Erbin facilitated the sensitivity of the MCF-7 cells to TRAIL via suppressing the ErbB2/AKT/NF-kappaB signalling pathway.",
        "Doc_title":"Erbin-regulated sensitivity of MCF-7 breast cancer cells to TRAIL via ErbB2/AKT/NF-kappaB pathway.",
        "Journal":"Journal of biochemistry",
        "Do_id":"18316330",
        "Doc_ChemicalList":"Acetophenones;Adaptor Proteins, Signal Transducing;Benzopyrans;ERBB2IP protein, human;Enzyme Inhibitors;NF-kappa B;RNA, Small Interfering;TNF-Related Apoptosis-Inducing Ligand;rottlerin;Receptor, ErbB-2;Proto-Oncogene Proteins c-akt;I-kappa B Kinase;Caspases",
        "Doc_meshdescriptors":"Acetophenones;Adaptor Proteins, Signal Transducing;Apoptosis;Benzopyrans;Blotting, Western;Breast Neoplasms;Caspases;Enzyme Inhibitors;Female;Humans;I-kappa B Kinase;Immunoblotting;Immunoprecipitation;NF-kappa B;Phosphorylation;Proto-Oncogene Proteins c-akt;RNA, Small Interfering;Receptor, ErbB-2;Signal Transduction;TNF-Related Apoptosis-Inducing Ligand",
        "Doc_meshqualifiers":"pharmacology;antagonists & inhibitors;genetics;pharmacology;physiology;pharmacology;metabolism;pathology;pharmacology;metabolism;genetics;metabolism;drug effects;metabolism;pharmacology;antagonists & inhibitors;genetics;metabolism;pharmacology",
        "_version_":1605850978526953472},
      {
        "Doc_abstract":"The product of the HER-2/neu proto-oncogene, HER2, is the second member of the human epidermal growth factor receptor (HER) family of tyrosine kinase receptors and has been suggested to be a ligand orphan receptor. Ligand-dependent heterodimerization between HER2 and another HER family member, HER1, HER3 or HER4, activates the HER2 signaling pathway. The intracellular signaling pathway of HER2 is thought to involve ras-MAPK, MAPK-independent S6 kinase and phospholipase C-gamma signaling pathways. However, the biological consequences of the activation of these pathways are not yet completely known. Amplification of the HER2 gene and overexpression of the HER2 protein induces cell transformation and has been demonstrated in 10% to 40% of human breast cancer. HER2 overexpression has been suggested to associate with tumor aggressiveness, prognosis and responsiveness to hormonal and cytotoxic agents in breast cancer patients. These findings indicate that HER2 is an appropriate target for tumor-specific therapies. A number of approaches have been investigated: (1) a humanized monoclonal antibody against HER2, rhuMAbHER2 (trastuzumab), which is already approved for clinical use in the treatment of patients with metastatic breast cancer; (2) tyrosine kinase inhibitors, such as emodin, which block HER2 phosphorylation and its intracellullar signaling; (3) active immunotherapy, such as vaccination; and (4) heat shock protein (Hsp) 90-associated signal inhibitors, such as radicicol derivatives, which induce degradation of tyrosine kinase receptors, such as HER2.",
        "Doc_title":"Biological and clinical significance of HER2 overexpression in breast cancer.",
        "Journal":"Breast cancer (Tokyo, Japan)",
        "Do_id":"11180765",
        "Doc_ChemicalList":"Antineoplastic Agents;Biomarkers, Tumor;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Antineoplastic Agents;Biomarkers, Tumor;Breast Neoplasms;Female;Gene Amplification;Genes, erbB-2;Humans;Prognosis;Receptor, ErbB-2",
        "Doc_meshqualifiers":"therapeutic use;metabolism;drug therapy;metabolism;genetics;metabolism",
        "_version_":1605746286269562880},
      {
        "Doc_abstract":"The human epidermal growth factor receptor-2 (HER2) plays an important role in breast cancer. Enhanced Ets-1 activity has recently been shown to be associated with breast cancer pathogenesis. To test the role of Ets-1 in breast cancer cells in relation to the expression of HER2 and MMP-1, we transiently overexpressed Ets-1 and/or HER2 in MCF-7 breast cancer cells and comprehensively searched for genes related to HER2 and Ets-1 using cDNA microarray analysis. The expression of matrix metalloproteinase (MMP) genes was enhanced by the overexpression of HER2/Ets-1. We analyzed the relationship between HER2-induced MMP-1 expression and the transcription factor Ets-1, which has significant activity in breast cancer pathogenesis. Our results demonstrate that HER2-induced MMP-1 expression is positively regulated by Ets-1 in breast cancer cells. This study confirms that Ets-1 is a downstream effector of oncogenic HER2, associated with MMP-1.",
        "Doc_title":"Ets-1 upregulates HER2-induced MMP-1 expression in breast cancer cells.",
        "Journal":"Biochemical and biophysical research communications",
        "Do_id":"18851945",
        "Doc_ChemicalList":"ETS1 protein, human;Proto-Oncogene Protein c-ets-1;Receptor, Epidermal Growth Factor;Receptor, ErbB-2;Matrix Metalloproteinase 1",
        "Doc_meshdescriptors":"Breast Neoplasms;Cell Line, Tumor;Down-Regulation;Humans;Matrix Metalloproteinase 1;Oligonucleotide Array Sequence Analysis;Phosphorylation;Promoter Regions, Genetic;Proto-Oncogene Protein c-ets-1;Receptor, Epidermal Growth Factor;Receptor, ErbB-2;Transfection",
        "Doc_meshqualifiers":"genetics;metabolism;genetics;metabolism;drug effects;genetics;metabolism;metabolism;antagonists & inhibitors;genetics;metabolism",
        "_version_":1605752177835376640},
      {
        "Doc_abstract":"The clinical role of HER-2/neu, a 185 kD epithelial transmembranous protein, has evolved after the approval of the anti-HER-2/neu targeted monoclonal antibody trastuzumab (Herceptin) for the therapy of metastatic breast cancer. The extracellular domain of HER-2/neu undergoes proteolytic cleavage from the full-length protein by metalloproteases, and is shed into the blood as a circulating antigen. While HER-2/neu gene amplification and/or protein overexpression are detected in approximately 25% of primary breast cancers, serum HER-2/neu levels are elevated beyond the upper limit of normal in 50 to 60% of stage IV breast cancer patients. HER-2/neu in serum can be detected by enzyme immunoassays (manual and automated versions). It has been shown to have prognostic and predictive information in breast cancer patients. Monitoring for recurrence by serum HER-2/neu reaches a high sensitivity for HER-2/neu positive tumors. Longitudinal follow-up of patients during any kind of systemic therapy allows for monitoring of the therapeutic success. When utilized in these applications, serum HER-2/neu testing is complementary to HER-2/neu tissue results and to the determination of classical tumor markers such as CA 15-3, CA 27.29 and CEA, which are not targeted by specific forms of systemic therapy.",
        "Doc_title":"Serum HER-2/neu in the management of breast cancer patients.",
        "Journal":"Clinical biochemistry",
        "Do_id":"12810150",
        "Doc_ChemicalList":"Receptor, ErbB-2",
        "Doc_meshdescriptors":"Algorithms;Breast Neoplasms;Enzyme-Linked Immunosorbent Assay;Female;Humans;Predictive Value of Tests;Prognosis;Receptor, ErbB-2",
        "Doc_meshqualifiers":"blood;diagnosis;methods;analysis;blood",
        "_version_":1605757789345415168},
      {
        "Doc_abstract":"Invasive breast carcinomas are heterogeneous and exhibit distinct molecular features and biological behavior. Understanding the underlying molecular events that promote breast cancer progression is necessary to improve treatment and prognostication. TGF-Î² receptor III (TBR3) is a member of the TGF-Î² signaling pathway, with functions in cell proliferation and migration in malignancies, including breast cancer. Recent studies propose that TBR3 may function as a tumor suppressor and that its loss may correlate with disease progression. However, there are limited data on the expression of TBR3 in breast cancer in relationship to tumor type, hormonal receptor status and HER-2/neu, and patient outcome. In this study, we investigated the expression of TBR3 in a cohort of 205 primary invasive breast carcinomas in tissue microarrays (TMAs), with comprehensive clinical, pathological and follow- up information. Sections were stained for TBR3 and evaluated for intensity of reactivity based on a 4-tiered scoring system (1 to 4; TBR3 lowâ€‰=â€‰scores 1-2; TBR3 highâ€‰=â€‰scores 3-4). Of the 205 invasive carcinomas, 123 were luminal type (95 type A, 28 type B), 8 were HER-2 type, and 62 were triple negative (TN). TBR3 was high in 112 (55Â %) and low in 93 (45Â %) cases. Low TBR3 was associated with higher histological grade and worse disease free and overall survival, all features of biologically aggressive breast carcinomas. TBR3 was significantly associated with the subtype of breast cancer, as low TBR3 was detected in 95Â % of TN compared to 22Â % of luminal tumors (pâ€‰<â€‰0.0001). We discovered a significant association between low TBR3 protein expression, TN breast cancer phenotype, and disease progression. These data suggest that TBR3 loss might be linked to the development of TN breast cancers and pave the way to investigating whether restoring TBR3 function may be a therapeutic strategy against TN breast carcinomas. ",
        "Doc_title":"Characterization of type III TGF-Î² receptor expression in invasive breast carcinomas: a potential new marker and target for triple negative breast cancer.",
        "Journal":"Journal of cell communication and signaling",
        "Do_id":"25135009",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605824678068224000},
      {
        "Doc_abstract":"Overexpression of the Her-2/neu (HER2) oncogene is known to confer important prognostic and predictive value to patients with breast cancer. Controversy exists as to the best method for its determination caused primarily by the variable sensitivities of the different antibodies and interobserver differences, particularly in the group of breast cancers with borderline levels of expression of the protein product. This study was therefore designed to determine the status of the HER2 gene amplification in a group of breast carcinomas with low levels of overexpression. After an initial validation of our procedures, a series of 52 consecutive cases of formalin-fixed, paraffin-embedded breast cancers with low levels of overexpression and a series of 22 cases with no expression by immunohistochemistry were analyzed by fluorescence in situ hybridization (FISH), and the results correlated statistically. Amplification of the HER2 gene was observed in 16% of equivocal to weakly positive cases. Those that were amplified showed low levels of amplification with ratios less than 4.5 and a characteristic scattered pattern of distribution of HER2 signals in the FISH assay. In addition, heterogeneity was noted in two cases in the amplification of the HER2 gene within the same tumor samples with pockets of amplified tumor cells amidst nonamplified tumor cells. In cases without amplification, a statistically significant number showed chromosome 17 polysomy. In conclusion, equivocal to low levels of HER2 overexpression in breast cancers are associated, in the majority of cases, with chromosome 17 polysomy and a corresponding increase in the HER2 gene numbers. True gene amplification is present in only a minority of cases. FISH analysis should be used for confirmation of gene amplification. Prior screening and selection of appropriate immunohistochemistry-positive areas for FISH analysis may prove beneficial.",
        "Doc_title":"Her-2/neu gene amplification in low to moderately expressing breast cancers: possible role of chromosome 17/Her-2/neu polysomy.",
        "Journal":"The breast journal",
        "Do_id":"11906444",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"Breast Neoplasms;Chromosomes, Human, Pair 17;Female;Gene Amplification;Gene Expression Regulation, Neoplastic;Genes, erbB-2;Humans;Immunohistochemistry;In Situ Hybridization, Fluorescence;Predictive Value of Tests",
        "Doc_meshqualifiers":"genetics;genetics;genetics",
        "_version_":1605766764844548096},
      {
        "Doc_abstract":"In cancer, the level of expression of breast cancer resistance protein (BCRP/ABCG2) can vary depending on cell type. However, its precise role in breast cancer has been controversial. The aim of this study was to investigate the expression of ABCG2 in breast carcinomas and relate the results to the established prognostic factors. An immunohistochemical study was conducted on 200 breast carcinoma specimens using the avidin-biotin peroxidase method. ABCG2 was expressed in 77% of cases of invasive ductal carcinoma. There was a statistically significant correlation between ABCG2 expression and each of the tumor grade, clinical stage, lymph node metastasis, and HER2 immunostaining, but no such association with progesterone receptor (PR) and estrogen receptor (ER) status. Increased expression of ABCG2 in invasive ductal carcinoma cells and its statistically significant correlation with HER2 expression are strongly correlated with tumor progression, invasion, and metastasis in human breast cancer and indicates that ABCG2 can be used as a target for the development of novel therapies.",
        "Doc_title":"The prognostic value of breast cancer resistance protein (BCRB/ABCG2) expression in breast carcinomas.",
        "Journal":"Journal of environmental pathology, toxicology and oncology : official organ of the International Society for Environmental Toxicology and Cancer",
        "Do_id":"23394449",
        "Doc_ChemicalList":"ABCG2 protein, human;ATP Binding Cassette Transporter, Sub-Family G, Member 2;Neoplasm Proteins;Receptors, Estrogen;ERBB2 protein, human;Receptor, ErbB-2",
        "Doc_meshdescriptors":"ATP Binding Cassette Transporter, Sub-Family G, Member 2;ATP-Binding Cassette Transporters;Adult;Aged;Breast Neoplasms;Carcinoma, Intraductal, Noninfiltrating;Female;Humans;Immunohistochemistry;Middle Aged;Neoplasm Proteins;Prognosis;Receptor, ErbB-2;Receptors, Estrogen",
        "Doc_meshqualifiers":"analysis;metabolism;diagnosis;metabolism;mortality;diagnosis;metabolism;mortality;analysis;metabolism;analysis;metabolism;analysis;metabolism",
        "_version_":1605747993592463360},
      {
        "Doc_abstract":"ErbB2, a receptor tyrosine kinase highly expressed in many tumors, is known to inhibit apoptotic signals. Overexpression of ErbB2 causes anoikis resistance that contributes to luminal filling in three-dimensional mammary epithelial acinar structures in vitro. Given that integrins and growth factor receptors are highly interdependent for function, we examined the role of integrin subunits in ErbB2-mediated survival signaling. Here, we show that MCF-10A cells overexpressing ErbB2 upregulate integrin alpha5 via the MAP-kinase pathway in three-dimensional acini and found elevated integrin alpha5 levels associated with ErbB2 status in human breast cancer. Integrin alpha5 is required for ErbB2-mediated anoikis resistance and for optimal ErbB2 signaling to the Mek-Erk-Bim axis as depletion of integrin alpha5 reverses anoikis resistance and Bim inhibition. Integrin alpha5 is required for full activation of ErbB2 tyrosine phosphorylation on Y877 and ErbB2 phosphorylation is associated with increased activity of Src in the absence of adhesion. Indeed, we show that blocking elevated Src activity during cell detachment reverses ErbB2-mediated survival and Bim repression. Thus, integrin alpha5 serves as a key mediator of Src and ErbB2-survival signaling in low adhesion states, which are necessary to block the pro-anoikis mediator Bim, and we suggest that this pathway represents a potential novel therapeutic target in ErbB2-positive tumors.",
        "Doc_title":"ErbB2 requires integrin alpha5 for anoikis resistance via Src regulation of receptor activity in human mammary epithelial cells.",
        "Journal":"Journal of cell science",
        "Do_id":"20332114",
        "Doc_ChemicalList":"Apoptosis Regulatory Proteins;BCL2L11 protein, human;Bcl-2-Like Protein 11;Integrin alpha5;Membrane Proteins;Proto-Oncogene Proteins;ERBB2 protein, human;Receptor, ErbB-2;src-Family Kinases;Extracellular Signal-Regulated MAP Kinases;Mitogen-Activated Protein Kinase Kinases",
        "Doc_meshdescriptors":"Anoikis;Apoptosis Regulatory Proteins;Bcl-2-Like Protein 11;Breast Neoplasms;Cell Adhesion;Cell Survival;Enzyme Activation;Epithelial Cells;Extracellular Signal-Regulated MAP Kinases;Female;Gene Expression Regulation, Neoplastic;Humans;Integrin alpha5;MAP Kinase Signaling System;Mammary Glands, Human;Membrane Proteins;Mitogen-Activated Protein Kinase Kinases;Morphogenesis;Proto-Oncogene Proteins;Receptor, ErbB-2;Up-Regulation;src-Family Kinases",
        "Doc_meshqualifiers":"metabolism;enzymology;genetics;pathology;enzymology;metabolism;genetics;metabolism;cytology;growth & development;metabolism;metabolism;metabolism;metabolism;genetics;metabolism",
        "_version_":1605845779971309568},
      {
        "Doc_abstract":"Breast cancer is a heterogeneous disease with molecular subtypes that have biological distinctness and different behavior. The objective of this study is to evaluate the value of molecular subtypes in breast cancer management according to a retrospective analysis of breast carcinoma molecular subtypes, histopathological grade, and TNM stage. A retrospective study of 475 paraffin-embedded tissues of breast cancer samples from the First Affiliated Hospital of Guangxi Medical University was performed. Expression of ER, PR, Her-2 and Ki-67 was analyzed to classify molecular subtypes of breast cancer by immunohistochemistry. The differences of molecular subtypes of breast cancers in regard to TNM staging and pathological grade were analyzed using Ï‡(2) tests. Values of P<0.05 were considered statistically significant. The frequency of luminal A, luminal B, HER2-positive luminal B, triple negative and non-luminal HER2-positive subtypes were: 35.5%, 22.5%, 13.1%, 15.2% and 13.7%, respectively. Among the five subtypes of breast cancer, the distribution of pathological grades showed a significant difference (P<0.001). There were significant differences in the distribution of TNM staging among the five subtypes of breast cancer (P<0.001). In addition to traditional prognostic indicators such as TNM staging and pathological grade, molecular subtype may aid clinical practice and research into breast cancer. Different molecular subtypes will lead to different prognosis and therapeutic option. Molecular subtyping is essential for breast cancer management. ",
        "Doc_title":"Clinicopathological classification and traditional prognostic indicators of breast cancer.",
        "Journal":"International journal of clinical and experimental pathology",
        "Do_id":"26339424",
        "Doc_ChemicalList":"Biomarkers, Tumor",
        "Doc_meshdescriptors":"Biomarkers, Tumor;Breast Neoplasms;Chi-Square Distribution;China;Female;Humans;Immunohistochemistry;Neoplasm Grading;Neoplasm Staging;Predictive Value of Tests;Retrospective Studies;Risk Factors",
        "Doc_meshqualifiers":"analysis;chemistry;classification;pathology",
        "_version_":1605818686373888000},
      {
        "Doc_abstract":"DNA copy number changes in cancer cells, in particular, amplifications, occur frequently, have prognostic impact and are associated with subtypes of breast cancer. Some amplicons contain well-characterized oncogenes, including 11q13 (CCND1) and 17q12 (HER2). HER2 amplification and overexpression defines the HER2+ subgroup of breast cancer patients and is both a prognostic marker for poor outcome and a predictive marker for response to anti-HER2 targeted therapies. Therefore, there is considerable interest in documenting the locations of other recurring amplifications in breast cancers as they may also provide a rich source of new biomarkers and novel therapeutic targets for these subgroups. This article focuses on the genomic profiling of breast cancer, with an emphasis on the characteristics of the amplifications found in subtypes of breast cancer, including luminal (ER+)/HER2(-)), HER2+ and basal-like (ER(-)/HER2(-)), and discusses their known or potential roles in cancer biology and their clinical implications.",
        "Doc_title":"DNA amplifications in breast cancer: genotypic-phenotypic correlations.",
        "Journal":"Future oncology (London, England)",
        "Do_id":"20528234",
        "Doc_ChemicalList":"DNA, Neoplasm;Estrogens",
        "Doc_meshdescriptors":"Aneuploidy;Breast Neoplasms;Carcinoma;Chromosome Aberrations;DNA, Neoplasm;Estrogens;Female;Forecasting;Gene Amplification;Gene Dosage;Gene Expression Profiling;Genes, Neoplasm;Genes, erbB-2;Genome-Wide Association Study;Genotype;Humans;Neoplasms, Hormone-Dependent;Oncogenes;Phenotype;Sequence Analysis, DNA",
        "Doc_meshqualifiers":"genetics;pathology;genetics;pathology;genetics;genetics;pathology",
        "_version_":1605766470119194624},
      {
        "Doc_abstract":"Estrogen receptor (ER), progesterone receptor (PR), and epidermal growth factor receptor 2 (HER2) status are well-established prognostic markers in breast cancer management. The triple negative breast carcinoma subtype (ER-/PR-/HER2-) has been associated with worse overall prognosis in comparison with other subtypes in study populations consisting of ethnic minorities and young women. We evaluated the prognostic value of breast cancer subtypes, Ki-67 proliferation index (Ki-67PI), and pathologic tumor characteristics on breast cancer survival in Caucasian women in our institution, where greater than 90% of the total patient population is white. From 628 new invasive breast cancer cases in our data base (2000-late 2004), 593 (94%) were identified in Caucasian women. ER/PR/HER2 breast cancer subtypes were classified based on St. Gallen International Expert Consensus recommendations from 2011. ER/PR/HER2 status and its effect on survival were analyzed using a Kaplan-Meier curve. ER/PR/HER2 status, grade, tumor-node-metastasis status (TNM)/anatomic stage, and age were analyzed in terms of survival in a multivariate fashion using a Cox regression. Ki-67PI was analyzed between ER/PR/HER2 groups using the Kruskal-Wallis, Mann-Whitney U-tests, and 2 Ã— 5 ANOVA. Our results showed that patients with stage IIB through stage IV breast carcinomas were 2.1-16 times more likely to die than patients with stages IA-B and IIA disease, respectively (95% CI 1.17-3.81 through 9.68-28.03, respectively), irrespective of ER/PR/HER2 subtype. Similar effect was seen with T2, N2/N3, or M1 tumors in comparison with T1, N0/N1, and M0 tumors. Chances of dying increase approximately 5% for every year increase in age. There was a significant main effect of Ki-67PI between ER/PR/HER2 subtypes, p < .001, but Ki-67PI could not predict survival. In summary, TNM status/anatomic stage of breast carcinomas and age are predictive of survival in our patient population of Caucasian women, but breast carcinoma subtypes and Ki-67 proliferation index are not.",
        "Doc_title":"Prognostic value of breast cancer subtypes, Ki-67 proliferation index, age, and pathologic tumor characteristics on breast cancer survival in Caucasian women.",
        "Journal":"The breast journal",
        "Do_id":"23240985",
        "Doc_ChemicalList":"Ki-67 Antigen;Receptors, Estrogen;Receptors, Progesterone;ERBB2 protein, human;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Adult;Age Factors;Aged;Aged, 80 and over;Analysis of Variance;Breast Neoplasms;Carcinoma;Cell Proliferation;European Continental Ancestry Group;Female;Humans;Kaplan-Meier Estimate;Ki-67 Antigen;Middle Aged;Multivariate Analysis;Neoplasm Grading;Neoplasm Staging;Predictive Value of Tests;Prognosis;Proportional Hazards Models;Receptor, ErbB-2;Receptors, Estrogen;Receptors, Progesterone;Retrospective Studies;Statistics, Nonparametric;Young Adult",
        "Doc_meshqualifiers":"classification;metabolism;pathology;classification;metabolism;pathology;metabolism;metabolism;metabolism;metabolism",
        "_version_":1605810785783644160},
      {
        "Doc_abstract":"The human epidermal growth factor receptor 2 (HER2) is overexpressed in 20% of breast carcinomas. Prior to the development of targeted therapies, HER2-positive breast cancer was associated with more aggressive disease and poor prognosis. Trastuzumab emtansine (T-DM1) is an antibody-drug conjugate that results from the combination of trastuzumab and DM1, a derivative of the antimicrotubule agent maytansine. This molecule has the ability to enhance cytotoxic drug delivery to specifically targeted cells that overexpress HER2, therefore, maximizing efficacy while sparing toxicity. In recent years, T-DM1 has shown to improve outcomes in metastatic HER2-positive breast cancer that is resistant to trastuzumab. In addition, T-DM1 is currently being tested in the neoadjuvant and adjuvant settings to identify patients who may benefit from this therapy. This review focuses on the mechanism of action, early and late-phase clinical trials, and ongoing studies of T-DM1 in HER2-positive breast cancer. ",
        "Doc_title":"Novel approaches to target HER2-positive breast cancer: trastuzumab emtansine.",
        "Journal":"Cancer management and research",
        "Do_id":"27274311",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605875599723724800},
      {
        "Doc_abstract":"Triple-negative breast cancer, so called because it lacks expression of the estrogen receptor, progesterone receptor, and HER2, is often, but not always, a basal-like breast cancer. This review focuses on its origin, molecular and clinical characteristics, and treatment.",
        "Doc_title":"Triple-negative breast cancer.",
        "Journal":"The New England journal of medicine",
        "Do_id":"21067385",
        "Doc_ChemicalList":"Antineoplastic Agents;Receptors, Estrogen;Receptors, Progesterone;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Antineoplastic Agents;Breast Neoplasms;Female;Genes, BRCA1;Humans;Mutation;Prognosis;Receptor, ErbB-2;Receptors, Estrogen;Receptors, Progesterone;Survival Rate",
        "Doc_meshqualifiers":"therapeutic use;drug therapy;immunology;mortality;pathology",
        "_version_":1605847061344813056},
      {
        "Doc_abstract":"The changes in DNA methylation status in cancer cells are characterized by hypermethylation of promoter CpG islands and diffuse genomic hypomethylation. Alu and long interspersed nucleotide element-1 (LINE-1) are non-coding genomic repetitive sequences and methylation of these elements can be used as a surrogate marker for genome-wide methylation status. This study was designed to evaluate the changes of Alu and LINE-1 hypomethylation during breast cancer progression from normal to pre-invasive lesions and invasive breast cancer (IBC), and their relationship with characteristics of IBC. We analyzed the methylation status of Alu and LINE-1 in 145 cases of breast samples including normal breast tissue, atypical ductal hyperplasia/flat epithelial atypia (ADH/FEA), ductal carcinoma in situ (DCIS) and IBC, and another set of 129 cases of IBC by pyrosequencing. Alu methylation showed no significant changes during multistep progression of breast cancer, although it tended to decrease during the transition from DCIS to IBC. In contrast, LINE-1 methylation significantly decreased from normal to ADH/FEA, while it was similar in ADH/FEA, DCIS and IBC. In IBC, Alu hypomethylation correlated with negative estrogen receptor (ER) status, and LINE-1 hypomethylation was associated with negative ER status, ERBB2 (HER2) amplification and p53 overexpression. Alu and LINE-1 methylation status was significantly different between breast cancer subtypes, and the HER2 enriched subtype had lowest methylation levels. In survival analyses, low Alu methylation status tended to be associated with poor disease-free survival of the patients. Our findings suggest that LINE-1 hypomethylation is an early event and Alu hypomethylation is probably a late event during breast cancer progression, and prominent hypomethylation of Alu and LINE-1 in HER2 enriched subtype may be related to chromosomal instability of this specific subtype. ",
        "Doc_title":"Alu and LINE-1 hypomethylation is associated with HER2 enriched subtype of breast cancer.",
        "Journal":"PloS one",
        "Do_id":"24971511",
        "Doc_ChemicalList":"Biomarkers, Tumor;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Adult;Aged;Aged, 80 and over;Alu Elements;Biomarkers, Tumor;Breast Neoplasms;DNA Methylation;Disease Progression;Epigenesis, Genetic;Female;Humans;Long Interspersed Nucleotide Elements;Middle Aged;Neoplasm Grading;Neoplasm Staging;Patient Outcome Assessment;Phenotype;Receptor, ErbB-2;Young Adult",
        "Doc_meshqualifiers":"diagnosis;genetics;metabolism;mortality;pathology;genetics;metabolism",
        "_version_":1605752817789698048},
      {
        "Doc_abstract":"Her-2/neu belongs to the family of tyrosine kinase transmembrane proteins whose overexpression has been associated with a poor prognosis in patients with breast cancer. The product of this proto-oncogene is overexpressed in 25-30% of human breast cancer and is the target of selective immunotherapy. Concerned about the ethnic differences on the expression of this oncogene, we have evaluated 143 consecutive specimens of primary breast cancer diagnosed in San Pablo Hospital, Puerto Rico. The specimens were analyzed for Her-2/neu expression using immunohistochemistry assays (Hercept test). We have related the expression of hormone receptor status, percent cells in S phase, DNA ploidy, tumor size, nodal status and menopausal state with the Her2/neu expression. Out of 143 specimens, 28 overexpressed the Her-2/neu (19.6%). Of the Her/2 negative 30/114 (26%) were estrogen receptor negative as compared to 9/27 (33%) (p = 0.464). The degree of aneuploidy was abnormal in 25/104 (24%) in the Her-2/neu negative vs 11/27 (41%) p = 0.083. The percent cell in DNA synthesis was high in 16/77 (21%) in Her-2/neu negative vs 4/15 (27%) p = 0.613. The tumor size was greater than 2 cm in 35/106 (33%) in Her-2/neu negative vs 9/23 (39%) p = 0.575. In the progesterone specimens negative for Her2, 44/114 (39%) were Her2/neu negative vs 15/27 (56%) p = 0.108. No differences were seen regarding menopausal status, age and nuclear grading. A trend favoring abnormal aneuploidy in Her2/neu positive was seen. Nodal involvement was significantly associated with Her2/neu overexpression. (p = 0.037). Although the incidence of Her2 overexpression found in this database was somewhat lower than the one reported in the literature, this might also be due to the small cohort examined or to the technique utilized.",
        "Doc_title":"Her-2/neu oncogene expression in Puerto Rican females with breast cancer.",
        "Journal":"Cellular and molecular biology (Noisy-le-Grand, France)",
        "Do_id":"11785652",
        "Doc_ChemicalList":"Biomarkers, Tumor;Oncogene Proteins;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Adenocarcinoma;Adult;Age Factors;Aged;Biomarkers, Tumor;Breast Neoplasms;Cohort Studies;Female;Hispanic Americans;Humans;Immunohistochemistry;Lymphatic Metastasis;Menopause;Middle Aged;Oncogene Proteins;Ploidies;Puerto Rico;Receptor, ErbB-2;S Phase",
        "Doc_meshqualifiers":"ethnology;genetics;metabolism;pathology;analysis;ethnology;genetics;metabolism;pathology;immunology;metabolism;ethnology;immunology;metabolism",
        "_version_":1605807478171238400},
      {
        "Doc_abstract":"Breast cancer risk is greatly increased in women who carry mutations in the BRCA1 or BRCA2 genes. Because breast cancer initiation is different between BRCA1/2 mutation carriers and women who do not carry mutations, it is possible that the mechanism of breast cancer progression is also different. Histopathologic and genetic studies have supported this hypothesis. To test this hypothesis further, we utilized a large cohort of women who underwent therapeutic mastectomy (TM) and contralateral prophylactic mastectomy (PM). From this cohort, we developed case groups of women with a family history of breast cancer with BRCA1/2 deleterious mutations, with unclassified variant alterations, and with no detected mutation and matched these cases with sporadic controls from the same TM and PM cohort. Fluorescence in situ hybridization was performed on paraffin sections by use of dual-color probes for ERBB2/CEP17, MYC/CEP8, TBX2/CEP17, and RPS6KB1/CEP17. All malignant and benign lesions, including putative precursor lesions, were studied. The invasive cancers from deleterious mutation carriers had a higher prevalence of duplication of MYC (P = 0.006) and TBX2 (P = 0.0008) compared to controls and a lower prevalence of ERBB2 amplification (P = 0.011). Coduplication of MYC and TBX2 was common in the in situ and invasive lesions from the deleterious mutation carriers. The odds ratio of having a BRCA1/2 mutation is 31.4 (95% CI = 1.7-569) when MYC and TBX2 are coduplicated but ERBB2 is normal. Unclassified variant carriers/no mutation detected and sporadic controls had a similar prevalence of alterations, suggesting that hereditary patients with no deleterious mutations follow a progression pathway similar to that of sporadic cases. With the exception of one atypical ductal hyperplasia lesion, no putative precursor lesion showed any detectable alteration of the probes tested. There was no significant intratumoral heterogeneity of genetic alterations. Our data confirm that a specific pattern of genomic instability characterizes BRCA1/2-related cancers and that this pattern has implications for the biology of these cancers. Moreover, our current and previous results emphasize the interaction between phenotype and genotype in BRCA1/2-related breast cancers and that a combination of morphologic features and alterations of ERBB2, MYC, and TBX2 may better define mechanisms of tumor progression, as well as determine which patients are more likely to carry BRCA1/2 mutations.",
        "Doc_title":"ERBB2, TBX2, RPS6KB1, and MYC alterations in breast tissues of BRCA1 and BRCA2 mutation carriers.",
        "Journal":"Genes, chromosomes & cancer",
        "Do_id":"15236312",
        "Doc_ChemicalList":"BRCA1 Protein;BRCA2 Protein;Proto-Oncogene Proteins c-myc;T-Box Domain Protein 2;T-Box Domain Proteins;Receptor, ErbB-2;Ribosomal Protein S6 Kinases, 70-kDa;ribosomal protein S6 kinase, 70kD, polypeptide 1",
        "Doc_meshdescriptors":"Adult;Aged;Aged, 80 and over;BRCA1 Protein;BRCA2 Protein;Breast;Breast Neoplasms;Female;Heterozygote;Humans;Middle Aged;Mutation;Proto-Oncogene Proteins c-myc;Receptor, ErbB-2;Ribosomal Protein S6 Kinases, 70-kDa;T-Box Domain Proteins",
        "Doc_meshqualifiers":"genetics;genetics;metabolism;physiopathology;genetics;genetics;genetics;genetics",
        "_version_":1605824247242948608},
      {
        "Doc_abstract":"The BRCA1 tumor suppressor gene and the HER-2/neu oncogene are located in close proximity on the long arm of chromosome 17 (17q11-21). Absence of BRCA1 or functional overexpression of the HER-2/neu gene presumably contributes to the somatic phenotype of breast cancer in premenopausal women, characterized by unfavorable prognostic features such as high tumor grade, hormone receptor negativity, and high proliferation rate. To examine whether amplification of HER-2/neu contributes to the aggressive biology of BRCA1-associated tumors, we have performed fluorescence in situ hybridization on formalin-fixed paraffin-embedded breast tumor tissue sections from 53 BRCA1 mutation carriers and 41 randomly selected, age-matched sporadic breast cancer cases. Although BRCA1-associated and sporadic tumors were equally likely (19% versus 22%) to exhibit HER-2/neu amplification [defined as a ratio of HER-2/neu copies to chromosome 17 centromere (CEP17) copies > or = 2], 6 (15%) of the sporadic tumors were highly amplified (defined as a ratio greater-than-or-equal 5) versus none of the BRCA1-associated tumors (P = 0.048). HER-2 protein overexpression as measured by immunohistochemical analysis was not observed among the BRCA1-associated cases (P = 0.042). Four of 21 (19%) sporadic tumors exhibited strong membranous staining of HER-2 (intensity level of 3+) as compared with 0 of 39 BRCA1-associated tumors. Our data suggest that a germ-line mutation in the BRCA1 tumor suppressor gene is associated with a significantly lower level of HER-2/neu amplification. Thus, it is possible that BRCA1-associated and HER-2/neu-highly amplified tumors progress through distinct molecular pathways, and the aggressive pathological features of BRCA1-associated tumors appear unrelated to amplification of the adjacent HER-2/neu oncogene.",
        "Doc_title":"Molecular-cytogenetic analysis of HER-2/neu gene in BRCA1-associated breast cancers.",
        "Journal":"Cancer research",
        "Do_id":"11888924",
        "Doc_ChemicalList":"Receptor, ErbB-2",
        "Doc_meshdescriptors":"Adult;Aged;Breast Neoplasms;Chromosomes, Human, Pair 17;Female;Gene Amplification;Gene Dosage;Genes, BRCA1;Genes, erbB-2;Humans;Loss of Heterozygosity;Middle Aged;Receptor, ErbB-2;Tumor Cells, Cultured",
        "Doc_meshqualifiers":"genetics;analysis",
        "_version_":1605844791406362624},
      {
        "Doc_abstract":"Functional loss of p53 and ErbB2 overexpression are the frequent genetic alterations in human breast carcinomas. Here, we found that ErbB2 expression was upregulated in primary cultured mammary epithelial cells (MECs) isolated from mice with a defect in exons 5 and 6 of the p53 gene (p53(Delta5,6)). The reporter gene activity in the p53(Delta5,6) MECs transfected with the -756bp flanking region of the hErbB2 gene was higher than the wild type MECs. p53 inactivation selectively increased the level of AP-2alpha, but not AP-2beta and AP-2gamma and a mutation of the two AP-2 binding sites completely inhibited the reporter activity.",
        "Doc_title":"ErbB2 overexpression in p53-inactivated mammary epithelial cells.",
        "Journal":"FEBS letters",
        "Do_id":"17101136",
        "Doc_ChemicalList":"Transcription Factor AP-2;Tumor Suppressor Protein p53;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Animals;Epithelial Cells;Exons;Female;Humans;Mammary Glands, Animal;Mice;Mice, Knockout;Mutation;Receptor, ErbB-2;Response Elements;Transcription Factor AP-2;Tumor Suppressor Protein p53;Up-Regulation",
        "Doc_meshqualifiers":"cytology;metabolism;genetics;cytology;metabolism;biosynthesis;genetics;metabolism;deficiency;genetics",
        "_version_":1605789419979145216},
      {
        "Doc_abstract":"The transition from epithelial keratin to mesenchymal vimentin expression marks an important step in the malignant progression of breast cancer. This study analyzed the clinical significance of cytokeratin and vimentin in patients with breast cancer.;Expression of cytokeratin and vimentin was evaluated by immunohistochemistry on paraffin-embedded tissue sections of patients with breast cancer.;Loss of cytokeratin was seen in 11% of the patients. A clearer trend towards loss of cytokeratin was observed in patients with stage IV disease and PR negativity. Weak cytokeratin expression was present in patients who developed recurrence or metastatic disease. Loss of cytokeratin was associated with reduced overall survival in univariate and multivariate analysis, gain of vimentin expression was seen in 57% of breast carcinoma patients. It was higher in patients with lymph node positivity, advanced stage, HER2 positivity, and disease recurrence or metastasis. Multivariate survival analysis indicated that gain of vimentin expression was associated with reduced relapse-free survival.;Loss of cytokeratin and gain of vimentin expression are indicators of biologically aggressive breast carcinoma.",
        "Doc_title":"Cytokeratin and vimentin expression in breast cancer.",
        "Journal":"The International journal of biological markers",
        "Do_id":"19404921",
        "Doc_ChemicalList":"Biomarkers, Tumor;Vimentin;Keratins;ERBB2 protein, human;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Adult;Aged;Biomarkers, Tumor;Breast Neoplasms;Disease-Free Survival;Female;Humans;Immunohistochemistry;Kaplan-Meier Estimate;Keratins;Middle Aged;Neoplasm Recurrence, Local;Prognosis;Receptor, ErbB-2;Retrospective Studies;Vimentin",
        "Doc_meshqualifiers":"metabolism;metabolism;mortality;pathology;secondary;metabolism;metabolism;metabolism;metabolism",
        "_version_":1605766432305446912},
      {
        "Doc_abstract":"Human epidermal growth factor receptor-2 (HER2/neu; erbB2) belongs to a family of four transmembrane receptor tyrosine kinases involved in signal transduction pathways that regulate cell growth and proliferation. Amplification or overexpression of HER2/neu occurs in about 30% of human breast and ovarian cancers and is associated with a poor clinical outcome, including short survival time and short time to relapse. Recent advances in our understanding of HER2/neu signaling pathways have greatly increased our knowledge of breast cancer tumorigenesis and have provided new targets for treating breast and ovarian tumors that overexpress HER2/neu. This review will focus on the signaling network mediated by HER2/neu in breast cancer and discuss our understanding of these pathways, which seem to be particularly important in mediating cell survival and growth under a wide variety of circumstances in breast cancer.",
        "Doc_title":"Dysregulation of cellular signaling by HER2/neu in breast cancer.",
        "Journal":"Seminars in oncology",
        "Do_id":"14613025",
        "Doc_ChemicalList":"Antineoplastic Agents;CTNNB1 protein, human;Cytoskeletal Proteins;NF-kappa B;Nuclear Proteins;Proto-Oncogene Proteins;Trans-Activators;Tumor Suppressor Protein p53;Wnt Proteins;Zebrafish Proteins;beta Catenin;MDM2 protein, human;Proto-Oncogene Proteins c-mdm2;Protein-Tyrosine Kinases;Receptor, ErbB-2;Protein-Serine-Threonine Kinases;Proto-Oncogene Proteins c-akt",
        "Doc_meshdescriptors":"Antineoplastic Agents;Apoptosis;Breast Neoplasms;Cell Cycle;Cytoskeletal Proteins;Gene Expression;Gene Expression Regulation, Neoplastic;Genes, erbB-2;Humans;NF-kappa B;Nuclear Proteins;Protein-Serine-Threonine Kinases;Protein-Tyrosine Kinases;Proto-Oncogene Proteins;Proto-Oncogene Proteins c-akt;Proto-Oncogene Proteins c-mdm2;Receptor, ErbB-2;Signal Transduction;Trans-Activators;Tumor Suppressor Protein p53;Wnt Proteins;Zebrafish Proteins;beta Catenin",
        "Doc_meshqualifiers":"pharmacology;drug therapy;genetics;metabolism;pathology;physiology;drug effects",
        "_version_":1605746295106961410},
      {
        "Doc_abstract":"Molecular subtyping of breast cancer by gene expression has proven its significance in females. Immunohistochemical surrogates have been used for this classification, because gene expression profiling is not yet routinely feasible. Male breast cancer is rare and large series are lacking. In this study, we used immunohistochemistry for molecular subtyping of male breast cancer. A total of 134 cases of male breast cancer were immunohistochemically stained on tissue microarrays for estrogen receptor (ER), progesterone receptor (PR), HER2 and epidermal growth factor receptor (EGFR), as well as for CK5/6, CK14, and Ki67. HER2 was also assessed by chromogen in situ hybridization. Cases were classified as luminal A (ER+ and/or PR+, and HER2- and Ki67 low), luminal B (ER+ and/or PR+, and HER2+ or Ki67 high), HER2 driven (ER-, PR-, HER2+), basal-like (ER-, PR-, HER2-, CK5/6+ and/or CK14+ and/or EGFR+), or unclassifiable triple-negative (negative for all six markers). Luminal type A was by far the most encountered type of male breast cancers, representing 75% of the cases. Luminal type B was seen in 21% and the remaining 4% of cases were classified as basal-like (n=4) and unclassifiable triple-negative (n=1). No HER2 driven cases were identified. Patients with basal-like cancer were significantly younger (P=0.034). Luminal B type cancers showed significantly higher histological grade (P<0.001), mitotic index (P<0.001), and PR negativity (P=0.005) compared with luminal type A cancers. In conclusion, most male breast cancers are luminal A and luminal B types, whereas basal-like, unclassifiable triple-negative, and HER2 driven male breast cancers are rare. Luminal type B seem to represent a subtype with an aggressive phenotype. This distribution of molecular subtypes in male breast cancer is clearly different compared with female breast cancers, pointing to possible important differences in carcinogenesis.",
        "Doc_title":"Molecular subtyping of male breast cancer by immunohistochemistry.",
        "Journal":"Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc",
        "Do_id":"22056953",
        "Doc_ChemicalList":"Biomarkers, Tumor;Ki-67 Antigen;Neoplasm Proteins;Receptors, Steroid;Keratins;ERBB2 protein, human;Receptor, Epidermal Growth Factor;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Adenocarcinoma;Adult;Aged;Aged, 80 and over;Biomarkers, Tumor;Breast Neoplasms, Male;Humans;Immunohistochemistry;In Situ Hybridization;In Situ Hybridization, Fluorescence;Keratins;Ki-67 Antigen;Male;Middle Aged;Neoplasm Proteins;Neoplasm Staging;Protein Array Analysis;Receptor, Epidermal Growth Factor;Receptor, ErbB-2;Receptors, Steroid",
        "Doc_meshqualifiers":"classification;metabolism;metabolism;classification;metabolism;methods;methods;metabolism;metabolism;metabolism;metabolism;genetics;metabolism;metabolism",
        "_version_":1605792355510648832},
      {
        "Doc_abstract":"We previously reported that the ErbB2 oncoprotein prolongs and amplifies growth factor signalling by impairing ligand-dependent downregulation of hetero-oligomerised epidermal growth factor receptors. Here we show that treatment of A431 cells with different epidermal growth factor receptor ligands can cause growth inhibition to an extent paralleling ErbB2 tyrosine phosphorylation. To determine whether such growth inhibition signifies an interaction between the cell cycle machinery and ErbB2-dependent alterations of cell signalling kinetics, we used MCF7 breast cancer cells (which express wild-type p53) to create transient and stable ErbB2 transfectants (MCF7-B2). Compared with parental cells, MCF7-B2 cells are characterised by upregulation of p53, p21(WAF) and Myc, downregulation of Bcl2, and apoptosis. In contrast, MCF7-B2 cells co-transfected with dominant negative p53 (MCF7-B2/Delta p53) exhibit reduced apoptosis and enhanced growth relative to both parental MCF7-B2 and control cells. These data imply that wild-type p53 limits survival of ErbB2-overexpressing breast cancer cells, and suggest that signals of varying length and/or intensity may evoke different cell outcomes depending upon the integrity of cell cycle control genes. We submit that acquisition of cell cycle control defects may play a permissive role in ErbB2 upregulation, and that the ErbB2 overexpression phenotype may in turn select for the survival of cells with p53 mutations or other tumour suppressor gene defects.",
        "Doc_title":"Dominant negative knockout of p53 abolishes ErbB2-dependent apoptosis and permits growth acceleration in human breast cancer cells.",
        "Journal":"British journal of cancer",
        "Do_id":"11953857",
        "Doc_ChemicalList":"Ligands;Tumor Suppressor Protein p53;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Apoptosis;Breast Neoplasms;Cell Cycle;Disease Progression;Female;Genes, erbB-2;Humans;Kinetics;Ligands;Phenotype;Receptor, ErbB-2;Signal Transduction;Transfection;Tumor Cells, Cultured;Tumor Suppressor Protein p53;Up-Regulation",
        "Doc_meshqualifiers":"pathology;biosynthesis;biosynthesis;genetics",
        "_version_":1605798334939791360},
      {
        "Doc_abstract":"The development of drug therapies (ZD1839) targeting epidermal growth factor receptor (EGFR) offers a pragmatic reason for exploring expression of EGFR in breast cancer, particularly metastatic breast cancer. There is a reported synergistic relationship between trastuzumab and ZD1839 therapy in patients with breast cancer. Although EGFR is the preferred dimerization partner for HER-2, it is unclear whether expression of these 2 interrelated receptors in a given patient with breast cancer would be parallel or mutually exclusive.;To assess EGFR status in primary breast carcinoma versus metastatic central nervous system (CNS) sites and to compare results with HER-2/neu status in the same tumor.;Central nervous system metastases (n = 51) from 33 patients and corresponding primary breast cancer specimens, when available (n = 11), were immunohistochemically stained for EGFR using a monoclonal mouse anti-EGFR antibody (clone 31G7) that recognizes both the wild-type form and the 145-kd variant III form of EGFR. The sections were evaluated by visual and image analysis techniques, and results were compared to previously assessed HER-2/neu status.;Epidermal growth factor receptor expression was found in CNS metastases from 39% of patients, with 82% concordance between the EGFR status of the primary breast and metastatic sites, and 92% concordance between the EGFR status among multiple CNS metastases in a given patient. Epidermal growth factor receptor and HER-2/neu status were concordant at the primary site in only 45% of patients. Additionally, EGFR and HER-2/neu status were concordant among multiple CNS metastases per individual case in only 45% of patients.;Thirty-nine percent of patients with metastatic breast cancer express EGFR, with parallel expression between metastatic sites and the primary neoplasm in 82% of the cases. The discordance in 18% of the cases, however, suggests that anti-EGFR agents might not show equal efficacy against metastatic tumor deposits and the primary tumor within a given patient. An additional corollary for pathologists based on this nonhomogeneity of receptor expression is that both the primary breast and multiple metastatic tumor deposits may need to be individually assessed for EGFR status. In our study, most metastatic tumor deposits showed expression for either EGFR or HER-2/neu, and less often for both, implying that drug therapies could be individualized for patients based on test results for both receptors.",
        "Doc_title":"Epidermal growth factor receptor status in breast cancer metastases to the central nervous system. Comparison with HER-2/neu status.",
        "Journal":"Archives of pathology & laboratory medicine",
        "Do_id":"15335267",
        "Doc_ChemicalList":"Receptor, Epidermal Growth Factor;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Adult;Breast Neoplasms;Central Nervous System Neoplasms;Female;Humans;Image Interpretation, Computer-Assisted;Immunohistochemistry;Middle Aged;Receptor, Epidermal Growth Factor;Receptor, ErbB-2",
        "Doc_meshqualifiers":"chemistry;pathology;chemistry;secondary;analysis;analysis",
        "_version_":1605819408941318144},
      {
        "Doc_abstract":"The group of luminal (Her2 negative) is distinguished from other subtypes of breast cancer. We aimed to produce a prognostic index specific for luminal (Her2 negative) subtype breast cancer that could assist clinical treatment.;The test set comprised 406 consecutive luminal (Her2 negative) breast cancer patients. The relationship of 11 clinicopathologic factors including survivin with the 5-year disease-free survival was analyzed.;In univariate analysis, TNM stage, surgery, tumor size, lymph node involvement, and survivin expression were prognostic factors. In multivariate analysis, tumor size [HR (95% CI): 1.98 (1.12-3.49), p=0.019], the number of lymph node metastasis [HR (95% CI): 1.75 (1.33-2.29), p<0.0001] and the expression of progesterone receptor [HR (95% CI): 0.58 (0.36-0.95), p=0.029] can independently predict prognosis. Prognostic index (PI) was calculated as 0.68Ã—tumor size+0.56Ã—the number of lymph node metastasis-0.54Ã—PR. According to the PI, patients were categorized into three groups: low, middle, and high risk group with the 5-year disease-free survival rates of 91.91%, 84.97% and 70.47%, respectively (P<0.001). In the validation set, the luminal prognostic index (LPI) remained significant.;The LPI may be a useful tool for evaluating the outcome of patients with luminal (Her-2 negative) breast cancer.",
        "Doc_title":"Luminal (Her2 negative) prognostic index and survival of breast cancer patients.",
        "Journal":"Cancer epidemiology",
        "Do_id":"24725965",
        "Doc_ChemicalList":"ERBB2 protein, human;Receptor, ErbB-2;Phenobarbital",
        "Doc_meshdescriptors":"Adult;Aged;Breast Neoplasms;China;Disease-Free Survival;Female;Humans;Middle Aged;Phenobarbital;Prognosis;Receptor, ErbB-2;Survival Analysis;Young Adult",
        "Doc_meshqualifiers":"enzymology;mortality;pathology;epidemiology;chemistry;analysis",
        "_version_":1605747071906742273},
      {
        "Doc_abstract":"Studies of amplification and/or overexpression of c-myc, HER-2/neu, and H-ras in breast cancer have shown that each is associated with a poor prognosis. The purpose of this study was to explore the possibility that there is a preferred sequence of amplification of these oncogenes in breast cancer. The frequencies of amplification and patterns of co-amplification of c-myc, HER-2/neu, and H-ras were studied in a group of 84 breast cancers. The data suggested a preferred sequence of amplification that consisted of c-myc amplification-HER-2/neu amplification-H-ras amplification. This model was supported by loglinear analysis. In addition, the levels of amplification of JC-A, a DNA fragment newly isolated from a patient with advanced breast cancer, were studied in 61 of these cases. The data suggested that JC-A amplification occurred early. Loglinear analysis supported a model in which JC-A amplification occurred either before or after c-myc amplification but was unrelated to Her-2/neu or ras amplification.",
        "Doc_title":"Assessing sequential oncogene amplification in human breast cancer.",
        "Journal":"Cytometry",
        "Do_id":"8529465",
        "Doc_ChemicalList":"Receptor, ErbB-2;HRAS protein, human;Proto-Oncogene Proteins p21(ras)",
        "Doc_meshdescriptors":"Adenocarcinoma;Breast Neoplasms;Colonic Neoplasms;Female;Gene Amplification;Genes, myc;Humans;Linear Models;Oncogenes;Proto-Oncogene Proteins p21(ras);Receptor, ErbB-2;Tumor Cells, Cultured",
        "Doc_meshqualifiers":"genetics;genetics;genetics;genetics;genetics;genetics;genetics;physiology",
        "_version_":1605762440132296704},
      {
        "Doc_abstract":"The transcriptional regulation of the human EGFR3 and ERBB2 genes has been extensively studied, particularly in the context of their overexpression in breast cancer. Here we summarize published work detailing the transcription factors which interact with the promoters of these and the rat ERBB2 homologue, neu, genes and discuss their possible relevance to gene activation in cancer. In addition we review the biologically significant molecules which modulate expression of these genes and discuss the nuclear factors involved in mediating these responses. We also describe novel therapies which may result from these studies and highlight directions for future research into the control of expression of the EGFR and ERBB2 genes in the normal mammary gland and in breast cancer.",
        "Doc_title":"Transcriptional regulation of type I receptor tyrosine kinases in the mammary gland.",
        "Journal":"Journal of mammary gland biology and neoplasia",
        "Do_id":"10882301",
        "Doc_ChemicalList":"Receptor Protein-Tyrosine Kinases;Receptor, Epidermal Growth Factor;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Animals;Breast;Breast Neoplasms;Female;Gene Expression Regulation;Gene Expression Regulation, Neoplastic;Genes, erbB-2;Humans;Mammary Glands, Animal;Rats;Receptor Protein-Tyrosine Kinases;Receptor, Epidermal Growth Factor;Receptor, ErbB-2;Transcription, Genetic;Transcriptional Activation",
        "Doc_meshqualifiers":"physiology;genetics;physiopathology;physiology;genetics;genetics;genetics",
        "_version_":1605906032460038144},
      {
        "Doc_abstract":"Signal transduction pathways play a crucial role in breast cancer development, progression, and response to different therapies. A major problem in breast cancer therapy is the heterogeneity among different tumor types and cell lines commonly used in preclinical studies. To characterize the signaling pathways of some of the commonly used breast cancer cell lines and dissect the relationship among a number of pathways and some key genetic and molecular events in breast cancer development, such as p53 mutation, ErbB2 expression, and estrogen receptor (ER)/progesterone receptor (PR) status, we performed pathway profiling of 14 breast cancer cell lines by measuring the expression and phosphorylation status of 40 different cell signaling proteins with 53 specific antibodies using a protein lysate array. Cluster analysis of the expression data showed that there was close clustering of phosphatidylinositol 3-kinase, Akt, mammalian target of rapamycin (mTOR), Src, and platelet-derived growth factor receptor beta (PDGFRbeta) in all of the cell lines. The most differentially expressed proteins between ER- and PR-positive and ER- and PR-negative breast cells were mTOR, Akt (pThr308), PDGFRbeta, PDGFRbeta (pTyr751), panSrc, Akt (pSer473), insulin-like growth factor-binding protein 5 (IGFBP5), Src (pTyr418), mTOR (pSer2448), and IGFBP2. Many apoptotic proteins, such as apoptosis-inducing factor, IGFBP3, bad, bax, and cleaved caspase 9, were overexpressed in mutant p53-carrying breast cancer cells. Hexokinase isoenzyme 1, ND2, and c-kit were the most differentially expressed proteins in high and low ErbB2-expressing breast cancer cells. This study demonstrated that ER/PR status, ErbB2 expression, and p53 status are major molecules that impact downstream signaling pathways.",
        "Doc_title":"Dissection of signaling pathways in fourteen breast cancer cell lines using reverse-phase protein lysate microarray.",
        "Journal":"Technology in cancer research & treatment",
        "Do_id":"17121430",
        "Doc_ChemicalList":"Biomarkers, Tumor;Phosphoproteins",
        "Doc_meshdescriptors":"Biomarkers, Tumor;Breast Neoplasms;Cell Line, Tumor;Female;Humans;Phosphoproteins;Protein Array Analysis;Signal Transduction",
        "Doc_meshqualifiers":"metabolism;metabolism;pathology;metabolism",
        "_version_":1605800795944517632},
      {
        "Doc_abstract":"To investigate the clinical characteristics and prognosis of patients with different subtypes of breast cancer: basaloid, HER-2 and luminal types, and try to find the evidence of individualized treatment for the patients.;1280 histologically and immunohistochemically proven patients with resectable breast cancer were treated, and the clinical data including characteristics, relapse and survival of the patients with different subtypes of breast cancer were analyzed retrospectively.;Of the 1280 breast cancer patients, basaloid, HER-2 and luminal types accounted for 20.9%, 23.2% and 55.9%, respectively. Basaloid type was more likely to be found in younger patients frequently with a family history of breast cancer. HER-2 type usually had a tumor of larger size with more advanced stage disease and more metastatic lymph nodes. Luminal type was likely to occur in aged patients with an earlier stage disease. The recurrence rates in basaloid, HER-2 and luminal types were 25.0%, 27.9% and 11.7%, respectively. Patients with basaloid or HER-2 type were found to have a significantly higher recurrence rate than the patients with luminal type breast cancer (P < 0.001), but no significant difference was observed between the basaloid and HER-2 types. However, patients with basaloid type breast cancer were more likely to develop lung metastasis than HER-2 type (13.4% vs. 7.1%, P = 0.017). Up to December 2006, the 5-year disease-free survival (DFS) rates for patients with basaloid, HER-2 and luminal types were 72.2%, 68.2% and 86.2% (P < 0.001), respectively. The overall 5-yr survival (OS) rates of the three groups were 88.6%, 83.8% and 95.8% (P < 0.001) , respectively. Of the patients with luminal type breast cancer, HER2-negative patients had a higher DFS (86.2% vs 57.0%, P < 0.001) and OS (95.8% vs 87.7%, P = 0.0001) compared with those with HER2-positive. The results of Multivariate Cox Regression showed that tumor size and lymph node state were the most important factors influencing the prognosis.;Each subtype of breast cancer has somewhat its own specific clinical features in terms of recurrence pattern and prognosis, therefore, individualized treatment regimen may be required.",
        "Doc_title":"[Clinical characteristics and prognosis of different subtypes of breast cancer].",
        "Journal":"Zhonghua zhong liu za zhi [Chinese journal of oncology]",
        "Do_id":"19024523",
        "Doc_ChemicalList":"Receptors, Estrogen;Receptors, Progesterone;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Adult;Aged;Breast Neoplasms;Chemotherapy, Adjuvant;Disease-Free Survival;Female;Follow-Up Studies;Humans;Lung Neoplasms;Lymphatic Metastasis;Mastectomy;Middle Aged;Neoplasm Recurrence, Local;Neoplasm Staging;Proportional Hazards Models;Radiotherapy, Adjuvant;Receptor, ErbB-2;Receptors, Estrogen;Receptors, Progesterone;Retrospective Studies;Survival Rate;Young Adult",
        "Doc_meshqualifiers":"classification;metabolism;pathology;therapy;secondary;methods;metabolism;metabolism;metabolism",
        "_version_":1605891404626657280},
      {
        "Doc_abstract":"Trastuzumab has substantially changed the prognosis of breast carcinomas. As HER2 over-expression/amplification is a prerequisite for treatment with trastuzumab, an accurate assessment of HER-2 status is the first step for successful treatment. In metastatic breast cancer, we routinely assess HER2 expression in the primary tumour, assuming that HER2 status remains stable through cancer progression. However, it is frequent to find reports that describe discordance between HER2 expression in primary and metastatic tumours. The aim of this paper was to verify whether HER2 status of breast carcinomas is maintained in the corresponding axillary metastasis. Immunohistochemistry was performed on 52 breast carcinomas and their matched axillary metastasis. HercepTest results were concordant in 46 out of 52 cases (88.5%). FISH proved that the differences observed were clinically relevant in only one of the 52 cases studied (98% concordance). We concluded that HER2 status was stable during axillary metastatic progression. Evaluation of gene HER2 status in axillary metastasis rather than in the primary can be useful in certain situations, e.g., small invasive component intimately mixed with in situ component and difficult to recognize in dark field, no tumor after biopsy, or axillary relapse (in this case we can find occasional de novo amplifications susceptible to trastuzumab treatment).",
        "Doc_title":"Whether to determine HER2 status for breast cancer in the primary tumour or in the metastasis.",
        "Journal":"Histology and histopathology",
        "Do_id":"19337966",
        "Doc_ChemicalList":"Receptor, ErbB-2",
        "Doc_meshdescriptors":"Adult;Aged;Aged, 80 and over;Breast Neoplasms;Female;Gene Amplification;Humans;Immunohistochemistry;In Situ Hybridization, Fluorescence;Lymphatic Metastasis;Middle Aged;Receptor, ErbB-2",
        "Doc_meshqualifiers":"metabolism;pathology;pathology;biosynthesis",
        "_version_":1605818716382035968},
      {
        "Doc_abstract":"Breast cancer is the most common tumor in women with Li-Fraumeni Syndrome (LFS), an inherited cancer syndrome associated with germline mutations in the TP53 tumor suppressor gene. Their lifetime breast cancer risk is 49% by age 60. Breast cancers in TP53 mutation carriers recently have more often been reported to be hormone receptor and HER-2 positive by immunohistochemistry and FISH in small series. We seek to complement the existing small literature with this report of a histopathologic analysis of breast cancers from women with documented LFS. Unstained slides and paraffin-embedded tumor blocks from breast cancers from 39 germline TP53 mutation carriers were assembled from investigators in the LFS consortium. Central histology review was performed on 93% of the specimens by a single breast pathologist from a major university hospital. Histology, grade, and hormone receptor status were assessed by immunohistochemistry; HER-2 status was defined by immunohistochemistry and/or FISH. The 43 tumors from 39 women comprise 32 invasive ductal carcinomas and 11 ductal carcinomas in situ (DCIS). No other histologies were observed. The median age at diagnosis was 32Â years (range 22-46). Of the invasive cancers, 84% were positive for ER and/or PR; and 81% were high grade. Sixty three percent of invasive and 73% of in situ carcinomas were positive for Her2/neu (IHC 3+ or FISH amplified). Of the invasive tumors, 53% were positive for both ER and HER2+; other ER/PR/HER2 combinations were observed. The DCIS were positive for ER and HER2 in 27% of the cases. This report of the phenotype of breast cancers from women with LFS nearly doubles the literature on this topic. Most DCIS and invasive ductal carcinomas in LFS are hormone receptor positive and/or HER-2 positive. These findings suggest that modern treatments may result in improved outcomes for women with LFS-associated breast cancer.",
        "Doc_title":"Breast cancer phenotype in women with TP53 germline mutations: a Li-Fraumeni syndrome consortium effort.",
        "Journal":"Breast cancer research and treatment",
        "Do_id":"22392042",
        "Doc_ChemicalList":"Receptors, Estrogen;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Adult;Breast Neoplasms;Female;Genes, p53;Germ-Line Mutation;Humans;Immunohistochemistry;Li-Fraumeni Syndrome;Middle Aged;Neoplasm Staging;Phenotype;Receptor, ErbB-2;Receptors, Estrogen;Young Adult",
        "Doc_meshqualifiers":"complications;genetics;metabolism;pathology;complications;genetics;genetics;metabolism;genetics;metabolism",
        "_version_":1605800360609316864},
      {
        "Doc_abstract":"In recent years several novel prognostic determinants of breast cancer have been identified, including HER-2/neu. The oncogene called HER-2/neu or c-erbB-2 located at 17q21 encodes a 185-kD transmembrane glycoprotein, p185. The HER-2/neu gene is frequently overexpressed in human breast cancers as a result of gene amplification and/or elevated transcription. In this study we investigated the association between the presence of HER-2/neu gene ampliflcation and appearance and/or progression of breast cancer. Paraffin embedded tumour tissue was obtained from 82 women with breast cancer. Blood samples from age matched healthy women served as control (n = 50). The amplification of HER-2/neu gene was determined by PCR amplification using appropriate primers. The amplification of HER-2/neu gene was significantly higher in women with breast cancer as compared with control (P < 0.05). Additionally, there were differences in the amplification status between node-positive and node-negative breast cancer patients. The results suggest that the presence of amplification of HER-2/neu gene may be linked with the appearance and/or progression of breast cancer.",
        "Doc_title":"Genetic analysis of HER-2/neu gene amplification in paraffin embedded tumour tissue in women with breast cancer.",
        "Journal":"Polish journal of pathology : official journal of the Polish Society of Pathologists",
        "Do_id":"12597335",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"Adult;Aged;Breast Neoplasms;Carcinoma, Ductal, Breast;Female;Gene Amplification;Genes, erbB-2;Humans;Lymphatic Metastasis;Middle Aged;Paraffin Embedding;Polymerase Chain Reaction;Postmenopause;Premenopause;Prognosis",
        "Doc_meshqualifiers":"genetics;pathology;genetics;pathology;genetics;genetics;pathology",
        "_version_":1605789373055369216},
      {
        "Doc_abstract":"In patients of Black African ethnicity, breast cancer is reportedly characterized by aggressive, poorly differentiated phenotype(s). To highlight possible differences between breast cancer in indigenous sub-Saharan African and European patients, two breast cancer case series, from Central Sudan (Khartoum) and Northern Italy (Milan), were compared for clinicopathological characteristics, expression of oestrogen receptor (ER), progesterone receptor (PR), Her-2/neu, basal cytokeratin (CK) 5/6 and CK17, and breast cancer subtypes.;After careful antigen retrieval, 114 and 138 consecutive formalin-fixed paraffin-embedded (FFPE) breast cancer cases from the Radiation and Isotope Centre (Khartoum) and from MultiMedica (Milan), respectively, were screened by immunohistochemistry for ER, PR, Her-2/neu, CK5/6 and CK17. Compared with the Italian patients, the Sudanese patients were younger (P < 0.0001) and their tumours were larger (P < 0.0001), more advanced in stage (P < 0.00001), higher grade (P < 0.00001) and more frequently positive for nodal metastases (P < 0.00001). ER expression varied between the two series (P < 0.0008), but no significant differences were found for PR (P < 0.32), combined hormone receptors (P < 0.12), Her-2/neu (P < 0.09), CK5/6 (P < 0.1), CK17 (P = 0.4), combined basal CK status (P = 1) or breast cancer subtypes (P = 0.12).;The differences between the Sudanese and Italian breast cancer series reflect stage at diagnosis rather than intrinsic biological characteristics. This may have relevant implications for breast cancer prevention and treatment in Africa.",
        "Doc_title":"Pathological, clinical and prognostic characteristics of breast cancer in Central Sudan versus Northern Italy: implications for breast cancer in Africa.",
        "Journal":"Histopathology",
        "Do_id":"18315597",
        "Doc_ChemicalList":"Biomarkers, Tumor;Receptors, Estrogen;Receptors, Progesterone",
        "Doc_meshdescriptors":"Adult;African Continental Ancestry Group;Aged;Aged, 80 and over;Biomarkers, Tumor;Breast Neoplasms;Breast Neoplasms, Male;Carcinoma, Ductal, Breast;Carcinoma, Lobular;European Continental Ancestry Group;Female;Humans;In Situ Hybridization, Fluorescence;Italy;Male;Middle Aged;Prognosis;Receptors, Estrogen;Receptors, Progesterone;Sudan",
        "Doc_meshqualifiers":"metabolism;ethnology;metabolism;pathology;ethnology;metabolism;pathology;genetics;metabolism;pathology;ethnology;metabolism;metabolism;ethnology",
        "_version_":1605883881716711424},
      {
        "Doc_abstract":"Epithelial cell adhesion molecule (Ep-CAM) recently received increased attention not only as a prognostic factor in breast cancer but also as a potential target for immunotherapy. We examined Ep-CAM expression in 402 consecutive node-negative breast cancer patients with long-term follow-up not treated in the adjuvant setting.;Ep-CAM expression was evaluated by immunostaining. Its prognostic effect was estimated relative to overexpression/amplification of HER-2, histologic grade, tumor size, age, and hormone receptor expression.;Ep-CAM status was positive in 106 (26.4%) patients. In multivariate analysis, Ep-CAM status was associated with disease-free survival independent of age, pT stage, histologic grade, estrogen receptor (ER), progesterone receptor (PR), as well as HER2 status (P = 0.028; hazard ratio, 1.60; 95% confidence interval, 1.05-2.44). Recently, so-called triple-negative (HER-2, ER, and PR) breast cancer has received increased attention. We noticed a similar association of Ep-CAM with disease-free survival in the triple-negative group as for the entire cohort.;In this study of untreated breast cancer patients, Ep-CAM overexpression was associated with poor survival in the entire cohort and in the subgroup of triple-negative breast cancer. This suggests that Ep-CAM may be a well-suited target for specific therapies particularly in HER-2-, ER-, and PR-negative tumors.",
        "Doc_title":"Prognostic effect of epithelial cell adhesion molecule overexpression in untreated node-negative breast cancer.",
        "Journal":"Clinical cancer research : an official journal of the American Association for Cancer Research",
        "Do_id":"18794096",
        "Doc_ChemicalList":"Antigens, Neoplasm;Biomarkers, Tumor;Cell Adhesion Molecules;EPCAM protein, human;Epithelial Cell Adhesion Molecule",
        "Doc_meshdescriptors":"Adult;Aged;Aged, 80 and over;Antigens, Neoplasm;Biomarkers, Tumor;Breast Neoplasms;Cell Adhesion Molecules;Drug Delivery Systems;Epithelial Cell Adhesion Molecule;Female;Humans;Lymphatic Metastasis;Middle Aged;Neoplasms, Hormone-Dependent;Prognosis",
        "Doc_meshqualifiers":"metabolism;metabolism;mortality;pathology;metabolism",
        "_version_":1605805808575053824},
      {
        "Doc_abstract":"Breast cancer remains the leading cause of death in American women 30 to 70 years of age, and research in the field of breast cancer continues at an explosive pace. Our understanding of the molecular basis of familial breast cancer has advanced significantly through investigation of the tumor suppressor gene BRCA1, as has our knowledge of the role of the ATM gene and predisposition to breast cancer in ataxia-telangiectasia carriers. In addition, progress has been made in understanding the role of HER-2/neu as a prognostic factor in breast cancer. In this review, some of the recent advances in breast cancer biology that are relevant to these areas of study are highlighted.",
        "Doc_title":"Recent advances in breast cancer biology.",
        "Journal":"Current opinion in oncology",
        "Do_id":"10550005",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"Animals;Breast Neoplasms;Female;Humans;Mammary Neoplasms, Experimental",
        "Doc_meshqualifiers":"epidemiology;genetics;metabolism;pathology;genetics;metabolism;pathology",
        "_version_":1605805285908152320},
      {
        "Doc_abstract":"Î’eta-2-microglobulin (Î²2-M) has been demonstrated as a growth factor and signaling molecule in breast cancer and leukemia. The purpose of the study is to characterize Î²2-M expression in molecular subtypes of breast cancer, thereby investigating the mechanism of Î²2-M action in breast cancer.;Î²2-M and B-Cell Lymphoma/Leukemia 2 (Bcl-2) transcript expression levels in breast cancer tissue and the corresponding normal tissue were quantified using real-time PCR. The protein expression levels of Î²2-M, estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER-2), tumor protein 53 (p53) and Ki67 were determined by immunohistochemical (IHC) staining. Following silencing of the Î²2-M by siRNA, the levels of Bcl-2, ER, PR and HER-2 transcripts and the protein expression levels in human breast cancer cells were measured by real-time PCR and western blotting, respectively.;The expression of Î²2-M transcripts demonstrated no significant differences between the four breast cancer molecular subtypes and no significant correlations with age, clinical stage or lymph node metastasis. Î²2-M transcript expression demonstrated a positive correlation when compared to Bcl-2 transcript expression (P<0.05). The Î²2-M protein expression was significantly higher in breast cancer when compared with benign breast tumors (P<0.01), and have no significant correlation with age, clinical stage or lymph node metastasis. There was a significant difference demonstrated in Î²2-M protein expression in the four breast cancer molecular subtypes (P<0.05), and between the ER+ and ER- groups (P<0.01); however, no significant difference was demonstrated between the HER-2+ and HER-2- groups. Î²2-M protein expression had a negative correlation with ER protein expression (P<0.01), a positive correlation with p53 protein expression (P<0.01), and no correlation with Ki67 protein expression. Î²2-M silencing significantly inhibited Bcl-2 mRNA expression, but did not inhibit ER, PR and HER-2 mRNA expression in MCF-7 cells (ER+, PR+ and HER-2-). In addition, Bcl-2 and HER-2 mRNA expression were significantly up-regulated in MDA-MB-231 cells (ER-, PR- and HER-2-), which is consistent with the silencing effect seen at the protein level.;Î²2-M expression demonstrated a significant difference in the four breast cancer molecular subtypes, and may be related to apoptosis regulation in breast cancer.",
        "Doc_title":"Characterization of Î²2-microglobulin expression in different types of breast cancer.",
        "Journal":"BMC cancer",
        "Do_id":"25292288",
        "Doc_ChemicalList":"Biomarkers, Tumor;Proto-Oncogene Proteins c-bcl-2;beta 2-Microglobulin",
        "Doc_meshdescriptors":"Adult;Aged;Biomarkers, Tumor;Breast Neoplasms;Female;Gene Expression;Gene Silencing;Humans;Middle Aged;Neoplasm Metastasis;Neoplasm Staging;Proto-Oncogene Proteins c-bcl-2;RNA Interference;beta 2-Microglobulin",
        "Doc_meshqualifiers":"genetics;metabolism;genetics;metabolism;pathology;genetics;metabolism;genetics;metabolism",
        "_version_":1605897352097300480},
      {
        "Doc_abstract":"In order to obtain a comprehensive DNA methylation signature of HER2-positive breast cancer (HER2+ breast cancer), we performed a genome-wide methylation analysis on 17 HER2+ breast cancer and compared with ten normal breast tissue samples using the Illumina Infinium HumanMethylation450 BeadChip (450K). In HER2+ breast cancer, we found altered DNA methylation in genes involved in multicellular development, differentiation and transcription. Within these genes, we observed an overrepresentation of homeobox family genes, including several genes that have not been previously reported in relation to cancer (DBX1, NKX2-6, SIX6). Other affected genes included several belonging to the PI3K and Wnt signaling pathways. Notably, HER2, AKT3, HK1, and PFKP, genes for which altered methylation has not been previously reported, were also identified in this analysis. In total, we report 69 candidate biomarker genes with maximum differential methylation in HER2+ breast cancer. External validation of gene expression in a selected group of these genes (n = 13) revealed lowered mean gene expression in HER2+ breast cancer. We analyzed DNA methylation in six top candidate genes (AKR1B1, INA, FOXC2, NEUROD1, CDKL2, IRF4) using EpiTect Methyl II Custom PCR Array and confirmed the 450K array findings. Future clinical studies focusing on these genes, as well as on homeobox-containing genes and HER2, AKT3, HK1, and PFKP, are warranted which could provide further insights into the biology of HER2+ breast cancer. ",
        "Doc_title":"Whole genome DNA methylation signature of HER2-positive breast cancer.",
        "Journal":"Epigenetics",
        "Do_id":"25089541",
        "Doc_ChemicalList":"Biomarkers, Tumor;Phosphatidylinositol 3-Kinases;ERBB2 protein, human;Receptor, ErbB-2;Proto-Oncogene Proteins c-akt",
        "Doc_meshdescriptors":"Biomarkers, Tumor;Breast Neoplasms;CpG Islands;DNA Methylation;Epigenesis, Genetic;Female;Genes, Homeobox;Genome, Human;Humans;Phosphatidylinositol 3-Kinases;Proto-Oncogene Proteins c-akt;Receptor, ErbB-2;Wnt Signaling Pathway",
        "Doc_meshqualifiers":"genetics;metabolism;genetics;metabolism;genetics;metabolism;genetics;metabolism;genetics;metabolism",
        "_version_":1605842488159895552},
      {
        "Doc_abstract":"The HER-2/neu oncogene encodes a transmembrane tyrosine kinase receptor with extensive homology to the epidermal growth factor receptor. The association of HER-2/neu gene and protein abnormalities with prognosis in breast cancer is presented by considering a series of 52 published studies including more than 16,000 patients. The relative advantages and disadvantages of Southern blot testing, polymerase chain reaction amplification, and fluorescence in situ hybridization assays designed to detect HER-2/neu gene amplification are compared with HER-2/neu protein overexpression assays performed with immunohistochemical techniques applied to frozen and paraffin-embedded tissues and enzyme immunoassays performed on tumor cytosols. The importance of HER-2/neu protein overexpression in ductal carcinoma in situ, and HER-2/neu protein status in uncommon breast diseases in female patients and breast cancer in male patients are also considered. The potential value of HER-2/neu protein status for the prediction of response to therapy in breast cancer is presented for standard hormonal therapy, cytotoxic chemotherapy, and radiation therapy. Also evaluated is the status of serum-based testing for circulating HER-2/neu receptor protein and its ability to predict disease outcome and therapy response. Finally, preliminary data concerning use of antibody-based therapies directed against HER-2/neu protein and their potential use in breast cancer treatment are considered.",
        "Doc_title":"HER-2/neu (c-erb-B2) gene and protein in breast cancer.",
        "Journal":"American journal of clinical pathology",
        "Do_id":"10396301",
        "Doc_ChemicalList":"Receptor, ErbB-2",
        "Doc_meshdescriptors":"Breast Neoplasms;Carcinoma in Situ;Carcinoma, Ductal, Breast;Female;Gene Expression;Genes, erbB-2;Genetic Techniques;Humans;Male;Receptor, ErbB-2",
        "Doc_meshqualifiers":"genetics;metabolism;pathology;genetics;metabolism;pathology;genetics;metabolism;pathology;biosynthesis",
        "_version_":1605802355271401472},
      {
        "Doc_abstract":"Soy isoflavone is associated with modification of breast cancer risk. Effects of dietary isoflavone on breast tissue carcinogenesis under varying endogenous oestrogen contexts were investigated.;Five-week-old mouse mammary tumour virus (MMTV)-erbB2 female transgenic  mice (n = 180) were divided into three equal groups: low-, normal- and high-oestrogen groups. Each group was then subdivided into an experimental group (given soybean feed) and a control group (given control feed).;In the high-oestrogen environment, breast cancer incidence  was significantly lower in the experimental versus the control group, whereas in the low-oestrogen environment, breast cancer incidence was significantly higher in the experimental versus the control group. There were no between-group differences in mean breast tumour latency, mean largest  tumour diameter and breast tumour tissue vascular endothelial growth factor levels.;Dietary soy isoflavones promote breast cancer at low oestrogen levels but inhibit breast cancer at high oestrogen levels. This effect may only occur during the initiation stage of breast cancer.",
        "Doc_title":"Effects of soy isoflavone and endogenous oestrogen on breast cancer in MMTV-erbB2 transgenic mice.",
        "Journal":"The Journal of international medical research",
        "Do_id":"23321163",
        "Doc_ChemicalList":"Estrogens;Isoflavones;Soybean Proteins;Vascular Endothelial Growth Factor A;vascular endothelial growth factor A, mouse",
        "Doc_meshdescriptors":"Animals;Diet;Estrogens;Female;Genes, erbB-2;Isoflavones;Mammary Neoplasms, Animal;Mammary Tumor Virus, Mouse;Mice;Mice, Transgenic;Ovariectomy;Soybean Proteins;Soybeans;Vascular Endothelial Growth Factor A",
        "Doc_meshqualifiers":"metabolism;pharmacology;genetics;administration & dosage;pharmacology;diet therapy;virology;drug effects;genetics;pharmacology;analysis",
        "_version_":1605742767212855296},
      {
        "Doc_abstract":"Tumor markers were studied in the sera of 883 untreated patients with primary breast cancer diagnosed between 1989 and 2007. Abnormal human epidermal growth factor receptor 2 (HER-2)/neu levels (>15 ng/mL) were found in 9.5%, carcinoembryonic antigen (CEA) in 15.9%, and cancer antigen (CA) 15.3 in 19.7% of the patients. One or more tumor markers were abnormal in 305 (34.5%) of the 883 studied patients. Significantly higher serum HER-2/neu levels were found in patients with tissue overexpression of this oncoprotein (p < 0.0001). CEA, CA 15.3, and HER-2/neu (only in those patients with tissue overexpression) serum levels were related with tumor stage (tumor size and nodal involvement) and steroid receptors (higher values in estrogen receptor-negative (ER-) tumors). Univariate analysis showed that HER-2/neu serum levels were prognostic factors in disease-free survival (DFS) and overall survival (OS) only in patients with tissue overexpression. Multivariate analysis in 834 patients show that nodal involvement, tumor size, ER, CEA, and adjuvant treatment were independent prognostic factors in DFS and OS. When only patients with HER-2/neu overexpression in tissue were studied, tumor size, nodal involvement, and tumor markers (one or another positive) were independent prognostic factors for both DFS and OS. HER-2/neu serum levels were also an independent prognostic factor, with CEA, ER, and nodes in 106 patients treated with neoadjuvant treatment. In summary, serum HER-2/neu, CEA, and CA 15.3 are useful tools in the prognostic evaluation of patients with primary breast cancer.",
        "Doc_title":"Evaluation of tumor markers (HER-2/neu oncoprotein, CEA, and CA 15.3) in patients with locoregional breast cancer: prognostic value.",
        "Journal":"Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine",
        "Do_id":"20361287",
        "Doc_ChemicalList":"Biomarkers, Tumor;Carcinoembryonic Antigen;Mucin-1;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Biomarkers, Tumor;Breast Neoplasms;Carcinoembryonic Antigen;Disease-Free Survival;Female;Humans;Middle Aged;Mucin-1;Receptor, ErbB-2",
        "Doc_meshqualifiers":"blood;blood;diagnosis;mortality;blood;blood;blood",
        "_version_":1605746290402000896},
      {
        "Doc_abstract":"The forkhead transcription factor FoxA1 is thought to be involved in mammary tumorigenesis. However, the precise role of FoxA1 in breast cancer development is controversial. We examined expression of FoxA1 in 35 human breast cancer cell lines and compared it with that of ErbB2, a marker of poor prognosis in breast cancer. We found that FoxA1 is expressed at high levels in all ErbB2-positive cell lines and a subset of ErbB2-negative cell lines. Down-regulation of FoxA1 by RNA interference significantly suppressed proliferation of ErbB2-negative and FoxA1-positive breast cancer cell lines. Down-regulation of FoxA1 also enhanced the toxic effect of Herceptin on ErbB2-positive cell lines through induction of apoptosis. Taken together with previous data that FoxA1 is a marker of luminal cells in mammary gland, our present results suggest that FoxA1 plays an important role as a lineage-specific oncogene in proliferation of cancer cells derived from mammary luminal cells.",
        "Doc_title":"FoxA1 as a lineage-specific oncogene in luminal type breast cancer.",
        "Journal":"Biochemical and biophysical research communications",
        "Do_id":"18039470",
        "Doc_ChemicalList":"Biomarkers, Tumor;FOXA1 protein, human;Hepatocyte Nuclear Factor 3-alpha;Neoplasm Proteins",
        "Doc_meshdescriptors":"Biomarkers, Tumor;Breast Neoplasms;Cell Line, Tumor;Cell Transformation, Neoplastic;Hepatocyte Nuclear Factor 3-alpha;Humans;Neoplasm Proteins;Oncogenes",
        "Doc_meshqualifiers":"metabolism;metabolism;pathology;metabolism;pathology;metabolism;metabolism;physiology",
        "_version_":1605852828422635520},
      {
        "Doc_abstract":"Breast cancer incidence is higher among black women than white women before age 40 years, but higher among white women than black women after age 40 years (black-white crossover). We used newly available population-based data to examine whether the age-specific incidences of breast cancer subtypes vary by race and ethnicity.;We classified 91908 invasive breast cancers diagnosed in California between January 1, 2006, and December 31, 2009, by subtype based on tumor expression of estrogen receptor (ER) and progesterone receptor (PR)-together referred to as hormone receptor (HR)-and human epidermal growth factor receptor 2 (HER2). Breast cancer subtypes were classified as ER or PR positive and HER2 negative (HR(+)/HER2(-)), ER or PR positive and HER2 positive (HR(+)/HER2(+)), ER and PR negative and HER2 positive (HR(-)/HER2(+)), and ER, PR, and HER2 negative (triple-negative). We calculated and compared age-specific incidence rates, incidence rate ratios, and 95% confidence intervals by subtype and race (black, white, Hispanic, and Asian). All P values are two-sided.;We did not observe an age-related black-white crossover in incidence for any molecular subtype of breast cancer. Compared with white women, black women had statistically significantly higher rates of triple-negative breast cancer at all ages but statistically significantly lower rates of HR(+)/HER2(-) breast cancers after age 35 years (all P < .05). The age-specific incidence of HR(+)/HER2(+) and HR(-)/HER2(+) subtypes did not vary markedly between white and black women.;The black-white crossover in breast cancer incidence occurs only when all breast cancer subtypes are combined and relates largely to higher rates of triple-negative breast cancers and lower rates of HR(+)/HER2(-) breast cancers in black vs white women.",
        "Doc_title":"Age-specific incidence of breast cancer subtypes: understanding the black-white crossover.",
        "Journal":"Journal of the National Cancer Institute",
        "Do_id":"22773826",
        "Doc_ChemicalList":"Biomarkers, Tumor;Receptors, Estrogen;Receptors, Progesterone;ERBB2 protein, human;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Adult;African Americans;Age Factors;Aged;Asian Americans;Biomarkers, Tumor;Breast Neoplasms;California;European Continental Ancestry Group;Female;Hispanic Americans;Humans;Incidence;Middle Aged;Receptor, ErbB-2;Receptors, Estrogen;Receptors, Progesterone;SEER Program;United States",
        "Doc_meshqualifiers":"statistics & numerical data;statistics & numerical data;analysis;chemistry;epidemiology;pathology;epidemiology;statistics & numerical data;statistics & numerical data;analysis;analysis;analysis;epidemiology",
        "_version_":1605897523854049280},
      {
        "Doc_abstract":"The cAMP-dependent protein kinase inhibitor-Î² (PKIB) is presumed to be one of the regulatory factors controlling the cAMP-dependent protein kinase A signaling pathway. The aim of this study was to investigate the frequency and patterns of PKIB overexpression in human breast cancer. We also examined the relationship between PKIB and phosphorylated Akt (pAkt) expression in the tumors. Using immunohistochemical techniques, we examined the expression of PKIB, ER, PR, HER2, and pAkt in 148 primary human breast carcinomas. We then analyzed the relationships between PKIB expression and that of pAkt, ER, PR, and HER2, as well as between PKIB expression and various clinicopathological characteristics. We assessed 64 and 27 cases, respectively, as positive for either PKIB or pAkt expression; 20 cases were positive for both PKIB and pAkt. We observed a significant positive correlation between the expression of PKIB and that of pAkt (P = 0.006). We showed by immunohistochemical analyses that PKIB expression was positively correlated with triple-negative breast cancers (P = 0.0004). These findings provide evidence for PKIB overexpression associated with pAkt expression. Furthermore, PKIB expression was strongly correlated with triple-negative breast cancer, suggesting that PKIB expression might contribute to the tumor behavior and development of breast cancer.",
        "Doc_title":"PKIB expression strongly correlated with phosphorylated Akt expression in breast cancers and also with triple-negative breast cancer subtype.",
        "Journal":"Medical molecular morphology",
        "Do_id":"23224602",
        "Doc_ChemicalList":"Intracellular Signaling Peptides and Proteins;PKIB protein, human;Receptors, Estrogen;Receptors, Progesterone;ERBB2 protein, human;Receptor, ErbB-2;Proto-Oncogene Proteins c-akt",
        "Doc_meshdescriptors":"Adult;Aged;Aged, 80 and over;Breast Neoplasms;Carcinoma;Female;Humans;Intracellular Signaling Peptides and Proteins;Middle Aged;Phosphorylation;Proto-Oncogene Proteins c-akt;Receptor, ErbB-2;Receptors, Estrogen;Receptors, Progesterone",
        "Doc_meshqualifiers":"metabolism;pathology;metabolism;pathology;metabolism;metabolism;metabolism;metabolism;metabolism",
        "_version_":1605742647570333696},
      {
        "Doc_abstract":"Inhibition of ErbB2 (HER2) with monoclonal antibodies, an effective therapy in some forms of breast cancer, is associated with cardiotoxicity, the pathophysiology of which is poorly understood. Recent data suggest, that dual inhibition of ErbB1 (EGFR) and ErbB2 signaling is more efficient in cancer therapy, however, cardiac safety of this therapeutic approach is unknown. We therefore tested an ErbB1-(CGP059326) and an ErbB1/ErbB2-(PKI166) tyrosine kinase inhibitor in an in-vitro system of adult rat ventricular cardiomyocytes and assessed their effects on 1. cell viability, 2. myofibrillar structure, 3. contractile function, and 4. MAPK- and Akt-signaling alone or in combination with Doxorubicin. Neither CGP nor PKI induced cardiomyocyte necrosis or apoptosis. PKI but not CGP caused myofibrillar structural damage that was additive to that induced by Doxorubicin at clinically relevant doses. These changes were associated with an inhibition of excitation-contraction coupling. PKI but not CGP decreased p-Erk1/2, suggesting a role for this MAP-kinase signaling pathway in the maintenance of myofibrils. These data indicate that the ErbB2 signaling pathway is critical for the maintenance of myofibrillar structure and function. Clinical studies using ErbB2-targeted inhibitors for the treatment of cancer should be designed to include careful monitoring for cardiac dysfunction.",
        "Doc_title":"Inhibition of ErbB2 by receptor tyrosine kinase inhibitors causes myofibrillar structural damage without cell death in adult rat cardiomyocytes.",
        "Journal":"Experimental cell research",
        "Do_id":"19331811",
        "Doc_ChemicalList":"Antibiotics, Antineoplastic;Connectin;GATA4 Transcription Factor;Muscle Proteins;Protein Kinase Inhibitors;Doxorubicin;Erbb4 protein, mouse;Erbb4 protein, rat;Receptor, Epidermal Growth Factor;Receptor, ErbB-2;Receptor, ErbB-4;Proto-Oncogene Proteins c-akt;Extracellular Signal-Regulated MAP Kinases;Calcium",
        "Doc_meshdescriptors":"Animals;Antibiotics, Antineoplastic;Calcium;Cell Death;Cells, Cultured;Connectin;Doxorubicin;Extracellular Signal-Regulated MAP Kinases;Female;GATA4 Transcription Factor;Male;Mice;Mitochondria;Muscle Proteins;Myocardial Contraction;Myocytes, Cardiac;Myofibrils;Protein Kinase Inhibitors;Proto-Oncogene Proteins c-akt;Rats;Rats, Wistar;Receptor, Epidermal Growth Factor;Receptor, ErbB-2;Receptor, ErbB-4;Signal Transduction",
        "Doc_meshqualifiers":"pharmacology;metabolism;physiology;pharmacology;metabolism;metabolism;metabolism;metabolism;drug effects;physiology;cytology;drug effects;metabolism;pathology;metabolism;ultrastructure;metabolism;pharmacology;metabolism;metabolism;antagonists & inhibitors;metabolism;physiology",
        "_version_":1605905948703981568},
      {
        "Doc_abstract":"The ubiquitously expressed 14-3-3 proteins are involved in numerous important cellular functions. The loss of 14-3-3sigma is a common event in breast cancer; however, the role of other 14-3-3s in breast cancer is unclear. Recently, we found that 14-3-3zeta overexpression occurs in early stage breast diseases and contributes to transformation of human mammary epithelial cells. Here, we show that 14-3-3zeta overexpression also persisted in invasive ductal carcinoma and contributed to the further progression of breast cancer. To examine the clinical effect of 14-3-3zeta overexpression in advanced stage breast cancer, we performed immunohistochemical analysis of 14-3-3zeta expression in primary breast carcinomas. 14-3-3zeta overexpression occurred in 42% of breast tumors and was determined to be an independent prognostic factor for reduced disease-free survival. 14-3-3zeta overexpression combined with ErbB2 overexpression and positive lymph node status identified a subgroup of patients at high risk for developing distant metastasis. To investigate whether 14-3-3zeta overexpression causally promotes breast cancer progression, we overexpressed 14-3-3zeta by stable transfection or reduced 14-3-3zeta expression by siRNA in cancer cell lines. Increased 14-3-3zeta expression enhanced anchorage-independent growth and inhibited stress-induced apoptosis, whereas down-regulation of 14-3-3zeta reduced anchorage-independent growth and sensitized cells to stress-induced apoptosis via the mitochondrial apoptotic pathway. Transient blockade of 14-3-3zeta expression by siRNA in cancer cells effectively reduced the onset and growth of tumor xenografts in vivo. Therefore, 14-3-3zeta overexpression is a novel molecular marker for disease recurrence in breast cancer patients and may serve as an effective therapeutic target in patients whose tumors overexpress 14-3-3zeta.",
        "Doc_title":"14-3-3zeta overexpression defines high risk for breast cancer recurrence and promotes cancer cell survival.",
        "Journal":"Cancer research",
        "Do_id":"19318578",
        "Doc_ChemicalList":"14-3-3 Proteins;Biomarkers, Tumor",
        "Doc_meshdescriptors":"14-3-3 Proteins;Apoptosis;Biomarkers, Tumor;Breast Neoplasms;Cell Adhesion;Cell Growth Processes;Cell Line, Tumor;Cell Survival;Female;Gene Amplification;Humans;Mitochondria;Neoplasm Recurrence, Local;Prognosis;Risk Factors",
        "Doc_meshqualifiers":"biosynthesis;genetics;physiology;biosynthesis;genetics;genetics;metabolism;pathology;physiology;physiology;physiology;genetics;metabolism;genetics;metabolism;pathology",
        "_version_":1605819675135967232},
      {
        "Doc_abstract":"HER2 and TOP2A are targets for the therapeutic agents trastuzumab and anthracyclines and are frequently amplified in breast cancers. The aims of this study were to provide a detailed molecular genetic analysis of the 17q12-q21 amplicon in breast cancers harbouring HER2/TOP2A co-amplification and to investigate additional recurrent co-amplifications in HER2/TOP2A-co-amplified cancers. In total, 15 breast cancers with HER2 amplification, 10 of which also harboured TOP2A amplification, as defined by chromogenic in situ hybridisation, and 6 breast cancer cell lines known to be amplified for HER2 were subjected to high-resolution microarray-based comparative genomic hybridisation analysis. This revealed that the genomes of 12 cases were characterised by at least one localised region of clustered, relatively narrow peaks of amplification, with each cluster confined to a single chromosome arm (ie 'firestorm' pattern) and 3 cases displayed many narrow segments of duplication and deletion affecting the vast majority of chromosomes (ie 'sawtooth' pattern). The smallest region of amplification (SRA) on 17q12 in the whole series extended from 34.73 to 35.48 Mb, and encompassed HER2 but not TOP2A. In HER2/TOP2A-co-amplified samples, the SRA extended from 34.73 to 36.54 Mb, spanning a region of approximately 1.8 Mb. Apart from HER2 and TOP2A, this region encompassed four additional genes whose expression levels as defined by quantitative real-time PCR are significantly higher in HER2/TOP2A-co-amplified vs HER2-amplified breast cancers: CASC3, CDC6, RARA and SMARCE1. Of the cell lines studied, SKBR3 and UACC812 showed HER2/TOP2A co-amplification. In conclusion, this is the first detailed genome-wide characterisation of HER2/TOP2A-amplified breast cancers; cell lines were identified that can be used to model these cancers in vitro. The 17q12 amplicon is complex and harbours multiple genes that may be associated with breast cancer development and progression, and potentially exploitable as therapeutic targets.",
        "Doc_title":"Genomic analysis of the HER2/TOP2A amplicon in breast cancer and breast cancer cell lines.",
        "Journal":"Laboratory investigation; a journal of technical methods and pathology",
        "Do_id":"18332872",
        "Doc_ChemicalList":"Antigens, Neoplasm;DNA-Binding Proteins;DNA Topoisomerases, Type II;DNA topoisomerase II alpha",
        "Doc_meshdescriptors":"Antigens, Neoplasm;Breast Neoplasms;Cell Line, Tumor;Chromosome Aberrations;Chromosome Mapping;Chromosomes, Human, Pair 17;DNA Topoisomerases, Type II;DNA-Binding Proteins;Female;Gene Amplification;Gene Expression Profiling;Genes, erbB-2;Genomics;Humans;In Situ Hybridization;Microarray Analysis;Nucleic Acid Hybridization",
        "Doc_meshqualifiers":"genetics;genetics;pathology;genetics;genetics;methods",
        "_version_":1605792057931071488},
      {
        "Doc_abstract":"Breast cancer is a heterogeneous group of diseases that are clinically subdivided as hormone receptor-positive, human epidermal growth factor receptor 2-positive (HER2(+)), and triple-negative breast cancer, to guide therapeutic interventions. Agents that target estrogen receptor (ER) and HER2 are among the most successful cancer therapeutics. However, de novo or acquired resistance is common, despite the development of newer agents against these pathways. As our understanding of tumor biology improves, novel targets are being identified. Notably, inhibitors against several pathways [including, among others, the phosphoinositide 3-kinase/mammalian target of rapamycin (PI3K/mTOR), cell-cycle regulation, heat shock protein, and epigenetic pathways] have demonstrated promising activity in clinical trials, and the mTOR-inhibitor everolimus has been approved for advanced or metastatic aromatase inhibitor-resistant ER(+) breast cancer. At present, there are no established targeted agents for triple-negative breast cancer (negative ER, progesterone receptor, and HER2). Although poly(ADP-ribose) polymerase inhibitors have shown promising activity in BRCA-related cancers, its value in the treatment of triple-negative breast cancers remains to be demonstrated. In this Review, we present a basic understanding of the major targeted agents in current practice and under development for the treatment of breast cancer in the context of the three clinical subgroups. ",
        "Doc_title":"Targeted therapy for breast cancer.",
        "Journal":"The American journal of pathology",
        "Do_id":"23988612",
        "Doc_ChemicalList":"Angiogenesis Inhibitors;Enzyme Inhibitors",
        "Doc_meshdescriptors":"Angiogenesis Inhibitors;Breast Neoplasms;Enzyme Inhibitors;Female;Humans;Molecular Targeted Therapy;Mutation;Signal Transduction",
        "Doc_meshqualifiers":"pharmacology;therapeutic use;drug therapy;genetics;pharmacology;therapeutic use;genetics;drug effects",
        "_version_":1605761787420999680},
      {
        "Doc_abstract":"It is well known that the amplification of the HER2 gene is closely associated with poor prognosis of breast cancer. However, there is controversy about the clinical significance of HER2 according to lymph node status in breast cancer. The aim of this study was to identify the differences in the prognostic significance of HER2 gene amplification according to the stages of breast cancer. We prepared a tissue array for fluorescence in situ hybridization (FISH) with breast cancer specimens from the surgery in 1994 to 1999. Total 338 cases of breast cancer were enrolled and the median follow-up period was 6.3 yr. The detection rates of HER2 gene amplification were as follows: 10.3% in stage I, 22.3% in stage II, and 43.8% in stage III. On survival analyses HER2-positive groups showed worse prognosis in stage III of breast cancer, but not in stage I or II. Multivariate analyses with a Cox-regression model also revealed that HER2 amplification was an independent prognostic factor only in stage III breast cancer. Regarding HER2 gene amplification as a prognostic factor of breast cancer, the clinical significance of the gene was found to be confined to advanced breast cancer.",
        "Doc_title":"Prognostic significance of HER2 gene amplification according to stage of breast cancer.",
        "Journal":"Journal of Korean medical science",
        "Do_id":"18583876",
        "Doc_ChemicalList":"Biomarkers, Tumor",
        "Doc_meshdescriptors":"Adult;Aged;Biomarkers, Tumor;Breast Neoplasms;Disease Progression;Female;Follow-Up Studies;Gene Amplification;Genes, erbB-2;Humans;In Situ Hybridization, Fluorescence;Middle Aged;Multivariate Analysis;Neoplasm Staging;Prognosis;Proportional Hazards Models",
        "Doc_meshqualifiers":"genetics;genetics;mortality;pathology;genetics",
        "_version_":1605907478427467776},
      {
        "Doc_abstract":"Although immunogenicity is typically associated with renal cell carcinomas and melanoma, there are several compelling reasons why immune-based therapies should be explored in breast cancer. First, breast cancers express multiple putative tumor-associated antigens, such as HER-2 and MUC-1, which have been the successful focus of vaccine development over the past decade, translating into tumor-specific immune responses and, in some cases, clinical benefit. Second, passive immune strategies with anti-HER-2 antibodies, such as trastuzumab and pertuzumab, have led to survival benefits in breast cancer. Finally, the successes observed with novel immunotherapeutic strategies, such as immune checkpoint blockade and adoptive T-cell therapies in other malignancies, combined with a growing body of literature that supports an interplay between solid tumors and the immune system, indicate that these strategies have the potential to revolutionize the treatment of breast cancer. ",
        "Doc_title":"Emerging immunotherapy strategies in breast cancer.",
        "Journal":"Immunotherapy",
        "Do_id":"24491092",
        "Doc_ChemicalList":"Antigens, Neoplasm",
        "Doc_meshdescriptors":"Animals;Antigens, Neoplasm;Breast Neoplasms;Female;Humans;Immunotherapy",
        "Doc_meshqualifiers":"immunology;immunology;therapy;trends",
        "_version_":1605742709949071360},
      {
        "Doc_abstract":"HER2 is overexpressed in approximately 20.0% to 30.0% of breast cancer patients. This alteration is associated with poor prognosis, and may affect response to hormonal therapy and chemotherapy. Chemotherapy combined with trastuzumab can significantly improve the treatment efficacy and survival of Her-2/neu overexpressing breast cancer patients. Docetaxel is an effective drug used for metastatic breast cancer recently. This study was to evaluate the efficacy and toxicity of trastuzumab combined with docetaxel in the treatment for metastatic breast cancer patients with overexpressed Her-2/neu.;Twenty-two metastatic breast cancer patients with overexpressed HER2/neu were entered into the study. Trastuzumab and docetaxel (75 mg/m(2)) were administrated on day 1 and repeated every 21 days. The initial dose of trastuzumab was 8 mg/kg and subsequent doses were 6 mg/kg.;Overall 96 cycles were administrated to the 22 patients (medium three cycles per patient, range 2-6 cycles). All cases were evaluable. The overall response rate was 63.6% (14/22). Two patients achieved complete response (CR), 12 patients achieved partial response (PR), four patients achieved stable disease (SD), and four patients had progressive disease (PD). The median time to progression was 5.4 months. One year overall survival was 59.0%. The major toxicity was myelosuppression. A few patients had fever at first infusion of trastuzumab and minor heart failure.;Trastuzumab combined with docetaxel is an effective and well-tolerated therapy for Her-2/neu overexpressing metastatic breast cancer.",
        "Doc_title":"[Efficacy and toxicity of trastuzumab combined with docetaxel for Her-2/neu overexpressing metastatic breast cancer].",
        "Journal":"Ai zheng = Aizheng = Chinese journal of cancer",
        "Do_id":"18799033",
        "Doc_ChemicalList":"Antibodies, Monoclonal;Antibodies, Monoclonal, Humanized;Taxoids;docetaxel;Receptor, ErbB-2;Trastuzumab",
        "Doc_meshdescriptors":"Adult;Anemia;Antibodies, Monoclonal;Antibodies, Monoclonal, Humanized;Antineoplastic Combined Chemotherapy Protocols;Breast Neoplasms;Carcinoma, Ductal, Breast;Exanthema;Female;Humans;Liver Neoplasms;Lung Neoplasms;Middle Aged;Nausea;Neutropenia;Receptor, ErbB-2;Remission Induction;Survival Rate;Taxoids;Thrombocytopenia;Trastuzumab",
        "Doc_meshqualifiers":"chemically induced;administration & dosage;adverse effects;adverse effects;therapeutic use;drug therapy;metabolism;pathology;drug therapy;metabolism;secondary;chemically induced;drug therapy;metabolism;secondary;drug therapy;metabolism;secondary;chemically induced;chemically induced;metabolism;administration & dosage;adverse effects;chemically induced",
        "_version_":1605742753808908289},
      {
        "Doc_abstract":"Gene amplification/overexpression of ERBB2 (HER2, neu) is a major event in human breast tumorigenesis. ERBB2-based therapeutic agents and ERBB2-specific gene therapy are under development. These new perspectives call for a sensitive and accurate method to screen breast cancer patients for ERBB2 alterations.;We have developed and validated a real-time quantitative reverse transcription (RT)-PCR assay, based on fluorescent TaqMan methodology, to quantify ERBB2 gene expression at the mRNA level in breast tumors. This recently developed method of nucleic acid quantification in homogeneous solutions has the potential for a wide dynamic range, interlaboratory agreement, and high-throughput capacity without tedious post-PCR processing. The ERBB2 mRNA signal was normalized to the signal for TATA box-binding protein mRNA.;The dynamic range was >1000-fold. The relationship between C(t) and log starting concentration was linear (r(2) >/=0.99). The mean (SD) normalized expression of ERBB2 in healthy breast tissue was 0.95 (0.37). Overexpression (>5 SD above mean for healthy breast) of the ERBB2 gene was observed (at 3.2- to 135-fold) in 23 (17%) of 134 breast tumor RNA samples. As expected, ERBB2 overexpression was present in all tumors with ERBB2 gene amplification but was uncommon and at a low ratio (<5) in breast cancers without gene amplification.;This new simple, rapid, semi-automated assay is a major alternative to fluorescence in situ hybridization and immunochemistry for gene alteration analysis in human tumors and may be a powerful tool for large randomized, prospective cooperative group trials and to support future ERBB2-based biological and gene therapy approaches.",
        "Doc_title":"Real-time reverse transcription-PCR assay for future management of ERBB2-based clinical applications.",
        "Journal":"Clinical chemistry",
        "Do_id":"10430778",
        "Doc_ChemicalList":"RNA, Messenger;RNA, Neoplasm;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Adult;Aged;Aged, 80 and over;Breast Neoplasms;Calibration;Female;Humans;Middle Aged;RNA, Messenger;RNA, Neoplasm;Receptor, ErbB-2;Reverse Transcriptase Polymerase Chain Reaction",
        "Doc_meshqualifiers":"metabolism;metabolism;metabolism;metabolism",
        "_version_":1605742013588701184},
      {
        "Doc_abstract":"Breast cancer is a rare disease in men representing nearly 1% of the total breast cancer cases worldwide. Due to the low incidence, there are no randomized clinical studies giving information on the optimal diagnostics and therapy for male breast cancer patients. Therefore, treatment recommendations are derived from established guidelines for breast cancer in women. However, the lack of awareness of this disease leads to its detection at a later stage in men associated with a worse prognostic outcome. The gender-specific differences in breast cancer are among others related to the differing genetic and hormonal environment and the anatomic constitution in men. For example, males have a much higher percentage of hormone receptor-positive tumors but a significantly lower fraction of carcinomas overexpressing HER2. This review focuses on epidemiology, pathogenesis, and clinical findings of male breast cancer, and discusses current findings available to treat this disease. To optimize disease outcome and tolerability of treatment, these data should be considered to improve the therapeutic index of male breast cancer patients.",
        "Doc_title":"Male Breast Cancer.",
        "Journal":"Breast care (Basel, Switzerland)",
        "Do_id":"20824037",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605746410132602881},
      {
        "Doc_abstract":"It is not known whether the HER2 status of malignant CSF cells coincides with that of the original breast carcinoma cells. We investigated whether CSF cytology specimens were suitable to evaluate HER2 status by fluorescence in situ hybridization (FISH) in patient with leptomeningeal metastasis (LM). Both formalin-fixed paraffin-embedded (FFPE) breast cancer tissue and liquid based CSF cytology specimens were evaluated for HER2 status in 16 patients with LM. We evaluated HER2 gene amplification using FISH on destained CSF cytology slides containing a minimum of 20 malignant cells per slide, and compared these with the HER2 status by immunohistochemistry (IHC) or FISH in FFPE tissues. HER2 was considered positive when the HER2:CEP17 ratio was >or=2.0 or IHC 3+. Of 16 cases, four were HER2 positive and 12 were HER2 negative by FISH analysis in CSF cytology. All CSF-positive cases were HER2 positive by IHC in FFPE tissue. Of 12 HER2 FISH-negative cases in CSF cytology, 10 were HER2 negative (IHC 0 or 1+) and two were IHC 2+ in FFPE tissue. Two IHC 2+ cases had HER2:CEP17 ratios of 1.27 and 2.1, respectively, by FISH in FFPE tissue. As a result, the HER2 status concordance rate between metastatic breast cancer cells in CSF and FFPE primary tissue by IHC and FISH was very high. When CSF cytology specimens were appropriately prepared and had adequate cellularity without dry artifacts, the CSF cytology was suitable to evaluate HER2 status by FISH analysis in patients with LM.",
        "Doc_title":"Concordant HER2 status between metastatic breast cancer cells in CSF and primary breast cancer tissue.",
        "Journal":"Breast cancer research and treatment",
        "Do_id":"19916047",
        "Doc_ChemicalList":"Biomarkers, Tumor;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Adult;Aged;Biomarkers, Tumor;Breast Neoplasms;Cerebrospinal Fluid;Female;Gene Amplification;Genes, erbB-2;Humans;Immunohistochemistry;In Situ Hybridization, Fluorescence;Meningeal Carcinomatosis;Middle Aged;Paraffin Embedding;Receptor, ErbB-2;Reproducibility of Results",
        "Doc_meshqualifiers":"analysis;genetics;cerebrospinal fluid;genetics;secondary;cytology;cerebrospinal fluid;genetics;secondary;biosynthesis",
        "_version_":1605742764336611329},
      {
        "Doc_abstract":"About 15 to 20% of breast cancer cases overexpress human epidermal growth factor receptor-2 (HER-2). This overexpression is associated with poor clinical prognosis but therapeutic success of trastuzumab or lapatinib. HER-2 extracellular domain (ECD) undergoes a proteolytic cleavage and is shed into biologic fluid as a circulating antigen called ECD/HER-2, which can be detected by immunochemical assays.;The aim of our review was to determine the clinical usefulness of ECD/HER-2 measurement in the management of breast cancer patients.;A Pubmed search for publications in English or French was carried out until March 31, 2010 (69 original articles and 8 reviews).;The measurement of ECD/HER-2 concentration does not exempt from the pathological determination of HER-2 expression in tumors; some HER-2 negative tumors are associated with high levels of ECD/HER-2, on the other hand, some HER-2 positive tumors present low levels of ECD/HER-2. The concentration of ECD/HER-2 is correlated to disease progression, since 10% of loco-regional breast cancers and more than a third of metastatic breast cancers have high levels of ECD/HER-2. The elevation of ECD/HER-2 levels generally occurs several months before the diagnosis of symptomatic metastases. The relevance of ECD/HER-2 measurements during chemotherapy, hormone therapy and trastuzumab treatment remains uncertain. Similarly, it is not commonly agreed that high levels of ECD/HER-2 before any treatment in the case of an early breast cancer, is an independent prognostic factor.;A close analysis of a variety of pathological, biochemical, clinical and methodological data may explain these discrepancies.;New prospective studies using immunochemical measurements of ECD/HER-2 (with a consensual threshold) and based on both detailed pathological analyses and a comprehensive collection of clinical data are still required to establish the clinical usefulness of circulating ECD/HER-2 measurement for breast cancer patients' management.",
        "Doc_title":"[Clinical usefulness of circulating ECD/HER-2 measurement for breast cancer patients' management].",
        "Journal":"Presse medicale (Paris, France : 1983)",
        "Do_id":"21074348",
        "Doc_ChemicalList":"Biomarkers, Tumor;ERBB2 protein, human;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Biomarkers, Tumor;Breast Neoplasms;Female;Humans;Receptor, ErbB-2",
        "Doc_meshqualifiers":"blood;blood;blood",
        "_version_":1605764818917130240},
      {
        "Doc_abstract":"To determine breast cancer metastasis suppressor 1 (BRMS1) expression in breast cancers and the efficacy of BRMS1 as a prognostic indicator, BRMS1 expression was assessed in two sets of breast cancer tissues.;Epithelial cells from 36 frozen samples of breast cancers and corresponding normal breast were collected by laser capture microdissection and assessed for BRMS1 by quantitative RT-PCR and immunohistochemistry. BRMS1 was also evaluated by immunohistochemistry in a tissue microarray of 209 breast cancers and correlated with indicators of prognosis [estrogen receptor (ER), progesterone receptor (PR), ErbB2, p53, p27(Kip1), Bcl2 and Ki-67].;BRMS1 mRNA and protein were higher in 94 and 81%, respectively, of breast cancers than in corresponding normal epithelium. BRMS1 localization was predominantly nuclear, but 60-70% of cancers also exhibited cytoplasmic immunostaining. Breast cancers with lower nuclear than cytoplasmic BRMS1 (nuclear score - cytoplasmic score < or =0; 11% of cancers) had lower ER, lower PR and higher Ki-67 expression. There was also a trend toward poorer overall survival in this group of cancers, but this was only of borderline significance (p = 0.073). In Cox proportional hazards models, loss of nuclear BRMS1 was not a significant predictor of overall survival.;Loss of nuclear BRMS1 was associated with ER-negative cancers and a high rate of proliferation, but was not an independent indicator of prognosis.",
        "Doc_title":"A shift from nuclear to cytoplasmic breast cancer metastasis suppressor 1 expression is associated with highly proliferative estrogen receptor-negative breast cancers.",
        "Journal":"Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine",
        "Do_id":"19609101",
        "Doc_ChemicalList":"BRMS1 protein, human;Biomarkers, Tumor;Neoplasm Proteins;Receptors, Estrogen;Repressor Proteins",
        "Doc_meshdescriptors":"Adult;Aged;Aged, 80 and over;Biomarkers, Tumor;Breast Neoplasms;Cell Nucleus;Cell Proliferation;Cytoplasm;Female;Gene Expression;Humans;Immunohistochemistry;Lasers;Microdissection;Middle Aged;Neoplasm Proteins;Neoplasm Staging;Prognosis;Receptors, Estrogen;Repressor Proteins;Reverse Transcriptase Polymerase Chain Reaction;Tissue Array Analysis",
        "Doc_meshqualifiers":"analysis;genetics;metabolism;pathology;metabolism;metabolism;biosynthesis;genetics;biosynthesis;genetics",
        "_version_":1605876959067242496},
      {
        "Doc_abstract":"Categorizing breast tumors based on the ER, PR and HER/Neu 2 receptor status is necessary in order to predict outcome and assist in management of breast cancer. Herfe we assessed this question in South Indian patients.;A total of 619 formalin fixed paraffin embedded breast tumor tissues were collected from pathology archives after receipt of ethical clearance. With the help of primary and secondary conjugated antibodies, expression status of ER, PR and HER2/neu was determined. All the experimental data were assessed for correlations with histopathological features of tumors and clinical presentation of the subjects.;In the present study, the ages ranged from 20-87 years with a mean of 50.0Â±12.q years, and majority of the tumors (84%) were of infiltrating duct cell carcinoma type. Assessment of ER, PR and Her-2/neu expression showed that 46% were triple negative. Interestingly, an inverse relation between ER, PR and HER-2/neu was apparent in 41.2% (p<0.0001) of the tumors, of which 24.5% (p<0.0001) were ER and PR co-negative but HER-2 positive.;ER and PR positive tumors are less common (i.e<30%) compared to HER-2/neu positive tumors (i.e>50%) in Indian breast cancer patients, underlining the need for effective diagnostic screening and specific therapeutic managements in order to improve the survival rate of patients in low resource countries such as India.",
        "Doc_title":"Her-2/neu status: a neglected marker of prognostication and management of breast cancer patients in India.",
        "Journal":"Asian Pacific journal of cancer prevention : APJCP",
        "Do_id":"23725118",
        "Doc_ChemicalList":"Biomarkers, Tumor;Receptors, Estrogen;Receptors, Progesterone;ERBB2 protein, human;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Adult;Aged;Aged, 80 and over;Biomarkers, Tumor;Breast Neoplasms;Female;Follow-Up Studies;Humans;India;Male;Middle Aged;Neoplasm Staging;Prognosis;Receptor, ErbB-2;Receptors, Estrogen;Receptors, Progesterone;Retrospective Studies;Young Adult",
        "Doc_meshqualifiers":"metabolism;diagnosis;metabolism;metabolism;metabolism;metabolism",
        "_version_":1605831291788328960},
      {
        "Doc_abstract":"Increased expression and activation of receptor tyrosine kinases occurs frequently in human breast carcinomas. Several therapies targeting these receptors are currently in clinical trials. Therapeutic strategies include blockade of individual receptors with monoclonal antibodies and inhibition of tyrosine kinase function. Trastuzumab is the first of these biologic therapies to be approved for patients with human epidermal growth factor receptor 2 (HER2)-overexpressing metastatic breast cancer. Novel trastuzumab-based combinations are being investigated in patients with advanced breast cancer. Large clinical trials have also been launched in the adjuvant setting. Small molecules that inhibit specific tyrosine kinases (e.g., epidermal growth factor receptor, HER2) are in phase I and phase II clinical trials. Other growth-factor-targeted drugs that have reached clinical development include STI571 and antibodies directed at the insulin-like growth factor pathway. Biologic therapies directed against these important receptors are promising. In this review we discuss challenges and opportunities for the development of growth-factor-targeted approaches for the treatment of breast cancer.",
        "Doc_title":"Growth factor receptors in breast cancer: potential for therapeutic intervention.",
        "Journal":"The oncologist",
        "Do_id":"12604728",
        "Doc_ChemicalList":"Antibodies, Monoclonal;Antibodies, Monoclonal, Humanized;Antineoplastic Agents;Receptors, Growth Factor;Receptor, Epidermal Growth Factor;Receptor, ErbB-2;Trastuzumab",
        "Doc_meshdescriptors":"Antibodies, Monoclonal;Antibodies, Monoclonal, Humanized;Antineoplastic Agents;Breast Neoplasms;Clinical Trials as Topic;Female;Humans;Neoplasm Metastasis;Receptor, Epidermal Growth Factor;Receptor, ErbB-2;Receptors, Growth Factor;Trastuzumab",
        "Doc_meshqualifiers":"pharmacology;therapeutic use;pharmacology;drug therapy;pathology;drug effects;physiology;drug effects;physiology",
        "_version_":1605812890605977600},
      {
        "Doc_abstract":"Akt is a serine/threonine kinase that has been demonstrated to play an important role in survival when cells are exposed to different apoptotic stimuli. Recent studies show that aberrant activation of Akt in breast carcinoma is associated with a poor prognosis and resistance to endocrine therapy and chemotherapy. The Akt signaling pathway is currently attracting considerable attention as a new target for effective therapeutic strategies. We investigated the incidence of Akt activation in 252 primary breast carcinomas and relationships among the activation of Akt, HER2 overexpression, hormone receptor expression, and alteration of the PTEN gene. Eighty-four cases (33.3%) were positive for pAkt expression. pAkt was significantly associated with HER2 overexpression (p<0.0001) and LOH at the PTEN gene locus (p<0.01). There was an inverse correlation between pAkt and PR (p<0.05). We also retrospectively examined the relationship between Akt activation and the efficacy of endocrine therapy for metastatic breast cancer. Of these 36 metastatic breast cancer cases, 12 cases (33.4%) were considered to show positive pAkt expression. In the pAkt-positive patients, endocrine therapy demonstrated worse efficacy than in pAkt-negative patients (p<0.01). In addition, the clinical benefit was the smallest in the patients positive both for HER2 and pAkt (p<0.01). The clinical benefit rate of estrogen deprivation therapy with AI or LH-RH agonist was significantly lower in the pAkt-positive patients than that in the pAkt-negative ones (p<0.05), and there was a tendency for the clinical benefit of SERM to be smaller in the pAkt-positive patients (p=0.09). These findings therefore suggest that Akt activation induces endocrine resistance in metastatic breast cancer, irrespective of the kind of endocrine agents that were administered. Our findings indicate that the activation of Akt in the downstream pathway of HER2 plays an important role in resistance to endocrine therapy for breast cancer. Our findings suggest that pAkt may be a useful predictor of resistance to endocrine therapy for breast cancer, while also suggesting that the inhibition of Akt may increase the efficacy of endocrine therapy.",
        "Doc_title":"Activation of PI3K/Akt signaling and hormone resistance in breast cancer.",
        "Journal":"Breast cancer (Tokyo, Japan)",
        "Do_id":"16755107",
        "Doc_ChemicalList":"Antineoplastic Agents, Hormonal;Phosphatidylinositol 3-Kinases;PIK3CA protein, human;PTEN Phosphohydrolase",
        "Doc_meshdescriptors":"Adult;Aged;Antineoplastic Agents, Hormonal;Base Sequence;Biopsy, Needle;Breast Neoplasms;Drug Resistance, Neoplasm;Female;Gene Expression Regulation, Neoplastic;Humans;Immunohistochemistry;Middle Aged;Molecular Sequence Data;PTEN Phosphohydrolase;Pharmacogenetics;Phosphatidylinositol 3-Kinases;Polymerase Chain Reaction;Predictive Value of Tests;Probability;Retrospective Studies;Risk Assessment;Sampling Studies;Sensitivity and Specificity;Signal Transduction",
        "Doc_meshqualifiers":"therapeutic use;drug therapy;genetics;genetics;genetics",
        "_version_":1605749781760573440},
      {
        "Doc_abstract":"The receptor tyrosine kinase ErbB2 (HER-2/neu) is overexpressed in up to 30% of breast cancers and is associated with poor prognosis and an increased likelihood of metastasis especially in node-positive tumors. In this proteomic study, to identify the proteins that are associated with the aggressive phenotype of HER-2/neu-positive breast cancer, tumor cells from both HER-2/neu-positive and -negative tumors were procured by laser capture microdissection. Differentially expressed proteins in the two subsets of tumors were identified by two-dimensional electrophoresis and MALDI-TOF/TOF MS/MS. We found differential expression of several key cell cycle modulators, which were linked with increased proliferation of the HER-2/neu-overexpressing cells. Nine proteins involved in glycolysis (triose-phosphate isomerase (TPI), phosphoglycerate kinase 1 (PGK1), and enolase 1 (ENO1)), lipid synthesis (fatty acid synthase (FASN)), stress-mediated chaperonage (heat shock protein 27 (Hsp27)), and antioxidant and detoxification pathways (haptoglobin, aldo-keto reductase (AKR), glyoxalase I (GLO), and prolyl-4-hydrolase beta-isoform (P4HB)) were found to be up-regulated in HER-2/neu-positive breast tumors. HER-2/neu-dependent differential expression of PGK1, FASN, Hsp27, and GLO was further validated in four breast cancer cell lines and 12 breast tumors by immunoblotting and confirmed by partially switching off the HER-2/neu signaling in the high HER-2/neu-expressing SKBr3 cell line with Herceptin treatment. Statistical correlations of these protein expressions with HER-2/neu status were further verified by immunohistochemistry on a tissue microarray comprising 97 breast tumors. Our findings suggest that HER-2/neu signaling may result, directly or indirectly, in enhanced activation of various metabolic, stress-responsive, antioxidative, and detoxification processes within the breast tumor microenvironment. We hypothesize that these identified changes in the cellular proteome are likely to drive cell proliferation and tissue invasion and that the key cell cycle modulators involved, when uncovered by future research, would serve as naturally useful targets for the development of therapeutic strategies to negate the metastatic potential of HER-2/neu-positive breast tumors.",
        "Doc_title":"Proteomic study reveals that proteins involved in metabolic and detoxification pathways are highly expressed in HER-2/neu-positive breast cancer.",
        "Journal":"Molecular & cellular proteomics : MCP",
        "Do_id":"16048908",
        "Doc_ChemicalList":"Antibodies, Monoclonal;Antibodies, Monoclonal, Humanized;HSP27 Heat-Shock Proteins;HSPB1 protein, human;Heat-Shock Proteins;Neoplasm Proteins;Proteome;Fatty Acid Synthases;Phosphoglycerate Kinase;Lactoylglutathione Lyase;Trastuzumab",
        "Doc_meshdescriptors":"Amino Acid Sequence;Antibodies, Monoclonal;Antibodies, Monoclonal, Humanized;Breast Neoplasms;Cell Line, Tumor;Fatty Acid Synthases;Gene Expression Regulation, Neoplastic;Genes, erbB-2;HSP27 Heat-Shock Proteins;Heat-Shock Proteins;Humans;Immunohistochemistry;Inactivation, Metabolic;Lactoylglutathione Lyase;Microarray Analysis;Molecular Sequence Data;Neoplasm Proteins;Phosphoglycerate Kinase;Proteome;Proteomics;Signal Transduction;Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization;Trastuzumab",
        "Doc_meshqualifiers":"pharmacology;metabolism;metabolism;drug effects;genetics;physiology;metabolism;metabolism;analysis;chemistry;metabolism;metabolism;analysis;chemistry;metabolism",
        "_version_":1605895832328994816},
      {
        "Doc_abstract":"HER2/neu is over expressed in 20-25% of breast cancers. HER2 breast cancers are aggressive and are associated with poor prognosis. The aim of this study was to develop the clinical grade Lu-177-trastuzumab and its preliminary evaluation for specific tumor targeting in HER2 positive breast cancer patients. Trastuzumab was conjugated to bifunctional chelator, DOTA, and characterized for integrity and the number of molecules conjugated. Radiolabeling of DOTA-conjugated trastuzumab was optimized using Lu-177. Quality control parameters including radiochemical purity, stability, sterility, pyrogenicity and immunoreactivity were assessed. A preliminary pilot study was conducted on breast cancer patients (nâ€‰=â€‰6 HER2 positive and nâ€‰=â€‰4 HER2 negative) to evaluate the ability of Lu-177-trastuzumab for HER2 specific tumor targeting. The conjugates were efficiently labeled with Lu-177 with high radiochemical purity (up to 91%) and specific activity (6-13 ÂµCi/Âµg). Lu-177-trastuzumab was stable up to 12 hr post labeling. The radioimmunoassay demonstrated good antigen binding ability and specificity for HER2 receptor protein. The patient studies showed the localization of Lu-177-trastuzumab at primary as well as metastatic sites (HER2 positive) in the planar and SPECT/CT images. No tracer uptake was observed in HER2 negative patients that indicated the specificity of Lu-177-trastuzumab. The study demonstrated that in-house developed Lu-177-trastuzumab has specific targeting ability for HER2 expressing lesions and may in future become a palliative treatment option in the form of targeted radionuclide therapy for disseminated HER2 positive breast cancer.",
        "Doc_title":"Development of Lu-177-trastuzumab for radioimmunotherapy of HER2 expressing breast cancer and its feasibility assessment in breast cancer patients.",
        "Journal":"International journal of cancer",
        "Do_id":"27813061",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605845827805249536},
      {
        "Doc_abstract":"ERBB2 overexpression in estrogen receptor (ER)-positive breast cancer cells such as BT474 (BT) cells has been found to confer resistance to tamoxifen, and suppression of ERBB2 improves the antiproliferative effects of tamoxifen. In this study, the responsiveness to tamoxifen in the BT/HerR, Herceptin-resistant BT cell lines established through constant Herceptin exposure, was evaluated. Compared with BT cells, improvement of sensitivity to tamoxifen in BT/HerR was demonstrated by ER functional analysis and cell proliferation assay. Tamoxifen in the resistant cell line was found to inhibit 17beta-estradiol-stimulating estrogen-responsive gene pS2 expression more effectively than in BT cells in real-time PCR assay. Western blot analysis showed that cross-phosphorylation between ER and downstream components of ERBB2 was attenuated in BT/HerR cells. ER redistribution from cytoplasm to nucleus could be found in these cells through immunofluorescence and confocal studies, and importantly, chromatin immunoprecipitation studies demonstrated that tamoxifen induced occupancy of the pS2 promoter by ER and nuclear receptor corepressor (NCOR1) instead of coactivator NCOA3 in these cells. Finally, combination of tamoxifen and Herceptin was found to improve the sensitivity of BT/HerR cells to Herceptin. Our results suggest that the ER genomic pathway in the ER-positive and Herceptin-resistant breast cancer cells may be reactivated, allowing tamoxifen therapy to be effective again, and a combination of tamoxifen and Herceptin can be a potential therapeutic strategy for ER-positive and Herceptin-resistant human breast cancer.",
        "Doc_title":"Improvement of sensitivity to tamoxifen in estrogen receptor-positive and Herceptin-resistant breast cancer cells.",
        "Journal":"Journal of molecular endocrinology",
        "Do_id":"18768663",
        "Doc_ChemicalList":"Antibodies, Monoclonal;Antibodies, Monoclonal, Humanized;Antineoplastic Agents;Protein Isoforms;Receptors, Estrogen;Transcription Factors;Tamoxifen;Histone Acetyltransferases;NCOA1 protein, human;Nuclear Receptor Coactivator 1;Receptor, ErbB-2;Trastuzumab",
        "Doc_meshdescriptors":"Antibodies, Monoclonal;Antibodies, Monoclonal, Humanized;Antineoplastic Agents;Breast Neoplasms;Cell Line, Tumor;Drug Resistance, Neoplasm;Female;Histone Acetyltransferases;Humans;Nuclear Receptor Coactivator 1;Protein Isoforms;Receptor, ErbB-2;Receptors, Estrogen;Signal Transduction;Tamoxifen;Transcription Factors;Trastuzumab",
        "Doc_meshqualifiers":"therapeutic use;therapeutic use;drug therapy;physiopathology;genetics;metabolism;genetics;metabolism;genetics;metabolism;genetics;metabolism;physiology;therapeutic use;genetics;metabolism",
        "_version_":1605809898398941184},
      {
        "Doc_abstract":"The HER-2/neu proto-oncogene is frequently amplified or overexpressed in human breast and ovarian cancers, and is significantly correlated with shorter survival. We have previously reported that the adenovirus type 5 early region 1A (E1A) gene product can repress HER-2/neu overexpression by repressing HER-2/neu promoter activity, and suppress the tumorigenic potential of HER-2/neu-overexpressing ovarian cancer cells. To examine E1A tumor suppressor function in breast cancer, we transduced E1A in vitro by adenovirus into both HER-2/neu-overexpressing and low expressing human breast cancer cell lines. In HER-2/neu-overexpressing cells, E1A greatly inhibited tumor cell growth in vitro. However, in HER-2/neu low expressing cancer cell lines, E1A had no significant effect on cell growth in culture medium. To test the therapeutic efficacy of E1A, we used both adenovirus-mediated and cationic liposome-mediated E1A gene delivery systems in an orthotopic breast cancer animal model. An advanced breast cancer model was established by inoculation of HER-2/neu-overexpressing human breast cancer cells in mammary fat pad and treated by local injections of either replication-deficient adenovirus expressing E1A, Ad.E1A(+) or a liposome-E1A DNA complex. As controls, mice bearing tumors were also treated with Ad.E1A(-) which is virtually the same adenovirus as Ad.E1A(+) except that E1A is deleted, a liposome-E1A frame-shift mutant DNA complex, or just PBS. In mice bearing a HER-2/neu-overexpressing breast cancer cell line, E1A delivered either by adenovirus or liposome significantly inhibited tumor growth and prolonged mouse survival compared with the controls. In fact, 60-80% of E1A-treated mice lived longer than 2 years versus only 0-20% of control mice (P<0.05). Western blot analysis showed that E1A protein was expressed in tumor tissue and immunohistochemical analysis showed that HER-2/neu p185 protein expression was suppressed. Taken together, our results indicated that both adenovirus and cationic liposome delivery systems were effective in transfering E1A gene for tumor suppression in a HER-2/neu-overexpressing breast cancer model.",
        "Doc_title":"The tumor suppression activity of E1A in HER-2/neu-overexpressing breast cancer.",
        "Journal":"Oncogene",
        "Do_id":"9053854",
        "Doc_ChemicalList":"Adenovirus E1A Proteins;Recombinant Proteins;Receptor, ErbB-2;beta-Galactosidase",
        "Doc_meshdescriptors":"Adenovirus E1A Proteins;Adenoviruses, Human;Adipose Tissue;Animals;Breast Neoplasms;Cell Division;Cell Line;Female;Genes, Reporter;Genetic Vectors;Humans;Mammary Glands, Animal;Mice;Mice, Nude;Receptor, ErbB-2;Recombinant Proteins;Transfection;Transplantation, Heterologous;Tumor Cells, Cultured;beta-Galactosidase",
        "Doc_meshqualifiers":"biosynthesis;metabolism;metabolism;pathology;biosynthesis;biosynthesis;biosynthesis",
        "_version_":1605759551783567360},
      {
        "Doc_abstract":"Alterations in ErbB2 or fibroblast growth factor receptor-4 (FGFR-4) expression and activity occur in a significant fraction of breast cancers. Because signaling molecules and pathways cooperate to drive cancer progression, simultaneous targeting of multiple pathways is an appealing therapeutic strategy. With this in mind, we examined breast tumor cells for their sensitivity to the ErbB2 and FGFR inhibitors, PKI166 and PD173074, respectively. Simultaneous blocking of ErbB2 and FGFR-4 in MDA-MB-453 tumor cells had a stronger anti-proliferative effect than treatment with individual inhibitors. Examination of cell cycle regulators revealed a novel translation-mediated mechanism whereby ErbB2 and FGFR-4 cooperate to regulate cyclin D1 levels. Our results showed that FGFR-4 and ErbB2 via the MAPK and the phosphatidylinositol 3-kinase/protein kinase B pathways, respectively, both contribute to the maintenance of constitutive activity of the mammalian target of rapamycin translational pathway. Dual inhibition of these receptors strongly blocked S6 kinase 1 (S6K1) activity and cyclin D1 translation, as attested by a decrease in cyclin D1 mRNA association with polysomes. Ectopic expression of active protein kinase B or active S6K1 abrogated the dual inhibitor-mediated down-regulation of cyclin D1 expression, demonstrating the importance of these FGFR-4/ErbB2 signaling targets in regulating cyclin D1 translation. S6K1 has the central role in this process, since small interfering RNA-targeted S6K1 depletion led to a decrease in cellular S6K1 activity and, as a consequence, repression of cyclin D1 expression. Thus, we propose a novel mechanism for controlling cyclin D1 expression downstream of combined activity of ErbB2 and FGFR-4 that involves S6K1-mediated translation.",
        "Doc_title":"Cooperation between fibroblast growth factor receptor-4 and ErbB2 in regulation of cyclin D1 translation.",
        "Journal":"The Journal of biological chemistry",
        "Do_id":"15377668",
        "Doc_ChemicalList":"Receptors, Fibroblast Growth Factor;Cyclin D1;Protein Kinases;Phosphatidylinositol 3-Kinases;MTOR protein, human;TOR Serine-Threonine Kinases;FGFR4 protein, human;Receptor, ErbB-2;Receptor, Fibroblast Growth Factor, Type 4;Ribosomal Protein S6 Kinases, 70-kDa;ribosomal protein S6 kinase, 70kD, polypeptide 1;Mitogen-Activated Protein Kinases",
        "Doc_meshdescriptors":"Breast Neoplasms;Cyclin D1;Gene Expression Regulation, Neoplastic;Humans;Mitogen-Activated Protein Kinases;Phosphatidylinositol 3-Kinases;Protein Kinases;Receptor, ErbB-2;Receptor, Fibroblast Growth Factor, Type 4;Receptors, Fibroblast Growth Factor;Ribosomal Protein S6 Kinases, 70-kDa;TOR Serine-Threonine Kinases",
        "Doc_meshqualifiers":"metabolism;biosynthesis;genetics;physiology;metabolism;metabolism;metabolism;metabolism;metabolism;metabolism",
        "_version_":1605882505122021376},
      {
        "Doc_abstract":"Autophagy is a process that degrades intracellular constituents, such as long-lived or damaged proteins and organelles, to buffer metabolic stress under starvation conditions. Deregulation of autophagy is involved in the progression of cancer. However, the predictive value of autophagy for breast cancer prognosis remains unclear. First, based on gene expression profiling, we found that autophagy genes were implicated in breast cancer. Then, using the Cox proportional hazard regression model, we detected autophagy prognostic signature for breast cancer in a training dataset. We identified a set of eight autophagy genes (BCL2, BIRC5, EIF4EBP1, ERO1L, FOS, GAPDH, ITPR1 and VEGFA) that were significantly associated with overall survival in breast cancer. The eight autophagy genes were assigned as a autophagy-related prognostic signature for breast cancer. Based on the autophagy-related signature, the training dataset GSE21653 could be classified into high-risk and low-risk subgroups with significantly different survival times (HR = 2.72, 95% CI =â€‰(1.91, 3.87); P = 1.37 Ã— 10(-5)). Inactivation of autophagy was associated with shortened survival of breast cancer patients. The prognostic value of the autophagy-related signature was confirmed in the testing dataset GSE3494 (HR = 2.12, 95% CI =â€‰(1.48, 3.03); P = 1.65 Ã— 10(-3)) and GSE7390 (HR = 1.76, 95% CI =â€‰(1.22, 2.54); P = 9.95 Ã— 10(-4)). Further analysis revealed that the prognostic value of the autophagy signature was independent of known clinical prognostic factors, including age, tumor size, grade, estrogen receptor status, progesterone receptor status, ERBB2 status, lymph node status and TP53 mutation status. Finally, we demonstrated that the autophagy signature could also predict distant metastasis-free survival for breast cancer.",
        "Doc_title":"Autophagy-related prognostic signature for breast cancer.",
        "Journal":"Molecular carcinogenesis",
        "Do_id":"25620657",
        "Doc_ChemicalList":"Biomarkers, Tumor;Tumor Suppressor Protein p53",
        "Doc_meshdescriptors":"Autophagy;Biomarkers, Tumor;Breast;Breast Neoplasms;Disease-Free Survival;Female;Gene Expression Profiling;Humans;Middle Aged;Mutation;Prognosis;Proportional Hazards Models;Survival Analysis;Tumor Suppressor Protein p53",
        "Doc_meshqualifiers":"genetics;metabolism;pathology;diagnosis;genetics;genetics",
        "_version_":1605809047897899008},
      {
        "Doc_abstract":"Triple-negative-breast-cancer that accounts for 10-20% of all breast carcinomas is defined by the lack of estrogen receptor, progesterone receptor, HER2 expression, and agressive clinical behavior. Triple-negative-breast-cancer is categorized into basal like and other types. The basal-like subtype is characterized by the expression of myoepithelial/basal markers.;We studied 41 immunohistochemically triplenegative- breast-cancer patients to determine EGFR, Cytokeratine 5/6, p53, Ki67, GCDFP-15 expression profiles, HER2 and Chromosome 17 centromere gene status by fluorescence-in-situ-hybridization method.;Histological type was invasive ductal carcinoma in 90.2% of the tumors. p53, Ki67, GCDFP-15 mean positivity rates were 55.6%, 51.7%, and 3.2%, respectively. GCDFP-15 positivity was noted in 8 cases of which 6 were Cytokeratine 5/6 negative. The cut-off value for Cytokeratine 5/6 positivity was 5%. EGFR immunoreactivity was grouped into 0, 1+ as negative; 2+, 3+ as positive categories. Cytokeratine 5/6 was positive in 56,1%, EGFR was positive in 51.2% of the patients. The relation between Cytokeratine 5/6 and EGFR expression was statistically significant (p < 0.01). None of the cases showed HER2 amplification by fluorescence-in-situ-hybridization method.;GCDFP-15 alone is not a useful marker to detect the metastasis of basaloid type breast cancers. Cytokeratine 5/6 and EGFR expressions showed correlation so these markers are reliable to diagnose basaloid type tumors with a 5% cut-off value.",
        "Doc_title":"[Immunohistochemical characteristics of triple negative/basal-like breast cancer].",
        "Journal":"Turk patoloji dergisi",
        "Do_id":"23011826",
        "Doc_ChemicalList":"Biomarkers, Tumor;Carrier Proteins;Glycoproteins;Keratin-5;Keratin-6;PIP protein, human;EGFR protein, human;Receptor, Epidermal Growth Factor",
        "Doc_meshdescriptors":"Biomarkers, Tumor;Breast Neoplasms;Carrier Proteins;Female;Glycoproteins;Humans;Immunohistochemistry;In Situ Hybridization, Fluorescence;Keratin-5;Keratin-6;Receptor, Epidermal Growth Factor",
        "Doc_meshqualifiers":"analysis;genetics;metabolism;pathology;analysis;biosynthesis;analysis;biosynthesis;analysis;biosynthesis;analysis;biosynthesis;analysis;biosynthesis",
        "_version_":1605818669296779264},
      {
        "Doc_abstract":"Patients with human epidermal growth factor receptor (HER)-2+ breast cancer are at particularly high risk for brain metastases; however, the biological basis is not fully understood. Using a novel HER-2 assay, we investigated the correlation between quantitative HER-2 expression in primary breast cancers and the time to brain metastasis (TTBM) in HER-2+ advanced breast cancer patients treated with trastuzumab.;The study group included 142 consecutive patients who were administered trastuzumab-based therapy for HER-2+ metastatic breast cancer. HER-2/neu gene copy number was quantified as the HER-2/centromeric probe for chromosome 17 (CEP17) ratio by central laboratory fluorescence in situ hybridization (FISH). HER-2 protein was quantified as total HER-2 protein expression (H2T) by the HERmarkÂ® assay (Monogram Biosciences, Inc., South San Francisco, CA) in formalin-fixed, paraffin-embedded tumor samples. HER-2 variables were correlated with clinical features and TTBM was measured from the initiation of trastuzumab-containing therapy.;A higher H2T level (continuous variable) was correlated with shorter TTBM, whereas HER-2 amplification by FISH and a continuous HER-2/CEP17 ratio were not predictive (p = .013, .28, and .25, respectively). In the subset of patients that was centrally determined by FISH to be HER-2+, an above-the-median H2T level was significantly associated with a shorter TTBM (hazard ratio, [HR], 2.4; p = .005), whereas this was not true for the median HER-2/CEP17 ratio by FISH (p = .4). Correlation between a continuous H2T level and TTBM was confirmed on multivariate analysis (HR, 3.3; p = .024).;These data reveal a strong relationship between the quantitative HER-2 protein expression level and the risk for brain relapse in HER-2+ advanced breast cancer patients. Consequently, quantitative assessment of HER-2 protein expression may inform and facilitate refinements in therapeutic treatment strategies for selected subpopulations of patients in this group.",
        "Doc_title":"Correlation between quantitative HER-2 protein expression and risk for brain metastases in HER-2+ advanced breast cancer patients receiving trastuzumab-containing therapy.",
        "Journal":"The oncologist",
        "Do_id":"22234627",
        "Doc_ChemicalList":"Antibodies, Monoclonal, Humanized;Receptor, ErbB-2;Trastuzumab",
        "Doc_meshdescriptors":"Adult;Aged;Antibodies, Monoclonal, Humanized;Antineoplastic Combined Chemotherapy Protocols;Brain Neoplasms;Breast Neoplasms;Female;Humans;In Situ Hybridization, Fluorescence;Middle Aged;Neoplasm Metastasis;Receptor, ErbB-2;Risk Factors;Trastuzumab",
        "Doc_meshqualifiers":"administration & dosage;therapeutic use;chemically induced;enzymology;secondary;drug therapy;enzymology;genetics;pathology;biosynthesis;genetics",
        "_version_":1605818681469698048},
      {
        "Doc_abstract":"Lapatinib (GW572016) is a small-molecule dual inhibitor of epidermal growth factor receptor (ErbB1) and ErbB2 receptor kinase activities currently in phase III clinical trials. We used phosphoprotein and microarray analyses to carry out targeted pathway studies of phosphorylation and gene expression changes in human breast cancer cell lines in the presence or absence of lapatinib. Studies were done in four breast cancer cell lines, two of which were responsive and two of which were nonresponsive to lapatinib. Responsive cell lines, BT474 and SKBr3, constitutively overexpress ErbB2 and show an IC(50) of 25 or 32 nmol/L for lapatinib, respectively. In contrast, nonresponsive MDA-MB-468 and T47D cells expressed a low basal level of ErbB2 and showed IC(50) values in the micromolar range. Cells responsive to lapatinib exhibited strong differential effects on multiple genes in the AKT pathway. After 12 h of exposure to 1.0 micromol/L of lapatinib, AKT1, MAPK9, HSPCA, IRAK1, and CCND1 transcripts were down-regulated 7- to 25-fold in responsive BT474 and SKBr3 cells. In contrast, lapatinib weakly down-regulated the AKT pathway in nonresponsive breast cancer cell lines (<5-fold down-regulation of most genes in the pathway). Furthermore, the proapoptotic gene FOXO3A, which is negatively regulated by AKT, was up-regulated 7- and 25-fold in lapatinib-responsive SKBr3 and BT474 cells, respectively. Phosphorylated Akt and Akt-mediated phosphorylation of FOXO3A also decreased in responsive breast cancer cell lines exposed to lapatinib. Gene expression profiling also revealed that lapatinib stimulated the expression of estrogen and progesterone receptors and modulated the expression of genes involved in cell cycle control, glycolysis, and fatty acid metabolism. In BT474 and T47D cells, which expressed moderate basal levels of the estrogen and progesterone receptors, 1.0 micromol/L of lapatinib induced expression by 7- to 11-fold. These data provide insight into the mechanism of action of lapatinib in breast cancer cells.",
        "Doc_title":"Delineation of molecular mechanisms of sensitivity to lapatinib in breast cancer cell lines using global gene expression profiles.",
        "Journal":"Molecular cancer therapeutics",
        "Do_id":"17513611",
        "Doc_ChemicalList":"Antineoplastic Agents;Quinazolines;lapatinib;Receptor, Epidermal Growth Factor",
        "Doc_meshdescriptors":"Antineoplastic Agents;Apoptosis;Breast Neoplasms;Cell Line, Tumor;Cell Proliferation;Gene Expression Profiling;Gene Expression Regulation, Neoplastic;Humans;Inhibitory Concentration 50;Models, Biological;Oligonucleotide Array Sequence Analysis;Proteomics;Quinazolines;Receptor, Epidermal Growth Factor;Time Factors",
        "Doc_meshqualifiers":"pharmacology;drug therapy;methods;pharmacology;metabolism",
        "_version_":1605841735367262208},
      {
        "Doc_abstract":"Significant targeted molecules for breast cancer treatment are hormone receptor and HER2. Since the concept of an \"intrinsic subtype\" was proposed, breast cancers have been treated according to subtypes including Luminal A, B, HER2 and triple negative. In this article, gene testing useful as a prognostic factor and to predict the chemotherapeutic effect on ER-positive breast cancers will be introduced, although it has not been approved in Japan. Gene testing is useful but expensive so far; therefore, it will be used in parallel to conventional tools, i.e. HE-stained sections and immunohistochemical methods.",
        "Doc_title":"[Genomic diagnosis in breast cancer practice].",
        "Journal":"Rinsho byori. The Japanese journal of clinical pathology",
        "Do_id":"23323462",
        "Doc_ChemicalList":"Biomarkers, Tumor",
        "Doc_meshdescriptors":"Biomarkers, Tumor;Breast Neoplasms;Female;Genetic Testing;Genomics;Humans;Japan;Molecular Targeted Therapy;Prognosis",
        "Doc_meshqualifiers":"genetics;diagnosis;drug therapy;genetics",
        "_version_":1605795833975930880},
      {
        "Doc_abstract":"The immunohistochemical determination of HER-2 to identify patients with advanced breast cancer candidates for Trastuzumab treatment proved neither accurate nor fully reliable, possibly because none of the current reagents detects the specific antigenic site target of Trastuzumab. To circumvent this problem, we conjugated the NH2 groups of Trastuzumab with biotin, and the compound obtained, designated BiotHER, was added directly to tissue sections. Biotin-labelling was revealed with horseradish peroxidase-conjugated streptavidin. Specificity and sensitivity of BiotHER immunostaining with respect to HER-2 amplification were tested on 164 breast carcinoma samples. BiotHER staining was detected on the tumour cell membrane of 12% of all specimens and in 49% specimens with gene amplification, while absent in nonamplified tumours. Predictivity of BiotHER status with respect to the clinical outcome was analysed in 54 patients with HER-2 amplified advanced breast cancer treated with Trastuzumab plus chemotherapy. BiotHER staining, detected in 50% of tumours with HER-2 amplification, was an independent predictor of clinical outcome. In fact, BiotHER positivity was independently associated with increased likelihood of tumour response and reduced risk of tumour progression and death. Biotinylated Trastuzumab can thus be used for immunohistochemical detection of HER-2 overexpression in breast cancer, and has the potential to identify patients likely to benefit from Trastuzumab treatment.",
        "Doc_title":"A modified Trastuzumab antibody for the immunohistochemical detection of HER-2 overexpression in breast cancer.",
        "Journal":"British journal of cancer",
        "Do_id":"15812476",
        "Doc_ChemicalList":"Antibodies, Monoclonal;Antibodies, Monoclonal, Humanized;Antigens, Neoplasm;Indicators and Reagents;Streptavidin;Receptor, ErbB-2;Trastuzumab",
        "Doc_meshdescriptors":"Adult;Aged;Antibodies, Monoclonal;Antibodies, Monoclonal, Humanized;Antigens, Neoplasm;Biotinylation;Breast Neoplasms;Female;Humans;Immunoassay;In Situ Hybridization;Indicators and Reagents;Middle Aged;Predictive Value of Tests;Prognosis;Receptor, ErbB-2;Risk Factors;Streptavidin;Trastuzumab;Treatment Outcome",
        "Doc_meshqualifiers":"immunology;therapeutic use;immunology;drug therapy;immunology;administration & dosage;biosynthesis;genetics",
        "_version_":1605895597015957504},
      {
        "Doc_abstract":"Human epidermal growth factor receptor-2 (HER2) is overexpressed in up to 30% of breast cancers; HER2 overexpression is indicative of poor prognosis. Trastuzumab, an anti-HER2 monoclonal antibody, has led to improved outcomes in patients with HER2-positive breast cancer, including improved overall survival in adjuvant and first-line settings. However, a large proportion of patients with breast cancer have intrinsic resistance to HER2-targeted therapies, and nearly all become resistant to therapy after initial response. Elucidation of underlying mechanisms contributing to HER2 resistance has led to development of novel therapeutic strategies, including those targeting HER2 and downstream pathways, heat shock protein 90, telomerase, and vascular endothelial growth factor inhibitors. Numerous clinical trials are ongoing or completed, including phase 3 data for the mammalian target of rapamycin inhibitor everolimus in patients with HER2-resistant breast cancer. This review considers the molecular mechanisms associated with HER2 resistance and evaluates the evidence for use of evolving strategies in patients with HER2-resistant breast cancer. ",
        "Doc_title":"Current Approaches and Emerging Directions in HER2-resistant Breast Cancer.",
        "Journal":"Breast cancer : basic and clinical research",
        "Do_id":"25125981",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605908219186642944},
      {
        "Doc_abstract":"In breast cancer, the HER-2/neu gene is amplified in 20-30 per cent of cases. The mechanism by which the amplification/overexpression occurs is not known. Elevated serum HER-2/neu levels have been shown to be associated with a poor clinical prognosis and decreased survival in early stage breast cancer patients, and thus might help in management of the disease. The present study was therefore to estimate the serum HER-2/neu levels in breast cancer patients and associate with other prognostic factors.;Serum HER-2/neu levels were studied in 207 patients with cancer breast, 15 benign breast diseases (BBD) and 175 age-matched healthy controls. Patients' age, menopausal status, node and hormone receptor status were compared with serum HER-2/neu levels.;Serum HER-2/neu overexpression was associated with age, disease stage and positive nodal status but not with menopausal status. Serum HER-2/neu levels were negatively related with hormone receptor positivity.;HER-2/neu serum test could be done more frequently in women with breast cancer irrespective of the hormone receptor status, to suggest modifications in systemic adjuvant therapy, including possibly the use of Herceptin.",
        "Doc_title":"Clinical utility of serum human epidermal receptor-2/neu detection in breast cancer patients.",
        "Journal":"The Indian journal of medical research",
        "Do_id":"17431282",
        "Doc_ChemicalList":"Receptor, ErbB-2",
        "Doc_meshdescriptors":"Age Factors;Breast Neoplasms;Female;Gene Expression Regulation, Neoplastic;Humans;India;Logistic Models;Neoplasm Staging;Receptor, ErbB-2",
        "Doc_meshqualifiers":"blood;diagnosis;methods;blood;genetics",
        "_version_":1605791214144061440},
      {
        "Doc_abstract":"To study the distribution and quantity of CD44+/CD24- cells in breast cancer tissue and the cell lines, and as well as its correlation with the expression of various breast cancer markers and molecular subtyping of breast carcinoma.;The expression of CD44/CD24, estrogen receptor, progesterone receptor, HER2, human estrogen-induced protein PS2, bcl-2 and nm23 in 60 cases of invasive ductal carcinoma of breast were studied by either single or double immunohistochemical staining. The co-expression of CD44 and CD24 in 3 breast cancer cell lines (MCF-7, MDA-MB-468, and MDA-MB-231) was also examined.;The quantity and distribution of CD44+/CD24- cells varied greatly and no specific patterns were identified. The percentage of CD44+/CD24- in breast cancer was 65%. The amount of CD44+/CD24- cells did not correlate with the age of patients, lymph node metastasis, tumor size, molecular subtypes and expression of various breast cancer markers in breast carcinoma. The proportion of CD44+/CD24- cells in MCF-7, MDA-MB-468, and MDA-MB-231 cell lines was <1%, 5% and >80%, respectively.;CD44+/CD24- cells are demonstrated in certain breast cancer tissues and cell lines. However, there is no relationship obtained between the quantity or the distribution of these cells and the molecular subtyping or the clinicopathologic parameters in breast cancer.",
        "Doc_title":"[Quantity and distribution of CD44+/CD24- cells in breast cancer tissue and the cell lines].",
        "Journal":"Zhonghua bing li xue za zhi = Chinese journal of pathology",
        "Do_id":"19781189",
        "Doc_ChemicalList":"Antigens, CD24;Antigens, CD44;Biomarkers, Tumor;NM23 Nucleoside Diphosphate Kinases;Proto-Oncogene Proteins c-bcl-2;Receptors, Progesterone;TFF1 protein, human;Trefoil Factor-1;Tumor Suppressor Proteins;Receptor, ErbB-2;NME1 protein, human",
        "Doc_meshdescriptors":"Adult;Aged;Antigens, CD24;Antigens, CD44;Biomarkers, Tumor;Breast Neoplasms;Carcinoma, Ductal, Breast;Cell Line, Tumor;Female;Humans;Lymphatic Metastasis;Middle Aged;NM23 Nucleoside Diphosphate Kinases;Proto-Oncogene Proteins c-bcl-2;Receptor, ErbB-2;Receptors, Progesterone;Trefoil Factor-1;Tumor Suppressor Proteins",
        "Doc_meshqualifiers":"metabolism;metabolism;classification;metabolism;pathology;classification;metabolism;pathology;metabolism;metabolism;metabolism;metabolism;metabolism",
        "_version_":1605747005705945089},
      {
        "Doc_abstract":"Her-2/neu is an oncogen related with a poor prognosis and high agresivity when overexpressed in breast cancer. Main objective was analyze the frecuency of positivity or negativity ofller/neu in patients with breast cancer after surgery and their relationship with hormone receptors. We perfomed a longitudinal, retrospective, descriptive and observational trial in all patients included in the Patology Service with a determination of Her-2/neu and hormone receptors analysis, between January 1st 2007 and December 31 st 2009.We used descriptive stadistic and association tests with correlation coefficients. We analyze 893 patients. The age range was between 24 and 94 years. The 16.% of all cases overexpressed Her-2/neu (150 patients). The 4.8% (43 patients) were included in the FISII test resulting in 29 positives to Her-2/neu. There were a total of 179 cases overexpressed. Negative estrogen receptores cases were 23%, negative progesterone receptores cases were 28% and triple negative receptors cases were 19%. We analyzed independient variables with Student I resulting age with P = 0.294. We analyzed distribution variables with Pearson test resulting in negative estrogen receptors with a P = 0.0001 negative progesterone receptres with a P = 0.0001 and triple negative receptors P= 0.0001. Relationship between hormone receptors and Her-2/neu in proporlionaly inverse in other vvords when a high hormone receptors negativitvis present there is algo a Her-2/neu highly overexpressed.",
        "Doc_title":"[Frequency factor Her-2/neu overexpression in patients with breast cancer].",
        "Journal":"Ginecologia y obstetricia de Mexico",
        "Do_id":"25016895",
        "Doc_ChemicalList":"Receptors, Estrogen;Receptors, Progesterone;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Adult;Aged;Aged, 80 and over;Breast Neoplasms;Female;Gene Expression Regulation, Neoplastic;Humans;In Situ Hybridization, Fluorescence;Longitudinal Studies;Middle Aged;Receptor, ErbB-2;Receptors, Estrogen;Receptors, Progesterone;Retrospective Studies;Young Adult",
        "Doc_meshqualifiers":"genetics;pathology;genetics;metabolism;metabolism",
        "_version_":1605879568517824512},
      {
        "Doc_abstract":"The phenotype imparted by expression of the HER2 gene in breast cancer and progress made in modifying the disease's natural history through pharmacologically modulating its function has served as a paradigm for rationally targeted therapy and personalized medicine. About 20-25% of breast cancer cases are associated with HER2 gene amplification and overexpression, creating a distinct subtype of breast cancer that is associated with more aggressive behaviour, higher likelihood of overall and brain metastases, and differential responsiveness to certain hormonal and chemotherapeutic agents. Anti-HER2 monoclonal antibodies have led to significant improvements in survival for both advanced and early stage HER2+ breast cancer, while newer agents, including other antibodies and HER2 receptor tyrosine kinase inhibitors and signal transduction modulators, are also demonstrating clinical activity and represent further opportunities to improve curability and quality of life.",
        "Doc_title":"HER2 status and breast cancer therapy: recent advances.",
        "Journal":"F1000 medicine reports",
        "Do_id":"20948761",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605896085420638208},
      {
        "Doc_abstract":"Deregulation of micro-RNAs (miRNAs) is emerging as a major aspect of cancer etiology because their capacity to direct the translation and stability of targeted transcripts can dramatically influence cellular physiology. To explore the potential of exogenously applied miRNAs to suppress oncogenic proteins, the ERBB oncogene family was chosen with a bioinformatics search identifying targeting seed sequences for miR-125a and miR-125b within the 3'-untranslated regions of both ERBB2 and ERBB3. Using the human breast cancer cell line SKBR3 as a model for ERBB2 and ERBB3 dependence, infection of these cells with retroviral constructs expressing either miR-125a or miR-125b resulted in suppression of ERBB2 and ERBB3 at both the transcript and protein level. Luciferase constructs containing the 3' 3'-untranslated regions of ERBB2 and ERBB3 demonstrated approximately 35% less activity in miR-125a- and miR-125b-expressing cells relative to controls. Additionally, phosphorylation of ERK1/2 and AKT was suppressed in SKBR3 cells overexpressing either miR-125a or miR-125b. Consistent with suppression of both ERBB2 and ERBB3 signaling, miR-125a-or miR-125b-overexpressing SKBR3 cells were impaired in their anchorage-dependent growth and exhibited reduced migration and invasion capacities. Parallel studies performed on MCF10A cells demonstrated that miR-125a or miR-125b overexpression produced only marginal influences on the growth and migration of these non-transformed human mammary epithelial cells. These results illustrate the feasibility of using miRNAs as a therapeutic strategy to suppress oncogene expression and function.",
        "Doc_title":"Coordinate suppression of ERBB2 and ERBB3 by enforced expression of micro-RNA miR-125a or miR-125b.",
        "Journal":"The Journal of biological chemistry",
        "Do_id":"17110380",
        "Doc_ChemicalList":"MicroRNAs;Receptor, ErbB-2;Receptor, ErbB-3;Proto-Oncogene Proteins c-akt;Mitogen-Activated Protein Kinase 1;Mitogen-Activated Protein Kinase 3",
        "Doc_meshdescriptors":"Breast Neoplasms;Cell Adhesion;Cell Division;Cell Line, Tumor;Cell Movement;Epithelial Cells;Gene Expression Regulation, Neoplastic;Genetic Therapy;Humans;MAP Kinase Signaling System;MicroRNAs;Mitogen-Activated Protein Kinase 1;Mitogen-Activated Protein Kinase 3;Proto-Oncogene Proteins c-akt;Receptor, ErbB-2;Receptor, ErbB-3;Retroviridae",
        "Doc_meshqualifiers":"physiology;physiology;physiology;cytology;physiology;methods;physiology;genetics;metabolism;metabolism;metabolism;genetics;genetics;genetics",
        "_version_":1605754916013342720},
      {
        "Doc_abstract":"Amplification and overexpression of the HER-2 (neu/ erbB-2) gene in human breast cancer are clearly important events that lead to the transformation of mammary epithelial cells in approximately one-third of breast cancer patients. Heterodimer interactions between HER-2 and HER-3 (erbB-3) are activated by neu differentiation factor/heregulin (HRG), and HER-2/HER-3 heterodimers are constitutively activated in breast cancer cells with HER-2 gene amplification. This indicates that inhibition of HER-2/HER-3 heterodimer function may be an especially effective and unique strategy for blocking the HER-2-mediated transformation of breast cancer cells. Therefore, we constructed a bicistronic retroviral expression vector (pCMV-dn3) containing a dominant negative form of HER-3 in which most of the cytoplasmic domain was removed for introduction into cells. By using a bicistronic retroviral vector in which the antibiotic resistance gene and the gene of interest are driven by a single promoter, we attained 100% coordinate coexpression of antibiotic resistance with the gene of interest in target cell populations. Breast carcinoma cells with HER-2 gene amplification (21 MT-1 cells) and normal mammary epithelial cells without HER-2 gene amplification from the same patient (H16N-2 cells) were infected with pCMV-dn3 and assessed for HER-2/ HER-3 receptor tyrosine phosphorylation, p85PI 3-kinase and SHC protein activation, growth factor-dependent and -independent proliferation, and transformed growth in culture. Dominant negative HER-3 inhibited the HRG-induced activation of HER-2/HER-3 and signaling in H16N-2 and 21 MT-1 cells as well as the constitutive activation of HER-2/HER-3 and signaling in 21 MT-1 cells. Responses to exogenous HRG were strongly inhibited by dominant negative HER-3. In contrast, the proliferation of cells stimulated by epidermal growth factor was not apparently affected by dominant negative HER-3. The growth factor-independent proliferation and transformed growth of 21 MT-1 cells were also strongly inhibited by dominant negative HER-3 in anchorage-dependent and independent growth assays in culture. Furthermore, the HRG-induced or growth factor-independent proliferation of 21 MT-1 cells was inhibited by dominant negative HER-3, whereas the epidermal growth factor-induced proliferation of these cells was not: this indicates that dominant negative HER-3 preferentially inhibits proliferation induced by HER-2/HER-3.",
        "Doc_title":"Blocking HER-2/HER-3 function with a dominant negative form of HER-3 in cells stimulated by heregulin and in breast cancer cells with HER-2 gene amplification.",
        "Journal":"Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research",
        "Do_id":"10768865",
        "Doc_ChemicalList":"Mitogens;Neuregulin-1;Receptor, ErbB-2;Receptor, ErbB-3",
        "Doc_meshdescriptors":"Breast Neoplasms;Cell Division;Female;Gene Amplification;Gene Expression Regulation;Gene Expression Regulation, Neoplastic;Genetic Vectors;Humans;Mitogens;Neuregulin-1;Receptor, ErbB-2;Receptor, ErbB-3;Signal Transduction;Tumor Cells, Cultured",
        "Doc_meshqualifiers":"genetics;metabolism;genetics;genetics;genetics;genetics;pharmacology;pharmacology;genetics;metabolism;genetics;metabolism;genetics;drug effects;metabolism",
        "_version_":1605746293509980161},
      {
        "Doc_abstract":"HER2-positive breast tumors are associated with a high risk of brain relapse. HER3 is thought to be an indispensible signaling substrate for HER2 (encoded by ERBB2) and is induced in breast cancer-brain metastases, though the molecular mechanisms by which this oncogenic dimer promotes the development of brain metastases are still elusive. We studied the effects of the HER3-HER2 ligand, heregulin (neuregulin-1, broadly expressed in the brain), on luminal breast cancer cell lines in vitro. Treatment of SKBr3 (ERBB2-amplified), MDA-MB-361 (ERBB2-amplified, metastatic brain tumor-derived) and MCF7 (HER2-positive, not ERBB2-amplified) cells with exogenous heregulin increased proliferation and adhesive potential, concomitant with induction of cyclin D1 and ICAM-1, and suppression of p27. All three cell lines invaded through matrigel toward a heregulin chemotactic signal in transwell experiments, associated with activation of extracellular cathepsin B and matrix metalloproteinase-9 (MMP-9). Moreover, heregulin induced breast cancer cell transmigration across a tight barrier of primary human brain microvascular endothelia. This was dependent on the activity of HER2, HER3 and MMPs, and was completely abrogated by combination HER2-HER3 blockade using HerceptinÂ® and the humanized HER3 monoclonal antibody, EV20. Collectively these data suggest mechanisms by which the HER3-HER2 dimer promotes development of metastatic tumors in the heregulin-rich brain microenvironment. ",
        "Doc_title":"Heregulin-HER3-HER2 signaling promotes matrix metalloproteinase-dependent blood-brain-barrier transendothelial migration of human breast cancer cell lines.",
        "Journal":"Oncotarget",
        "Do_id":"25668816",
        "Doc_ChemicalList":"NRG1 protein, human;Neuregulin-1;ERBB2 protein, human;ERBB3 protein, human;Receptor, ErbB-2;Receptor, ErbB-3;Matrix Metalloproteinase 2;Matrix Metalloproteinase 9",
        "Doc_meshdescriptors":"Blood-Brain Barrier;Brain;Breast Neoplasms;Cell Line, Tumor;Cell Movement;Endothelial Cells;Female;Humans;MCF-7 Cells;Matrix Metalloproteinase 2;Matrix Metalloproteinase 9;Neuregulin-1;Receptor, ErbB-2;Receptor, ErbB-3;Signal Transduction",
        "Doc_meshqualifiers":"enzymology;metabolism;pathology;blood supply;enzymology;genetics;metabolism;pathology;physiology;metabolism;metabolism;metabolism;metabolism;metabolism;metabolism",
        "_version_":1605831986814910464},
      {
        "Doc_abstract":"The majority of deaths due to breast cancer occur in the context of complications secondary to metastatic disease. Trastuzumab, as a second line treatment, has shown a 15% objective response rate in patients with metastatic breast cancer. We present the case of a patient with two breast tumours, the second of more aggressive characteristics, with negative hormone receptors and c-erb-B2 +++, and with few therapeutic options due to her hepatic insufficiency secondary to metastatic disease; she was administered herceptin as monotherapy, and she had a complete clinical response. Trastuzumab has revolutionised the management of patients with metastatic breast cancer and Her-2- neu overexpression. Its combination with chemotherapy agents achieves a synergic activity.",
        "Doc_title":"A patient with breast cancer with hepatic metastases and a complete response to herceptin as monotherapy.",
        "Journal":"Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico",
        "Do_id":"17074677",
        "Doc_ChemicalList":"Antibodies, Monoclonal;Antibodies, Monoclonal, Humanized;Antineoplastic Agents;Antineoplastic Agents, Hormonal;Tamoxifen;Receptor, ErbB-2;Trastuzumab;Cisplatin;Fluorouracil;Methotrexate",
        "Doc_meshdescriptors":"Aged;Antibodies, Monoclonal;Antibodies, Monoclonal, Humanized;Antineoplastic Agents;Antineoplastic Agents, Hormonal;Antineoplastic Combined Chemotherapy Protocols;Biopsy;Bone Neoplasms;Breast;Breast Neoplasms;Carcinoma, Ductal, Breast;Cisplatin;Combined Modality Therapy;Disease-Free Survival;Female;Fluorouracil;Follow-Up Studies;Humans;Karnofsky Performance Status;Liver Neoplasms;Lymphatic Metastasis;Mastectomy, Modified Radical;Methotrexate;Radiotherapy Dosage;Receptor, ErbB-2;Tamoxifen;Time Factors;Tomography, X-Ray Computed;Trastuzumab;Treatment Outcome",
        "Doc_meshqualifiers":"administration & dosage;therapeutic use;administration & dosage;therapeutic use;administration & dosage;therapeutic use;therapeutic use;drug therapy;secondary;pathology;drug therapy;pathology;radiotherapy;surgery;drug therapy;pathology;radiotherapy;secondary;surgery;therapeutic use;therapeutic use;diagnostic imaging;drug therapy;secondary;therapeutic use;administration & dosage;therapeutic use",
        "_version_":1605760004101505024},
      {
        "Doc_abstract":"Recent studies suggest that the poorer breast cancer outcome observed in African-American women (AAW) may, in part, result from underlying molecular factors. The purpose of this study was to investigate gene expression differences between Caucasian-American women (CAW) and AAW that may contribute to this poorer prognosis.;The expression of 84 genes involved in breast carcinoma prognosis, response to therapy, estrogen signaling, and tumor aggressiveness was assessed in age- and stage-matched CAW and AAW paraffin-embedded breast cancer specimens. The Wilcoxon-Mann-Whitney Test was used to identify genes with a significant difference in expression between CAW and AAW. To determine if the differentially expressed genes could segregate between the CAW and AAW, we performed semi-supervised principal component analysis (SSPCA).;Twenty genes were differentially expressed between AAW and CAW. SSPCA incorporating these 20 genes segregated AAW and CAW into two distinct groups. AAW were significantly (p < 0.05) more likely to display aberrations in G(1)/S cell-cycle regulatory genes, decreased expression of cell-adhesion genes, and low to no expression of ESR1, PGR, ERBB2 and estrogen pathway targets.;The gene expression differences identified between AAW and CAW may contribute to more aggressive disease, resistance to therapy, enhanced metastatic potential and poor clinical outcome. These findings support the hypothesis that breast cancer specimens collected from AAW display distinct gene expression differences compared to similar tissues obtained from CAW. Additional population-based studies are necessary to determine if these gene expression variations contribute to the highly aggressive and treatment-resistant breast cancer phenotype frequently observed in AAW.",
        "Doc_title":"Differential expression of breast cancer-associated genes between stage- and age-matched tumor specimens from African- and Caucasian-American Women diagnosed with breast cancer.",
        "Journal":"BMC research notes",
        "Do_id":"22616718",
        "Doc_ChemicalList":"Biomarkers, Tumor",
        "Doc_meshdescriptors":"African Americans;Age Factors;Biomarkers, Tumor;Biopsy;Breast Neoplasms;Carcinoma, Ductal, Breast;Chi-Square Distribution;European Continental Ancestry Group;Female;Gene Expression Profiling;Gene Expression Regulation, Neoplastic;Genetic Predisposition to Disease;Humans;Immunohistochemistry;Multivariate Analysis;Neoplasm Staging;Phenotype;Principal Component Analysis;Prognosis;Risk Assessment;Risk Factors",
        "Doc_meshqualifiers":"genetics;analysis;genetics;chemistry;ethnology;genetics;pathology;therapy;chemistry;ethnology;genetics;pathology;therapy;genetics",
        "_version_":1605758971051769856},
      {
        "Doc_abstract":"Accumulating data indicate that human epidermal growth factor receptor-2 (HER2)-positive breast cancer is a heterogeneous disease. We undertook a study to correlate lipid profiles with heterogeneous clinicopathological features of HER2-positive breast cancer.;Histology-directed matrix-assisted laser desorption/ionization (MALDI)-mass spectrometry (MS) analyses were performed on 22 retrospective frozen tissue samples collected from patients with HER2-positive metastatic breast cancer, in order to correlate lipid profiles with clinicopathological characteristics. Additionally, a pair of tumor and adjacent normal tissue was profiled to identify cancer-associated changes in lipid profiles.;Sphingomyelin 34:1, phosphatidylcholine (PC) 32:0, and PC 34:1, and PC 36:2 were overexpressed in HER2-positive breast cancer compared to adjacent normal tissue (HER2 signature). Lipid MALDI-MS profiles were different between Ki-67-high and Ki-67-low tumors. The proliferation signature (Ki-67-high vs. Ki-67-low) and the HER2 signature (cancer vs. normal) did not significantly overlap with each other.;For the first time to our knowledge, this study describes lipid profiles correlated with various clinicopathological characteristics of HER2-positive breast cancer. Lipid profiling might be helpful for the molecular characterization of this disease.",
        "Doc_title":"Lipid profiles for HER2-positive breast cancer.",
        "Journal":"Anticancer research",
        "Do_id":"23749897",
        "Doc_ChemicalList":"Biomarkers, Tumor;Ki-67 Antigen;Lipids;Phosphatidylcholines;Sphingomyelins;ERBB2 protein, human;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Adult;Aged;Aged, 80 and over;Biomarkers, Tumor;Breast Neoplasms;Female;Humans;Ki-67 Antigen;Lipid Metabolism;Lipids;Middle Aged;Phosphatidylcholines;Receptor, ErbB-2;Retrospective Studies;Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization;Sphingomyelins",
        "Doc_meshqualifiers":"metabolism;metabolism;metabolism;analysis;metabolism;metabolism;metabolism",
        "_version_":1605824461069615104},
      {
        "Doc_abstract":"The study aim was to investigate the methods of breast cancer diagnosis and treatment for women at advanced ages.;We identified 134 patients â‰¥ 80 years old treated for breast cancer. Data included patient and tumor characteristics, treatment, and outcomes.;Of 134 women â‰¥ 80 years old, 146 breast cancers were diagnosed. Sixty-five (45%) were detected by mammography. Surgical therapy included partial mastectomy in 50% and mastectomy in 50%. Although 12 (9%) women had no axillary staging, 22 (16%) underwent axillary lymph node dissection for node-negative disease. Of 73 patients undergoing partial mastectomy, 34 (47%) received adjuvant radiation. Of 113 cancers with known estrogen receptor (ER) status, 83% were ER positive; 95% received endocrine therapy. Fourteen (10%) received adjuvant chemotherapy. Eleven (8%) were Her-2 neu-amplified; one patient received adjuvant trastuzumab. At follow-up, 87 (65%) patients were alive without evidence of disease, while 6 (4%) died of breast cancer.;Breast cancer in women â‰¥ 80 years is more likely to be early-stage with favorable tumor biology. While most women eligible for anti-estrogen therapy received it, adjuvant radiation, chemotherapy, and/or trastuzumab were utilized infrequently. Despite these variations, older women with breast cancer are unlikely to suffer breast cancer-related mortality.",
        "Doc_title":"Breast cancer in elderly women (â‰¥ 80 years): variation in standard of care?",
        "Journal":"Journal of surgical oncology",
        "Do_id":"21337547",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"Aged, 80 and over;Breast Neoplasms;Female;Humans;Mastectomy, Segmental;Neoplasm Staging;Randomized Controlled Trials as Topic;Treatment Outcome",
        "Doc_meshqualifiers":"epidemiology;pathology;therapy",
        "_version_":1605928748935282688},
      {
        "Doc_abstract":"Previous studies have shown that basal breast cancers, which may have an inherent \"BRCAness\" phenotype and sensitivity to inhibitors of poly (ADP-Ribose) polymerase (PARP), express elevated levels of PARP1. Our lab recently reported that HER2+ breast cancers also exhibit sensitivity to PARP inhibitors (PARPi) by attenuating the NF-ÎºB pathway. In this study, we assessed PARP1 and phospho-p65, a marker of activated NF-ÎºB levels in human breast cancer tissues. PARP1 and PARP2 copy number, mRNA, and protein expression was assessed by interrogating the PAM-50 defined breast cancer patient set from the TCGA using cBioPortal. PARP1 and phospho-p65 immunohistochemistry and correlation to clinical parameters was conducted using 307 primary breast cancer specimens (132 basal, 82 luminal, 93 HER2+) through univariate and multivariate analyses. In the PAM50 breast cancer data set, PARP1 and 2 expression was altered in 24/58 (41 %) HER2+, 32/81 (40 %) basal, and 75/324 (23 %) luminal A/B breast cancer patients. This correlated with a statistically significant increase in PARP1 protein levels in HER2+ and basal but not luminal breast cancers (p = 0.003, p = 0.027, p = 0.289, respectively). No change in PARP2 protein level was observed. Interestingly, using breast cancer specimens from 307 patients, HER2 positivity correlated with elevated PARP1 expression (p < 0.0001) and was three times more likely than HER2 negative breast cancers to exhibit high PARP1 levels. No significant differences were noted between race, ER status, or PR status for PARP1 expression. Additionally, we found a significant correlation between HER2 status and phospho-p65 expression (p < 0.0001). Lastly, a direct correlation between PARP1 and phospho-p65 (p < 0.0001) was noted. These results indicate a potential connection between HER2, PARP1, and phospho-p65. Furthermore, these data suggest that the PARPi sensitivity we previously observed in HER2+ breast cancer cells may be due to elevated PARP1 expression.",
        "Doc_title":"PARP1 and phospho-p65 protein expression is increased in human HER2-positive breast cancers.",
        "Journal":"Breast cancer research and treatment",
        "Do_id":"25833211",
        "Doc_ChemicalList":"RELA protein, human;Transcription Factor RelA;PARP1 protein, human;Poly (ADP-Ribose) Polymerase-1;Poly(ADP-ribose) Polymerases;ERBB2 protein, human;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Adult;Aged;Aged, 80 and over;Breast Neoplasms;Female;Humans;Middle Aged;Phosphorylation;Poly (ADP-Ribose) Polymerase-1;Poly(ADP-ribose) Polymerases;Receptor, ErbB-2;Signal Transduction;Transcription Factor RelA;Young Adult",
        "Doc_meshqualifiers":"genetics;metabolism;pathology;genetics;metabolism;metabolism;metabolism",
        "_version_":1605783823783559168},
      {
        "Doc_abstract":"Determination of Her-2/neu overexpression in breast cancer has previously been shown to be of prognostic significance. In this study, Her-2/neu expression in breast cancer was characterised by real-time PCR (RLT-PCR) based LightCycler-HER-2/neu DNA Quantification with immunohistochemistry (IHC) and fluorescence in situ hybridisation (FISH).;Fifteen specimens of invasive breast cancer - whole tissue sections as well as microdissected tumour cells - were subjected to RLT-PCR. Additionally, IHC and FISH were performed.;Her-2/neu overexpression was detected by FISH and by real-time PCR in the same tumours. In contrast, IHC revealed discordant results.;Determination of Her-2/neu amplification by real-time PCR is a sensitive and specific method with some advantages over FISH. This method is simple and reliable and has the potential of categorizing those tumours with borderline Her-2/neu overexpression as determined by IHC.",
        "Doc_title":"Her-2/neu expression in breast cancer--A comparison of different diagnostic methods.",
        "Journal":"Anticancer research",
        "Do_id":"16158923",
        "Doc_ChemicalList":"Receptor, ErbB-2",
        "Doc_meshdescriptors":"Breast Neoplasms;Carcinoma, Ductal, Breast;Carcinoma, Lobular;Gene Amplification;Gene Expression;Humans;Immunohistochemistry;In Situ Hybridization, Fluorescence;Polymerase Chain Reaction;Receptor, ErbB-2",
        "Doc_meshqualifiers":"genetics;metabolism;genetics;metabolism;genetics;metabolism;methods;biosynthesis;genetics",
        "_version_":1605766507745247232},
      {
        "Doc_abstract":"Trastuzumab (or Herceptin), as the first erbB2-targeted therapy, has been successfully used to treat breast cancer patients with erbB2-overexpressing tumors. However, resistances to trastuzumab frequently occur, and novel strategies/agents are urgently needed to abrogate the resistant phenotype. Our current study explores the potential of SNDX-275, a class I HDAC inhibitor, to overcome trastuzumab resistance and investigates the combinational effects of SNDX-275 and trastuzumab on both sensitive and resistant breast cancer cells. Cell proliferation assays showed that SNDX-275 significantly enhanced trastuzumab-induced growth inhibition in trastuzumab-sensitive, erbB2-overexpressing breast cancer cells. Importantly, SNDX-275 at its therapeutic range re-sensitized trastuzumab-resistant cells to trastuzumab-mediated growth inhibition. SNDX-275 in combination with trastuzumab resulted in a dramatic reduction of erbB3 and its phosphorylation (P-erbB3), and inhibition of Akt signaling. Apoptotic-ELISA and western blot analyses confirmed that the combinations of SNDX-275 and trastuzumab as compared to SNDX-275 alone significantly enhanced DNA fragmentation and induced more PARP cleavage and caspase-3 activation in both trastuzumab-sensitive and -resistant breast cancer cells. Furthermore, co-immunoprecipitation assays revealed that SNDX-275 mainly attenuated the interactions of erbB2 and erbB3 receptors, but had no significant effect on erbB2/IGF-1R or erbB3/IGF-1R associations in the trastuzumab-resistant breast cancer cells. These data indicated that SNDX-275 enhanced trastuzumab efficacy against erbB2-overexpressing breast cancer cells, and exhibited potential to overcome trastuzumab resistance via disrupting erbB2/erbB3 interactions and inactivating PI-3K/Akt signaling. SNDX-275 may be included in erbB2-targeted regimen as a novel strategy to treat breast cancer patients whose tumors overexpress erbB2.",
        "Doc_title":"HDAC inhibitor SNDX-275 enhances efficacy of trastuzumab in erbB2-overexpressing breast cancer cells and exhibits potential to overcome trastuzumab resistance.",
        "Journal":"Cancer letters",
        "Do_id":"21497990",
        "Doc_ChemicalList":"Antibodies, Monoclonal;Antibodies, Monoclonal, Humanized;Benzamides;Histone Deacetylase Inhibitors;Pyridines;entinostat;Receptor, ErbB-2;Receptor, ErbB-3;Proto-Oncogene Proteins c-akt;Trastuzumab",
        "Doc_meshdescriptors":"Antibodies, Monoclonal;Antibodies, Monoclonal, Humanized;Antineoplastic Combined Chemotherapy Protocols;Apoptosis;Benzamides;Blotting, Western;Breast Neoplasms;Cell Proliferation;Drug Resistance, Neoplasm;Drug Synergism;Female;Histone Deacetylase Inhibitors;Humans;Immunoprecipitation;Proto-Oncogene Proteins c-akt;Pyridines;Receptor, ErbB-2;Receptor, ErbB-3;Trastuzumab;Tumor Cells, Cultured",
        "Doc_meshqualifiers":"pharmacology;drug effects;pharmacology;drug therapy;drug effects;drug effects;pharmacology;pharmacology;metabolism;antagonists & inhibitors;metabolism",
        "_version_":1605756004078714880},
      {
        "Doc_abstract":"Metastatic spread of tumours is the major cause of death in patients with breast cancer. Despite the importance of the lymphatic system in tumour metastasis, little is known about the role of lymphangiogenesis in tumour growth and metastasis. This study was undertaken to evaluate the potential usefulness of plasma levels of lymphanagiogenesis factor, vascular endothelial cell growth factor-C (VEGF-C) as a prognostic factor in 122 patients with breast cancer. There was no significant difference between plasma levels of VEGF-C in patients with early (n =81), advanced (n =32) or inflammatory breast cancer (n =9) and 64 age matched healthy controls. We found no significant correlation between VEGF-C with age, tumour size, tumour grade, or disease-free and over-all survival. Plasma VEGF-C levels did not significantly differ in patients with positive oestrogen, progesterone, and Her-2 neu compared to those who were negative for these parameters. In conclusion our study has failed to show any prognostic value for plasma VEGF-C level in patients with breast cancer.",
        "Doc_title":"Vascular endothelial growth factor-C in patients with breast cancer.",
        "Journal":"In vivo (Athens, Greece)",
        "Do_id":"17591368",
        "Doc_ChemicalList":"Biomarkers, Tumor;Vascular Endothelial Growth Factor C",
        "Doc_meshdescriptors":"Adenocarcinoma;Adult;Aged;Biomarkers, Tumor;Breast Neoplasms;Disease-Free Survival;Female;Humans;Middle Aged;Vascular Endothelial Growth Factor C",
        "Doc_meshqualifiers":"blood;mortality;secondary;blood;blood;mortality;pathology;blood",
        "_version_":1605747065319587840},
      {
        "Doc_abstract":"Although ERBB2 amplification and overexpression is correlated with poor outcome in breast cancer, the molecular mechanisms underlying the aggressive nature of these tumors has not been fully elucidated. To investigate this further, we have used a transgenic mouse model of ErbB2-driven tumor progression (ErbB2(KI) model) that recapitulates clinically relevant events, including selective amplification of the core erbB2 amplicon. By comparing the transcriptional profiles of ErbB2(KI) mammary tumors and human ERBB2-positive breast cancers, we show that ErbB2(KI) tumors possess molecular features of the basal subtype of ERBB2-positive human breast cancer, including activation of canonical Î²-catenin signaling. Inhibition of Î²-catenin-dependent signaling in ErbB2(KI)-derived tumor cells using RNA interference impaired tumor initiation and metastasis. Furthermore, treatment of ErbB2(KI) or human ERBB2-overexpressing tumor cells with a selective Î²-catenin/CBP inhibitor significantly decreased proliferation and ErbB2 expression. Collectively, our data indicate that ERBB2-mediated breast cancer progression requires Î²-catenin signaling and can be therapeutically targeted by selective Î²-catenin/CBP inhibitors.",
        "Doc_title":"Î²-Catenin signaling is a critical event in ErbB2-mediated mammary tumor progression.",
        "Journal":"Cancer research",
        "Do_id":"23720052",
        "Doc_ChemicalList":"beta Catenin;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Animals;Breast Neoplasms;Cell Line, Tumor;Cell Proliferation;Disease Progression;Down-Regulation;Female;Gene Expression Regulation, Neoplastic;Humans;MCF-7 Cells;Mammary Neoplasms, Experimental;Mice;Receptor, ErbB-2;Signal Transduction;Transcription, Genetic;beta Catenin",
        "Doc_meshqualifiers":"enzymology;genetics;metabolism;pathology;enzymology;genetics;metabolism;pathology;genetics;metabolism;genetics;metabolism",
        "_version_":1605837215399673856},
      {
        "Doc_abstract":"Protein kinase C betaII (PKCÎ²II) represents a novel potential target for anticancer therapies in breast cancer. In order to identify patient subgroups which might benefit from PKC-targeting therapies, we investigated the expression of PKCÎ²II in human breast cancer cell lines and in a tissue microarray (TMA). We first screened breast cancer cell line representatives of breast cancer subtypes for PKCÎ²II expression at the mRNA and at the protein levels. We analyzed a TMA comprising of tumors from 438 patients with a median followup of 15.4 years for PKCÎ²II expression by immunohistochemistry along with other prognostic factors in breast cancer. Among a panel of human breast cancer cell lines, only MDA-MB-436, a triple negative basal cell line, showed overexpression for PKCÎ²II both at the mRNA and at the protein levels. In breast cancer patients, cytoplasmic expression of PKCÎ²II correlated positively with human epidermal growth factor receptor-2 (HER-2; P = 0.01) and Ki-67 (P = 0.016), while nuclear PKCÎ²II correlated positively with estrogen receptor (ER; P = 0.016). The positive correlation of CK5/6 with cytoplasmic PKCÎ²II (P = 0.033) lost statistical significance after adjusting for multiple comparisons (P = 0.198). Cytoplasmic PKCÎ²II did not correlate with cyclooxygenase (COX-2; P = 0.925) and vascular endothelial growth factor (P = 1). There was no significant association between PKCÎ²II staining and overall survival. Cytoplasmic PKCÎ²II correlates with HER-2 and Ki-67, while nuclear PKCÎ²II correlates with ER in breast cancer. Our study suggests the necessity for assessing the subcellular localization of PKCÎ²II in breast cancer subtypes when evaluating the possible effectiveness of PKCÎ²II-targeting agents.",
        "Doc_title":"Differential subcellular expression of protein kinase C betaII in breast cancer: correlation with breast cancer subtypes.",
        "Journal":"Breast cancer research and treatment",
        "Do_id":"20099025",
        "Doc_ChemicalList":"Biomarkers, Tumor;KRT5 protein, human;Keratin-5;Keratin-6;Ki-67 Antigen;RNA, Messenger;Receptors, Estrogen;VEGFA protein, human;Vascular Endothelial Growth Factor A;Cyclooxygenase 2;PTGS2 protein, human;ERBB2 protein, human;Receptor, ErbB-2;Protein Kinase C;Protein Kinase C beta",
        "Doc_meshdescriptors":"Biomarkers, Tumor;Breast Neoplasms;Cell Line, Tumor;Cell Nucleus;Cyclooxygenase 2;Cytoplasm;Female;Humans;Immunohistochemistry;Kaplan-Meier Estimate;Keratin-5;Keratin-6;Ki-67 Antigen;Prognosis;Protein Kinase C;Protein Kinase C beta;RNA, Messenger;Receptor, ErbB-2;Receptors, Estrogen;Time Factors;Tissue Array Analysis;Vascular Endothelial Growth Factor A",
        "Doc_meshqualifiers":"genetics;metabolism;enzymology;genetics;mortality;pathology;enzymology;metabolism;enzymology;metabolism;metabolism;metabolism;genetics;metabolism;metabolism;metabolism;metabolism;metabolism",
        "_version_":1605845229722664960},
      {
        "Doc_abstract":"Cyclooxygenase-2 (COX-2) is an inducible enzyme that converts arachidonic acid to prostaglandins. Overexpression of the COX-2 gene in mammary glands of transgenic mice was sufficient to induce tumorigenesis. We analyzed COX-2 expression in human breast cancers (and breast cancer cell lines) and adjacent ductal carcinoma in situ (DCIS) as well as its association with HER2/neu and clinicopathological variables. Archival primary breast carcinomas (n = 57), adjacent DCIS (n = 14) and DCIS alone (n = 2) were analyzed for COX-2 and HER2 expression by immunohistochemistry using specific monoclonal antibodies. An immunohistochemical scoring system was used. HER2 gene amplification had been analyzed previously by fluorescence in situ hybridization (n = 20). Histology of carcinomas included infiltrating ductal (n = 44), lobular (n = 2), and other (n = 7). Frozen breast cancers and adjacent normal tissue pairs (n = 9) were analyzed for COX-2 mRNA by reverse transcription-PCR. COX-2 and HER2 expression were also analyzed in human breast cancer cell lines (MCF-7, MCF-7/HER2, SK-BR-3, and MDA-MB-231) by immunoblotting. Cytoplasmic COX-2 expression was detected at an intermediate or high level in epithelial cells in 18 of 42 (43%) invasive breast cancers and in 10 of 16 (63%) cases of DCIS. Normal-appearing breast epithelia adjacent to cancer expressed COX-2 in 81% of cases and was generally focal and of similar or decreased intensity relative to adjacent neoplastic epithelia. COX-2 mRNA was detected in all samples analyzed by reverse transcription-PCR and was increased in eight of nine breast cancers relative to paired normal tissue. In archival tumors, no significant correlation was found between COX-2 and HER2 expression/amplification and clinicopathological variables. COX-2 expression was induced in MCF-7 cells stably transfected with HER2, in contrast to parental MCF-7 cells, and was detected in MDA-MB-231, but not SK-BR-3 cells. COX-2 is frequently overexpressed in invasive breast cancers and in adjacent DCIS and, thus, may be an early event in mammary tumorigenesis. Forced HER2 expression in MCF-7 cells was shown to up-regulate COX-2, although no association was found in human tumors. Our results suggest that nonsteroidal anti-inflammatory drugs and selective COX-2 inhibitors may be useful in the chemoprevention and therapy of human breast cancer.",
        "Doc_title":"Cyclooxygenase-2 expression in human breast cancers and adjacent ductal carcinoma in situ.",
        "Journal":"Cancer research",
        "Do_id":"11912139",
        "Doc_ChemicalList":"Isoenzymes;Membrane Proteins;RNA, Messenger;Receptors, Estrogen;Receptors, Progesterone;Cyclooxygenase 2;PTGS2 protein, human;Prostaglandin-Endoperoxide Synthases;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Adult;Aged;Breast Neoplasms;Carcinoma in Situ;Carcinoma, Ductal, Breast;Cyclooxygenase 2;Female;Gene Amplification;Humans;Isoenzymes;Membrane Proteins;Middle Aged;Neoplasm Staging;Prostaglandin-Endoperoxide Synthases;RNA, Messenger;Receptor, ErbB-2;Receptors, Estrogen;Receptors, Progesterone;Reverse Transcriptase Polymerase Chain Reaction;Tumor Cells, Cultured",
        "Doc_meshqualifiers":"enzymology;pathology;enzymology;pathology;enzymology;pathology;biosynthesis;genetics;biosynthesis;genetics;biosynthesis;genetics;biosynthesis;genetics;biosynthesis;biosynthesis",
        "_version_":1605883385868189696},
      {
        "Doc_abstract":"Antibody therapy with trastuzumab has greatly impacted breast cancer treatment. Combination treatment with trastuzumab is regarded currently as a first-line therapy for metastatic breast cancers that overexpress Her-2. It has become routine practice to examine the status of Her-2 expression in primary tumors. The impact of this therapy might be as great as that of endocrine therapy from a historical point of view. A number of new approaches using trastuzumab for seeking individualized treatment are being tested in current clinical trials. We reviewed recent advances in trastuzumab treatment and discuss the future of antibody therapy for breast cancer.",
        "Doc_title":"Current status of antibody therapy for breast cancer.",
        "Journal":"Breast cancer (Tokyo, Japan)",
        "Do_id":"14718785",
        "Doc_ChemicalList":"Antibodies, Monoclonal;Antibodies, Monoclonal, Humanized;Antineoplastic Agents;Receptor, ErbB-2;Trastuzumab",
        "Doc_meshdescriptors":"Antibodies, Monoclonal;Antibodies, Monoclonal, Humanized;Antineoplastic Agents;Breast Neoplasms;Clinical Trials as Topic;Female;Genes, erbB-2;Humans;Neoplasm Metastasis;Receptor, ErbB-2;Trastuzumab",
        "Doc_meshqualifiers":"pharmacology;therapeutic use;pharmacology;therapeutic use;drug therapy;pathology;genetics;drug effects;genetics",
        "_version_":1605747529489580033},
      {
        "Doc_abstract":"We analyzed DNA from 105 primary breast cancers to assess amplification of the ERBB2 gene and loss of heterozygosity (LOH) on chromosome 17 using 4 polymorphic markers, and investigated the relationships of these genetic alterations to clinicopathological characteristics including DNA ploidy. Amplification of the ERBB2 gene was observed in 28% of the tumors. ERBB2 was amplified in tumors of all clinical stages and amplification was significantly linked to lymph node metastasis. LOH at D17S5 was observed in 28 of 57 informative tumors, while 17 of 62 informative tumors showed allelic loss at TP53. Among the 37 tumors informative for both loci, 32% showed LOH at these loci and 49% retained both alleles, indicating that there was a significant relationship between LOH at D17S5 and at TP53. We also examined LOH at the D17S74 and NME1 loci on chromosome 17q. LOH at D17S74 and NME1 was observed in 20% and 22% of the informative tumors, respectively, but there was no significant association between LOH at these loci. Of the 4 loci tested, LOH at TP53, D17S74, and NME1 was associated with clinical stage. Lymph node metastasis was correlated with LOH at NME1. Moreover, allelic loss was more frequent in aneuploid tumors than in diploid tumors. These results suggest that certain combinations of genetic alterations on chromosome 17 may cooperate in the development and/or progression of breast cancer. Furthermore, it seems likely that analysis of these alterations in breast cancer patients may provide useful prognostic information.",
        "Doc_title":"Genetic alterations on chromosome 17 in human breast cancer: relationships to clinical features and DNA ploidy.",
        "Journal":"Breast cancer research and treatment",
        "Do_id":"7912561",
        "Doc_ChemicalList":"DNA Probes;DNA, Neoplasm;Proto-Oncogene Proteins;Receptor, Epidermal Growth Factor;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Alleles;Breast Neoplasms;Chromosome Aberrations;Chromosome Deletion;Chromosomes, Human, Pair 17;DNA Probes;DNA, Neoplasm;Female;Gene Amplification;Genetic Variation;Humans;Ploidies;Prognosis;Proto-Oncogene Proteins;Receptor, Epidermal Growth Factor;Receptor, ErbB-2",
        "Doc_meshqualifiers":"genetics;genetics;genetics;genetics",
        "_version_":1605831461378719744},
      {
        "Doc_abstract":"Previous studies provide an ambiguous picture of creatine kinase (CK) expression and activities in malignancy. The aim of this study was to investigate the role of serum CK level in breast cancer patients.;823 female patients diagnosed with breast cancer were consecutively recruited as cases, and 823 age-match patients with benign breast disease were selected as controls. Serum CK was analyzed by commercially available standardized methods.;Serum CK level was significantly associated with breast cancer (Pâ€Š=â€Š0.005) and subtypes of breast cancer, including breast cancer with diameter>2 cm (Pâ€Š=â€Š0.031) and stage IIIbreast cancer (Pâ€Š=â€Š0.025). The mean serum CK level in patients with>2 cm tumor was significantly lower than that inâ‰¤2 cm (Pâ€Š=â€Š0.0475), and the mean serum CK level of stage III breast cancer patients was significantly lower than that of stage I and II breast cancer patients (Pâ€Š=â€Š0.0246). Furthermore, a significant difference (Pâ€Š=â€Š0.004) was observed between serum CK level and ERBB2+breast cancer not other molecular subtypes.;Serum CK levels in cases was significantly lower compared with controls. Notably, our results indicated for the first time that there was a negative correlation between serum CK levels and breast cancer stage. Serum CK level, which may reflect the status of host immunity, may be an important factor in determining breast cancer development and progression.",
        "Doc_title":"Low serum creatine kinase levels in breast cancer patients: a case-control study.",
        "Journal":"PloS one",
        "Do_id":"23614022",
        "Doc_ChemicalList":"Creatine Kinase",
        "Doc_meshdescriptors":"Adult;Aged;Aged, 80 and over;Breast Neoplasms;Case-Control Studies;Creatine Kinase;Female;Humans;Lymphatic Metastasis;Middle Aged;Multivariate Analysis;Neoplasm Staging;Risk Assessment;Tumor Burden;Young Adult",
        "Doc_meshqualifiers":"blood;enzymology;pathology;blood",
        "_version_":1605873955228352512},
      {
        "Doc_abstract":"The objective of this study was the detection of circulating tumor cells (CTCs) in metastatic breast cancer patients.;Since only small numbers of circulating tumor cells (CTCs) are found in peripheral blood, at first we performed immunomagnetic separation as a concentration method suitable for selecting circulating tumor cells in peripheral blood. This was followed by analysis of isolated cells with the aid of laser scanning cytometry (LSC). Twenty eight patients with metastatic breast cancer were enrolled in the study and the control group consisted of 19 clinically healthy women. Six milliliters of peripheral blood was drawn for the analyses, but only in two patients the blood has been drawn twice. Blood samples were taken when no chemotherapy was administered, but hormonal therapy has been allowed.;The positivity for CTCs was found in 20 (50.0 %) patients with metastatic breast cancer patients, while in 6 (31.6 %) healthy controls false positive circulating epithelial-like cells were detected. Because we did not use CD45 staining, we could not distinguish these circulating epithelial-like cells from CTCs. In a majority of metastatic breast cancer patients we found a mixed population of HER-2 gene expressing CTCs. We found that HER2+ CTCs in high numbers are CK19 + CTCs, while almost all HER2-CTCs are CK19- CTCs.;The described method was found promising for estimating HER2 status on CTCs from peripheral blood in metastatic breast cancer patients.",
        "Doc_title":"Detection of circulating tumor cells in metastatic breast cancer patients.",
        "Journal":"Endocrine regulations",
        "Do_id":"21793623",
        "Doc_ChemicalList":"Biomarkers, Tumor;Keratin-19;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Adult;Aged;Aged, 80 and over;Biomarkers, Tumor;Breast Neoplasms;Carcinoma, Ductal, Breast;Carcinoma, Lobular;Female;Gene Expression Profiling;Genes, erbB-2;Humans;Keratin-19;Laser Scanning Cytometry;Middle Aged;Neoplastic Cells, Circulating;Receptor, ErbB-2;Statistics, Nonparametric",
        "Doc_meshqualifiers":"blood;blood;enzymology;genetics;pathology;blood;enzymology;genetics;pathology;blood;enzymology;genetics;pathology;methods;genetics;pathology;biosynthesis;genetics",
        "_version_":1605880960864223232},
      {
        "Doc_abstract":"To investigate the expressions of human epidermal growth factor receptor 2 (Her-2) and vascular endothelial growth factor (VEGF) in primary and recurrent metastatic breast cancers and explore their relationship.;The expressions of Her-2 and VEGF in 60 primary and recurrent metastatic breast cancers were detected using immunohistochemical methods. Their relationship was analyzed.;The positive rates of Her-2 and VEGF in the recurrent metastatic breast cancer were 40.00% and 53.33%, respectively, which were significantly higher than that in the primary breast cancer (18.33% and 31.67%) (P < 0.05). The total diversify rates of Her-2 and VEGF were 28.33% and 35.00%, respectively. Her-2 and VEGF expressions were significantly correlated between the primary and the recurrent metastatic breast cancers( P < 0.05).;Her-2 and VEGF may play synergic roles in the occurrence and development of breast cancer. Over-expressions of Her-2 and VEGF predict poor prognosis.",
        "Doc_title":"[Expressions of human epidermal growth factor receptor 2 and vascular endothelial growth factor in primary or recurrent metastatic breast cancers].",
        "Journal":"Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae",
        "Do_id":"20868598",
        "Doc_ChemicalList":"VEGFA protein, human;Vascular Endothelial Growth Factor A;ERBB2 protein, human;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Adult;Aged;Breast Neoplasms;Female;Humans;Middle Aged;Neoplasm Metastasis;Neoplasm Recurrence, Local;Prognosis;Receptor, ErbB-2;Vascular Endothelial Growth Factor A",
        "Doc_meshqualifiers":"metabolism;pathology;metabolism;metabolism;metabolism",
        "_version_":1605804961351860224},
      {
        "Doc_abstract":"To study the molecular mechanism of inhibition of angiogenesis in HER-2/neu-overexpressing breast cancer by genistein, HER-2/neu negative expression breast cancer MCF-7 cells were transfected with HER-2/neu to establish HER-2/neu-overexpressing MCF-7 cells (named MCF-7/HER-2). Expression of vascular endothelial growth factor (VEGF), urokinase-type plasminogen activator (uPA), matrix metalloproteinase-2,9 (MMP-2,9) in MCF-7, MCF-7/HER-2 as well as genistein-treated MCF-7/HER-2 were measured by immunocytochemistry and Western blot. We found that the expression of VEGF, MMP-2,9 and uPA in MCF-7/HER-2 cells were highter than that in MCF-7 cells, those angiogenesis related factors expression in MCF-7/HER-2 cells significantly decreased after treatment with genistein. Genistein could inhibit expression of angiogenesis-related factors VEGF, MMP-2,9 and uPA in HER-2/neu-overexpressing breast cancer cells, and this may be part of molecular mechanism of its anti-angiogenesis in HER-2/neu-overexpressing breast cancer.",
        "Doc_title":"[Effect of genistein on expression of angiogenesis related factors in HER-2/neu-overexpressing breast cancer cells].",
        "Journal":"Shi yan sheng wu xue bao",
        "Do_id":"15323430",
        "Doc_ChemicalList":"Anticarcinogenic Agents;Vascular Endothelial Growth Factor A;Genistein;Receptor, ErbB-2;Urokinase-Type Plasminogen Activator;Matrix Metalloproteinase 2;Matrix Metalloproteinase 9",
        "Doc_meshdescriptors":"Anticarcinogenic Agents;Blotting, Western;Breast Neoplasms;Cell Line, Tumor;Female;Gene Expression;Gene Expression Regulation, Neoplastic;Genistein;Humans;Immunohistochemistry;Matrix Metalloproteinase 2;Matrix Metalloproteinase 9;Receptor, ErbB-2;Urokinase-Type Plasminogen Activator;Vascular Endothelial Growth Factor A",
        "Doc_meshqualifiers":"pharmacology;therapeutic use;drug therapy;metabolism;drug effects;drug effects;genetics;pharmacology;therapeutic use;metabolism;metabolism;metabolism;metabolism;metabolism",
        "_version_":1605836978291474432},
      {
        "Doc_abstract":"Prognostic factors are in interest for breast cancer as the second cause of malignancy deaths. Some have predictive values as human epidermal growth factor receptor-2 (HER-2) and estrogen receptor (ER). To access the incidence of HER2 and its relations to other factors, like age, pathology, ER, progesterone receptor (PR), and P53, 2000 pathologic blocks from 2750 total samples have been selected from 2011 to 2013 in Cancer Institute of Tehran. Incidence of HER2, ER, PR, and P53 was; 58.5%, 33.4%, 43.3%, and 65.4%, respectively. Invasive ductal carcinoma was the most pathologic type (82.2%) and 60%-70% positive HER2 and P53 had negative ER and PR (poor prognosis). The peak age of incidence of breast cancer was perimenopausal age group (46-55 years). Our cases had more positive HER2 and P53 and less positive PR and ER compared to other studies. High perimenopausal incidence as another finding assures the importance of breast cancer screening in these age groups. ",
        "Doc_title":"Prevalence of HER-2 and Hormone Receptors and P53 Mutations in the Pathologic Specimens of Breast Cancer Patients.",
        "Journal":"International journal of breast cancer",
        "Do_id":"25478233",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605902803621904384},
      {
        "Doc_abstract":"Synuclein gamma (SNCG), previously identified as a breast cancer-specific gene (BCSG1), is highly expressed in breast carcinomas but not in normal epithelium. SNCG regulates many pathways in growth and progression of breast cancer. To determine if SNCG is a biomarker for clinical prognosis of breast cancer, we generated a panel of murine monoclonal antibodies (mAbs) against human SNCG and correlated SNCG protein expression in 358 clinical breast cancer specimens with clinical outcome. A panel of 14 mAbs was characterized by ELISA, immunoprecipitation (IP), Western blot, immunocytochemistry and immunohistochemistry. SNCG protein expression was determined in 438 clinical breast specimens by immunohistochemical analysis using mAb 5C5. Expression of SNCG was strongly correlated with the stage, lymph node involvement, metastasis, tumor size and Her-2 status, but its expression was not associated with ER and PR expression status. While 71.4% of advanced breast cancers were positive for SNCG expression, only 26.8% of Stage I/II breast cancers were positive for SNCG expression and 5.2% of benign hyperplasia expressed SNCG. SNCG protein was not detectable in normal tissue adjacent to breast cancer. After a median follow-up of 64 months, patients with an SNCG-positive tumor had a significantly shorter disease-free survival and overall survival and a high probability of death compared no expression of SNCG. Multivariate analysis demonstrated that SNCG was a strong independent prognostic variable. SNCG is a new unfavorable prognostic marker for breast cancer progression and a potential target for breast cancer treatment.",
        "Doc_title":"Neuronal protein synuclein gamma predicts poor clinical outcome in breast cancer.",
        "Journal":"International journal of cancer",
        "Do_id":"17534899",
        "Doc_ChemicalList":"Antibodies, Monoclonal;Biomarkers, Tumor;Neoplasm Proteins;SNCG protein, human;gamma-Synuclein",
        "Doc_meshdescriptors":"Amino Acid Sequence;Animals;Antibodies, Monoclonal;Biomarkers, Tumor;Blotting, Western;Breast Neoplasms;Disease-Free Survival;Enzyme-Linked Immunosorbent Assay;Female;Gene Expression;Humans;Immunohistochemistry;Immunoprecipitation;Kaplan-Meier Estimate;Lymphatic Metastasis;Mice;Middle Aged;Molecular Sequence Data;Neoplasm Proteins;Neoplasm Staging;Prognosis;gamma-Synuclein",
        "Doc_meshqualifiers":"analysis;metabolism;mortality;pathology;genetics;metabolism;genetics;metabolism",
        "_version_":1605799115594137600},
      {
        "Doc_abstract":"We recently identified CGA (coding for the alpha subunit of glycoprotein hormones) as a new estrogen receptor alpha (ER alpha)-responsive gene in human breast tumors. Here, we assessed the relationship between CGA status (as determined by real-time quantitative RT-PCR) and the response to tamoxifen therapy in a well-defined cohort of 125 ER alpha-positive postmenopausal breast cancer patients treated with primary surgery followed by adjuvant tamoxifen alone. CGA overexpression, observed in 37.6% of patients, was associated with good relapse-free survival (P=0.037; univariate analysis). CGA status, combined with ERBB2 status (a marker of poor outcome), was an independent predictor of the response to tamoxifen (P=0.020; multivariate analysis). CGA status, especially when combined with ERBB2 status, may thus provide useful predictive information on tamoxifen responsiveness in breast cancer.",
        "Doc_title":"The CGA gene as new predictor of the response to endocrine therapy in ER alpha-positive postmenopausal breast cancer patients.",
        "Journal":"Oncogene",
        "Do_id":"11687975",
        "Doc_ChemicalList":"Antineoplastic Agents, Hormonal;Biomarkers, Tumor;Estrogen Antagonists;Estrogen Receptor alpha;Glycoprotein Hormones, alpha Subunit;RNA, Neoplasm;Receptors, Estrogen;Tamoxifen;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Aged;Antineoplastic Agents, Hormonal;Biomarkers, Tumor;Breast Neoplasms;Chemotherapy, Adjuvant;Cohort Studies;Disease-Free Survival;Estrogen Antagonists;Estrogen Receptor alpha;Female;Genes;Glycoprotein Hormones, alpha Subunit;Humans;Middle Aged;Postmenopause;RNA, Neoplasm;Receptor, ErbB-2;Receptors, Estrogen;Reverse Transcriptase Polymerase Chain Reaction;Tamoxifen;Treatment Outcome",
        "Doc_meshqualifiers":"therapeutic use;genetics;metabolism;drug therapy;metabolism;surgery;therapeutic use;genetics;metabolism;biosynthesis;analysis;therapeutic use",
        "_version_":1605818632618639363},
      {
        "Doc_abstract":"VEGFR and HER2 are both important transmembrane proteins associated with several types of cancer. Overexpression of these 2 proteins had long been thought to contribute to cancer progression and poor outcomes, thus, therapies targeting HER-2 and VEGFA signaling pathways have been applied in recent years. Herceptin is a HER-2 targeted antibody that being widely used for the management of HER-2 positive breast cancer, which demonstrate significant benefits in both the metastatic and adjuvant settings. However, acquired resistance develops in most treated patients despite treatment in as early as 10 months. Identification of subpopulations best suited for and most likely to respond to Herceptin is of utmost importance. We analyzed the signaling pathways of HER-2 and found that HER-2 shares a very similar downstream network with VEGFA, while LGR5 lies in the upstream of VEGFA and could promotes its expression through CTNNB1. This discovery suggests that the LGR5 directed VEGFA overexpression may activate downstream signals of HER-2 despite Herceptin treatment. Here, we hypothesized that in LGR5 overexpressing breast cancer cases, activation of VEGFA-VRGFR bypass may account for the resistance to HER-2 directed therapies. Concurrent inhibition of VEGFR might enhance Herceptin sensitivity and moreover reverse the resistant phenotype in HER-2 positive breast cancer. Thus, we proposed alternate regimens to increase the efficacy of Herceptin-based therapy. Nevertheless, wet lab experiments and clinical trials are still required.",
        "Doc_title":"LGR5 is a biomarker for stratification of HER-2 positive breast cancer patients and personalized treatment.",
        "Journal":"Medical hypotheses",
        "Do_id":"23830593",
        "Doc_ChemicalList":"Antibodies, Monoclonal, Humanized;Biomarkers, Tumor;LGR5 protein, human;Receptors, G-Protein-Coupled;VEGFA protein, human;Vascular Endothelial Growth Factor A;ERBB2 protein, human;Receptor, ErbB-2;Trastuzumab",
        "Doc_meshdescriptors":"Antibodies, Monoclonal, Humanized;Biomarkers, Tumor;Breast Neoplasms;Female;Humans;Models, Biological;Precision Medicine;Receptor, ErbB-2;Receptors, G-Protein-Coupled;Signal Transduction;Trastuzumab;Vascular Endothelial Growth Factor A",
        "Doc_meshqualifiers":"pharmacology;drug therapy;metabolism;methods;metabolism;metabolism;drug effects;metabolism",
        "_version_":1605906370562883584},
      {
        "Doc_abstract":"HOX transcription factors play an important role in determining body patterning and cell fate during embryogenesis. Accumulating evidence has shown that these genes act as positive and/or negative modulators in many types of cancer, including breast cancer, in a tissue-specific manner. We have previously reported that HOXB5 is aberrantly overexpressed in breast cancer tissues and cell lines. Here, we investigated the biological roles and clinical relevance of HOXB5 in breast cancer. Immunohistochemical analysis of HOXB5 on tissue microarray (TMA) including 34 normal and 67 breast cancer specimens revealed that HOXB5 was highly expressed in cancer tissues, particularly from estrogen receptor (ER)-positive breast cancer patients. An online survival analysis confirmed the correlation between HOXB5 expression and poor distant metastasis-free survival in ER-positive, but not in ER-negative, breast cancer. In vitro studies indicated that HOXB5 silencing in ER-positive cells significantly decreased cell proliferation and anchorage-independent cell growth. In contrast, overexpression of HOXB5 displayed EMT characteristics with a greater invasive ability, higher cell proliferation and colony formation in soft agar. HOXB5 knockdown or overexpression led to changes in the expression levels of RET, ERBB2, and EGFR, but not of ESR1. In conclusion, we suggest that HOXB5 acts as a positive modulator most likely by promoting cell proliferative response and invasiveness in ER-positive breast cancer. These results would help predict prognosis of breast cancer and identify a new valuable therapeutic target. ",
        "Doc_title":"HOXB5 Promotes the Proliferation and Invasion of Breast Cancer Cells.",
        "Journal":"International journal of biological sciences",
        "Do_id":"25999793",
        "Doc_ChemicalList":"HOXB5 protein, human;Homeodomain Proteins",
        "Doc_meshdescriptors":"Breast Neoplasms;Cell Line, Tumor;Cell Proliferation;Female;Gene Expression Regulation, Neoplastic;Gene Knockdown Techniques;Homeodomain Proteins;Humans;Immunohistochemistry;Neoplasm Invasiveness",
        "Doc_meshqualifiers":"genetics;metabolism;pathology;genetics;genetics;metabolism;physiology;genetics",
        "_version_":1605832293394415616},
      {
        "Doc_abstract":"Abnormal activation of human epidermal growth factor receptor 2 (HER2; ErbB-2) in breast tumors results in increased metastasis and angiogenesis, as well as reduced survival. Here, we show that angiopoietin-2 (Ang-2) expression correlates with HER2 activity in human breast cancer cell lines. Inhibiting HER2 activity with anti-HER2 monoclonal antibody trastuzumab (Herceptin) or HER2 short interfering RNA in tumor cells down-regulates Ang-2 expression. Consistent with the important roles of AKT and mitogen-activated protein kinase in the HER2 signaling pathway, AKT and ERK mitogen-activated protein kinase (MAPK) kinase activity is necessary for Ang-2 up-regulation by HER2. Moreover, overexpression of HER2 protein up-regulates Ang-2 expression. Heregulin-beta1-induced Ang-2 up-regulation is abrogated when AKT and ERK kinase activity are blocked. Immunohistochemical analysis of HER2 and Ang-2 proteins in human breast carcinomas shows that Ang-2 expression in breast cancer correlates with HER2 expression. These studies provide evidence that the Ang-2 gene is regulated by HER2 activity in breast cancer, and propose an additional mechanism for HER2 contributing to tumor angiogenesis and metastasis.",
        "Doc_title":"Human epidermal growth factor receptor 2 regulates angiopoietin-2 expression in breast cancer via AKT and mitogen-activated protein kinase pathways.",
        "Journal":"Cancer research",
        "Do_id":"17308086",
        "Doc_ChemicalList":"Angiopoietin-2;RNA, Messenger;Phosphatidylinositol 3-Kinases;Receptor, ErbB-2;Proto-Oncogene Proteins c-akt;Mitogen-Activated Protein Kinase Kinases",
        "Doc_meshdescriptors":"Angiopoietin-2;Breast Neoplasms;Cell Line, Tumor;Down-Regulation;Humans;Immunohistochemistry;MAP Kinase Signaling System;Mitogen-Activated Protein Kinase Kinases;Phosphatidylinositol 3-Kinases;Proto-Oncogene Proteins c-akt;RNA, Messenger;Receptor, ErbB-2;Transfection;Up-Regulation",
        "Doc_meshqualifiers":"biosynthesis;genetics;enzymology;genetics;metabolism;metabolism;metabolism;metabolism;biosynthesis;genetics;biosynthesis;genetics;metabolism",
        "_version_":1605785352658747392},
      {
        "Doc_abstract":"Triple-negative breast cancer (TNBC) is defined as a type of breast carcinoma that is negative for expression of oestrogene and progesterone hormone receptors (ER, PR) and HER2. This form of breast cancer is marked by its aggressiveness, low survival rate and lack of specific therapies. Recently, important molecular characteristics of TNBC have been highlighted and led to the identification of some biomarkers that could be used in diagnosis, as therapeutic targets or to assess the prognosis. In this review, we summarize recent progress in TNBC research focusing on the genetic and epigenetic alterations of TNBC and the potential use of these biomarkers in the targeted therapy for better management of TNBC. ",
        "Doc_title":"Recent Progress in Triple Negative Breast Cancer Research.",
        "Journal":"Asian Pacific journal of cancer prevention : APJCP",
        "Do_id":"27221827",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605906348913983488},
      {
        "Doc_abstract":"The HER family of the receptor tyrosine kinases epidermal growth factor receptor (EGFR), HER2, HER3 and HER4 are involved in the pathogenesis of many human malignancies. Although there is extensive literature on the expression of single HER-2 and EGFR receptors in breast cancer, little is known concerning the simultaneous expression at the mRNA level of these four receptors in human breast tissue and their influence in downstream signaling pathways that control cell cycle and proliferation.;The mRNA expression pattern of the four HER-receptors has been investigated and correlated with the expression of the cyclin-dependent kinase (CDK) inhibitors p21(Waf1) and p27(Kip1) in 67 breast cancer specimens.;A positive correlation between HER-3 and HER-4 mRNA levels and a negative correlation between HER-2 and HER-3 was found. Compared to normal breast tissue, all four receptors were overexpressed in breast tumors and the strongest overexpression was found for HER-3 (p = 0.001). HER-4 expression was inversely related to histopathological grading (HPG), suggesting that elevated HER-4 mRNA expressions could be a biological marker of a more differentiated phenotype. The expression of p21(Waf1) protein was higher in HER-2-negative tumors, compared to HER-2-positive breast carcinomas. Compared to normal breast tissue, p21delta, the 19 kDa degraded form of p21 protein, was markedly expressed in breast cancer (p < 0.001). Conversely, p27(Kip1) was positively associated with HER-2 receptor and inversely associated with HER-3.;The HER family members are overexpressed in breast cancer. Complex patterns of HER family expression were observed and the effect on cell cycle regulation was dependent on that pattern.",
        "Doc_title":"Expression of the HER family mRNA in breast cancer tissue and association with cell cycle inhibitors p21(waf1) and p27(kip1).",
        "Journal":"Anticancer research",
        "Do_id":"17465220",
        "Doc_ChemicalList":"CDKN1A protein, human;CDKN1B protein, human;Cyclin-Dependent Kinase Inhibitor p21;Intracellular Signaling Peptides and Proteins;RNA, Messenger;Cyclin-Dependent Kinase Inhibitor p27;Receptor Protein-Tyrosine Kinases",
        "Doc_meshdescriptors":"Adult;Aged;Aged, 80 and over;Breast Neoplasms;Cyclin-Dependent Kinase Inhibitor p21;Cyclin-Dependent Kinase Inhibitor p27;Female;Humans;Intracellular Signaling Peptides and Proteins;MAP Kinase Signaling System;Middle Aged;RNA, Messenger;Receptor Protein-Tyrosine Kinases",
        "Doc_meshqualifiers":"enzymology;genetics;metabolism;pathology;biosynthesis;metabolism;biosynthesis;genetics;biosynthesis;genetics",
        "_version_":1605807293163634688},
      {
        "Doc_abstract":"Breast cancer is one of the major causes of deaths in women. During the incidence of breast cancer, the HER-2 is amplified and over expressed. This transmembrane receptor is involved in the signal transduction pathway. The present article evaluates 14 naturally available breast cancer drugs, in silico and the ADMET studies were conducted. The HER-2, a validate breast cancer target was taken for the present study. The protein was prepared for docking on the Discovery Studio 2.5. About 14 ligand molecules were used to dock with HER-2 after they were prepared for docking. The ADMET assessment was also done. The dock results showed that the ligand 4'-epidoxorubicin to be the potential drug with the highest dock score of 49.386. Among the 14 naturally available breast cancer drugs, our results evaluated that 4'-epidoxorubicin as the best drug for breast cancer. Further, the ADMET studies give an idea about the drug molecules.",
        "Doc_title":"In silico evaluation for the potential naturally available drugs for breast cancer.",
        "Journal":"Journal of receptor and signal transduction research",
        "Do_id":"24329533",
        "Doc_ChemicalList":"Antineoplastic Agents;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Antineoplastic Agents;Breast Neoplasms;Computer Simulation;Humans;Models, Chemical;Models, Molecular;Molecular Targeted Therapy;Protein Binding;Receptor, ErbB-2",
        "Doc_meshqualifiers":"chemistry;pharmacokinetics;therapeutic use;drug therapy;metabolism;methods;chemistry;metabolism",
        "_version_":1605850695471202304},
      {
        "Doc_abstract":"KrÃ¼ppel-like factor 15 (KLF15) is a transcription factor that is involved in various biological processes, including cellular proliferation, differentiation and death. In addition, KLF15 has recently been implicated in the development of several human malignancies, including breast cancer. In vitro breast cancer studies have pointed at a putative role in the regulation of cell proliferation. As yet, however, KLF15 expression analyses in primary human breast cancers have not been reported. Here, we set out to investigate the clinical and biological significance of KLF15 expression in human breast cancers.;KLF15 expression was evaluated by immunohistochemistry in 54 primary invasive ductal breast carcinomas, and its status was correlated with various clinicopathological parameters. We also assessed KLF15 expression in vitro in 4 breast cancer-derived cell lines using Western blotting, and examined the effects of exogenous KLF15 expression on cell cycle progression using flow cytometry. Concomitant (changes in) p21, p27 and TOPO2A expression levels were examined using real-time RT-PCR and immunocytochemistry, respectively.;In ~90% of the primary breast carcinoma tissues tested, KLF15 was found to be expressed and localized in either the cytoplasm, the nucleus or both. Predominant nuclear immunoreactivity was found to be associated with clinicopathological factors predicting a better clinical outcome (i.e., ER positive, HER2 negative, low grade, low Ki-67 expression). The breast cancer-derived cell lines tested showed a low KLF15 expression with a predominant cytoplasmic localization. Subsequent exogenous KLF15 over-expression resulted in a predominant nuclear localization and a concomitant decreased cellular proliferation and an arrest at the G0/G1 phase of the cell cycle. In addition, we found that nuclear KLF15 expression results in up-regulation of p21, a pivotal suppressor of the G1 to S phase transition of the cell cycle.;Our results indicate that nuclear KLF15 expression suppresses breast cancer cell proliferation at least partially through p21 up-regulation and subsequent cell cycle arrest. This is a first study addressing the role of KLF15 in breast cancer development.",
        "Doc_title":"KLF15 in breast cancer: a novel tumor suppressor?",
        "Journal":"Cellular oncology (Dordrecht)",
        "Do_id":"25869021",
        "Doc_ChemicalList":"KLF15 protein, human;Kruppel-Like Transcription Factors;Nuclear Proteins",
        "Doc_meshdescriptors":"Adult;Aged;Aged, 80 and over;Blotting, Western;Breast Neoplasms;Carcinoma, Ductal, Breast;Cell Cycle;Cell Line, Tumor;Female;Flow Cytometry;Genes, Tumor Suppressor;Humans;Immunohistochemistry;Kruppel-Like Transcription Factors;Middle Aged;Nuclear Proteins;Real-Time Polymerase Chain Reaction;Transfection",
        "Doc_meshqualifiers":"genetics;pathology;genetics;pathology;genetics;biosynthesis;genetics;biosynthesis;genetics",
        "_version_":1605891646526849024},
      {
        "Doc_abstract":"Breast carcinoma is moderately sensitive to multiple antitumor agents. Cytotoxic combination regimens developed in the 1970s were shown to produce higher response rates and longer durations of response and survival than single-agent therapy. These regimens became the standard of care for the management of metastatic, hormone-refractory breast carcinoma, and more recently, for primary breast carcinoma. Randomized trials also have demonstrated that anthracycline-containing combinations were more effective than combinations without anthracyclines. The development of several new cytotoxic agents and novel antitumor strategies prompted this review.;The author conducted a computerized literature search of MEDLINE and CANCERLIT and also reviewed the abstracts of major oncology meetings (ASCO, American Association for Cancer Research, ESMO, and San Antonio Breast Cancer Symposium) over the past 10 years.;Effective new cytotoxic drugs include the taxanes (paclitaxel and docetaxel), vinorelbine, gemcitabine, and capecitabine. The identification of specific molecular abnormalities (HER-2/neu or epidermal growth factor receptor [EGFR] overexpression) led to the development of targeted therapeutic intervention (monoclonal antibodies and tyrosine kinase inhibitors). Trastuzumab, a monoclonal antibody against the HER-2/neu oncoprotein, produced objective regression in 15-20% of patients with HER-2/neu-overexpressing breast carcinoma and improved the efficacy of paclitaxel. Other productive directions of therapeutic research include inhibition of intracellular signaling, interference with tumor angiogenesis, cell cycle regulation, and the development of vaccines.;Expanded understanding of the biology of breast carcinoma led to the development of rational therapeutic interventions, many of which are currently under active clinical development.",
        "Doc_title":"Developments in chemotherapy of breast cancer.",
        "Journal":"Cancer",
        "Do_id":"10898354",
        "Doc_ChemicalList":"Receptor, ErbB-2",
        "Doc_meshdescriptors":"Breast Neoplasms;Female;Humans;Receptor, ErbB-2",
        "Doc_meshqualifiers":"drug therapy;analysis;antagonists & inhibitors",
        "_version_":1605756913421647872},
      {
        "Doc_abstract":"Breast cancers can be classified into those which express the estrogen (ER) and progesterone (PR) receptors, those with HER-2 amplification, and those without expression of ER, PR, or amplified HER-2 (referred to as triple-negative or basal-like breast cancer). Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) activates apoptosis upon binding to its receptors in many tumor types and the ligand and agonist antibodies are currently being studied in patients in clinical phases I and II trials. Cell line studies suggest that many breast cancer cell lines are very resistant to TRAIL-induced apoptosis. However, recent data suggest that a subset of triple-negative/basal-like breast cancer cells is sensitive to TRAIL as a single agent. In addition, many studies have demonstrated that resistance to TRAIL-mediated apoptosis in breast cancer cells can be overcome by combinations of TRAIL with chemotherapy, radiation, and various targeted agents. This chapter will discuss the current understanding of the mechanisms, which control TRAIL-mediated apoptosis in breast cancer cells. The preclinical data supporting the use of TRAIL ligands and agonistic antibodies alone and in combination in breast cancer will also be discussed.",
        "Doc_title":"The TRAIL to targeted therapy of breast cancer.",
        "Journal":"Advances in cancer research",
        "Do_id":"19854352",
        "Doc_ChemicalList":"Antineoplastic Agents;Receptors, TNF-Related Apoptosis-Inducing Ligand;TNF-Related Apoptosis-Inducing Ligand;TNFSF10 protein, human",
        "Doc_meshdescriptors":"Animals;Antineoplastic Agents;Apoptosis;Breast Neoplasms;Drug Delivery Systems;Drug Resistance, Neoplasm;Female;Humans;Receptors, TNF-Related Apoptosis-Inducing Ligand;TNF-Related Apoptosis-Inducing Ligand",
        "Doc_meshqualifiers":"therapeutic use;drug effects;drug therapy;pathology;methods;physiology;agonists;physiology;agonists;physiology;therapeutic use",
        "_version_":1605799266389852160},
      {
        "Doc_abstract":"Triple-negative breast cancer (TNBC) has been recently recognized as an important subgroup of breast cancer with a distinct outcome and therapeutic approach compared with other breast cancer subgroups. Because TNBC is defined by the absence of a target (either hormone receptors or HER-2), conventional cytotoxic therapy is still the mainstay of treatment. This report focuses on the current state and recent advances in managing TNBC.",
        "Doc_title":"Recent advances in managing triple-negative breast cancers.",
        "Journal":"F1000 medicine reports",
        "Do_id":"20948704",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605830880811548672},
      {
        "Doc_abstract":"In oestrogen receptor-positive (ER+) breast cancer, HER-2/neu and the progesterone receptor (PR) are inversely associated. This explains a lower response to anti-oestrogens if ER+ breast cancers are HER-2/neu positive. One randomized study however, showed that premenopausal women with an ER+ breast cancer respond to anti-oestrogens independent of HER-2/neu. We therefore hypothesized an age-related association between HER-2/neu and PR in ER+ breast cancers. Receptors for ER, PR and HER-2/neu were analysed by immunohistochemistry (IHC). A uni- and multivariate analyses was carried out to assess this relationship in 1104 women with an ER+ breast cancer. We observed an inverse association between HER-2/neu and PR only after age 45. There were 173 women of age<or=45 and 931 of age>45 years. In multivariate analysis, only tumour grade (p=0.005) but not PR status was associated with HER-2/neu in women age<or=45 years. However, in age>45 years group, both PR status (p=0.001) and tumour grade (p=0.001) were independently associated with HER-2/neu. In ER+ breast cancers from women age>45, PR was positive in 76.9% if HER-2/neu negative but in 53.4% if HER-2/neu positive (p<0.001) and the median quantitative PR levels are 150 and 75 respectively in HER-2/neu negative and HER-2/neu positive tumours (p=0.002). This age effect of HER-2/neu on the PR status was not seen in women age<or=45 years and the median quantitative PR levels are 200 and 220 respectively in HER-2/neu negative and HER-2/neu positive tumours (p=0.518). The study confirms an age-related inverse relationship between HER-2/neu and PR only in women age>45 years but not in women age<or=45 years.",
        "Doc_title":"Association between HER-2/neu and the progesterone receptor in oestrogen-dependent breast cancer is age-related.",
        "Journal":"Breast cancer research and treatment",
        "Do_id":"15868434",
        "Doc_ChemicalList":"Biomarkers, Tumor;Receptors, Estrogen;Receptors, Progesterone;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Adult;Aged;Aging;Biomarkers, Tumor;Breast Neoplasms;Female;Humans;Immunohistochemistry;Middle Aged;Multivariate Analysis;Postmenopause;Predictive Value of Tests;Premenopause;Prognosis;Receptor, ErbB-2;Receptors, Estrogen;Receptors, Progesterone",
        "Doc_meshqualifiers":"physiology;analysis;genetics;physiopathology;biosynthesis;genetics;analysis;analysis",
        "_version_":1605909528951390208},
      {
        "Doc_abstract":"Human epidermal growth factor receptor 2 (HER2) is one of the oncogenes closely associated with the development and prognosis of breast carcinoma. Down-regulation of HER2 mRNA by antisense oligodeoxynucleotide (ASO) HER2 has been suggested to be a feasible treatment for patients with breast carcinoma.;The antitumor effects of ASO HA6722 were investigated in vitro and in vivo.;In this study, SK-BR-3, a HER2-overexpressing breast carcinoma cell line, was used as the model for in vitro experiments. Inhibitory effects of the ASO HA6722 were detected by methyl-thiazoldiphenyl tetrazolium (MTT) assay. Meanwhile, HER2 mRNA levels were monitored by reverse transcription polymerase chain reaction (RT-PCR). The in vivo antitumor effects were evaluated in nude mice xenograft model.;Our results showed that HA6722 alone could inhibit the growth of SK-BR-3 cells in a dose-dependent manner with the IC(50) value of 41.8â€‰Â±â€‰8.1 nM. In addition, the antitumor effect of docetaxel (TXT) could be sensitized by low dose of HA6722 both in vitro and in vivo, suggesting that ASO HA6722 could inhibit the growth of breast cancer cells and enhance the cytotoxic effects of TXT.;The combination treatment of TXT and HA6722 could be a more effective approach for breast cancer treatment. The future study should focus on the antitumor effect in other models.",
        "Doc_title":"Antisense oligodeoxynucleotide targeting HER2 mRNA sensitized docetaxel in breast cancer treatment.",
        "Journal":"Pharmaceutical biology",
        "Do_id":"22014264",
        "Doc_ChemicalList":"Antineoplastic Agents;Oligodeoxyribonucleotides, Antisense;RNA, Messenger;Taxoids;docetaxel;ERBB2 protein, human;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Animals;Antineoplastic Agents;Breast Neoplasms;Cell Line, Tumor;Cell Proliferation;Dose-Response Relationship, Drug;Down-Regulation;Female;Genetic Therapy;Humans;Inhibitory Concentration 50;Mice;Mice, Inbred BALB C;Mice, Nude;Oligodeoxyribonucleotides, Antisense;RNA, Messenger;Receptor, ErbB-2;Reverse Transcriptase Polymerase Chain Reaction;Taxoids;Time Factors;Transfection;Tumor Burden;Xenograft Model Antitumor Assays",
        "Doc_meshqualifiers":"pharmacology;drug therapy;genetics;metabolism;pathology;therapy;drug effects;methods;metabolism;metabolism;genetics;metabolism;pharmacology;drug effects",
        "_version_":1605792225153777664},
      {
        "Doc_abstract":"One of the most recent advances in the management of Her-2/neu positive breast cancer is the validation of a targeted therapy from bench to the clinic, particularly towards the adjuvant setting. The recommended dose of trastuzumab (Herceptin), a humanized monoclonal antibody targeting the HER-2 antigen, has been determined in phase I studies. In the metastatic patients two randomised trials have demonstrated its efficacy when associated to taxanes. In less than 10 years, trastuzumab became the standard of care in the adjuvant treatment of HER-2/neu positive breast cancer. In this setting, two combinations regimen with chemotherapy (concomitant or sequential) have been recently published. The concomitant schedule has been used in three studies (North American Group, BCIRG, FinHer), whereas in the Hera trial trastuzumab was started after the end of neo-adjuvant and adjuvant chemotherapy. In this article, the advantages and uncertainties on efficacy and toxicities of the trastuzumab administration modalities, associated or not to chemotherapy and radiation therapy, are discussed.",
        "Doc_title":"[HER-2/neu positive breast cancer: how to prescribe adjuvant trastuzumab (Herceptin)?].",
        "Journal":"Bulletin du cancer",
        "Do_id":"17074658",
        "Doc_ChemicalList":"Anthracyclines;Antibodies, Monoclonal;Antibodies, Monoclonal, Humanized;Antineoplastic Agents;Receptor, ErbB-2;Trastuzumab",
        "Doc_meshdescriptors":"Anthracyclines;Antibodies, Monoclonal;Antibodies, Monoclonal, Humanized;Antineoplastic Agents;Antineoplastic Combined Chemotherapy Protocols;Breast Neoplasms;Female;France;Heart;Humans;Receptor, ErbB-2;Trastuzumab",
        "Doc_meshqualifiers":"adverse effects;administration & dosage;adverse effects;administration & dosage;adverse effects;administration & dosage;adverse effects;drug therapy;metabolism;drug effects;immunology;metabolism",
        "_version_":1605746366225580033},
      {
        "Doc_abstract":"Epidermal growth factor receptor (EGFR) and ErbB2 are currently recognized as validated target molecules in cancer treatment strategies. MP-412 (AV-412) is a potent dual inhibitor of EGFR and ErbB2 tyrosine kinases, including the mutant EGFR(L858R,T790M), which is clinically resistant to the EGFR-specific kinase inhibitors erlotinib and gefitinib. In an enzyme assay, MP-412 inhibited the EGFR variants and ErbB2 in the nanomolar range with over 100-fold selectivity compared with other kinases, apart from abl and flt-1, which were both moderately sensitive to the compound. In cells, MP-412 inhibited autophosphorylation of EGFR and ErbB2 with IC(50) of 43 and 282 nM, respectively. It also inhibited epidermal growth factor (EGF)-dependent cell proliferation with an IC(50) of 100 nM. Moreover, MP-412 abrogated EGFR signaling in the gefitinib-resistant H1975 cell line, which harbors a double mutation of L858R and T790M in EGFR. In animal studies using cancer xenograft models, MP-412 (30 mg/kg) demonstrated complete inhibition of tumor growth of the A431 and BT-474 cell lines, which overexpress EGFR and ErbB2, respectively. MP-412 suppressed autophosphorylation of EGFR and ErbB2 at the dose corresponding to its antitumor efficacy. When various dosing schedules were applied, MP-412 showed significant effects with daily and every-other-day schedules, but not with a once-weekly schedule, suggesting that frequent dosing is preferable for this compound. Furthermore, MP-412 showed a significant antitumor effect on the ErbB2-overexpressing breast cancer KPL-4 cell line, which is resistant to gefitinib. These studies indicate that MP-412 has potential as a therapeutic agent for the treatment of cancers expressing EGFR and ErbB2, especially those resistant to the first generation of small-molecule inhibitors.",
        "Doc_title":"Pharmacological characterization of MP-412 (AV-412), a dual epidermal growth factor receptor and ErbB2 tyrosine kinase inhibitor.",
        "Journal":"Cancer science",
        "Do_id":"17888033",
        "Doc_ChemicalList":"Antineoplastic Agents;MP 412;Piperazines;Protein Kinase Inhibitors;Quinazolines;Recombinant Proteins;Receptor, Epidermal Growth Factor;Receptor, ErbB-2;gefitinib",
        "Doc_meshdescriptors":"Antineoplastic Agents;Carcinoma, Squamous Cell;Cell Line, Tumor;Cell Membrane;Esophageal Neoplasms;Humans;Piperazines;Protein Kinase Inhibitors;Quinazolines;Receptor, Epidermal Growth Factor;Receptor, ErbB-2;Recombinant Proteins",
        "Doc_meshqualifiers":"pharmacology;enzymology;pharmacology;pharmacology;pharmacology;antagonists & inhibitors;antagonists & inhibitors;antagonists & inhibitors",
        "_version_":1605827174557810688},
      {
        "Doc_abstract":"Breast cancer is the leading cause of death affecting women worldwide, according to mortality estimation and incidence. In Chile, breast cancer ranks third among cancer mortality rates. Two-hundred and eighty-three breast cancer patients registered at the Gustavo Fricke Hospital of ViÃ±a del Mar, Chile, were studied to assess the influence of several factors on the recurrence and survival of breast cancer patients. Patients selected had 5-year post-surgery recurrences of breast cancer and had an average of 58.5 years of age. The variables considered in these patients were the quadrants involved, stage of the tumor, type of recurrence, type of exams, type of surgery, the grade of tumor in relation to Broder's classification and pathology of tumor. The results indicated that the superior external right and left quadrants, Stage IIA, loco-regional recurrences, lumpectomies with axillar lymph node removal and after 5 years, Grade II were prevalent in this population. Among the pathologies analyzed, the ductal carcinomas were the most commonly found and were positive for PCNA, beta-catenin, cytokeratin 18 and ErbB2 protein expression. A median follow-up of 60 months of survival was achieved in 95% of patients. However, those cases with a recurrence of breast cancer had only 40% survival. The risk of mortality was significantly greater when recurrence was present (P<0.0001). The global probability of survival of the patients reached 72% after 5 years. It can be concluded that early detection of breast cancer allows for control of the disease and avoids remissions, or at least extends survival.",
        "Doc_title":"Patterns of recurrence and survival in breast cancer.",
        "Journal":"Oncology reports",
        "Do_id":"18695902",
        "Doc_ChemicalList":"Proliferating Cell Nuclear Antigen;ERBB2 protein, human;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Adult;Aged;Aged, 80 and over;Breast Neoplasms;Chile;Female;Fluorescent Antibody Technique;Humans;Middle Aged;Neoplasm Recurrence, Local;Proliferating Cell Nuclear Antigen;Receptor, ErbB-2;Retrospective Studies;Survival Rate",
        "Doc_meshqualifiers":"mortality;pathology;surgery;mortality;pathology;surgery;metabolism;metabolism",
        "_version_":1605830512159490048},
      {
        "Doc_abstract":"To investigate whether alterations of the HER2 gene occur more frequently in histologically unfavourable subtypes of invasive breast cancer.;The study was composed of nine invasive apocrine, six lipid-rich, 12 glycogen-rich, 11 micropapillary and 33 pleomorphic lobular breast carcinomas. Lymph node involvement was represented in all subgroups. HER2 status was confirmed in all cases by using immunohistochemistry (CB11, Herceptest) and fluorescent in-situ hybridization (FISH) analysis (Vysis).;Micropapillary and apocrine carcinomas showed the highest rate of protein overexpression (72% and 66%) and gene amplification (45% and 44%). Protein overexpression was common in poorly differentiated pleomorphic lobular carcinomas (56%); however, this subgroup failed to show an increased number of gene copies by FISH (31%). The incidence of HER2 overexpression (33% and 50%, respectively) and gene amplification (25% and 33%, respectively) among glycogen-rich and lipid-rich carcinomas was not higher than that observed in breast cancer generally.;Our data suggest that preferential involvement of the HER2 gene in micropapillary and apocrine breast carcinomas may contribute to their aggressive behaviour.",
        "Doc_title":"Preferential HER-2/neu overexpression and/or amplification in aggressive histological subtypes of invasive breast cancer.",
        "Journal":"Histopathology",
        "Do_id":"15049898",
        "Doc_ChemicalList":"Receptor, ErbB-2",
        "Doc_meshdescriptors":"Aged;Breast Neoplasms;Carcinoma;Female;Gene Amplification;Humans;Immunohistochemistry;Middle Aged;Neoplasm Invasiveness;Receptor, ErbB-2",
        "Doc_meshqualifiers":"metabolism;pathology;metabolism;pathology;biosynthesis;genetics",
        "_version_":1605883096509448192},
      {
        "Doc_abstract":"FANCD2 is involved in DNA damage repair and maintenance of chromosome stability. The purpose of this study was to investigate the expression of FANCD2 in sporadic breast cancer tissues and its association with clinicopathological features. A total of 162 Chinese women with invasive breast carcinoma who had no family history in first-degree relatives and 12 normal breast tissues were examined. The expression of FANCD2 was detected by immunohistochemical staining based on a tissue microarray technique. SAS system was used to analyze the data. Twenty-one out of the 162 invasive breast cancers (13%) were negative for FANCD2. The mean percentage of FANCD2 positive cells was significantly lower in breast cancers than in controls (P<0.05). FANCD2 expression was significantly inversely associated with histological grade and TNM stage (P<0.05), but not with axillary lymph node status or other conventional prognostic markers such as ER, PR, Her-2 and PCNA (P>0.05). It was suggested that FANCD2 may play a critical role in breast carcinogenesis. It may become a valuable and independent marker for identifying women with sporadic breast cancer and evaluating the prognosis.",
        "Doc_title":"Expression of FANCD2 in sporadic breast cancer and clinicopathological analysis.",
        "Journal":"Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban",
        "Do_id":"20556575",
        "Doc_ChemicalList":"Biomarkers, Tumor;FANCD2 protein, human;Fanconi Anemia Complementation Group D2 Protein",
        "Doc_meshdescriptors":"Adult;Aged;Aged, 80 and over;Biomarkers, Tumor;Breast Neoplasms;Carcinoma, Ductal, Breast;Fanconi Anemia Complementation Group D2 Protein;Female;Humans;Middle Aged;Neoplasm Invasiveness",
        "Doc_meshqualifiers":"metabolism;metabolism;pathology;metabolism;pathology;metabolism",
        "_version_":1605742007941070848},
      {
        "Doc_abstract":"BACKGROUND Over-expression of the human epidermal growth factor receptor 2 (Her2) protooncogene is associated with poor prognosis among female patients with breast cancer. A polymorphism in the HER2 gene (I655V) has been associated with an elevated risk of breast cancer in some ethnic groups. METHODS Subjects from a community-based study of 5318 Ashkenazim from the Washington, DC area were selected for analysis of the I655V HER2 germline polymorphism. We estimated age-specific breast cancer risk from HER2 I655V based on the family history data, using the female first-degree relatives of the study participants and a novel extension of the kin cohort method. RESULTS The estimated cumulative risk of breast cancer to age 70 was approximately 30% higher among HER2 I655V carriers than noncarriers (RR = 1.33; 95% confidence interval [CI] = 1.03-1.83). The effect of the allele seems stronger at younger ages (among women younger than 50 years, RR = 2.11; CI = 1.39-3.28) and especially among younger women with a family history of breast cancer (RR = 8.9; CI = 1.9-19.7). Increased risk of breast cancer associated with the I655V allele was also observed among BRCA1/2 mutation carriers, although these results are based on small numbers. CONCLUSION These analyses suggest that the HER2 valine allele might be associated with increased risk of breast cancer, especially in young women and in women with a family history of the disease.",
        "Doc_title":"The HER2 I655V polymorphism and breast cancer risk in Ashkenazim.",
        "Journal":"Epidemiology (Cambridge, Mass.)",
        "Do_id":"14569185",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"Adult;Aged;Breast Neoplasms;Cohort Studies;District of Columbia;Female;Genes, erbB-2;Genetic Predisposition to Disease;Humans;Jews;Male;Middle Aged;Polymorphism, Genetic;Risk Factors",
        "Doc_meshqualifiers":"ethnology;genetics;genetics",
        "_version_":1605831911040614400},
      {
        "Doc_abstract":"Overexpression of HER-2/neu proto-oncogene is found in many human cancers including 20-30% of breast cancer and is a predictor of poor prognosis. To target breast cancer cells that overexpress HER-2/neu mRNA, we previously described a novel strategy that combines the principle of antisense (AS) and translational inhibitory activity conferred by an iron-responsive element (IRE) (AS-IRE). Here, we showed that three potential AS-IREs, i.e. AS-IRE1, 4, and 5, derived from HER-2/neu antisense sequence could bind endogenous iron regulatory protein (IRP) and, when placed in 5' untranslated region (5'UTR) of a reporter gene, the gene expression could be translationally repressed by recombinant IRP in vitro. Using AS-IRE4 as our model, we demonstrated that it is regulated by iron, and importantly, such regulation is impaired in HER-2/neu-overexpressing breast cancer cells. Furthermore, we showed that AS-IRE4 could preferentially direct the expression of a reporter gene in HER-2/neu-overexpressing breast cancer cells. Interestingly, when AS-IRE4 was placed in 5'UTR of Bax gene, a pro-apoptotic protein in the Bcl-2 protein family, we observed a preferential cell killing in breast cancer cells that overexpress HER-2/neu. Taken together, our results suggest that AS-IRE behaves as a functional IRE and it may direct therapeutic gene expression to preferentially target HER-2/neu-overexpressing breast cancer cells.",
        "Doc_title":"Targeting HER-2/neu-overexpressing breast cancer cells by an antisense iron responsive element-directed gene expression.",
        "Journal":"Cancer letters",
        "Do_id":"11689290",
        "Doc_ChemicalList":"Antisense Elements (Genetics);BAX protein, human;DNA Primers;Iron-Regulatory Proteins;Iron-Sulfur Proteins;Proto-Oncogene Proteins;Proto-Oncogene Proteins c-bcl-2;RNA, Messenger;RNA, Neoplasm;RNA-Binding Proteins;Recombinant Proteins;bcl-2-Associated X Protein;Iron;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Antisense Elements (Genetics);Breast Neoplasms;Consensus Sequence;DNA Primers;Female;Gene Expression;Gene Targeting;Humans;In Vitro Techniques;Iron;Iron-Regulatory Proteins;Iron-Sulfur Proteins;Protein Biosynthesis;Proto-Oncogene Proteins;Proto-Oncogene Proteins c-bcl-2;RNA, Messenger;RNA, Neoplasm;RNA-Binding Proteins;Receptor, ErbB-2;Recombinant Proteins;Transfection;Tumor Cells, Cultured;bcl-2-Associated X Protein",
        "Doc_meshqualifiers":"genetics;genetics;metabolism;chemistry;metabolism;genetics;genetics;genetics;genetics;genetics;metabolism;isolation & purification;metabolism",
        "_version_":1605841869931020288},
      {
        "Doc_abstract":"Breast cancer accounts for approximately 30% of all new cancer cases each year, with an annual incidence of approximately 200,000. Additionally, almost 25% of breast cancers are noted to overexpress Her2, which is an epidermal growth factor receptor. Overexpression of Her2 has been associated with a more aggressive phenotype with decreased survival. Trastuzumab, a recombinant monoclonal antibody against the Her2 receptor, is the only FDA-approved targeted agent for treatment of Her2-overexpressing breast cancer. However, despite the great success achieved with trastuzumab, many women will either not respond or eventually progress despite trastuzumab treatment. As a result, significant efforts have been applied to finding other therapies besides trastuzumab for the treatment of Her2-positive breast cancer. Work has been directed at trying to elucidate the exact mechanism of resistance to trastuzumab and identifying ways to overcome them, at increasing the efficacy of trastuzumab by combining it with other therapeutic agents and at investigating other novel agents.",
        "Doc_title":"Her2-positive breast cancer: herceptin and beyond.",
        "Journal":"European journal of cancer (Oxford, England : 1990)",
        "Do_id":"19022660",
        "Doc_ChemicalList":"Antibodies, Monoclonal;Antibodies, Monoclonal, Humanized;Antineoplastic Agents;Biomarkers, Tumor;Receptor, ErbB-2;Trastuzumab",
        "Doc_meshdescriptors":"Antibodies, Monoclonal;Antibodies, Monoclonal, Humanized;Antineoplastic Agents;Biomarkers, Tumor;Breast Neoplasms;Drug Resistance, Neoplasm;Female;Genes, erbB-2;Humans;Receptor, ErbB-2;Trastuzumab;Treatment Outcome",
        "Doc_meshqualifiers":"therapeutic use;therapeutic use;metabolism;drug therapy;genetics;metabolism;antagonists & inhibitors;metabolism",
        "_version_":1605783713256308736},
      {
        "Doc_abstract":"Accurate assessment of HER-2 status is essential for identifying patients who will benefit from HER-2 targeted therapy. The aim of the present study was to show results on the concordance between local and central laboratory testing results in HER-2 positive breast cancer patients. In cases with discordant findings, the immunohistochemical (IHC) and/or in situ hybridization (FISH/SISH) analysis was performed in central laboratories. A total of 104 out of 143 (72.72%) breast carcinoma cases were HER-2 positive (score 3+), while nearly 14% of tumors (20/43) showed weak (score 2+) and 12% (19/143) negative IHC staining (score 0 and 1+). After repeated IHC and ISH, 88% (126/143) were classified as HER-2 positive and 12% (17/143) as HER-2 negative cases. The results obtained are in agreement with many studies that confirmed similar discordance in HER-2 testing by IHC and/or FISH between local and central laboratory. Thus, our findings as well as those from other studies support the importance of regular quality assessment of the staining procedures performed and consistency of interpretation of HER-2 test results.",
        "Doc_title":"INTERLABORATORY CONCORDANCE IN HER-2 POSITIVE BREAST CANCER.",
        "Journal":"Acta clinica Croatica",
        "Do_id":"27017723",
        "Doc_ChemicalList":"ERBB2 protein, human;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Adult;Breast Neoplasms;Carcinoma, Intraductal, Noninfiltrating;Clinical Laboratory Services;Female;Gene Expression Regulation, Neoplastic;Humans;Immunohistochemistry;In Situ Hybridization, Fluorescence;Middle Aged;Receptor, ErbB-2",
        "Doc_meshqualifiers":"diagnosis;genetics;metabolism;diagnosis;genetics;metabolism;standards;methods;metabolism",
        "_version_":1605880665720487936},
      {
        "Doc_abstract":"HER-2 over-expression is implicated in the pathogenesis of breast cancer and represents a key marker and determinant of patient outcome. Trastuzumab/Herceptin (TZ) is a recombinant humanised monoclonal antibody which targets HER-2. Introduction into clinical practice has significantly improved the natural history of HER-2 over-expressing tumors and has altered the standard of care for these women. This article reviews the established and emerging roles of TZ in the management of breast cancer (BC).;Literature review facilitated by Medline and PubMed databases.;The clinical utility of TZ was first established in the management of HER-2 over-expressing metastatic breast cancer (MBC), with improvements recognised in both the quality and quantity of life. Prospective randomized controlled trials have consistently demonstrated the efficacy of TZ for early breast cancer (EBC) in the adjuvant setting with significant improvements in disease free and overall survival. Emerging roles for TZ include neo-adjuvant therapy and the treatment of progressive disease. TZ is well tolerated and safe, however, associated cardiac dysfunction remains a significant clinical concern.;HER-2 status is critically important in the management algorithm for BC and should be determined in all cases. Quality assurance of laboratory testing is of paramount importance. TZ has an established role in the management of HER-2 positive MBC and EBC in conjunction with conventional chemotherapy. Appropriate patient selection and monitoring for cardiac dysfunction are required.",
        "Doc_title":"Herceptin and breast cancer: an overview for surgeons.",
        "Journal":"Surgical oncology",
        "Do_id":"19097883",
        "Doc_ChemicalList":"Antibodies, Monoclonal;Antibodies, Monoclonal, Humanized;Antineoplastic Agents;ERBB2 protein, human;Receptor, ErbB-2;Trastuzumab",
        "Doc_meshdescriptors":"Algorithms;Antibodies, Monoclonal;Antibodies, Monoclonal, Humanized;Antineoplastic Agents;Breast Neoplasms;Chemotherapy, Adjuvant;Female;Humans;Neoplasm Recurrence, Local;Prognosis;Receptor, ErbB-2;Risk Factors;Trastuzumab;Treatment Outcome",
        "Doc_meshqualifiers":"pharmacology;therapeutic use;pharmacology;therapeutic use;drug therapy;metabolism;pathology;prevention & control;biosynthesis;drug effects",
        "_version_":1605807480875515904},
      {
        "Doc_abstract":"Breast cancer is the second cause for brain metastases. Their incidence is rising, partly due to the therapeutic improvements which alter the natural history of breast cancer. Predictive factors for brain metastases have been identified: HER2 oncogene overexpression, lack of expression of hormone receptors, young age and triple negative status. Brain metastases prognosis remains poor with a median survival shorter than 1 year, except for solitary lesions treated by surgery or radiosurgery. We have analysed two series of data from Institut Curie (Paris and Saint-Cloud). In women younger than 65 years, with HER2 negative breast carcinoma, median survival was 7.1 months. In women older than 65 years, median survival was 4 months.",
        "Doc_title":"[Brain metastases in breast cancer. Epidemiology and natural history. The Institut Curie experience].",
        "Journal":"Bulletin du cancer",
        "Do_id":"21540139",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"Adult;Age Factors;Aged;Brain Neoplasms;Breast Neoplasms;Cancer Care Facilities;Female;France;Humans;Incidence;Middle Aged;Neoplasm Metastasis;Prognosis;Retrospective Studies",
        "Doc_meshqualifiers":"epidemiology;mortality;secondary;epidemiology;pathology;statistics & numerical data;epidemiology;physiopathology",
        "_version_":1605796792445698048},
      {
        "Doc_abstract":"Breast cancer is characterized by hormone dependency, and endocrine therapy is a key treatment in breast cancer. Recently, targeted therapies such as Trastuzumab treatment for HER2-positive breast cancer has been important. Triple-negative (TN) breast cancer is characterized by lack of expression of estrogen receptor (ER) and progesterone receptor (PgR), and the absence of HER2 protein overexpression, and so there is no targeted therapy for this subtype. In this study, we examined the biological and prognostic characteristics in TN breast cancer.;Between January 1998 and September 2006, 1,552 patients with primary breast cancer were investigated retrospectively in this study and ER, PgR and HER2 status were evaluated in all cases. Furthermore, p53 overexpression and Ki67 values were examined immunohistochemically.;Patient distribution according to ER, PgR or HER2 status was as follows: ER and PgR positive: 57.9%, and ER and PgR negative: 25.1%. With regards to the HER2 status, HER2 positive was 23.3%, and triple negative (TN) was 14.0%. TN breast cancer has a high proliferation rate, high nuclear grade and frequent p53 overexpression. Patients with TN tumors had a significantly poorer disease-free survival (DFS) than those with non-TN tumors. After recurrence the overall survival (OS) rate in TN cases was significantly lower than that of the non-TN cases. Multivariate analysis revealed that TN was a significant factor for DFS and OS after recurrence.;TN breast cancer is a rare subtype with a high proliferation rate and a high nuclear grade, p53 overexpression, and lower DFS/OS. To improve the prognosis of TN breast cancer, a new effective strategy needs to be developed.",
        "Doc_title":"Is triple negative a prognostic factor in breast cancer?",
        "Journal":"Breast cancer (Tokyo, Japan)",
        "Do_id":"18369692",
        "Doc_ChemicalList":"Antineoplastic Agents;Biomarkers, Tumor;Receptors, Estrogen;Receptors, Progesterone;TP53 protein, human;Tumor Suppressor Protein p53;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Adult;Aged;Aged, 80 and over;Antineoplastic Agents;Biomarkers, Tumor;Breast Neoplasms;Cell Proliferation;Female;Humans;Immunoenzyme Techniques;Middle Aged;Neoplasm Staging;Phenotype;Prognosis;Receptor, ErbB-2;Receptors, Estrogen;Receptors, Progesterone;Retrospective Studies;Survival Rate;Treatment Outcome;Tumor Suppressor Protein p53",
        "Doc_meshqualifiers":"therapeutic use;metabolism;diagnosis;drug therapy;metabolism;metabolism;metabolism;metabolism;metabolism",
        "_version_":1605746448631070720},
      {
        "Doc_abstract":"Breast cancer is not a homogeneous disease, but several different and unique subtypes defined by gene expression analysis. Incidence and mortality rates vary by almost 3-fold between Alaska (highest) and the Southwestern tribes (lowest). We hypothesized that these differences may be due to, in part, varying levels of biologic tumor aggressiveness.;A biorepository of the North Central Cancer Treatment Group with 95 cases of American Indian and Alaska Native (AIAN) women with adenocarcinoma of the breast surgically treated from 1990 to 2000 was tested for several biomarkers. Comparison distributions of biomarker values across state of residence using t tests for continuous (p53, MIB-1, cyclin D) and ordinally scaled markers [EGF receptor (EGFR), BCL-2, Her2] and Ï‡(2) tests of significance for binary markers [estrogen receptor (ER), progesterone receptor (PR)] were done.;Significant regional differences in some biomarker expression levels were seen. No increase was observed in \"triple-negative\" breast cancer or Her2 overexpression in these cases.;Despite a 3-fold difference in breast cancer mortality in Alaska Native versus Southwestern American Indians, standard biomarkers such as ER, PR, and Her2 neu expression did not explain the disparity.;There is a need for research to understand the biologic basis of breast cancer disparities in AIAN women. Potential for a prospective trial will be explored with tribes.",
        "Doc_title":"Regional differences in breast cancer biomarkers in american Indian and Alaska native women.",
        "Journal":"Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology",
        "Do_id":"24609850",
        "Doc_ChemicalList":"Biomarkers, Tumor",
        "Doc_meshdescriptors":"Adenocarcinoma;Alaska;Arizona;Biomarkers, Tumor;Breast Neoplasms;Female;Humans;Indians, North American;Middle Aged",
        "Doc_meshqualifiers":"ethnology;genetics;metabolism;pathology;analysis;metabolism;ethnology;genetics;metabolism;pathology",
        "_version_":1605909746024448000},
      {
        "Doc_abstract":"HER2 has been thought to play a critical role in both breast cancer development and progression. Any functional polymorphisms can potentially affect breast cancer risk as well as cancer phenotype and outcome. In our study, we analyzed three polymorphisms in the HER2 gene: the single-nucleotide polymorphism (SNP) HER2 Ile(655)Val as well as another SNP (rs903506) close to it and a new screened dinucleotide repeat H(AC)I4 in intron 4, in a sample of 148 cases and 290 controls from the Tunisian population and investigated their association with breast cancer risk. For the HER2 Ile(655)Val, we found similar allele frequencies between cases and controls (frequency of I allele was 0.92 and 0.91, respectively). The same was observed for the noncoding SNP (rs903506). These two SNPs also showed no association with any clinical parameters, except the association of HER2 Ile(655)Val with tumor size (p = 0.002). But, a significant association was found between the short tandem repeat (STR) [H(AC)I4] and breast cancer risk at both genotypic and allelic levels (p = 0.0004 and p = 0.0001, respectively). Multivariate analysis with binary logistic regression of disease status on genotypes of the three polymorphisms confirmed the association of STR with breast cancer risk (p = 0.016). Therefore, this STR seems to be a promising biomarker in breast cancer and deserves further investigation.",
        "Doc_title":"HER2 polymorphisms and breast cancer in Tunisian women.",
        "Journal":"Genetic testing and molecular biomarkers",
        "Do_id":"19929405",
        "Doc_ChemicalList":"Biomarkers, Tumor;DNA Primers",
        "Doc_meshdescriptors":"Adult;Aged;Aged, 80 and over;Alleles;Amino Acid Substitution;Base Sequence;Biomarkers, Tumor;Breast Neoplasms;Case-Control Studies;DNA Primers;Dinucleotide Repeats;Female;Gene Frequency;Genes, erbB-2;Humans;Introns;Middle Aged;Multivariate Analysis;Polymorphism, Genetic;Polymorphism, Single Nucleotide;Retrospective Studies;Tunisia;Young Adult",
        "Doc_meshqualifiers":"genetics;genetics;metabolism;pathology;genetics",
        "_version_":1605774972623519744},
      {
        "Doc_abstract":"MLN64, is invariably coamplified and coexpressed with erbB-2 in breast cancers. The human MLN64 and ERBB2 genes are positioned at less than 50 kb from each other, on chromosome 17q12. To understand the molecular basis of MLN64 overexpression in cancer, the genomic region containing the MLN64 and ERBB2 genes was isolated and mapped. The two genes, DARPP32 and Telethonin, flanking MLN64 respectively on its centromeric and telomeric sides, although coamplified, are not overexpressed in breast cancer cells, indicating that gene amplification is not sufficient to allow overexpression. The MLN64 minimal promoter was isolated and found to be a housekeeping gene promoter containing four potential Sp1 binding elements. Using Sp1-deficient Drosophila SL2 cells, MLN64 promoter activity was induced in a dose-dependent manner by exogenous Sp1 addition. Furthermore, mutation of each individual Sp1 element resulted in a significant decrease in reporter gene activity, indicating that all the Sp1 binding elements are functional and act together to promote gene expression. Since the ERBB2 promoter is also positively regulated by Sp1, this study indicates that MLN64 and ERBB2 genes share common transcriptional controls together with a physical link on chromosome 17q. We speculate that, in addition to the oncogenic potential of erbB-2 overexpression, the unbalanced action of MLN64 contributes to the poor clinical outcome of breast tumors bearing this amplified region.",
        "Doc_title":"Metastatic lymph node 64 (MLN64), a gene overexpressed in breast cancers, is regulated by Sp/KLF transcription factors.",
        "Journal":"Oncogene",
        "Do_id":"12802284",
        "Doc_ChemicalList":"CCAAT-Enhancer-Binding Protein-beta;Carrier Proteins;Membrane Proteins;STARD3 protein, human;Sp1 Transcription Factor",
        "Doc_meshdescriptors":"Amino Acid Sequence;Base Sequence;Binding Sites;Breast Neoplasms;CCAAT-Enhancer-Binding Protein-beta;Carrier Proteins;Cell Line;Conserved Sequence;Female;Gene Amplification;Gene Expression Regulation, Neoplastic;Genes, erbB-2;Humans;Membrane Proteins;Molecular Sequence Data;Promoter Regions, Genetic;Sp1 Transcription Factor",
        "Doc_meshqualifiers":"genetics;physiology;chemistry;genetics;physiology",
        "_version_":1605852481130070016},
      {
        "Doc_abstract":"The HER-2/neu oncogene encodes a transmembrane tyrosine kinase receptor with extensive homology to the epidermal growth factor receptor. HER-2/neu has been widely studied in breast cancer. In this review, the association of HER-2/neu gene and protein abnormalities studied by Southern and slot blotting, immunohistochemistry, enzyme immunoassays, and fluorescence in situ hybridization with prognosis in breast cancer is studied in depth by review of a series of 47 published studies encompassing more than 15,000 patients. The relative advantages of gene amplification assays and frozen/fresh tissue immunohistochemistry over paraffin section immunohistochemistry are discussed. The significance of HER-2/neu overexpression in ductal carcinoma in situ and the HER-2/neu status in uncommon female breast conditions and male breast cancer are also considered. The potential value of HER-2/neu status for the prediction of response to therapy in breast cancer is presented in the light of a series of recently published studies showing a range of impact on the outcome of patients treated with hormonal, cytotoxic, and radiation therapies. The evidence that HER-2/neu gene and protein abnormalities in breast cancer predict resistance to tamoxifen therapy and relative sensitivity to chemotherapy regimens including adriamycin is presented. The review will also evaluate the status of serum-based testing for circulating the HER-2/neu receptor protein and its ability to predict disease outcome and therapy response. In the final section, the review will briefly present preliminary data concerning the use of antibody-based therapies directed against the HER-2/neu protein and their potential to become a new modality for breast cancer treatment. The recently presented phase III clinical trial evidence that systemic administration of anti-HER2 antibodies (Herceptin&reg;), alone and in combination with cytotoxic chemotherapy in patients with HER-2/neu overexpressing primary tumors, can increase the time to recurrence and overall response rates in metastatic breast cancer is reviewed.",
        "Doc_title":"The HER-2/neu Oncogene in Breast Cancer: Prognostic Factor, Predictive Factor, and Target for Therapy.",
        "Journal":"The oncologist",
        "Do_id":"10388110",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605765722612432896},
      {
        "Doc_abstract":"The HER-2/neu oncogene encodes a transmembrane tyrosine kinase receptor with extensive homology to the epidermal growth factor receptor. HER-2/neu has been widely studied in breast cancer. In this review, the association of HER-2/neu gene and protein abnormalities studied by Southern and slot blotting, immunohistochemistry, enzyme immunoassays, and fluorescence in situ hybridization with prognosis in breast cancer is studied in depth by review of a series of 47 published studies encompassing more than 15,000 patients. The relative advantages of gene amplification assays and frozen/fresh tissue immunohistochemistry over paraffin section immunohistochemistry are discussed. The significance of HER-2/neu overexpression in ductal carcinoma in situ and the HER-2/neu status in uncommon female breast conditions and male breast cancer are also considered. The potential value of HER-2/neu status for the prediction of response to therapy in breast cancer is presented in the light of a series of recently published studies showing a range of impact on the outcome of patients treated with hormonal, cytotoxic, and radiation therapies. The evidence that HER-2/neu gene and protein abnormalities in breast cancer predict resistance to tamoxifen therapy and relative sensitivity to chemotherapy regimens including adriamycin is presented. The review will also evaluate the status of serum-based testing for circulating the HER-2/neu receptor protein and its ability to predict disease outcome and therapy response. In the final section, the review will briefly present preliminary data concerning the use of antibody-based therapies directed against the HER-2/neu protein and their potential to become a new modality for breast cancer treatment. The recently presented phase III clinical trial evidence that systemic administration of anti-HER2 antibodies (Herceptin), alone and in combination with cytotoxic chemotherapy in patients with HER-2/neu overexpressing primary tumors, can increase the time to recurrence and overall response rates in metastatic breast cancer is reviewed.",
        "Doc_title":"The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy.",
        "Journal":"Stem cells (Dayton, Ohio)",
        "Do_id":"9831867",
        "Doc_ChemicalList":"Biomarkers, Tumor;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Animals;Biomarkers, Tumor;Breast Neoplasms;Breast Neoplasms, Male;Carcinoma in Situ;Carcinoma, Ductal, Breast;Female;Humans;Male;Predictive Value of Tests;Prognosis;Receptor, ErbB-2",
        "Doc_meshqualifiers":"genetics;physiopathology;therapy;genetics;physiopathology;therapy;genetics;metabolism;genetics;metabolism;genetics;physiology",
        "_version_":1605830633457713152},
      {
        "Doc_abstract":"The concordance rate between fluorescence in situ hybridization (FISH) and immunohistochemistry (IHC) on evaluating HER-2/neu status is still controversial, especially for the IHC 2+/equivocal cases. In this study, we investigated the amplification of HER-2/neu gene by FISH in IHC (2+)/equivocal specimens to clarify the correlation between HER-2/neu and clinicopathologic features of breast cancers. HER-2/neu amplification was determined by FISH on 528 specimens of breast carcinomas with equivocal expression of HER-2/neu protein by IHC detection. 65.5 % of IHC 2+ patients were negative for HER-2/neu amplification, 29.0 % were positive and the remaining was equivocal. A statistically significant inverse association was found between hormone receptor expression and HER-2/neu amplification (P < 0.05). Furthermore, polysomy of CEP17 was detected in 60 % of breast carcinomas. The results highlight the necessity of FISH test for further categorization when breast carcinoma cases are scored 2+ by IHC.",
        "Doc_title":"HER-2 gene amplification by fluorescence in situ hybridization (FISH) compared with immunohistochemistry (IHC) in breast cancer: a study of 528 equivocal cases.",
        "Journal":"Breast cancer research and treatment",
        "Do_id":"22678158",
        "Doc_ChemicalList":"ERBB2 protein, human;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Adult;Aged;Breast Neoplasms;Carcinoma;Chromosomes, Human, Pair 17;Female;Gene Amplification;Gene Dosage;Humans;Immunohistochemistry;In Situ Hybridization, Fluorescence;Middle Aged;Receptor, ErbB-2",
        "Doc_meshqualifiers":"diagnosis;genetics;metabolism;diagnosis;genetics;metabolism;genetics",
        "_version_":1605830311414857728},
      {
        "Doc_abstract":"Prolactin (PRL) promotes the proliferation and survival of breast cancer cells in part via the transactivation of human epidermal growth factor receptor 2 (HER2), also known as Neu in rodents. A PRL receptor (PRLR) antagonist, G129R, has been developed, which indirectly inhibits the tyrosine phosphorylation of HER2 (p-HER2) in human breast cancer cell lines. In this study, we investigate the effects of cancer-associated fibroblasts (CAFs) upon this molecular cross-talk using tumor cells and CAFs derived from spontaneous mammary tumors of female MMTV-neu transgenic mice. Tumors were resected and cultured as small tumor chunks (~3 mm3) or were cultured in monolayer. G129R reduced tyrosine phosphorylation of Neu (p-Neu) in a dose-dependent manner (IC50~10 Î¼g/ml) in tumor chunks, but had no effect on primary tumor epithelial cells grown in monolayer. Direct co-culture of mouse or human tumor epithelial cell lines with CAFs restored the epithelial cells' response to G129R, similar to that observed in mouse tumor chunks. The addition of PRL, as expected, induced p-Neu in both the tumor chunk and co-culture models. The inhibitory effect of G129R was absent when CAFs were physically separated from mouse tumor epithelial cells using a transwell system, or when CAFs were replaced with normal fibroblasts in direct co-culture with human or mouse tumor epithelial cells. In vivo, G129R reduced p-Neu levels in primary mammary tumors of mice in a time- and dose-dependent manner. In conclusion, CAFs play a critical role in bridging the cross-talk between PRL and HER2/Neu in both mouse and human models of breast cancer. The inhibitory effects of G129R on p-Neu and on tumor growth are dependent upon interactions of tumor epithelial cells with CAFs.",
        "Doc_title":"Stromal-epithelial interactions modulate cross-talk between prolactin receptor and HER2/Neu in breast cancer.",
        "Journal":"Breast cancer research and treatment",
        "Do_id":"22270933",
        "Doc_ChemicalList":"Antineoplastic Agents;Receptors, Prolactin;prolactin, Arg(129)-;Prolactin;Erbb2 protein, rat;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Animals;Antineoplastic Agents;Cell Communication;Coculture Techniques;Epithelial Cells;Female;Fibroblasts;Humans;Mammary Neoplasms, Animal;Mice;Mice, Transgenic;Phosphorylation;Prolactin;Protein Processing, Post-Translational;Rats;Receptor Cross-Talk;Receptor, ErbB-2;Receptors, Prolactin;Signal Transduction;Tumor Cells, Cultured;Tumor Microenvironment",
        "Doc_meshqualifiers":"pharmacology;therapeutic use;metabolism;metabolism;drug therapy;metabolism;pathology;pharmacology;metabolism;antagonists & inhibitors;metabolism",
        "_version_":1605800135136116736},
      {
        "Doc_abstract":"Triple Negative Breast Cancer (TNBC) is defined by a lack of expression of the steroid hormone receptors (oestrogen and progesterone), and the human epidermal growth factor receptor-2 (HER-2). It is characterized by distinct molecular, histological and clinical features. It is a high risk breast cancer that lacks the benefit of a specific therapy. Our study was aimed at pathologically illustrating triple-negative breast carcinoma and at evaluating the expression of the Epidermal Growth Factor Receptor (EGFR) ,cytokeratin 5/6 (CK 5/6) and Ki-67 among triple-negative breast cancer cases. Further, we aimed to probe whether triple-negative phenotype could be a surrogate marker for the basal phenotype and to correlate the expression of the basal markers (CK 5/6 and EGFR) with the clinico-pathological prognostic parameters.;The expression of EGFR, CK 5/6 and Ki-67 were studied by immunohistochemistry (IHC) in 50 triple-negative breast cancer cases.;A statistical analysis was implemented by using the SPSS version 20.0. The Chi-square test was conducted to assess the relationship between the immunohistochemical markers and other variables. The Fischer exact test was used when the expected cell counts were less than 5.;The women with triple-negative breast cancer were younger, with the adverse pathological characteristics of a high tumour grade, tumour necrosis, frequent nodal metastases and high proliferation. 37 (74%) of the 50 triple-negative breast carcinomas showed the expression of the basal markers (EGFR and /or CK 5/6). We observed a statistically significant association between the basal marker expression and the presence of tumour necrosis.;The triple-negative breast cancers in our population harbour adverse pathobiological features and a five marker immunohistochemical panel can be reliably used to define the basal-like cancers. The \"Triple-negative\" status cannot be used as a surrogate for the \"basal marker expression\".",
        "Doc_title":"Immunohistochemical profile and morphology in triple - negative breast cancers.",
        "Journal":"Journal of clinical and diagnostic research : JCDR",
        "Do_id":"23998066",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605826672240623616},
      {
        "Doc_abstract":"Identifying breast cancer patients with high risk and treating them with relevant treatments is a key to improve their survival. This study was to investigate the correlations of human epidermal receptor-2 (HER-2), proliferating cell nuclear antigen (PCNA), Bcl-2, and Bax expression to the prognosis of breast cancer.;The expression of HER-2, PCNA, Bcl-2, and Bax in 50 specimens of breast cancer was detected by immunohistochemistry with EnVision staining. Their correlations to the survival time of the patients were analyzed.;The positive rates of HER-2, PCNA, Bcl-2, and Bax in breast cancer tissues were 44.0%, 82.0%, 48.0% and 54.0%, respectively. The median survival for the patients was 62 months, and the 5-year overall survival rate and disease-free survival rate were 82.0% and 38.0%, respectively. Univariate survival analysis suggested that HER-2 and Bax had significant influence on tumor recurrence (P< 0.001). Cox multivariate analysis indicated that the expression of HER-2 and Bax were correlated to regional recurrence and distant metastasis (P < 0.05 and P < 0.01), and Bcl-2 and Bax proteins were independent predictors of overall survival (P < 0.05).;HER-2 and Bax are related to poor prognosis of breast cancer, while Bcl-2 is related to good prognosis.",
        "Doc_title":"[Correlations of HER-2, PCNA, Bcl-2, and Bax expression to prognosis of breast cancer].",
        "Journal":"Ai zheng = Aizheng = Chinese journal of cancer",
        "Do_id":"17626754",
        "Doc_ChemicalList":"Proliferating Cell Nuclear Antigen;Proto-Oncogene Proteins c-bcl-2;bcl-2-Associated X Protein;ERBB2 protein, human;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Adult;Aged;Breast Neoplasms;Carcinoma, Ductal, Breast;Disease-Free Survival;Female;Follow-Up Studies;Humans;Immunohistochemistry;Lymphatic Metastasis;Middle Aged;Neoplasm Metastasis;Neoplasm Recurrence, Local;Neoplasm Staging;Proliferating Cell Nuclear Antigen;Proportional Hazards Models;Proto-Oncogene Proteins c-bcl-2;Receptor, ErbB-2;Survival Rate;bcl-2-Associated X Protein",
        "Doc_meshqualifiers":"metabolism;pathology;metabolism;pathology;metabolism;metabolism;metabolism;metabolism",
        "_version_":1605822739402194944},
      {
        "Doc_abstract":"Breast cancer is the commonest cancer affecting women world wide. Breast cancer is a leading cause of cancer related mortality in Asian countries. Management of breast cancer depends on several tumour-related and patient related factors. HER-2/neu over-expression has been associated with a poor prognosis in breast cancer. We assessed HER-2/neu over expression pattern in unselected breast cancer cases in terms of clinico-pathologic parameters to identify any associations between them.;Two hundred cases of breast cancer were evaluated at Advanced Medical and Dental Institute and Hospital Kepala Batas from 2002 to 2007. HER-2/neu status was confirmed in breast cancer tissues by immunohistochemistry. Immunohistochemical expression of HER-2/neu was evaluated according to the published scoring guidelines of the 'Hercep Test' (Dako, Carpinteria, CA). Data were analysed to identify any association between HER-2/neu and clinico-pathologic parameters.;HER-2/neu over expression was found in 63 (31.5%) tumours out of 200. When assessed for various age groups no significant association was found. However, a high percentage (75%) of over-expression was noted in the 81-85 years age group. No association was found with different racial groups (Malay, Chinese and Indians), with lymph node status or with grade of tumour. However a positive association was observed with oestrogen receptor and progesterone receptor expression.;There was no association between HER-2/neu over expression and age, race, lymph node status or tumor grade. However a positive association was found with oestrogen and progesterone receptor status.",
        "Doc_title":"Association between HER-2/neu over-expression and clinico-pathologic parameters of breast cancer in northern Malaysia.",
        "Journal":"The Ceylon medical journal",
        "Do_id":"20446534",
        "Doc_ChemicalList":"Receptor, ErbB-2",
        "Doc_meshdescriptors":"Adult;Aged;Aged, 80 and over;Breast Neoplasms;Female;Humans;Immunohistochemistry;Lymphatic Metastasis;Malaysia;Middle Aged;Receptor, ErbB-2",
        "Doc_meshqualifiers":"metabolism;pathology;metabolism",
        "_version_":1605795270315999232},
      {
        "Doc_abstract":"Ceramide and sphingosine mediate response to cancer therapy, inhibit cell growth and induce apoptosis in vitro. Only a few clinical data about the impact of ceramide and sphingosine iny vivo are available. We investigated the relevance of ceramide- and sphingosine-generating enzymes in breast cancer (acid ceramidase 1 (ASAH1), ceramide synthases 4 (LASS4) and 6 (LASS6)) by means of gene expression analysis.;We analyzed differences in ASAH1, LASS4 and LASS6 on mRNA level between breast cancer subgroups using microarray data from 1581 tumor samples.;High ASAH1, LASS4 and LASS6 expression correlates with pathohistological grading (p < 0.001) and estrogen receptor (ER) status (p < 0.001). High ASAH1 expression was associated with a larger tumor size >2 cm (p = 0.003), while high LASS6 expression was correlated with ErbB2 negativity (p < 0.001). In survival analysis, we detected a significant better prognosis of patients with higher ASAH1 expression (p = 0.002) in the ER-positive subgroup. In contrast, expression of LASS4 or LASS6 did not show any prognostic impact. In the multivariate analysis, only ASAH1 expression (p = 0.002), tumor size (p < 0.0001) and ErbB2 positivity (p = 0.041) remained significant.;ASAH1 is an estrogen-dependent member of the sphingolipid metabolism, which might provide further prognostic information in ER-positive breast cancers.",
        "Doc_title":"Acid ceramidase 1 expression correlates with a better prognosis in ER-positive breast cancer.",
        "Journal":"Climacteric : the journal of the International Menopause Society",
        "Do_id":"19905902",
        "Doc_ChemicalList":"RNA, Messenger;Receptors, Estrogen;Sphingolipids;Oxidoreductases;dihydroceramide desaturase;ASAH1 protein, human;Acid Ceramidase",
        "Doc_meshdescriptors":"Acid Ceramidase;Breast Neoplasms;Female;Gene Expression;Genes, erbB-2;Humans;Immunohistochemistry;Middle Aged;Oligonucleotide Array Sequence Analysis;Oxidoreductases;Prognosis;Proportional Hazards Models;RNA, Messenger;Receptors, Estrogen;Sphingolipids",
        "Doc_meshqualifiers":"genetics;chemistry;enzymology;pathology;genetics;genetics;analysis;analysis;metabolism",
        "_version_":1605746842062028803},
      {
        "Doc_abstract":"Male breast cancer (MBC) is a poorly characterized disease because of its rarity. Clinical management is based on results obtained from randomized trials conducted in women notwithstanding data in the literature suggesting relevant gender-associated differences in terms of biological and clinical behavior. However, a genome-wide characterization of MBC on a transcriptional level is lacking. In this study, gene expression profiles of 37 estrogen receptor positive (ER+) MBC specimens were compared to that of 53 ER+ Female Breast Cancer (FBC) samples similar for clinical and patho-biological features. Almost 1000 genes were found differentially expressed (FDR < 1%) between female and male patients and biological interpretation highlighted a gender-associated modulation of key biological processes ranging from energy metabolism to regulation of translation and matrix remodeling as well as immune system recruitment. Moreover, an analysis of genes correlated to steroid receptors and ERBB2 suggested a prominent role for the androgen receptor in MBC with a minor relevance for progesterone receptor and ERBB2, although, similarly to FBC, a genomic amplification could be observed. Our findings support the idea that breast cancer is a quite different disease in male and female patients and the underlying gender-related biological differences are likely to have clinical implications connected with different susceptibility to treatment.",
        "Doc_title":"Gene expression analysis reveals a different transcriptomic landscape in female and male breast cancer.",
        "Journal":"Breast cancer research and treatment",
        "Do_id":"20625818",
        "Doc_ChemicalList":"Chemokines;Receptors, Androgen;Receptors, Progesterone;ERBB2 protein, human;Receptor, ErbB-2;rho GTP-Binding Proteins",
        "Doc_meshdescriptors":"Adult;Aged;Aged, 80 and over;Breast Neoplasms, Male;Chemokines;Female;Gene Expression Profiling;Gene Expression Regulation, Neoplastic;Genes, BRCA1;Genes, BRCA2;Humans;Male;Microarray Analysis;Middle Aged;Polymerase Chain Reaction;Receptor, ErbB-2;Receptors, Androgen;Receptors, Progesterone;Sex Factors;rho GTP-Binding Proteins",
        "Doc_meshqualifiers":"genetics;analysis;genetics;genetics;genetics;analysis",
        "_version_":1605798343593689088},
      {
        "Doc_abstract":"erbB2, a member of the epidermal growth factor (EGF) receptor-type tyrosine kinase receptor family, is overexpressed in breast carcinomas with poor prognosis. We examined the cell surface association of this receptor with itself and with other cell surface proteins by the FÃ¶rster-type fluorescence resonance energy transfer using whole antibodies and Fab fragments. We found that erbB2 molecules homoassociate in unstimulated SK-BR-3, BT474 and BT474-M (a metastatic version of the parent BT474 line) breast tumor cells, and that the interaction was enhanced by EGF treatment in suspensions of SK-BR-3 and BT474-M cells. BT474 cells (with low EGF receptor expression) and attached SK-BR-3 cells do not respond to EGF. Image microscopic energy transfer measurements found considerable pixel-by-pixel heterogeneity in the homoassociation state of erbB2. In accordance with the EGF-induced redistribution of erbB2, EGF receptor was found to be in close proximity to erbB2 in FRET measurements. By labeling different epitopes on erbB2 and the lipid bilayer, we were able to prepare an epitope map of erbB2 molecule. Our data suggest the existence of dynamic cell surface patterns of erbB2 and point to functions fulfilled by these molecular complexes.",
        "Doc_title":"EGF-induced redistribution of erbB2 on breast tumor cells: flow and image cytometric energy transfer measurements.",
        "Journal":"Cytometry",
        "Do_id":"9627225",
        "Doc_ChemicalList":"Receptors, Transferrin;Epidermal Growth Factor;Receptor, Epidermal Growth Factor;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Breast Neoplasms;Carcinoma, Squamous Cell;Cell Membrane;Energy Transfer;Epidermal Growth Factor;Female;Flow Cytometry;Humans;Models, Molecular;Receptor, Epidermal Growth Factor;Receptor, ErbB-2;Receptors, Transferrin;Tumor Cells, Cultured",
        "Doc_meshqualifiers":"metabolism;metabolism;drug effects;metabolism;ultrastructure;pharmacology;methods;biosynthesis;biosynthesis;chemistry;analysis;chemistry",
        "_version_":1605929009890197504},
      {
        "Doc_abstract":"Through isolation and purification pri-mary HER2 overexpression human breast cancer cells from malignant pleural effusion and identification the HER2 expression level of the cells to establish the primary HER2 overexpression human breast cancer cell model. METH-ODS: Malignant pleural effusion of HER2 overexpression breast cancer patient was collected. The primary cells were extracted from malignant pleural effusion by Lymphocyte separation medium and the method of density gradient centrifugation. When the primary cells were cultured and spreaded to the 5th generation, the HER2 expression level of the primary cells were detected by the methods of Q-PCR,Western blot and flow cytometry (FCM). Ability of tumor-bearing was detected by tumor-bearing nude mice assay.;The primary HER2 overexpression human breast cancer cells were extracted and identified by the methods of Q-PCR, Western blot and tumor-bearing nude mice assay,even though the FCM showed Negative results.;The primary HER2 overexpression human breast cancer cell model was established; Identification of primary cells need to be confirmed by different methods.",
        "Doc_title":"[Establishment of primary Her-2 over-  expression human breast cancer cell  model].",
        "Journal":"Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular immunology",
        "Do_id":"22238824",
        "Doc_ChemicalList":"Receptor, ErbB-2",
        "Doc_meshdescriptors":"Animals;Breast Neoplasms;Female;Gene Expression;Gene Expression Regulation, Neoplastic;Humans;Mice;Mice, Inbred BALB C;Mice, Nude;Neoplasm Transplantation;Pleural Effusion, Malignant;Receptor, ErbB-2;Tumor Cells, Cultured",
        "Doc_meshqualifiers":"genetics;metabolism;genetics;pathology;genetics;metabolism",
        "_version_":1605742092042108928},
      {
        "Doc_abstract":"One of the most aggressive breast cancer subtypes includes tumors with high expression of HER2. Gene expression and functional studies have shown a link between HER2 overexpression and oxidative stress. Because of this, we hypothesized that Oncoxin Oral Solution (OOS), a composite product that contains several antioxidants, could have an antitumoral effect against HER2+ tumors. Dose-response studies, biochemical and cytometric assessment of the effect of OOS on cell cycle and apoptosis, and drug combination analyses were performed on BT474 and SKBR3 cells, 2 HER2-overexpressing breast cancer cell lines. OOS reduced the proliferation of these cells, and augmented the action of lapatinib, a HER2 inhibitor used in the breast cancer clinic. Moreover, OOS decreased growth of HER2+ tumors in mice. Mechanistically, OOS provoked cell cycle blockade through upregulation of p27 expression and downregulation of cyclin D levels. OOS also caused apoptotic cell death in HER2+ breast cancer cells, as indicated by increases in PARP cleavage as well as upregulation of caspase 8 and caspase 3 activities. These results demonstrate an antitumoral action of OOS in preclinical models of HER2+ breast cancer and suggest that it can be used with anti-HER2 therapies currently adopted as standard of care in the oncology clinic. ",
        "Doc_title":"Effect of Oncoxin Oral Solution in HER2-Overexpressing Breast Cancer.",
        "Journal":"Nutrition and cancer",
        "Do_id":"26241555",
        "Doc_ChemicalList":"Antioxidants;Quinazolines;lapatinib;ERBB2 protein, human;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Administration, Oral;Animals;Antineoplastic Combined Chemotherapy Protocols;Antioxidants;Apoptosis;Breast Neoplasms;Cell Cycle;Cell Line, Tumor;Cell Proliferation;Dietary Supplements;Female;Mice, Inbred BALB C;Quinazolines;Receptor, ErbB-2;Xenograft Model Antitumor Assays",
        "Doc_meshqualifiers":"pharmacology;administration & dosage;pharmacology;drug effects;diet therapy;drug therapy;metabolism;pathology;drug effects;drug effects;drug effects;administration & dosage;metabolism",
        "_version_":1605824294574620672},
      {
        "Doc_abstract":"The ASCO/CAP Expert Panel recommends that all invasive breast carcinomas and breast cancer recurrences be tested for ER, PR and HER-2 expression. The guidelines for testing of surgical specimens by immunohistochemistry (IHC) are well defined, whereas they are lacking for cytological samples. We evaluated various fixation protocols for optimal receptor testing by immunohistochemistry and immunocytochemistry (ICC) of human breast cancer cell lines MCF-7 (ER/PR positive) and SKBR-3 (overexpressing HER-2). The cells were fixed in 10% neutral buffered formalin or Saccomanno Fixative (SF) for various time points, and either embedded in paraffin as cell blocks or prepared as cytospins. ER and PR slides were assigned a proportion score (PS; 0-5), an intensity score (IS; 0-3) and a total score (TS = PS + IS). Standard DAKO scoring system ranging from 0 to 3+ was used for the evaluation of HER-2 staining. Human breast cancer cells stained successfully for ER, PR and HER-2 when fixed in formalin and prepared as cell blocks. The optimal fixation time for formalin-fixed cells ranged from 2 to 96 hours. Cells fixed in SF from 2 to 96 hours also stained well for ER and PR. However, SF produced variable results for HER-2 staining; particularly, SF fixation beyond 24 hours caused false negative results. The interpretation of HER-2 staining on cytospins was not feasible irrespective of the fixative and fixation time. In summary, formalin fixation from 2 to 96 hours and preparation of cells as cell blocks produces optimal results for ER, PR, and HER-2 testing in human breast cancer cells.",
        "Doc_title":"Estrogen, progesterone, and HER-2 receptor immunostaining in cytology: the effect of varied fixation on human breast cancer cells.",
        "Journal":"Diagnostic cytopathology",
        "Do_id":"23447357",
        "Doc_ChemicalList":"Estrogens;Progesterone;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Breast Neoplasms;Case-Control Studies;Estrogens;Female;Humans;Immunohistochemistry;MCF-7 Cells;Progesterone;Receptor, ErbB-2;Tissue Fixation",
        "Doc_meshqualifiers":"chemistry;diagnosis;analysis;immunology;methods;analysis;immunology;analysis;immunology;methods",
        "_version_":1605841246267375616},
      {
        "Doc_abstract":"Cyclohexyl thiosemicarbazone derivatives (C1-14) were synthesized, characterized and evaluated against HER-2 over expressed breast cancer cells. The synthesized compounds were screened in vitro against four breast cancer cell lines; SKBr-3, MCF-7, MDA-MB-468 and MDA-MB-231. All the compounds showed activity against HER-2 over expressed SKBr-3 cells with (ICâ‚…â‚€ = 25.6 Â± 0.07 Î¼M-61.6 Â± 0.4 Î¼M). The most active compounds inhibit ALDHâº breast cancer stem cells more effectively than the cancer stem cells specific agent Salinomycin. Immunohistochemistry staining also confirmed that these compounds inhibit the expression of HER-2 on SKBr-3 cells. Compound C2 significantly inhibited the cell migration and cell adhesion of breast cancer cell lines. Compound C2 was found to most active compound of this series targeting HER-2 over expressed breast cancer cells.",
        "Doc_title":"Targeting HER-2 over expressed breast cancer cells with 2-cyclohexyl-N-[(Z)-(substituted phenyl/furan-2-yl/thiophene-2-yl)methylidene]hydrazinecarbothioamide.",
        "Journal":"Bioorganic & medicinal chemistry letters",
        "Do_id":"25466196",
        "Doc_ChemicalList":"Thiosemicarbazones;ERBB2 protein, human;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Breast Neoplasms;Drug Delivery Systems;Female;Gene Expression Regulation, Neoplastic;Humans;MCF-7 Cells;Receptor, ErbB-2;Thiosemicarbazones",
        "Doc_meshqualifiers":"drug therapy;metabolism;methods;antagonists & inhibitors;biosynthesis;administration & dosage;chemical synthesis",
        "_version_":1605798268220997632},
      {
        "Doc_abstract":"Neoadjuvant treatment is the standard therapy for inflammatory and locally advanced breast cancer but is also applied in patients with primary operable breast cancer to facilitate breast-conserving surgery. Disease-free survival and overall survival are equivalent between patients treated with preoperative chemotherapy and patient receiving the same regimen postoperatively. Nevertheless, pathologic complete response can be a predictive indicator of long-term outcomes. Initially encompassing chemotherapy, it is actually extended to hormonotherapy for hormonoresponsive tumor and to targeted therapy such as trastuzumab for the HER2 positive tumor. The neoadjuvant approach of breast cancer will provide better understanding of breast cancer biology and promote translational research. In this paper, a review of the role of preoperative treatment in the management of breast cancer disease is discussed.",
        "Doc_title":"[Neoadjuvant therapy in breast cancer].",
        "Journal":"Revue medicale de Bruxelles",
        "Do_id":"22034752",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"Breast Neoplasms;Female;Humans;Neoadjuvant Therapy",
        "Doc_meshqualifiers":"therapy",
        "_version_":1605852784591110144},
      {
        "Doc_abstract":"to determine whether serum HER-2/neu level could be used as a prognostic factor in locally advanced breast cancer (LABC) and metastatic breast cancer (MBC).;a prospective cohort study was done in LABC and MBC patients in dr. Sardjito Hospital Yogyakarta from April 2006 to March 2008. Serum concentration of HER-2/neu was measured by ELISA done before and after chemotherapy. HER-2/neu expression tissue examination was done by immunohistochemistry. The clinical responses on therapy, survival and progression were recorded.;twenty seven cases were obtained. Average concentration of serum HER-2/neu was 21.02 Â± 7.1 ng/ml. The level of serum HER-2/neu in LABC was lower than MBC (17.21 ng/ml vs 28.64 ng/ml; p=0.32). Average concentration of serum HER-2/neu in partial responders was 13.20 ng/ml (95% Cl 0.142 - 26.25), stable responders was 19.42 ng/ml (95% Cl -0.255 - 39.09) and 29.35 ng/ml(95% Cl 1.95 - 56.74) in progressors (p=0.468). Patients with better clinical response had a lower average HER-2/neu serum level (16.12 ng/ml vs 29.35 ng/ml; p=0.247). HER-2/neu over expression was found in 40.7% of the tissues, 44% of LABC and 33.3% of MBC tissues (p=0.692). Negative HER-2/neu tissue protein expression had better clinical response (75% vs 45.5% p=0.224), and longer survival (p=0.08).;neither the expression of HER-2/neu in the tissue nor the level of serum HER-2/neu can be used as clinical prognosis factor on advanced stage breast cancer in our study population.",
        "Doc_title":"Concentration of serum HER-2/neu as a prognostic factor in locally advanced breast cancer (LABC) and metastatic breast cancer (MBC).",
        "Journal":"Acta medica Indonesiana",
        "Do_id":"21339542",
        "Doc_ChemicalList":"Biomarkers, Tumor;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Adult;Aged;Biomarkers, Tumor;Breast Neoplasms;Disease Progression;Enzyme-Linked Immunosorbent Assay;Female;Humans;Immunohistochemistry;Indonesia;Middle Aged;Neoplasm Metastasis;Neoplasm Recurrence, Local;Prognosis;Prospective Studies;Receptor, ErbB-2;Risk Factors;Survival Analysis",
        "Doc_meshqualifiers":"analysis;genetics;mortality;pathology;secondary;blood;secondary;biosynthesis;blood",
        "_version_":1605742641522147329},
      {
        "Doc_abstract":"Treatment of selected patients with anti-HER-2/neu antibodies alone (1) or in combination with chemotherapy (2) may be of benefit to patients with refractory breast cancer. Approximately 30% of breast cancers overexpress HER-2/neu, a member of the epidermal growth factor receptor family. These patients may have a poorer overall prognosis (3) due to relative resistance to both hormonal therapy and chemotherapy (4-6). We recently observed a patient with refractory breast cancer who responded to rhuMAB HER-2 (trastuzumab) plus paclitaxel after progressing on paclitaxel alone. While on combination treatment she developed cerebellar metastases. Follow-up computed tomography (CT) scan revealed that her disease continued to respond in the liver, lungs, and bone. This case suggests that failure of trastuzumab to cross the blood-brain barrier may compromise its overall effectiveness and raises the possibility that the central nervous system (CNS), or other sanctuary sites, may become clinically more significant in patients with breast cancer in the era of antibody-based therapies.",
        "Doc_title":"Central nervous system progression during systemic response to trastuzumab, humanized anti-HER-2/neu antibody, plus paclitaxel in a woman with refractory metastatic breast cancer.",
        "Journal":"The breast journal",
        "Do_id":"12603385",
        "Doc_ChemicalList":"Antibodies, Monoclonal;Antibodies, Monoclonal, Humanized;Antineoplastic Agents, Phytogenic;Receptor, ErbB-2;Trastuzumab;Paclitaxel",
        "Doc_meshdescriptors":"Antibodies, Monoclonal;Antibodies, Monoclonal, Humanized;Antineoplastic Agents, Phytogenic;Antineoplastic Combined Chemotherapy Protocols;Blood-Brain Barrier;Breast Neoplasms;Central Nervous System Neoplasms;Cerebellar Neoplasms;Fatal Outcome;Female;Humans;Middle Aged;Paclitaxel;Receptor, ErbB-2;Time Factors;Tomography, X-Ray Computed;Trastuzumab",
        "Doc_meshqualifiers":"administration & dosage;administration & dosage;therapeutic use;drug therapy;pathology;secondary;diagnostic imaging;secondary;administration & dosage;drug effects",
        "_version_":1605800934957383680},
      {
        "Doc_abstract":"A gene responsible for an inherited predisposition to breast and ovarian cancer has been localized to the long arm of chromosome 17 and termed BRCA1. As well as being closely linked to breast/ovarian cancer cases, this gene may be involved in up to 45% of site-specific breast cancers. The identification and cloning of the BRCA1 gene is imminent, and will facilitate the screening and counselling of families at risk of breast cancer, and in the longer term may open up new therapeutic possibilities. The tumour suppressor gene TP53 is mutated in 25%-40% of cases of sporadic breast cancer, and is associated with an aggressive tumour phenotype and poor prognosis in both node-positive and node-negative cases. The pattern of mutations in this tumour suppressor gene shows a higher than expected frequency of G to T transversions, mostly restricted to the highly conserved domain in exons 5 to 8. In many, but not all cases, point mutation of one allele is accompanied by deletion of the remaining normal allele at chromosome 17p13. Abnormalities of TP53 appear to be relatively early events in tumorigenesis, being present in ductal carcinoma in situ lesions. The retinoblastoma gene RB1 shows a variety of abnormalities in about 20% of breast cancers, and there may be an association with TP53 mutations. Other abnormalities which occur with a particularly high incidence in breast cancer include allele loss at chromosome 1p/1q, 3p, 6q, 11p, 16q and 18q. The ERBB2 oncogene encodes a transmembrane receptor tyrosine kinase whose ligand has recently been claimed to be the heregulin family in man.(ABSTRACT TRUNCATED AT 250 WORDS)",
        "Doc_title":"Molecular biology of breast cancer.",
        "Journal":"Annals of oncology : official journal of the European Society for Medical Oncology",
        "Do_id":"7914742",
        "Doc_ChemicalList":"Proto-Oncogene Proteins;Receptor, Epidermal Growth Factor;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Animals;Breast Neoplasms;Chromosomes, Human, Pair 17;Female;Genes, Retinoblastoma;Genes, p53;Humans;Mammary Neoplasms, Experimental;Mice;Molecular Biology;Mutation;Oncogenes;Proto-Oncogene Proteins;Receptor, Epidermal Growth Factor;Receptor, ErbB-2",
        "Doc_meshqualifiers":"genetics;genetics;genetics;genetics;genetics;genetics;genetics",
        "_version_":1605846519395647488},
      {
        "Doc_abstract":"The nuclear phosphoprotein p53 is expressed in all normal cells and appears to function in cell cycle regulation. Abnormally high levels of the protein are found in many different types of cancer. In breast carcinoma overexpression of p53 is associated with point mutations within highly conserved regions of the p53 gene. These altered genes encode stable p53 proteins that can be detected by standard immunohistochemical techniques unable to detect rapidly degraded wild-type protein. The level of p53 expression in 184 primary breast cancer specimens was assessed by immunohistochemical analysis and related to the following established prognostic factors for breast cancer: age, stage, metastatic involvement, concentration of estrogen and progesterone receptors, proliferative index, and HER-2/neu overexpression. Fifty (27%) of these primary breast cancer specimens had widespread overexpression of p53. Highly significant associations were found between p53 overexpression and late stage, metastatic spread, and low concentration of progesterone receptors. The presence of elevated levels of mutant p53 may itself be a prognostic factor in human breast cancer and activation of this oncogene may be important in the ability of a tumor to metastasize.",
        "Doc_title":"Relation between p53 overexpression and established prognostic factors in breast cancer.",
        "Journal":"Surgery",
        "Do_id":"1858036",
        "Doc_ChemicalList":"Tumor Suppressor Protein p53",
        "Doc_meshdescriptors":"Breast Neoplasms;Carcinoma;Female;Gene Expression Regulation, Neoplastic;Genes, p53;Humans;Immunohistochemistry;Mutation;Neoplasm Staging;Prognosis;Tumor Suppressor Protein p53",
        "Doc_meshqualifiers":"genetics;pathology;genetics;pathology;secondary;physiology;genetics;genetics;genetics",
        "_version_":1605910612840284160},
      {
        "Doc_abstract":"Inflammatory breast cancer (IBC) is one of the most aggressive forms of breast cancer. Although the survival of patients with IBC has been greatly improved by the use of combined treatment modalities, women with IBC still have lower survival rates. We have summarized a single-center experience involving IBC patients. Our objectives are to clarify molecular alterations of HER-2/neu and p53 in IBC and to investigate the prognostic factors.;Between January 1990 and December 2000, 57 patients with IBC were referred to the Cancer Institute Hospital of the Japanese Foundation for Cancer Research. The incidence of IBC among primary breast cancers was 1.0% (57/5,757) in our hospital. Forty-six patients meeting Haagensen's criteria for inflammatory breast carcinoma were evaluated. All patients had biopsy-proven carcinomas but no distant metastases at referral. The median age at diagnosis for IBC was 51.8 (range, 28 to 70). All patients underwent a mastectomy. Chemotherapy was performed pre- or post-operatively. Three-year and 5-year survival rates were 56.5%, and 40.7%, respectively. Expressions of HER-2/neu and the p53 protein were determined retrospectively by immunohistochemical (IHC) staining of thin paraffin-embedded sections of primary tumors.;Of 46 patients, 23 (50.0%) with tumors testing positive for HER-2/neu fared somewhat worse than those with negative tumors, but the differences were not significant for either overall survival (OS) or disease-free survival (DFS). Of 46 patients, 19 (41.3%) whose tumors were positive for p53 fared somewhat better than patients with negative tumors, with no significant differences in either OS or DFS. Patients presenting with less than ten pathologically involved axillary lymph nodes showed significantly better OS and DFS.;Overexpression of HER-2/neu and the p53 protein were not significant prognostic factors in inflammatory breast cancer. However, the increased incidence of HER-2/neu and the poor outcome of IBC may be of clinical interest, suggesting the need for clinical trials of antibody therapy targeted to HER-2/neu. Moreover, a high prevalence of p53 may be useful in determining the specific use of chemotherapy.",
        "Doc_title":"High prevalence of HER-2/neu and p53 overexpression in inflammatory breast cancer.",
        "Journal":"Breast cancer (Tokyo, Japan)",
        "Do_id":"16755113",
        "Doc_ChemicalList":"Biomarkers, Tumor;Tumor Suppressor Protein p53;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Adenocarcinoma;Adult;Age Factors;Aged;Biomarkers, Tumor;Breast Neoplasms;Cause of Death;Cohort Studies;Disease-Free Survival;Female;Gene Expression Regulation, Neoplastic;Humans;Japan;Middle Aged;Neoplasm Staging;Predictive Value of Tests;Prevalence;Prognosis;Receptor, ErbB-2;Retrospective Studies;Risk Assessment;Sensitivity and Specificity;Survival Analysis;Tumor Suppressor Protein p53",
        "Doc_meshqualifiers":"genetics;mortality;therapy;metabolism;genetics;mortality;therapy;epidemiology;analysis;analysis",
        "_version_":1605836125723688960},
      {
        "Doc_abstract":"The current histoclinical breast cancer classification is simple but imprecise. Several molecular classifications of breast cancers based on expression profiling have been proposed as alternatives. However, their reliability and clinical utility have been repeatedly questioned, notably because most of them were derived from relatively small initial patient populations. We analyzed the transcriptomes of 537 breast tumors using three unsupervised classification methods. A core subset of 355 tumors was assigned to six clusters by all three methods. These six subgroups overlapped with previously defined molecular classes of breast cancer, but also showed important differences, notably the absence of an ERBB2 subgroup and the division of the large luminal ER+ group into four subgroups, two of them being highly proliferative. Of the six subgroups, four were ER+/PR+/AR+, one was ER-/PR-/AR+ and one was triple negative (AR-/ER-/PR-). ERBB2-amplified tumors were split between the ER-/PR-/AR+ subgroup and the highly proliferative ER+ LumC subgroup. Importantly, each of these six molecular subgroups showed specific copy-number alterations. Gene expression changes were correlated to specific signaling pathways. Each of these six subgroups showed very significant differences in tumor grade, metastatic sites, relapse-free survival or response to chemotherapy. All these findings were validated on large external datasets including more than 3000 tumors. Our data thus indicate that these six molecular subgroups represent well-defined clinico-biological entities of breast cancer. Their identification should facilitate the detection of novel prognostic factors or therapeutical targets in breast cancer.",
        "Doc_title":"A refined molecular taxonomy of breast cancer.",
        "Journal":"Oncogene",
        "Do_id":"21785460",
        "Doc_ChemicalList":"Biomarkers, Tumor",
        "Doc_meshdescriptors":"Biomarkers, Tumor;Breast Neoplasms;Cluster Analysis;Databases, Genetic;Female;Gene Expression Profiling;Humans;Prognosis;Reproducibility of Results;Signal Transduction;Survival Analysis;Transcriptome;Treatment Outcome",
        "Doc_meshqualifiers":"genetics;classification;drug therapy;genetics;mortality",
        "_version_":1605844629996961792},
      {
        "Doc_abstract":"We report a case of a patient with invasive breast carcinoma that demonstrated HER-2 gene amplification on core biopsy, who relapsed while on adjuvant trastuzumab therapy after her mastectomy and ultimately died 15 months after diagnosis. Surprisingly, analysis of multiple metastases harvested at rapid autopsy demonstrated no evidence of HER-2 gene amplification. Retrospective examination of the carcinoma in the patient's mastectomy specimen revealed only focal HER-2 amplification within the tumor, localized to the region of the prior core biopsy site. This case highlights several important issues in HER-2 testing of breast cancer, including core biopsy-excision specimen discordance, primary-metastasis discordance, and potential selection for unamplified portions of a heterogeneously amplified tumors by trastuzumab.",
        "Doc_title":"Intratumoral heterogeneity of HER-2 gene amplification and protein overexpression in breast cancer.",
        "Journal":"Human pathology",
        "Do_id":"20338615",
        "Doc_ChemicalList":"Antibodies, Monoclonal;Antibodies, Monoclonal, Humanized;Antineoplastic Agents;ERBB2 protein, human;Receptor, ErbB-2;Trastuzumab",
        "Doc_meshdescriptors":"Adult;Antibodies, Monoclonal;Antibodies, Monoclonal, Humanized;Antineoplastic Agents;Breast Neoplasms;Carcinoma, Ductal, Breast;Fatal Outcome;Female;Genes, erbB-2;Humans;Neoadjuvant Therapy;Neoplasm Recurrence, Local;Pleural Neoplasms;Receptor, ErbB-2;Trastuzumab",
        "Doc_meshqualifiers":"therapeutic use;therapeutic use;drug therapy;metabolism;pathology;drug therapy;metabolism;secondary;secondary;biosynthesis;genetics",
        "_version_":1605765698704900096},
      {
        "Doc_abstract":"Cells from breast cancers lacking hormone receptors (estrogen receptor [ER], progesterone receptor [PgR]) and human epidermal growth factor receptor (HER) 2 strongly express the cell proliferation marker Ki-67. However, the mechanisms of and stimulus signals involved in cell proliferation of this type of breast cancer are not well understood. The aim of the present study was to examine the characteristics of signal transduction in triple-negative (ER-, PgR-, and HER2-negative) breast cancers. For 44 tumor samples, western blotting analysis was conducted to examine the phosphorylation of HER2, external signal-regulated kinase (ERK)1 and -2 and Akt, and the immunohistochemical phenotypes of the samples with respect to ER and HER2 were also assessed. Phosphorylation of HER2 was detected in 4 of 15 immunohistochemically HER2-positive tumor samples (26.7%). ERK1/2 was more highly phosphorylated in triple-negative breast cancers. Phosphorylation of Akt kinase was significantly higher in triple-negative breast cancers. Triple-negative breast cancers are characterized by increased phosphorylation of Akt kinase. In the present study, we found for the first time that there is a population with a significantly activated Akt pathway in this type of breast cancer.",
        "Doc_title":"Increased phosphorylation of Akt in triple-negative breast cancers.",
        "Journal":"Cancer science",
        "Do_id":"17892507",
        "Doc_ChemicalList":"Receptors, Estrogen;Receptors, Progesterone;ERBB2 protein, human;Receptor, ErbB-2;Proto-Oncogene Proteins c-akt",
        "Doc_meshdescriptors":"Breast Neoplasms;Carcinoma in Situ;Carcinoma, Intraductal, Noninfiltrating;Female;Humans;Immunohistochemistry;Neoplasm Invasiveness;Phosphorylation;Proto-Oncogene Proteins c-akt;Receptor, ErbB-2;Receptors, Estrogen;Receptors, Progesterone",
        "Doc_meshqualifiers":"pathology;surgery;pathology;surgery;pathology;surgery;analysis;metabolism;analysis;analysis;analysis",
        "_version_":1605831818667360256},
      {
        "Doc_abstract":"A set of common epidemiologic risk factors have been associated with the risk of breast cancer despite of its molecular sub-classifications. We implemented a case series study with the primary objective of evaluating if obesity is associated with the diagnostic risk of \"ER+ and/or PR+, HER2+\", \"ER-/PR-, HER2-\", or \"ER-/PR-, HER2+\" relative to the most commonly diagnosed subtype of breast carcinoma, \"ER+ and/or PR+, HER2-\".;Demographic, clinical and pathologic data were collected from existing databases. The statuses of HER2/neu biomarker and hormone receptors were dichotomized as either positive or negative. Immunohistochemical staining was used to assess the prevalence of different subtypes. Body mass index was calculated from weight and height data collected at the time of consultation.;Findings from the present study suggest that excess body weight decreases the diagnostic risk of \"ER-/PR-, HER2-\", or \"ER-/PR-, HER2-\" relative to \"ER+ and/or PR+, HER2-\". Obese and overweight women are more likely to be diagnosed with to \"ER+ and/or PR+, HER2-\", the subtype that has best prognosis and mostly associated with personal lifestyle. Weight gain with the population attributable-risk factor of 21.3% contributes the most to the incidence of invasive post menopausal breast cancer. Younger pre-menopausal women were more likely to be diagnosed with \"ER+ and/or PR+, HER2+\". In younger women biology of breast cancers with positive expression for hormone receptors and epidermal growth factor is a complex that extends beyond the currently assessed prognostic markers.",
        "Doc_title":"Obesity and risk of the less commonly diagnosed subtypes of breast cancer.",
        "Journal":"European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology",
        "Do_id":"19121564",
        "Doc_ChemicalList":"Biomarkers, Tumor;Receptors, Estrogen;Receptors, Progesterone;Epidermal Growth Factor;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Biomarkers, Tumor;Body Mass Index;Breast Neoplasms;Epidermal Growth Factor;Female;Humans;Logistic Models;Middle Aged;Obesity;Receptor, ErbB-2;Receptors, Estrogen;Receptors, Progesterone;Risk Factors;United States",
        "Doc_meshqualifiers":"metabolism;epidemiology;pathology;metabolism;epidemiology;metabolism;metabolism;metabolism;epidemiology",
        "_version_":1605822842930200576},
      {
        "Doc_abstract":"The term triple-negative breast cancer (TNBC) defines breast tumors that do not express estrogen receptors, progesterone receptor or epidermal growth factor receptor HER2 on immunohistochemical analysis. TNBC accounts for 12-17% of all types of breast cancer. Molecular profiling indicated that triple-negative breast cancer represents a heterogeneous subgroup of breast cancer. Triple-negative breast cancer shares histological and genetic abnormalities with basal-like subtype of breast cancer; however, this overlap is incomplete. Breast cancer found in BRCA1 mutation carriers is also frequently TNBC. Triple-negative breast cancer does not benefit from hormonal therapies or treatments targeted against HER2. The results of ongoing studies as well as the results of clinical trials suggest that poly(ADP-ribose) polymerase inhibitors, EGFR, Hedgehog, Notch, Wnt/Î²-catenin, VEGF signaling inhibitors, and mTOR, Src, and Bcr/Abl kinase inhibitors used alone or in combination with other anticancer drugs might be effective in triple-negative breast cancer treatment. In this review, current knowledge on molecular characteristics of triple-negative breast cancer and its subtypes' treatment options is presented. ",
        "Doc_title":"[Triple-negative breast cancer: molecular characteristics and potential therapeutic approaches].",
        "Journal":"Postepy higieny i medycyny doswiadczalnej (Online)",
        "Do_id":"24379250",
        "Doc_ChemicalList":"Hedgehog Proteins;Poly(ADP-ribose) Polymerase Inhibitors;Receptors, Notch;beta Catenin;BRAP protein, human;Ubiquitin-Protein Ligases;Receptor, Epidermal Growth Factor;Receptors, Vascular Endothelial Growth Factor",
        "Doc_meshdescriptors":"Animals;Antineoplastic Combined Chemotherapy Protocols;Hedgehog Proteins;Humans;Mutation;Poly(ADP-ribose) Polymerase Inhibitors;Receptor, Epidermal Growth Factor;Receptors, Notch;Receptors, Vascular Endothelial Growth Factor;Triple Negative Breast Neoplasms;Ubiquitin-Protein Ligases;beta Catenin",
        "Doc_meshqualifiers":"therapeutic use;antagonists & inhibitors;antagonists & inhibitors;antagonists & inhibitors;antagonists & inhibitors;drug therapy;genetics;pathology;genetics;antagonists & inhibitors",
        "_version_":1605755041513209856},
      {
        "Doc_abstract":"Breast cancers can display distinct clinical characteristics in different ethnic populations. Previous studies involving European and United States patients have shown that breast tumors can be divided by their gene expression profiles into distinct \"molecular subtypes.\" In this report, we surveyed a series of invasive and preinvasive breast tumors from Asian-Chinese patients to investigate whether similar subtypes could also be observed in this ethnic group.;An analysis of expression profiles generated from 11 nonmalignant breast tissues, 17 ductal carcinomas in situ (DCIS) and 98 invasive carcinomas identified three broad molecular subtypes of breast [estrogen receptor (ER)+, ERBB2+ and ER-] in the Asian-Chinese population. These subtypes were highly similar to the \"Luminal,\" \"ERBB2+,\" and \"Basal\" molecular subtypes defined in previous studies, and the subtype-specific expression signatures were also observed in preinvasive DCIS tumors. By comparing the expression profiles of nonmalignant DCIS and invasive breast cancers for two subtypes (ER+ and ERBB2+), we identified several genes that were regulated in both a common and subtype-specific manner during the normal/DCIS and DCIS/invasive carcinoma transitions. Several of these genes were validated by comparison with another recently published similar, but not identical, study.;Our results suggest that molecularly similar subtypes of breast cancer are indeed broadly conserved between Asian and Caucasian patients, and that these subtypes are already present at the preinvasive stage of carcinogenesis. To our knowledge, this study is among the first to directly compare the expression profiles of breast tumors across two different ethnic populations.",
        "Doc_title":"Conservation of breast cancer molecular subtypes and transcriptional patterns of tumor progression across distinct ethnic populations.",
        "Journal":"Clinical cancer research : an official journal of the American Association for Cancer Research",
        "Do_id":"15328190",
        "Doc_ChemicalList":"Receptors, Estrogen;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Asian Continental Ancestry Group;Breast Neoplasms;Disease Progression;European Continental Ancestry Group;Female;Gene Expression Profiling;Humans;Neoplasm Invasiveness;Oligonucleotide Array Sequence Analysis;Receptor, ErbB-2;Receptors, Estrogen;Singapore",
        "Doc_meshqualifiers":"genetics;classification;genetics;pathology;genetics;genetics;genetics",
        "_version_":1605896287132057600},
      {
        "Doc_abstract":"Crosstalk and compensatory circuits within cancer signaling networks limit the activity of most targeted therapies. For example, altered signaling in the networks activated by the ErbB family of receptors, particularly in ERBB2-amplified cancers, contributes to drug resistance. We developed a multiscale systems model of signaling networks in ERBB2-amplified breast cancer to quantitatively investigate relationships between biomarkers (markers of network activity) and combination drug efficacy. This model linked ErbB receptor family signaling to breast tumor growth through two kinase cascades: the PI3K/AKT survival pathway and the Ras/MEK/ERK growth and proliferation pathway. The model predicted molecular mechanisms of resistance to individual therapeutics. In particular, ERBB2-amplified breast cancer cells stimulated with the ErbB3 ligand heregulin were resistant to growth arrest induced by inhibitors of AKT and MEK or coapplication of two inhibitors of the receptor ErbB2 [Herceptin (trastuzumab) and Tykerb (lapatinib)]. We used model simulations to predict the response of ErbB2-positive breast cancer xenografts to combination therapies and verified these predictions in mice. Treatment with trastuzumab, lapatinib, and the ErbB3 inhibitor MM-111 was more effective in inhibiting tumor growth than the combination of AKT and MEK inhibitors and even induced tumor regression, indicating that targeting both ErbB3 and ErbB2 may be an improved therapeutic approach for ErbB2-positive breast cancer patients. ",
        "Doc_title":"Computational modeling of ERBB2-amplified breast cancer identifies combined ErbB2/3 blockade as superior to the combination of MEK and AKT inhibitors.",
        "Journal":"Science signaling",
        "Do_id":"23943608",
        "Doc_ChemicalList":"Antibodies, Bispecific;Antibodies, Monoclonal, Humanized;Biomarkers, Tumor;MM-111;Neuregulin-1;Quinazolines;lapatinib;Erbb2 protein, mouse;Receptor, ErbB-2;Receptor, ErbB-3;Oncogene Protein v-akt;Trastuzumab",
        "Doc_meshdescriptors":"Animals;Antibodies, Bispecific;Antibodies, Monoclonal, Humanized;Antineoplastic Combined Chemotherapy Protocols;Biomarkers, Tumor;Breast Neoplasms;Computer Simulation;Feedback, Physiological;Female;MAP Kinase Signaling System;Mice;Models, Biological;Neuregulin-1;Oncogene Protein v-akt;Quinazolines;Receptor, ErbB-2;Receptor, ErbB-3;Signal Transduction;Trastuzumab",
        "Doc_meshqualifiers":"pharmacology;metabolism;drug therapy;physiopathology;physiology;drug effects;antagonists & inhibitors;antagonists & inhibitors;metabolism;antagonists & inhibitors;metabolism;physiology",
        "_version_":1605824775961182208},
      {
        "Doc_abstract":"ADAMs (a disintegrin and metalloproteinase) family have been associated with the process of proteolytic \"shedding\" of membrane-associated proteins ectodomain and hence the rapid modulation of key cell signaling pathways in tissues microenvironment. A variety of cytokines, chemokines and growth factors which are initially produced as transmembrane proforms are activated by these sheddase activities. ADAM12 is highly expressed in rapidly growing tissues such as placenta and malignant tumors and it was found as one of the Candidate Cancer Genes in a comprehensive mutational analysis of human breast cancers. Our aim was to determine the gene expression profile of ADAM12 in breast cancers in comparison with normal breast and to correlate their level of expression with the clinical and pathological characteristics of breast cancers. Gene expression of ADAM12 spliced variants (12L and 12S) was evaluated using quantitative reverse-transcription PCR in samples obtained by laser capture microdissection from 38 patients with breast cancers and compared with adjacent healthy breast tissues. Both ADAM12L and 12S expression were significantly up-regulated in breast cancers, while in the normal breast, we found a very low expression. ADAM12L expression was significantly correlated with the histopathological types and, although not statistically significant, ADAM12 both variants were up-regulated in high-grade, highly-proliferative and HER2Ã·neu positive tumors. From these preliminary results, we found that ADAM12 could be an interesting marker and eventually a therapeutic target for breast cancer.",
        "Doc_title":"Molecular profiling of ADAM12 gene in breast cancers.",
        "Journal":"Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie",
        "Do_id":"21103624",
        "Doc_ChemicalList":"Biomarkers, Tumor;Membrane Proteins;ADAM Proteins;ADAM12 Protein;ADAM12 protein, human",
        "Doc_meshdescriptors":"ADAM Proteins;ADAM12 Protein;Adult;Aged;Alternative Splicing;Biomarkers, Tumor;Breast;Breast Neoplasms;Female;Gene Expression Profiling;Humans;Membrane Proteins;Middle Aged;Up-Regulation",
        "Doc_meshqualifiers":"genetics;genetics;metabolism;genetics;pathology;genetics",
        "_version_":1605746443839078401},
      {
        "Doc_abstract":"ALK has emerged as a novel tumorigenic factor in several epithelial human cancers. Crizotinib, an ALK tyrosine kinase inhibitor, is currently approved to treat lung cancer patients exhibiting ALK gene rearrangements. Our goal was to determine the incidence of ALK aberrations in relation to different breast cancer types. Tissue micro-arrays were constructed of ER+/PRÂ±/HER2- (nÂ =Â 37), ER-/PR-/HER2+ (nÂ =Â 15), ER-/PR-/HER2- (nÂ =Â 61) and ER+/PR+/HER2+ (nÂ =Â 20) breast cancers; including 13 inflammatory breast carcinomas. FISH was performed using ALK break-apart and chromosome 2 centromere enumeration probes (CEP2). Neither ALK rearrangements nor amplification were identified in the 133 breast cancer cases evaluated. However, copy number gains (CNG) of ALK were identified in 82 of 133 patients (62Â %). The CEP2 analysis revealed polysomy of chromosome 2 in all HCNG and LCNG cases, indicating the CNG of ALK are due to polysomy of chromosome 2, rather than true amplification of ALK. To conclude, we observed CNG of ALK secondary to chromosome 2 polysomy in a significant percentage of breast cancer cases, a phenomenon similar to polysomy 17. This study is one of the largest studies to have investigated ALK aberrations in breast cancer and the only study to include all subtypes. ",
        "Doc_title":"Analysis of ALK gene in 133 patients with breast cancer revealed polysomy of chromosome 2 and no ALK amplification.",
        "Journal":"SpringerPlus",
        "Do_id":"26312204",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605799445171011584},
      {
        "Doc_abstract":"Experimental evidence suggests that matrix metalloproteinase-13 (MMP-13) protein may promote breast tumor progression. However, its relevance to the progression of human breast cancer is yet to be established. Furthermore, it is not clear whether MMP-13 can be used as an independent breast cancer biomarker. This study was conducted to assess the expression profile of MMP-13 protein in invasive breast carcinomas to determine its diagnostic and prognostic significance, as well as its correlation with other biomarkers including estrogen receptor (ER), progesterone receptor (PR), Her-2/neu, MMP-2, MMP-9, tissue inhibitor of MMP-1 and -2 (TIMP-1 and TIMP-2).;Immunohistochemistry (IHC) was performed on paraffin-embedded tissue microarray containing specimens from 263 breast carcinomas. The intensity and the extent of IHC were scored by pathologists in blind fashion. The correlation of the gene expression profiles with patients' clinicopathological features and clinical outcomes were analyzed for statistical significance.;MMP-13 protein was detected in the cytoplasm of the malignant cells and the peritumoral stromal cells. MMP-13 expression by tumor cells (p < 0.001) and stromal fibroblasts (p <0.001) both correlated with carcinoma infiltration of lymph nodes. MMP-13 also correlated with the expression of Her-2/neu (p = 0.015) and TIMP-1 (p < 0.010), respectively in tumor cells. Tumor-derived, but not stromal fibroblast-derived, MMP-13 correlated with aggressive tumor phenotypes. Moreover, high levels of MMP-13 expression were associated with decreased overall survival. In parallel, the prognostic value of MMP-13 expressed by peritumoral fibroblasts seems less significant. Our data suggest that lymph node status, tumor size, Her-2/neu expression, TIMP-1 and MMP-13 expression in cancer cells are independent prognostic factors.;Tumor-derived, but not stromal fibroblast-derived, MMP-13 correlated with aggressive tumor phenotypes, and inversely correlated with the overall survival of breast cancer patients. MMP-13 may serve as an independent prognostic factor for invasive breast cancer patients. MMP-13 may be particularly useful as a prognostic marker when evaluated along with Her-2/neu and lymph node status.",
        "Doc_title":"Tumor-derived matrix metalloproteinase-13 (MMP-13) correlates with poor prognoses of invasive breast cancer.",
        "Journal":"BMC cancer",
        "Do_id":"18373849",
        "Doc_ChemicalList":"Antigens, Neoplasm;Biomarkers, Tumor;Tissue Inhibitor of Metalloproteinases;Receptor, ErbB-2;Matrix Metalloproteinase 13;Matrix Metalloproteinase 2;Matrix Metalloproteinase 9",
        "Doc_meshdescriptors":"Antigens, Neoplasm;Biomarkers, Tumor;Breast Neoplasms;Carcinoma, Ductal, Breast;Cytoplasm;Disease Progression;Female;Humans;Lymphatic Metastasis;Matrix Metalloproteinase 13;Matrix Metalloproteinase 2;Matrix Metalloproteinase 9;Middle Aged;Neoplasm Invasiveness;Prognosis;Receptor, ErbB-2;Stromal Cells;Survival Rate;Tissue Distribution;Tissue Inhibitor of Metalloproteinases",
        "Doc_meshqualifiers":"metabolism;metabolism;enzymology;mortality;pathology;enzymology;mortality;pathology;secondary;enzymology;metabolism;metabolism;metabolism;physiopathology;metabolism;enzymology;metabolism",
        "_version_":1605742104762384384},
      {
        "Doc_abstract":"Histone deacetylase inhibitors induce hyperacetylation of the amino-terminal lysine residues of the core nucleosomal histones, which results in chromatin remodeling and altered gene expression. Present studies demonstrate that exposure to a novel hydroxamic acid analogue histone deacetylase inhibitor, LAQ824, induced p21WAF1 and p27KIP1 and caused growth arrest and apoptosis of human breast cancer SKBR-3 and BT-474 cells that possess amplification and overexpression of Her-2/neu. Treatment with LAQ824 depleted the mRNA and protein levels of Her-2/neu-encoded Her-2, which was associated with attenuation of pAKT, c-Raf-1, and phosphorylated mitogen-activated protein kinase levels. LAQ824 also induced the acetylation of heat shock protein (hsp) 90, resulting in inhibition of its binding to ATP, which has been shown to impair the chaperone association of hsp 90 with its client proteins, Her-2, AKT, and c-Raf-1. Consistent with this, treatment with LAQ824 shifted the binding of Her-2 from hsp 90 to hsp 70, promoting proteasomal degradation of Her-2. Thus, LAQ824 depletes Her-2 through two mechanisms: attenuation of its mRNA levels and promotion of its degradation by the proteasome. Following LAQ824 treatment, the cell membrane association, autotyrosine phosphorylation, and colocalization of Her-2 with HER-3 also declined. Cotreatment with LAQ824 significantly increased trastuzumab-induced apoptosis of BT-474 and SKBR-3 cells. This was associated with greater attenuation of Her-2, c-Raf-1, and pAKT levels. LAQ824 also enhanced taxotere-induced, epothilone B-induced, and gemcitabine-induced apoptosis of BT-474 and SKBR-3 cells. These findings suggest that LAQ824 is active against human breast cancer cells and has the potential to improve the efficacy of trastuzumab, taxotere, gemcitabine, and epothilone B against breast cancer with Her-2/neuamplification.",
        "Doc_title":"Histone deacetylase inhibitor LAQ824 down-regulates Her-2 and sensitizes human breast cancer cells to trastuzumab, taxotere, gemcitabine, and epothilone B.",
        "Journal":"Molecular cancer therapeutics",
        "Do_id":"14578462",
        "Doc_ChemicalList":"Annexin A5;Antibodies, Monoclonal;Antibodies, Monoclonal, Humanized;Antimetabolites, Antineoplastic;Antineoplastic Agents;Antineoplastic Agents, Phytogenic;CDKN1A protein, human;Chromatin;Coloring Agents;Cyclin-Dependent Kinase Inhibitor p21;Cyclins;Detergents;Enzyme Inhibitors;Epothilones;Histone Deacetylase Inhibitors;Hydroxamic Acids;LAQ824;Multienzyme Complexes;Taxoids;Tetrazolium Salts;Thiazoles;Deoxycytidine;docetaxel;Sepharose;gemcitabine;Receptor, ErbB-2;Cysteine Endopeptidases;Proteasome Endopeptidase Complex;thiazolyl blue;Trastuzumab;epothilone B",
        "Doc_meshdescriptors":"Annexin A5;Antibodies, Monoclonal;Antibodies, Monoclonal, Humanized;Antimetabolites, Antineoplastic;Antineoplastic Agents;Antineoplastic Agents, Phytogenic;Apoptosis;Blotting, Northern;Blotting, Western;Breast Neoplasms;Cell Line, Tumor;Chromatin;Coloring Agents;Cyclin-Dependent Kinase Inhibitor p21;Cyclins;Cysteine Endopeptidases;Deoxycytidine;Detergents;Dose-Response Relationship, Drug;Down-Regulation;Enzyme Inhibitors;Epothilones;Flow Cytometry;Histone Deacetylase Inhibitors;Humans;Hydroxamic Acids;Microscopy, Fluorescence;Multienzyme Complexes;Phosphorylation;Precipitin Tests;Proteasome Endopeptidase Complex;Receptor, ErbB-2;Reverse Transcriptase Polymerase Chain Reaction;Sepharose;Taxoids;Tetrazolium Salts;Thiazoles;Time Factors;Trastuzumab",
        "Doc_meshqualifiers":"pharmacology;pharmacology;pharmacology;pharmacology;pharmacology;drug therapy;metabolism;pharmacology;metabolism;metabolism;analogs & derivatives;pharmacology;pharmacology;pharmacology;pharmacology;pharmacology;metabolism;biosynthesis;pharmacology;pharmacology;pharmacology;pharmacology",
        "_version_":1605797753869303808},
      {
        "Doc_abstract":"While the acquisition of invasiveness is a critical step in early stage breast carcinomas (DCIS), no established molecular markers reliably identify tumor progression. The metastasis gene osteopontin is subject to alternative splicing, which yields 3 messages, osteopontin-a, osteopontin-b and osteopontin-c. Osteopontin-c is selectively expressed in invasive, but not in noninvasive, breast tumor cell lines, and it effectively supports anchorage independence. We evaluated osteopontin-c as a biomarker. The RNA message for osteopontin-c was present in 16 of 20 breast cancers (80%), but was undetectable in 22 normal specimens obtained from reduction mammoplasty. In contrast, osteopontin-a RNA was expressed at various levels in all 20 breast cancers, 11 tumor-surrounding tissues and 21 normal samples. The splice variant osteopontin-b was present at barely detectable levels in 18 of 20 cancers and in 6 of 22 normal breasts. By immunohistochemistry, 66 of 69 normal breasts were negative, while 3 showed low level staining. Among the breast cancers, 43 of 56 cores (77%) stained positive for osteopontin-c. When correlated with tumor grade, the staining for osteopontin-c increased from grade 1 to grade 3. In a total of 178 breast specimens analyzed, osteopontin-c was present in 78% of cancers, 36% of surrounding tissues and 0% of normal tissues. Furthermore, osteopontin-c detects a higher fraction of breast cancers than estrogen receptor (ER), progesterone receptor or HER2. In conjunction, osteopontin-c, ER and HER2 reliably predict grade 2-3 breast cancer. Hence, osteopontin-c is a diagnostic and prognostic marker that may have value in a diagnostic panel together with conventional breast cancer markers.",
        "Doc_title":"Osteopontin-c is a selective marker of breast cancer.",
        "Journal":"International journal of cancer",
        "Do_id":"17960616",
        "Doc_ChemicalList":"Biomarkers, Tumor;Protein Isoforms;Receptors, Estrogen;Osteopontin;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Aged;Aged, 80 and over;Alternative Splicing;Biomarkers, Tumor;Breast;Breast Neoplasms;Carcinoma, Ductal, Breast;Case-Control Studies;Female;Gene Expression Regulation, Neoplastic;Humans;Immunoenzyme Techniques;Middle Aged;Neoplasm Invasiveness;Neoplasm Staging;Osteopontin;Prognosis;Protein Isoforms;Receptor, ErbB-2;Receptors, Estrogen;Reverse Transcriptase Polymerase Chain Reaction",
        "Doc_meshqualifiers":"genetics;metabolism;metabolism;pathology;genetics;metabolism;pathology;genetics;metabolism;pathology;pathology;genetics;metabolism;genetics;metabolism;metabolism",
        "_version_":1605879601713643520},
      {
        "Doc_abstract":"The calcium-activated chloride channel Ano1 (TMEM16A) is overexpressed in many tumors. Although Ano1 overexpression is found in breast cancer due to 11q13 amplification, it remains unclear whether signaling pathways are involved in Ano1 overexpression during breast cancer tumorigenesis in vivo. Estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) have been known to contribute to breast cancer progression. It is unclear whether Ano1 is associated with clinical outcomes in breast cancer patients with different ER, PR and HER2 status. In the present study, we investigated the Ano1 expression in 431 patients with invasive ductal breast carcinoma and 46 patients with fibroadenoma, using immunohistochemistry, and analyzed the association between Ano1 expression and clinical characteristics and outcomes of breast cancer patients with different ER, PR, and HER2 status. Ano1 was overexpressed in breast cancer compared with fibroadenoma. Ano1 was significantly more associated with breast cancer with the lower clinical stage (stage I or II), or triple-negative status. Mostly importantly, Ano1 overexpression was associated with good prognosis in patients with the PR-positive or HER2-negative status, and in patients following tamoxifen treatment. Multivariate Cox regression analysis showed that Ano1 overexpression was a prognostic factor for longer overall survival in PR-positive or HER2-negative patients, and a predictive factor for longer overall survival in patients following tamoxifen treatment. Our findings suggest that Ano1 may be a potential marker for good prognosis in PR-positive or HER2-negative patients following tamoxifen treatment. The PR and HER2 status defines a subtype of breast cancer in which Ano1 overexpression is associated with good prognosis following tamoxifen treatment. ",
        "Doc_title":"Ano1/TMEM16A Overexpression Is Associated with Good Prognosis in PR-Positive or HER2-Negative Breast Cancer Patients following Tamoxifen Treatment.",
        "Journal":"PloS one",
        "Do_id":"25961581",
        "Doc_ChemicalList":"ANO1 protein, human;Biomarkers, Tumor;Chloride Channels;Neoplasm Proteins;Receptors, Progesterone;Tamoxifen;ERBB2 protein, human;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Adult;Aged;Aged, 80 and over;Biomarkers, Tumor;Breast Neoplasms;Chloride Channels;Female;Humans;Immunohistochemistry;In Vitro Techniques;Middle Aged;Neoplasm Proteins;Prognosis;Receptor, ErbB-2;Receptors, Progesterone;Retrospective Studies;Tamoxifen;Young Adult",
        "Doc_meshqualifiers":"metabolism;drug therapy;metabolism;metabolism;metabolism;metabolism;metabolism;therapeutic use",
        "_version_":1605906281899491328},
      {
        "Doc_abstract":"HER2 amplification occurs in 10-15% of breast cancers. It is associated with poor breast cancer-specific survival (BCSS) and is an important prognostic and predictive marker. While it has been accepted that the HER2:chromosome 17 centromere (CEP17) ratio determines HER2 status, recent guidelines acknowledge the significance of HER2 copy number alone. The aims of this study were to assess BCSS according to mean HER2 copy number and HER2 status expressed as a HER2:CEP17 ratio with and without increased CEP17 copy number.;The study population comprised breast cancer patients treated with surgery only and with long-term follow-up. In situ hybridization for HER2:CEP17 was performed on tissue microarrays and was successful in 679 cases. These were included in the study. Kaplan-Meier methods were used to estimate BCSS. A total of 47 cases had â‰¥4 < 6 HER2 copies; 16 were HER2",
        "Doc_title":"HER2 gene copy number and breast cancer-specific survival.",
        "Journal":"Histopathology",
        "Do_id":"27271096",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605913375722700800},
      {
        "Doc_abstract":"RET finger protein (RFP), which belongs to the large B-box RING finger protein family, has been reported to be expressed in breast carcinoma cell lines. We conducted this study to evaluate the expression level of RFP in breast carcinomas. Tissue microarrays were constructed from 133 cases of invasive breast carcinoma. Sections obtained from tissue arrays and whole sections from 10 non-neoplastic breast tissues were stained for ER, PR, ErbB2, and RFP using immunohistochemistry, and ErbB2 gene status was evaluated by FISH. The correlation between various immunohistochemical markers was determined. We found nuclear RFP expression in 41.4% of invasive carcinomas and in none of the non-neoplastic breast tissues. We also stained whole sections of 29 cases of invasive breast carcinoma, which included the TMA study, and 10 cases of ductal carcinoma in situ (DCIS) by RFP. We observed that four (40%) of the DCIS cases were positive with RFP. In statistical analysis, there was a significant, positive association between RFP and ErbB2 status at the protein level (p=0.002) and the gene level (p=0.049). There was no statistically significant association between the expression of RFP and tumor size, LN status, ER, PR, and grade (p>0.05). However, we found a significant association between age and RFP expression. RFP expression was stronger in patients 50 years or older (p=0.048). In our study, the expression of RFP correlated strongly with ErbB2 status. Our study is the first in the literature to show expression of RFP in patients with breast carcinoma. However, the possible role of RFP in breast carcinogenesis needs to be investigated in more detailed clinical and experimental studies.",
        "Doc_title":"RET finger protein expression in invasive breast carcinoma: relationship between RFP and ErbB2 expression.",
        "Journal":"Pathology, research and practice",
        "Do_id":"19232840",
        "Doc_ChemicalList":"Biomarkers, Tumor;DNA-Binding Proteins;Nuclear Proteins;Receptors, Estrogen;Receptors, Progesterone;TRIM27 protein, human;ERBB2 protein, human;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Adult;Age Factors;Aged;Aged, 80 and over;Biomarkers, Tumor;Breast Neoplasms;Carcinoma in Situ;Carcinoma, Ductal, Breast;DNA-Binding Proteins;Female;Gene Expression;Humans;Immunohistochemistry;In Situ Hybridization, Fluorescence;Middle Aged;Neoplasm Staging;Nuclear Proteins;Receptor, ErbB-2;Receptors, Estrogen;Receptors, Progesterone;Tissue Array Analysis",
        "Doc_meshqualifiers":"analysis;genetics;metabolism;pathology;genetics;metabolism;pathology;genetics;metabolism;pathology;biosynthesis;biosynthesis;biosynthesis;biosynthesis;biosynthesis",
        "_version_":1605831441997889536},
      {
        "Doc_abstract":"Cancer is a genetic disease. Breast cancer tumorigenesis can be described as a multi-step process in which each step is thought to correlate with one or more distinct mutations in major regulatory genes. The question addressed is how far a multi-step progression model for sporadic breast cancer would differ from that for hereditary breast cancer. Hereditary breast cancer is characterized by an inherited susceptibility to breast cancer on basis of an identified germline mutation in one allele of a high penetrance susceptibility gene (such as BRCA1, BRCA2, CHEK 2, TP53 or PTEN). Inactivation of the second allele of these tumour suppressor genes would be an early event in this oncogenic pathway (Knudson's \"two-hit\" model). Sporadic breast cancers result from a serial stepwise accumulation of acquired and uncorrected mutations in somatic genes, without any germline mutation playing a role. Mutational activation of oncogenes, often coupled with non-mutational inactivation of tumour suppressor genes, is probably an early event in sporadic tumours, followed by more, independent mutations in at least four or five other genes, the chronological order of which is likely less important. Oncogenes that have been reported to play an early role in sporadic breast cancer are MYC, CCND1 (Cyclin D1) and ERBB2 (HER2/neu). In sporadic breast cancer, mutational inactivation of BRCA1/2 is rare, as inactivation requires both gene copies to be mutated or totally deleted. However, non-mutational functional suppression could result from various mechanisms, such as hypermethylation of the BRCA1 promoter or binding of BRCA2 by EMSY. In sporadic breast tumorigenesis, at least three different pathway-specific mechanisms of tumour progression are recognizable, with breast carcinogenesis being different in ductal versus lobular carcinoma, and in well differentiated versus poorly differentiated ductal cancers. Thus, different breast cancer pathways emerge early in the process of carcinogenesis, ultimately leading to clinically different tumour types. As mutations acquired early during tumorigenesis will be present in all later stages, large-scale gene expression profiling using DNA microarray analysis techniques can help to classify breast cancers into clinically relevant subtypes.",
        "Doc_title":"Oncogenic pathways in hereditary and sporadic breast cancer.",
        "Journal":"Maturitas",
        "Do_id":"15351094",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"Breast Neoplasms;Cell Transformation, Neoplastic;Disease Progression;Female;Genetic Predisposition to Disease;Humans;Models, Genetic;Mutation",
        "Doc_meshqualifiers":"genetics",
        "_version_":1605750930877186048},
      {
        "Doc_abstract":"Cancer is a genetic disease. Breast cancer tumorigenesis can be described as a multi-step process in which each step is thought to correlate with one or more distinct mutations in major regulatory genes. The question addressed is how far a multi-step progression model for sporadic breast cancer would differ from that for hereditary breast cancer. Hereditary breast cancer is characterized by an inherited susceptibility to breast cancer on basis of an identified germline mutation in one allele of a high penetrance susceptibility gene (such as BRCA1, BRCA2, CHEK 2, TP53 or PTEN). Inactivation of the second allele of these tumour suppressor genes would be an early event in this oncogenic pathway (Knudson's \"two-hit\" model). Sporadic breast cancers result from a serial stepwise accumulation of acquired and uncorrected mutations in somatic genes, without any germline mutation playing a role. Mutational activation of oncogenes, often coupled with non-mutational inactivation of tumour suppressor genes, is probably an early event in sporadic tumours, followed by more, independent mutations in at least four or five other genes, the chronological order of which is likely less important. Oncogenes that have been reported to play an early role in sporadic breast cancer are MYC, CCND1 (Cyclin D1) and ERBB2 (HER2/neu). In sporadic breast cancer, mutational inactivation of BRCA1/2 is rare, as inactivation requires both gene copies to be mutated or totally deleted. However, non-mutational functional suppression could result from various mechanisms, such as hypermethylation of the BRCA1 promoter or binding of BRCA2 by EMSY. In sporadic breast tumorigenesis, at least three different pathway-specific mechanisms of tumour progression are recognizable, with breast carcinogenesis being different in ductal versus lobular carcinoma, and in well differentiated versus poorly differentiated ductal cancers. Thus, different breast cancer pathways emerge early in the process of carcinogenesis, ultimately leading to clinically different tumour types. As mutations acquired early during tumorigenesis will be present in all later stages, large-scale gene expression profiling using DNA microarray analysis techniques can help to classify breast cancers into clinically relevant subtypes.",
        "Doc_title":"Oncogenic pathways in hereditary and sporadic breast cancer.",
        "Journal":"Maturitas",
        "Do_id":"19434886",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605852006385188864},
      {
        "Doc_abstract":"To investigate the efficacy and toxicity of recombinant humanized anti-Her-2/neu antibody (Herceptin) and Taxol for patients with Her-2/neu overexpressing metastatic breast cancer.;Sixty patients with Her-2/neu overexpressing metastatic breast cancer were investigated. Of the 60 cases, 22 were treated with Herceptin and Taxol and 38 with Taxol and doxorubicin.;The total response rate (RR) of Herceptin and Taxol was 68.2%, and that of Taxol and doxorubicin was 44.7%. The RR of patients with Her-2/neu(+++) was 75%, while that of patients with Her-2/neu(++) was 50%. The major adverse effects were gastro-intestinal tract reactions, myopathy, bone marrow suppression and alopecia.;The treatment with Herceptin and Taxol is effective and safe for patients with Her-2/neu overexpressing metastatic breast cancer. The therapeutic effect is related to the degree of Her-2/neu overexpression.",
        "Doc_title":"[Effect of Herceptin combined with Taxol on patients with Her-2/neu overexpressing metastatic breast cancer].",
        "Journal":"Zhonghua zhong liu za zhi [Chinese journal of oncology]",
        "Do_id":"15059359",
        "Doc_ChemicalList":"Antibodies, Monoclonal;Antibodies, Monoclonal, Humanized;Receptor, ErbB-2;Trastuzumab;Paclitaxel",
        "Doc_meshdescriptors":"Adult;Aged;Antibodies, Monoclonal;Antibodies, Monoclonal, Humanized;Antineoplastic Combined Chemotherapy Protocols;Breast Neoplasms;Female;Humans;Middle Aged;Paclitaxel;Receptor, ErbB-2;Trastuzumab",
        "Doc_meshqualifiers":"administration & dosage;adverse effects;therapeutic use;chemistry;drug therapy;administration & dosage;adverse effects;analysis",
        "_version_":1605898964101496832},
      {
        "Doc_abstract":"Invasive breast cancer is a heterogeneous disease sustained by intercorrelated and complex growth pathways. Classically, human breast carcinoma has been classified for therapeutic purposes in two distinct categories: one hormone-correlated, the other hormone-uncorrelated. However, the recent advancements of the technology applied to molecular biology by genomic and proteomic analyses have suggested that many more factors are involved in breast cancer growth and progression and that some clusters of these distinguish subgroups of patients at different prognosis. The knowledge of the diversities between tumor and normal tissue of origin is the key to identify novel targets for new selective therapeutic strategies. In fact, the principal goal of molecular-targeted therapy is the suppression of the transformed phenotype minimally affecting normal cells. This review focuses on the molecular targeting compounds directed against the known molecular pathways involved in breast cancer such as: type I growth factors (HER-2/neu; epidermal growth factor receptor [EGFR]), angiogenesis, cyclooxigenase-2 (COX-2) and farnesylation. Presently, trastuzumab is the first agent approved for therapy of HER-2/neu overexpressing tumors. Several other compounds directed against different targets have entered clinical evaluation and the preliminary results are here presented and commented. The major challenges on the clinical development of targeted therapy include the proper selection of patients, the identification of the optimal dosage and schedule of administration, the combinations with conventional treatments and the more appropriate therapeutic strategy.",
        "Doc_title":"Therapy of breast cancer with molecular targeting agents.",
        "Journal":"Annals of oncology : official journal of the European Society for Medical Oncology",
        "Do_id":"15923426",
        "Doc_ChemicalList":"Angiogenesis Inhibitors;Antibodies, Monoclonal;Antibodies, Monoclonal, Humanized;Protein Kinase Inhibitors;Quinazolines;Taxoids;docetaxel;Vinblastine;Erlotinib Hydrochloride;Cyclooxygenase 2;PTGS2 protein, human;Receptor, ErbB-2;Trastuzumab;Paclitaxel;vinorelbine;gefitinib",
        "Doc_meshdescriptors":"Angiogenesis Inhibitors;Antibodies, Monoclonal;Antibodies, Monoclonal, Humanized;Antineoplastic Combined Chemotherapy Protocols;Breast Neoplasms;Cyclooxygenase 2;Erlotinib Hydrochloride;Female;Humans;Paclitaxel;Prenylation;Protein Kinase Inhibitors;Quinazolines;Receptor, ErbB-2;Taxoids;Trastuzumab;Vinblastine",
        "Doc_meshqualifiers":"administration & dosage;administration & dosage;therapeutic use;drug therapy;genetics;drug effects;administration & dosage;drug effects;administration & dosage;administration & dosage;drug effects;physiology;administration & dosage;administration & dosage;analogs & derivatives",
        "_version_":1605746355306758145},
      {
        "Doc_abstract":"Breast cancer patients who have HER2 gene amplification and, consequently, protein overexpression, generally show an aggressive course with short disease-free and overall survivals. Trastuzumab, a humanized monoclonal antibody against the extracellular domain of HER2 protein, has been shown to benefit patients who have HER2-positive metastatic breast cancer, and recently, the results of five adjuvant trials involving more than 13,000 women have been released. Here, the authors summarize the main results and outline the differences among these trials, which have demonstrated an important role of trastuzumab in the treatment of women who have HER2-overexpressing/amplified early breast cancer.",
        "Doc_title":"Trastuzumab (herceptin) for early-stage breast cancer.",
        "Journal":"Hematology/oncology clinics of North America",
        "Do_id":"17512447",
        "Doc_ChemicalList":"Antibodies, Monoclonal;Antibodies, Monoclonal, Humanized;Antineoplastic Agents;Receptor, ErbB-2;Trastuzumab",
        "Doc_meshdescriptors":"Antibodies, Monoclonal;Antibodies, Monoclonal, Humanized;Antineoplastic Agents;Breast Neoplasms;Clinical Trials as Topic;Female;Humans;Neoplasm Staging;Receptor, ErbB-2;Trastuzumab;Treatment Outcome",
        "Doc_meshqualifiers":"administration & dosage;adverse effects;therapeutic use;administration & dosage;adverse effects;therapeutic use;drug therapy;metabolism;pathology;biosynthesis;genetics",
        "_version_":1605746336329629697},
      {
        "Doc_abstract":"Trastuzumab has conferred significant clinical benefits in HER-2-positive breast carcinomas. HER-2 status is determined by immunohistochemistry (IHC) and/or fluorescence in situ hybridisation (FISH), but appropriate assessment of HER2 status remains subject to considerable debate. Data on the health economic impact of HER-2 test strategies are limited. A life-long Markov state transition model was used to assess costs and effectiveness of HER-2 assay strategies (based on IHC, FISH, both combined or FISH confirmation of IHC2+) for a hypothetical cohort of early breast cancer patients from the perspective of the Swiss health system. We compared clinically relevant strategies of predictive testing and subsequent trastuzumab treatment of HER-2-positive patients only. FISH testing was the most cost-effective strategy with an incremental cost-effectiveness ratio of â‚¬12,245 per additional quality-adjusted life-year (QALY) gained, compared to no trastuzumab treatment. The next best strategy was parallel IHC and FISH, with costs of â‚¬400,154/QALY gained compared to FISH alone. FISH as primary HER-2 testing modality remained the preferred option in deterministic and probabilistic sensitivity analysis. Predictive testing to identify adjuvant breast cancer patients who benefit from trastuzumab treatment is a clinical and economic necessity. Our model identifies FISH as the most cost-effective approach.",
        "Doc_title":"Human epidermal growth factor receptor 2 expression in early breast cancer patients: a Swiss cost-effectiveness analysis of different predictive assay strategies.",
        "Journal":"Breast cancer research and treatment",
        "Do_id":"20364309",
        "Doc_ChemicalList":"Antibodies, Monoclonal;Antibodies, Monoclonal, Humanized;Antineoplastic Agents;Biomarkers, Tumor;ERBB2 protein, human;Receptor, ErbB-2;Trastuzumab",
        "Doc_meshdescriptors":"Antibodies, Monoclonal;Antibodies, Monoclonal, Humanized;Antineoplastic Agents;Biomarkers, Tumor;Breast Neoplasms;Chemotherapy, Adjuvant;Cost-Benefit Analysis;Drug Costs;Female;Health Care Costs;Humans;Immunohistochemistry;In Situ Hybridization, Fluorescence;Markov Chains;Mass Screening;Models, Economic;National Health Programs;Predictive Value of Tests;Quality-Adjusted Life Years;Receptor, ErbB-2;Sensitivity and Specificity;Switzerland;Trastuzumab;Treatment Outcome",
        "Doc_meshqualifiers":"economics;therapeutic use;economics;therapeutic use;analysis;genetics;chemistry;drug therapy;genetics;pathology;economics;economics;economics;methods;economics;analysis;genetics",
        "_version_":1605746461036773376},
      {
        "Doc_abstract":"There is limited data on the impact of specific patient characteristics, tumor subtypes or treatment interventions on survival in breast cancer LM.;A systematic review was conducted to assess the impact of hormone receptor and HER-2 status on survival in breast cancer LM. A search for clinical studies published between 1/1/2007 and 7/1/2012 and all randomized-controlled trials was performed. Survival data from all studies are reported by study design (prospective trials, retrospective cohort studies, case studies).;A total of 36 studies with 851 LM breast cancer subjects were identified. The majority (87%) were treated with intrathecal chemotherapy. Pooled median overall survival ranged from 14.9-18.1 weeks depending on study type. Breast cancer LM survival (15 weeks) was longer than other solid tumor LM 8.3 weeks and lung cancer LM 8.7 weeks, but shorter than LM lymphoma (15.4 versus 24.2 weeks). The impact of hormone receptor and HER-2 status on survival could not be determined.;A median overall survival of 15 weeks in prospective studies of breast cancer LM provides a historical comparison for future LM breast cancer trials. Other outcomes including the impact of molecular status on survival could not be determined based on available studies.",
        "Doc_title":"Leptomeningeal metastasis in breast cancer - a systematic review.",
        "Journal":"Oncotarget",
        "Do_id":"26543235",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"Breast Neoplasms;Female;Humans;Meningeal Neoplasms",
        "Doc_meshqualifiers":"pathology;secondary",
        "_version_":1605850653915086848},
      {
        "Doc_abstract":"Prognostic subgroup classification of operable breast cancers using cDNA clustering of breast cancer-related genes resembles the classification based on the combined immunohistochemical (IHC) expression of the hormone and HER-2 receptors. We here report the short-term disease-free interval (DFI) of operable breast cancers by their joint hormone receptor/HER-2 phenotype.;Short-term follow-up (FU) of a prospective cohort of 1,958 breast-cancer patients primary operated at our institution between 2000 and 2005. Receptors were evaluated using IHC. Steroid receptors were considered positive for any nuclear staining; HER-2 for strong (3+) membrane staining or positive fluorescence in situ hybridization (FISH). Kaplan-Meier (KM) DFI curves were calculated for any relapse defined as a local, regional, contralateral, or distant breast cancer event for the six predefined breast cancer subgroups: ER + PR + HER-2 - (PPN), ER + PR - HER-2 - (PNN), ER + PR + HER-2 + (PPP), ER - PR - HER-2 - (NNN), ER - PR - HER-2 + (NNP), and ER + PR - HER-2 + (PNP). P-values were calculated for comparison of the six different survival curves using two possible adaptations for multiple testing. A multivariate model for the receptors predicting DFI did incorporate local and systemic adjuvant therapy.;Median patient age was 57 years (ranges 26-96) and median FU was 3.35 years. Overall, DFI at median FU was 91%; 94% for PPN, 89% for PNN, 86% for NNN, 81% for PPP, 80% for PNP, and 76% for NNP cases. Some receptor subgroups had a significantly better DFI than others based on multiple testing, especially when the PPN group was compared against the four most frequent subtypes. The multivariate model with local and systemic adjuvant therapy confirmed the prognostic value of ER, PR, and HER-2 for short-term DFI.;It is possible to distinguish short-term prognostic breast cancer subgroups only on the basis of ER, PR, and HER-2 even when stratified for local and systemic adjuvant therapy. While gene expression profiles based on microarray data of over hundreds of genes will probably teach us much about breast cancer biology, heterogeneity, and prognosis, we emphasize the important short-term prognostic value of currently used IHC markers for ER, PR, and HER-2.",
        "Doc_title":"Short-term outcome of primary operated early breast cancer by hormone and HER-2 receptors.",
        "Journal":"Breast cancer research and treatment",
        "Do_id":"18629635",
        "Doc_ChemicalList":"Biomarkers, Tumor;Receptors, Estrogen;Receptors, Progesterone;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Biomarkers, Tumor;Breast Neoplasms;Female;Humans;Immunohistochemistry;In Situ Hybridization, Fluorescence;Kaplan-Meier Estimate;Middle Aged;Phenotype;Prognosis;Receptor, ErbB-2;Receptors, Estrogen;Receptors, Progesterone;Treatment Outcome",
        "Doc_meshqualifiers":"analysis;metabolism;mortality;surgery;metabolism;metabolism;metabolism",
        "_version_":1605820654171455488},
      {
        "Doc_abstract":"The association between nuclear factor I/B (NFIB) gene and triple negative breast cancer has been previously suggested.;We investigated the relationship between NFIB mRNA and protein expression and molecular subtypes of breast cancer as well as the effect of NFIB silencing on the proliferation and apoptosis of breast cancer cells. Also, the clinical importance of NFIB expression was investigated in 163 breast cancer patients.;By using 20 frozen human breast cancer tissues and various breast cancer cell lines, we observed a significant high level of NFIB mRNA level in triple negative breast cancer. NFIB protein was upregulated in ER negative breast cancer tissues but the expression level was similar between HER2 subtype and triple negative subtype. The clinical significance of NFIB was further examined in a tissue microarray from 163 invasive breast cancer patients, and the immunohistochemistry results showed a significant association between NFIB expression and nuclear grade, ER, and HER2 expression status. NFIB positive tumors were more likely to have high nuclear grade, ER negativity and HER2 over-expression. HCC1954 cells transfected with siRNA against NFIB showed a significant reduction in cell proliferation and increase in apoptotic signaling pathway.;Our results show a potential role of NFIB as a novel target in ER negative breast cancers.",
        "Doc_title":"NFIB is a potential target for estrogen receptor-negative breast cancers.",
        "Journal":"Molecular oncology",
        "Do_id":"21925980",
        "Doc_ChemicalList":"NFI Transcription Factors;RNA, Messenger;Receptors, Estrogen;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Adult;Breast;Breast Neoplasms;Cell Line, Tumor;Cell Proliferation;Female;Gene Expression Regulation, Neoplastic;Humans;Immunohistochemistry;Middle Aged;NFI Transcription Factors;RNA, Messenger;Receptor, ErbB-2;Receptors, Estrogen",
        "Doc_meshqualifiers":"metabolism;pathology;genetics;metabolism;pathology;genetics;genetics;genetics;metabolism",
        "_version_":1605746986943774720},
      {
        "Doc_abstract":"Trastuzumab (Herceptin) is a humanized antibody directed against the extracellular domain of the tyrosine kinase orphan receptor Her-2/neu (erbB-2) that has shown therapeutic efficacy against Her-2/neu-overexpressing breast tumors. However, less than 35% of patients with Her-2/neu-overexpressing metastatic breast cancer respond to trastuzumab as a single agent, whereas the remaining cases do not demonstrate tumor regression. Furthermore, the majority of patients who achieve an initial response generally acquire resistance within one year. Therefore, the identification of the potential mechanisms of resistance to trastuzumab can be very helpful for the development of new compounds, which might overcome that resistance and/or have additive/synergistic antitumor effect when given in association with trastuzumab. Recent studies in breast cancer cells have revealed a bi-directional connection between Her-2/neu and fatty acid synthase (FAS), a major lipogenic enzyme catalyzing the synthesis of long-chain saturated fatty acids from the 2-carbon donors malonyl-CoA and acetyl-CoA. Her-2/neu overexpression stimulates the FAS promoter and ultimately mediates increased endogenous fatty synthesis, and this Her-2/neu-mediated induction of breast cancer-associated FAS is inhibitable by trastuzumab. On the other hand, chemical FAS inhibitors as well as RNA interference-mediated silencing of FAS gene repress Her-2/neu gene expression at the transcriptional level. Moreover, specific FAS blockade synergistically sensitizes breast cancer cells carrying Her-2/neu-oncogene amplification and/or overexpression to trastuzumab-induced cell growth inhibition and apoptotic cell death. Strikingly, FAS inhibition synergistically interacts with trastuzumab in Her-2/neu-negative breast cancer cells engineered to overexpress Her-2/neu, thus suggesting that the molecular linkage between FAS activity and functioning of Her-2/neu cannot be explained only on the basis of a transcriptional repression of Her-2/neu gene promoter. Interestingly, while in liver and adipose tissue FAS produces fat from excess carbon consumed as carbohydrates, which is ultimately stored as triglycerides, in epithelial cancer cells, FAS activity is mainly involved in the production of phospholipids partitioning into detergent-resistant membrane microdomains (lipid raft-aggregates), which point to an active role of FAS in the deregulation of membrane functioning in tumor cells. Importantly, clusters of Her-2/neu and EGFR (erbB-1) co-localize with lipid rafts and the lipid environment in the cell membrane of breast cancer cells profoundly influences their association properties and biological functions. We hypothesize that pharmacological or small interference RNA-induced inhibition of breast cancer-associated FAS will result in major changes in the synthesis of phospholipids which, in turn, should impair a correct cellular localization of Her-2/neu at the cellular membrane of breast cancer cells. In this working model, FAS inhibition could induce a shift in the equilibrium between transport of Her-2/neu to and from the membrane favoring an increased Her-2/neu internalization followed by intracellular degradation, thus enhancing the mechanism of action of the anti-Her-2/neu antibody trastuzumab. Moreover, the inhibition of FAS-driven lipid rafts will also negatively affect EGFR-Her-2/neu cross-talk, an important mechanism of trastuzumab resistance. In summary, the specific blockade of a novel molecular linkage between FAS-regulated membrane composition and functioning of transmembrane growth factor receptors EGFR and Her-2/neu may represent a previously unrecognized therapeutic approach circumventing trastuzumab resistance in breast carcinomas.",
        "Doc_title":"Targeting fatty acid synthase-driven lipid rafts: a novel strategy to overcome trastuzumab resistance in breast cancer cells.",
        "Journal":"Medical hypotheses",
        "Do_id":"15780499",
        "Doc_ChemicalList":"Antibodies, Monoclonal;Antibodies, Monoclonal, Humanized;Antineoplastic Agents;Fatty Acid Synthases;Receptor, ErbB-2;Trastuzumab",
        "Doc_meshdescriptors":"Antibodies, Monoclonal;Antibodies, Monoclonal, Humanized;Antineoplastic Agents;Breast Neoplasms;Drug Resistance, Neoplasm;Fatty Acid Synthases;Humans;Lipid Metabolism;Receptor, ErbB-2;Trastuzumab",
        "Doc_meshqualifiers":"pharmacology;therapeutic use;drug therapy;enzymology;pathology;metabolism;metabolism",
        "_version_":1605804875141087232},
      {
        "Doc_abstract":"Breast cancer is the second most common type of cancer in women after skin cancer. Between 15 to 25% of breast cancers are characterized by overexpression of human epidermal growth factor receptor 2 (HER-2). HER-2 overexpression has been associated with more aggressive tumor phenotype, poor prognosis and shortened survival. Humanized monoclonal antibody trastuzumab was the first targeted therapy against HER-2 used in clinical practice. Trastuzumab has significantly improved the prognosis of HER-2 overexpressing breast cancer, is effective as a single agent or in combination with chemotherapy, has proven efficacy in the treatment of metastatic breast cancer and also in adjuvant and neoadjuvant setting. Despite trastuzumab success in treatment, several important questions are still not clearly answered. The most discussed issues are the optimal selection of patients with regard to HER-2 testing, combination of trastuzumab with anthracyclines, comparison of the efficacy of trastuzumab in combination with different chemotherapy regimens, the ideal scheduling of trastuzumab administration, the duration of treatment, especially in adjuvant therapy, continuation of trastuzumab treatment beyond disease progression and after development of brain metastasis. Trastuzumab is generally well tolerated and the clinically most important adverse effect is potential for congestive heart failure, therefore careful cardiac monitoring is required for all patients receiving this therapy. Aim of this article is to summarize the results of clinical trials with trastuzumab and refer to some issues concerning trastuzumab administration and toxicity.",
        "Doc_title":"[Clinical aspects of trastuzumab treatment in breast cancer].",
        "Journal":"Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti",
        "Do_id":"19534433",
        "Doc_ChemicalList":"Antibodies, Monoclonal;Antibodies, Monoclonal, Humanized;Antineoplastic Agents;Trastuzumab",
        "Doc_meshdescriptors":"Antibodies, Monoclonal;Antibodies, Monoclonal, Humanized;Antineoplastic Agents;Breast Neoplasms;Female;Humans;Trastuzumab",
        "Doc_meshqualifiers":"therapeutic use;therapeutic use;drug therapy",
        "_version_":1605741974215720960},
      {
        "Doc_abstract":"The phosphatidylinositol-3-kinase (PI3K)-AKT signaling pathway is considered to play an important role in tumorigenesis. Frequent somatic mutations in the PI3K subunit p110alpha (PIK3CA) occur in a variety of cancer types. We screened 250 primary human breast tumors for mutations in PIK3CA in order to determine associations with pathological features and with patient outcome. The frequency of PIK3CA mutations in the C2, helical and kinase domains was 35% (88/250). Mutations were associated with larger tumor size (p = 0.004) and positive estrogen receptor status (p = 0.008). Patients with PIK3CA mutations showed significantly worse survival (p = 0.004), particularly those with positive estrogen receptor expression or non-amplified erbB2 (both p = 0.002). PIK3CA mutation was an independent factor for worse survival in breast cancer patients with non-amplified erbB2 (RR = 2.6, 95%CI [1.2-5.5], p = 0.016).",
        "Doc_title":"PIK3CA mutations in breast cancer are associated with poor outcome.",
        "Journal":"Breast cancer research and treatment",
        "Do_id":"16317585",
        "Doc_ChemicalList":"Receptors, Estrogen;Receptors, Progesterone;Phosphatidylinositol 3-Kinases;PIK3CA protein, human",
        "Doc_meshdescriptors":"Adolescent;Adult;Aged;Aged, 80 and over;Breast Neoplasms;Carcinoma, Ductal, Breast;Cell Differentiation;DNA Mutational Analysis;Female;Humans;Middle Aged;Mutation;Neoplasm Invasiveness;Phosphatidylinositol 3-Kinases;Polymerase Chain Reaction;Polymorphism, Single-Stranded Conformational;Receptors, Estrogen;Receptors, Progesterone;Treatment Outcome",
        "Doc_meshqualifiers":"genetics;therapy;genetics;therapy;genetics;pathology;genetics;metabolism;metabolism",
        "_version_":1605837359056683008},
      {
        "Doc_abstract":"Breast cancer may be classified into luminal A, luminal B, HER2+/ER-, basal-like and normal-like subtypes based on gene expression profiling or immunohistochemical (IHC) characteristics. The main aim of the present study was to classify breast cancer into molecular subtypes based on immunohistochemistry findings and correlate the subtypes with clinicopathological factors. Two hundred and seventeen primary breast carcinomas tumor tissues were immunostained for ER, PR, HER2, CK5/6, EGFR, CK8/18, p53 and Ki67 using tissue microarray technique. All subtypes were significantly associated with Malay ethnic background (p=0.035) compared to other racial origins. The most common subtypes of breast cancers were luminal A and was significantly associated with low histological grade (p<0.000) and p53 negativity (p=0.003) compared to HER2+/ER-, basal-like and normal-like subtypes with high histological grade (p<0.000) and p53 positivity (p=0.003). Luminal B subtype had the smallest mean tumor size (p=0.009) and also the highest mean number of lymph nodes positive (p=0.032) compared to other subtypes. All markers except EGFR and Ki67 were significantly associated with the subtypes. The most common histological type was infiltrating ductal carcinoma, NOS. Majority of basal-like subtype showed comedo-type necrosis (68.8%) and infiltrative margin (81.3%). Our studies suggest that IHC can be used to identify the different subtypes of breast cancer and all subtypes were significantly associated with race, mean tumor size, mean number of lymph node positive, histological grade and all immunohistochemical markers except EGFR and Ki67.",
        "Doc_title":"Identification of different subtypes of breast cancer using tissue microarray.",
        "Journal":"Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie",
        "Do_id":"21655659",
        "Doc_ChemicalList":"Biomarkers, Tumor",
        "Doc_meshdescriptors":"Biomarkers, Tumor;Breast Neoplasms;Demography;Female;Humans;Immunohistochemistry;Male;Middle Aged;Neoplasm Invasiveness;Tissue Array Analysis",
        "Doc_meshqualifiers":"metabolism;classification;pathology;methods",
        "_version_":1605879645276733440},
      {
        "Doc_abstract":"Breast cancer is one of the most common cancers in women worldwide and metastasis is the major cause of breast cancer death. Development of new therapeutic agents for inhibiting breast cancer metastasis is therefore an urgent need. We previously demonstrated that recombinant DNA-derived viral capsid protein VP1 (rVP1) of foot-and-mouth disease virus-induced apoptosis of MCF-7 breast cancer cells in vitro. Here, we investigated whether rVP1 exhibits any inhibitory effects on migration/metastasis and human epidermal growth factor receptor 2 (HER-2), a well-known biomarker for poor prognosis of breast cancer. The effects of rVP1 on cancer cell migration/invasion and metastasis were evaluated using Transwell migration assay and animal cancer models of metastasis. Western blotting, RT-PCR, flow cytometry, immunohistochemistry, and immunofluorescence staining techniques were used to investigate the effects of rVP1 on HER-2 and signal transduction mediators. Non-cytotoxic concentrations of rVP1-induced mesenchymal-epithelial transition and significantly suppressed AP-2Î± and HER-2 expression as well as the migration and invasion of a variety of breast cancer cell lines in a Î²1-integrin-dependent manner in vitro. Gross and histopathologic examinations showed that rVP1 also suppressed metastasis of several breast cancer cell lines, including HER-2-overexpressing SK-BR-3 and BT-474 cells to lung, liver, or peripheral lymph node in orthotopic allograft/xenograft murine models. In addition, rVP1 significantly prolonged survival in breast cancer-bearing mice. Notably, no apparent side effects of rVP1 were detected, as shown by normal complete blood count levels and serum biochemistry profiles, including AST, ALT, BUN, and creatine. This study demonstrates that rVP1 suppresses the migration, invasion, and metastasis of breast cancer cells via binding to Î²1 integrin receptor and down-regulation of AP-2Î± and HER-2 expression. The effectiveness of rVP1 on inhibiting migration/metastasis of breast cancer and HER-2 expression suggests that it may be suitable for serving as potential therapeutics for metastatic breast cancer particularly HER-2-overexpressing cancer.",
        "Doc_title":"Recombinant viral protein VP1 suppresses HER-2 expression and migration/metastasis of breast cancer.",
        "Journal":"Breast cancer research and treatment",
        "Do_id":"22983836",
        "Doc_ChemicalList":"Capsid Proteins;Recombinant Proteins;Transcription Factor AP-2;VP1 protein, Foot-and-mouth disease virus;ERBB2 protein, human;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Animals;Breast Neoplasms;Capsid Proteins;Cell Movement;Epithelial-Mesenchymal Transition;Female;Gene Expression Regulation, Neoplastic;Humans;MCF-7 Cells;Mice;Neoplasm Invasiveness;Neoplasm Metastasis;Receptor, ErbB-2;Recombinant Proteins;Transcription Factor AP-2;Transplantation, Heterologous",
        "Doc_meshqualifiers":"drug therapy;genetics;metabolism;pathology;administration & dosage;drug effects;drug effects;drug effects;genetics;pathology;genetics;metabolism;administration & dosage;metabolism",
        "_version_":1605746458286358529},
      {
        "Doc_abstract":"The term 'triple-negative breast cancer' defines tumors that do not express estrogen receptors, progesterone receptors or Her2 on immunohistochemical analysis. This subgroup accounts for 15% of all types of breast cancer. Histologically, triple-negative breast cancers are poorly differentiated and are characterized by an aggressive clinical history. A significant overlap exists in biological and clinical characteristics of basal-like breast cancer and triple-negative breast cancer. Treatment options are limited, as these tumors lack a therapeutic target and are naturally resistant to existing targeted therapies, i.e., endocrine treatment and trastuzumab. As there are no specific treatment guidelines for this subgroup, triple-negative breast cancers are managed with standard treatment; however, local and systemic relapse rates are high due to the adverse biology of the disease. Triple-negative breast cancer has many histological and genetic similarities with BRCA-1-associated breast cancer, suggesting a common pathogenesis and the potential use of common chemotherapeutics in both cancers. This review discusses current and future treatment options in the light of the new insights in major proliferative pathways active in the pathogenesis of triple-negative breast cancer.",
        "Doc_title":"Pharmacotherapy of triple-negative breast cancer.",
        "Journal":"Expert opinion on pharmacotherapy",
        "Do_id":"19640211",
        "Doc_ChemicalList":"Antineoplastic Agents;BRCA1 Protein;Biomarkers, Tumor;Receptors, Estrogen;Receptors, Progesterone;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Antineoplastic Agents;BRCA1 Protein;Biomarkers, Tumor;Breast Neoplasms;Female;Humans;Neoplasms, Basal Cell;Prognosis;Receptor, ErbB-2;Receptors, Estrogen;Receptors, Progesterone",
        "Doc_meshqualifiers":"therapeutic use;metabolism;metabolism;drug therapy;metabolism;pathology;drug therapy;metabolism;pathology;metabolism;metabolism;metabolism",
        "_version_":1605883385451905024},
      {
        "Doc_abstract":"The HER-2/neu gene is amplified in 20-30% of human breast cancers and has been shown to have prognostic and predictive value for treatment with chemotherapy, hormone therapy and antibodies against the HER-2/neu domain (trastuzumab). The aim of our study was to evaluate the reliability of HER-2/neu determination by fluorescence in situ hybridization (FISH) on fine-needle aspirates (FNAs) from primary breast cancer patients by comparison with the results obtained by FISH and immunohistochemistry (IHC) on the corresponding histological sections.;HER-2/neu amplification was determined by FISH on 66 breast cancer FNAs. Twenty-three and 36 corresponding formalin-fixed, paraffin-embedded sections were assayed by FISH and by IHC, respectively, in order to detect HER-2/neu amplification and HER-2/neu protein expression.;Twenty-seven per cent (18/66) of breast cancer FNAs showed amplification of HER-2/neu by FISH. Paired results by FISH cytology and FISH histology were available in 22 cases. Concordance was 91% (20/22). Paired results by FISH cytology and IHC were available in 36 cases. Concordance was 92% (33/36). Eighteen of 66 breast cancer FNAs were also submitted to flow cytometric DNA analysis. None of the diploid cases showed HER-2/neu amplification by FISH. Six out of the eight aneuploid cases were amplified and two were polysomic.;HER-2/neu gene amplification can be reliably estimated by FISH on breast cancer FNAs and a good correlation has been found between FISH and IHC results from the corresponding histological sections.",
        "Doc_title":"HER-2/neu amplification detected by fluorescence in situ hybridization in fine needle aspirates from primary breast cancer.",
        "Journal":"Annals of oncology : official journal of the European Society for Medical Oncology",
        "Do_id":"12196365",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"Biopsy, Needle;Breast Neoplasms;Culture Techniques;Female;Gene Amplification;Genes, erbB-2;Humans;Immunohistochemistry;In Situ Hybridization, Fluorescence;Paraffin Embedding;Reproducibility of Results;Sensitivity and Specificity",
        "Doc_meshqualifiers":"epidemiology;genetics;pathology;genetics;methods",
        "_version_":1605873986090041344},
      {
        "Doc_abstract":"To study the relationship between clinical pathologic characteristics, treatment modalities and prognostic factors in HER-2 (Human Epidermal growth factor Receptor-2) overexpressed breast carcinoma.;Major clinico-pathological factors including therapeutic modalities and survival status of 371 breast cancer patients with HER2 over-expression, teated at Yantai Yuhuangding Hospital from March of 2002 to December of 2010 were retrospectively studied, with special attention focused on survival-related factors.;The median age of the total 371 patients in this study was 48 years at time of diagnosis, among which, the leading pathological type was infiltrating ductal carcinoma (92.5%); 62.8% presented with a primary tomor larger than 2 cm in diameter at diagnosis, 51.0% had axillary lymph node (ALN) metastases; ER (Estrogen receptor) /PR (Progesterone receptor) double negative occured in 52.8% of cases, and PCNA (proliferation cell nuclear antigen) (+ + +) was found in 55.1%. HER-2 overexpressed patients were usually in advanced stage when the diagnosis was made (72.8% at stages IIA~IIIC). The prognosis and survival were assessed in 259 patients with complete follow-up data. 5-year DFS (disease-free survival) and OS (overall survival) rate was 68.0% and 78.0% respectively. Univariate analysis revealed that age, tumor size, ALN metastases, LVSI (lymph-vascular space involvement), PCNA status, hormonal therapy, chemotherapy cycles, and HER-2 overexpression, correlated closely with the prognosis. ALN metastases, LVSI, PCNA status and chemotherapy cycles were independent predictors of survival.;HER-2 overexpressed breast cancer has special clinical and pathological characteristics, with advanced clinical stages and high rate of ER/PR double negative. Lymph node metastases, LVSI, PCNA and chemotherapy cycles are independent predictors of prognosis.",
        "Doc_title":"Clinicopathologic characteristics and prognostic factors in patients with operable HER-2 overexpressing breast cancer.",
        "Journal":"Asian Pacific journal of cancer prevention : APJCP",
        "Do_id":"22799305",
        "Doc_ChemicalList":"Antineoplastic Agents;Proliferating Cell Nuclear Antigen;Receptors, Estrogen;Receptors, Progesterone;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Age Factors;Antineoplastic Agents;Breast Neoplasms;Carcinoma;Chemotherapy, Adjuvant;Disease-Free Survival;Female;Humans;Kaplan-Meier Estimate;Lymphatic Metastasis;Middle Aged;Multivariate Analysis;Proliferating Cell Nuclear Antigen;Proportional Hazards Models;Receptor, ErbB-2;Receptors, Estrogen;Receptors, Progesterone;Retrospective Studies;Tumor Burden",
        "Doc_meshqualifiers":"administration & dosage;metabolism;pathology;therapy;metabolism;secondary;therapy;metabolism;metabolism;metabolism;metabolism",
        "_version_":1605760762195738624},
      {
        "Doc_abstract":"To investigate the role of the PER3 circadian rhythm gene, located within the commonly deleted region of chromosome 1p36, in human breast cancer development.;The frequency of genetic alterations at 1p36 and PER3 gene copy number status were analyzed in 180 lymph node-negative breast cancers from patients who had received treatment with chemotherapy and/or tamoxifen. The expression levels of PER3 were also analyzed using published microarray profiles from > 400 breast cancer samples. Finally, the effect of loss of Per3 on tumor susceptibility was tested using two mouse models of breast cancer.;Deletion of PER3 is directly related to tumor recurrence in patients with estrogen receptor (ER) - positive breast cancers treated with tamoxifen. Low expression of PER3 mRNA is associated with poor prognosis, particularly in a subset of tumors that are ER positive, and either luminal A or ERBB2-positive tumors. Mice deficient in Per3 showed increased susceptibility to breast cancer induced by carcinogen treatment or by overexpression of Erbb2.;Disruption of PER3 function may serve as an indicator of probability of tumor recurrence in patients with ER-positive tumors. Further investigations of this pathway may reveal links between deregulation of sleep homeostasis and breast tumorigenesis.",
        "Doc_title":"Deletion of the PER3 gene on chromosome 1p36 in recurrent ER-positive breast cancer.",
        "Journal":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
        "Do_id":"20625127",
        "Doc_ChemicalList":"PER3 protein, human;Period Circadian Proteins;Receptors, Estrogen",
        "Doc_meshdescriptors":"Animals;Breast Neoplasms;Chromosomes, Human, Pair 1;Disease Models, Animal;Female;Gene Dosage;Gene Expression;Genetic Predisposition to Disease;Humans;Mice;Neoplasm Recurrence, Local;Period Circadian Proteins;Prognosis;Receptors, Estrogen;Sequence Deletion;Survival Analysis",
        "Doc_meshqualifiers":"genetics;metabolism;therapy;genetics;genetics",
        "_version_":1605881456008101888},
      {
        "Doc_abstract":"YKL-40 is a glycoprotein involved in cellular growth, migration, and the inflammatory process. Elevation in serum levels of YKL-40 has been associated with worse prognosis in various cancers, including breast cancer. Given that the clinical significance of YKL-40 expression in breast cancer tissue is unclear, we aimed to determine the prognostic value of YKL-40 expression in breast cancer tissue using immunohistochemistry. We performed tissue microarray (TMA) analysis of 425 breast cancer tissues collected during operation. Immunohistochemical staining was performed to measure expression of YKL-40 and several breast cancer biomarkers, such as aldehyde dehyadrogenase1, TGF-beta, and Gli-1 as well as hormonal receptor and Her-2/neu status. Statistical analysis of the relationship of YKL-40 expression with clinicopathological characteristics was performed for 390 TMA samples. YKL-40 was expressed to varying degrees in 84.9% of breast cancer tissues. YKL-40 expression was correlated with estrogen receptor and progesterone receptor negativity and was positively correlated with TGF-beta and Gli-1 expression. Strong YKL-40 expression was associated with a larger proportion of Her-2/neu-enriched and basal-like tumors. The results of this study demonstrate that YKL-40 expression in breast cancer tissues is associated with hormone receptor negativity and Her-2/neu-enriched molecular subtypes of breast cancer, and therefore could be considered a poor prognostic predictor.",
        "Doc_title":"YKL-40 expression could be a poor prognostic marker in the breast cancer tissue.",
        "Journal":"Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine",
        "Do_id":"23918300",
        "Doc_ChemicalList":"Adipokines;Biomarkers, Tumor;CHI3L1 protein, human;Chitinase-3-Like Protein 1;Lectins",
        "Doc_meshdescriptors":"Adipokines;Adult;Aged;Aged, 80 and over;Biomarkers, Tumor;Breast Neoplasms;Chitinase-3-Like Protein 1;Female;Humans;Immunohistochemistry;Lectins;Middle Aged;Neoplasm Staging;Prognosis;Retrospective Studies;Young Adult",
        "Doc_meshqualifiers":"genetics;metabolism;metabolism;genetics;metabolism;mortality;pathology;genetics;metabolism",
        "_version_":1605746978240593922},
      {
        "Doc_abstract":"The human epidermal receptor-2 (HER-2) is overexpressed or amplified in 15% to 25% of breast cancers. Determination of HER-2 tumor status offers clinically useful information, as it selects patients who may benefit from treatment with trastuzumab, the monoclonal antibody against HER-2. Currently approved methods for HER-2 testing include immunohistochemistry or fluorescent in situ hybridization using tumor tissue. A fragment of HER-2 composed of its extracellular domain (ECD) can also be detected in the serum of some patients with breast cancer. As an easily accessible tumor marker, it could offer additional useful prognostic or predictive information. This review will briefly address the biology of the circulating HER-2 ECD and discuss the evidence to support the role, if any, for measuring HER-2 ECD levels in women with breast cancer. In particular, we focus on the value and limitations of serum ECD in both early and advanced breast cancer in the following clinical contexts: as a marker of HER-2 tumor tissue status; clinical implications of raised levels in women who have a tumor not overexpressing HER-2; as a prognostic indicator and as a predictor of response to treatment; and as a monitoring tool for early recurrence. On the basis of our review of the literature, we conclude that there is currently insufficient evidence to support the use of serum HER-2 ECD in the routine management of individual patients with breast cancer. This conclusion is in agreement with the 2007 American Society of Clinical Oncology guidelines on the use of biomarkers in breast cancer.",
        "Doc_title":"Value and limitations of measuring HER-2 extracellular domain in the serum of breast cancer patients.",
        "Journal":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
        "Do_id":"19255333",
        "Doc_ChemicalList":"Biomarkers, Tumor;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Biomarkers, Tumor;Breast Neoplasms;Female;Humans;Receptor, ErbB-2",
        "Doc_meshqualifiers":"blood;blood;blood",
        "_version_":1605896987555659776},
      {
        "Doc_abstract":"Approximately 20-30% of breast cancer tumors overexpress or amplify human epidermal growth factor receptor 2 (HER2). The role of this receptor in the progression of HER2+ breast cancer and resistance to certain anticancer monotherapies was investigated. The results of several pre-clinical and clinical trials, with the aim of determining the most safe and effective course of treatment for HER2+ breast cancer, were also thoroughly examined.;A thorough search of databases including Pubmed, Springer, and The American Society of Clinical Oncology was performed, and pertinent studies were identified. The most relevant studies were preclinical, phase II, and III clinical trials identifying the function of the HER2 receptor in HER2+ breast cancer progression, as well as studies assessing the efficacy of monotherapy and combination therapy in the treatment of this aggressive form of cancer.;The HER2 receptor belongs to a family of receptors that consists of four cell-surface receptors (HER1-4) that share strong homology with the epidermal growth factor receptor (EGFR). All HER receptors interact with specific types of ligands to induce receptor activation, except for HER2, for which no known ligand has yet been identified. HER2 is activated by forming dimers with other HER receptors, and this results in a stronger and more prolonged signal transduction event. When expressed at normal levels, HER2 regulates cell growth, differentiation, and survival. However, under pathological conditions of HER2 overexpression, numerous HER2 heterodimers are formed resulting in aggressive tumor growth. Therefore, the prognosis associated with HER2-positive breast cancer is usually poor. A specific cohort of patients with breast cancer whose tumors test both hormone receptor (estrogen receptor [ER] and progesterone receptor [PR]) and HER2 positive have been found to be resistant to targeted hormone therapy. Studies investigating the etiology of this resistance have found that the cell membrane estrogen receptor communicates with HER2 in promoting the release of ER coactivators that cause the endocrine drug and selective estrogen receptor modulator, tamoxifen, to act as an agonist rather than an antagonist of the hormone estrogen. Thus, research has directed its inquiry toward the development of therapies specifically targeting HER2. The development of trastuzumab, a recombinant monoclonal antibody against HER2, initially proved to be a well-tolerated first line of treatment. However, in the long-term patients, trastuzumab was shown to develop resistance to this monotherapy. Therefore, research on HER2 positive breast cancer has focused on the study of different anti-HER2 combination therapies over the past decade.;While the development and approval of the HER2-targeted recombinant monoclonal antibody trastuzumab (Herceptin) has been efficacious in slowing HER2 cancer progression, combining this and other anti-HER2 therapy with either chemotherapy or endocrine therapy has proven more effective in improving overall and progression free survival.",
        "Doc_title":"Progression and treatment of HER2-positive breast cancer.",
        "Journal":"Cancer chemotherapy and pharmacology",
        "Do_id":"20087739",
        "Doc_ChemicalList":"Antibodies, Monoclonal;Antineoplastic Agents;Receptors, Estrogen;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Animals;Antibodies, Monoclonal;Antineoplastic Agents;Antineoplastic Combined Chemotherapy Protocols;Breast Neoplasms;Clinical Trials as Topic;Disease Progression;Drug Evaluation, Preclinical;Drug Resistance, Neoplasm;Drug Therapy;Female;Humans;Models, Biological;Receptor Cross-Talk;Receptor, ErbB-2;Receptors, Estrogen;Survival Analysis",
        "Doc_meshqualifiers":"therapeutic use;therapeutic use;therapeutic use;drug therapy;metabolism;pathology;methods;immunology;metabolism;metabolism",
        "_version_":1605917260975702016},
      {
        "Doc_abstract":"To determine the impact of age and health status on adjuvant treatment recommendations for older patients with breast cancer from the perspective of medical oncologists and primary care physicians with geriatric expertise.;One hundred fifty-one oncologists and 158 primary care physicians with geriatric expertise participated in an online survey. The survey described hypothetical patients of varying ages (70, 75, 80, and 85 years) and health status (good, average, and poor) who had node-positive, hormone receptor-positive, human epidermal growth factor receptor 2 (HER-2)/neu-negative; and hormone receptor-negative, HER-2/neu-positive breast cancers. The effects of patient age and health status on the survey participants' adjuvant treatment recommendations were examined using generalized estimation equation methods.;The majority of both oncologists and primary care physicians recommended some form of adjuvant therapy for patients of all ages (70, 75, 80, and 85 years) and health status. Both oncologists and primary care providers were less likely to recommend adjuvant treatment as a patient's age increased or health status declined (P < .0001). There were no significant differences in treatment recommendations among primary care physicians and oncologists for patients with hormone receptor-negative, HER-2/neu-positive tumors (P = .54). However, primary care providers were more likely than oncologists to recommend no adjuvant treatment for patients age 75 years or older with hormone receptor-positive, HER-2/neu-negative tumors (P < .01).;Age and health status influence oncologists' and primary care providers' adjuvant treatment recommendations. Evidence-based guidelines for breast cancer treatment in older adults taking into account age and health status are needed.",
        "Doc_title":"Role of age and health in treatment recommendations for older adults with breast cancer: the perspective of oncologists and primary care providers.",
        "Journal":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
        "Do_id":"18955446",
        "Doc_ChemicalList":"Receptors, Estrogen;Receptors, Progesterone;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Age Factors;Aged;Aged, 80 and over;Breast Neoplasms;Chemotherapy, Adjuvant;Data Collection;Female;Geriatrics;Health Status;Humans;Medical Oncology;Physicians, Family;Receptor, ErbB-2;Receptors, Estrogen;Receptors, Progesterone",
        "Doc_meshqualifiers":"chemistry;therapy;analysis;analysis;analysis",
        "_version_":1605806945491484672},
      {
        "Doc_abstract":"Advances in molecular biology have led to the identification of potential markers of prognostic and therapeutic importance in human cancers. HER-2 testing and targeted therapy now represents a critical cornerstone in the management of breast cancer. The objectives of the current study were to determine the frequency and prognostic significance of HER-3 over-expression and HER-4 over-expression by invasive breast cancer.;Tissue microarrays were constructed using clinically annotated formalin-fixed and paraffin-embedded tumor samples from 4046 patients diagnosed with invasive breast carcinoma with a median 12.5 years of follow-up. Type 1 growth factor receptor family members HER-1, HER-2, HER-3, and HER-4 expression levels were determined by immunohistochemistry, and HER-2 status was further resolved by fluorescent in-situ hybridization. The study cohort was randomly divided and analyzed as a core data set and a validation data set.;HER-3 over-expression was identified in 10.0% of tumors and was a significant marker of reduced patient breast cancer-specific survival on univariate analysis (P = 1.32 x 10(-5)). Furthermore, in tumors with normal expression levels of HER-1 and HER-2, the overexpression of HER-3 had a significant negative prognostic effect on disease-specific survival (HR: 1.541, 95% CI: 1.166-2.036, P = 2.37 x 10(-3)) independent of patient age at diagnosis, Estrogen receptor status, tumor grade, tumor size, nodal status, and the presence of lymphatic or vascular invasion by cancer. HER-4 overexpression was identified in 78.2% of breast cancers and was not a significant marker of patient survival (P = 0.214). Results of all statistical tests were positively confirmed in the validation data set analysis.;HER-3 status is an important prognostic marker of disease-specific survival in patients with invasive breast cancer. Accordingly, evaluation of the HER-3 expression level may identify a subset of patients with a poor disease prognosis, and who could undergo further evaluation for the efficacy of HER-3 targeted anticancer agents.",
        "Doc_title":"HER-3 overexpression is prognostic of reduced breast cancer survival: a study of 4046 patients.",
        "Journal":"Annals of surgery",
        "Do_id":"20485140",
        "Doc_ChemicalList":"EGFR protein, human;ERBB2 protein, human;ERBB4 protein, human;Receptor, Epidermal Growth Factor;Receptor, ErbB-2;Receptor, ErbB-3;Receptor, ErbB-4",
        "Doc_meshdescriptors":"Adult;Aged;Breast Neoplasms;Female;Humans;Middle Aged;Prognosis;Receptor, Epidermal Growth Factor;Receptor, ErbB-2;Receptor, ErbB-3;Receptor, ErbB-4;Survival Rate;Tissue Array Analysis",
        "Doc_meshqualifiers":"metabolism;mortality;metabolism;metabolism;metabolism",
        "_version_":1605831056993288192},
      {
        "Doc_abstract":"The purpose of this study was to determine whether the presence of HER-2/neu gene amplification and/or overexpression in benign breast disease was associated with an increased risk of subsequent breast cancer.;We conducted a nested case-control study of a cohort of women who were diagnosed with benign breast disease at the Mayo Clinic and who were subsequently observed for the development of breast cancer. Patients who developed breast cancer formed the case group, and a matched sample from the remaining cohort served as controls. Benign tissue samples from 137 cases and 156 controls and malignant tissues from 99 cases provided DNA or tissue for evaluation of HER-2/neu amplification and protein overexpression.;Among the controls, seven benign tissues (4.5%) demonstrated low-level HER-2/neu amplification, whereas 13 benign (9.5%) and 18 malignant (18%) tissue specimens from cases exhibited amplification. HER-2/neu amplification in benign breast biopsies was associated with an increased risk of breast cancer (odds ratio Â¿OR = 2.2; 95% confidence interval Â¿CI, 0.9 to 5.8); this association approached statistical significance. The risks for breast cancer associated with benign breast histopathologic diagnoses were OR = 1.1 (95% CI, 0.6 to 1.9) for lesions exhibiting proliferation without atypia and OR = 1.5 (95% CI, 0.4 to 5.6) for the diagnosis of atypical ductal hyperplasia. For women having both HER-2/neu amplification and a proliferative histopathologic diagnosis (either typical or atypical), the risk of breast cancer was more than seven-fold (OR = 7.2; 95% CI, 0.9 to 60.8). Overexpression of the HER-2/neu protein product, defined as membrane staining in 10% or more of epithelial cells, was found in 30% of the breast tumors but was not detected in any of the benign breast tissues. Case patients who had HER-2/neu gene amplification in their malignant tumor were more likely to have had HER-2/neu amplification in their prior benign biopsy (P =.06, Fisher's exact test).;Women with benign breast biopsies demonstrating both HER-2/neu amplification and a proliferative histopathologic diagnosis may be at substantially increased risk for subsequent breast cancer.",
        "Doc_title":"HER-2/neu amplification in benign breast disease and the risk of subsequent breast cancer.",
        "Journal":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
        "Do_id":"10637239",
        "Doc_ChemicalList":"Receptor, ErbB-2",
        "Doc_meshdescriptors":"Adult;Breast Diseases;Breast Neoplasms;Case-Control Studies;Female;Gene Amplification;Gene Expression Regulation, Neoplastic;Humans;Receptor, ErbB-2;Risk Assessment",
        "Doc_meshqualifiers":"genetics;pathology;etiology;genetics;pathology;biosynthesis;genetics",
        "_version_":1605763011999432704},
      {
        "Doc_abstract":"The HER-2/erbB-2/c-neu (HER-2) proto-oncogene is a M(r) 185,000 transmembrane tyrosine kinase that is amplified and/or overexpressed by 20-40% of breast cancers. HER-2 has been associated with worse prognosis and resistance or sensitivity to specific treatment. We evaluated circulating levels of extracellular domain of HER-2 (ECD/HER-2) in metastatic breast cancer patients and investigated the prognostic and predictive significance of circulating HER-2 levels regarding endocrine therapy or chemotherapy.;Plasma samples from 242 patients were assayed for circulating ECD/HER-2 levels, using a sandwich enzyme immunoassay. ECD/HER-2 was correlated with clinical data gathered from these patients while they were participating in prospective Cancer and Leukemia Group B (CALGB) therapeutic protocols for metastatic breast cancer.;Eighty-nine (37%) of 242 patients had elevated ECD/HER-2 levels (> or =10.5 ng/ml). ECD/HER-2 was significantly associated with tumor burden, progesterone receptor levels, and presence of visceral metastases. Patients with elevated pretreatment levels had a significantly shorter OS but not time-to-progression than did those with ECD/HER-2 levels <10.5 ng/ml in univariate analysis. In univariate but not multivariate subset analyses, among patients treated with endocrine therapy (megestrol acetate), elevated initial ECD/HER-2 was associated with worse OS compared with nonelevated patients. However, among patients treated with chemotherapy (mainly anthracycline-containing regimens), OS did not differ significantly. Rates of response to either endocrine therapy or chemotherapy were similar for patients with elevated and nonelevated ECD/HER-2 levels.;ECD/HER-2 levels are elevated in 35-40% of patients with metastatic breast cancer. Elevated ECD/HER-2 levels are associated with a poorer prognosis in these patients. However, no predictive role for ECD/HER-2 was identified, either for endocrine therapy or for anthracycline-based chemotherapy in the metastatic setting.",
        "Doc_title":"Circulating HER-2/erbB-2/c-neu (HER-2) extracellular domain as a prognostic factor in patients with metastatic breast cancer: Cancer and Leukemia Group B Study 8662.",
        "Journal":"Clinical cancer research : an official journal of the American Association for Cancer Research",
        "Do_id":"11555582",
        "Doc_ChemicalList":"Receptor, ErbB-2",
        "Doc_meshdescriptors":"Adult;Breast Neoplasms;Female;Humans;Middle Aged;Multivariate Analysis;Neoplasm Metastasis;Prognosis;Randomized Controlled Trials as Topic;Receptor, ErbB-2;Survival Analysis;Time Factors;Treatment Outcome",
        "Doc_meshqualifiers":"blood;drug therapy;pathology;blood",
        "_version_":1605826099352174592},
      {
        "Doc_abstract":"Anti-HER2-autoantibodies (HER2-AAbs) are found in breast cancer patients as well as healthy individuals. However, the clinical relevance of the antibodies is unknown. We established an enzyme-linked immunosorbent assay with high sensitivity and quantified serum HER2-AAbs in 100 healthy women, 100 untreated patients with ductal carcinoma in situ (DCIS), and 500 untreated patients with invasive breast carcinoma (IBC). The associations between the levels of HER2-AAbs and breast cancer risk, and recurrence-free survival, were examined. High levels of HER2-AAbs were significantly associated with a reduced risk of DCIS (odds ratio [OR] 0.19, PÂ =Â 4.6Â Ã—Â 10(-7)) or IBC (OR 0.31, PÂ =Â 3.7Â Ã—Â 10(-7)). Subgroup analysis of IBC revealed a stronger association of HER2-AAbs with a reduced risk of the hormone receptor (HR)(-)/HER2(+) subtype (OR 0.12) than the other subtypes (HR(+)/HER2(-) [ORÂ =Â 0.32], HR(+)/HER2(+) [OR 0.38], and HR(-)/HER2(-) [OR 0.29]). When we set the cutoff of HER2-AAbs at 20Â ng/mL, recurrence-free survival of HER2-AAb-positive patients (NÂ =Â 74) was significantly better than that of HER2-AAb-negative patients (NÂ =Â 426) (PÂ =Â 0.015). Univariate and multivariate analyses demonstrated that HER2-AAbs, as well as histological grade, were independently and significantly (PÂ =Â 0.0065 and 0.049, respectively) associated with recurrence-free survival. Our exploratory study suggests a protective effect of naturally occurring HER2-AAbs on the development of primary and recurrent breast cancer. Further studies on HER2-AAbs are warranted. ",
        "Doc_title":"Protective effect of naturally occurring anti-HER2 autoantibodies on breast cancer.",
        "Journal":"Breast cancer research and treatment",
        "Do_id":"27113738",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605785447077773312},
      {
        "Doc_abstract":"AMP-activated Protein Kinase (AMPK) activity retards growth of many types of cancers. Investigating effects of AMPK activation on breast cancer cell signaling and survival, we found that breast cancer cell lines with amplification and over-expression of HER2 or EGFR are 2- to 5-fold more sensitive to cytotoxic effects of AICAR, a canonical pharmacological activator of AMPK, than breast cancer cell lines lacking HER2 or EGFR overexpression. Paralleling effects on cell survival, AICAR leads to dose- and time-dependent inhibition of HER2 and EGFR in HER2-amplified breast cancer cells, with activation of AMPK and suppression of HER2/ EGFR activity preceding commitment to cell death. Transfection of constitutively active AMPKÎ± also leads to decreased HER2 and EGFR phosphorylation, reduced downstream signaling associated with these receptor tyrosine kinases (RTKs), and reduced breast cancer cell growth, confirming effects of AMPK activity on HER2/ EGFR. Ensuing co-immunoprecipitation experiments demonstrated an interaction of HER2 with AMPK and an in vitro phosphorylation assay found that HER2 and EGFR contain sequences that are potential substrates for AMPK. Our results lead us to postulate that AMPK regulates HER2 and EGFR activity in HER2-amplified breast cancer cells and thus activation of AMPK might provide therapeutic benefit in such cancers. ",
        "Doc_title":"AMP-activated kinase (AMPK) regulates activity of HER2 and EGFR in breast cancer.",
        "Journal":"Oncotarget",
        "Do_id":"26143491",
        "Doc_ChemicalList":"Ribonucleotides;Aminoimidazole Carboxamide;Receptor, Epidermal Growth Factor;Receptor, ErbB-2;AMP-Activated Protein Kinases;AICA ribonucleotide",
        "Doc_meshdescriptors":"AMP-Activated Protein Kinases;Aminoimidazole Carboxamide;Animals;Blotting, Western;Breast Neoplasms;Cell Line;Cell Line, Tumor;Cell Survival;Humans;MCF-7 Cells;Mice, Inbred NOD;Mice, SCID;RNA Interference;Receptor, Epidermal Growth Factor;Receptor, ErbB-2;Ribonucleotides;Xenograft Model Antitumor Assays",
        "Doc_meshqualifiers":"genetics;metabolism;analogs & derivatives;pharmacology;genetics;metabolism;prevention & control;drug effects;genetics;metabolism;metabolism;pharmacology",
        "_version_":1605746325947678722},
      {
        "Doc_abstract":"HER2 amplification in breast cancer is associated with a more aggressive disease, greater likelihood of recurrence, and decreased survival compared to women with HER2-negative breast cancer. Trastuzumab is a monoclonal antibody that inhibits HER2 activity, making this compound an important therapeutic option for patients with HER2-positive breast cancer. However, resistance to trastuzumab develops rapidly in a large number of breast cancer patients. The objective of this study was to determine whether GRN163L, a telomerase template antagonist currently in clinical trials for cancer treatment, can augment the effects of trastuzumab in breast cancer cells with HER2 amplification. GRN163L was effective in inhibiting telomerase activity and shortening telomeres in HER2-positive breast cancer cells. We show that GRN163L acts synergistically with trastuzumab in inhibiting HER2-positive breast cancer cell growth. More importantly, we show that GRN163L can restore the sensitivity of therapeutic-resistant breast cancer cells to trastuzumab. These findings implicate that telomerase template antagonists have potential use in the treatment of cancers that have developed resistance to traditional cancer therapy.",
        "Doc_title":"Lipid-conjugated telomerase template antagonists sensitize resistant HER2-positive breast cancer cells to trastuzumab.",
        "Journal":"Breast cancer research and treatment",
        "Do_id":"18853252",
        "Doc_ChemicalList":"5'-oleic-TAGGGTTAGACAA-3';Antibodies, Monoclonal;Antibodies, Monoclonal, Humanized;Enzyme Inhibitors;GRN163L peptide;Neoplasm Proteins;Oligonucleotides;Oligopeptides;Protein Kinase Inhibitors;telomerase RNA;RNA;ERBB2 protein, human;Receptor, ErbB-2;Telomerase;Trastuzumab",
        "Doc_meshdescriptors":"Antibodies, Monoclonal;Antibodies, Monoclonal, Humanized;Breast Neoplasms;Cell Line, Tumor;Drug Resistance, Neoplasm;Drug Screening Assays, Antitumor;Drug Synergism;Enzyme Inhibitors;Female;Genes, erbB-2;Humans;Neoplasm Proteins;Oligonucleotides;Oligopeptides;Protein Kinase Inhibitors;RNA;Receptor, ErbB-2;Telomerase;Trastuzumab",
        "Doc_meshqualifiers":"pharmacology;enzymology;pathology;drug effects;enzymology;drug effects;pharmacology;antagonists & inhibitors;pharmacology;pharmacology;pharmacology;antagonists & inhibitors;antagonists & inhibitors;antagonists & inhibitors",
        "_version_":1605795537367334912},
      {
        "Doc_abstract":"Breast cancer is a genetically and phenotypically complex disease. To understand the role of miRNAs in this molecular complexity, we performed miRNA expression analysis in a cohort of molecularly well-characterized human breast cancer cell lines to identify miRNAs associated with the most common molecular subtypes and the most frequent genetic aberrations.;Using a microarray carrying LNAâ„¢ modified oligonucleotide capture probes), expression levels of 725 human miRNAs were measured in 51 breast cancer cell lines. Differential miRNA expression was explored by unsupervised cluster analysis and was then associated with the molecular subtypes and genetic aberrations commonly present in breast cancer.;Unsupervised cluster analysis using the most variably expressed miRNAs divided the 51 breast cancer cell lines into a major and a minor cluster predominantly mirroring the luminal and basal intrinsic subdivision of breast cancer cell lines. One hundred and thirteen miRNAs were differentially expressed between these two main clusters. Forty miRNAs were differentially expressed between basal-like and normal-like/claudin-low cell lines. Within the luminal-group, 39 miRNAs were associated with ERBB2 overexpression and 24 with E-cadherin gene mutations, which are frequent in this subtype of breast cancer cell lines. In contrast, 31 miRNAs were associated with E-cadherin promoter hypermethylation, which, contrary to E-cadherin mutation, is exclusively observed in breast cancer cell lines that are not of luminal origin. Thirty miRNAs were associated with p16INK4 status while only a few miRNAs were associated with BRCA1, PIK3CA/PTEN and TP53 mutation status. Twelve miRNAs were associated with DNA copy number variation of the respective locus.;Luminal-basal and epithelial-mesenchymal associated miRNAs determine the subdivision of miRNA transcriptome of breast cancer cell lines. Specific sets of miRNAs were associated with ERBB2 overexpression, p16INK4a or E-cadherin mutation or E-cadherin methylation status, which implies that these miRNAs may contribute to the driver role of these genetic aberrations. Additionally, miRNAs, which are located in a genomic region showing recurrent genetic aberrations, may themselves play a driver role in breast carcinogenesis or contribute to a driver gene in their vicinity. In short, our study provides detailed molecular miRNA portraits of breast cancer cell lines, which can be exploited for functional studies of clinically important miRNAs.",
        "Doc_title":"miRNA expression profiling of 51 human breast cancer cell lines reveals subtype and driver mutation-specific miRNAs.",
        "Journal":"Breast cancer research : BCR",
        "Do_id":"23601657",
        "Doc_ChemicalList":"Cadherins;Cyclin-Dependent Kinase Inhibitor p16;MicroRNAs;ERBB2 protein, human;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Breast Neoplasms;Cadherins;Chromosome Aberrations;Cyclin-Dependent Kinase Inhibitor p16;DNA Copy Number Variations;DNA Methylation;Female;Gene Expression Profiling;Gene Expression Regulation, Neoplastic;Humans;MicroRNAs;Mutation;Oligonucleotide Array Sequence Analysis;Polymorphism, Single Nucleotide;Promoter Regions, Genetic;Receptor, ErbB-2;Tumor Cells, Cultured",
        "Doc_meshqualifiers":"classification;genetics;genetics;genetics;genetics;genetics;genetics;genetics;genetics",
        "_version_":1605810813388455936},
      {
        "Doc_abstract":"Breast carcinoma is the most common malignant tumour and the main cause of carcinoma death in women. There has been a sharp increase in the detection of breast carcinoma, although mortality is still unvaried. In the last ten years the incidence of breast cancer measuring less than 1 cm, corresponding to pT1a, pT1b in TNM stadiation, has greatly increased. The present study describes the biologic characterisation of small breast carcinomas. The Nottingham/Tenovus Primary Breast Cancer Study stated that tumour size is a significant, independent factor for breast cancer prognosis. Cases were selected among formalin-fixed, paraffin-embedded tissues from 360 ductal breast cancers. In one-half of cases, the tumour was less than 1 cm in diameter, pT1a- pT1b; in the other half the tumour size was greater than 1 cm, but less than 2 cm, pT1c. Histological grading was assessed with the Scarff-Bloom-Richardson method, without Nottingham grade. Immunohistochemical determinations for ER, PgR, Ki-67, Her-2/Neu, CD34, p53, EGFR were done with an automated method. From the above analyses, it was demonstrated that the tumour size is indeed an important prognostic factor, particularly in cases without lymph node metastasis (N0). In particular, we observed significant differences between pT1a-b and pT1c cases, confirming that tumour size is an important criterion for prognostic valuation in ductal breast cancer without lymph node metastasis.",
        "Doc_title":"[Breast cancer less than 1 cm: bio-morphologic characterization with ER, PgR, Ki67, Her-2/Neu, MDV, MAGS, p53, EGF-R].",
        "Journal":"Pathologica",
        "Do_id":"18841818",
        "Doc_ChemicalList":"Intracellular Signaling Peptides and Proteins;Ki-67 Antigen;MRFAP1 protein, human;Nuclear Proteins;Receptors, Estrogen;Tumor Suppressor Protein p53;ERBB2 protein, human;Receptor, Epidermal Growth Factor;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Adult;Breast Neoplasms;Carcinoma, Ductal, Breast;Female;Humans;Immunohistochemistry;Intracellular Signaling Peptides and Proteins;Ki-67 Antigen;Middle Aged;Nuclear Proteins;Prognosis;Receptor, Epidermal Growth Factor;Receptor, ErbB-2;Receptors, Estrogen;Tumor Suppressor Protein p53",
        "Doc_meshqualifiers":"chemistry;pathology;chemistry;pathology;analysis;analysis;analysis;analysis;analysis;analysis;analysis",
        "_version_":1605898777608060928},
      {
        "Doc_abstract":"Breast cancer is the most commonly diagnosed malignancy and one of the major causes of death among women. Breast cancer is also one of the most investigated diseases but whose biological features are still not well understood, several effective treating strategies having been explored in dealing with different types of advanced breast cancer, such as endocrine therapy and molecular targeted therapy. Trastuzumab is the first approved targeted anti-cancer agent to show an attractive response rate and outcomes in treating HER-2 positive metastatic breast cancer patients. However, primary or acquired trastuzumab resistance usually occurs some time into the use of trastuzumab and leads to treatment resistance or tumour progression. The promising results with trastuzumab targeted therapy encouraged further investigations in this area exploring several novel targeted agents aiming to overcome the resistance drawback of trastuzumab. In this review we discuss the major newly developed targeted agents in breast cancer treatment, including the novel anti-HER-2 monoclonal antibody pertuzumab or ertumaxomab, small molecular tyrosine inhibitor lapatinib, selective PARP1 inhibitor olaparib, mTOR inhibitor rapamycin analogues, and sheddase inhibitors. Many of these novel targeted drugs or molecules showed additional or complementary effects to trastuzumab therapy that need further and wider investigation.",
        "Doc_title":"Targeted therapy in breast cancer: what's new?",
        "Journal":"Swiss medical weekly",
        "Do_id":"21706452",
        "Doc_ChemicalList":"Antibodies, Monoclonal;HSP90 Heat-Shock Proteins;Protein Kinase Inhibitors;Vascular Endothelial Growth Factor A;ADAM Proteins",
        "Doc_meshdescriptors":"ADAM Proteins;Antibodies, Monoclonal;Breast Neoplasms;Female;Genes, BRCA1;Genes, BRCA2;Genes, erbB-2;HSP90 Heat-Shock Proteins;Humans;Molecular Targeted Therapy;Neovascularization, Pathologic;Protein Kinase Inhibitors;Signal Transduction;Vascular Endothelial Growth Factor A",
        "Doc_meshqualifiers":"antagonists & inhibitors;therapeutic use;blood supply;drug therapy;antagonists & inhibitors;prevention & control;therapeutic use;antagonists & inhibitors",
        "_version_":1605810867982565376},
      {
        "Doc_abstract":"Obesity in postmenopausal women is associated with increased breast cancer risk, development of more aggressive tumors and resistance to certain anti-breast cancer treatments. Some of these effects might be mediated by obesity hormone leptin, acting independently or modulating other signaling pathways. Here we focused on the link between leptin and HER2. We tested if HER2 and the leptin receptor (ObR) can be coexpressed in breast cancer cell models, whether these two receptors can physically interact, and whether leptin can transactivate HER2. Next, we studied if leptin/ObR can coexist with HER2 in breast cancer tissues, and if presence of these two systems correlates with specific clinicopathological features.;Expression of ObR, HER2, phospho-HER2 was assessed by immunoblotting. Physical interactions between ObR and HER2 were probed by immunoprecipitation and fluorescent immunostaining. Expression of leptin and ObR in breast cancer tissues was detected by immunohistochemistry (IHC). Associations among markers studied by IHC were evaluated using Fisher's exact test for count data.;HER2 and ObR were coexpressed in all studied breast cancer cell lines. In MCF-7 cells, HER2 physically interacted with ObR and leptin treatment increased HER2 phosphorylation on Tyr 1248. In 59 breast cancers, the presence of leptin was correlated with ObR (the overall association was about 93%). This result was confirmed both in HER2-positive and in HER2-negative subgroups. The expression of leptin or ObR was numerically more frequent in larger (> 10 mm) tumors.;Coexpression of HER2 and the leptin/ObR system might contribute to enhanced HER2 activity and reduced sensitivity to anti-HER2 treatments.",
        "Doc_title":"Leptin/HER2 crosstalk in breast cancer: in vitro study and preliminary in vivo analysis.",
        "Journal":"BMC cancer",
        "Do_id":"18945363",
        "Doc_ChemicalList":"Leptin;Receptors, Leptin;leptin receptor, human;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Breast Neoplasms;Carcinoma, Ductal, Breast;Cell Line, Tumor;Female;Gene Expression Regulation, Neoplastic;Humans;Immunohistochemistry;Leptin;Obesity;Postmenopause;Protein Binding;Receptor Cross-Talk;Receptor, ErbB-2;Receptors, Leptin;Risk Factors;Transcriptional Activation",
        "Doc_meshqualifiers":"genetics;metabolism;pathology;genetics;metabolism;pathology;genetics;metabolism;genetics;genetics;genetics;metabolism;genetics;metabolism",
        "_version_":1605818584902139906},
      {
        "Doc_abstract":"Racial disparity in presentation and outcome of breast cancer is established but cause is unexplained. Many studies show various molecular markers for racial differences in the prognosis of breast cancer. There is scarcity of data on prognostic significance of HER-2/neu in Indian breast cancer.;To know incidence and prognostic significance of HER-2/neu expression in Indian patients. To correlate HER-2/neu Expression with other prognostic markers and ER/PR Receptor status.;112 consecutive patients with breast cancer attending the Department of Surgical Oncology from March 1997 to March 2000 were included in this study. The clinical data along with ER/PR status, follow up data and HER-2/neu expression examined by immuno-histochemical method was recorded.;Data was analyzed by univariate and multivariate analysis for all prognostic factors. Significance was calculated by using Chi square test and survival analysis by using Kaplan Meier survival curve.;The median age of 112 patients was 46.56 (Â±9.55) years. HER-2/neu over expression was present in 46.37%. Significant correlation was found between HER-2/neu over expression and lymph node status, grade of tumor and ER/PR receptor status. Median follow up period of 23 months. There was significant tumour free survival advantage (p < 0.01) and overall survival advantage (p < 0.001) in patients with HER-2/neu negative expression.;HER-2/neu oncogene over expression is higher (46.37%) among Indian patients in comparison to 25-30% shown in most western literature. HER-2/neu oncogene over expression significantly correlates with grade, lymph node involvement, ER/PR status and also affects survival.",
        "Doc_title":"Significance of Her-2/neu protein over expression in Indian breast cancer patients.",
        "Journal":"The Indian journal of surgery",
        "Do_id":"23132963",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605746356566097920},
      {
        "Doc_abstract":"Breast cancer is the most common malignancy among females in Malaysia. Attempts have been made to investigate the association between breast cancer and human leukocyte antigen (HLA) types. However, data from those previous studies are highly variable. The aim of this study is to investigate the association between HLA-A types and clinicopathological factors in breast cancer. The frequencies of HLA-A type in 59 female patients with infiltrating ductal of the breast were determined by polymerase chain reaction method. HLA-A2/A30 and A2/A31 haplotype (5.1%; P = 0.045) as well as HLA-A30 (5.1%, P = 0.045) and A31 (6.8%; P = 0.020) allele were significant higher in the patients than controls (0%). HLA-A24 allele was negatively related to lymph node metastasis (r = -0.316; P = 0.021) whereas, A26 (r = -0.430; P = 0.001) and A36 (r = -0.430; P = 0.001) alleles were negatively correlated to distant metastasis in breast cancer. Negative correlations between HLA-A26/A36 (r = -0.430; P = 0.001), A2/A11 (r = -0.276; P = 0.044), A24/A34 (r = -0.430; P = 0.001) haplotypes and distant metastasis were identified. Interestingly, Her2 expression in breast carcinoma was negatively correlated to A11/24 haplotypes (r = -0.294; P = 0.034) but positively correlated to homozygous HLA-A24 (r = 0.396; P = 0.040). In conclusion, HLA-A2, -A30 and A31 were associated with breast cancer.",
        "Doc_title":"HLA-A and breast cancer in West Peninsular Malaysia.",
        "Journal":"Medical oncology (Northwood, London, England)",
        "Do_id":"20069393",
        "Doc_ChemicalList":"HLA-A Antigens",
        "Doc_meshdescriptors":"Adult;Aged;Breast;Breast Neoplasms;Carcinoma, Ductal, Breast;Case-Control Studies;Female;HLA-A Antigens;Humans;Lymphatic Metastasis;Malaysia;Middle Aged",
        "Doc_meshqualifiers":"pathology;genetics;metabolism;genetics;metabolism;genetics;metabolism",
        "_version_":1605813122840395776},
      {
        "Doc_abstract":"Immunotoxins are chimeric proteins comprising a specific cellular targeting domain linked to a cytotoxic factor. Here we describe the design and use of a novel, peptide-based immunotoxin that can initiate selective cytotoxicity on ErbB2-positive cells. ErbB2 is a receptor tyrosine kinase that is overexpressed in the tumor cells of approximately 30% of breast cancer patients. Immunotoxin candidates were designed to incorporate a targeting ligand with affinity for ErbB2 along with a membrane lysin-based toxin domain. One particular peptide candidate, NL1.1-PSA, demonstrated selective cytotoxicity towards ErbB2-overexpressing cell lines. We utilized a bioengineering strategy to show that recombinant NL1.1-PSA immunotoxin expression by Escherichia coli also conferred selective cytotoxicity towards ErbB2-overexpressing cells. Our findings hold significant promise for the use of effective immunotoxins in cancer therapeutics. ",
        "Doc_title":"Design and evaluation of a peptide-based immunotoxin for breast cancer therapeutics.",
        "Journal":"FEBS open bio",
        "Do_id":"25853036",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605818647100522497},
      {
        "Doc_abstract":"This study aimed to investigate the expression and significance of 5 types of miRNAs in breast cancer to provide a theoretical and practical foundation for using these miRNAs in the diagnosis and treatment of breast cancer, thereby improving medical services.;Stem-loop real-time RT-PCR was used to detect the expression levels of miR-145, miR-21, miR-10b, miR-125a, and miR-206 in 35 cases of breast cancer and adjacent normal breast tissues, and to analyze the relationship of miRNAs expression with clinicopathological features of breast cancer. The expression levels of estrogen receptor (ER) and progesterone receptor (PR) were examined by immunohistochemistry. Fluorescence in situ hybridization was used for the detection of HER-2 and TOP 2A.;The expression levels of miR-145, miR-125a, and miR-206 in breast cancer were lower than those in adjacent normal tissues. MiR-145 was negatively correlated with tumor size, lymph node metastasis, ER, HER-2, and TOP 2A (P<0.05), regardless of age, menstruation, and PR. MiR-125a was correlated with negative node status, negative HER-2 status (P<0.05), whereas tumor size, age, menstruation, ER, and PR were independent factors. MiR-206 expression was correlated with negative ER status, negative PR status, and negative HER-2 status (P<0.05), regardless of age, menstruation, lymph node metastasis, and TOP 2A. MiR-21 and miR-10b expression in breast cancer tissues was significantly higher than that in adjacent tissues (P<0.05). MiR-21 in post-menstrual patients with lymph node metastasis was highly expressed (P<0.05), and had no correlations with tumor size, ER, PR, and TOP 2A expression. MiR-10b expression was positively correlated with breast cancer tumor size, lymph node metastasis, and TOP 2A status (P<0.05), but had no correlations with age, menstruation, ER, PR, and HER-2.;MiR-145, miR-21, miR-10b, miR-125a, and miR-206 may play important roles in breast cancer development and invasion.",
        "Doc_title":"The expression and significance of five types of miRNAs in breast cancer.",
        "Journal":"Medical science monitor basic research",
        "Do_id":"25047098",
        "Doc_ChemicalList":"Antigens, Neoplasm;DNA-Binding Proteins;MicroRNAs;Receptor, ErbB-2;DNA Topoisomerases, Type II;DNA topoisomerase II alpha",
        "Doc_meshdescriptors":"Adult;Antigens, Neoplasm;Breast Neoplasms;DNA Topoisomerases, Type II;DNA-Binding Proteins;Female;Gene Expression Regulation, Neoplastic;Humans;In Situ Hybridization, Fluorescence;MicroRNAs;Middle Aged;Receptor, ErbB-2",
        "Doc_meshqualifiers":"metabolism;genetics;pathology;metabolism;metabolism;genetics;metabolism;metabolism",
        "_version_":1605904164577083392},
      {
        "Doc_abstract":"The growth factor receptor-bound protein-7 gene (GRB7) encodes a multi-domain signal transduction molecule. The purpose of this study was to examine the clinical significance of GRB7 protein expression in human breast cancer. Western blotting analysis of protein extracts from 563 annotated frozen breast tumors was performed. Expression status of GRB7 and HER-2 was correlated with clinical covariates and outcomes. Cox proportional hazards were used to identify factors associated with breast cancer-free interval. The median follow-up was 71 months. P values <0.05 were considered statistically significant (two-sided). A discrepancy between HER-2 and GRB7 protein over-expression was observed. GRB7 protein over-expression was associated with negative estrogen and progesterone receptor status, higher tumor grade, larger primary tumor size, (more) axillary lymph node involvement, higher clinical stage, and shortened breast cancer-free interval. HER-2 protein over-expression was associated only with higher tumor grade. Multi-variate analysis revealed that GRB7 protein over-expression was an independent adverse prognostic factor for breast cancer-free interval (hazard ratio 1.69, 95% confidence interval 1.07-2.67; P = 0.024). The same was true of the subset of patients who did not receive any adjuvant systemic therapy (hazard ratio 1.68, 95% confidence interval 1.16-2.31; P = 0.0055). Using FISH analysis, 32/32 (100%; 95% CI 89-100%) tumors which over-expressed both HER-2 and GRB7 proteins and 1/35 (3%; 95% CI 0-15%) tumors with HER-2 but no GRB7 protein over-expression with Western blotting analysis demonstrated HER-2 gene amplification. GRB7 protein over-expression is an independent adverse prognostic factor in human breast cancer.",
        "Doc_title":"GRB7 protein over-expression and clinical outcome in breast cancer.",
        "Journal":"Breast cancer research and treatment",
        "Do_id":"20635137",
        "Doc_ChemicalList":"Biomarkers, Tumor;GRB7 protein, human;GRB7 Adaptor Protein;ERBB2 protein, human;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Adult;Aged;Aged, 80 and over;Biomarkers, Tumor;Blotting, Western;Breast Neoplasms;Female;GRB7 Adaptor Protein;Humans;Middle Aged;Proportional Hazards Models;Receptor, ErbB-2;Signal Transduction;Treatment Outcome",
        "Doc_meshqualifiers":"genetics;metabolism;genetics;metabolism;pathology;biosynthesis;genetics;biosynthesis;genetics",
        "_version_":1605764151671521280},
      {
        "Doc_abstract":"Unlocking the mysteries of cell metastasis, a major cause of cancer mortality, is essential in the development of novel therapies. In this issue of Cancer Cell, Li et al. (2004) identify a link between HER2 and CXCR4, two receptors previously implicated in breast cancer progression and metastasis. HER2 enhances the expression of CXCR4 by stimulating CXCR4 translation and attenuating CXCR4 degradation. Importantly, coexpression of HER2 and CXCR4 occurs in approximately 22% of human breast tumors and correlates with poor survival of breast cancer patients.",
        "Doc_title":"A new key in breast cancer metastasis.",
        "Journal":"Cancer cell",
        "Do_id":"15542424",
        "Doc_ChemicalList":"Proto-Oncogene Proteins;Receptors, CXCR4;Receptor, ErbB-2;Protein-Serine-Threonine Kinases;Proto-Oncogene Proteins c-akt",
        "Doc_meshdescriptors":"Breast Neoplasms;Cell Adhesion;Cell Movement;Humans;Models, Biological;Neoplasm Metastasis;Protein-Serine-Threonine Kinases;Proto-Oncogene Proteins;Proto-Oncogene Proteins c-akt;Receptor, ErbB-2;Receptors, CXCR4;Survival Rate;Up-Regulation",
        "Doc_meshqualifiers":"pathology;metabolism;metabolism;metabolism;metabolism",
        "_version_":1605742683554316289},
      {
        "Doc_abstract":"Breast cancer has long been recognized as a heterogeneous entity, with distinct subsets characterized by differences in tumor biology and response to therapy. With the advent of molecular profiling, we have gained a further appreciation of the heterogeneity of this complex disease. While the last decade has seen advances in the treatment of hormone receptor (HR) and human epidermal growth factor receptor 2/erb-B2 (HER2)-positive breast cancers, outcomes for women with estrogen receptor (ER)-, progesterone receptor (PR)-, and HER2-negative-or \"triple-negative\"-breast cancer (TNBC) remain poor. A better understanding of the shared biology of BRCA1-associated breast cancer and sporadic TNBC holds much promise for changing the outlook for women with this aggressive disease. This review focuses on our current understanding of the clinicopathological features of TNBC, therapeutic options and ongoing research efforts.",
        "Doc_title":"\"Targeting\" triple-negative breast cancer: the lessons learned from BRCA1-associated breast cancers.",
        "Journal":"Seminars in oncology",
        "Do_id":"21421115",
        "Doc_ChemicalList":"Angiogenesis Inhibitors;Poly(ADP-ribose) Polymerase Inhibitors;Receptors, Estrogen;Receptors, Progesterone;ERBB2 protein, human;Receptor, Epidermal Growth Factor;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Angiogenesis Inhibitors;Breast Neoplasms;Female;Gene Expression Profiling;Genes, BRCA1;Germ-Line Mutation;Humans;Neoplasm Recurrence, Local;Poly(ADP-ribose) Polymerase Inhibitors;Prognosis;Receptor, Epidermal Growth Factor;Receptor, ErbB-2;Receptors, Estrogen;Receptors, Progesterone",
        "Doc_meshqualifiers":"therapeutic use;chemistry;drug therapy;genetics;pathology;antagonists & inhibitors;analysis;analysis;analysis",
        "_version_":1605825501356621824},
      {
        "Doc_abstract":"Trastuzumab (Herceptin) is a therapeutic monoclonal antibody specific for the human epidermal growth factor receptor type 2 (HER2), a cell-surface tyrosine kinase receptor overexpressed by 25% to 30% of breast cancers. The drug is now regarded as one option for standard therapy in HER2-overexpressing metastatic breast cancers. It is associated with a moderate response rate as a single agent, and in combination with standard chemotherapy, can produce greater response rates and prolong the survival of women with advanced breast cancer. Its activity in metastatic breast cancer has led to active clinical trials examining its potential role in the neoadjuvant and adjuvant settings. The successful clinical development of trastuzumab provides further proof of principle that biologically targeted therapies can have a profound impact on the management of breast cancer. Here we review the clinical development of this novel agent, emphasizing the potential for therapeutic synergy when trastuzumab is combined with both standard chemotherapy and innovative molecularly targeted and biologic agents.",
        "Doc_title":"Trastuzumab in breast cancer.",
        "Journal":"Oncology (Williston Park, N.Y.)",
        "Do_id":"15471197",
        "Doc_ChemicalList":"Antibodies, Monoclonal;Antibodies, Monoclonal, Humanized;Antineoplastic Agents;Receptor, ErbB-2;Trastuzumab",
        "Doc_meshdescriptors":"Antibodies, Monoclonal;Antibodies, Monoclonal, Humanized;Antineoplastic Agents;Breast Neoplasms;Combined Modality Therapy;Female;Humans;Immunohistochemistry;Neoplasm Metastasis;Prognosis;Receptor, ErbB-2;Trastuzumab",
        "Doc_meshqualifiers":"therapeutic use;therapeutic use;drug therapy;genetics;pathology",
        "_version_":1605845102181220352},
      {
        "Doc_abstract":"Determination of HER2 status in breast cancer has become important to identify potential candidates for anti-HER2 therapy. In this study we compared fluorescence in situ hybridization (FISH) and immunohistochemistry (IHC) for the determination of HER2 status in breast cancer patients referred to a tertiary care referral centre.;A total of 200 cases of invasive breast cancer were evaluated for HER2 status using IHC and FISH and results were compared.;The IHC 3+ (93.9%) and IHC negative (85.9%) cases showed good concordance with the corresponding FISH results; while 66.6 per cent of IHC 2+ cases showed gene amplification by FISH. In addition, hormone receptor expression and HER2 gene status showed a statistically significant inverse association (P<0.05).;These findings reaffirm IHC as a prudent first-step to screen tissue samples for HER2 status and to determine suitability for technically demanding FISH test and the dual coloured FISH as a gold standard for determination of HER2/neu status in IHC equivocal cases of breast carcinoma.",
        "Doc_title":"Assessment of HER-2/neu status in breast cancer using fluorescence in situ hybridization & immunohistochemistry: Experience of a tertiary cancer referral centre in India.",
        "Journal":"The Indian journal of medical research",
        "Do_id":"20847375",
        "Doc_ChemicalList":"Biomarkers;ERBB2 protein, human;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Adult;Aged;Biomarkers;Breast Neoplasms;Female;Humans;Immunoenzyme Techniques;In Situ Hybridization, Fluorescence;India;Male;Middle Aged;Receptor, ErbB-2;Sensitivity and Specificity",
        "Doc_meshqualifiers":"analysis;diagnosis;pathology;methods;methods;analysis;genetics",
        "_version_":1605746446210957314},
      {
        "Doc_abstract":"EGFR and HER2 are highly expressed in 15-30% of breast cancer tissues. Therefore, EGFR and its downstream signaling pathways are promising anti-tumour targets. HER2 overexpression is often associated with estrogen receptor (ER) and progesterone receptor (PR) negativity, high histological grade, high rates of cell proliferation and lymph node involvement. Moreover, it is correlated with disease aggressiveness, increased rates of recurrence and poorer survival in node-positive breast cancer patients, whereas the prognostic significance in patients with node-negative tumors remains somewhat controversial. This paper focuses on the therapeutic strategy for treatment of HER2 overexpressing breast cancer in advanced stages of disease, as well as in the adjuvant and neo-adjuvant settings.",
        "Doc_title":"Which role for EGFR therapy in breast cancer?",
        "Journal":"Frontiers in bioscience (Scholar edition)",
        "Do_id":"22202041",
        "Doc_ChemicalList":"Antineoplastic Agents;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Antineoplastic Agents;Breast Neoplasms;Female;Humans;Molecular Targeted Therapy;Receptor, ErbB-2",
        "Doc_meshqualifiers":"pharmacology;therapeutic use;drug therapy;enzymology;pathology;biosynthesis;metabolism",
        "_version_":1605845271220060160},
      {
        "Doc_abstract":"Early detection of breast cancer in blood is both appealing clinically and challenging technically due to the disease's illusive nature and heterogeneity. Today, even though major breast cancer subtypes have been characterized, i.e., luminal A, luminal B, HER2+, and basal-like, little is known about the heterogeneity of breast cancer in blood, which could help to discover minimally invasive protein biomarkers with which clinical researchers can detect, classify, and monitor different breast cancer subtypes.;In this study, we performed an integrative pathway-assisted clustering analysis of breast cancer subtypes from plasma proteome samples collected from 80 patients diagnosed with breast cancer and 80 healthy women. First, four breast cancer subtypes and additionally unknown subtype (according to existing annotation) were determined based on pathology lab test results in primary tumors of enrolled patients. Next, we developed and applied four distance metrics, i.e., Protein Intensity, Q-Value, Pathway Profile, and Distance Score Function, to measure and characterize these cancer subtypes. Then, we developed a permutation test to evaluate the significant protein level changes in each biological pathway for each breast cancer subtype, using q-value. Lastly, we developed a pathway-protein matrix for each of the four distance methods to estimate the distance between breast cancer subtypes, for which further Pathway Association Network analysis were performed.;We found that 1) the luminal group (luminal A and luminal B) are clustered together, as well as the basal group (basal-like and HER2+) and 2) luminal A and luminal B are more close to each other than basal-like and HER2+ to each other. Our results were consistent with a recent independent breast cancer research from the Cancer Genome Atlas Network using genomic DNA copy number arrays, DNA methylation, exome sequencing, messenger RNA arrays, microRNA sequencing and reverse-phase protein arrays. Our results showed that changes of different breast cancer subtypes at the pathway level are more profound and less variable than those at the molecular level. Similar subtypes share distinct yet similar pathway activation networks, while dissimilar subtypes are different also at the level of pathway activation networks. The results also showed that distance or similarity of cancer subtypes based on pathway analysis might be able to provide further insight into the intrinsic relationship of breast cancer subtypes. We believe integrative pathway-assisted proteomics analysis described here can become a model for reliable clustering or classification of other cancer subtypes.",
        "Doc_title":"Breast cancer subtyping from plasma proteins.",
        "Journal":"BMC medical genomics",
        "Do_id":"23369492",
        "Doc_ChemicalList":"Biomarkers;Blood Proteins;Proteome",
        "Doc_meshdescriptors":"Adult;Algorithms;Biomarkers;Blood Proteins;Breast Neoplasms;Cluster Analysis;Female;Humans;Middle Aged;Neoplasm Grading;Oligonucleotide Array Sequence Analysis;Proteome;Proteomics",
        "Doc_meshqualifiers":"blood;genetics;metabolism;blood;classification;pathology;metabolism",
        "_version_":1605765445073240064},
      {
        "Doc_abstract":"This study is to investigate the estrogen receptor Î² (ERÎ²) expression in molecular subtypes of breast cancer and clinic significance of ERÎ² expression.;The ERÎ² expression was detected in 730 cases of breast cancer tissue specimens by immunohistochemistry. Twenty-one patients were censored during 2-10Â years follow-up. The difference in ERÎ² expression was analyzed by Pearson Chi-square Test. Its correlation with estrogen receptor Î± (ERÎ±), progesterone receptor (PR) and human epidermal growth factor receptor 2 (Her-2) was analyzed by Spearman rank correlation. The accumulative tumor-free survival rate was calculated by Kaplan-Meier method and difference in survival rate was analyzed by Log-rank test. Cox regression was used for multi-factor analysis.;The ERÎ² expression was significantly different among the molecular subtypes of breast cancer (Pâ€‰<â€‰0.05). The ERÎ² expression in breast cancer was positively correlated with Her-2 (Pâ€‰<â€‰0.05) while it had no correlation with ERÎ± and Her-2. The expression of ERÎ± was negatively correlated with Her-2 (Pâ€‰<â€‰0.01) whereas positively correlated with PR (Pâ€‰<â€‰0.01). The expression of PR was negatively correlated with Her-2 (Pâ€‰<â€‰0.05). The tumor-free survival rate in patients with positive ERÎ² expression was significantly lower than that in patients with negative ERÎ² expression.;Positive ERÎ² expression is a poor prognostic factor of breast cancer.;The virtual slides for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/1084557586106833.",
        "Doc_title":"Significance of ERÎ² expression in different molecular subtypes of breast cancer.",
        "Journal":"Diagnostic pathology",
        "Do_id":"24457087",
        "Doc_ChemicalList":"Biomarkers, Tumor;Estrogen Receptor alpha;Estrogen Receptor beta;estrogen receptor alpha, human;ERBB2 protein, human;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Adult;Aged;Biomarkers, Tumor;Breast Neoplasms;Disease-Free Survival;Estrogen Receptor alpha;Estrogen Receptor beta;Female;Humans;Immunohistochemistry;Kaplan-Meier Estimate;Middle Aged;Prognosis;Proportional Hazards Models;Receptor, ErbB-2",
        "Doc_meshqualifiers":"analysis;metabolism;mortality;analysis;biosynthesis;analysis;biosynthesis;analysis;biosynthesis",
        "_version_":1605906707475595264},
      {
        "Doc_abstract":"Breast cancer is one of the leading causes of mortality in Indian women. Although breast cancer is an epithelial malignancy, stroma plays a key role in its development and pathogenesis. Stromal markers are now emerging as novel markers in assessing the prognosis of invasive breast cancer and have not been studied extensively till date. The aim of the present study is to study the stromal expression of CD10 in breast carcinoma, find its relationship with other prognostic markers and study the role stroma plays in breast cancer pathogenesis.;A total of 70 cases of breast cancer were included in the study. Representative sections were taken and hematoxylin and eosin staining was done. Immunohistochemistry was performed with ER, PR, Her2neu and CD10. Stromal expression of CD10 (>10% stromal positivity was considered positive) in invasive breast carcinoma was noted and was statistically analyzed with different known prognostic markers of breast carcinoma.;Stromal expression of CD10 was found to be significantly associated with increasing tumor grade (P = 0.04), increasing mitotic rate (P = 0.33), worsening prognosis (P = 0.01), ER negativity (P = 0.0001), Her2neu positivity (P = 0.19) and with molecular subtypes (CD10 positivity with the HER2 type, and CD10 negativity with Luminal type). No correlation was found between CD10 overexpression and PR, age, menopausal status, tumor size, lymph node positivity and tumor stage.;This study gives substantial proof to the various models/research papers explaining the role of stroma/CD10 in breast cancer pathogenesis. Keeping the role stroma plays in predicting prognosis and tumor response, CD10 should be included as a routine pre-chemotherapy marker in breast carcinoma. Further studies should be performed to see the role stroma plays in hormonal expression and the usefulness of CD10 to predict treatment failure in breast carcinomas receiving neoadjuvant therapy.",
        "Doc_title":"CD10-a new prognostic stromal marker in breast carcinoma, its utility, limitations and role in breast cancer pathogenesis.",
        "Journal":"Indian journal of pathology & microbiology",
        "Do_id":"25308002",
        "Doc_ChemicalList":"Receptors, Estrogen;Receptors, Progesterone;TIMP1 protein, human;Tissue Inhibitor of Metalloproteinase-1;Transforming Growth Factor beta;ERBB2 protein, human;Receptor, ErbB-2;Matrix Metalloproteinases;Neprilysin",
        "Doc_meshdescriptors":"Adult;Breast Neoplasms;Extracellular Matrix;Female;Humans;Matrix Metalloproteinases;Middle Aged;Neoplasm Grading;Neoplasm Invasiveness;Neprilysin;Prognosis;Receptor, ErbB-2;Receptors, Estrogen;Receptors, Progesterone;Tissue Inhibitor of Metalloproteinase-1;Transforming Growth Factor beta",
        "Doc_meshqualifiers":"diagnosis;etiology;pathology;genetics;metabolism;biosynthesis;genetics;genetics;metabolism;metabolism;metabolism;metabolism;biosynthesis;biosynthesis",
        "_version_":1605758233316687872},
      {
        "Doc_abstract":"Approximately 15% of primary breast cancers have amplification/overexpression of the cell surface receptor HER2. Despite the major improvements in survival achieved by the use of adjuvant trastuzumab, many of these patients still develop metastatic disease, and other patients with HER2 overexpressing breast cancer have overt metastases at first diagnosis. There remains therefore a pressing medical need to identify better therapies for these patients. Pertuzumab is a humanized antibody that targets and binds HER2. Although only modestly active against breast cancer when used as a single agent, pertuzumab has demonstrated significant activity when combined with trastuzumab against trastuzumab-resistant and -sensitive disease. Multiple clinical trials are underway to define the optimal use of pertuzumab (combined with either trastuzumab or trastuzumab-DM1) together with a range of cytotoxic agents or endocrine therapy in multiple settings of HER2-overexpressing breast cancer. This article summarizes the use of pertuzumab in the metastatic disease setting.",
        "Doc_title":"Pertuzumab for the treatment of metastatic breast cancer.",
        "Journal":"Expert review of anticancer therapy",
        "Do_id":"23984893",
        "Doc_ChemicalList":"Antibodies, Monoclonal, Humanized;Antineoplastic Agents;Receptor, ErbB-2;pertuzumab",
        "Doc_meshdescriptors":"Animals;Antibodies, Monoclonal, Humanized;Antineoplastic Agents;Breast Neoplasms;Female;Humans;Prognosis;Receptor, ErbB-2",
        "Doc_meshqualifiers":"therapeutic use;therapeutic use;drug therapy;metabolism;secondary;antagonists & inhibitors;metabolism",
        "_version_":1605792513770127360},
      {
        "Doc_abstract":"Eighteen to twenty percent of breast cancer tumors show abnormal amplification of the Human Epidermal growth factor Receptor 2 (HER2) gene and increased expression of the associated protein. HER2 amplification is associated with rapid tumor proliferation and shorter disease-free and overall survival. Because women with HER2 amplification are more likely to benefit from treatment with the drug trastuzumab, testing for HER2 is recommended to guide therapy. However, little is known about use of HER2 testing in real-world settings. This study examined uptake, use, appropriateness of HER2 testing, and the relationship between HER2 test results and treatment decisions.;We assessed electronic data from 3,634 patients with invasive breast cancer diagnosed from 1998 to 2007 in a large integrated health system. We collected data on patient and tumor characteristics, HER2 testing status, test results, and trastuzumab treatment.;From 1998 to 2000, the percent of patients who underwent HER2 evaluation increased from 12 to 94%; <3% of women with ductal carcinoma in situ, for whom HER2 testing is not recommended, were tested. Trastuzumab use increased 5-fold after 2004, when guidelines expanded to include recommending adjuvant treatment for early-stage breast cancer in addition to metastatic treatment. Ninety-five percent of women receiving trastuzumab had a positive HER2 result. After 2004, 55% of women with invasive breast cancer and overexpression of HER2 received trastuzumab treatment; this ranged from 44% of women with localized breast cancer to 80% of women with distant metastatic disease.;These findings illustrate appropriate and effective implementation of a HER2 testing strategy in a managed care setting.",
        "Doc_title":"HER2 evaluation and its impact on breast cancer treatment decisions.",
        "Journal":"Public health genomics",
        "Do_id":"21540562",
        "Doc_ChemicalList":"Antibodies, Monoclonal, Humanized;Antineoplastic Agents;ERBB2 protein, human;Receptor, ErbB-2;Trastuzumab",
        "Doc_meshdescriptors":"Adult;Aged;Antibodies, Monoclonal, Humanized;Antineoplastic Agents;Breast Neoplasms;Carcinoma, Intraductal, Noninfiltrating;Cohort Studies;Decision Making;Female;Genetic Testing;Humans;Immunoenzyme Techniques;In Situ Hybridization, Fluorescence;Neoplasm Invasiveness;Receptor, ErbB-2;SEER Program;Trastuzumab",
        "Doc_meshqualifiers":"therapeutic use;therapeutic use;drug therapy;genetics;metabolism;drug therapy;genetics;metabolism;utilization;genetics;metabolism",
        "_version_":1605903677475782656},
      {
        "Doc_abstract":"The carcinogenic process is characterized, in part, by the dysfunction of cellular communication pathways, such as the one involving HER2. HER2 is a member of the EGF receptor family, which participates in cell growth and proliferation. HER2 may be overexpressed in 15 to 30% of breast cancer cases and is associated with poor prognosis, shortened overall survival and shorter time to disease progression. Furthermore, an increasing number of studies have demonstrated the relevance of HER2 serum concentrations (sHER2, extracellular domain released into the blood by proteolysis) as a predictive marker of resistance to chemotherapy in HER2-overexpressing metastatic breast cancer. The determination of HER2 overexpression/ amplification in the diagnosis of relapse of breast cancer is currently a routine procedure. Immunohistochemistry (IHC) and fluorescent in situ hybridization (FISH) techniques, used to detect HER2 expression in the tumor, are improving constantly and other parallel techniques such as chromogenic in situ hybridization (CISH) are emerging. sHER2 concentrations can be measured using ELISA techniques, which can be automated. All of these procedures still need to be standardized. The discovery of a monoclonal antibody (4D5) that can inhibit the growth and proliferation of cells overexpressing HER2 led to the development of trastuzumab. Like 4D5, trastuzumab recognizes an epitope on the extracellular domain of HER2. Moreover, trastuzumab is also able to stimulate antibody-dependent cellular toxicity (ADCC). It is administered alone or in combination (with navelbine, taxol, carboplatin, etc.) in patients with metastatic breast cancer overexpressing HER2. Other active antibodies have since been discovered, as well as other specific molecules, such as tyrosine kinase inhibitors which will undoubtedly find a place in the therapeutic arsenal used in breast cancer, especially to avoid resistance to treatment.",
        "Doc_title":"Prospect for anti-her2 receptor therapy in breast cancer.",
        "Journal":"Anticancer research",
        "Do_id":"16739343",
        "Doc_ChemicalList":"Antibodies, Monoclonal;Antibodies, Monoclonal, Humanized;Oligonucleotides, Antisense;Receptor, ErbB-2;Trastuzumab",
        "Doc_meshdescriptors":"Antibodies, Monoclonal;Antibodies, Monoclonal, Humanized;Breast Neoplasms;Humans;Oligonucleotides, Antisense;Receptor, ErbB-2;Trastuzumab",
        "Doc_meshqualifiers":"therapeutic use;genetics;metabolism;therapy;genetics;antagonists & inhibitors;biosynthesis;genetics;immunology",
        "_version_":1605852771393732608},
      {
        "Doc_abstract":"This study investigates the influence of epithelial-mesenchymal transition on prognosis in breast cancer.;Eighty breast carcinomas as well as 6 breast cancer cell lines were analysed immunohistochemically for the expression of epithelial keratins (K) K8, K19 and mesenchymal vimentin. Protein expression was correlated with histopathological factors and clinical follow-up.;Suppression of K8 and K19 occurred in the majority of the tumours (72.5% and 65%), while aberrant expression of vimentin was found in 21.2% of the tumours. Suppression of K8 as well as expression of vimentin was significantly correlated with short survival (p < 0.004 and p < 0.006). Moreover HER2 overexpression significantly correlated with K19 (p < 0.0004) and vimentin (p < 0.0005). In cell lines with increasing invasive potential, epithelial keratins were lost in favour of mesenchymal vimentin.;The transition from epithelial keratin to mesenchymal vimentin expression marks an important step in the malignant progression of breast cancer.",
        "Doc_title":"The prognostic significance of epithelial-mesenchymal transition in breast cancer.",
        "Journal":"Anticancer research",
        "Do_id":"12530097",
        "Doc_ChemicalList":"KRT8 protein, human;Keratin-8;Receptors, Estrogen;Vimentin;Keratins;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Adult;Aged;Aged, 80 and over;Breast Neoplasms;Carcinoma, Ductal, Breast;Epithelial Cells;Female;Humans;Immunohistochemistry;Keratin-8;Keratins;Mesoderm;Middle Aged;Prognosis;Receptor, ErbB-2;Receptors, Estrogen;Survival Rate;Tumor Cells, Cultured;Vimentin",
        "Doc_meshqualifiers":"metabolism;pathology;metabolism;pathology;metabolism;pathology;biosynthesis;metabolism;pathology;biosynthesis;biosynthesis;biosynthesis",
        "_version_":1605884603283800064},
      {
        "Doc_abstract":"Circulating tumour cells in women with advanced oestrogen-receptor (ER)-positive/human epidermal growth factor receptor 2 (HER2)-negative breast cancer acquire a HER2-positive subpopulation after multiple courses of therapy. In contrast to HER2-amplified primary breast cancer, which is highly sensitive to HER2-targeted therapy, the clinical significance of acquired HER2 heterogeneity during the evolution of metastatic breast cancer is unknown. Here we analyse circulating tumour cells from 19 women with ER",
        "Doc_title":"HER2 expression identifies dynamic functional states within circulating breast cancer cells.",
        "Journal":"Nature",
        "Do_id":"27556950",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605790005676998656},
      {
        "Doc_abstract":"Differences in the incidence and outcome of breast cancer among Hispanic women compared with white women are well documented and are likely explained by ethnic differences in genetic composition, lifestyle, or environmental exposures.  METHODOLGY/PRINCIPAL FINDINGS: A population-based study was conducted in Galicia, Spain. A total of 510 women diagnosed with operable invasive breast cancer between 1997 and 2010 participated in the study. Data on demographics, breast cancer risk factors, and clinico-pathological characteristics were collected. The different breast cancer tumor subtypes were compared on their clinico-pathological characteristics and risk factor profiles, particularly reproductive variables and breastfeeding. Among the 501 breast cancer patients (with known ER and PR receptors), 85% were ER+/PR+ and 15% were ER-&PR-. Among the 405 breast cancer with known ER, PR and HER2 status, 71% were ER+/PR+/HER2- (luminal A), 14% were ER+/PR+/HER2+ (luminal B), 10% were ER-/PR-/HER2- (triple negative breast cancer, TNBC), and 5% were ER-/PR-/HER2+ (non-luminal). A lifetime breastfeeding period equal to or longer than 7 months was less frequent in case patients with TNBC (ORâ€Š=â€Š0.25, 95% CIâ€Š=â€Š0.08-0.68) compared to luminal A breast cancers. Both a low (2 or fewer pregnancies) and a high (3-4 pregnancies) number of pregnancies combined with a long breastfeeding period were associated with reduced odds of TNBC compared with luminal A breast cancer, although the association seemed to be slightly more pronounced among women with a low number of pregnancies (ORâ€Š=â€Š0.09, 95% CIâ€Š=â€Š0.005-0.54).;In case-case analyses with the luminal A cases as the reference group, we observed a lower proportion of TNBC among women who breastfed 7 or more months. The combination of longer breastfeeding duration and lower parity seemed to further reduce the odds of having a TNBC compared to a luminal A breast cancer.",
        "Doc_title":"Breast feeding, parity and breast cancer subtypes in a Spanish cohort.",
        "Journal":"PloS one",
        "Do_id":"22792365",
        "Doc_ChemicalList":"Receptors, Estrogen;Receptors, Progesterone;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Adult;Aged;Aged, 80 and over;Breast Feeding;Breast Neoplasms;European Continental Ancestry Group;Female;Humans;Middle Aged;Parity;Pregnancy;Receptor, ErbB-2;Receptors, Estrogen;Receptors, Progesterone;Risk Factors;Spain",
        "Doc_meshqualifiers":"classification;epidemiology;metabolism;metabolism;metabolism;epidemiology",
        "_version_":1605836670553292800},
      {
        "Doc_abstract":"The membrane mucin Muc4 is aberrantly expressed in numerous epithelial carcinomas and is currently used as a cancer diagnostic and prognostic tool. Muc4 can also potentiate signal transduction by modulating differential ErbB2 phosphorylation in the absence and in the presence of the ErbB3 soluble ligand heregulin (HRG-beta1). These features of Muc4 suggest that Muc4 is not merely a cancer marker, but an oncogenic factor with a unique-binding/activation relationship with the receptor ErbB2. In the present study, we examined the signaling mechanisms that are associated with the Muc4-ErbB2 module by analyzing ErbB2 differential signaling in response to Muc4 expression. Our study was carried out in the A375 human melanoma and BT-474 breast cancer cell lines as our model systems. Quantitative and comparative signaling modulations were evaluated by immunoblot using phospho-specific antibodies, and densitometry analysis. Signaling complex components were identified by chemical cross-linking, fractionation by gel filtration, immunoprecipitation, and immunoblotting. Activated downstream signaling pathways were analyzed by an antibody microarray screen and immunoblot analyses. Our results indicate that Muc4 modulates ErbB2 signaling potential significantly by stabilizing and directly interacting with the ErbB2-ErbB3 heterodimer. Further analyses indicate that Muc4 promotes ErbB2 autocatalysis, but it has no effect on ErbB3 phosphorylation, although the chemical cross-linking data indicated that the signaling module is composed of Muc4, ErbB2, and ErbB3. Our microarray analysis indicates that Muc4 expression promotes cell migration by increasing the phosphorylation of the focal adhesion kinase and also through an increase in the levels of beta-catenin.",
        "Doc_title":"Mechanistic and signaling analysis of Muc4-ErbB2 signaling module: new insights into the mechanism of ligand-independent ErbB2 activity.",
        "Journal":"Journal of cellular physiology",
        "Do_id":"20432461",
        "Doc_ChemicalList":"Biomarkers, Tumor;Ligands;Mucin-4;Protein Subunits;ERBB2 protein, human;Receptor, ErbB-2;Receptor, ErbB-3;Focal Adhesion Protein-Tyrosine Kinases",
        "Doc_meshdescriptors":"Animals;Biomarkers, Tumor;Cell Line, Tumor;Focal Adhesion Protein-Tyrosine Kinases;Humans;Ligands;Microarray Analysis;Mucin-4;Protein Subunits;Receptor, ErbB-2;Receptor, ErbB-3;Signal Transduction",
        "Doc_meshqualifiers":"metabolism;metabolism;metabolism;metabolism;chemistry;genetics;metabolism;chemistry;genetics;metabolism;physiology",
        "_version_":1605763801645318144},
      {
        "Doc_abstract":"In this study, we aimed to clarify the expression profiles of Yes-associated protein (YAP) and phosphorylated YAP (pYAP) protein and to verify the clinical implication of the expression of YAP protein in human breast cancer. We selected 678 cases of formalin-fixed paraffin-embedded (FFPE) breast cancer tissue to construct tissue microarray (TMA) blocks. We performed immunohistochemical staining of estrogen receptor (ER), progesterone receptor (PR), human epidermal growth receptor-2 (HER-2) and Ki-67 and fluorescent in situ hybridization (FISH) assay for HER-2 on the TMA sections and divided breast cancers into molecular subtypes: luminal A, luminal B, HER-2, triple negative breast cancer (TNBC). Then, we examined YAP and pYAP expression status using immunohistochemical analysis according to the molecular subtypes of breast cancer. We found that HER-2 type breast cancer demonstrated elevated expression level in tumoral cytoplasmic YAP (P = 0.011) and pYAP (P = 0.049). Expressions of stromal YAP (P = 0.002) and pYAP (P < 0.001) were higher in luminal B and HER-2 type breast cancer but lower in TNBC. In univariate analysis, nuclear YAP expression of tumor cells was associated with shorter overall survival (OS) (P = 0.024). Cytoplasmic YAP expression of HER-2 type breast cancer cells negatively affected disease-free survival (DFS) (P = 0.034). In conclusion, we concluded that there was a significant difference in YAP and pYAP expression status according to molecular subtypes and tumoral and cellular components of breast cancers. Finally, we found that nuclear and cytoplasmic YAP expression could be a prognostic marker for breast cancer patients. ",
        "Doc_title":"Yes-associated protein (YAP) is differentially expressed in tumor and stroma according to the molecular subtype of breast cancer.",
        "Journal":"International journal of clinical and experimental pathology",
        "Do_id":"25031743",
        "Doc_ChemicalList":"Adaptor Proteins, Signal Transducing;Biomarkers, Tumor;Ki-67 Antigen;Phosphoproteins;Receptors, Estrogen;Receptors, Progesterone;YAP1 (Yes-associated) protein, human;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Adaptor Proteins, Signal Transducing;Biomarkers, Tumor;Breast Neoplasms;Disease-Free Survival;Female;Humans;Immunohistochemistry;In Situ Hybridization, Fluorescence;Kaplan-Meier Estimate;Ki-67 Antigen;Phenotype;Phosphoproteins;Phosphorylation;Proportional Hazards Models;Receptor, ErbB-2;Receptors, Estrogen;Receptors, Progesterone;Tissue Array Analysis;Tumor Microenvironment",
        "Doc_meshqualifiers":"analysis;biosynthesis;analysis;metabolism;mortality;pathology;biosynthesis;analysis;biosynthesis;biosynthesis;biosynthesis;biosynthesis",
        "_version_":1605884145735565312},
      {
        "Doc_abstract":"Therapeutics based on short interfering RNAs (siRNAs) have great potential to treat human diseases. However, the clinical application of siRNAs has been limited by their poor intracellular uptake, low serum stability, and inability to target specific cells. In this study, we addressed this lack of specificity by synthesizing a molecularly targeted CXCR4-siRNA (CXCR4si) for the treatment of HER2(+) breast cancers using a HER2-scFv-arginine nonamer peptide fusion protein (e23sFv-9R) as an siRNA carrier. The e23sFv-9R binding siRNA is able to specifically deliver the siRNA to HER2(+) breast cancer cells and concentrate and persist in orthotopic HER2(+) breast cancer xenografts for at least 36 h. CXCR4si delivered by e23sFv-9R inhibited CXCR4 gene expression, reduced proliferation and metastasis and induced apoptosis in the HER2(+) breast cancer BT-474 cell line in vitro. Moreover, the systemic delivery of CXCR4si by e23sFv-9R is able to suppress tumor growth, reduce metastasis and prolong survival in mice bearing HER2(+) xenografts. This approach causes no systemic toxicity and does not activate the innate immune response, suggesting that a fusion protein carrying CXCR4si shows promise in the treatment of HER2-overexpressing breast cancer.",
        "Doc_title":"Targeted delivery of CXCR4-siRNA by scFv for HER2(+) breast cancer therapy.",
        "Journal":"Biomaterials",
        "Do_id":"25956853",
        "Doc_ChemicalList":"CXCR4 protein, human;RNA, Small Interfering;Receptors, CXCR4;Single-Chain Antibodies",
        "Doc_meshdescriptors":"Animals;Breast Neoplasms;Genes, erbB-2;Humans;Mice;RNA, Small Interfering;Receptors, CXCR4;Single-Chain Antibodies;Xenograft Model Antitumor Assays",
        "Doc_meshqualifiers":"genetics;pathology;therapy;administration & dosage;genetics;genetics;administration & dosage",
        "_version_":1605905873678368768},
      {
        "Doc_abstract":"Triple-negative breast cancers (TNBCs) are defined by lack of expressions of estrogen, progesterone, and ERBB2 receptors. Because biology of TNBC is poorly understood, no targeted therapy has been developed for this breast cancer subtype and chemotherapy is its only systemic treatment modality. In this study, we firstly determined that the expression of human ecto-ADP-ribosyltransferase 3 (ART3) is significantly associated with the basal-like breast cancer subgroup, which is largely overlapped with TNBC, through analyzing published data sets. We also found that ART3 protein is significantly overexpressed in human TNBC tumors tissue and cell lines through using immunohistochemistry and immunoblotting. Overexpression of ART3 in MDA-MB-231 breast cancer cells increased cell proliferation, invasion, and survival in vitro and growth of xenograft tumors. Conversely, knockdown of ART3 in breast cancer cells inhibited cell proliferation and invasion. In addition, we showed that ART 3 overexpression activated AKT and ERK in vitro and in xenograft tumors. Together, our findings demonstrate that ART3 is a critical TNBC marker with functional significance.",
        "Doc_title":"ART3 regulates triple-negative breast cancer cell function via activation of Akt and ERK pathways.",
        "Journal":"Oncotarget",
        "Do_id":"27374177",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605819935555059712},
      {
        "Doc_abstract":"BACKGROUND: An expanded understanding of the biology of breast cancer has led to the identification of the HER-2 receptor as an important growth factor. This receptor possesses intrinsic tyrosine kinase activity and has been associated with aggressive biological behavior and poor clinical outcome. METHODS: Data have been reviewed regarding the role of HER-2 expression as a prognostic variable, as a predictive factor for response to chemotherapy and hormonal therapies, and as a directed therapeutic target for breast cancer. RESULTS: Therapy with a humanized monoclonal antibody to HER-2 (trastuzumab) can be effective treatment in some patients with metastatic breast cancer, either given alone or in combination with some chemotherapeutic agents. Cardiac toxicity limits concurrent use with anthracyclines. Clinical trials will further define optimal combination regimens with this agent, and its value in patients with localized or locally advanced stages. CONCLUSIONS: Trastuzumab is a significant addition to the armamentarium against breast cancer. Standardization of the optimal method to evaluate for HER-2 overexpression is necessary to better define its role as a prognostic, predictor, and therapeutic target in this disease.",
        "Doc_title":"HER-2 as a Prognostic, Predictive, and Therapeutic Target in Breast Cancer.",
        "Journal":"Cancer control : journal of the Moffitt Cancer Center",
        "Do_id":"10758552",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605783649340358656},
      {
        "Doc_abstract":"Alterations of the human epidermal growth factor receptor 2 (HER2) protooncogene have been implicated in the carcinogenesis and prognosis of breast cancer. A polymorphism has been identified at codon 655 (ATC/isoleucine to GTC/valine [I655V]) in the transmembrane domain-coding region of this gene, which may be associated with the risk of breast cancer. In this study we aimed to determine whether the risk of breast cancer is associated with the I655V polymorphism of HER2 transmembrane domain-coding region at codon 655. The genomic DNA from breast cancer patients and control subjects underwent analysis by the polymerase chain reaction-fragment length polymorphism. We observed no overall association between HER2 genotype and breast cancer (p = 0.53). However, an elevated positive association was observed for Ile/Val+Val/Val versus Ile/Ile genotypes in women >age 60 years (p = 0.02). Further, other risk factors--namely, the body mass index and family history--were found to be risk factors for developing breast cancer (p = 0.006 and p = 0.00, respectively). In conclusion, results of this study suggest that polymorphisms of the HER2 gene may be important susceptibility biomarkers for breast cancer risk among older women.",
        "Doc_title":"The influence of HER2 genotypes as molecular markers on breast cancer outcome.",
        "Journal":"DNA and cell biology",
        "Do_id":"18721072",
        "Doc_ChemicalList":"DNA, Neoplasm;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Adult;Breast;Breast Neoplasms;Case-Control Studies;DNA, Neoplasm;Female;Genotype;Humans;Middle Aged;Phenotype;Polymorphism, Genetic;Receptor, ErbB-2",
        "Doc_meshqualifiers":"pathology;genetics;pathology;genetics;genetics;genetics",
        "_version_":1605804573585309696},
      {
        "Doc_abstract":"Breast cancer tumors that demonstrate gene amplification or overexpression of human epidermal growth factor receptor 2 (HER2) are classified as HER2-positive. They account for approximately 15% of all breast cancers and represent an adverse prognostic factor. Over the past years, many new therapies have become available for the treatment of breast cancer. Particularly, the treatment of patients with HER2-positive breast cancer has developed with the arrival of anti-HER2 targeted therapies that have been proven to increase survival in both the metastatic and early-stage settings of the disease. Trastuzumab, a monoclonal antibody targeting HER2, significantly improves survival in HER2-positive breast cancer. Nevertheless, it is still a challenge to evolve anti-HER2 therapies, as the disease may progress. Pertuzumab inhibits HER2 by binding to a different HER2 epitope than trastuzumab and represents a complementary mechanism of action to trastuzumab. The efficacy and safety of pertuzumab in combination with trastuzumab with or without chemotherapy have been demonstrated in both advanced and early stages of HER2-positive breast cancer. Herein, we review the available data on the use of pertuzumab for the treatment of patients with HER2-positive breast cancer. ",
        "Doc_title":"The expanding role of pertuzumab in the treatment of HER2-positive breast cancer.",
        "Journal":"Breast cancer (Dove Medical Press)",
        "Do_id":"26056489",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605807439542747136},
      {
        "Doc_abstract":"Ligands of the EGF/Heregulin family control the growth of epithelial cells by binding to receptors of the erbB family. By searching a large database of cDNA sequences at Human Genome Sciences Inc. we have identified a new encoded protein sequence containing all the conserved elements of the EGF/Heregulin family. The same sequence has recently been independently identified as NRG-3. The EGF-like domain of NRG-3 was generated as a recombinant protein in E. coli and used to test the specificity of receptor binding. In human breast cancer cells and in 32D cells transfected by erbB family members, NRG-3 activated multiple erbB family members. These include EGF receptor (erbB1) and erbB4 when expressed individually and erbB2 and erbB3 when expressed together. Recombinant NRG-3 altered the growth of human breast cancer cells growing in vitro. NRG-3 was expressed in cell lines derived from breast cancer. These results indicate that NRG-3 is a potential regulator of normal and malignant breast epithelial cells in vivo.",
        "Doc_title":"NRG-3 in human breast cancers: activation of multiple erbB family proteins.",
        "Journal":"International journal of oncology",
        "Do_id":"9772300",
        "Doc_ChemicalList":"Carrier Proteins;Intracellular Signaling Peptides and Proteins;NRG3 protein, human;Neuregulins;Oncogene Proteins v-erbB;RNA, Messenger;Recombinant Proteins;Epidermal Growth Factor",
        "Doc_meshdescriptors":"Amino Acid Sequence;Breast Neoplasms;Carrier Proteins;Cell Division;Cell Line;Databases, Factual;Epidermal Growth Factor;Epithelial Cells;Humans;Intracellular Signaling Peptides and Proteins;Molecular Sequence Data;Neuregulins;Oncogene Proteins v-erbB;Protein Conformation;RNA, Messenger;Recombinant Proteins;Sequence Homology, Amino Acid;Tumor Cells, Cultured",
        "Doc_meshqualifiers":"metabolism;chemistry;metabolism;chemistry;metabolism;genetics;metabolism;metabolism;metabolism",
        "_version_":1605742651135492097},
      {
        "Doc_abstract":"To determine the biopathologic profiles of breast cancer for greater knowledge of tumor natural history and clinical outcome.;In 99 in situ (ISC) and 2718 infiltrating breast carcinomas (IC), biologic markers (estrogen receptor [ER], progesterone receptor [PR] proliferation index, cerbB-2/NEU, p53, bcl-2 and DNA ploidy) were evaluated with an image analysis system (CAS 200/486). In 105 mixed invasive cancers with size < or = 1 cm, a separate analysis of in situ (ISCm) and invasive component (ICm) was obtained. A clinical study of 836 invasive breast cancers was performed.;Different biophenotypes were obtained: among ISCs, cribriform type exhibited biologic behavior similar to that of normal breast tissue (ER+, PR+, proliferation index [PI] low, NEU-, p53-, bcl-2+) the opposite profile was displayed by comedo type, and intermediate phenotypes were observed in noncomedo and lobular types. Comparing ISC and ISCm, PI and p53 expression had the highest levels in ISCm with respect to other groups. NEU overexpression exhibited a decreasing value from ICm to IC. Younger women (< or = 40 years) with IC demonstrated a worse biologic profile (high PI, p53+, ER- and size > 2 cm). In multivariate analysis, PI and NEU in node-negative patients, and NEU, PR and size in node-positive ones emerged as prognostic parameters.;The results underline the importance of the quantitative biologic profile for defining tumor behavior and patient management.",
        "Doc_title":"Quantitative immunoprofiles of breast cancer performed by image analysis.",
        "Journal":"Analytical and quantitative cytology and histology",
        "Do_id":"10560485",
        "Doc_ChemicalList":"Biomarkers, Tumor;DNA, Neoplasm",
        "Doc_meshdescriptors":"Adult;Aged;Aged, 80 and over;Biomarkers, Tumor;Breast;Breast Neoplasms;Carcinoma in Situ;Carcinoma, Ductal, Breast;DNA, Neoplasm;Female;Humans;Image Cytometry;Image Processing, Computer-Assisted;Immunoenzyme Techniques;Middle Aged;Phenotype;Premenopause",
        "Doc_meshqualifiers":"metabolism;metabolism;pathology;genetics;metabolism;pathology;genetics;metabolism;pathology;genetics;metabolism;pathology;genetics;methods",
        "_version_":1605742670872838145},
      {
        "Doc_abstract":"Iron is a fundamental nutrient that enables the functions of vital enzymes involved in cell replication, metabolism and growth. Cancer cells contain higher systemic iron levels relative to normal cells. In breast cancer cells, human epidermal growth factor receptor 2 (HER2) is overexpressed more than 30% of normal and its poorly prognosis results in elevated the proportion of cancer stem cells (CSCs) which are the main drivers in cancer recurrence. Finding a relation between increases of iron levels, HER2 expression and CSC population may provide new tools for breast cancer therapy. In this study, therefore, iron dependency in HER2 overexpression and CSC survival is examined in breast cancer cell line, MCF7. It has shown that cells overexpressing HER2 require iron more than their vector counterparts and HER2-increased CSCs are vulnerable to iron chelation. Additionally, this sensitivity of CSCs to iron reduction is obviously indicated in various breast cancer cell lines; HCC1954, MDA-MB-435 and Hs578T. Finally, the concept is also shown in neoplastically transformed breast cancer cell line, HMLER. Altogether, this study demonstrates that iron depletion causes toxicity for CSCs. ",
        "Doc_title":"The role of Iron on breast cancer stem-like cells.",
        "Journal":"Cellular and molecular biology (Noisy-le-Grand, France)",
        "Do_id":"27188730",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605818680279564288},
      {
        "Doc_abstract":"Growing evidence has demonstrated that human epidermal growth factor receptor 2 (HER2) is involved in the radiation response to breast cancer. However, the underlying mechanism remains elusive. Therefore, we investigated if HER2 overexpression is associated with radiosensitivity of breast cancer. We constructed breast cancer cell lines differing in HER2 expression by transducing HER2 cDNA or short hairpin RNA against HER2. We then assessed the radiosensitivity and investigated the potential mechanism by using cell proliferation assay, cell adhesion assays, anoikis assays, colony formation assays, and western blotting analyses. We found that HER2 introduction in breast cancer cell lines MCF-7 (low HER2 expression) and MDA-MB-231 (HER2 is not expressed) promoted cell proliferation and invasion and enhanced cell adhesion and resistance to anoikis. Moreover, HER2 reduced radiosensitivity in these two cells compared with the corresponding control. The opposite results were observed when HER2 was silenced in breast cancer cell lines ZR-7530 and SK-BR-3 (both cells with high expression of HER2) using HER2 shRNA. In addition, animal experiment results showed HER2 could enhance the radioresistance of xenograft tumors. Further studies showed HER2 promoted the phosphorylation of focal adhesion kinase (Fak) and thereby up-regulated the expression of proteins associated with the epithelial-to-mesenchymal transition such as Claudin-1, ZO-1, and ZEB-1. The inhibition of Fak activity using the Fak inhibitor (PF-562281) restored the radiosensitivity in HER2-overexpressing cells. In conclusion, HER2 reduces the radiosensitivity of breast cancer by activating Fak in vitro and in vivo. Fak might be a potential target for the radiosensitization of HER2-overexpressed breast cancer.",
        "Doc_title":"HER2 reduces breast cancer radiosensitivity by activating focal adhesion kinase in vitro and in vivo.",
        "Journal":"Oncotarget",
        "Do_id":"27286256",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605763777432649728},
      {
        "Doc_abstract":"Gene expression profiling of breast cancer has identified two biologically distinct estrogen receptor (ER)-positive subtypes of breast cancer: luminal A and luminal B. Luminal B tumors have higher proliferation and poorer prognosis than luminal A tumors. In this study, we developed a clinically practical immunohistochemistry assay to distinguish luminal B from luminal A tumors and investigated its ability to separate tumors according to breast cancer recurrence-free and disease-specific survival.;Tumors from a cohort of 357 patients with invasive breast carcinomas were subtyped by gene expression profile. Hormone receptor status, HER2 status, and the Ki67 index (percentage of Ki67-positive cancer nuclei) were determined immunohistochemically. Receiver operating characteristic curves were used to determine the Ki67 cut point to distinguish luminal B from luminal A tumors. The prognostic value of the immunohistochemical assignment for breast cancer recurrence-free and disease-specific survival was investigated with an independent tissue microarray series of 4046 breast cancers by use of Kaplan-Meier curves and multivariable Cox regression.;Gene expression profiling classified 101 (28%) of the 357 tumors as luminal A and 69 (19%) as luminal B. The best Ki67 index cut point to distinguish luminal B from luminal A tumors was 13.25%. In an independent cohort of 4046 patients with breast cancer, 2847 had hormone receptor-positive tumors. When HER2 immunohistochemistry and the Ki67 index were used to subtype these 2847 tumors, we classified 1530 (59%, 95% confidence interval [CI] = 57% to 61%) as luminal A, 846 (33%, 95% CI = 31% to 34%) as luminal B, and 222 (9%, 95% CI = 7% to 10%) as luminal-HER2 positive. Luminal B and luminal-HER2-positive breast cancers were statistically significantly associated with poor breast cancer recurrence-free and disease-specific survival in all adjuvant systemic treatment categories. Of particular relevance are women who received tamoxifen as their sole adjuvant systemic therapy, among whom the 10-year breast cancer-specific survival was 79% (95% CI = 76% to 83%) for luminal A, 64% (95% CI = 59% to 70%) for luminal B, and 57% (95% CI = 47% to 69%) for luminal-HER2 subtypes.;Expression of ER, progesterone receptor, and HER2 proteins and the Ki67 index appear to distinguish luminal A from luminal B breast cancer subtypes.",
        "Doc_title":"Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer.",
        "Journal":"Journal of the National Cancer Institute",
        "Do_id":"19436038",
        "Doc_ChemicalList":"Ki-67 Antigen;Receptors, Estrogen;Receptors, Progesterone;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Adult;Aged;Breast Neoplasms;Cohort Studies;Gene Expression Profiling;Gene Expression Regulation, Neoplastic;Humans;Ki-67 Antigen;Middle Aged;Prognosis;Receptor, ErbB-2;Receptors, Estrogen;Receptors, Progesterone;Treatment Outcome",
        "Doc_meshqualifiers":"diagnosis;metabolism;therapy;biosynthesis;biosynthesis;metabolism;metabolism",
        "_version_":1605784482613297152},
      {
        "Doc_abstract":"The emergence of trastuzumab has drastically changed therapy for breast cancer. Trastuzumab (Herceptin; Genentech) is a recombinant humanized monoclonal antibody that targets an epitope in the extracellular domain of the human epidermal growth factor receptor 2 (HER2) protein. HER2 is a member of a family of four transmembrane receptor tyrosine kinases that regulate cell growth, survival, and differentiation via multiple signal transduction pathways. Overexpression of HER2 or amplification of the HER2 gene occurs in 20%-30% of human breast cancers. Preclinical models have demonstrated that this antibody has significant antitumor activity as a single agent, and it also has a synergy with certain chemotherapeutic drugs. Phase II and III clinical trials performed in women with metastatic breast cancers that overexpress HER2 have shown trastuzumab to have clinical activity when used as monotherapy, while also improving survival when used as a first-line therapy in combination with chemotherapy. At present, clinical investigations are focusing attention on the efficacy of trastuzumab in both the adjuvant and neoadjuvant setting, as well as in the metastatic setting. In this review, we describe the developments and current status of trastuzumab-based treatment for breast cancer.",
        "Doc_title":"Trastuzumab and breast cancer: developments and current status.",
        "Journal":"International journal of clinical oncology",
        "Do_id":"16850126",
        "Doc_ChemicalList":"Antibodies, Monoclonal;Antibodies, Monoclonal, Humanized;Antineoplastic Agents;Receptor, ErbB-2;Trastuzumab",
        "Doc_meshdescriptors":"Antibodies, Monoclonal;Antibodies, Monoclonal, Humanized;Antineoplastic Agents;Antineoplastic Combined Chemotherapy Protocols;Breast Neoplasms;Chemotherapy, Adjuvant;Drug Resistance, Neoplasm;Female;Humans;Receptor, ErbB-2;Trastuzumab",
        "Doc_meshqualifiers":"administration & dosage;adverse effects;therapeutic use;administration & dosage;adverse effects;therapeutic use;therapeutic use;drug therapy;pathology;antagonists & inhibitors",
        "_version_":1605800847571156992},
      {
        "Doc_abstract":"Tumor infiltrating lymphocytes (TIL) play an essential role in mediating response to chemotherapy and improving clinical outcomes in all subtypes of breast cancer. Triple negative breast cancers (TN) are most likely to have tumors with >50Â % lymphocytic infiltrate, termed lymphocyte predominant breast cancer, and derive the greatest survival benefit from each 10Â % increase in TIL. The majority of HER2",
        "Doc_title":"Clinical significance of tumor-infiltrating lymphocytes in breast cancer.",
        "Journal":"Journal for immunotherapy of cancer",
        "Do_id":"27777769",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605751267006611456},
      {
        "Doc_abstract":"Over the past decade, the management of HER2-positive breast cancer has evolved dramatically. In addition to advances in screening, genetic testing, imaging, surgical and radiation techniques, innovations in medical therapy including widespread use of HER2-directed therapy in early and advanced breast cancer have revolutionized breast cancer care and changed the natural history of HER2-positive breast cancer. A substantial number of HER2-targeted agents are being developed including monoclonal antibodies, small molecule inhibitors, and antibody drug conjugates. Trastuzumab is the prototype HER2-directed therapy that was introduced in the late 1990s for the management of metastatic breast cancer and later showed efficacy in early stage disease. Despite the practice changing impact of trastuzumab and improvement in outcomes of women with HER2-positive breast cancer resistance to trrastuzumab is a major clinical issue, occurring in both early stage and advanced disease, and new treatment strategies are clearly required. Combining HER2-targeted agents and dual HER2 blockade has been successful in early and advanced breast cancer. Furthermore, selected delivery of potent chemotherapeutic agent coupled with HER2 inhibition promises new treatment options. This review is focused on current HER2-directed treatments for women with HER2-positive breast cancer including monoclonal antibodies, small molecule inhibitors, and antibody drug conjugates. ",
        "Doc_title":"HER2-directed therapy: current treatment options for HER2-positive breast cancer.",
        "Journal":"Breast cancer (Tokyo, Japan)",
        "Do_id":"25634227",
        "Doc_ChemicalList":"Antibodies, Monoclonal;Antibodies, Monoclonal, Humanized;Antineoplastic Agents;Quinazolines;Small Molecule Libraries;lapatinib;Maytansine;ERBB2 protein, human;Receptor, ErbB-2;pertuzumab;Trastuzumab;ado-trastuzumab emtansine",
        "Doc_meshdescriptors":"Antibodies, Monoclonal;Antibodies, Monoclonal, Humanized;Antineoplastic Agents;Antineoplastic Combined Chemotherapy Protocols;Breast Neoplasms;Drug Resistance, Neoplasm;Female;Humans;Maytansine;Molecular Targeted Therapy;Neoadjuvant Therapy;Quinazolines;Receptor, ErbB-2;Small Molecule Libraries;Trastuzumab",
        "Doc_meshqualifiers":"therapeutic use;pharmacology;therapeutic use;pharmacology;therapeutic use;therapeutic use;drug therapy;metabolism;pathology;surgery;drug effects;analogs & derivatives;pharmacology;therapeutic use;administration & dosage;therapeutic use;antagonists & inhibitors;metabolism;pharmacology;administration & dosage;pharmacology;therapeutic use",
        "_version_":1605881254490669056},
      {
        "Doc_abstract":"Knowledge of estrogen receptor (ER) and progesterone receptor (PR) status has been critical in the evolution of modern targeted therapy of breast cancer and remains essential for making informed therapeutic decisions. Recently, growth factor receptor HER2/neu (ERBB2) status has made it possible to provide another form of targeted therapy linked to the overexpression of this protein. Presently, pathologists determine the receptor status in formalin-fixed, paraffin-embedded sections using subjective, semiquantitative immunohistochemistry (IHC) assays and quantitative fluorescence in situ hybridization for HER2. We developed a single-tube multiplex TaqMan (mERPR+HER2) assay to quantitate mRNA levels of ER, PR, HER2, and two housekeeping genes for breast cancer formalin-fixed, paraffin-embedded sections. Using data from the discovery sample sets, we evaluated IHC-status-dependent cutoff-point and IHC-status-independent clustering methods for the classification of receptor status and then validated these results with independent sample sets. Compared with IHC-status, the accuracies of the mERPR+HER2 assay with the cutoff-point classification method were 0.98 (95% CI: 0.97-1.00), 0.92 (95% CI: 0.88-0.95), and 0.97 (95% CI: 0.95-0.99) for ER, PR, and HER2, respectively, for the validation sets. Furthermore, the areas under the receiver operating-characteristic curves were 0.997 (95% CI: 0.994-1.000), 0.967 (95% CI: 0.949-0.985), and 0.968 (95% CI: 0.915-1.000) for ER, PR, and HER2, respectively. This multiplex assay provides a sensitive and reliable method to quantitate hormonal and growth factor receptors.",
        "Doc_title":"A single-tube quantitative assay for mRNA levels of hormonal and growth factor receptors in breast cancer specimens.",
        "Journal":"The Journal of molecular diagnostics : JMD",
        "Do_id":"19225135",
        "Doc_ChemicalList":"RNA, Messenger;Receptors, Estrogen;Receptors, Progesterone;Formaldehyde;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Breast Neoplasms;Female;Formaldehyde;Humans;Molecular Diagnostic Techniques;Paraffin Embedding;RNA, Messenger;Receptor, ErbB-2;Receptors, Estrogen;Receptors, Progesterone;Reproducibility of Results;Sensitivity and Specificity;Tissue Fixation;Up-Regulation",
        "Doc_meshqualifiers":"diagnosis;chemistry;methods;analysis;genetics;genetics;genetics;genetics",
        "_version_":1605800317302079488},
      {
        "Doc_abstract":"Vaccinia-related kinase 1 (VRK1) belongs to a group of sixteen kinases associated to a poorer prognosis in human breast carcinomas, particularly in estrogen receptor positive cases based on gene expression arrays. In this work we have studied the potential molecular mechanism by which the VRK1 protein can contribute to a poorer prognosis in this disease. For this aim it was first analyzed by immunohistochemistry the VRK1 protein level in normal breast and in one hundred and thirty six cases of human breast cancer. The effect of VRK1 to protect against DNA damage was determined by studying the effect of its knockdown on the formation of DNA repair foci assembled on 53BP1 in response to treatment with ionizing radiation or doxorubicin in two breast cancer cell lines. VRK1 protein was detected in normal breast and in breast carcinomas at high levels in ER and PR positive tumors. VRK1 protein level was significantly lower in ERBB2 positive cases. Next, to identify a mechanism that can link VRK1 to poorer prognosis, VRK1 was knocked-down in two breast cancer cell lines that were treated with ionizing radiation or doxorubicin, both inducing DNA damage. Loss of VRK1 resulted in reduced formation of DNA-damage repair foci complexes assembled on the 53BP1 scaffold protein, and this effect was independent of damaging agent or cell type. This observation is consistent with detection of high VRK1 protein levels in ER and PR positive breast cancers. We conclude that VRK1 can contribute to make these tumors more resistant to DNA damage-based therapies, such as ionizing radiation or doxorubicin, which is consistent with its association to a poor prognosis in ER positive breast cancer. VRK1 is potential target kinase for development of new specific inhibitors which can facilitate sensitization to other treatments in combination therapies; or alternatively be used as a new cancer drugs. ",
        "Doc_title":"Vaccinia-related kinase 1 (VRK1) confers resistance to DNA-damaging agents in human breast cancer by affecting DNA damage response.",
        "Journal":"Oncotarget",
        "Do_id":"24731990",
        "Doc_ChemicalList":"Intracellular Signaling Peptides and Proteins;Receptors, Estrogen;Receptors, Progesterone;TP53BP1 protein, human;Tumor Suppressor p53-Binding Protein 1;Doxorubicin;ERBB2 protein, human;Receptor, ErbB-2;Protein-Serine-Threonine Kinases;VRK1 protein, human",
        "Doc_meshdescriptors":"Breast;Breast Neoplasms;Carcinoma;Cell Line, Tumor;DNA Damage;DNA Repair;Doxorubicin;Female;Gene Knockdown Techniques;Humans;Intracellular Signaling Peptides and Proteins;Prognosis;Protein-Serine-Threonine Kinases;Radiation, Ionizing;Receptor, ErbB-2;Receptors, Estrogen;Receptors, Progesterone;Tumor Suppressor p53-Binding Protein 1",
        "Doc_meshqualifiers":"enzymology;chemistry;enzymology;chemistry;enzymology;genetics;analysis;genetics;metabolism;analysis;genetics;metabolism;analysis;analysis;analysis",
        "_version_":1605891654677430272},
      {
        "Doc_abstract":"To analyze the clinicopathologic features and prognosis of triple negative breast cancer.;The clinical datas of 477 patients of primary breast cancer which were diagnosed by pathology in the 4th Hospital of Hebei Medical University from Jan. 2004 to Dec. 2004 were analyzed. All of the patients were divided into two groups according to the results of immunohistochemistry: one was triple negative breast cancer (TNBC) which included estrogen receptor (ER) negative, progesterone receptor (PR) negative and human epidermal growth factor receptor (HER2) negative and other was non-triple negative breast cancer. We compared TNBC with the group of non-triple negative breast cancer in the clinicopathologic features. The disease-free survival (DFS) and overall survival (OS) were analyzed by Kaplan-Meier method.;Of the 477 patients, 12.6% (60/477) was TNBC patients in which 76.7% of age was younger than fifty years(46/60), 28.3% of T > 5 cm (17/60), 68.3% of lymph nodes metastasis (41/60), 31.7% of grade III (19/60) and 13.3% of family history of breast cancer (8/60), (P < 0. 05). Till June 2008, the median time of follow-up was 48 months (42-54 months). Local recurrence or distant metastasis were 26.7% (16/60) of TNBC which was higher than 15.3% (64/417) of non-triple negative cases; DFS was 68.3% in TNBC group and 79.6% in the non-triple negative breast cancer group. The OS was 81.7% in TNBC group and 90.9% in the non-triple negative breast cancer group (Log-Rank = 3.917, P = 0.048; Log-Rank = 4.838, P = 0.028).;These patients of triple negative breast carcinoma were usually young (age < 50), with tumor growth fast, much more invasion and poorly prognosis.",
        "Doc_title":"[Clinicopathologic features and prognosis of triple negative breast cancer].",
        "Journal":"Zhonghua yi xue za zhi",
        "Do_id":"20095338",
        "Doc_ChemicalList":"Receptors, Estrogen;Receptors, Progesterone;ERBB2 protein, human;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Adult;Aged;Breast Neoplasms;Female;Humans;Kaplan-Meier Estimate;Middle Aged;Prognosis;Receptor, ErbB-2;Receptors, Estrogen;Receptors, Progesterone;Young Adult",
        "Doc_meshqualifiers":"diagnosis;metabolism;pathology;metabolism;metabolism;metabolism",
        "_version_":1605747019170709505},
      {
        "Doc_abstract":"The aim of the present study was to assess the clinical value of five serum tumour markers AFP, CA 15-3, CEA, TPS and Neu oncoprotein (p 185) in the diagnosis of breast cancer. The serum values were measured in a prospective series of patients with breast cancer (n = 233), benign breast disease (n = 176) and healthy control subjects (n = 215). The cut-off levels (90% specificity) were determined for each test. Using these cut-off levels the diagnostic sensitivity of the CEA test was 0.23, for the AFP test it was 0.16, for the CA 15-3 test 0.27, for the TPS test 0.18 and for the Neu oncoprotein test 0.19 in detecting breast cancer. Correlation coefficients (Pearson's) were statistically significant between CEA and CA 15-3, and between CA 15-3 and Neu oncoprotein measurements in breast cancer patients. In patients with benign breast disease the serum levels of AFP, CA 15-3, CEA and TPS correlated with age, being somewhat higher in older patients. Similarly, in population controls higher age correlated with higher levels of AFP, CA 15-3, Neu and TPS. In breast cancer patients there was no correlation between the age at diagnosis and any of the measured markers. The only marker statistically significantly associated with the stage of breast cancer was CA 15-3. In conclusion, our results indicate that serum CEA, AFP, CA 15-3, TPS and Neu oncoprotein are only of limited value in the diagnosis of breast cancer.",
        "Doc_title":"Serum tumour markers CEA, AFP, CA 15-3, TPS and Neu in diagnosis of breast cancer.",
        "Journal":"Anticancer research",
        "Do_id":"9137478",
        "Doc_ChemicalList":"Biomarkers, Tumor;Carcinoembryonic Antigen;Mucin-1;Peptides;alpha-Fetoproteins;tissue polypeptide specific antigen;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Adult;Age Factors;Aged;Aged, 80 and over;Biomarkers, Tumor;Breast Neoplasms;Carcinoembryonic Antigen;Female;Humans;Middle Aged;Mucin-1;Peptides;Receptor, ErbB-2;alpha-Fetoproteins",
        "Doc_meshqualifiers":"blood;blood;diagnosis;blood;blood;blood;blood;analysis",
        "_version_":1605831525685788672},
      {
        "Doc_abstract":"Breast cancer survivors have a 60 % higher risk of developing a second primary asynchronous contralateral breast cancer (CBC) compared to women's risk of developing a first primary breast cancer (FBC). However, little is known about how expression of tumor markers in first breast cancers influences CBC risk. We conducted a population-based nested case-control study among women 20-74 years of age diagnosed with a first breast cancer between 1996 and 2008 in western Washington State to evaluate the association between their tumor's estrogen receptor (ER), progesterone receptor (PR) and HER2-neu (HER2) expression, and risk of CBC. The study included 482 cases diagnosed with both a FBC and a CBC and 1,506 control women diagnosed only once with breast cancer identified through our local Surveillance, Epidemiology and End Results (SEER) cancer registry. Compared to the women whose FBC was ER+/PR+, those with ER-/PR- first tumors had a 1.6-fold (95 % confidence interval (CI): 1.2-2.3) increased risk of developing a CBC. When evaluated by joint ER/PR/HER2 status, compared to women with ER+/HER2- first cancers, those with HER2-overexpressing (ER-/HER2+) and triple-negative disease (ER-/PR-/HER2-) had 2.0-fold (95 % CI: 1.1-3.8) and 1.4-fold (95 % CI: 0.9-2.3) elevated risks of developing CBC, respectively. Beyond the known higher risks of mortality among patients diagnosed with more aggressive BC subtypes, here, we observe that they may also have increased risks of developing CBC.",
        "Doc_title":"Estrogen receptor, progesterone receptor, and HER2-neu expression in first primary breast cancers and risk of second primary contralateral breast cancer.",
        "Journal":"Breast cancer research and treatment",
        "Do_id":"22903686",
        "Doc_ChemicalList":"Biomarkers, Tumor;Receptors, Estrogen;Receptors, Progesterone;ERBB2 protein, human;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Adult;Aged;Biomarkers, Tumor;Breast Neoplasms;Case-Control Studies;Female;Humans;Middle Aged;Neoplasms, Second Primary;Receptor, ErbB-2;Receptors, Estrogen;Receptors, Progesterone;Risk Factors;SEER Program;Washington;Young Adult",
        "Doc_meshqualifiers":"epidemiology;metabolism;pathology;therapy;epidemiology;metabolism;pathology;therapy;metabolism;metabolism;metabolism",
        "_version_":1605876674152366080},
      {
        "Doc_abstract":"High leptin serum levels, overexpression of leptin and its two main receptor isoforms, OBR-L and OBR-S, have been documented in breast cancer patients. In the present study, the relationship between tissue leptin levels and breast cancer was evaluated.;Thirty-three normal breast tissue samples and 33 breast cancer tissue samples from 33 patients with breast cancer were evaluated. The association of tissue leptin levels and important prognostic factors related to breast cancer was analyzed.;Mean tissue leptin levels in breast cancer tissue samples (5.02 + or - 1.06 pg/ml) were significantly higher than those found in normal breast tissue (2.02 + or - 0.83 pg/ml; p=0.01). No correlation was found in tissue leptin levels and menopausal status, hormone receptor and HER-2/neu status, lymph node involvement, and histopathologic features.;High leptin levels were significantly higher in breast cancer tissue compared with normal tissue. No special correlation was found between tissue leptin levels and different clinicopathological characteristics.",
        "Doc_title":"Tissue leptin levels in patients with breast cancer.",
        "Journal":"Journal of B.U.ON. : official journal of the Balkan Union of Oncology",
        "Do_id":"20658737",
        "Doc_ChemicalList":"Blood Glucose;Carcinoembryonic Antigen;Leptin;Mucin-1;Receptors, Estrogen;Receptors, Progesterone",
        "Doc_meshdescriptors":"Adult;Aged;Blood Glucose;Body Mass Index;Breast Neoplasms;Carcinoembryonic Antigen;Female;Humans;Leptin;Lymphatic Metastasis;Middle Aged;Mucin-1;Postmenopause;Premenopause;Receptors, Estrogen;Receptors, Progesterone",
        "Doc_meshqualifiers":"metabolism;blood;genetics;metabolism;surgery;metabolism;blood;genetics;metabolism;metabolism;metabolism;metabolism",
        "_version_":1605818703741452290},
      {
        "Doc_abstract":"Multidrug resistance (MDR) has been linked to sphingolipid metabolism and preclinical data ascribe glucosylceramide synthase (GCS) a major role for MDR especially in breast cancer cells but no profound data are available on the expression of this potential therapeutic target in clinical breast cancer specimens.;We analyzed microarray data of GCS expression in a large cohort of 1,681 breast tumors.;Expression of GCS was associated with a positive estrogen receptor (ER) status, lower histological grading, low Ki67 levels and ErbB2 negativity (P < 0.001 for all). In univariate analysis there was a benefit for disease free survival for patients with tumors displaying low levels of GCS expression but this significance was lost in multivariate Cox regression.;Our results suggest ER positive tumors may be the most promising candidates for a potential therapeutic application of GCS inhibitors.",
        "Doc_title":"Prognostic relevance of glucosylceramide synthase (GCS) expression in breast cancer.",
        "Journal":"Journal of cancer research and clinical oncology",
        "Do_id":"18560890",
        "Doc_ChemicalList":"Biomarkers, Tumor;Ki-67 Antigen;Receptors, Estrogen;Glucosyltransferases;ceramide glucosyltransferase;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Adolescent;Adult;Aged;Aged, 80 and over;Biomarkers, Tumor;Breast Neoplasms;Carcinoma, Ductal, Breast;Carcinoma, Lobular;Cell Proliferation;Child;Female;Gene Expression Profiling;Glucosyltransferases;Humans;Ki-67 Antigen;Middle Aged;Oligonucleotide Array Sequence Analysis;Prognosis;Receptor, ErbB-2;Receptors, Estrogen;Survival Rate;Young Adult",
        "Doc_meshqualifiers":"genetics;metabolism;enzymology;genetics;pathology;enzymology;genetics;secondary;enzymology;genetics;secondary;genetics;metabolism;genetics;metabolism;genetics;metabolism;genetics;metabolism",
        "_version_":1605902744848171008},
      {
        "Doc_abstract":"Following the discovery that the prognostic impact of preoperative chemotherapy depends on the primary breast cancer subtype, the treatment strategy for primary breast cancer changed. Pathologic complete response(pCR)with preoperative chemotherapy is predictive of a favorable prognosis in patients with HER2 type or triple-negative type breast cancer, but not in patients with ER-positive/HER2-negative, the so-called Luminal type, breast cancer. However, the role of preoperative chemotherapy in patients with Luminal-B type breast cancer who may need chemotherapy should be further assessed. Recent studies have reported severalsubtypes of triple-negative breast cancer, distinguishable by gene expression analysis, which may respond differently to treatment. Furthermore, novel agents, including pertuzumab or T-DM1 for HER2 type breast cancer, bevacizumab or PARP inhibitors for triple negative-breast cancer, or combination regimens with these novelagents, are expected to achieve higher pCR rates and improve patient prognosis. The tumor microenvironment may also play an important role in predicting treatment response or prognosis. It is important that tailor-made treatment strategies for patients with primary breast cancer, especially for patients who will not respond favorably to current standard therapies, consider both the treatment effects and the medicaleconomic effects.",
        "Doc_title":"[The Role of Preoperative Chemotherapy Depending on Breast Cancer Subtype].",
        "Journal":"Gan to kagaku ryoho. Cancer & chemotherapy",
        "Do_id":"27760931",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605876141320568832},
      {
        "Doc_abstract":"Breast cancer is a heterogeneous disease that represents a major public health problem. The immunohistochemical determination of breast cancer subtypes with regard to estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor (HER2) status can contribute to improved selection of therapy and patientcare. The purpose of this study was to determine the prevalence of the molecular breast cancer subtypes and to assess their associations with classical clinicopathologic parameters for better therapeutic decisions in women with breast cancer in the Ivory Coast.;Formalin- fixed and paraffin-embedded blocks of patients diagnosed with primary breast carcinoma were subjected to immunohistochemical assay for the assessment of ER/RP and HER2 expression. The one-way analysis of variance evaluated the difference between breast cancer subtypes and mean age of patients. The Chi-square Test was used to compare standard clinicopathologic prognostic parameters with tumor subtypes.;Among 302 patients, 57% were premenopausal and 43% were postmenopausal. The invasive ductal carcinoma not otherwise specified (IDC NOS) (82.8%) was the most frequent histological type, and the tumor grade 2 (56%) was predominant followed by grade 3 (20.9%). The proportion of positivity of ER, PR, and HER2 was 56%, 49%, and 15.6%, respectively. Half of patients of this study (51.6%) had luminal A breast tumor type followed by TN (32.1%). Other subtypes were luminal B (10.1% ) and non-luminal HER2+ (6.3%).;The findings of the present study are in line with the literature and should assist in management of breast cancer in our country.",
        "Doc_title":"Breast Cancer Molecular Subtypes Defined by ER/PR and HER2 Status: Association with Clinicopathologic Parameters in Ivorian Patients.",
        "Journal":"Asian Pacific journal of cancer prevention : APJCP",
        "Do_id":"27221883",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605747030678831106},
      {
        "Doc_abstract":"To investigate the expression of apoptotic regulator c-FLIP(L) in invasive breast carcinoma tissues, and to evaluate its correlation with molecular subtyping and clinical prognosis.;Immunohistochemistry using EnVision staining for c-FLIP(L) was performed in 264 cases of invasive breast carcinomas and matched adjacent normal breast tissue samples from January 1996 to December 1999. ER, PR, HER2, Ki-67, CK5/6 and EGFR were evaluated by immunohistochemistry in order to classify the tumors into five molecular subtypes and the difference of c-FLIP(L) expression in these molecular subtypes was also analyzed. The influence of c-FLIP(L) expression on prognosis was evaluated by Kaplan-Meier curves and multi-factor Cox proportional risk model.;High expression of c-FLIP(L) was observed in 84.5% (223/264) of cases of invasive breast carcinomas which were significantly higher than the 45.1% (119/264) of cases in adjacent normal epithelium of breast (Ï‡Â² = 89.78, P = 0.000). The expression of c-FLIP(L) in luminal B (HER2 positive) and basal-like breast cancers was 78.1% (25/32) and 46.2% (18/39), respectively, with significant difference (P < 0.05). Moreover, the expression of c-FLIP(L) in luminal B (HER2 positive) was higher than in luminal A cancers (P < 0.05), and the expression of c-FLIP(L) in HER2 positive cancers was higher than in basal-like cancers (P < 0.01). C-FLIP(L) showed deep yellow staining in node positive breast cancer with a high-expression rate of 93.1% (134/144); whereas the expression was sporadic and light yellow in node negative breast cancer with a lower high-expressed rate of 72.5% (87/120, P < 0.01). C-FLIP(L) expression had significant influence on disease-free survival time, with c-FLIP(L)-positive patients showing poor prognosis (P < 0.01). Multi-factor Cox proportional risk model analysis showed that expression of c-FLIP(L), lymph nodes status and molecular subtypes were independent prognostic factors for invasive breast carcinomas (P < 0.05).;C-FLIP(L) is highly expressed in invasive breast carcinomas, and its expression level is closely related to the molecular subtypes and clinical prognosis of breast cancer patients. Thus, c-FLIP(L) could be used as an important tumor marker for personalized cancer therapy and prognostic prediction.",
        "Doc_title":"[Relationship of c-FLIP(L) protein expression with molecular subtyping and clinical prognosis in invasive breast cancer].",
        "Journal":"Zhonghua bing li xue za zhi = Chinese journal of pathology",
        "Do_id":"25327791",
        "Doc_ChemicalList":"Biomarkers, Tumor;CASP8 and FADD-Like Apoptosis Regulating Protein;CFLAR protein, human;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Aged;Biomarkers, Tumor;Breast;Breast Neoplasms;CASP8 and FADD-Like Apoptosis Regulating Protein;Disease-Free Survival;Female;Humans;Immunohistochemistry;Prognosis;Receptor, ErbB-2",
        "Doc_meshqualifiers":"metabolism;metabolism;classification;metabolism;mortality;metabolism;metabolism",
        "_version_":1605747015107477504},
      {
        "Doc_abstract":"Triple negative breast tumors are described by the lack of immunohistochemical expression for hormone receptors (ER and PgR) and Her2 neu. The immunophenotype is, in general,associated with young age and high biological aggressiveness,its frequency in the literature ranging from 10 to 20%. In our study we performed a retrospective classification of triple negative breast cancers in order to show the large spectrum of lesions that can embrace this very special phenotype.Clinicopathological parameters evaluated included age, tumorsize and macroscopic appearance, histological subtype and association with in situ component, the degree of tumor differentiation (nuclear pleomorphism, mitosis count, the formation of tubules), presence of lymph nodes or distant metastases. Triple negative breast cancers represent a particular subtype of tumors but their, now famous, aggressiveness applies only to some histological subtypes. It is very important to correlate the histological features and the phenotypical expression.",
        "Doc_title":"The many faces of triple negative breast cancer.",
        "Journal":"Chirurgia (Bucharest, Romania : 1990)",
        "Do_id":"25149609",
        "Doc_ChemicalList":"Biomarkers, Tumor;Receptors, Estrogen;Receptors, Progesterone;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Adenocarcinoma, Mucinous;Adult;Aged;Aged, 80 and over;Biomarkers, Tumor;Breast Neoplasms;Carcinoma, Ductal, Breast;Carcinoma, Lobular;Carcinoma, Papillary;Female;Humans;Middle Aged;Neoplasm Staging;Predictive Value of Tests;Prognosis;Receptor, ErbB-2;Receptors, Estrogen;Receptors, Progesterone;Sensitivity and Specificity;Triple Negative Breast Neoplasms",
        "Doc_meshqualifiers":"metabolism;pathology;metabolism;metabolism;pathology;metabolism;pathology;metabolism;pathology;metabolism;pathology;metabolism;metabolism;metabolism;metabolism;pathology",
        "_version_":1605832156276326400},
      {
        "Doc_abstract":"PARP and BRCA are both known as DNA repair enzymes. Functional loss of BRCA cell with PARP inhibition indicates apoptosis. Triple negative breast(TNB)cancer(estrogen receptor-negative, progesterone receptor-negative, HER-2 expression negative)are well associated with basal-type breast cancer. Basal-type breast cancer often has loss of BRCA and showed poor clinical outcomes. Considering the similar molecular profiles of Basal-type breast cancer and TNB cancer, clinical trials using PARP inhibitor for patients with TNB cancer has been warranted. A randomized phase II trial comparing gemcitabine and carboplatin(GC)to GC plus BSI-201(PARP inhibitor)in patients with metastatic TNB cancer showed significantly longer progression-free survival and overall survival. We herein summarized up-to-date knowledge of PARP inhibitor in association with TNB and BRCA.",
        "Doc_title":"[Breakthrough breast cancer treatment--PARP inhibitor, BRCA, and triple negative breast cancer].",
        "Journal":"Gan to kagaku ryoho. Cancer & chemotherapy",
        "Do_id":"20647696",
        "Doc_ChemicalList":"Antineoplastic Agents;Enzyme Inhibitors;Poly(ADP-ribose) Polymerase Inhibitors;Tumor Suppressor Proteins",
        "Doc_meshdescriptors":"Antineoplastic Agents;Breast Neoplasms;Clinical Trials as Topic;Enzyme Inhibitors;Humans;Poly(ADP-ribose) Polymerase Inhibitors;Prognosis;Tumor Suppressor Proteins",
        "Doc_meshqualifiers":"therapeutic use;diagnosis;drug therapy;metabolism;therapeutic use;genetics;metabolism",
        "_version_":1605742093961003010},
      {
        "Doc_abstract":"Sphingolipids are bioactive lipids implicated in apoptosis, cell survival and proliferation. We analyzed the prognostic value of enzymes from sphingolipid metabolism in breast cancer.;Differences in expression of ceramide galactosyl transferase (UGT8), ceramide kinase (CERK), and Ganglioside GD3-Synthase (ST8SIA1) in breast cancer cells were investigated by using microarray data of 1,581 tumor samples.;UGT8, CERK, and ST8SIA1 were associated with poor pathohistological grading (P < 0.001). High CERK expression was correlated with ErbB2 status (P = 0.006). Among ER positive breast cancers a significant worse prognosis for patients with tumors showing low ST8SIA1 and UGT8 expression was observed. In the ER negative subgroup those samples with high CERK expression displayed a worse prognosis. In a multivariate analysis only ST8SIA1 and tumor size remained significant.;Our experiments reveal that expression of enzymes from the sphingolipid metabolism has prognostic implications in breast cancer.",
        "Doc_title":"Gene expression of ceramide kinase, galactosyl ceramide synthase and ganglioside GD3 synthase is associated with prognosis in breast cancer.",
        "Journal":"Journal of cancer research and clinical oncology",
        "Do_id":"19125296",
        "Doc_ChemicalList":"UGT8 protein, human;Ganglioside Galactosyltransferase;Sialyltransferases;alpha-N-acetylneuraminate alpha-2,8-sialyltransferase;Phosphotransferases (Alcohol Group Acceptor);ceramide kinase;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Adult;Breast Neoplasms;Disease-Free Survival;Female;Ganglioside Galactosyltransferase;Gene Expression Regulation, Neoplastic;Humans;Middle Aged;Phosphotransferases (Alcohol Group Acceptor);Prognosis;Receptor, ErbB-2;Sialyltransferases;Tissue Array Analysis",
        "Doc_meshqualifiers":"diagnosis;enzymology;genetics;genetics;metabolism;genetics;metabolism;genetics;metabolism;genetics;metabolism",
        "_version_":1605748863485870080},
      {
        "Doc_abstract":"Targeting HER2 for the treatment of HER2-positive breast cancers is now a validated treatment paradigm. However, evidence suggests that this family of receptors may have important roles outside of the realm of HER2 amplification. There is considerable interest in the development of biomarkers to identify such breast cancers.",
        "Doc_title":"HER Targeting in HER2-Negative Breast Cancers: Looking for the HER3 Positive.",
        "Journal":"Clinical cancer research : an official journal of the American Association for Cancer Research",
        "Do_id":"25609069",
        "Doc_ChemicalList":"Antineoplastic Agents;Quinazolines",
        "Doc_meshdescriptors":"Antineoplastic Agents;Breast Neoplasms;Carcinoma, Ductal, Breast;Female;Humans;Quinazolines",
        "Doc_meshqualifiers":"therapeutic use;drug therapy;drug therapy;therapeutic use",
        "_version_":1605818580026261506},
      {
        "Doc_abstract":"The relationship between reproductive breast risk factors and breast cancer survival in patients with different breast cancer subtypes is not well known.;We examined a large-sized, retrospective study of 23,882 subjects from the Korean Breast Cancer Registry. The breast cancer subtype was determined by immunohistochemical staining for estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 (HER2). Information regarding reproductive factors, including breastfeeding, age at first birth (AFB), and parity, was gathered. Multivariate Cox regression analysis was used to estimate the association among breast cancer subtypes, such as luminal A, luminal B, Her-2/neu overexpressing, and triple negative breast cancer (TNBC), and breast cancer survival as dependent variables and adjusting for age and stage.;High parity (â‰¥ 5) increased the recurrence risk of luminal A and B breast cancer (hazard ratio [HR], 1.95; 95% confidence interval [CI], 0.96-3.97; PÂ = .0055 and HR, 1.12; 95% CI, 0.42-3.02, respectively; PÂ = .0073) in breast cancer-specific survival (BCSS), but 1 to 3 child births decreased the recurrence risk of luminal A breast cancer (HR, 0.56; 95% CI, 0.34-0.91; PÂ = .0055) and luminal B breast cancer (HR, 0.32; 95% CI, 0.17-0.61; PÂ = .0073) in BCSS. Early AFB (< 20 years) increased the recurrence risk of luminal A breast cancers (HR, 1.61; 95% CI, 0.62-4.26; PÂ = .039) in BCSS and of TNBC (HR, 1.31; 95% CI, 0.78-2.21; PÂ = .0006) in overall survival. Her-2/neu overexpressing breast cancer had no correlation with parity and AFB in breast cancer survival.;High parity (â‰¥ 5) and early AFB (< 20 years) were correlated with worse clinical outcomes in patients with luminal breast cancer, but not with other subtyped breast cancers.",
        "Doc_title":"Reproductive factors and subtypes of breast cancer defined by estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2: a register-based study from Korea.",
        "Journal":"Clinical breast cancer",
        "Do_id":"25034438",
        "Doc_ChemicalList":"Biomarkers, Tumor;Receptors, Estrogen;Receptors, Progesterone;ERBB2 protein, human;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Adult;African Americans;Age Factors;Biomarkers, Tumor;Breast Neoplasms;Case-Control Studies;European Continental Ancestry Group;Female;Follow-Up Studies;Humans;Menopause;Middle Aged;Neoplasm Grading;Neoplasm Staging;Prognosis;Receptor, ErbB-2;Receptors, Estrogen;Receptors, Progesterone;Registries;Reproductive History;Republic of Korea;Retrospective Studies;Risk Factors;Survival Rate",
        "Doc_meshqualifiers":"statistics & numerical data;metabolism;epidemiology;metabolism;pathology;statistics & numerical data;metabolism;metabolism;metabolism;epidemiology",
        "_version_":1605907151592620032},
      {
        "Doc_abstract":"Breast cancer is the most common cancer in women all around the world. Presently, the prognosis of breast cancer is predicted based on histopathologic tumor characteristics. Molecular markers could help to predict the prognosis and treatment response in breast cancer. According to gene expression profile, invasive breast cancers are classified into four subtypes (luminal A, luminal B, HER2 overexpressing and basal-like) and associated with different prognosis. The basal-like subtype is associated with poor prognosis. This article simply introduced the distribution of molecular subtypes, summed up recent researches on the characteristics and prognosis of basal-like phenotype.",
        "Doc_title":"[Research progress on basal-like breast cancer].",
        "Journal":"Ai zheng = Aizheng = Chinese journal of cancer",
        "Do_id":"18479610",
        "Doc_ChemicalList":"Caveolin 1;Keratin-5;Receptors, Estrogen;Receptors, Progesterone;ERBB2 protein, human;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Breast Neoplasms;Carcinoma, Basal Cell;Carcinoma, Ductal, Breast;Caveolin 1;Female;Humans;Keratin-17;Keratin-5;Prognosis;Receptor, ErbB-2;Receptors, Estrogen;Receptors, Progesterone",
        "Doc_meshqualifiers":"classification;drug therapy;metabolism;drug therapy;metabolism;drug therapy;metabolism;metabolism;metabolism;metabolism;metabolism;metabolism;metabolism",
        "_version_":1605759617222049792},
      {
        "Doc_abstract":"Recent studies in HER-2/neu-targeted immunotherapy demonstrated that polymorphonuclear neutrophils (PMN) mediated Ab-dependent cellular cytotoxicity against HER-2/neu-positive breast cancer cell lines. However, the mechanism of cell death remained unclear. We used several assays to analyze the induction of apoptosis in the breast cancer cell line SK-BR-3 via PMN-dependent Ab-dependent cellular cytotoxicity. In the presence of the HER-2/neu Ab 520C9 and PMN from healthy donors, apoptosis occurred as detected by annexin V binding and disappearance of euploid SK-BR-3 nuclei, which can be differentiated from PMN nuclei by their increased DNA contents. Apoptosis induction was observed with E:T cell ratios as low as 10:1. Laser scanning fluorescence microscopy of TUNEL tumor cells or staining for cleaved cytokeratin-18 further confirmed apoptosis of the SK-BR-3 breast cancer cells. Killing via 520C9 was dependent on the interaction with FcR on PMN, because 1) F(ab')(2) fragments of 520C9 mediated no cytotoxicity, 2) target cell death was influenced by a biallelic polymorphism of FcgammaRIIa on the effector cells, and 3) a bispecific Ab against HER-2/neu and the IgA receptor (FcalphaRI) expressed on effector cells significantly induced apoptosis. Thus, PMN induce Ab-dependent apoptosis against human breast cancer cells targeted with HER-2/neu-directed mAbs or FcR directed bispecific Abs.",
        "Doc_title":"Polymorphonuclear granulocytes induce antibody-dependent apoptosis in human breast cancer cells.",
        "Journal":"Journal of immunology (Baltimore, Md. : 1950)",
        "Do_id":"14607911",
        "Doc_ChemicalList":"Antibodies, Monoclonal;Chromium Radioisotopes;DNA, Neoplasm;Immunoglobulin G;Keratins",
        "Doc_meshdescriptors":"Alleles;Antibodies, Monoclonal;Antibody-Dependent Cell Cytotoxicity;Apoptosis;Breast Neoplasms;Cell Line, Tumor;Chromium Radioisotopes;Coculture Techniques;Cytotoxicity Tests, Immunologic;DNA, Neoplasm;Dose-Response Relationship, Immunologic;Down-Regulation;G1 Phase;Homozygote;Humans;Hydrolysis;Immunoglobulin G;In Situ Nick-End Labeling;Keratins;Leukocyte Count;Neutrophils",
        "Doc_meshqualifiers":"pharmacology;immunology;immunology;immunology;metabolism;pathology;metabolism;metabolism;immunology;immunology;pharmacology;metabolism;immunology;metabolism",
        "_version_":1605893869393674240},
      {
        "Doc_abstract":"In early breast cancer, prognostic tests are used to guide decisions on adjuvant systemic hormonal therapy, chemotherapy and targeted therapy treatment. This has led to large research efforts to identify novel prognostic markers in breast cancer. At present, the tissue factors used to guide treatment of breast cancer patients are tumor size, lymph node status, histologic grade, ER status, PR status, and HER2 status; in addition, multigene-expression-based prognostic tests are rapidly emerging. While identification of prognostic gene expression profiles has been successful, it has not been possible yet to identify robust clinically useful predictors of response to systemic treatment. As a result of rapid advances in technology and bioinformatics, it has become possible to analyze large series of breast carcinomas using high-throughput genetic techniques, including whole genome sequence analysis and gene expression profiling. These genomic studies will lead to the development of additional prognostic and predictive tissue-based tests. The most important aspects of the currently used tissue-based prognostic and predictive tests and the research in this area are reviewed.",
        "Doc_title":"Molecular tests as prognostic factors in breast cancer.",
        "Journal":"Virchows Archiv : an international journal of pathology",
        "Do_id":"24487789",
        "Doc_ChemicalList":"Biomarkers, Tumor",
        "Doc_meshdescriptors":"Antineoplastic Combined Chemotherapy Protocols;Biomarkers, Tumor;Breast Neoplasms;Gene Expression Profiling;Humans;Pathology, Molecular;Prognosis",
        "Doc_meshqualifiers":"therapeutic use;genetics;metabolism;diagnosis;drug therapy;genetics;metabolism;methods;methods",
        "_version_":1605808824370855936},
      {
        "Doc_abstract":"Genetic factors related to cancer have been extensively studied and several polymorphisms have been associated to breast cancer. The FGFR4, MTHFR, and HFE genes have been associated with neoplastic diseases development. The current report outlines the analysis of the polymorphisms G388A (FGFR4), C677T (MTHFR), C282Y, and H63D (HFE) in Brazilian breast cancer patients. We studied 68 patients with invasive ductal and operable breast carcinoma and 85 women as a control group. The polymorphism frequencies in the breast cancer and control groups were analyzed, but no significant difference was observed by comparing the two groups. The presence of each polymorphism was analyzed according to the clinical features and markers already established as prognostic in the breast cancer group. The C677T, H63D, and G388A polymorphisms were not associated to histological grade, age of diagnosis, expression of HER2 receptor, or estrogen and progesterone receptor. The H63D polymorphism showed a significant association (P = 0.02) with the presence of p53 mutations, and C667T showed association to lymph node involvement (P = 0.05). Lymph node involvement, G388A polymorphism, and histological grade were independently associated to metastasis/death. Our data suggests that the polymorphisms G388A, C677T, and H63D are not useful in breast cancer diagnosis, but they may be significant additional prognostic markers related to breast cancer survival.",
        "Doc_title":"HFE, MTHFR, and FGFR4 genes polymorphisms and breast cancer in Brazilian women.",
        "Journal":"Molecular and cellular biochemistry",
        "Do_id":"21625954",
        "Doc_ChemicalList":"HFE protein, human;Hemochromatosis Protein;Histocompatibility Antigens Class I;Membrane Proteins;Receptors, Estrogen;Receptors, Progesterone;Methylenetetrahydrofolate Reductase (NADPH2);ERBB2 protein, human;FGFR4 protein, human;Receptor, ErbB-2;Receptor, Fibroblast Growth Factor, Type 4",
        "Doc_meshdescriptors":"Brazil;Breast Neoplasms;Female;Genetic Association Studies;Hemochromatosis Protein;Heterozygote;Histocompatibility Antigens Class I;Homozygote;Humans;Membrane Proteins;Methylenetetrahydrofolate Reductase (NADPH2);Middle Aged;Neoplasm Staging;Polymorphism, Genetic;Prognosis;Receptor, ErbB-2;Receptor, Fibroblast Growth Factor, Type 4;Receptors, Estrogen;Receptors, Progesterone;Survival Analysis",
        "Doc_meshqualifiers":"epidemiology;genetics;pathology;genetics;genetics;genetics;analysis;genetics;analysis;analysis",
        "_version_":1605798299027111936},
      {
        "Doc_abstract":"The status of human epidermal growth factor receptor type 2 (HER2) in breast-cancer cells predicts clinical outcomes in women who receive adjuvant anthracycline-based chemotherapy. We hypothesized that HER2 positivity predicts a benefit from adjuvant doxorubicin doses above standard levels, from the addition of paclitaxel after adjuvant chemotherapy with doxorubicin plus cyclophosphamide, or from both.;We randomly selected 1500 women from 3121 women with node-positive breast cancer who had been randomly assigned to receive doxorubicin (60, 75, or 90 mg per square meter of body-surface area) plus cyclophosphamide (600 mg per square meter) for four cycles, followed by four cycles of paclitaxel (175 mg per square meter) or observation. Tissue blocks from 1322 of these 1500 women were available. Immunohistochemical analyses of these tissue specimens for HER2 with the CB11 monoclonal antibody against HER2 or with a polyclonal-antibody assay kit and fluorescence in situ hybridization for HER2 amplification were performed.;No interaction was observed between HER2 positivity and doxorubicin doses above 60 mg per square meter. HER2 positivity was, however, associated with a significant benefit from paclitaxel. The interaction between HER2 positivity and the addition of paclitaxel to the treatment was associated with a hazard ratio for recurrence of 0.59 (P=0.01). Patients with a HER2-positive breast cancer benefited from paclitaxel, regardless of estrogen-receptor status, but paclitaxel did not benefit patients with HER2-negative, estrogen-receptor-positive cancers.;The expression or amplification, or both, of HER2 by a breast cancer is associated with a benefit from the addition of paclitaxel after adjuvant treatment with doxorubicin (<60 mg per square meter) plus cyclophosphamide in node-positive breast cancer, regardless of estrogen-receptor status. Patients with HER2-negative, estrogen-receptor-positive, node-positive breast cancer may gain little benefit from the administration of paclitaxel after adjuvant chemotherapy with doxorubicin plus cyclophosphamide.",
        "Doc_title":"HER2 and response to paclitaxel in node-positive breast cancer.",
        "Journal":"The New England journal of medicine",
        "Do_id":"17928597",
        "Doc_ChemicalList":"Antineoplastic Agents, Phytogenic;Receptors, Estrogen;Doxorubicin;Cyclophosphamide;Receptor, ErbB-2;Paclitaxel",
        "Doc_meshdescriptors":"Adult;Antineoplastic Agents, Phytogenic;Antineoplastic Combined Chemotherapy Protocols;Breast Neoplasms;Chemotherapy, Adjuvant;Cyclophosphamide;Doxorubicin;Female;Follow-Up Studies;Humans;Middle Aged;Paclitaxel;Receptor, ErbB-2;Receptors, Estrogen;Treatment Outcome",
        "Doc_meshqualifiers":"administration & dosage;therapeutic use;chemistry;drug therapy;surgery;administration & dosage;administration & dosage;administration & dosage;analysis;analysis",
        "_version_":1605809003868192768},
      {
        "Doc_abstract":"This review aims to present the preclinical and clinical data regarding efficacy and safety of lapatinib alone and in combination with other agents in the treatment of human epidermal growth factor receptor-2 (HER2)-overexpressing breast cancer.;HER2-positive (HER2+) breast cancer remains a treatment challenge. It is more aggressive than other breast cancers and it is associated with a poor outcome. Targeted therapy for HER2+ breast cancer has significantly changed the clinical course of the disease. Despite advances in therapy, there remains an unmet need in the treatment of HER2+ breast cancer. Lapatinib is a novel, orally bioavailable epidermal growth factor receptor/HER2+ targeted agent. Many trials have investigated the efficacy and safety of lapatinib alone and in conjunction with other agents in the treatment of HER2+ breast cancer.;Preclinical and clinical trials of lapatinib have shown that it is effective in the treatment on HER2+ breast cancer. More important, studies show that it is effective in the setting of trastuzumab resistance and in the treatment of central nervous system metastases, both of which are current treatment challenges. Furthermore, lapatinib is effective in conjunction with trastuzumab in the treatment of early breast cancer. Data regarding the safety of lapatinib show that it is generally well tolerated; however, multiple studies have shown significant (grade 3 and 4) diarrhea and rash associated with lapatinib, thereby limiting its use. Carditoxicity has not been a significant adverse event associated with the use of lapatinib.;Lapatinib is effective alone and in conjunction with other agents in the treatment of HER2+ breast cancer. However, its use is limited by significant diarrhea and rash.",
        "Doc_title":"Role of lapatinib alone or in combination in the treatment of HER2-positive breast cancer.",
        "Journal":"Breast cancer (Dove Medical Press)",
        "Do_id":"24367193",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605818588542795776},
      {
        "Doc_abstract":"The background, rationale, and preliminary results of a phase II trial of gemcitabine plus trastuzumab in heavily pretreated metastatic breast cancer patients are presented. Gemcitabine and trastuzumab both exhibit single-agent activity in previously treated metastatic breast cancer. Preclinical studies of gemcitabine and trastuzumab in combination showed additive or synergistic antitumor effects in human breast cancer cell lines that overexpress HER2. A multicenter phase II trial was thus conducted to define the safety and efficacy of gemcitabine/trastuzumab in patients previously treated for metastatic breast cancer. Women with measurable metastatic breast cancer whose primary or secondary tumor overexpressed HER2 were eligible for inclusion. Gemcitabine 1,200 mg/m(2) was administered on days 1 and 8 of a 21-day cycle. Trastuzumab was administered at a loading dose of 4 mg/kg initially, then at 2 mg/kg weekly thereafter. Preliminary analysis of 38 evaluable patients showed that gemcitabine/trastuzumab was well tolerated and had significant antitumor activity in this patient population. The study is now concluded, and final analysis of the data is nearing completion. Publication of the results is anticipated in 2003.",
        "Doc_title":"Gemcitabine and trastuzumab in metastatic breast cancer.",
        "Journal":"Seminars in oncology",
        "Do_id":"12722022",
        "Doc_ChemicalList":"Antibodies, Monoclonal;Antibodies, Monoclonal, Humanized;Deoxycytidine;gemcitabine;Receptor, ErbB-2;Trastuzumab",
        "Doc_meshdescriptors":"Antibodies, Monoclonal;Antibodies, Monoclonal, Humanized;Antineoplastic Combined Chemotherapy Protocols;Breast Neoplasms;Deoxycytidine;Female;Humans;Middle Aged;Neoplasm Metastasis;Receptor, ErbB-2;Trastuzumab",
        "Doc_meshqualifiers":"administration & dosage;pharmacology;therapeutic use;drug therapy;metabolism;pathology;administration & dosage;analogs & derivatives;pharmacology;metabolism",
        "_version_":1605884186140344320},
      {
        "Doc_abstract":"Personalized medicine uses genomic information for selecting therapy in patients with metastatic cancer. An issue is the optimal tissue source (primary tumor or metastasis) for testing. We compared the DNA copy number and mutational profiles of primary breast cancers and paired metastases from 23 patients using whole-genome array-comparative genomic hybridization and next-generation sequencing of 365 \"cancer-associated\" genes. Primary tumors and metastases harbored copy number alterations (CNAs) and mutations common in breast cancer and showed concordant profiles. The global concordance regarding CNAs was shown by clustering and correlation matrix, which showed that each metastasis correlated more strongly with its paired tumor than with other samples. Genes with recurrent amplifications in breast cancer showed 100% (ERBB2, FGFR1), 96% (CCND1), and 88% (MYC) concordance for the amplified/non-amplified status. Among all samples, 499 mutations were identified, including 39 recurrent (AKT1, ERBB2, PIK3CA, TP53) and 460 non-recurrent variants. The tumors/metastases concordance of variants was 75%, higher for recurrent (92%) than for non-recurrent (73%) variants. Further mutational discordance came from very different variant allele frequencies for some variants. We showed that the chosen targeted therapy in two clinical trials of personalized medicine would be concordant in all but one patient (96%) when based on the molecular profiling of tumor and paired metastasis. Our results suggest that the genotyping of primary tumor may be acceptable to guide systemic treatment if the metastatic sample is not obtainable. However, given the rare but potentially relevant divergences for some actionable driver genes, the profiling of metastatic sample is recommended. ",
        "Doc_title":"Comparative genomic analysis of primary tumors and metastases in breast cancer.",
        "Journal":"Oncotarget",
        "Do_id":"27028851",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605747057957535745},
      {
        "Doc_abstract":"The transition from ductal carcinoma in situ (DCIS) to invasive breast cancer (IBC) is a crucial step in breast cancer progression. The specific alterations that govern this transition have not been elucidated. HER2/neu is frequently overexpressed in DCIS but is less common in IBC, thereby suggesting additional requirements for transformation. To identify genes capable of cooperating with HER2/neu to fully transform mammary epithelial cells, we used an insertional mutagenesis screen on cells isolated from wild-type neu expressing mice and identified the E3 ligase HACE1 as HER2 cooperative tumor suppressor gene. Loss of HACE1 expression is commonly seen in clinical breast cancer data sets. HACE1 downregulation in normal human mammary epithelial cells (HMECs) results in the accumulation of the activated GTP-bound Rac1 partially transforming these cells. Overexpression of HER2 activates Rac1, which further accumulates upon HACE1 loss resulting in Rac1 hyperactivation. Although the knockdown of HACE1 or overexpression of HER2 alone in HMECs is not sufficient for tumorigenesis, HER2 overexpression combined with HACE1 downregulation fully transforms HMECs resulting in robust tumor formation. The pharmaceutical interference of Rac function abrogates the effects of HACE1 loss both in vitro and in vivo, resulting in marked reduction in tumor burden. Our work supports a critical role for HACE1 in breast cancer progression and identifies patients that may benefit from Rac-targeted therapies. ",
        "Doc_title":"Loss of the E3 ubiquitin ligase HACE1 results in enhanced Rac1 signaling contributing to breast cancer progression.",
        "Journal":"Oncogene",
        "Do_id":"25659579",
        "Doc_ChemicalList":"HACE1 protein, human;Ubiquitin-Protein Ligases;ERBB2 protein, human;Receptor, ErbB-2;rac1 GTP-Binding Protein",
        "Doc_meshdescriptors":"Animals;Breast Neoplasms;Cell Line, Tumor;Cell Transformation, Neoplastic;Disease Progression;Female;Humans;Mice;Mice, SCID;Mutagenesis, Insertional;Receptor, ErbB-2;Signal Transduction;Ubiquitin-Protein Ligases;rac1 GTP-Binding Protein",
        "Doc_meshqualifiers":"etiology;physiology;physiology;physiology;physiology",
        "_version_":1605804233958883328},
      {
        "Doc_abstract":"The need for early detection of various diseases, including breast cancer, has motivated research into nanomaterials that can be assembled in organized films which serve as biosensors. Owing to the variety of possible materials and film architectures, procedures are required to design optimized biosensors. In this study, we combine surface-specific methods to monitor the assembly of antibodies on nanostructured films with two distinct architectures. In the first, a layer of the antibody type mouse anti-HER2 (clone tab250) was immobilized on a self-assembled monolayer (SAM) of 11-mercaptoundecanoic acid modified with N-hydroxysuccinimide (NHS) and 1-ethyl-3-(3-(dimethylamino)propyl)carbodiimide (EDC). In the second approach, a SAM of cysteamine was coated with a biotin/spreptavidin bilayer on which a layer of biotinylated antibody type MSx2HUp185/her biotin was adsorbed. The rougher, less passivating coating with cysteamine determined from cyclic voltammetry and scanning electron microscopy led to biosensors that are more sensitive to detect the breast cancer ERBB2 (HER2) biomarker in impedance spectroscopy measurements. This higher distinguishing ability of the cysteamine-containing film architecture was proven with information visualization methods to treat the impedance data. Polarization-modulated infrared reflection absorption spectroscopy (PM-IRRAS) confirmed that biosensing resulted from the antibody-ERBB2 antigen affinity. ",
        "Doc_title":"Supramolecular Control in Nanostructured Film Architectures for Detecting Breast Cancer.",
        "Journal":"ACS applied materials & interfaces",
        "Do_id":"25989820",
        "Doc_ChemicalList":"11-mercaptoundecanoic acid;Antibodies;Carbodiimides;Dimethylamines;Fatty Acids;N-ethyl-N'-(3-(dimethylamino)-propyl)carbodiimide;Succinimides;Sulfhydryl Compounds;Gold;N-hydroxysuccinimide",
        "Doc_meshdescriptors":"Animals;Antibodies;Biosensing Techniques;Breast Neoplasms;Carbodiimides;Dielectric Spectroscopy;Dimethylamines;Fatty Acids;Female;Gold;Humans;Mice;Nanostructures;Succinimides;Sulfhydryl Compounds",
        "Doc_meshqualifiers":"chemistry;immunology;pharmacology;diagnosis;pathology;chemistry;chemistry;chemistry;chemistry;chemistry;therapeutic use;chemistry;chemistry",
        "_version_":1605844298229612544},
      {
        "Doc_abstract":"While the small GTPase Rac1 and its effectors are well-established mediators of mitogenic and motile signaling by tyrosine kinase receptors and have been implicated in breast tumorigenesis, little is known regarding the exchange factors (Rac-GEFs) that mediate ErbB receptor responses. Here, we identify the PIP(3)-GÎ²Î³-dependent Rac-GEF P-Rex1 as an essential mediator of Rac1 activation, motility, cell growth, and tumorigenesis driven by ErbB receptors in breast cancer cells. Notably, activation of P-Rex1 in breast cancer cells requires the convergence of inputs from ErbB receptors and a GÎ²Î³- and PI3KÎ³-dependent pathway. Moreover, we identified the GPCR CXCR4 as a crucial mediator of P-Rex1/Rac1 activation in response to ErbB ligands. P-Rex1 is highly overexpressed in human breast cancers and their derived cell lines, particularly those with high ErbB2 and ER expression. In addition to the prognostic and therapeutic implications, our findings reveal an ErbB effector pathway that is crucial for breast cancer progression.",
        "Doc_title":"Identification of the Rac-GEF P-Rex1 as an essential mediator of ErbB signaling in breast cancer.",
        "Journal":"Molecular cell",
        "Do_id":"21172654",
        "Doc_ChemicalList":"Guanine Nucleotide Exchange Factors;Oncogene Proteins v-erbB;PREX1 protein, human;rac1 GTP-Binding Protein",
        "Doc_meshdescriptors":"Breast Neoplasms;Disease Progression;Female;Guanine Nucleotide Exchange Factors;Humans;Oncogene Proteins v-erbB;Signal Transduction;Tumor Cells, Cultured;rac1 GTP-Binding Protein",
        "Doc_meshqualifiers":"metabolism;pathology;genetics;metabolism;metabolism;metabolism",
        "_version_":1605807981182582784},
      {
        "Doc_abstract":"Breast cancer is the most common cancer in women. The mortality remains significant despite advanced treatment possibilities. The management of breast cancer is guided by immunohistochemical data that are summarized into molecular subtypes, namely, luminal A, luminal B, HER2 positive and triple negative. HER2 positive and triple negative subtypes of breast cancer are considered to be biologically distinct. We present a case of clinically aggressive breast cancer in a 58-year-old female. Along the course of the disease, the molecular type switched from HER2 positive to triple negative. The patient deteriorated despite combined therapy. We recommend making a possible change of the molecular subtype and employing repeated immunohistochemical investigation in case of relapse.",
        "Doc_title":"Molecular subtype shift in breast cancer upon trastuzumab treatment: a case report.",
        "Journal":"Polish journal of pathology : official journal of the Polish Society of Pathologists",
        "Do_id":"21574108",
        "Doc_ChemicalList":"Antibodies, Monoclonal;Antibodies, Monoclonal, Humanized;Antineoplastic Agents;Receptors, Estrogen;Receptors, Progesterone;ERBB2 protein, human;Receptor, ErbB-2;Trastuzumab",
        "Doc_meshdescriptors":"Antibodies, Monoclonal;Antibodies, Monoclonal, Humanized;Antineoplastic Agents;Breast Neoplasms;Carcinoma, Ductal, Breast;Fatal Outcome;Female;Humans;Immunohistochemistry;Middle Aged;Receptor, ErbB-2;Receptors, Estrogen;Receptors, Progesterone;Trastuzumab",
        "Doc_meshqualifiers":"therapeutic use;therapeutic use;drug therapy;metabolism;pathology;drug therapy;metabolism;secondary;metabolism;metabolism;metabolism",
        "_version_":1605818729992552448},
      {
        "Doc_abstract":"To investigate the concordance of detecting human epidermal growth factor receptor 2 (HER-2) status of patients with invasive breast cancer by fluorescence in situ hybridization (FISH) for gene amplification and immunohistochemistry (IHC) for protein overexpression and to evaluate the association between tumour characteristics and HER-2 gene amplification.;The HER-2 status was evaluated in 41 invasive ductal breast carcinomas by both FISH and IHC. The associations between HER-2 gene amplification and other clinicopathological factors, tumour grade, estrogen receptor (ER), tumor emboli, lymph node status, were evaluated using the chi-square test.;HER-2 amplifications by FISH were seen in 15 patients, including 8 IHC+++ patients (88.89%, 8/9 of all+++ cases), 6 IHC++ patients (42.68%, 6/14 of all++ cases), 1 IHC+ patient (8.33%, 1/12 of all+ cases) and none IHC negative patient (0%, 0/6 of all negative cases). ER negative or weak positive breast cancers were more often HER-2 FISH positive than ER strong positive cancers (P=0.018). HER-2 amplifications were more often negative in tumor emboli negative or lymph node negative patients than in tumor emboli positive or lymph node positive patients (P=0.000, P=0.025). There was no statistical difference in HER-2 gene amplification among different grades of tumors(P=0.095).;HER-2 amplification in breast cancer can be determined by FISH accurately. ER is negatively associated with HER-2 amplification, whereas tumor emboli and lymph node status are positively associated with HER-2.",
        "Doc_title":"[Detection of human epidermal growth factor receptor 2 gene in invasive breast cancer by fluorescence in situ hybridization and research of its association with tumor characteristics].",
        "Journal":"Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences",
        "Do_id":"21503112",
        "Doc_ChemicalList":"Receptors, Estrogen;ERBB2 protein, human;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Breast Neoplasms;Female;Gene Amplification;Humans;In Situ Hybridization, Fluorescence;Neoplasm Invasiveness;Receptor, ErbB-2;Receptors, Estrogen",
        "Doc_meshqualifiers":"genetics;pathology;genetics;metabolism",
        "_version_":1605742021512790016},
      {
        "Doc_abstract":"The receptor tyrosine kinase ErbB2 is a breast cancer biomarker whose posttranslational modifications (PTMs) are a key indicator of its activation. Quantifying the expression and PTMs of biomarkers such as ErbB2 by selected reaction monitoring (SRM) mass spectrometry has several limitations, including minimal coverage and extensive assay development time. Therefore, we assessed the utility of two high resolution, full scan mass spectrometry approaches, MS1 Filtering and SWATH MS2, for targeted ErbB2 proteomics. Endogenous ErbB2 immunoprecipitated from SK-BR-3 cells was in-gel digested with trypsin, chymotrypsin, Asp-N, or trypsin plus Asp-N in triplicate. Data-dependent acquisition with an AB SCIEX TripleTOF 5600 and MS1 Filtering data processing was used to assess peptide and PTM coverage as well as the reproducibility of enzyme digestion. Data-independent acquisition (SWATH) was also performed for MS2 quantitation. MS1 Filtering and SWATH MS2 allow quantitation of all detected analytes after acquisition, enabling the use of multiple proteases for quantitative assessment of target proteins. Combining high resolution proteomics with multiprotease digestion enabled quantitative mapping of ErbB2 with excellent reproducibility, improved amino acid sequence and PTM coverage, and decreased assay development time compared to typical SRM assays. These results demonstrate that high resolution quantitative proteomic approaches are an effective tool for targeted biomarker quantitation.",
        "Doc_title":"Label-Free Quantitation and Mapping of the ErbB2 Tumor Receptor by Multiple Protease Digestion with Data-Dependent (MS1) and Data-Independent (MS2) Acquisitions.",
        "Journal":"International journal of proteomics",
        "Do_id":"23710360",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605883652598661120},
      {
        "Doc_abstract":"Breast cancer is the most common cancer worldwide among women and the second most common cancer. Approximately 15-23% of breast cancers over-express human epidermal growth factor receptor2 (HER2), a 185-kDa transmembrane tyrosine kinase, which is mainly found at the cell surface of tumor cells. HER2-positive breast cancer, featuring amplification of HER2/neu and negative expression of ER and PR, has the three following characteristics: rapid tumor growth, lower survival rate, and better response to adjuvant therapies. Clinically, it is notable for its role in a pathogenesis that is associated with increased disease recurrence and acts as a worse prognosis. At the same time, it represents a good target for anti-cancer immunotherapy despite the prevalence of drug resistance. New treatments are a major topic of research, and a brighter future can be expected. This review discusses the role of HER2 in breast cancer, therapeutic modalities available and prognostic factors. ",
        "Doc_title":"Recent progress in HER2 associated breast cancer.",
        "Journal":"Asian Pacific journal of cancer prevention : APJCP",
        "Do_id":"25854334",
        "Doc_ChemicalList":"Antineoplastic Agents;Receptors, Estrogen;Receptors, Progesterone;Phosphatidylinositol 3-Kinases;EGFR protein, human;ERBB2 protein, human;Receptor, Epidermal Growth Factor;Receptor, ErbB-2;Proto-Oncogene Proteins c-akt",
        "Doc_meshdescriptors":"Antineoplastic Agents;Breast Neoplasms;Female;Gene Expression Regulation, Neoplastic;Humans;Immunotherapy;MAP Kinase Signaling System;Neoplasm Recurrence, Local;Phosphatidylinositol 3-Kinases;Prognosis;Proto-Oncogene Proteins c-akt;Receptor, Epidermal Growth Factor;Receptor, ErbB-2;Receptors, Estrogen;Receptors, Progesterone;Survival Rate",
        "Doc_meshqualifiers":"therapeutic use;drug therapy;mortality;pathology;methods;physiology;metabolism;metabolism;metabolism;metabolism;metabolism;metabolism",
        "_version_":1605763077598347264},
      {
        "Doc_abstract":"The HER-2 proto-oncogene (also called c-erbB-2/neu) encodes the protein, p185, which is closely related to the growth and metastasis of adenocarcinoma, and is overexpressed in 25-30% of human breast cancers. In this study, we attempt to reverse the malignant phenotype of the breast cancer cell line, MCF-7, using a HER-2-specific hammerhead ribozyme. Two anti-HER-2 hammerhead ribozymes, RZ1 and RZ2, were synthesized, inserted separately into the nonviral eukaryotic expression vector, pcDNA3.1(-), and transfected into MCF-7 cells. Analyses showed that the HER-2 mRNA and p185, as well as oncogene k-ras were down-regulated remarkably in the ribozyme-transfected cells, while the onco-suppressor gene, p53, was up-regulated. Furthermore, the tumorigenicity of the RZ1-stably transfected MCF-7 cells was decreased dramatically in nude mice. These results demonstrate that the use of anti-HER-2 ribozymes may be a beneficial strategy for gene therapy of breast cancer.",
        "Doc_title":"pcDNA3.1(-)-mediated ribozyme targeting of HER-2 suppresses breast cancer tumor growth.",
        "Journal":"Molecular biology reports",
        "Do_id":"19444644",
        "Doc_ChemicalList":"DNA Primers;RNA, Catalytic;ERBB2 protein, human;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Adenocarcinoma;Animals;Blotting, Western;Breast Neoplasms;Cell Line, Tumor;DNA Primers;Female;Flow Cytometry;Gene Expression Regulation, Neoplastic;Gene Targeting;Genetic Therapy;Genetic Vectors;Humans;Mice;Mice, Nude;RNA, Catalytic;Receptor, ErbB-2;Reverse Transcriptase Polymerase Chain Reaction;Transfection",
        "Doc_meshqualifiers":"therapy;therapy;genetics;genetics;methods;methods;genetics;genetics;pharmacology;genetics;metabolism",
        "_version_":1605800867260268544},
      {
        "Doc_abstract":"The receptor tyrosine kinase HER2 is overexpressed in approximately 25% of breast cancers. HER2 acts as a signal amplifier for its siblings, namely three different transmembrane receptors that collectively bind with 11 distinct growth factors of the EGF family. Thus, overexpression of HER2 confers aggressive invasive growth in preclinical models and in patients. Specific therapies targeting HER2 include monoclonal antibodies, antibody-drug conjugates, small molecule tyrosine kinase inhibitors, as well as heat shock protein and sheddase inhibitors. Two of these drugs have shown impressive - yet mostly transient - efficacy in patients with HER2 overexpressing breast cancer. We highlight the biological roles of HER2 in breast cancer progression, and overview the available therapeutic armamentarium directed against this receptor-kinase molecule. Focusing on the mechanisms that confer resistance to individual HER2 targeting agents, we envisage therapeutic approaches to delay or overcome the evolvement of resistance in patients.",
        "Doc_title":"Therapeutic strategies and mechanisms of tumorigenesis of HER2-overexpressing breast cancer.",
        "Journal":"Critical reviews in oncology/hematology",
        "Do_id":"20951604",
        "Doc_ChemicalList":"Antibodies, Monoclonal, Humanized;Antinematodal Agents;Quinazolines;lapatinib;Receptor, ErbB-2;Trastuzumab",
        "Doc_meshdescriptors":"Animals;Antibodies, Monoclonal, Humanized;Antinematodal Agents;Breast;Breast Neoplasms;Drug Resistance, Neoplasm;Female;Humans;Molecular Targeted Therapy;Quinazolines;Receptor, ErbB-2;Trastuzumab;Up-Regulation",
        "Doc_meshqualifiers":"pharmacology;therapeutic use;pharmacology;therapeutic use;drug effects;metabolism;drug therapy;genetics;metabolism;methods;pharmacology;therapeutic use;antagonists & inhibitors;genetics;metabolism",
        "_version_":1605751463225589760},
      {
        "Doc_abstract":"Recent microarray profiling studies on breast cancer have identified distinct subtypes that are associated with different clinical outcomes. Promoter hypermethylation of several known or putative tumor suppressor genes occurs frequently during the pathogenesis of breast cancer. We proposed that immunohistopathologic subtypes of breast cancer are likely to contain distinct promoter methylation patterns. A panel of 10 gene promoters was assessed by quantitative multiplex methylation-specific PCR in 114 invasive ductal carcinomas from Korea representing the three major subtypes [57 luminal, 24 human epidermal growth factor 2 (HER2), and 33 basal-like] based on immunohistochemical findings of estrogen receptor, progesterone receptor, HER2, cytokeratin 5/6 and epidermal growth factor receptor. The median methylation levels of HIN1, RASSF1A and TWIST, and the average methylation ratio were significantly lower in basal-like subtype compared to luminal or HER2 subtypes. In contrast, BRCA1 methylation level was significantly higher in basal-like subtype than in luminal subtype. The methylation status of a panel of four genes (APC1, CDH, BRCA1 and RAR-Î²) in luminal and HER2 subtypes were dissimilar, where HER2 tumors showed a significantly higher level of methylation compared to luminal tumors. These results suggest that gene methylation in breast cancer can potentially serve as epigenetic biomarkers and may contribute further to current breast cancer classification.",
        "Doc_title":"Basal-like breast cancer displays distinct patterns of promoter methylation.",
        "Journal":"Cancer biology & therapy",
        "Do_id":"20505321",
        "Doc_ChemicalList":"Genetic Markers",
        "Doc_meshdescriptors":"Adult;Aged;Aged, 80 and over;Breast Neoplasms;Carcinoma, Ductal, Breast;Cell Line, Tumor;DNA Methylation;Female;Gene Expression Profiling;Gene Silencing;Genes, BRCA1;Genes, Tumor Suppressor;Genetic Markers;Humans;Immunohistochemistry;Middle Aged;Polymerase Chain Reaction;Prognosis;Promoter Regions, Genetic",
        "Doc_meshqualifiers":"classification;genetics;classification;genetics;genetics",
        "_version_":1605819655013793792},
      {
        "Doc_abstract":"Treatment with histone deacetylase inhibitors (HDACI) results in potent cytotoxicity of a variety of cancer cell types, and these drugs are used clinically to treat hematological tumors. They are known to repress the transcription of ERBB2 and many other oncogenes, but little is known about this mechanism. Using global run-on sequencing (GRO-seq) to measure nascent transcription, we find that HDACI cause transcriptional repression by blocking RNA polymerase II elongation. Our data show that HDACI preferentially repress the transcription of highly expressed genes as well as high copy number genes in HER2+ breast cancer genomes. In contrast, genes that are activated by HDACI are moderately expressed. We analyzed gene copy number in combination with microarray and GRO-seq analysis of expression level, in normal and breast cancer cells to show that high copy number genes are more likely to be repressed by HDACI than non-amplified genes. The inhibition of transcription of amplified oncogenes, which promote survival and proliferation of cancer cells, might explain the cancer-specific lethality of HDACI, and may represent a general therapeutic strategy for cancer.",
        "Doc_title":"HDAC inhibitors induce transcriptional repression of high copy number genes in breast cancer through elongation blockade.",
        "Journal":"Oncogene",
        "Do_id":"23435418",
        "Doc_ChemicalList":"Antineoplastic Agents;Histone Deacetylase Inhibitors;Hydroxamic Acids;RNA, Messenger;trichostatin A;ERBB2 protein, human;Receptor, ErbB-2;RNA Polymerase II",
        "Doc_meshdescriptors":"Antineoplastic Agents;Breast Neoplasms;Cell Line, Tumor;Female;Gene Dosage;Gene Expression Regulation, Neoplastic;Gene Silencing;Genome, Human;Histone Deacetylase Inhibitors;Humans;Hydroxamic Acids;Oligonucleotide Array Sequence Analysis;Oncogenes;RNA Polymerase II;RNA, Messenger;Receptor, ErbB-2;Transcription Elongation, Genetic;Transcription Initiation, Genetic;Transcriptome",
        "Doc_meshqualifiers":"pharmacology;drug effects;drug effects;pharmacology;pharmacology;antagonists & inhibitors;metabolism;genetics;metabolism;genetics;metabolism;drug effects",
        "_version_":1605774793835020288},
      {
        "Doc_abstract":"A fundamental mechanism of genetic alteration is amplification of entire gene sequences that results in overexpression of a gene product or protein. If the amplified gene is a member of the oncogene family and/or a regulator of DNA replication or cell cycle progression, overexpression of this oncoprotein may result in enhanced growth advantages for these cells. Amplification of one such oncogene, HER2 (neu, erbB-2), in up to 35% of human breast cancers is associated with a poor prognosis but may predict response to various therapeutic modalities. FDA-approved assays are available to detect the HER2 protein receptor or the HER2 gene sequence to determine eligibility for Herceptin treatment or adriamycin treatment in node positive patients, respectively. As testing for HER2 is becoming more common in the clinical laboratory, we provide an overview of the biology, diagnostic methods, and emerging clinical value of HER2 gene amplification.",
        "Doc_title":"HER2: the neu prognostic marker for breast cancer.",
        "Journal":"Critical reviews in clinical laboratory sciences",
        "Do_id":"11347719",
        "Doc_ChemicalList":"Biomarkers, Tumor",
        "Doc_meshdescriptors":"Biomarkers, Tumor;Breast Neoplasms;Genes, erbB-2;Humans;Prognosis",
        "Doc_meshqualifiers":"diagnosis;genetics;pathology",
        "_version_":1605763631974187008},
      {
        "Doc_abstract":"Breast cancer is a polymorphic disease and, until now, nodal invasion and steroid receptor levels remain the most powerful and widely used prognostic indicators. Molecular oncology has proven the importance of somatic genetic events in cancer genesis and evolution. In breast cancer a number of genetic aberrations have been proposed to bear impact on disease outcome. Greatest significance has been associated to ERBB2 amplification and overexpression. More recently p53 mutations have been suggested to bear meaning in terms of cancer evolution. We discuss here the molecular epidemiology of p53 mutations in human breast tumors and the clinico-pathological significance that can be associated to them.",
        "Doc_title":"p53 mutations in breast cancer: incidence and relations to tumor aggressiveness and evolution of the disease.",
        "Journal":"Pathologie-biologie",
        "Do_id":"9769953",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"Breast Neoplasms;Disease Progression;Female;Gene Expression Regulation, Neoplastic;Genes, p53;Humans;Immunohistochemistry;Incidence;Neoplasm Invasiveness;Prognosis",
        "Doc_meshqualifiers":"epidemiology;genetics;pathology;physiology",
        "_version_":1605742067113263104},
      {
        "Doc_abstract":"Whether and how cancer-associated fibroblasts induce trastuzumab resistance in HER2+ breast cancer is still elusive. We analyzed the percentage of cancer stem cells and multiple pathway status before and after trastuzumab treatment in HER2 positive breast cancer cells co-cultured with conditional medium (CM) from CAFs. The results suggest that CAFs induce trastuzumab resistance by expanding cancer stem cells and activating multiple pathways, such as NF-ÎºB, JAK/STAT3 and PI3K/AKT; combination of an anti-IL6 antibody, or multiple pathway inhibitors with trastuzumab in HER2 positive breast cancer maybe a novel strategy to reverse trastuzumab resistance. ",
        "Doc_title":"Cancer-associated fibroblasts induce trastuzumab resistance in HER2 positive breast cancer cells.",
        "Journal":"Molecular bioSystems",
        "Do_id":"25648538",
        "Doc_ChemicalList":"ACTA2 protein, human;Actins;Antineoplastic Agents;CAV1 protein, human;Caveolin 1;IL6 protein, human;Interleukin-6;Receptor, ErbB-2;Trastuzumab",
        "Doc_meshdescriptors":"Actins;Antineoplastic Agents;Breast Neoplasms;Caveolin 1;Cell Communication;Cell Line, Tumor;Cell Proliferation;Drug Resistance, Neoplasm;Female;Fibroblasts;Humans;Interleukin-6;Neoplastic Stem Cells;Receptor, ErbB-2;Trastuzumab",
        "Doc_meshqualifiers":"metabolism;pharmacology;metabolism;metabolism;drug effects;drug effects;physiology;metabolism;antagonists & inhibitors;metabolism;pharmacology",
        "_version_":1605895565533511680},
      {
        "Doc_abstract":"Breast cancer is a heterogeneous disease. Thanks to extensive efforts from research scientists and clinicians, treatment for breast cancer has advanced into the era of targeted medicine. With the use of several well-established biomarkers, such as hormone receptors (HRs) (i.e., estrogen receptor [ER] and progesterone receptor [PgR]) and human epidermal growth factor receptor-2 (HER2), breast cancer patients can be categorized into multiple subgroups with specific targeted treatment strategies. Although therapeutic strategies for HR-positive (HR+) HER2-negative (HER2-) breast cancer and HR-negative (HR-) HER2-positive (HER2+) breast cancer are well-defined, HR+ HER2+ breast cancer is still an overlooked subgroup without tailored therapeutic options. In this review, we have summarized the molecular characteristics, etiology, preclinical tools and therapeutic options for HR+ HER2+ breast cancer. We hope to raise the attention of both the research and the medical community on HR+ HER2+ breast cancer, and to advance patient care for this subtype of disease. ",
        "Doc_title":"From bench to bedside: What do we know about hormone receptor-positive and human epidermal growth factor receptor 2-positive breast cancer?",
        "Journal":"The Journal of steroid biochemistry and molecular biology",
        "Do_id":"25998416",
        "Doc_ChemicalList":"Antineoplastic Agents;Receptors, Estrogen;Receptors, Progesterone;ERBB2 protein, human;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Animals;Antineoplastic Agents;Breast;Breast Neoplasms;Female;Humans;Molecular Targeted Therapy;Receptor, ErbB-2;Receptors, Estrogen;Receptors, Progesterone;Signal Transduction",
        "Doc_meshqualifiers":"pharmacology;therapeutic use;drug effects;metabolism;pathology;drug therapy;metabolism;pathology;methods;analysis;metabolism;analysis;metabolism;analysis;metabolism;drug effects",
        "_version_":1605746305671364608},
      {
        "Doc_abstract":"Human epidermal growth factor receptor-2 (HER2) has been implicated in the progression of multiple tumor types, including breast cancer, and many downstream effectors of HER2 signaling are primary regulators of cellular metabolism, including Ras and Akt. A key downstream metabolic target of Ras and Akt is the 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 3 isozyme (PFKFB3), whose product, fructose-2,6-bisphosphate (F26BP), is a potent allosteric activator of a rate-limiting enzyme in glycolysis, 6-phosphofructo-1-kinase (PFK-1). We postulate that PFKFB3 may be regulated by HER2 and contribute to HER2-driven tumorigenicity.;Immunohistochemistry and Kaplan-Meier analysis of HER2+ patient samples investigated the relevance of PFKFB3 in HER2+ breast cancer. In vitro genetic and pharmacological inhibition of PFKFB3 was utilized to determine effects on HER2+ breast cancer cells, while HER2 antagonist treatment assessed the mechanistic regulation on PFKFB3 expression and glucose metabolism. Administration of a PFKFB3 inhibitor in a HER2-driven transgenic breast cancer model evaluated this potential therapeutic approach in vivo.;PFKFB3 is elevated in human HER2+ breast cancer and high PFKFB3 transcript correlated with poorer progression-free (PFS) and distant metastatic-free (DFMS) survival. Constitutive HER2 expression led to elevated PFKFB3 expression and increased glucose metabolism, while inhibition of PFKFB3 suppressed glucose uptake, F26BP, glycolysis, and selectively decreased the growth of HER2-expressing breast cancer cells. In addition, treatment with lapatinib, an FDA-approved HER2 inhibitor, decreased PFKFB3 expression and glucose metabolism in HER2+ cells. In vivo administration of a PFKFB3 antagonist significantly suppressed the growth of HER2-driven breast tumors and decreased ",
        "Doc_title":"Inhibition of 6-phosphofructo-2-kinase (PFKFB3) suppresses glucose metabolism and the growth of HER2+ breast cancer.",
        "Journal":"Breast cancer research and treatment",
        "Do_id":"27613609",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605802584421957632},
      {
        "Doc_abstract":"Patient-derived xenograft (PDX) models of human breast cancer are proving useful for preclinical evaluation of experimental therapeutics. However, until recently, generation of PDX models reflecting the full spectrum of human breast cancers has been an elusive goal. We recently developed a method for establishing serially transplantable, phenotypically stable, human breast cancer xenograft models in immunocompromised mice with comparatively high efficiency (overall âˆ¼25%). These xenografts represent the major clinically defined subtypes of breast cancer [e.g. estrogen receptor positive (ER+), HER2 positive (HER2+), and \"triple negative\" (TN) breast cancers]. This method, and methods being developed in other laboratories, may soon allow for conducting \"animal clinical trials\" once sufficient numbers of clinically relevant models are generated. Curr. Protoc. Mouse Biol. 3:21-29 Â© 2013 by John Wiley & Sons, Inc. ",
        "Doc_title":"Establishment of Patient-Derived Xenograft (PDX) Models of Human Breast Cancer.",
        "Journal":"Current protocols in mouse biology",
        "Do_id":"26069021",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605818754942369793},
      {
        "Doc_abstract":"Autophagy, a lysosome-mediated degradation and recycling process, functions in advanced malignancies to promote cancer cell survival and contribute to cancer progression and drug resistance. While various autophagy inhibition strategies are under investigation for cancer treatment, corresponding patient selection criteria for these autophagy inhibitors need to be developed. Due to its central roles in the autophagy process, the cysteine protease ATG4B is one of the autophagy proteins being pursued as a potential therapeutic target. In this study, we investigated the expression of ATG4B in breast cancer, a heterogeneous disease comprised of several molecular subtypes. We examined a panel of breast cancer cell lines, xenograft tumors, and breast cancer patient specimens for the protein expression of ATG4B, and found a positive association between HER2 and ATG4B protein expression. We showed that HER2-positive cells, but not HER2-negative breast cancer cells, require ATG4B to survive under stress. In HER2-positive cells, cytoprotective autophagy was dependent on ATG4B under both starvation and HER2 inhibition conditions. Combined knockdown of ATG4B and HER2 by siRNA resulted in a significant decrease in cell viability, and the combination of ATG4B knockdown with trastuzumab resulted in a greater reduction in cell viability compared to trastuzumab treatment alone, in both trastuzumab-sensitive and -resistant HER2 overexpressing breast cancer cells. Together these results demonstrate a novel association of ATG4B positive expression with HER2 positive breast cancers and indicate that this subtype is suitable for emerging ATG4B inhibition strategies.",
        "Doc_title":"Identification of breast cancer cell subtypes sensitive to ATG4B inhibition.",
        "Journal":"Oncotarget",
        "Do_id":"27556700",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605820233266757632},
      {
        "Doc_abstract":"To identify the signatures of miRNAs differentially expressed in HER2(+) versus HER2(-) breast cancers that accurately predict the HER2 status of breast cancer, and to provide further insight into breast cancer therapy.;By the methods of literature search, aberrant expressed miRNAs were collected. By target prediction algorithm of TargetScan and PicTar and the data enrichment analysis, target gene sets of miRNAs differentially expressed in HER2(+) versus HER2(-) breast cancers were built. Then, using the Database for Annotation, Visualization, and Integrated Discovery (DAVID) database, the function modules of Gene Ontology categories and Kyoto Encyclopedia of Genes and Genomes (KEGG) and BIOCARTA pathway, biological functions and signaling pathways that are probably regulated by miRNAs, were analyzed.;We got five sets of miRNAs expressed in different HER2 status of breast cancers finally. The five sets of data contain 22; 32; 3; 38; and 62 miRNAs, respectively. After miRNAs target prediction and data enrichment, 5,734; 22,409; 1,142; 22,293; and 43,460 target genes of five miRNA sets were collected. Gene ontology analysis found these genes may be involved in transcription, protein transport, angiogenesis, and apoptosis. Moreover, certain KEGG and BIOCARTA signaling pathways related toHER2 status were found.;Using TargetScan and PicTar for data enrichment, and DAVID database, Gene Ontology categories, KEGG and BIOCARTA pathway for analysis of miRNAs different expression, we conducted a new method for biological interpretation of miRNA profiling data in HER2(+) versus HER2(-) breast cancers. It may improve understanding the regulatory roles of miRNAs in different molecular subtypes of breast cancers. Therefore, it is beneficial to improve the accuracy of experimental efforts to breast cancer and potential therapeutic targets.",
        "Doc_title":"The bioinformatics analysis of miRNAs signatures differentially expressed in HER2(+) versus HER2(-) breast cancers.",
        "Journal":"Cancer biotherapy & radiopharmaceuticals",
        "Do_id":"23009584",
        "Doc_ChemicalList":"Biomarkers, Tumor;MicroRNAs;ERBB2 protein, human;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Biomarkers, Tumor;Breast Neoplasms;Computational Biology;Female;Gene Expression Profiling;Gene Regulatory Networks;Humans;MicroRNAs;Oligonucleotide Array Sequence Analysis;Receptor, ErbB-2;Signal Transduction",
        "Doc_meshqualifiers":"genetics;genetics;metabolism;genetics;metabolism",
        "_version_":1605747028651933696},
      {
        "Doc_abstract":"Polymorphism of the genes of Human Epidermal growth factor receptor1 (HER1) and receptor2 (HER2) have been reported to be linked to pathogenesis of several malignant tumors but still there is contradiction regarding their association with breast cancer.;In this case control study we aimed to analyze the frequency of HER1 R497K (rs 11543848) and HER2 I655V (rs 1136201) Polymorphisms in breast cancer.;The frequency of HER1 Arg(R) 497Lys (K) and HER2 Ile (I) 655Val (V) polymorphisms were tested in 64 breast cancer patients and 86 normal control by polymerase chain reaction followed by restriction fragment polymorphism detection. Immunohistochemical analysis was done for HER2 protein on the available 18 malignant tissue samples.;HER1 497K and HER2 655V variant had significantly increased breast cancer risk (OR=2.6, 95% CI 1.6-4.2, OR=2.2, 95% CI 1.2-4.1, p< 0.05) respectively. Moreover, combined HER1 K497 and HER2 V655 variant was detected in 26.6% malignant in comparison to 8.14% of control group (OR=4.1, 95% CI 1.58-10.57), but, no significant association was noticed between both Polymorphisms and clinicopathological features of the disease. As regard HER2 immunohistochemical expression no significant correlation was revealed with HER2 655V polymorphism.;our findings suggest that HER1 497K and HER2 655V polymorphisms are potential risk factor for development of breast cancer.",
        "Doc_title":"HER1 R497K and HER2 I655V polymorphisms are linked to development of breast cancer.",
        "Journal":"Disease markers",
        "Do_id":"23594562",
        "Doc_ChemicalList":"EGFR protein, human;ERBB2 protein, human;Receptor, Epidermal Growth Factor;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Adult;Aged;Breast Neoplasms;Carcinoma;Case-Control Studies;Female;Fibroadenoma;Gene Frequency;Genetic Association Studies;Humans;Middle Aged;Mutation, Missense;Polymorphism, Restriction Fragment Length;Polymorphism, Single Nucleotide;Receptor, Epidermal Growth Factor;Receptor, ErbB-2;Risk Factors",
        "Doc_meshqualifiers":"diagnosis;genetics;diagnosis;genetics;genetics;metabolism;genetics;metabolism;genetics;metabolism",
        "_version_":1605764775684341760},
      {
        "Doc_abstract":"Fatty acid binding protein-7 (FABP-7) is normally expressed in the mammary gland. The aim of this study was to clarify the phenotype of breast cancers with respect to the overexpression of FABP-7. Reverse transcription PCR (RT-PCR) analysis was carried out on 16 cases, including 4 ER(+)/HER2(-), 2 ER(+)/HER2(+), 3 ER(-)/HER2(+), and 5 ER(-)/HER2(-) samples, and 2 non-neoplastic mammary glands as control tissue. Breast cancers categorized as ER(-)/HER2(-) revealed a high cDNA level of FABP-7 as compared to other groups of breast cancer (p=0.004). An immunohistochemical study carried out on 88 cases showed that FABP-7 overexpression had a strong relationship with triple-negative cases (45.8%, p=0.001) and the basal-like subtype (37.5%, p=0.001). Estrogen receptor (ER) and progesterone receptor (PgR) expressions had reverse correlation with FABP-7 overexpression (p=0.003, p<0.0001), but no significant associations can be identified between human epidermal growth factor receptor-2 (HER2) and FABP-7 (p=0.219). In conclusion, this study is the first to demonstrate overexpression of FABP-7 in triple-negative breast cancers [ER(-), PgR(-)/HER2(-)], especially in basal-like breast cancer, and to give a probable interpretation of the high histological grade and poor prognosis of basal-like breast cancer.",
        "Doc_title":"Overexpression of fatty acid binding protein-7 correlates with basal-like subtype of breast cancer.",
        "Journal":"Pathology, research and practice",
        "Do_id":"19608352",
        "Doc_ChemicalList":"Carrier Proteins;FABP7 protein, human;Fatty Acid-Binding Protein 7;Receptors, Estrogen;Receptors, Progesterone;Tumor Suppressor Proteins;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Breast Neoplasms;Carrier Proteins;Fatty Acid-Binding Protein 7;Female;Humans;Immunohistochemistry;Neoplasm Staging;Phenotype;Receptor, ErbB-2;Receptors, Estrogen;Receptors, Progesterone;Reverse Transcriptase Polymerase Chain Reaction;Tumor Suppressor Proteins",
        "Doc_meshqualifiers":"genetics;metabolism;pathology;biosynthesis;genetics;metabolism;genetics;metabolism;genetics;metabolism;biosynthesis",
        "_version_":1605874567558987776},
      {
        "Doc_abstract":"Macroautophagy (referred to as autophagy here) is an intracellular degradation pathway enhanced in response to a variety of stresses and in response to nutrient deprivation. This process provides the cell with nutrients and energy by degrading aggregated and damaged proteins as well as compromised organelles. Since autophagy has been linked to diverse diseases including cancer, it has recently become a very interesting target in breast cancer treatment. Indeed, current clinical trials are trying to use chloroquine or hydroxychloroquine, alone or in combination with other drugs to inhibit autophagy during breast cancer therapy since chemotherapy and radiation, regimens that are used to treat breast cancer, are known to induce autophagy in cancer cells. Importantly, in breast cancer, autophagy has been involved in the development of resistance to chemotherapy and to anti-estrogens. Moreover, a close relationship has recently been described between autophagy and the HER2 receptor. Here, we discuss some of the recent findings relating autophagy and cancer with a particular focus on breast cancer therapy. ",
        "Doc_title":"Targeting autophagy in breast cancer.",
        "Journal":"World journal of clinical oncology",
        "Do_id":"25114840",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605766496116539392},
      {
        "Doc_abstract":"Inflammatory breast cancer (IBC) is an aggressive form of locally advanced breast cancer characterized by rapidly progressive breast erythema, pain and tenderness, oedema and paeu d'orange appearance. It accounts for 1-3% of all newly diagnosed cases of breast cancer in the west. Data on IBC from India are lacking. The aim of our study was to assess the clinical-pathological parameters and outcome of IBC at, All India Institute of Medical Sciences, a large tertiary care centre.;We screened 3,650 breast cancer cases registered from January 2004 to December 2012 and found 41 cases of IBC. Data included demographics as well as clinical, radiological and histopathological characteristics, and were collected from clinical case records using the International Classification of Diseases code (C-50). Patients who presented with IBC as a recurrence, or who had a neglected and advanced breast cancer that simulated an IBC were excluded from this study.;The median age was 45 years (range 23-66). The median duration of symptoms was 5 months. The American Joint Committee on Cancer stage (AJCC) distribution was Stage III - 26 and IV - 15 patients. Estrogen receptor (ER), progesterone receptor (PR) positivity and human epidermal growth factor receptor 2 (HER2/neu) positivity were 50%, 46% and 60%, respectively. Triple negativity was found in 15% of the cases. All the non metastatic IBC patients received anthracycline and/ or taxane based chemotherapy followed by modified radical mastectomy , radiotherapy and hormonal therapy as indicated. Pathological complete remission rate was 15%. At a median follow-up of 30 months, the 3 year relapse free survival and overall survival were 30% and 40%respectively.;IBC constituted 1.1% of all breast cancer patients at our centre. One third of these had metastatic disease at presentation. Hormone positivity and Her2 neu positivity were found in 50% and 60% of the cases, respectively.",
        "Doc_title":"Inflammatory breast cancer: a single centre analysis.",
        "Journal":"Asian Pacific journal of cancer prevention : APJCP",
        "Do_id":"24815472",
        "Doc_ChemicalList":"Anthracyclines;Bridged-Ring Compounds;Receptors, Estrogen;Receptors, Progesterone;Taxoids;taxane;ERBB2 protein, human;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Adult;Aged;Anthracyclines;Antineoplastic Combined Chemotherapy Protocols;Bridged-Ring Compounds;Female;Humans;India;Inflammatory Breast Neoplasms;Mastectomy, Modified Radical;Middle Aged;Neoplasm Recurrence, Local;Neoplasm Staging;Receptor, ErbB-2;Receptors, Estrogen;Receptors, Progesterone;Taxoids;Triple Negative Breast Neoplasms;Young Adult",
        "Doc_meshqualifiers":"therapeutic use;therapeutic use;therapeutic use;epidemiology;drug therapy;epidemiology;radiotherapy;surgery;metabolism;metabolism;metabolism;therapeutic use;drug therapy;epidemiology;radiotherapy;surgery",
        "_version_":1605800054293004288},
      {
        "Doc_abstract":"HER-2/neu (c-erbB2) is overexpressed or amplified in 15%-35% of breast cancers. HER-2 testing has become of paramount importance as it represents a key therapeutic, prognostic and predictive parameter. HER-2 is associated with ER/PgR negativity, high histologic grade, high proliferative index, and increased number of metastatic lymph nodes. In N+ patients, HER-2 represents a negative prognostic factor. HER-2 also represents a predictive factor. In fact, HER-2+ patients appear to be resistant to the CMF regimen and comparatively more sensitive to anthracyclins such as Herceptin. HER-2 testing is currently performed utilizing two main methods: gene amplification is usually determined by fluorescence in situ hybridization (FISH), whereas protein overexpression is determined by immunohistochemistry (IHC). The comparison between FISH and IHC assays demonstrates a considerably high degree of concordance (around 90%). When dealing with cases scored as 3+ (according to the FDA licensed scoring method), such a concordance approaches 100%. In consideration of greater technical simplicity as well as of cost-effectiveness, IHC represents the ideal screening method for HER-2 testing. FISH analysis remains valid for HER-2 evaluation in those cases in which IHC fails to provide unequivocal data.",
        "Doc_title":"[Measurement of HER-2/neu in breast cancer: which methodologic approach?].",
        "Journal":"Pathologica",
        "Do_id":"11433610",
        "Doc_ChemicalList":"Neoplasm Proteins;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Breast Neoplasms;Carcinoma;Chemotherapy, Adjuvant;Cost-Benefit Analysis;Drug Resistance, Neoplasm;Female;Gene Expression Regulation, Neoplastic;Genes, erbB-1;Humans;Immunohistochemistry;In Situ Hybridization, Fluorescence;Mass Screening;Neoplasm Proteins;Prognosis;Receptor, ErbB-2;Reproducibility of Results",
        "Doc_meshqualifiers":"drug therapy;genetics;mortality;drug therapy;genetics;mortality;economics;economics;economics;analysis;biosynthesis;analysis;biosynthesis",
        "_version_":1605805520768204800},
      {
        "Doc_abstract":"Over the last two decades, various research protocols were applied for scintigraphic imaging, prognosis and treatment of breast cancer, using monoclonal antibodies. Monoclonal antibodies approved by the United States Food and Drug Administration (FDA) include the anti-carcinoembryonic antigen (CEA), and B72.3, prepared against the tumour-associated glycoprotein, TAG-72. The recombinant humanized \"cold\" anti-HER2 monoclonal antibody (trastuzumab), which targets oncogene receptor HER2 has hitherto been the only monoclonal antibody widely used for the treatment of breast cancer in the USA, with or without chemotherapy. Trastuzumab is constructed against the HER2 oncogene receptor (also known as neu or c-erb-B2), which is overexpressed in 25%-30% of breast cancer cell lines and is associated with poor prognosis. Immuno-lymphoscintigraphy is also applied to guide and monitor the effect of treatment regimes. Radiolabelled, \"hot\" monoclonal antibodies are currently being applied for the treatment of primary or metastatic breast cancer, in experimental, pre-clinical, or clinical trials, in combination with traditional external beam radiotherapy and/or chemotherapy. Radioimmunotherapy comprises systemically administered monoclonal antibodies, linked to high-energy, beta-emitting radionuclides. Radioactive antibodies, in the form of yttrium-90 (90Y)-BrE-3, 90Y- m170 and 131I- or 90Y- labelled L6 antibody, are applied with adjuvant autologous peripheral blood stem cells transfusion, to prevent myelotoxicity. Partial or rarely complete responses to \"hot\" antibody treatment, of breast cancer have been reported. Innovative strategies using this combined-modality treatment hold promise for better disease-free and survival rates.",
        "Doc_title":"Monoclonal antibodies: old and new trends in breast cancer imaging and therapeutic approach.",
        "Journal":"Hellenic journal of nuclear medicine",
        "Do_id":"16142251",
        "Doc_ChemicalList":"Antibodies, Monoclonal;Radioisotopes;Radiopharmaceuticals",
        "Doc_meshdescriptors":"Antibodies, Monoclonal;Breast Neoplasms;Clinical Trials as Topic;Humans;Practice Patterns, Physicians';Radioimmunodetection;Radioimmunotherapy;Radioisotopes;Radiopharmaceuticals",
        "Doc_meshqualifiers":"therapeutic use;diagnostic imaging;radiotherapy;methods;trends;methods;trends;therapeutic use;therapeutic use",
        "_version_":1605891951722233856},
      {
        "Doc_abstract":"Breast cancer in African Americans in the US is more aggressive and has a worse outcome than breast cancer in Caucasians. Although the incidence of breast cancer among US whites is higher than among blacks, the mortality rates for blacks are much higher. Breast cancer in blacks is also associated with a more advanced stage at presentation and pathologically aggressive tumors commonly exhibiting estrogen receptor negativity, higher S-phase fractions, and higher numbers of involved lymph nodes. This paper reviews some of the genetic factors that have been shown to be associated with a difference in breast cancer outcome between African Americans and Caucasians in the US such as the BRCA1 and BRCA2 genes, p53 mutations, UGT1A1 gene polymorphisms, and HER-2/neu gene amplifications/overexpression.",
        "Doc_title":"Racial differences in genetic factors associated with breast cancer.",
        "Journal":"Cancer metastasis reviews",
        "Do_id":"12716036",
        "Doc_ChemicalList":"Biomarkers, Tumor",
        "Doc_meshdescriptors":"African Americans;Biomarkers, Tumor;Breast Neoplasms;European Continental Ancestry Group;Female;Genetic Predisposition to Disease;Humans;Prognosis;Risk Factors;United States",
        "Doc_meshqualifiers":"genetics;diagnosis;ethnology;genetics;genetics;epidemiology",
        "_version_":1605808727352410112},
      {
        "Doc_abstract":"Breast cancer is the leading cause of cancer-related mortality among females worldwide, and therefore the development of new therapeutic approaches is still needed. Rosemary (Rosmarinus officinalis L.) extract possesses antitumor properties against tumor cells from several organs, including breast. However, in order to apply it as a complementary therapeutic agent in breast cancer, more information is needed regarding the sensitivity of the different breast tumor subtypes and its effect in combination with the currently used chemotherapy. Here, we analyzed the antitumor activities of a supercritical fluid rosemary extract (SFRE) in different breast cancer cells, and used a genomic approach to explore its effect on the modulation of ER-Î± and HER2 signaling pathways, the most important mitogen pathways related to breast cancer progression. We found that SFRE exerts antitumor activity against breast cancer cells from different tumor subtypes and the downregulation of ER-Î± and HER2 receptors by SFRE might be involved in its antitumor effect against estrogen-dependent (ER+) and HER2 overexpressing (HER2+) breast cancer subtypes. Moreover, SFRE significantly enhanced the effect of breast cancer chemotherapy (tamoxifen, trastuzumab, and paclitaxel). Overall, our results support the potential utility of SFRE as a complementary approach in breast cancer therapy. ",
        "Doc_title":"Modulation of estrogen and epidermal growth factor receptors by rosemary extract in breast cancer cells.",
        "Journal":"Electrophoresis",
        "Do_id":"24615943",
        "Doc_ChemicalList":"Antineoplastic Agents, Phytogenic;Plant Extracts;Receptors, Estrogen;Receptor, Epidermal Growth Factor",
        "Doc_meshdescriptors":"Antineoplastic Agents, Phytogenic;Breast;Breast Neoplasms;Cell Line, Tumor;Female;Humans;Plant Extracts;Receptor, Epidermal Growth Factor;Receptors, Estrogen;Rosmarinus;Signal Transduction",
        "Doc_meshqualifiers":"isolation & purification;pharmacology;drug effects;metabolism;pathology;drug therapy;metabolism;pathology;isolation & purification;pharmacology;metabolism;metabolism;chemistry;drug effects",
        "_version_":1605800968654422016},
      {
        "Doc_abstract":"Knowledge of estrogen receptor (ER), progesterone receptor (PgR) and human epidermal growth factor receptor-2 (HER2) status is necessary for determining the optimal treatment of breast cancer patients. At the same time, the discordance between marker profiles (ER/PR and HER2) of primary and metastatic breast cancer is well documented. Whether discordant cases are secondary to \"clonal selection\" in the face of targeted anti-estrogen or anti-HER2 therapy or whether they are a laboratory artifact is still debated; both scenarios are likely. This article outlines current modalities for ER, PR, and HER2 testing in primary breast carcinoma and its metastases and reviews prospective and retrospective studies that have addressed these issues, as well as recent advances in the field.",
        "Doc_title":"The need to examine metastatic tissue at the time of progression of breast cancer: is re-biopsy a necessity or a luxury?",
        "Journal":"Current oncology reports",
        "Do_id":"21053108",
        "Doc_ChemicalList":"Receptors, Estrogen;Receptors, Progesterone;ERBB2 protein, human;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Biopsy;Breast Neoplasms;Disease Progression;Female;Humans;Prospective Studies;Receptor, ErbB-2;Receptors, Estrogen;Receptors, Progesterone;Retrospective Studies",
        "Doc_meshqualifiers":"methods;metabolism;pathology;therapy;analysis;metabolism;analysis;metabolism;analysis;metabolism",
        "_version_":1605841636363862016},
      {
        "Doc_abstract":"The introduction of trastuzumab in the treatment of HER-2-positive metastatic breast cancer patients favorably changed the natural history of this disease. First-line treatment with trastuzumab and taxanes demonstrated a significant improvement in overall survival and progression-free survival compared with taxane alone. Despite such a major advance, HER-2-positive metastatic breast cancer will eventually progress in most patients. Moreover chemotherapy-associated toxicities, such as myelosuppression (docetaxel) and neurotoxicity (paclitaxel), may hamper the possibility to adequately treat metastatic breast cancer and may have a negative effect on patients' quality of life. The need for more effective and better-tolerated therapy for HER-2-positive metastatic breast cancer led to the development of new anti-HER-2 agents. Pertuzumab and trastuzumab emtansine are two of the new agents that will change the approach to the treatment of HER-2-positive metastatic breast cancer. Pertuzumab is a humanized monoclonal antibody that binds HER-2 at a different epitope of the HER-2 extracellular domain (subdomain II) than that at which trastuzumab binds. Trastuzumab emtansine is a HER-2-targeted antibody-drug conjugate, composed of the cytotoxic microtubule polymerization inhibitor DM1 that is conjugated to the monoclonal antibody trastuzumab, able to selectively deliver a cytotoxic agent to HER-2-positive tumor cells. TDM-1 is superior and less toxic than lapatinib plus capecitabine in metastatic breast cancer patients previously treated with trastuzumab and taxanes, and its role as a first-line therapy is currently under investigation.",
        "Doc_title":"Trastuzumab emtansine in the treatment of HER-2-positive metastatic breast cancer patients.",
        "Journal":"Future oncology (London, England)",
        "Do_id":"23837759",
        "Doc_ChemicalList":"Antibodies, Monoclonal, Humanized;Antineoplastic Agents;Taxoids;Maytansine;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Antibodies, Monoclonal, Humanized;Antineoplastic Agents;Breast Neoplasms;Female;Humans;Maytansine;Receptor, ErbB-2;Taxoids",
        "Doc_meshqualifiers":"therapeutic use;administration & dosage;therapeutic use;drug therapy;analogs & derivatives;analysis;administration & dosage",
        "_version_":1605797098206265344},
      {
        "Doc_abstract":"Herceptin failure is a major clinical problem in breast cancer. A subset of breast cancer patients with high HER-2/neu levels eventually experience metastatic disease progression when treated with Herceptin as a single agent. Mechanistic details of development of this aggressive disease are not clear. Therefore, there is a dire need to better understand the mechanisms by which drug resistance develops and to design new combined treatments that benefit patients with aggressive breast cancer and have minimal toxicity. We hypothesized that 3, 3'-diindolylmethane (DIM), a non-toxic agent can be combined with Herceptin to treat breast cancers with high levels of HER-2/neu. Here, we evaluated the effects of Herceptin alone and in combination with DIM on cell viability, apoptosis and clonogenic assays in SKBR3 (HER-2/neu-expressing) and MDA-MB-468 (HER-2/neu negative) breast cancer cells. We found that DIM could enhance the effectiveness of Herceptin by significantly reducing cell viability, which was associated with apoptosis-induction and significant inhibition of colony formation, compared with single agent treatment. These results were consistent with the down-regulation of Akt and NF-kB p65. Mechanistic investigations revealed a significant upregulation of miR-200 and reduction of FoxM1 expression in DIM and Herceptin-treated breast cancer cells. We, therefore, transfected cells with pre-miR-200 or silenced FoxM1 in these cells for understanding the molecular mechanism involved. These results provide experimental evidence, for the first time, that DIM plus Herceptin therapy could be translated to the clinic as a therapeutic modality to improve treatment outcome of patients with breast cancer, particularly for the patients whose tumors express high levels of HER-2/neu.",
        "Doc_title":"3, 3'-Diindolylmethane enhances the effectiveness of herceptin against HER-2/neu-expressing breast cancer cells.",
        "Journal":"PloS one",
        "Do_id":"23372748",
        "Doc_ChemicalList":"Antibodies, Monoclonal, Humanized;Antineoplastic Agents;FOXM1 protein, human;Forkhead Box Protein M1;Forkhead Transcription Factors;Indoles;MIRN200 microRNA, human;MicroRNAs;RNA Precursors;diindolylmethane;Receptor, ErbB-2;Trastuzumab",
        "Doc_meshdescriptors":"Antibodies, Monoclonal, Humanized;Antineoplastic Agents;Apoptosis;Breast Neoplasms;Cell Line, Tumor;Cell Proliferation;Drug Synergism;Female;Forkhead Box Protein M1;Forkhead Transcription Factors;Gene Expression Regulation, Neoplastic;Humans;Indoles;MicroRNAs;RNA Interference;RNA Precursors;Receptor, ErbB-2;Transfection;Trastuzumab;Tumor Stem Cell Assay",
        "Doc_meshqualifiers":"pharmacology;pharmacology;drug effects;genetics;drug effects;genetics;drug effects;pharmacology;genetics;genetics",
        "_version_":1605809635020767232},
      {
        "Doc_abstract":"Breast cancer is a major cause of death in Western women, with a 10% lifetime risk of the disease. Most breast cancers are estrogen-dependent. Molecular therapies for breast cancer have developed rapidly in the past few decades and future treatment strategies are being investigated. The selective estrogen receptor (ER) modulator tamoxifen, which until now has served as a standard therapy, functions not only as an estrogen antagonist but also as an estrogen agonist in terms of bone maintenance. Aromatase inhibitors have performed well in international trials and have become a new standard therapy for estrogen-dependent breast cancer. The systematic study of estrogen activation pathways suggests that the enzymes steroid sulfatase and 17beta-hydroxysteroid dehydrogenase type 1, which both have pivotal roles in estrogen biosynthesis, are promising targets; the results of a phase I trial of steroid sulfatase inhibitors are encouraging. The activity of the human epidermal growth factor receptor (HER) pathway correlates negatively with that of the ER. HER2 is overexpressed in 22% of all breast cancers. In the decade since HER2 began being targeted, the monoclonal antibody trastuzumab has been used as well as pertuzumab and HER2 vaccines. Among the estrogen-independent breast cancers, the basal-like subtype has low survival, and therapeutic improvement is a priority. Crosstalk between ER and HER2 signaling pathways means that combinatory therapies may hold the key to enhancement of treatment responses. Other molecular therapies involving functional genomics and RNA interference studies also hold promise.",
        "Doc_title":"Molecular therapy of breast cancer: progress and future directions.",
        "Journal":"Nature reviews. Endocrinology",
        "Do_id":"20644568",
        "Doc_ChemicalList":"Antineoplastic Agents, Hormonal;Estrogen Antagonists;RNA, Small Interfering;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Antineoplastic Agents, Hormonal;Breast Neoplasms;Carcinoma;Estrogen Antagonists;Female;Humans;Models, Biological;Molecular Targeted Therapy;RNA Interference;RNA, Small Interfering;Receptor, ErbB-2",
        "Doc_meshqualifiers":"therapeutic use;genetics;immunology;therapy;genetics;immunology;therapy;therapeutic use;methods;trends;physiology;therapeutic use;antagonists & inhibitors;genetics",
        "_version_":1605812295959576576},
      {
        "Doc_abstract":"We aimed to assess protein expressions of p16 and pRB in breast cancer and explore the clinicopathologic implications. Tissue microarray (TMA) was constructed with 406 cases of breast cancer. The cases were subgrouped into luminal A, luminal B, HER-2, and triple negative breast cancer (TNBC) based on the results of immunohistochemical stains for ER, PR, HER-2, and Ki-67 and fluorescent in situ hybridization (FISH) for HER-2. One hundred and sixty-eight cases were allocated to the subgroup luminal A; 87 cases to the luminal B; 32 cases to the HER-2; and 119 cases to the TNBC. The TNBC group showed the highest negative rate for p16, and the luminal B and HER-2 groups showed the highest positive rate for p16 (P < 0.001). Alteration of p16 was the highest in the luminal B and HER-2 groups, and pRB expression rate was the highest in the HER-2 group and lowest in the luminal A group. In addition, p16(+)/pRB(+) type was the most common in the luminal B group, p16(+)/pRB(-) in the luminal A group, and p16(-)/pRB(+) in the TNBC group (P < 0.001). Altered p16/pRB(+) and non-altered p16/pRB(+) type was the most common in the luminal B, and altered p16/pRB(-) and non-altered p16/pRB(+) type was the most common in the luminal A (P < 0.001). Alteration of p16 was correlated with higher Ki67 labeling index (LI) (P = 0.013), and p16 negativity was correlated with ER negativity (P = 0.002), PR negativity (P = 0.004), and higher Ki67 LI (P < 0.001). pRB positivity was correlated with PR negativity (P = 0.009), HER-2 positivity (P = 0.001), and higher Ki-67 LI (P < 0.001). In luminal group A, p16 alteration was correlated with shorter DFS in univariate analysis (P = 0.024). In conclusion, Expression rates of p16 and pRB differ according to the molecular subgroups of breast cancer and they subsequently correlate with clnicopathologic factors.",
        "Doc_title":"Expression of p16 and pRB in invasive breast cancer.",
        "Journal":"International journal of clinical and experimental pathology",
        "Do_id":"26339389",
        "Doc_ChemicalList":"Biomarkers, Tumor;Cyclin-Dependent Kinase Inhibitor p16;Receptors, Estrogen;Receptors, Progesterone;Retinoblastoma Protein;ERBB2 protein, human;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Biomarkers, Tumor;Breast Neoplasms;Cyclin-Dependent Kinase Inhibitor p16;Disease-Free Survival;Female;Humans;Immunohistochemistry;In Situ Hybridization, Fluorescence;Kaplan-Meier Estimate;Middle Aged;Neoplasm Invasiveness;Proportional Hazards Models;Receptor, ErbB-2;Receptors, Estrogen;Receptors, Progesterone;Retinoblastoma Protein;Time Factors;Treatment Outcome;Triple Negative Breast Neoplasms",
        "Doc_meshqualifiers":"analysis;genetics;chemistry;genetics;mortality;pathology;therapy;analysis;analysis;genetics;analysis;analysis;analysis;chemistry;genetics;pathology",
        "_version_":1605847187192807424},
      {
        "Doc_abstract":"Triple-negative breast cancer (TNBC) is defined by a lack of expression of estrogen, progesterone, and HER2 receptors, and genetically most of them fall into the basal subgroup of breast cancer. The important issue of TNBC is poorer clinical outcome and absence of effective targeted therapy. In this study, we sought to identify DNA copy number alterations and expression of relevant genes characteristic of TNBC to discover potential therapeutic targets. Frozen tissues from 114 breast cancers were analyzed using high-resolution array comparative genomic hybridization. The classification into subtype was determined by estrogen and progesterone receptor expression, and by the presence or absence of gain on the ERBB2 containing clone. The ACE algorithm was used for calling gain and loss of clones. Twenty-eight cases (25%) were classified as TNBC. Recurrent gains (> or =25%) unique to TNBC were 9p24-p21, 10p15-p13, 12p13, 13q31-q34, 18q12, 18q21-q23, and 21q22. Two published gene expression array data sets comparing basal subtype versus other subtype breast cancers were used for searching candidate genes. Of the genes upregulated in the basal subtype, 45 of 686 genes in one data set and 59 of 1,428 in the second data set were found to be located in the gained regions. Of these candidate genes, gain of NFIB (9p24.1) was specific for TNBC in a validation set by real-time PCR. In conclusion, we have identified recurrently gained regions characteristic of TNBC, and found that NFIB copy number and expression is increased in TNBC across the data sets. This article contains Supplementary Material available at http://www.interscience.wiley.com/jpages/1045-2257/suppmat.",
        "Doc_title":"DNA copy number alterations and expression of relevant genes in triple-negative breast cancer.",
        "Journal":"Genes, chromosomes & cancer",
        "Do_id":"18314908",
        "Doc_ChemicalList":"DNA, Neoplasm;Neoplasm Proteins;Receptors, Estrogen;Receptors, Progesterone",
        "Doc_meshdescriptors":"Adult;Aged;Algorithms;Breast Neoplasms;Carcinoma, Ductal, Breast;Computer Systems;DNA, Neoplasm;Female;Gene Amplification;Gene Dosage;Gene Expression Profiling;Gene Expression Regulation, Neoplastic;Genes, erbB-2;Humans;Middle Aged;Neoplasm Proteins;Nucleic Acid Hybridization;Oligonucleotide Array Sequence Analysis;Polymerase Chain Reaction;Receptors, Estrogen;Receptors, Progesterone",
        "Doc_meshqualifiers":"classification;genetics;mortality;classification;genetics;mortality;genetics;biosynthesis;genetics;genetics;genetics",
        "_version_":1605818647113105409},
      {
        "Doc_abstract":"Many genetic traits common to aggressive breast carcinoma have been identified; yet little is known about the interrelationships of such traits during tumor development, especially in women prone to aggressive cancer. This study examined the expression of four biological markers associated with poor prognosis at each stage of breast cancer progression in primary tumors from women of lower economic status and assessed the relationship between these markers.;Archived primary breast tumors from 77 patients were assessed by immunohistochemical analysis for expression of human epidermal growth receptor 2 (HER-2), p53, vascular endothelial growth factor (VEGF), and e-cadherin, and the relationships between the expressions of these molecules were studied.;Twenty-two (29%) patients had advanced (stage III or IV) disease. HER-2, VEGF, e-cadherin, and p53 signal were positive for 31 (40%), 58 (75%), 63 (82%), and 37 (48%) of patients, respectively. Among the markers tested, only p53 exhibited a significant association between expression and stage of the disease ( P = 0.012). Expression of e-cadherin was positively associated with HER-2 overexpression ( P = 0.004), and high levels of HER-2 occurred with strongly positive e-cadherin tumors. Marginally significant positive associations were observed between HER-2 and p53 signal ( P = 0.06), and between disease stage and e-cadherin expression ( P = 0.08).;The significant tendency toward expression of e-cadherin in conjunction with HER-2 overexpression in breast cancer is a novel finding. The association of p53 with more advanced stages of cancer emphasizes it as a key participant in metastatic processes in breast cancer. Many genetic traits common to aggressive breast carcinoma have been identified; yet little is known about the interrelationships of such traits during tumor development, especially in women prone to aggressive cancer. This study examined the expression of four biological markers associated with poor prognosis at each stage of breast cancer progression in primary tumors from women of lower economic status and assessed the relationship between these markers.",
        "Doc_title":"Correlation and expression of p53, HER-2, vascular endothelial growth factor (VEGF), and e-cadherin in a high-risk breast-cancer population.",
        "Journal":"International journal of clinical oncology",
        "Do_id":"15221598",
        "Doc_ChemicalList":"Biomarkers, Tumor;Cadherins;Tumor Suppressor Protein p53;Vascular Endothelial Growth Factor A;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Adult;Aged;Aged, 80 and over;Biomarkers, Tumor;Breast Neoplasms;Cadherins;Female;Humans;Immunohistochemistry;Middle Aged;Prognosis;Receptor, ErbB-2;Risk Factors;Socioeconomic Factors;Tumor Suppressor Protein p53;Vascular Endothelial Growth Factor A",
        "Doc_meshqualifiers":"analysis;metabolism;pathology;metabolism;metabolism;metabolism;metabolism",
        "_version_":1605774259704037376},
      {
        "Doc_abstract":"The human epidermal growth factor receptor 2 (HER2) is a validated therapeutic target in breast cancer. Heterodimerization of HER2 with other HER family members results in enhanced tyrosine phosphorylation and activation of signal transduction pathways. HER2 overexpression increases the translation of fatty acid synthase (FASN), and FASN overexpression markedly increases HER2 signaling, which results in enhanced cell growth. However, the molecular mechanism and regulation of HER2 and FASN interaction are not well defined. Lapatinib is a small-molecule tyrosine kinase inhibitor that blocks phosphorylation of the epidermal growth factor receptor and HER2 in breast cancer cells, resulting in apoptosis. We hypothesized that FASN is directly phosphorylated by HER2, resulting in enhanced signaling and tumor progression in breast cancer cells.;Using mass spectrometry, we identified FASN as one of the proteins that is dephosphorylated by lapatinib in SKBR3 breast cancer cells. Immunofluorescence, immunoprecipitation, Western blotting, a kinase assay, a FASN enzymatic activity assay, an invasion assay, a cell viability assay and zymography were used to determine the role of FASN phosphorylation in invasion of SKBR3 and BT474 cells. The FASN inhibitor C75 and small interfering RNA were used to downregulate FASN expression and/or activity.;Our data demonstrated that FASN is phosphorylated when it is in complex with HER2. FASN phosphorylation was induced by heregulin in HER2-overexpressing SKBR3 and BT474 breast cancer cells. Heregulin-induced FASN phosphorylation resulted in increased FASN enzymatic activity, which was inhibited by lapatinib. The FASN inhibitor C75 suppressed FASN activity by directly inhibiting HER2 and FASN phosphorylation. Blocking FASN phosphorylation and activity by lapatinib or C75 suppressed the activity of matrix metallopeptidase 9 and inhibited invasion of SKBR3 and BT474 cells.;FASN phosphorylation by HER2 plays an important role in breast cancer progression and may be a novel therapeutic target in HER2-overexpressing breast cancer cells.",
        "Doc_title":"Fatty acid synthase phosphorylation: a novel therapeutic target in HER2-overexpressing breast cancer cells.",
        "Journal":"Breast cancer research : BCR",
        "Do_id":"21080941",
        "Doc_ChemicalList":"4-methylene-2-octyl-5-oxofuran-3-carboxylic acid;Antineoplastic Agents;Matrix Metalloproteinase Inhibitors;Neuregulin-1;Protein Kinase Inhibitors;Quinazolines;RNA, Small Interfering;lapatinib;Fatty Acid Synthases;ERBB2 protein, human;Receptor, ErbB-2;Matrix Metalloproteinase 9;4-Butyrolactone",
        "Doc_meshdescriptors":"4-Butyrolactone;Antineoplastic Agents;Apoptosis;Blotting, Western;Breast Neoplasms;Cell Line, Tumor;Fatty Acid Synthases;Female;Fluorescent Antibody Technique;Gene Expression;Humans;Mass Spectrometry;Matrix Metalloproteinase 9;Matrix Metalloproteinase Inhibitors;Neuregulin-1;Phosphorylation;Protein Kinase Inhibitors;Quinazolines;RNA, Small Interfering;Receptor, ErbB-2;Signal Transduction",
        "Doc_meshqualifiers":"analogs & derivatives;metabolism;pharmacology;pharmacology;drug effects;genetics;metabolism;antagonists & inhibitors;metabolism;metabolism;metabolism;drug effects;pharmacology;metabolism;pharmacology;antagonists & inhibitors;genetics;metabolism;drug effects",
        "_version_":1605801959507361792},
      {
        "Doc_abstract":"The HER2 protein is encoded by the HER2/neu gene and it is homologous to the epidermal growth factor receptor. Overexpression of HER2, usually in association with gene amplification, occurs in approximately 25-30% of breast cancers. There are currently several different methods available to evaluate HER2 status, e.g. immunohistochemical (IHC), and fluorescence in situ hybridization (FISH) assays. The HER2 protein is a viable therapeutic target. The humanized anti-HER2 monoclonal antibody trastuzumab (Herceptin) has demonstrated activity in clinical trials in women with metastatic breast cancer overexpressing HER2. The mechanisms of the action of this antibody involve disruption of DNA repair and induction of antibody-dependent cellular cytotoxicity. Response rates to the antibody given as a single agents in the treatment of HER2 overexpressing metastatic breast cancer have ranged from 12 to 27%. Patients who received trastuzumab in combination with chemotherapy had a significantly longer time to progression, higher overall survival compared with patients who had received chemotherapy alone. In the treatment of women with HER2 overexpressing tumors an overall response rate of 57% for combination trastuzumab plus paclitaxel compared with 25% for paclitaxel alone was found. Trastuzumab has an important role in the treatment of HER2 overexpressing metastatic breast cancer. Its place in adjuvant treatment has not been proved up to now. The optimal use of trastuzumab in the treatment of HER2 positive advanced breast cancer is under active investigation. Due to the high rate of clinical activity and low incidence of severe toxicity trastuzumab is a very promising drug in the treatment of breast cancer. The author's purpose was to summarize the results of the trials using trastuzumab treatment, and discuss the methods used to determine the HER2 status.",
        "Doc_title":"[Human recombinant anti-HER2 monoclonal antibody--a new targeted treatment in breast cancer].",
        "Journal":"Orvosi hetilap",
        "Do_id":"11770175",
        "Doc_ChemicalList":"Antibodies, Monoclonal;Antibodies, Monoclonal, Humanized;Antineoplastic Agents;Receptor, ErbB-2;Trastuzumab",
        "Doc_meshdescriptors":"Antibodies, Monoclonal;Antibodies, Monoclonal, Humanized;Antineoplastic Agents;Antineoplastic Combined Chemotherapy Protocols;Breast Neoplasms;Disease-Free Survival;Female;Gene Expression Regulation, Neoplastic;Humans;Receptor, ErbB-2;Trastuzumab;Treatment Outcome;Up-Regulation",
        "Doc_meshqualifiers":"therapeutic use;therapeutic use;therapeutic use;drug therapy;metabolism;drug effects;drug effects;drug effects",
        "_version_":1605774497681506304},
      {
        "Doc_abstract":"To test the hypothesis of an association between HER2 and chemotherapy resistance, we performed a prospective assessment of the predictive value of the circulating HER2 extracellular domain (ECD) in patients with advanced breast carcinoma in the setting of a multicenter Phase II trial using paclitaxel and doxorubicin. Serum samples were collected from 58 patients with metastatic breast carcinoma before first-line chemotherapy for advanced disease, and the levels of circulating HER2 ECD were measured using an enzyme immunoassay. Immunohistochemistry with anti-HER2 monoclonal antibody CB11 was used to assess the overexpression of HER2 in the primary tumors. When 450 fmol/ml was used as a cutoff, 24 cases (41%) had elevated HER2 ECD levels. Elevated levels of circulating HER2 ECD were associated with the expression of HER2 in the primary tumor tissue and with the metastatic tumor burden (evaluated with the marker CA 15-3; P = 0.032 and P = 0.002, respectively) but not with variables such as menopausal status, stage at diagnosis, previous adjuvant therapy, or the number of metastatic sites. The levels of circulating HER2 ECD correlated inversely with the response to treatment. The probability of obtaining a complete response to chemotherapy was significantly lower (P = 0.021) in patients with elevated HER2 ECD levels (0%; 95% confidence interval, 0-13%) compared with patients with nonelevated HER2 (26%; 95% confidence interval, 12-45%). In addition, the duration of clinical response was significantly shorter in patients with elevated HER2 ECD, compared with the cases with nonelevated HER2 (7.5 versus 11 months; P = 0.035). In conclusion, elevated levels of circulating HER2 ECD in patients with metastatic breast cancer correlate with reduced efficacy of a paclitaxel-doxorubicin chemotherapy combination. We suggest that the poor response rate associated with HER2 expression in advanced breast cancer may not be reversed by aggressive chemotherapy alone.",
        "Doc_title":"Circulating HER2 extracellular domain and resistance to chemotherapy in advanced breast cancer.",
        "Journal":"Clinical cancer research : an official journal of the American Association for Cancer Research",
        "Do_id":"10873087",
        "Doc_ChemicalList":"Antibodies, Monoclonal;Antineoplastic Agents;Antineoplastic Agents, Phytogenic;Mucin-1;Doxorubicin;Receptor, ErbB-2;Paclitaxel",
        "Doc_meshdescriptors":"Antibodies, Monoclonal;Antineoplastic Agents;Antineoplastic Agents, Phytogenic;Breast Neoplasms;Doxorubicin;Drug Resistance, Neoplasm;Enzyme-Linked Immunosorbent Assay;Extracellular Matrix;Female;Humans;Immunohistochemistry;Menopause;Mucin-1;Multivariate Analysis;Paclitaxel;Prospective Studies;Protein Structure, Tertiary;Receptor, ErbB-2;Time Factors;Treatment Outcome",
        "Doc_meshqualifiers":"metabolism;pharmacology;pharmacology;blood;drug therapy;metabolism;pharmacology;metabolism;biosynthesis;pharmacology;biosynthesis;blood;chemistry",
        "_version_":1605795458040463360},
      {
        "Doc_abstract":"Special AT-rich sequence binding protein 1 (SATB1) is found acting as a \"genome organizer\" that functions as a landing platform to regulate tissue-specific gene ex-pression. In breast cancer cell lines it has been proven that SATB1 could upregulate the expression of the HER2. In this paper, the relevance of SATB1 and HER2 expression was assessed in human breast cancer tissues, and their influence on tumor histological grade and patients' survival was explored.;Using immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH), 169 patients with breast cancer were assessed for SATB1 expression, HER2 amplification and hormone-receptor (HR) expression. The effects of SATB1 expression on HER2 and HR expression as well as their association with clinicopathologic characteristics were further analyzed by statistical evaluation.;SATB1 expression was correlated with HER2 expression in breast cancer(râ€‰=â€‰0.191; pâ€‰=â€‰0.013). SATB1, HER2 and SATB1/HER2 co-expression was negatively correlated with HR expression (râ€‰=â€‰-0.228, pâ€‰=â€‰0.003; râ€‰=â€‰-0.338, pâ€‰=â€‰0.000; râ€‰=â€‰-0.527, pâ€‰=â€‰0.000, respectively). SATB1 and HER2 single positive and their co-expression were all significantly correlated with higher histological grade (râ€‰=â€‰0.239, pâ€‰=â€‰0.002; râ€‰=â€‰0.160, pâ€‰=â€‰0.038; râ€‰=â€‰0.306, pâ€‰=â€‰0.003, respectively). Multivariate cox regression analyses showed that SATB1 and HER2 were independent risk factors for breast cancer patients, while HR was a protective factor for patients' survival. Comparing to SATB1 or HER2 single positive expression, SATB1/HER2 co-expression tended to have even worse prognosis.;SATB1 and HER2 performed a synergistic effect in breast cancer. Their expression correlated with poorly differentiated breast cancer and indicated an unfavorable prognosis.;The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/1400555050159723 .",
        "Doc_title":"Expression of SATB1 and HER2 in breast cancer and the correlations with clinicopathologic characteristics.",
        "Journal":"Diagnostic pathology",
        "Do_id":"25956130",
        "Doc_ChemicalList":"Biomarkers, Tumor;Matrix Attachment Region Binding Proteins;Receptors, Estrogen;Receptors, Progesterone;SATB1 protein, human;ERBB2 protein, human;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Adult;Aged;Aged, 80 and over;Biomarkers, Tumor;Breast Neoplasms;Cell Differentiation;Chi-Square Distribution;Female;Gene Amplification;Humans;Immunohistochemistry;In Situ Hybridization, Fluorescence;Kaplan-Meier Estimate;Matrix Attachment Region Binding Proteins;Middle Aged;Multivariate Analysis;Neoplasm Grading;Predictive Value of Tests;Proportional Hazards Models;Protective Factors;Receptor, ErbB-2;Receptors, Estrogen;Receptors, Progesterone;Risk Factors",
        "Doc_meshqualifiers":"analysis;genetics;chemistry;genetics;mortality;pathology;analysis;analysis;genetics;analysis;analysis",
        "_version_":1605851849062088704},
      {
        "Doc_abstract":"Overexpression of HER-2 accounts for approximately 25% of all breast cancer cases, while 87.7% of HER-2 positive breast cancers are associated with upregulated VEGF. The objective of this study is to explore the combination therapy of blocking HER-2 and VEGF expressions simultaneously using siRNA. This is the first report to examine the effect of dual silencing of HER-2 and VEGF genes on tumor growth and invasiveness. We have designed nine HER-2 siRNAs and ten VEGF siRNAs, and identified potent siRNA which can silence the target gene up to 75-83.5%. The most potent HER-2 and VEGF siRNAs were used to conduct functional studies in HER-2 positive breast cancer cells. Tumor invasiveness properties including cell morphology change, in vitro migration, cell spreading, and adhesion to ECM were evaluated. In addition, cell proliferation and apoptosis were examined after the siRNA treatment. Our data demonstrated for the first time that HER-2 siRNA could inhibit cell migration and invasion abilities. Combination of HER-2 and VEGF siRNAs exhibited synergistic silencing effect on VEGF. Both HER-2 siRNA and VEGF siRNA showed significant inhibition on cell migration and proliferation. HER-2 siRNA also demonstrated dramatic suppression on cell spreading and adhesion to ECM, as well as induction of apoptosis. Dual silencing of HER-2 and VEGF exhibited significant cell morphology change, and substantial suppression on migration, spreading, cell adhesion, and proliferation. Our observations suggested that HER-2 positive breast cancer may be more effectively treated by dual inhibition of HER-2 and VEGF gene expressions using siRNA.",
        "Doc_title":"Inhibition of breast cancer cell growth and invasiveness by dual silencing of HER-2 and VEGF.",
        "Journal":"Molecular pharmaceutics",
        "Do_id":"20047302",
        "Doc_ChemicalList":"RNA, Small Interfering;Vascular Endothelial Growth Factors;ERBB2 protein, human;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Apoptosis;Breast Neoplasms;Cell Adhesion;Cell Line;Cell Line, Tumor;Cell Movement;Cell Proliferation;Enzyme-Linked Immunosorbent Assay;Female;Gene Silencing;Genetic Therapy;Humans;RNA, Small Interfering;Receptor, ErbB-2;Reverse Transcriptase Polymerase Chain Reaction;Vascular Endothelial Growth Factors",
        "Doc_meshqualifiers":"genetics;physiology;genetics;metabolism;therapy;genetics;physiology;genetics;physiology;physiology;methods;genetics;genetics;metabolism;genetics;metabolism",
        "_version_":1605821081306791936},
      {
        "Doc_abstract":"Topoisomerase IIalpha (topo IIalpha) plays a key role in DNA replication and is a target for multiple chemotherapeutic agents. In breast cancer, topo II expression has been linked to cell proliferation and HER2/neu protein overexpression. However, its relationship with outcome variables is not well established. Formalin-fixed, paraffin-embedded primary breast cancers from 184 women (mean age, 60 years) were stained for topo II by automated immunohistochemistry. A topo II expression index (TI) was determined by counting the number of positive cells per high-power field and calculating an overall mean number of positive cells per high-power field. Tumors with a TI of more than 1 were considered positive, and those with a TI of 1 or less were considered negative. A cell proliferation index was determine d by automated immunohistochemistry using the MIB-1 antibody in an identical technique. HER-2/neu gene amplification (HER-2 amp) was determined by automated fluorescence in situ hybridization using the Ventana unique sequence probe. Fifty-nine (32%) of the tumors had a TI greater than 1. On univariate analysis, increased topo II expression correlated with decreased patient survival (p = .001), advanced tumor stage (p = .034), lymph node metastasis (p = .018), and HER-2 amp (p = .016). Tumor stage (p < .0001), node-positive status (p < .0001), tumor grade (p = .025), HER-2 amp (p < .0001), and MIB-1 overexpression (p = .002) also correlated with survival on univariate analysis. Topo II expression did not correlate with tumor size, grade, estrogen receptor/progesterone receptor status, or disease recurrence. On multivariate analysis, stage (p < .0001), lymph node metastasis (p < .0001), and tumor grade (p = .002) all independently predicted disease-related death. Increased topo II expression is associated with an aggressive form of breast cancer featuring HER-2 amp and predicts disease-related death, lymph node metastasis, and advanced tumor stage.",
        "Doc_title":"Topoisomerase IIalpha expression in breast cancer: correlation with outcome variables.",
        "Journal":"Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc",
        "Do_id":"10824926",
        "Doc_ChemicalList":"Antigens, Neoplasm;Antigens, Nuclear;DNA-Binding Proteins;Isoenzymes;Ki-67 Antigen;Nuclear Proteins;Receptors, Estrogen;Receptors, Progesterone;Receptor, ErbB-2;DNA Topoisomerases, Type II;DNA topoisomerase II alpha",
        "Doc_meshdescriptors":"Adult;Aged;Aged, 80 and over;Antigens, Neoplasm;Antigens, Nuclear;Breast Neoplasms;Carcinoma, Ductal, Breast;DNA Topoisomerases, Type II;DNA-Binding Proteins;Female;Humans;Immunohistochemistry;In Situ Hybridization, Fluorescence;Isoenzymes;Ki-67 Antigen;Lymphatic Metastasis;Middle Aged;Multivariate Analysis;Neoplasm Recurrence, Local;Neoplasm Staging;Nuclear Proteins;Proportional Hazards Models;Receptor, ErbB-2;Receptors, Estrogen;Receptors, Progesterone;Survival Analysis",
        "Doc_meshqualifiers":"enzymology;genetics;pathology;enzymology;genetics;pathology;biosynthesis;biosynthesis;analysis;genetics;analysis;analysis",
        "_version_":1605840704595034112},
      {
        "Doc_abstract":"To introduce the College of American Pathologists/American College of Medical Genetics Cytogenetics Resource Committee criteria for genetic heterogeneity (GH) in HER2 testing, and investigate the clinicopathological significance of HER2 genetic heterogeneity in invasive breast cancer.;The clinical parameters of 100 cases of invasive breast carcinomas were collected. HER2 expression level and HER2 gene copy number in formalin-fixed and paraffin embedded tumor samples were detected by immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH), and the relationship between HER2 gene GH and clinicopathological characteristics were analyzed.;Among the 100 patients, HER2 gene GH was observed in 20 (20%) cases. When the number of HER2 amplified cells was more than 25%, the frequencies of FISH positive were higher than those cases with less than 25% HER2 amplified cells. The results showed that HER2 gene GH was associated with the degree of HER2 protein expression (P=0.004), and ER expression (P=0.002).;HER2 gene GH may be correlated with the HER2 protein IHC 1+/2+, and ER expression in breast carcinoma. It is important for doctors to avoid ignoring or only counting FISH positive cells leading to incorrect diagnosis for these patients.",
        "Doc_title":"[Association of HER2 genetic heterogeneity with clinicopathological characteristics in breast cancer].",
        "Journal":"Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics",
        "Do_id":"20931533",
        "Doc_ChemicalList":"Receptors, Estrogen;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Adult;Breast Neoplasms;Carcinoma;Female;Gene Dosage;Gene Expression Regulation, Neoplastic;Genetic Heterogeneity;Humans;Middle Aged;Receptor, ErbB-2;Receptors, Estrogen",
        "Doc_meshqualifiers":"genetics;metabolism;pathology;genetics;metabolism;pathology;genetics;metabolism;genetics;metabolism",
        "_version_":1605818760621457408},
      {
        "Doc_abstract":"Overexpression of human epidermal growth factor receptor (HER-2) occurs in 20-30% of breast cancers and confers survival and proliferative advantages on the tumour cells making HER-2 an ideal therapeutic target for drugs like Herceptin. Continued delineation of tumour biology has identified splice variants of HER-2, with contrasting roles in tumour cell biology. For example, the splice variant Î”16HER-2 (results from exon 16 skipping) increases transformation of cancer cells and is associated with treatment resistance; conversely, Herstatin (results from intron 8 retention) and p100 (results from intron 15 retention) inhibit tumour cell proliferation. This review focuses on the potential clinical implications of the expression and coexistence of HER-2 splice variants in cancer cells in relation to breast cancer progression and drug resistance. \"Individualised\" strategies currently guide breast cancer management; in accordance, HER-2 splice variants may prove valuable as future prognostic and predictive factors, as well as potential therapeutic targets. ",
        "Doc_title":"Clinical Significance of HER-2 Splice Variants in Breast Cancer Progression and Drug Resistance.",
        "Journal":"International journal of cell biology",
        "Do_id":"23935627",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605883221983100928},
      {
        "Doc_abstract":"Co-amplification and co-overexpression of ErbB2 and Grb7 are frequently found in various cancers, including breast cancer. Biochemical and functional correlations of the two molecules have identified Grb7 to be a pivotal mediator downstream of ErbB2-mediated oncogenesis. However, it remains largely unknown how Grb7 is involve in the ErbB2-mediated tumorigenesis. In this study, we show that Grb7-mediated cell proliferation and growth are essential for the tumorigenesis that occurs in ErbB2-Grb7-overexpressing breast cancer cells. Intrinsically, EGF-induced de novo Grb7 tyrosine phosphorylation/activation recruits and activates Ras-GTPases and subsequently promotes the phosphorylation of ERK1/2, thereby stimulating tumor growth. Furthermore, we also found the anti-tumor effect could be synergized by co-treatment with Herceptin plus Grb7 knockdown in Sk-Br3 breast cancer cells. Our findings illustrate an underlying mechanism by which Grb7 promotes tumorigenesis through the formation of a novel EGFR-Grb7-Ras signaling complex, thereby highlighting the potential strategy of targeting Grb7 as an anti-breast cancer therapy.",
        "Doc_title":"EGF-induced Grb7 recruits and promotes Ras activity essential for the tumorigenicity of Sk-Br3 breast cancer cells.",
        "Journal":"The Journal of biological chemistry",
        "Do_id":"20622016",
        "Doc_ChemicalList":"Antibodies, Monoclonal;Antibodies, Monoclonal, Humanized;GRB7 Adaptor Protein;Epidermal Growth Factor;Receptor, Epidermal Growth Factor;ras Proteins;Trastuzumab",
        "Doc_meshdescriptors":"Animals;Antibodies, Monoclonal;Antibodies, Monoclonal, Humanized;Blotting, Western;Breast Neoplasms;Cell Line, Tumor;Epidermal Growth Factor;Female;GRB7 Adaptor Protein;Humans;Immunoprecipitation;Mice;Mice, SCID;NIH 3T3 Cells;Phosphorylation;Receptor, Epidermal Growth Factor;Signal Transduction;Trastuzumab;ras Proteins",
        "Doc_meshqualifiers":"therapeutic use;drug therapy;genetics;metabolism;genetics;pharmacology;genetics;metabolism;drug effects;genetics;metabolism;drug effects;genetics;genetics;metabolism",
        "_version_":1605822913840152576},
      {
        "Doc_abstract":"We have investigated the role of t-DARPP in trastuzumab resistance in ERBB2-amplified and overexpressed breast cancer cell lines.;We have used the HR-5 and HR-6 trastuzumab-resistant cells that were established from tumors that recurred in the presence of trastuzumab therapy following xenografts of BT-474 cells in nude mice. In addition, SKBR-3 cells, engineered for stable expression of t-DARPP, and HCC-1569 cells, which have constitutive expression of t-DARPP and are de novo resistant to trastuzumab, were used.;We reported > or =15-fold up-regulation of mRNA and protein levels of t-DARPP in HR-5 and HR-6 cells compared with their progenitor BT-474 trastuzumab-sensitive cells. The t-DARPP expression was not regulated by changes in its promoter DNA methylation levels. The SKBR-3 cells stably expressing t-DARPP developed resistance to trastuzumab compared with their parental cells and empty vector controls (P < 0.01). The trastuzumab-resistant cell lines showed a significant increase in pAKT (Ser(473)) and BCL2 protein levels. The small interfering RNA knockdown of t-DARPP in all trastuzumab-resistant cells led to a significant reduction in ERBB2, pAKT (Ser(473)), and BCL2 protein levels with a significant decrease in cell viability (P < or = 0.001) and an increase in cleaved caspase-3 levels, indicating the progression of these cells toward apoptosis. The t-DARPP protein was associated with both heat shock protein 90 and ERBB2 forming a potential protein complex. This association may play a role in regulating ERBB2 protein in trastuzumab-resistant cells.;We conclude that t-DARPP is a novel molecular target that can mediate the therapeutic resistance to trastuzumab in breast cancer cells.",
        "Doc_title":"Expression of t-DARPP mediates trastuzumab resistance in breast cancer cells.",
        "Journal":"Clinical cancer research : an official journal of the American Association for Cancer Research",
        "Do_id":"18579663",
        "Doc_ChemicalList":"Antibodies, Monoclonal;Antibodies, Monoclonal, Humanized;Antineoplastic Agents;Dopamine and cAMP-Regulated Phosphoprotein 32;Protein Isoforms;RNA, Small Interfering;ERBB2 protein, human;Receptor, ErbB-2;Trastuzumab",
        "Doc_meshdescriptors":"Animals;Antibodies, Monoclonal;Antibodies, Monoclonal, Humanized;Antineoplastic Agents;Apoptosis;Blotting, Western;Breast Neoplasms;Cell Line, Tumor;Dopamine and cAMP-Regulated Phosphoprotein 32;Drug Resistance, Neoplasm;Female;Gene Expression;Humans;Immunoprecipitation;In Situ Nick-End Labeling;Mice;Protein Isoforms;RNA, Small Interfering;Receptor, ErbB-2;Reverse Transcriptase Polymerase Chain Reaction;Trastuzumab;Xenograft Model Antitumor Assays",
        "Doc_meshqualifiers":"therapeutic use;therapeutic use;drug effects;physiology;drug therapy;genetics;metabolism;biosynthesis;physiology;biosynthesis;biosynthesis",
        "_version_":1605754891329863680},
      {
        "Doc_abstract":"Several data support a central role for angiogenesis in breast cancer growth and metastasis. Observational studies have demonstrated that microvascular density (MVD) is a prognostic factor in invasive breast cancer, whereas others reached the opposite conclusion. Vascular endothelial growth factor is the most important angiogenic factor with proven significance in breast cancer, as it has been assessed in both experimental and clinical studies. Triple-negative breast cancer (TNBC) is a type of breast cancer which lacks estrogen, progesterone, and HER-2/neu receptors. MVD in both basal-like and TNBC is significantly higher than in non-basal-like and non-TNBC. In breast cancer and other malignancies, the development of agents that inhibit tumor angiogenesis has been an active area of investigation. In TNBC, clinical trials combining targeted agents and chemotherapy have failed to show substantial survival improvement. There is evidence that patients with TNBC may have a greater probability of obtaining some kind of clinical efficacy benefit from bevacizumab-based therapy.",
        "Doc_title":"Angiogenesis and Antiangiogenesis in Triple-Negative Breast cancer.",
        "Journal":"Translational oncology",
        "Do_id":"27751350",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605880434487459840},
      {
        "Doc_abstract":"Up to 25% of patients diagnosed with breast cancer have tumors that overexpress HER2. HER2-positive breast cancer is highly proliferative, difficult to treat, and confers a poor prognosis. The advent of the anti-HER2 monoclonal antibody trastuzumab (Herceptin) has markedly altered the clinical course of both early and advanced HER2-driven breast cancer. Despite the use of trastuzumab, however, patients with HER2-positive breast cancer still experience disease progression. Overcoming that resistance to therapy is our next challenge. This review examines the current understanding of HER2 biology, the mechanisms of action of and resistance to trastuzumab, as well as new therapies on the horizon.",
        "Doc_title":"Trastuzumab and beyond: New possibilities for the treatment of HER2-positive breast cancer.",
        "Journal":"Oncology (Williston Park, N.Y.)",
        "Do_id":"17263127",
        "Doc_ChemicalList":"Antibodies, Monoclonal;Antibodies, Monoclonal, Humanized;Antineoplastic Agents;Receptor, ErbB-2;Trastuzumab",
        "Doc_meshdescriptors":"Antibodies, Monoclonal;Antibodies, Monoclonal, Humanized;Antineoplastic Agents;Breast Neoplasms;Female;Humans;Receptor, ErbB-2;Trastuzumab;Up-Regulation",
        "Doc_meshqualifiers":"therapeutic use;therapeutic use;drug therapy;immunology;metabolism;antagonists & inhibitors;immunology;metabolism;drug effects",
        "_version_":1605892813689454592},
      {
        "Doc_abstract":"The estrogen receptor (ER) and the human epithelial growth factor receptor 2 (HER2) genes have been implicated in the development and prognosis of breast cancer. Several genetic polymorphic sites in these genes have been identified and associated with the risk of breast cancer. We have investigated the association between the estrogen receptor codon 594 (ACA to ACG) and HER2 codon 655 (ATC to GTC) polymorphisms and breast cancer risk. Genomic DNA from breast cancer patients and control subjects was analyzed by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP). When allelic frequencies of the ER codon 594 and HER2 codon 655 gene were compared, no significant differences were observed between the patient and control groups. (P = 0.063, OR = 1.55, 95% CI = 0.25-9.41 and P = 0.949, OR = 1.01, 95% CI = 0.55-1.88, respectively). In conclusion, our results support the view that both the ER codon 594 and HER2 codon 655 polymorphisms are not associated with increased risk of breast cancer.",
        "Doc_title":"Estrogen receptor codon 594 and HER2 codon 655 polymorphisms and breast cancer risk.",
        "Journal":"Experimental and molecular pathology",
        "Do_id":"15126109",
        "Doc_ChemicalList":"RNA, Messenger;Receptors, Estrogen;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Adult;Breast;Breast Neoplasms;Case-Control Studies;Female;Gene Frequency;Genotype;Humans;Middle Aged;Neoplasm Invasiveness;Neoplasms, Ductal, Lobular, and Medullary;Polymorphism, Genetic;RNA, Messenger;Receptor, ErbB-2;Receptors, Estrogen;Reverse Transcriptase Polymerase Chain Reaction;Risk Factors",
        "Doc_meshqualifiers":"pathology;genetics;genetics;pathology;genetics;genetics;genetics;genetics;genetics",
        "_version_":1605851732066172928},
      {
        "Doc_abstract":"Having previously demonstrated the co-expression status of the Lin28A and androgen receptor (AR) in ER-/Her2+ breast cancer, we tested the hypothesis that Lin28A can activate AR and promotes growth of ER-/Her2+ breast cancer. The expression of Lin28A and AR were examined after Lin28A siRNA and Lin28A plasmid were transfected into ER-/Her2+ breast cancer cells. Chromatin immune-precipitation (ChIP) analysis and Luciferase Assays were used to evaluate the effect of Lin28A and c-myc on AR promoter activity. MTT assays, Boyden chamber invasion assays, colony formation assays and flow cytometry analysis were performed. ER-/Her2+ breast cancer cells which transfected with Lin28A siRNAs and Lin28A plasmid were injected into nude mice, and tumorigenesis was monitored. Our data showed that Lin28A can induced AR expression in ER-/Her2+ breast cancer cells. ChIP analysis showed that Lin28A stimulates the recruitment of c-Myc to the promoter of the AR gene. Lin28A enhanced growth ability, colonies ability, cells proliferation activities, invasive ability and inhibited cells apoptosis of ER-/Her2+ breast cancer cells. Lin28A high expression cells exhibited significantly higher tumorigenic ability in vivo. Our study demonstrates that Lin28A can activates androgen receptor via regulation of c-myc and promotes malignancy of ER-/Her2+ breast cancer. Our findings underline a novel role for Lin28A in breast cancer development and activation of the AR axis.",
        "Doc_title":"Lin28A activates androgen receptor via regulation of c-myc and promotes malignancy of ER-/Her2+ breast cancer.",
        "Journal":"Oncotarget",
        "Do_id":"27494865",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605775026925076480},
      {
        "Doc_abstract":"HJURP (Holliday Junction Recognition Protein) is a newly discovered gene reported to function at centromeres and to interact with CENPA. However its role in tumor development remains largely unknown. The goal of this study was to investigate the clinical significance of HJURP in breast cancer and its correlation with radiotherapeutic outcome.;We measured HJURP expression level in human breast cancer cell lines and primary breast cancers by Western blot and/or by Affymetrix Microarray; and determined its associations with clinical variables using standard statistical methods. Validation was performed with the use of published microarray data. We assessed cell growth and apoptosis of breast cancer cells after radiation using high-content image analysis.;HJURP was expressed at higher level in breast cancer than in normal breast tissue. HJURP mRNA levels were significantly associated with estrogen receptor (ER), progesterone receptor (PR), Scarff-Bloom-Richardson (SBR) grade, age and Ki67 proliferation indices, but not with pathologic stage, ERBB2, tumor size, or lymph node status. Higher HJURP mRNA levels significantly decreased disease-free and overall survival. HJURP mRNA levels predicted the prognosis better than Ki67 proliferation indices. In a multivariate Cox proportional-hazard regression, including clinical variables as covariates, HJURP mRNA levels remained an independent prognostic factor for disease-free and overall survival. In addition HJURP mRNA levels were an independent prognostic factor over molecular subtypes (normal like, luminal, Erbb2 and basal). Poor clinical outcomes among patients with high HJURP expression were validated in five additional breast cancer cohorts. Furthermore, the patients with high HJURP levels were much more sensitive to radiotherapy. In vitro studies in breast cancer cell lines showed that cells with high HJURP levels were more sensitive to radiation treatment and had a higher rate of apoptosis than those with low levels. Knock down of HJURP in human breast cancer cells using shRNA reduced the sensitivity to radiation treatment. HJURP mRNA levels were significantly correlated with CENPA mRNA levels.;HJURP mRNA level is a prognostic factor for disease-free and overall survival in patients with breast cancer and is a predictive biomarker for sensitivity to radiotherapy.",
        "Doc_title":"The expression level of HJURP has an independent prognostic impact and predicts the sensitivity to radiotherapy in breast cancer.",
        "Journal":"Breast cancer research : BCR",
        "Do_id":"20211017",
        "Doc_ChemicalList":"Biomarkers, Tumor;DNA-Binding Proteins;Holliday junction recognizing protein, human;RNA, Messenger",
        "Doc_meshdescriptors":"Biomarkers, Tumor;Blotting, Western;Breast Neoplasms;Cell Line, Tumor;DNA-Binding Proteins;Disease-Free Survival;Female;Gene Expression Profiling;Gene Expression Regulation, Neoplastic;Humans;Oligonucleotide Array Sequence Analysis;Predictive Value of Tests;Prognosis;RNA Interference;RNA, Messenger",
        "Doc_meshqualifiers":"analysis;genetics;pathology;radiotherapy;genetics;metabolism;radiation effects;genetics;metabolism",
        "_version_":1605800473697189888},
      {
        "Doc_abstract":"Triple-negative breast cancer (TNBC) is a subgroup of breast cancers that by definition lack expression of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 (HER2). A diverse group of tumors, TNBC shares some morphologic and molecular features with basal-like breast cancer, a category of breast cancer defined by gene expression profiling. More likely to occur in young women and African Americans, TNBCs may exhibit aggressive behavior and are associated with poor prognosis despite their initial response to conventional chemotherapy. Because hormonal or HER2-targeted therapies are ineffective for these tumors, the main therapeutic option is systemic chemotherapy. Therefore, identification of new targets for therapy is urgently needed for this group.;To review and present recent literature along with our own experience regarding the clinical and morphologic characteristics and the prevalence of androgen receptor (AR) expression in TNBC, and to discuss the potential use of AR as a therapeutic target for AR(+) TNBC.;Data sources are published articles from peer-reviewed journals in PubMed (US National Library of Medicine).;AR is the most commonly expressed hormone receptor among all breast carcinomas, with a prevalence of 25% to 75% among TNBCs. Therefore, we strongly support the routine assessment of AR in TNBC, and preferably in all breast carcinomas.",
        "Doc_title":"A targetable androgen receptor-positive breast cancer subtype hidden among the triple-negative cancers.",
        "Journal":"Archives of pathology & laboratory medicine",
        "Do_id":"25310144",
        "Doc_ChemicalList":"AR protein, human;Biomarkers, Tumor;Receptors, Androgen",
        "Doc_meshdescriptors":"Biomarkers, Tumor;Breast Neoplasms;Female;Humans;Receptors, Androgen;Triple Negative Breast Neoplasms",
        "Doc_meshqualifiers":"genetics;metabolism;pathology;therapy;genetics;metabolism;pathology;therapy",
        "_version_":1605909671474888704},
      {
        "Doc_abstract":"Breast cancer is comprised of a number of complex and heterogeneous subtypes with differing clinical behavior and outcomes. In recent years, significant advances have been made in discerning the molecular drivers of this disease, and characterizing distinct subtypes of breast cancer based on gene expression profiles. These advances have begun to translate into greater individualization of treatment for patients. Although these advances have shaped our understanding of the underlying biology of breast cancer, most clinical decisions are currently based on tumor expression of the estrogen receptor (ER), progesterone receptor (PR) and the human epidermal growth factor receptor 2 (HER2). These biomarkers have prognostic and predictive significance in breast cancer and have important implications for tumor growth and metastatic patterns. In this review, we focus on the three broad phenotypes of breast cancer used in clinical practice; ER/PR positive, HER2 positive and triple negative breast cancer (TNBC), which is characterized by lack of expression of ER, PR and HER2. We discuss the influence of these tumor-related factors as well as histological subtype, on the potential for breast cancer recurrence and patterns of disease spread. ",
        "Doc_title":"Biological subtypes of breast cancer: current concepts and implications for recurrence patterns.",
        "Journal":"The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of...",
        "Do_id":"24322788",
        "Doc_ChemicalList":"Biomarkers, Tumor;Receptors, Estrogen;Receptors, Progesterone;ERBB2 protein, human;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Biomarkers, Tumor;Breast Neoplasms;Evidence-Based Medicine;Female;Humans;Neoplasm Recurrence, Local;Prevalence;Prognosis;Receptor, ErbB-2;Receptors, Estrogen;Receptors, Progesterone;Risk Factors;Survival Analysis",
        "Doc_meshqualifiers":"metabolism;diagnosis;metabolism;mortality;diagnosis;metabolism;mortality;metabolism;metabolism;metabolism",
        "_version_":1605798151012220928},
      {
        "Doc_abstract":"Mitogen-activated protein kinase phosphatase 1 (MKP1 or DUSP1) is an antiapoptotic phosphatase that is overexpressed in many cancers, including breast cancer. MKP1 expression is inducible in radiation-treated breast cancer cells, and correlates with human epidermal growth factor receptor 2 (ERBB2, HER2) expression. The role of MKP1 in therapy resistance suggests that targeting MKP1 in HER2-positive breast tumors may significantly enhance the efficacy of anti-HER2 and other anticancer therapies. ",
        "Doc_title":"MKP1 mediates resistance to therapy in HER2-positive breast tumors.",
        "Journal":"Molecular & cellular oncology",
        "Do_id":"27308517",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605880864655278080},
      {
        "Doc_abstract":"Trastuzumab (Herceptin) is the first clinically available oncogene-targeted therapy to produce a significant survival advantage in advanced breast cancer. This monoclonal humanized antibody is indicated as a single-agent second-line or third-line treatment or in combination with paclitaxel for metastatic breast cancer with HER2 gene amplification or high overexpression of HER2 (3+ on immunohistochemistry). Assessment with regular monitoring of the left-ventricular function during therapy is necessary to detect and manage potential cardiac dysfunction. International randomized trials in the adjuvant setting are ongoing.",
        "Doc_title":"[Indications for Herceptin in breast cancer treatment].",
        "Journal":"Gynecologie, obstetrique & fertilite",
        "Do_id":"15123142",
        "Doc_ChemicalList":"Antibodies, Monoclonal;Antibodies, Monoclonal, Humanized;Antineoplastic Agents;Trastuzumab",
        "Doc_meshdescriptors":"Antibodies, Monoclonal;Antibodies, Monoclonal, Humanized;Antineoplastic Agents;Breast Neoplasms;Female;Humans;Survival Rate;Trastuzumab;Treatment Outcome",
        "Doc_meshqualifiers":"adverse effects;pharmacokinetics;therapeutic use;adverse effects;pharmacokinetics;therapeutic use;drug therapy;mortality;pathology",
        "_version_":1605913612380012544},
      {
        "Doc_abstract":"Alterations of c-erbB-2 (neu or HER-2) proto-oncogene have been associated with carcinogenesis and poor prognosis of breast cancer. A single nucleotide polymorphism (SNP) at codon 655 resulting in a G to A transition (Ile655Val) in the transmembrane domain-coding region of this gene has been associated with an increased risk of breast cancer. This study aims to determine the prevalence of the HER-2 genotype and its association with breast cancer in the Greek Christian and Greek Muslim population of Thrace, Greece. In this case-control study, we genotyped 56 patients (43 Christians and 13 Muslims) with primary breast cancer and 45 healthy women (32 Christians and 13 Muslims) for the Ile655Val polymorphism, with the PCR-RFLP method. The Val allele and the Val-containing genotypes were significantly more frequent in Muslims than in Christians (p=0.020 and p=0.008, respectively). Among the Greek Christian population, a 5-fold and a 3.1-fold increase in risk of breast cancer was associated with the Val-Val genotype and the Ile-Val or Val-Val genotypes (95% CI, 1.3-18.4; p=0.017 and aOR, 3.1; 95% CI, 1.2-8.3; p=0.025; respectively) compared to homozygous Ile-Ile. No significant association was found in the Muslim population. Among the entire cohort, the Val allele confers a modest increase in breast cancer risk (OR, 2.6; 95% CI, 0.9-7.6; p=0.076, for Val-Val and OR, 2.2; 95% CI, 0.9-5.2; p=0.079 for Ile-Val or Val-Val). This effect was even more pronounced in younger women. Among breast cancer patients, invasive carcinomas, low differentiation tumors, advanced stages, positive lymph nodes, high number of lymph nodes and HER-2 overexpression were more frequent in patients with allele Val than those with allele Ile. Our study proposes the allelic imbalance of Ile655Val polymorphism between Greek Christian and Greek Muslim populations of Thrace contributes to the inconsistent association between this SNP and breast cancer risk across these two different ethnic groups. The association of the HER-2 genotype with clinicopathologic characteristics and HER-2 expression may indicate its possible implication on the more aggressive phenotype.",
        "Doc_title":"Allelic imbalance of HER-2 codon 655 polymorphism among different religious/ethnic populations of northern Greece and its association with the development and the malignant phenotype of breast cancer.",
        "Journal":"Neoplasma",
        "Do_id":"17918664",
        "Doc_ChemicalList":"Codon;ERBB2 protein, human;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Adult;Aged;Allelic Imbalance;Breast Neoplasms;Christianity;Codon;Ethnic Groups;Female;Greece;Humans;Islam;Menopause;Middle Aged;Phenotype;Polymorphism, Single Nucleotide;Receptor, ErbB-2",
        "Doc_meshqualifiers":"genetics;pathology;genetics;genetics",
        "_version_":1605747016828190720},
      {
        "Doc_abstract":"Cyclooxygenase (COX)-2 is overexpressed in breast cancer and may have a role in regulating tumor growth via effects on angiogenesis, cell proliferation, or apoptosis. This study aimed to derive data from human breast carcinomas to help substantiate or refute these relationships.;We performed immunohistochemical analysis of a set of 86 breast tumors for COX-2, estrogen receptor (ER), progesterone receptor (PGR), HER-2, Ki67 (a marker of proliferation), and CD31 (an endothelial cell marker of angiogenesis).;COX-2 protein expression was detected in 79% of all tumors studied, ER was detected in 79% of all tumors studied, PGR was detected in 73% of all tumors studied, and HER-2 was detected in 16% of all tumors studied. COX-2 protein expression did not significantly correlate with tumor size, grade, axillary lymph node status, or the presence of vascular invasion. A significant negative correlation (P < 0.001) was observed between ER and Ki67. COX-2 expression showed a significant linear correlation with CD31 staining (P < 0.001). No significant correlations were observed between COX-2 and ER, PGR, or HER-2.;This study demonstrates a novel relationship between COX-2 expression and the neovasculature of human breast adenocarcinomas. If this is a functional relationship, it provides support for a potential therapeutic role of COX-2 inhibitors in human breast cancer tissue via their antiangiogenic properties.",
        "Doc_title":"Correlation between cyclooxygenase-2 expression and angiogenesis in human breast cancer.",
        "Journal":"Clinical cancer research : an official journal of the American Association for Cancer Research",
        "Do_id":"12855643",
        "Doc_ChemicalList":"Antigens, CD31;Isoenzymes;Ki-67 Antigen;Membrane Proteins;Receptors, Estrogen;Receptors, Progesterone;Cyclooxygenase 2;PTGS2 protein, human;Prostaglandin-Endoperoxide Synthases;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Adult;Aged;Antigens, CD31;Apoptosis;Breast Neoplasms;Cell Division;Cell Line, Tumor;Cyclooxygenase 2;Gene Expression Regulation, Enzymologic;Humans;Immunohistochemistry;In Situ Hybridization, Fluorescence;Isoenzymes;Ki-67 Antigen;Lymphatic Metastasis;Membrane Proteins;Middle Aged;Neovascularization, Pathologic;Prostaglandin-Endoperoxide Synthases;Receptor, ErbB-2;Receptors, Estrogen;Receptors, Progesterone",
        "Doc_meshqualifiers":"biosynthesis;enzymology;biosynthesis;biosynthesis;biosynthesis;biosynthesis;biosynthesis;biosynthesis",
        "_version_":1605831527051034624},
      {
        "Doc_abstract":"MammaTyper is a novel CE-marked in vitro diagnostic RT-qPCR assay which assigns routinely processed breast cancer specimens into the molecular subtypes Luminal A-like, Luminal B-like (HER2 positive or negative), HER2 positive (non-luminal) and Triple negative (ductal) according to the mRNA expression of ERBB2, ESR1, PGR and MKI67 and the St Gallen consensus surrogate clinical definition. Until now and regarding formalin-fixed, paraffin-embedded material (FFPE), this has been a task mostly accomplished by immunohistochemistry (IHC). However the discrepancy rates of IHC for the four breast cancer biomarkers are frequently under debate, especially for Ki-67 which carries the highest degree of inter- and even intra-observer variability. Herein we describe a series of studies in FFPE specimens which aim to fully validate the analytical performance of the MammaTyper assay, including the site to site reproducibility of the individual marker measurements.;Tumor RNA was extracted with the novel RNXtract RNA extraction kit. Synthetic RNA was used to assess the sensitivity of the RNXtract kit. DNA and RNA specific qPCR assays were used so as to determine analyte specificity of RNXtract. For the assessment of limit of blank, limit of detection, analytical measurement range and PCR efficiency of the MammaTyper kit serial dilutions of samples were used. Analytical precision studies of MammaTyper were built around two different real time PCR platforms and involved breast tumor samples belonging to different subtypes analyzed across multiple sites and under various stipulated conditions. The MammaTyper assay robustness was tested against RNA input variations, alternative extraction methods and tumor cell content.;Individual assays were linear up to at least 32.33 and 33.56 Cqs (quantification cycles) for the two qPCR platforms tested. PCR efficiency ranged from 99 to 109Â %. In qPCR platform 1, estimates for assay specific inter-site standard deviations (SD) were between 0.14 and 0.20 Cqs accompanied by >94Â % concordant single marker assignments for all four markers. In platform 2, the inter-site SD estimates were between 0.40 and 0.66 Cqs while the concordance for single marker assignments was >94Â % for all four markers. The agreement reached between the two qPCR systems located in one site was 100Â % for ERBB2, 96.9Â % for ESR1, 97.2Â % for PGR and 98.6Â % for MKI67. RT-qPCR for individual markers was stable up to a 64-fold dilution for a typical clinical sample. There was no change in assay performance detected at the level of individual markers or subtypes after using different RNA isolation methods. The presence of up to 80Â % of surrounding non-tumor tissue including in situ carcinoma did not affect the assay output. Sixteen out of 20 RNXtract eluates yielded more than 50Â ng/Î¼l of RNA (average RNA output: 233Â ng/Î¼l), whereas DNA contamination per sample was restricted to less than 15Â ng/Î¼l. Median recovery rate of RNA extraction was 91.0Â %.;In this study the performance characteristics of MammaTyper were successfully validated. The various sources of analytical perturbations resulted in negligible variations in individual marker assessments. Therefore, MammaTyper may serve as a technical improvement to current standards for decentralized FFPE-based routine assessment of the commonly used breast cancer biomarkers and for molecular subtyping of breast cancer specimens.",
        "Doc_title":"Technical validation of an RT-qPCR in vitro diagnostic test system for the determination of breast cancer molecular subtypes by quantification of ERBB2, ESR1, PGR and MKI67 mRNA levels from formalin-fixed paraffin-embedded breast tumor specimens.",
        "Journal":"BMC cancer",
        "Do_id":"27389414",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605836733004382208},
      {
        "Doc_abstract":"Neutrophil gelatinase-associated lipocalin (NGAL) is a small, secreted glycoprotein with proposed functions in cell proliferation, survival and morphogenesis. NGAL is expressed in a variety of tumor types including breast carcinomas, but it is not known whether NGAL contributes directly to breast cancer progression. This study examines the relationship between NGAL expression in breast carcinomas and established clinical prognostic markers as well as clinical outcome. Using immunohistochemistry in tissue microarrays containing well characterized tumor samples from 207 breast cancer patients, NGAL was detected in 68 breast carcinomas in a cytoplasmic location. NGAL expression correlated strongly with negative steroid receptor status, HER-2/neu overexpression, poor histologic grade, the presence of lymph node metastases and a high Ki-67 proliferation index. In univariate survival analysis, NGAL expression was associated with decreased disease-specific survival and decreased disease-free survival in the entire cohort. In multivariate analysis, NGAL remained an independent prognostic marker for disease-free survival. In a subset of patients with estrogen receptor positive tumors, NGAL was significantly associated with decreased disease-free survival. The results show that NGAL expression is a predictor of poor prognosis in primary human breast cancer and suggest that NGAL detection may provide information for risk assessment and identify a subset of patients requiring more aggressive adjuvant therapy.",
        "Doc_title":"Neutrophil gelatinase-associated lipocalin (NGAL) is a predictor of poor prognosis in human primary breast cancer.",
        "Journal":"Breast cancer research and treatment",
        "Do_id":"17554627",
        "Doc_ChemicalList":"Acute-Phase Proteins;Biomarkers, Tumor;LCN2 protein, human;Lipocalin-2;Lipocalins;Proto-Oncogene Proteins",
        "Doc_meshdescriptors":"Acute-Phase Proteins;Biomarkers, Tumor;Breast Neoplasms;Disease-Free Survival;Female;Humans;Immunohistochemistry;Kaplan-Meier Estimate;Lipocalin-2;Lipocalins;Middle Aged;Prognosis;Proto-Oncogene Proteins;Tissue Array Analysis",
        "Doc_meshqualifiers":"biosynthesis;analysis;metabolism;mortality;pathology;biosynthesis;biosynthesis",
        "_version_":1605906848185057280},
      {
        "Doc_abstract":"Several recent epidemiologic studies examined the association between breast cancer risk and an inherited, single-nucleotide polymorphism in the HER2 gene, codon 655 G to A, which leads to an amino acid substitution of Ile to Val. Results of previous studies have been mixed, with most studies showing no association but some suggesting an association in younger women or women with a family history of breast cancer.;We conducted an association study of HER2 codon 655 genotype and breast cancer within the Carolina Breast Cancer study, a population-based, case-control study of in situ and invasive breast cancer in African American and white women in North Carolina. A total of 2015 cases and 1808 controls were genotyped.;We observed no overall association between HER2 genotype and breast cancer. However, a modest positive association (OR = 2.3, 95% CI 1.0-5.3) was observed for Val/Val + Ile/Val versus Ile/Ile genotypes in women age 45 or younger with a family history of breast cancer. Val/Val homozygotes were more common among cases with in situ versus invasive disease (P = 0.002). Breast tumors from women with Val/Val genotype were more likely to exhibit HER2 overexpression, but the results were not statistically significant (P = 0.17).;The HER2 codon 655 polymorphism may be one of many low-penetrant genes that make a minor contribution to breast cancer, particularly in subgroups of women. Additional large studies, as well as data pooling, will be needed to estimate the contribution of such genes to breast cancer risk.",
        "Doc_title":"HER2 codon 655 polymorphism and risk of breast cancer in African Americans and whites.",
        "Journal":"Breast cancer research and treatment",
        "Do_id":"12846420",
        "Doc_ChemicalList":"Codon",
        "Doc_meshdescriptors":"Adult;African Continental Ancestry Group;Aged;Breast Neoplasms;Case-Control Studies;Codon;European Continental Ancestry Group;Female;Genes, erbB-2;Genetic Predisposition to Disease;Genotype;Humans;Immunohistochemistry;Middle Aged;Neoplasm Invasiveness;Odds Ratio;Pedigree;Point Mutation;Polymerase Chain Reaction;Polymorphism, Genetic;Risk Factors",
        "Doc_meshqualifiers":"genetics;genetics;pathology;genetics;genetics",
        "_version_":1605805392010412032},
      {
        "Doc_abstract":"Breast cancer subtypes defined by estrogen receptor (ER), progesterone receptor (PR), and HER2 expression are biologically distinct and thus, may have distinct etiologies. In particular, it is plausible that risk factors operating through hormonal mechanisms are differentially related to risk of such tumor subtypes. Using data from the Breast Cancer Surveillance Consortium, we explored associations between reproductive history and three breast cancer subtypes. Data on parity and age at first birth were collected from 743,623 women, 10,896 of whom were subsequently diagnosed with breast cancer. Cases were classified into three subtypes based on tumor maker expression: (1) ER positive (ER+, N = 8,203), (2) ER negative/PR negative/HER2 positive (ER-/PR-/HER2+, N = 288), or (3) ER-, PR-, and HER2-negative (triple-negative, N = 645). Associations with reproductive history, evaluated using Cox regression, differed significantly across tumor subtypes. Nulliparity was most strongly associated with risk of ER+ breast cancer [hazard ratio (HR) = 1.31, 95% confidence interval (CI): 1.23-1.39]; late age at first birth was most strongly associated with risk of ER-/PR-/HER2+ disease (HR = 1.83, 95% CI: 1.31-2.56). Neither parity nor age at first birth was associated with triple-negative breast cancer. In contrast to ER+ and ER-/PR-/HER2+ subtypes, reproductive history does not appear to be a risk factor for triple-negative breast cancer.",
        "Doc_title":"Reproductive history and risk of three breast cancer subtypes defined by three biomarkers.",
        "Journal":"Cancer causes & control : CCC",
        "Do_id":"21184265",
        "Doc_ChemicalList":"Biomarkers;Receptors, Estrogen;Receptors, Progesterone;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Adult;Aged;Aged, 80 and over;Biomarkers;Breast Neoplasms;Female;Humans;Middle Aged;Neoplasm Staging;Parity;Pregnancy;Receptor, ErbB-2;Receptors, Estrogen;Receptors, Progesterone;Reproductive History;Risk Factors",
        "Doc_meshqualifiers":"analysis;metabolism;epidemiology;metabolism;pathology;metabolism;metabolism;metabolism",
        "_version_":1605906429438328832},
      {
        "Doc_abstract":"CXCR4 is a chemokine receptor that has recently been implicated to play a pivotal role in breast cancer growth and metastasis. In animal models, reduction of CXCR4 expression significantly abrogated metastatic disease and prolonged survival. In human breast cancers, CXCR4 overexpression may portend a worse clinical course. Recent data suggest that HER-2 up-regulates CXCR4, but whether this is applicable in the clinical setting is not known. In this study, we evaluated the role of CXCR4 overexpression in breast cancer and determined whether it can serve as a potential marker of tumor recurrence in HER-2 negative tumors.;One hundred three patients with stages I to III breast cancers and 6 benign breast tissues were prospectively accrued and analyzed. Study homogeneity was maintained by standardized treatment, surveillance, and compliance protocols. CXCR4 levels were detected using Western blots and results were quantified against 1 microg of HeLa cells (positive controls). HER-2 expression was evaluated using the Hercep program, (Dako Corp., Carpinteria, CA) with a positive result defined as > or = 2. CXCR4 expression was defined as low (<6.6-fold) or high (> or = 6.6-fold). Primary endpoints were cancer recurrence and death. Statistical analysis performed included Spearman's correlation, independent samples t-test, Kaplan-Meier survival analysis, and log-rank test.;All 103 cancer specimens had CXCR4 overexpression (mean 6.6 +/- 4.7), while none of the 6 benign breast tissues had detectable level of CXCR4. There were 36 HER-2 (+) tumors and 67 HER-2 (-) tumors. There was no statistical significance in mean CXCR4 overexpression between HER-2 (+) [5.6] and HER-2 (-) [6.6] cancers (P = 0.3; independent samples t-test). Recurrences occurred in 18 of 103 patients (17%); 10 occurred in HER-2 (+) tumors, and 8 occurred in HER-2 (-) patients. CXCR4 expression level was not predictive of cancer recurrence (P = 0.80) or overall survival (P = 0.70) in the HER-2 (+) group. However, among HER-2 negative tumors, 7 of 8 recurrences occurred in the high CXCR4 group (P = 0.037). There was no correlation between the degree of CXCR4 overexpression with tumor size (r = 0.13, P = 0.22), nodal status (r = 0.019, P = 0.4), ER/PR status (r = 0.12, P = 0.29), and HER-2 status (r = 0.091, P = 0.36).;CXCR4 overexpression was observed in all 103 breast cancer specimens but was undetectable in benign breast tissues. CXCR4 overexpression does not correlate with tumor size, nodal status, ER/PR status, and HER-2 status. High CXCR4 overexpression had a significant impact on disease-free survival in HER-2 negative breast cancer patients and may help identify a subset of HER-2 negative breast cancers that have a more aggressive biological behavior.",
        "Doc_title":"Elevated levels of chemokine receptor CXCR4 in HER-2 negative breast cancer specimens predict recurrence.",
        "Journal":"The Journal of surgical research",
        "Do_id":"17574038",
        "Doc_ChemicalList":"Receptors, CXCR4;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Breast Neoplasms;Disease Progression;Disease-Free Survival;Female;Gene Expression Regulation, Neoplastic;Humans;Middle Aged;Neoplasm Recurrence, Local;Predictive Value of Tests;Prognosis;Prospective Studies;Receptor, ErbB-2;Receptors, CXCR4;Risk Factors",
        "Doc_meshqualifiers":"genetics;metabolism;pathology;diagnosis;etiology;metabolism;genetics;metabolism;genetics;metabolism",
        "_version_":1605875683227074560},
      {
        "Doc_abstract":"Metabolic syndrome (MS) has been shown to increase the risk of breast cancer. Existing data suggest that the strength of metabolic syndrome-breast cancer link varies by intrinsic molecular subtype, but results from worldwide literature are controversial. Primary endpoint of the study was to assess whether MS is a predictor of specific breast cancer (BC) subtype. Secondary endpoint was to determine whether components of MS can individually increase the risk of specific breast cancer subtype.;Anthropometric and metabolic variables were correlated to breast cancer specific subgroups, retrospectively. Statistical significance was considered when pâ€‰â‰¤â€‰0.05 and 95% CI.;Data analysis suggests that MS per se represents a modifiable risk factor for BC in postmenopausal [OR 6.28 (95% CI 2.79-14.11) pâ€‰<â€‰0.00001]. MS per se prevalence is higher among Luminal breast cancers in postmenopausal [OR 1.37 (95% CI 1.07-2.80) pâ€‰=â€‰0.03]. Body Mass Index (BMI) alone is associated to Luminal A subtype breast cancer risk [OR 1.12 (95% CI 0.96-2.196 pâ€‰=â€‰0.2]. Waist Circumferenceâ€‰>â€‰88Â cm has been shown to be specifically and statistically significant associated to HER-2+ breast cancer subtypes in postmenopausal [OR 2.72 (95% CI 1.69- 10.72) pâ€‰=â€‰0.01], whilst in Luminal B it was only marginally statistical associated [OR 2.21 (95% CI 0.77-2.60) pâ€‰=â€‰0.1]. Insulin resistance showed statistical significant association to HER-2+ and Luminal B tumors [OR 2.11 (95% CI 1.66-6.69) pâ€‰=â€‰0.05] and [OR 2.33 (95% CI 1.2-4.2) pâ€‰=â€‰0.006], respectively. Hence, it has emerged that BMI is weakly associated to Luminal A breast cancers in this case series, whereas visceral obesity and insulin resistance are likely to be linked to more aggressive breast cancer subtypes.;New molecular biomarkers unveiling metabolic syndrome related breast carcinogenesis need to be detected to further stratify breast cancer risk by subtypes.",
        "Doc_title":"Metabolic syndrome-breast cancer link varies by intrinsic molecular subtype.",
        "Journal":"Diabetology & metabolic syndrome",
        "Do_id":"25285159",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605898574079459328},
      {
        "Doc_abstract":"Breast cancer characterized by overexpression of human epidermal growth factor receptor 2 (HER2) has been associated with more aggressive disease progression and a poorer prognosis. Although an improved understanding of breast cancer pathogenesis and the role of HER2 signaling has resulted in significant survival improvements in the past 20 years, resistance to HER2-targeted therapy remains a concern. A number of strategies to prevent or overcome resistance to HER2-targeted therapy in breast cancer are being evaluated. This article provides a comprehensive review of (a) the role of HER2 signaling in breast cancer pathogenesis, (b) potential receptor and downstream therapeutic targets in breast cancer to overcome resistance to HER2-targeted therapy, and (c) clinical trials evaluating agents targeting one or more members of the HER family and/or downstream pathways for the treatment of breast cancer, with a focus on metastatic disease. ",
        "Doc_title":"Human epidermal growth factor receptor family-targeted therapies in the treatment of HER2-overexpressing breast cancer.",
        "Journal":"The oncologist",
        "Do_id":"24436312",
        "Doc_ChemicalList":"Antibodies, Monoclonal, Humanized;Quinazolines;lapatinib;ERBB2 protein, human;Receptor, ErbB-2;Trastuzumab",
        "Doc_meshdescriptors":"Antibodies, Monoclonal, Humanized;Antineoplastic Combined Chemotherapy Protocols;Breast Neoplasms;Clinical Trials, Phase III as Topic;Disease Progression;Drug Resistance, Neoplasm;Female;Humans;Molecular Targeted Therapy;Quinazolines;Randomized Controlled Trials as Topic;Receptor, ErbB-2;Signal Transduction;Trastuzumab",
        "Doc_meshqualifiers":"administration & dosage;administration & dosage;drug therapy;enzymology;administration & dosage;antagonists & inhibitors;biosynthesis",
        "_version_":1605746793378742272},
      {
        "Doc_abstract":"The proteolytic breakdown product corresponding to the extracellular domain (ECD) of the HER-2/neu oncoprotein p185 is found in the circulation of healthy individuals and patients having cancers of epithelial origin. For the current evaluation we sought to determine the analytical performance as well as the clinical utility of the newly developed ADVIA Centaur HER-2/neu assay (Bayer HealthCare LLC, Diagnostics Division, Tarrytown, NY, USA) in monitoring patients with metastatic breast cancer during the course of disease and treatment and to compare the obtained results with those of CA 15-3.;The analytical performance (including precision, normal range, interfering substances, minimum detectable concentration, dilution recovery, spiking recovery and high-dose hook effect) were determined. HER-2/neu and CA 15-3 values were measured in retrospective samples obtained from 59 patients with metastatic breast cancer undergoing treatment over a 6-12 month period. Serial changes in serum HER-2/neu and CA 15-3 were correlated with changes in clinical status on a visit-to-visit basis. For each pair of serial measurements, changes of equal to or greater than, or less than 15% for HER-2/neu and 21% for CA 15-3 were considered to indicate progression or lack of progression, respectively.;The ADVIA Centaur HER-2/neu assay demonstrated within-run imprecision and total imprecision ranging from 3.0-5.6% and from 3.2-5.7%, respectively. The upper limit of normal was 15.2 ng/mL (90% CI: 14.2-17.0 ng/mL). No significant interference (<5%) was seen with bilirubins, hemoglobin, triglycerides and cholesterol or therapeutic drugs commonly present in the sera of breast cancer patients. The minimum detectable concentration (analytical sensitivity) was found to be 0.5 ng/mL. The patient population in the clinical study included breast cancer patients who responded to therapy (stable, partial or complete response) or had disease progression. HER-2/neu levels showed a concordance of 78.1% (82/105 restaging time points) with the clinical course of disease, whereas CA 15-3 levels showed a concordance of 76.2% (80/105 restaging time points). The concordance with clinical status increased to 85.7% (90/105 restaging time points) when both results were used in combination as a series test.;The ADVIA Centaur HER-2/neu assay provides excellent analytical performance for serial testing of serum HER-2/neu levels. The clinical data demonstrate the usefulness of serum HER-2/neu in monitoring metastatic breast cancer patients during treatment. Furthermore, the results indicate that serum HER-2/neu and CA 15-3 may be useful in identifying disease progression or therapeutic response in different subgroups of women with metastatic breast cancer.",
        "Doc_title":"ADVIA Centaur HER-2/neu shows value in monitoring patients with metastatic breast cancer.",
        "Journal":"The International journal of biological markers",
        "Do_id":"15503818",
        "Doc_ChemicalList":"Antibodies;Antineoplastic Agents;Receptor, Epidermal Growth Factor;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Adult;Aged;Aged, 80 and over;Antibodies;Antineoplastic Agents;Breast Neoplasms;Disease Progression;Female;Humans;Immunoassay;Immunotherapy;Middle Aged;Neoplasm Metastasis;Receptor, Epidermal Growth Factor;Receptor, ErbB-2;Retrospective Studies;Sensitivity and Specificity",
        "Doc_meshqualifiers":"blood;immunology;therapeutic use;blood;diagnosis;drug therapy;immunology;blood;blood",
        "_version_":1605806433946828800},
      {
        "Doc_abstract":"It has become apparent that estrogen receptor (ER) -â€Špositive and -â€Šnegative breast lesions are completely distinct diseases. Precursors of low-grade breast cancer are low-grade premalignant lesions, usually ER and progesterone receptor (PR) positive and HER2 negative. On the other hand, precursors of high-grade breast cancer are high-grade premalignant lesions, usually ER and PR negative and HER2 positive. Lobular neoplasia (LN) and ductal carcinoma in situ (DCIS) are important from the clinical point of view. LN increases the risk of bilateral breast cancer. This is why the recommendation for the treatment of LN is very different -â€Š from just followingâ€Šup up to bilateral mastectomy. The complete surgical excision of the lesion with negative margins is the usual treatment of DCIS. Several big randomized clinical trials showed the benefit of adjuvant radiotherapy (RT). Some of them suppose that there is a group of patients who do not need adjuvant treatment. The benefit of adjuvant tamoxifen is clear only for patients with ER positive disease. The UK/â€ŠANZ study showed the benefit of tamoxifen only in patients without RT.",
        "Doc_title":"[Precursors of breast cancer].",
        "Journal":"Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti",
        "Do_id":"24325156",
        "Doc_ChemicalList":"Antineoplastic Agents;Receptors, Estrogen;Tamoxifen",
        "Doc_meshdescriptors":"Antineoplastic Agents;Breast Neoplasms;Carcinoma, Intraductal, Noninfiltrating;Carcinoma, Lobular;Female;Humans;Mastectomy;Radiotherapy, Adjuvant;Receptors, Estrogen;Tamoxifen",
        "Doc_meshqualifiers":"therapeutic use;diagnosis;therapy;diagnosis;therapy;diagnosis;therapy;metabolism;therapeutic use",
        "_version_":1605751677964517376},
      {
        "Doc_abstract":"HER2, is a member of the ErbB family of receptor tyrosine kinases, that plays a key role in the pathogenesis of breast cancer, and when overexpressed, can correlate with a particularly aggressive clinical phenotype. It is estimated in roughly 18 to 20% of breast cancer patients, there is amplification of the HER2 gene resulting in aberrant overexpression of p185HER2 protein. As such, HER2 represents an attractive therapeutic target. In this review, we explore the clinical evolution of trastuzumab, a humanized monoclonal antibody with high specificity and affinity for the HER2 extracellular domain, and additionally examine more recent efforts targeting the intracellular tyrosine kinase domain of HER2 using small molecule tyrosine kinase inhibitors.",
        "Doc_title":"HER2 targeted therapy in breast cancer...beyond Herceptin.",
        "Journal":"Reviews in endocrine & metabolic disorders",
        "Do_id":"17899385",
        "Doc_ChemicalList":"Antibodies, Monoclonal;Antibodies, Monoclonal, Humanized;Antineoplastic Agents;Quinazolines;lapatinib;ERBB2 protein, human;Receptor, ErbB-2;Trastuzumab",
        "Doc_meshdescriptors":"Antibodies, Monoclonal;Antibodies, Monoclonal, Humanized;Antineoplastic Agents;Breast Neoplasms;Female;Humans;Quinazolines;Receptor, ErbB-2;Trastuzumab",
        "Doc_meshqualifiers":"immunology;therapeutic use;therapeutic use;drug therapy;etiology;therapeutic use;drug effects;immunology;physiology",
        "_version_":1605824021339832320},
      {
        "Doc_abstract":"Ethanol is a tumor promoter and may promote metastasis of breast cancer. However, the underlying cellular/molecular mechanisms remain unknown. Overexpression and high activity of matrix metalloproteinase-2 (MMP-2) are frequently associated with metastatic breast cancers and serve as a prognostic indicator of clinical outcome. MMP-2 is predominantly expressed in stromal fibroblasts and plays a pivotal role in regulating the invasive behavior of breast tumor cells. We hypothesized that ethanol may enhance the invasion of breast tumor cells by modulating the activity of fibroblastic MMP-2. With in vitro models (HS68 and CCD1056SK human fibroblasts), we showed that ethanol at physiologically relevant concentrations (50-200 mg/dl) activated MMP-2; conversely, at a higher concentration (400 mg/dl), it inhibited the MMP-2 activity. Consistently, conditioned medium collected from ethanol (50-200 mg/dl)-exposed fibroblasts markedly enhanced the invasive potential of breast cancer cells and mammary epithelial cells overexpressing ErbB2/HER2 (BT474, SKBR-3 and HB2(ErbB2) cells) but had little effect on cells with low ErbB2 levels (BT20 and HB2 cells). In contrast, conditioned medium obtained from ethanol (400 mg/dl)-treated fibroblasts inhibited cell invasion. Selective inhibitors of MMP-2 (SB-3CT and OA-Hy) eliminated ethanol-stimulated invasion, indicating that the effect of ethanol was mediated by MMP-2. Ethanol activated conventional PKCs and JNKs in fibroblasts; inhibitors of PKC (Go6850 and Go6976) and JNKs (SP600125) significantly inhibited ethanol-mediated MMP-2 activation as well as cell invasion, indicating that PKCs and JNKs play a role in ethanol-induced MMP-2 activation and cell invasion in vitro. Thus, ethanol-promoted breast cancer cell invasion may be mediated by the modulation of fibroblastic MMP-2.",
        "Doc_title":"Ethanol-induced in vitro invasion of breast cancer cells: the contribution of MMP-2 by fibroblasts.",
        "Journal":"International journal of cancer",
        "Do_id":"15386367",
        "Doc_ChemicalList":"Central Nervous System Depressants;Ethanol;Matrix Metalloproteinase 2",
        "Doc_meshdescriptors":"Biological Assay;Breast Neoplasms;Central Nervous System Depressants;Dose-Response Relationship, Drug;Ethanol;Female;Fibroblasts;Humans;Matrix Metalloproteinase 2;Neoplasm Invasiveness;Tumor Cells, Cultured",
        "Doc_meshqualifiers":"pathology;pharmacology;pharmacology;physiology;biosynthesis;pharmacology;physiopathology",
        "_version_":1605802631314276352},
      {
        "Doc_abstract":"Detection of cytokeratin-19 (CK19) expression as an epithelial-specific marker in circulating tumor cells (CTCs) of breast cancer patients can be important for diagnostic purposes. Comparison of CK19 expression in breast cancer cell lines can indicate that expression of this marker is different in various breast cancer cell lines based on their category. Thirty-five breast cancer patients were evaluated for detection of CK19 mRNA in their peripheral blood using CK19-specific primers and a nested reverse transcriptase polymerase chain reaction (RT-PCR) technique. CK19 expression levels were detected in MCF7, T47D, SK-BR-3, and MDA-MB-231 cell lines by semiquantitative RT-PCR and Western blot analyses. Statistical analysis of our data indicates that there is no significant difference between CK19 expression and histopathological parameters and some molecular markers, including Ki-67, HER-2, and P53, but there are statistically significant correlations between estrogen receptor (P = 0.040) and progesterone receptor (P = 0.046) with CK19 expression. CK19 expression was detected in MCF7, T47D, and SK-BR-3 cell lines but not in MDA-MB-231 cell line. More studies are needed to determine the relationship between this marker and other markers in the diagnosis and treatment of breast cancer. On the other hand, the study of different markers using breast cancer cell lines as experimental models of breast cancer could have an impact on improving the health outcomes of patients with breast cancer. ",
        "Doc_title":"Assessment of Cytokeratin-19 Gene Expression in Peripheral Blood of Breast Cancer Patients and Breast Cancer Cell Lines.",
        "Journal":"Biomarkers in cancer",
        "Do_id":"27147896",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605843599641018368},
      {
        "Doc_abstract":"Cancer cell lines have been shown to be reliable tools in genetic studies of breast cancer, and the characterization of these lines indicates that they are good models for studying the biological mechanisms underlying this disease. Here, we describe the molecular cytogenetic/genetic characterization of two sister rat mammary tumor cell lines, HH-16 cl.2/1 and HH-16.cl.4, for the first time. Molecular cytogenetic analysis using rat and mouse chromosome paint probes and BAC/PAC clones allowed the characterization of clonal chromosome rearrangements; moreover, this strategy assisted in revealing detected breakpoint regions and complex chromosome rearrangements. This comprehensive cytogenetic analysis revealed an increase in the number of copies of the Mycn and Erbb2 genes in the investigated cell lines. To analyze its possible correlation with expression changes, relative RNA expression was assessed by real-time reverse transcription quantitative PCR and RNA FISH. Erbb2 was found to be overexpressed in HH-16.cl.4, but not in the sister cell line HH-16 cl.2/1, even though these lines share the same initial genetic environment. Moreover, the relative expression of Erbb2 decreased after global genome demethylation in the HH-16.cl.4 cell line. As these cell lines are commercially available and have been used in previous studies, the present detailed characterization improves their value as an in vitro cell model. We believe that the development of appropriate in vitro cell models for breast cancer is of crucial importance for revealing the genetic and cellular pathways underlying this neoplasy and for employing them as experimental tools to assist in the generation of new biotherapies.",
        "Doc_title":"Defining the sister rat mammary tumor cell lines HH-16 cl.2/1 and HH-16.cl.4 as an in vitro cell model for Erbb2.",
        "Journal":"PloS one",
        "Do_id":"22253826",
        "Doc_ChemicalList":"MYCN protein, mouse;N-Myc Proto-Oncogene Protein;Proto-Oncogene Proteins;Receptor, ErbB-2;Azacitidine",
        "Doc_meshdescriptors":"Animals;Azacitidine;Cell Line, Tumor;Cell Shape;Chromosome Breakage;Chromosomes, Artificial, Bacterial;Chromosomes, Mammalian;Clone Cells;Computational Biology;Cytogenetic Analysis;DNA Methylation;Female;Gene Expression Regulation, Neoplastic;Genes, Neoplasm;In Situ Hybridization, Fluorescence;Mammary Neoplasms, Animal;Mice;Models, Biological;N-Myc Proto-Oncogene Protein;Ploidies;Proto-Oncogene Proteins;Rats;Rats, Sprague-Dawley;Receptor, ErbB-2",
        "Doc_meshqualifiers":"pharmacology;drug effects;drug effects;genetics;genetics;drug effects;genetics;drug effects;genetics;genetics;pathology;genetics;metabolism;genetics;metabolism",
        "_version_":1605929011554287616},
      {
        "Doc_abstract":"The aim of this retrospective study was to evaluate the prognostic factors in patients operated for stage IIIC breast carcinoma who had > 10 positive axillary lymph nodes (pN3a).;The medical records of 302 operated N3a breast cancer patients without distant metastasis followed up in 2 medical oncology clinics in Ankara between January 1998 and June 2013 were evaluated retrospectively.;The median age was 50 (21-83) years. The median follow-up time was 43 (5-191) months. The patients were divided into 4 subgroups according to hormone receptor (HR) and human epidermal growth factor receptor 2 (HER2) status. There were 151 (50.0%) patients in the HR+/HER2- group, 80 (26.5%) patients in the HR+/HER2+ group, 42 (13.9%) patients in the HR-/HER2+ group, and 29 (9.6%) patients in the triple negative (TN) group. At the time of analysis, 155 (51.3%) patients had recurrent disease and 117 (38.7%) patients had died. The median disease-free survival (DFS) and overall survival (OS) times were 46.0 and 78.0 months, respectively. Both the DFS and OS in the HR+/HER2- group were longer than in the other groups (log-rank p = 0.034 and p = 0.016, respectively). Menopausal status, progesterone receptor (PgR) status, and lymph node ratio (LNR; defined as the number of positive lymph nodes compared to the total number of removed lymph nodes) were found to be independent prognostic factors (p = 0.019, p = 0.001, and p = 0.012, respectively).;Menopausal status, PgR status, and LNR were independent prognostic factors in operated N3a breast cancer patients, who are underrepresented in breast cancer trials.",
        "Doc_title":"Prognostic Factors in Operated Stage IIIC, Pathological N3a Breast Cancer Patients.",
        "Journal":"Breast care (Basel, Switzerland)",
        "Do_id":"25759625",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605759063000350720},
      {
        "Doc_abstract":"Most breast cancers are hormone receptor positive and exhibit a slow growth pattern. Based on biological properties, breast cancers are divided into four different biological subtypes. Furthermore, these subtypes are indicative of the risk of recurrence, which is also influenced by the size of the tumor and extension to lymph nodes. Postoperative adjuvant drug therapy is chosen on the basis of the biological type. Chemotherapy can be used in all subtypes. Hormonal therapies are used exclusively for the treatment of hormone receptor positive breast cancer. Trastuzumab antibody belongs to the treatment of the HER2 positive subtype.",
        "Doc_title":"[Adjuvant drug therapies for breast cancer].",
        "Journal":"Duodecim; laaketieteellinen aikakauskirja",
        "Do_id":"26245052",
        "Doc_ChemicalList":"Antibodies, Monoclonal, Humanized;Antineoplastic Agents;Trastuzumab",
        "Doc_meshdescriptors":"Antibodies, Monoclonal, Humanized;Antineoplastic Agents;Breast Neoplasms;Chemotherapy, Adjuvant;Female;Humans;Lymphatic Metastasis;Neoplasm Recurrence, Local;Trastuzumab",
        "Doc_meshqualifiers":"therapeutic use;therapeutic use;drug therapy;pathology;drug therapy",
        "_version_":1605754604577882112},
      {
        "Doc_abstract":"Advances in breast cancer control will be greatly aided by early detection so as to diagnose and treat breast cancer in its preinvasive state prior to metastasis. For breast cancer, the second leading cause of cancer-related death among women in the United States, early detection does allow for increased treatment options, including surgical resection, with a corresponding better patient response. Unfortunately, however, many patients' tumors are diagnosed following metastasis, thus making it more difficult to successfully treat the malignancy. There are, at present, no existing validated plasma/serum biomarkers for breast cancer. Only a few biomarkers (such as HER-2/neu, estrogen receptor, and progesterone receptor) have utility for diagnosis and prognosis. Thus, there is a great need for new biomarkers for breast cancer. This paper will focus on the identification of new serum protein biomarkers with utility for the early detection of breast cancer.",
        "Doc_title":"Protein biomarkers for the early detection of breast cancer.",
        "Journal":"International journal of proteomics",
        "Do_id":"22084684",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605812940439552000},
      {
        "Doc_abstract":"Indigenous MÄori women have a 60% higher breast cancer mortality rate compared with European women in New Zealand. We investigated differences in cancer biological characteristics and their impact on breast cancer mortality disparity between MÄori and NZ European women.;Data on 2849 women with primary invasive breast cancers diagnosed between 1999 and 2012 were extracted from the Waikato Breast Cancer Register. Differences in distribution of cancer biological characteristics between MÄori and NZ European women were explored adjusting for age and socioeconomic deprivation in logistic regression models. Impacts of socioeconomic deprivation, stage and cancer biological characteristics on breast cancer mortality disparity between MÄori and NZ European women were explored in Cox regression models.;Compared with NZ European women (n=2304), MÄori women (n=429) had significantly higher rates of advanced and higher grade cancers. MÄori women also had non-significantly higher rates of ER/PR negative and HER-2 positive breast cancers. Higher odds of advanced stage and higher grade remained significant for MÄori after adjusting for age and deprivation. MÄori women had almost a 100% higher age and deprivation adjusted breast cancer mortality hazard compared with NZ European women (HR=1.98, 1.55-2.54). Advanced stage and lower proportion of screen detected cancer in MÄori explained a greater portion of the excess breast cancer mortality (HR reduction from 1.98 to 1.38), while the additional contribution through biological differences were minimal (HR reduction from 1.38 to 1.35).;More advanced cancer stage at diagnosis has the greatest impact while differences in biological characteristics appear to be a minor contributor for inequities in breast cancer mortality between MÄori and NZ European women. Strategies aimed at reducing breast cancer mortality in MÄori should focus on earlier diagnosis, which will likely have a greater impact on reducing breast cancer mortality inequity between MÄori and NZ European women.",
        "Doc_title":"Breast cancer biology and ethnic disparities in breast cancer mortality in new zealand: a cohort study.",
        "Journal":"PloS one",
        "Do_id":"25849101",
        "Doc_ChemicalList":"Biomarkers, Tumor;Receptors, Estrogen;Receptors, Progesterone;ERBB2 protein, human;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Biomarkers, Tumor;Breast Neoplasms;Carcinoma, Ductal, Breast;Carcinoma, Lobular;Cohort Studies;Early Detection of Cancer;Ethnic Groups;Female;Healthcare Disparities;Humans;Immunoenzyme Techniques;Middle Aged;Neoplasm Grading;Neoplasm Invasiveness;Neoplasm Staging;New Zealand;Prognosis;Receptor, ErbB-2;Receptors, Estrogen;Receptors, Progesterone;Registries;Risk Factors;Survival Rate",
        "Doc_meshqualifiers":"metabolism;epidemiology;metabolism;mortality;pathology;epidemiology;metabolism;mortality;pathology;epidemiology;metabolism;mortality;pathology;statistics & numerical data;epidemiology;metabolism;metabolism;metabolism",
        "_version_":1605825911807016960},
      {
        "Doc_abstract":"HER2 plays an important role in breast cancer progression and provides predictive and prognostic information. HER2 receptor family members function through dimerisation, which can lead to impact on cell function, growth and differentiation; however, their value in breast cancer development remains to be defined. This study aims to examine the relationships of HER2 heterodimers to breast cancer characteristics in trastuzumab naÃ¯ve and treated cases. HER2 protein (IHC), HER2 gene (chromogenic ISH) and HER2 heterodimerisation status [chromogenic in situ proximity ligation assay (PLA)] were assessed in two breast cancer series prepared in tissue microarray (TMA) format. A range of signals/cell for each HER2 heterodimer was detected (0-34.6 signals/cell). The vast majority of cases with HER2 heterodimers showed HER2 gene amplification and/or protein expression. There was an association between HER2 dimerisation with HER3 and HER4 and their protein expression level but no such association was found in with HER1 (EGFR). Of the HER2+ cases, 74, 66, and 58 % showed heterodimers with EGFR, HER3 and HER4, respectively. 51 % of HER2+ tumours expressed all three heterodimers whereas 23 % of the cases did not show expression of any of the three heterodimers. There was an inverse association between the presence and levels of HER2 heterodimers and hormone receptor expression in HER2+ tumours. Tumours exhibiting high levels of HER2 heterodimers demonstrated aggressive clinicopathological features and poor outcome. In the HER2+ cases, dimerisation with EGFR and HER3 but not with HER4 showed an association with aggressive features. There was no association between HER2 heterodimers with patient breast cancer-specific survival or recurrence in HER2+ breast cancer in those patients receiving trastuzumab or not. Our results demonstrate that HER2 dimerisation is a complex process that may underlie the biological heterogeneity of HER2 positive tumours and may identify patients suitable for a specific targeted therapy but does not predict patient outcome for those receiving trastuzumab. PLA proved to be a useful tool for detecting, visualising and quantifying the frequency of protein-protein interactions in archival formalin-fixed paraffin-embedded tissue samples.",
        "Doc_title":"Characterisation of HER heterodimers in breast cancer using in situ proximity ligation assay.",
        "Journal":"Breast cancer research and treatment",
        "Do_id":"24557338",
        "Doc_ChemicalList":"Antibodies, Monoclonal, Humanized;ERBB2 protein, human;Receptor, ErbB-2;Trastuzumab",
        "Doc_meshdescriptors":"Adult;Aged;Antibodies, Monoclonal, Humanized;Breast Neoplasms;Female;Humans;Immunohistochemistry;In Situ Hybridization;Middle Aged;Neoplasm Recurrence, Local;Protein Multimerization;Receptor, ErbB-2;Trastuzumab",
        "Doc_meshqualifiers":"therapeutic use;drug therapy;enzymology;genetics;pathology;genetics;metabolism;pathology;genetics;metabolism",
        "_version_":1605883960252956672},
      {
        "Doc_abstract":"Global genomic approaches in cancer research have provided new and innovative strategies for the identification of signatures that differentiate various types of human cancers. Computational analysis of the promoter composition of the genes within these signatures may provide a powerful method for deducing the regulatory transcriptional networks that mediate their collective function. In this study we have systematically analyzed the promoter composition of gene classes derived from previously established genetic signatures that recently have been shown to reliably and reproducibly distinguish five molecular subtypes of breast cancer associated with distinct clinical outcomes. Inferences made from the trends of transcription factor binding site enrichment in the promoters of these gene groups led to the identification of regulatory pathways that implicate discrete transcriptional networks associated with specific molecular subtypes of breast cancer. One of these inferred pathways predicted a role for nuclear factor-kappaB in a novel feed-forward, self-amplifying, autoregulatory module regulated by the ERBB family of growth factor receptors. The existence of this pathway was verified in vivo by chromatin immunoprecipitation and shown to be deregulated in breast cancer cells overexpressing ERBB2. This analysis indicates that approaches of this type can provide unique insights into the differential regulatory molecular programs associated with breast cancer and will aid in identifying specific transcriptional networks and pathways as potential targets for tumor subtype-specific therapeutic intervention.",
        "Doc_title":"Transcriptional networks inferred from molecular signatures of breast cancer.",
        "Journal":"The American journal of pathology",
        "Do_id":"18187569",
        "Doc_ChemicalList":"Biomarkers, Tumor",
        "Doc_meshdescriptors":"Biomarkers, Tumor;Breast Neoplasms;Cell Line, Tumor;Chromatin Immunoprecipitation;Cluster Analysis;Disease Progression;Female;Gene Regulatory Networks;Genes, Neoplasm;Humans;Principal Component Analysis;Promoter Regions, Genetic",
        "Doc_meshqualifiers":"genetics;genetics;genetics;genetics",
        "_version_":1605824858365624320},
      {
        "Doc_abstract":"It is important when treating a patient who has advanced breast cancer to establish the biologic characteristics of the tumor. In addition to knowing the hormone receptor status (estrogen and progesterone), human epidermal receptor 2 (HER2) should be evaluated. The measurement of this parameter is essential to optimizing the systemic management. This article reviews the biology of HER2, testing for HER2, clinical studies evaluating HER2-based therapies, side effects (specifically cardiotoxicity), and strategies for HER2-based therapies.",
        "Doc_title":"HER2-positive advanced breast cancer.",
        "Journal":"Hematology/oncology clinics of North America",
        "Do_id":"17512450",
        "Doc_ChemicalList":"Antibodies, Monoclonal;Antibodies, Monoclonal, Humanized;Antineoplastic Agents;Receptor, ErbB-2;Trastuzumab",
        "Doc_meshdescriptors":"Antibodies, Monoclonal;Antibodies, Monoclonal, Humanized;Antineoplastic Agents;Breast Neoplasms;Clinical Trials as Topic;Female;Humans;Neoplasm Metastasis;Receptor, ErbB-2;Trastuzumab;Treatment Outcome",
        "Doc_meshqualifiers":"administration & dosage;adverse effects;therapeutic use;administration & dosage;adverse effects;therapeutic use;drug therapy;metabolism;pathology;biosynthesis",
        "_version_":1605796666011549696},
      {
        "Doc_abstract":"Trastuzumab is used for breast cancer patients with high expression levels of HER2 (human epidermal growth factor receptor 2)/neu; however, it has no effect on cancers with low levels of HER2/neu. SM (solamargine), a major steroidal alkaloid glycoside purified from Solanum incanum, triggered apoptosis of breast cancer cells (MCF-7 and SK-BR-3 cells) and non-cancerous breast epithelial cells (HBL-100 cells) within 3 h. To extend the application of trastuzumab in breast cancer patients, the regulation of HER2/neu expression by SM was investigated. SM significantly up-regulates HER2/neu expression in breast cancer cells with low and high expression levels of HER2/neu, and synergistically enhanced the effect of trastuzumab in inhibiting cell proliferation. Additionally, HER2/neu and TOP2A [TopoII (topoisomerase II) alpha] genes share the same amplicon on an identical chromosome. Notably, SM co-regulates HER2/neu and TopoIIalpha expression markedly, and enhances TopoII inhibitor-EPI (epirubicin)-induced cytotoxicity to breast cancer cells.",
        "Doc_title":"Solamargine induces apoptosis and enhances susceptibility to trastuzumab and epirubicin in breast cancer cells with low or high expression levels of HER2/neu.",
        "Journal":"Bioscience reports",
        "Do_id":"18699774",
        "Doc_ChemicalList":"Antibodies, Monoclonal;Antibodies, Monoclonal, Humanized;Antineoplastic Agents;Drug Combinations;Solanaceous Alkaloids;beta-solamarine;Epirubicin;Trastuzumab",
        "Doc_meshdescriptors":"Antibodies, Monoclonal;Antibodies, Monoclonal, Humanized;Antineoplastic Agents;Apoptosis;Breast Neoplasms;Cell Line;Cell Line, Tumor;Cell Proliferation;Drug Combinations;Epirubicin;Female;Gene Expression Regulation, Neoplastic;Genes, erbB-2;Humans;Solanaceous Alkaloids;Trastuzumab",
        "Doc_meshqualifiers":"pharmacology;pharmacology;drug effects;drug therapy;drug effects;pharmacology;drug effects;pharmacology",
        "_version_":1605896561523425280},
      {
        "Doc_abstract":"Breast cancer is the most common cancer and the most frequent cause of cancer death among women worldwide. Breast cancer is a complex, heterogeneous disease classified into hormone-receptor-positive, human epidermal growth factor receptor-2 overexpressing (HER2+) and triple-negative breast cancer (TNBC) based on histological features. Endocrine therapy, the mainstay of treatment for hormone-responsive breast cancer involves use of selective estrogen receptor modulators (SERMs), selective estrogen receptor downregulators (SERDs) and aromatase inhibitors (AIs). Agents that target estrogen receptor (ER) and HER2 such as tamoxifen and trastuzumab have been the most extensively used therapeutics for breast cancer. Crosstalk between ER and other signalling networks as well as epigenetic mechanisms have been envisaged to contribute to endocrine therapy resistance. TNBC, a complex, heterogeneous, aggressive form of breast cancer in which the cells do not express ER, progesterone receptor or HER2 is refractory to therapy. Several molecular targets are being explored to target TNBC including androgen receptor, epidermal growth factor receptor (EGFR), poly(ADP-ribose) polymerase (PARP), and vascular endothelial growth factor (VEGF). Receptors, protein tyrosine kinases, phosphatases, proteases, PI3K/Akt signalling pathway, microRNAs (miRs) and long noncoding RNAs (lnRNAs) are potential therapeutic targets. miR-based therapeutic approaches include inhibition of oncomiRs by antisense oligonucleotides, restoration of tumour suppressors using miR mimics, and chemical modification of miRs. The lnRNA HOTAIR, a new player in tumour development and prognosis may have theranostic applications in breast cancer. Integration of nucleic acid sequencing studies with mass spectrometry-based peptide sequencing and posttranslational modifications will provide a more comprehensive understanding of the pathophysiology of breast cancer and help in evolving therapeutic strategies.",
        "Doc_title":"Breast Cancer: Current Molecular Therapeutic Targets and New Players.",
        "Journal":"Anti-cancer agents in medicinal chemistry",
        "Do_id":"27137076",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605746346243915776},
      {
        "Doc_abstract":"The study aimed to investigate the influence of some generally recognized risk factors for hormone receptor (HR)- and human epidermal growth factor receptor 2 (HER2)-defined breast cancer among Slovenian postmenopausal women.;Eligible women diagnosed with breast cancer were compared with 709 controls of the same age and ethnicity. Immunohistochemistry and FISH analyses were used to classify cases into molecular subtypes: 454 HR(+), 106 HR(-), 81 HER2(+) and 603 HER2(-). Adjusted odds ratios and 95% confidence intervals were estimated using multivariate logistic regression analysis.;Overweight and obese women were at increased risk of HR(+), HER2(-) and of HR(+), HR(-), HER2(-) tumors, respectively. Women who started menstruating at the age of 11 years or earlier were at decreased risk of ER(-)PR(-) tumors. Users of hormone replacement therapy (HRT) were negatively associated with HR(+) and HER2(-) tumors. The inverse effect was most pronounced with the use of estrogen-only HRT, and longer duration of HRT use did not result in a significant change in risk. In contrast, combined HRT decreased the risk of HER2(+) tumors. Having a first-degree relative with breast and/or ovarian cancer increased the risk of HR(+) and HER2(-) tumors.;We conclude that certain breast cancer risk factors may vary by molecular subtypes. According to our results, HRT use may have a greater influence on HR (+) and HER2(-) breast cancers and the risk of HER2-defined breast cancer may differ with respect to the regimen of HRT.",
        "Doc_title":"Risk factors for HR- and HER2-defined breast cancer in Slovenian postmenopausal women.",
        "Journal":"Climacteric : the journal of the International Menopause Society",
        "Do_id":"22132797",
        "Doc_ChemicalList":"Receptors, Estrogen;Receptors, Progesterone;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Age Factors;Aged;Breast Neoplasms;Confidence Intervals;Estrogen Replacement Therapy;Female;Humans;Immunohistochemistry;In Situ Hybridization, Fluorescence;Menarche;Middle Aged;Obesity;Odds Ratio;Organs at Risk;Ovarian Neoplasms;Receptor, ErbB-2;Receptors, Estrogen;Receptors, Progesterone;Risk Factors;Slovenia;Time",
        "Doc_meshqualifiers":"diagnosis;epidemiology;metabolism;adverse effects;methods;statistics & numerical data;epidemiology;diagnosis;epidemiology;metabolism;metabolism;metabolism;metabolism;epidemiology",
        "_version_":1605762864093593600},
      {
        "Doc_abstract":"In a phase 3 randomized, multicenter, double-blind, placebo-controlled study, first-line therapy with lapatinib plus paclitaxel significantly improved clinical outcomes based on a pre-planned analysis of ErbB2+ metastatic breast cancer patients (GSK Study #EGF30001; ClinicalTrials.gov identifier: NCT00075270). Patients with ErbB2- or untested did not significantly benefit. This article focuses on the quality of life (QOL) and quality-adjusted survival outcomes (Q-TWiST) in the study.;QOL was assessed using the Functional Assessment of Cancer Therapy-Breast (FACT-B). Changes from baseline were analyzed using ANCOVAs, repeated measures and pattern mixture modeling. The Q-TWiST method was used to examine the trade-off between toxicities and delayed progression.;The study included 579 subjects, of whom 86 were ErbB2+. In the ITT population, no significant differences in QOL or Q-TWiST scores were observed. In the ErbB2+ subgroup, the lapatinib plus paclitaxel (L + P) arm demonstrated stable FACT-B scores over the first year, while average scores for patients on P + placebo (P + pla) monotherapy decreased (change from baseline: L + P, p = 0.99; P + pla, p = 0.01). Clinically meaningful differences were observed between treatment arms on the FACT-B, Trial Outcome Index and breast cancer subscale scores. Pattern mixture models suggested more QOL differentiation between treatments among patients who progressed or withdrew early. Q-TWiST differences between the arms in the ErbB2+ subgroup ranged from 2 to 15 weeks with an L + P advantage across all utility weight combinations.;In the ITT population, results provide no evidence of QOL differences between treatment groups. In a small, prospectively-defined subgroup of ErbB2+ patients, L + P resulted in more stable QOL and more quality-adjusted survival than paclitaxel monotherapy, representing clinically important differences between treatments.",
        "Doc_title":"Quality-of-life and quality-adjusted survival (Q-TWiST) in patients receiving lapatinib in combination with paclitaxel as first-line treatment for metastatic breast cancer.",
        "Journal":"Current medical research and opinion",
        "Do_id":"20095796",
        "Doc_ChemicalList":"Quinazolines;lapatinib;Receptor, ErbB-2;Paclitaxel",
        "Doc_meshdescriptors":"Antineoplastic Combined Chemotherapy Protocols;Breast Neoplasms;Disease-Free Survival;Female;Health Status;Humans;Neoplasm Metastasis;Paclitaxel;Quality of Life;Quinazolines;Receptor, ErbB-2",
        "Doc_meshqualifiers":"adverse effects;therapeutic use;drug therapy;pathology;administration & dosage;adverse effects;administration & dosage;adverse effects",
        "_version_":1605839102700158976},
      {
        "Doc_abstract":"The aim of this study was to investigate the association between urinary cadmium and clinicopathological characteristics of breast cancer.;The clinicopathological characteristics of 240 patients with breast cancer were obtained and urine specimens were collected from October 2009 to July 2010. The concentration of urinary cadmium was determined by inductively coupled plasma mass spectrometry (ICP-MS). Ï‡(2) test and Wilcoxon rank sum test were used to analyze whether urinary cadmium is associated with clinicopathological characteristics of breast cancer.;The median concentration of urine cadmium of 240 patients was 1.99 Âµg/g (25th percentile, 1.32 Âµg/g; 75th percentile, 2.88 Âµg/g). HER-2 positive rate, regional/distant metastasis rate, and advanced stage rate in patients with the highest tertile of cadmium concentration were significantly higher than those in the patients with second and lowest Cd tertiles (P = 0.042, P = 0.028 and P = 0.017, respectively), and 28.2% vs. 16.5% for HER-2 and 47.2% vs. 32.0% for regional/distant metastasis, respectively. There were still significant associations between urinary cadmium levels and these clinicopathological parameters after being adjusted in age by unconditional logistic regression model, respectively (P < 0.05).;The results of this study suggest that urinary cadmium levels are associated with the HER-2 status, regional/distant metastasis status and stages of breast cancer, respectively. Cadmium may induce highly aggressive breast cancer in humans.",
        "Doc_title":"[Association between urinary cadmium and clinicopathological characteristics of breast cancer].",
        "Journal":"Zhonghua zhong liu za zhi [Chinese journal of oncology]",
        "Do_id":"24314225",
        "Doc_ChemicalList":"Cadmium;ERBB2 protein, human;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Adult;Age Factors;Breast Neoplasms;Cadmium;Female;Humans;Lymphatic Metastasis;Middle Aged;Neoplasm Metastasis;Neoplasm Staging;Receptor, ErbB-2",
        "Doc_meshqualifiers":"metabolism;pathology;urine;urine;metabolism",
        "_version_":1605765312776503296},
      {
        "Doc_abstract":"Serum HER-2/neu concentrations were evaluated in 172 healthy subjects, 176 primary and 55 metastatic breast cancer patients, employing a new automated assay (Bayer Immuno 1 serum HER-2/neu). Using 13 ng/mL as the cutoff, abnormal HER-2/neu serum levels were found in 8% (14/176) of primary and 50.9% (28/55) of metastatic breast cancer patients. Both in primary and metastatic breast cancer a significant relationship was found with the stage of the disease when serum HER-2/neu was considered as a categorized variable (p=0.0003 and p=0.02, respectively), but not when it was taken as a continuous variable (p=0.247 and p=0.146, respectively). Moreover, we evaluated the correlation between Immuno 1 HER-2/neu and Oncogene Research Products ELISA assay in 53 normal subjects, 46 primary and 34 metastatic breast cancer patients. The correlation was relatively good (p<0.0001), although substantial differences could be found in single cases. The Immuno 1 assay was also evaluated for the first time in breast cancer tissue. The method, which showed good performance both in terms of imprecision and linearity, was used to measure HER-2/neu protein in 140 cytosol samples from primary breast cancer tissue and in homogenates from 40 matched cases. The correlation between the two matrixes was very close (p<0.0001). By contrast, no correlation was found between serum and matched cytosol (p=0.101) or homogenate samples (p=0.511).",
        "Doc_title":"Evaluation of HER-2/neu in serum and tissue of primary and metastatic breast cancer patients using an automated enzyme immunoassay.",
        "Journal":"The International journal of biological markers",
        "Do_id":"11820721",
        "Doc_ChemicalList":"Receptor, ErbB-2",
        "Doc_meshdescriptors":"Adult;Aged;Aged, 80 and over;Breast Neoplasms;Enzyme-Linked Immunosorbent Assay;Female;Humans;Middle Aged;Neoplasm Metastasis;Receptor, ErbB-2",
        "Doc_meshqualifiers":"blood;chemistry;pathology;analysis;blood",
        "_version_":1605836761608486912},
      {
        "Doc_abstract":"HER2 overexpression in breast cancer confers increased tumor aggressiveness. Although anti-HER2 therapies have improved patient outcome, resistance ultimately occurs. PARP inhibitors target homologous recombination (HR)-deficient tumors, such as the BRCA-associated breast and ovarian cancers. In this study, we show that HER2+ breast cancers are susceptible to PARP inhibition independent of an HR deficiency. HER2 overexpression in HER2 negative breast cancer cells was sufficient to render cells susceptible to the PARP inhibitors ABT-888 and AZD-2281 both in vitro and in vivo, which was abrogated by HER2 reduction. In addition, ABT-888 significantly inhibited NF-ÎºB (p65/RelA) transcriptional activity in HER2+ but not HER2 negative breast cancer cells. This corresponded with a reduction in phosphorylated p65 and total IKKÎ± levels, with a concomitant increase in IÎºBÎ±. Overexpression of p65 abrogated cellular sensitivity to ABT-888, whereas IÎºBÎ± overexpression reduced cell viability to a similar extent as ABT-888. Therefore, susceptibility of HER2+ breast cancer cells to PARP inhibition may be because of inhibition of NF-ÎºB signaling driven by HER2. Our findings indicate that PARP inhibitors may be a novel therapeutic strategy for sporadic HER2+ breast cancer patients.",
        "Doc_title":"HER2 overexpression renders human breast cancers sensitive to PARP inhibition independently of any defect in homologous recombination DNA repair.",
        "Journal":"Cancer research",
        "Do_id":"22987487",
        "Doc_ChemicalList":"Antineoplastic Agents;Enzyme Inhibitors;Poly(ADP-ribose) Polymerase Inhibitors;ERBB2 protein, human;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Antineoplastic Agents;Breast Neoplasms;Cell Line, Tumor;Drug Resistance, Neoplasm;Enzyme Inhibitors;Female;Fluorescent Antibody Technique;Gene Knockdown Techniques;Humans;Immunoblotting;Poly(ADP-ribose) Polymerase Inhibitors;Receptor, ErbB-2;Recombinational DNA Repair;Signal Transduction;Transfection",
        "Doc_meshqualifiers":"pharmacology;drug therapy;genetics;metabolism;physiology;pharmacology;biosynthesis;genetics;drug effects",
        "_version_":1605812773670879232},
      {
        "Doc_abstract":"Breast cancer is the most common cancer among women. It is estimated that 7% of women who have breast cancer will develop a subsequent second independent breast tumor within 10 years of the first. The status of estrogen (ER), progesterone (PR) and human growth hormone (HER2) receptors, individually and as phenotypic combinations, impacts the clinical course of breast cancer and may impact the course of subsequent primary tumors and patient survival. Our aims were to determine tumor marker phenotype concordance between first and second primary breast cancers (FPBC and SPBC), describe demographic and clinical characteristics, and examine first tumor treatments associated with phenotype concordance. A total of 76,209 cases of female invasive breast cancer were identified in the California Cancer Registry from 1999 to 2004. Of those, 1,407 women who had not undergone a prophylactic mastectomy, had information on the status of three tumor markers, and were diagnosed with an SPBC during the study period were selected. SPBCs were significantly smaller, diagnosed at a higher stage and were node positive. Patients whose FPBC was ER(+)/-/PR(+)/-/HER2- and triple negative (TN) (ER-/PR-/HER2-), often had concordant phenotypes for their SPBC. ER(+)/-/PR(+)/-/HER2+ and HER2-positive (ER-/PR-/HER2+) FPBCs, often had discordant phenotypes for their SPBC. ER(+)/-/PR(+)/-/HER2- SPBCs often lacked HER2 expression and were ER and/or PR positive. Tumor laterality and synchronicity significantly predicted concordance as did having a FPBC whose phenotypes were ER(+)/-/PR(+)/-/HER2+, HER2-positive and TN, while first primary tumor treatment with chemotherapy predicted discordance. The relationship between multiple primary breast cancer phenotype concordance and patient prognosis has yet to be determined. Our results indicate that SPBC surveillance strategies include consideration of FPBC phenotype. Although our results are provocative, they may have been influenced by current criteria used to determine tumor independence.",
        "Doc_title":"Tumor marker phenotype concordance in second primary breast cancer, California, 1999-2004.",
        "Journal":"Breast cancer research and treatment",
        "Do_id":"19629680",
        "Doc_ChemicalList":"Biomarkers, Tumor;Receptors, Estrogen;Receptors, Progesterone;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Adult;Aged;Aged, 80 and over;Biomarkers, Tumor;Breast Neoplasms;California;Female;Humans;Middle Aged;Neoplasm Staging;Neoplasms, Second Primary;Phenotype;Receptor, ErbB-2;Receptors, Estrogen;Receptors, Progesterone;Registries;Retrospective Studies",
        "Doc_meshqualifiers":"analysis;metabolism;pathology;metabolism;pathology;metabolism;metabolism;metabolism",
        "_version_":1605746293412462594},
      {
        "Doc_abstract":"We studied the expression of BRCA1, ERCC1, and RRM1 which play an important role in DNA repair systems in breast cancer. Immunohistochemical staining for EGFR, BRCA1, ERCC1, and RRM1 were performed by using a tissue microarray made from 230 breast cancer patients. Patients were classified into luminal A, luminal B, HER-2, and triple negative breast cancer (TNBC) types according to ER, PR, and HER-2 expression. The expression of ERCC1, RRM1, and BRCA1 were correlated (P < 0.05). The expression level of ERCC1 was the lowest in TNBC type (P = 0.031), ERCC1 negativity was more prominent in TNBC and luminal B groups than luminal A and HER-2 groups (P = 0.013). Cases with EGFR overexpression showed high expression of RRM1 and BRCA1 (P = 0.046, and 0.004, respectively). In conclusion, the expression of ERCC1 is particularly lower in TNBCs than other types of breast cancers.",
        "Doc_title":"The expression of ERCC1, RRM1, and BRCA1 in breast cancer according to the immunohistochemical phenotypes.",
        "Journal":"Journal of Korean medical science",
        "Do_id":"21394302",
        "Doc_ChemicalList":"BRCA1 Protein;Biomarkers, Tumor;DNA-Binding Proteins;RRM1 protein, human;Tumor Suppressor Proteins;Receptor, Epidermal Growth Factor;ERCC1 protein, human;Endonucleases",
        "Doc_meshdescriptors":"Adult;BRCA1 Protein;Biomarkers, Tumor;Breast Neoplasms;DNA Repair;DNA-Binding Proteins;Disease-Free Survival;Endonucleases;Female;Gene Expression;Humans;Immunohistochemistry;Middle Aged;Phenotype;Prognosis;Protein Array Analysis;Receptor, Epidermal Growth Factor;Tumor Suppressor Proteins",
        "Doc_meshqualifiers":"genetics;metabolism;genetics;metabolism;genetics;metabolism;pathology;genetics;metabolism;genetics;metabolism;genetics;metabolism;genetics;metabolism",
        "_version_":1605928411091435520},
      {
        "Doc_abstract":"Response to endocrine therapy in breast cancer correlates with estrogen receptor (ER) and progesterone receptor (PR) status. Generally, hormone receptor-positive (HR+) breast cancers have favorable prognosis. In order to understand the exact clinical characteristics and prognosis of single HR-positive breast cancer (ER + PR- tumors and ER-PR+ tumors), we compared these tumors to double HR+ tumors as well as HR- negative tumors (ER-PR-).;We examined the clinical and biological features of 6,980 women with invasive ductal carcinoma, and these patients were stratified according to ER and PR expression as double HR+ (ER + PR+), single HR+ (ER + PR- and ER-PR+) and double HR-negative (HR-, ER-PR-) tumors.;In this study, 571 (8.2%) cases were single HR+ tumors, of which 90 (1.3%) were ER-PR+ tumors and 481 (6.9%) were ER + PR- tumors. Our multivariate analysis showed that in patients without HER2 overexpression ER + PR- tumors were associated with an increased risk of recurrence and death compared with ER + PR+ tumors, with a hazard ratio of 2.12 for disease-free survival (DFS) and 4.79 for overall survival (OS). In patients without HER2 overexpression ER-PR+ tumors had increased risk of recurrence and death compared with ER + PR+ tumor, with a hazard ratio of 4.19 for DFS and 7.22 for OS. In contrast, in patients with HER2 overexpression, the difference in survival between single HR+ tumors and double HR+ HR- tumors was not statistically significant. In patients without HER2 overexpression the DFS and OS of ER + PR- and ER-PR+ tumors were not significantly different from those of ER-PR- tumors.;We have identified clinically and biologically distinct features of single HR+ tumors (ER-PR+ and ER + PR-) through comparison with both ER + PR+ and ER-PR- tumors. These differences were only significant in HER2- tumors, not in HER2+ tumors. Single HR+ tumors without HER2 overexpression (ER + PR-HER2- or ER-PR + HER2-) were associated with poorer survival than ER + PR + HER2- tumors, and had comparable poor survival to ER-PR-HER2- tumors (triple-negative breast cancer).",
        "Doc_title":"Poor prognosis of single hormone receptor- positive breast cancer: similar outcome as triple-negative breast cancer.",
        "Journal":"BMC cancer",
        "Do_id":"25880075",
        "Doc_ChemicalList":"Biomarkers, Tumor;Receptors, Estrogen;Receptors, Progesterone;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Adult;Aged;Aged, 80 and over;Biomarkers, Tumor;Breast Neoplasms;Female;Follow-Up Studies;Gene Expression;Humans;Middle Aged;Neoplasm Grading;Neoplasm Recurrence, Local;Neoplasm Staging;Prognosis;Receptor, ErbB-2;Receptors, Estrogen;Receptors, Progesterone;Risk Factors;Survival Analysis;Triple Negative Breast Neoplasms;Young Adult",
        "Doc_meshqualifiers":"drug therapy;genetics;metabolism;mortality;pathology;genetics;metabolism;genetics;metabolism;genetics;metabolism;drug therapy;genetics;mortality",
        "_version_":1605909879882514432},
      {
        "Doc_abstract":"The incidence of brain metastases is particularly high in HER2-overexpressing (HER2+) breast cancer. Several hypotheses have been raised trying to explain this peculiar phenomenon, including a better control of extra-cerebral metastases with HER2-targeting agents, but also the own effect of HER2+ tumor cells that may have a marked brain tropism. In this context, the development of prevention strategies is highly relevant. After a brief description of the natural history of HER2+ breast cancer, three different prevention strategies are discussed in this article, including a secondary prevention strategy by systematic screening of brain metastases, and two primary prevention strategies with prophylactic cerebral irradiation and the optimisation of the adjuvant treatment. None of these strategies has been validated to date. A prolonged follow-up is crucial in order to detail the natural history of HER2+ breast cancers and to evaluate the impact of new treatments on the incidence of brain metastases.",
        "Doc_title":"[Prevention strategies for brain metastases from HER2-positive breast cancer].",
        "Journal":"Bulletin du cancer",
        "Do_id":"21540148",
        "Doc_ChemicalList":"Antineoplastic Agents;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Antineoplastic Agents;Brain Neoplasms;Breast Neoplasms;Chemotherapy, Adjuvant;Cranial Irradiation;Female;Humans;Receptor, ErbB-2",
        "Doc_meshqualifiers":"therapeutic use;chemistry;prevention & control;secondary;metabolism;pathology;methods;metabolism",
        "_version_":1605807909659213824},
      {
        "Doc_abstract":"Pin1 is the only known cis-to-trans isomerase that recognizes the phosphorylated pThr/pSer-Pro motifs in many signaling molecules, playing unique roles in the pathogenesis of breast cancer. First, Pin1 is prevalently over-expressed in kinds of breast cancer cell lines and tissues, such as MDA-MB-231 cell, MCF-7 cell, Her2+, ERÎ±+, and basal-like breast cancer subtypes. Second, Pin1 amplifies many oncogenic signaling pathways, inhibits multiple tumor suppressors, promotes the angiogenesis and metastasis of breast cancer cells, and enhances the resistance of breast cancer cells to anti-tumor medicines. Third, inhibiting Pin1 blocks most of these detrimental effects in a great number of breast cancer cell lines. These findings suggest Pin1 as a promising diagnostic biomarker as well as an efficient therapeutic target for breast cancer. It is strongly expected that a Pin1-positive subtype of breast cancers should be extremely concerned and that the therapeutic efficacy of Pin1 inhibitors on breast cancer patients should be evaluated as soon as possible. Nonetheless, Pin1-based therapeutic strategies for breast cancer still deserve some debates. Hence, we give the predictions of several important issues, such as application precondition, side effects, and personalized medication, when Pin1 inhibitors are used in the breast cancer therapy. These proposals are meaningful for the further development of Pin1-based diagnostic and therapeutic strategies in order to conquer breast cancer. ",
        "Doc_title":"Pin1-based diagnostic and therapeutic strategies for breast cancer.",
        "Journal":"Pharmacological research",
        "Do_id":"25553719",
        "Doc_ChemicalList":"Biomarkers;NIMA-Interacting Peptidylprolyl Isomerase;PIN1 protein, human;Peptidylprolyl Isomerase",
        "Doc_meshdescriptors":"Biomarkers;Breast Neoplasms;Female;Humans;NIMA-Interacting Peptidylprolyl Isomerase;Peptidylprolyl Isomerase;Prognosis",
        "Doc_meshqualifiers":"metabolism;diagnosis;drug therapy;metabolism;antagonists & inhibitors;metabolism",
        "_version_":1605742020281761792},
      {
        "Doc_abstract":"The Nottingham prognostic index (NPI) is a widely adopted prognostic tool in breast cancer. The HER-2 oncogene overexpression is also associated with higher risk. The aim of our study is to investigate the correlation between the NPI and HER-2 in breast cancer. Two hundred and five patients with breast cancer managed in the Department of Surgery, University of Hong Kong Medical Centre, at Queen Mary Hospital between January 1995 and December 1997 were studied. This is a retrospective analysis of prospectively collected database. Variables evaluated for the analysis of prognostic significance included tumor size, axillary lymph node status, histological grade, estrogen and progesterone receptor status and HER-2 oncogene expression. NPI was calculated from tumor size, lymph node status and histological grade. In univariate analysis, tumor size, axillary lymph node status, distant metastasis status, HER-2 oncogene overexpression and NPI score were found to be significant variables. Significant poorer overall survival was also observed with higher NPI category and positive HER-2. Only tumor size and NPI category with subdivision by HER-2 status were independent factors in multivariate analysis . The combination of the HER-2 oncogene expression status with the widely adopted NPI provides a reliable way to predict prognosis in breast cancer patients.",
        "Doc_title":"Prognostic contribution of the HER-2 oncogene overexpression to the Nottingham Prognostic Index in breast cancer.",
        "Journal":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie",
        "Do_id":"16828252",
        "Doc_ChemicalList":"Receptor, ErbB-2",
        "Doc_meshdescriptors":"Adult;Aged;Aged, 80 and over;Breast Neoplasms;Carcinoma;Disease-Free Survival;Female;Humans;Middle Aged;Prognosis;Receptor, ErbB-2",
        "Doc_meshqualifiers":"diagnosis;metabolism;diagnosis;metabolism;metabolism",
        "_version_":1605790002523930624},
      {
        "Doc_abstract":"The HER-2/neu oncogene and its p185 receptor protein are indicators of a more aggressive form of breast cancer. HER-2/neu status guides Herceptin therapy, specifically directed to the extracellular domain (ECD) of the HER-2/neu oncoprotein. The HER-2/neu ECD is shed from cancer cells into the circulation and is measurable by immunoassay.;We performed a systematic review of the peer-reviewed literature on circulating ECD with respect to prevalence, prognosis, prediction of response to therapy, and monitoring of breast cancer.;The prevalence of increased ECD in patients with primary breast cancer varied between 0% and 38% (mean, 18.5%), whereas in metastatic disease the range was from 23% to 80% (mean, 43%). Some women with HER-2/neu-negative tumors by tissue testing develop increased ECD concentrations in metastatic disease. Increased ECD has been correlated with indicators of poor prognosis, e.g., overall survival and disease-free survival. Increased ECD predicts a poor response to hormone therapy and some chemotherapy regimens but can predict improved response to combinations of Herceptin and chemotherapy. Many studies support the value of monitoring ECD during breast cancer progression because serial increases precede the appearance of metastases and longitudinal ECD changes parallel the clinical course of disease.;The monitoring of circulating HER-2/neu ECD provides a tool for assessing prognosis, for predicting response to therapy, and for earlier detection of disease progression and timely intervention with appropriate therapy.",
        "Doc_title":"Potential clinical utility of serum HER-2/neu oncoprotein concentrations in patients with breast cancer.",
        "Journal":"Clinical chemistry",
        "Do_id":"14500583",
        "Doc_ChemicalList":"Biomarkers, Tumor;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Biomarkers, Tumor;Breast Neoplasms;Disease Progression;Disease-Free Survival;Female;Humans;Prognosis;Receptor, ErbB-2",
        "Doc_meshqualifiers":"blood;blood;diagnosis;mortality;blood",
        "_version_":1605742062548811777},
      {
        "Doc_abstract":"Despite an obvious central role of p53 in the hallmarks of cancer, TP53 status is not yet used for the management of breast cancer. Recent findings may lead to reconsider the role of p53 in breast cancer. TP53 mutations are the most frequent genetic alterations in breast cancer, observed in 30% of breast carcinomas. Their distribution is highly linked to molecular tumor subtypes found in 26% of luminal tumors (17% of luminal A, 41% of luminal B), in 50% of HER2 amplified tumors, in 69% of molecular apocrine breast carcinomas and in 88% of basal-like carcinomas. The type of mutation is linked to the tumor subtype with higher frequency of base-pair substitutions in luminal tumors, whereas molecular apocrine and basal-like tumors present much higher frequency of complex mutations (deletions/insertions). The timing of TP53 mutation also depends on the tumor subtype, being the first important event in luminal tumors but occurring after PTEN loss in basal-like tumors. Regarding response to cytotoxic chemotherapy, the situation is far from the p53-dependent apoptosis paradigm with subsequent clinical response. We reported that TP53 mutated non inflammatory locally advanced breast carcinomas had a high rate of complete pathological response to dose-dense doxorubicin-cyclophosphamide chemotherapy, while TP53 wild-type (WT) tumors never achieved complete response. Using human breast cancer xenograft models, we suggested that this could be due to the induction of senescence in TP53 WT tumor cells. A recent work confirmed these findings in MMTV-Wnt1 mammary tumors, showing that growth arrest and senescent phenotype, not apoptosis, were induced in TP53 WT tumors following doxorubicin treatment, while lack of arrest in mutant tumors resulted in aberrant mitoses, cell death and a superior clinical response. Furthermore, in ER positive (ER(+)) breast tumors, it has been recently reported that ER represses the p53-mediated apoptotic response induced by DNA damage. Taken together, these data can help to better understand p53-mediated response to doxorubicin-based chemotherapy in breast cancer: in ER(+) TP53 WT breast cancers, ER-induced inhibition of p53 apoptotic response would lead preferentially to tumor cell senescence and subsequent resistance to treatment. Conversely, in ER negative (ER(-)) TP53 mutated breast cancers, accumulation of genetic abnormalities would lead to mitotic catastrophe and subsequent better response. In view of these recent results, p53 impact in breast cancer should be reconsidered. ",
        "Doc_title":"p53 in breast cancer subtypes and new insights into response to chemotherapy.",
        "Journal":"Breast (Edinburgh, Scotland)",
        "Do_id":"24074787",
        "Doc_ChemicalList":"Antineoplastic Agents, Hormonal;TP53 protein, human;Tumor Suppressor Protein p53",
        "Doc_meshdescriptors":"Antineoplastic Agents, Hormonal;Antineoplastic Combined Chemotherapy Protocols;Breast Neoplasms;Female;Gene Expression Regulation, Neoplastic;Humans;Molecular Targeted Therapy;Mutation;Prognosis;Randomized Controlled Trials as Topic;Risk Assessment;Survival Analysis;Treatment Outcome;Tumor Suppressor Protein p53",
        "Doc_meshqualifiers":"therapeutic use;therapeutic use;drug therapy;genetics;mortality;pathology;methods;drug effects;genetics",
        "_version_":1605884380577792000},
      {
        "Doc_abstract":"The HER2 gene is amplified in up to 30% of human breast cancers, leading to overexpression of the HER2 protein on the cell surface. Overexpression of HER2 is associated with a more aggressive cancer and hence a poorer overall survival.;To evaluate the association between clinico-pathological features and HER2 overexpression in breast cancer.;This is a retrospective study conducted in the Department of Surgery, University Malaya Medical Centre. The association between HER2 overexpression, determined by immunohistochemistry, and other clinicopathological factors was evaluated in 996 patients with newly diagnosed breast cancer treated from 2005 to 2007 using univariate and multivariate logistic regression.;HER2 overexpression occurred in 30.3% of patients. On bivariate analysis, HER2 overexpression was inversely related to ER expression (p<0.01) and PR expression (p<0.01). This overexpression was associated with a higher tumour grade, lymphovascular positivity and infiltrating ductal carcinoma subtype. On multivariate analysis, HER2 overexpression was significantly associated with higher tumour grade (p= 0.018, CI 1.25-11.04), PR negativity (p= 0.002, CI 0.30-0.77) and lymphovascular positivity (p= 0.042, CI 1.01-2.12).;HER2 overexpression was observed in 30.3% of Malaysian female breast cancer patients. This group of patients represents a more aggressive subtype of breast cancer with higher tumour grade, PR negativity and lymphovascular positivity. No significant relationship was established between HER2 overexpression and age, race, lymph node, ER, pathology subtype and stage of disease from this study.",
        "Doc_title":"Factors associated with HER2 overexpression in breast cancer: Experience in an Asian developing country.",
        "Journal":"Asian Pacific journal of cancer prevention : APJCP",
        "Do_id":"20104975",
        "Doc_ChemicalList":"Biomarkers, Tumor;Receptors, Estrogen;Receptors, Progesterone;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Adult;Aged;Aged, 80 and over;Asian Continental Ancestry Group;Biomarkers, Tumor;Breast Neoplasms;Carcinoma, Ductal, Breast;Developing Countries;Female;Humans;Immunoenzyme Techniques;Middle Aged;Neoplasm Staging;Prognosis;Receptor, ErbB-2;Receptors, Estrogen;Receptors, Progesterone;Retrospective Studies;Young Adult",
        "Doc_meshqualifiers":"metabolism;metabolism;pathology;metabolism;pathology;metabolism;metabolism;metabolism",
        "_version_":1605901629622583296},
      {
        "Doc_abstract":"Despite the availability of several potent HER2-directed targeted agents, primary and acquired resistance continues to influence patient outcomes in HER2-positive breast cancer. Neratinib is an irreversible pan-HER tyrosine kinase inhibitor in late-phase clinical development.;This review article focuses on neratinib in the treatment of HER2-positive breast cancer - early and metastatic stage - and HER2-mutant breast cancer, with particular emphasis on the pharmacokinetics and pharmacodynamics of the drug.;The phase III ExteNET trial shows that neratinib improves 2-year invasive disease-free survival after trastuzumab-based adjuvant therapy in early-stage HER2-positive breast cancer, and in particular HER2+/HR+ tumors. Survival data are awaited. The investigational role of neratinib in high-risk patients or conversely in de-escalation dual regimens with other anti-HER2 therapies and without chemotherapy are of interest. Phase II trials show that neratinib has efficacy, either as monotherapy or in combination with other chemotherapeutic or endocrine agents, in patients with HER2-positive metastatic breast cancer and in tumors harboring HER2 mutations. The role of neratinib in therapeutic algorithms of HER2-positive patients, as well as delaying CNS events, awaits the results of ongoing trials such as NALA. Diarrhea, the main toxicity of neratinib, can be effectively managed with early loperamide prophylaxis.",
        "Doc_title":"Pharmacodynamics, pharmacokinetics and clinical efficacy of neratinib in HER2-positive breast cancer and breast cancer with HER2 mutations.",
        "Journal":"Expert opinion on drug metabolism & toxicology",
        "Do_id":"27284682",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605801853747986432},
      {
        "Doc_abstract":"To elucidate the clinicopathologic features and their implications on the immunohistochemistry in cases of molecular apocrine breast cancer (MABC).;Immunohistochemical (IHC) staining for estrogen receptor (ER), human epidermal growth factor receptor 2 (HER-2), cytokeratin (CK) 5/6, epidermal growth factor receptor (EGFR), androgen receptor (AR), gamma-glutamyltrasferase 1 (GGT1) and Ki-67 was performed on tissue microarray breast cancer samples from 204 patients. Phenotypes of breast cancer were divided based on the IHC status of ER, AR and GGT1 into the following: luminal type, ER positive and AR and/or GGT1 positive; basal type, ER, AR, and GGT1 negative; non-basal type, ER positive and AR and GGT1 negative; and MABC type, ER negative and AR and/or GGT1 positive.;In our series of patients (n=204), there were 26 cases of MABC. Besides, there were 18, 60, and 100 cases of luminal type, basal type and non-basal type, respectively. The MABC demonstrated apocrine histology and a higher prevalence of HER-2 positivity than other phenotypes. With the basal type, the MABC manifested a more frequent expression of CK5/6 and EGFR and a higher Ki-67 index than other phenotypes (p<0.001). There were no significant differences in patient prognosis between the phenotypes of breast cancer.;MABC are distinguishable from other phenotypes based on the apocrine histology and a higher expression rate of HER-2.",
        "Doc_title":"The clinicopathologic features of molecular apocrine breast cancer.",
        "Journal":"Korean journal of pathology",
        "Do_id":"23109997",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605798281774891008},
      {
        "Doc_abstract":"The triple receptor-negative breast cancer (TNBC) subtype is characterized by the lack of expression of both hormone receptors as well as lack of over-expression and/or lack of gene amplification of human epidermal growth factor receptor 2 (HER2). Approximately 10-15% of breast carcinomas are known to be of the TNBC subtype, which constitutes approximately 80% of all 'basal-like tumours'. Risk factors for TNBC include young age at breast cancer diagnosis, young age at menarche, high parity, lack of breast feeding, high body mass index and African American ethnicity. The majority of BRCA1 tumours are TNBC. TNBC has a worse prognosis and tends to relapse early compared with other subtypes of breast cancer. Conversely, it displays increased chemosensitivity compared with other breast tumour subtypes. Several agents are currently being investigated as potential therapeutic agents for the treatment of women with TNBC including agents targeted against EGFR, anti-angiogenic agents, multityrosine kinase inhibitors and poly (ADP-ribose) polymerase (PARP) inhibitors. This review focuses on the epidemiology of TNBC, its pathological features, natural history and recurrence patterns as well as current and future management options.",
        "Doc_title":"Triple-negative breast cancer: epidemiology and management options.",
        "Journal":"Drugs",
        "Do_id":"21080741",
        "Doc_ChemicalList":"Receptors, Estrogen;Receptors, Progesterone;ERBB2 protein, human;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Brain Neoplasms;Breast Neoplasms;Female;Humans;Neoplasm Recurrence, Local;Prognosis;Receptor, ErbB-2;Receptors, Estrogen;Receptors, Progesterone",
        "Doc_meshqualifiers":"secondary;chemistry;epidemiology;pathology;therapy;analysis;analysis;analysis",
        "_version_":1605742640383393793},
      {
        "Doc_abstract":"The human epidermal growth factor receptor-2 (HER2) is overexpressed/amplified in 20%-30% of human breast tumors and is a marker for a poor prognosis. For these reasons, HER2 has been selected as a therapeutic target for breast cancer treatment. Oncologists can no longer ignore the importance of HER2 status for treatment algorithms in breast cancer. In light of the consequences of HER2 status on treatment selection, further research is warranted to refine and standardize HER2 testing in order to minimize false-negative results and optimize selection of treatment pathways. The anti-HER2 monoclonal antibody (MAb) trastuzumab (Herceptin) has proven valuable in treating HER2-positive, advanced-disease patients. and the availability of this novel biologic agent has important implications for clinical practice. This review describes a set of guidelines based on the current options for treatment of breast cancer. Two important factors have been taken into account in compiling these recommendations: (1) the lack of level I evidence to convincingly demonstrate the value of HER2 as a predictive marker for resistance or sensitivity to chemo- and hormonal therapy, and (2) the recently published pivotal phase II and III trial data proving the efficacy of trastuzumab as a single agent and in combination with chemotherapy in HER2-positive metastatic breast cancer.",
        "Doc_title":"Proposed treatment guidelines for HER2-positive metastatic breast cancer in Europe.",
        "Journal":"Annals of oncology : official journal of the European Society for Medical Oncology",
        "Do_id":"11521728",
        "Doc_ChemicalList":"Antibodies, Monoclonal;Antibodies, Monoclonal, Humanized;Antineoplastic Agents;Biomarkers, Tumor;Receptor, ErbB-2;Trastuzumab",
        "Doc_meshdescriptors":"Antibodies, Monoclonal;Antibodies, Monoclonal, Humanized;Antineoplastic Agents;Biomarkers, Tumor;Breast Neoplasms;Clinical Trials as Topic;Europe;Female;Humans;Practice Guidelines as Topic;Predictive Value of Tests;Prognosis;Receptor, ErbB-2;Risk Factors;Trastuzumab",
        "Doc_meshqualifiers":"therapeutic use;therapeutic use;analysis;chemistry;drug therapy;pathology;analysis",
        "_version_":1605810656601178112},
      {
        "Doc_abstract":"The development of new therapeutic strategies, such as monoclonal antibodies directed against human epidermal growth factor receptor-2 (HER2), has offered new hopes for women with early breast cancer whose tumors overexpress HER2. We retrospectively analyzed the population-based data of Breast Cancer Registry of Palermo in 2004-2006, and selected 1401 invasive breast cancer cases, nonmetastatic at diagnosis, having HER2/neu oncogene expression determined. We have correlated this information to age, tumor stage at diagnosis (TNM), nodal involvement, and receptor status (ER and PgR). Survival analysis was conducted dividing the patients in two different groups according to date of diagnosis: one group diagnosed in 2004 and a second group in 2005-2006. In the 460 cases of 2004, nodal involvement, receptor status, age at diagnosis and TNM maintained a strong predictive value (pâ€‰<â€‰0.0001). In this group of patients, overall survival was significantly different according to the HER2 expression levels (pâ€‰=â€‰0.001). In the second group of patients (941 incident cases in 2005-2006) there was a statistically significant survival difference comparing patients with high levels of HER2 expression treated with trastuzumab versus those untreated (pâ€‰=â€‰0.006). Our data show that elevated levels of HER2 are a negative prognostic factor. In addition, patients overexpressing HER2 show a significant increase of overall survival when treated with trastuzumab.",
        "Doc_title":"Target therapy in HER2-overexpressing breast cancer patients.",
        "Journal":"Omics : a journal of integrative biology",
        "Do_id":"21568729",
        "Doc_ChemicalList":"Antibodies, Monoclonal;Antibodies, Monoclonal, Humanized;Antineoplastic Agents;ERBB2 protein, human;Receptor, ErbB-2;Trastuzumab",
        "Doc_meshdescriptors":"Adult;Aged;Aged, 80 and over;Antibodies, Monoclonal;Antibodies, Monoclonal, Humanized;Antineoplastic Agents;Breast Neoplasms;Female;Humans;Kaplan-Meier Estimate;Middle Aged;Molecular Targeted Therapy;Neoplasm Staging;Prognosis;Receptor, ErbB-2;Retrospective Studies;Trastuzumab",
        "Doc_meshqualifiers":"therapeutic use;therapeutic use;diagnosis;drug therapy;metabolism;mortality;immunology;metabolism",
        "_version_":1605742665086795776},
      {
        "Doc_abstract":"Overexpression of the HER2/neu gene in breast cancer is associated with an increased incidence of metastatic disease and with a poor prognosis. Although passive immunotherapy with the humanized monoclonal antibody trastuzumab (Herceptin) has shown some effect, a vaccine capable of inducing T-cell and humoral immunity could be more effective.;Virus-like replicon particles (VRP) of Venezuelan equine encephalitis virus containing the gene for HER2/neu (VRP-neu) were tested by an active immunotherapeutic approach in tumor prevention models and in a metastasis prevention model.;VRP-neu prevented or significantly inhibited the growth of HER2/neu-expressing murine breast cancer cells injected either into mammary tissue or intravenously. Vaccination with VRP-neu completely prevented tumor formation in and death of MMTV-c-neu transgenic mice, and resulted in high levels of neu-specific CD8+ T lymphocytes and serum IgG.;On the basis of these findings, clinical testing of this vaccine in patients with HER2/neu+ breast cancer is warranted.",
        "Doc_title":"Alphavirus replicon particles containing the gene for HER2/neu inhibit breast cancer growth and tumorigenesis.",
        "Journal":"Breast cancer research : BCR",
        "Do_id":"15642163",
        "Doc_ChemicalList":"Cancer Vaccines",
        "Doc_meshdescriptors":"Animals;Breast Neoplasms;Cancer Vaccines;Cell Transformation, Neoplastic;Encephalitis Virus, Venezuelan Equine;Female;Genes, erbB-2;Genetic Therapy;Genetic Vectors;Immunotherapy;Mammary Neoplasms, Animal;Mice;Mice, Inbred BALB C;Replicon;Tumor Cells, Cultured",
        "Doc_meshqualifiers":"immunology;prevention & control;therapy;immunology;genetics;methods;immunology;prevention & control",
        "_version_":1605820868203642880},
      {
        "Doc_abstract":"Our previous studies show that Î²2-adrenergic receptor (Î²2-AR) is highly expressed in most Her2-overexpressing breast cancers. However, the mechanisms underlying upregulation of the Î²2-AR expression in Her2-overexpressing breast cancer cells are not fully understood. The clinical significance of the Î²2-AR overexpression in breast cancer is unclear.;Human breast cancer cells MCF-7 and MCF-7/Her2 were transfected with the let-7 mimics or inhibitors. The expression of Î²2-AR was analyzed by Western blot. The Î²2-AR status in primary and metastatic sites of breast cancer and the human breast cancer tissue microarrays containing 49 primary tumors and 50 metastatic lymph node tissues was analyzed by immunohistochemistry. The correlation of lymph node metastasis with the Î²2-AR level was determined in 59 primary tumor tissues from the patients with Her2-positive breast cancer. The clinical prognostic significance of the Î²2-AR overexpression in the patients with Her2-positive breast cancers was evaluated by a retrospective study.;The let-7f level in Her2-overexpressing breast cancer cells SKBR3 and BT474 was significantly lower than that in MCF-7 cells, which express low level of Her2. Ectopic expression of Her2 in MCF-7 cells (MCF-7/Her2) represses the expression of microRNA let-7f, which is previously identified to regulate baseline Î²2-AR expression. The treatment with MEK1/2 inhibitors PD98059 or PD184352 effectively restored the let-7f level, suggesting that Her2-overexpression-mediated ERK constitutive activation inhibited let-7f, leading to the upregulation of the Î²2-AR expression. The transfection with the let-7f mimics markedly downregulated the Î²2-AR level, whereas the let-7 inhibitor significantly upregulated the Î²2-AR expression in both parental MCF-7 and MCF-7/Her2 cells. In addition, treatment of MCF-7/Her2 cells with isoproterenol resulted in a concentration-dependent reduction of the let-7f expression, demonstrating that the inhibitory effect of Her2 overexpression on let-7f can be reinforced by agonist-triggered Î²2-AR activation. We further demonstrate that high level of Î²2-AR associates with lymph node metastasis and poor outcome in the patients with Her2-positive breast cancer.;The mutual and reciprocal interaction between Her2, Î²2-AR, and let-7f may maintain a high level of Î²2-AR in breast cancer cells. Our data suggest that Î²2-AR may be a new useful biomarker for predicting prognosis in Her2-positive breast cancer and may also be a promising selective therapeutic target for the aggressive subtype of breast cancer.",
        "Doc_title":"A Her2-let-7-Î²2-AR circuit affects prognosis in patients with Her2-positive breast cancer.",
        "Journal":"BMC cancer",
        "Do_id":"26526356",
        "Doc_ChemicalList":"MicroRNAs;Receptors, Adrenergic, beta-2;mirnlet7 microRNA, human;ERBB2 protein, human;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Breast Neoplasms;Female;Gene Expression Regulation, Neoplastic;Humans;MCF-7 Cells;MicroRNAs;Prognosis;Receptor, ErbB-2;Receptors, Adrenergic, beta-2;Signal Transduction",
        "Doc_meshqualifiers":"genetics;pathology;biosynthesis;genetics;biosynthesis;genetics;biosynthesis;genetics",
        "_version_":1605818618753318912},
      {
        "Doc_abstract":"To investigate the relationship between HER-2 expression and the efficacy of neoadjuvant chemotherapy in local advanced breast cancer.;Different neoadjuvant chemotherapy regimens, namely CMF, CEF, and NEF, were administered in 132 patients with local advanced breast cancer for 2 cycles, each lasting for 28 days. According to the criteria recommended by WHO, the efficacy and safety of the regimens were evaluated after two cycles of neoadjuvant chemotherapy. HER-2 expression was examined by immunohistochemistry using specific monoclonal antibodies before chemotherapy and after surgery.;The overall response rate (RR) of CMF, CEF, and NEF regimens were 39.5% (17/43), 54.3% (25/46) and 72.1% (31/43), with incidence of leukopenia of 34.9% (15/43), 58.7% (27/46) and 60.5% (26/43), respectively. Other adverse effects including decreased hemoglobin (Hb) level, thrombocytopenia, gastrointestinal irritation and alopecia were similar between the 3 groups (P>0.05). No significant variation in HER-2 expression occurred after administration of the 3 regimens. The overall RR to CMF regimen in HER-2-negative breast cancer patients was significantly higher than that in HER-2-positive patients, but showed no significant difference with CEF and NEF regimens.;HER-2 expression is not decreased after neoadjuvant chemotherapy in breast cancer patients, and HER-2-positive breast cancer can be resistant to CMF regimen, but not to CEF and NEF regimens.",
        "Doc_title":"[HER-2 expression in local advanced breast cancer and the efficacy of neoadjuvant chemotherapy regimens].",
        "Journal":"Nan fang yi ke da xue xue bao = Journal of Southern Medical University",
        "Do_id":"17884787",
        "Doc_ChemicalList":"Receptor, ErbB-2",
        "Doc_meshdescriptors":"Adult;Aged;Breast Neoplasms;Drug Resistance, Neoplasm;Female;Gene Expression Regulation, Neoplastic;Humans;Male;Middle Aged;Neoadjuvant Therapy;Receptor, ErbB-2;Treatment Outcome",
        "Doc_meshqualifiers":"drug therapy;genetics;pathology;therapy;drug effects;adverse effects;methods;metabolism",
        "_version_":1605898160952049664},
      {
        "Doc_abstract":"Overexpression of the adverse prognostic marker ERBB2 occurs in 30% of breast cancers and is associated with aggressive disease and poor outcomes. Our recent findings have shown that NR1D1 and the peroxisome proliferator-activated receptor-Î³ (PPARÎ³)-binding protein (PBP) act through a common pathway in upregulating several genes in the de novo fatty acid synthesis network, which is highly active in ERBB2-positive breast cancer cells. NR1D1 and PBP are functionally related to PPARÎ³, a well-established positive regulator of adipogenesis and lipid storage. Here, we report that inhibition of the PPARÎ³ pathway reduces the aldehyde dehydrogenase (ALDH)-positive population in ERBB2-positive breast cancer cells. Results from in vitro tumorsphere formation assays demonstrate that the PPARÎ³ antagonists GW9662 and T0070907 decrease tumorsphere formation in ERBB2-positive cells, but not other breast cells. We show that the mechanism by which GW9662 treatment causes a reduction in ALDH-positive population cells is partially due to ROS, as it can be rescued by treatment with N-acetyl-cysteine. Furthermore, global gene expression analyses show that GW9662 treatment suppresses the expression of several lipogenic genes, including ACLY, MIG12, FASN and NR1D1, and the stem-cell related genes KLF4 and ALDH in BT474 cells. Antagonist treatment also decreases the level of acetylation in histone 3 and histone 4 in BT474 cells, compared with MCF7 cells. In vivo, GW9662 pre-treatment inhibits the tumor-seeding ability of BT474 cells. Together, these results show that the PPARÎ³ pathway is critical for the cancer stem cell properties of ERBB2-positive breast cancer cells. ",
        "Doc_title":"PPARÎ³ maintains ERBB2-positive breast cancer stem cells.",
        "Journal":"Oncogene",
        "Do_id":"23770845",
        "Doc_ChemicalList":"2-chloro-5-nitrobenzanilide;Anilides;Benzamides;Mediator Complex Subunit 1;NR1D1 protein, human;Nuclear Receptor Subfamily 1, Group D, Member 1;PPAR gamma;Pyridines;Reactive Oxygen Species;T 0070907;Aldehyde Dehydrogenase;ERBB2 protein, human;Receptor, ErbB-2;Acetylcysteine",
        "Doc_meshdescriptors":"Acetylcysteine;Aldehyde Dehydrogenase;Anilides;Animals;Benzamides;Breast Neoplasms;Cell Line, Tumor;Female;Humans;MCF-7 Cells;Mediator Complex Subunit 1;Mice;Mice, Inbred NOD;Mice, SCID;Neoplasm Transplantation;Neoplastic Stem Cells;Nuclear Receptor Subfamily 1, Group D, Member 1;PPAR gamma;Pyridines;Reactive Oxygen Species;Receptor, ErbB-2",
        "Doc_meshqualifiers":"pharmacology;metabolism;pharmacology;pharmacology;metabolism;pathology;metabolism;metabolism;pathology;metabolism;antagonists & inhibitors;metabolism;pharmacology;metabolism",
        "_version_":1605839663101116416},
      {
        "Doc_abstract":"Insulin-like growth factor 1 receptor (IGF-1R) is commonly expressed in primary breast cancers. Understanding the role of IGF-1R signaling in the different subtypes of breast cancer is important because each subtype has a different outcome and requires different treatment modalities. However, the precise biological significance of IGF-1R expression in cancer cells is still unclear. In this study, we examined the expression of IGF-1R in the different molecular subtypes of breast cancer. The effects of IGF-1R expression on the survival rates and outcomes of breast cancer were also examined.;IGF-1R expression was evaluated immunohistochemically in tissue microarray blocks constructed from 1,198 invasive breast cancer samples collected from six medical institutions. IGF-1R expression was interpreted according to the human epidermal growth factor receptor 2 (HER2)/neu immunohistochemistry scoring system. Scores of 2+ and 3+ were considered positive.;Positive IGF-1R expression was observed in 65.4% of invasive breast cancer samples. IGF-1R expression was detected in all cancer subtypes (luminal A, 84.4%; luminal B, 75.9%; HER2, 21.2%; triple-negative, 46.6%) and was found to be associated with a positive hormone receptor status and the absence of HER2 amplification (p<0.001). Positive IGF-1R expression was significantly associated with high survival rates (p=0.014). However, a multivariate analysis revealed that the expression levels of IGF-1R did not achieve statistical significance. In the triple-negative cancer subtype, IGF-1R expression was found to be associated with a lower disease-free survival rate (p=0.031).;Positive IGF-1R expression is associated with a favorable prognosis in breast cancer. IGF-1R is frequently expressed in the luminal A/B subtypes of breast cancer, and its expression is related to the hormone receptor status.",
        "Doc_title":"Positive expression of insulin-like growth factor-1 receptor is associated with a positive hormone receptor status and a favorable prognosis in breast cancer.",
        "Journal":"Journal of breast cancer",
        "Do_id":"25013431",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605845187908599808},
      {
        "Doc_abstract":"Associations of reproductive history with breast cancer risk differ by oestrogen receptor (ERÂ±) status and possibly by the joint expression of ER and the human epidermal growth factor receptor-2 (ERÂ±/HER2Â±). However, large sample sizes are needed to establish ER-specific risks by HER2Â± expression.;We linked a cancer registry covering nearly 95% of the primary breast cancer diagnoses in Denmark with a research parity database to assess associations for parity, number of live births and age at first live birth (AFLB) with receptor-specific risk. Relative risks (RRs) for associations were estimated with Poisson regression models.;With nearly 31 million women-years of follow-up, 45Â 786 Danish women aged 20-84 years developed invasive breast cancer during 1992-2011. ERÂ± expression was available for the entire study period and HER2Â± after 2006. Of the breast cancers with known ER expression, 79% were ER+. Most breast cancers with known ER and HER2 were HER2- (90% of ER+ cancers and 65% of ER- cancers). RRs differed by ERÂ± expression for all reproductive variables (p-homogeneity < 0.001). Associations were stronger for ER+ than ER- cancers and for those diagnosed before age 50. Parity and later AFLB showed a protective association with ER+/HER2- and risk association with ER-/HER2- cancers.;Associations of reproductive history with breast cancer risk varied among Danish women by ERÂ± and ERÂ±/HER2Â± expression and age-at-diagnosis, consistent with receptor-specific and age-related etiological heterogeneity. Further stratification by HER2 status demonstrated dual (or opposite) effects for ER+/HER2- and ER-/HER2- cancers.",
        "Doc_title":"Associations of parity-related reproductive histories with ERÂ± and HER2Â± receptor-specific breast cancer aetiology.",
        "Journal":"International journal of epidemiology",
        "Do_id":"27818374",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605905434707755008},
      {
        "Doc_abstract":"We conducted this study to estimate the prevalence of biomarkers, including estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) among patients with breast cancer and to explore their effects on disease mortality.;We conducted this registry-based retrospective cohort study in Tehran, in 2014, using the data on 1622 patients with breast cancer, diagnosed pathologically and registered with the Comprehensive Cancer Control Center from 1998 to 2013. The outcome of interest was the survival probability of patients with breast cancer based on receptor status along with other prognostic factors such as age, histopathology, stage/grade of tumor, metastatic status, and surgical procedures using the life table, Kaplan-Meier curves, and multivariate Cox proportional hazard model. We generated different subtypes based on expression of ER, PR, and HER2, positive (+) and/or negative (-).;ER+/PR+/HER2- subtype (51.5%) was the most common form of breast cancer cells. Compared to the ER+/PR+/HER- subtype, the hazard ratio (95% confidence interval) of cancer mortality was 2.14 (1.13, 4.03) for ER-/PR-/HER2- subtype, 1.92 (1.03, 3.59) for ER-/PR-/HER2+ subtype and 5.19 (1.51, 17.86) for ER-/PR+/HER2+ subtype.;In this study, breast cancer cases with ER-/HER2+ tumors had shorter survival than those with ER+/PR+/HER2- tumors. Triple negative tumors were the only other subtype with a statistically significant poorer prognosis. The results of this study in a middle-income country further indicate the importance of receptor status, in particular HER2 status, in the prognosis of breast cancer.",
        "Doc_title":"Breast Cancer Survival Analysis Based on Immunohistochemistry Subtypes (ER/PR/HER2): a Retrospective Cohort Study.",
        "Journal":"Archives of Iranian medicine",
        "Do_id":"27743431",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605792845071908864},
      {
        "Doc_abstract":"Breast cancer, the second leading cause of cancer mortality among women in the U.S., following lung cancer is described and the number of treatment options for patients with breast cancer, which has been accompanied by a trend toward declining cancer mortality, is reviewed.;Despite these advances in cancer therapy, many patients with early stage breast cancer eventually progress to metastatic disease. Several prognostic factors have been identified for patients with metastatic breast cancer, including tumor volume and location, comorbid conditions, response to prior therapy, and the presence of molecular tumor markers (e.g., estrogen receptors [ER] and human epidermal growth factor receptor 2 [HER2]). Metastatic breast cancer is usually incurable, and the goals of therapy are palliation of symptoms, extending survival, and improving quality of life. Options for the medical management of metastatic breast cancer include endocrine therapy, cytotoxic chemotherapy, and targeted biologic agents. Treatment guidelines developed by the National Comprehensive Cancer Network generally recommend endocrine therapy for patients with ER-positive or progesterone receptor (PR)-positive disease, for patients with bone or soft tissue metastasis, or those with asymptomatic visceral disease. Cytotoxic chemotherapy alone is usually recommended for patients with ER-negative/PR-negative disease, who have symptomatic visceral disease, or whose tumors are HER2-negative or rapidly growing. Biologic agents (e.g., trastuzumab and lapatinib) alone or in combination are recommended for patients with HER2-positive disease.;Treatment options for meta-static breast cancer continue to increase as new antitumor medications enter clinical practice and controlled clinical trials evaluate the optimal combinations of established and novel medications.",
        "Doc_title":"Treatment-experienced breast cancer.",
        "Journal":"American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists",
        "Do_id":"18463331",
        "Doc_ChemicalList":"Antineoplastic Agents",
        "Doc_meshdescriptors":"Antineoplastic Agents;Breast Neoplasms;Humans;Neoplasm Metastasis;Survival Analysis;United States",
        "Doc_meshqualifiers":"therapeutic use;mortality;pathology;therapy;epidemiology",
        "_version_":1605819769811894272},
      {
        "Doc_abstract":"Amplification and overexpression of the HER-2 oncogene in breast cancer is felt to be stable over the course of disease and concordant between primary tumor and metastases. Therefore, patients with HER-2-negative primary tumors rarely will receive anti-Her-2 antibody (trastuzumab, Herceptin) therapy. A very sensitive blood test was used to capture circulating tumor cells (CTCs) and evaluate their HER-2 gene status by fluorescence in situ hybridization. The HER-2 status of the primary tumor and corresponding CTCs in 31 patients showed 97% agreement, with no false positives. In 10 patients with HER-2-positive tumors, the HER-2/chromosome enumerator probe 17 ratio in each tumor was about twice that of the corresponding CTCs (mean 6.64 +/- 2.72 vs. 2.8 +/- 0.6). Hence, the ratio of the CTCs is a reliable surrogate marker for the expected high ratio in the primary tumor. Her-2 protein expression of 10 CTCs was sufficient to make a definitive diagnosis of the HER-2 gene status of the whole population of CTCs in 19 patients with recurrent breast cancer. Nine of 24 breast cancer patients whose primary tumor was HER-2-negative each acquired HER-2 gene amplification in their CTCs during cancer progression, i.e., 37.5% (95% confidence interval of 18.8-59.4%). Four of the 9 patients were treated with Herceptin-containing therapy. One had a complete response and 2 had a partial response.",
        "Doc_title":"HER-2 gene amplification can be acquired as breast cancer progresses.",
        "Journal":"Proceedings of the National Academy of Sciences of the United States of America",
        "Do_id":"15194824",
        "Doc_ChemicalList":"Antibodies, Monoclonal;Antibodies, Monoclonal, Humanized;Biomarkers, Tumor;Trastuzumab",
        "Doc_meshdescriptors":"Antibodies, Monoclonal;Antibodies, Monoclonal, Humanized;Biomarkers, Tumor;Breast Neoplasms;Chromosome Mapping;Disease Progression;Female;Gene Amplification;Genes, erbB-2;Humans;In Situ Hybridization, Fluorescence;Neoplasm Staging;Patient Selection;Predictive Value of Tests;Trastuzumab",
        "Doc_meshqualifiers":"therapeutic use;analysis;genetics;pathology;genetics",
        "_version_":1605742110049304577},
      {
        "Doc_abstract":"The purpose of this study was to determine the impact of serum HER-2/neu level dynamics during the course of disease and treatment on the prognosis of patients with metastatic breast cancer. Two thousand and thirty-eight serum samples collected sequentially after disease relapse in 286 patients with metastatic breast cancer were measured by Bayer Immuno 1 trade mark assay retrospectively for serum HER-2/neu (cut-off level 15 ng/ml). One hundred and five patients (37%) presented with serum HER-2/neu continuously </=15 ng/ml after disease recurrence, 71 (25%) had continuously elevated levels and 110 patients (38%) had both non-elevated and elevated values in the course of metastatic breast cancer. Patients with continuously elevated serum HER-2/neu levels had a significantly poorer survival after disease recurrence compared to patients with continuously or temporarily non-elevated serum HER-2/neu values (log-rank test: p<0.001). Including the number of palliative antitumor therapies and therapy response in Cox regression analysis, serum HER-2/neu dynamics revealed to be an independent prognostic factor for survival. In conclusion, 63% of 286 patients with metastatic breast cancer demonstrated either continuously or temporarily elevated serum HER-2/neu levels. Decrease of elevated serum HER-2/neu to levels </=15 ng/ml and levels continuously </=15 ng/ml during the course of disease correlated significantly with longer survival.",
        "Doc_title":"The course of serum HER-2/neu levels as an independent prognostic factor for survival in metastatic breast cancer.",
        "Journal":"Oncology reports",
        "Do_id":"15138574",
        "Doc_ChemicalList":"Antineoplastic Agents;Biomarkers, Tumor;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Adult;Aged;Aged, 80 and over;Antineoplastic Agents;Biomarkers, Tumor;Breast Neoplasms;Disease Progression;Enzyme-Linked Immunosorbent Assay;Female;Gene Amplification;Humans;Immunoenzyme Techniques;In Situ Hybridization, Fluorescence;Middle Aged;Neoplasm Recurrence, Local;Prognosis;Receptor, ErbB-2;Retrospective Studies;Survival Rate",
        "Doc_meshqualifiers":"therapeutic use;analysis;blood;drug therapy;secondary;blood;drug therapy;secondary;blood;genetics",
        "_version_":1605747043318366210},
      {
        "Doc_abstract":"Overexpression of human epidermal growth factor receptor-2 (HER-2/neu) in breast cancer patients is a prerequisite for treatment with trastuzumab. In the present study, we demonstrate by fluorescence in situ hybridization (FISH) analysis that HER-2/neu gene amplification and chromosome 17 (CEP17) polysomy can be induced by irradiation in human breast cancer cell lines with low basal level of HER-2/neu.;The irradiation-induced HER-2/neu gene amplification and CEP17 polysomy enhanced HER-2/neu at the protein level in both human MDA-MB-231 and MDA-MB-435 breast cancer cell lines which was determined by immunohistochemistry and fluorescence analysis and was correlated with mRNA levels.;Irradiation affected to a high degree the responsiveness of both cell lines to in vitro treatment with trastuzumab. The direct antiproliferative effect of trastuzumab, as well as its capacity to induce natural killer (NK) cell-mediated antibody-dependent cell-mediated cytotoxicity (ADCC), was considerably higher in the irradiated tumor cells compared to their non-irradiated counterparts.;Our data demonstrate that irradiation induces HER-2/neu gene amplification and CEP17 polysomy thereby enhancing expression of this protein in breast cancer cell lines rendering them susceptible to treatment with trastuzumab. They also suggest that patients with HER-2/neu negative inoperable tumors undergoing local radiation therapy may benefit from treatment with trastuzumab.",
        "Doc_title":"Gamma-irradiation induces HER-2/neu overexpression in breast cancer cell lines and sensitivity to treatment with trastuzumab.",
        "Journal":"International journal of radiation biology",
        "Do_id":"23311575",
        "Doc_ChemicalList":"Antibodies, Monoclonal, Humanized;Receptor, ErbB-2;Trastuzumab",
        "Doc_meshdescriptors":"Antibodies, Monoclonal, Humanized;Breast Neoplasms;Cell Line, Tumor;Cell Proliferation;Chromosome Aberrations;Chromosomes, Human, Pair 17;Combined Modality Therapy;Drug Resistance, Neoplasm;Gamma Rays;Gene Expression Regulation, Neoplastic;Humans;In Situ Hybridization, Fluorescence;Receptor, ErbB-2;Trastuzumab",
        "Doc_meshqualifiers":"pharmacology;therapeutic use;pathology;drug effects;radiation effects;drug effects;radiation effects;drug effects;genetics;radiation effects;methods;radiation effects;therapeutic use;drug effects;radiation effects;metabolism",
        "_version_":1605742025657810944},
      {
        "Doc_abstract":"Understanding the molecular pathways that contribute to the aggressive behavior of HER2-positive breast cancers may aid in the development of novel therapeutic interventions. Here, we show that CDCP1 and HER2 are frequently co-overexpressed in metastatic breast tumors and associated with poor patient prognosis. HER2 and CDCP1 co-overexpression leads to increased transformation ability, cell migration, and tumor formation in vivo, and enhanced HER2 activation and downstream signaling in different breast cancer cell lines. Mechanistically, we demonstrate that CDCP1 binds to HER2 through its intracellular domain, thereby increasing HER2 interaction with the non-receptor tyrosine kinase c-SRC (SRC), leading to trastuzumab resistance. Taken together, our findings establish that CDCP1 is a modulator of HER2 signaling and a biomarker for the stratification of breast cancer patients with poor prognosis. Our results also provide a rationale for therapeutic targeting of CDCP1 in HER2-positive breast cancer patients.",
        "Doc_title":"Interaction of CDCP1 with HER2 enhances HER2-driven tumorigenesis and promotes trastuzumab resistance in breast cancer.",
        "Journal":"Cell reports",
        "Do_id":"25892239",
        "Doc_ChemicalList":"Antigens, CD;Antineoplastic Agents;CDCP1 protein, human;Cell Adhesion Molecules;Neoplasm Proteins;ERBB2 protein, human;Receptor, ErbB-2;src-Family Kinases;Trastuzumab",
        "Doc_meshdescriptors":"Animals;Antigens, CD;Antineoplastic Agents;Breast Neoplasms;Carcinogenesis;Cell Adhesion Molecules;Drug Resistance, Neoplasm;Female;Humans;MCF-7 Cells;Mice;Neoplasm Proteins;Protein Binding;Receptor, ErbB-2;Trastuzumab;src-Family Kinases",
        "Doc_meshqualifiers":"genetics;metabolism;pharmacology;genetics;metabolism;genetics;metabolism;genetics;metabolism;genetics;metabolism;genetics;metabolism;pharmacology;metabolism",
        "_version_":1605746339136667649},
      {
        "Doc_abstract":"In a previous gene expression array study, we identified some 300 genes that were differentially expressed in human epidermal growth factor receptor tyrosine kinase 2 (HER2)-positive versus HER2-negative breast cancer cells. We have now done validation experiments on a group of three cell membrane components that had previously not been implicated in breast cancer. We also studied the expression of three other cell membrane proteins known to play a role in mammary neoplasia.;By immunohistochemistry, we examined up to 130 archival breast carcinomas for Celsr2, E-cadherin, Kai1, and CD9 expression. The expression levels of NET-6 and TROP-2 were determined by quantitative reverse transcription-PCR in a subset of frozen tumors. We also studied fresh pellets and paraffin-embedded cell buttons of nine human breast cell lines. The relationship between the expression of all six membrane proteins and a variety of pathologic and biological variables, including estrogen receptor, HER2, and epidermal growth factor receptor status, was also examined. The NET-6 gene was transfected into a low-expressing cell line, and the effect on cellular morphology, growth, and invasion in vitro was recorded.;Celsr2 was down-regulated in one cell line and in 7% of breast cancers. E-cadherin, Kai1, and CD9 were down-regulated in 35%, 76%, and 79% of tumors, respectively, confirming the important role of these markers in human mammary neoplasia. In breast cancer cell lines and tissues, TROP-2 was generally expressed at low levels, although a few specimens showed relative overexpression. NET-6 levels were lower in HER2-negative breast carcinoma cells. In addition, NET-6 was markedly down-regulated in estrogen receptor-negative breast cancers, and expression was lowest in \"basal-like\" tumors. Ectopic expression of NET-6 in low-expressing MDA-MB-231 cells altered cellular morphology, inhibited growth in vitro, and decreased invasion in a Boyden chamber assay.;We have confirmed the expression of three new membrane markers that had previously not been implicated in human breast cancer, and one of them (NET-6) was correlated with HER2 and estrogen receptor status. NET-6 levels were decreased in estrogen receptor-negative and high-grade tumors, and ectopic expression of this gene had an inhibitory effect on proliferation and invasion. Thus, NET-6 may represent a novel breast cancer suppressor gene.",
        "Doc_title":"Aberrant expression of novel and previously described cell membrane markers in human breast cancer cell lines and tumors.",
        "Journal":"Clinical cancer research : an official journal of the American Association for Cancer Research",
        "Do_id":"15958618",
        "Doc_ChemicalList":"Antigens, CD;Antigens, CD82;Antigens, CD9;Antigens, Neoplasm;Biomarkers, Tumor;CD82 protein, human;CD9 protein, human;CELSR2 protein, human;Cadherins;Cell Adhesion Molecules;Membrane Glycoproteins;Membrane Proteins;Proto-Oncogene Proteins;RNA, Messenger;Receptors, Estrogen;TACSTD2 protein, human;TSPAN13 protein, human;Tetraspanins;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Antigens, CD;Antigens, CD82;Antigens, CD9;Antigens, Neoplasm;Biomarkers, Tumor;Breast Neoplasms;Cadherins;Cell Adhesion Molecules;Cell Line, Tumor;Cell Proliferation;Down-Regulation;Female;Gene Expression Regulation, Neoplastic;Humans;Immunohistochemistry;Membrane Glycoproteins;Membrane Proteins;Proto-Oncogene Proteins;RNA, Messenger;Receptor, ErbB-2;Receptors, Estrogen;Reverse Transcriptase Polymerase Chain Reaction;Tetraspanins",
        "Doc_meshqualifiers":"analysis;genetics;analysis;genetics;genetics;metabolism;pathology;analysis;genetics;analysis;analysis;genetics;analysis;genetics;metabolism;analysis;analysis;methods",
        "_version_":1605797986163490816},
      {
        "Doc_abstract":"Overexpression of HER-2 is of frequent (20-30%) occurrence in breast cancer. Therapeutic targeting of HER-2 with humanized antibody derived oligopeptide may be a promising approach to the treatment of breast cancer. HER-2 gene is part of a family of genes that play critical roles in regulating transmembrane growth of breast cancer cells. Pertuzumab, a recombinant humanized monoclonal antibody (2C4), binds to extracellular domain II of the HER-2 receptor and inhibits its ability to dimerize with other HER receptors blocking the cell growth, signaling and apoptosis induction. The unique binding pocket on HER-2 for pertuzumab provides an important target domain for creation of new anticancer drugs. In the present work an efficient oligopeptide was designed by our computational method that interacts with pertuzumab binding sites of HER-2. In silico docking study demonstrated the best specific interaction of RASPADREV oligopeptide with the dimerization domain in the HER-2 molecule among various screened oligopeptides. ADMET and SAR properties prove the drug likeness of designed oligopeptide as having value 0.98.",
        "Doc_title":"In silico designing and optimization of anti-breast cancer antibody mimetic oligopeptide targeting HER-2 in women.",
        "Journal":"Journal of molecular graphics & modelling",
        "Do_id":"20149699",
        "Doc_ChemicalList":"Antibodies, Monoclonal;Antibodies, Monoclonal, Humanized;Antibodies, Neoplasm;Oligopeptides;ERBB2 protein, human;Receptor, ErbB-2;pertuzumab",
        "Doc_meshdescriptors":"Amino Acid Sequence;Antibodies, Monoclonal;Antibodies, Monoclonal, Humanized;Antibodies, Neoplasm;Breast Neoplasms;Computational Biology;Drug Design;Female;Humans;Isoelectric Point;Models, Molecular;Molecular Mimicry;Molecular Sequence Data;Oligopeptides;Protein Conformation;Protein Structure, Tertiary;Receptor, ErbB-2;Thermodynamics",
        "Doc_meshqualifiers":"chemistry;chemistry;immunology;methods;chemistry;chemistry;immunology",
        "_version_":1605926135466557440},
      {
        "Doc_abstract":"Recent protein expression profiling of breast cancer has identified specific subtypes with clinical, biological, and therapeutic implications. The aim of this study was to identify the mammographic correlates of these novel molecular classes of invasive breast cancer.;The mammographic findings of 415 patients with operable breast cancer were correlated with the previously described protein expression classes identified by our group using immunohistochemical (IHC) assessment of a large series of breast cancer cases prepared as tissue microarrays (TMAs). Twenty-five proteins of known relevance in breast cancer were assessed, including hormone receptors, HER-2 status, basal and luminal markers, p53 expression, and E-cadherin.;The mammographic background pattern and proportion of lesions that were mammographically occult were similar in all groups. Groups characterized by luminal and hormone receptor positivity had significantly more spiculate lesions at mammography. Groups characterized by HER-2 overexpression, basal characteristics, and E-cadherin positivity had a significantly higher proportion of ill-defined masses. These findings were independent of histological grade.;The mammographic features of breast cancer show significant correlation with molecular classes of invasive breast cancer identified by protein expression IHC analysis. The biological reasons for the findings and implications of these regarding imaging protocols require further study and may provide mechanisms for improvement of detection of these lesions.",
        "Doc_title":"The mammographic correlations of a new immunohistochemical classification of invasive breast cancer.",
        "Journal":"Clinical radiology",
        "Do_id":"18929040",
        "Doc_ChemicalList":"Biomarkers, Tumor;Cadherins;Neoplasm Proteins;Tumor Suppressor Protein p53;ERBB2 protein, human;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Adult;Aged;Biomarkers, Tumor;Breast Neoplasms;Cadherins;Female;Humans;Lymphatic Metastasis;Mammography;Middle Aged;Neoplasm Invasiveness;Neoplasm Proteins;Receptor, ErbB-2;Retrospective Studies;Tumor Suppressor Protein p53",
        "Doc_meshqualifiers":"metabolism;diagnostic imaging;metabolism;pathology;metabolism;metabolism;metabolism;metabolism",
        "_version_":1605753320111079424},
      {
        "Doc_abstract":"In this podcast, we talk to Dr Sunil Verma about the evolution of HER2 as a therapeutic target in breast cancer, and about how targeted therapy has revolutionized breast cancer treatment. We also discuss new agents in clinical development and the ways in which advances in treating HER2-positive breast cancer can be used to inform treatment decisions in other areas of medicine. ",
        "Doc_title":"Advances in treating HER2-positive breast cancer: an interview with Sunil Verma.",
        "Journal":"BMC medicine",
        "Do_id":"25285580",
        "Doc_ChemicalList":"Receptor, ErbB-2",
        "Doc_meshdescriptors":"Antineoplastic Combined Chemotherapy Protocols;Breast Neoplasms;Female;Humans;Receptor, ErbB-2",
        "Doc_meshqualifiers":"therapeutic use;drug therapy;genetics;genetics",
        "_version_":1605831885898907648},
      {
        "Doc_abstract":"HER-2/neu extracellular domain (ECD) can be detected in blood as a soluble circulating protein. The aim of this study was to analyze the relationship between HER-2/neu extracellular domain in the serum and the prognosis in breast cancer patients. We also correlated HER-2/neu ECD with various clinicopathological factors including steroid receptor, HER-2/neu receptor coexpression. The serum from seventy nine patients with invasive breast cancer and twenty individuals without malignancy was analyzed using the enzyme-linked immune adsorbent assay method. The cut-off value was estimated by the ROC curve analysis (15.86 Î¼g/L). HER-2/neu ECD values in the serum of patients with breast cancer were significantly higher than in control subjects. Circulating HER-2/neu ECD was significantly associated with the histological grade of tumors and the status of axillary lymph nodes. Negative correlation was observed between HER-2/neu ECD in the serum and estrogen receptor positivity. When we analyzed HER-2/neu ECD in relation with coexpression of steroid receptor and HER-2/neu receptor in tissue, statistically higher values were found in the subgroup of patients with steroid receptor negative, HER-2/neu negative tumors than in the other subgroups. HER-2/neu ECD was not an independent factor in the univariate and multivariate analysis. However, elevated HER-2/neu ECD levels were found in patients with breast cancer possessing more aggressive phenotype.",
        "Doc_title":"Circulating Her-2/neu extracellular domain in breast cancer patients-correlation with prognosis and clinicopathological parameters including steroid receptor, Her-2/neu receptor coexpression.",
        "Journal":"Pathology oncology research : POR",
        "Do_id":"25367073",
        "Doc_ChemicalList":"Biomarkers, Tumor;Receptors, Estrogen;Receptors, Progesterone;ERBB2 protein, human;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Biomarkers, Tumor;Breast Neoplasms;Case-Control Studies;Female;Follow-Up Studies;Humans;Immunoenzyme Techniques;Lymphatic Metastasis;Middle Aged;Neoplasm Grading;Neoplasm Invasiveness;Neoplasm Staging;Neoplastic Cells, Circulating;Prognosis;Receptor, ErbB-2;Receptors, Estrogen;Receptors, Progesterone;Survival Rate",
        "Doc_meshqualifiers":"metabolism;metabolism;mortality;pathology;metabolism;pathology;blood;metabolism;metabolism",
        "_version_":1605754532786077696},
      {
        "Doc_abstract":"Inflammatory breast cancers (IBC) have specific immunophenotypic profiles as compared to non-inflammatory (non-IBC): combined differential expression of estrogen receptor, Ki67, E-cadherin, MUC1, and ERBB2 can be used as an IBC signature. It is thought that IBC occurs with a high frequency in Tunisia. The aim of this study is to evaluate this signature on a Tunisian series.;The expression of five proteins (E-cadherin, ERBB2, estrogen receptor, Ki67, MUC1) was studied by immunohistochemistry on a consecutive series of 91 cases of IBC (T4D) treated at Tunisian Salah Azaiz Institute (ISA) and deposited in a tissue microarray (TMA). Results were compared to the same study on a series of 85 cases treated in France.;The ISA cases were characterized by a significantly younger age of patients (median: 42 years old in ISA for 53.5 in IPC, p=0.00042) and a higher frequency of invasive micropapillary pattern. None of the five parameters was expressed differentially in the two series. In non-metastatic patients, high level of proliferation (Ki67) and overexpression of ERBB2 were associated with poor outcome.;The IBC from Tunisia were not different from those observed in France on the basis of IHC profiles. However, the younger age of the patients suggest a specific epidemiological context that should be investigated.",
        "Doc_title":"Inflammatory breast cancers in Tunisia and France show similar immunophenotypes.",
        "Journal":"Breast (Edinburgh, Scotland)",
        "Do_id":"17360185",
        "Doc_ChemicalList":"Cadherins;Ki-67 Antigen;MUC1 protein, human;Mucin-1;Receptors, Estrogen;ERBB2 protein, human;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Adult;Breast Neoplasms;Cadherins;Carcinoma;Female;France;Humans;Ki-67 Antigen;Middle Aged;Mucin-1;Receptor, ErbB-2;Receptors, Estrogen;Tunisia",
        "Doc_meshqualifiers":"immunology;metabolism;pathology;metabolism;immunology;metabolism;pathology;metabolism;metabolism;metabolism;metabolism",
        "_version_":1605746360583192577},
      {
        "Doc_abstract":"Fatty acid synthase (FAS)-catalyzed de novo fatty acid biosynthesis, an anabolic energy-storage pathway largely considered of minor importance in humans, actively contributes to the cancer phenotype by virtue of its ability to specifically regulate the expression and activity of Her-2/neu (erbB-2) oncogene. First, a positive correlation between high levels of FAS expression and/or activity and the amplification and/or overexpression of Her-2/neu oncogene exists in human breast cancer cell lines. Second, Her-2/neu overexpression stimulates the activity of FAS gene promoter and ultimately mediates increased endogenous fatty acid biosynthesis, while this Her-2/neu-induced upregulation of breast cancer-associated FAS is inhibitable by anti-Her-2/neu antibodies such as trastuzumab (Herceptin(TM)). Third, pharmacological inhibition of FAS activity negatively regulates the expression and tyrosine-kinase activity of Her-2/neu-coded p185(Her-2/neu) oncoprotein.",
        "Doc_title":"Targeting fatty acid synthase: potential for therapeutic intervention in her-2/neu-overexpressing breast cancer.",
        "Journal":"Drug news & perspectives",
        "Do_id":"16247515",
        "Doc_ChemicalList":"Antineoplastic Agents;Cerulenin;alpha-methylene gamma-butyrolactone;Catechin;epigallocatechin gallate;Fatty Acid Synthases;Receptor, ErbB-2;4-Butyrolactone",
        "Doc_meshdescriptors":"4-Butyrolactone;Animals;Antineoplastic Agents;Breast Neoplasms;Catechin;Cerulenin;Drug Delivery Systems;Fatty Acid Synthases;Female;Gene Expression Regulation, Neoplastic;Humans;Lipid Metabolism;Receptor, ErbB-2",
        "Doc_meshqualifiers":"administration & dosage;analogs & derivatives;administration & dosage;drug therapy;genetics;metabolism;prevention & control;administration & dosage;analogs & derivatives;administration & dosage;antagonists & inhibitors;biosynthesis;metabolism;drug effects;drug effects;antagonists & inhibitors;genetics;metabolism",
        "_version_":1605818571649187840},
      {
        "Doc_abstract":"The roles of the chemokine CCL5 and its receptor CCR5 in breast cancer progression remain unclear. Here, we conducted microarray analysis on 2,254 human breast cancer specimens and found increased expression of CCL5 and its receptor CCR5, but not CCR3, in the basal and HER-2 genetic subtypes. The subpopulation of human breast cancer cell lines found to express CCR5 displayed a functional response to CCL5. In addition, oncogene transformation induced CCR5 expression, and the subpopulation of cells that expressed functional CCR5 also displayed increased invasiveness. The CCR5 antagonists maraviroc or vicriviroc, developed to block CCR5 HIV coreceptor function, reduced in vitro invasion of basal breast cancer cells without affecting cell proliferation or viability, and maraviroc decreased pulmonary metastasis in a preclinical mouse model of breast cancer. Taken together, our findings provide evidence for the key role of CCL5/CCR5 in the invasiveness of basal breast cancer cells and suggest that CCR5 antagonists may be used as an adjuvant therapy to reduce the risk of metastasis in patients with the basal breast cancer subtype.",
        "Doc_title":"CCR5 antagonist blocks metastasis of basal breast cancer cells.",
        "Journal":"Cancer research",
        "Do_id":"22637726",
        "Doc_ChemicalList":"Antineoplastic Agents;CCR5 Receptor Antagonists;Chemokine CCL5;Cyclohexanes;Piperazines;Pyrimidines;Receptors, CCR5;Triazoles;maraviroc;vicriviroc",
        "Doc_meshdescriptors":"Animals;Antineoplastic Agents;Breast Neoplasms;CCR5 Receptor Antagonists;Chemokine CCL5;Cyclohexanes;Female;Gene Expression Regulation, Neoplastic;Humans;Mice;Mice, Inbred NOD;Mice, SCID;Neoplasm Metastasis;Neoplasms, Basal Cell;Piperazines;Pyrimidines;Receptors, CCR5;Triazoles;Tumor Cells, Cultured;Xenograft Model Antitumor Assays",
        "Doc_meshqualifiers":"pharmacology;therapeutic use;genetics;pathology;prevention & control;physiology;pharmacology;therapeutic use;drug effects;genetics;pathology;prevention & control;pharmacology;therapeutic use;pharmacology;therapeutic use;genetics;metabolism;pharmacology;therapeutic use",
        "_version_":1605747552275136514},
      {
        "Doc_abstract":"Adjuvant chemotherapy targets micrometastases. If micrometastases are destroyed, patients with breast cancer will be cured. Currently, in Japan, standard breast cancer therapy is decided based on subtypes that are defined according to ER, PgR, HER2, and Ki-67 expression. We present here an outline of the recommended chemotherapy regimens based on evidence.",
        "Doc_title":"[Choice of Adjuvant Chemotherapy Based on Breast Cancer Subtype].",
        "Journal":"Gan to kagaku ryoho. Cancer & chemotherapy",
        "Do_id":"27067682",
        "Doc_ChemicalList":"Biomarkers, Tumor",
        "Doc_meshdescriptors":"Antineoplastic Combined Chemotherapy Protocols;Biomarkers, Tumor;Breast Neoplasms;Chemotherapy, Adjuvant;Humans;Prognosis",
        "Doc_meshqualifiers":"therapeutic use;analysis;chemistry;drug therapy;pathology",
        "_version_":1605883270578307072},
      {
        "Doc_abstract":"Molecular markers and the rich biological information they contain have great potential for cancer diagnosis, prognostication and therapy prediction. So far, however, they have not superseded routine histopathology and staging criteria, partly because the few studies performed on molecular subtyping have had little validation and limited clinical characterization.;We obtained gene expression and clinical data for 412 breast cancers obtained from population-based cohorts of patients from Stockholm and Uppsala, Sweden. Using the intrinsic set of approximately 500 genes derived in the Norway/Stanford breast cancer data, we validated the existence of five molecular subtypes--basal-like, ERBB2, luminal A/B and normal-like--and characterized these subtypes extensively with the use of conventional clinical variables.;We found an overall 77.5% concordance between the centroid prediction of the Swedish cohort by using the Norway/Stanford signature and the k-means clustering performed internally within the Swedish cohort. The highest rate of discordant assignments occurred between the luminal A and luminal B subtypes and between the luminal B and ERBB2 subtypes. The subtypes varied significantly in terms of grade (p < 0.001), p53 mutation (p < 0.001) and genomic instability (p = 0.01), but surprisingly there was little difference in lymph-node metastasis (p = 0.31). Furthermore, current users of hormone-replacement therapy were strikingly over-represented in the normal-like subgroup (p < 0.001). Separate analyses of the patients who received endocrine therapy and those who did not receive any adjuvant therapy supported the previous hypothesis that the basal-like subtype responded to adjuvant treatment, whereas the ERBB2 and luminal B subtypes were poor responders.;We found that the intrinsic molecular subtypes of breast cancer are broadly present in a diverse collection of patients from a population-based cohort in Sweden. The intrinsic gene set, originally selected to reveal stable tumor characteristics, was shown to have a strong correlation with progression-related properties such as grade, p53 mutation and genomic instability.",
        "Doc_title":"Intrinsic molecular signature of breast cancer in a population-based cohort of 412 patients.",
        "Journal":"Breast cancer research : BCR",
        "Do_id":"16846532",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"Breast Neoplasms;Cohort Studies;Female;Gene Expression;Genes, p53;Genomic Instability;Humans;Mutation",
        "Doc_meshqualifiers":"classification;genetics;pathology;genetics",
        "_version_":1605742712370233344},
      {
        "Doc_abstract":"Previous studies have demonstrated a synergistic interaction between rhuMAb HER2 and the cytotoxic drug cisplatin in human breast and ovarian cancer cells. To define the nature of the interaction between rhuMAb HER2 and other classes of cytotoxic drugs, we applied multiple drug effect/combination index (CI) isobologram analysis to a variety of chemotherapeutic drug/rhuMAb HER2 combinations in vitro. Synergistic interactions at clinically relevant drug concentrations were observed for rhuMAb HER2 in combination with cisplatin (CI=0.48, P=0.003), thiotepa (CI=0.67, P=0.0008), and etoposide (CI=0.54, P=0.0003). Additive cytotoxic effects were observed with rhuMAb HER2 plus doxorubicin (CI=1.16, P=0.13), paclitaxel (CI=0.91, P=0.21), methotrexate (CI=1.15, P=0.28), and vinblastine (CI=1.09, P=0.26). One drug, 5-fluorouracil, was found to be antagonistic with rhuMAb HER2 in vitro (CI=2.87, P=0.0001). In vivo drug/rhuMAb HER2 studies were conducted with HER-2/neu-transfected, MCF7 human breast cancer xenografts in athymic mice. Combinations of rhuMAb HER2 plus cyclophosphamide, doxorubicin, paclitaxel, methotrexate, etoposide, and vinblastine in vivo resulted in a significant reduction in xenograft volume compared to chemotherapy alone (P<0.05). Xenografts treated with rhuMAb HER2 plus 5-fluorouracil were not significantly different from 5-fluorouracil alone controls consistent with the subadditive effects observed with this combination in vitro. The synergistic interaction of rhuMAb HER2 with alkylating agents, platinum analogs and topoisomerase II inhibitors, as well as the additive interaction with taxanes, anthracyclines and some antimetabolites in HER-2/neu-overexpressing breast cancer cells demonstrates that these are rational combinations to test in human clinical trials.",
        "Doc_title":"Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers.",
        "Journal":"Oncogene",
        "Do_id":"10327070",
        "Doc_ChemicalList":"Antibiotics, Antineoplastic;Antibodies, Monoclonal;Antibodies, Monoclonal, Humanized;Antimetabolites, Antineoplastic;Antineoplastic Agents;Antineoplastic Agents, Alkylating;Neoplasm Proteins;Recombinant Proteins;Topoisomerase II Inhibitors;Vinblastine;Etoposide;Doxorubicin;Cyclophosphamide;Thiotepa;Receptor, ErbB-2;Trastuzumab;Paclitaxel;Cisplatin;Fluorouracil",
        "Doc_meshdescriptors":"Adenocarcinoma;Animals;Antibiotics, Antineoplastic;Antibodies, Monoclonal;Antibodies, Monoclonal, Humanized;Antimetabolites, Antineoplastic;Antineoplastic Agents;Antineoplastic Agents, Alkylating;Breast Neoplasms;Cell Cycle;Cisplatin;Combined Modality Therapy;Cyclophosphamide;Doxorubicin;Drug Screening Assays, Antitumor;Drug Synergism;Etoposide;Female;Fluorouracil;Gene Expression Regulation, Neoplastic;Humans;Immunization, Passive;Mice;Mice, Nude;Neoplasm Proteins;Neoplasm Transplantation;Neoplasms, Hormone-Dependent;Paclitaxel;Phosphorylation;Protein Processing, Post-Translational;Receptor, ErbB-2;Recombinant Proteins;Thiotepa;Topoisomerase II Inhibitors;Transplantation, Heterologous;Trastuzumab;Treatment Outcome;Vinblastine",
        "Doc_meshqualifiers":"drug therapy;pathology;therapy;pharmacology;therapeutic use;pharmacology;therapeutic use;pharmacology;therapeutic use;pharmacology;therapeutic use;pharmacology;therapeutic use;drug therapy;pathology;therapy;drug effects;pharmacology;pharmacology;therapeutic use;pharmacology;therapeutic use;pharmacology;therapeutic use;antagonists & inhibitors;pharmacology;therapeutic use;drug effects;antagonists & inhibitors;biosynthesis;genetics;immunology;drug therapy;pathology;therapy;pharmacology;therapeutic use;drug effects;drug effects;antagonists & inhibitors;biosynthesis;genetics;immunology;pharmacology;therapeutic use;pharmacology;pharmacology;therapeutic use",
        "_version_":1605746846775377920},
      {
        "Doc_abstract":"The HER-2/neu oncogene encodes a transmembrane tyrosine kinase receptor with extensive homology to the epidermal growth factor receptor. In this review, the association of HER-2/neu gene and protein abnormalities with prognosis and response to therapy with trastuzumab and to other therapies in breast cancer is presented. By considering a series of 80 published studies encompassing more than 25,000 patients, the relative advantages and disadvantages of Southern blotting, polymerase chain reaction amplification, and fluorescence in situ hybridization assays designed to detect HER-2/neu gene amplification are compared with HER-2/neu protein overexpression assays performed by immunohistochemical techniques applied to frozen and paraffin-embedded tissues and enzyme immunoassays performed on tumor cytosols. The significance of HER-2/neu overexpression in ductal carcinoma in situ and the HER-2/neu status in uncommon female breast conditions and male breast cancer are also considered. The role of HER-2/neu testing for the prediction of response to trastuzumab therapy in breast cancer is presented as well as its potential impact on responses to standard and newer hormonal therapies, cytotoxic chemotherapy, and radiation. The review also evaluates the status of serum-based testing for circulating HER-2/neu receptor protein and its ability to predict disease outcome and therapy response.",
        "Doc_title":"The Her-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy.",
        "Journal":"The oncologist",
        "Do_id":"12897328",
        "Doc_ChemicalList":"Antibodies, Monoclonal;Antibodies, Monoclonal, Humanized;Biomarkers, Tumor;Trastuzumab",
        "Doc_meshdescriptors":"Adult;Age Distribution;Aged;Antibodies, Monoclonal;Antibodies, Monoclonal, Humanized;Biomarkers, Tumor;Breast Neoplasms;Breast Neoplasms, Male;Combined Modality Therapy;Education, Medical, Continuing;Female;Gene Expression Regulation, Neoplastic;Genes, erbB-2;Genetic Predisposition to Disease;Humans;Incidence;Male;Middle Aged;Neoplasm Staging;Prognosis;Risk Assessment;Sensitivity and Specificity;Survival Analysis;Trastuzumab;Treatment Outcome",
        "Doc_meshqualifiers":"therapeutic use;analysis;genetics;mortality;pathology;therapy;genetics;mortality;pathology;therapy;genetics",
        "_version_":1605825345304395776},
      {
        "Doc_abstract":"The aim of this study was to evaluate the association of breast cancer with thyroid diseases. Many authors have already studied the possible relationship between these two diseases, but the results are nowadays conflicting.;Our study examining 867 patients with breast cancer (862 women and 5 men, average ageÂ =Â 61Â years old) of whom 141 also had thyroid disease evaluated the recurrence of thyroid diseases and their association with different types of breast cancer. Statistical analyses were performed using SPSS software for Windows; we used nonparametric tests (Chi-square and Mann-Whitney), and the level of significance was set at pÂ <Â 0.05.;We found a significant association between breast cancer diagnosed after menopause and thyroid disease (pÂ <Â 0.003). Moreover, we analyzed the role of thyroid autoimmunity identifying an association between chronic autoimmune thyroiditis and breast cancer diagnosed before menopause (pÂ <Â 0.05). Regarding receptor profile of breast carcinoma, we have found an increased expression of estrogen receptors in patients with autoimmune thyroiditis compared to patients with any other thyroid diseases (pÂ <Â 0.03). Contrariwise, we do not have found any difference between the group with every thyroid disease and the group without thyroid disease (pÂ <Â 1.00). We did not find other statistically significant associations with breast cancer's parameters like family history, tumor size, lymph node metastasis, distant metastasis, cancer clinical and pathological stage, differentiation grade and expression of Ki67, p53 and Her2 in the two main groups with or without thyroid disease. Likewise, we did not found other statistically significant association between hypothyroidism or hyperthyroidism and breast cancer.",
        "Doc_title":"Breast cancer and thyroid diseases: analysis of 867 consecutive cases.",
        "Journal":"Journal of endocrinological investigation",
        "Do_id":"27624298",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605812742324748288},
      {
        "Doc_abstract":"Metastatic breast cancer is a partially chemotherapy-sensitive neoplasm. Most chemotherapy groups have activity in this disease, and the most active single drugs are the taxanes, especially docetaxel (Taxotere; Aventis Pharmaceuticals, Inc, Parsippany, NJ), and the anthracyclines. The alkylating agents, antimetabolites, and vinca alkaloids are also widely used. The platinum coordination complexes, which are widely used in oncology, are also active in metastatic breast cancer, but the availability of other drugs that are less toxic and easier to administer has resulted in their having a strictly limited use in this setting. Cisplatin appears to be somewhat more active than carboplatin, but direct comparative studies are lacking. The identification of the prominent activity of the taxanes has led to the investigation of wholly novel non-anthracycline-containing combination regimens, and platinum/taxane doublets appear to be particularly active. More recently, reports that trastuzumab (Herceptin, Genentech, South San Francisco, CA), a novel monoclonal antibody directed against the protein product of the HER2/(neu) oncogene, has a powerful synergistic interaction with docetaxel and with platinum agents have prompted evaluation of the triplet docetaxel/platinum/trastuzumab in the therapy of metastatic breast cancer.",
        "Doc_title":"The platinum agents: a role in breast cancer treatment?",
        "Journal":"Seminars in oncology",
        "Do_id":"11301372",
        "Doc_ChemicalList":"Antibodies, Monoclonal;Antibodies, Monoclonal, Humanized;Antineoplastic Agents;Taxoids;docetaxel;Carboplatin;Trastuzumab;Paclitaxel;Cisplatin",
        "Doc_meshdescriptors":"Antibodies, Monoclonal;Antibodies, Monoclonal, Humanized;Antineoplastic Agents;Antineoplastic Combined Chemotherapy Protocols;Breast Neoplasms;Carboplatin;Cisplatin;Clinical Trials as Topic;Humans;Paclitaxel;Taxoids;Trastuzumab",
        "Doc_meshqualifiers":"administration & dosage;therapeutic use;therapeutic use;drug therapy;administration & dosage;therapeutic use;administration & dosage;therapeutic use;administration & dosage;analogs & derivatives",
        "_version_":1605766317742227456},
      {
        "Doc_abstract":"HER2, a member of the human epidermal growth factor (EGF) receptor family, not only plays important roles in the progression of breast cancer tumorigenesis and metastasis, but may protect cancer cells from conventional cytotoxic therapies as well. In the current study, we evaluated the effect of targeting HER2 on radiosensitization of human breast cancer cells. Using six breast cancer cell lines with various levels of HER2 (BT474, SKBR3, MDA453, MCF7, ZR75B, and MDA468), we found that trastuzumab (Herceptin), a humanized monoclonal antibody that may inhibit breast cancer cell proliferation but does not induce apoptosis when used alone, enhanced radiation-induced apoptosis of the cells in a HER2 level-dependent manner. We furthered this study in MCF7 cells transfected for high levels of HER2 (MCF7HER2). Compared with parental or control vector-transfected MCF7 cells, MCF7HER2 cells showed increased phosphorylation of at least two important HER2 downstream molecules, protein kinase B/Akt and mitogen-activated protein kinase (MAPK), and increased resistance to radiotherapy, as shown by reduced induction of apoptosis and increased cell clonogenic survival after radiation. Exposure of the cells to trastuzumab down-regulated the levels of HER2 and reduced phosphorylation levels of Akt and MAPK in MCF7HER2 cells, and sensitized these cells to radiotherapy. When specific inhibitors of the phosphatidylinositol 3-kinase (PI3-K) and MAPK kinase (MEK) pathways were used, we found that exposure of MCF7HER2 cells to the PI3-K inhibitor LY294002 inhibited Akt phosphorylation and radiosensitized the cells, whereas the radiosensitization effect by the MEK inhibitor PD98059 was relatively weaker, albeit the phosphorylation of MAPK was reduced by PD98059 treatment. Our results indicate that the PI3-K pathway might be the major pathway for trastuzumab-mediated radiosensitization of breast cancer cells.",
        "Doc_title":"Sensitization of breast cancer cells to radiation by trastuzumab.",
        "Journal":"Molecular cancer therapeutics",
        "Do_id":"14617784",
        "Doc_ChemicalList":"Antibodies, Monoclonal;Antibodies, Monoclonal, Humanized;Antineoplastic Agents;Phosphatidylinositol 3-Kinases;Receptor, ErbB-2;Mitogen-Activated Protein Kinase Kinases;Trastuzumab",
        "Doc_meshdescriptors":"Antibodies, Monoclonal;Antibodies, Monoclonal, Humanized;Antineoplastic Agents;Apoptosis;Breast Neoplasms;Cell Division;Cell Line, Tumor;Gene Expression Regulation, Neoplastic;Humans;Mitogen-Activated Protein Kinase Kinases;Phosphatidylinositol 3-Kinases;Phosphorylation;Radiation Tolerance;Radiation, Ionizing;Receptor, ErbB-2;Signal Transduction;Trastuzumab",
        "Doc_meshqualifiers":"pharmacology;pharmacology;drug effects;radiation effects;drug therapy;genetics;immunology;radiotherapy;drug effects;radiation effects;antagonists & inhibitors;metabolism;antagonists & inhibitors;metabolism;drug effects;drug effects;antagonists & inhibitors;genetics;metabolism;drug effects",
        "_version_":1605840927716278272},
      {
        "Doc_abstract":"Breast cancer is a heterogeneous disease, and patients are categorized into subtypes according to gene expression. We studied the associations among molecular, immunohistochemical, and clinicopathologic features and their distribution according to the subtypes luminal, HER2, basal, and normal-like in 60 patients with invasive ductal breast carcinoma without distant metastasis at the time of diagnosis (M0). We evaluated the hypermethylation of the CDH-1, RASSF1A, SIAH-1 and TSLC-1 genes by methylation-specific polymerase chain reaction and the expression of p53, bcl-2, cyclin D1, E-cadherin, and beta-catenin proteins in tissue microarrays by immunohistochemical analysis. Expression of bcl-2 was associated with the luminal subtype (P=.003), and CDH-1 hypermethylation was present preferentially in HER2 tumors (P=.038). The basal subtype was characterized by the expression of beta-catenin (P=.003). The hypermethylation of CDH-1 and the expression of bcl-2, cyclin D1, and beta-catenin proteins differ among breast cancer subtypes.",
        "Doc_title":"Differences and molecular immunohistochemical parameters in the subtypes of infiltrating ductal breast cancer.",
        "Journal":"American journal of clinical pathology",
        "Do_id":"18701415",
        "Doc_ChemicalList":"CADM1 protein, human;CDH1 protein, human;Cadherins;Cell Adhesion Molecules;Immunoglobulins;Membrane Proteins;RASSF1 protein, human;Tumor Suppressor Proteins",
        "Doc_meshdescriptors":"Adult;Aged;Aged, 80 and over;Breast Neoplasms;Cadherins;Carcinoma, Ductal, Breast;Cell Adhesion Molecules;DNA Methylation;Disease-Free Survival;Female;Humans;Immunoglobulins;Immunohistochemistry;Membrane Proteins;Middle Aged;Polymerase Chain Reaction;Retrospective Studies;Survival Analysis;Tumor Suppressor Proteins",
        "Doc_meshqualifiers":"pathology;genetics;pathology;genetics;genetics;methods;genetics",
        "_version_":1605919469069139968},
      {
        "Doc_abstract":"The diagnosis of breast cancer is morphologically based. Pathologic parameters, such as tumor size, lymph node status, and histological grade are well accepted to guide treatment decisions in clinical practice. Estrogen receptor, progesterone receptor and HER2 status are also routinely assessed in today's pathology laboratories to provide further information on predictive and prognostic factors affecting patients' care. Newer molecular techniques, including gene-expression profiling have been widely used to study breast cancer and several molecular prognostic tests already available for clinical use stemmed from these scientific efforts. Authors review prognostically important aspects of the diagnostic pathology and the molecular classification of invasive breast cancer.",
        "Doc_title":"[Modern pathologic diagnostics in breast cancer].",
        "Journal":"Orvosi hetilap",
        "Do_id":"22204831",
        "Doc_ChemicalList":"Biomarkers, Tumor;Receptors, Estrogen;Receptors, Progesterone;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Biomarkers, Tumor;Breast Neoplasms;Female;Gene Expression Profiling;Gene Expression Regulation, Neoplastic;Histocytochemistry;Humans;Immunohistochemistry;In Situ Hybridization, Fluorescence;Lymph Nodes;Neoplasm Grading;Predictive Value of Tests;Prognosis;Receptor, ErbB-2;Receptors, Estrogen;Receptors, Progesterone",
        "Doc_meshqualifiers":"analysis;chemistry;genetics;pathology;pathology;analysis;analysis;analysis",
        "_version_":1605839840857817088},
      {
        "Doc_abstract":"To investigate the relationship between the survival time and the high-expression of epidermal growth factor receptor (EGFR) and human epidermal receptor 2 (HER2) in breast cancer patients, and assess the feasibility of using the two markers either alone or in combination for predicting the prognosis of the patients.;Breast cancer samples were obtained from 185 patients and measured for the expressions of EGFR and HER-2 by way of immunohistochemistry, and 120 patients (64.9%) were followed up and their survival time recorded. Sixty-five patients (35.1%) failed to be followed for various reasons.;Of the 120 patients followed up, death occurred in 28 (15%). Positive HER2 expression was detected in 57.8% and EGFR expression in 40.5% of the all the samples examined. The over-expression of either HER2 or EGFR was in inverse correlation with the survival time (P<0.05 and P<0.01, respectively), and the over-expression of both related to the survival time in similar manner (P<0.05 and P<0.01).;The high expression of HER2 or/and EGFR suggests a short survival time and an unfavorable prognosis.",
        "Doc_title":"[Association between the survival time and high-expression of EGFR and HER-2 in breast cancer].",
        "Journal":"Di 1 jun yi da xue xue bao = Academic journal of the first medical college of PLA",
        "Do_id":"14559703",
        "Doc_ChemicalList":"Receptor, Epidermal Growth Factor;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Adult;Aged;Aged, 80 and over;Breast Neoplasms;Female;Humans;Immunohistochemistry;Middle Aged;Receptor, Epidermal Growth Factor;Receptor, ErbB-2",
        "Doc_meshqualifiers":"chemistry;mortality;therapy;analysis;analysis",
        "_version_":1605901822429495296},
      {
        "Doc_abstract":"Several interesting aspects of breast cancer were covered at this year's American Society of Clinical Oncology meeting. Sentinel lymph node (SN) mapping is now in widespread use, in concert with the general trend toward trying to decrease the morbidity of breast cancer surgery. With every advance, however, comes new challenges, and there was a timely presentation from Giuliano's group addressing the controversial issue of how to interpret the presence of cells in the SN seen only with keratin stains but not by routine hematoxylin and eosin stains. Two abstracts addressed the issue of whether for certain women with invasive breast cancer radiation therapy could be omitted after lumpectomy. Another interesting topic related to hormonal issues in the adjuvant treatment of premenopausal women. An analysis from the ZIPP-TRIAL reported on bone marrow density studies in young women given two years of ovarian suppression in the adjuvant setting: it seems that the loss of bone density may be reversible and, more interestingly, may be prevented with concurrent tamoxifen. Two other presentations looked at the prognostic significance of drug-induced amenorrhea in young women treated with adjuvant chemotherapy and at the efficacy of ovarian suppression during chemotherapy in preserving fertility. In an unpublicized presentation, Mary-Claire King presented very interesting results from the National Surgical Adjuvant Breast and Bowel Project Breast Cancer Prevention Trial suggesting that tamoxifen may be an effective chemopreventive drug for women with BRCA2, but not BRCA1, mutations. Two important presentations re-analyzed the outcome of the pivotal trials using Herceptin to treat metastatic breast cancer and nicely show that FISH analysis of HER-2 overexpression is a more accurate indicator of response to Herceptin than immunohistochemical staining. Finally, there were two interesting presentations related to tamoxifen resistance which may be relevant clinically, pertaining to subsequent raloxifene use and the interaction of the estrogen receptor and EGF receptor pathways, respectively.",
        "Doc_title":"Breast cancer.",
        "Journal":"The oncologist",
        "Do_id":"11524552",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"Antineoplastic Combined Chemotherapy Protocols;Breast Neoplasms;Chemoprevention;Chemotherapy, Adjuvant;Clinical Trials as Topic;Female;Humans;Radiotherapy, Adjuvant",
        "Doc_meshqualifiers":"therapeutic use;genetics;therapy",
        "_version_":1605892559817670657},
      {
        "Doc_abstract":"Overexpression of glucosylceramide synthase (GCS) increases multidrug resistance (MDR) in many cancer cells. However, its mechanism is unknown. The aim of the present study is to detect the association of methylation at the GCS gene promoter with its expression and MDR in invasive ductal breast cancer. 40 cases GCS-positive and 40 cases GCS-negative primary breast carcinoma samples, three drug-sensitive breast cancer cell lines and one multidrug-resistant breast cancer cell line were used. Immunohistochemistry, methylation-specific PCR (MSP), quantitative real-time (qPCR), westernblot and cytotoxicity assay techniques were employed. Thwe results revealed that there was a statistically negative correlation between GCS CpG islands methylation and GCSphenotype in patients with breast cancer. GCS CpG islands methylation was negatively associated with high ER, meanwhile positively with high HER-2 status. Similar results were obtained from the analysis of breast cancer cell lines. Treatment with the demethylating agent 5-aza-2'-deoxycytidine (5-Aza-dc) changed the GCS promoter methylation pattern in three sensitive cells and also caused increased drug resistance of them. These results suggested that the changes of DNA methylation status of the GCS promoter correlates with multidrug resistance in breast cancer.",
        "Doc_title":"Altered methylation of glucosylceramide synthase promoter regulates its expression and associates with acquired multidrug resistance in invasive ductal breast cancer.",
        "Journal":"Oncotarget",
        "Do_id":"27191984",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605839663625404416},
      {
        "Doc_abstract":"Human epidermal growth factor receptor-2 (HER-2)-positive breast cancer tends to be aggressive, highly metastatic, and drug resistant and spreads rapidly. Studies have indicated that emodin inhibits HER-2 expression. This study compared the HER-2-inhibitory effects of two compounds extracted from rhubarb roots: aloe-emodin (AE) and rhein. Our results indicated that AE exerted the most potent inhibitory effect on HER-2 expression. Treatment of HER-2-overexpressing breast cancer cells with AE reduced tumor initiation, cell migration, and cell invasion. AE was able to suppress YB-1 expression, further suppressing downstream HER-2 expression. AE suppressed YB-1 expression through the inhibition of Twist in HER-2-overexpressing breast cancer cells. Our data also found that AE inhibited cancer metastasis and cancer stem cells through the inhibition of EMT. Interestingly, AE suppressed YB-1 expression through the downregulation of the intracellular integrin-linked kinase (ILK)/protein kinase B (Akt)/mTOR signaling pathway in HER-2-overexpressing breast cancer cells. In vivo study showed the positive result of antitumor activity of AE in nude mice injected with human HER-2-overexpressing breast cancer cells. These findings suggest the possible application of AE in the treatment of HER-2-positive breast cancer.",
        "Doc_title":"Aloe-emodin inhibits HER-2 expression through the downregulation of Y-box binding protein-1 in HER-2-overexpressing human breast cancer cells.",
        "Journal":"Oncotarget",
        "Do_id":"27391337",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605784832271450112},
      {
        "Doc_abstract":"To display the association between the apolipoprotein E (APOE) genotypes and breast cancer patients, a cross sectional study including 291 patients and 148 controls was performed. The APOE genotypes were measured in all participants, and the pathological diagnosis, estrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 (HER-2) among breast cancer patients were collected. The results showed the APOE allele frequency in breast cancer patients was 11.7% epsilon2 carriers, 74.6% epsilon3 carriers and 13.7% epsilon4 carriers, and there was no significant difference when they were compared with those of the control group (15.5% epsilon2 carriers, 74.3% epsilon3 carriers and 10.1% epsilon4 carriers; p=0.342). Among the patients in pre-menopause, showed a higher frequency of epsilon2 carriers had the cancer site on the left than that of the epsilon3 carriers (78.6% versus 40.3%; p=0.019). Among breast cancer patients, there was no significant association between the APOE genotypes and menopausal status, pathological diagnosis, estrogen receptor, progesterone receptor, and HER-2. Our findings demonstrated that the APOE genotypes were not associated with breast cancer patients, and epsilon2 allele tended to induce breast cancer on the left site among those patients in pre-menopause.",
        "Doc_title":"Association between the apolipoprotein E genotypes and breast cancer patients in Taiwanese.",
        "Journal":"Breast cancer research and treatment",
        "Do_id":"16752225",
        "Doc_ChemicalList":"Apolipoproteins E",
        "Doc_meshdescriptors":"Adult;Alleles;Apolipoproteins E;Breast Neoplasms;Case-Control Studies;Female;Gene Expression Regulation, Neoplastic;Genotype;Humans;Menopause;Middle Aged;Polymerase Chain Reaction;Polymorphism, Restriction Fragment Length;Taiwan",
        "Doc_meshqualifiers":"genetics;epidemiology;ethnology;genetics",
        "_version_":1605760872885518336},
      {
        "Doc_abstract":"Evaluation of: Lee C, Dhillon J, Wang MY et al.: Targeting YB-1 in HER-2 overexpressing breast cancer cells induces apoptosis via the mTOR/STAT3 pathway and suppresses tumor growth in mice. Cancer Res. 68 (21), 8661-8666 (2008). The transcription factor Y-box binding protein (YB)-1 is highly expressed in breast cancer cells and is strongly linked with breast cancer patient prognosis. In this paper, siRNA knockdown of YB-1 was used to investigate breast cancer cell proliferation. Six breast cancer cell lines that either overexpress HER-2 or were triple negative demonstrated growth inhibition following YB-1 knockdown. In particular, YB-1 knockdown induced apoptosis in BT-474-m1 and Au565 cells. Knockdown of YB-1 also decreased phosphorylation of STAT3S727, ERK1/2T202/Y204, mTORS2448 and total mTOR expression. When STAT3 was knocked down by siSTAT3, apoptosis was induced and constitutively active phosphorylated STAT3 was found to rescue YB-1-induced apoptosis. Furthermore, YB-1 knockdown remarkably suppressed colony formation in a soft agar assay, while delayed tumor formation was observed in mice. YB-1 knockdown inhibited cell growth and it is thought to involve induction of apoptosis via the mTOR/STAT3 intracellular signaling pathway. YB-1 is a promising molecular target for HER-2-overexpressing or triple-negative breast cancer cells.",
        "Doc_title":"YB-1 prevents apoptosis via the mTOR/STAT3 pathway in HER-2-overexpressing breast cancer cells.",
        "Journal":"Future oncology (London, England)",
        "Do_id":"19284373",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605759585334853632},
      {
        "Doc_abstract":"Anti-oestrogen is effective for the treatment of oestrogen receptor (ER)-positive breast carcinomas, but most of these tumours become resistant to anti-oestrogen. It has been suggested that anti-oestrogen therapy may induce a HER2 signalling pathway in breast cancer cells and this may cause resistance to anti-oestrogen. Thus, it is conceivable that combined therapy with anti-oestrogen and anti-HER2 antibody might be more effective. In the present study, we investigated the effect of combined treatment with a humanized anti-HER2 monoclonal antibody, rhumAbHER2 (trastuzumab), and an anti-oestrogen, ICI 182,780, on the cell growth of three human breast cancer cell lines which respectively express different levels of ER and HER2. The combined treatment enhanced the growth inhibitory effect on ML-20 cells, which express a high level of ER and a moderate level of HER2, but showed no additive effect on either KPL-4 cells, which express no ER and a moderate level of HER2, or MDA-MB-231 cells, which express no ER and a low level of HER2. It is also suggested that both the antibody and anti-oestrogen induce a G1-S blockade and apoptosis. These findings indicate that combined treatment with anti-HER2 antibody and anti-oestrogen may be useful for the treatment of patients with breast cancer expressing both ER and HER2.",
        "Doc_title":"Anti-HER2 antibody enhances the growth inhibitory effect of anti-oestrogen on breast cancer cells expressing both oestrogen receptors and HER2.",
        "Journal":"British journal of cancer",
        "Do_id":"10638965",
        "Doc_ChemicalList":"Antibodies, Monoclonal;Antineoplastic Agents;Estrogen Antagonists;Neoplasm Proteins;Receptors, Estrogen;fulvestrant;Estradiol;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Antibodies, Monoclonal;Antineoplastic Agents;Apoptosis;Breast Neoplasms;Dose-Response Relationship, Drug;Estradiol;Estrogen Antagonists;Female;Humans;Interphase;Neoplasm Proteins;Receptor, ErbB-2;Receptors, Estrogen;S Phase;Tumor Cells, Cultured",
        "Doc_meshqualifiers":"therapeutic use;therapeutic use;metabolism;physiopathology;therapy;analogs & derivatives;therapeutic use;therapeutic use;drug effects;metabolism;immunology;metabolism;metabolism;drug effects;drug effects",
        "_version_":1605774142762647552},
      {
        "Doc_abstract":"Wilms' tumor 1 (WT1) gene has different functional properties depending on the isoform type. This gene correlates with cell proliferation in various types of cancer. Here, we investigated the expression of WT1 isoforms in breast cancer tissues, and focused on the oncogenic role through estrogen receptor-alpha (ER-Î±) and human epidermal growth factor receptor 2 (HER2).;Expression of WT1(17AA+) and (17AA-) was investigated in adjacent normal breast and breast cancer using Reverse transcription-polymerase chain reaction and western blotting. The correlation of WT1 isoforms with HER2 and ER-Î± was examined using MCF-7 cells stably-overexpressing WT1s and siRNA against WT1 gene.;The expression of WT(17AA-) was significantly found in adjacent normal breast tissues. A mixture of WT1(17AA+) and WT1(17AA-) were highly expressed in breast carcinoma tissues. MCF-7 cells overexpressing WT1+/+ and WT1+/- represented strong expression of ER-Î± and HER2. Moreover, the silencing of WT1+/+ and WT1+/- resulted in a decrease of both ER-Î± and HER2 and led to a decrease of cell numbers.;Our results suggest that WT1(17AA+) was exhibited dominantly in breast carcinoma tissues. WT1+/+ and WT1+/- correlated with the high expression of ER-Î± and HER2, leading to cell proliferation and might be involved in cancer development and progression.",
        "Doc_title":"Correlation of Wilms' tumor 1 isoforms with HER2 and ER-Î± and its oncogenic role in breast cancer.",
        "Journal":"Anticancer research",
        "Do_id":"24596380",
        "Doc_ChemicalList":"Estrogen Receptor alpha;Protein Isoforms;RNA, Messenger;RNA, Small Interfering;WT1 Proteins;estrogen receptor alpha, human;ERBB2 protein, human;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Adult;Aged;Apoptosis;Blotting, Western;Breast Neoplasms;Carcinoma, Ductal, Breast;Cell Proliferation;Estrogen Receptor alpha;Female;Follow-Up Studies;Humans;Lymphatic Metastasis;Middle Aged;Neoplasm Grading;Prognosis;Protein Isoforms;RNA, Messenger;RNA, Small Interfering;Real-Time Polymerase Chain Reaction;Receptor, ErbB-2;Reverse Transcriptase Polymerase Chain Reaction;Tumor Cells, Cultured;WT1 Proteins",
        "Doc_meshqualifiers":"genetics;metabolism;pathology;genetics;metabolism;pathology;genetics;metabolism;genetics;genetics;genetics;metabolism;antagonists & inhibitors;genetics;metabolism",
        "_version_":1605808731123089408},
      {
        "Doc_abstract":"Breast cancer is the most common cancer affecting women. Many patients ultimately progress to metastatic disease and optimal management of this disease remains a significant therapeutic challenge. Lapatinib, a dual tyrosine kinase inhibitor, is in clinical development for treatment of this disease.;The objective of this article is to review the published evidence for the treatment of metastatic breast cancer with lapatinib, and assess its therapeutic potential.;Most evidence has appeared in meeting abstract reports of phase I and II studies in healthy volunteers and cancer patients. Four studies have included patients with exclusively breast cancer. Complete and partial responses and stable disease has been reported in some patients. Emerging evidence indicates that complete and partial responses can be achieved in some patients with metastatic breast cancer. Lapatinib appears to be well tolerated in cancer patients and the maximum tolerated dose is in the region of 1800 mg/day. In addition, it has been used in combination with other cancer treatments. Five ongoing or planned phase II monotherapy and three phase III combination-therapy studies with lapatinib have been identified.;The phase I and II studies reported to date have provided safety data and preliminary indications regarding efficacy. There is preliminary evidence that lapatinib can achieve objective response rates of 10-38% in patients with metastatic breast cancer. Patients with tumors overexpressing ErbB1 and/or ErbB2 are likely to benefit from lapatinib treatment.",
        "Doc_title":"Lapatinib: the evidence for its therapeutic value in metastatic breast cancer.",
        "Journal":"Core evidence",
        "Do_id":"22500146",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605820890269876224},
      {
        "Doc_abstract":"To examine the occurrence and outcomes of de novo metastatic (Stage IV) breast cancer, particularly with respect to tumor HER2 expression.;We studied all 6,268 de novo metastatic breast cancer cases diagnosed from 1 January 2005 to 31 December 2011 and reported to the California Cancer Registry. Molecular subtypes were classified according to HER2 and hormone receptor (HR, including estrogen and/or progesterone receptor) expression. Multivariable logistic regression was used to estimate odds ratios (ORs) and 95Â % confidence intervals (CIs) of Stage IV versus Stage I-III breast cancer; Cox proportional hazards regression was used to assess relative hazard (RH) of mortality.;Five percent of invasive breast cancer was metastatic at diagnosis. Compared to patients with earlier stage disease, patients with de novo metastatic disease were significantly more likely to have HER2+ tumors (HR+/HER2+: OR 1.29, 95Â % CI 1.17-1.42; HR-/HER2+: OR 1.40, 95Â %CI 1.25-1.57, vs. HR+/HER2-). Median survival improved over time, but varied substantially across race/ethnicity (Asians: 34Â months; African Americans: 6Â months), neighborhood socioeconomic status (SES) (highest: 34Â months, lowest: 20Â months), and molecular subtype (HR+/HER2+: 45Â months; triple negative: 12Â months). In a multivariable model, triple negative (RH 2.85, 95Â % CI 2.50-3.24) and HR-/HER2+ (RH 1.60, 95Â % CI 1.37-1.87) had worse, while HR+/HER2+ had similar, risk of all-cause death compared to HR+/HER2- breast cancer.;De novo metastatic breast cancer was more likely to be HER2+. Among metastatic tumors, those that were HER2+ had better survival than other subtypes.",
        "Doc_title":"Occurrence and outcome of de novo metastatic breast cancer by subtype in a large, diverse population.",
        "Journal":"Cancer causes & control : CCC",
        "Do_id":"27496200",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605818581705031680},
      {
        "Doc_abstract":"The commonest cancer in Egyptian females occurs in the breast cfDNA is a non-invasive marker for tumor detetion and prognostic assessment in many types of cancer including breast cancer. This study aimed to assess the role of cfDNA and its fragmentation pattern in breast cancer prognosis and treatment response. Forty female patients with malignant breast tumors and a comparable group of healthy blood donors were enrolled prospectively. cfDNA levels and fragmentation patterns were investigated after cfDNA extraction, gel electrophoresis and gel analysis. The percentage of breast cancer patients positive for cfDNA (92.5%) was significantly higher than that of controls (55%). Also, mean concentration of cfDNA was significantly higher than in the control group (<0.05). Most Her-2 positive patients had long cfDNA fragments, this being significant as compared to Her-2 negative patients (<0.05). Metastasis was also positively linked to significantly higher cfDNA (<0.05) and the mean cfDNA integrity index was significantly higher in non-responders compared to treatment responders (<0.05). In conclusion, both qualitative and quantitative aspects of cfDNA and its different fragments in breast cancer patients could be related to prognosis, metastasis and treatment response. Long cfDNA fragments could be particularly useful for prediction purposes. ",
        "Doc_title":"Circulating DNA in Egyptian Women with Breast Cancer.",
        "Journal":"Asian Pacific journal of cancer prevention : APJCP",
        "Do_id":"27356723",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605892507864924160},
      {
        "Doc_abstract":"The molecular classification of human breast tumors has afforded insights into subtype specific biological processes, patient prognosis and response to therapies. However, using current methods roughly one quarter of breast tumors cannot be classified into one or another molecular subtype. To explore the possibility that the unclassifiable samples might comprise one or more novel subtypes we employed a collection of publically available breast tumor datasets with accompanying clinical information to assemble 1,593 transcript profiles: 25% of these samples could not be assigned to one of the current molecular subtypes of breast cancer. All of the unclassifiable samples could be grouped into a new molecular subtype, which we termed \"luminal-like\". We also identified the luminal-like subtype in an independent collection of tumor samples (NKI295). We found that patients harboring tumors of the luminal-like subtype have a better prognosis than those with basal-like breast cancer, a similar prognosis to those with ERBB2+, luminal B or claudin-low tumors, but a worse prognosis than patients with luminal A or normal-like breast tumors. Our findings suggest the occurrence of another molecular subtype of breast cancer that accounts for the vast majority of previously unclassifiable breast tumors. ",
        "Doc_title":"Identification of a novel luminal molecular subtype of breast cancer.",
        "Journal":"PloS one",
        "Do_id":"25076125",
        "Doc_ChemicalList":"Biomarkers, Tumor;Receptors, Estrogen;Receptors, Progesterone;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Biomarkers, Tumor;Breast Neoplasms;Cluster Analysis;Databases, Factual;Female;Gene Expression Regulation, Neoplastic;Humans;Receptor, ErbB-2;Receptors, Estrogen;Receptors, Progesterone;Survival Analysis",
        "Doc_meshqualifiers":"genetics;classification;mortality;pathology;genetics;metabolism;genetics;metabolism;genetics;metabolism",
        "_version_":1605823798929522688},
      {
        "Doc_abstract":"One-third of breast cancers display amplifications of the ERBB2 gene encoding the HER2 kinase receptor. Trastuzumab, a humanized antibody directed against an epitope on subdomain IV of the extracellular domain of HER2 is used for therapy of HER2-overexpressing mammary tumors. However, many tumors are either natively resistant or acquire resistance against Trastuzumab. Antibodies directed to different epitopes on the extracellular domain of HER2 are promising candidates for replacement or combinatorial therapy. For example, Pertuzumab that binds to subdomain II of HER2 extracellular domain and inhibits receptor dimerization is under clinical trial. Alternative antibodies directed to novel HER2 epitopes may serve as additional tools for breast cancer therapy. Our aim was to generate novel anti-HER2 monoclonal antibodies inhibiting the growth of breast cancer cells, either alone or in combination with tumor necrosis factor-Î± (TNF-Î±).;Mice were immunized against SK-BR-3 cells and recombinant HER2 extracellular domain protein to produce monoclonal antibodies. Anti-HER2 antibodies were characterized with breast cancer cell lines using immunofluorescence, flow cytometry, immunoprecipitation, western blot techniques. Antibody epitopes were localized using plasmids encoding recombinant HER2 protein variants. Antibodies, either alone or in combination with TNF-Î±, were tested for their effects on breast cancer cell proliferation.;We produced five new anti-HER2 monoclonal antibodies, all directed against conformational epitope or epitopes restricted to the native form of the extracellular domain. When tested alone, some antibodies inhibited modestly but significantly the growth of SK-BR-3, BT-474 and MDA-MB-361 cells displaying ERBB2 amplification. They had no detectable effect on MCF-7 and T47D cells lacking ERBB2 amplification. When tested in combination with TNF-Î±, antibodies acted synergistically on SK-BR-3 cells, but antagonistically on BT-474 cells. A representative anti-HER2 antibody inhibited Akt and ERK1/2 phosphorylation leading to cyclin D1 accumulation and growth arrest in SK-BR-3 cells, independently from TNF-Î±.;Novel antibodies against extracellular domain of HER2 may serve as potent anti-cancer bioactive molecules. Cell-dependent synergy and antagonism between anti-HER2 antibodies and TNF-Î± provide evidence for a complex interplay between HER2 and TNF-Î± signaling pathways. Such complexity may drastically affect the outcome of HER2-directed therapeutic interventions.",
        "Doc_title":"Novel anti-HER2 monoclonal antibodies: synergy and antagonism with tumor necrosis factor-Î±.",
        "Journal":"BMC cancer",
        "Do_id":"23033967",
        "Doc_ChemicalList":"Antibodies, Monoclonal;Epitopes;Tumor Necrosis Factor-alpha;Cyclin D1;Receptor, ErbB-2;Proto-Oncogene Proteins c-akt;MAPK1 protein, human;Mitogen-Activated Protein Kinase 1;Mitogen-Activated Protein Kinase 3",
        "Doc_meshdescriptors":"Animals;Antibodies, Monoclonal;Antibody Affinity;Blotting, Western;Breast Neoplasms;Cell Line, Tumor;Cell Proliferation;Cyclin D1;Dose-Response Relationship, Drug;Drug Antagonism;Drug Synergism;Epitopes;Female;Fluorescent Antibody Technique, Indirect;Humans;In Situ Hybridization, Fluorescence;MCF-7 Cells;Mice;Mitogen-Activated Protein Kinase 1;Mitogen-Activated Protein Kinase 3;Phosphorylation;Protein Binding;Proto-Oncogene Proteins c-akt;Receptor, ErbB-2;Tumor Necrosis Factor-alpha",
        "Doc_meshqualifiers":"immunology;metabolism;pharmacology;immunology;genetics;metabolism;pathology;drug effects;metabolism;immunology;metabolism;metabolism;metabolism;drug effects;immunology;metabolism;genetics;immunology;metabolism;metabolism;pharmacology",
        "_version_":1605903060160217088},
      {
        "Doc_abstract":"We describe a survey of genetic changes by comparative genomic hybridization (CGH) in 11 human breast cancer cell lines recently established in our laboratory. The most common gains took place at 8q (73%), 1 q (64%), 7q (64%), 3q (45%) and 7p (45%), whereas losses were most frequent at Xp (54%), 8p (45%), 18q (45%) and Xq (45%). Many of the cell lines displayed prominent, localized DNA amplifications by CGH. One-third of these loci affected breast cancer oncogenes, whose amplifications were validated with specific probes: 17q12 (two cell lines with ERBB2 amplifications), 11q13 (two with cyclin-D1), 8p11-p12 (two with FGFR1) and 10q25 (one with FGFR2). Gains and amplifications affecting 8q were the most common genetic alterations in these cell lines with the minimal, common region of involvement at 8q22-q23. No high-level MYC (at 8q24) amplifications were found in any of the cell lines. Two-thirds of the amplification sites took place at loci not associated with established oncogenes, such as 1q41-q43, 7q21-q22, 7q31, 8q23, 9p21-p23, 11p12-p14, 15q12-q14, 16q13-q21, 17q23, 20p11-p12 and 20q13. Several of these locations have not been previously reported and may harbour important genes whose amplification is selected for during cancer development. In summary, this set of breast cancer cell lines displaying prominent DNA amplifications should facilitate discovery and functional analysis of genes and signal transduction pathways contributing to breast cancer development.",
        "Doc_title":"Molecular cytogenetic analysis of 11 new breast cancer cell lines.",
        "Journal":"British journal of cancer",
        "Do_id":"10604729",
        "Doc_ChemicalList":"DNA, Neoplasm",
        "Doc_meshdescriptors":"Breast Neoplasms;DNA, Neoplasm;Gene Amplification;Humans;Nucleic Acid Hybridization;Oncogenes;Sequence Deletion;Tumor Cells, Cultured",
        "Doc_meshqualifiers":"genetics;genetics",
        "_version_":1605761863107215360},
      {
        "Doc_abstract":"Human epidermal growth factor receptor 2 (HER2) is one of the most important prognostic and predictive factors for breast cancer patients. Recently, serum HER2 ECD level of patients detected by enzyme-linked immunoabsorbent assay (ELISA) has been shown to predict tumor HER2 status and reveal its association with tumor progression, recurrence and poor prognosis. In this study, we established a new method, dot blot assay, to measure the serum HER2 level in breast cancer patients and further to evaluate the clinical value for monitoring breast cancer progression. We found that the serum HER2 level measured by dot blot assay was significantly correlated with tissue HER2 status in breast cancer patients (Pâ€Š=â€Š0.001), and also significantly correlated with HER2 level measured by ELISA (Pâ€Š=â€Š1.06Ã—10(-11)). Compared with ELISA method, the specificity and sensitivity of dot blot assay were 95.3% and 65.0%, respectively. The serum HER2 levels of patients with grade III or ER-negative were higher than those with grade I-II (Pâ€Š=â€Š0.004) and ER-positive (Pâ€Š=â€Š0.033), respectively. Therefore, the novel dot blot method to detect serum HER2 level is a valid and inexpensive assay with potential application in monitoring breast cancer progression in clinical situations.",
        "Doc_title":"Serum HER2 level measured by dot blot: a valid and inexpensive assay for monitoring breast cancer progression.",
        "Journal":"PloS one",
        "Do_id":"21533253",
        "Doc_ChemicalList":"Biomarkers, Tumor;ERBB2 protein, human;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Biomarkers, Tumor;Breast Neoplasms;Disease Progression;Enzyme-Linked Immunosorbent Assay;Female;Humans;Receptor, ErbB-2",
        "Doc_meshqualifiers":"blood;blood;pathology;blood",
        "_version_":1605825282659319808},
      {
        "Doc_abstract":"Human epidermal growth factor receptor-2 (HER-2) gene status is crucial to guide treatment decisions regarding the use of HER-2-targeted therapies in breast cancer. An invasive breast cancer with HER-2 2+ score is regarded as HER-2 status equivocal and should further determine by fluorescent in situ hybridization (FISH), which is considered the standard test for HER-2 status. Here, we aimed to establish a risk score to allow for prediction of the presence of HER-2 gene status.;A total of 182 HER-2 2+ by immunohistochemistry (IHC) invasive breast cancer cases were enrolled in this study. The association between clinicopathological variables like age, sex, tumor grade, hormone receptor (HR) status, P53 and proliferation index (Ki67), and FISH result using US Food and Drug Administration (FDA) criteria was evaluated. Also, we compared the HER-2 FISH results using FDA criteria and 2013 American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) guideline.;The study population had a median age of 48 years (range, 29-78 years). Estrogen receptor (ER) was expressed in 131 (72.0%) patients. 73.1% of patients (133/182) were progesterone receptor (PR) positive. The median Ki67 value was 20% (range, 3-90%). There was good agreement between the FDA and 2013 ASCO/CAP guideline. Sixty-three of all patients were HER-2 FISH amplified (positive) based on FDA criteria. Tumors with HER-2 amplified were more likely to harbor ER negative (58.8% vs. 25.2%, P<0.001) or PR negative (57.1% vs. 26.3%, P<0.001) or P53 negative (44.8% vs. 29.8%, P=0.048). A significant high level of Ki67 was detected in HER-2 amplified groups (P=0.006). We created a risk score that comprised HR, P53 and Ki67. A significant association between risk score and HER-2 FISH amplification was observed (Ï‡(2)=30.41, P<0.001).;This novel immunohistochemical risk score could be highly useful to predict the presence of HER-2 gene status in invasive breast cancer.",
        "Doc_title":"Clinicopathological variables predicting HER-2 gene status in immunohistochemistry-equivocal (2+) invasive breast cancer.",
        "Journal":"Journal of thoracic disease",
        "Do_id":"25093085",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605898765183483904},
      {
        "Doc_abstract":"Breast cancer is an etiologically heterogeneous disease with marked geographical variations. Joint consideration of the relationship between specific molecular alterations and known or suspected epidemiologic risk factors for this disease should help distinguish subgroups of women that are at elevated risk of developing breast cancer. In this article, we present a comprehensive literature review of the etiologic and prognostic roles of Her-2/neu and P53 among women. In addition, we discuss the advantages and limitations of using biomarkers in epidemiological studies. We conclude that more research is needed to understand the complex relationships between genetic alterations and etiologic risk factors for breast cancer.",
        "Doc_title":"The epidemiology of Her-2/neu and P53 in breast cancer.",
        "Journal":"Salud publica de Mexico",
        "Do_id":"10850134",
        "Doc_ChemicalList":"Genetic Markers",
        "Doc_meshdescriptors":"Breast Neoplasms;European Continental Ancestry Group;Female;Gene Expression Regulation, Neoplastic;Genes, erbB-2;Genes, p53;Genetic Markers;Humans;Risk Factors;Survival Rate",
        "Doc_meshqualifiers":"epidemiology;genetics;genetics;genetics",
        "_version_":1605764097085800448},
      {
        "Doc_abstract":"Approximately 25-30% of breast cancers are assumed to be HER-2/neu positive. It is well known that HER-2/neu-positive cancers after treatment with trastuzumab can become HER-2/neu negative. Change in HER-2/neu status from negative to positive following treatment has not been well studied. We describe a patient with inflammatory breast cancer who was initially HER-2/neu negative but became positive after treatment. A 59-year-old postmenopausal white female saw her surgeon for violaceous discoloration of the left breast for 4 months. The surgeon palpated a mass measuring 6 cm in the patient's left breast. Additionally, there was violaceous discoloration involving two thirds of the breast. Biopsy of the breast mass and skin revealed inflammatory breast cancer. The tumor was estrogen receptor positive, progesterone receptor positive and HER-2/neu negative. The patient was given four cycles of chemotherapy with cyclophosphamide, doxorubicin and docetaxol. She subsequently underwent a mastectomy, excision of the skin over the chest wall and axillary node dissection. Of the axillary lymph nodes, 14/14 were involved. The tumor was still estrogen receptor positive and progesterone receptor positive, but HER-2/neu was 2+ by immunohistochemistry and amplified at 3.3 as detected by fluorescent in situ hybridization. The patient received trastuzumab along with chemotherapy followed by radiation therapy and letrozole. She is currently receiving trastuzumab and letrozole in the adjuvant setting and appears to be doing well.;A breast cancer which was initially HER-2/neu negative can become positive following treatment. Therefore, re-biopsy may be necessary during the course of treatment of breast cancer to re-assess the HER-2/neu status. This gives the clinician the opportunity to include drugs like trastuzumab and lapatinib in the treatment of patients with a transformation to HER-2/neu-positive cancer.",
        "Doc_title":"Change in HER-2/neu Status from Negative to Positive following Treatment in Breast Cancer: A Case Report.",
        "Journal":"Case reports in oncology",
        "Do_id":"21526002",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605891355321565184},
      {
        "Doc_abstract":"Adiponectin is a new adipocyte-secreted protein and associated with insulin-resistant status, such as type 2 diabetes mellitus and obesity. The inverse correlation between serum adiponectin levels and breast cancer risk was recently documented. On the other hand, the association of tissue adiponectin levels with breast cancer has not been previously reported. Thus, in the present study, the relationship between tissue adiponectin levels and breast cancer was evaluated.;We analyzed the correlation between tissue adiponectin levels and the occurrence of breast cancer in a case-control study comprising 27 women with diagnosed and histologically confirmed breast cancer and 33 women with fibroadenoma. In addition, the association of tissue adiponectin levels with the various classical risk factors, such as body mass index, menopausal status and, tumor size, stage, lymph node status, hormonal status were also studied.;Tissue adiponectin levels in patients with breast cancer (0.75 +/- 0.06) were significantly higher than those in controls (0.68 +/- 0.1) (P = 0.02). The high tissue adiponectin levels were associated with significantly (P = 0.001) an increased risk for breast cancer compared with those in the low tissue adiponectin levels (OR, 1.34; 95% CI, 1.12-1.84) in breast cancer patients. In addition, postmenopausal women with the high tissue adiponectin levels showed a significantly (P = 0.003) an increased risk for breast cancer compared with women in low tissue adiponectin levels (OR, 1.63; 95% CI, 1.23-1.90). The correlation between BMI and breast cancer was not found (P > 0.05). Furthermore, the status of estrogen receptor, progesterone receptor, HER-2/neu receptor and lymph nodes involvement were established, no effect on the tissue adiponectin levels in patients with breast cancer and no correlations were detected among tumor stage, tumor size and the levels of tissue adiponectin (P > 0.05).;Our results suggest that the high tissue adiponectin levels significantly detected in breast cancer patients and associated with an increased risk for breast cancer.",
        "Doc_title":"Tissue levels of adiponectin in breast cancer patients.",
        "Journal":"Medical oncology (Northwood, London, England)",
        "Do_id":"17917082",
        "Doc_ChemicalList":"Adiponectin;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Adiponectin;Adult;Aged;Breast Neoplasms;Case-Control Studies;Female;Humans;Incidence;Middle Aged;Neoplasm Staging;Receptor, ErbB-2",
        "Doc_meshqualifiers":"analysis;diagnosis;epidemiology;pathology",
        "_version_":1605839153468014592},
      {
        "Doc_abstract":"Breast cancer is the most common cancer in the UK. Advances in the methods of early diagnosis as well as newer and more effective treatments have led to improvements of disease-free and overall survival over the last decade. Almost one-third of breast cancers present with an aggressive form characterized by increased expression of human epidermal growth receptor 2 (HER2) proteins. A targeted treatment using monoclonal antibodies against HER2 expression such as trastuzumab has been shown to improve survival. Unfortunately, there is a degree of cardiotoxicity associated with these agents, as inhibition of HER2 pathways can also impair cardioprotective pathways. In the present review, we discuss the mechanisms by which trastuzumab might affect vascular homeostasis leading to endothelial dysfunction. We also provide suggestions for future research examining the effects of trastuzumab on the vasculature in breast cancer. ",
        "Doc_title":"Breast cancer therapy and cardiovascular risk: focus on trastuzumab.",
        "Journal":"Vascular health and risk management",
        "Do_id":"25897242",
        "Doc_ChemicalList":"Antineoplastic Agents;Reactive Oxygen Species;Trastuzumab",
        "Doc_meshdescriptors":"Antineoplastic Agents;Breast Neoplasms;Endothelium, Vascular;Genes, erbB-2;Heart Failure;Homeostasis;Humans;Oxidative Stress;Reactive Oxygen Species;Trastuzumab",
        "Doc_meshqualifiers":"therapeutic use;drug therapy;drug effects;drug effects;chemically induced;physiopathology;drug effects;drug effects;adverse effects;therapeutic use",
        "_version_":1605906914834644992},
      {
        "Doc_abstract":"This study was conducted to determine the prognostic effect hormone receptor (HR) status in early HER2 positive (HER2+) breast cancer patients, since it has not yet been established whether HR status can be used in the prognosis of patients with (HER2+) breast cancer.;We obtained data from 299 patients with early HER2+ breast cancer who underwent surgery and received standard adjuvant chemotherapy, hormonal therapy and/or radiation between 2000 and 2002 at the Instituto Nacional De Enfermedades Neoplasicas, PerÃº. Clinical and pathological features were compared. Endpoints analyzed were disease free survival (DFS) and overall survival (OS).;Overall, 155 patients were HR-positive (HR+) and 144 were negative (HR-). The two groups had similar characteristics except for histologic grade and extracapsular extension. With a median follow-up of 93 months, 5-year DFS was statistically different between the two groups: 65.0% for (HER2+/ HR-) and 74.6% for the (HER2+/ HR+) patients (p=.045). OS at 5 years was not statistically different between the two groups with 75.5% for (HER2+/ HR-) patients and 82.4% for the (HER2+/ HR+)(p=.140).;Patients with (HER2+/ HR-) breast cancers treated with surgery and standard adjuvant chemotherapy exhibited a statistically worse DFS compared to those with (HER2+/ HR+) tumors. However, OS was similar in both groups.",
        "Doc_title":"Prognostic effect of hormone receptor status in early HER2 positive breast cancer patients.",
        "Journal":"Hematology/oncology and stem cell therapy",
        "Do_id":"20890067",
        "Doc_ChemicalList":"Receptors, Estrogen;Receptors, Progesterone;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Adult;Breast Neoplasms;Chemotherapy, Adjuvant;Combined Modality Therapy;Female;Follow-Up Studies;Humans;Immunohistochemistry;In Situ Hybridization, Fluorescence;Kaplan-Meier Estimate;Middle Aged;Neoplasm Staging;Outcome Assessment (Health Care);Prognosis;Proportional Hazards Models;Radiotherapy;Receptor, ErbB-2;Receptors, Estrogen;Receptors, Progesterone;Retrospective Studies",
        "Doc_meshqualifiers":"metabolism;pathology;therapy;statistics & numerical data;genetics;metabolism;metabolism;metabolism",
        "_version_":1605810874992295936},
      {
        "Doc_abstract":"Breast cancer is the most frequent gynecological tumor. The HER-2/neu oncogene may play a role in the prognosis and management of patients with breast cancer. In a retrospective study on 100 patients, we correlated the expression of this oncogene with the classic clinical and pathological factors. 32 % of patients exhibited overexpression of HER-2/neu. There was no significant correlation with classic parameters. This finding could indicate that HER-2/neu expression is a new independent prognostic factor. Prospective studies correlating HER-2/neu overexpression with prognosis might provide additional data.",
        "Doc_title":"[Immunohistochemical research on breast cancer cell proliferation and hormonal receptor status with special emphasis on HER-2/neu expression].",
        "Journal":"Zentralblatt fur Gynakologie",
        "Do_id":"12712389",
        "Doc_ChemicalList":"Receptors, Estrogen;Receptors, Progesterone;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Breast Neoplasms;Cell Division;Female;Genes, erbB-2;Humans;Immunohistochemistry;Lymphatic Metastasis;Middle Aged;Neoplasm Staging;Receptor, ErbB-2;Receptors, Estrogen;Receptors, Progesterone",
        "Doc_meshqualifiers":"genetics;pathology;methods;analysis;analysis;analysis",
        "_version_":1605876524369575936},
      {
        "Doc_abstract":"Based on the expression of estrogen receptor (ER), progesterone receptor (PR) and HER2/neu (HER2), breast cancer is classified into several subtypes: luminal A (ER+ and/or PR+, HER2-), luminal B (ER+ and/or PR+, HER2+), HER2-overexpressing (ER-, PR-, and HER2+) and triple-negative (ER-, PR-, and HER2-). The aim of this case-control study is to determine reproductive factors associated with breast cancer subtypes in Chinese women. A total of 1,417 patients diagnosed with breast cancer in the First Affiliated Hospital, China Medical University, Shenyang, China between 2001 and 2009 and 1,587 matched controls without a prior breast cancer were enrolled. Personal interviews were conducted to obtain information on reproductive characteristics and clinical history. Relationships between the factors and the subtypes of breast cancer were examined using logistic regression to compute odds ratios (OR) and 95% confidence intervals (CI). Notably, luminal A (50.0%) was the most prevalent subtype relative to luminal B (15.10%), HER2-overexpressing (10.87%) and triple-negative (23.08%). Menarche at an early age was associated with a reduced risk of luminal A (OR, 2.35; 95% CI, 1.45-3.81). Breastfeeding protected parous women from any subtype of breast cancer. Postmenopause and spontaneous abortion were inversely associated with the risk of luminal tumors. By contrast, multiparity, family history of breast cancer and induced abortion increased the risk of breast cancer. Collectively, our findings suggest that reproductive factors such as age at menarche, parity, breastfeeding, menopausal status and abortion history have different effects on the subtypes of breast cancer in Chinese women.",
        "Doc_title":"A case-control study of reproductive factors associated with subtypes of breast cancer in Northeast China.",
        "Journal":"Medical oncology (Northwood, London, England)",
        "Do_id":"19771534",
        "Doc_ChemicalList":"Biomarkers, Tumor;Estrogens;Receptors, Estrogen;Receptors, Progesterone;Progesterone;ERBB2 protein, human;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Adult;Aged;Biomarkers, Tumor;Breast Feeding;Breast Neoplasms;Carcinoma;Case-Control Studies;China;Estrogens;Female;Genetic Predisposition to Disease;Humans;Leiomyoma;Middle Aged;Neoplasms, Hormone-Dependent;Neoplasms, Second Primary;Progesterone;Receptor, ErbB-2;Receptors, Estrogen;Receptors, Progesterone;Reproductive History;Risk Factors;Uterine Neoplasms",
        "Doc_meshqualifiers":"analysis;chemistry;classification;epidemiology;pathology;chemistry;classification;epidemiology;pathology;epidemiology;epidemiology;chemistry;classification;epidemiology;pathology;epidemiology;analysis;analysis;analysis;epidemiology",
        "_version_":1605752020639154176},
      {
        "Doc_abstract":"To identify the genetic variants associated with breast cancer survival, a genome-wide association study (GWAS) was conducted of Korean breast cancer patients.;From the Seoul Breast Cancer Study (SEBCS), 3,226 patients with breast cancer (1,732 in the discovery and 1,494 in the replication set) were included in a two-stage GWAS on disease-free survival (DFS) by tumor subtypes based on hormone receptor (HR) and human epidermal growth factor receptor 2 (HER2). The associations of the re-classified combined prognostic markers through recursive partitioning analysis (RPA) of DFS for breast cancer were assessed with the Cox proportional hazard model. The prognostic predictive values of the clinical and genetic models were evaluated by Harrell's C.;In the two-stage GWAS stratified by tumor subtypes, rs166870 and rs10825036 were consistently associated with DFS in the HR+ HER2- and HR- HER2- breast cancer subtypes, respectively (Prs166870 = 2.88 Ã— 10(-7) and Prs10825036 = 3.54 Ã— 10(-7) in the combined set). When patients were classified by the RPA in each subtype, genetic factors contributed significantly to differentiating the high risk group associated with DFS inbreast cancer, specifically the HR+ HER2- (P discovery=1.18 Ã— 10(-8) and P replication = 2.08 Ã— 10(-5)) and HR- HRE2- subtypes (P discovery = 2.35 Ã— 10(-4) and P replication = 2.60 Ã— 10(-2)). The inclusion of the SNPs tended to improve the performance of the prognostic models consisting of age, TNM stage and tumor subtypes based on ER, PR, and HER2 status.;Combined prognostic markers that include clinical and genetic factors by tumor subtypes could improve the prediction of survival in breast cancer.",
        "Doc_title":"Prediction of breast cancer survival using clinical and genetic markers by tumor subtypes.",
        "Journal":"PloS one",
        "Do_id":"25867717",
        "Doc_ChemicalList":"Genetic Markers",
        "Doc_meshdescriptors":"Adult;Aged;Aged, 80 and over;Breast Neoplasms;Case-Control Studies;Female;Genetic Markers;Genome-Wide Association Study;Humans;Middle Aged;Prognosis;Republic of Korea",
        "Doc_meshqualifiers":"classification;genetics;pathology",
        "_version_":1605760757972074496},
      {
        "Doc_abstract":"Accumulating evidence supports the theory that breast cancer arises from a subpopulation of mammary stem/progenitor cell which posses the ability to self-renew. However, the involvement of estrogen signaling in regulation of breast cancer stem/progenitor cells has not been fully established, mainly because expression and function of ER-Î± in breast cancer stem cells remains controversial. Previously, our laboratory cloned a variant of ER-Î±, ER-Î±36, and found that ER-Î±36-mediated non-genomic estrogen signaling plays an important role in malignant growth of triple-negative breast cancer cells. In this study, we found that ER-Î±36 was highly expressed in ER-negative breast cancer SK-BR-3 cells and mediated non-genomic estrogen signaling such as activation of the MAPK/ERK signaling in these cells. Knock-down of ER-Î±36 expression in these cells using the shRNA method diminished their responsiveness to estrogen and significantly down-regulated HER2 expression. HER2 signaling activated ER-Î±36 transcription through an AP1 site in the ER-Î±36 promoter and ER-Î±36 physically interacted with HER2. We also found that ER-Î±36 is highly expressed in a subset of SK-BR-3 cells that was positive for ALDH1, a breast cancer stem cell marker, and knock-down of ER-Î±36 expression reduced the population of ALDH1 positive cells. Our results thus demonstrated that ER-Î±36 positively regulates HER2 expression and the population of ALDH1 positive breast cancer cells, and suggested that non-genomic estrogen signaling mediated by ER-Î±36 is involved in maintenance and regulation of breast cancer stem cells.",
        "Doc_title":"A positive cross-regulation of HER2 and ER-Î±36 controls ALDH1 positive breast cancer cells.",
        "Journal":"The Journal of steroid biochemistry and molecular biology",
        "Do_id":"21907803",
        "Doc_ChemicalList":"DNA Primers;Estrogen Receptor alpha;Estrogens;Isoenzymes;aldehyde dehydrogenase 1;Retinal Dehydrogenase;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Base Sequence;Breast Neoplasms;Cell Line, Tumor;DNA Primers;Estrogen Receptor alpha;Estrogens;Female;Humans;Isoenzymes;MAP Kinase Signaling System;Polymerase Chain Reaction;Receptor, ErbB-2;Retinal Dehydrogenase;Signal Transduction",
        "Doc_meshqualifiers":"metabolism;pathology;physiology;metabolism;metabolism;physiology;metabolism",
        "_version_":1605751381910618112},
      {
        "Doc_abstract":"Bilateral breast cancer (BBC) is not an uncommon entity in contemporary breast clinics. Improved life expectancy after breast cancer treatment and routine use of contra-lateral breast mammography has led to increased incidence of BBC. Our study objective was to define the epidemiological and tumour characteristics of BBC in India.;A total of 1251 breast cancer patients were treated during the period January 2007 to March 2015 and 30 patients were found to have BBC who constituted the study population (60 tumour samples). Synchronous bilateral breast cancers (SBC) was defined as two tumours diagnosed within an interval of 6 months and a second cancer diagnosed after 6 months was labelled as metachronous breast cancer (MBC). Analyses of patient and tumour characteristics were done in this prospective data base of BBC patients.;Median patient age was 66 years (range 39-85). Majority of the patients had SBC (n=28) and in 12 patients the second tumour was clinically occult and detected only by mammography of the contra-lateral breast. The second tumour was found at lower tumour size compared to the first in 73% of cases and was negative for axillary metastasis in 80% of cases (24/30). Infiltrating ductal carcinoma was the commonest histological type (n=51) and majority of the tumours were ER/PR positive (50/60). Her2 was overexpressed in 13 tumours (21%). Over 70% (22/30) of patients had similar histology in both breasts and amongst them grade concordance was present in about 69% (15/22) of patients. Concordance rates of ER, PR and Her2 statuses were 83%, 80% and 90% respectively. Bilateral mastectomy was the commonest surgery performed in 80% of the patients followed by bilateral breast conservation in 13%. At the end of study period, 26 patients were alive and disease free. Median survival was 29 months (range 3-86 months).;In most patients with BBC, the second tumour is identified at an early stage than index tumours supporting the importance of contralateral breast cancer screening at the time of primary diagnosis and during follow-up. BBC occurs more frequently in old age group and majority of these tumours are estrogen dependent. There is good pathological concordance between the index tumour and the contralateral breast cancer.",
        "Doc_title":"Synchronous Bilateral Breast Cancers.",
        "Journal":"Journal of clinical and diagnostic research : JCDR",
        "Do_id":"26500995",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605810751147081728},
      {
        "Doc_abstract":"The distribution of breast cancer molecular subtypes has been shown to vary by race/ethnicity, highlighting the importance of host factors in breast tumor biology. We undertook the current analysis to determine population-based distributions of breast cancer subtypes among six ethnic Asian groups in California. We defined immunohistochemical (IHC) surrogates for each breast cancer subtype among Chinese, Japanese, Filipina, Korean, Vietnamese, and South Asian patients diagnosed with incident, primary, invasive breast cancer between 2002 and 2007 in the California Cancer Registry as: hormone receptor-positive (HR+)/HER2- [estrogen receptor-positive (ER+) and/or progesterone receptor-positive (PR+), human epidermal growth factor receptor 2-negative (HER2-)], triple-negative (ER-, PR-, and HER2-), and HER2-positive (ERÂ±, PRÂ±, and HER2+). We calculated frequencies of breast cancer subtypes among Asian ethnic groups and evaluated their associations with clinical and demographic factors. Complete IHC data were available for 8,140 Asian women. Compared to non-Hispanic White women, Korean [odds ratio (OR) = 1.8, 95% confidence interval (CI) = 1.5-2.2], Filipina (OR = 1.3, 95% CI = 1.2-1.5), Vietnamese (OR = 1.3, 95% CI = 1.1-1.6), and Chinese (OR = 1.1, 95% CI = 1.0-1.3) women had a significantly increased risk of being diagnosed with HER2-positive breast cancer subtypes after adjusting for age, stage, grade, socioeconomic status, histology, diagnosis year, nativity, and hospital ownership status. We report a significant ethnic disparity in HER2-positive breast cancer in a large population-based cohort enriched for Asian-Americans. Given the poor prognosis and high treatment costs of HER2-positive breast cancer, our results have implications for healthcare resource utilization, cancer biology, and clinical care.",
        "Doc_title":"Asian ethnicity and breast cancer subtypes: a study from the California Cancer Registry.",
        "Journal":"Breast cancer research and treatment",
        "Do_id":"20957431",
        "Doc_ChemicalList":"Receptors, Estrogen;Receptors, Progesterone;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Adult;Aged;Asian Continental Ancestry Group;Breast Neoplasms;California;Female;Humans;Middle Aged;Receptor, ErbB-2;Receptors, Estrogen;Receptors, Progesterone;Registries",
        "Doc_meshqualifiers":"ethnology;ethnology;pathology;ethnology;metabolism;metabolism;metabolism",
        "_version_":1605907471400960000},
      {
        "Doc_abstract":"Epidermal growth factor receptor (EGFR/ErbB1) and HER2 (ErbB2/neu), members of the ErbB receptor tyrosine kinase family, are frequently overexpressed in breast cancer and are known to drive tumor growth and progression, making them promising targets for cancer therapy. Lapatinib is a selective competitive inhibitor of both the HER2 and EGFR tyrosine kinases. Although lapatinib showed significant activity in patients with HER2-positive breast cancer, the role of EGFR in the response of breast cancer to lapatinib has not been defined. Here, we examined the role of EGFR expression levels in the sensitivity of HER2-overexpressing breast cancer cells to lapatinib. Depletion of EGFR by EGFR small-interfering RNA knockdown did not affect lapatinib sensitivity in these cells, whereas treated HER2 siRNA knockdown cells became more resistant to lapatinib. We conclude that the in vitro activity of lapatinib is not dependent on EGFR expression level in HER2-overexpressing breast cancer cells.",
        "Doc_title":"Activity of lapatinib is independent of EGFR expression level in HER2-overexpressing breast cancer cells.",
        "Journal":"Molecular cancer therapeutics",
        "Do_id":"18644997",
        "Doc_ChemicalList":"Antineoplastic Agents;Quinazolines;lapatinib;Receptor, Epidermal Growth Factor;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Antineoplastic Agents;Breast Neoplasms;Cell Line, Tumor;Drug Resistance, Neoplasm;Drug Screening Assays, Antitumor;Female;Humans;Quinazolines;Receptor, Epidermal Growth Factor;Receptor, ErbB-2",
        "Doc_meshqualifiers":"pharmacology;pathology;drug effects;pharmacology;deficiency;metabolism;metabolism",
        "_version_":1605805531420688384},
      {
        "Doc_abstract":"HER2-targeted therapies have revolutionized the outcome of patients with HER2-positive breast cancer. Pertuzumab is the first in a new class of monoclonal antibodies that target the extracellular dimerization domain of HER2 receptors, also known as HER dimerization inhibitors. The development of pertuzumab and preclinical and clinical data in breast cancer are reviewed. Regulatory affairs related to pertuzumab and the recent accelerated approval granted by the FDA for the treatment of breast cancer in the neoadjuvant setting are also covered. This process opens doors for further approvals which could considerably shorten the time between initial drug development and availability. ",
        "Doc_title":"Pertuzumab for the treatment of breast cancer.",
        "Journal":"Cancer investigation",
        "Do_id":"24921704",
        "Doc_ChemicalList":"Antibodies, Monoclonal, Humanized;Antineoplastic Agents;pertuzumab",
        "Doc_meshdescriptors":"Animals;Antibodies, Monoclonal, Humanized;Antineoplastic Agents;Breast Neoplasms;Female;Humans;Treatment Outcome",
        "Doc_meshqualifiers":"pharmacokinetics;pharmacology;therapeutic use;pharmacokinetics;pharmacology;therapeutic use;drug therapy",
        "_version_":1605742704734502912},
      {
        "Doc_abstract":"Breast cancer is the most common malignancy to affect women of reproductive age. As more women are delaying fertility into the 4th and 5th decade of life, more women face the possibility of a breast cancer diagnosis prior to accomplishing their reproductive goals.;Literature review PubMed, EMBASE.;From expectant management, hormonal suppression, in vitro fertilization with embryo freezing, to egg and ovarian tissue cryopreservation, numerous fertility sparing options are available to women with breast cancer. Therapy will be individualized based on a patient's age, financial resources, availability of services, cancer prognosis, ER/PR receptor, HER2 and BRCA status.",
        "Doc_title":"Fertility sparing options for breast cancer patients.",
        "Journal":"Breast disease",
        "Do_id":"16823169",
        "Doc_ChemicalList":"Gonadotropin-Releasing Hormone",
        "Doc_meshdescriptors":"Breast Neoplasms;Cryopreservation;Female;Fertility;Fertilization in Vitro;Genes, BRCA1;Genes, BRCA2;Gonadotropin-Releasing Hormone;Humans;Prognosis;Tissue Donors",
        "Doc_meshqualifiers":"genetics;mortality;physiopathology;drug effects;radiation effects;agonists;antagonists & inhibitors",
        "_version_":1605742127923331072},
      {
        "Doc_abstract":"Triple-negative breast cancers (TNBCs) are known to be an aggressive group of breast cancers with higher rates of relapse stage for stage compared to ER/PR positive and HER2 positive breast cancers despite optimal loco-regional and systemic therapies. To date, not a single targeted therapy has been approved for the treatment of TNBC, and cytotoxic chemotherapy remains the standard systemic treatment. Recently, gene expression analyses identified six distinct TNBC subtypes, each displaying a unique biology. In this review we will discuss current and upcoming therapeutic strategies exploring novel approaches to targeted treatment of these TNBC subtypes.",
        "Doc_title":"Molecular Heterogeneity of Triple Negative Breast Cancer.",
        "Journal":"Current breast cancer reports",
        "Do_id":"25419441",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605795223985717248},
      {
        "Doc_abstract":"Her-2/neu gene amplification is an established prognostic factor in breast cancer, and Her-2/neu protein is the target of the therapeutic monoclonal antibody Herceptin. More recently, topoisomerase IIÎ± became a new focus of breast cancer research because of its role as a target for anthracycline therapy. Therefore, we compared Her-2/neu and topoisomerase IIÎ± amplification/deletion in a large series of advanced breast cancer using fluorescence in situ hybridization. Paraffin-embedded archival tissue from 245 patients was retrieved and assessed for Her-2/neu and topoisomerase IIÎ± amplification/deletion by fluorescence in situ hybridization according to standard protocols. Relation to clinical data and survival was sought. A total of 245 cases were analyzed. Amplification for Her-2/neu was seen in 57 cases (23.3%), and for topoisomerase IIÎ± in 12 cases (4.9%). Coamplification was found in 9 samples (3.7%), 3 cases (1.2%) showed amplification of topoisomerase IIÎ± but not of Her-2/neu, and 48 samples (19.8%) displayed amplification for Her-2/neu but not for topoisomerase IIÎ±. Correlation to the histologic type, the stage, or the grade could not be found. Only the amplification of topoisomerase IIÎ± was associated with very poor outcome; survival of cases with amplification of Her-2/neu only was slightly lower than the mean overall survival (27.4 vs. 31.9 mo). Amplification of Her-2/neu and/or topoisomerase IIÎ± is associated with poor overall survival. Amplification of topoisomerase IIÎ± does not seem to be necessarily linked to Her-2/neu-amplification. However, independent determination of these 2 markers seems to be valuable for an individualized therapy of breast cancer patients.",
        "Doc_title":"Her-2/neu and topoisomerase IIÎ± in advanced breast cancer: a comprehensive FISH analysis of 245 cases.",
        "Journal":"Diagnostic molecular pathology : the American journal of surgical pathology, part B",
        "Do_id":"22555090",
        "Doc_ChemicalList":"Antigens, Neoplasm;Biomarkers, Tumor;DNA-Binding Proteins;Receptors, Estrogen;Receptors, Progesterone;ERBB2 protein, human;Receptor, ErbB-2;DNA Topoisomerases, Type II;DNA topoisomerase II alpha",
        "Doc_meshdescriptors":"Adult;Aged;Aged, 80 and over;Antigens, Neoplasm;Biomarkers, Tumor;Breast Neoplasms;Carcinoma, Ductal, Breast;Carcinoma, Lobular;DNA Copy Number Variations;DNA Topoisomerases, Type II;DNA-Binding Proteins;Female;Gene Amplification;Genetic Association Studies;Humans;In Situ Hybridization, Fluorescence;Kaplan-Meier Estimate;Lymphatic Metastasis;Middle Aged;Neoplasm Staging;Prognosis;Receptor, ErbB-2;Receptors, Estrogen;Receptors, Progesterone",
        "Doc_meshqualifiers":"genetics;metabolism;genetics;metabolism;metabolism;mortality;pathology;metabolism;mortality;secondary;metabolism;mortality;secondary;genetics;metabolism;genetics;metabolism;genetics;metabolism;metabolism;metabolism",
        "_version_":1605742686458871809},
      {
        "Doc_abstract":"To investigate the relationship between breast cancer molecular classification and prognosis.;From January 2002 to December 2003, 708 female primary breast cancer patients with a mean age of 53 years old were retrospectively analyzed. The classification of breast cancer was according to the immunohistochemical results of estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor (HER2) status. Molecular classification definitions included highly endocrine responsive, incompletely endocrine responsive, triple negative, and HER2 positive. The prognosis among different molecular classifications of breast cancer was investigated. The survival rates of different classifications were compared by Log-rank test.;The proportion of highly endocrine responsive, incompletely endocrine responsive, HER2 positive and triple-negative breast cancer was 33.2% (235/708), 23.6% (167/708), 21.3% (151/708) and 21.9% (155/708). The follow-up period were from 3 to 68 months with a median of 40.2 months. A total of 100 cases were identified to had disease recurrence or death. Factors affecting the prognosis were tumor size, axillary lymph node status, molecular classification, adjuvant radiotherapy and adjuvant endocrine therapy by univariate analysis. Multivariate analysis revealed that the molecular classification and lymph node status were the independent prognostic factors with the hazard ratio 1.205 (P = 0.047) and 4.512 (P = 0.000), respectively. Survival analysis showed that highly endocrine responsive breast cancer was with superior prognosis versus others.;Molecular classification of breast cancer is an independent predictor of prognosis. Breast cancer patients classified as highly endocrine responsive subtype have the best outcome.",
        "Doc_title":"[A study on the relationship between breast cancer molecular classification and prognosis].",
        "Journal":"Zhonghua wai ke za zhi [Chinese journal of surgery]",
        "Do_id":"19094512",
        "Doc_ChemicalList":"Receptors, Estrogen;Receptors, Progesterone;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Adult;Aged;Aged, 80 and over;Breast Neoplasms;Female;Follow-Up Studies;Humans;Middle Aged;Prognosis;Receptor, ErbB-2;Receptors, Estrogen;Receptors, Progesterone;Retrospective Studies;Survival Analysis",
        "Doc_meshqualifiers":"metabolism;pathology;metabolism;metabolism;metabolism",
        "_version_":1605741968747397122},
      {
        "Doc_abstract":"An estimated 1 million cases of breast cancer are diagnosed annually worldwide. Of these, more than 170,000 are described as triple-negative. Triple-negative breast cancer (TNBC) is defined by the lack of protein expression of estrogen receptor (ER) and progesterone receptor (PR) and the absence of HER2 protein overexpression. TNBC is a subtype of breast cancer that overlaps with the \"basal-like\" breast cancer. TNBC has significant clinical implications.;The epidemiology, diagnosis, clinical course, prognosis, and pathology of this subtype of breast cancer are reviewed. The authors compare the \"triple-negative\" and \"basal-like\" definitions of breast cancer. A discussion of both standard and experimental treatments for TNBC is included.;The poor prognosis of high-grade TNBC relates to poor disease-free interval in the adjuvant setting, shortened progression-free survival in the metastatic setting, and the lack of targeted therapy. However, not all TNBCs are associated with a poor prognosis.;Although chemotherapy is the main current treatment of this subtype of breast cancer, new agents such as PARP inhibitors, which show promise in the treatment of TNBC, are currently in clinical trials.",
        "Doc_title":"A review of triple-negative breast cancer.",
        "Journal":"Cancer control : journal of the Moffitt Cancer Center",
        "Do_id":"20664514",
        "Doc_ChemicalList":"Antineoplastic Agents;Receptors, Estrogen;Receptors, Progesterone;ERBB2 protein, human;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Antineoplastic Agents;Breast Neoplasms;Clinical Trials as Topic;Female;Humans;Prognosis;Receptor, ErbB-2;Receptors, Estrogen;Receptors, Progesterone",
        "Doc_meshqualifiers":"therapeutic use;diagnosis;genetics;therapy;biosynthesis;genetics;biosynthesis;genetics;biosynthesis;genetics",
        "_version_":1605846033651204096},
      {
        "Doc_abstract":"Breast cancer is the most common cancer among women in the UK, with 46,000 new cases and 12,000 deaths due to this disease estimated to have occurred in 2008. Around three-quarters of breast cancers express the estrogen receptor and are therefore presumed to be hormone-responsive and potentially treatable or preventable by anti-estrogenic agents. Expression of the HER2 receptor occurs in a fifth of breast cancers and is associated with limited endocrine response in hormone receptor-positive tumours and directs treatment with HER2-targeted agents. Despite improvements in the clinical outcome of breast cancer patients through the development of endocrine and targeted agents, overcoming de novo or acquired resistance remains a considerable therapeutic hurdle. In addition, as our understanding of the complexity of breast cancer biology increases, it is clear that existing therapies will fall short of offering an effective treatment solution to many patients. The ability to profile molecular pathways in drug-responsive and drug-resistant tumours has provided an important step in identifying novel targets in breast cancer. To this end, a number of new targeted therapeutics are currently being investigated both as single agents and as a means to improve existing therapeutic regimens.",
        "Doc_title":"New therapeutic approaches in breast cancer.",
        "Journal":"Maturitas",
        "Do_id":"21144683",
        "Doc_ChemicalList":"Antineoplastic Agents;Receptors, Estrogen;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Antineoplastic Agents;Breast Neoplasms;Drug Resistance, Neoplasm;Female;Humans;Receptor, ErbB-2;Receptors, Estrogen",
        "Doc_meshqualifiers":"pharmacology;therapeutic use;drug therapy;metabolism;metabolism;metabolism",
        "_version_":1605774153621700608},
      {
        "Doc_abstract":"Alternative survival pathways are commonly seen to be upregulated upon inhibition of receptor tyrosine kinases (RTK), including Her-2. It is established that treatment with Herceptin leads to selective overexpression and activation of epidermal growth factor receptor (EGFR) and Src which further contributes to oncogenesis in Herceptin resistant and triple negative breast cancer (TNBC) patients. Here, we show a co-regulated upregulation in the expression of Annexin A2 (AnxA2), a known substrate of Src and one of the regulators of EGFR receptor endocytosis, in Herceptin resistant and Her-2 negative breast cancer. Immunohistochemical expression analysis revealed a reciprocal regulation between Her-2 and AnxA2 in breast cancer clinical samples as well as in cell lines as confirmed by protein and RNA analysis. The siRNA and Herceptin mediated downregulation/inhibition of Her-2 in Her-2 amplified cells induced AnxA2 expression and membrane translocation. In this study we report a possible involvement of AnxA2 in maintaining constitutively activated EGFR downstream signaling intermediates and hence in cell proliferation, migration and viability. This effect was consistent in Herceptin resistant JIMT-1 cells as well as in Her-2 negative breast cancer. The siRNA mediated AnxA2 downregulation leads to increased apoptosis, decreased cell viability and migration. Our studies further indicate the role of AnxA2 in EGFR-Src membrane bound signaling complex and ligand induced activation of downstream signaling pathways. Targeting this AnxA2 dependent positive regulation of EGFR signaling cascade may be of therapeutic value in Her-2 negative breast cancer.",
        "Doc_title":"Reciprocal regulation of annexin A2 and EGFR with Her-2 in Her-2 negative and herceptin-resistant breast cancer.",
        "Journal":"PloS one",
        "Do_id":"22957061",
        "Doc_ChemicalList":"Annexin A2;Antibodies, Monoclonal, Humanized;Drug Combinations;Laminin;Ligands;Proteoglycans;matrigel;Collagen;ERBB2 protein, human;Receptor, Epidermal Growth Factor;Receptor, ErbB-2;src-Family Kinases;Trastuzumab",
        "Doc_meshdescriptors":"Annexin A2;Antibodies, Monoclonal, Humanized;Apoptosis;Breast Neoplasms;Cell Line, Tumor;Cell Movement;Cell Survival;Collagen;Drug Combinations;Drug Resistance, Neoplasm;Female;Humans;Immunohistochemistry;Laminin;Ligands;Phenotype;Proteoglycans;Receptor, Epidermal Growth Factor;Receptor, ErbB-2;Signal Transduction;Trastuzumab;src-Family Kinases",
        "Doc_meshqualifiers":"metabolism;pharmacology;drug therapy;pathology;chemistry;methods;chemistry;chemistry;metabolism;metabolism;metabolism",
        "_version_":1605928055917772800},
      {
        "Doc_abstract":"The aim of this study was to investigate the incidence and prognostic value of disseminated tumor cells in bone marrow of breast carcinoma patients with early disease, and to analyze this finding in relation to lymph node involvement, determined by sentinel lymph node (SLN) biopsy analysis, and to prognostic factors of interest.;104 patients with operable (T<3 cm) breast cancer and clinically- and sonographically-negative axillary lymph nodes were scheduled for SLN biopsy. Bone marrow aspirates were collected before the start of surgery from both iliac crests, and mononuclear cell layers were separated by density centrifugation (Lymphoprep). Slide preparations were then examined for the presence of disseminated tumor cells by immunocytochemistry with anti-cytokeratin antibodies (A45-B/B3). Lymphoscintigraphy was performed 2 hours after intratumor administration of 2 mCi (74 MBq) of 99mTc colloidal albumin. The SLN was evaluated for the presence of tumor cells by hematoxylin-eosin staining and, when negative, by immunocytochemistry using anti-cytokeratin antibody (CAM 5.2). Survival analyses and comparative analyses were performed on the results of bone marrow determinations, SLN biopsy, and known prognostic factors, including breast cancer subtypes according to the simplified classification based on ER, PR and HER2.;Lymph node and hematogenous dissemination occur in one-third of patients with early-stage breast cancer, although not necessarily simultaneously. In our study, disseminated tumor cells were identified in 22% of bone marrow aspirates, whereas 28% of patients had axillary lymph node involvement. Simultaneous lymph node and bone marrow involvement was found in only 5 patients (nonsignificant). In the survival study (60 months), a higher, although nonsignificant rate of disease-related events (13%) was seen in patients with disseminated tumor cells in bone marrow, and a significant association of events was documented with the known, more aggressive tumor subtypes: triple negative receptor status (21%) and positive ERBB2 status (29%).;Tumor cell detection in bone marrow can be considered a valid prognostic parameter in patients with early disease. However, the classic prognostic factors remain highly relevant, and the newer breast cancer subtypes are also useful for this purpose.",
        "Doc_title":"Prognostic value of hematogenous dissemination and biological profile of the tumor in early breast cancer patients: a prospective observational study.",
        "Journal":"BMC cancer",
        "Do_id":"21679400",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"Adult;Aged;Aged, 80 and over;Antineoplastic Combined Chemotherapy Protocols;Axilla;Bone Marrow;Breast Neoplasms;Carcinoma;Chemotherapy, Adjuvant;Combined Modality Therapy;Female;Humans;Lymphatic Metastasis;Mastectomy;Middle Aged;Neoplasm Staging;Neoplastic Cells, Circulating;Prognosis;Prospective Studies;Radionuclide Imaging;Sentinel Lymph Node Biopsy;Survival Analysis;Treatment Outcome",
        "Doc_meshqualifiers":"therapeutic use;pathology;blood;drug therapy;mortality;pathology;surgery;drug therapy;mortality;secondary;surgery;diagnostic imaging",
        "_version_":1605851075922886656},
      {
        "Doc_abstract":"The results of radiation on the local control of triple receptor-negative breast cancer (negative estrogen [ER], progesterone [PR], and HER-2/neu receptors) was studied.;Conservative surgery and radiation were used in 753 patients with T1-T2 breast cancer. Three groups were defined by receptor status: Group 1: ER or PR (+); Group 2: ER and PR (-) but HER-2 (+); and Group 3: triple-negative (TN). Factors analyzed were age, menopausal status, race, stage, tumor size, lymph node status, presentation, grade, extensive in situ disease, margins, and systemic therapy. The primary endpoint was 5-year locoregional recurrence (LRR) isolated or total with distant metastases.;ER- and PR-negative patients were statistically significantly more likely to be black, have T2 disease, have tumors detectable on both mammography and physical examination, have grade 3 tumors, and receive chemotherapy. There were no significant differences noted with regard to ER- and PR- patients by HER-2 status. There was a significant difference noted in rates of first distant metastases (3%, 12%, and 7% for Groups 1, 2, and 3, respectively; P = .009). However, the isolated 5-year LRR was not significantly different (2.3%, 4.6%, and 3.2%, respectively; P = .36) between the 3 groups.;Patients with TN breast cancer do not appear to be at a significantly increased risk for isolated LRR at 5 years and therefore remain appropriate candidates for breast conservation.",
        "Doc_title":"Locoregional recurrence of triple-negative breast cancer after breast-conserving surgery and radiation.",
        "Journal":"Cancer",
        "Do_id":"19156929",
        "Doc_ChemicalList":"Receptors, Estrogen;Progesterone;ERBB2 protein, human;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Breast Neoplasms;Combined Modality Therapy;Female;Humans;Mastectomy, Segmental;Middle Aged;Neoplasm Recurrence, Local;Neoplasms, Hormone-Dependent;Progesterone;Receptor, ErbB-2;Receptors, Estrogen",
        "Doc_meshqualifiers":"pathology;radiotherapy;surgery;pathology;metabolism;metabolism;metabolism",
        "_version_":1605788819200671744},
      {
        "Doc_abstract":"A BAC-array platform for comparative genomic hybridization was constructed from a library of 32,433 clones providing complete genome coverage, and evaluated by screening for DNA copy number changes in 10 breast cancer cell lines (BT474, MCF7, HCC1937, SK-BR-3, L56Br-C1, ZR-75-1, JIMT1, MDA-MB-231, MDA-MB-361, and HCC2218) and one cell line derived from fibrocystic disease of the breast (MCF10A). These were also characterized by gene expression analysis and found to represent all five recently described breast cancer subtypes using the \"intrinsic gene set\" and centroid correlation. Three cell lines, HCC1937 and L56BrC1 derived from BRCA1 mutation carriers and MDA-MB-231, were of basal-like subtype and characterized by a high frequency of low-level gains and losses of typical pattern, including limited deletions on 5q. Four estrogen receptor positive cell lines were of luminal A subtype and characterized by a different pattern of aberrations and high-level amplifications, including ERBB2 and other 17q amplicons in BT474 and MDA-MB-361. SK-BR-3 cells, characterized by a complex genome including ERBB2 amplification, massive high-level amplifications on 8q and a homozygous deletion of CDH1 at 16q22, had an expression signature closest to luminal B subtype. The effects of gene amplifications were verified by gene expression analysis to distinguish targeted genes from silent amplicon passengers. JIMT1, derived from an ERBB2 amplified trastuzumab resistant tumor, was of the ERBB2 subtype. Homozygous deletions included other known targets such as PTEN (HCC1937) and CDKN2A (MDA-MB-231, MCF10A), but also new candidate suppressor genes such as FUSSEL18 (HCC1937) and WDR11 (L56Br-C1) as well as regions without known genes. The tiling BAC-arrays constitute a powerful tool for high-resolution genomic profiling suitable for cancer research and clinical diagnostics.",
        "Doc_title":"High-resolution genomic profiles of breast cancer cell lines assessed by tiling BAC array comparative genomic hybridization.",
        "Journal":"Genes, chromosomes & cancer",
        "Do_id":"17334996",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"Breast Neoplasms;Cell Line, Tumor;Chromosomes, Artificial, Bacterial;Chromosomes, Human;Chromosomes, Human, X;Female;Gene Dosage;Genome, Human;Humans;Male;Nucleic Acid Hybridization;Oligonucleotide Array Sequence Analysis",
        "Doc_meshqualifiers":"genetics;metabolism;genetics;genetics;metabolism;genetics;methods;methods;standards",
        "_version_":1605747008526614528},
      {
        "Doc_abstract":"Expression of the SASH1 protein is reduced in a range of human cancers and has been implicated in apoptotic cancer cell death. This study investigated whether increasing SASH1 expression could be a useful therapeutic strategy in breast cancer. Ectopic SASH1 expression increased apoptosis in 7/8 breast cancer cell lines. Subsequent in silico connectivity screening demonstrated that the clinically approved antihistamine drug, chloropyramine, increased SASH1 mRNA levels. Chloropyramine has previously been shown to have anti-tumour activity in breast cancer in part through modulation of FAK signalling, a pathway also regulated by SASH1. This study demonstrated that chloropyramine increased SASH1 protein levels in breast cancer cells. Consistent with this the agent reduced cell confluency in 7/8 cell lines treated irrespective of their ER status but not apoptosis incompetent MCF7 cells. In contrast SASH1 siRNA-transfected breast cancer cells exhibited reduced chloropyramine sensitivity. The prognostic significance of SASH1 expression was also investigated in two breast cancer cohorts. Expression was associated with favourable outcome in ER-positive cases, but only those of low histological grade/proliferative status. Conversely, we found a very strong inverse association in HER2+ disease irrespective of ER status, and in triple-negative, basal-like cases. Overall, the data suggest that SASH1 is prognostic in breast cancer and could have subtype-dependent effects on breast cancer progression. Pharmacologic induction of SASH1 by chloropyramine treatment of breast cancer warrants further preclinical and clinical investigation.",
        "Doc_title":"SASH1 mediates sensitivity of breast cancer cells to chloropyramine and is associated with prognosis in breast cancer.",
        "Journal":"Oncotarget",
        "Do_id":"27637080",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605903865029328896},
      {
        "Doc_abstract":"HER2 is a transmembrane tyrosine kinase receptor in the EGFR (epidermal growth factor receptor) family. The role of HER2 has been most thoroughly studied in breast cancer, in which constitutively active HER2 is overexpressed in 18-22% of cases and is correlated with a poor prognosis. Hence, effective inhibition of the constitutive HER2 signaling in cancer cells has been a major goal in the design of therapies. Therapeutic targeting of HER2 with humanized antibodies such as trastuzumab (Herceptin TM, Genentech) South San Francisco, CA) has proven to be an effective approach for the treatment of breast cancer cells that over-express HER2. The encouraging results of trastuzumab in patients with metastatic and early breast cancer diseases have prompted the evaluation of new HER2 inhibitors for increasing the potential for combinatorial therapies. This review will focus on patents that target HER2 in anti-cancer treatment.",
        "Doc_title":"Anti-HER2 treatment and breast cancer: state of the art, recent patents, and new strategies.",
        "Journal":"Recent patents on anti-cancer drug discovery",
        "Do_id":"19149684",
        "Doc_ChemicalList":"Receptor, ErbB-2",
        "Doc_meshdescriptors":"Breast Neoplasms;Dimerization;Female;Humans;Patents as Topic;Protein Structure, Tertiary;RNA Interference;Receptor, ErbB-2",
        "Doc_meshqualifiers":"drug therapy;analysis;antagonists & inhibitors;chemistry;genetics",
        "_version_":1605757310322343936},
      {
        "Doc_abstract":"Rapidly evolving advances in the understanding of theorized unique driver mutations within individual patient's cancers, as well as dramatic reduction in the cost of genomic profiling, have stimulated major interest in the role of such testing in routine clinical practice. The aim of this study was to report our initial experience with genomic testing in heavily pretreated breast cancer patients.;Patients with primary or recurrent breast cancer managed at any of our five hospitals and whose malignancy had failed to respond to therapy or had progressed on all recognized standard-of-care options were offered the opportunity to have their cancer undergo next-generation sequencing genomic profiling.;Of a total of 101 patients, 98 (97 %) had at least one specific genomic alteration identified. A total of 465 different somatic genetic abnormalities were revealed in this group of patients. Although 52 % of patients were found to have an abnormality for which an U.S. Food and Drug Administration (FDA)-approved drug was available, 69 % of patients had an FDA-approved agent for an indication other than breast cancer. The most common genomic alterations of potential clinical consequence were PIK3 (25 %), FGFR1 (16 %), AKT (11 %), PTEN (10 %), ERBB2 (8 %), JAK2 (6 %), and RAF1 (5 %).;Almost all advanced breast cancers possess at least one well-characterized genomic alteration that might be actionable at the clinical level. Further, in most cases, a plausible argument can be advanced for the potential biological and clinical relevance of an FDA-approved antineoplastic agent not currently indicated in the treatment of breast cancer.",
        "Doc_title":"Initial experience with genomic profiling of heavily pretreated breast cancers.",
        "Journal":"Annals of surgical oncology",
        "Do_id":"25047475",
        "Doc_ChemicalList":"Biomarkers, Tumor",
        "Doc_meshdescriptors":"Adult;Aged;Biomarkers, Tumor;Breast Neoplasms;Combined Modality Therapy;Female;Follow-Up Studies;Gene Expression Profiling;Genetic Predisposition to Disease;Genomics;High-Throughput Nucleotide Sequencing;Humans;Middle Aged;Mutation;Neoplasm Metastasis;Neoplasm Recurrence, Local;Neoplasm Staging;Patient Selection;Precision Medicine;Predictive Value of Tests;Retrospective Studies;Young Adult",
        "Doc_meshqualifiers":"genetics;genetics;pathology;therapy;genetics;genetics;pathology;therapy",
        "_version_":1605891596093489152},
      {
        "Doc_abstract":"Rab coupling protein (FIP1C), an effector of the Rab11 GTPases, including Rab25, is amplified and overexpressed in 10% to 25% of primary breast cancers and correlates with poor clinical outcome. Rab25 is also frequently silenced in triple-negative breast cancer, suggesting its ability to function as either an oncogene or a tumor suppressor, depending on the breast cancer subtype. However, the pathobiologic role of FIP family members, such as FIP1C, in a tumor-specific setting remains elusive. In this study, we used ErbB2 mouse models of human breast cancer to investigate FIP1C function in tumorigenesis. Doxycycline-induced expression of FIP1C in the MMTV-ErbB2 mouse model resulted in delayed mammary tumor progression. Conversely, targeted deletion of FIP1C in the mammary epithelium of an ErbB2 model coexpressing Cre recombinase led to accelerated tumor onset. Genetic and biochemical characterization of these FIP1C-proficient and -deficient tumor models revealed that FIP1C regulated E-cadherin (CDH1) trafficking and ZONAB (YBX3) function in Cdk4-mediated cell-cycle progression. Furthermore, we demonstrate that FIP1C promoted lysosomal degradation of ErbB2. Consistent with our findings in the mouse, the expression of FIP1C was inversely correlated with ErbB2 levels in breast cancer patients. Taken together, our findings indicate that FIP1C acts as a tumor suppressor in the context of ErbB2-positive breast cancer and may be therapeutically exploited as an alternative strategy for targeting aberrant ErbB2 expression. Cancer Res; 76(9); 2662-74. Â©2016 AACR. ",
        "Doc_title":"Rab11-FIP1C Is a Critical Negative Regulator in ErbB2-Mediated Mammary Tumor Progression.",
        "Journal":"Cancer research",
        "Do_id":"26933086",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605823995076149248},
      {
        "Doc_abstract":"There is little information about the impact of breast cancer subtype on prognosis after ipsilateral breast tumor recurrence (IBTR).;One hundred eighty-five patients were classified according to breast cancer subtype, as approximated by estrogen receptor, human epidermal growth factor receptor 2 (HER2), and Ki-67, of IBTR, and we evaluated whether breast cancer subtype was associated with distant recurrence after IBTR.;There was a significant difference in distant disease-free survival (DDFS) after IBTR according to breast cancer subtype defined by a cutoff of the Ki-67 index of 20Â % (pÂ =Â 0.0074, log-rank test). The 5-year DDFS rates for patients with luminal A, luminal B, triple-negative, and HER2 types were 86.3, 57.1, 56.6, and 65.9Â %, respectively. In addition, breast cancer subtype was significantly associated with distant recurrence after IBTR on adjustment for various clinicopathologic factors (pÂ =Â 0.0027, Cox proportional hazards model).;Our study suggests that breast cancer subtype based on immunohistochemical staining predicts the outcomes of patients with IBTR. Further analyses are needed (UMIN-CTR number UMIN000008136).",
        "Doc_title":"Breast cancer subtype and distant recurrence after ipsilateral breast tumor recurrence.",
        "Journal":"Annals of surgical oncology",
        "Do_id":"23292516",
        "Doc_ChemicalList":"Ki-67 Antigen;Receptors, Estrogen;ERBB2 protein, human;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Adult;Aged;Aged, 80 and over;Antineoplastic Combined Chemotherapy Protocols;Blood Vessels;Breast Neoplasms;Carcinoma, Ductal, Breast;Carcinoma, Lobular;Chemotherapy, Adjuvant;Disease-Free Survival;Female;Humans;Kaplan-Meier Estimate;Ki-67 Antigen;Lymphatic Vessels;Mastectomy, Segmental;Middle Aged;Multivariate Analysis;Neoplasm Invasiveness;Neoplasm Recurrence, Local;Proportional Hazards Models;Radiotherapy, Adjuvant;Receptor, ErbB-2;Receptors, Estrogen",
        "Doc_meshqualifiers":"therapeutic use;pathology;metabolism;pathology;therapy;metabolism;secondary;therapy;metabolism;secondary;therapy;metabolism;pathology;metabolism;pathology;therapy;metabolism;metabolism",
        "_version_":1605818656780976129},
      {
        "Doc_abstract":"Preliminary data indicate that tyrosine kinase inhibitors (TKIs) function through rearranged during transfection (RET) in breast cancer. However, TKIs are not specific and can block several receptor tyrosine kinases (RTKs). This study used cell lines and primary breast cancer specimens to determine factors associated with TKI response.;Proliferation was assessed after short interfering RNA knockdown with or without sunitinib in breast cancer cell lines by MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide). Breast cancer tissue and matched normal breast was obtained from 30 women with invasive breast carcinoma. Gene expression was assessed by reverse transcriptase-polymerase chain reaction. Fresh tissue was treated in vitro with sunitinib or control media for 30 min, and response was assessed by phosphorylation-specific western blot.;The RTKs including epidermal growth factor receptor (EGFR), vascular endothelial growth factor receptor (VEGFR1-3), platelet-derived growth factor receptor (PDGFRa/b), and Kit were overexpressed in triple-negative breast tumors relative to HER2- and estrogen receptor-alpha (ERÎ±)-positive tumors and normal breast tissue. Knockdown of EGFR reduced in vitro proliferation in MCF-7 and MDA-MB-231 but not in SKBR-3 or ZR-75-1 breast cancer cells. With the exception of RET, response to sunitinib was independent of RTK expression in all four cell lines. Both ERÎ±-positive and low-EGFR-expressing tumors had an increased in vitro sunitinib response, as determined by alteration of Erk activation. Expression of other RTKs and additional clinical factors were not associated with response.;Triple-negative breast cancers overexpress RTKs but have decreased in vitro response to the TKI sunitinib. In addition to RET, TKIs that block EGFR may increase the therapeutic efficacy of TKIs in breast cancer.",
        "Doc_title":"Receptor Tyrosine Kinase Expression Predicts Response to Sunitinib in Breast Cancer.",
        "Journal":"Annals of surgical oncology",
        "Do_id":"25971960",
        "Doc_ChemicalList":"Indoles;Protein Kinase Inhibitors;Pyrroles;RNA, Messenger;EGFR protein, human;Receptor, Epidermal Growth Factor;sunitinib",
        "Doc_meshdescriptors":"Apoptosis;Blotting, Western;Breast Neoplasms;Cell Proliferation;Drug Resistance, Neoplasm;Female;Humans;Indoles;Middle Aged;Neoplasm Staging;Phosphorylation;Prognosis;Protein Kinase Inhibitors;Pyrroles;RNA, Messenger;Real-Time Polymerase Chain Reaction;Receptor, Epidermal Growth Factor;Reverse Transcriptase Polymerase Chain Reaction;Signal Transduction;Tumor Cells, Cultured",
        "Doc_meshqualifiers":"drug effects;drug therapy;metabolism;pathology;drug effects;pharmacology;drug effects;pharmacology;pharmacology;genetics;antagonists & inhibitors;genetics;metabolism;drug effects",
        "_version_":1605742030899642369},
      {
        "Doc_abstract":"Molecular imaging of breast cancer can potentially be used for breast cancer screening, staging, restaging, response evaluation and guiding therapies. Techniques for molecular breast cancer imaging include magnetic resonance imaging (MRI), optical imaging, and radionuclide imaging with positron emission tomography (PET) or single photon emission computed tomography (SPECT). This review focuses on PET and SPECT imaging which can provide sensitive serial non invasive information of tumor characteristics. Most clinical data are gathered on the visualization of general processes such as glucose metabolism with the PET-tracer [(18)F]fluorodeoxyglucose (FDG) and DNA synthesis with [18F]fluoro-L-thymidine (FLT). Increasingly more breast cancer specific targets are imaged such as the estrogen receptor (ER), growth factors and growth factor receptors. Imaging of the ER with the PET tracer 16-alpha-[(18)F]fluoro-17-beta-estradiol (FES) has shown a good correlation between FES tumor uptake and ER density. (111)In-trastuzumab SPECT to image the human epidermal growth factor receptor 2 (HER2) showed that in most patients with metastatic HER2 overexpressing disease more lesions were detected than with conventional staging procedures. The PET tracer (89)Zr-trastuzumab showed excellent, quantifiable, and specific tumor uptake. (111)In-bevacizumab for SPECT and (89)Zr-bevacizumab for PET-imaging have been developed for vascular endothelial growth factor (VEGF) imaging as an angiogenic marker. Lastly, tracers for the receptors EGFR, IGF-1R, PDGF-betaR and the ligand TGFbeta are under development. Although molecular imaging of breast cancer is still not commonly used in daily clinical practice, its application portfolio is expanding rapidly.",
        "Doc_title":"Molecular imaging of breast cancer.",
        "Journal":"Breast (Edinburgh, Scotland)",
        "Do_id":"19914546",
        "Doc_ChemicalList":"Radiopharmaceuticals;Receptors, Estrogen;Vascular Endothelial Growth Factor A;Fluorodeoxyglucose F18;ERBB2 protein, human;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Breast Neoplasms;Female;Fluorodeoxyglucose F18;Humans;Molecular Imaging;Positron-Emission Tomography;Radiopharmaceuticals;Receptor, ErbB-2;Receptors, Estrogen;Tomography, Emission-Computed, Single-Photon;Vascular Endothelial Growth Factor A",
        "Doc_meshqualifiers":"diagnostic imaging;drug therapy;methods;methods;analysis;analysis;methods;analysis",
        "_version_":1605763527848493056},
      {
        "Doc_abstract":"The etiology of human breast cancer is poorly understood and no specific marker of transformation has been identified. Amplification of HER-2/neu, as reported in a comprehensive study by Slamon et al, was found to be the most powerful predictor of disease-free and overall survival after the status of the axillary lymph nodes. Our study examines the HER-2/neu oncogene in 61 primary human breast cancers at both the DNA level (by Southern blotting) and the protein level (by immunohistochemical methods). Of the 61 tumors analyzed in our study, 17 (28%) had amplification of HER-2/neu. There was no significant correlation of HER-2/neu amplification with age, tumor diameter or hormone receptor status; however, amplification and overexpression of HER-2/neu was significantly correlated with the status of the axillary lymph nodes (P = 0.02). Of 16 patients with amplification of HER-2/neu, 14 (88%) had positive regional nodes. One of the two node negative cases with amplified HER-2/neu had bone marrow micrometastasis. Overall, 16 out of 17 (94%) tumors of the patients having amplified HER-2/neu had metastatic disease at the time of diagnosis. In summary, HER-2/neu amplification is associated with early tumor dissemination in primary human breast cancer and may be a marker of poor prognosis.",
        "Doc_title":"HER-2/neu amplification and overexpression in primary human breast cancer is associated with early metastasis.",
        "Journal":"Anticancer research",
        "Do_id":"1349794",
        "Doc_ChemicalList":"Proto-Oncogene Proteins;DNA;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Breast Neoplasms;DNA;Female;Gene Amplification;Gene Expression;Humans;Neoplasm Metastasis;Proto-Oncogene Proteins;Proto-Oncogenes;Receptor, ErbB-2",
        "Doc_meshqualifiers":"genetics;pathology;analysis;genetics",
        "_version_":1605818662899417088},
      {
        "Doc_abstract":"HER2-positive breast cancer (HER2+) occurs in approximately 15-20% of all breast cancers. Biologically this cancer subtype is characterized by an aggressive clinical course (often spread to regional lymph nodes at the time of diagnosis), and after successful treatment high risk of recurrence. Deregulation of the cell cycle is the basis for cancer aggressiveness. The RB protein is one of the key regulators of the cell cycle. There are only a few published studies on the expression and localization of RB protein in the cells of HER2-positive breast cancer. The aim of this study was to determine whether there are differences in the expression and localization of RB protein in HER2-positive breast cancers compared to breast cancers showing no expression of HER2. We used 50 tissue samples from HER2 positive breast cancer and 21 tissue samples derived from patients with HER2 negative breast cancer. The RB protein expression was measured by immunohistochemical techniques in tissue microarray format. Cytoplasmic RB expression was observed in 29 out of 50 (58%) HER2 positive breast cancers. In this group only cytoplasmic expression was observed. There was no case with nuclear expression. In contrast, in the HER2-negative breast cancer control group, in no case RB expression was observed in the cytoplasm (0/21, 0%). All 21 samples (100%) showed expression of RB protein in the nucleus (p < 0.0001). We can speculate that lack of expression suggests alternative mechanisms in the development of HER2 positive breast cancer. We hypothesize that HER2 overexpression is in some way associated with active transport of RB protein from the nucleus to the cytoplasm. This may be an indirect mechanism of inactivation of tumor suppressor protein in breast cancer exhibiting overexpression of HER2.",
        "Doc_title":"Active transport of RB protein from the nucleus to the cytoplasm as one of the development mechanisms of HER2-positive breast cancer.",
        "Journal":"Polish journal of pathology : official journal of the Polish Society of Pathologists",
        "Do_id":"23625594",
        "Doc_ChemicalList":"Biomarkers, Tumor;Retinoblastoma Protein;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Biological Transport, Active;Biomarkers, Tumor;Breast Neoplasms;Case-Control Studies;Cell Nucleus;Cytoplasm;Disease-Free Survival;Female;Gene Expression Regulation, Neoplastic;Humans;Middle Aged;Models, Molecular;Prognosis;Protein Transport;Receptor, ErbB-2;Retinoblastoma Protein;Tissue Array Analysis",
        "Doc_meshqualifiers":"metabolism;metabolism;pathology;metabolism;metabolism;metabolism;metabolism",
        "_version_":1605836405254127616},
      {
        "Doc_abstract":"Breast cancer is a heterogeneous malignancy; its age-specific incidence profile rises exponentially until menopause and increases more slowly thereafter, reflecting the superimposition of early-onset and late-onset breast cancer rates. While early-onset breast cancers largely represent inherited or early life transforming effects on immature mammary epithelium, late-onset breast cancers likely follow extended exposures to promoting stimuli of susceptible epithelium that has failed to age normally. Among stimuli thought to promote late-onset breast tumorigenesis are the altered extracellular matrix and secreted products of senescent fibroblasts; however, the extent to which these senescent influences exist within the aging breast remains unknown. Clinical observations and biomarker studies indicate that late-onset breast cancers grow more slowly and are biologically less aggressive than early-onset breast cancers, even when controlled for hormone receptor (e.g. estrogen receptor, ER) and growth factor receptor (e.g. HER2) expression, supporting the conclusion that the biology of breast cancer is age-dependent.",
        "Doc_title":"Impact of aging on the biology of breast cancer.",
        "Journal":"Critical reviews in oncology/hematology",
        "Do_id":"17949989",
        "Doc_ChemicalList":"Receptors, Estrogen",
        "Doc_meshdescriptors":"Age of Onset;Aging;Breast;Breast Neoplasms;Cell Transformation, Neoplastic;Epithelial Cells;Female;Humans;Menopause;Neoplasm Invasiveness;Neovascularization, Pathologic;Receptors, Estrogen;Stromal Cells",
        "Doc_meshqualifiers":"pathology;physiology;pathology;etiology;pathology;physiology;etiology;analysis;pathology",
        "_version_":1605832395930468352},
      {
        "Doc_abstract":"Serum vitamin D levels measured as 25-hydroxyvitamin D have been shown to be low in cancer patients, including breast cancer patients. However, the vitamin D status has yet to be studied in different breast cancer phenotypes: luminal A, luminal B, HER2+/ER-, and triple negative comprising the majority of basal-like.;Fifteen triple-negative breast cancer patients have presented to our medical oncology office in the last five years. Thirteen of these fifteen patients (87%) were found to be vitamin D deficient, defined as serum 25(OH)D less than 80 nmol/L, prior to initiation of adjuvant therapy. Ninety-one breast cancer patients from our office were classified as: luminal A (ER+ &/or PR+ and HER2-), luminal B (ER+ &/or PR+ and HER2+), HER2+/ER- (ER-, PR-, and HER2+), and triple-negative or basal-like (ER-, PR-, and HER2-). A normal mean was found from 78 volunteers. The breast cancer patients were found to be statistically different than the normal population. The triple-negative phenotype was found to be the most statistically different than the normal population.;The triple-negative breast cancer phenotype has the lowest average vitamin D level and the highest percentage of patients that are vitamin D deficient. These data suggests that low vitamin D levels are characteristic of the triple-negative phenotype.",
        "Doc_title":"Triple negative breast cancer patients presenting with low serum vitamin D levels: a case series.",
        "Journal":"Cases journal",
        "Do_id":"19830074",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605830512709992448},
      {
        "Doc_abstract":"To ensure the accuracy and reproducibility of immunohistochemical assays for determining HER-2/neu status of patients with breast cancer, a reliable standard for monitoring assay sensitivity is necessary. We optimally fixed and paraffin processed human ovarian and breast carcinoma cell lines SKOV-3, MDA-MB-453, BT-20, and MCF-7 in quantities sufficient to meet the needs of a laboratory for the foreseeable future. The material was tested, alongside HercepTest kit cell lines (DAKO, Carpinteria, CA), by 7 breast cancer centers in the United Kingdom and France with different immunohistochemical assays and markers. The cell lines also were analyzed by fluorescence in situ hybridization (FISH) by 2 centers using HER-2/neu kits. FISH produced 100% agreement between the 2 centers: SKOV-3 and MDA-MB-453 showed HER-2/neu amplification and BT-20 and MCF-7 did not. Immunohistochemical analysis and a common evaluation method produced 100% agreement that SKOV-3 and MCF-7 showed 3+ and zero HER-2/neu overexpression, respectively. For MDA-MB-453, there was 71% (5/7) concordance of 2+ immunohistochemical staining and 86% (6/7) concordance of zero or 1 + staining for BT-20. The cell lines provide a valuable standard for gauging HER-2/neu assay sensitivity irrespective of the antibody, antigen retrieval system, detection system, or method of evaluation used.",
        "Doc_title":"A formalin-fixed, paraffin-processed cell line standard for quality control of immunohistochemical assay of HER-2/neu expression in breast cancer.",
        "Journal":"American journal of clinical pathology",
        "Do_id":"11789735",
        "Doc_ChemicalList":"Formaldehyde;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Breast Neoplasms;Female;Formaldehyde;Humans;Immunohistochemistry;In Situ Hybridization, Fluorescence;Paraffin Embedding;Quality Control;Receptor, ErbB-2;Reference Standards;Tissue Fixation;Tumor Cells, Cultured",
        "Doc_meshqualifiers":"immunology;pathology;standards;standards;analysis;standards",
        "_version_":1605839888681271296},
      {
        "Doc_abstract":"HER2-positive (HER2+) breast cancer accounts for 18%-20% of all breast cancer cases and has the second poorest prognosis among breast cancer subtypes. Trastuzumab, the first Food and Drug Administration-approved targeted therapy for breast cancer, established the era of personalized treatment for HER2+ metastatic disease. It is well tolerated and improves overall survival and time-to-disease progression; with chemotherapy, it is part of the standard of care for patients with HER2+ metastatic disease. However, many patients do not benefit from it because of resistance. Substantial research has been performed to understand the mechanism of trastuzumab resistance and develop combination strategies to overcome the resistance. In this review, we provide insight into the current pipeline of drugs used in combination with trastuzumab and the degree to which these combinations have been evaluated, especially in patients who have experienced disease progression on trastuzumab. We conclude with a discussion of the current challenges and future therapeutic approaches to trastuzumab-based combination therapy. ",
        "Doc_title":"Personalized drug combinations to overcome trastuzumab resistance in HER2-positive breast cancer.",
        "Journal":"Biochimica et biophysica acta",
        "Do_id":"25065528",
        "Doc_ChemicalList":"Antibodies, Monoclonal, Humanized;Antineoplastic Agents;ERBB2 protein, human;Receptor, ErbB-2;Trastuzumab",
        "Doc_meshdescriptors":"Antibodies, Monoclonal, Humanized;Antineoplastic Agents;Antineoplastic Combined Chemotherapy Protocols;Breast Neoplasms;Drug Resistance, Neoplasm;Female;Humans;Precision Medicine;Receptor, ErbB-2;Trastuzumab",
        "Doc_meshqualifiers":"therapeutic use;therapeutic use;therapeutic use;chemistry;drug therapy;analysis",
        "_version_":1605746404433592320},
      {
        "Doc_abstract":"Despite the excellent overall prognosis, unpredictable breast cancer recurrences and deaths also occur among T1N0M0 patients. We have evaluated clinically applicable methods for identifying aggressive outcome in T1N0M0 breast cancer. The material is based on aggressive T1N0M0 invasive ductal and lobular carcinomas diagnosed in Turku University Hospital and JyvÃ¤skylÃ¤ Central Hospital, Finland, during 1987-1997. We studied all the T1N0M0 breast cancers that had led to recurrency or death (n=21, 95% T1cN0M0) during the follow-up period (4-14 years). The study is based on statistical analyses of matched case-control data in which the prognostic factors of each individual patient with aggressive disease were compared with control patients (n=45) individually matched by tumour size, age at diagnosis, histological type of tumour and length of follow-up. The cancer cases were examined for clinically applicable conventional and immunohistochemical pathologic prognostic factors. High Ki-67 immunopositivity was the strongest prognosticator of breast cancer death or recurrence in T1N0M0 breast cancer. Also, high p53 immunopositivity, low oestrogen receptor immunopositivity and Her-2/neu oncogene amplification by chromogen in situ hybridisation were reliable indicators of unfavourable outcome. Our statistical methods also allowed us to determine for the present material a range of clinical significance for each immunohistochemical prognostic feature with the associated relative risk for breast cancer death and recurrence. The paper suggests guidelines for predicting aggressive outcome in T1N0M0 breast cancer.",
        "Doc_title":"Predicting aggressive outcome in T1N0M0 breast cancer.",
        "Journal":"British journal of cancer",
        "Do_id":"15199391",
        "Doc_ChemicalList":"Biomarkers, Tumor;Ki-67 Antigen;Receptors, Estrogen",
        "Doc_meshdescriptors":"Adult;Aged;Biomarkers, Tumor;Breast Neoplasms;Carcinoma, Ductal, Breast;Carcinoma, Lobular;Case-Control Studies;Female;Finland;Follow-Up Studies;Gene Amplification;Genes, erbB-2;Humans;Ki-67 Antigen;Middle Aged;Neoplasm Staging;Predictive Value of Tests;Prognosis;Receptors, Estrogen",
        "Doc_meshqualifiers":"genetics;pathology;genetics;pathology;genetics;pathology;metabolism;metabolism",
        "_version_":1605797951078137856},
      {
        "Doc_abstract":"Human breast cancers cells overexpressing HER2/neu are more aggressive tumors with poor prognosis, and resistance to chemotherapy. This study investigates antiproliferation effects of anthraquinone derivatives of rhubarb root on human breast cancer cells. Of 7 anthraquinone derivatives, only rhein showed antiproliferative and apoptotic effects on both HER2-overexpressing MCF-7 (MCF-7/HER2) and control vector MCF-7 (MCF-7/VEC) cells. Rhein induced dose- and time-dependent manners increase in caspase-9-mediated apoptosis correlating with activation of ROS-mediated activation of NF-ÎºB- and p53-signaling pathways in both cell types. Therefore, this study highlighted rhein as processing anti-proliferative activity against HER2 overexpression or HER2-basal expression in breast cancer cells and playing important roles in apoptotic induction of human breast cancer cells.",
        "Doc_title":"Rhein induces apoptosis in human breast cancer cells.",
        "Journal":"Evidence-based complementary and alternative medicine : eCAM",
        "Do_id":"22007260",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605790944460800000},
      {
        "Doc_abstract":"Phosphatases are proteins with the ability to dephosphorylate different substrates and are involved in critical cellular processes such as proliferation, tumor suppression, motility and survival. Little is known about their role in the different breast cancer (BC) phenotypes. We carried out microarray phosphatome profiling in 41 estrogen receptor-negative (ER-) BC patients, as determined by immunohistochemistry (IHC), containing both ERBB2+ and ERBB2- in order to characterize the differences between these two groups. We characterized and confirmed the distinct phosphatome of the two main ER- BC subgroups (in two independent microarrays series) and that of ER+ BC (in three large independent series). Our findings point to the importance of the MAPK and PI3K pathways in ER- BCs as some of the most differentially expressed phosphatases (like DUSP4 and DUSP6) sharing ERK as substrate, or regulating the PI3K pathway (INPP4B, PTEN). It was possible to identify a selective group of phosphatases upregulated only in the ER- ERBB2+ subgroup and not in ER+ (like DUSP6, DUSP10 and PPAPDC1A among others), suggesting a role of these phosphatases in specific BC subtypes, unlike other differentially expressed phosphatases (DUSP4 and ENPP1) that seemed to have a role in multiple BC subtypes. Significant correlation was found at the protein level by IHC between the expression of DUSP6 and phospho-ERK (p=0.04) but not of phospho-ERK with DUSP4. To show the potential prognostic relevance of phosphatases as a functional group of genes, we derived and validated in two large independent BC microarray series a multiphosphatase signature enriched in differentially expressed phosphatases, to predict distant metastasis-free survival (DMFS). ER- ERBB2+, ER- ERBB2- and ER+ BC patients have a distinct pattern of phosphatase RNA expression with a potential prognostic relevance. Further studies of the most relevant phosphatases found in this study are warranted.",
        "Doc_title":"Microarray phosphatome profiling of breast cancer patients unveils a complex phosphatase regulatory role of the MAPK and PI3K pathways in estrogen receptor-negative breast cancers.",
        "Journal":"International journal of oncology",
        "Do_id":"25201346",
        "Doc_ChemicalList":"Receptors, Estrogen;Phosphatidylinositol 3-Kinases;Mitogen-Activated Protein Kinase Kinases;Mitogen-Activated Protein Kinase Phosphatases;DUSP4 protein, human;DUSP6 protein, human;Dual Specificity Phosphatase 6;Dual-Specificity Phosphatases",
        "Doc_meshdescriptors":"Adult;Aged;Aged, 80 and over;Breast Neoplasms;Disease-Free Survival;Dual Specificity Phosphatase 6;Dual-Specificity Phosphatases;Female;Gene Expression Profiling;Gene Expression Regulation, Neoplastic;Humans;Microarray Analysis;Middle Aged;Mitogen-Activated Protein Kinase Kinases;Mitogen-Activated Protein Kinase Phosphatases;Phosphatidylinositol 3-Kinases;Phosphorylation;Prognosis;Receptors, Estrogen;Signal Transduction",
        "Doc_meshqualifiers":"genetics;pathology;biosynthesis;biosynthesis;biosynthesis;genetics;biosynthesis;biosynthesis;genetics;genetics",
        "_version_":1605929321657008128},
      {
        "Doc_abstract":"Breast cancer is a common form of cancer in women of varying age. Due to the relationship between breasts, sexuality and reproduction, this form of cancer has an interconnected psychological and psychosocial influence on the well-being of women. Current understanding of the aetiology and pathogenesis of the disease has evolved as evidence supporting a role for genes such as the HER2 gene has emerged. HER2-positive breast cancer is a particularly progressive form of the disease as a result of its ability to differentiate and spread. Trastuzumab (Herceptin) forms part of the current treatment for this form of breast cancer; albeit costly, it has been shown to improve survival rates in women. For this reason it is now a recommended treatment for early-stage breast cancer. During and after treatment cycles, the breast cancer nurse and medical practitioners should be available to provide emotional support and advice on the manifestations of the disease, coping strategies and how breast cancer patients manage close family relatives.",
        "Doc_title":"Advanced breast cancer: aetiology, treatment and psychosocial features.",
        "Journal":"British journal of nursing (Mark Allen Publishing)",
        "Do_id":"17353817",
        "Doc_ChemicalList":"Antibodies, Monoclonal;Antibodies, Monoclonal, Humanized;Antineoplastic Agents;Receptor, ErbB-2;Trastuzumab",
        "Doc_meshdescriptors":"Adaptation, Psychological;Antibodies, Monoclonal;Antibodies, Monoclonal, Humanized;Antineoplastic Agents;Breast Neoplasms;Cost of Illness;Drug Costs;Female;Health Services Needs and Demand;Humans;Neoplasm Staging;Nurse's Role;Oncology Nursing;Patient Education as Topic;Receptor, ErbB-2;Social Support;State Medicine;Survival Rate;Trastuzumab;Treatment Outcome;United Kingdom",
        "Doc_meshqualifiers":"economics;therapeutic use;economics;therapeutic use;etiology;psychology;therapy;organization & administration;genetics",
        "_version_":1605795128813813760},
      {
        "Doc_abstract":"The aim of the study was to explore possible differences in DNA flow cytometric characteristics, particularly differences in distribution of DNA indices of aneuploid clones, between male and female breast cancers. We retrospectively analyzed 31 male breast cancers. Clinicopathological and DNA flow cytometric characteristics of male breast cancers (patient age, tumor size, histological type, histological grade, axillary lymph node status, hormone receptor expression, ploidy, and S-phase fraction) were compared with that of the control group of matched female breast cancers. Hormone receptors and HER-2/neu were investigated immunohistochemically with additional chromogenic in situ hybridization (CISH) analysis of HER-2/neu 2+ cases. Ploidy and S-phase fraction were determined by DNA flow cytometry. Comparison with clinicopathological features was made using Ï‡ (2) and t test. Aneuploidy was found in 78% of the cases, with the predomination of hypotetraploid clones (39%), followed by tetraploid (23%) and hypertetraploid clones (16%). We found higher frequency of hypertetraploidy in male breast cancers (16 and 6%, respectively) than in the control group of matched female breast cancers. Clinicopathological features of hypertetraploid male breast cancers did not differ from that of non-hypertetraploid cancers. Higher frequency of hypertetraploidy among male breast cancers might indicate different cytogenetical evolutionary pathway between male and female breast cancer.",
        "Doc_title":"Flow cytometric DNA hypertetraploidy tends to be more frequent in male than in female breast cancers.",
        "Journal":"Virchows Archiv : an international journal of pathology",
        "Do_id":"25471639",
        "Doc_ChemicalList":"DNA, Neoplasm",
        "Doc_meshdescriptors":"Adult;Aged;Aged, 80 and over;Breast Neoplasms, Male;DNA, Neoplasm;Female;Flow Cytometry;Humans;Male;Middle Aged;Ploidies;Retrospective Studies",
        "Doc_meshqualifiers":"genetics;genetics",
        "_version_":1605746424406867968},
      {
        "Doc_abstract":"Expression of the estrogen receptor (ER), the progesterone receptor (PgR) or the human epidermal growth factor receptor-2 (HER2) in tumors is a good prognostic marker for breast cancer patients. However, approximately 15-20% of breast cancer patients have triple-negative breast cancer (TNBC; negative for ER, PgR and HER2), and efficient therapeutic modalities for these patients are under investigation. We focused on thymidine phosphorylase (TP), an enzyme metabolizing 5'-DFUR, an intermediate of capecitabine, to 5-fluorouracil in order to investigate the application of well-known therapeutics for TNBC. Results of a gene expression analysis showed that TP expression in TNBC and basal-like breast cancer (BLBC) was higher than that of other subtypes. Immunohistochemically, the high expression of TP in TNBC and BLBC reflected expression in stromal but not tumor cells. Notably, a high TP expression was observed in the stromal cells of EGFR- and/or CK5/6-positive breast tumors. Our present results showing a high expression of TP in BLBC indicate that capecitabine-based chemotherapy would be of benefit for patients with TNBC.",
        "Doc_title":"High expression of thymidine phosphorylase in basal-like breast cancers: Stromal expression in EGFR- and/or CK5/6-positive breast cancers.",
        "Journal":"Oncology letters",
        "Do_id":"22966291",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605846372851908608},
      {
        "Doc_abstract":"The tumor necrosis factor-alpha (TNF-Î±) gene plays an important role in cell proliferation, differentiation, apoptosis, lipid metabolism, coagulation, insulin resistance, and endothelial function. Polymorphisms of TNF-Î± have been associated with cancer. We examined the role of the -308G>A polymorphism in this gene by comparing the genotypes of 294 healthy Mexican women with those of 465 Mexican women with breast cancer. The observed genotype frequencies for controls and breast cancer patients were 1 and 14% for AA, 13 and 21% for GA, and 86 and 65% for GG, respectively. We found that the odds ratio (OR) for AA genotype was 2.4, with a 95% confidence interval (95%CI) of 5.9-101.1 (P = 0.0001). The association was also evident when comparing the distribution of the AA-GA genotype in patients in the following categories: 1) premenopause and obesity I (OR = 3.5, 95%CI = 1.3-9.3, P = 0.008), 2) Her-2 neu and tumor stage I-II (OR = 2.5, 95%CI = 1.31-4.8, P = 0.004), 3) premenopause and tumor stage III-IV (OR = 1.7, 95%CI = 1.0-2.9, P = 0.034), 4) chemotherapy non-response and abnormal hematocrit (OR = 2.4, 95%CI = 1.2-4.8, P = 0.015), 5) body mass index and Her-2 neu and III-IV tumor stage (OR = 2.8, 95%CI = 1.2- 6.6, P = 0.016), and 6) nodule metastasis and K-I67 (OR = 4.0, 95%CI = 1.01-15.7, P = 0.038). We concluded that the genotypes AA-GA of the -308G>A polymorphism in TNF-Î± significantly contribute to breast cancer susceptibility in the analyzed sample from the Mexican population. ",
        "Doc_title":"Association of the tumor necrosis factor-alpha -308G>A polymorphism with breast cancer in Mexican women.",
        "Journal":"Genetics and molecular research : GMR",
        "Do_id":"24301937",
        "Doc_ChemicalList":"Tumor Necrosis Factor-alpha",
        "Doc_meshdescriptors":"Adult;Aged;Breast Neoplasms;Case-Control Studies;Female;Genetic Association Studies;Humans;Mexico;Middle Aged;Polymorphism, Single Nucleotide;Tumor Necrosis Factor-alpha",
        "Doc_meshqualifiers":"genetics;genetics",
        "_version_":1605796871653031936},
      {
        "Doc_abstract":"The results of clinical trials evaluating the efficacy of HER2 inhibitors in patients with breast cancer indicate that the correlation between HER2 receptor levels and patient outcomes is as low as 50%. The relatively weak correlation between HER2 status and response to HER2-targeting drugs suggests that measurement of HER2 signaling activity, rather than absolute HER2 levels, may more accurately diagnose HER2-driven breast cancer. A new diagnostic test, the CELx HER2 Signaling Profile (CELx HSP) test, is demonstrated to measure real-time HER2 signaling function in live primary cells. In the present study, epithelial cells extracted fresh from breast cancer patient tumors classified as HER2 negative (HER2-, n = 34 of which 33 were estrogen receptor positive) and healthy subjects (n = 16) were evaluated along with reference breast cancer cell lines (n = 19). Live cell response to specific HER2 agonists (NRG1b and EGF) and antagonist (pertuzumab) was measured. Of the HER2- breast tumor cell samples tested, 7 of 34 patients (20.5%; 95% CI = 10%-37%) had HER2 signaling activity that was characterized as abnormally high. Amongst the tumor samples there was no correlation between HER2 protein status (by cell cytometry) and HER2 signaling activity (hyperactive or normal) (Regression analysis P = 0.144, R2 = 0.068). One conclusion is that measurement of HER2 signaling activity can identify a subset of breast cancers with normal HER2 receptor levels with abnormally high levels of HER2 signaling. This result constitutes a new subtype of breast cancer that should be considered for treatment with HER2 pathway inhibitors.",
        "Doc_title":"A functional signal profiling test for identifying a subset of HER2-negative breast cancers with abnormally amplified HER2 signaling activity.",
        "Journal":"Oncotarget",
        "Do_id":"27713176",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605818717357211649},
      {
        "Doc_abstract":"Approximately 40% of HER2-positive breast cancer patients will develop brain metastases, usually during the first 2-3 years following initial diagnosis and up to 2 years after overt metastatic spread. However, there are no data about brain metastases development as a late disease relapse. In addition, there are no data whether the high incidence of brain metastases is maintained in patients with HER2 overexpression even in late brain metastases. The aim of this paper was to determine the incidence of brain metastases and the HER2 status in patients who developed late relapse, at least 5 years after the initial diagnosis.;Among 384 consecutive breast cancer patients with late relapse, only 8 developed brain metastases. Archival pathological specimens of the primary tumors of those 8 patients were tested by immunohistochemistry (IHC) for HER2 status.;The incidence of late brain metastases was 2% (8/384). None of these patients had HER2 3+ primary breast cancer.;This study shows that the risk for brain metastases in HER2 3+ breast cancer patients is very low or might be even absent as a late relapse. Absence of late brain metastases in HER2 3+ breast cancer might be attributed to specific biological characteristics of HER2 3+ carcinomas to develop brain metastases mostly in the early course of metastatic disease.",
        "Doc_title":"Brain metastases as late breast cancer relapse. Single institution experience and review of the literature.",
        "Journal":"Journal of B.U.ON. : official journal of the Balkan Union of Oncology",
        "Do_id":"19650170",
        "Doc_ChemicalList":"ERBB2 protein, human;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Adult;Brain Neoplasms;Breast Neoplasms;Carcinoma, Ductal, Breast;Carcinoma, Lobular;Female;Humans;Immunoenzyme Techniques;Incidence;Medical Records;Middle Aged;Neoplasm Recurrence, Local;Prognosis;Receptor, ErbB-2;Treatment Outcome",
        "Doc_meshqualifiers":"drug therapy;epidemiology;secondary;drug therapy;epidemiology;pathology;drug therapy;epidemiology;secondary;drug therapy;epidemiology;secondary;diagnosis;metabolism",
        "_version_":1605898044491956224},
      {
        "Doc_abstract":"The expression of the oestrogen receptor (ER) is one of the more important clinical parameters of breast cancer. However, the relationship between the ER and its ligand, oestradiol, and the enzymes that synthesise it are not well understood. The expression of mRNA transcripts of members of the oestradiol metabolic and signalling pathways including the ER was studied in detail.;mRNA transcripts for aromatase (CYP19), 17-beta-hydroxysteroid dehydrogenase I, 17-beta-hydroxysteroid dehydrogenase II, ERalpha, ERbeta, steroid sulfatase (STS), oestradiol sulfotransferase (EST), cyclin D1 (CYCLD1) and ERBB2 were fluorometrically quantified by competitive RT-PCR using an internal standard in 155 breast carcinomas. In addition, the transcripts of CYP19 were analysed for alternative splicing/usage of exon 1 and an alternative poly A tail.;A great variability of expression was observed, ranging from 0 to 2376 amol/mg RNA. The highest levels were observed for STS and EST, and the lowest levels (close to zero) were observed for the 17-beta-hydroxysteroid dehydrogenase isoenzymes. The levels of mRNA expression were analysed with respect to clinical and histopathological parameters as well as for disease-free survival. High correlation of the mRNA expression of STS, EST and 17-beta-hydroxysteroid dehydrogenase in the tumours suggested a common regulation, possibly by their common metabolite (oestradiol). Hierarchical clustering analysis in the 155 patients resulted in two main clusters, representing the ERalpha-negative and ERalpha-positive breast cancer cases. The mRNA expression of the oestradiol metabolising enzymes did not follow the expression of the ERalpha in all cases, leading to the formation of several subclasses of tumours. Patients with no expression of CYP19 and patients with high levels of expression of STS had significantly shorter disease-free survival time (P > 0.0005 and P < 0.03, respectively). Expression of ERbeta mRNA was a better prognostic factor than that of ERalpha in this material.;Our results indicate the importance of CYP19 and the enzymes regulating the oestrone sulfate metabolism as factors of disease-free survival in breast cancer, in addition to the well-known factors ER and ERBB2.",
        "Doc_title":"Intratumoural mRNA expression of genes from the oestradiol metabolic pathway and clinical and histopathological parameters of breast cancer.",
        "Journal":"Breast cancer research : BCR",
        "Do_id":"14979917",
        "Doc_ChemicalList":"RNA, Messenger;RNA, Neoplasm;Estradiol;Aromatase",
        "Doc_meshdescriptors":"Adult;Aged;Aged, 80 and over;Alternative Splicing;Aromatase;Breast Neoplasms;Cluster Analysis;Disease-Free Survival;Estradiol;Exons;Gene Expression Profiling;Genes, Neoplasm;Humans;Lymph Nodes;Menopause;Middle Aged;Oligonucleotide Array Sequence Analysis;RNA, Messenger;RNA, Neoplasm;Signal Transduction",
        "Doc_meshqualifiers":"genetics;genetics;diagnosis;enzymology;genetics;secondary;genetics;metabolism;genetics;methods;statistics & numerical data;genetics;chemistry;metabolism;pathology;genetics;methods;statistics & numerical data;biosynthesis;biosynthesis;genetics",
        "_version_":1605896546869575680},
      {
        "Doc_abstract":"The anti-HER2 drugs trastuzumab and lapatinib are increasingly changing the natural history of early and metastatic HER2-overexpressing breast cancer. Many other agents targeted against the HER2 signaling network are in clinical development, and these are or will soon be combined with the currently approved anti-HER2 therapies. We review herein recent data in support of the early use of combinations of agents targeted to the HER2 network as the most rational approach against this subtype of breast cancer. We propose that the optimal combination or combinations of anti-HER2 agents delivered early in the natural history of HER2+ breast cancer should close to eliminate acquired drug resistance, shorten the duration of therapy, and potentially dispense with the need of concurrent chemotherapy.",
        "Doc_title":"New strategies in HER2-overexpressing breast cancer: many combinations of targeted drugs available.",
        "Journal":"Clinical cancer research : an official journal of the American Association for Cancer Research",
        "Do_id":"21248299",
        "Doc_ChemicalList":"Antibodies, Monoclonal;Antibodies, Monoclonal, Humanized;Quinazolines;lapatinib;ERBB2 protein, human;Receptor, ErbB-2;Trastuzumab",
        "Doc_meshdescriptors":"Antibodies, Monoclonal;Antibodies, Monoclonal, Humanized;Antineoplastic Combined Chemotherapy Protocols;Breast Neoplasms;Female;Gene Expression Regulation, Neoplastic;Humans;Molecular Targeted Therapy;Quinazolines;Receptor, ErbB-2;Signal Transduction;Trastuzumab",
        "Doc_meshqualifiers":"therapeutic use;therapeutic use;drug therapy;genetics;metabolism;drug effects;methods;therapeutic use;genetics",
        "_version_":1605763195037810688},
      {
        "Doc_abstract":"Patients with human epidermal growth factor receptor 2 (HER-2) overexpressing breast carcinomas have a more aggressive clinical behavior and their tumors are often hormone receptor negative. However, the recently introduced anti-HER-2 antibody trastuzumab has been proven to improve the survival and controls the disease in a significant proportion of these patients. Therefore, the analysis of HER-2 in patients with breast cancer has become an important and routine test to select those who may benefit from the gene-based targeted therapy trastuzumab (herceptin). There is good correlation between HER-2/neu protein overexpression and HER-2 gene amplification in breast cancer. However, inconsistent results have been reported in the rate of HER-2/neu protein overexpression in other malignant neoplasms. Furthermore, only rare studies have investigated the correlation between the HER-2/neu protein overexpression and the status of HER-2 gene in these tumors. We investigated the HER-2 gene and protein status in several cases of Paget disease of the nipple and vulva by using a chromogenic in situ hybridization assay and immunohistochemistry. We find that the majority of the Paget disease of the breast demonstrate HER-2 gene amplification, whereas most of the extramammary Paget disease lack HER-2 gene amplification. In addition, our results show a good correlation between HER-2/neu protein overexpression and HER-2 gene amplification in Paget disease of the nipple, but we were unable to confirm this correlation in HER-2/neu protein overexpressing Paget disease of the vulva.",
        "Doc_title":"HER-2 gene amplification in Paget disease of the nipple and extramammary site: a chromogenic in situ hybridization study.",
        "Journal":"Diagnostic molecular pathology : the American journal of surgical pathology, part B",
        "Do_id":"16932067",
        "Doc_ChemicalList":"RNA, Messenger;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Aged;Breast Neoplasms;Female;Gene Amplification;Humans;Immunochemistry;In Situ Hybridization;Middle Aged;Nipples;Paget Disease, Extramammary;Paget's Disease, Mammary;RNA, Messenger;Receptor, ErbB-2;Vulvar Neoplasms",
        "Doc_meshqualifiers":"diagnosis;pathology;pathology;diagnosis;pathology;diagnosis;pathology;analysis;metabolism;analysis;genetics;diagnosis;pathology",
        "_version_":1605906439599030272},
      {
        "Doc_abstract":"Hyperexpression of HER-2/neu is found in tissues of 25-30% patients with primary breast cancer. Monotherapy with antitumor drug trastuzumab as second-third line therapy and its combination with cytostatics prolong the interval before disease progress and the overall survival of patients with metastatic HER-2/neu+ tumors. Trastuzumab is now prescribed after evaluation of HER-2/neu status by the immunohistochemical method and/or fluorescent in situ hybridization. We have developed a method for evaluating the HER-2/neu status of breast cancer biopsy specimens by real time reverse transcription PCR. Based on the analysis of published data, six candidate genes in the pericentromer region of chromosome 17 are selected for data normalization. Stability of these genes is verified on the cell model (MCF-7 and SK-BR-3) and on biopsy materials. The sensitivity and specificity of the method is evaluated on a collection of biopsy specimens. ",
        "Doc_title":"Express analysis of HER-2/neu status in breast cancer biopsy specimens.",
        "Journal":"Bulletin of experimental biology and medicine",
        "Do_id":"24143382",
        "Doc_ChemicalList":"ERBB2 protein, human;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Adult;Aged;Aged, 80 and over;Biopsy;Breast Neoplasms;Female;Gene Amplification;Gene Expression;Gene Expression Profiling;Humans;MCF-7 Cells;Mammary Glands, Human;Middle Aged;Real-Time Polymerase Chain Reaction;Receptor, ErbB-2;Reverse Transcriptase Polymerase Chain Reaction;Sensitivity and Specificity",
        "Doc_meshqualifiers":"metabolism;metabolism;pathology;genetics;metabolism",
        "_version_":1605841401851936768},
      {
        "Doc_abstract":"To exam the relationship between HER2 over-expression and different adjuvant chemotherapies in breast cancer.;A total of 1625 primary breast cancer patients who received post-surgery adjuvant chemotherapy in Tianjin Cancer Hospital, China, from July 2002 to November 2005 were included in the study. Among them, 600 patients were given CMF (CTX+MTX+5-Fu) regimen, 600 given CEF (CTX+E-ADM+5-Fu) regimen, and 425 given anthracyclines plus taxanes regimen, with mean follow-up time of 42 months.;In CMF treatment group, the 3-year disease free survival (DFS) in HER2 over-expressed patients was lower than that of the HER2-negative ones (89.80% vs 91.24%, P=0.0348); in node-positive subgroup, the 3-year DFS was 84.72% in HER2 over-expressed patients, and 90.18% in the HER-2-negative ones (P=0.0271). Compared to CMF regimen, anthracyclines and anthracyclines plus taxanes regimens are more effective (P<0.05) in node-positive HER2 over-expression than those in the node-negative.;HER2 over-expression is an independent index for predicting poor prognosis and short DFS for breast cancer patients. HER2 over-expressed patients are resistant to CMF regimen chemotherapy, but sensitive to anthracyclines-based or anthracyclines plus taxanes regimen. HER2 expression can be taken as a marker for therapies in breast cancer.",
        "Doc_title":"HER2 over-expression and response to different chemotherapy regimens in breast cancer.",
        "Journal":"Journal of Zhejiang University. Science. B",
        "Do_id":"18196606",
        "Doc_ChemicalList":"Epirubicin;Cyclophosphamide;ERBB2 protein, human;Receptor, ErbB-2;Fluorouracil;Methotrexate",
        "Doc_meshdescriptors":"Adult;Aged;Aged, 80 and over;Antineoplastic Combined Chemotherapy Protocols;Breast Neoplasms;Cyclophosphamide;Epirubicin;Female;Fluorouracil;Humans;Methotrexate;Middle Aged;Receptor, ErbB-2",
        "Doc_meshqualifiers":"administration & dosage;therapeutic use;chemistry;drug therapy;mortality;administration & dosage;administration & dosage;administration & dosage;administration & dosage;analysis",
        "_version_":1605826449106796544},
      {
        "Doc_abstract":"Growth factors and their receptors play an important role in the pathogenesis of human cancer. The human epidermal growth factor receptor-2 (HER2) is overexpressed in approximately 30% of breast cancers and this is associated with poor clinical outcome. Overexpression of HER2 has been demonstrated to play a direct role in oncogenic transformation. Murine monoclonal antibodies (muMAbs) targeting the extracellular domain of the HER2 receptors suppress HER2-positive cancer cell growth, with muMAb 4D5 having particularly potent activity. A humanized form of muMAb 4D5 was generated by converting all but the antigen-binding region of muMAb 4D5 into human IgG consensus sequences. The humanized monoclonal antibody, Herceptin, preferentially targets HER2-overexpressing cells, produces responses in breast cancer patients and is well tolerated. In a pivotal phase III trial, Herceptin administered in combination with chemotherapy (anthracycline/cyclophosphamide or paclitaxel) was compared with chemotherapy alone. The combination was found to produce significant survival benefits in HER2-positive metastatic breast cancer patients. These results have led to the approval of Herceptin for clinical use in the USA and elsewhere.",
        "Doc_title":"Herceptin: increasing survival in metastatic breast cancer.",
        "Journal":"European journal of oncology nursing : the official journal of European Oncology Nursing Society",
        "Do_id":"12849614",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605902040011112448},
      {
        "Doc_abstract":"Testing for alterations in HER-2/neu in breast cancer has become increasingly popular in recent years, particularly with the recent development of a humanized antiHER-2/neu monoclonal antibody, trastuzumab, which is currently being employed in conjunction with cytotoxic chemotherapy to treat metastatic breast cancer in patients whose tumors exhibit this HER-2/neu alteration. Controversy exists not only on the optimal method of laboratory testing for this HER-2/neu alteration (i.e., fluorescence in situ hybridization (FISH) versus immunohistochemistry (IHC) versus others), but also on the type of reagents used for a given method. A plethora of published studies on tissue-based HER-2/neu testing has recently appeared in many peer-reviewed journals; many have concluded that IHC could be used as a first-line screening test, with the recommendation of FISH to confirm indeterminate results. In contrast to these studies, a recent study by Pauletti et al. showed that HER-2/neu testing by IHC does not predict clinical outcome as accurately as does FISH. This commentary discusses the findings of this study, within a broader review of critical issues relating to HER-2/neu testing in breast cancer.",
        "Doc_title":"Testing for HER-2/neu in breast cancer: is fluorescence in situ hybridization superior in predicting outcome?",
        "Journal":"Advances in anatomic pathology",
        "Do_id":"12409642",
        "Doc_ChemicalList":"Antibodies, Monoclonal;Antibodies, Monoclonal, Humanized;Receptor, ErbB-2;Trastuzumab",
        "Doc_meshdescriptors":"Antibodies, Monoclonal;Antibodies, Monoclonal, Humanized;Breast Neoplasms;Female;Humans;Immunoenzyme Techniques;In Situ Hybridization, Fluorescence;Mass Screening;Pilot Projects;Prognosis;Receptor, ErbB-2;Reproducibility of Results;Survival Rate;Trastuzumab",
        "Doc_meshqualifiers":"diagnosis;genetics;mortality;analysis;genetics",
        "_version_":1605742721976238080},
      {
        "Doc_abstract":"To explore the survival status after treatment for patients with different molecular subtypes of breast cancers.;A total of 4491 patients with invasive breast cancer from January 2000 to July 2011 were retrospectively recruited to receive pathological verification and treatment at our clinic. According to the immunohistochemical results of hormone receptor (HR) and human epidermal growth factor receptor 2 (HER2), they were assigned into 3 groups of HR+/HER2-, HER2+ and HR-/ HER2-. Survival analyses were conducted to examine the effects of molecular subtypes and lymph node status on survival.;The 3-year recurrence free survival for HR+/HER2-, HER2+ and HR-/HER2- were 94.9%, 89.5% ane 92.3% respectively. Different molecular subtypes presented different survival patterns (P = 0.0001). The 3-year recurrence-free survival (RFS) for LN+ and LN- was 87.1% and 97.8% respectively. And statistical difference existed (P < 0.01). No difference was detected among three molecular subtypes of LN- (P = 0.102); However, for LN+ patients, HR+/HER2- showed a higher RFS than HER2+ and HR-/HER2 (P = 0.001).;Different molecular subtypes of breast cancers have varying survival. And lymph node status is probably an important prognostic factor.",
        "Doc_title":"[Survival analysis for different molecular subtypes of breast cancers after treatment].",
        "Journal":"Zhonghua yi xue za zhi",
        "Do_id":"24534345",
        "Doc_ChemicalList":"Receptors, Estrogen;ERBB2 protein, human;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Breast Neoplasms;Disease-Free Survival;Female;Humans;Lymphatic Metastasis;Prognosis;Receptor, ErbB-2;Receptors, Estrogen;Retrospective Studies;Survival Analysis",
        "Doc_meshqualifiers":"classification;mortality;pathology;metabolism;metabolism",
        "_version_":1605765077552594944},
      {
        "Doc_abstract":"The American Cancer Society (ACS), Centers for Disease Control and Prevention (CDC), National Cancer Institute (NCI), and North American Association of Central Cancer Registries (NAACCR) collaborate annually to produce updated, national cancer statistics. This Annual Report includes a focus on breast cancer incidence by subtype using new, national-level data.;Population-based cancer trends and breast cancer incidence by molecular subtype were calculated. Breast cancer subtypes were classified using tumor biomarkers for hormone receptor (HR) and human growth factor-neu receptor (HER2) expression.;Overall cancer incidence decreased for men by 1.8% annually from 2007 to 2011 [corrected]. Rates for women were stable from 1998 to 2011. Within these trends there was racial/ethnic variation, and some sites have increasing rates. Among children, incidence rates continued to increase by 0.8% per year over the past decade while, like adults, mortality declined. HR+/HER2- breast cancers, the subtype with the best prognosis, were the most common for all races/ethnicities with highest rates among non-Hispanic white women, local stage cases, and low poverty areas (92.7, 63.51, and 98.69 per 100000 non-Hispanic white women, respectively). HR+/HER2- breast cancer incidence rates were strongly, positively correlated with mammography use, particularly for non-Hispanic white women (Pearson 0.57, two-sided P < .001). Triple-negative breast cancers, the subtype with the worst prognosis, were highest among non-Hispanic black women (27.2 per 100000 non-Hispanic black women), which is reflected in high rates in southeastern states.;Progress continues in reducing the burden of cancer in the United States. There are unique racial/ethnic-specific incidence patterns for breast cancer subtypes; likely because of both biologic and social risk factors, including variation in mammography use. Breast cancer subtype analysis confirms the capacity of cancer registries to adjust national collection standards to produce clinically relevant data based on evolving medical knowledge.",
        "Doc_title":"Annual Report to the Nation on the Status of Cancer, 1975-2011, Featuring Incidence of Breast Cancer Subtypes by Race/Ethnicity, Poverty, and State.",
        "Journal":"Journal of the National Cancer Institute",
        "Do_id":"25825511",
        "Doc_ChemicalList":"Biomarkers, Tumor;Receptors, Estrogen;Receptors, Progesterone;ERBB2 protein, human;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Adult;African Americans;Age Distribution;Aged;Aged, 80 and over;Biomarkers, Tumor;Breast Neoplasms;Breast Neoplasms, Male;Confounding Factors (Epidemiology);Continental Population Groups;Early Detection of Cancer;Ethnic Groups;European Continental Ancestry Group;Female;Hispanic Americans;Humans;Incidence;Male;Mammography;Middle Aged;Neoplasm Staging;Poverty;Prognosis;Receptor, ErbB-2;Receptors, Estrogen;Receptors, Progesterone;Registries;United States",
        "Doc_meshqualifiers":"statistics & numerical data;analysis;chemistry;diagnosis;epidemiology;ethnology;mortality;pathology;epidemiology;pathology;statistics & numerical data;methods;statistics & numerical data;statistics & numerical data;statistics & numerical data;statistics & numerical data;trends;utilization;analysis;analysis;analysis;epidemiology",
        "_version_":1605841969522671616},
      {
        "Doc_abstract":"HER2 amplification/overexpression is a marker of poor prognosis in breast cancer. The prognostic impact of HER2 positivity is lower in node-negative compared with node-positive women. The only significant, independent prognostic factors in breast cancer are node status, HER2 status and menopausal status. HER2-positive tumors also contain p53 abnormalities, tend to be hormone receptor and bcl-2 negative, have lymphoid infiltration (LI) and a high mitotic index. Patients with LI who are HER2 positive have a better prognosis than those who are HER2 negative, whereas HER2-positive patients without LI have a significantly worse prognosis than HER2-negative patients. Morphological and biological alterations appear to identify two categories of breast tumor. Two hypotheses may explain the progression to two tumor types: (1) atypical ductal hyperplasia (ADH) is a precursor of ductal carcinoma in situ (DCIS), which is a precursor of invasive ductal carcinoma (IDC); or (2) ADH is a precursor of HER2-negative IDC whereas DCIS is a precursor of HER2-positive IDC. The second theory fits well with two breast cancer subsets and the characteristics of ADH and DCIS. The first type of IDC occurs in older patients, progresses slowly due to estrogen dependency but is aggressive long term. The other type progresses rapidly, is HER2 positive and is more likely to occur in young patients.",
        "Doc_title":"HER2 as a prognostic factor in breast cancer.",
        "Journal":"Oncology",
        "Do_id":"11694790",
        "Doc_ChemicalList":"Biomarkers, Tumor;Estrogens;Neoplasm Proteins;Receptors, Estrogen;Receptors, Progesterone;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Adult;Age of Onset;Aged;Biomarkers, Tumor;Breast;Breast Neoplasms;Carcinoma, Ductal, Breast;Carcinoma, Intraductal, Noninfiltrating;Cell Transformation, Neoplastic;Diagnostic Tests, Routine;Disease Progression;Estrogens;Female;Genes, bcl-2;Genes, erbB-2;Genes, p53;Humans;Hyperplasia;Lymphatic Metastasis;Lymphocytes, Tumor-Infiltrating;Middle Aged;Mitotic Index;Models, Biological;Necrosis;Neoplasm Invasiveness;Neoplasm Proteins;Neoplasms, Hormone-Dependent;Phenotype;Precancerous Conditions;Prognosis;Receptor, ErbB-2;Receptors, Estrogen;Receptors, Progesterone;Risk Factors",
        "Doc_meshqualifiers":"analysis;chemistry;pathology;chemistry;classification;genetics;mortality;pathology;chemistry;genetics;mortality;pathology;chemistry;genetics;pathology;genetics;analysis;chemistry;genetics;mortality;pathology;metabolism;pathology;analysis;analysis;analysis",
        "_version_":1605755729094901760},
      {
        "Doc_abstract":"Breast cancer is a heterogeneous disease with different molecular drivers regulating its growth, survival and response to therapy. Breast cancer is divided in three major subtypes based on the pattern of expression of hormone receptors and HER2: luminal tumors (or HR positive), HER2 amplified tumors, and the remaining subtypes being collectively referred to as triple-negative breast cancer. While tumors within these subtypes have similar gene-expression patterns, clinical outcomes, and response to therapy, this division is far from perfect and subgroups within these groups are beginning to be identified. In terms of therapy, an increasingly rational drug development effort has resulted in agents against new molecular targets that are active against only those tumors with the targeted molecular alteration or phenotype. These agents include receptor and non-receptor tyrosine kinase inhibitors (HER1, HER2, HER3, insulin-like growth factor receptor, c-met, fibroblast growth factor receptor and HSP 90 inhibitors), intracellular signaling pathways (PI3K, AKT, mTOR), angiogenesis inhibitors and agents that interfere with DNA repair (PARP inhibitors). Thus, the overall management of breast cancer will increasingly require an understanding of breast cancer heterogeneicity, the biological nature of any given tumor as well the existence of increased personalized treatment options.",
        "Doc_title":"Management of breast cancer with targeted agents: importance of heterogeneity. [corrected].",
        "Journal":"Nature reviews. Clinical oncology",
        "Do_id":"20125090",
        "Doc_ChemicalList":"Antineoplastic Agents;Biomarkers, Tumor;Enzyme Inhibitors",
        "Doc_meshdescriptors":"Antineoplastic Agents;Biomarkers, Tumor;Breast Neoplasms;Enzyme Inhibitors;Female;Humans;Neoplasm Staging;Treatment Outcome",
        "Doc_meshqualifiers":"therapeutic use;antagonists & inhibitors;metabolism;drug therapy;metabolism;therapeutic use",
        "_version_":1605896861881729024},
      {
        "Doc_abstract":"The Nottingham prognostic index (NPI) is a widely used clinicopathological staging system for breast cancer prognostication. Using a step-wise classification approach where breast tumor expression profiles were first divided into general \"molecular subtypes\" [estrogen receptor (ER)+, ER-, ERBB2+], followed by an independent analysis of each subtype, we identified a 62-gene expression signature (NPI-ES) highly correlated to the NPI in ER+ tumors. The NPI-ES classified the majority of ER+ tumors into two distinct groups with high confidence and was significantly correlated to NPI status in two independent sets of ER+ tumors derived from different centers. The NPI-ES is comparable to the classical NPI in identifying patients likely to exhibit a poor clinical prognosis, as well as to a recently described \"prognosis signature\" for breast cancer. Our findings demonstrate how expression profiling can complement classical staging systems employing histopathological parameters scored over a continuous range of values.",
        "Doc_title":"A molecular signature of the Nottingham prognostic index in breast cancer.",
        "Journal":"Cancer research",
        "Do_id":"15126326",
        "Doc_ChemicalList":"Receptors, Estrogen;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Breast Neoplasms;Cluster Analysis;Gene Expression Profiling;Humans;Neoplasm Staging;Prognosis;Receptor, ErbB-2;Receptors, Estrogen;Survival Rate",
        "Doc_meshqualifiers":"classification;genetics;metabolism;pathology;biosynthesis;genetics;biosynthesis;genetics",
        "_version_":1605756195818176512},
      {
        "Doc_abstract":"Breast cancers which do not express oestrogen, progesterone, or HER-2 neu receptors are known as triple negative breast carcinomas. In western literature they have been found to be extremely aggressive with a poor prognosis. However there is scarcity of data regarding this variety of breast cancer in India.To examine the clinical and pathological character of triple negative breast carcinomas and to compare their characteristics with other variants of breast carcinomas which presented to Medical College, Kolkata, a randomised sample of 72 patients were included with breast cancer attending the department of surgery from January 2008 to June 2008.The clinical and histopathological data along with ER/PR status and HER-2 neu expression examined by immunohistochemical methods were recorded.Twenty patients (27.78%) were found to be triple negative.The mean age at presentation was 35.4 +/- 1.95 years with 17 (85%) out of 20 being premenopausal. At presentation, mean tumour size was 4.7 +/- 0.21 cm. Though 15 patients (75%) presented with stage III disease and 16 patients (80%) had grade III histology, 14 (70%) were node negative and 20 (80%) did not have involvement of nipple areola complex and 19(95%) did not have multicentric disease. Triple negative breast cancer is prevalent in eastern India.They are locally aggressive, common in premenopausal women, but strangely do not tend to present with lymph node involvement or involvement of nipple areola complex. Therefore a more conservative approach might have a role in these seemingly aggressive tumours.",
        "Doc_title":"A clinical and pathological study of triple negative breast carcinoma: experience of a tertiary care centre in eastern India.",
        "Journal":"Journal of the Indian Medical Association",
        "Do_id":"23738399",
        "Doc_ChemicalList":"Receptors, Estrogen;Receptors, Progesterone;ERBB2 protein, human;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Adult;Breast Neoplasms;Carcinoma, Ductal, Breast;Female;Humans;India;Lymphatic Metastasis;Middle Aged;Neoplasm Grading;Neoplasm Staging;Nipples;Premenopause;Receptor, ErbB-2;Receptors, Estrogen;Receptors, Progesterone;Tertiary Care Centers",
        "Doc_meshqualifiers":"metabolism;pathology;metabolism;secondary;pathology;metabolism;metabolism",
        "_version_":1605746284901171201},
      {
        "Doc_abstract":"The estrogen receptor alpha (ERalpha), progesterone receptor (PR), and erbB2 (Her2 in humans) are important prognostic markers of human breast cancer, and they are variably expressed in different subtypes of breast cancer. The basal subtype, for example, is negative for ERalpha, PR, and Her2 by immunohistochemistry. We investigated the expression of these signaling molecules in enriched populations of mouse mammary stem cells and luminal cells that were isolated according to their differential expression of CD24 and the alpha6beta1-integrin complex. We found that the basal population, which is enriched in mouse mammary stem cells, did not express ERalpha, PR, or ErbB2/Her2 but did express epidermal growth factor receptor (EGFR)/ErbB1, whereas the subset of cells enriched for luminal cells expressed ERalpha (37% of cells) and PR (40% of cells) but not ErbB2/Her2 or EGFR/ErbB1. Ovariectomy confirmed the importance of estrogen signaling to luminal cell proliferation but had no effect on the size of the mouse mammary stem cell-enriched population. Thus, mouse mammary stem cells were negative for ERalpha, PR, and ErbB2 and appeared to share common properties with poor-prognosis basal breast cancer.",
        "Doc_title":"Steroid hormone receptor status of mouse mammary stem cells.",
        "Journal":"Journal of the National Cancer Institute",
        "Do_id":"16849684",
        "Doc_ChemicalList":"Biomarkers, Tumor;Estrogen Receptor alpha;Receptors, Progesterone;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Animals;Biomarkers, Tumor;Breast Neoplasms;Cell Proliferation;Estrogen Receptor alpha;Female;Mammary Glands, Animal;Mice;Ovariectomy;Phenotype;Receptor, ErbB-2;Receptors, Progesterone;Signal Transduction;Stem Cells",
        "Doc_meshqualifiers":"analysis;chemistry;analysis;chemistry;cytology;analysis;analysis;chemistry",
        "_version_":1605826425166757888},
      {
        "Doc_abstract":"To assess the expression of receptors for androgen (AR), oestrogen (ER) and progesterone (PR) as well as human epidermal growth factor receptor type 2 (Her-2/neu) status of breast carcinomas in breast cancer susceptibility gene (BRCA) BRCA1/2 mutation carriers and BRCA1/2 negative tested women.;One hundred and thirty-five breast cancers in women tested for BRCA1/2 mutations. Screening for BRCA1 and BRCA2 mutations was performed by direct sequencing of all BRCA1 and BRCA2 exons as well as the surrounding intronic sequences. Additionally, BRCA genes were analysed with multiplex ligation-dependent probe amplification. Consecutive paraffin sections were examined immunohistochemically for AR, ER, PR and Her-2/neu.;Of the 135 tumours, 43 (32%) were BRCA1-related, 18 (13%) were BRCA2-related and 74 (55%) were BRCA1/2-negative. Seventy-two per cent of the BRCA1-related, 22% of the BRCA2-related and 12% of the BRCA1/2-negative tumours were triple (ER, PR, Her2neu)-negative. Eighty-four per cent of BRCA1 mutated cancers were high-grade (G3) tumours. ARs were expressed in 30% (13 of 43) of BRCA1-related, in 78% (14 of 18) in BRCA2-related tumours and in 76% (56 of 74) in BRCA1/2 negative tumours. Twenty-one per cent of ER-negative BRCA1-related tumours expressed androgen receptors.;Approximately one in five BRCA1 mutated breast cancers negative for ER and PR express androgen receptors. Modulation of AR might open a new avenue for treating these high-risk cancers.",
        "Doc_title":"Androgen receptor expression in breast cancer patients tested for BRCA1 and BRCA2 mutations.",
        "Journal":"Histopathology",
        "Do_id":"21166701",
        "Doc_ChemicalList":"BRCA1 Protein;BRCA2 Protein;Biomarkers, Tumor;Receptors, Androgen;Receptors, Estrogen;Receptors, Progesterone",
        "Doc_meshdescriptors":"Adult;Aged;BRCA1 Protein;BRCA2 Protein;Biomarkers, Tumor;Breast Neoplasms;Carcinoma;Cluster Analysis;Female;Genetic Predisposition to Disease;Humans;Immunohistochemistry;Middle Aged;Mutation;Receptors, Androgen;Receptors, Estrogen;Receptors, Progesterone",
        "Doc_meshqualifiers":"genetics;metabolism;genetics;metabolism;genetics;metabolism;genetics;metabolism;genetics;metabolism;metabolism;metabolism;metabolism",
        "_version_":1605809112341282816},
      {
        "Doc_abstract":"Breast cancer is a heterogeneous disease that is affected by ethnicity of patients. According to hormone receptor status and gene expression profiling, breast cancers are classified into four molecular subtypes, each showing distinct clinical behavior. Lack of sufficient data on molecular subtypes of breast cancer in Iran, prompted us to investigate the prevalence and the clinicopathological features of each subtype among Iranian women. A total of 428 women diagnosed with breast cancer from 2002 to 2011 were included and categorized into four molecular subtypes using immunohistochemistry. Prevalence of each subtype and its association with patients' demographics and tumor characteristics, such as size, grade, lymph-node involvement and vascular invasion, were investigated using Chi-square, analysis of variance and multivariate logistic regression. Luminal A was the most common molecular subtype (63.8%) followed by Luminal B (8.4%), basal-like (15.9%) and HER-2 (11.9%). Basal-like and HER-2 subtypes were mostly of higher grades while luminal A tumors were more of grade 1 (P<0.001). Vascular invasion was more prevalent in HER-2 subtype, and HER-2 positive tumors were significantly associated with vascular invasion (P=0.013). Using muti-variate analysis, tumor size greater than 5 cm and vascular invasion were significant predictors of 3 or more nodal metastases. Breast cancer was most commonly diagnosed in women around 50 years of age and the majority of patients had lymph node metastasis at the time of diagnosis. This points to the necessity for devising an efficient screening program for breast cancer in Iran. Further, prospective surveys are suggested to evaluate prognosis of different subtypes in Iranian patients.",
        "Doc_title":"Breast cancer molecular subtypes and associations with clinicopathological characteristics in Iranian women, 2002- 2011.",
        "Journal":"Asian Pacific journal of cancer prevention : APJCP",
        "Do_id":"22901141",
        "Doc_ChemicalList":"Receptors, Estrogen;Receptors, Progesterone;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Adult;Aged;Aged, 80 and over;Breast Neoplasms;Carcinoma, Ductal, Breast;Carcinoma, Lobular;Female;Humans;Iran;Lymphatic Metastasis;Middle Aged;Neoplasm Staging;Prognosis;Receptor, ErbB-2;Receptors, Estrogen;Receptors, Progesterone",
        "Doc_meshqualifiers":"classification;metabolism;pathology;metabolism;pathology;metabolism;pathology;metabolism;metabolism;metabolism",
        "_version_":1605811129251004416},
      {
        "Doc_abstract":"Trastuzumab has been shown to improve the survival outcomes of HER2 positive breast cancer patients. However, a significant proportion of HER2-positive patients are either inherently resistant or develop resistance to trastuzumab. We assessed the effects of neratinib, an irreversible panHER inhibitor, in a panel of 36 breast cancer cell lines. We further assessed its effects with or without trastuzumab in several sensitive and resistant breast cancer cells as well as a BT474 xenograft model. We confirmed that neratinib was significantly more active in HER2-amplified than HER2 non-amplified cell lines. Neratinib decreased the activation of the 4 HER receptors and inhibited downstream pathways. However, HER3 and Akt were reactivated at 24 hours, which was prevented by the combination of trastuzumab and neratinib. Neratinib also decreased pHER2 and pHER3 in acquired trastuzumab resistant cells. Neratinib in combination with trastuzumab had a greater growth inhibitory effect than either drug alone in 4 HER2 positive cell lines. Furthermore, trastuzumab in combination with neratinib was growth inhibitory in SKBR3 and BT474 cells which had acquired resistance to trastuzumab as well as in a BT474 xenograft model. Innately trastuzumab resistant cell lines showed sensitivity to neratinib, but the combination did not enhance response compared to neratinib alone. Levels of HER2 and phospho-HER2 showed a direct correlation with sensitivity to neratinib. Our data indicate that neratinib is an effective anti-HER2 therapy and counteracted both innate and acquired trastuzumab resistance in HER2 positive breast cancer. Our results suggest that combined treatment with trastuzumab and neratinib is likely to be more effective than either treatment alone for both trastuzumab-sensitive breast cancer as well as HER2-positive tumors with acquired resistance to trastuzumab. ",
        "Doc_title":"Neratinib overcomes trastuzumab resistance in HER2 amplified breast cancer.",
        "Journal":"Oncotarget",
        "Do_id":"24009064",
        "Doc_ChemicalList":"Antibodies, Monoclonal, Humanized;N-(4-(3-chloro-4-(2-pyridinylmethoxy)anilino)-3-cyano-7-ethoxy-6-quinolyl)-4-(dimethylamino)-2-butenamide;Quinolines;ERBB2 protein, human;Receptor, ErbB-2;Trastuzumab",
        "Doc_meshdescriptors":"Animals;Antibodies, Monoclonal, Humanized;Breast Neoplasms;Cell Growth Processes;Cell Line, Tumor;Drug Interactions;Drug Resistance, Neoplasm;Female;Humans;Mice;Mice, Inbred BALB C;Mice, Nude;Phosphorylation;Quinolines;Receptor, ErbB-2;Trastuzumab;Treatment Outcome;Xenograft Model Antitumor Assays",
        "Doc_meshqualifiers":"pharmacology;drug therapy;enzymology;pathology;physiology;pharmacology;antagonists & inhibitors;metabolism",
        "_version_":1605746807617355777},
      {
        "Doc_abstract":"Breast cancer (BC) is one of the most common forms of cancer amongst females. Early diagnosis, prognosis and therapy plays crucial role in the survival of patients with breast cancer. The study was aimed on identification of potential markers for early BC diagnostics by means of genome-wide comparative analysis of gene expression in cancer and normal tissue of breast.;The analysis of gene expression in 15 invasive adenocarcinoma specimens and 15 normal breast tissue was conducted using the full-genome microarrays Sentrix HumanWD-6V3 BeadChip (Illumina). Methylation of TP53INK1 and TUSÐ¡5 promoters was interrogated by the combined bisulfite restriction analysis (COBRA).;Analysis of gene expression in the samples of breast adenocarcinoma revealed abnormal expression of more than 2,300 genes. While genes TFF1, S100P, ERBB2, TOP2A, CDF15, HOOK1, DNAJC12, CORO2A were up-regulated in cancer, decreased expression was found for genes TUSC5, SFRP1, PPPQR1B, NTRK4, TIMP4, BARD1, AKR1C2, TP53INK1 and others. Analysis of DNA methylation of TUSC5 by COBRA revealed higher levels of exon 1 methylation (11/12) in samples of breast cancer, whereas the gene was essentially unmethylated in matched normal appearing tissue of breast (2/12). TP53INK1 gene was methylated neither in cancer nor in normalcy.;A total of 149 genes exhibited the highest difference in expression in cancer versus normal appearing tissue of breast. Most prominent down-regulated candidates, TUSC5 and TP53INK1, were reported for the first time in breast cancer and may be considered as potential markers of the disease. Aberrant DNA hypermethylation of TUSC5 suggests epigenetic mechanism of cancer associated down-regulation.",
        "Doc_title":"Hypermethylation of TUSC5 genes in breast cancer tissue.",
        "Journal":"Experimental oncology",
        "Do_id":"23302999",
        "Doc_ChemicalList":"Carrier Proteins;Heat-Shock Proteins;Membrane Proteins;TP53INP1 protein, human;TUSC5 protein, human;Tumor Suppressor Proteins",
        "Doc_meshdescriptors":"Adenocarcinoma;Breast Neoplasms;Carrier Proteins;DNA Methylation;Down-Regulation;Epigenesis, Genetic;Female;Genome-Wide Association Study;Heat-Shock Proteins;Humans;Membrane Proteins;Oligonucleotide Array Sequence Analysis;Reverse Transcriptase Polymerase Chain Reaction;Transcriptome;Tumor Suppressor Proteins",
        "Doc_meshqualifiers":"genetics;metabolism;genetics;metabolism;biosynthesis;genetics;biosynthesis;genetics;metabolism;genetics;metabolism",
        "_version_":1605810332605874176},
      {
        "Doc_abstract":"Currently, decision-making for breast cancer treatment in the clinical setting is mainly based on clinical data, histomorphological features of the tumor tissue and a few cancer biomarkers such as steroid hormone receptor status (estrogen and progesterone receptors) and oncoprotein HER2 status. Although various therapeutic options were introduced into the clinic in recent decades, with the objective of improving surgery, radiotherapy, biochemotherapy and chemotherapy, varying response of individual patients to certain types of therapy and therapy resistance is still a challenge in breast cancer care. Therefore, since breast cancer treatment should be based on individual features of the patient and her tumor, tailored therapy should be an option by integrating cancer biomarkers to define patients at risk and to reliably predict their course of the disease and/or response to cancer therapy. Recently, candidate-marker approaches and genome-wide transcriptomic and epigenetic screening of different breast cancer tissues and bodily fluids resulted in new promising biomarker panels, allowing breast cancer prognosis, prediction of therapy response and monitoring of therapy efficacy. These biomarkers are now subject of validation in prospective clinical trials.",
        "Doc_title":"Emerging biomarkers in breast cancer care.",
        "Journal":"Biomarkers in medicine",
        "Do_id":"20701440",
        "Doc_ChemicalList":"Biomarkers, Tumor",
        "Doc_meshdescriptors":"Biomarkers, Tumor;Breast Neoplasms;Humans",
        "Doc_meshqualifiers":"metabolism;diagnosis;metabolism;therapy",
        "_version_":1605896092946268160},
      {
        "Doc_abstract":"The expression of additional genes, other than oestrogen receptor (ER), may be important to the hormone-responsive phenotype of breast cancer. Microarray analyses have revealed that forkhead box A1 (FOXA1) and GATA binding protein 3 (GATA-3) are expressed in close association with ERalpha, both encoding for transcription factors with a potential involvement in the ERalpha-mediated action in breast cancer. The purpose of this study was to explore if the expression of FOXA1 and GATA-3 may provide an opportunity to stratify subsets of patients that could have better outcome, among the ERalpha-negative/poor prognosis breast cancer group.;We evaluate FOXA1 and GATA-3 expression in 249 breast carcinomas by immunohistochemistry, associating it with breast cancer molecular markers, clinicopathological features and patient's survival. The clinicopathological features and immunohistochemical markers of the tumours were compared using the chi-square test and ANOVA. Disease-free survival was analysed through Kaplan-Meier survival curves and Cox regression.;FOXA1 expression was demonstrated in 42% of invasive carcinomas, while GATA-3 was detected in 48% of the cases. FOXA1 expression was inversely associated with tumour size, Nottingham Prognostic Index, histological grade, lymph vascular invasion, lymph node stage and human epidermal growth factor receptor-2 (HER-2) overexpression, while GATA-3 expression showed inverse association with histological grade and HER-2. Both FOXA1 and GATA-3 were directly associated with ERalpha and progesterone receptor. Among FOXA1-positive tumours, 83.1% are comprised in the luminal A subtype, similar to GATA-3 where 87.7% of positive tumours were classified within this molecular subtype. In the subset of ERalpha-negative patients, those who were FOXA1-negative had a 3.61-fold increased risk of breast cancer recurrence when compared with the FOXA1-positive.;FOXA1 was a significant predictor of good outcome in breast cancer, whereas GATA-3 was an important luminal marker. The expression of FOXA1 may be used for risk stratification among ERalpha-negative patients.",
        "Doc_title":"Expression of FOXA1 and GATA-3 in breast cancer: the prognostic significance in hormone receptor-negative tumours.",
        "Journal":"Breast cancer research : BCR",
        "Do_id":"19549328",
        "Doc_ChemicalList":"FOXA1 protein, human;GATA3 Transcription Factor;GATA3 protein, human;Hepatocyte Nuclear Factor 3-alpha;Receptors, Estrogen",
        "Doc_meshdescriptors":"Adult;Aged;Aged, 80 and over;Disease-Free Survival;Female;GATA3 Transcription Factor;Gene Expression Regulation, Neoplastic;Hepatocyte Nuclear Factor 3-alpha;Humans;Immunohistochemistry;Middle Aged;Prognosis;Proportional Hazards Models;Receptors, Estrogen;Treatment Outcome",
        "Doc_meshqualifiers":"biosynthesis;biosynthesis;methods;metabolism",
        "_version_":1605805219004809216},
      {
        "Doc_abstract":"Overexpression of the epidermal growth factor receptor family member Her-2/neu in breast cancer is associated with poor prognosis. With evidence accumulating for a chemopreventive role of green tea polyphenols, the effects of epigallocatechin-3 gallate (EGCG) on Her-2/neu-overexpressing breast cancer cells were examined. EGCG inhibited mouse mammary tumor virus (MMTV)-Her-2/neu NF639 cell growth in culture and soft agar. EGCG reduced signaling via the phosphatidylinositol 3- kinase, Akt kinase to NF-kappaB pathway because of inhibition of basal Her-2/neu receptor tyrosine phosphorylation. EGCG similarly inhibited basal receptor phosphorylation in SMF and Ba/F3 2 + 4 cells, which suggests the potential beneficial use of EGCG in adjuvant therapy of tumors with Her-2/neu overexpression.",
        "Doc_title":"Green tea polyphenol epigallocatechin-3 gallate inhibits Her-2/neu signaling, proliferation, and transformed phenotype of breast cancer cells.",
        "Journal":"Cancer research",
        "Do_id":"11830514",
        "Doc_ChemicalList":"Anticarcinogenic Agents;Growth Inhibitors;NF-kappa B;Proto-Oncogene Proteins;Catechin;epigallocatechin gallate;Phosphatidylinositol 3-Kinases;Receptor, ErbB-2;Protein-Serine-Threonine Kinases;Proto-Oncogene Proteins c-akt",
        "Doc_meshdescriptors":"Animals;Anticarcinogenic Agents;Beverages;Catechin;Cell Division;Cell Transformation, Neoplastic;Female;Growth Inhibitors;Mammary Neoplasms, Experimental;Mice;NF-kappa B;Phosphatidylinositol 3-Kinases;Phosphorylation;Protein-Serine-Threonine Kinases;Proto-Oncogene Proteins;Proto-Oncogene Proteins c-akt;Receptor, ErbB-2;Signal Transduction",
        "Doc_meshqualifiers":"pharmacology;analogs & derivatives;pharmacology;drug effects;drug effects;pharmacology;pathology;prevention & control;antagonists & inhibitors;physiology;antagonists & inhibitors;physiology;drug effects;antagonists & inhibitors;physiology;antagonists & inhibitors;physiology;drug effects",
        "_version_":1605876187033239552},
      {
        "Doc_abstract":"Trastuzumab, the HER2 oncogene targeting drug, shows remarkable clinical efficacy in HER2-amplified breast cancer patients. Despite of robust activity, some of the patients with HER2-positive breast cancers do not get the benefit due to trastuzumab resistance. Overexpression of p95HER2 is one of the molecular mechanisms of trastuzumab resistance. The purpose of this study was to investigate whether p95HER2 overexpressing breast cancers were resistant to trastuzumab.;p95HER2 (truncated HER2) and HER2 were determined by real-time polymerase chain reaction (RT-PCR) analysis. HER2 protein expression and HER2 gene amplification were also determined by immunohistochemistry (IHC) and chromogenic in situ hybridization (CISH). Archival material from 80 formalin-fixed paraffin-embedded (FFPE) breast cancer tumor tissues was used for the study. None of the cases had metastases at the initial diagnosis. HER2-positive cases were treated with trastuzumab with/without chemotherapy.;Of 80 breast cancer cases 39 (48.7%) were HER2-positive and had trastuzumab treatment. Of these 39 cases 11 (28.2%) were trastuzumab-resistant and 28 (71.8%) were not, 17 (43.6%) were recurrent cases and 22 (56.4%) were not. Three patients died during follow-up. p95HER2 mean ratio was 11.01Â±19.73 in 11 cases which were trastuzumab-resistant, while p95HER2 mean ratio was 1.99Â±1.37 in 28 cases without trastuzumab resistance. If p95HER2 ratio was low, there was no trastuzumab resistance. However, when p95HER2 ratio was high, there was trastuzumab resistance (p=0.210, Mann-Whitney U test).;p95HER2 was correlated with trastuzumab resistance, but it was not an independent factor of trastuzumab resistance. We claim that p95HER2 is sensitive but not specific for the prediction of trastuzumab resistance.",
        "Doc_title":"The role of p95HER2 in trastuzumab resistance in breast cancer.",
        "Journal":"Journal of B.U.ON. : official journal of the Balkan Union of Oncology",
        "Do_id":"27273948",
        "Doc_ChemicalList":"Biomarkers, Tumor;Protein Kinase Inhibitors;ERBB2 protein, human;Receptor, ErbB-2;Trastuzumab",
        "Doc_meshdescriptors":"Adult;Aged;Antineoplastic Combined Chemotherapy Protocols;Biomarkers, Tumor;Breast Neoplasms;Drug Resistance, Neoplasm;Female;Gene Amplification;Humans;Immunohistochemistry;In Situ Hybridization;Kaplan-Meier Estimate;Middle Aged;Predictive Value of Tests;Protein Kinase Inhibitors;Real-Time Polymerase Chain Reaction;Receptor, ErbB-2;Risk Factors;Trastuzumab;Treatment Outcome;Up-Regulation",
        "Doc_meshqualifiers":"adverse effects;therapeutic use;antagonists & inhibitors;genetics;metabolism;drug therapy;enzymology;genetics;mortality;pathology;adverse effects;therapeutic use;antagonists & inhibitors;genetics;metabolism;adverse effects;therapeutic use",
        "_version_":1605812921715130368},
      {
        "Doc_abstract":"Trastuzumab or lapatinib treatment with chemotherapy or hormonotherapy are the gold standard treatments for human epidermal growth factor receptor 2 (HER2)-positive breast cancer (early breast cancer or metastatic breast cancer). Older patients have been largely underrepresented in clinical trials, and few data on trastuzumab or lapatinib efficacy and toxicity have been reported for this subgroup. This article has reviewed the main articles that have analyzed these items. ",
        "Doc_title":"Targeted anti-HER2 cancer therapy in elderly women diagnosed with breast cancer.",
        "Journal":"Anti-cancer agents in medicinal chemistry",
        "Do_id":"23438846",
        "Doc_ChemicalList":"Antibodies, Monoclonal, Humanized;Antineoplastic Agents;Quinazolines;lapatinib;ERBB2 protein, human;Receptor, ErbB-2;Trastuzumab",
        "Doc_meshdescriptors":"Aged;Aging;Antibodies, Monoclonal, Humanized;Antineoplastic Agents;Breast Neoplasms;Female;Humans;Molecular Targeted Therapy;Quinazolines;Receptor, ErbB-2;Trastuzumab",
        "Doc_meshqualifiers":"physiology;adverse effects;therapeutic use;adverse effects;therapeutic use;drug therapy;metabolism;pathology;adverse effects;therapeutic use;antagonists & inhibitors;metabolism",
        "_version_":1605796283305426944},
      {
        "Doc_abstract":"Letrozole, a third-generation aromatase inhibitor, has been the only aromatase inhibitor to date to show unequivocal superiority to tamoxifen as first-line treatment of metastatic postmenopausal breast cancer. The superiority of letrozole compared with tamoxifen was also reflected in the neoadjuvant setting, in both estrogen receptor-positive and estrogen receptor-unknown patients with differing HER-2 status. Currently, studies are being performed in the adjuvant setting, which will provide important data on the long-term safety of letrozole and help determine its suitability as a chemopreventive agent in healthy women at risk of developing breast cancer. Nevertheless, the superior clinical efficacy and survival data of letrozole suggest that it has the potential to displace tamoxifen as the gold standard in breast cancer treatment in the coming years.",
        "Doc_title":"Letrozole for the management of breast cancer.",
        "Journal":"Expert review of anticancer therapy",
        "Do_id":"12113048",
        "Doc_ChemicalList":"Androstadienes;Antineoplastic Agents;Aromatase Inhibitors;Estrogen Receptor Modulators;Estrogens;Nitriles;Progestins;Receptors, Estrogen;Triazoles;anastrozole;letrozole;exemestane",
        "Doc_meshdescriptors":"Androstadienes;Antineoplastic Agents;Aromatase Inhibitors;Breast Neoplasms;Drug Tolerance;Estrogen Receptor Modulators;Estrogens;Female;Humans;Neoadjuvant Therapy;Nitriles;Postmenopause;Progestins;Receptors, Estrogen;Treatment Outcome;Triazoles",
        "Doc_meshqualifiers":"pharmacology;pharmacokinetics;therapeutic use;drug therapy;mortality;prevention & control;pharmacology;biosynthesis;metabolism;pharmacokinetics;pharmacology;therapeutic use;pharmacology;metabolism;pharmacokinetics;pharmacology;therapeutic use",
        "_version_":1605757790124507136},
      {
        "Doc_abstract":"Five breast cancer subtypes have been described in sporadic breast cancer (SBC) using expression arrays: basal-like, ERBB2, normal breast-like, luminal A and B. These molecular subtypes show different genomic aberration patterns (GAPs). Recently, our group described these breast cancer subtypes in 50 non-BRCA1/2 familial tumors using immunohistochemistry assays. We extended this study to the other classes of familial breast cancer (FBC), including 62 tumors (18 BRCA1, 16 BRCA2 and 28 non-BRCA1/2), with the same panel of 25 immunohistochemical (IHC) markers and histological grade obtaining a similar classification. We combined these data with results generated by a 1 Mb BAC array-based CGH study to evaluate the genomic aberrations of each group. We found that BRCA1-related tumors are preferentially basal-like, whereas non-BRCA1/2 familial tumors are mainly luminal A subtype. We described distinct GAPs related to each IHC subtype. Basal tumors had a greater number of gains/losses, while luminal B tumors had more high-level DNA amplifications. Our data are similar to those obtained in SBC studies, highlighting the existence of distinct genetic pathways of tumor evolution, common to both SBC and FBC.",
        "Doc_title":"Distinct genomic aberration patterns are found in familial breast cancer associated with different immunohistochemical subtypes.",
        "Journal":"Oncogene",
        "Do_id":"18071313",
        "Doc_ChemicalList":"Biomarkers, Tumor",
        "Doc_meshdescriptors":"Adult;Biomarkers, Tumor;Breast Neoplasms;Chromosome Aberrations;Chromosomes, Human, Pair 8;Cluster Analysis;Family;Female;Gene Amplification;Gene Expression Profiling;Gene Expression Regulation, Neoplastic;Gene Frequency;Genes, BRCA1;Genes, BRCA2;Genetic Heterogeneity;Humans;Immunohistochemistry;Male;Middle Aged;Oligonucleotide Array Sequence Analysis",
        "Doc_meshqualifiers":"metabolism;classification;genetics;metabolism",
        "_version_":1605800985728385024},
      {
        "Doc_abstract":"Background. Tumour characteristics are the most important prognostic factors in breast cancer. Patient-related factors such as young age at diagnosis, obesity, and smoking behaviour may also modify disease outcome. Due to the absence of a unique definition for \"young age breast cancer\" and the resulting variation in disease management, findings on the association between young age and prognosis of breast cancer are controversial. Methods. This study included 1500 patients with a primary diagnosis of breast cancer in six Iranian hospitals from 5 provinces. We modelled the relative excess risk (RER) of breast cancer death to age at diagnosis and tumour characteristics. Results. Excess risks of death were observed for stage IV disease and poorly differentiated tumours: RER of 4.3 (95% CI: 1.05-17.65) and 3.4 (95% CI: 1.17-9.87), respectively. \"Older\" patients, particularly those aged 50 and over, presented more often with advanced and poorly differentiated tumours (P = 0.001). After adjustment for stage, histological grade, Her-2 expression, estrogen and progesterone receptors, and place of residency, breast cancer mortality was not significantly different across age groups. Conclusion. We conclude that there is no prognostic effect of age at diagnosis of breast cancer among breast cancer patients treated at cancer centres in different parts of Iran; young and relatively old women have similar risks of dying from breast cancer.",
        "Doc_title":"Age at diagnosis and breast cancer survival in iran.",
        "Journal":"International journal of breast cancer",
        "Do_id":"23227345",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605747005235134464},
      {
        "Doc_abstract":"This study was conducted to analyze the clinicopathological characteristics and patient survival factors in triple-negative breast cancer (TNBC).;A retrospective analysis was performed on 14 506 breast cancer patients admitted to the Departmrnt of Breast Surgery, Tianjin Medical University Cancer Hospital from January 2004 to June 2010. The correlation of pathological characteristics, recurrence time and patterns, and prognosis with TNBC was analyzed.;Among the 14 506 cases, there were 1886 (13.0%) cases of triple-negative breast cancer, 7282 (50.2%) cases of luminal A breast caner, 3380 (23.3%) cases of luminal B breast caner, and 1958 (13.5%) cases of HER-2 overexpressing breast cancer. Compared with the other groups, the triple-negative breast cancer patients had significantly higher histological grade, lower percentage of invasive breast ductal carcinoma and higher pathological stage (P < 0.001) . The 5-year disease-free survival rate of the triple negative breast cancer was 79.5%, significantly lower than that of the other subtype breast cancer (P < 0.001), but the difference in 5-year overall survival rate was not significant (P = 0.113). The independent factors of DFS in TNBC including: age, tumor size, clinical stage, surgery and chemotherapy (P < 0.05).;Compared with the other subtype breast cancers, the patients with triple-negative breast cancer have higher histological grade, lower percentage of invasive breast ductal carcinoma and higher pathological stage, and they also have a poor prognosis.",
        "Doc_title":"[Clinicopathological features and prognosis of triple-negative breast cancer].",
        "Journal":"Zhonghua zhong liu za zhi [Chinese journal of oncology]",
        "Do_id":"24119909",
        "Doc_ChemicalList":"Receptor, ErbB-2",
        "Doc_meshdescriptors":"Female;Humans;Prognosis;Receptor, ErbB-2;Retrospective Studies;Survival Rate;Triple Negative Breast Neoplasms",
        "Doc_meshqualifiers":"metabolism;diagnosis;pathology",
        "_version_":1605879522835562496},
      {
        "Doc_abstract":"The prognosis of breast cancer-derived brain metastasis is poor, but new drugs and recent therapeutic strategies have helped extend survival in patients. Prediction of therapeutic responses and outcomes is not yet possible, however. In a retrospective study, we examined prognostic factors in patients with breast cancer-derived brain metastasis, and we tested the prognostic utility of a breast cancer-specific Graded Prognostic Assessment in these patients.;Sixty-three patients diagnosed with brain metastasis from breast cancer treated surgically and adjuvantly were included. We examined clinical variables per primary tumor subtype: ER+/HER2- (luminal), HER2+ (human epidermal growth factor receptor type 2-enriched) or ER-/PR-/HER2- (triple negative). We also categorized patients' breast cancer-specific Graded Prognostic Assessment scores and analyzed post-brain metastasis survival time in relation to these categories.;The breast cancers comprised the following subtypes: luminal, n = 18; human epidermal growth factor receptor type 2-enriched, n = 27 and triple-negative, n = 18; median survival per subtype was 11, 37 and 3 months, respectively. Survival of human epidermal growth factor receptor type 2-enriched patients was longer, though not significantly (P = 0.188), than that of luminal patients. Survival of triple-negative patients was significantly short (vs. human epidermal growth factor receptor type 2-enriched patients, P < 0.001). Karnofsky performance status, HER2 status and the disease-free interval (from initial treatment to first recurrence) were shown to be significant prognostic factors (Karnofsky performance status < 70: relative risk 2.08, P = 0.028; HER2+: relative risk 2.911, P = 0.004; disease-free interval < 24 months: relative risk 1.933, P = 0.011). Breast cancer-specific Graded Prognostic Assessment scores reflected disease-free intervals and survival times.;Our data indicate that breast cancer-specific Graded Prognostic Assessment-based prediction will be helpful in determining appropriate therapeutic strategies for patients with brain metastasis from breast cancer.",
        "Doc_title":"Prolonged survival after diagnosis of brain metastasis from breast cancer: contributing factors and treatment implications.",
        "Journal":"Japanese journal of clinical oncology",
        "Do_id":"25981620",
        "Doc_ChemicalList":"Biomarkers, Tumor;Receptors, Estrogen;Receptors, Progesterone;ERBB2 protein, human;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Adult;Aged;Biomarkers, Tumor;Brain Neoplasms;Breast Neoplasms;Female;Humans;Karnofsky Performance Status;Middle Aged;Prognosis;Receptor, ErbB-2;Receptors, Estrogen;Receptors, Progesterone;Retrospective Studies;Risk Factors",
        "Doc_meshqualifiers":"analysis;chemistry;mortality;secondary;chemistry;mortality;pathology;analysis;analysis;analysis",
        "_version_":1605766724294017024},
      {
        "Doc_abstract":"Overexpression of HER2 is encountered in approximately 20% of invasive breast cancers. It is an independent adverse prognostic factor and, more importantly, it is currently the best predictive factor for the activity of trastuzumab, an anti-HER2 monoclonal antibody (MoAb), which has revolutionized the treatment of this breast cancer subgroup. Increasing knowledge of molecular pathways involving the HER family of growth factor receptors has paved the way toward new efficient targeted therapies. Herein, we will review the targeted therapies of clinical importance for HER2-positive breast cancer, which include anti-HER2 MoAbs and tyrosine kinase inhibitors that directly interfere at the receptor level. Clinicians are still facing many uncertainties concerning the optimal use of these new agents, and scientists are working on dissecting the mechanisms of resistance developed by HER2-positive cancer cells. Interesting perspectives in the treatment of HER2-positive breast cancer will be discussed. They consist of designing HER2 peptide-based vaccines, targeting downstream pathway molecules beyond the membrane receptor, and exploring synergistic antineoplasic strategies.",
        "Doc_title":"HER2-positive breast cancer: from trastuzumab to innovatory anti-HER2 strategies.",
        "Journal":"Clinical breast cancer",
        "Do_id":"18501058",
        "Doc_ChemicalList":"Antibodies, Monoclonal;Antibodies, Monoclonal, Humanized;Antineoplastic Agents;Protein Kinase Inhibitors;Trastuzumab",
        "Doc_meshdescriptors":"Antibodies, Monoclonal;Antibodies, Monoclonal, Humanized;Antineoplastic Agents;Breast Neoplasms;Female;Gene Expression;Gene Expression Regulation, Neoplastic;Genes, erbB-2;Humans;Protein Kinase Inhibitors;Trastuzumab",
        "Doc_meshqualifiers":"therapeutic use;therapeutic use;drug therapy;genetics;therapeutic use",
        "_version_":1605852896570638336},
      {
        "Doc_abstract":"The NCCN HER2 Testing in Breast Cancer Task Force was convened to critically evaluate the ability of the level of HER2 expression or gene amplification in breast cancer tumors to serve as a prognostic and a predictive factor in the metastatic and adjuvant settings, to assess the reliability of the methods of measuring HER2 expression or gene amplification in the laboratory, and to make recommendations regarding the interpretation of test results. The Task Force is a multidisciplinary panel of 24 experts in breast cancer representing the disciplines of medical oncology, pathology, radiation oncology, surgical oncology, epidemiology, and patient advocacy. Invited members included members of the NCCN Breast Cancer Panel and other needed experts selected solely by the NCCN. During a 2-day meeting, individual task force members provided didactic presentations critically evaluating important aspects of HER2 biology and epidemiology: HER2 as a prognostic and predictive factor; results from clinical trials in which trastuzumab was used as a targeted therapy against HER2 in the adjuvant and metastatic settings; the available testing methodologies for HER2, including sensitivity, specificity, and ability to provide prognostic and predictive information; and the principles on which HER2 testing should be based. Each task force member was charged with identifying evidence relevant to their specific expertise and presentation. Following the presentations, an evidence-based consensus approach was used to formulate recommendations relating to the pathologic and clinical application of the evidence to breast cancer patient evaluation and care. In areas of controversy, this process extended beyond the meeting to achieve consensus. The Task Force concluded that accurate assignment of the HER2 status of invasive breast cancer is essential to clinical decision making in the treatment of breast cancer in both adjuvant and metastatic settings. Formal validation and concordance testing should be performed and reported by laboratories performing HER2 testing for clinical purposes. If appropriate quality control/assurance procedures are in place, either immunohistochemistry (IHC) or fluorescence in situ hybridization (FISH) methods may be used. A tumor with an IHC score of 0 or 1+, an average HER2 gene/chromosome 17 ratio of less than 1.8, or an average number of HER2 gene copies/cell of 4 or less as determined by FISH is considered to be HER2 negative. A tumor with an IHC score of 3+, an average HER2 gene/chromosome 17 ratio of greater than 2.2 by FISH, or an average number of HER2 gene copies/cell of 6 or greater is considered HER2 positive. A tumor with an IHC score of 2+ should be further tested using FISH, with HER2 status determined by the FISH result. Tumor samples with an average HER2 gene/chromosome ratio of 1.8 to 2.2 or average number of HER2 gene copies/cell in the range of greater than 4 to less than 6 are considered to be borderline, and strategies to assign the HER2 status of such samples are proposed.",
        "Doc_title":"HER2 testing in breast cancer: NCCN Task Force report and recommendations.",
        "Journal":"Journal of the National Comprehensive Cancer Network : JNCCN",
        "Do_id":"16813731",
        "Doc_ChemicalList":"Antibodies, Monoclonal;Antibodies, Monoclonal, Humanized;Antineoplastic Agents;Receptor, ErbB-2;Trastuzumab",
        "Doc_meshdescriptors":"Advisory Committees;Antibodies, Monoclonal;Antibodies, Monoclonal, Humanized;Antineoplastic Agents;Breast Neoplasms;Genetic Testing;Humans;Immunohistochemistry;In Situ Hybridization, Fluorescence;Prognosis;Quality Assurance, Health Care;Receptor, ErbB-2;Trastuzumab",
        "Doc_meshqualifiers":"pharmacology;pharmacology;drug therapy;genetics;standards;methods;genetics",
        "_version_":1605761304441651200},
      {
        "Doc_abstract":"To review the efficacy of chemotherapy and human epidermal growth factor receptor 2 (HER2)-targeted therapy when used in addition to hormonal therapy for the optimal management of estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-positive (HER2+) breast cancer.;Literature published from January 2003 to March 2008 was reviewed to assess the use of chemotherapy and biologic therapy in addition to hormonal agents.;Aromatase inhibitors (AIs) demonstrated greater effectiveness in the adjuvant setting than tamoxifen for the management of ER+ and HER2+ breast cancer. Evidence of cross talk between HER2- and ER-signaling pathways suggests that combined treatment with HER2 blockade and hormonal therapy may offer clinical advantages beyond those provided by hormonal therapy alone in ER+/HER2+ disease. Combined therapy with trastuzumab plus an aromatase AI significantly improves progression-free survival, response rates, and clinical benefits when compared with AI monotherapy in postmenopausal women. Several large studies demonstrated that trastuzumab significantly improves disease-free and overall survival when given in combination with, or following, chemotherapy, regardless of hormone receptor status.;HER2-targeted therapy maybe combined with AIs for the treatment of ER+/HER2+ metastatic breast cancer in postmenopausal women. HER2-targeted therapy in combination with AIs for treatment of ER+/HER2+ early breast cancer needs to be prospectively evaluated.",
        "Doc_title":"Role of biologic therapy and chemotherapy in hormone receptor- and HER2-positive breast cancer.",
        "Journal":"Annals of oncology : official journal of the European Society for Medical Oncology",
        "Do_id":"19150946",
        "Doc_ChemicalList":"Antineoplastic Agents;Receptors, Estrogen;Receptors, Progesterone;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Antineoplastic Agents;Biological Therapy;Breast Neoplasms;Drug Resistance, Neoplasm;Female;Humans;Receptor, ErbB-2;Receptors, Estrogen;Receptors, Progesterone;Signal Transduction",
        "Doc_meshqualifiers":"therapeutic use;drug therapy;metabolism;biosynthesis;biosynthesis;biosynthesis",
        "_version_":1605766764770099200},
      {
        "Doc_abstract":"Cyclooxygenases (Cox) are prostaglandin synthetase enzymes which play a key role in mammary carcinogenesis. Several connections were demonstrated between Cox and a few oncogenes (v-src, v-Ha-ras, HER-2\\neu, Wnt, p53 mutated), alimentary products (PUFAs), transcription factors (c-jun and c-fos), proapoptotic proteins [Bax et Bcl-x(L)] or antiapoptotic (Bcl-2), CYP19 aromatase gene, NFkappaB receptor (RANKL), angiogenesis (via VEGF, TXA2, oxid nitric synthetase, alphaVbeta3 integrin receptor), peroxisome gamma proliferator receptor (PPARgamma) and its ligand PGJ2 and with antitubuline chemotherapy drugs. No correlation of Cox2 expression with hormonal receptors was shown. In epidemiologic studies there is evidence of breast cancer risk reduction for women who take AINS for a lon time. Alimentary factors like resveratrol or insaturated fat acid reduce Cox2 expression in animal and could be investigated in human studies. Clinical trials are planed with the anti Cox2 celecoxib for breast cancer prevention, in adjuvant setting, in metastatic situation combined with exemestane or antitubulin drugs or in neoadjuvant therapy.",
        "Doc_title":"[Cyclooxygenase 2 and breast cancer. From biological concepts to clinical trials].",
        "Journal":"Bulletin du cancer",
        "Do_id":"15899633",
        "Doc_ChemicalList":"Anti-Inflammatory Agents, Non-Steroidal;Antineoplastic Agents;Cyclooxygenase 2 Inhibitors;Cyclooxygenase Inhibitors;Membrane Proteins;Neoplasm Proteins;Pyrazoles;Sulfonamides;Aromatase;Cyclooxygenase 2;PTGS2 protein, human;Prostaglandin-Endoperoxide Synthases;Celecoxib;Dinoprostone",
        "Doc_meshdescriptors":"Animals;Anti-Inflammatory Agents, Non-Steroidal;Antineoplastic Agents;Aromatase;Breast Neoplasms;Celecoxib;Cyclooxygenase 2;Cyclooxygenase 2 Inhibitors;Cyclooxygenase Inhibitors;Dinoprostone;Female;Genes, erbB-2;Humans;Membrane Proteins;Mice;Neoplasm Proteins;Prostaglandin-Endoperoxide Synthases;Pyrazoles;Sulfonamides",
        "Doc_meshqualifiers":"therapeutic use;therapeutic use;metabolism;enzymology;genetics;prevention & control;therapeutic use;metabolism;antagonists & inhibitors;metabolism;metabolism;therapeutic use;therapeutic use",
        "_version_":1605852352300974080},
      {
        "Doc_abstract":"Knowledge concerning concordance of epidermal growth factor receptor 2 (HER2) expression between primary breast cancers and asynchronous local-regional recurrences is sparse. Receptor characteristics could be altered with time and may be affected by anticancer treatment. It remains uncertain whether recurrences have the identical or similar HER2 receptor expression pattern as the primary breast cancer. The aim of the present study was to evaluate whether HER2 is stable during the process of recurrence. Expression of HER2 was investigated immunohistochemically in paired samples of primary breast cancers and corresponding asynchronous local-regional recurrences (n=35). HER2 expression was scored as 0, 1+, 2+ or 3+. HER2 overexpression (2+ or 3+) was found in 48.57% (17/35) of the primary breast cancers and 45.71% (16/35) of the corresponding local-regional recurrences. A concordance of HER2 overexpression between the primary lesions and matching regional recurrences was observed in 85.71% of the breast cancer cases. Five out of the 35 paired samples (14.28%) were discordant. Only 3 patients who had 2+ HER2 expression in the primary tumors showed HER2 down-regulation (0 or 1+) in the recurrences, while the HER2 score in 2 patients changed oppositely. Moreover, all of the cases with 3+ HER2 staining in the primary lesions retained HER2 overexpression in the recurrences. The HER2 is commonly expressed in breast cancer, and its expression in the primary tumors and the corresponding recurrences was concordant in the majority of the cases. As the receptor expression may lose or gain in recurrences at a probability of approximately 10%, assessment of the receptor status in recurrences is still encouraged.",
        "Doc_title":"Human epidermal growth factor receptor 2 protein expression between primary breast cancer and paired asynchronous local-regional recurrences.",
        "Journal":"Experimental and therapeutic medicine",
        "Do_id":"22977642",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605818597538529280},
      {
        "Doc_abstract":"Trastuzumab (Herceptin), a monoclonal antibody directed against the human epidermal growth-factor receptor 2 (HER2), is the poster child for antibody-based targeted therapy in breast cancer. Pertuzumab, another humanized monoclonal antibody, binds to a different domain of HER2 and prevents the formation of HER2:HER3 dimers, which is the most potent heterodimer in the HER family. The combination of trastuzumab and pertuzumab has synergistic activity, and is associated with improved clinical outcomes. The US Food and Drug Administration (FDA) approved pertuzumab in combination with trastuzumab-based chemotherapy originally as first-line therapy for metastatic HER2-positive breast cancer in 2012, and more recently as neoadjuvant therapy for localized disease in 2013. Pertuzumab is the first neoadjuvant drug to receive accelerated approval by the FDA based on pathological complete response as the primary end point. In this article, we review the mechanism of action, pharmacokinetics, clinical efficacy, safety, and current role of pertuzumab in the management of breast cancer, as well as ongoing clinical trials and future directions regarding the utility of pertuzumab as a personalized therapeutic option for HER2-positive breast cancer. In the coming years, we anticipate increased utilization of neoadjuvant trials for drug development, biomarker discovery, and validation, and envision conduct of personalized breast cancer clinics in which therapies will be routinely selected based on genetic alterations in the tumor. Regardless of the targeted therapy combinations employed based on tumor genomic profile, trastuzumab and pertuzumab will likely continue to form the backbone of the personalized regimen for HER2-positive breast cancer. ",
        "Doc_title":"Precision medicine and personalized breast cancer: combination pertuzumab therapy.",
        "Journal":"Pharmacogenomics and personalized medicine",
        "Do_id":"24715764",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605742783424888834},
      {
        "Doc_abstract":"The expressions of estrogen receptor (ER) and cell surface receptor, Tyrosine Kinase Human Epidermal Growth Factor Receptor 2 (HER 2), have emerged as the most important molecular biomarkers determining the breast cancer prognosis. In this study, interactions between ER and HER2 were assessed to determine if they modulate tumor characteristics.;Tissue samples from 120 patients with early stage breast cancer receiving adjuvant chemotherapy were reviewed to evaluate ER and HER2 status quantified by immunohistochemistry and fluorescence in situ hybridization, and the correlation of ER and HER2 with patient characteristics and tumor pathology was studied.;A total of 37(30.8%) and 80(66.6%) out of 120 samples were HER2 (3+ by immunohistochemistry or positive by fluorescent in situ hybridization) and ER positive (by immunohistochemistry), respectively. ER-negative tumors were significantly more likely to be HER-2 positive than were ER-positive tumors (21.25%; odds ratio, 0.270; 95% CI, 0.119 to 0.612; P = 0.002). ER positivity was associated with <2 cm tumor size and higher histological grade (P = 0.007 and 0.019, respectively). No significant correlation was seen between the co-expression of HER2 and ER and tumor characteristics.;HER2 positive tumors were less common compared to ER positive tumors in early stage breast cancer Iranian patients. Also, higher histological grade among ER negative tumors showed higher aggressiveness of the tumor. Future studies are needed to evaluate the effect of receptor status on prognosis.",
        "Doc_title":"Human epidermal growth factor receptor 2 and estrogen receptor status in respect to tumor characteristics in non-metastatic breast cancer.",
        "Journal":"Tanaffos",
        "Do_id":"25191491",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605826463978749952},
      {
        "Doc_abstract":"We aimed to determine the prognostic impact of time between primary breast cancer and diagnosis of distant metastasis (metastatic-free interval, MFI) on the survival of metastatic breast cancer patients.;Consecutive patients diagnosed with metastatic breast cancer in 2007-2009 in eight hospitals in the Southeast of the Netherlands were included and categorised based on MFI. Survival curves were estimated using the Kaplan-Meier method. Cox proportional hazards model was used to determine the prognostic impact of de novo metastatic breast cancer vs recurrent metastatic breast cancer (MFI â©½24 months and >24 months), adjusted for age, hormone receptor and HER2 status, initial site of metastasis and use of prior (neo)adjuvant systemic therapy.;Eight hundred and fifteen patients were included and divided in three subgroups based on MFI; 154 patients with de novo metastatic breast cancer, 176 patients with MFI <24 months and 485 patients with MFI >24 months. Patients with de novo metastatic breast cancer had a prolonged survival compared with patients with recurrent metastatic breast cancer with MFI <24 months (median 29.4 vs 9.1 months, P<0.0001), but no difference in survival compared with patients with recurrent metastatic breast cancer with MFI >24 months (median, 29.4 vs 27.9 months, P=0.73). Adjusting for other prognostic factors, patients with MFI <24 months had increased mortality risk (hazard ratio 1.97, 95% CI 1.49-2.60, P<0.0001) compared with patients with de novo metastatic breast cancer. When comparing recurrent metastatic breast cancer with MFI >24 months with de novo metastatic breast cancer no significant difference in mortality risk was found. The association between MFI and survival was seen irrespective of use of (neo)adjuvant systemic therapy.;Patients with de novo metastatic breast cancer had a significantly better outcome when compared with patients with MFI <24 months, irrespective of the use of prior adjuvant systemic therapy in the latter group. However, compared with patients with MFI >24 months, patients with de novo metastatic breast cancer had similar outcome.",
        "Doc_title":"Prognosis of metastatic breast cancer: are there differences between patients with de novo and recurrent metastatic breast cancer?",
        "Journal":"British journal of cancer",
        "Do_id":"25880008",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"Adult;Aged;Aged, 80 and over;Breast Neoplasms;Combined Modality Therapy;Female;Follow-Up Studies;Humans;Middle Aged;Neoplasm Grading;Neoplasm Metastasis;Neoplasm Recurrence, Local;Neoplasm Staging;Prognosis;Survival Rate",
        "Doc_meshqualifiers":"mortality;pathology;therapy;mortality;pathology;therapy",
        "_version_":1605831795869220864},
      {
        "Doc_abstract":"Overexpression by the HER2 gene plays a significant role in breast cancer pathogenesis, and the phenomenon is commonly regarded as a predictor of a poor prognosis. HER2 overexpression has been linked to sensitivity and/or resistance to hormone therapy and chemotherapeutic regimens, including CMF (cyclophosphamide, methotrexate, and fluoruracil) and anthracyclines. Studies of patients with advanced disease demonstrate that, despite the association of HER2 overexpression with poor prognosis, the odds of HER2-positive patients responding clinically to taxanes were greater than three times those of HER2-negative patients. Further studies in preclinical models used combination therapy for breast cancer cells that overexpress HER2, and the use of agents that interfere with HER2 function plus paclitaxel (Taxol) resulted in significant antitumor effects.",
        "Doc_title":"HER2 overexpression and paclitaxel sensitivity in breast cancer: therapeutic implications.",
        "Journal":"Oncology (Williston Park, N.Y.)",
        "Do_id":"9110342",
        "Doc_ChemicalList":"Antibodies, Monoclonal;Antineoplastic Agents, Phytogenic;Receptor, ErbB-2;Paclitaxel",
        "Doc_meshdescriptors":"Antibodies, Monoclonal;Antineoplastic Agents, Phytogenic;Antineoplastic Combined Chemotherapy Protocols;Breast Neoplasms;Combined Modality Therapy;Female;Gene Expression Regulation, Neoplastic;Humans;Paclitaxel;Receptor, ErbB-2",
        "Doc_meshqualifiers":"therapeutic use;pharmacology;therapeutic use;therapeutic use;drug therapy;metabolism;drug effects;pharmacology;therapeutic use;metabolism",
        "_version_":1605897229548126208},
      {
        "Doc_abstract":"Identification of more and more novel tumor antigens and autoantibodies will lead to the earlier diagnosis, better prognosis prediction, and more efficient therapy of cancer in the future. Immunoproteomics techniques have successfully been used for finding novel cancer biomarkers in different subgroups of cancer patients. HER2 is a marker for an aggressive breast cancer, particularly in node-positive (NP) cases. The aim of our study was to identify antigens eliciting a humoral immune response in HER2+ and HER2- NP breast cancers by two-dimensional electrophoresis (2D), Western blotting, and mass spectrometry. Sera from 18 women with newly diagnosed NP breast cancer (9 HER2+ and 9 HER2-) and 9 healthy volunteers were individually investigated for the presence of antibodies to MCF7 breast cancer cell line proteome. Reactive spots in 2D blots were matched to stained 2D gels. Twenty-eight of matched spots were identified by mass spectrometry. Among them were LDH-A, glyceraldehydes-3-phosphate dehydrogenase, enolase-Î±, phosphoglycerate dehydrogenase, proteasome 26S non-ATPase subunit 13, triosephosphate isomerase, hnRNP K, hsp27, hsp90, prohibitin, nucleophosmin, 14-3-3É›, PP2A regulatory subunit, and ribonuclease inhibitor-angiogenin. The five former antigens were more commonly reacted with sera from HER2+ cases, and the three latter antigens were more commonly reacted with sera from HER2- cases. Noteworthy, the antigenicity of the 28 spots showed a few differences when SBR3 cell line was used as the source of antigens. Although some of the identified antigens were previously defined as tumor antigens, others were novel. Further investigations for their utilizations as markers for breast cancer diagnosis, progression, and therapy are warranted.",
        "Doc_title":"Immunoproteomics of HER2-positive and HER2-negative breast cancer patients with positive lymph nodes.",
        "Journal":"Omics : a journal of integrative biology",
        "Do_id":"21568730",
        "Doc_ChemicalList":"Antigens, Neoplasm;Biomarkers, Tumor;Proteome;ERBB2 protein, human;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Adult;Antigens, Neoplasm;Biomarkers, Tumor;Breast Neoplasms;Case-Control Studies;Cell Line, Tumor;Electrophoresis, Gel, Two-Dimensional;Female;Humans;Lymphatic Metastasis;Middle Aged;Proteome;Receptor, ErbB-2",
        "Doc_meshqualifiers":"metabolism;metabolism;blood;immunology;metabolism;pathology;immunology;metabolism;metabolism",
        "_version_":1605742735346630659},
      {
        "Doc_abstract":"Breast cancers are stratified into distinct subtypes, which influence therapeutic responsiveness and patient outcome. Patients with luminal breast cancers are often associated with a better prognosis relative to that with other subtypes. However, subsets of patients with luminal disease remain at increased risk of cancer-related death. A critical process that increases the malignant potential of breast cancers is the epithelial-to-mesenchymal transition (EMT). The p66ShcA adaptor protein stimulates the formation of reactive oxygen species in response to stress stimuli. In this paper, we report a novel role for p66ShcA in inducing an EMT in HER2(+) luminal breast cancers. p66ShcA increases the migratory properties of breast cancer cells and enhances signaling downstream of the Met receptor tyrosine kinase in these tumors. Moreover, Met activation is required for a p66ShcA-induced EMT in luminal breast cancer cells. Finally, elevated p66ShcA levels are associated with the acquisition of an EMT in primary breast cancers spanning all molecular subtypes, including luminal tumors. This is of high clinical relevance, as the luminal and HER2 subtypes together comprise 80% of all newly diagnosed breast cancers. This study identifies p66ShcA as one of the first prognostic biomarkers for the identification of more aggressive tumors with mesenchymal properties, regardless of molecular subtype. ",
        "Doc_title":"p66ShcA promotes breast cancer plasticity by inducing an epithelial-to-mesenchymal transition.",
        "Journal":"Molecular and cellular biology",
        "Do_id":"25071152",
        "Doc_ChemicalList":"Biomarkers, Tumor;SHC1 protein, human;Shc Signaling Adaptor Proteins;Src Homology 2 Domain-Containing, Transforming Protein 1;ERBB2 protein, human;MET protein, human;Proto-Oncogene Proteins c-met;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Animals;Biomarkers, Tumor;Breast Neoplasms;Cell Line, Tumor;Cell Movement;Epithelial-Mesenchymal Transition;Female;Gene Expression Regulation, Neoplastic;Humans;Mammary Neoplasms, Experimental;Mice;Mice, SCID;Proto-Oncogene Proteins c-met;Receptor, ErbB-2;Shc Signaling Adaptor Proteins;Signal Transduction;Src Homology 2 Domain-Containing, Transforming Protein 1",
        "Doc_meshqualifiers":"metabolism;metabolism;pathology;metabolism;metabolism;metabolism",
        "_version_":1605790637319258112},
      {
        "Doc_abstract":"Some molecular subtypes of breast cancer have preferential sites of distant relapse. The protein expression pattern of the primary tumor may influence the first distant metastasis site.;We identified from the files of the Finnish Cancer Registry patients diagnosed with breast cancer in five geographical regions Finland in 1991-1992, reviewed the hospital case records, and collected primary tumor tissue. Out of the 2,032 cases identified, 234 developed distant metastases after a median follow-up time of 2.7 years and had the first metastatic site documented (a total of 321 sites). Primary tumor microarray (TMA) cores were analyzed for 17 proteins using immunohistochemistry and for erbB2 using chromogenic in situ hybridization, and their associations with the first metastasis site were examined. The cancers were classified into luminal A, luminal B, HER2+ enriched, basal-like or non-expressor subtypes.;A total of 3,886 TMA cores were analyzed. Luminal A cancers had a propensity to give rise first to bone metastases, HER2-enriched cancers to liver and lung metastases, and basal type cancers to liver and brain metastases. Primary tumors that gave first rise to bone metastases expressed frequently estrogen receptor (ER) and SNAI1 (SNAIL) and rarely COX2 and HER2, tumors with first metastases in the liver expressed infrequently SNAI1, those with lung metastases expressed frequently the epidermal growth factor receptor (EGFR), cytokeratin-5 (CK5) and HER2, and infrequently progesterone receptor (PgR), tumors with early skin metastases expressed infrequently E-cadherin, and breast tumors with first metastases in the brain expressed nestin, prominin-1 and CK5 and infrequently ER and PgR.;Breast tumor biological subtypes have a tendency to give rise to first distant metastases at certain body sites. Several primary tumor proteins were associated with homing of breast cancer cells.",
        "Doc_title":"Breast cancer biological subtypes and protein expression predict for the preferential distant metastasis sites: a nationwide cohort study.",
        "Journal":"Breast cancer research : BCR",
        "Do_id":"21914172",
        "Doc_ChemicalList":"AC133 Antigen;Antigens, CD;Cadherins;Glycoproteins;Intermediate Filament Proteins;Keratin-5;NES protein, human;Nerve Tissue Proteins;Nestin;PROM1 protein, human;Peptides;Proteins;Receptors, Estrogen;Receptors, Progesterone;SNAI1 protein, human;Snail Family Transcription Factors;Transcription Factors;Cyclooxygenase 2;PTGS2 protein, human;EGFR protein, human;ERBB2 protein, human;Receptor, Epidermal Growth Factor;Receptor, ErbB-2",
        "Doc_meshdescriptors":"AC133 Antigen;Antigens, CD;Bone Neoplasms;Brain Neoplasms;Breast Neoplasms;Cadherins;Cohort Studies;Cyclooxygenase 2;Female;Finland;Follow-Up Studies;Glycoproteins;Humans;Intermediate Filament Proteins;Keratin-5;Liver Neoplasms;Lung Neoplasms;Nerve Tissue Proteins;Nestin;Peptides;Proteins;Receptor, Epidermal Growth Factor;Receptor, ErbB-2;Receptors, Estrogen;Receptors, Progesterone;Skin Neoplasms;Snail Family Transcription Factors;Transcription Factors",
        "Doc_meshqualifiers":"metabolism;metabolism;secondary;metabolism;secondary;metabolism;pathology;metabolism;metabolism;metabolism;metabolism;metabolism;metabolism;secondary;metabolism;secondary;metabolism;metabolism;analysis;metabolism;metabolism;metabolism;metabolism;metabolism;metabolism;secondary;metabolism",
        "_version_":1605747554705735680},
      {
        "Doc_abstract":"Lapatinib and bortezomib are highly active against breast cancer cells. Breast cancer patients who initially respond to lapatinib may eventually manifest acquired resistance to this treatment. Thus, the identification of novel agents that may prevent or delay the development of acquired resistance to lapatinib is critical. In the current study, we show that the combination of lapatinib and bortezomib results in a synergistic growth inhibition in human epidermal receptor 2 (HER2)-overexpressing breast cancer cells and that the combination enhances apoptosis of SK-BR-3 cells. Importantly, we found that the combination of lapatinib plus bortezomib more effectively blocked activation of the HER2 pathway in SK-BR-3 cells, compared with monotherapy. In addition, we established a model of acquired resistance to lapatinib by chronically challenging SK-BR-3 breast cancer cells with increasing concentrations of lapatinib. Here, we showed that bortezomib notably induced apoptosis of lapatinib-resistant SK-BR-3 pools and further inhibited HER2 signaling in the resistant cells. Taken together, the current data indicate a synergistic interaction between lapatinib and bortezomib in HER2-overexpressing breast cancer cells and provide the rationale for the clinical evaluation of these two noncross-resistant targeted therapies. The combination of lapatinib and bortezomib may be a potentially novel approach to prevent or delay the onset of acquired resistance to lapatinib in HER2-overxpressing/estrogen receptor (ER)-negative breast cancers.",
        "Doc_title":"Combined effects of lapatinib and bortezomib in human epidermal receptor 2 (HER2)-overexpressing breast cancer cells and activity of bortezomib against lapatinib-resistant breast cancer cells.",
        "Journal":"Cancer science",
        "Do_id":"20701607",
        "Doc_ChemicalList":"Antineoplastic Agents;Boronic Acids;CDKN1B protein, human;Intracellular Signaling Peptides and Proteins;Protein Kinase Inhibitors;Pyrazines;Quinazolines;lapatinib;Cyclin-Dependent Kinase Inhibitor p27;Bortezomib;ERBB2 protein, human;Receptor, ErbB-2;Proto-Oncogene Proteins c-akt;Extracellular Signal-Regulated MAP Kinases",
        "Doc_meshdescriptors":"Antineoplastic Agents;Apoptosis;Boronic Acids;Bortezomib;Breast Neoplasms;Cell Line, Tumor;Cyclin-Dependent Kinase Inhibitor p27;Drug Resistance, Neoplasm;Extracellular Signal-Regulated MAP Kinases;Female;Humans;Intracellular Signaling Peptides and Proteins;Phosphorylation;Protein Kinase Inhibitors;Proto-Oncogene Proteins c-akt;Pyrazines;Quinazolines;Receptor, ErbB-2",
        "Doc_meshqualifiers":"administration & dosage;drug effects;administration & dosage;pharmacology;chemistry;drug therapy;pathology;physiology;analysis;administration & dosage;metabolism;administration & dosage;pharmacology;administration & dosage;analysis",
        "_version_":1605806892374818816},
      {
        "Doc_abstract":"Trastuzumab, a humanized monoclonal antibody, has become an important targeted therapy for patients with all stages of human epidermal growth factor receptor-2 (HER2)-positive breast cancer. However, primary and acquired resistance to trastuzumab remains a significant problem. Pertuzumab, a humanized monoclonal antibody that binds to a domain of the HER2 receptor separate from trastuzumab, may have the potential to overcome trastuzumab resistance. Clinical trials have shown that pertuzumab can be effectively combined with other biologic therapy or chemotherapy in patients with metastatic HER2-positive breast cancer. Pertuzumab is relatively well tolerated with minimal increases in hematologic and cardiac toxicity observed when added to trastuzumab and/or docetaxel. In addition to becoming the standard of care in combination with docetaxel and trastuzumab in patients with newly diagnosed HER2-positive metastatic breast cancer, clinical trials continue to evaluate pertuzumab in combination with other targeted therapy, chemotherapy, and in patients with early stage breast cancer. These trials will help to further determine the role of pertuzumab in the treatment of HER2-positive breast cancer. ",
        "Doc_title":"Pertuzumab: a new targeted therapy for HER2-positive metastatic breast cancer.",
        "Journal":"Pharmacotherapy",
        "Do_id":"23918291",
        "Doc_ChemicalList":"Antibodies, Monoclonal, Humanized;Antineoplastic Agents;ERBB2 protein, human;Receptor, ErbB-2;pertuzumab",
        "Doc_meshdescriptors":"Antibodies, Monoclonal, Humanized;Antineoplastic Agents;Breast Neoplasms;Clinical Trials as Topic;Drug Delivery Systems;Female;Humans;Receptor, ErbB-2;Treatment Outcome",
        "Doc_meshqualifiers":"administration & dosage;administration & dosage;drug therapy;genetics;secondary;trends;trends;genetics",
        "_version_":1605763944892334080},
      {
        "Doc_abstract":"Breast cancers exhibit highly heterogeneous molecular profiles. Although gene expression profiles have been used to predict the risks and prognostic outcomes of breast cancers, the high variability of gene expression limits its clinical application. In contrast, genetic mutation profiles would be more advantageous than gene expression profiles because genetic mutations can be stably detected and the mutational heterogeneity widely exists in breast cancer genomes. We analyzed 98 breast cancer whole exome samples that were sorted into three subtypes, two grades and two stages. The sum deleterious effect of all mutations in each gene was scored to identify differentially mutated genes (DMGs) for this case-control study. DMGs were corroborated using extensive published knowledge. Functional consequences of deleterious SNVs on protein structure and function were also investigated. Genes such as ERBB2, ESP8, PPP2R4, KIAA0922, SP4, CENPJ, PRCP and SELP that have been experimentally or clinically verified to be tightly associated with breast cancer prognosis are among the DMGs identified in this study. We also identified some genes such as ARL6IP5, RAET1E, and ANO7 that could be crucial for breast cancer development and prognosis. Further, SNVs such as rs1058808, rs2480452, rs61751507, rs79167802, rs11540666, and rs2229437 that potentially influence protein functions are observed at significantly different frequencies in different comparison groups. Protein structure modeling revealed that many non-synonymous SNVs have a deleterious effect on protein stability, structure and function. Mutational profiling at gene- and SNV-level revealed differential patterns within each breast cancer comparison group, and the gene signatures correlate with expected prognostic characteristics of breast cancer classes. Some of the genes and SNVs identified in this study show high promise and are worthy of further investigation by experimental studies. ",
        "Doc_title":"Exome analysis reveals differentially mutated gene signatures of stage, grade and subtype in breast cancers.",
        "Journal":"PloS one",
        "Do_id":"25803781",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"Adult;Breast Neoplasms;Case-Control Studies;Exome;Female;Genetic Association Studies;Humans;Mutation;Neoplasm Grading;Neoplasm Staging;Prognosis;Sequence Analysis, DNA;Transcriptome",
        "Doc_meshqualifiers":"genetics;pathology",
        "_version_":1605790783621824512},
      {
        "Doc_abstract":"The human epidermal growth factor receptor 2 gene (HER2) is overexpressed and/or amplified in ~15% of breast cancer patients and was identified a quarter century ago as a marker of poor prognosis. By 1998, antibody therapy targeting the HER2 pathway was shown to demonstrably improve progression-free and overall survival in metastatic disease, and in 2005 evidence of improvement in disease-free and overall survival from the first generation of trastuzumab adjuvant trials became available. However, not all patients with HER2 overexpression benefit from trastuzumab. Second-generation studies in metastatic disease led to the approval of several new HER2-targeted therapies using small molecule tyrosine kinase inhibitors such as lapatinib, new HER2/HER3 antibodies such as pertuzumab, and the new antibody chemotherapy conjugate ado-trastuzumab emtansine. These successes supported the launch of second-generation adjuvant trials testing single and dual HER2-targeted agents, administered concomitantly or sequentially with chemotherapy that will soon complete accrual. HER2-positive breast cancer in the setting of HER2-targeted therapy is no longer associated with poor prognosis, and recent guidance by the US Food and Drug Administration suggests that pathologic response to HER2-targeted therapy given preoperatively may allow an earlier assessment of their clinical benefit in the adjuvant setting. An adjuvant trial of trastuzumab in patient whose tumors express normal levels of HER2 and trials of single/dual HER2-targeting without chemotherapy are also ongoing. In this article, we review the current data on the therapeutic management of HER2-positive breast cancer.",
        "Doc_title":"Treatment of HER2-positive breast cancer.",
        "Journal":"Breast (Edinburgh, Scotland)",
        "Do_id":"24360619",
        "Doc_ChemicalList":"Antibodies, Monoclonal, Humanized;Antineoplastic Agents;ERBB2 protein, human;Receptor, ErbB-2;Trastuzumab",
        "Doc_meshdescriptors":"Antibodies, Monoclonal, Humanized;Antineoplastic Agents;Breast Neoplasms;Female;Humans;Neoadjuvant Therapy;Receptor, ErbB-2;Trastuzumab;Treatment Outcome",
        "Doc_meshqualifiers":"therapeutic use;therapeutic use;drug therapy;metabolism;pathology;methods;metabolism",
        "_version_":1605896691109593088},
      {
        "Doc_abstract":"Recently there has been a resurgence in interest in the use of HER2 protein overexpression or gene amplification to refine prognostic estimates of breast cancer patient outcomes and to predict which therapies might be most appropriate for individual breast cancer patients. To bring HER2 testing into clinical practice, two hurdles must be cleared. First, HER2 tests must be developed that accurately reflect HER2 status and that can be reliably performed. Second, HER2 test results must be correlated with patient outcome and response to therapy. Much progress has been made in both of these areas, but the full implementation and utility of this work have yet to be realized.",
        "Doc_title":"The use of HER2 testing in the management of breast cancer.",
        "Journal":"Seminars in oncology",
        "Do_id":"11049055",
        "Doc_ChemicalList":"Antibodies, Monoclonal;Antibodies, Monoclonal, Humanized;Antineoplastic Agents;Receptor, ErbB-2;Trastuzumab",
        "Doc_meshdescriptors":"Antibodies, Monoclonal;Antibodies, Monoclonal, Humanized;Antineoplastic Agents;Breast Neoplasms;Gene Amplification;Gene Expression;Humans;Immunohistochemistry;In Situ Hybridization, Fluorescence;Receptor, ErbB-2;Trastuzumab",
        "Doc_meshqualifiers":"therapeutic use;therapeutic use;drug therapy;genetics;metabolism;genetics;metabolism",
        "_version_":1605747093241069568},
      {
        "Doc_abstract":"The Panel of the St. Gallen 2011 consensus meeting considered the major breast cancer subtypes classified by the expression of hormone receptors and HER2, and the Ki67-labelling index was substituted for microarray-based intrinsic subtypes. When choosing a treatment strategy for breast cancer, the biological property of the tumor itself is given greater importance than the anatomical spreading in the hosts recently. The treatment strategy of adjuvant therapies for breast cancer will be decided according to these simplified intrinsic subtypes: luminal A, luminal B, HER2 positive, and triple negative. The biological markers and targeted therapies will contribute to the advancement of personalized medicine.",
        "Doc_title":"[Current status and future direction of postoperative adjuvant therapy in breast cancer].",
        "Journal":"Gan to kagaku ryoho. Cancer & chemotherapy",
        "Do_id":"21918336",
        "Doc_ChemicalList":"Antineoplastic Agents",
        "Doc_meshdescriptors":"Antineoplastic Agents;Breast Neoplasms;Combined Modality Therapy;Guidelines as Topic;Hormone Replacement Therapy;Humans;Molecular Targeted Therapy",
        "Doc_meshqualifiers":"therapeutic use;drug therapy;pathology;surgery",
        "_version_":1605750645197897728},
      {
        "Doc_abstract":"Tumor-infiltrating lymphocytes (TILs) have prognostic significance in breast cancer. The tertiary lymphoid structure (TLS) is related to the influx of TILs, and expression of major histocompatibility complex (MHC) I in tumor cells is necessary for the effective action of TILs.;We retrospectively evaluated the relationship of TILs and TLS and the expression of MHC I in 447 HER2-positive breast cancers treated with chemotherapy and 1 year of trastuzumab.;TILs were more abundant in hormone receptor (HR)-/HER2+ tumors than in HR+/HER2+ tumors. HR-/HER2+ breast cancers with abundant TILs showed a higher histologic grade, the absence of lymphovascular invasion, the presence of peritumoral lymphocytic infiltration, moderate to abundant TLSs in adjacent tissue, and stronger HLA-ABC and HLA-A expression. Abundant TILs and the absence of lymphovascular invasion were found to be good, independent prognostic factors for disease-free survival in patients with HR-/HER2+ breast cancer. The level of TILs was not associated with the patients' prognosis in HR+ tumors.;Abundant TILs are an independent prognostic factor in HR-/HER2+ breast cancers. Evaluation of TILs in HR-/HER2+ breast cancers may provide valuable information regarding the prognosis of patients treated using adjuvant chemotherapy and trastuzumab.",
        "Doc_title":"Prognostic Significance of Tumor-Infiltrating Lymphocytes and the Tertiary Lymphoid Structures in HER2-Positive Breast Cancer Treated With Adjuvant Trastuzumab.",
        "Journal":"American journal of clinical pathology",
        "Do_id":"26185313",
        "Doc_ChemicalList":"Antibodies, Monoclonal, Humanized;Antineoplastic Agents;Histocompatibility Antigens Class I;ERBB2 protein, human;Receptor, ErbB-2;Trastuzumab",
        "Doc_meshdescriptors":"Adult;Aged;Antibodies, Monoclonal, Humanized;Antineoplastic Agents;Breast Neoplasms;Chemotherapy, Adjuvant;Disease-Free Survival;Female;Histocompatibility Antigens Class I;Humans;Immunohistochemistry;Kaplan-Meier Estimate;Lymphocytes, Tumor-Infiltrating;Lymphoid Tissue;Middle Aged;Prognosis;Proportional Hazards Models;Receptor, ErbB-2;Tissue Array Analysis;Trastuzumab",
        "Doc_meshqualifiers":"therapeutic use;therapeutic use;drug therapy;mortality;pathology;pathology;pathology;metabolism",
        "_version_":1605765578250780672},
      {
        "Doc_abstract":"Nonanatomic factors, such as histologic grade and biomarkers, can guide breast cancer management but are not included in the current TNM staging system.;To use as an example the triple-negative phenotype (TNP) defined by the absence of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor 2 (HER2) to examine whether such inclusion improves the prognostic accuracy of TNM staging for breast cancer.;Women diagnosed with primary invasive ductal breast cancer from January 1, 1991, through December 31, 2008, were identified from a prospective institutional database. Excluded were patients who received neoadjuvant therapy, those whose staging information was incomplete, or those whose tumor lacked ER, PR, and HER2 data. Breast cancers were categorized by TNM stage and by the presence or absence of TNP.;Overall survival at 5 years.;Database review identified 1842 consecutive eligible patients with breast cancer. When patients were stratified by TNM stage, overall survival curves for those with TNP breast cancer matched those for patients whose non-TNP breast cancer was 1 TNM stage higher. Multivariable analysis showed that TNP status was a powerful prognostic variable, and the likelihood ratio test revealed that the prognostic accuracy of the TNM staging system that incorporated TNP was superior to the current TNM staging system (P<â€‰.001). A TNM staging system that incorporated TNP reduced early-stage compression by 15%.;The internationally recognized and easily reproducible examination of ER, PR, and HER2 status exemplifies how nonanatomic factors can improve the prognostic accuracy of breast cancer staging.",
        "Doc_title":"Personalizing breast cancer staging by the inclusion of ER, PR, and HER2.",
        "Journal":"JAMA surgery",
        "Do_id":"24306257",
        "Doc_ChemicalList":"Biomarkers, Tumor;Estrogen Receptor alpha;Receptors, Progesterone;estrogen receptor alpha, human;ERBB2 protein, human;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Biomarkers, Tumor;Breast Neoplasms;Carcinoma, Ductal, Breast;Estrogen Receptor alpha;Female;Follow-Up Studies;Humans;Immunohistochemistry;Neoplasm Staging;Prognosis;Prospective Studies;Receptor, ErbB-2;Receptors, Progesterone;Reproducibility of Results;Survival Rate;Time Factors;United States",
        "Doc_meshqualifiers":"metabolism;diagnosis;metabolism;mortality;diagnosis;metabolism;mortality;metabolism;methods;metabolism;metabolism;trends;epidemiology",
        "_version_":1605742072281694209},
      {
        "Doc_abstract":"Nuclear factor-kappaB (NF-kappaB), a transcription factor with pleotropic effects, is a downstream mediator of growth signaling in estrogen receptor (ER)-negative and erbB family particularly erbB2 (HER-2/neu) receptor-positive cancer. We previously reported activation of NF-kappaB in ER-negative breast cancer cells and breast tumor specimens, but the consequence of inhibiting NF-kappaB activation in this subclass of breast cancer has not been shown. In this study, we investigated the role of NF-kappaB activation by studying the tumorigenic potential of cells expressing genetically manipulated, inducible, dominant-negative inhibitory kappaB kinase (IKK) beta in xenograft tumor model. Conditional inhibition of NF-kappaB activation by the inducible expression of dominant-negative IKKbeta simultaneously blocked cell proliferation, reinstated apoptosis, and dramatically blocked xenograft tumor formation. Secondly, the humanized anti-erbB2 antibody trastuzumab (Herceptin) and the specific IKK inhibitor NF-kappaB essential modifier-binding domain peptide both blocked NF-kappaB activation and cell proliferation and reinstated apoptosis in two ER-negative and erbB2-positive human breast cancer cell lines that are used as representative model systems. Combinations of these two target-specific inhibitors synergistically blocked cell proliferation at concentrations that were singly ineffective. Inhibition of NF-kappaB activation with two other low molecular weight compounds, PS1145 and PS341, which inhibited IKK activity and proteasome-mediated phosphorylated inhibitory kappaB protein degradation, respectively, blocked erbB2-mediated cell growth and reversed antiapoptotic machinery. These results implicate NF-kappaB activation in the tumorigenesis and progression of ER-negative breast cancer. It is postulated that this transcription factor and its activation cascade offer therapeutic targets for erbB2-positive and ER-negative breast cancer.",
        "Doc_title":"Nuclear factor-kappaB activation: a molecular therapeutic target for estrogen receptor-negative and epidermal growth factor receptor family receptor-positive human breast cancer.",
        "Journal":"Molecular cancer therapeutics",
        "Do_id":"17620428",
        "Doc_ChemicalList":"Antineoplastic Agents;NF-kappa B;Receptors, Estrogen;Receptor, Epidermal Growth Factor;Receptor, ErbB-2;I-kappa B Kinase",
        "Doc_meshdescriptors":"Animals;Antineoplastic Agents;Apoptosis;Breast Neoplasms;Cell Line, Tumor;Cell Proliferation;Drug Synergism;Humans;I-kappa B Kinase;Mice;Mice, Nude;NF-kappa B;Phosphorylation;Receptor, Epidermal Growth Factor;Receptor, ErbB-2;Receptors, Estrogen;Xenograft Model Antitumor Assays",
        "Doc_meshqualifiers":"pharmacology;drug effects;classification;metabolism;therapy;drug effects;metabolism;antagonists & inhibitors;metabolism;drug effects;metabolism;antagonists & inhibitors;metabolism",
        "_version_":1605836454559219712},
      {
        "Doc_abstract":"Human epidermal growth factor receptor (HER)-2 testing in patients with operable breast cancer is aimed at identifying candidates for adjuvant anti-HER-2 treatment. However, commonly defined \"HER-2(-)\" tumors express variable levels of the HER-2 protein, which can influence prognosis. We compared the clinical outcomes of operable breast cancer patients stratified according to a common HER-2 testing algorithm.;We studied 1,150 women (median age, 58 years; range, 22-94 years) undergoing surgery for early breast cancer at our institution. HER-2 status was determined using the HercepTestâ„¢ (Dako, Glostrup, Denmark) and, when needed, by fluorescence in situ hybridization (FISH). Patients receiving adjuvant trastuzumab were excluded. The impact of HER-2 status on the disease-free survival (DFS) time was studied using multivariate Cox proportional regression analysis.;Four hundred-fifty seven (40%), 454 (39%), 116 (10%), and 123 (11%) patients were considered HER-2 0+, HER-2 1+, HER-2 2+/HER-2(-) by FISH, and HER-2(+) (3+ or HER-2(+) by FISH), respectively. Compared with a HER-2 0 or 1+ status, a HER-2 2+/HER-2(-) by FISH status was associated with a worse DFS outcome on multivariate analysis. Compared with a HER-2(+) status, a HER-2 2+/HER-2(-) status showed a time-dependent effect on the DFS probability, with an initial advantage that worsened every year by a factor of 1.649.;A HER-2 2+/HER-2(-) status is an adverse prognostic factor in patients with operable breast cancer. Because of suggestions from randomized trials that the benefits of adjuvant trastuzumab may not be limited to patients with HER-2(+) tumors, patients with a HER-2 2+/HER-2(-) status are ideal candidates for studies testing this hypothesis.",
        "Doc_title":"Moderate immunohistochemical expression of HER-2 (2+) without HER-2 gene amplification is a negative prognostic factor in early breast cancer.",
        "Journal":"The oncologist",
        "Do_id":"22951668",
        "Doc_ChemicalList":"Antibodies, Monoclonal, Humanized;Biomarkers, Tumor;ERBB2 protein, human;Receptor, ErbB-2;Trastuzumab",
        "Doc_meshdescriptors":"Adult;Aged;Aged, 80 and over;Antibodies, Monoclonal, Humanized;Biomarkers, Tumor;Breast Neoplasms;Disease-Free Survival;Female;Gene Amplification;Gene Expression Regulation, Neoplastic;Humans;In Situ Hybridization, Fluorescence;Middle Aged;Receptor, ErbB-2;Trastuzumab;Young Adult",
        "Doc_meshqualifiers":"therapeutic use;genetics;genetics;metabolism;surgery;genetics;metabolism",
        "_version_":1605746795759009792},
      {
        "Doc_abstract":"The HER2 gene is amplified and overexpressed in 25-30% of breast carcinomas. Assessment of HER2 status for prognosis and treatment of breast cancer patients can be performed by immunohistochemistry and/or fluorescence in situ hybridization (FISH). To develop a testing algorithm for HER2 in breast cancers, we used FISH analysis to determine the HER2 gene copy number and immunostaining to detect the p185 protein. Interlaboratory, interobserver, and intermethod variabilities of immunohistochemistry were assessed. In 24 invasive breast carcinomas, the indices of HER2 status obtained by FISH and by a reference laboratory's DAKO HercepTest (immunostain) gave an overall concordance of 96%. The reference laboratory's stained slides were re-interpreted by an in-house panel of pathologists; the interpretation differed in one case. The panel's interpretations were concordant with the FISH results in all 24 cases. Interobserver variability for the panel's immunohistochemistry interpretations was assessed using three different immunostaining methods on 70 slides. The numerical (0-1+, 2+, 3+) scores showed greater variability among observers than did the overall positive/negative results. One pathologist reported inconsistent results in >30% of the slides evaluated. Borderline scoring of 1-2+ was reported in 18 slides (23%) by at least one observer. Incongruent interobserver immunohistochemistry scores, leading to different positive and negative interpretations, were obtained with 5 slides (7%). The majority of consensus positive cases exhibited strong membrane staining (3+). The majority of consensus negative cases scored as 0. Based on these observations, we developed a testing algorithm that maximizes the benefits of FISH and immunohistochemistry, providing physicians with accurate results for appropriate clinical care.",
        "Doc_title":"A testing algorithm for determination of HER2 status in patients with breast cancer.",
        "Journal":"Annals of clinical and laboratory science",
        "Do_id":"11848614",
        "Doc_ChemicalList":"Receptor, ErbB-2",
        "Doc_meshdescriptors":"Algorithms;Breast Neoplasms;Female;Gene Dosage;Genes, erbB-2;Humans;Immunohistochemistry;In Situ Hybridization, Fluorescence;Observer Variation;Receptor, ErbB-2;Single-Blind Method",
        "Doc_meshqualifiers":"genetics;metabolism;metabolism",
        "_version_":1605759269286707200},
      {
        "Doc_abstract":"The prognostic value of the Ki67 expression level is yet unclear in breast cancer. The aim of this study was to investigate the association between Ki67 expression levels and prognostic factors such as grade, Her2 and hormone receptor expression status in breast cancers.;Clinical and pathological features of the patients with breast cancer were retreived from the hospital records.;In this study, 163 patients with breast cancer were analyzed, with a mean age of 53.4Â±12.2 years. Median Ki67 positivity was 20% and Ki67-high tumors were significantly associated with high grade (p<0.001), lymphovascular invasion (p=0.001), estrogen receptor (ER) negativity (p=0.035), Her2 positivity (p=0.001), advanced stage (p<0.001) and lymph node positivity (p<0.003) . Lower Ki67 levels were significantly associated with longer median relapse-free and overall survival compared to those of higher Ki67 levels.;High Ki67 expression is associated with ER negativity, Her2 positivity, higher grade and axillary lymph node involvement in breast cancers. The level of Ki67 expression is a prognostic factor predicting relapse-free and overall survival in breast cancer patients.",
        "Doc_title":"Higher Ki67 expression is associates with unfavorable prognostic factors and shorter survival in breast cancer.",
        "Journal":"Asian Pacific journal of cancer prevention : APJCP",
        "Do_id":"24606469",
        "Doc_ChemicalList":"Biomarkers, Tumor;Ki-67 Antigen;Receptors, Estrogen;Receptors, Progesterone;ERBB2 protein, human;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Axilla;Biomarkers, Tumor;Breast Neoplasms;Cell Proliferation;Disease-Free Survival;Female;Humans;Ki-67 Antigen;Lymph Nodes;Lymphatic Metastasis;Middle Aged;Neoplasm Grading;Neoplasm Invasiveness;Neoplasm Recurrence, Local;Prognosis;Receptor, ErbB-2;Receptors, Estrogen;Receptors, Progesterone",
        "Doc_meshqualifiers":"biosynthesis;mortality;pathology;biosynthesis;pathology;metabolism;metabolism;metabolism",
        "_version_":1605804453151113216},
      {
        "Doc_abstract":"Human epidermal growth factor receptor 2 (HER2) testing of samples from recurrent or metastatic breast cancer is recommended by the 2013 update of the American Society of Clinical Oncology/College of American Pathologists guidelines. Although cytological analysis can be applied to several types of metastatic lesions, the practical method for HER2 testing of cytological specimens is yet to be resolved. We conducted immunohistochemical (IHC) staining for HER2 in breast cancer cell blocks (CBs) and compared the results with those from the corresponding histological specimens. In cases of discrepancy between the two types of specimen, the bright-field HER2 dual in situ hybridization (DISH) assay was performed.;CBs were prepared from 54 surgically excised breast cancers. The cells were fixed in 10% buffered formalin and embedded in paraffin. A Ventana BenchMark ULTRA (Roche Diagnostics) with anti-HER-2/neu (4B5) rabbit monoclonal primary antibody and INFORM HER2/neu Dual ISH DNA Probe Cocktail was used for the assays.;Successful results were obtained in 52 of 54 CBs. Forty cases showed agreement between CBs and the histological specimens. No discrepancy was observed between the two types of specimens in cases where HER2 expression was positive. IHC results of CB in 12 discrepant cases were HER2 intermediate or negative. The DISH results of 11 of these cases were negative.;IHC staining of HER2 for breast cancer CBs can be used in the same way as that used for histological specimens, although the number of equivocal cases in CBs is greater than that in histological specimens. Diagn. Cytopathol. 2016;44:274-279. Â© 2016 The Authors Diagnostic Cytopathology Published by Wiley Periodicals, Inc.",
        "Doc_title":"HER 2 immunohistochemistry for breast cancer cell blocks can be used in the same way as that used for histological specimens.",
        "Journal":"Diagnostic cytopathology",
        "Do_id":"26800514",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605837500744466432},
      {
        "Doc_abstract":"To evaluate the association between HER2 codon 655 polymorphism and breast cancer risk in this meta-analysis. A comprehensive search was performed to identify all case-control studies investigating such association. Statistical analyses were conducted with software MIX 1.54. Twenty eligible reports, including 10,642 cases/11,259 controls, were identified. In overall analysis, the Val allele frequency in cases was significantly higher than that in controls (OR = 1.0921, 95% CI: 1.0013-1.191, P = 0.0466), while no associations were found in both recessive and dominant models. In subgroup analysis, HER2 codon 655 polymorphism was weakly associated with breast cancer risk in recessive (OR = 2.4624, 95% CI: 1.0619-5.7104, P = 0.0357), dominant (OR = 1.2781, 95% CI: 1.0353-1.5779, P = 0.0225), and co-dominant genetic models (OR = 1.2947, 95% CI: 1.0682-1.5693, P = 0.0085) in Asian population, respectively. Meanwhile, the susceptibility to breast cancer in people aged < or =45 was significantly increased in both recessive (OR = 2.2408; 95% CI: 1.2876-3.8998, P = 0.0043), and dominant models (OR = 1.2902, 95% CI: 1.1035-1.5085, P = 0.0014). No significant associations were observed in Caucasian, European, and Family history subgroups. So our analyses suggest HER2 codon 655 Val allele is weakly associated with an increased risk of breast cancer, and SNP at HER2 codon 655 could be considered as a susceptibility biomarker for breast cancer for Asian females or women age 45 years or younger.",
        "Doc_title":"HER2 codon 655 polymorphism and breast cancer risk: a meta-analysis.",
        "Journal":"Breast cancer research and treatment",
        "Do_id":"18438707",
        "Doc_ChemicalList":"Codon",
        "Doc_meshdescriptors":"Breast Neoplasms;Case-Control Studies;Codon;Female;Genes, erbB-2;Genotype;Humans;Middle Aged;Polymorphism, Genetic",
        "Doc_meshqualifiers":"genetics;pathology;genetics;genetics;genetics",
        "_version_":1605882643071631360},
      {
        "Doc_abstract":"Epidemiological studies have suggested that the consumption of fruits and vegetables that provide several classes of compounds, including Indole-3-carbinol (I3C), may have chemopreventive activity against breast cancer. Several in vitro and in vivo animal studies also provide convincing evidence for the anti-tumor activity of I3C, however, the molecular mechanism(s) by which I3C exerts its biological effects on breast cancer cells has not been fully elucidated. In this study, we investigated the effects of I3C in Her-2/neu over-expressing MDA-MB-435 breast cancer cells and compared these results with parental cells transfected with control vector. We focused our investigation in elucidating the molecular mechanism(s) by which I3C induces apoptosis in breast cancer cells. Our data show that I3C inhibits breast cancer cell growth in a dose dependent manner in Her-2/neu over-expressing and in normal Her-2/neu expressing cells. Induction of apoptosis was also observed in these cell lines when treated with I3C, as measured by poly (ADPribose) polymerase (PARP) and caspase-3 activation. In addition, we found that I3C up-regulates Bax, down-regulates Bcl-2 and, thereby, increased the ratio of Bax to Bcl-2 favoring apoptosis. These results suggest that the alteration in the expression of these genes may play an important role in mediating the biological effects of I3C. Moreover, we also show the cellular localization of Bax by confocal microscopy, which showed diffuse distribution of Bax throughout the cytoplasmic compartment in breast cancer cells in control culture. However, in I3C treated cells, Bax showed a punctate pattern of distribution that was localized in the mitochondria. From these results, we conclude that the over-expression and translocation of Bax to mitochondria causes mitochondrial depolarization and activation of caspases, which may be one of the mechanism(s) by which I3C induces apoptotic processes in I3C treated breast cancer cells. Overall, our present data provide a novel molecular mechanism(s) by which I3C elicits its biological effects on both Her-2/neu over-expressing and with normal Her-2/neu expressing breast cancer cells, suggesting that I3C could be an effective agent in inducing apoptosis in breast cancer cells.",
        "Doc_title":"Translocation of Bax to mitochondria induces apoptotic cell death in indole-3-carbinol (I3C) treated breast cancer cells.",
        "Journal":"Oncogene",
        "Do_id":"11126363",
        "Doc_ChemicalList":"Anticarcinogenic Agents;BAX protein, human;Growth Inhibitors;Indoles;Proto-Oncogene Proteins;Proto-Oncogene Proteins c-bcl-2;bcl-2-Associated X Protein;indole-3-carbinol;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Anticarcinogenic Agents;Apoptosis;Breast Neoplasms;Cell Cycle;Cell Division;Dose-Response Relationship, Drug;Gene Expression;Growth Inhibitors;Humans;Indoles;Intracellular Membranes;Microscopy, Confocal;Mitochondria;Proto-Oncogene Proteins;Proto-Oncogene Proteins c-bcl-2;Receptor, ErbB-2;Transfection;Tumor Cells, Cultured;bcl-2-Associated X Protein",
        "Doc_meshqualifiers":"pharmacology;drug effects;genetics;genetics;metabolism;pathology;drug effects;drug effects;drug effects;pharmacology;pharmacology;drug effects;metabolism;drug effects;metabolism;biosynthesis;genetics;metabolism;biosynthesis;genetics;biosynthesis;genetics;drug effects",
        "_version_":1605852332074991616},
      {
        "Doc_abstract":"The aim of this study was to evaluate the outcomes and patterns of recurrence in the different subtypes of breast cancer. We analyzed 1432 stage I-III breast cancer patients who had undergone surgery at Seoul National University Bundang Hospital between June 2003 and August 2011. Five subtypes were defined according to estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2 (HER2), and Ki-67. Overall survival (OS) and breast cancer-free interval (BCFI) rates were estimated using the Kaplan-Meier method. Site-specific recurrence was estimated using Gray's test. The median follow-up period was 53Â months. There were 22 local recurrences, 18 cases of contralateral breast cancer, 19 regional nodal recurrences, and 70 distant metastases. The 5-year BCFIs by subtype were luminal B-HER2 (+), 94.2Â %; luminal A, 93.9Â %; luminal B-HER2 (-), 91.4Â %; HER2, 83.1Â %; and triple-negative, 81.9Â % (pÂ <Â 0.001). Cases with the luminal A had a 5-year OS rate of 98.3Â % that was the longest compared to those of cases with luminal B-HER2 (-), 95.8Â %; luminal B-HER2 (+), 98.0Â %; HER2, 90.8Â %; and triple-negative, 89.9Â % (pÂ <Â 0.001). The triple-negative had a higher rate of local recurrence at the first site than others (pÂ =Â 0.013). HER2 and triple-negative had higher rates of nodal recurrence at the first site than others (pÂ <Â 0.001). The outcomes and patterns of site-specific recurrence in Korean breast cancer patients were different for each subtype. Defining recurrence patterns by breast cancer subtypes can help determine the appropriate method of surveillance and treatment. ",
        "Doc_title":"Outcomes and recurrence patterns according to breast cancer subtypes in Korean women.",
        "Journal":"Breast cancer research and treatment",
        "Do_id":"25893592",
        "Doc_ChemicalList":"Biomarkers, Tumor;Ki-67 Antigen;Receptors, Progesterone;ERBB2 protein, human;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Adult;Aged;Biomarkers, Tumor;Breast Neoplasms;Disease-Free Survival;Female;Humans;Ki-67 Antigen;Lymphatic Metastasis;Middle Aged;Neoplasm Recurrence, Local;Neoplasm Staging;Receptor, ErbB-2;Receptors, Progesterone",
        "Doc_meshqualifiers":"genetics;classification;epidemiology;genetics;pathology;genetics;classification;epidemiology;genetics;pathology;genetics;genetics",
        "_version_":1605763972677500928},
      {
        "Doc_abstract":"Previous research identified differences in breast cancer-specific mortality across 4 intrinsic tumor subtypes: luminal A, luminal B, basal-like, and human epidermal growth factor receptor 2 positive/estrogen receptor negative (HER2(+)/ER(-)).;We used immunohistochemical markers to subtype 1,149 invasive breast cancer patients (518 African American, 631 white) in the Carolina Breast Cancer Study, a population-based study of women diagnosed with breast cancer. Vital status was determined through 2006 using the National Death Index, with median follow-up of 9 years.;Cancer subtypes luminal A, luminal B, basal-like, and HER2(+)/ER(-) were distributed as 64%, 11%, 11%, and 5% for whites, and 48%, 8%, 22%, and 7% for African Americans, respectively. Breast cancer mortality was higher for participants with HER2(+)/ER(-) and basal-like breast cancer compared with luminal A and B. African Americans had higher breast cancer-specific mortality than whites, but the effect of race was statistically significant only among women with luminal A breast cancer. However, when compared with the luminal A subtype within racial categories, mortality for participants with basal-like breast cancer was higher among whites (HR = 2.0, 95% CI: 1.2-3.4) than African Americans (HR = 1.5, 95% CI: 1.0-2.4), with the strongest effect seen in postmenopausal white women (HR = 3.9, 95% CI: 1.5-10.0).;Our results confirm the association of basal-like breast cancer with poor prognosis and suggest that basal-like breast cancer is not an inherently more aggressive disease in African American women compared with whites. Additional analyses are needed in populations with known treatment profiles to understand the role of tumor subtypes and race in breast cancer mortality, and in particular our finding that among women with luminal A breast cancer, African Americans have higher mortality than whites.",
        "Doc_title":"Intrinsic breast tumor subtypes, race, and long-term survival in the Carolina Breast Cancer Study.",
        "Journal":"Clinical cancer research : an official journal of the American Association for Cancer Research",
        "Do_id":"21169259",
        "Doc_ChemicalList":"Receptors, Estrogen;Receptors, Progesterone;ERBB2 protein, human;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Adult;Aged;Aged, 80 and over;Breast Neoplasms;Carcinoma;Case-Control Studies;Cause of Death;Cohort Studies;Continental Population Groups;Female;Follow-Up Studies;Humans;Menopause;Middle Aged;North Carolina;Receptor, ErbB-2;Receptors, Estrogen;Receptors, Progesterone;Survival Rate",
        "Doc_meshqualifiers":"classification;epidemiology;ethnology;mortality;classification;epidemiology;ethnology;mortality;metabolism;physiology;epidemiology;metabolism;metabolism;metabolism",
        "_version_":1605898809418711040},
      {
        "Doc_abstract":"It is recognized that hormone receptors and HER2 are important as prognostic factors in breast cancer. Moreover, it seems likely that hormone receptors and HER2 are important predictive factors for response to chemotherapy in breast cancer. We report a case of bilateral T4 breast cancer with different expression for hormone receptors and HER2. The patient was a 67-year-old woman. The Stage was T4bN2aM0, respectively. The right tumor was negative for hormone receptors and positive for HER2, while the left tumor was positive for hormone receptors and negative for HER2. After primary chemotherapy with FEC, paclitaxel and docetaxel, the efficacy for the right local tumor was judged as cCR. However, brain metastases appeared and were treated by resection and radiation. The efficacy for the left tumor was judged as PR. Modified radical mastectomy with axillary lymph node dissection was performed. The patient has survived with no recurrence.",
        "Doc_title":"[A case of bilateral T4 breast cancer with different responses to chemotherapy].",
        "Journal":"Gan to kagaku ryoho. Cancer & chemotherapy",
        "Do_id":"18931591",
        "Doc_ChemicalList":"Antineoplastic Agents;Biomarkers, Tumor",
        "Doc_meshdescriptors":"Aged;Antineoplastic Agents;Biomarkers, Tumor;Breast Neoplasms;Combined Modality Therapy;Female;Humans;Tomography, X-Ray Computed",
        "Doc_meshqualifiers":"therapeutic use;blood;blood;diagnostic imaging;drug therapy;surgery",
        "_version_":1605775349015117824},
      {
        "Doc_abstract":"In addition to achieve breast conserving surgery after neoadjuvant chemotherapy, its indications are growing, especially in Her2 overexpressing and triple negative breast cancers owing to the emergence of new targeted therapies. Radiotherapy belongs to breast cancer management. However, some questions are still unresolved regarding nodes area irradiation after neoadjuvant chemotherapy. This short communication reviews indications of radiotherapy of node areas in breast cancer after neoadjuvant chemotherapy. ",
        "Doc_title":"[Which node area should be irradiated after neoadjuvant chemotherapy in breast cancer?].",
        "Journal":"Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique",
        "Do_id":"26004843",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"Breast Neoplasms;Chemotherapy, Adjuvant;Female;Humans;Lymphatic Irradiation;Neoadjuvant Therapy;Neoplasm Recurrence, Local",
        "Doc_meshqualifiers":"drug therapy;prevention & control;radiotherapy;surgery;methods;prevention & control",
        "_version_":1605784388586438656},
      {
        "Doc_abstract":"Due to its rarity, male breast cancer (mBC) remains an inadequately characterized disease, and current evidence for treatment derives from female breast cancer (FBC).;We retrospectively analyzed the clinicopathological characteristics, treatment patterns, and outcomes of mBCs treated from 2000 to 2013.;From a total of 97 patients with mBC, 6 (6.2%) with ductal in situ carcinoma were excluded, and 91 patients with invasive carcinoma were analyzed. Median age was 65 years (range: 25-87 years). Estrogen receptors were positive in 88 patients (96.7%), and progesterone receptors were positive in 84 patients (92.3%). HER-2 was overexpressed in 13 of 85 patients (16%). Median follow-up was 51.5 months (range: 0.5-219.3 months). Five-year progression-free survival (PFS) was 50%, whereas overall survival (OS) was 68.1%. Patients with grades 1 and 2 presented 5-year PFS of 71% versus 22.5% for patients with grade 3 disease; 5-year OS was 85.7% for patients with grades 1 and 2 versus 53.3% of patients with grade 3. Ki-67 score >20% and adjuvant chemotherapy were also statistically significant for OS on univariate analyses. Twenty-six of 87 patients (29.8%) experienced recurrent disease and 16 of 91 patients (17.6%) developed a second neoplasia.;Male breast cancer shows different biological patterns compared with FBC, with higher positive hormone-receptor status and lower HER-2 overexpression. Grade 3 and Ki-67 >20% were associated with shorter OS.;There is little evidence that prognostic features established in female breast cancer, such as grading and Ki-67 labeling index, could be applied to male breast cancer as well. This study found that grade 3 was associated with shorter overall survival and a trend for Ki-67 >20%; this could help in choosing the best treatment option in the adjuvant setting. Many questions remain regarding the impact of HER-2 positivity on survival and treatment with adjuvant anti-HER-2 therapy. Regarding metastatic male breast cancer, the results suggest that common regimens of chemo-, endocrine and immunotherapy used in female breast cancer are safe and effective for men. Male breast cancer patients show a higher incidence of second primary tumors, especially prostate and colon cancers and should therefore be carefully monitored.",
        "Doc_title":"Clinicopathological and Immunohistochemical Characteristics in Male Breast Cancer: A Retrospective Case Series.",
        "Journal":"The oncologist",
        "Do_id":"25948676",
        "Doc_ChemicalList":"Receptors, Estrogen;Receptors, Progesterone;ERBB2 protein, human;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Adult;Aged;Aged, 80 and over;Breast Neoplasms, Male;Carcinoma, Ductal, Breast;Carcinoma, Intraductal, Noninfiltrating;Disease-Free Survival;Female;Gene Expression Regulation, Neoplastic;Humans;Male;Middle Aged;Neoplasms, Second Primary;Prognosis;Receptor, ErbB-2;Receptors, Estrogen;Receptors, Progesterone;Retrospective Studies",
        "Doc_meshqualifiers":"classification;drug therapy;genetics;pathology;drug therapy;genetics;pathology;drug therapy;genetics;pathology;drug therapy;genetics;pathology;biosynthesis;genetics;genetics;genetics",
        "_version_":1605746485337522176},
      {
        "Doc_abstract":"MicroRNAs (miRNAs) are non-coding RNAs regulating gene expression post-transcriptionally. We have characterized the role of miRNAs in regulating the human epidermal growth factor receptor 2 (HER2)-pathway in breast cancer. We performed miRNA gain-of-function assays by screening two HER2 amplified cell lines (KPL-4 and JIMT-1) with a miRNA mimic library consisting of 810 human miRNAs. The levels of HER2, phospho-AKT, phospho-ERK1/2, cell proliferation (Ki67) and apoptosis (cPARP) were analyzed with reverse-phase protein arrays. Rank product analyses identified 38 miRNAs (qÂ <Â 0.05) as inhibitors of HER2 signaling and cell growth, the most effective being miR-491-5p, miR-634, miR-637 and miR-342-5p. We also characterized miRNAs directly targeting HER2 and identified seven novel miRNAs (miR-552, miR-541, miR-193a-5p, miR-453, miR-134, miR-498, and miR-331-3p) as direct regulators of the HER2 3'UTR. We demonstrated the clinical relevance of the miRNAs and identified miR-342-5p and miR-744* as significantly down-regulated in HER2-positive breast tumors as compared to HER2-negative tumors from two cohorts of breast cancer patients (101 and 1302 cases). miR-342-5p specifically inhibited HER2-positive cell growth, as it had no effect on the growth of HER2-negative control cells inÂ vitro. Furthermore, higher expression of miR-342-5p was associated with better survival in both breast cancer patient cohorts. In conclusion, we have identified miRNAs which are efficient negative regulators of the HER2 pathway that may play a role inÂ vivo during breast cancer progression. These results give mechanistic insights in HER2 regulation which may open potential new strategies towards prevention and therapeutic inhibition of HER2-positive breast cancer. ",
        "Doc_title":"High-throughput screens identify microRNAs essential for HER2 positive breast cancer cell growth.",
        "Journal":"Molecular oncology",
        "Do_id":"24148764",
        "Doc_ChemicalList":"MicroRNAs;ERBB2 protein, human;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Breast;Breast Neoplasms;Cell Line, Tumor;Cell Proliferation;Female;Gene Expression Regulation, Neoplastic;Humans;MicroRNAs;Protein Array Analysis;Receptor, ErbB-2;Signal Transduction",
        "Doc_meshqualifiers":"metabolism;pathology;genetics;metabolism;pathology;genetics;metabolism;genetics;metabolism",
        "_version_":1605752261903908864},
      {
        "Doc_abstract":"Identification of metastatic potential of breast cancer cells is necessary for proper management of this disease. This work aimed to estimate likelihood of axillary lymph node (ALN) involvement in breast cancer patients based on human epidermal growth factor receptor 2 (HER2) expression. Primary tumors of 317 breast cancer patients were evaluated for estrogen receptor (ER), progesterone receptor (PR) and HER2 expression by immunohistochemistry. The validity of these molecules to predict ALN metastasis was measured statistically and compared to predictive effect of other clinicopathological parameters. ER, PR and HER2 expression was detected in 75.7%, 73.2% and 19.9% of tumors, respectively. Although increased tumor size and grade, ER and PR negativity and HER2 positivity were strong indicators of ALN metastasis on univariate analyses, only tumor size and HER2 expression were independent predictors of ALN involvement on multivariate analysis. ROC curve showed a strong validity of the model using these two parameters to predict ALN status (AUC 0.86; p<0001). HER2-rich, luminal B and triple negative tumors had 6.87, 6.32 and 3.58 times increased risk of metastasis compared to luminal A tumors; respectively. HER2 expression in pT1 and pT2 tumors raised the risk of ALN metastasis by 7.7 and 7.6 times, respectively and grade 1 and 2 tumors that expressed HER2 were 16.0 and 7.8 times more likely to have ALN metastasis, respectively. To conclude, HER2 expression is associated with a significant rise of metastatic potential of breast cancer cells and could be a strong indicator of regional and distant metastasis of breast cancer.",
        "Doc_title":"HER2 expression is a strong independent predictor of nodal metastasis in breast cancer.",
        "Journal":"Journal of the Egyptian National Cancer Institute",
        "Do_id":"27756653",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605821129170092032},
      {
        "Doc_abstract":"Breast cancer prognosis and breast cancer molecular subtype vary by race/ethnicity. We determined whether the distribution of breast cancer subtypes varies among different Asian ethnic groups. Using immunohistochemical surrogates for the four molecularly defined breast cancer subtypes, we characterized breast cancer subtype for 346 Asian subjects treated at two New York City institutions. We found that Chinese and Japanese had a higher proportion of good-prognosis luminal A cancers (66.7 and 80.0%, respectively) compared to Filipinos and Koreans (48.5 and 47.1%) (P = 0.001). Filipinos had a higher proportion of HER-2/neu positive cancers (45.6%) compared to other ethnic groups (23.6%) (P = 0.002).Koreans had a higher proportion of triple negative cancers(23.5%) compared to other ethnic groups (7.5%) (P =0.06). The results suggest that differences exist in breast cancer tumor biology among distinct Asian ethnic groups and have implications for cancer care and research. Future studies of breast cancer in Asian-Americans should distinguish among the different ethnic groups.",
        "Doc_title":"Breast cancer subtypes in Asian-Americans differ according to Asian ethnic group.",
        "Journal":"Journal of immigrant and minority health",
        "Do_id":"22286607",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"Adult;Asian Americans;Breast Neoplasms;China;Female;Genes, erbB-2;Humans;Japan;Middle Aged;Neoplasm Staging;New York City;Philippines;Republic of Korea",
        "Doc_meshqualifiers":"statistics & numerical data;ethnology;genetics;pathology;ethnology;ethnology;ethnology;ethnology",
        "_version_":1605832496668213248},
      {
        "Doc_abstract":"We review recent advances leading to a new understanding of immunology of breast cancer with its potential clinical applications.;With the exception of antibody-based HER2 targeting, immunotherapy in breast cancer has largely been an unsatisfying experience. To improve the efficacy of breast cancer immunotherapeutics, a better understanding of the relation between innate and adaptive immune responses, of the immune escape mechanisms, the discovery of mechanisms underlying immunological tolerance, and the acknowledgment of the importance of both cell-mediated and humoral adaptive immunity for the control of tumor growth are needed.;Cancer takes advantage of the ability to hide from the immune system by exploiting a series of immune escape mechanisms. Among these mechanisms are the hijackings of immune cell-intrinsic checkpoints that are induced on T-cell activation. Blockade of these checkpoints - cytotoxic T-lymphocyte-associated antigen 4 or the programmed death 1 receptor - recently provided the first evidence of activity of an immune-modulation approach in the treatment of solid tumors. The future frontier in the immunotherapeutics of breast cancer requires identification of predictive factors. The immune system remembers what it targets, so once the system is correctly activated, it may mediate a long-lasting tumor response.",
        "Doc_title":"Immunotherapeutics for breast cancer.",
        "Journal":"Current opinion in oncology",
        "Do_id":"24076578",
        "Doc_ChemicalList":"Antigens, Neoplasm;CTLA-4 Antigen;CTLA4 protein, human;Cancer Vaccines;DNA-Binding Proteins;PDCD1 protein, human;Programmed Cell Death 1 Receptor",
        "Doc_meshdescriptors":"Antigens, Neoplasm;Breast Neoplasms;CTLA-4 Antigen;Cancer Vaccines;DNA-Binding Proteins;Female;Humans;Immunotherapy;Molecular Targeted Therapy;Programmed Cell Death 1 Receptor;T-Lymphocytes, Cytotoxic;Tumor Escape",
        "Doc_meshqualifiers":"immunology;immunology;pathology;therapy;drug effects;immunology;therapeutic use;immunology;methods;trends;methods;drug effects;immunology;drug effects;immunology;immunology",
        "_version_":1605812610962292736},
      {
        "Doc_abstract":"The HER2/neu proto-oncogene encodes a 185-kd transmembrane receptor with tyrosine kinase activity. Amplification of HER2 with overexpression of the p185HER2 receptor occurs in 20%-30% of breast cancers and has been established as an independent prognostic factor in numerous studies. Increasing evidence suggests that HER2 may be a predictive marker for response to chemotherapy and hormonal therapy. HER2 overexpression has provided a new target in breast cancer therapy, as evidenced by the development of trastuzumab (Herceptin(R)), a monoclonal antibody targeted against HER2. Detection of HER2 in the clinical setting is performed by immunohistochemistry or fluorescence in situ hybridization in tissue, and by detection of the shed extracellular domain in serum or plasma. Differences in methodology, reagents, and scoring systems have led to varying results in different patient cohorts, contributing to the debate on the role of HER2 as a prognostic and predictive factor. This review focuses on the prognostic and predictive value of serum HER2 detection in the management of HER2-positive breast cancer.",
        "Doc_title":"The HER2 extracellular domain as a prognostic and predictive factor in breast cancer.",
        "Journal":"Clinical breast cancer",
        "Do_id":"12123536",
        "Doc_ChemicalList":"Receptor, ErbB-2",
        "Doc_meshdescriptors":"Breast Neoplasms;Extracellular Space;Female;Humans;Outcome Assessment (Health Care);Predictive Value of Tests;Prognosis;Receptor, ErbB-2",
        "Doc_meshqualifiers":"genetics;therapy;genetics;genetics",
        "_version_":1605806869709848576},
      {
        "Doc_abstract":"MicroRNAs regulate numerous aspects of normal and pathologic cellular processes, including cancer. Breast cancer is a heterogeneous form of cancer that is derived from mammary epithelial cells. This review discusses the involvement of microRNAs in the regulation of normal mammary epithelial stem cells, their differentiation into basal and luminal phenotypes, and their control of breast cancer stem cells, also referred to as tumor-initiating cells. In the second section, we summarize the findings of differential microRNA expression in normal versus breast tumor tissue and among the various subtypes of breast cancer (primarily luminal, basal-like, and HER2). In the third and fourth sections of the review, specific mRNA targets of microRNAs in breast cancer are discussed, including those encoding the estrogen receptor-alpha and epidermal growth factor receptor, as well as survival, tumor suppressor, and cell-cycle-related proteins. Finally, the involvement of microRNAs in the promotion and suppression of breast cancer metastasis is reviewed. The studies presented herein provide a rationale for the design of therapeutic agents that target specific microRNAs in the treatment of breast cancer. Hopefully, this review will provide an impetus for more studies on the role of microRNAs in the regulation of normal mammary gland development and function.",
        "Doc_title":"Involvement of microRNAs in breast cancer.",
        "Journal":"Seminars in reproductive medicine",
        "Do_id":"18951334",
        "Doc_ChemicalList":"MicroRNAs;EGFR protein, human;Receptor, Epidermal Growth Factor",
        "Doc_meshdescriptors":"Adult Stem Cells;Animals;Breast Neoplasms;Cell Survival;Female;Gene Expression Regulation, Neoplastic;Humans;Mammary Glands, Human;MicroRNAs;Models, Biological;Neoplasm Metastasis;Neoplastic Stem Cells;Receptor, Epidermal Growth Factor;Signal Transduction",
        "Doc_meshqualifiers":"metabolism;genetics;pathology;genetics;cytology;genetics;metabolism;physiology;metabolism;pathology;physiology;genetics;physiology",
        "_version_":1605818642645123073},
      {
        "Doc_abstract":"Continued use of trastuzumab in PTEN-deficient HER2+ breast cancer induces the epithelial-to-mesenchymal transition (EMT), transforms HER2+ to triple negative breast cancer, and expands breast cancer stem cells (BCSCs). Using cancer cell lines with two distinct states, epithelial and mesenchymal, we identified novel targets during EMT in PTEN-deficient trastuzumab-resistant breast cancer. Differential gene expression and distinct responses to a small molecule in BT474 (HER2+ trastuzumab-sensitive) and the PTEN-deficient trastuzumab-resistant derivative (BT474-PTEN-LTT) provided the selection tools to identify targets during EMT. siRNA knockdown and small molecule inhibition confirmed MEOX1 as one of the critical molecular targets to regulate both BCSCs and mesenchymal-like cell proliferation. MEOX1 was associated with poor survival, lymph node metastasis, and stage of breast cancer patients. These findings suggest that MEOX1 is a clinically relevant novel target in BCSCs and mesenchymal-like cancer cells in PTEN-deficient trastuzumab resistant breast cancer and may serve as target for future drug development.",
        "Doc_title":"Novel cancer stem cell targets during epithelial to mesenchymal transition in PTEN-deficient trastuzumab-resistant breast cancer.",
        "Journal":"Oncotarget",
        "Do_id":"27285982",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605795423782436864},
      {
        "Doc_abstract":"We aimed to identify, through a review of the literature, candidate genes for a prospective predictive chemosensitivity test in patients with breast cancer.;Papers demonstrating an association between gene alterations in tumor tissue and clinical chemosensitivity in breast cancer patients were selected by Medline searches. We calculated odds ratios (ORs) and their 95% confidence intervals (CIs) of response rates for patients who had tumors with or without gene alteration. Combined ORs and CIs were estimated using the DerSimonian-Laird method.;A total of 18 genes were evaluated for association with clinical chemosensitivity in 6378 patients registered in 69 studies. The median (range) number of patients in each study was 73 (29-319). Overexpression of ABCB1 (P-glycoprotein) was associated with poor responses to first-line chemotherapy (combined OR [CI], 0.16 [0.05-0.59]; n = 322). Overexpression and amplification of TOP2A (topoisomerase II-alfa) were more frequently observed in patients who responded to first-line chemotherapy (combined OR [CI], 2.73 [1.02-7.27]; n = 323). Overexpression of ERBB2 (c-erbB2) was associated with favorable responses in patients treated with both first-line anthracycline-based chemotherapy and second-line taxane-based chemotherapy (combined ORs [CIs], 1.60 [1.19-2.17]; n = 1807 and 2.24 [1.06-4.74]; n = 259, respectively). BCL2 overexpression was associated with resistance to first-line chemotherapy (combined OR [CI], 0.44 [0.21-0.91]; n = 816).;ABCB1, TOP2A, ERBB2, and BCL2 were good candidates for future clinical trials of predictive chemosensitivity tests in patients with breast cancer.",
        "Doc_title":"A literature review of molecular markers predictive of clinical response to cytotoxic chemotherapy in patients with breast cancer.",
        "Journal":"International journal of clinical oncology",
        "Do_id":"19390941",
        "Doc_ChemicalList":"ABCB1 protein, human;Antigens, Neoplasm;DNA-Binding Proteins;P-Glycoprotein;P-Glycoproteins;DNA Topoisomerases, Type II;DNA topoisomerase II alpha",
        "Doc_meshdescriptors":"Antigens, Neoplasm;Breast Neoplasms;DNA Topoisomerases, Type II;DNA-Binding Proteins;Drug Resistance, Neoplasm;Female;Genes, bcl-2;Genes, erbB-2;Genes, p53;Humans;P-Glycoprotein;P-Glycoproteins",
        "Doc_meshqualifiers":"genetics;drug therapy;genetics;genetics;genetics;genetics",
        "_version_":1605898669745242112},
      {
        "Doc_abstract":"The link between BRCA1 dysfunction and basal-like breast cancer or triple-negative breast cancer (TNBC) has been suggested; however, the associations of other factors involved in the Fanconi anemia (FA)/BRCA pathway with the pathogenesis of basal-like breast cancer remain unidentified. FANCF protein is a component of the FA core complex. The methylation of CpG islands in the FANCF gene plays an important role in occurrence of ovarian cancer and also is an important regulator of cisplatin sensitivity of ovarian cancer. The purpose of this study is to investigate the frequency of FANCF methylation, and to discuss its involvement in the pathogenesis of TNBC and its potency as a predictor of cisplatin sensitivity for breast cancer.;The methylation of the FANCF gene promoter was investigated, using methylation-specific PCR, in genomic DNA of 99 invasive breast carcinoma specimens obtained from Japanese patients.;FANCF methylation was recognized in only 4 of 99 cases (4.0%). No significant correlation was found between FANCF methylation and the expression of ER, PR, HER2, and TNBC.;FANCF methylation is a rare event in Japanese primary invasive breast cancer. This suggests it is not involved in the pathogenesis of TNBC, and it could not be used as a predictor of cisplatin sensitivity in breast cancer.",
        "Doc_title":"Low incidence of methylation of the promoter region of the FANCF gene in Japanese primary breast cancer.",
        "Journal":"Breast cancer (Tokyo, Japan)",
        "Do_id":"19813073",
        "Doc_ChemicalList":"FANCF protein, human;Fanconi Anemia Complementation Group F Protein;Receptors, Estrogen",
        "Doc_meshdescriptors":"Asian Continental Ancestry Group;Breast Neoplasms;DNA Methylation;Fanconi Anemia Complementation Group F Protein;Female;Humans;Promoter Regions, Genetic;Receptors, Estrogen",
        "Doc_meshqualifiers":"chemistry;genetics;genetics;analysis",
        "_version_":1605880888877383680},
      {
        "Doc_abstract":"The HER2 gene and its role in pathogenicity in human breast cancer were detected in the 1980s. Trastuzumab is a monoclonal antibody directed against the HER2 membrane receptor. The aim of this article is to describe chemotherapy-trastuzumab combinations that have been evaluated in patients with HER2-positive metastatic breast cancer, and to define the possible standards and options.",
        "Doc_title":"What is the best choice of partner chemotherapy with trastuzumab for metastatic breast cancer?",
        "Journal":"Expert review of anticancer therapy",
        "Do_id":"22316367",
        "Doc_ChemicalList":"Antibodies, Monoclonal, Humanized;ERBB2 protein, human;Receptor, ErbB-2;Trastuzumab",
        "Doc_meshdescriptors":"Animals;Antibodies, Monoclonal, Humanized;Antineoplastic Combined Chemotherapy Protocols;Breast Neoplasms;Female;Humans;Neoplasm Metastasis;Randomized Controlled Trials as Topic;Receptor, ErbB-2;Trastuzumab",
        "Doc_meshqualifiers":"pharmacology;therapeutic use;administration & dosage;pharmacology;drug therapy;pathology;methods;antagonists & inhibitors",
        "_version_":1605809339267809280},
      {
        "Doc_abstract":"A significant proportion of breast cancers with HER2 amplification have simultaneous amplification of topoisomerase II-alpha (topoII). Amplification of HER2 and topoII was assayed using a novel chromogenic in situ hybridisation (CISH) method. HER2 and topoII amplification status and the response to preoperative doxorubicin chemotherapy were analysed in 67 locally advanced breast cancer patients. Response to chemotherapy was increased in the cases with coamplification of HER2 and topoII (18/19), whereas the response rate was significantly decreased in the cases without HER2 and topoII amplification (17/36). The 12 cases with HER2 amplification alone showed an intermediate response rate (9/12). The findings of the current study indicate that topoII amplification may play a role in determining chemosensitivity of breast cancers to doxorubicin chemotherapy.",
        "Doc_title":"Topoisomerase II-alpha (topoII) and HER2 amplification in breast cancers and response to preoperative doxorubicin chemotherapy.",
        "Journal":"European journal of cancer (Oxford, England : 1990)",
        "Do_id":"12628842",
        "Doc_ChemicalList":"Antineoplastic Agents;Doxorubicin;Receptor, ErbB-2;DNA Topoisomerases, Type II",
        "Doc_meshdescriptors":"Adult;Aged;Antineoplastic Agents;Breast Neoplasms;DNA Topoisomerases, Type II;Doxorubicin;Female;Gene Amplification;Genes, erbB-2;Humans;Middle Aged;Receptor, ErbB-2",
        "Doc_meshqualifiers":"therapeutic use;drug therapy;enzymology;genetics;metabolism;therapeutic use;genetics;genetics",
        "_version_":1605897096496414720},
      {
        "Doc_abstract":"The present study aimed to determine the association between levels of the gender hormones, follicle-stimulating hormone (FSH), luteinizing hormone (LH), progesterone (P) and prolactin (PRL), and two breast cancer molecular markers, human epidermal growth factor receptor 2 (Her-2) and Ki67, in post-menopausal patients with breast cancer. A retrospective study of the serum hormone levels of FSH, LH, P and PRL and the expression status of Her-2 and Ki67 was performed using 187 post-menopausal females with breast cancer. Her-2",
        "Doc_title":"Serum follicle-stimulating hormone level is associated with human epidermal growth factor receptor type 2 and Ki67 expression in post-menopausal females with breast cancer.",
        "Journal":"Oncology letters",
        "Do_id":"24137476",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605853130558275584},
      {
        "Doc_abstract":"ErbB2 over-expression is detected in approximately 25% of invasive breast cancers and is strongly associated with poor patient survival. We have previously demonstrated that p130Cas adaptor is a crucial mediator of ErbB2 transformation. Here, we analysed the molecular mechanisms through which p130Cas controls ErbB2-dependent invasion in three-dimensional cultures of mammary epithelial cells. Concomitant p130Cas over-expression and ErbB2 activation enhance PI3K/Akt and Erk1/2 MAPK signalling pathways and promote invasion of mammary acini. By using pharmacological inhibitors, we demonstrate that both signalling cascades are required for the invasive behaviour of p130Cas over-expressing and ErbB2 activated acini. Erk1/2 MAPK and PI3K/Akt signalling triggers invasion through distinct downstream effectors involving mTOR/p70S6K and Rac1 activation, respectively. Moreover, in silico analyses indicate that p130Cas expression in ErbB2 positive human breast cancers significantly correlates with higher risk to develop distant metastasis, thus underlying the value of the p130Cas/ErbB2 synergism in regulating breast cancer invasion. In conclusion, high levels of p130Cas favour progression of ErbB2-transformed cells towards an invasive phenotype.",
        "Doc_title":"p130Cas promotes invasiveness of three-dimensional ErbB2-transformed mammary acinar structures by enhanced activation of mTOR/p70S6K and Rac1.",
        "Journal":"European journal of cell biology",
        "Do_id":"20961652",
        "Doc_ChemicalList":"BCAR1 protein, human;Crk-Associated Substrate Protein;RAC1 protein, human;MTOR protein, human;TOR Serine-Threonine Kinases;Receptor, ErbB-2;Oncogene Protein v-akt;Ribosomal Protein S6 Kinases, 70-kDa;Mitogen-Activated Protein Kinases;rac1 GTP-Binding Protein",
        "Doc_meshdescriptors":"Breast;Breast Neoplasms;Cell Adhesion;Cell Line, Tumor;Cell Transformation, Neoplastic;Crk-Associated Substrate Protein;Enzyme Activation;Female;Humans;Imaging, Three-Dimensional;MAP Kinase Signaling System;Mitogen-Activated Protein Kinases;Neoplasm Invasiveness;Oncogene Protein v-akt;Receptor, ErbB-2;Ribosomal Protein S6 Kinases, 70-kDa;TOR Serine-Threonine Kinases;rac1 GTP-Binding Protein",
        "Doc_meshqualifiers":"metabolism;pathology;genetics;metabolism;pathology;physiology;metabolism;pathology;biosynthesis;metabolism;metabolism;metabolism;biosynthesis;genetics;metabolism;genetics;metabolism;metabolism;metabolism",
        "_version_":1605766732744491008},
      {
        "Doc_abstract":"Her-2/neu-positive tumors account for approximately 20% of all breast cancer and these tumors carry poor prognosis. Trastuzumab and lapatinib are 2 agents that have gained FDA approval for treating Her-2/neu-positive breast cancer. Trastuzumab has been shown to improve all endpoints when added to chemotherapy compared to chemotherapy alone, both in the adjuvant and metastatic phases. The addition of lapatinib to capecitabine has recently been shown to improve time to progression in trastuzumab-refractory patients with unique activity against brain metastasis. In spite of their impressive results, a significant fraction of patients still develop either primary or secondary resistance, a fact that entails the discussion of possible mechanisms of resistance. Biomarkers including PTEN, p95HER2, IGF1R and others have been linked to response to Her-2/neu-targeting agents. In this article, we overview the Her-2/neu signaling pathways and how a better understanding of the different molecular aspects of this oncogene could serve in optimizing the use of Her-2/neu-targeting agents. We also discuss the preclinical and clinical data of these biomarkers that may guide clinicians in choosing the right drug whenever possible.",
        "Doc_title":"Targeting Her-2/neu in breast cancer: as easy as this!",
        "Journal":"Oncology",
        "Do_id":"18708732",
        "Doc_ChemicalList":"Antibodies, Monoclonal;Antibodies, Monoclonal, Humanized;Antineoplastic Agents;Quinazolines;lapatinib;Receptor, ErbB-2;Trastuzumab",
        "Doc_meshdescriptors":"Antibodies, Monoclonal;Antibodies, Monoclonal, Humanized;Antineoplastic Agents;Breast Neoplasms;Humans;Quinazolines;Receptor, ErbB-2;Trastuzumab",
        "Doc_meshqualifiers":"therapeutic use;therapeutic use;drug therapy;metabolism;therapeutic use;antagonists & inhibitors;metabolism",
        "_version_":1605818799052816386},
      {
        "Doc_abstract":"Preclinical studies have shown that human epidermal growth factor receptor 2 (HER2) status is associated with resistance to radiotherapy (RT). In this study, we evaluated the overall survival of a T1N0M0 breast cancer cohort in Korea according to the use of RT and the HER2 status.;We analyzed data collected from 11,552 patients with invasive breast cancer who were enrolled in the Korean Breast Cancer Society Registration Program between 1999 and 2007. Data on the TNM stage, estrogen receptor status, progesterone receptor status, HER2 status, operation method, and the use of RT were analyzed.;The median follow-up period was 51 months. A significant improvement in overall survival after RT was observed only in the HER2(-) group. In this group, the 10-year overall survival rate was 95.5% for patients who did not receive RT and 96.3% for patients who received RT (p=0.037). In contrast, in the HER2(+) group, RT was not associated with a survival benefit (p=0.887). Multivariate analysis showed that RT was significantly associated with a reduction in mortality in the HER2(-) group (hazard ratio, 0.738; 95% confidence interval, 0.549-0.993; p=0.045).;We found that postoperative RT was not associated with a survival benefit in HER2(+) breast cancer patients, suggesting that HER2(+) breast cancers could be RT resistant.",
        "Doc_title":"Association of Human Epidermal Growth Factor Receptor 2 with Radiotherapy Resistance in Patients with T1N0M0 Breast Cancer.",
        "Journal":"Journal of breast cancer",
        "Do_id":"24155755",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605799600711532544},
      {
        "Doc_abstract":"Human reovirus can replicate and induce tumor cell lysis in several cancer types with an activated Ras signaling pathway. The aim of this study was to investigate the oncolytic effect of reovirus against breast cancer cells, and clarify the relationship between the susceptibility to reovirus and HER2 expression, which is associated with the Ras signaling pathway. Reovirus (serotype 3), 6 human breast cancer cell lines and normal mammary gland epithelial cell line were used in this study. The mRNA expression of HER2 receptor was examined by RT-PCR, and the protein of HER2 and activated Ras protein were examined by a Western blot analysis. In vitro, the cytopathic effects, viral protein synthesis, and cell viability on infection by reovirus were examined. Reovirus can infect all the 6 examined cancer cell lines, but the control cell line was not susceptible to the reovirus infection. The cytopathic effect appeared from day 1 after infection, and a 50% or greater cytotolysis was demonstrated at day 7 after infection. The Ras activities in all examined cell lines were higher than those in the control cell line. No relationship was observed in the susceptibility to the reovirus and HER2 expression. The increased Ras activity itself, regardless of the HER2 expression, may therefore play an important role in the susceptibility to reovirus of breast cancer cells. As a result, breast cancer may thus become a candidate target for oncolytic reovirus therapy.",
        "Doc_title":"Efficacy of oncolytic reovirus against human breast cancer cells.",
        "Journal":"Oncology reports",
        "Do_id":"18497942",
        "Doc_ChemicalList":"RNA, Messenger;ERBB2 protein, human;Receptor, ErbB-2;ras Proteins",
        "Doc_meshdescriptors":"Blotting, Western;Breast Neoplasms;Cell Survival;Female;Humans;Oncolytic Virotherapy;RNA, Messenger;Receptor, ErbB-2;Reoviridae;Reverse Transcriptase Polymerase Chain Reaction;Signal Transduction;Tumor Cells, Cultured;ras Proteins",
        "Doc_meshqualifiers":"metabolism;pathology;therapy;genetics;metabolism;metabolism;genetics;metabolism",
        "_version_":1605763853562413056},
      {
        "Doc_abstract":"Epidemiological and animal model studies have suggested that non-steroidal anti-inflammatory drugs (NSAIDs) can act as chemopreventive agents. The cyclooxygenase-2 (COX-2) inhibitor nimesulide shows anti-cancer effect in different type of cancers. In the current study, five breast carcinoma cell lines were used to explore the anti-cancer mechanisms of a nimesulide derivative compound 76. The compound dose dependently suppressed SKBR-3, BT474 and MDA-MB-453 breast cancer cell proliferation with IC(50) of 0.9microM, 2.2microM and 4.0microM, respectively. However, it needs much higher concentrations to inhibit MCF-7 and MDA-MB-231 breast cancer cell growth with IC(50) at 22.1microM and 19.6microM, respectively. Further investigation reveals that compound 76 induced apoptosis in SKBR-3 and BT474 cells. Since these cells are Her2 overexpressing cells, the Her2 intracellular signaling pathways were examined after the treatment. There was no significant changing of kinase activity. However, the cytochrome c release assay indicated that the apoptosis induced by the compound was mediated by the mitochondria. These results suggest that compound 76 selectively induce apoptosis in Her2 overexpressing breast cancer cells through the mitochondria, and could be used as a lead to design more potent derivatives.",
        "Doc_title":"A COX-2 inhibitor nimesulide analog selectively induces apoptosis in Her2 overexpressing breast cancer cells via cytochrome c dependent mechanisms.",
        "Journal":"Biochemical pharmacology",
        "Do_id":"19428334",
        "Doc_ChemicalList":"Anti-Inflammatory Agents, Non-Steroidal;Cyclooxygenase 2 Inhibitors;Sulfonamides;Cytochromes c;Receptor, ErbB-2;nimesulide",
        "Doc_meshdescriptors":"Anti-Inflammatory Agents, Non-Steroidal;Apoptosis;Breast Neoplasms;Cell Line, Tumor;Cell Proliferation;Cyclooxygenase 2 Inhibitors;Cytochromes c;Female;Humans;Inhibitory Concentration 50;Mitochondria;Receptor, ErbB-2;Sulfonamides",
        "Doc_meshqualifiers":"pharmacology;drug effects;drug therapy;pathology;drug effects;pharmacology;metabolism;drug effects;genetics;pharmacology",
        "_version_":1605795460772003840},
      {
        "Doc_abstract":"The ATP-binding cassette (ABC) of active transporters comprises a group of proteins that which facilitate efflux of anticancer drugs from cancer cells. We focused on the gene amplification and protein expression of ABCC3 (also known as MRP3) in breast cancer cell lines and clinical tumor samples. Fluorescence and chromogenic in situ hybridization, using an ABCC3-specific probe, was used to analyze 11 breast cancer cell lines and 112 clinical tumor samples. The results of ABCC3 were correlated with the amplification status of HER2 and topoisomerase II alpha (TOP2A), which are located close to ABCC3 at 17q12-q21. Immunohistochemistry was used to assess ABCC3 protein overexpression. Of the cell lines studied 6 HER2-positive lines and 1 HER2-negative line exhibited amplification of ABCC3. In the HER-2-negative clinical tumor samples, only 4/55 (7.3%) exhibited ABCC3 amplification. In the HER2-positive tumors, ABCC3 was amplified in 16/57 tumors (28.1%, P=0.0059). TOP2A did not exhibit any consistent coamplification pattern. ABCC3 (MRP3) protein overexpression was more common in tumors with gene amplification (P=0.069). In silico analysis of 804 breast cancers with matched gene expression and copy number microarray data revealed significant differences ABCC3 across the molecular subtypes. Specifically, increased ABCC3 mRNA and gene copy numbers were most prominent in HER2 amplified and/or HER2-enriched classified tumors. Moreover, differential ABCC3 mRNA levels were found within the HER-2 amplified subset when stratified by the estrogen receptor status. We conclude that ABCC3 is frequently amplified and overexpressed in HER2-positive breast cancer, and something that warrants further studies correlating the results with therapeutic outcome.",
        "Doc_title":"Amplification and overexpression of the ABCC3 (MRP3) gene in primary breast cancer.",
        "Journal":"Genes, chromosomes & cancer",
        "Do_id":"22585709",
        "Doc_ChemicalList":"Antigens, Neoplasm;DNA-Binding Proteins;Multidrug Resistance-Associated Proteins;multidrug resistance-associated protein 3;Receptor, ErbB-2;DNA Topoisomerases, Type II;DNA topoisomerase II alpha",
        "Doc_meshdescriptors":"Antigens, Neoplasm;Breast Neoplasms;Comparative Genomic Hybridization;DNA Topoisomerases, Type II;DNA-Binding Proteins;Female;Gene Amplification;Gene Dosage;Gene Expression Regulation, Neoplastic;Humans;Immunoenzyme Techniques;In Situ Hybridization, Fluorescence;Multidrug Resistance-Associated Proteins;Receptor, ErbB-2;Tumor Cells, Cultured",
        "Doc_meshqualifiers":"genetics;metabolism;genetics;metabolism;pathology;genetics;metabolism;genetics;metabolism;genetics;metabolism;genetics;metabolism",
        "_version_":1605826833838768128},
      {
        "Doc_abstract":"Breast cancer is no longer seen as a single disease but rather a multifaceted disease composed of distinct biological subtypes with diverse natural history, clinical, pathological, and molecular features. Recent attention has been directed at the molecular classification of breast cancer.;To evaluate the prognostic value of triple-negative subtype in stage II/III breast cancer and to define the role of clinical stage in prognosis of breast cancer.;We used the immunohistochemical technique to divide 255 cases of breast cancer, stages II and III, into four subtypes according to estrogen receptor/progesterone receptor and Her-2 expression.;Triple-negative subtype comprised 76.5% of the cases with 12.3% recurrence rate. Luminal A subtype also carried a poor outcome with 16.7% recurrence rate.;Triple-negative subtype has the worst overall and disease-free survival in stage II/III breast cancer. Clinical stage is still an independent prognostic factor in the breast cancers of all types.",
        "Doc_title":"The prognostic value of triple negative in stage II/III breast cancer.",
        "Journal":"Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners",
        "Do_id":"21422149",
        "Doc_ChemicalList":"Receptors, Estrogen;Receptors, Progesterone;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Adult;Aged;Breast Neoplasms;Cohort Studies;Disease-Free Survival;Female;Follow-Up Studies;Gene Expression Regulation, Neoplastic;Humans;Immunohistochemistry;Middle Aged;Neoplasm Recurrence, Local;Neoplasm Staging;Prognosis;Receptor, ErbB-2;Receptors, Estrogen;Receptors, Progesterone;Survival Rate;Young Adult",
        "Doc_meshqualifiers":"genetics;pathology;genetics;genetics;genetics",
        "_version_":1605742048620576768},
      {
        "Doc_abstract":"Although overexpression of human epidermal growth factor receptor 2 (HER2) protein, amplification of the gene or both are associated with poor prognosis in breast cancer, trastuzumab has clearly provided clinical benefits in metastatic breast cancer, adjuvant treatment settings and primary systemic therapy. However, even in those HER2 overexpressors, the majority of patients who achieve an initial response generally acquire resistance within 1 year. Therefore, it is critical to elucidate the mechanism of resistance and to search for better combination treatments with chemotherapeutic agents or other novel modalities. Here, we discuss both clinical and preclinical data regarding these issues.",
        "Doc_title":"Improving the efficacy of trastuzumab in breast cancer.",
        "Journal":"Cancer science",
        "Do_id":"17428260",
        "Doc_ChemicalList":"Antibodies, Monoclonal;Antibodies, Monoclonal, Humanized;Antineoplastic Agents;Receptor, ErbB-2;Trastuzumab",
        "Doc_meshdescriptors":"Antibodies, Monoclonal;Antibodies, Monoclonal, Humanized;Antineoplastic Agents;Breast Neoplasms;Chemotherapy, Adjuvant;Clinical Trials as Topic;Drug Resistance, Neoplasm;Humans;Neoadjuvant Therapy;Neoplasm Metastasis;Receptor, ErbB-2;Trastuzumab",
        "Doc_meshqualifiers":"pharmacology;therapeutic use;therapeutic use;drug therapy;pathology;metabolism",
        "_version_":1605845976410488832},
      {
        "Doc_abstract":"Predictors of intrinsic breast cancer subtypes, including the triple-negative (TN) subtype, are largely unknown. We evaluated whether anthropometrics, demographics, and reproductive history were associated with distinct breast cancer subtypes.;Invasive breast tumors from a population-based case-control study of 476 (116 black and 360 white) Atlanta women aged 20-54, diagnosed between 1990 and 1992, were centrally reviewed and immunohistochemically analyzed for estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2); then grouped [TN (ER-PR-HER2-); ER-PR-HER2+; ER/PR+HER2+; ER/PR+HER2- (case-only reference group)]. Data were from interviews and anthropometric measurements; adjusted odds ratios (OR) and 95% confidence intervals (CI) were estimated using logistic regression, including both case-only and case-control comparisons.;From the case-only analyses and compared with the ER/PR+HER2- subtype, women with TN tumors were more likely to be obese than normal/underweight [OR = 1.89 (95% CI = 1.22, 2.92)]. Regardless of HER2 status, ER-PR- tumors were associated with black race, young age at first birth, having a recent birth, and being overweight.;Distinct breast cancer subtypes have unique sociodemographic, anthropometric and reproductive characteristics and possibly different pathways for development.",
        "Doc_title":"The epidemiology of triple-negative breast cancer, including race.",
        "Journal":"Cancer causes & control : CCC",
        "Do_id":"19343511",
        "Doc_ChemicalList":"Receptors, Estrogen;Receptors, Progesterone;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Adult;African Americans;Breast Neoplasms;Case-Control Studies;Demography;European Continental Ancestry Group;Female;Humans;Middle Aged;Multivariate Analysis;Receptor, ErbB-2;Receptors, Estrogen;Receptors, Progesterone;Young Adult",
        "Doc_meshqualifiers":"classification;epidemiology;ethnology;analysis;analysis;analysis",
        "_version_":1605751298432434176},
      {
        "Doc_abstract":"With the growing knowledge of key cellular pathways in tumor induction and evolution, targeted therapies make up an increasing proportion of new drugs entering clinical testing. In the treatment of breast cancer, humanized antibodies have become a major option. The humanized monoclonal antibody trastuzumab (Herceptin); Genentech, Inc., CA, USA) for HER2-overexpressing, metastatic breast cancer, represents a successful agent associated with impressive survival benefits when combined with chemotherapy. Based on impressive results, trastuzumab will become a standard in the adjuvant treatment of HER2-overexpressing breast cancer. The role of trastuzumab in the neoadjuvant setting is promising, but must be further evaluated in large prospective, randomized trials. However, there is still a large proportion of patients overexpressing HER2 that do not respond to trastuzumab. Regarding this patient cohort, the optimal combination of trastuzumab with other agents needs further evaluation. In breast cancer lacking HER2 amplification, the role of the new antibody pertuzumab remains to be defined. The role of antibodies interfering with angiogenesis, tumor stroma or glycoproteins is of a preliminary nature and warrants further investigation. Here, an overview of humanized antibodies in human breast cancer is provided, with emphasis on the recent advances and future prospects in treating malignant breast cancer.",
        "Doc_title":"Potential use of humanized antibodies in the treatment of breast cancer.",
        "Journal":"Expert review of anticancer therapy",
        "Do_id":"16831078",
        "Doc_ChemicalList":"Antibodies, Monoclonal;Antibodies, Monoclonal, Humanized;Immunotoxins;Receptor, ErbB-2;Trastuzumab",
        "Doc_meshdescriptors":"Antibodies, Monoclonal;Antibodies, Monoclonal, Humanized;Breast Neoplasms;Clinical Trials as Topic;Female;Gene Amplification;Humans;Immunotherapy;Immunotoxins;Receptor, ErbB-2;Signal Transduction;Survival Analysis;Trastuzumab",
        "Doc_meshqualifiers":"therapeutic use;immunology;therapy;methods;therapeutic use;genetics;physiology",
        "_version_":1605742705747427328},
      {
        "Doc_abstract":"The clinical impact of the biological heterogeneity within HER2-positive (HER2+) breast cancer is not fully understood. Here, we evaluated the molecular features and survival outcomes of the intrinsic subtypes within HER2+ breast cancer.;We interrogated The Cancer Genome Atlas (n = 495) and Molecular Taxonomy of Breast Cancer International Consortium (METABRIC) datasets (n = 1730) of primary breast cancers for molecular data derived from DNA, RNA and protein, and determined intrinsic subtype. Clinical HER2 status was defined according to American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) guidelines or DNA copy-number aberration by single nucleotide polymorphism arrays. Cox models tested the prognostic significance of each variable in patients not treated with trastuzumab (n = 1711).;Compared with clinically HER2 (cHER2)-negative breast cancer, cHER2+ breast cancer had a higher frequency of the HER2-enriched (HER2E) subtype (47.0% vs 7.1%) and a lower frequency of Luminal A (10.7% vs 39.0%) and Basal-like (14.1% vs 23.4%) subtypes. The likelihood of cHER2-positivity in HER2E, Luminal B, Basal-like and Luminal A subtypes was 64.6%, 20.0%, 14.4% and 7.3%, respectively. Within each subtype, only 0.3% to 3.9% of genes were found differentially expressed between cHER2+ and cHER2-negative tumors. Within cHER2+ tumors, HER2 gene and protein expression was statistically significantly higher in the HER2E and Basal-like subtypes than either luminal subtype. Neither cHER2 status nor the new 10-subtype copy number-based classification system (IntClust) added independent prognostic value to intrinsic subtype.;When the intrinsic subtypes are taken into account, cHER2-positivity does not translate into large changes in the expression of downstream signaling pathways, nor does it affect patient survival in the absence of HER2 targeting.",
        "Doc_title":"Molecular features and survival outcomes of the intrinsic subtypes within HER2-positive breast cancer.",
        "Journal":"Journal of the National Cancer Institute",
        "Do_id":"25139534",
        "Doc_ChemicalList":"Antineoplastic Agents;Biomarkers, Tumor;ERBB2 protein, human;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Adult;Aged;Antineoplastic Agents;Biomarkers, Tumor;Breast Neoplasms;Confounding Factors (Epidemiology);DNA Copy Number Variations;Female;Gene Expression Regulation, Neoplastic;Humans;Kaplan-Meier Estimate;Middle Aged;Molecular Targeted Therapy;Polymorphism, Single Nucleotide;Receptor, ErbB-2;Signal Transduction",
        "Doc_meshqualifiers":"pharmacology;genetics;metabolism;genetics;metabolism;mortality;drug effects;genetics",
        "_version_":1605742742673031168},
      {
        "Doc_abstract":"By analyzing over 2000 samples from a randomized clinical trial, we have recently associated high levels of tumor-infiltrating lymphocytes with an excellent prognosis among triple negative breast cancer patients as well with improved clinical responses to immunogenic chemotherapy among patients bearing HER2 over-expression. These findings suggest that immunomodulation could represent a new approach to treat these aggressive breast cancer subtypes.",
        "Doc_title":"Tumor-infiltrating lymphocytes, breast cancer subtypes and therapeutic efficacy.",
        "Journal":"Oncoimmunology",
        "Do_id":"24073365",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605831554638020608},
      {
        "Doc_abstract":"Receptor status discordance, such as estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2) status between primary breast cancer and metastatic lesions has been reported. The aim of this study was to evaluate the biopsy of clinically diagnosed metastatic lesions and to determine the changes in hormonal receptor and HER2 status of the metastatic lesions.;Sixty-three patients with clinically diagnosed metastatic breast cancer underwent an excisional biopsy or core needle aspiration guided by computed tomography/ultrasound. ER, PR and HER2 were assessed by immunohistochemistry (IHC).;A total of 48 metastases (76.2%) and nine second primary malignancies (14.3%, seven primary lung cancers and two primary pancreatic cancers) were found. The discrepancies between ER, PR and HER2 status between the primary breast cancer and metastatic lesions were 14.6%, 16.7% and 8.3%, respectively. Six lesions (9.5%) were proved benign upon biopsy.;The biopsy of clinically suspicious metastatic lesions could histologically confirm the diagnosis of metastasis, evaluate discrepancies between ER, PR and HER2 status and exclude secondary malignancy, which might change the therapeutic strategy for breast cancer patients.",
        "Doc_title":"The importance of biopsy in clinically diagnosed metastatic lesions in patients with breast cancer.",
        "Journal":"World journal of surgical oncology",
        "Do_id":"24721777",
        "Doc_ChemicalList":"Biomarkers, Tumor;Receptors, Estrogen;Receptors, Progesterone;ERBB2 protein, human;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Adult;Aged;Biomarkers, Tumor;Biopsy, Large-Core Needle;Breast Neoplasms;Carcinoma, Ductal, Breast;Female;Follow-Up Studies;Humans;Immunoenzyme Techniques;Middle Aged;Neoplasm Metastasis;Neoplasm Staging;Prognosis;Receptor, ErbB-2;Receptors, Estrogen;Receptors, Progesterone;Retrospective Studies;Tomography, X-Ray Computed;Ultrasonography, Mammary",
        "Doc_meshqualifiers":"metabolism;metabolism;pathology;surgery;metabolism;secondary;surgery;metabolism;metabolism;metabolism",
        "_version_":1605774588727263232},
      {
        "Doc_abstract":"Human epidermal growth factor receptor (HER)-2 overexpression or amplification occurs in about 20% of all breast cancers and results in a worse prognosis. Nevertheless, anti-HER2 treatments have recently been developed, resulting in dramatic improvements in the clinical outcome of patients with HER2-positive breast cancer. Trastuzumab has shown efficacy in early and advanced breast cancer treatment and lapatinib is currently approved for the treatment of advanced disease. Other anti-HER2 agents are being investigated. Mechanisms of resistance to trastuzumab treatment include crosstalk with heterologous receptors and amplification of HER2 signalling; amplification of the phosphoinositide 3-kinase (PI3K)/AKT pathway; alteration in binding of trastuzumab to HER2; and loss of HER2 expression. Proposed mechanisms of resistance to lapatinib involve derepression and/or activation of compensatory survival pathways through increased PI3K/AKT or estrogen receptor (ER) signalling. Several strategies to overcome resistance to anti-HER2 treatment are in different phases of development and include treatment with pertuzumab, T-DM1 and mammalian target of rapamycin (mTOR) inhibitors.",
        "Doc_title":"Overcoming treatment resistance in HER2-positive breast cancer: potential strategies.",
        "Journal":"Drugs",
        "Do_id":"22686613",
        "Doc_ChemicalList":"Antibodies, Monoclonal, Humanized;Antineoplastic Agents;Quinazolines;Receptors, Estrogen;lapatinib;Phosphatidylinositol 3-Kinase;ERBB2 protein, human;Receptor, ErbB-2;Trastuzumab",
        "Doc_meshdescriptors":"Antibodies, Monoclonal, Humanized;Antineoplastic Agents;Breast Neoplasms;Drug Resistance, Neoplasm;Female;Humans;Phosphatidylinositol 3-Kinase;Quinazolines;Randomized Controlled Trials as Topic;Receptor, ErbB-2;Receptors, Estrogen;Signal Transduction;Trastuzumab",
        "Doc_meshqualifiers":"therapeutic use;therapeutic use;drug therapy;metabolism;metabolism;therapeutic use;metabolism;metabolism;drug effects",
        "_version_":1605818586957348864},
      {
        "Doc_abstract":"Triple-negative breast cancer is a subtype of breast cancer that is clinically negative for expression of estrogen and progesterone receptors (ER/PR) and HER2 protein. It is characterized by its unique molecular profile, aggressive behavior, distinct patterns of metastasis, and lack of targeted therapies. Although not synonymous, the majority of triple-negative breast cancers carry the \"basal-like\" molecular profile on gene expression arrays. The majority of BRCA1-associated breast cancers are triple-negative and basal-like; the extent to which the BRCA1 pathway contributes to the behavior of sporadic basal-like breast cancers is an area of active research. Epidemiologic studies illustrate a high prevalence of triple-negative breast cancers among younger women and those of African descent. Increasing evidence suggests that the risk factor profile differs between this subtype and the more common luminal subtypes. Although sensitive to chemotherapy, early relapse is common and a predilection for visceral metastasis, including brain metastasis, is seen. Targeted agents, including epidermal growth factor receptor (EGFR), vascular endothelial growth factor (VEGF), and poly (ADP-ribose) polymerase (PARP) inhibitors, are currently in clinical trials and hold promise in the treatment of this aggressive disease.",
        "Doc_title":"Understanding and treating triple-negative breast cancer.",
        "Journal":"Oncology (Williston Park, N.Y.)",
        "Do_id":"18980022",
        "Doc_ChemicalList":"Receptors, Estrogen;Receptors, Progesterone;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Breast Neoplasms;Female;Humans;Receptor, ErbB-2;Receptors, Estrogen;Receptors, Progesterone",
        "Doc_meshqualifiers":"metabolism;therapy;metabolism;metabolism;metabolism",
        "_version_":1605791827105939456},
      {
        "Doc_abstract":"Breast cancer is a heterogeneous disease that develops through a multistep process whose molecular basis remains poorly understood. The molecular mechanisms of breast cancer progression have been extensively studied using the MCF10 model. We summarized recent results on differential expression of proteins in the MCF10 cell series - MCF10A, MCF10AT1, MCF10DCIS.com and MCF10CA1a - and compared the ability of the latter 3 lines to form tumors in immunodeficient mice. In addition, we also investigated expression of several key signaling proteins in the MCF10 cell series corresponding to different stages of breast cancer progression. MCF10DCIS.com and MCF10CA1a cells were highly tumorigenic; MCF10CA1a cells showed more aggressive tumor growth than MCF10DCIS.com cells. HRAS-driven cancer initiation stage was accompanied by the increased expression of c-Myc, cyclin D1 and IGF-IR. Tumorigenic cell lines expressed higher levels of pErk, pAkt, Stat3 and Pak4 compared to nontumorigenic cells. The expression of CD44v, CD44v3, CD44v6, ERBB2, Cox2 and Smad4 correlated with the increased tumorigenicity of the MCF10 cell lines. The differences in expression of signaling proteins involved in breast cancer progression may provide new insight into the mechanisms of tumorigenesis and useful information for development of targeted therapeutics.",
        "Doc_title":"Differential Expression of Key Signaling Proteins in MCF10 Cell Lines, a Human Breast Cancer Progression Model.",
        "Journal":"Molecular and cellular pharmacology",
        "Do_id":"24558516",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605749516752912384},
      {
        "Doc_abstract":"Current studies indicate that triple negative breast cancer (TNBC), an aggressive breast cancer subtype, is associated with poor prognosis and an early pattern of metastasis. Emerging evidence suggests that MUC4 mucin is associated with metastasis of various cancers, including breast cancer. However, the functional role of MUC4 remains unclear in breast cancers, especially in TNBCs.;In the present study, we investigated the functional and mechanistic roles of MUC4 in potentiating pathogenic signals including EGFR family proteins to promote TNBC aggressiveness using in vitro and in vivo studies. Further, we studied the expression of MUC4 in invasive TNBC tissue and normal breast tissue by immunostaining.;MUC4 promotes proliferation, anchorage-dependent and-independent growth of TNBC cells, augments TNBC cell migratory and invasive potential in vitro, and enhances tumorigenicity and metastasis in vivo. In addition, our studies demonstrated that MUC4 up-regulates the EGFR family of proteins, and augments downstream Erk1/2, PKC-Î³, and FAK mediated oncogenic signaling. Moreover, our studies also showed that knockdown of MUC4 in TNBC cells induced molecular changes suggestive of mesenchymal to epithelial transition. We also demonstrated in this study, for the first time, that knockdown of MUC4 was associated with reduced expression of EGFR and ErbB3 (EGFR family proteins) in TNBC cells, suggesting that MUC4 uses an alternative to ErbB2 mechanism to promote aggressiveness. We further demonstrate that MUC4 is differentially over-expressed in invasive TNBC tissues compared to normal breast tissue.;MUC4 mucin expression is associated with TNBC pathobiology, and its knockdown reduced aggressiveness in vitro, and tumorigenesis and metastasis in vivo. Overall, our findings suggest that MUC4 mucin promotes invasive activities of TNBC cells by altering the expression of EGFR, ErbB2, and ErbB3 molecules and their downstream signaling.",
        "Doc_title":"MUC4 overexpression augments cell migration and metastasis through EGFR family proteins in triple negative breast cancer cells.",
        "Journal":"PloS one",
        "Do_id":"23408941",
        "Doc_ChemicalList":"MUC4 protein, human;Mucin-4;Receptor, Epidermal Growth Factor",
        "Doc_meshdescriptors":"Animals;Breast Neoplasms;Cell Cycle;Cell Line, Tumor;Female;Humans;Immunohistochemistry;Mice;Mice, Nude;Mucin-4;Neoplasm Invasiveness;Neoplasm Metastasis;Oligonucleotide Array Sequence Analysis;Receptor, Epidermal Growth Factor",
        "Doc_meshqualifiers":"metabolism;pathology;metabolism;metabolism",
        "_version_":1605846214871351296},
      {
        "Doc_abstract":"To describe new clinical findings, efficacy, and safety regarding the use of targeted agents in the treatment of HER2-positive metastatic breast cancer.;Published research articles, abstracts, and clinical experience.;HER2-positive cases of breast cancer tend to be more aggressive and more likely to become resistant to therapy than HER2-negative tumors. The current standard approach to patients with HER2-positive metastatic breast cancer includes the use of trastuzumab. Because cellular mechanisms can arise that can block the efficacy of this approach (and result in clinical resistance), recent research has led to the development of lapatinib, a targeted therapy that can act on HER2 inside the cell to disrupt the signaling pathways thought to be part of tumorigenic mechanisms.;Oncology nurses should be aware of the treatment strategies for HER2-positive metastatic breast cancer and its limitations, which is essential for providing optimal nursing care.",
        "Doc_title":"Overcoming treatment challenges in advanced breast cancer.",
        "Journal":"Seminars in oncology nursing",
        "Do_id":"18054677",
        "Doc_ChemicalList":"Antibodies, Monoclonal;Antibodies, Monoclonal, Humanized;Quinazolines;lapatinib;Receptor, ErbB-2;Trastuzumab",
        "Doc_meshdescriptors":"Antibodies, Monoclonal;Antibodies, Monoclonal, Humanized;Antineoplastic Combined Chemotherapy Protocols;Breast Neoplasms;Female;Humans;Quinazolines;Receptor, ErbB-2;Trastuzumab;Treatment Outcome",
        "Doc_meshqualifiers":"administration & dosage;adverse effects;pharmacology;adverse effects;pharmacology;therapeutic use;drug therapy;pathology;administration & dosage;adverse effects;pharmacology;metabolism",
        "_version_":1605766531324575744},
      {
        "Doc_abstract":"The Van Nuys (VN) classification system for ductal carcinoma in situ (DCIS) of the breast is a simplified morphology-based system that uses the presence of nuclear pleomorphism and comedo-type necrosis to stratify DCIS lesions into 3 prognostic groups.;To determine if there is an underlying biological basis that correlates with the morphologic aspects of the VN classification system.;We evaluated the expression of markers implicated in the development of breast cancer (p53, ErbB2, and TAG-72) in DCIS classified with the VN system. Forty-five cases of pure DCIS were classified as 8 cases of VN1, 7 cases of VN2, and 30 cases of VN3. p53, ErbB2, and TAG-72 antigen expression was measured by immunohistologic means in each of the cases.;Nuclear accumulation of p53 was only observed in VN3 (30%). ErbB2 overexpression was found only in VN2 (14%) and VN3 (43%). TAG-72 expression was observed in all categories of lesions but was more frequent in VN2 (71%) and VN3 (70%) compared with VN1 (25%). It appears that overexpression of ErbB2 and p53 are features associated with the high-grade lesions.;The simplified VN classification system for DCIS has a clear underlying biological basis as evidenced by differential expression of tumor-associated antigens in each of the 3 morphologic categories. These differences may contribute to the differential clinical behavior of the separate groups.",
        "Doc_title":"p53, ErbB2, and TAG-72 expression in the spectrum of ductal carcinoma in situ of the breast classified by the Van Nuys system.",
        "Journal":"Archives of pathology & laboratory medicine",
        "Do_id":"10656732",
        "Doc_ChemicalList":"Antigens, Neoplasm;Biomarkers, Tumor;Glycoproteins;Tumor Suppressor Protein p53;tumor-associated antigen 72;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Antigens, Neoplasm;Biomarkers, Tumor;Breast Neoplasms;Carcinoma in Situ;Carcinoma, Ductal, Breast;Female;Glycoproteins;Humans;Immunohistochemistry;Receptor, ErbB-2;Tumor Suppressor Protein p53",
        "Doc_meshqualifiers":"metabolism;metabolism;classification;metabolism;pathology;classification;metabolism;pathology;classification;metabolism;pathology;metabolism;metabolism;metabolism",
        "_version_":1605762964266156032},
      {
        "Doc_abstract":"The effects of soy products and isoflavone on breast cancer recurrence were compared according to receptor status including epidermal growth factor receptor-2 (HER2) with 339 Korean women. Dietary intake of soy foods was assessed using a validated food frequency questionnaire with 103 food items. Twenty-five patients experienced breast cancer recurrence, 17 patients were HER2 negative, and 8 patients were HER2 positive. Legume intake (mostly from black soybeans) was inversely associated with the risk of breast cancer recurrence in HER2 negative cancer patients (HR: 0.27, 95% CI: 0.13-0.57, P for trend < 0.01), whereas legume intake was positively associated in HER2 positive cancer patients (P for trend = 0.02). In HER2 negative cancer patients, isoflavone was inversely associated with breast cancer recurrence (HR: 0.23, 95% CI: 0.06-0.89; P for trend = 0.01). Total soy intake was not associated with an increased risk of cancer recurrence. In conclusion, overall soy food intake might not affect the risk of cancer recurrence, but high intake of soy isoflavones increased the risk of cancer recurrence in HER2-positive breast cancer patients. However, further research is needed to confirm these results due to the small number of cancer recurrence events.",
        "Doc_title":"Differential influence of dietary soy intake on the risk of breast cancer recurrence related to HER2 status.",
        "Journal":"Nutrition and cancer",
        "Do_id":"22211813",
        "Doc_ChemicalList":"Isoflavones;Receptors, Estrogen;Receptors, Progesterone;ERBB2 protein, human;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Adult;Aged;Breast Neoplasms;Diet;Female;Humans;Isoflavones;Korea;Middle Aged;Neoplasm Recurrence, Local;Postmenopause;Premenopause;Receptor, ErbB-2;Receptors, Estrogen;Receptors, Progesterone;Risk Factors;Soy Foods;Soybeans",
        "Doc_meshqualifiers":"chemistry;epidemiology;prevention & control;administration & dosage;chemistry;epidemiology;prevention & control;analysis;analysis;analysis;chemistry",
        "_version_":1605831265105215488},
      {
        "Doc_abstract":"The cell cycle is controlled by cyclin-dependent kinases and one of the key players is the cyclin-dependent kinase inhibitor p27. The F-box protein Skp2 is a regulator of G1-S transition and promotes specifically the ubiquitin-mediated proteolysis of p27 via the proteasome pathway. In breast carcinomas, overexpression of Skp2 has been implicated in cell transformation and oncogenesis, but no data are available on the association of Skp2 and p27. The purpose was to evaluate the prevalence of Skp2 and p27 expression and determine whether a combined index has prognostic power in breast carcinomas.;Three hundred and thirty-eight breast cancer specimens were analyzed for Skp2 and p27 expression by immunohistochemistry. Results were compared with classical histopathological criteria as well as other prognostic markers (ER, PR, HER2, p53, Ki-67) and correlated with the clinical outcome.;Thirty-four percent of breast cancers analyzed showed both a high expression for Skp2 and a low expression for p27. In univariate Kaplan-Meier analysis, this combination was found to be significantly associated with a worse clinical course (p<0.0001). Including staging, grading and the other tested marker, the Skp2/p27 index proved to be of prognostic relevance in multivariate analysis.;The combined assessment of Skp2 and p27 identifies aggressive breast cancer. In long-term follow-up, high Skp2 and low p27 indicate an unfavorable course. Beyond the prognostic importance of the Skp2/p27 index, it could serve as a predictive marker for new molecular targeted therapies aiming at Skp2.",
        "Doc_title":"Prognostic impact of Skp2 and p27 in human breast cancer.",
        "Journal":"Breast cancer research and treatment",
        "Do_id":"16636894",
        "Doc_ChemicalList":"Biomarkers, Tumor;S-Phase Kinase-Associated Proteins;Cyclin-Dependent Kinase Inhibitor p27",
        "Doc_meshdescriptors":"Biomarkers, Tumor;Breast Neoplasms;Carcinoma, Ductal, Breast;Cyclin-Dependent Kinase Inhibitor p27;Female;Humans;Immunoenzyme Techniques;Neoplasm Invasiveness;Prognosis;Retrospective Studies;S-Phase Kinase-Associated Proteins;Tissue Array Analysis",
        "Doc_meshqualifiers":"metabolism;diagnosis;metabolism;diagnosis;metabolism;metabolism;pathology;metabolism",
        "_version_":1605826754973270016},
      {
        "Doc_abstract":"Hormonal dependent breast cancer is a heterogeneous disease from a molecular and clinical perspective. The relapse risk of early breast cancer patients treated with adjuvant hormonal therapy varies. Validated predictive markers concerning adjuvant cytotoxic treatment are still lacking in ER+/â€ŠHER2-â€Š breast cancer, which has a good prognosis in general. This can lead to the inefficient chemotherapy indication. Molecular classification of breast cancer reports evidence about the heterogeneity of hormonal dependent breast cancer and its stratification to different groups with different characteristics. Multigene assays work on the molecular level, and their aim is to provide patients risk stratification and therapy efficacy prediction. The position of multigene assays in clinical practice is not stabile yet. Nonâ€Šuniform level of evidence connected to patients prognosis interpretations and difficult comparison of tests are the key problems, which prevent their wide clinical use. The article is a summary of some of the most important multigene assays in breast cancer and their current position in oncology practice.",
        "Doc_title":"[Genomic Tests as Predictors of Breast Cancer Patients Prognosis].",
        "Journal":"Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti",
        "Do_id":"26879059",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"Breast Neoplasms;Female;Humans;Prognosis",
        "Doc_meshqualifiers":"drug therapy;etiology;genetics",
        "_version_":1605759922832670720},
      {
        "Doc_abstract":"HER2/neu overexpression on cell membranes of breast cancer cells is due to HER2/neu gene amplification and it is important to identify potential candidates for anti HER2 therapy with trastuzumab. IHC, FISH and CISH are standard FDA approved assays currently used to determine HER2 status in routine practice. The aim of this study was to determine HER2 gene amplification, using the CISH method in breast carcinoma samples which had IHC +2 reactions.;This study was conducted from 2008- 2010 using 334 consecutive breast carcinoma samples referred from local laboratories to Mehr Hospital. CISH assays were performed for all cases, and IHC tests were also done for determining efficacy and accuracy of local labs. HER2 status in local IHC tests was compared with central IHC and CISH results.;Of 334 breast cancer patients, 16 were negative for HER2 IHC (0, +1), 201 cases were equivocal (+2), and 31 positive (+3). Of 334 referral cases, 88 were CISH positive (26.3%) and 246 were CISH negative (73.7%). Of 201 IHC +2 cases, HER2 gene amplification was observed in 42 cases (kappa: 0.42). A 29.9% concordance was found between local IHC and central IHC. Sensitivity and specificity of local IHC were 90% and 53.8%, respectively.;Low accuracy of IHC results in local labs was associated with the following factors: using former FDA-approved criteria for HER2 interpretation, utilizing non-validated kits, and lack of any quality assurance program. Therefore, following the new 2014 ASCO/CAP guideline and comprehensive quality assurance should be implemented to ensure accuracy of HER2 testing.",
        "Doc_title":"Chromogenic In Situ Hybridisation Test for Breast Cancer Patients with Equivocal IHC Results--a Study from Iran.",
        "Journal":"Asian Pacific journal of cancer prevention : APJCP",
        "Do_id":"26625783",
        "Doc_ChemicalList":"Antineoplastic Agents;Biomarkers, Tumor;Chromogenic Compounds;ERBB2 protein, human;Receptor, ErbB-2;Trastuzumab",
        "Doc_meshdescriptors":"Antineoplastic Agents;Biomarkers, Tumor;Breast Neoplasms;Chromogenic Compounds;Female;Gene Amplification;Genes, erbB-2;Humans;Immunohistochemistry;In Situ Hybridization, Fluorescence;Iran;Receptor, ErbB-2;Sensitivity and Specificity;Trastuzumab",
        "Doc_meshqualifiers":"therapeutic use;genetics;diagnosis;drug therapy;genetics;chemistry;genetics;genetics;methods;genetics;therapeutic use",
        "_version_":1605801139477938176},
      {
        "Doc_abstract":"To refine the analysis of gene amplification in breast cancer, the authors have developed sensitive methods that can be used to screen nucleic acid prepared from a variety of sources. In their analysis, Southern hybridization and DNA dot-blot analysis were used to screen 49 breast cancer DNAs for Myc, Neu, and Int-2 gene amplification. The analysis detected minimal one extra gene copy) as well as expanded (two or more extra gene copies) gene amplifications, and in addition, distinguished between gene amplification and aneuploidy as the cause of extra gene copies. These quantitative methods were adapted to patient specimens routinely available in the anatomic pathology laboratory, including fresh tumor tissue, tumor nuclei discarded during estrogen receptor analysis, and paraffin blocks. One minimal gene amplification was found in three cases of intraductal cancer. Of 25 cases of nonmetastatic invasive cancer, 28% had at least one extra Myc gene, whereas 24% had Neu, and 21% had Int-2 gene amplification. Of 21 cases of metastatic invasive cancer, 43% had Myc, 43% had Neu, and 40% had Int-2 gene amplification. Among the nonmetastatic cancers, 47% had one, 12% had two, and 4% had three amplified genes. Within the metastatic cancers, 48% had one, 28% had two, and 5% had three amplified genes. Our data suggest relationships between tumor progression and both incidence and size of Myc, Neu, and Int-2 gene amplification.",
        "Doc_title":"Oncogene amplification in breast cancer.",
        "Journal":"The American journal of pathology",
        "Do_id":"1849359",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"Breast Neoplasms;Carcinoma, Intraductal, Noninfiltrating;Gene Amplification;Humans;Neoplasm Invasiveness;Nucleic Acid Hybridization;Oncogenes",
        "Doc_meshqualifiers":"genetics;pathology;genetics;pathology",
        "_version_":1605907532970196992},
      {
        "Doc_abstract":"Breast cancer is not considered anymore a unique disease. Microarray gene expression analysis led to the identification of 4 major breast cancer \"intrinsic\" subtypes, including hormone receptor (HR)-positive luminal A and B, human epidermal growth receptor 2 (HER2)-positive and basal-like breast cancer (BLBC). These subtypes have distinct phenotypes, molecular profiles, clinical behaviour and response to therapy, with the BLBC carrying the worst outcome. Microarray analysis is not feasible in routine practice and therefore oncologists rely on a simpler immunohistochemical (IHC) classification to identify relevant breast cancer subtypes. Triple negative breast cancer (TNBC) is defined by the absence of oestrogen receptor, progesterone receptor and HER2 expression at IHC analysis. TNBC is strictly related to BLBC and, given the lack of common therapeutic targets, represent a major challenge for breast oncologist. In this review we will summarize the updated knowledge on TNBC, with emphasis on its current treatment and on the new therapeutic options under development.",
        "Doc_title":"Treatment of triple negative breast cancer (TNBC): current options and future perspectives.",
        "Journal":"Cancer treatment reviews",
        "Do_id":"21129616",
        "Doc_ChemicalList":"Receptors, Estrogen;Receptors, Growth Factor;Receptors, Progesterone;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Breast Neoplasms;Female;Forecasting;Humans;Receptor, ErbB-2;Receptors, Estrogen;Receptors, Growth Factor;Receptors, Progesterone",
        "Doc_meshqualifiers":"classification;drug therapy;metabolism;drug effects;metabolism;drug effects;metabolism;drug effects;metabolism;drug effects;metabolism",
        "_version_":1605799639065296896},
      {
        "Doc_abstract":"Overexpression of HER2 - found in approximately 15-20% of all breast cancers - is a negative prognostic factor. Although trastuzumab significantly improves the prognosis of HER2-positive breast cancer, half of the patients with metastatic breast cancer experience disease progression within 1 year. Pertuzumab is a novel HER2-targeted humanized monoclonal antibody that binds to the dimerization domain of HER2 and acts synergically with trastuzumab in inhibiting tumor progression. The CLEOPATRA trial demonstrated that adding pertuzumab to trastuzumab plus docetaxel significantly prolonged progression-free survival and overall survival without increasing severe adverse events. Conclusively, pertuzumab was approved by the US FDA in June 2012 for use in combination with trastuzumab and docetaxel for the treatment of patients with HER2-positive metastatic breast cancer. Furthermore, various clinical trials to evaluate the efficacy and safety of pertuzumab combined with other cytotoxic agents are ongoing at present. Thus, pertuzumab has been becoming important for the treatment of patients with HER2-positive metastatic breast cancer. ",
        "Doc_title":"Pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer.",
        "Journal":"Expert review of anticancer therapy",
        "Do_id":"25494663",
        "Doc_ChemicalList":"Antibodies, Monoclonal, Humanized;Taxoids;docetaxel;Receptor, ErbB-2;pertuzumab;Trastuzumab",
        "Doc_meshdescriptors":"Antibodies, Monoclonal, Humanized;Antineoplastic Combined Chemotherapy Protocols;Breast Neoplasms;Clinical Trials as Topic;Female;Humans;Neoplasm Metastasis;Receptor, ErbB-2;Taxoids;Trastuzumab",
        "Doc_meshqualifiers":"administration & dosage;therapeutic use;drug therapy;pathology;antagonists & inhibitors;administration & dosage",
        "_version_":1605796314399899648},
      {
        "Doc_abstract":"Understanding the signaling differences that distinguish human HER2-amplified (HER2-positive (HER2+)) breast cancers from other breast cancer subtypes may help to identify protein drug targets for the specific treatment of HER2+ breast cancers. We performed two kinome-wide small interfering RNA (siRNA) screens on five HER2+ breast cancer cell lines, seven breast cancer cell lines in which HER2 was not amplified and two normal breast cell lines. To pinpoint the main kinases driving HER2 signaling, we performed a comprehensive siRNA screen that identified loss of the HER2/HER3 heterodimer as having the most prominent inhibitory effect on the growth of HER2+ breast cancer cells. In a second siRNA screen focused on identifying genes that could sensitize HER2+ cells to trastuzumab treatment, we found that loss of signaling members downstream of phosphatidylinositol 3 kinase (PI3K) potentiated the growth inhibitory effects of trastuzumab. Loss of HER2 and HER3, as well as proteins involved in mitogenic and environmental stress pathways inhibited the proliferation of HER2+ cells only in the absence of trastuzumab, suggesting that these pathways are inhibited by trastuzumab treatment. Loss of essential G2/M cell cycle mediators or proteins involved in vesicle organization exerted inhibitory effects on HER2+ cell growth that were unaffected by trastuzumab. Furthermore, the use of a sensitization index (SI) identified targeting the PI3K pathway to sensitize to trastuzumab treatment. Antagonism using the SI identified MYO3A, MYO3B and MPZL1 as antagonizers to trastuzumab treatment among HER2+ cell lines. Our results suggest that the dimerization partners of HER2 are important for determining the activation of downstream proliferation pathways. Understanding the complex layers of signaling triggered downstream of HER2 homodimers and heterodimers will facilitate the selection of better targets for combination therapies intended to treat HER2+ breast cancers. ",
        "Doc_title":"Kinome-wide screening of HER2+ breast cancer cells for molecules that mediate cell proliferation or sensitize cells to trastuzumab therapy.",
        "Journal":"Oncogenesis",
        "Do_id":"25500906",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605896650078814208},
      {
        "Doc_abstract":"Intratumoral heterogeneity of human epidermal growth factor receptor 2 (HER2) gene amplification has been reported to occur with variable frequencies in breast cancers. However, there have been few studies of its clinicopathological significance. We used tissue microarrays to evaluate two aspects of intratumoral heterogeneity of HER2 gene amplification: regional heterogeneity and genetic heterogeneity. We examined 96 invasive breast cancers in which HER2 amplification had been diagnosed in whole sections, and determined the clincopathological characteristics of those tumors. HER2 regional heterogeneity, defined as the existence of amplification/negative or amplification/equivocal patterns in different tissue microarray cores of a tumor, was present in 17 (18%) of the 96 cases. HER2 genetic heterogeneity, defined as the presence of tumor cells with a HER2/chromosome enumeration probe 17 ratio higher than 2.2 in 5-50% of the tumor cells, was found in 11 cases (11%), all of which showed HER2 regional heterogeneity. The cases with intratumoral heterogeneity of HER2 gene amplification were characterized by low grade or equivocal HER2 amplification and equivocal (2+) HER2 expression in whole sections. The patients with intratumoral heterogeneity of HER2 gene amplification had significantly shorter disease-free survival times than those with homogeneous HER2 gene amplification, and this effect was also evident in subgroup analysis by hormone receptor status. In multivariate analysis, intratumoral HER2 heterogeneity retained its status as an independent prognostic factor for disease-free survival. In conclusion, intratumoral heterogeneity of HER2 gene amplification is present in a subset of HER2-amplified breast cancers, especially in cases with low-grade HER2 amplification and equivocal HER2 expression, indicating a need for HER2 testing on more representative, larger tumor samples for accurate assessment of HER2 status in such cases. The patients with this heterogeneity have decreased disease-free survival, suggesting that genetic instability, and hence aberrant HER2 amplification in subclones of such tumors, may be associated with breast cancer progression.",
        "Doc_title":"Intratumoral heterogeneity of HER2 gene amplification in breast cancer: its clinicopathological significance.",
        "Journal":"Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc",
        "Do_id":"22388760",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"Adult;Aged;Aged, 80 and over;Breast Neoplasms;Disease-Free Survival;Female;Gene Amplification;Genes, erbB-2;Humans;In Situ Hybridization, Fluorescence;Kaplan-Meier Estimate;Middle Aged;Neoplasm Staging;Proportional Hazards Models;Tissue Array Analysis",
        "Doc_meshqualifiers":"genetics;mortality;pathology;genetics",
        "_version_":1605796339676872704},
      {
        "Doc_abstract":"Several recent publications have re-opened the question of whether HER2 status should be determined for all patients with newly diagnosed breast cancer. The barrier in the past to the use of HER2 has been the nonstandardization of HER2 status determination, which is the major caveat to its use today. Two test kits have been recently approved by the Food and Drug Administration for HER2 testing, one for determining HER2 amplification by fluorescence in situ hybridization and the other for measuring HER2 overexpression by immunohistochemistry. Neither of these tests, nor any of the other myriad tests used for HER2 determinations, has been validated in all the potential arenas for the use of HER2: refinement of estimates of prognosis of untreated low-risk patients, selection among treatment options for adjuvant therapy, and selection of patients for treatment with trastuzumab (Herceptin; Genentech, San Francisco, CA). The nonstandardization of testing has led to conflicting results and controversy as to the value of HER2 in evaluating breast cancer patient prognosis and the selection among therapeutic options. Thus, testing for HER2 is not yet routine for patients with newly diagnosed breast cancer, although it is of value for patients who develop metastatic disease and who need to know if they are candidates for trastuzumab.",
        "Doc_title":"Should HER2 status be routinely measured for all breast cancer patients?",
        "Journal":"Seminars in oncology",
        "Do_id":"10482203",
        "Doc_ChemicalList":"Antibodies, Monoclonal;Antibodies, Monoclonal, Humanized;Antineoplastic Agents;Receptor, ErbB-2;Trastuzumab",
        "Doc_meshdescriptors":"Antibodies, Monoclonal;Antibodies, Monoclonal, Humanized;Antineoplastic Agents;Antineoplastic Combined Chemotherapy Protocols;Breast Neoplasms;Gene Expression;Humans;Prognosis;Receptor, ErbB-2;Trastuzumab",
        "Doc_meshqualifiers":"therapeutic use;therapeutic use;therapeutic use;drug therapy;genetics;metabolism;genetics;metabolism",
        "_version_":1605801451415666688},
      {
        "Doc_abstract":"Signal transducers and activators of transcription (STATs) are latent cytoplasmic transcription factors that are activated and translocated into the nucleus after phosphorylation at a conserved tyrosine residue. Mouse model studies have demonstrated that activated Stat5a acts as a critical survival factor for normal, preneoplastic and malignant mammary epithelial cells. Very limited information is available, however, on the expression, tyrosine phosphorylation status and nuclear localization of Stat5a in human breast cancers. In our study, the pattern of Stat5a cellular localization was analyzed by immunohistochemistry in a series of 83 randomly selected primary human breast adenocarcinomas. Immunoprecipitation/Western blotting and immunohistochemistry assays employing different phospho-specific antibodies verified Stat5a tyrosine phosphorylation status. Stat5a was nuclear localized and tyrosine phosphorylated in 59 of 78 (76%) breast cancers examined; 38 of 78 (49%) demonstrated Stat5a nuclear localization in more than 25% of the breast cancer cells within the adenocarcinomas. Nuclear localized Stat5a was associated positively with increased levels of histologic differentiation (p = 0.03). A statistically significant positive association with p27 nuclear localization also was identified (p = 0.05). No relationship was found between nuclear localized Stat5a and menopausal status, tumor size, ploidy, percentage of cells in S-phase, lymph node metastases, ER, ErbB2, nuclear localized p21 or nuclear localized Stat5b/Stat3. As its role in human breast cancer progression and response to therapy is defined, Stat5a could become a new molecular target for breast cancer therapy.",
        "Doc_title":"Stat5a is tyrosine phosphorylated and nuclear localized in a high proportion of human breast cancers.",
        "Journal":"International journal of cancer",
        "Do_id":"14696092",
        "Doc_ChemicalList":"DNA-Binding Proteins;Microfilament Proteins;Milk Proteins;Muscle Proteins;STAT3 Transcription Factor;STAT3 protein, human;STAT5 Transcription Factor;STAT5A protein, human;STAT5B protein, human;Tagln protein, mouse;Trans-Activators;Tumor Suppressor Proteins;Tyrosine",
        "Doc_meshdescriptors":"Adenocarcinoma;Adult;Aged;Breast Neoplasms;Cell Differentiation;Cell Nucleus;DNA-Binding Proteins;Female;Humans;Microfilament Proteins;Milk Proteins;Muscle Proteins;Phosphorylation;STAT3 Transcription Factor;STAT5 Transcription Factor;Trans-Activators;Tumor Suppressor Proteins;Tyrosine",
        "Doc_meshqualifiers":"metabolism;metabolism;metabolism;metabolism;metabolism;metabolism;metabolism",
        "_version_":1605791506069716992},
      {
        "Doc_abstract":"Assessment of HER-2/neu status in invasive breast cancer is crucial to establish eligibility for trastuzumab and taxane based chemotherapy. Next to immunohistochemistry (IHC) to evaluate protein overexpression, a second line gene amplification test is required for cases with equivocal protein expression. This study aimed to validate a new PCR based test, called Multiplex Ligation-dependent Probe Amplification (MLPA), as a simple and quick method to assess HER-2/neu gene amplification status in invasive breast cancer.;MPLA results were compared with gene amplification status assessed by fluorescence in situ hybridization (FISH) and chromogenic in situ hybridization (CISH) as gold standard, and with protein overexpression by IHC in 518 breast carcinoma patients.;About 10% of cases overexpressed HER-2/neu at the protein level (IHC), and 11% of cases showed gene-amplification by MLPA. A high concordance was found between FISH and CISH, MLPA and IHC, and MLPA and CISH. MLPA showed amplification in 7/36 (19%) of the equivocal IHC 2+ cases. However, of the IHC 0/1+ cases, 6/434 (1.4%) were also amplified by MLPA, and amplification was confirmed in all of these cases by FISH/CISH. On the other hand, one of the 48 (2%) IHC 3+ cases was normal by MLPA and lack of amplification was confirmed by FISH/CISH.;MLPA is a fast, accurate and cheap method to detect breast cancer HER-2/neu amplification in small quantities of DNA extracted from paraffin blocks, and thereby a reliable alternative to FISH and CISH.",
        "Doc_title":"HER-2/neu amplification testing in breast cancer by multiplex ligation-dependent probe amplification in comparison with immunohistochemistry and in situ hybridization.",
        "Journal":"Cellular oncology : the official journal of the International Society for Cellular Oncology",
        "Do_id":"19096145",
        "Doc_ChemicalList":"Molecular Probes;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Breast Neoplasms;Female;Gene Amplification;Humans;Immunohistochemistry;In Situ Hybridization, Fluorescence;Ligase Chain Reaction;Molecular Probes;Receptor, ErbB-2",
        "Doc_meshqualifiers":"genetics;metabolism;methods;methods;economics;methods;genetics;genetics;metabolism",
        "_version_":1605905936787963904},
      {
        "Doc_abstract":"Neuroendocrine breast carcinoma (NEBC) diagnosis relies on (i) presence of morphologic neuroendocrine features, and (ii) neuroendocrine markers expressed in more than 50% of tumor cells. The World Health Organization classification describes 3 main histologic types: the solid, the small/oat cell, and the large cell variant. In addition, we have recently proposed a further categorization into 5 subgroups: the first 3 categories encompass solid lesions and include (i) solid cohesive carcinomas, (ii) alveolar carcinomas, and (iii) small cell carcinoma; the last subgroups include mucin-producing tumors which are (iv) solid papillary carcinomas and (v) cellular mucinous carcinomas. Chromogranin A and synaptophysin have been considered as the most sensitive and specific neuroendocrine markers in NEBC. At the molecular level, recent gene expression profiling studies have shown that NEBCs pertain to the luminal molecular type, being positive for hormone receptors and negative for HER2. Moreover, it has been demonstrated that mucinous and neuroendocrine carcinomas are transcriptionally distinct from conventional invasive ductal carcinomas. Following the above criteria, NEBCs constitute approximately 1% of all breast carcinomas. The clinical effect of neuroendocrine breast cancer is still a matter of debate; however, when compared with unselected breast cancers, NEBCs show a less aggressive clinical behavior.",
        "Doc_title":"Neuroendocrine differentiation in breast cancer: established facts and unresolved problems.",
        "Journal":"Seminars in diagnostic pathology",
        "Do_id":"20306832",
        "Doc_ChemicalList":"Biomarkers, Tumor;Chromogranin A;DNA, Neoplasm;Synaptophysin",
        "Doc_meshdescriptors":"Adenocarcinoma, Mucinous;Biomarkers, Tumor;Breast Neoplasms;Carcinoma, Ductal, Breast;Carcinoma, Neuroendocrine;Cell Transformation, Neoplastic;Chromogranin A;DNA, Neoplasm;Diagnosis, Differential;Female;Gene Expression Profiling;Humans;Synaptophysin",
        "Doc_meshqualifiers":"pathology;metabolism;classification;metabolism;pathology;pathology;classification;metabolism;pathology;metabolism;analysis;metabolism",
        "_version_":1605764434910773248},
      {
        "Doc_abstract":"Breast cancer is the most common type of cancer among women worldwide. In low and middle-income countries (LMICs), appropriate selection of medicines on national essential medicines lists (NEMLs) is a first step towards adequate access to treatment. We studied selection of systemic treatments for breast cancer on NEMLs and assessed its alignment with treatment guidelines for different types of early and advanced breast cancer. Furthermore, influence of country characteristics on the selection was investigated.;NEMLs from 75 LMICs were studied for inclusion of all components of therapy in each stage of breast cancer according to international consensus guidelines. The results were then grouped by income level, WHO region and the NEMLs' release date. Non parametric tests were used for statistical analysis.;Unlike HER2-targeted therapies (<10%), aromatase inhibitors (12%) and taxanes (28%); tamoxifen and first generation chemotherapeutic regimens (e.g., anthracycline-based regimens) were frequently found in the NEMLs (71-78%). Consequently, all components of treatment for \"Luminal A\" early breast cancer and non HER2 overexpressed advanced breast cancer were found on the NEMLs of over 70% of countries. However, 40% of the low income countries did not have all the components of therapy for any type of early breast cancer in their NEMLs, and adequate treatment of HER2 overexpressed breast cancer was hardly possible with the current selections. Recent NEMLs were more aligned with the guidelines (pâ€‰<â€‰0.05). Eastern Mediterranean and African regions less frequently incorporated all components of breast cancer treatment in their NEMLs.;Alignment of selection with guidelines' recommendations was inconsistent for different types of early and advanced breast cancer in NEMLs. Regular updates and more attention to clinical guidelines is therefore recommended.",
        "Doc_title":"Essential medicines for breast cancer in low and middle income countries.",
        "Journal":"BMC cancer",
        "Do_id":"26283654",
        "Doc_ChemicalList":"Drugs, Essential;Tamoxifen",
        "Doc_meshdescriptors":"Breast Neoplasms;Decision Making;Developing Countries;Drugs, Essential;Female;Humans;Poverty;Tamoxifen",
        "Doc_meshqualifiers":"drug therapy;pathology;economics;economics;therapeutic use",
        "_version_":1605764013229080576},
      {
        "Doc_abstract":"Focal adhesion kinase (FAK) regulates multiple cellular processes including growth, differentiation, adhesion, motility and apoptosis. In breast carcinoma, FAK overexpression has been linked to cancer progression but the prognostic relevance remains unknown. In particular, with regard to lymph node-negative breast cancer it is important to identify high-risk patients who would benefit from further adjuvant therapy.;We analyzed 162 node-negative breast cancer cases to determine the prognostic relevance of FAK expression, and we investigated the relationship of FAK with major associated signaling pathways (HER2, Src, Akt and extracellular regulated kinases) by immunohistochemistry and western blot analysis.;Elevated FAK expression did not predict patient outcome, in contrast to tumor grading (P = 0.005), Akt activation (P = 0.0383) and estrogen receptor status (P = 0.0033). Significant positive correlations were observed between elevated FAK expression and HER2 overexpression (P = 0.001), as well as phospho-Src Tyr-215 (P = 0.021) and phospho-Akt (P < 0.001), but not with phospho-ERK1/2 (P = 0.108). Western blot analysis showed a significant correlation of FAK Tyr-861 activation and HER2 overexpression (P = 0.01).;Immunohistochemical detection of FAK expression is of no prognostic significance in node-negative breast cancer but provides evidence that HER2 is involved in tumor malignancy and metastatic ability of breast cancer through a novel signaling pathway participating FAK and Src.",
        "Doc_title":"High expression of focal adhesion kinase (p125FAK) in node-negative breast cancer is related to overexpression of HER-2/neu and activated Akt kinase but does not predict outcome.",
        "Journal":"Breast cancer research : BCR",
        "Do_id":"15743500",
        "Doc_ChemicalList":"Receptor, ErbB-2;Focal Adhesion Kinase 1;Oncogene Protein v-akt;Mitogen-Activated Protein Kinase 1;Mitogen-Activated Protein Kinase 3",
        "Doc_meshdescriptors":"Blotting, Western;Breast Neoplasms;Female;Focal Adhesion Kinase 1;Gene Expression Profiling;Humans;Immunohistochemistry;Lymphatic Metastasis;Middle Aged;Mitogen-Activated Protein Kinase 1;Mitogen-Activated Protein Kinase 3;Oncogene Protein v-akt;Predictive Value of Tests;Prognosis;Receptor, ErbB-2;Risk Assessment;Signal Transduction;Treatment Outcome",
        "Doc_meshqualifiers":"genetics;pathology;therapy;biosynthesis;metabolism;metabolism;metabolism;physiology",
        "_version_":1605884367980199936},
      {
        "Doc_abstract":"Breast cancers are classified into five intrinsic subtypes: Luminal subtype A, Luminal subtype B, HER2+, Basal, and Normal-like. In this study, we compared the plasma proteome of patients with Luminal A, Luminal B, HER2+, and Basal subtype with plasma from healthy individuals. Protein changes were considered significant if q-value (false discovery rate) was less than 5%. The highest number of changes in the plasma proteome was observed in patients with Luminal type B followed by Basal type breast cancers. The plasma proteome of Luminal A and HER2+ breast cancer patients did not differ significantly from healthy individuals. In Basal breast cancer, a significant number of plasma proteins were downregulated compared with healthy individuals. Acute phase-response proteins Î±-glycoprotein orosomucoid 1 and serum amyloid protein P were specifically upregulated in the plasma of Luminal B breast cancer patients, suggesting prevalence of low-grade inflammation. Proteins involved in immune response and free radical scavenging were downregulated in the plasma of Luminal B patients, which is in agreement with defective immune system observed in cancer patients. These results reveal intrinsic subtype specific changes in the plasma proteome that may influence tumor progression as well as the systemic effects of cancer.",
        "Doc_title":"Intrinsic subtype-associated changes in the plasma proteome in breast cancer.",
        "Journal":"Proteomics. Clinical applications",
        "Do_id":"21136952",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605845836287180800},
      {
        "Doc_abstract":"Breast cancers can be classified into those that express the estrogen (ER) and progesterone (PR) receptors, those with ERBB2 (HER-2/Neu) amplification, and those without expression of ER, PR, or amplification of ERBB2 (referred to as triple-negative or basal-like breast cancer). In order to identify potential molecular targets in breast cancer, we performed a synthetic siRNA-mediated RNAi screen of the human tyrosine kinome. A primary RNAi screen conducted in the triple-negative/basal-like breast cancer cell line MDA-MB231 followed by secondary RNAi screens and further studies in this cell line and two additional triple-negative/basal-like breast cancer cell lines, BT20 and HCC1937, identified the G2/M checkpoint protein, WEE1, as a potential therapeutic target. Similar sensitivity to WEE1 inhibition was observed in cell lines from all subtypes of breast cancer. RNAi-mediated silencing or small compound inhibition of WEE1 in breast cancer cell lines resulted in an increase in gammaH2AX levels, arrest in the S-phase of the cell cycle, and a significant decrease in cell proliferation. WEE1-inhibited cells underwent apoptosis as demonstrated by positive Annexin V staining, increased sub-G1 DNA content, apoptotic morphology, caspase activation, and rescue by the pan-caspase inhibitor, Z-VAD-FMK. In contrast, the non-transformed mammary epithelial cell line, MCF10A, did not exhibit any of these downstream effects following WEE1 silencing or inhibition. These results identify WEE1 as a potential molecular target in breast cancer.",
        "Doc_title":"Identification of WEE1 as a potential molecular target in cancer cells by RNAi screening of the human tyrosine kinome.",
        "Journal":"Breast cancer research and treatment",
        "Do_id":"19821025",
        "Doc_ChemicalList":"Caspase Inhibitors;Cell Cycle Proteins;Cysteine Proteinase Inhibitors;H2AFX protein, human;Histones;Nuclear Proteins;Protein Kinase Inhibitors;Receptors, Estrogen;Receptors, Progesterone;ERBB2 protein, human;Protein-Tyrosine Kinases;Receptor, ErbB-2;WEE1 protein, human;Caspases",
        "Doc_meshdescriptors":"Apoptosis;Breast Neoplasms;Caspase Inhibitors;Caspases;Cell Cycle;Cell Cycle Proteins;Cell Line, Tumor;Cell Proliferation;Cell Survival;Cysteine Proteinase Inhibitors;Female;Histones;Humans;Nuclear Proteins;Protein Kinase Inhibitors;Protein-Tyrosine Kinases;RNA Interference;Receptor, ErbB-2;Receptors, Estrogen;Receptors, Progesterone;Time Factors",
        "Doc_meshqualifiers":"enzymology;genetics;pathology;metabolism;drug effects;genetics;antagonists & inhibitors;genetics;metabolism;drug effects;pharmacology;metabolism;antagonists & inhibitors;genetics;metabolism;pharmacology;antagonists & inhibitors;genetics;metabolism;analysis;analysis;analysis",
        "_version_":1605891820638699520},
      {
        "Doc_abstract":"The transmembrane protein HER2 is over-expressed in approximately 15% of invasive breast cancers as a result of HER2 gene amplification. HER2 proteolytic cleavage (HER2 shedding) generates soluble truncated HER2 molecules that include only the extracellular domain and the concentration of which can be measured in the serum fraction of blood. HER2 shedding also generates a constitutively active truncated intracellular receptor of 95kDa (p95(HER2)). Another soluble truncated HER2 protein (Herstatin), which can also be found in serum, is the product of an alternatively spliced HER2 transcript. Recent preclinical findings may provide crucial insights into the biological and clinical relevance of increased sHER2 concentrations for the outcome of HER2-positive breast cancer and sensitivity to trastuzumab and lapatinib treatment. We present here the most recent findings about the role and biology of sHER2 based on data obtained using a standardized test, which has been cleared by FDA in 2000, for measuring sHER2. This test includes quality control assessments and has been already widely used to evaluate the clinical utility of sHER2 as a biomarker in breast cancer. We will describe in detail data concerning the assessment of sHER2 as a surrogate maker to optimize the evaluation of the HER2 status of a primary tumor and as a prognosis and predictive marker of response to therapies, both in early and metastatic breast cancer.",
        "Doc_title":"HER2 shedding and serum HER2 extracellular domain: biology and clinical utility in breast cancer.",
        "Journal":"Cancer treatment reviews",
        "Do_id":"21549508",
        "Doc_ChemicalList":"Biomarkers, Tumor;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Animals;Biomarkers, Tumor;Breast Neoplasms;Female;Humans;Mammary Neoplasms, Experimental;Protein Structure, Tertiary;Receptor, ErbB-2",
        "Doc_meshqualifiers":"blood;metabolism;enzymology;blood;metabolism;blood;metabolism",
        "_version_":1605742705575460864},
      {
        "Doc_abstract":"Trastuzumab (herceptin) and pertuzumab (Omnitarg, 2C4) are recombinant humanized monoclonal antibodies that target different extracellular regions of the HER-2 tyrosine kinase receptor. We explored combination effects of these agents in the HER-2-overexpressing BT474 breast cancer cell line. Trastuzumab and 2C4 synergistically inhibited the survival of BT474 cells, in part, because of increased apoptosis. Trastuzumab increased 2C4-mediated disruption of HER-2 dimerization with the epidermal growth factor receptor and HER-3. Combination drug treatment reduced levels of total and phosphorylated HER-2 protein and blocked receptor signaling through Akt but did not affect mitogen-activated protein kinase. These results suggest that combining HER-2-targeting agents may be a more effective therapeutic strategy in breast cancer rather than treating with a single HER-2 monoclonal antibody.",
        "Doc_title":"The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells.",
        "Journal":"Cancer research",
        "Do_id":"15059883",
        "Doc_ChemicalList":"Antibodies, Monoclonal;Antibodies, Monoclonal, Humanized;Proto-Oncogene Proteins;Receptor, ErbB-2;AKT1 protein, human;Protein-Serine-Threonine Kinases;Proto-Oncogene Proteins c-akt;pertuzumab;Trastuzumab",
        "Doc_meshdescriptors":"Antibodies, Monoclonal;Antibodies, Monoclonal, Humanized;Antineoplastic Combined Chemotherapy Protocols;Apoptosis;Breast Neoplasms;Cell Division;Cell Survival;Dimerization;Drug Synergism;Humans;MAP Kinase Signaling System;Protein-Serine-Threonine Kinases;Proto-Oncogene Proteins;Proto-Oncogene Proteins c-akt;Receptor, ErbB-2;Signal Transduction;Trastuzumab",
        "Doc_meshqualifiers":"administration & dosage;pharmacology;pharmacology;drug effects;drug therapy;immunology;metabolism;pathology;drug effects;drug effects;drug effects;metabolism;biosynthesis;immunology;metabolism;drug effects",
        "_version_":1605760614400000000},
      {
        "Doc_abstract":"An increase in the incidence of breast cancer patients with brain metastases has been observed over the last years, mainly because the recent development of new drugs including therapies targeting HER2 (human epidermal growth factor receptor 2) resulted in an increased survival of these patients. With HER2+ patients living longer and the well-known neurotropism of HER2+ tumour cells, the resulting high incidence of brain metastases is not really surprising. Moreover, brain metastases more often occur within a context of existing extracranial metastases. These need to be treated at the same time in order to favourably impact patients' survival. Consequently, the management of breast cancer patients with brain metastases clearly relies on a multidisciplinary approach, including systemic treatment. A working group including neuro-oncologists, neurosurgeons, radiation oncologists and oncologists was created in order to provide French national guidelines for the management of brain metastases within the \"Association des neuro-oncologues d'expression franÃ§aise\" (ANOCEF). The recommendations regarding the systemic treatment in breast cancer patients are reported here including key features of their management. ",
        "Doc_title":"[Systemic treatment of brain metastases from breast cancer].",
        "Journal":"Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique",
        "Do_id":"25662600",
        "Doc_ChemicalList":"Angiogenesis Inhibitors;Antibodies, Monoclonal, Humanized;Antineoplastic Agents;Antineoplastic Agents, Hormonal;Quinazolines;lapatinib;ERBB2 protein, human;Receptor, ErbB-2;Trastuzumab",
        "Doc_meshdescriptors":"Adenocarcinoma;Angiogenesis Inhibitors;Antibodies, Monoclonal, Humanized;Antineoplastic Agents;Antineoplastic Agents, Hormonal;Antineoplastic Combined Chemotherapy Protocols;Brain Neoplasms;Breast Neoplasms;Combined Modality Therapy;Female;Genes, erbB-2;Humans;Medicine;Molecular Targeted Therapy;Patient Care Team;Quinazolines;Receptor, ErbB-2;Trastuzumab;Treatment Outcome",
        "Doc_meshqualifiers":"drug therapy;secondary;therapeutic use;administration & dosage;therapeutic use;therapeutic use;therapeutic use;therapeutic use;drug therapy;secondary;pathology;therapy;administration & dosage;therapeutic use;antagonists & inhibitors",
        "_version_":1605832437119582208},
      {
        "Doc_abstract":"Lymphovascular invasion (LVI) is a widely recognized prognostic factor in lymph node-negative breast cancers. However, there are only limited and controversial data about its prognostic significance in lymph node-positive patients.;Among 931 patients operated on and monitored at the authors' institution for an invasive breast carcinoma between 1989 and 1992, all 374 lymph node-positive breast cancers entered the study (median follow-up, 126 months).;LVI was present in 46% of tumors and was associated with age < or = 40 years (P = .02), high histological grade (P = .01), and negative estrogen receptor status (P = .032), but not with tumor size, number of involved lymph nodes, or HER-2/neu status. LVI was an independent prognostic factor for distant metastases (P = .002). Furthermore, in HER-2/neu-negative/hormone receptor-positive (n = 287) tumors, the number of independent prognostic factors (LVI, age, histological grade, number of involved lymph nodes, and tumor size) was associated with a 5-years metastasis-free survival ranging from 100% if no factors (n = 25) to 89% +/- 2% if 1 or 2 factors (n = 186) and 67% +/- 6 if 3, 4, or 5 factors (n = 76) were present (P < .001).;LVI is an independent prognostic factor in lymph node-positive breast cancer and merits further prospective investigations as a decision tool in the adjuvant chemotherapy setting.",
        "Doc_title":"Is it useful to detect lymphovascular invasion in lymph node-positive patients with primary operable breast cancer?",
        "Journal":"Cancer",
        "Do_id":"20564641",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"Adult;Breast Neoplasms;Chemotherapy, Adjuvant;Endothelium, Vascular;Female;Humans;Lymphatic Metastasis;Neoplasm Metastasis;Prognosis",
        "Doc_meshqualifiers":"blood supply;mortality;pathology;surgery;pathology;pathology",
        "_version_":1605905424722165760},
      {
        "Doc_abstract":"Overexpression of the tumor suppressor gene melanoma differentiation-associated gene-7 (mda-7) induces apoptosis in many cancer cells, and adenoviral-mediated overexpression of mda-7 downregulates beta-catenin and PI 3-kinase signaling in breast cancer cells. Trastuzumab (Herceptin) improves the efficacy of chemotherapeutics against Her-2/neu-overexpressing breast cancer cells. We sought to evaluate the impact of combination therapy of a recombinant adenovirus vector encoding for human mda-7 (Ad-mda7) and Herceptin on Her-2/neu-overexpressing breast cancer.;The MCF-7-Her-18 cell line was subjected to treatment with Ad-mda7 with and without Herceptin. Western blot analysis was performed with antibodies to beta-catenin, Akt, and phosphorylated Akt (p-Akt). The same treatment groups were utilized in a nude mouse model in vivo. Treatment was initiated when the tumors reached 100 mm3 in size.;In Western blotting, the combination of Ad-mda7 + Herceptin showed decreased levels of beta-catenin, Akt and p-Akt compared with Ad-mda7 or Herceptin alone (P < .05). The in vivo analysis revealed a marked decrease in tumor size with the Ad-mda7 + Herceptin combination (P < .05).;These studies demonstrate the growth inhibitory effect of Ad-mda7 + Herceptin on Her-2/neu-overexpressing breast cancer cells in vitro and in vivo. This combination appears to inhibit the pathways involving beta-catenin and Akt, which play important roles in the growth of breast cancer cells.",
        "Doc_title":"Combination therapy of Ad-mda7 and trastuzumab increases cell death in Her-2/neu-overexpressing breast cancer cells.",
        "Journal":"Surgery",
        "Do_id":"15300212",
        "Doc_ChemicalList":"Antibodies, Monoclonal;Antibodies, Monoclonal, Humanized;CTNNB1 protein, human;CTNNB1 protein, mouse;Cytoskeletal Proteins;Interleukins;Proto-Oncogene Proteins;Trans-Activators;beta Catenin;interleukin-24;Receptor, ErbB-2;AKT1 protein, human;Protein-Serine-Threonine Kinases;Proto-Oncogene Proteins c-akt;Trastuzumab",
        "Doc_meshdescriptors":"Adenoviridae;Animals;Antibodies, Monoclonal;Antibodies, Monoclonal, Humanized;Apoptosis;Breast Neoplasms;Cell Line, Tumor;Cytoskeletal Proteins;Female;Genes, Tumor Suppressor;Genetic Therapy;Humans;Interleukins;Mice;Protein-Serine-Threonine Kinases;Proto-Oncogene Proteins;Proto-Oncogene Proteins c-akt;Receptor, ErbB-2;Trans-Activators;Trastuzumab;beta Catenin",
        "Doc_meshqualifiers":"genetics;therapeutic use;chemistry;pathology;therapy;analysis;genetics;analysis;analysis;analysis;analysis",
        "_version_":1605836355872489472},
      {
        "Doc_abstract":"Neoadjuvant chemotherapy (NAC) is now a relatively standard treatment for breast carcinoma. However, some tumors are known to develop resistance to chemotherapies. We investigated whether the status of estrogen receptor (ER), progesterone receptor (PR) and Her-2 expressions in breast cancer cases prior to NAC could be changed after NAC. We used immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) methods. No differences were found in ER or Her-2 status, but a significant difference was found in PR status. Changes in Her-2 status were suspected in four specimens after NAC (3+ to 1+ for 3 patients, and 1+ to 3+ for one patient) according to the IHC results. However, in all four of these cases, FISH of the resections showed no change. When IHC indicates a change in Her-2 expression after NAC, FISH is recommended.",
        "Doc_title":"Comparison of estrogen receptor, progesterone receptor and Her-2 status in breast cancer pre- and post-neoadjuvant chemotherapy.",
        "Journal":"Breast (Edinburgh, Scotland)",
        "Do_id":"18534850",
        "Doc_ChemicalList":"Receptors, Estrogen;Receptors, Progesterone;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Adult;Aged;Aged, 80 and over;Antineoplastic Combined Chemotherapy Protocols;Biopsy;Breast Neoplasms;Case-Control Studies;Female;Humans;Immunohistochemistry;In Situ Hybridization, Fluorescence;Japan;Middle Aged;Neoadjuvant Therapy;Receptor, ErbB-2;Receptors, Estrogen;Receptors, Progesterone",
        "Doc_meshqualifiers":"administration & dosage;therapeutic use;drug therapy;genetics;pathology;adverse effects;metabolism;genetics;metabolism;genetics;metabolism",
        "_version_":1605746297006981122},
      {
        "Doc_abstract":"Pregnancy-associated plasma protein-A (PAPP-A) is a zinc metalloproteinase in the insulin-like growth factor system that is expressed by tissues outside of pregnancy and involved in normal and dysregulated growth. PAPP-A has been implicated in several cancers. However, studies of PAPP-A expression in breast cancer are limited. In this study, we assessed PAPP-A expression in different subtypes of human malignant breast cancer. Design Formalin-fixed paraffin-embedded tumor samples from 46 female patients with invasive breast cancer were divided into five defined groups [using markers for HER2, estrogen receptor, progesterone receptor, proliferation] that roughly correlate with molecularly defined subtypes (luminal A, luminal B, luminal/HER2 +, HER2 +, triple negative). These samples were analyzed for PAPP-A expression by immunohistochemistry.;PAPP-A staining in tumor tissue was detected in 45 of 46 specimens. There were significantly greater extent and intensity of PAPP-A expression in luminal B specimens with high proliferation index than luminal A specimens (P = 0.01). However, there were no differences between specimens positive or negative for HER2 (P = 0.14) or positive and negative for estrogen receptor (P = 0.31).;PAPP-A was detected in almost all breast cancer specimens and a more intense and greater extent of its expression was associated with luminal B specimens compared to luminal A specimens. The role of PAPP-A in breast cancer prognosis, and possibly therapeutics, warrants further investigation.",
        "Doc_title":"Pregnancy-associated plasma protein-A expression in human  breast cancer.",
        "Journal":"Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society",
        "Do_id":"25468445",
        "Doc_ChemicalList":"Biomarkers, Tumor;Estrogen Receptor alpha;Receptors, Estrogen;Receptors, Progesterone;estrogen receptor alpha, human;Pregnancy-Associated Plasma Protein-A;PAPPA1 protein, human",
        "Doc_meshdescriptors":"Aged;Biomarkers, Tumor;Breast Neoplasms;Carcinoma, Ductal, Breast;Carcinoma, Lobular;Estrogen Receptor alpha;Female;Humans;Immunoenzyme Techniques;Middle Aged;Neoplasm Grading;Neoplasm Staging;Pregnancy;Pregnancy-Associated Plasma Protein-A;Prognosis;Receptors, Estrogen;Receptors, Progesterone",
        "Doc_meshqualifiers":"metabolism;metabolism;pathology;metabolism;pathology;metabolism;pathology;metabolism;metabolism;metabolism;metabolism",
        "_version_":1605742721307246594},
      {
        "Doc_abstract":"Although the incidence of breast cancer has been declining in recent years, the disease is still one of the leading causes of cancer deaths in women. Recently, breast cancer has been treated with innovative approaches that use hormone-sensitive therapies. This is because in at least one-third of breast cancers, estrogens mediated via the estrogen receptor pathway act as endocrine growth factors. Fulvestrant has been studied as both first- and second-line therapy for locally advanced and metastatic breast cancer, but few studies have shown its effect as third-line therapy alone. To observe the disease time to progression (TTP) obtained with fulvestrant when used on metastatic breast cancer as first-, second-, and also third-line therapy. We also aimed to correlate the TTP obtained with fulvestrant with hormone receptor, HER2 expression, and metastatic site. This was a cohort study that retrospectively examined medical records of 73 postmenopausal women with advanced breast cancer who were treated with fulvestrant (250 mg/month i.m. injection) and followed at the Department of Medical Oncology at Hospital do Cancer A. C. Camargo in SÃ£o Paulo, Brazil from August 2003 to December 2006. The median TTP with fulvestrant was about 11 months. When used as the first-line therapy, TTP was about 13 months; when used as second-line, TTP was about 6 months; and when used as third-line, it was about 12 months. No statistically significant difference was observed regarding the therapy line. In patients with positive ER tumors, TTP was 11 months. No significant difference in TTP was observed in negative ER tumors (TTP = 10 months). In patients with positive PgR tumors, TTP was 13 months and for negative PgR, TTP was 6 months (P = 0.008). According to the HER2 status, the TTP was 5 months for HER2+ and 10 months for HER2-. Our findings indicate that fulvestrant is an effective alternative for treatment of metastatic breast cancer.",
        "Doc_title":"Prolonged time to progression with fulvestrant for metastatic breast cancer.",
        "Journal":"Medical oncology (Northwood, London, England)",
        "Do_id":"20306159",
        "Doc_ChemicalList":"Antineoplastic Agents, Hormonal;Receptors, Estrogen;Receptors, Progesterone;fulvestrant;Estradiol",
        "Doc_meshdescriptors":"Antineoplastic Agents, Hormonal;Breast Neoplasms;Cohort Studies;Disease Progression;Disease-Free Survival;Estradiol;Female;Genes, erbB-2;Humans;Immunohistochemistry;Kaplan-Meier Estimate;Receptors, Estrogen;Receptors, Progesterone;Retrospective Studies",
        "Doc_meshqualifiers":"therapeutic use;drug therapy;genetics;pathology;analogs & derivatives;therapeutic use;biosynthesis;genetics;biosynthesis;genetics",
        "_version_":1605842081330233344},
      {
        "Doc_abstract":"Recent data have suggested considerable molecular differences in cancers from various ethnical groups. As molecular features are increasingly used for predicting cancer prognosis and response to therapy, better knowledge of ethnic molecular features is important. To identify potential molecular differences between breast cancers in Europe and the Middle East, we analyzed consecutive breast cancer series from Switzerland (n=2197) and Saudi Arabia (n=204). Tissue microarrays were analyzed by fluorescence in situ hybridization for HER2, CCND1, MYC, and EGFR amplification. The data revealed marked differences between Saudi and Swiss patients. Saudi breast cancers had a markedly higher frequency of HER2 (31 vs 17%; P<0.0001) and MYC (16 vs 5%; P<0.0001) amplifications than Swiss breast cancers. Remarkably, this was partly due to a much higher incidence of grade 3 cancers in the Saudi than in the Swiss population (65 vs 32%; P<0.0001). However, differences in amplification frequency hold also true within grade 3 cancers (HER2: 40 vs 30%, P<0.05; MYC: 22 vs 11%, P=0.002). Interestingly, in combination with known age standardized incidence rates of breast cancer in Saudi Arabia (21.6/100 000) and Switzerland (70.1/100 000), these data suggest that the incidence of high-grade breast cancer is comparable for Saudi and Swiss women, while the incidence of low-grade breast cancers is about 14 times lower in Saudi than for Swiss women. These observations suggest that a difference in genetic susceptibility and/or lifestyle between Saudi and Swiss women has a substantial and much higher than expected impact on the risk of low-grade breast cancer.",
        "Doc_title":"Predominance of high-grade pathway in breast cancer development of Middle East women.",
        "Journal":"Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc",
        "Do_id":"15803183",
        "Doc_ChemicalList":"Biomarkers, Tumor;MYC protein, human;Proto-Oncogene Proteins c-myc;Cyclin D1;Receptor, Epidermal Growth Factor;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Adult;Aged;Aged, 80 and over;Biomarkers, Tumor;Breast Neoplasms;Cyclin D1;Female;Gene Amplification;Genetic Predisposition to Disease;Humans;In Situ Hybridization, Fluorescence;Middle Aged;Neoplasm Staging;Proto-Oncogene Proteins c-myc;Receptor, Epidermal Growth Factor;Receptor, ErbB-2;Saudi Arabia;Switzerland;Tissue Array Analysis",
        "Doc_meshqualifiers":"genetics;ethnology;genetics;pathology;genetics;genetics;genetics;genetics;genetics;methods",
        "_version_":1605897203475283968},
      {
        "Doc_abstract":"HER2 gene amplification is observed in about 15% of breast cancers. The subgroup of HER2-positive breast cancers appears to be heterogeneous and presents complex patterns of gene amplification at the locus on chromosome 17q12-21. The molecular variations within the chromosome 17q amplicon and their clinical implications remain largely unknown. Besides the well-known TOP2A gene encoding Topoisomerase IIA, other genes might also be amplified and could play functional roles in breast cancer development and progression. This review will focus on the current knowledge concerning the HER2 amplicon heterogeneity, its clinical and biological impact and the pitfalls associated with the evaluation of gene amplifications at this locus, with particular attention to TOP2A and the link between TOP2A and anthracycline benefit. In addition it will discuss the clinical and biological implications of the amplification of ten other genes at this locus (MED1, STARD3, GRB7, THRA, RARA, IGFPB4, CCR7, KRT20, KRT19 and GAST) in breast cancer.",
        "Doc_title":"The HER2 amplicon in breast cancer: Topoisomerase IIA and beyond.",
        "Journal":"Biochimica et biophysica acta",
        "Do_id":"23628726",
        "Doc_ChemicalList":"Anthracyclines;Antigens, Neoplasm;Antineoplastic Agents;DNA-Binding Proteins;Receptor, ErbB-2;DNA Topoisomerases, Type II;DNA topoisomerase II alpha",
        "Doc_meshdescriptors":"Animals;Anthracyclines;Antigens, Neoplasm;Antineoplastic Agents;Breast Neoplasms;DNA Topoisomerases, Type II;DNA-Binding Proteins;Female;Gene Amplification;Humans;Receptor, ErbB-2",
        "Doc_meshqualifiers":"therapeutic use;metabolism;therapeutic use;drug therapy;enzymology;genetics;metabolism;metabolism;genetics",
        "_version_":1605902812092301312},
      {
        "Doc_abstract":"During the last 15 years we have witnessed an unprecedented expansion in the drugs developed to target human epidermal growth factor receptor-2 (HER-2) positive breast cancer. Trastuzumab, pertuzumab, ado-trastuzumab emtansine and lapatinib are currently food and drug administration (FDA)-approved for the treatment of breast cancer patients with HER-2 over-expressed. However, given the amount of information gathered from years of uninterrupted clinical research, it is essential to have periodic updates that succinctly recapitulate what we have learnt over these last years and help us to apply that information in our daily practice. This review will pursue that objective. We will summarize the most relevant and updated information related to the state of the art management of HER-2 positive breast cancer in all the clinical scenarios including the adjuvant, neoadjuvant and metastatic settings. But we will also critically appraise that literature in order to highlight some key clinical concepts that should not be overlooked. Lastly, this review will also point out some of the most promising strategies that are currently being tested and may soon become available. ",
        "Doc_title":"Therapeutic options for HER-2 positive breast cancer: Perspectives and future directions.",
        "Journal":"World journal of clinical oncology",
        "Do_id":"25114858",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605812296956772352},
      {
        "Doc_abstract":"Therapeutic modalities in node-negative breast cancer patients remain a matter of controversy. Various prognostic factors have been proposed to help select those patients that would most likely benefit from adjuvant therapy. In view of this notion the triple negative phenotype (hormone receptors and HER2 negative tumors) has gained increasing attention.;To evaluate the clinicopathologic characteristics of triple negative (TN) tumors in node-negative invasive breast carcinomas.;We retrospectively analyzed the archival pathology tissues of 160 patients with node-negative invasive carcinomas, diagnosed and treated in two surgical departments in Greece from 1999 to 2006. Statistical analysis was used to examine the association between TN tumors and other clinicopathological factors.;Triple negative breast cancers correlated with higher histologic grade, mitotic activation index and Ki-67 expression (p < 0.05). Moreover TN tumors were correlated with negative staining for bcl-2 (p < 0.05).;In node-negative breast cancer patients, triple negativity is associated with aggressive biologic behavior. Further studies are required to better understand the clinical implications of these findings.",
        "Doc_title":"Analysis of clinical and molecular associations of triple negative breast cancers in node-negative patients.",
        "Journal":"European journal of gynaecological oncology",
        "Do_id":"21077474",
        "Doc_ChemicalList":"Ki-67 Antigen;Receptors, Estrogen;Receptors, Progesterone;Tumor Suppressor Protein p53;ERBB2 protein, human;Receptor, Epidermal Growth Factor;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Adult;Aged;Breast Neoplasms;Female;Humans;Ki-67 Antigen;Lymphatic Metastasis;Male;Middle Aged;Receptor, Epidermal Growth Factor;Receptor, ErbB-2;Receptors, Estrogen;Receptors, Progesterone;Retrospective Studies;Tumor Suppressor Protein p53",
        "Doc_meshqualifiers":"chemistry;pathology;analysis;analysis;analysis;analysis;analysis;analysis",
        "_version_":1605845813828780032},
      {
        "Doc_abstract":"Gene expression patterns as well as gene interactions are under investigation             for their involvement in tumour heterogeneity. The molecular classification of             breast cancer based on hormone receptor expression, grade and HER2 receptor levels,             is indicative but not adequate enough to complete the prognostic data. The objectives             of this study were to validate the prognostic value of 19 genes, solely, and as             parts of classifiers (sets of genes), in breast cancer patients and to determine             whether the expression of these genes and classifiers is correlated with breast             cancer molecular classification. Gene expression was examined in the blood of             88 breast cancer patients and 50 healthy controls using multiplex quantitative             real-time PCR. Patients with a second primary malignancy showed a statistically             significant difference when compared with: i) patients with a single breast cancer,             for an 8-gene classifier (p<0.02); and ii) healthy individuals (classifier             FBX033, FLJ339115) (p<0.01), with respect to gene expression. The classifier             ENY2, USP38 was associated with the development of primary breast cancer. A newly             established classifier (ENY2, USP38, RPS7, Osbpl-1 and ETF1) indicated a statistically             significant association with HER2 subtype patients, compared to patients with             a different molecular classification (p<0.04). The gene FLJ33915 was differentially             expressed in a subgroup of HER2-positive patients with infiltrated axillary lymph             nodes (p<0.028). We validated the prognostic value of 4 classifiers for primary             and second primary malignancy. Evidence of a classifier predicting the HER2 subtype             and the gene FLJ33915 which subdivides HER2 subtype patients is also presented.",
        "Doc_title":"Subdivision of molecularly-classified groups by new gene signatures             in breast cancer patients.",
        "Journal":"Oncology reports",
        "Do_id":"22961600",
        "Doc_ChemicalList":"Biomarkers, Tumor",
        "Doc_meshdescriptors":"Adult;Aged;Biomarkers, Tumor;Breast Neoplasms;Female;Gene Expression Profiling;Gene Expression Regulation, Neoplastic;Humans;Middle Aged;Prognosis;Transcriptome",
        "Doc_meshqualifiers":"genetics;blood;genetics",
        "_version_":1605752200442675200},
      {
        "Doc_abstract":"When breast cancer patients develop distant metastases, the choice of systemic treatment is usually based on tissue characteristics of the primary tumor as determined by immunohistochemistry (IHC) and/or molecular analysis. Several previous studies have shown that the immunophenotype of distant breast cancer metastases may be different from that of the primary tumor (\"receptor conversion\"), leading to inappropriate choice of systemic treatment. The studies published so far are however small and/or methodologically suboptimal. Therefore, definite conclusions that may change clinical practice could not yet be drawn. We therefore aimed to study receptor conversion for estrogen receptor alpha (ERÎ±), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) in a large group of distant (non-bone) breast cancer metastases by re-staining all primary tumors and metastases with current optimal immunohistochemical and in situ hybridization methods on full sections.;233 distant breast cancer metastases from different sites (76 skin, 63 liver, 43 lung, 44 brain and 7 gastro-intestinal) were IHC stained for ERÎ±, PR and HER2, and expression was compared to that of the primary tumor. HER2 in situ hybridization (ISH) was done in cases of IHC conversion or when primary tumors or metastases showed an IHC 2+ result.;Using a 10% threshold, receptor conversion by IHC for ERÎ±, PR occurred in 10.3%, 30.0% of patients, respectively. In 10.7% of patients, conversion from \"ER+ or PR+\" to ER-/PR- and in 3.4% from ER-/PR- to \"ER+ or PR+\" was found. Using a 1% threshold, ERÎ± and PR conversion rates were 15.1% and 32.6%. In 12.4% of patients conversion from \"ER+ or PR+\" to ER-/PR-, and 8.2% from ER-/PR- to \"ER+ or PR+\" occurred. HER2 conversion occurred in 5.2%. Of the 12 cases that showed HER2 conversion by IHC, 5 showed also conversion by ISH. One further case showed conversion by ISH, but not by IHC. Conversion was mainly from positive in the primary tumor to negative in the metastases for ERÎ± and PR, while HER2 conversion occurred equally both ways. PR conversion occurred significantly more often in liver, brain and gastro-intestinal metastases.;Receptor conversion by immunohistochemistry in (non-bone) distant breast cancer metastases does occur, is relatively uncommon for ERÎ± and HER2, and more frequent for PR, especially in brain, liver and gastro-intestinal metastases.",
        "Doc_title":"Receptor conversion in distant breast cancer metastases.",
        "Journal":"Breast cancer research : BCR",
        "Do_id":"20863372",
        "Doc_ChemicalList":"Biomarkers, Tumor;Estrogen Receptor alpha;Receptors, Progesterone;ERBB2 protein, human;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Adult;Aged;Aged, 80 and over;Biomarkers, Tumor;Brain Neoplasms;Breast Neoplasms;Estrogen Receptor alpha;Female;Gastrointestinal Neoplasms;Gene Expression Regulation, Neoplastic;Humans;Immunohistochemistry;Liver Neoplasms;Lung Neoplasms;Middle Aged;Neoplasm Metastasis;Receptor, ErbB-2;Receptors, Progesterone;Skin Neoplasms",
        "Doc_meshqualifiers":"genetics;metabolism;metabolism;secondary;metabolism;pathology;metabolism;metabolism;secondary;metabolism;secondary;metabolism;secondary;metabolism;metabolism;metabolism;secondary",
        "_version_":1605818592349126658},
      {
        "Doc_abstract":"To investigate the effect of quercetin on the reversal of tamoxifen resistance in breast cancer cells, and explore the underlying mechanism.;We established a tamoxifen-resistant breast cancer cell line (MCF-7Ca/TAM-R), and exposed it to different concentrations of quercetin (experimental group 1: 10 Î¼M, group 2: 25 Î¼M, and group 3: 50Î¼M). Each group was further subdivided into 2 subgroups: 1) simultaneous administration of quercetin and 4-hydroxytamoxifen (OHT); 2) sequential administration of quercetin (12-h induction) followed by OHT. No drug exposure and OHT alone were used as controls. We determined cell survival, apoptosis, and expression of ERÎ± (estrogen receptor Î±) and Her-2 (human epidermal growth factor receptor 2).;With increasing dosage of quercetin, significant decrease in proliferation and increase in apoptosis was observed. Low concentrations of quercetin (10 Î¼M) had no effects. We found no significant difference between simultaneous and sequential mode of drug administration. Further, with increasing dosage of quercetin, we observed a gradual reduction in Her-2 expression and upregulation of ERÎ±. Again, no difference in Her-2 and ERÎ± protein levels between simultaneous and sequential drug administration was noticed.;Proliferation inhibition and apoptosis in MCF-7Ca/TAM-R cells increase with increasing dosage of quercetin. This suggests that quercetin can reverse tamoxifen resistance in breast cancer cells. The underlying mechanism likely involves upregulation of ERÎ± combined with downregulation of Her-2. However, this effect is independent of whether quercetin and tamoxifen are administered simultaneously or sequentially.",
        "Doc_title":"Quercetin reverses tamoxifen resistance in breast cancer cells.",
        "Journal":"Journal of B.U.ON. : official journal of the Balkan Union of Oncology",
        "Do_id":"26214621",
        "Doc_ChemicalList":"Antineoplastic Agents, Hormonal;Estrogen Antagonists;Estrogen Receptor alpha;estrogen receptor alpha, human;Tamoxifen;afimoxifene;Quercetin;ERBB2 protein, human;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Antineoplastic Agents, Hormonal;Apoptosis;Breast Neoplasms;Cell Proliferation;Cell Survival;Dose-Response Relationship, Drug;Drug Resistance, Neoplasm;Estrogen Antagonists;Estrogen Receptor alpha;Female;Humans;MCF-7 Cells;Quercetin;Receptor, ErbB-2;Signal Transduction;Tamoxifen;Time Factors",
        "Doc_meshqualifiers":"pharmacology;drug effects;metabolism;pathology;drug effects;drug effects;drug effects;pharmacology;antagonists & inhibitors;metabolism;pharmacology;metabolism;drug effects;analogs & derivatives;pharmacology",
        "_version_":1605928721056792576},
      {
        "Doc_abstract":"The introduction of trastuzumab into clinical practice changed the natural course of HER2-positive breast cancer. Currently, treatment with trastuzumab represents the standard of care for HER2-positive breast cancer and this treatment has been approved in the adjuvant, neoadjuvant, and metastatic settings. Besides trastuzumab, two other anti-HER2 agents-lapatinib and pertuzumab-have been approved for the treatment of HER2-positive advanced breast cancer. Strong biologic data support the concept of dual HER2 blockade, with different anti-HER2 agents demonstrating complementary mechanisms of action. Several neoadjuvant and metastatic studies performed in HER2-positive breast cancer using dual HER2 blockade have been proven to outperform anti-HER2 monotherapies. These dual combinations of agents represent a promising therapeutic strategy that is now reaching clinical practice. In this review we describe the results of studies utilizing dual blockade in patients with HER2-positive breast cancer.",
        "Doc_title":"Dual human epidermal growth factor receptor 2 blockade for the treatment of HER2-positive breast cancer.",
        "Journal":"Breast cancer (Tokyo, Japan)",
        "Do_id":"23377763",
        "Doc_ChemicalList":"Antibodies, Monoclonal;ERBB2 protein, human;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Antibodies, Monoclonal;Breast Neoplasms;Female;Humans;Neoadjuvant Therapy;Receptor, ErbB-2",
        "Doc_meshqualifiers":"therapeutic use;drug therapy;metabolism;antagonists & inhibitors;metabolism",
        "_version_":1605746834340315136},
      {
        "Doc_abstract":"Human epidermal growth factor receptor 2 (HER2) Ile655Val polymorphism may affect the efficacy of trastuzumab treatment of breast cancer.;HER2 Ile655Val polymorphism was determined in 4167 patients with primary breast cancer using a polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) assay. We investigated the associations between the HER2 Ile655Val polymorphism and clinical outcomes in women with HER2-negative breast cancer and with HER2-positive breast cancer who received trastuzumab or who did not.;At a median follow-up of 44 months, HER2 Ile655Val polymorphism was not significantly associated with survival either in the entire study population of 4167 patients or in 2976 HER2-negative breast cancer patients. Among 816 HER2-positive patients who received adjuvant chemotherapy and/or endocrine therapy without trastuzumab treatment, patients with the Val/Ile or the Val/Val genotype had a significantly worse disease-free survival (DFS) and distant DFS (DDFS) than those with the Ile/Ile genotype (DFS, adjusted hazard ratio [HR] 1.5; 95% confidence interval [CI] 1.0-2.3; P = 0.037; DDFS, adjusted HR 1.9; 95% CI 1.2-2.9 P = 0.005). In contrast, among 212 HER2-positive patients who received chemotherapy in combination with trastuzumab treatment, patients with the Val/Ile or the Val/Val genotype had a significantly better DFS and DDFS than those with the Ile/Ile genotype (5-year DFS, 100% versus 83%; P = 0.008; 5-year DDFS, 100% versus 89%; P = 0.031).;HER2 Ile655Val polymorphism affects the function of HER2 gene only restricted in HER2-positive breast cancers. HER2-positive breast cancer patients with the Val variant have an aggressive phenotype, but are sensitive to trastuzumab treatment.",
        "Doc_title":"Association between the HER2 Ile655Val polymorphism and response to trastuzumab in women with operable primary breast cancer.",
        "Journal":"Annals of oncology : official journal of the European Society for Medical Oncology",
        "Do_id":"24608202",
        "Doc_ChemicalList":"Antibodies, Monoclonal, Humanized;Antineoplastic Agents;ERBB2 protein, human;Receptor, ErbB-2;Trastuzumab",
        "Doc_meshdescriptors":"Adult;Aged;Antibodies, Monoclonal, Humanized;Antineoplastic Agents;Breast Neoplasms;Drug Resistance, Neoplasm;Female;Genes, erbB-2;Humans;In Situ Hybridization, Fluorescence;Kaplan-Meier Estimate;Middle Aged;Polymerase Chain Reaction;Polymorphism, Restriction Fragment Length;Polymorphism, Single Nucleotide;Proportional Hazards Models;Receptor, ErbB-2;Trastuzumab",
        "Doc_meshqualifiers":"therapeutic use;therapeutic use;drug therapy;genetics;pathology;genetics;genetics;genetics",
        "_version_":1605841315925327872},
      {
        "Doc_abstract":"Amplification of the HER2 oncogene in breast cancer identifies patients who are likely to respond to anti-HER2 mAb therapy. Current clinical practice dictates that all breast cancers first undergo HER2 screening by IHC. Strongly positive (3+ on a 0-to-3+ scale) IHC cases are considered as HER2-amplified tumors and are not evaluated further because of the strong correlation between HER2 gene amplification as measured by FISH and 3+ IHC. This strong correlation has recently been questioned, and some data suggest that over 50% of 3+ IHC HER2 immunostains may not be due to HER2 gene amplification. To help resolve this discrepancy, the authors developed a quantitative PCR assay for HER2. Quantitative PCR was used to determine the amount of HER2 DNA relative to a control gene, IF2 (eukaryotic translation initiation factor, 2p11.1-q11.1). The PCR assay is performed on genomic DNA isolated from paraffin-embedded breast cancer tissue. The PCR assay developed is a monoplex assay in which the HER2 and IF2 PCRs are performed in separate cuvettes. Cases of HER2 FISH amplified breast cancer and HER2 FISH nonamplified breast cancer were chosen for study by monoplex HER2 PCR. HER2 overexpression was evaluated by IHC. Twenty-two cases of HER2-positive and 22 cases of HER2-negative breast cancer, as determined by FISH, were assayed for HER2 by PCR and IHC. Sixteen of the 44 cases were interpreted as 3+ IHC. All 16 showed HER2 amplification by PCR and 15 showed HER2 amplification by FISH. One FISH negative case was found to be HER2 amplified by PCR and showed 3+ IHC stain, suggesting the FISH result in this case was underinterpreted. Two FISH positive cases were found to be negative by PCR and negative in IHC as well, suggesting the FISH result in these cases was overinterpreted. The authors conclude that 3+ IHC membrane staining correctly identifies neoplasms showing HER2 gene amplification. Monoplex HER2 PCR may offer significant advantages over both IHC and FISH for HER2 testing in breast cancer.",
        "Doc_title":"Correlation of HER2 gene amplification with immunohistochemistry in breast cancer as determined by a novel monoplex polymerase chain reaction assay.",
        "Journal":"Applied immunohistochemistry & molecular morphology : AIMM",
        "Do_id":"16280662",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"Breast Neoplasms;Female;Gene Amplification;Genes, erbB-2;Humans;Immunohistochemistry;In Situ Hybridization, Fluorescence;Polymerase Chain Reaction;Reproducibility of Results",
        "Doc_meshqualifiers":"genetics;pathology;methods",
        "_version_":1605875186413862912},
      {
        "Doc_abstract":"In this specifically designed, prospective study, the authors addressed the predictive value of circulating levels of the extracellular domain (ECD) of HER2 in patients with metastatic breast cancer who were treated with letrozole.;Two hundred twenty-six patients with hormone receptor-positive, metastatic breast cancer received letrozole (2.5 mg daily) until they developed either disease progression or unacceptable toxicity. Efficacy was measured primarily as the time to progression (TTP) and, secondarily, as the objective response rate (ORR) and overall survival. HER2 ECD levels were determined by using a sandwich enzyme HER2/neu immunoassay before letrozole treatment was initiated. Positive HER2 ECD status was correlated with treatment efficacy.;Forty-two patients (19%) had elevated HER2 ECD levels, which were associated with primary tumor HER2 expression (P < .001) but not with age, performance status, location, or number of metastatic sites. The median TTP was significantly shorter among patients who had elevated HER2 ECD compared with the median TTP among patients who had normal levels (4 months vs 14 months; P = .0004), and the ORR was lower in the group with elevated HER2 ECD levels (14% vs 30%; P < .036). Overall survival was significantly shorter among patients with elevated serum HER-2 ECD (P < .0005).;Elevated HER2 ECD concentrations predicted poorer outcomes in postmenopausal women with metastatic hormone receptor-positive breast cancer who were treated with aromatase inhibitors like letrozole.",
        "Doc_title":"High circulating HER2 extracellular domain levels correlate with reduced efficacy of an aromatase inhibitor in hormone receptor-positive metastatic breast cancer: a confirmatory prospective study.",
        "Journal":"Cancer",
        "Do_id":"17926331",
        "Doc_ChemicalList":"Aromatase Inhibitors;Nitriles;Receptors, Estrogen;Receptors, Progesterone;Triazoles;letrozole;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Aromatase Inhibitors;Breast Neoplasms;Cohort Studies;Female;Humans;Neoplasm Metastasis;Nitriles;Prospective Studies;Receptor, ErbB-2;Receptors, Estrogen;Receptors, Progesterone;Treatment Outcome;Triazoles",
        "Doc_meshqualifiers":"therapeutic use;drug therapy;metabolism;pathology;therapeutic use;blood;metabolism;metabolism;therapeutic use",
        "_version_":1605783247516598272},
      {
        "Doc_abstract":"In a retrospective study of 265 patients with breast cancer over 3 years (January 2007-September 2009) we examined the epidemiological profile of breast cancer to determine the impact of biological and prognostic factors on survival over 3 years and on the epidemiology of this cancer. Estrogen (RE), progesterone (RP) and human epidermal growth factor receptors (HER2) were evaluated and RE/RP/HER2 status determined. The patients were young (median age 45 years). Invasive tumours were found in 95.5% of the women. The average tumour size was big [3.6 (SD 2.6) cm] and only 14% were histological grade 1. Large tumour size and high histological grade were independent of patient's age. Overall survival at 3 years was only 49% for the RE-/RP-/HER2- subtype and 75% for the RE-/RP-/HER2+ subtype, while it was 96% for the RE+/RP+/HER2- subtype. The young age, large tumour size and high histological grade in our population suggest a lack of awareness of women about breast cancer.",
        "Doc_title":"[Epidemiological and biologic profile of breast cancer in Fez-Boulemane, Morocco].",
        "Journal":"Eastern Mediterranean health journal = La revue de sante de la Mediterranee orientale = al-Majallah al-sihhiyah li-sharq al-mutawassit",
        "Do_id":"22355946",
        "Doc_ChemicalList":"Biomarkers, Tumor",
        "Doc_meshdescriptors":"Adolescent;Adult;Aged;Aged, 80 and over;Biomarkers, Tumor;Breast Neoplasms;Female;Humans;Middle Aged;Morocco;Prognosis;Retrospective Studies;Risk Factors;Survival Rate",
        "Doc_meshqualifiers":"epidemiology;pathology;epidemiology",
        "_version_":1605765679039905792},
      {
        "Doc_abstract":"Breast cancer is a heterogeneous disease and there is a continual drive to identify markers that will aid in predicting prognosis and response to therapy. To date, relatively few markers have established prognostic power. Oestrogen receptor (ER) is probably the most powerful predictive marker in breast cancer management, both in determining prognosis and in predicting response to hormone therapies. Progesterone receptor (PR) is also a widely used marker, although its value is less well established. HER-2 status has also become a routine prognostic and predictive factor in breast cancer. Given the importance of these biological markers in patient management, it is essential that assays are robust and quality controlled, and that interpretation is standardized. Furthermore, it is important to be aware of the limitations in their predictive power, and how this may be refined through addition of further biological markers. The aim of this review is to provide an overview of the established role of ER, PR and HER-2 in patient management, the current standards for assessing these markers, as well as highlighting the controversies that still surround their use and methods of assessment.",
        "Doc_title":"Predictive markers in breast cancer--the present.",
        "Journal":"Histopathology",
        "Do_id":"18171419",
        "Doc_ChemicalList":"Biomarkers, Tumor;Receptors, Estrogen;Receptors, Progesterone;ERBB2 protein, human;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Biomarkers, Tumor;Breast Neoplasms;Female;Humans;Predictive Value of Tests;Prognosis;Receptor, ErbB-2;Receptors, Estrogen;Receptors, Progesterone",
        "Doc_meshqualifiers":"metabolism;diagnosis;metabolism;metabolism;metabolism;metabolism",
        "_version_":1605752977270767616},
      {
        "Doc_abstract":"Many epidemiologic studies have demonstrated that younger women with breast cancer have a worse survival than older women, which may potentially be related to more aggressive tumor biology. Despite aggressive treatment, local and distant failure rates are higher. This review examines the studies that have investigated whether young age at diagnosis is associated with biologically more aggressive cancers for young women with invasive breast cancer, ductal carcinoma in situ, BRCA 1 and 2 mutations, and breast cancer during pregnancy. Young women with breast cancer are more likely to present with higher stage than their older counterparts. Their tumors are more likely to be estrogen receptor-negative, higher grade, and have increased LVI, Ki-67, and p53; yet most studies show no difference in HER-2/neu expression between younger and older women. Recent advances in molecular biology have shown that lymph node negative, estrogen receptor-positive young women are more likely than older women to have a higher Recurrence Scoretrade mark and therefore a worse prognosis. Molecular profiling has also revealed that young African-American women with breast cancer are more likely to have the more aggressive basal type of breast cancer, which may contribute to their worse prognosis compared to young white women.",
        "Doc_title":"Tumor biology of breast cancer in young women.",
        "Journal":"Breast disease",
        "Do_id":"16823162",
        "Doc_ChemicalList":"Biomarkers, Tumor;Receptors, Estrogen;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Adult;Age Factors;Aged;Biomarkers, Tumor;Breast Neoplasms;Female;Genes, BRCA1;Genes, BRCA2;Humans;Middle Aged;Mutation;Prognosis;Receptor, ErbB-2;Receptors, Estrogen",
        "Doc_meshqualifiers":"analysis;chemistry;genetics;mortality;analysis;analysis",
        "_version_":1605750778191937536},
      {
        "Doc_abstract":"ZD1839 is a tyrosine kinase inhibitor of the epidermal growth factor receptor (EGFR) that has shown clinical activity against EGFR-expressing tumors. Our aim was to explore the effects of ZD1839 in breast cancer cell lines expressing different levels of EGFR and the closely related HER2 receptor.;We studied the growth-inhibitory effects of ZD1839 in a series of breast carcinoma cell lines. In HER2-overexpressing BT-474 breast cancer cells, we studied the effects of ZD1839 on cell growth and heterodimerization of receptors under basal and ligand-stimulated conditions.;ZD1839 was an equally potent inhibitor of growth in breast cancer cells expressing high levels of EGFR and HER2. In BT-474 breast cancer cells, ZD1839 abolished EGF- and heregulin-induced activation of ErbB receptors and downstream signaling molecules. Because ZD1839 does not inhibit the HER2 tyrosine kinase in vitro, and because heregulin is a ligand that activates HER2 by binding to HER3 and HER4 but does not bind to the EGFR, our findings suggested that ZD1839 interfered with HER2 function in intact cells. Searching for mechanisms, we report that ZD1839 induces the formation of inactive unphosphorylated EGFR/HER2 and EGFR/HER3 heterodimers. Furthermore, ZD1839 completely abolishes basal and heregulin-induced formation of active phosphorylated HER2/HER3 heterodimers.;ZD1839 inhibits the growth of HER2-overexpressing breast cancer cells, possibly by sequestration of HER2 and HER3 receptors in an inactive heterodimer configuration with the EGFR. Our findings suggest that there is a strong rationale to conduct clinical trials of ZD1839 in patients with HER2-overexpressing breast tumors.",
        "Doc_title":"ZD1839, a specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, induces the formation of inactive EGFR/HER2 and EGFR/HER3 heterodimers and prevents heregulin signaling in HER2-overexpressing breast cancer cells.",
        "Journal":"Clinical cancer research : an official journal of the American Association for Cancer Research",
        "Do_id":"12684395",
        "Doc_ChemicalList":"Antineoplastic Agents;Ligands;Neuregulin-1;Quinazolines;Receptor, Epidermal Growth Factor;Receptor, ErbB-2;Receptor, ErbB-3;Fluorescein-5-isothiocyanate;gefitinib",
        "Doc_meshdescriptors":"Antineoplastic Agents;Apoptosis;Blotting, Western;Breast Neoplasms;Cell Division;Cell Line, Tumor;Dimerization;Dose-Response Relationship, Drug;Flow Cytometry;Fluorescein-5-isothiocyanate;Humans;Ligands;Models, Biological;Neuregulin-1;Phosphorylation;Precipitin Tests;Quinazolines;Receptor, Epidermal Growth Factor;Receptor, ErbB-2;Receptor, ErbB-3;Signal Transduction;Time Factors",
        "Doc_meshqualifiers":"pharmacology;metabolism;metabolism;pharmacology;antagonists & inhibitors;metabolism;metabolism",
        "_version_":1605809853059563520},
      {
        "Doc_abstract":"We investigated the effects of combined treatment with 5-fluorouracil and apigenin on proliferation and apoptosis, as well as the underlying mechanism, in human breast cancer MDA-MB-453 cells. The MDA-MB-453 cells, which have been shown to overexpress ErbB2, were resistant to 5-fluorouracil; 5-fluorouracil exhibited a small dose-dependent anti-proliferative effect, with an IC50 of 90 microM. Interestingly, combined treatment with apigenin significantly decreased the resistance. Cellular proliferation was significantly inhibited in cells exposed to 5-fluorouracil at its IC50 and apigenin (5, 10, 50 and 100 microM), compared with proliferation in cells exposed to 5-fluorouracil alone. This inhibition in turn led to apoptosis, as evidenced by an increased number of apoptotic cells and the activation of caspase-3. To investigate the mechanism by which the combination of 5-fluorouracil and apigenin induces apoptosis, ErbB2 expression was analyzed. The level of ErbB2 was unchanged by 5-fluorouracil alone but was drastically reduced in cells treated with 5-fluorouracil plus apigenin. Moreover, compared with 5-fluorouracil alone, 5-fluorouracil in combination with apigenin at concentrations >10 microM exerted a pro-apoptotic effect via the inhibition of Akt expression. Taken together, our results suggest that 5-fluorouracil acts synergistically with apigenin inhibiting cell growth and inducing apoptosis via the down-regulation of ErbB2 expression and Akt signaling.",
        "Doc_title":"5-Fluorouracil combined with apigenin enhances anticancer activity through induction of apoptosis in human breast cancer MDA-MB-453 cells.",
        "Journal":"Oncology reports",
        "Do_id":"19885610",
        "Doc_ChemicalList":"Apigenin;Receptor, ErbB-2;Proto-Oncogene Proteins c-akt;Caspase 3;Fluorouracil",
        "Doc_meshdescriptors":"Antineoplastic Combined Chemotherapy Protocols;Apigenin;Apoptosis;Breast Neoplasms;Caspase 3;Cell Line, Tumor;Cell Proliferation;Down-Regulation;Drug Screening Assays, Antitumor;Drug Synergism;Fluorouracil;Humans;Inhibitory Concentration 50;Proto-Oncogene Proteins c-akt;Receptor, ErbB-2",
        "Doc_meshqualifiers":"therapeutic use;administration & dosage;drug therapy;metabolism;administration & dosage;metabolism;metabolism",
        "_version_":1605839441799151616},
      {
        "Doc_abstract":"Breast cancer is the most common neoplasm affecting women in the Western world with approximately 1 in 11 developing the malignancy and 1 in 30 dying from the disease. For optimum management of these patients, assay of certain biochemical markers is necessary. Clinically, the most useful markers in breast cancer are the estrogen and progesterone receptors that are used to predict response to hormone therapy. Both American and European Expert Panels have recommended routine determination of these steroid hormone receptors in all patients with breast cancer. For surveillance of patients with diagnosed breast cancer, both CA 15-3 and BR 27.29 can be used. Serial determinations of these markers have the potential to preclinically detect recurrent disease and monitor the treatment of advanced disease. However, the benefit of this monitoring on patient outcome or quality of life is not clear. New or potentially new markers for breast cancer include BRCA1 and BRCA2 for selecting patients at high risk of developing breast cancer, urokinase plasminogen activator and PA1-1 for assessing prognosis and HER-2 for predicting response to the therapeutic antibody, Herceptin.",
        "Doc_title":"Biochemical markers in breast cancer: which ones are clinically useful?",
        "Journal":"Clinical biochemistry",
        "Do_id":"11522269",
        "Doc_ChemicalList":"Biomarkers;Plasminogen Inactivators;Receptors, Estrogen;Receptors, Progesterone;Receptor, ErbB-2;Urokinase-Type Plasminogen Activator",
        "Doc_meshdescriptors":"Biomarkers;Breast Neoplasms;Female;Follow-Up Studies;Humans;Plasminogen Inactivators;Prognosis;Receptor, ErbB-2;Receptors, Estrogen;Receptors, Progesterone;Risk Assessment;Urokinase-Type Plasminogen Activator",
        "Doc_meshqualifiers":"analysis;diagnosis;genetics;analysis;analysis;analysis;metabolism;analysis;metabolism;analysis",
        "_version_":1605802468955914240},
      {
        "Doc_abstract":"In the last 25 years new treatment options in breast cancer have evolved. We wanted to determine whether the survival of; patients with metastatic breast cancer have improved during this period.;Patients consecutively diagnosed with disseminated breast cancer 1985-2014 in the County of Kalmar, Sweden, were identified and followed to 2016. Survival was calculated for each successive 5 year interval. Separate analyses were performed for pts with ER and/or PR and HER2 positive tumours resp.;Median survival of the 784 patients increased successively from 13 to 33 months. Five year survival increased from 10 to 27%. Patients with high grade primary tumours had the shortest post recurrence survival time but their median survival increased significantly by time from 12 to 30 months, 3 year survival from 16 to 38% and 5 year from 5 to 20%. Median survival for patients with grade 2 tumours was 2 years and did not improve. Only 47 patients had grade 1 tumours and their median survival of 4 years did not change. Median survival for HER2 positive patients treated before the introduction of trastuzumab in year 2000 was 14 months and after 2000 29 months, 5 year survival improved from 2 to 31%.;Survival in metastatic breast cancer improved 1985-2016. For the first time a significant increase in survival time for patients with metastasis from fast-growing grade 3 tumours was seen. The most striking improvement was achieved in the HER2 positive subset.",
        "Doc_title":"Improved survival in metastatic breast cancer 1985-2016.",
        "Journal":"Breast (Edinburgh, Scotland)",
        "Do_id":"27810699",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605837384878915584},
      {
        "Doc_abstract":"To investigate the predictive value of HER-2 and ER expression for chemosensitivity of taxane in the treatment of advanced breast cancer.;Of 268 advanced breast cancer patients treated: 71 were by paclitaxel alone, 32 by docetaxel alone, 110 by paclitaxel combined with anthracylines or gemcitabine or platins and 55 by docetaxel-based combinations. HER-2 and ER expression of all patients treated by taxane underwent immunohistochemical (IHC) assay.;Univariate analysis showed: the response rate (RR) in HER-2 overexpression group was 56.7%, and in HER-2 weak expression group 33.3% (P = 0.003). The response rate in ER positive group and ER negative group was 33.3% and 48.9%, respectively, with a significant difference (P = 0.015). The RR was 67.6% in ER negative but HER-2 overexpression group. However, in ER positive but HER-2 weak expression group and the other groups, the RR were around 35% (P < 0. 01). Multivariate analysis showed that overexpression of HER-2 was the only significant factor to predict the chemosensitivity of taxane (P = 0. 007), but the ER, Karnofsky performance score (KPS), anthracylines, metastatic sites were not the statistically significant chemo-sensitivity predictive factors for taxane.;ER negative and/or HER-2 overexpression, especially latter, may be associated with good response in advanced breast cancers treated by taxane.",
        "Doc_title":"[HER-2 and ER expression in prediction of chemo-sensitivity of taxane for advanced breast cancer].",
        "Journal":"Zhonghua zhong liu za zhi [Chinese journal of oncology]",
        "Do_id":"17152493",
        "Doc_ChemicalList":"Antineoplastic Agents, Phytogenic;Receptors, Estrogen;Taxoids;docetaxel;Receptor, ErbB-2;Paclitaxel",
        "Doc_meshdescriptors":"Antineoplastic Agents, Phytogenic;Breast Neoplasms;Female;Humans;Immunohistochemistry;Multivariate Analysis;Neoplasm Staging;Paclitaxel;Predictive Value of Tests;Prognosis;Receptor, ErbB-2;Receptors, Estrogen;Remission Induction;Retrospective Studies;Taxoids",
        "Doc_meshqualifiers":"therapeutic use;drug therapy;metabolism;pathology;therapeutic use;metabolism;metabolism;therapeutic use",
        "_version_":1605907334922502144},
      {
        "Doc_abstract":"We examined an economical method for evaluating the amplification of the human epidermal growth factor receptor 2 (HER2) gene in breast cancer specimens.;We compared HER2 amplification determined by fluorescence in situ hybridization (FISH) on whole-tissue (WT) blocks used for diagnostic and on tissue microarray (TMA) sections for a cohort of 521 consecutive patients with breast cancer. In a subset of 116 patients, we examined HER2 concordance from the WT section and a TMA section from a randomly chosen additional block (a proxy of the core biopsy).;Overall concordance for HER2 amplification between WT and TMA sections was 98.2%, and between sections from WT and from the additional block was 99.0%.;The high concordance rates support the use of TMA for the evaluation of HER2 amplification in breast cancer and suggest that FISH can be used to assess HER2 using core biopsies.",
        "Doc_title":"Tissue Microarray Is a Reliable Tool for the Evaluation of HER2 Amplification in Breast Cancer.",
        "Journal":"Anticancer research",
        "Do_id":"27630309",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605819945704226816},
      {
        "Doc_abstract":"Molecular profiling studies have identified subtypes of breast cancer that can be approximately classified by estrogen receptor (ER), progesterone receptor (PR), and HER-2/neu (HER-2) expression. These molecular subtypes are prognostically significant, but to the authors' knowledge, differences in their etiologic profiles have not been established. Reproductive factors may plausibly be differentially correlated with the risk of different breast cancer subtypes because these factors are presumed to impact exposure to endogenous sex hormones.;The authors pooled 2 population-based, case-control studies of breast cancer in women ages 55 to 79 years for an analysis including 1476 controls and 1023 cases of luminal breast cancer, 39 cases of HER-2-overexpressing breast cancer, and 78 cases of triple-negative breast cancer. Polytomous logistic regression was used to compare each case group with controls.;Associations varied by molecular subtype. Early age at menarche was only found to be associated with risk of HER-2-overexpressing disease (odds ratio [OR] of 2.7; 95% confidence interval [95% CI], 1.4-5.5), whereas breastfeeding for > or =6 months was only found to be protective for luminal and triple-negative disease (OR of 0.8 [95% CI, 0.6-1.0] and OR of 0.5 [95% CI, 0.3-0.9], respectively). Both late age at menopause and the use of estrogen plus progestin hormone therapy were only found to be associated with risk of luminal disease (OR of 1.6 [95% CI, 1.1-2.2] and OR of 1.7 [95% CI, 1.3-2.1], respectively). No differences in risks associated with parity or age at first live birth were observed by subtype.;Certain reproductive factors may have a greater impact on the risk of certain molecular subtypes of disease compared with others. Future studies that further define the etiology of breast cancer subtypes will add to the biologic understanding of this disease.",
        "Doc_title":"Reproductive and hormonal risk factors for postmenopausal luminal, HER-2-overexpressing, and triple-negative breast cancer.",
        "Journal":"Cancer",
        "Do_id":"18726992",
        "Doc_ChemicalList":"Receptor, ErbB-2",
        "Doc_meshdescriptors":"Aged;Breast Feeding;Breast Neoplasms;Case-Control Studies;Female;Hormone Replacement Therapy;Humans;Middle Aged;Neoplasms, Hormone-Dependent;Odds Ratio;Parity;Postmenopause;Pregnancy;Receptor, ErbB-2;Reproductive History;Risk Factors",
        "Doc_meshqualifiers":"etiology;adverse effects;etiology;metabolism",
        "_version_":1605824872716435456},
      {
        "Doc_abstract":"There is a growing body of evidence that HER2 status can change during disease recurrence or progression in breast cancer patients. In this context, re-evaluation of HER2 status by assessment of HER2 expression on circulating tumor cells (CTCs) is a strategy with potential clinical application. The aim of this trial was to determine the HER2 status of CTCs in metastatic breast cancer patients comparing two CTC assays. A total of 254 patients with metastatic breast cancer from nine German university breast cancer centers were enrolled in this prospective study. HER2 status of CTCs was assessed using both the FDA-approved CellSearchÂ® assay and AdnaTest BreastCancerâ„¢. Using the CellSearch assay, 122 of 245 (50%) patients had â‰¥5 CTCs, and HER2-positive CTCs were observed in 50 (41%) of these patients. Ninety of 229 (39%) patients were CTC positive using AdnaTest BreastCancer, and HER2 positivity rate was 47% (42 of 90). The rate of breast cancer patients with HER2-negative primary tumors but HER2-positive CTCs was 32% (25 of 78) and 49% (28 of 57) using the CellSearch assay and AdnaTest BreastCancer, respectively. Considering only those patients who had CTCs on both tests (n = 62), concordant results regarding HER2 positivity were obtained in 50% of the patients (31/62) (P = 0.96, Îº = -0.006). HER2-positive CTCs can be detected in a relevant number of patients with HER2 negative primary tumors. Therefore, it will be mandatory to correlate the assay-dependent HER2 status of CTCs to the clinical response on HER2-targeted therapies.",
        "Doc_title":"HER2 status of circulating tumor cells in patients with metastatic breast cancer: a prospective, multicenter trial.",
        "Journal":"Breast cancer research and treatment",
        "Do_id":"20859679",
        "Doc_ChemicalList":"Biomarkers, Tumor;RNA, Neoplasm;Reagent Kits, Diagnostic;ERBB2 protein, human;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Biomarkers, Tumor;Breast Neoplasms;Disease-Free Survival;Female;Fluorescent Antibody Technique;Germany;Humans;Neoplastic Cells, Circulating;Predictive Value of Tests;Prospective Studies;RNA, Neoplasm;Reagent Kits, Diagnostic;Receptor, ErbB-2;Reverse Transcriptase Polymerase Chain Reaction;Time Factors;Treatment Outcome",
        "Doc_meshqualifiers":"blood;chemistry;genetics;secondary;therapy;chemistry;pathology;blood;blood;genetics",
        "_version_":1605742748512550912},
      {
        "Doc_abstract":"Humans are exposed to a huge amount of environmental pollutants called endocrine disrupting chemicals (EDCs). These molecules interfere with the homeostasis of the body, usually through mimicking natural hormones leading to activation or blocking of their receptors. Many of these compounds have been associated with a broad range of diseases including the development or increased susceptibility to breast cancer, the most prevalent cancer in women worldwide, according to the World Health Organization. Thus, this article presents a virtual high-throughput screening (vHTS) to evaluate the affinity of proteins related to breast cancer, such as ESR1, ERBB2, PGR, BCRA1, and SHBG, among others, with EDCs from urban sources. A blind docking strategy was employed to screen each protein-ligand pair in triplicate in AutoDock Vina 2.0, using the computed binding affinities as ranking criteria. The three-dimensional structures were previously obtained from EDCs DataBank and Protein Data Bank, prepared and optimized by SYBYL X-2.0. Some of the chemicals that exhibited the best affinity scores for breast cancer proteins in each category were 1,3,7,8-tetrachlorodibenzo-p-dioxin, bisphenol A derivatives, perfluorooctanesulfonic acid, and benzo(a)pyrene, for catalase, several proteins, sex hormone-binding globulin, and cytochrome P450 1A2, respectively. An experimental validation of this approach was performed with a complex that gave a moderate binding affinity in silico, the sex hormone binding globulin (SHBG), and bisphenol A (BPA) complex. The protein was obtained using DNA recombinant technology and the physical interaction with BPA assessed through spectroscopic techniques. BPA binds on the recombinant SHBG, and this results in an increase of its Î± helix content. In short, this work shows the potential of several EDCs to bind breast cancer associated proteins as a tool to prioritize compounds to perform in vitro analysis to benefit the regulation or exposure prevention by the general population. ",
        "Doc_title":"Urban Endocrine Disruptors Targeting Breast Cancer Proteins.",
        "Journal":"Chemical research in toxicology",
        "Do_id":"26700111",
        "Doc_ChemicalList":"Benzhydryl Compounds;Dioxins;Endocrine Disruptors;Environmental Pollutants;Phenols;Recombinant Proteins;Sex Hormone-Binding Globulin;Catalase;Cytochrome P-450 CYP1A2;bisphenol A",
        "Doc_meshdescriptors":"Benzhydryl Compounds;Binding Sites;Breast Neoplasms;Catalase;Cytochrome P-450 CYP1A2;Databases, Chemical;Databases, Protein;Dioxins;Endocrine Disruptors;Environmental Pollutants;Female;Humans;Molecular Dynamics Simulation;Phenols;Protein Binding;Protein Structure, Tertiary;Recombinant Proteins;Sex Hormone-Binding Globulin",
        "Doc_meshqualifiers":"chemistry;metabolism;etiology;chemistry;metabolism;chemistry;metabolism;chemistry;metabolism;chemistry;metabolism;chemistry;metabolism;chemistry;metabolism;biosynthesis;chemistry;isolation & purification;chemistry;genetics;metabolism",
        "_version_":1605831489594851328},
      {
        "Doc_abstract":"The purpose of this study is to investigate the relationship between nestin expression and clinicopathological characteristics, immunohistochemical markers and to determine the prognostic impact of nestin expression in breast cancer so as to lay a foundation for the treatment of breast cancer. A total of 109 patients who were histologically diagnosed with breast cancer and underwent radical operations from January 2006 to September 2007 in China Medical University were enrolled in the study. Nestin protein expression was evaluated by immunohistochemistry. The relationship between nestin and other parameters was analyzed by using chi-square test and Fisher's exact test. Nestin expression was observed in 37.6% (41/109) of cases. There were no significant differences between the age of >40 and â‰¤40 years group in terms of nestin expression (39.8 vs 18.2%; Pâ€‰=â€‰0.161). The rate of nestin expression between those with and without lymph node metastasis was not significantly different (X (2)â€‰=â€‰0.086; Pâ€‰=â€‰0.769). The 5-year survival rates of the patients with nestin expression and those without were 34.1% (14/41) and 55.9% (38/68), respectively (Pâ€‰=â€‰0.028). Overall, triple-negative breast cancers had higher expression rates than other cancers (54.1 vs 29.2%; Pâ€‰=â€‰0.011). Nestin expression rate in ER- and PR-negative tumors was found to be significantly higher than cases that were ER- and PR-positive (Pâ€‰=â€‰0.011 and Pâ€‰=â€‰0.036, respectively). However, it was not found that HER2 expression was related to nestin expression (Pâ€‰=â€‰0.120). These results suggest that the expression of nestin might play an important role in the prognosis of breast carcinoma, especially in the triple-negative subgroups.",
        "Doc_title":"Nestin: predicting specific survival factors for breast cancer.",
        "Journal":"Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine",
        "Do_id":"24443256",
        "Doc_ChemicalList":"Biomarkers, Tumor;NES protein, human;Nestin",
        "Doc_meshdescriptors":"Adult;Aged;Biomarkers, Tumor;Breast Neoplasms;Carcinoma, Ductal, Breast;Female;Humans;Immunohistochemistry;Kaplan-Meier Estimate;Middle Aged;Nestin;Prognosis;Proportional Hazards Models;Triple Negative Breast Neoplasms",
        "Doc_meshqualifiers":"analysis;metabolism;mortality;pathology;metabolism;mortality;pathology;analysis;biosynthesis;metabolism;mortality;pathology",
        "_version_":1605821897088434176},
      {
        "Doc_abstract":"In breast cancer tumor expression of estrogen receptors (ERs) is important as a marker of prognosis and mostly as a predictor of response to endocrine therapy. In fact, the loss of Î±-ER expression leads to unresponsiveness to anti-hormone treatment. In a significant fraction of breast cancers, this loss of expression is a result of epigenetic mechanisms, such as DNA methylation and histone deacetylation, within the Î±-ER promoter. Previous studies have shown that pharmacologic inhibition of these mechanisms using the DNA methyltransferase inhibitor, 5-aza-2-deoxycytidine (AZA), and the histone deacetylase (HDAC) inhibitor, Trichostatin A (TSA), results in expression of functional Î±-ER mRNA and protein. Moreover, the activity of a novel HDAC inhibitor, Scriptaid, has been shown to induce inhibition of tumor growth in breast cancer and to cause re-expression of functional Î±-ER in Î±-ER negative breast cancer cells. We sought to better characterize the effects of Scriptaid on cell growth, apoptosis, and Î±-ER expression in Î±-ER-positive (MCF-7), Î±-ER-negative (MDA-MB-231), and Î±-ER-negative/Her-2 over-expressing (SKBr-3) human breast cancer cell lines. In all of these cell lines Scriptaid treatment resulted in significant growth inhibition and apoptosis, and RT-PCR confirmed an increase of Î±-ER mRNA transcript in MDA-MB-231 after 48â€‰h of Scriptaid treatment. Furthermore, following treatment with Scriptaid, the formerly unresponsive MDA-MB-231 and SKBr-3 breast cancer cells became responsive to tamoxifen. These results show that the HDAC inhibitor Scriptaid is able to sensitize tamoxifen hormone-resistant breast cancer cells, and that Scriptaid or related HDAC inhibitors are candidates for further study in breast cancer.",
        "Doc_title":"Scriptaid effects on breast cancer cell lines.",
        "Journal":"Journal of cellular physiology",
        "Do_id":"22213035",
        "Doc_ChemicalList":"Estrogen Receptor alpha;Histone Deacetylase Inhibitors;Hydroxylamines;NF-kappa B;Quinolines;RNA, Messenger;estrogen receptor alpha, human;scriptaid;Tamoxifen;ERBB2 protein, human;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Apoptosis;Breast Neoplasms;Cell Cycle;Cell Line, Tumor;Cell Proliferation;Down-Regulation;Estrogen Receptor alpha;Female;Gene Expression Regulation, Neoplastic;Histone Deacetylase Inhibitors;Humans;Hydroxylamines;NF-kappa B;Quinolines;RNA, Messenger;Receptor, ErbB-2;Tamoxifen",
        "Doc_meshqualifiers":"drug effects;genetics;drug therapy;genetics;metabolism;drug effects;genetics;drug effects;genetics;metabolism;drug effects;pharmacology;pharmacology;genetics;metabolism;pharmacology;biosynthesis;genetics;genetics;metabolism;pharmacology",
        "_version_":1605807480170872832},
      {
        "Doc_abstract":"Trastuzumab emtansine (T-DM1), trastuzumab-conjugated with a cytotoxic agent, has shown promising antitumor effects in breast cancer. Since a good therapeutic response using T-DM1 treatment requires high human epidermal growth factor receptor 2 (HER2) expression, breast cancers with low or no HER2 expression have not been used for T-DM1 treatment. The aim of the present study was to show that treatment of low HER2-expressing breast cancer cells with gemcitabine (GEM) enhanced HER2 expression using RT-qPCR, immunoblot and flow cytometric analysis. The results showed that GEM treatment significantly enhanced HER2 expression in MDA-MB-231, MCF7 and BT-20 breast cancer cells, while paclitaxel (PTX) treatment induced lower or no enhancement in HER2 expression. The expression of HER2 mRNA was also enhanced in GEM-treated MCF7 cells. Treatment with an inhibitor for nuclear factor-(NF)-ÎºB suppressed GEM-induced HER2 upregulation, indicating that NF-ÎºB activation by GEM may be associated with HER2 upregulation. T-DM1 binding to HER2 on MCF-7 cells was enhanced by GEM pretreatment and the combined treatment of GEM and T-DM1 synergistically inhibited the proliferation of MCF7 cells. Thus, the combined treatment with GEM and T-DM1 may be a promising therapeutic modality for low HER2-expressing breast cancers, which was facilitated by the unique HER2-upregulating effect of GEM.",
        "Doc_title":"Gemcitabine treatment enhances HER2 expression in low HER2-expressing breast cancer cells and enhances the antitumor effects of trastuzumab emtansine.",
        "Journal":"Oncology reports",
        "Do_id":"25976081",
        "Doc_ChemicalList":"Antibodies, Monoclonal, Humanized;Antineoplastic Agents;Deoxycytidine;Maytansine;gemcitabine;ERBB2 protein, human;Receptor, ErbB-2;Paclitaxel;ado-trastuzumab emtansine",
        "Doc_meshdescriptors":"Antibodies, Monoclonal, Humanized;Antineoplastic Agents;Breast Neoplasms;Cell Line, Tumor;Cell Proliferation;Deoxycytidine;Drug Synergism;Female;Humans;MCF-7 Cells;Maytansine;Paclitaxel;Receptor, ErbB-2;Up-Regulation",
        "Doc_meshqualifiers":"pharmacology;pharmacology;drug therapy;genetics;metabolism;drug effects;analogs & derivatives;pharmacology;analogs & derivatives;pharmacology;pharmacology;genetics;metabolism",
        "_version_":1605844726394650624},
      {
        "Doc_abstract":"Results from clinical trials have demonstrated that it is possible to prevent estrogen-responsive breast cancers by targeting the estrogen receptor with selective estrogen receptor modulators (SERMs) (tamoxifen, raloxifene, or lasofoxifene) or with aromatase inhibitors (AIs) (anastrozole, letrozole, or exemestene). Results from breast cancer treatment trials suggest that aromatase inhibitors may be even more effective in preventing breast cancer than SERMs. However, while SERMs and aromatase inhibitors do prevent the development of many ER-positive breast cancers, these drugs do not prevent ER-negative breast cancer. These results show that new approaches are needed for the prevention of this aggressive form of breast cancer. Our laboratory and clinical efforts have been focused on identifying critical molecular pathways in breast cells that can be targeted for the prevention of ER-negative breast cancer. Our preclinical studies have demonstrated that other nuclear receptors, such as RXR receptors, vitamin D receptors, as well as others are critical for the growth of ER-negative breast cells and for the transformation of these cells into ER-negative cancers. Other studies show that growth factor pathways including those activated by EGFR, Her2, and IGFR, which are activated in many ER-negative breast cancers, can be targeted for the prevention of ER-negative breast cancer in mice. Clinical studies have also shown that PARP inhibitors are effective for the treatment of breast cancers arising in BRCA-1 or -2 mutation carriers, suggesting that targeting PARP may also be useful for the prevention of breast cancers arising in these high-risk individuals. Most recently, we have demonstrated that ER-negative breast cancers can be subdivided into four distinct groups based on the kinases that they express. These groups include ER-negative/Her-2-positive groups (the MAPK and immunomodulatory groups) and ER-negative/Her2-negative groups (the S6K and the cell cycle checkpoint groups). These groups of ER-negative breast cancers can be targeted with kinase inhibitors specific for each subgroup. These preclinical studies have supported the development of several clinical trials testing targeted agents for the prevention of breast cancer. The results of a completed Phase II cancer prevention trial using the RXR ligand bexarotene in women at high risk of breast cancer will be reviewed, and the current status of an ongoing Phase II trial using the EGFR and Her2 kinase inhibitor lapatinib for the treatment of women with DCIS breast cancer will be presented. It is anticipated that in the future these molecularly targeted drugs will be combined with hormonal agents such as SERMs or aromatase inhibitors to prevent all forms of breast cancer.",
        "Doc_title":"Chemoprevention of hormone receptor-negative breast cancer: new approaches needed.",
        "Journal":"Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer",
        "Do_id":"21253797",
        "Doc_ChemicalList":"Aromatase Inhibitors;Hydroxymethylglutaryl-CoA Reductase Inhibitors;Poly(ADP-ribose) Polymerase Inhibitors;Receptors, Estrogen;Retinoids;Selective Estrogen Receptor Modulators;Metformin",
        "Doc_meshdescriptors":"Aromatase Inhibitors;Breast Neoplasms;Female;Humans;Hydroxymethylglutaryl-CoA Reductase Inhibitors;Metformin;Poly(ADP-ribose) Polymerase Inhibitors;Receptors, Estrogen;Retinoids;Selective Estrogen Receptor Modulators",
        "Doc_meshqualifiers":"therapeutic use;chemistry;prevention & control;therapeutic use;therapeutic use;analysis;therapeutic use;therapeutic use",
        "_version_":1605746990911586304},
      {
        "Doc_abstract":"Aromatase (product of CYP19 gene), the critical enzyme in estrogen biosynthesis, is up-regulated in 70% of all breast cancers and is highly correlated with cyclooxygenase 2 (COX-2), the rate-determining enzyme in prostanoid biosynthesis. Expression of COX-2 also is correlated with the oncogene HER-2/neu. The efficacy of current endocrine therapies for breast cancer is predicted only if the tumor contains significant amounts of estrogen receptor. Because the progesterone receptor (PR) is an estrogen-induced target gene, it has been suggested that its presence may serve as an indicator of estrogen receptor functional capacity and the differentiation state of the tumor. In the present study, we tested the hypothesis that PR serves a crucial protective role by antagonizing inflammatory response pathways in the breast. We observed that progesterone antagonized the stimulatory effects of cAMP and IL-1beta on aromatase, COX-2, and HER-2/neu expression in T47D breast cancer cells. These actions of progesterone were associated with increased expression of the nuclear factor-kappaB inhibitor, IkappaBalpha. In 28 breast cancer cell lines, IkappaBalpha expression was positively correlated with PR mRNA levels; overexpression of a phosphorylation-defective mutant of IkappaBalpha inhibited expression of aromatase, COX-2, and HER-2/neu. Moreover, in breast cancer cell lines cultured in the absence of progesterone, up-regulation of endogenous PR caused decreased expression of aromatase, COX-2, and HER-2/neu expression, whereas down-regulation of endogenous PR resulted in a marked induction of aromatase and HER-2/neu mRNA. Collectively, these findings suggest that PR plays an important antiinflammatory role in breast cancer cells via ligand-dependent and ligand-independent mechanisms.",
        "Doc_title":"Progesterone receptor inhibits aromatase and inflammatory response pathways in breast cancer cells via ligand-dependent and ligand-independent mechanisms.",
        "Journal":"Molecular endocrinology (Baltimore, Md.)",
        "Do_id":"18483177",
        "Doc_ChemicalList":"I-kappa B Proteins;Interleukin-1beta;Ligands;NFKBIA protein, human;Protein Isoforms;RNA, Small Interfering;Receptors, Progesterone;Transcription Factor RelA;NF-KappaB Inhibitor alpha;Progesterone;Cyclic AMP;Aromatase;Cyclooxygenase 2;PTGS2 protein, human;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Aromatase;Breast Neoplasms;Cell Line, Tumor;Cyclic AMP;Cyclooxygenase 2;Enzyme Induction;Gene Expression Regulation, Neoplastic;Humans;I-kappa B Proteins;Inflammation;Interleukin-1beta;Ligands;NF-KappaB Inhibitor alpha;Progesterone;Protein Binding;Protein Isoforms;RNA, Small Interfering;Receptor, ErbB-2;Receptors, Progesterone;Response Elements;Transcription Factor RelA",
        "Doc_meshqualifiers":"biosynthesis;metabolism;enzymology;genetics;pathology;pharmacology;biosynthesis;genetics;drug effects;drug effects;metabolism;enzymology;pharmacology;pharmacology;drug effects;metabolism;metabolism;genetics;metabolism;metabolism;metabolism",
        "_version_":1605846218054828032},
      {
        "Doc_abstract":"Estrogen receptor (ER)-negative breast cancer cells are probably more aggressive with larger metastatic potential than ER-positive cells. Loss of ER in recurrent breast cancer is associated with poor response to endocrine therapy. G protein-coupled receptor 30 (GPR30) is expressed in half of ER-negative breast cancers. Tumor cell-derived heregulin-Î²1 (HRG-Î²1) is also found mainly in ER-negative cancer. In SkBr3 breast cancer cells that lack ER but express GPR30, HRG-Î²1 upregulates mRNA and protein levels of GPR30 by promoting ErbB2-ErbB3 heterodimerization and activating the downstream MAPK-ERK signaling pathway. Moreover, GPR30 boosts HRG-Î²1-induced migration and invasion of SkBr3 cells after combinative treatment with E2, 4-hydroxy-tamoxifen or the specific GPR30 agonist G-1, which are blocked by the specific GPR30 antagonist G-15 or the transfection with the small interfering RNA for GPR30. The ErbB2 inhibitor AG825 and the MEK1/2 inhibitor U0126 also partly inhibit the enhanced migration and invasion. Therefore, HRG-Î²1-induced migration and invasion partly depend on the upregulation of GPR30 expression through activation of the ErbB2-ERK pathway in SkBr3 cells. The results of this study indicate that the crosstalk between GPR30 and HRGs signaling is important for endocrine therapy resistance and may provide a new therapeutic way to treat breast cancer.",
        "Doc_title":"Heregulin-Î²1-induced GPR30 upregulation promotes the migration and invasion potential of SkBr3 breast cancer cells via ErbB2/ErbB3-MAPK/ERK pathway.",
        "Journal":"Biochemical and biophysical research communications",
        "Do_id":"22425775",
        "Doc_ChemicalList":"GPER protein, human;Neuregulin-1;Receptors, Estrogen;Receptors, G-Protein-Coupled;heregulin beta1;ERBB2 protein, human;Receptor, ErbB-2;Receptor, ErbB-3;Mitogen-Activated Protein Kinase Kinases",
        "Doc_meshdescriptors":"Breast Neoplasms;Cell Line, Tumor;Cell Movement;Female;Humans;MAP Kinase Signaling System;Mitogen-Activated Protein Kinase Kinases;Neoplasm Invasiveness;Neuregulin-1;Receptor, ErbB-2;Receptor, ErbB-3;Receptors, Estrogen;Receptors, G-Protein-Coupled;Up-Regulation",
        "Doc_meshqualifiers":"metabolism;pathology;metabolism;metabolism;metabolism;metabolism;biosynthesis;biosynthesis",
        "_version_":1605754534883229696},
      {
        "Doc_abstract":"Gene expression analysis identifies several breast cancer subtypes. We examined the relationship of neoadjuvant chemotherapy response to outcome among these breast cancer subtypes.;We used immunohistochemical profiles [human epidermal growth factor receptor 2-positive (HER2+)/hormone receptor-negative for HER2+/estrogen receptor-negative (ER-), hormone receptor and HER2- for basal-like, hormone receptor-positive for luminal] to subtype a prospectively maintained data set of patients with breast cancer treated with neoadjuvant anthracycline-based (doxorubicin plus cyclophosphamide, AC) chemotherapy. We analyzed each subtype for clinical and pathologic response to neoadjuvant chemotherapy and examined the relationship of response to distant disease-free survival and overall survival.;Of the 107 patients tested, 34 (32%) were basal-like, 11 (10%) were HER2+/ER-, and 62 (58%) were luminal. After neoadjuvant AC, 75% received subsequent chemotherapy and all received endocrine therapy if hormone receptor-positive. The chemotherapy regimen and pretreatment stage did not differ by subtype. Clinical response to AC was higher among the HER2+/ER- (70%) and basal-like (85%) than the luminal subtypes (47%; P < 0.0001). Pathologic complete response occurred in 36% of HER2+/ER-, 27% of basal-like, and 7% of luminal subtypes (P = 0.01). Despite initial chemosensitivity, patients with the basal-like and HER2+/ER- subtypes had worse distant disease-free survival (P = 0.04) and overall survival (P = 0.02) than those with the luminal subtypes. Regardless of subtype, only 2 of 17 patients with pathologic complete response relapsed. The worse outcome among basal-like and HER+/ER- subtypes was due to higher relapse among those with residual disease (P = 0.003).;Basal-like and HER2+/ER- subtypes are more sensitive to anthracycline-based neoadjuvant chemotherapy than luminal breast cancers. Patients that had pathologic complete response to chemotherapy had a good prognosis regardless of subtype. The poorer prognosis of basal-like and HER2+/ER- breast cancers could be explained by a higher likelihood of relapse in those patients in whom pathologic complete response was not achieved.",
        "Doc_title":"The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes.",
        "Journal":"Clinical cancer research : an official journal of the American Association for Cancer Research",
        "Do_id":"17438091",
        "Doc_ChemicalList":"Antineoplastic Agents;Receptors, Estrogen;Receptors, Progesterone;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Adult;Aged;Antineoplastic Agents;Antineoplastic Combined Chemotherapy Protocols;Breast Neoplasms;Female;Humans;Immunohistochemistry;Middle Aged;Neoplasm Staging;Receptor, ErbB-2;Receptors, Estrogen;Receptors, Progesterone;Survival Analysis",
        "Doc_meshqualifiers":"therapeutic use;therapeutic use;drug therapy;mortality;pathology;analysis;analysis;analysis",
        "_version_":1605742742193831937},
      {
        "Doc_abstract":"Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) binds to death receptors expressed on cancer cells and induces apoptosis. Triple-negative breast cancer cell lines are more sensitive to TRAIL or TRAIL-death receptor agonistic monoclonal antibody-induced apoptosis compared with HER-2/neu-overexpressing or luminal cell lines. The paper under evaluation sought to determine whether the His64/Pro64 polymorphism of galectin-3, which is associated with breast cancer incidence, affects sensitivity to TRAIL. None of five breast cancer cell lines homozygous for Pro64 galectin-3 were sensitive to TRAIL, but two out of two homozygous His64 cell lines and one out of two heterozygous His64 cell lines were sensitive. Transfection of galectin-3 null BT549 breast cancer cells with His64 galectin-3 rendered them sensitive to TRAIL, while Pro64 galectin-3-transfected cells remained resistant to TRAIL. This article highlights that galectin-3 receptor expression and genotype may be useful markers in predicting TRAIL or agonistic antibody sensitivity of breast cancer patients.",
        "Doc_title":"Relationship between galectin-3 expression and TRAIL sensitivity in breast cancer.",
        "Journal":"Expert review of anticancer therapy",
        "Do_id":"21916572",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605929133652574208},
      {
        "Doc_abstract":"ErbB1 and ErbB2 receptors are well-characterized targets for anticancer drugs, but the clinical relevance of the related ErbB4 receptor is unknown. Here, we have assessed the clinical significance of the proteolytically cleavable ErbB4 isoforms in breast cancer patients and investigated their functions in vitro. The expression of transcripts encoding the cleavable ErbB4 isoforms associated with estrogen receptor-alpha (ER) expression (P < 0.001) and a high histologic grade of differentiation (P </= 0.002) in real-time reverse transcription-PCR analysis of 62 breast cancer samples. Despite high ErbB4 mRNA expression levels in a subset of samples, ErbB4 gene amplification was not observed. High ErbB4 protein expression levels, as assessed by immunohistochemistry, associated with a favorable outcome in ER-positive cases from a series of 458 breast cancer patients (P = 0.01), whereas no association between ErbB4 expression and survival was found among women with ER-negative cancer (P = 0.86). However, nuclear ErbB4 immunoreactivity was associated with poor survival as compared with women whose cancer had membranous ErbB4 staining (P = 0.04). In vitro, overexpression of a cleavable ErbB4 isoform in ER-positive breast cancer cells resulted in translocation of a proteolytically released intracellular ErbB4 receptor fragment into the nucleus, as well as, enhanced proliferation, anchorage-independent growth, and estrogen response element-mediated transcriptional activity. These results suggest that the association of ErbB4 expression with clinical outcome is dependent on the subcellular localization of ErbB4 and that a proteinase-cleavable ErbB4 isoform promotes growth of ER-positive breast cancer and enhances ER-mediated gene transcription.",
        "Doc_title":"Cleavable ErbB4 isoform in estrogen receptor-regulated growth of breast cancer cells.",
        "Journal":"Cancer research",
        "Do_id":"15735025",
        "Doc_ChemicalList":"Estrogens;Protein Isoforms;RNA, Messenger;Receptors, Estrogen;ERBB4 protein, human;Receptor, Epidermal Growth Factor;Receptor, ErbB-2;Receptor, ErbB-4",
        "Doc_meshdescriptors":"Alternative Splicing;Breast Neoplasms;Cell Growth Processes;Cell Line, Tumor;Cell Nucleus;Estrogens;Female;Gene Amplification;Humans;Protein Isoforms;RNA, Messenger;Receptor, Epidermal Growth Factor;Receptor, ErbB-2;Receptor, ErbB-4;Receptors, Estrogen;Reverse Transcriptase Polymerase Chain Reaction",
        "Doc_meshqualifiers":"genetics;metabolism;pathology;physiology;metabolism;metabolism;biosynthesis;genetics;biosynthesis;genetics;biosynthesis;genetics;physiology",
        "_version_":1605789747222937600},
      {
        "Doc_abstract":"To compare the efficacy of lapatinib or lapatinib plus trastuzumab versus trastuzumab in the neoadjuvant therapy of human epidermal growth factor receptor 2 (HER-2) positive breast cancer.;MEDLINE database, American Society of Clinical Oncology (ASCO), San Antonio Breast Cancer Symposium (SABCS), European Society for Medical Oncology (ESMO) proceedings and China Biomedical Database were searched for literatures of trastuzumab or lapatinib in neoadjuvant therapy for breast cancer. There was no limit of language or time. A meta-analysis was performed for retrieved literatures meeting the inclusion criteria.;A total of 1 794 breast cancer patients from 5 clinical trials were included. And the regimens were lapatinib plus neoadjuvant chemotherapy (n = 719), trastuzumab plus neoadjuvant chemotherapy (n = 714) and both drugs plus neoadjuvant chemotherapy (n = 361). The rate of pathological complete remission (pCR) was lower in lapatinib group than that in trastuzumab group (28.2% vs 35.4%). And the difference was statistically significant (P = 0.004). The pCR rate was significantly higher in lapatinib plus trastuzumab therapy group than that in trastuzumab group (53.2% vs 38.1%, P < 0.001).;Lapatinib can not replace trastuzumab as a first-choice agent in neoadjuvant therapy of HER-2 positive breast cancer. Lapatinib plus trastuzumab achieves better pCR than trastuzumab so that it and may become a first-choice of neoadjuvant therapy for HER-2 positive breast cancer regardless of economic affordability for patients.",
        "Doc_title":"[Efficacy of lapatinib versus trastuzumab in neoadjuvant therapy of HER-2 positive breast cancer: a meta-analysis].",
        "Journal":"Zhonghua yi xue za zhi",
        "Do_id":"25623322",
        "Doc_ChemicalList":"Antibodies, Monoclonal, Humanized;Quinazolines;lapatinib;ERBB2 protein, human;Receptor, ErbB-2;Trastuzumab",
        "Doc_meshdescriptors":"Antibodies, Monoclonal, Humanized;Antineoplastic Combined Chemotherapy Protocols;Breast Neoplasms;China;Humans;Neoadjuvant Therapy;Quinazolines;Receptor, ErbB-2;Trastuzumab",
        "Doc_meshqualifiers":"None",
        "_version_":1605825250433433600},
      {
        "Doc_abstract":"Recently there have been significant advances in rational drug design for the treatment of breast cancer, especially in the area of targeted drug therapy. These include drugs which target the HER2 receptor and angiogenesis and the novel class of drug the PARP inhibitors. Some of these agents, for example, trastuzumab used in the treatment of HER2 positive breast cancer are already established as the standard of care. However, the duration of adjuvant trastuzumab, whether to continue it beyond progression in metastatic disease and the mechanism for developing trastuzumab resistance, remain to be determined. There is also much still to be learnt regarding other targeted therapies; the efficacy of different agents, the optimal duration of use and combination of therapies. Many of these agents are already in clinical trials, the results of which are likely to change clinical practice.",
        "Doc_title":"New drugs for breast cancer.",
        "Journal":"British medical bulletin",
        "Do_id":"20870669",
        "Doc_ChemicalList":"Angiogenesis Inhibitors;Antineoplastic Agents;Enzyme Inhibitors;Poly Adenosine Diphosphate Ribose;ERBB2 protein, human;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Angiogenesis Inhibitors;Antineoplastic Agents;Breast Neoplasms;Drug Design;Enzyme Inhibitors;Female;Humans;Poly Adenosine Diphosphate Ribose;Receptor, ErbB-2",
        "Doc_meshqualifiers":"therapeutic use;pharmacology;therapeutic use;drug therapy;pharmacology;therapeutic use;antagonists & inhibitors;antagonists & inhibitors",
        "_version_":1605746987668340736},
      {
        "Doc_abstract":"The aim of this study was to characterize the hematogeneous spread, in vivo, of breast cancer (BC) cell lines that express hormonal receptors (HR) comparing with triple-negative (TN) BC, particularly considering the lung and liver. Female Balb/c nu nu mice (n=30) were injected with two breast cancer cell lines (MCF7 and HCC1806). Nuclear medicine imaging with Technetium ((99m)Tc)-hydroxymethylene diphosphonate ((99m)Tc-HMDP) and (99m)Tc-Hexakis 2-methoxy-2-methylpropylisonitrile (MIBI) were performed between the 7th and 8th weeks after injection. The histological metastatic foci were analyzed by morphometric and immunohistochemistry studies regarding estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (ERBB2) and cytokeratin (CK)-5/6. The mean area of lung metastasis in MCF7 cases was significantly higher (p=0.023), although the number of liver foci was higher in the HCC1806 group (p=0.006). Logistic regression revealed a potentiating model for liver metastasis with HCC1806 cells (odds ratio=16; p=0.03). The number and area of lung-metastatic foci were not predictive of liver dissemination. Lung metastasis study showed ER positivity in 57.1% of the MCF7 group, compared to 80% of the HCC1806 group. PR was positive in 42.9% of MCF7 cases and negative in 60% of HCC1806 cases. HR-positive cells developed massive lung metastization. TN cells seem to potentiate liver metastasis. ER, PR, ERBB2 and basal-like CK expression in metastases was not uniformly correlated with that of primary tumor cells. ",
        "Doc_title":"Hematogenic Dissemination of Triple-negative Versus Hormonal Receptor-positive Breast Cancer Cells.",
        "Journal":"In vivo (Athens, Greece)",
        "Do_id":"26130788",
        "Doc_ChemicalList":"Biomarkers, Tumor;Receptors, Estrogen;Receptors, Progesterone;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Animals;Biomarkers, Tumor;Breast Neoplasms;Cell Line, Tumor;Disease Models, Animal;Female;Humans;Liver Neoplasms;Lung Neoplasms;Mice;Neoplasm Metastasis;Neoplastic Cells, Circulating;Receptor, ErbB-2;Receptors, Estrogen;Receptors, Progesterone;Triple Negative Breast Neoplasms",
        "Doc_meshqualifiers":"diagnosis;metabolism;pathology;diagnosis;secondary;diagnosis;secondary;pathology;metabolism;metabolism;metabolism;diagnosis;metabolism;pathology",
        "_version_":1605746369980530689},
      {
        "Doc_abstract":"Human epidermal growth factor receptor 2 (HER2) is a breast cancer biomarker that plays a major role in promoting breast cancer cell proliferation and malignant growth. The extracellular domain (ECD) of HER2 can be shed into the blood stream and its concentration is measurable in the serum fraction of blood. In this work an electrochemical immunosensor for the analysis of HER2 ECD in human serum samples was developed. To achieve this goal a screen-printed carbon electrode, modified with gold nanoparticles, was used as transducer surface. A sandwich immunoassay, using two monoclonal antibodies, was employed and the detection of the antibody-antigen interaction was performed through the analysis of an enzymatic reaction product by linear sweep voltammetry. Using the optimized experimental conditions the calibration curve (ip vs. log[HER2 ECD]) was established between 15 and 100 ng/mL and a limit of detection (LOD) of 4.4 ng/mL was achieved. These results indicate that the developed immunosensor could be a promising tool in breast cancer diagnostics, patient follow-up and monitoring of metastatic breast cancer since it allows quantification in a useful concentration range and has an LOD below the established cut-off value (15 ng/mL).",
        "Doc_title":"Electrochemical immunosensor for the analysis of the breast cancer biomarker HER2 ECD.",
        "Journal":"Talanta",
        "Do_id":"25127638",
        "Doc_ChemicalList":"Biomarkers, Tumor;Carbon;Gold;ERBB2 protein, human;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Antigen-Antibody Reactions;Biomarkers, Tumor;Breast Neoplasms;Calibration;Carbon;Cell Proliferation;Electrochemistry;Electrodes;Female;Gold;Humans;Immunoassay;Limit of Detection;Metal Nanoparticles;Nanotechnology;Neoplasm Metastasis;Protein Structure, Tertiary;Receptor, ErbB-2;Transducers",
        "Doc_meshqualifiers":"blood;diagnosis;chemistry;methods;chemistry;methods;chemistry;methods;blood",
        "_version_":1605798420893663232},
      {
        "Doc_abstract":"The human epidermal growth factor receptor 2 (HER2) is overexpressed/amplified in up to 25% of breast cancer patients, and this feature is associated with an aggressive phenotype, a high recurrence rate, and reduced survival. Until recently, combination chemotherapy was the most effective and only adjuvant treatment for HER2-positive patients. Trastuzumab, a monoclonal antibody directed against the HER2 extracellular domain, has recently demonstrated highly reproducible and astonishing benefit in halving the recurrence rate and reducing mortality in five adjuvant breast cancer trials. But such unfettered success has come at a cost, both in terms of cardiotoxic risk and substantial financial burden. Though trastuzumab has been able to significantly improve clinical outcomes of many patients with early breast cancer, the reality is that an unacceptable proportion will still relapse. Beyond trastuzumab, what is the next step for these HER2-positive breast cancers? This review first discusses the individual results of the five adjuvant trastuzumab studies in terms of efficacy and safety, highlighting their similarities and differences. It also evaluates the current status of trastuzumab as a result of these studies and explores the possible future direction for HER2-positive breast cancers in light of recent advances in translational oncology.",
        "Doc_title":"Trastuzumab for early breast cancer: current status and future directions.",
        "Journal":"Clinical advances in hematology & oncology : H&O",
        "Do_id":"17982412",
        "Doc_ChemicalList":"Antibodies, Monoclonal;Antibodies, Monoclonal, Humanized;Antineoplastic Agents;Receptor, ErbB-2;Trastuzumab",
        "Doc_meshdescriptors":"Antibodies, Monoclonal;Antibodies, Monoclonal, Humanized;Antineoplastic Agents;Breast Neoplasms;Chemotherapy, Adjuvant;Clinical Trials as Topic;Female;Heart Diseases;Humans;Neoplasm Recurrence, Local;Protein Structure, Tertiary;Receptor, ErbB-2;Survival Rate;Trastuzumab",
        "Doc_meshqualifiers":"adverse effects;economics;therapeutic use;adverse effects;economics;therapeutic use;drug therapy;economics;mortality;chemically induced;drug therapy;economics;mortality;antagonists & inhibitors",
        "_version_":1605884636474376192},
      {
        "Doc_abstract":"A modified comparative genomic hybridization (mCGH) technique was used to identify and map amplified DNA sequences in six homogeneously staining regions (hsr) from three primary breast carcinomas. Five different chromosomal regions and bands were identified as sites of amplification: 8p1, 17q21.1, 17q23 (two cases), 19q13.3, and 20q13.3. The mCGH site located on 17q21.1 was demonstrated to correspond to a 50-100-fold amplification of ERBB2. Further in situ hybridization experiments were used to confirm the mCGH results and to characterize the organization of the amplified sequences within the hsr. In five of six instances, two or more chromosomal regions were found amplified in the same hsr. In the tumor with the less modified karyotype, the two hsr comprised DNA sequences from three different chromosomes and showed different patterns of amplification. In the tumor with the most rearranged karyotype, the hsr-carrying chromosomes were formed by the translocation and amplification of sequences from three or four different chromosomal sites. This illustrates the complexity of the amplification process in breast cancers.",
        "Doc_title":"Identification of amplified DNA sequences in breast cancer and their organization within homogeneously staining regions.",
        "Journal":"Genes, chromosomes & cancer",
        "Do_id":"8589031",
        "Doc_ChemicalList":"DNA, Neoplasm",
        "Doc_meshdescriptors":"Breast Neoplasms;Carcinoma, Ductal, Breast;Chromosome Aberrations;DNA, Neoplasm;Female;Gene Amplification;Humans;In Situ Hybridization;In Situ Hybridization, Fluorescence;Karyotyping;Oncogenes;Translocation, Genetic;Tumor Cells, Cultured",
        "Doc_meshqualifiers":"genetics;pathology;genetics;pathology;genetics",
        "_version_":1605795436011978752},
      {
        "Doc_abstract":"The Ets family of transcription factors regulate expression of multiple genes involved in tumour progression. The aim of this study was to investigate the expression of Ets-1 in a large panel of human breast cancers and relate its levels to the parameters of tumour progression and metastasis. Using RT-PCR, Ets-1 mRNA was detected in 30 out of 42 (71%) fibroadenomas and 131 out of 179 (73%) primary breast carcinomas. Similarly, levels of Ets-1 mRNA were not significantly different in fibroadenomas and primary breast carcinomas. Using Western blotting, four forms of the Ets-1 protein were detected, that is, p33, p42, p51 and p52. Levels of both p51 and p52 but not p33 and p42 were present at significantly higher levels in the carcinomas compared to the fibroadenomas (for p51, P<0.007; for p52, P<0.02; Mann-Whitney U-test). Levels of p52, p51 and p33 correlated significantly with uPA protein levels (P<0.01), while only levels of p52 correlated significantly with HER-2/neu protein levels (P<0.01). Using immunohistochemistry, Ets-1 was found predominantly in tumour cells, but was also detected in some stromal cells surrounding tumour islands. We conclude that, while at the mRNA level, Ets-1 was found at similar levels in fibroadenomas and primary breast carcinomas, higher protein levels were detected in the cancers compared to the benign specimens. Since p52, p51 and p33 correlate with uPA levels, these forms of Ets-1 may play a role in breast cancer metastasis.",
        "Doc_title":"Overexpression of the Ets-1 transcription factor in human breast cancer.",
        "Journal":"British journal of cancer",
        "Do_id":"15365563",
        "Doc_ChemicalList":"Biomarkers, Tumor;ETS1 protein, human;Proto-Oncogene Protein c-ets-1;Proto-Oncogene Proteins;Proto-Oncogene Proteins c-ets;Transcription Factors;Protein-Tyrosine Kinases",
        "Doc_meshdescriptors":"Biomarkers, Tumor;Breast Neoplasms;Carcinoma;Disease Progression;Enzyme-Linked Immunosorbent Assay;Female;Fibroadenoma;Humans;Neoplasm Metastasis;Protein-Tyrosine Kinases;Proto-Oncogene Protein c-ets-1;Proto-Oncogene Proteins;Proto-Oncogene Proteins c-ets;Reverse Transcriptase Polymerase Chain Reaction;Transcription Factors",
        "Doc_meshqualifiers":"analysis;genetics;pathology;genetics;pathology;genetics;pathology;biosynthesis;biosynthesis",
        "_version_":1605852068159946752},
      {
        "Doc_abstract":"Racial disparity in the presentation of breast cancer and the outcome of its treatment is well established. However, the causes remain unexplained. The scarcity of reports about the prognostic significance of p53, bcl-2, and HER-2/neu in Arab females with breast cancer has been the impetus to this study. We evaluated the prognostic significance of altered expression of p53, bcl-2, HER-2/neu in Omani Arab females with non-metastatic breast cancer with correlation to other established prognostic factors. We have retrospectively analyzed the immunohistochemical expression of p53, HER-2/neu and bcl-2 in paraffin embedded blocks of 72 females diagnosed with invasive breast cancer between 1992 and 2002. The expression of the above proteins was correlated with other prognostic factors and univariate and multivariate analysis was carried out for all prognostic factors. Overexpression of p53 significantly correlated with younger age (<40), pre-menopausal status, poor differentiation with inverse correlation with bcl-2 expression. Expression of bcl-2 immunopostivity significantly correlated to low histological grade and positive estrogen and progesterone receptor status. On univariate and multivariate p53 overexpression and lack of bcl-2 immunostaining resulted in worse survival outcome, but not Her-2/neu overexpression. Expression patterns of p53 and bcl-2 are independent predictors of survival in Omani Arab population which may help to stratify these patients into different risk groups.",
        "Doc_title":"Significance of p53, Bcl-2, and HER-2/neu protein expression in Omani Arab females with breast cancer.",
        "Journal":"Pathology oncology research : POR",
        "Do_id":"14688828",
        "Doc_ChemicalList":"Proto-Oncogene Proteins c-bcl-2;Receptors, Estrogen;Receptors, Progesterone;Tumor Suppressor Protein p53;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Adult;Age Factors;Aged;Aged, 80 and over;Arabs;Breast Neoplasms;Female;Humans;Immunohistochemistry;Lymphatic Metastasis;Middle Aged;Neoplasm Staging;Oman;Prognosis;Proto-Oncogene Proteins c-bcl-2;Receptor, ErbB-2;Receptors, Estrogen;Receptors, Progesterone;Retrospective Studies;Risk Factors;Tumor Suppressor Protein p53",
        "Doc_meshqualifiers":"metabolism;mortality;pathology;biosynthesis;biosynthesis;biosynthesis",
        "_version_":1605876100734386176},
      {
        "Doc_abstract":"Two isoforms of Rho-associated coiled-coil kinase (ROCK), ROCKI and ROCKII, play an important role in many cellular processes. Despite the accumulating evidence showing that ROCK could be a potential cancer therapeutic target, the relevant tumor types to ROCK activation are not well clarified. The aim of this study was to evaluate the ROCK activation status in different tumor types of breast cancer.;We evaluated the immunoreactivities of phosphorylation-specific antibodies of ROCKI and ROCKII to inform their kinase activation in 275 of breast carcinoma tissues, including 56 of carcinoma in situ, 116 of invasive carcinoma, and 103 of invasive carcinoma with metastasis. ROCKII activation signal detected in nucleus was significantly correlated with tumor metastasis, while ROCKI and cytosolic ROCKII activation signals made no significant difference in that metastasis. Furthermore, nuclear ROCKII activation signal was associated with poor clinical outcome and correlated with late tumor stage, low expression of estrogen receptor (ER) and progesterone receptor (PR), overexpression of human epidermal growth factor receptor 2 (HER2) and high Ki67 labeling index.;Nuclear ROCKII activation signal might contribute to the tumor metastasis in breast cancer. Differences in ROCK activation that underlie the phenotypes of breast cancer could enhance our understanding for the use of ROCK inhibitors in cancer therapy.",
        "Doc_title":"Immunohistochemical evaluation of ROCK activation in invasive breast cancer.",
        "Journal":"BMC cancer",
        "Do_id":"26626121",
        "Doc_ChemicalList":"ROCK1 protein, human;ROCK2 protein, human;rho-Associated Kinases",
        "Doc_meshdescriptors":"Adult;Aged;Aged, 80 and over;Breast Neoplasms;Cell Nucleus;Enzyme Activation;Female;Gene Expression Regulation, Neoplastic;Humans;Immunohistochemistry;Middle Aged;Neoplasm Metastasis;Prognosis;rho-Associated Kinases",
        "Doc_meshqualifiers":"enzymology;pathology;enzymology;metabolism",
        "_version_":1605877201168760832},
      {
        "Doc_abstract":"Molecular characterization of circulating tumor cells (CTCs) is crucial to identify novel diagnostic and therapeutic targets for individualized therapies. We developed a multiplexed PCR-coupled liquid bead array to detect the expression of multiple genes in CTCs.;mRNA isolated from immunomagnetically enriched CTCs was subjected to multiplex PCR for KRT19 (keratin 19; also known as CK19), ERBB2 [v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog (avian); also known as HER2], SCGB2A2 (secretoglobin, family 2A, member 2; also known as MGB1, mammaglobin A), MAGEA3 (melanoma antigen family A, 3), TWIST-1 [twist homolog 1 (Drosophila)], and HMBS (hydroxymethylbilane synthase; also known as PBGD). Biotinylated amplicons were hybridized against fluorescent microspheres carrying gene-specific capture probes and incubated with streptavidin-phycoerythrin. We quantified the captured labeled amplicons and decoded the beads by Luminex flow cytometry. The assay was validated for limit of detection, specificity, and comparison with reverse-transcription quantitative PCR (RT-qPCR), and its clinical performance was evaluated in 64 patients with operable breast cancer, 20 patients with metastasis, and 17 healthy individuals.;The assay was specific for each gene in complex multiplexed formats and could detect the expression of each gene at the level of a single SK-BR-3 cell. The assay produced results comparable to those for RT-qPCR for each gene. None of the genes tested was detected in the CTC fraction of healthy donors. We detected KRT19, ERBB2, MAGEA3, SCGB2A2, and TWIST1 in 26.6%, 12.5%, 18.7%, 10.9%, and 31.2% of operable breast cancer patients, respectively, and detected the corresponding genes in 65%, 20%, 30%, 20%, and 20% of patients with verified metastasis, respectively.;The expression of 6 genes in CTCs can be measured simultaneously and reliably, thereby saving precious sample and reducing the costs and time of analysis.",
        "Doc_title":"Molecular characterization of circulating tumor cells in breast cancer by a liquid bead array hybridization assay.",
        "Journal":"Clinical chemistry",
        "Do_id":"21245367",
        "Doc_ChemicalList":"Biomarkers, Tumor;RNA, Messenger",
        "Doc_meshdescriptors":"Biomarkers, Tumor;Breast Neoplasms;Case-Control Studies;Cell Line, Tumor;Early Detection of Cancer;Female;Gene Expression Regulation, Neoplastic;Humans;Microspheres;Neoplastic Cells, Circulating;Nucleic Acid Hybridization;RNA, Messenger;Reproducibility of Results;Reverse Transcriptase Polymerase Chain Reaction;Sensitivity and Specificity",
        "Doc_meshqualifiers":"blood;metabolism;blood;diagnosis;genetics;pathology;methods;chemistry;metabolism;methods;genetics;metabolism",
        "_version_":1605758837020688384},
      {
        "Doc_abstract":"Heregulin (HRG) is a family of polypeptide growth factors derived from alternatively spliced genes. HRG can bind to receptor tyrosine kinases erbB3 and erbB4, thereby inducing erbB3 and erbB4 heterodimerization with erbB2, leading to receptor tyrosine phosphorylation and activating downstream signal transduction. Cell-cell homophilic adhesion (cell aggregation) is important in determining the structural organization and behavior of cells in tissues. In addition, tumor cell homophilic adhesion may affect invasive and metastatic potentials of cells. We report that HRG-beta1 can enhance aggregation of MCF-7 and SKBR3 human breast cancer cells. While investigating the downstream signals involved in HRG-beta1-enhanced cell aggregation, we observed that HRG-beta1 induced tyrosine phosphorylation of erbB2 and crbB3 receptor heterodimers and increased the association of the dimerized receptors with the 85-kDa subunit of phosphatidylinositol 3-kinase (PI3K). HRG-beta also increased the kinase activities of extracellular signal-regulated protein kinase (ERK) and PI3K in these cells. By using the mitogen-activated protein kinase/ERK 1 (MEK1) inhibitor PD98059 and PI3K inhibitors wortmannin and LY294002, we found that blocking the MEK1-ERK pathway had no effect on HRG-pbeta1-enhanced cell aggregation; however, blocking the PI3K pathway greatly inhibited HRG-beta1-mediated cell aggregation. Our study indicated that the HRG-beta1-activated MEK1-ERK pathway has no demonstrable role in the induction of cell aggregation, whereas HRG-beta1-activated PI3K is required for enhancing breast cancer cell aggregation. Because aggregation can contribute to invasion/metastasis phenotype of cancer cells, our results have provided one mechanism by which HRG-beta1-activated signaling of erbB receptors may affect invasive/metastatic properties of MCF-7 and SKBR3 breast cancer cells.",
        "Doc_title":"Heregulin beta1-activated phosphatidylinositol 3-kinase enhances aggregation of MCF-7 breast cancer cells independent of extracellular signal-regulated kinase.",
        "Journal":"Cancer research",
        "Do_id":"10197638",
        "Doc_ChemicalList":"Carrier Proteins;Glycoproteins;Neuregulin-1;Proto-Oncogene Proteins;heregulin beta1;Tyrosine;Phosphatidylinositol 3-Kinases;Receptor, Epidermal Growth Factor;Receptor, ErbB-2;Receptor, ErbB-3;Calcium-Calmodulin-Dependent Protein Kinases;Mitogen-Activated Protein Kinase 3;Mitogen-Activated Protein Kinases",
        "Doc_meshdescriptors":"Breast Neoplasms;Calcium-Calmodulin-Dependent Protein Kinases;Carrier Proteins;Cell Aggregation;Female;Glycoproteins;Humans;Mitogen-Activated Protein Kinase 3;Mitogen-Activated Protein Kinases;Neuregulin-1;Phosphatidylinositol 3-Kinases;Phosphorylation;Proto-Oncogene Proteins;Receptor, Epidermal Growth Factor;Receptor, ErbB-2;Receptor, ErbB-3;Tumor Cells, Cultured;Tyrosine",
        "Doc_meshqualifiers":"pathology;physiology;pharmacology;pharmacology;physiology;metabolism;metabolism;metabolism;metabolism",
        "_version_":1605881088795738112},
      {
        "Doc_abstract":"Abnormal expression of the HER-2/neu oncogene, a tyrosine kinase-type transmembrane growth factor receptor localized to chromosome 17q, has been associated with poor prognosis and the prediction of therapy response in invasive breast cancer. The comparative incidence and significance of HER-2/neu gene amplification for lobular and ductal breast cancer have not been previously characterized.;Formalin-fixed, paraffin-embedded primary breast cancer tissue sections from 71 women diagnosed with invasive lobular carcinoma were tested for HER-2/neu gene amplification by fluorescence in situ hybridization (FISH) method using the Ventana unique sequence probe (Ventana Medical Systems, Tucson, AZ). A series of 106 cases of invasive ductal carcinoma was similarly processed and tested. Lymph node status was available for 155 (88%) of the 177 cases and 82 (46%) were lymph node-negative (LN-) and 73 (41%) were lymph node-positive (LN+). Patients were treated for a mean of 65 months (range 1-169 months).;9 of 71 (13%) cases of lobular cancer featured HER-2/neu gene amplification, whereas 51 (48%) of 106 cases of ductal cancer showed amplification (P < 0.0001). On univariate analysis of combined lobular and ductal cases, HER-2/neu gene amplification detected by FISH predicted disease-related death (P < 0.0001). HER-2/neu gene amplification also predicted disease-related death in lobular cases alone (P = 0.003), LN+ lobular cases separately (P = 0.019), and LN- and LN+ ductal cases separately and alone (P < 0.0001). Multivariate analysis of the lobular group alone revealed that LN+ status (P = 0.015) and stage (P = 0.01) were independent predictors of disease-related death, and HER-2/neu gene amplification reached near significance (P = 0.086). In the ductal carcinoma group alone, HER-2/neu gene amplification (P = 0.03), lymph node status (P = 0.0001), tumor stage (P = 0.0001), and tumor grade (P = 0.044) were independent predictors of overall disease survival.;HER-2/neu gene amplification detected by FISH was identified at a significantly lower rate in lobular compared with ductal breast cancer. HER-2/neu gene amplification when present in lobular breast cancer is a significant adverse prognostic factor.",
        "Doc_title":"Comparison of HER-2/neu oncogene amplification detected by fluorescence in situ hybridization in lobular and ductal breast cancer.",
        "Journal":"Applied immunohistochemistry & molecular morphology : AIMM",
        "Do_id":"11893034",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"Breast Neoplasms;Carcinoma, Ductal, Breast;Carcinoma, Lobular;Female;Gene Amplification;Genes, erbB-2;Humans;In Situ Hybridization, Fluorescence;Oncogenes",
        "Doc_meshqualifiers":"genetics;pathology;genetics;pathology;genetics;pathology",
        "_version_":1605876560542302208},
      {
        "Doc_abstract":"Flax is a food and dietary supplement commonly used for menopausal symptoms. Flax is known for its lignan, Î±-linolenic acid, and fiber content, components that may possess phytogestrogenic, anti-inflammatory, and hormone modulating effects, respectively. We conducted a systematic review of flax for efficacy in improving menopausal symptoms in women living with breast cancer and for potential impact on risk of breast cancer incidence or recurrence.;We searched MEDLINE, Embase, the Cochrane Library, and AMED from inception to January 2013 for human interventional or observational data pertaining to flax and breast cancer.;Of 1892 records, we included a total of 10 studies: 2 randomized controlled trials, 2 uncontrolled trials, 1 biomarker study, and 5 observational studies. Nonsignificant (NS) decreases in hot flash symptomatology were seen with flax ingestion (7.5 g/d). Flax (25 g/d) increased tumor apoptotic index (P< .05) and decreased HER2 expression (P< .05) and cell proliferation (Ki-67 index; NS) among newly diagnosed breast cancer patients when compared with placebo. Uncontrolled and biomarker studies suggest beneficial effects on hot flashes, cell proliferation, atypical cytomorphology, and mammographic density, as well as possible anti-angiogenic activity at doses of 25 g ground flax or 50 mg secoisolariciresinol diglycoside daily. Observational data suggests associations between flax and decreased risk of primary breast cancer (adjusted odds ratio [AOR] = 0.82; 95% confidence interval [CI] = 0.69-0.97), better mental health (AOR = 1.76; 95% CI = 1.05-2.94), and lower mortality (multivariate hazard ratio = 0.69; 95% CI = 0.50-0.95) among breast cancer patients.;Current evidence suggests that flax may be associated with decreased risk of breast cancer. Flax demonstrates antiproliferative effects in breast tissue of women at risk of breast cancer and may protect against primary breast cancer. Mortality risk may also be reduced among those living with breast cancer.",
        "Doc_title":"Flax and Breast Cancer: A Systematic Review.",
        "Journal":"Integrative cancer therapies",
        "Do_id":"24013641",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605747548368142336},
      {
        "Doc_abstract":"Alterations of the HER2 (also known as erbB-2 or neu) proto-oncogene have been implicated in the carcinogenesis and prognosis of breast cancer. A polymorphism at codon 655 (GTC/valine to ATC /isoleucine [Val(655)Ile]) in the transmembrane domain-coding region of this gene has been identified and may be associated with the risk of breast cancer. We evaluated this hypothesis in a subgroup of women who participated in a large-scale, population-based, case-control study of breast cancer in Shanghai, China.;Genomic DNA from 339 patients with breast cancer and 361 healthy control subjects was examined for the Val(655)Ile polymorphism with a polymerase chain reaction-restriction fragment-length polymorphism-based assay. All study subjects completed a structured questionnaire during an in-person interview. All P values are from two-sided tests.;We found that 25.1% of the case patients and 21.7% of the control subjects were heterozygous for the Val allele and 3.2% of the case patients and 0. 3% of the control subjects were homozygous for this allele (P =.005). Compared with women with the Ile/Ile genotype, women who had the Ile/Val or Val/Val genotype had an elevated risk of breast cancer (odds ratio [OR] = 1.4; 95% confidence interval [CI] = 1.0-2.0; P =. 05) after adjustment for age, educational level, study period, history of breast fibroadenoma, leisure physical activity, and age at first live birth. The risk was elevated even more among women who were homozygous for the Val allele (OR = 14.1; 95% CI = 1.8-113.4). The association was more pronounced among younger women (</=45 years) than among older women (>45 years). The adjusted OR associated with the Val allele was 1.7 (95% CI = 1.1-2.6) for younger women and 1.0 (95% CI = 0.5-1.9) for older women.;Results of this study suggest that polymorphisms of the HER2 gene may be important susceptibility biomarkers for breast cancer risk, particularly among younger women.",
        "Doc_title":"Population-based, case-control study of HER2 genetic polymorphism and breast cancer risk.",
        "Journal":"Journal of the National Cancer Institute",
        "Do_id":"10699071",
        "Doc_ChemicalList":"Isoleucine;Receptor, ErbB-2;Valine",
        "Doc_meshdescriptors":"Adult;Age Factors;Amino Acid Substitution;Body Mass Index;Breast Neoplasms;Case-Control Studies;Chi-Square Distribution;China;Confidence Intervals;Exercise;Female;Fibroadenoma;Gene Frequency;Genes, erbB-2;Genotype;Heterozygote Detection;Humans;Isoleucine;Menarche;Middle Aged;Odds Ratio;Polymorphism, Restriction Fragment Length;Receptor, ErbB-2;Reference Values;Risk Factors;Valine",
        "Doc_meshqualifiers":"epidemiology;genetics;epidemiology;epidemiology;genetics;genetics",
        "_version_":1605876175420260352},
      {
        "Doc_abstract":"Glutamate-ammonia ligase (GLUL) belongs to the glutamine synthetase family. It catalyzes the synthesis of glutamine from glutamate and ammonia in an ATP-dependent reaction. Here, we found higher expression of GLUL in the breast cancer patients was associated with larger tumor size and higher level of HER2 expression. In addition, GLUL was heterogeneously expressed in various breast cancer cells. The mRNA and protein expression levels of GLUL in SK-BR-3 cells were obviously higher than that in the other types of breast cancer cells. Results showed GLUL knockdown in SK-BR-3 cells could significantly decrease the proliferation ability. Furthermore, GLUL knockdown markedly inhibited the p38 MAPK and ERK1/ERK2 signaling pathways in SK-BR-3 cells. Thus, GLUL may represent a novel target for selectively inhibiting p38 MAPK and ERK1/ERK2 signaling pathways and the proliferation potential of breast cancer cells. This article is protected by copyright. All rights reserved.",
        "Doc_title":"GLUL Promotes Cell Proliferation in Breast Cancer.",
        "Journal":"Journal of cellular biochemistry",
        "Do_id":"27791265",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605883077407539200},
      {
        "Doc_abstract":"Our objective was to determine whether imaging with a human epidermal growth factor receptor 2 (HER2)-targeted PET tracer can detect HER2-positive metastases in patients with HER2-negative primary breast cancer.;Patients with HER2-negative primary breast cancer and evidence of distant metastases were enrolled in an Institutional Review Board-approved prospective clinical trial. Archived pathologic samples from the patient's primary breast cancer were retested to confirm HER2-negative disease. Patients with confirmed HER2-negative primary breast cancer underwent ",
        "Doc_title":"Detection of HER2-Positive Metastases in Patients with HER2-Negative Primary Breast Cancer Using 89Zr-Trastuzumab PET/CT.",
        "Journal":"Journal of nuclear medicine : official publication, Society of Nuclear Medicine",
        "Do_id":"27151988",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605752408292458496},
      {
        "Doc_abstract":"The purpose of this study was to determine HER-2/neu in the serum of patients with solid tumors and to investigate its potential usefulness in predicting the clinical course of the disease. At the same time, we compared the ability of serum HER-2/neu, CA15.3, CA12-5, CA19-9, carcino embryonic antigen (CEA), and alpha-feto-protein (AFP) in breast, colorectal, and lung cancer patients. Forty, thirty-six, and twenty-three patients with lung, colon and breast cancer were included in this study, respectively. Serum levels of HER-2/neu, CA15.3, CA12-5, CA19-9, CEA, and AFP were measured. Her-2 neu levels were significantly higher in the breast cancer groups than colorectal and lung cancer and controls groups (P < 0.01). There is no significant difference when compared with others groups (P > 0.05). There was a positive correlation between the HER-2/neu and CA15-3 values in breast cancer groups. We found 0.75(0.59-0.90) for Her-2/neu from the area under the curve (AUC). P-value for breast cancer is 0.003, and we discovered that 9 ng/ml was the best inersection point. In this situation, we calculated that sensitivity was 65.2%, specificity was 100%, positive predictive value was 100%, negative predictive value 75.8%, and accuracy was 83.4%. These findings indicate that serum HER2/neu levels are clinically valuable in monitoring metastatic breast cancer and non-small cell lung cancer patients. Prognosis of breast cancer provides an additional value over the commonly used CA15-3 test. Measurements of levels of serum HER-2/neu provide prognostic and predictive information to the clinician and can especially be used for monitoring metastatic breast cancer patients. Further clinical validation is needed to confirm these findings.",
        "Doc_title":"Clinical significance and prognostic value of serum sHER-2/neu levels in patients with solid tumors.",
        "Journal":"Medical oncology (Northwood, London, England)",
        "Do_id":"18855148",
        "Doc_ChemicalList":"Biomarkers, Tumor;Carcinoembryonic Antigen;alpha-Fetoproteins;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Biomarkers, Tumor;Breast;Breast Neoplasms;Carcinoembryonic Antigen;Colon;Colorectal Neoplasms;Extracellular Fluid;Female;Humans;Lung;Lung Neoplasms;Receptor, ErbB-2;Sensitivity and Specificity;alpha-Fetoproteins",
        "Doc_meshqualifiers":"blood;metabolism;diagnosis;blood;metabolism;diagnosis;metabolism;metabolism;diagnosis;blood;metabolism",
        "_version_":1605825087467945984},
      {
        "Doc_abstract":"Cyclooxygenase-2 (Cox-2) expression can induce mammary tumorigenesis in transgenic mice, and selective Cox-2 inhibitors are both chemopreventive and chemotherapeutic in rat models of breast cancer. We analyzed the expression of Cox-2 protein by immunohistochemistry in tissue array specimens of 1576 invasive breast cancers. Moderate to strong (elevated) expression of Cox-2 protein was observed in 37.4% of the tumors, and it was associated with unfavorable distant disease-free survival (P < 0.0001). Elevated Cox-2 expression was associated with a large tumor size, a high histological grade, a negative hormone receptor status, a high proliferation rate (identified by Ki-67), high p53 expression, and the presence of HER-2 oncogene amplification (P < 0.0001 for all comparisons), along with axillary node metastases and a ductal type of histology (P = 0.0001 and P = 0.0017, respectively). Interestingly, association with the unfavorable outcome was especially apparent in the subgroups defined by estrogen receptor positivity, low p53 expression, and no HER-2 amplification (P < 0.0001 for all comparisons). These results indicate that elevated Cox-2 expression is more common in breast cancers with poor prognostic characteristics and is associated with an unfavorable outcome. The present findings support efforts to initiate clinical trials on the efficacy of Cox-2 inhibitors in adjuvant treatment of breast cancer.",
        "Doc_title":"Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer.",
        "Journal":"Cancer research",
        "Do_id":"11830510",
        "Doc_ChemicalList":"Isoenzymes;Membrane Proteins;Cyclooxygenase 2;PTGS2 protein, human;Prostaglandin-Endoperoxide Synthases",
        "Doc_meshdescriptors":"Breast Neoplasms;Carcinoma, Ductal, Breast;Carcinoma, Lobular;Cyclooxygenase 2;Disease-Free Survival;Female;Humans;Immunohistochemistry;Isoenzymes;Membrane Proteins;Middle Aged;Multivariate Analysis;Prostaglandin-Endoperoxide Synthases",
        "Doc_meshqualifiers":"enzymology;pathology;enzymology;pathology;enzymology;pathology;biosynthesis;biosynthesis",
        "_version_":1605804514637512704},
      {
        "Doc_abstract":"The role of HER4 in breast cancer is controversial and its role in relation to trastuzumab resistance remains unclear. We showed that trastuzumab treatment and its acquired resistance induced HER4 upregulation, cleavage and nuclear translocation. However, knockdown of HER4 by specific siRNAs increased trastuzumab sensitivity and reversed its resistance in HER2 positive breast cancer cells. Preventing HER4 cleavage by a Î³-secretase inhibitor and inhibiting HER4 tyrosine kinase activity by neratinib decreased trastuzumab-induced HER4 nuclear translocation and enhanced trastuzumab response. There was also increased nuclear HER4 staining in the tumours from BT474 xenograft mice and human patients treated with trastuzumab. Furthermore, nuclear HER4 predicted poor clinical response to trastuzumab monotherapy in patients undergoing a window study and was shown to be an independent poor prognostic factor in HER2 positive breast cancer. Our data suggest that HER4 plays a key role in relation to trastuzumab resistance in HER2 positive breast cancer. Therefore, our study provides novel findings that HER4 activation, cleavage and nuclear translocation influence trastuzumab sensitivity and resistance in HER2 positive breast cancer. Nuclear HER4 could be a potential prognostic and predictive biomarker and understanding the role of HER4 may provide strategies to overcome trastuzumab resistance in HER2 positive breast cancer. ",
        "Doc_title":"Nuclear HER4 mediates acquired resistance to trastuzumab and is associated with poor outcome in HER2 positive breast cancer.",
        "Journal":"Oncotarget",
        "Do_id":"25153719",
        "Doc_ChemicalList":"Antineoplastic Agents;ERBB2 protein, human;ERBB4 protein, human;Receptor, ErbB-2;Receptor, ErbB-4;Trastuzumab",
        "Doc_meshdescriptors":"Animals;Antineoplastic Agents;Breast Neoplasms;Cell Line, Tumor;Cell Nucleus;Drug Resistance, Neoplasm;Female;Heterografts;Humans;MCF-7 Cells;Mice;Prognosis;Receptor, ErbB-2;Receptor, ErbB-4;Trastuzumab",
        "Doc_meshqualifiers":"pharmacology;drug therapy;enzymology;pathology;enzymology;metabolism;metabolism;pharmacology",
        "_version_":1605746385081073665},
      {
        "Doc_abstract":"Metastasis, which remains incompletely characterized at the molecular and biochemical levels, is a highly specific process. Despite the ability of disseminated cancer cells to intravasate into distant tissues, it has been long recognized that only a limited subset of target organs develop clinically overt metastases. Therefore, subsequent adaptation of disseminated cancer cells to foreign tissue microenvironment determines the metastatic latency and tissue tropism of these cells. As a result, studying interactions between the disseminated cancer cells and the adjacent stromal cells will provide a better understanding of what constitutes a favorable or unfavorable microenvironment for disseminated cancer cells in a tissue-specific manner. Previously, we reported a protein signature of brain metastasis showing increased ability of brain metastatic breast cancer cells to counteract oxidative stress. In this study, we showed that another protein from the brain metastatic protein signature, neurotrophin-3 (NT-3), has a dual function of regulating the metastatic growth of metastatic breast cancer cells and reducing the activation of immune response in the brain. More importantly, increased NT-3 secretion in metastatic breast cancer cells results in a reversion of mesenchymal-like (EMT) state to epithelial-like (MET) state and vice versa. Ectopic expression of NT-3 in EMT-like breast cancer cells reduces their migratory ability and increases the expression of HER2 (human epidermal growth factor receptor 2) and E-cadherin at the cell-cell junction. In addition, both endogenous and ectopic expression of NT-3 reduced the number of fully activated cytotoxic microglia. In summary, NT-3 appears to promote growth of metastatic breast cancer cells in the brain by facilitating the re-epithelialization of metastatic breast cancer cells and downmodulating the cytotoxic response of microglia. Most importantly, our results provide new insights into the latency and development of central nervous system macrometastases in patients with HER2-positive breast tumors and provide mechanistic rationale to target HER2 signaling for HER2-positive breast cancer brain metastasis.",
        "Doc_title":"Neurotrophin-3 modulates breast cancer cells and the microenvironment to promote the growth of breast cancer brain metastasis.",
        "Journal":"Oncogene",
        "Do_id":"23001042",
        "Doc_ChemicalList":"Neurotrophin 3;Receptor, ErbB-2;Receptor, trkA",
        "Doc_meshdescriptors":"Animals;Brain Neoplasms;Breast Neoplasms;Cell Line, Tumor;Cell Proliferation;Epithelial-Mesenchymal Transition;Female;Humans;Immune Evasion;Mice;Mice, SCID;Neurotrophin 3;Receptor, ErbB-2;Receptor, trkA;Tumor Microenvironment",
        "Doc_meshqualifiers":"secondary;pathology;analysis;physiology;physiology;analysis",
        "_version_":1605895673647988736},
      {
        "Doc_abstract":"There have been recent new developments in the treatment of breast cancer that over-expresses HER2 (ERRB2/HER2 positive) and the mechanistic understanding of trastuzumab response. We review these findings and reflect on how they may influence the next generation of clinical trials in this breast cancer subtype.;Two recent trials in the neoadjuvant setting report that treatment with dual anti-HER2 agents was superior, in terms of rates of pathological complete response, to trastuzumab alone. Recent data also highlight that HER2 positive disease is biologically different according to estrogen receptor status and for long lasting clinical remissions, anti-HER2 therapy also seems to require an effective adaptive immune response.;We are currently in a very exciting era for therapeutic approaches in HER2 positive disease. Recent data suggest that intensive chemotherapy regimens may not be required for some women if we can determine the most potent combinations of signal inhibitors. We also propose that different clinical trials may need to be designed for HER2 positive breast cancer according to estrogen receptor status and consider incorporating immunotherapeutic approaches.",
        "Doc_title":"HER2-overexpressing breast cancer:  time for the cure with less chemotherapy?",
        "Journal":"Current opinion in oncology",
        "Do_id":"21918439",
        "Doc_ChemicalList":"Protein Kinase Inhibitors;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Animals;Antineoplastic Combined Chemotherapy Protocols;Breast Neoplasms;Female;Humans;Mammary Neoplasms, Experimental;Molecular Targeted Therapy;Protein Kinase Inhibitors;Receptor, ErbB-2",
        "Doc_meshqualifiers":"therapeutic use;drug therapy;enzymology;drug therapy;enzymology;administration & dosage;antagonists & inhibitors;biosynthesis",
        "_version_":1605765091555278848},
      {
        "Doc_abstract":"Breast cancer is a heterogeneous disease composed of different subtypes, characterized by their different clinicopathological characteristics, prognoses and responses to treatment. In the past decade, significant advances have been made in the treatment of breast cancer sensitive to hormonal treatments, as well as in patients whose malignant cells overexpress or amplify HER2. In contrast, mainly due to the lack of molecular targets, little progress has been made in the treatment of patients with triple-negative breast cancer. Recent improved understanding of the natural history, pathophysiology, and molecular features of triple-negative breast cancers have provided new insights into management and therapeutic strategies for women affected with this entity. Ongoing and planned translational clinical trials are likely to optimize and improve treatment of women with this disease.",
        "Doc_title":"Treatment options for patients with triple-negative breast cancer.",
        "Journal":"Journal of hematology & oncology",
        "Do_id":"20979652",
        "Doc_ChemicalList":"Angiogenesis Inhibitors;Receptors, Estrogen;Receptors, Progesterone;ERBB2 protein, human;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Angiogenesis Inhibitors;Breast Neoplasms;Female;Genes, BRCA1;Genes, BRCA2;Humans;Mutation;Prognosis;Receptor, ErbB-2;Receptors, Estrogen;Receptors, Progesterone",
        "Doc_meshqualifiers":"therapeutic use;chemistry;drug therapy;genetics;analysis;analysis;analysis",
        "_version_":1605766553749422080},
      {
        "Doc_abstract":"Trastuzumab (Herceptin; Genentech, Inc., CA, USA) is a humanized monoclonal antibody developed to target the HER-2/neu receptor, which is overexpressed in 20 - 25% of breast carcinomas. Clinical studies showed that trastuzumab is effective as single-agent therapy and that it has greater antitumour activity in combination with chemotherapy than chemotherapy alone in metastatic breast cancer. The indication for trastuzumab monotherapy and the combination with various chemotherapy agents is country-specific and is largely based on trials of efficacy and safety. Patients with a HER-2/neu overexpression level of 3+, determined by immunohistochemical assay or amplification using fluorescence in situ hybridisation, derive most clinical benefit from trastuzumab. Trastuzumab is generally well-tolerated. Cardiotoxicity is the main concern; thus, monitoring of cardiac function is recommended. Ongoing trials investigate the role of trastuzumab in the adjuvant and neoadjuvant settings.",
        "Doc_title":"A monoclonal antibody as an effective therapeutic agent in breast cancer: trastuzumab.",
        "Journal":"Expert opinion on biological therapy",
        "Do_id":"15952915",
        "Doc_ChemicalList":"Antibodies, Monoclonal;Antibodies, Monoclonal, Humanized;Antimetabolites, Antineoplastic;Antineoplastic Agents;Antineoplastic Agents, Phytogenic;Taxoids;Deoxycytidine;Vinblastine;Capecitabine;Receptor, ErbB-2;Trastuzumab;vinorelbine;Fluorouracil",
        "Doc_meshdescriptors":"Antibodies, Monoclonal;Antibodies, Monoclonal, Humanized;Antimetabolites, Antineoplastic;Antineoplastic Agents;Antineoplastic Agents, Phytogenic;Breast Neoplasms;Capecitabine;Chemotherapy, Adjuvant;Deoxycytidine;Female;Fluorouracil;Heart Diseases;Humans;Neoadjuvant Therapy;Neoplasm Metastasis;Patient Selection;Randomized Controlled Trials as Topic;Receptor, ErbB-2;Taxoids;Trastuzumab;Vinblastine",
        "Doc_meshqualifiers":"adverse effects;therapeutic use;therapeutic use;adverse effects;therapeutic use;therapeutic use;metabolism;pathology;therapy;analogs & derivatives;therapeutic use;analogs & derivatives;etiology;immunology;metabolism;therapeutic use;analogs & derivatives;therapeutic use",
        "_version_":1605807049715744768},
      {
        "Doc_abstract":"Brain metastases occur in as many as one third of patients with disseminated breast cancer. In this article, we discuss various presentations of brain metastases from breast cancer and review evidence that supports different treatment options. Because no prospective, randomized, controlled studies, to our knowledge, have focused solely on patients with brain metastases from breast cancer, we will first review retrospective studies of patients with brain metastases from breast cancer. Randomized studies of patients with brain metastases caused by multiple primary cancers will also be examined, and the conclusions from these studies will be extrapolated to patients with breast cancer. Because brain metastases from breast cancer occur in a variety of different clinical settings, ranging from a single metastasis without extensive extracranial disease to multiple brain metastases with widespread extracranial disease, treatment approaches must be tailored to the specific circumstances of each patient. For different clinical scenarios, neurosurgical resection, radiosurgery, and/or whole-brain radiation therapy may be appropriate treatment options. For patients with brain metastases from breast cancer that overexpresses HER2/neu, trastuzumab could alter the natural history of the non-central nervous system (CNS) disease. Therefore, HER2 status could also influence the treatment of brain metastases from breast cancer. Given the prevalence of brain metastases in patients with metastatic breast cancer in contemporary series, the rationale for clinical trials of CNS screening and prophylactic cranial irradiation will be discussed.",
        "Doc_title":"Brain metastases in patients with breast cancer: new horizons.",
        "Journal":"Clinical breast cancer",
        "Do_id":"16001989",
        "Doc_ChemicalList":"Receptor, ErbB-2",
        "Doc_meshdescriptors":"Brain Neoplasms;Breast Neoplasms;Clinical Trials as Topic;Combined Modality Therapy;Cranial Irradiation;Female;Humans;Receptor, ErbB-2",
        "Doc_meshqualifiers":"diagnosis;drug therapy;radiotherapy;secondary;pathology;biosynthesis",
        "_version_":1605742807213932545},
      {
        "Doc_abstract":"Brain metastases (BM) occur in up to one third of patients with metastatic breast cancer (MBC), whose incidences and prognoses by breast cancer subtypes in BM have not been well delineated.;Retrospective survival analyses were performed in 126 BM patients from 805 MBC patients treated at the National Cancer Center between August 2001 and April 2006, according to clinical characteristics, breast cancer subtypes, and receipt of trastuzumab. Estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth receptor-2 (HER2) statuses were tested by immunohistochemical (IHC) staining, and HER2 FISH analysis conducted for IHC 2+.;The proportion of HER2+/ER- (29% vs 16%) and triple-negative (37% vs 25%) tumors was higher in the 126 BM patients than those without BM. While median survival after recurrence was longer in patients with luminal A disease (median survival of luminal A vs luminal B vs HER2+/ER- vs triple-negative: p = 0.0246; 39.6 vs 27.4 vs 20.9 vs 15.5 months), survival was shorter from BM to death in luminal A and triple negatives (median survival: p = 0.0113; 4.0 vs 9.2 vs 5.0 vs 3.4 months). Receipt of trastuzumab after BM was a significant variable for survival in HER2+ patients. Multivariate analyses identified ER-negative, HER2-negative, or triple-negative, as well as older age, presence of leptomeningeal disease, and three or more extracranial disease sites, as poor prognostic factors for survival after BM.;MBC patients who developed BM had higher proportions of triple-negative and HER2+/ER- tumor status. Triple receptor status is a useful prognostic marker for predicting survival after BM in metastatic breast cancer patients.",
        "Doc_title":"Breast cancer subtypes and survival in patients with brain metastases.",
        "Journal":"Breast cancer research : BCR",
        "Do_id":"18307763",
        "Doc_ChemicalList":"Biomarkers, Tumor;Receptors, Estrogen;Receptors, Progesterone;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Biomarkers, Tumor;Brain Neoplasms;Breast Neoplasms;Female;Humans;Receptor, ErbB-2;Receptors, Estrogen;Receptors, Progesterone;Survival Analysis",
        "Doc_meshqualifiers":"analysis;mortality;secondary;therapy;chemistry;classification;pathology;analysis;analysis;analysis",
        "_version_":1605801813779415040},
      {
        "Doc_abstract":"Dilated cardiomyopathy is a leading cause of congestive heart failure and a debilitating complication of antineoplastic therapies. Despite disparate causes for dilated cardiomyopathy, maladaptive cardiac remodeling and decreased systolic function are common clinical consequences, begging an investigation of in vivo contractile dynamics in development and disease, one that has been impossible to date.;To image myocardial contractile filament dynamics in vivo and to assess potential causes of dilated cardiomyopathy in antineoplastic therapies targeting the epidermal growth factor receptor Erbb2.;We generated a transgenic zebrafish line expressing an actin-binding green fluorescent protein in cardiomyocytes, allowing an in vivo imaging of myofilaments. Analysis of this line revealed architectural differences in myofibrils of the distinct cardiomyocyte subtypes. We used this model to investigate the effects of Erbb2 signaling on myofibrillar organization because drugs targeting ERBB2 (HER2/NEU) signaling, a mainstay of breast cancer chemotherapy, cause dilated cardiomyopathy in many patients. High-resolution in vivo imaging revealed that Erbb2 signaling regulates a switch between a dense apical network of filamentous myofibrils and the assembly of basally localized myofibrils in ventricular cardiomyocytes.;Using this novel line, we compiled a reference for myofibrillar microarchitecture among myocardial subtypes in vivo and at different developmental stages, establishing this model as a tool to analyze in vivo cardiomyocyte contractility and remodeling for a broad range of cardiovascular questions. Furthermore, we applied this model to study Erbb2 signaling in cardiomyopathy. We show a direct link between Erbb2 activity and remodeling of myofibrils, revealing an unexpected mechanism with potentially important implications for prevention and treatment of cardiomyopathy.",
        "Doc_title":"Actin binding GFP allows 4D in vivo imaging of myofilament dynamics in the zebrafish heart and the identification of Erbb2 signaling as a remodeling factor of myofibril architecture.",
        "Journal":"Circulation research",
        "Do_id":"25228389",
        "Doc_ChemicalList":"Actins;Green Fluorescent Proteins;ERBB2 protein, human;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Actins;Amino Acid Sequence;Animals;Animals, Genetically Modified;Cells, Cultured;Green Fluorescent Proteins;Heart;Imaging, Three-Dimensional;Molecular Sequence Data;Myofibrils;Protein Binding;Receptor, ErbB-2;Signal Transduction;Time Factors;Zebrafish",
        "Doc_meshqualifiers":"metabolism;metabolism;anatomy & histology;physiology;methods;chemistry;metabolism;physiology;analysis;genetics;metabolism;physiology",
        "_version_":1605746296357912577},
      {
        "Doc_abstract":"Although HER2 gene status determines the eligibility of breast cancer patients to trastuzumab therapy, only a fraction of HER2 gene-amplified cancers are actually responsive, indicating that complex genotypical profiles might sustain HER2-targeted therapy responsiveness. To identify genetic factors modulating the response to HER2-targeted therapy, the numerical status of chromosome 17 was evaluated in HER2 gene-amplified tumor specimens from 43 patients who received trastuzumab-based treatment for advanced breast cancer, and in 60 unamplified breast carcinomas. Archival tumor specimens were analyzed by interphase fluorescence in situ hybridization (FISH) using a centromeric probe for chromosome 17 simultaneously with the HER2/neu human gene-specific probe. In the 43 patients who received trastuzumab-based treatment, response rate and time to progression (TTP) were compared between subgroups according to chromosome 17 status. Numerical aberrations of chromosome 17 were found in 65% of HER2-amplified tumors (single centromeric signal, 44%; >3 centromeric signals, 21%) and 60% of unamplified cancers (single centromeric signal, 43%; >3 centromeric, 17%). In the 43 treated metastatic breast cancer patients, trastuzumab was combined with docetaxel (35 patients), paclitaxel (2 patients), or vinorelbine (6 patients). Response rate was 92% in patients with >2 centromeric signals (chromosome 17 eusomy/polysomy), and 53% in patients whose tumor showed a single signal (chromosome 17 monosomy) (p=0.005). Chromosome 17 numerical status was not found to affect TTP. Multivariate logistic regression analysis confirmed that the effect of chromosome 17 monosomy on tumor response was independent of other potential clinical variables. Our findings suggest that 17 monosomy defines a subgroup of HER2 gene-amplified breast cancer characterized by reduced responsiveness to trastuzumab-based treatment. Further studies on the imbalance between the amplified HER2 gene and functionally antagonist gene(s) on chromosome 17 are warranted.",
        "Doc_title":"HER2 gene-amplified breast cancers with monosomy of chromosome 17 are poorly responsive to trastuzumab-based treatment.",
        "Journal":"Oncology reports",
        "Do_id":"15643516",
        "Doc_ChemicalList":"Antibodies, Monoclonal;Antibodies, Monoclonal, Humanized;Taxoids;docetaxel;Trastuzumab",
        "Doc_meshdescriptors":"Adult;Aged;Antibodies, Monoclonal;Antibodies, Monoclonal, Humanized;Antineoplastic Combined Chemotherapy Protocols;Breast Neoplasms;Chromosomes, Human, Pair 17;Disease Progression;Female;Genes, erbB-2;Humans;Middle Aged;Monosomy;Taxoids;Time Factors;Trastuzumab",
        "Doc_meshqualifiers":"administration & dosage;therapeutic use;therapeutic use;drug therapy;genetics;administration & dosage",
        "_version_":1605799239966785536},
      {
        "Doc_abstract":"The predictive role of human epidermal growth factor receptor 2 (HER2) to adjuvant anthracycline-based chemotherapy remains controversial. Here, we investigated the association between HER2 status and pathological response in breast cancer patients who received neoadjuvant anthracycline-based regimens.;Women (n = 538) with operable primary breast cancer received neoadjuvant anthracycline-based chemotherapy. Pathological complete response (pCR) was defined as no invasive breast tumor cells in breast after completion of neoadjuvant chemotherapy. HER2 status was determined by immunohistochemistry and/or by fluorescence in situ hybridization in core biopsy breast cancer tissue obtained before initiation of neoadjuvant chemotherapy.;In this cohort of 538 patients, 23.9% of patients achieved a pCR in their breast. HER2-positive tumors had a lower rate of pCR than did HER2-negative tumors (14.7% versus 25.7%, P = 0.013); negative HER2 status remained as an independent favorable predictor of pCR after adjusted for age, estrogen receptor, progesterone receptor, tumor size, chemotherapy cycles, and tumor grade in a multivariate analysis (odds ratio = 3.14; 95% confidence interval = 1.60-6.16, P = 0.001). Furthermore, patients with a pCR had a higher 3-year disease-free survival (DFS) rate than did patients without a pCR (P = 0.007).;Women with HER2-negative breast cancers rather than HER2-positive tumors benefit from anthracycline-based neoadjuvant chemotherapy.",
        "Doc_title":"HER2 and response to anthracycline-based neoadjuvant chemotherapy in breast cancer.",
        "Journal":"Annals of oncology : official journal of the European Society for Medical Oncology",
        "Do_id":"21196440",
        "Doc_ChemicalList":"Anthracyclines;Antineoplastic Agents;Biomarkers, Tumor;Receptors, Estrogen;Receptors, Progesterone;ERBB2 protein, human;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Anthracyclines;Antineoplastic Agents;Antineoplastic Combined Chemotherapy Protocols;Biomarkers, Tumor;Breast Neoplasms;Disease-Free Survival;Female;Humans;In Situ Hybridization, Fluorescence;Multivariate Analysis;Neoadjuvant Therapy;Receptor, ErbB-2;Receptors, Estrogen;Receptors, Progesterone",
        "Doc_meshqualifiers":"therapeutic use;therapeutic use;therapeutic use;metabolism;drug therapy;mortality;pathology;metabolism;metabolism;metabolism",
        "_version_":1605806828941213696},
      {
        "Doc_abstract":"Tamoxifen(TAM) is one of the most effective endocrine treatment for estrogen receptor(ER)-positive breast cancer, however drug resistance greatly limits benefit of it. Our purpose is to uncover the role of Beclin 1 in tamoxifen resistance and prognosis of ER positive breast cancer. We established a tamoxifen resistant ER-positive breast cancer cell subline MCF-7R presenting with higher Beclin 1 and human epidermal growth factor receptor 2(HER2) levels than MCF-7. Silencing Beclin 1 decreased levels of HER2 and significantly promoted TAM sensitivity of MCF-7 and MCF-7R in vitro. Overexpression of HER2 could reverse TAM sensitivity, which was formerly increased in Beclin 1 downregulated cell. Beclin 1 level was not only positively correlated with level of HER2 but also negatively correlated with overall survival of ER-positive breast cancer patients. Using bioinformatic methods, Beclin 1 mRNA was found to be negatively correlated with overall survival in breast cancer patients receiving TAM treatment. This study indicated for the first time that lower HER2 expression by Beclin 1 downregulation contributes to alteration of tamoxifen sensitivity and low Beclin 1 predicts favorable outcome in ER-positive breast cancer.",
        "Doc_title":"Lower Beclin 1 downregulates HER2 expression to enhance tamoxifen sensitivity and predicts a favorable outcome for ER positive breast cancer.",
        "Journal":"Oncotarget",
        "Do_id":"27509176",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605799750968279040},
      {
        "Doc_abstract":"Breast cancer is the second-leading cause of metastatic disease in the central nervous system (CNS). Recent advances in the biological understanding of breast cancer have facilitated an unprecedented increase of survival in a subset of patients presenting with metastatic breast cancer. Patients with HER2 positive (HER2+) or triple negative breast cancer are at highest risk of developing CNS metastasis, and typically experience a poor prognosis despite treatment with local and systemic therapies. Among the obstacles ahead in the realm of developmental therapeutics for breast cancer CNS metastasis is the improvement of our knowledge on its biological nuances and on the interaction of the blood brain barrier with new compounds. This manuscript reviews recent discoveries related to the underlying biology of breast cancer brain metastases, clinical progress to date and suggests rational approaches for investigational therapies.",
        "Doc_title":"Developmental therapeutics for patients with breast cancer and central nervous system metastasis: current landscape and future perspectives.",
        "Journal":"Annals of oncology : official journal of the European Society for Medical Oncology",
        "Do_id":"27701069",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605897863530807296},
      {
        "Doc_abstract":"Heat shock protein 90 (Hsp90) is an attractive target for breast cancer treatment, as it is required for the proper folding and stabilization of several proteins known to be involved in breast cancer growth and development. These proteins include the epidermal growth factor receptor, human epidermal growth factor receptor 2 (HER2), estrogen receptor (ER), progesterone receptor (PR), and src. 17-Allylamino-17-demethoxygeldanamycin (17-AAG) is an intravenous Hsp90 inhibitor in development for breast cancer treatment. We conducted a phase II study of 17-AAG 220Â mg/m(2) on days 1, 4, 8, and 11 every 21Â days in patients with metastatic and locally advanced breast cancer. Since we expected the molecular effects of Hsp90 inhibition to extend beyond just ER, PR, and HER2 down regulation and to impact a variety of other cellular proteins, patients were not selected based on ER, PR, or HER2 status. Eleven patients, including 6 patients with triple negative breast cancer, were enrolled and treated. There were no responses and 3 patients had stable disease as their best response. Five patients developed grade 3/4 toxicities, which were primarily hepatic and pulmonary. Based on these results, we do not recommend further study of 17-AAG at this dosing schedule or in unselected breast cancer patients.",
        "Doc_title":"A phase II study of 17-allylamino-17-demethoxygeldanamycin in metastatic or locally advanced, unresectable breast cancer.",
        "Journal":"Breast cancer research and treatment",
        "Do_id":"22083229",
        "Doc_ChemicalList":"Antineoplastic Agents;Benzoquinones;HSP90 Heat-Shock Proteins;Lactams, Macrocyclic;tanespimycin",
        "Doc_meshdescriptors":"Adult;Aged;Antineoplastic Agents;Benzoquinones;Breast Neoplasms;Female;HSP90 Heat-Shock Proteins;Humans;Lactams, Macrocyclic;Middle Aged;Neoplasm Metastasis;Neoplasm Staging;Treatment Outcome",
        "Doc_meshqualifiers":"adverse effects;therapeutic use;adverse effects;therapeutic use;drug therapy;pathology;antagonists & inhibitors;adverse effects;therapeutic use",
        "_version_":1605831739662401536},
      {
        "Doc_abstract":"Historically, the selection of the most effective adjuvant regimen for breast cancer patients was based on tumor size and nodal status but this approach took into account the stage only, without considering that the biology of the tumor matters as well, as breast cancer is a heterogeneous disease at the molecular level. In the present manuscript we will attempt to address the issue of selecting the most appropriate cytotoxic agents for adjuvant programs in the clinically and biologically distinct subgroups of endocrine responsive (luminal A and luminal B), HER2 positive and triple negative breast cancer patients. ",
        "Doc_title":"Optimal adjuvant chemotherapy in breast cancer: selection of agents.",
        "Journal":"Expert review of clinical pharmacology",
        "Do_id":"25080998",
        "Doc_ChemicalList":"Antineoplastic Agents;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Antineoplastic Agents;Breast Neoplasms;Chemotherapy, Adjuvant;Female;Humans;Lymphatic Metastasis;Neoplasm Staging;Receptor, ErbB-2;Triple Negative Breast Neoplasms",
        "Doc_meshqualifiers":"therapeutic use;drug therapy;pathology;methods;metabolism;drug therapy;pathology",
        "_version_":1605783450074218496},
      {
        "Doc_abstract":"In the year 2006, breast cancer was estimated to affect >200,000 American women and cause nearly 56,000 deaths. Furthermore, breast cancer is the most common cancer diagnosed and second most common cause of cancer-related deaths in women. The current treatment armamentarium for breast cancer includes chemotherapy, endocrine therapy and biological therapy. Treatment has become more individualised based on characteristics of the tumour including overexpression of the human epidermal growth factor receptor (HER)-2. Between 20 and 30% of all breast cancers overexpress HER2, which means 40,000 - 60,000 patients will have this type of cancer.Previously, overexpression of HER2 was a negative prognostic and predictive risk factor for survival; however, with the advent of trastuzumab, patients' prognosis is improving in all treatment settings. Much controversy exists in the use of trastuzumab, including (i) the sequence of adjuvant trastuzumab (concurrent with chemotherapy or sequential); (ii) the treatment duration (<1 year, 1 year or 2 years); and (iii) the treatment choice upon disease progression (whether to continue or not with trastuzumab and add another cytotoxic agent). Current trials are ongoing to help answer these questions.Furthermore, there has been interest in predicting which HER2-positive patients would require anthracycline therapy, and which could avoid anthracycline therapy and its toxicities. Novel therapeutics, such as lapatinib, an oral tyrosine kinase inhibitor, which blocks both the epidermal growth factor receptor and HER2 receptor has recently been approved by the US FDA. Whereas pertuzumab, a humanised monoclonal antibody, directed against heterodimerisation of HER2 and HER3 has entered phase II and III clinical trials.",
        "Doc_title":"HER2-positive breast cancer: current and future treatment strategies.",
        "Journal":"Drugs",
        "Do_id":"17547474",
        "Doc_ChemicalList":"Antibodies, Monoclonal;Antibodies, Monoclonal, Humanized;Antineoplastic Agents;Quinazolines;lapatinib;Receptor, ErbB-2;pertuzumab;Trastuzumab",
        "Doc_meshdescriptors":"Antibodies, Monoclonal;Antibodies, Monoclonal, Humanized;Antineoplastic Agents;Breast Neoplasms;Clinical Trials as Topic;Female;Humans;Quinazolines;Receptor, ErbB-2;Trastuzumab;Treatment Outcome",
        "Doc_meshqualifiers":"administration & dosage;adverse effects;therapeutic use;administration & dosage;adverse effects;therapeutic use;drug therapy;metabolism;methods;trends;administration & dosage;adverse effects;therapeutic use;analysis;antagonists & inhibitors",
        "_version_":1605748651474288640},
      {
        "Doc_abstract":"The use of gene expression profiling has impacted our understanding of breast cancer biology and increasingly has played a role in guiding clinical decisions. We have used hormone receptor (HR) and human epidermal growth factor receptor 2 (HER2) status for years to guide selection of therapy. More recently, gene expression analysis has facilitated the identification of at least five intrinsic subtypes of breast cancer. Potential therapeutic targets have also been identified using genomic profiling. Several tests, such as the 21-gene recurrence score assay (Oncotype DX) and the 70-gene prognosis signature (MammaPrint), have been well validated as prognostic tools for early-stage breast cancer, and have aided in adjuvant therapy decisions for early-stage, HR-positive breast cancer patients. Genomic profiling has the potential to provide additional insight into drug discovery and clinical trial design by identifying appropriate targeted therapies for subtypes of breast cancer.",
        "Doc_title":"Genomic subtypes in choosing adjuvant therapy for breast cancer.",
        "Journal":"Oncology (Williston Park, N.Y.)",
        "Do_id":"23687790",
        "Doc_ChemicalList":"Biomarkers, Tumor",
        "Doc_meshdescriptors":"Biomarkers, Tumor;Breast Neoplasms;Chemotherapy, Adjuvant;Decision Making;Female;Gene Expression Profiling;Gene Expression Regulation, Neoplastic;Genomics;Humans;Oligonucleotide Array Sequence Analysis;Practice Guidelines as Topic",
        "Doc_meshqualifiers":"genetics;classification;drug therapy;genetics",
        "_version_":1605818628502978560},
      {
        "Doc_abstract":"We previously described and validated a breast cancer staging system (CPS+EG, clinical-pathologic scoring system incorporating estrogen receptor-negative disease and nuclear grade 3 tumor pathology) for assessing prognosis after neoadjuvant chemotherapy using pretreatment clinical stage, posttreatment pathologic stage, estrogen receptor (ER) status, and grade. Development of the CPS+EG staging system predated routine administration of trastuzumab in patients with ERBB2-positive disease (formerly HER2 or HER2/neu).;To validate the CPS+EG staging system using the new definition of ER positivity (â‰¥1%) and to develop an updated staging system (Neo-Bioscore) that incorporates ERBB2 status into the previously developed CPS+EG.;Retrospective review of data collected prospectively from January 2005 through December 2012 on patients with breast cancer treated with neoadjuvant chemotherapy at The University of Texas MD Anderson Cancer Center.;Prognostic scores were computed using 2 versions of the CPS+EG staging system, one with ER considered positive if it measured 10% or higher, the other with ER considered positive if it measured 1% or higher. Fits of the Cox proportional hazards model for the 2 sets of prognostic scores were compared using the Akaike Information Criterion (AIC). Status of ERBB2 was added to the model, and the likelihood ratio test was used to determine improvement in fit.;A total of 2377 patients were included; all were women (median age, 50 years [range, 21-87 years]); ER status was less than 1% in 28.9%, 1% to 9% in 8.3%, and 10% or higher in 62.8%; 591 patients were ERBB2 positive. Median follow-up was 4.2 years (range, 0.5-11.7 years). Five-year disease-specific survival was 89% (95% CI, 87%-90%). Using 1% or higher as the cutoff for ER positivity, 5-year disease-specific survival estimates determined using the CPS+EG stage ranged from 52% to 98%, thereby validating our previous finding that the CPS+EG score facilitates more refined categorization into prognostic subgroups than clinical or final pathologic stage alone. The AIC value for this model was 3333.06, while for a model using 10% or higher as the cutoff for ER positivity, it was 3333.38, indicating that the model fits were nearly identical. The improvement in fit of the model when ERBB2 status was added was highly significant, with 5-year disease-specific survival estimates ranging from 48% to 99% (Pâ€‰<â€‰.001). Incorporating ERBB2 into the staging system defined the Neo-Bioscore, which provided improved stratification of patients with respect to prognosis.;The Neo-Bioscore improves our previously validated staging system and allows its application in ERBB2-positive patients. We recommend that treatment response and biologic markers be incorporated into the American Joint Committee on Cancer staging system.",
        "Doc_title":"The Neo-Bioscore Update for Staging Breast Cancer Treated With Neoadjuvant Chemotherapy: Incorporation of Prognostic Biologic Factors Into Staging After Treatment.",
        "Journal":"JAMA oncology",
        "Do_id":"26986538",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605874892553584640},
      {
        "Doc_abstract":"Treatment strategies in oncology are nowadays largely based on the \"target therapy model\", which allows to personalize the cure of each patient depending on distinctive host and disease features. As a general concept \"targeted drugs\" are effective only when the tumor exhibits the \"target\", which in breast cancer pathology may correspond to the expression of Estrogen Receptors and/or of HER2. These biomarkers are evaluated on breast cancer tissues by companion diagnostic tests, however, evidence suggests that the first step in breast cancer predictive pathology is still represented by morphology. For instance, histological types, such as tubular and cribriform carcinomas, define patients who may not need any treatments other than surgical excision. Neoadjuvant studies have shown that patients affected by lobular carcinomas are not likely to have any beneficial effects from chemotherapy. The second step in prediction is represented by immunophenotyping. If the immunohistochemical evaluation of four markers (estrogen and progesterone receptors, HER2 and Ki67) remains the best practice for breast cancer predictive pathology, molecular pathology has certainly reshaped the way we approach breast cancer diagnosis. The aim of this review is to discuss current knowledge in predictive pathology for the management of breast cancer patients, focusing on the benefits and drawbacks of traditional tools and of novel improvements of molecular biology.",
        "Doc_title":"Predictive Diagnostic Pathology in the Target Therapy Era in Breast Cancer.",
        "Journal":"Current drug targets",
        "Do_id":"25654739",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605755697963728896},
      {
        "Doc_abstract":"We investigate retrospectively the demographic and clinico-pathological characteristics of patients with triple-negative breast cancer (TNBC) compared to those with non-TNBC. Patients with breast cancer diagnosed from 1981 to 2008 in our clinic were retrospectively analyzed. Patient demographics including survival data and tumor characteristics were obtained from charts. A total of 795 patients were assessed in the study, including 140 patients (17.6%) with TNBC and 655 patients (82.4%) with non-TNBC. Patients with non-TNBC were further classified into 3 groups according to hormone receptor (HR) and HER-2 status. Median age was 49 (range 38-60 years) and similar between patients with TNBC and non-TNBC. Patients with TNBC had an increased likelihood of a higher histological grade III compared with HR(+) HER-2(-) subgroup (P > 0.001) and lower stage compared with HR(+)/HER2(+) and HR(-)/HER2(+) subgroups (P < 0.001 and P = 0.002, respectively). In patients with TNBC, the disease-free survival (DFS) rate was 66% at 5 years. In subgroup analysis of non-TNBCs, 5-year-DFS rates of the patients in HR(+)/HER2(-), HR(+)/HER2(+) and HR(-)/HER2(+) subgroups were 59, 66, and 57%, respectively. There was no significant difference between the TNBC and non-TNBC subgroups (P = 0.238). In multivariate analysis, nodal involvement (RR = 2.8, 95% CI: 0.99-8.3, P = 0.052) and the presence of lymphovascular invasion (RR = 3.2, 95% CI: 1.1-9.2, P = 0.029) were significantly associated with increased recurrence risk in patients with TNBC. Although there are differences in patient and tumor features, patients with TNBC had similar clinical course with those with non-TNBC.",
        "Doc_title":"Demographic and clinico-pathological characteristics in patients with triple-negative and non-triple-negative breast cancer.",
        "Journal":"Medical oncology (Northwood, London, England)",
        "Do_id":"20963641",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"Adult;Breast Neoplasms;Cohort Studies;Disease-Free Survival;Female;Follow-Up Studies;Humans;Middle Aged;Neoplasm Grading;Neoplasm Staging;Retrospective Studies;Survival Rate",
        "Doc_meshqualifiers":"mortality;pathology",
        "_version_":1605892762298744832},
      {
        "Doc_abstract":"The epidermal growth factor (EGF) receptor HER2 is a transmembrane receptor tyrosine kinase that plays a crucial role in the regulation of cell proliferation and survival. The overexpression of HER2 correlates strongly with prognosis in breast cancer. The targeted blockade of HER2 activity with monoclonal antibodies (e.g., trastuzumab [Herceptin]) and small-molecule tyrosine kinase inhibitors (e.g., lapatinib) results in the inhibition of tumor growth in HER2-positive cancers. Anti-HER2 therapies have also shown efficacy in combination with chemotherapy in clinical trials in patients with HER2-positive breast cancer. Their efficacy may, however, be limited by molecular mechanisms that compensate for HER2 suppression (e.g., activity of EGF receptor) or mechanisms of resistance (e.g., loss of PTEN). HER2 continues, however, to be overexpressed by the cancer cells, and the continued suppression of HER2 may be required for maximum antitumor effect. It should be noted that in the absence of definitive data from randomized trials showing an absence or presence of benefit, the use of anti-HER2 agents such as trastuzumab in multiple sequential regimens has become the standard of care. Combining HER2 blockers with agents that overcome the compensatory or resistance mechanisms may increase the efficacy of anti-HER2 therapies. In addition, anti-HER2 therapies can have synergy with common chemotherapy regimens and remain effective through multiple lines of therapy. Optimizing the use of therapies that target HER2 signaling will lead to further advances in the treatment of breast cancer.",
        "Doc_title":"Optimizing outcomes in HER2-positive breast cancer: the molecular rationale.",
        "Journal":"Oncology (Williston Park, N.Y.)",
        "Do_id":"19364051",
        "Doc_ChemicalList":"Antibodies, Monoclonal;Antibodies, Monoclonal, Humanized;Antineoplastic Agents;HSP90 Heat-Shock Proteins;Protein Kinase Inhibitors;Receptor, Epidermal Growth Factor;Receptor, ErbB-2;pertuzumab;Trastuzumab",
        "Doc_meshdescriptors":"Antibodies, Monoclonal;Antibodies, Monoclonal, Humanized;Antineoplastic Agents;Breast Neoplasms;Cell Proliferation;Combined Modality Therapy;Disease Progression;Drug Resistance, Neoplasm;Female;Genetic Therapy;HSP90 Heat-Shock Proteins;Humans;Protein Kinase Inhibitors;Receptor, Epidermal Growth Factor;Receptor, ErbB-2;Trastuzumab",
        "Doc_meshqualifiers":"pharmacology;therapeutic use;pharmacology;therapeutic use;drug therapy;metabolism;pathology;antagonists & inhibitors;pharmacology;therapeutic use;antagonists & inhibitors;metabolism;antagonists & inhibitors;metabolism",
        "_version_":1605763326693867520},
      {
        "Doc_abstract":"Human epidermal growth factor receptor 2 (ErbB2) is a transmembrane oncoprotein that is over expressed in breast cancer. A successful therapeutic treatment is a monoclonal antibody called trastuzumab which interacts with the ErbB2 extracellular domain (ErbB2-ECD). A better understanding of the detailed structure of the receptor-antibody interaction is indeed of prime interest for the design of more effective anticancer therapies. In order to discuss the flexibility of the complex ErbB2-ECD/trastuzumab, we present, in this study, a multi-nanosecond molecular dynamics simulation (MD) together with an analysis of fluctuations, through a principal component analysis (PCA) of this system. Previous to this step and in order to validate the simulations, we have performed a detailed analysis of the variable antibody domain interactions with the extracellular domain IV of ErbB2. This structure has been statically elucidated by x-ray studies. Indeed, the simulation results are in excellent agreement with the available experimental information during the full trajectory. The PCA shows eigenvector fluctuations resulting in a hinge motion in which domain II and C(H) domains approach each other. This move is likely stabilized by the formation of H-bonds and salt bridge interactions between residues of the dimerization arm in the domain II and trastuzumab residues located in the C(H) domain. Finally, we discuss the flexibility of the MD/PCA model in relation with the static x-ray structure. A movement of the antibody toward the dimerization domain of the ErbB2 receptor is reported for the first time. This finding could have important consequences on the biological action of the monoclonal antibody.",
        "Doc_title":"Conformational flexibility of the ErbB2 ectodomain and trastuzumab antibody complex as revealed by molecular dynamics and principal component analysis.",
        "Journal":"Journal of molecular modeling",
        "Do_id":"23160933",
        "Doc_ChemicalList":"Antibodies, Monoclonal, Humanized;Antineoplastic Agents;ERBB2 protein, human;Receptor, ErbB-2;Trastuzumab",
        "Doc_meshdescriptors":"Antibodies, Monoclonal, Humanized;Antineoplastic Agents;Binding Sites;Breast Neoplasms;Female;Humans;Models, Molecular;Molecular Dynamics Simulation;Principal Component Analysis;Protein Binding;Protein Conformation;Protein Structure, Tertiary;Receptor, ErbB-2;Trastuzumab",
        "Doc_meshqualifiers":"chemistry;immunology;metabolism;immunology;metabolism;metabolism;chemistry;immunology;metabolism",
        "_version_":1605906576199122944},
      {
        "Doc_abstract":"Pertuzumab is a monoclonal antibody that represents the first among a new class of agents known as human epidermal growth factor receptor (HER) dimerization inhibitors. This is the first systematic review according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines to synthesize all available data of pertuzumab in breast cancer. The search strategy retrieved 11 studies that evaluated pertuzumab. One study was conducted in the neoadjuvant setting (417 patients), whereas all the others dealt with patients with recurrent, metastatic, or refractory disease (1023 patients). Six studies were conducted in HER2(+) breast cancer population (1354 patients), whereas 5 studies (86 patients) were conducted in HER2(-) (or unknown HER2 status) disease. Pertuzumab is the most recent agent approved by the US Food and Drug Administration in combination with trastuzumab and docetaxel for the treatment of patients with HER2(+) metastatic breast cancer who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease. This approval has been based on data from a phase III Clinical Evaluation of Pertuzumab and Trastuzumab (CLEOPATRA) study. The antitumor activity with the significant reduction in the risk of progression or death, as reflected upon the increase of 6.1 months in median progression-free survival, indicates that pertuzumab may provide an avenue for achieving additional benefit for patients with HER2(+). Moreover, pertuzumab seems to have a putative role in the management of patients with HER2 who are resistant to trastuzumab. The promising role of pertuzumab in the neoadjuvant and adjuvant settings remains to be further investigated and established in the future. ",
        "Doc_title":"Pertuzumab in breast cancer: a systematic review.",
        "Journal":"Clinical breast cancer",
        "Do_id":"23810292",
        "Doc_ChemicalList":"Antibodies, Monoclonal, Humanized;Antineoplastic Agents;pertuzumab",
        "Doc_meshdescriptors":"Antibodies, Monoclonal, Humanized;Antineoplastic Agents;Breast Neoplasms;Female;Genes, erbB-2;Humans",
        "Doc_meshqualifiers":"adverse effects;therapeutic use;adverse effects;therapeutic use;drug therapy;epidemiology;genetics",
        "_version_":1605881230330429440},
      {
        "Doc_abstract":"Cyclooxygenase-2 (COX-2) overexpression clearly plays an important role in the pathogenesis of breast cancer. In this study, we analysed the relationship between COX-2 expression and various clinicopathological factors in human breast cancer.;Using immunohistochemistry, we analysed archival specimens of human breast cancer (n=29) using antibodies to COX-2, ER, PgR and HER2 and, from medical records, obtained clinicopathological data.;We observed a significant association between COX-2 overexpression and distant metastasis. COX-2 expression was not significantly associated with any other clinical or pathological variable.;These findings lend support to the hypothesis that COX-2 overexpression represents an adverse prognostic event in human breast cancer and are encouraging for proposed strategies of COX-2 suppression to treat the disease.",
        "Doc_title":"Elevated cyclooxygenase-2 expression correlates with distant metastases in breast cancer.",
        "Journal":"Anticancer research",
        "Do_id":"15330183",
        "Doc_ChemicalList":"Isoenzymes;Membrane Proteins;Receptors, Estrogen;Receptors, Progesterone;Cyclooxygenase 2;PTGS2 protein, human;Prostaglandin-Endoperoxide Synthases;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Breast Neoplasms;Cyclooxygenase 2;Humans;Immunohistochemistry;Isoenzymes;Membrane Proteins;Neoplasm Metastasis;Neoplasm Staging;Paraffin Embedding;Prostaglandin-Endoperoxide Synthases;Receptor, ErbB-2;Receptors, Estrogen;Receptors, Progesterone;Retrospective Studies",
        "Doc_meshqualifiers":"enzymology;metabolism;pathology;biosynthesis;biosynthesis;biosynthesis;biosynthesis;biosynthesis",
        "_version_":1605746291081478145},
      {
        "Doc_abstract":"Breast cancers that are negative for estrogen receptor (ER), progesterone receptors (PR) and HER2, using standard clinical assays, have been dubbed triple-negative (TN). Unlike other molecular subtypes of invasive breast cancer, validated targeted therapies are currently unavailable for patients with TN breast cancer. Preclinical studies however, have identified several potential targets such as epidermal growth factor receptor (EGFR), SRC, MET and poly ADP ribose polymerase 1/2 (PARP1/2). Because of tumor heterogeneity, it is unlikely that any single targeted therapy will be efficacious in all patients with TN breast cancer. The rational way forward for treating these patients is likely to be biomarker-driven, combination targeted therapies or combination of targeted therapy with cytotoxic chemotherapy.",
        "Doc_title":"Targeted therapy for triple-negative breast cancer: where are we?",
        "Journal":"International journal of cancer",
        "Do_id":"22581656",
        "Doc_ChemicalList":"Receptors, Estrogen;Receptors, Progesterone;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Animals;Antineoplastic Combined Chemotherapy Protocols;Breast Neoplasms;Female;Humans;Molecular Targeted Therapy;Receptor, ErbB-2;Receptors, Estrogen;Receptors, Progesterone",
        "Doc_meshqualifiers":"therapeutic use;drug therapy;genetics;metabolism;methods;genetics;metabolism;genetics;metabolism;genetics;metabolism",
        "_version_":1605742688007618561},
      {
        "Doc_abstract":"Overexpression of human epidermal growth factor receptor 2 (HER2) or amplification of its gene is a prognostic factor in primary breast cancer and a predictor for tamoxifen treatment efficacy in oestrogen receptor (ER) positive disease. In the present study we explored a defined cohort of breast cancer patients included in a randomised trial in order to assess prognostic and tamoxifen treatment information yielded by HER2 status.;Premenopausal breast cancer patients with stage II tumours (n = 564) were included and allocated to 2 years of adjuvant tamoxifen treatment versus no adjuvant treatment. ER, progesterone receptor (PR) status and HER2 status was determined by immunohistochemistry using a tissue microarray. HER2 amplification was analysed by fluorescent in situ hybridisation and tumours being amplified and/or HER2 3+ were considered HER2+. HER2 status was evaluable in 83% of the patients and 12.6% were HER2+. In untreated patients, HER2 was a negative prognostic factor in ER+ patients, HR 2.95; 95% CI: 1.61-5.38, p < 0.001, but not in ER- patients, HR 0.67; 95% CI: 0.28-1.61, p = 0.4, and a significant interaction between the two markers was found, p < 0.01. HER2 status was not related to tamoxifen treatment efficacy in ER+ patients (term of interaction p = 0.95). When stratifying for PR status, similar results were achieved.;HER2+ and ER+ breast cancer constituted a subgroup of tumours with poor prognosis in premenopausal breast cancer, whereas no treatment interaction was found between HER2 status and tamoxifen in ER+ tumours. The poor prognosis in HER2+ and ER+ patients may interfere with the interpretation of HER2 data in non-randomised trials of adjuvant tamoxifen.",
        "Doc_title":"HER2 status in hormone receptor positive premenopausal primary breast cancer adds prognostic, but not tamoxifen treatment predictive, information.",
        "Journal":"Breast cancer research and treatment",
        "Do_id":"17636399",
        "Doc_ChemicalList":"Receptors, Estrogen;Receptors, Progesterone;Selective Estrogen Receptor Modulators;Tamoxifen;ERBB2 protein, human;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Adult;Breast Neoplasms;Chemotherapy, Adjuvant;Female;Humans;Immunohistochemistry;In Situ Hybridization, Fluorescence;Kaplan-Meier Estimate;Middle Aged;Neoplasms, Hormone-Dependent;Premenopause;Prognosis;Receptor, ErbB-2;Receptors, Estrogen;Receptors, Progesterone;Selective Estrogen Receptor Modulators;Tamoxifen;Tissue Array Analysis",
        "Doc_meshqualifiers":"drug therapy;metabolism;mortality;drug therapy;metabolism;metabolism;metabolism;metabolism;therapeutic use;therapeutic use",
        "_version_":1605884535472390144},
      {
        "Doc_abstract":"Triple negative (TN) breast cancers are defined by a lack of expression of oestrogen, progesterone, and HER2 receptors. They tend to have a higher grade, with a poorer outcome compared to non-TN breast cancers.;The aim of this study is to determine the incidence of TN breast cancer in an Asian country consisting of Malays, Chinese and Indians, and to determine the factors associated with this type of breast cancer.;The incidence of TN breast cancer in the University Malaya Medical Center is 17.6%. There is no significant difference amongst the Malays, Chinese and Indians. In bivariate analysis, TN breast cancer was significantly associated with younger age and Grade 3. However, in multivariate analysis using logistic regression, TN breast cancer was only associated with Grade 3.;The incidence of TN breast cancer in our study is similar to other studies, and associated with a higher grade.",
        "Doc_title":"Clinical characteristics of triple-negative breast cancer: experience in an Asian developing country.",
        "Journal":"Asian Pacific journal of cancer prevention : APJCP",
        "Do_id":"19640180",
        "Doc_ChemicalList":"Receptors, Estrogen;Receptors, Progesterone;ERBB2 protein, human;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Adult;Aged;Aged, 80 and over;Asian Continental Ancestry Group;Breast Neoplasms;Carcinoma, Ductal, Breast;Female;Humans;Malaysia;Male;Middle Aged;Prognosis;Receptor, ErbB-2;Receptors, Estrogen;Receptors, Progesterone;Retrospective Studies;Young Adult",
        "Doc_meshqualifiers":"metabolism;pathology;metabolism;pathology;metabolism;metabolism;metabolism",
        "_version_":1605850700577767424},
      {
        "Doc_abstract":"Prognostic value of ErbB3 in human breast cancer is still controversial. However, the roles of ErbB3 receptors in drug resistance are recently emerging. The objective of this study was to evaluate the relationship between ErbB3 expression and survival of breast cancer via meta-analysis. A systematic literature search was conducted and 32 potentially relevant studies were included in the meta-analysis. Outcomes presented in searched literatures can be classified as disease free survival (DFS), overall survival (OS), and progress free survival (PFS) values. Meta-analysis was performed for each group. Results showed no statistically significant difference in survival. The overall hazard ratio of PFS, DFS, and OS of ErbB3 expression was 1.40 [95% confidence interval/CI (0.51, 3.83)], 1.07 [95% CI (0.82, 1.40)], and 1.15 [95% CI (0.91, 1.44)], respectively. Subgroup analysis according to ErbB2 receptor status, ErbB3 assessment methods (immunohistochemistry/IHC vs non-IHC), and analysis type (multivariate and univariate analysis) were performed. No significant association was found. Using various assessment methods and patient populations, our results revealed that there was no significant correlation between ErbB3 expression and breast cancer survival. Further studies on heterodimers of ErbB3 and other molecular markers involved in ErbB3 related pathway are merited.",
        "Doc_title":"Meta-analysis reveals no significant correlation between breast cancer survival and ErbB3 expression.",
        "Journal":"APMIS : acta pathologica, microbiologica, et immunologica Scandinavica",
        "Do_id":"25912128",
        "Doc_ChemicalList":"Biomarkers, Tumor;ERBB2 protein, human;ERBB3 protein, human;Receptor, ErbB-2;Receptor, ErbB-3",
        "Doc_meshdescriptors":"Biomarkers, Tumor;Breast Neoplasms;Disease-Free Survival;Female;Humans;Kaplan-Meier Estimate;Prognosis;Receptor, ErbB-2;Receptor, ErbB-3;Retrospective Studies",
        "Doc_meshqualifiers":"metabolism;metabolism;mortality;metabolism;metabolism",
        "_version_":1605850869961588736},
      {
        "Doc_abstract":"Approximately 80% of breast cancers overexpress the kinase BRK/PTK6, which has various oncogenic roles in breast cancer cell proliferation, survival and migration. However, BRK inhibitors have yet to be explored as possible therapeutic tools. In this study, we employed a parallel compound-centric approach to discover a new class of pharmaceutical agents, exemplified by XMU-MP-2, as potent and selective BRK inhibitors. XMU-MP-2 exhibited target-specific inhibition of BRK kinase activity and disrupted signaling pathways mediated by this activity, thereby reducing proliferation in BRK-positive breast cancer cells. In mouse xenograft models, XMU-MP-2 repressed the growth of tumors driven by oncogenic BRK, including BRK-transformed Ba/F3 cells and BRK-positive breast cancer cells. Notably, XMU-MP-2 cooperated strongly with HER2 inhibitor or ER blockade to block breast cancer cell proliferation in vitro and in vivo. Overall, our findings offer a preclinical proof of concept for therapeutic targeting of the BRK kinase in breast cancer.",
        "Doc_title":"Targeting BRK-positive breast cancers with small molecule kinase inhibitors.",
        "Journal":"Cancer research",
        "Do_id":"27758886",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605873809999527936},
      {
        "Doc_abstract":"It is suggested that tumour stromal myofibroblasts exert an unfavourable effect on the biology of breast cancer. We are aware of only a single study which examined relationships between manifestation of myofibroblasts in the stroma of breast cancer and clinicopathological data of the patients. The present study was aimed at estimation of the effect exerted by myofibroblasts present in the tumour stroma on principal pathological parameters and on expression of Ki67, P53 and HER-2 proteins in the group of the most frequent breast cancers, the ductal cancers. In paraffin sections of 60 ductal breast cancers (20 cases in G1, 20 in G2 and 20 in G3), immunohistochemical reactions were performed to detect expression of smooth muscle actin (SMA) in order to visualize myofibroblasts, Ki67, P53 and HER-2. The studies demonstrated that the most numerous myofibroblasts were present in G3 cases and they were the least frequent in G1 cases (P = 0.02). Positive correlations were observed between the presence of myofibroblasts in tumour stroma and expression of Ki67 and HER-2 in breast cancer cells in the entire group (P < 0.001 and P = 0.001, respectively), in G2 cases (P = 0.003 and P = 0.03) and in G3 cases (P = 0.01 and P = 0.03). Considering that the higher grade, Ki67 and HER-2 are thought to represent unfavourable prognostic factors, the elevated content of myofibroblasts in tumour stroma is probably typical for cases with worse prognosis.",
        "Doc_title":"Stromal myofibroblasts in breast cancer: relations between their occurrence, tumor grade and expression of some tumour markers.",
        "Journal":"Folia histochemica et cytobiologica",
        "Do_id":"16805136",
        "Doc_ChemicalList":"Actins;Biomarkers, Tumor;Ki-67 Antigen;Tumor Suppressor Protein p53;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Actins;Aged;Biomarkers, Tumor;Breast Neoplasms;Fibroblasts;Humans;Ki-67 Antigen;Middle Aged;Muscle, Smooth;Neoplasm Staging;Receptor, ErbB-2;Stromal Cells;Tumor Suppressor Protein p53",
        "Doc_meshqualifiers":"metabolism;metabolism;metabolism;pathology;pathology;metabolism;metabolism;metabolism;pathology;metabolism",
        "_version_":1605759988869890048},
      {
        "Doc_abstract":"This study aims to investigate clinical significance of topoisomerase 2A (TOP2A) expression and TOP2A gene change in operable invasive breast cancer. This is a retrospective analysis, which includes 256 patients diagnosed as operable invasive breast cancer. All postoperational waxed specimens were subjected to resectioning for staining. Estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER-2), KI-67, TOP2A expression, and TOP2A gene changes were detected by immunohistochemistry (IHC) and fluorescent in situ hybridization technique (FISH), respectively. Correlation between TOP2A expression and clinicopathological characteristics was also investigated. Effects of TOP2A protein or gene changes on survival rate were detected. Results indicated that 165 were TOP2A positive (64.5 %), and 31 were gene amplification positive (12.1 %). Positive rate of TOP2A expression showed significant correlations with ER, KI-67, and HER-2. The difference of 5-year overall survival (OS) between TOP2A-positive and TOP2A-negative groups did not reach statistical significance (OS: Pâ€‰=â€‰0.321, 85.9 vs. 79.6 %; disease-free survival [DFS]: Pâ€‰=â€‰0.247, 83.3 vs. 75.3 %). Five-year OS in TOP2A amplification group was 68.8 %, which is lower than deficiency and control group (Pâ€‰>â€‰0.05). Subgroup analysis showed no significant differences of OS and DFS either between TOP2A-positive and TOP2A-negative groups or between TOP2A amplification and control group in population of patients with HER-2 amplification, triple negative breast cancer, or hormone-positive breast cancer. In conclusion, positive rate of TOP2A expression correlates significantly with ER, KI-67, and HER-2. However, prognostic significance of either TOP2A expression or TOP2A gene changes in breast cancer and its various subtypes is limited.",
        "Doc_title":"Clinical significance of topoisomerase 2A expression and gene change in operable invasive breast cancer.",
        "Journal":"Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine",
        "Do_id":"25846735",
        "Doc_ChemicalList":"Antigens, Neoplasm;DNA-Binding Proteins;Receptors, Estrogen;Receptors, Progesterone;ERBB2 protein, human;Receptor, ErbB-2;DNA Topoisomerases, Type II;DNA topoisomerase II alpha",
        "Doc_meshdescriptors":"Adult;Aged;Aged, 80 and over;Antigens, Neoplasm;Breast Neoplasms;DNA Topoisomerases, Type II;DNA-Binding Proteins;Disease-Free Survival;Female;Gene Expression Regulation, Neoplastic;Humans;In Situ Hybridization, Fluorescence;Middle Aged;Neoplasm Invasiveness;Prognosis;Receptor, ErbB-2;Receptors, Estrogen;Receptors, Progesterone",
        "Doc_meshqualifiers":"biosynthesis;genetics;genetics;pathology;biosynthesis;genetics;biosynthesis;genetics;genetics;biosynthesis;genetics;biosynthesis;genetics;biosynthesis;genetics",
        "_version_":1605836994055766016},
      {
        "Doc_abstract":"Breast cancer is one of the most common cancers with greater than 1,300,000 cases and 450,000 deaths each year worldwide. The development of breast cancer involves a progression through intermediate stages until the invasive carcinoma and finally into metastatic disease. Given the variability in clinical progression, the identification of markers that could predict the tumor behavior is particularly important in breast cancer. The determination of tumor markers is a useful tool for clinical management in cancer patients, assisting in diagnostic, staging, evaluation of therapeutic response, detection of recurrence and metastasis, and development of new treatment modalities. In this context, this review aims to discuss the main tumor markers in breast carcinogenesis. The most well-established breast molecular markers with prognostic and/or therapeutic value like hormone receptors, HER-2 oncogene, Ki-67, and p53 proteins, and the genes for hereditary breast cancer will be presented. Furthermore, this review shows the new molecular targets in breast cancer: CXCR4, caveolin, miRNA, and FOXP3, as promising candidates for future development of effective and targeted therapies, also with lower toxicity. ",
        "Doc_title":"Molecular markers for breast cancer: prediction on tumor behavior.",
        "Journal":"Disease markers",
        "Do_id":"24591761",
        "Doc_ChemicalList":"Biomarkers, Tumor;MicroRNAs;Neoplasm Proteins",
        "Doc_meshdescriptors":"Animals;Biomarkers, Tumor;Breast Neoplasms;Female;Gene Expression;Humans;MicroRNAs;Neoplasm Proteins;Prognosis",
        "Doc_meshqualifiers":"genetics;metabolism;diagnosis;genetics;metabolism;genetics;metabolism;genetics;metabolism",
        "_version_":1605852137399517184},
      {
        "Doc_abstract":"The EndoPredict (EP) signature is a prognostic 11-gene expression signature specifically developed in ER+/HER2- node-negative/positive breast cancer. It is associated with relapse-free survival in patients treated with adjuvant hormone therapy, suggesting that EP low-risk patients could be treated with adjuvant hormone therapy alone whereas high-risk patients would deserve addition of adjuvant chemotherapy. Thus, it is important to determine whether EP high-risk patients are or are not more sensitive to chemotherapy than low-risk patients. Here, we have assessed the EP predictive value for pathological complete response to neoadjuvant chemotherapy in ER+/HER2- breast cancer. We gathered gene expression and histoclinical data of 553 pre-treatment ER+/HER2- breast carcinomas treated with anthracycline-based neoadjuvant chemotherapy. We searched for correlation between the pathological complete response (pCR) and the EP score-based classification. The overall pCR rate was 12%. Fifty-one percent of samples were classified as low-risk according to the EP score and 49% as high-risk. EP classification was associated with a pCR rate of 7% in the low-risk group and 17% in the high-risk group (pâ€‰<â€‰0.001). In multivariate analysis, the EP score remained significantly associated with pCR. Many genes upregulated in the high-risk tumours were involved in cell proliferation, whereas many genes upregulated in the low-risk tumours were involved in ER-signalling and stroma. Despite higher chemosensitivity, the high-risk group was associated with worse disease-free survival. In conclusion, EP high-risk ER+/HER2- breast cancers are more likely to respond to anthracycline-based chemotherapy. ",
        "Doc_title":"EndoPredict predicts for the response to neoadjuvant chemotherapy in ER-positive, HER2-negative breast cancer.",
        "Journal":"Cancer letters",
        "Do_id":"25218596",
        "Doc_ChemicalList":"Anthracyclines;Biomarkers, Tumor;Receptors, Estrogen;ERBB2 protein, human;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Anthracyclines;Biomarkers, Tumor;Breast Neoplasms;Chemotherapy, Adjuvant;Disease-Free Survival;Female;Gene Expression Profiling;Genetic Testing;Humans;Kaplan-Meier Estimate;Linear Models;Middle Aged;Multivariate Analysis;Neoadjuvant Therapy;Neoplasm Grading;Neoplasm Staging;Patient Selection;Predictive Value of Tests;Receptor, ErbB-2;Receptors, Estrogen;Retrospective Studies;Risk Assessment;Risk Factors;Treatment Outcome",
        "Doc_meshqualifiers":"therapeutic use;analysis;drug therapy;genetics;metabolism;pathology;methods;analysis;analysis",
        "_version_":1605818612293042176},
      {
        "Doc_abstract":"We tested the relationships between total hemoglobin concentration (THC), as measured with ultrasound (US)-guided optical tomography, and clinicopathologic variables in invasive ductal cancers; and we evaluated the clinical significance of THC. Fifty-three patients with 65 invasive ductal carcinomas underwent US-guided biopsy and were scanned with a hand-held probe consisting of a co-registered US transducer and an NIR (near-infrared) imager. The lesion location provided by co-registered US was used to guide optical imaging. Light absorption was measured at two optical wavelengths. From this measurement, tumor angiogenesis was assessed on the basis of calculated THC. We investigated the relationships between maximum THC and clinicopathologic variables (tumor size [â‰¤2 cm or >2 cm], metastasis to lymph node or distant organ, histologic grade, lymphovascular invasion, status of ER, PR, HER2 and Ki-67, and triple negativity). The mean maximum THC in the breast cancers was 223.3 Â± 106.3 Î¼mol/L. In univariate analysis, HER2 positivity, tumor size, and Ki-67 positivity showed significant correlations with maximum THC (p < 0.05). In multivariate analysis including tumor size, and ER, PR, HER2, and Ki-67 status, HER2 positivity correlated with maximum THC significantly (p = 0.007, parameter estimate 76.44). Maximum THC correlated with HER2, Ki-67 and tumor size in this group of ductal breast carcinomas. Thus, US-guided diffuse optical tomography (US-DOT) may potentially be used to predict tumor aggressiveness in patients with invasive breast cancers.",
        "Doc_title":"US-guided optical tomography: correlation with clinicopathologic variables in breast cancer.",
        "Journal":"Ultrasound in medicine & biology",
        "Do_id":"23219038",
        "Doc_ChemicalList":"Biomarkers;Hemoglobins",
        "Doc_meshdescriptors":"Adult;Aged;Biomarkers;Breast Neoplasms;Carcinoma, Ductal, Breast;Female;Hemoglobins;Humans;Male;Middle Aged;Reproducibility of Results;Sensitivity and Specificity;Statistics as Topic;Tomography, Optical;Ultrasonography, Mammary",
        "Doc_meshqualifiers":"analysis;diagnosis;metabolism;diagnosis;metabolism;analysis;methods;methods",
        "_version_":1605742057756819456},
      {
        "Doc_abstract":"The measurement of serum human epidermal growth factor receptor 2 (HER2) extracellular domain levels is a well-established method for evaluating whether a metastatic HER2-positive breast cancer patient will respond to HER2-targeted treatment. However, little is known about the value of serum HER2 for detecting disease relapse following curative surgical treatment in breast cancer patients. The purpose of this study was to evaluate the sensitivity of serum HER2, carcinoembryonic antigen (CEA), and carcinoma antigen 15-3 (CA 15-3) for the detection of disease recurrence in postoperative breast cancer patients with a primary HER2-positive tumor.;Serial measurements were taken of serum HER2, CEA, and CA 15-3 levels in patients with primary invasive HER2-positive breast cancer who underwent curative surgical treatment between January 2008 and December 2010. Following treatment, serum HER2 levels were monitored every 6 months using a chemiluminescence immunoassay.;Overall, 264 patients were analyzed in this retrospective study. The median follow-up period was 27.7 months, and 24 patients relapsed during follow-up. The sensitivity of serum HER2, CEA, and CA 15-3 for the detection of disease recurrence was 37.5%, 25.1%, and 12.5%, respectively. Sensitivity increased to 45.8% when all three tumor markers were combined in the analysis. In a subgroup of patients without liver disease, the sensitivity of serum HER2, CEA, and CA 15-3 was 57.1%, 21.4%, and 14.3%, respectively. Of the 264 patients in this study, 80 patients had chronic hepatitis, liver cirrhosis, or abnormal aspartate aminotransferase or alanine aminotransferase levels during the follow-up period. Following the exclusion of these patients, the sensitivity of serum HER2 for the detection of disease recurrence increased to 57.1%.;Serial serum HER2 measurement may be useful for the detection of disease relapse in patients with HER2-positive breast cancer. Abnormal liver function can result in elevated serum HER2 in the absence of disease recurrence.",
        "Doc_title":"Serial Serum HER2 Measurements for the Detection of Breast Cancer Recurrence in HER2-Positive Patients.",
        "Journal":"Journal of breast cancer",
        "Do_id":"24744795",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605747559531282432},
      {
        "Doc_abstract":"Overexpression of the human epidermal growth factor receptor 2 (HER-2) represents a biological subclass of breast cancer with distinct molecular alterations, clinical behavior, and response to systemic therapy. Trastuzumab is a monoclonal antibody directed against HER-2 which has revolutionized the management of both early and advanced breast cancer. It may exert its anti-cancer effects through inhibition of intracellular signaling, upregulation of p27, impaired angiogenesis, induction of immune-mediated destruction, and blockade of cleavage of the extracellular domain of HER-2. In spite of its robust clinical activity, most women with metastatic HER-2 overexpressing breast cancer eventually progress on trastuzumab therapy. Possible mechanisms of resistance include: altered receptor antibody interaction, PTEN loss and enhanced Akt signaling, p27 loss, signaling through other receptors. Preclinical experiments, clinical experience with the use of trastuzumab beyond progression, and a recent phase III clinical trial with Lapatinib, a dual EGFR/HER-2 tyrosine kinase inhibitor, demonstrate that the HER-2 signaling axis remains an important therapeutic target even after progression on trastuzumab. A variety of novel strategies are currently in development to exploit this pathway following the onset of resistance, such as receptor antibodies, sheddase inhibitors, signal transduction inhibitors, heat shock protein inhibitors, proteasome inhibitors, anti-angiogenic agents, and immune-stimulatory therapies, either as single agents or in combination with trastuzumab. Rational clinical trial design, with attention to appropriate patient selection and prospective collection of biological material, is needed to ensure that the new generation of anti-HER-2 targeted therapies realizes its promise in the treatment of trastuzumab-resistant disease.",
        "Doc_title":"Beyond trastuzumab: overcoming resistance to targeted HER-2 therapy in breast cancer.",
        "Journal":"Current cancer drug targets",
        "Do_id":"19275756",
        "Doc_ChemicalList":"Antibodies, Monoclonal;Antibodies, Monoclonal, Humanized;Antineoplastic Agents;ERBB2 protein, human;Receptor, Epidermal Growth Factor;Receptor, ErbB-2;Trastuzumab",
        "Doc_meshdescriptors":"Animals;Antibodies, Monoclonal;Antibodies, Monoclonal, Humanized;Antineoplastic Agents;Breast Neoplasms;Drug Resistance, Neoplasm;Female;Humans;Receptor, Epidermal Growth Factor;Receptor, ErbB-2;Signal Transduction;Trastuzumab",
        "Doc_meshqualifiers":"pharmacology;therapeutic use;pharmacology;therapeutic use;drug therapy;genetics;drug effects;genetics;genetics;genetics;drug effects",
        "_version_":1605896013325795328},
      {
        "Doc_abstract":"Breast tissues undergo extensive physiologic changes during pregnancy, which may affect breast carcinogenesis. Gestational hypertension, preeclampsia/eclampsia, gestational diabetes, pregnancy weight gain, and nausea and vomiting (N&V) during pregnancy may be indicative of altered hormonal and metabolic profiles and could impact breast cancer risk. Here, we examined associations between these characteristics of a woman's pregnancy and her subsequent breast cancer risk. Participants were parous women that were recruited to a population-based case-control study (Western New York Exposures and Breast Cancer Study). Cases (n = 960), aged 35-79 years, had incident, primary, histologically confirmed breast cancer. Controls (n = 1,852) were randomly selected from motor vehicle records (< 65 years) or Medicare rolls (â‰¥ 65 years). Women were queried on their lifetime pregnancy experiences. Multivariable-adjusted logistic regression was used to estimate odds ratios (ORs) and 95% confidence intervals (CIs). N&V during pregnancy was inversely associated with breast cancer risk. Relative to those who never experienced N&V, ever experiencing N&V was associated with decreased risk (OR 0.69, 95% CI 0.56-0.84) as were increased N&V severity (p trend < 0.001), longer duration (p trend < 0.01), and larger proportion of affected pregnancies (p trend < 0.0001) among women with â‰¥ 3 pregnancies. Associations were stronger for more recent pregnancies (< 5 years). Findings did not differ by menopausal status or breast cancer subtype including estrogen receptor and HER2 expression status. Other pregnancy characteristics examined were not associated with risk. We observed strong inverse associations between pregnancy N&V and breast cancer risk. Replication of these findings and exploration of underlying mechanisms could provide important insight into breast cancer etiology and prevention.",
        "Doc_title":"Pregnancy-related characteristics and breast cancer risk.",
        "Journal":"Cancer causes & control : CCC",
        "Do_id":"23737027",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"Adult;Aged;Breast Neoplasms;Case-Control Studies;Female;Humans;Middle Aged;New York;Pregnancy;Pregnancy Complications;Risk Factors;Weight Gain",
        "Doc_meshqualifiers":"epidemiology;pathology;epidemiology;epidemiology",
        "_version_":1605808120332812288},
      {
        "Doc_abstract":"Some of HER-2 positive breast cancer patients failed to trastuzumab treatment. Recent reports have indicated the correlation between plasma coagulation parameters and clinical characteristics in breast cancer. The aim of this study was to analyze the role of coagulation parameters in trastuzumab treated patients. Coagulation parameters from trastuzumab treated breast cancer patients were retrospectively studied from 2006 to 2010. The correlation between routine coagulation levels and clinical characteristics were analyzed, including prothrombin time (PT), activated partial thromboplastin time (APTT), thrombin time (TT), fibrinogen (Fib) and D-dimer (DD). The Kaplan-Meier analysis and Cox regression hazard model were applied to assess their effect on prognosis. Totally 102 hospitalized breast cancer patients who received trastuzumab were collected and followed-up. All patients were HER-2 positive advanced breast cancer, with a median age of 45 years old. Extended PT, APTT, and TT were found in trastuzumab treatment non-effective group, as well as increased Fib and DD. But significant increase was only found in Fib. High Fib status (Fibâ€Š>â€Š2.88â€Šg/L) was correlated with clinical characteristics, such as pathological grade, and reversely correlated with PTEN expression. More importantly, poor disease-free survival (DFS) and overall survival (OS) to trastuzumab treatment were found in high Fib breast cancer patients. This retrospective study suggests high Fib status was correlated with poor treatment response to trastuzumab. Our findings indicated that Fibâ€Š>â€Š2.88 should alert physicians to consider a pretreatment for reducing Fib levels before trastuzumab treatment in HER-2 positive breast cancer patients.",
        "Doc_title":"High plasma fibrinogen is correlated with poor response to trastuzumab treatment in HER2 positive breast cancer.",
        "Journal":"Medicine",
        "Do_id":"25654390",
        "Doc_ChemicalList":"Antibodies, Monoclonal, Humanized;Antineoplastic Agents;Fibrin Fibrinogen Degradation Products;fibrin fragment D;Fibrinogen;Receptor, ErbB-2;Trastuzumab",
        "Doc_meshdescriptors":"Adult;Antibodies, Monoclonal, Humanized;Antineoplastic Agents;Breast Neoplasms;Disease-Free Survival;Female;Fibrin Fibrinogen Degradation Products;Fibrinogen;Humans;Kaplan-Meier Estimate;Middle Aged;Partial Thromboplastin Time;Prognosis;Prothrombin Time;Receptor, ErbB-2;Retrospective Studies;Trastuzumab",
        "Doc_meshqualifiers":"therapeutic use;therapeutic use;drug therapy;mortality;analysis;analysis",
        "_version_":1605880536896634880},
      {
        "Doc_abstract":"Growth of human breast cells is closely regulated by steroid hormone as well as peptide hormone receptors. Members of both receptor classes are important prognostic factors in human breast cancer. Clinical data indicate that overexpression of the HER-2 gene is associated with an estrogen receptor-negative phenotype. In this study, we demonstrate that introduction of a HER-2 cDNA, converting non-overexpressing breast cancer cells to those which overexpress this receptor, results in development of estrogen-independent growth which is insensitive to both estrogen and the antiestrogen, tamoxifen. Moreover, activation of the HER-2 receptor in breast cancer cells by the peptide growth factor, heregulin, leads to direct and rapid phosphorylation of ER on tyrosine residues. This is followed by interaction between ER and the estrogen-response elements in the nucleus and production of an estrogen-induced protein, progesterone receptor. In addition, overexpression of HER-2 receptor in estrogen-dependent tumor cells promotes ligand-independent down-regulation of ER and a delayed autoregulatory suppression of ER transcripts. These data demonstrate a direct link between these two receptor pathways and suggest one mechanism for development of endocrine resistance in human breast cancers.",
        "Doc_title":"HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells.",
        "Journal":"Oncogene",
        "Do_id":"7784095",
        "Doc_ChemicalList":"Carrier Proteins;Estrogens;Glycoproteins;Neuregulin-1;Receptors, Estrogen;Receptors, Progesterone;Tamoxifen;heregulin beta1;Estradiol;Receptor, Epidermal Growth Factor",
        "Doc_meshdescriptors":"Animals;Breast Neoplasms;Carrier Proteins;Cell Division;Cell Nucleus;Down-Regulation;Drug Resistance;Estradiol;Estrogens;Glycoproteins;Humans;Mice;Neoplasms, Hormone-Dependent;Neuregulin-1;Phosphorylation;Receptor, Epidermal Growth Factor;Receptors, Estrogen;Receptors, Progesterone;Tamoxifen;Tumor Cells, Cultured",
        "Doc_meshqualifiers":"metabolism;pathology;pharmacology;drug effects;metabolism;pharmacology;pharmacology;pharmacology;metabolism;pathology;metabolism;metabolism;metabolism;pharmacology",
        "_version_":1605827179438931968},
      {
        "Doc_abstract":"To compare fluorescence in situ hybridization (FISH) and immunohistochemistry (IHC) in the determination of HER-2/neu status of breast cancers.;FISH and IHC for HER-2/neu were performed on formalin-fixed paraffin sections of 100 consecutive invasive breast cancers. FISH was performed at Beth Israel Deaconess Medical Center, Boston, MA, using the Oncor/Ventana INFORM kit (Ventana Medical Systems, Tucson, AZ; formerly sold by Oncor, Inc, Gaithersburg, MD) in a laboratory certified as proficient in this procedure. IHC was performed at PhenoPath Laboratories, Seattle, WA, using a polyclonal antibody to the HER-2/neu protein. FISH and IHC were analyzed in a blinded fashion, and the results were then compared. Procedure and interpretation times and reagent costs for FISH and IHC were also compared.;HER-2/neu was amplified by FISH in 26% of cases, and 23% were HER-2/neu-positive by IHC. FISH and IHC were both assessable in 90 cases. Concordance between FISH and IHC results was seen in 82 of these cases (91%, P <.001). The FISH procedure required more technologist time and more interpretation time per case for the pathologist than IHC. Reagent costs were substantially higher for FISH than for IHC.;There is a high level of correlation between FISH and IHC in the evaluation of HER-2/neu status of breast cancers using formalin-fixed paraffin-embedded specimens. Although the choice of which assay to use should be left for individual laboratories to make based on technical and economic considerations, our results may make it difficult to justify the routine use of FISH for determination of HER-2/neu status in breast cancer.",
        "Doc_title":"Comparison of fluorescence in situ hybridization and immunohistochemistry for the evaluation of HER-2/neu in breast cancer.",
        "Journal":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
        "Do_id":"10561247",
        "Doc_ChemicalList":"Receptor, ErbB-2",
        "Doc_meshdescriptors":"Adult;Aged;Aged, 80 and over;Breast Neoplasms;Cohort Studies;Female;Health Care Costs;Humans;Immunohistochemistry;In Situ Hybridization, Fluorescence;Middle Aged;Receptor, ErbB-2;Sensitivity and Specificity;Statistics, Nonparametric;Time Factors",
        "Doc_meshqualifiers":"pathology;economics;economics;analysis",
        "_version_":1605874258082267136},
      {
        "Doc_abstract":"Trastuzumab, a humanized monoclonal antibody against the HER-2 receptor, was the first targeted therapy for HER-2 positive breast cancer. The treatment of HER-2 positive breast cancer in monotherapy, but mainly in combination with cytostatics trastuzumab, showed significant efficacy and increased the time to progression/relapse and overall survival. On the other hand, despite it being administered to only a selected patient population, the response rate varies in range and duration due to the primary or acquired tumor resistance to trastuzumab. Several mechanisms contributing to the drug resistance are presumed and overcoming strategies are in development. In connection with the drug resistance there are the mechanisms of trastuzumab's action on tumor cells and the search for feasible biomarkers in order to predict the response of trastuzumab-based targeted therapies. Furthermore, we present here the actual possibilities to overcome primary or acquired trastuzumab resistance.",
        "Doc_title":"[Trastuzumab in the breast cancer treatment: efficacy and resistance mechanisms].",
        "Journal":"Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti",
        "Do_id":"19522373",
        "Doc_ChemicalList":"Antibodies, Monoclonal;Antibodies, Monoclonal, Humanized;Antineoplastic Agents;Trastuzumab",
        "Doc_meshdescriptors":"Antibodies, Monoclonal;Antibodies, Monoclonal, Humanized;Antineoplastic Agents;Breast Neoplasms;Drug Resistance, Neoplasm;Female;Genes, erbB-2;Humans;Trastuzumab",
        "Doc_meshqualifiers":"therapeutic use;therapeutic use;drug therapy;genetics",
        "_version_":1605755641437093888},
      {
        "Doc_abstract":"Cancers are the most deadly diseases in the world and their incidences continue to increase over time. Particularly, breast cancer in females places 1(st) rank among other types of cancers in term of cancer cases (23%) and death incidence (14%). Recent findings support the correlation between (Ile)655(Val) SNP in the HER2 gene with breast cancer risk. Moreover, the (Ile)655(Val) HER2 gene polymorphism could be a predictive factor in a neoadjuvant therapy setting. Precise detection of the (Ile)655(Val) HER2 gene SNP in early breast cancer patients will be beneficial in designing the most suitable treatment and in increasing the efficacy of anticancer drugs. Here we develop a rapid and inexpensive method for (Ile)655(Val) SNP detection in the HER2 gene based on allele-specific PCR technology. Two forward primers and one common reverse primer were designed to anneal specifically either on the HER2 gene fragment containing the GG genotype or to the HER2 gene fragment containing the AA genotype where one of these primers had been added with poly-GC at 5' upstream. Moreover, to increase discrimination level, mismatch bases at the SNP site and the 3(rd) base of each forward primers from 3'end were added. To test the performance of the designed primers in discriminating a polymorphism and its annealing temperature, breast cancer specimen-derived genomic DNA (with GG genotype) and pGEM_HER2/AA (with AA genotype) were used as templates in the PCR reaction. The optimal annealing temperature for SNP detection was at 51.5Â°C as showed by the appearance of a 150 base pair (bp) band as AA genotype (pGEM_HER2/AA template), 116bp band as GG genotype (genomic DNA template), and both types of bands as AG genotype (mix of pGEM_HER2/AA and genomic DNA template). Allelic types of breast cancer patients were also determined using this optimized method compared to sanger sequencing. The 100% accordance was shown for all types of genotypes in both methods. The allele-specific PCR in this study may have application in determining polymorphisms of the breast cancers-originated (Ile)655(Val) HER2 gene.",
        "Doc_title":"Detection of HER2 Gene Polymorphism in Breast Cancer: PCR Optimization Study.",
        "Journal":"Scientia pharmaceutica",
        "Do_id":"27110502",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605757855105810432},
      {
        "Doc_abstract":"Advances in genomic and transcriptome sequencing are revealing the massive scale of previously unrecognised alterations occurring during neoplastic transformation. Breast cancers are genetically and phenotypically heterogeneous. Each of the three major subtypes [ERBB2 amplified, estrogen receptor (ESR)-positive and triple-negative] poses diagnostic and therapeutic challenges. Here we show, using high-resolution next-generation transcriptome sequencing, that in all three breast cancer subtypes, but not matched controls, there was significant overexpression of transcripts from intronic and untranslated regions in addition to exons from specific genes, particularly amplified oncogenes and hormone receptors. For key genes ERBB2 and ESR1, we demonstrate that overexpression is linked to the production of highly modified and truncated splice variants in tumours, but not controls, correlated with tumour subtype. Translation of these tumour-specific splice variants generates truncated proteins with altered subcellular locations and functions, modifying the phenotype, affecting tumour biology, and targeted antitumour therapies. In contrast, tumour suppressors TP53, BRCA1/2 and NF1 did not show intronic overexpression or truncated splice variants in cancers. These findings emphasize the detection of intronic as well as exonic changes in the transcriptional landscapes of cancers have profound therapeutic implications. ",
        "Doc_title":"Transcriptome sequencing of human breast cancer reveals aberrant intronic transcription in amplicons and dysregulation of alternative splicing with major therapeutic implications.",
        "Journal":"International journal of oncology",
        "Do_id":"26530297",
        "Doc_ChemicalList":"BRCA1 Protein;BRCA2 Protein;Estrogen Receptor alpha;Neurofibromin 1;TP53 protein, human;Tumor Suppressor Protein p53;estrogen receptor alpha, human;ERBB2 protein, human;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Alternative Splicing;BRCA1 Protein;BRCA2 Protein;Breast Neoplasms;Estrogen Receptor alpha;Exons;Female;Gene Expression Regulation, Neoplastic;High-Throughput Nucleotide Sequencing;Humans;Introns;Mutation;Neurofibromin 1;Receptor, ErbB-2;Transcription, Genetic;Transcriptome;Tumor Suppressor Protein p53",
        "Doc_meshqualifiers":"genetics;biosynthesis;biosynthesis;classification;genetics;pathology;biosynthesis;genetics;genetics;biosynthesis;biosynthesis;genetics;genetics;biosynthesis",
        "_version_":1605796473759334400},
      {
        "Doc_abstract":"Adjuvant endocrine therapy as well as other forms of targeted therapy such as HER2 inhibitors and antiangiogenic agents reduce the risk of recurrence and improve survival among women with hormone receptor positive breast cancer. However, a significant percentage of women who receive targeted therapy as adjuvant or metastatic treatment do not benefit from this therapy, while a number of women who initially respond will eventually develop disease progression and relapse while on therapy. The observed variability in treatment response to targeted breast cancer treatment could be partly explained by pharmacogenomics. This paper reviews evidence on the role of pharmacogenomics of breast targeted therapy focusing on the clinical relevance of genetic variation. In particular, this article reviews the role of pharmacogenomics of tamoxifen, aromatase inhibitors, HER-2 inhibitors and anti-angiogenic agents. In addition, recent patents in the field are presented that provide promising steps in the field of personalized treatment of breast cancer, although future studies are needed for determining the clinical benefit of the proposed inventions. Finally, we present a testable hypothesis to aide the search for biologically meaningful genetic variation Specifically, we suggest the publication of negative results in the field of pharmacogenomics and pharmacoproteomics, will benefit future research in the field.",
        "Doc_title":"Pharmacogenomics of breast cancer targeted therapy: focus on recent patents.",
        "Journal":"Recent patents on DNA & gene sequences",
        "Do_id":"22239682",
        "Doc_ChemicalList":"Angiogenesis Inhibitors;Antineoplastic Agents, Hormonal;Aromatase Inhibitors;Tamoxifen;Aromatase;Aryl Hydrocarbon Hydroxylases;CYP2C19 protein, human;Cytochrome P-450 CYP2C19;Cytochrome P-450 CYP2D6;Cytochrome P-450 CYP3A;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Angiogenesis Inhibitors;Antineoplastic Agents, Hormonal;Aromatase;Aromatase Inhibitors;Aryl Hydrocarbon Hydroxylases;Breast Neoplasms;Cytochrome P-450 CYP2C19;Cytochrome P-450 CYP2D6;Cytochrome P-450 CYP3A;Female;Humans;Patents as Topic;Receptor, ErbB-2;Tamoxifen",
        "Doc_meshqualifiers":"therapeutic use;therapeutic use;chemistry;genetics;metabolism;therapeutic use;genetics;metabolism;drug therapy;genetics;genetics;metabolism;genetics;metabolism;antagonists & inhibitors;genetics;metabolism;therapeutic use",
        "_version_":1605903401210609664},
      {
        "Doc_abstract":"Human epidermal growth factor receptor 2 (HER2) is overexpressed, usually as a result of HER2 proto-oncogene amplification, in 20-30% of breast cancers. A HER2-positive status is generally associated with more aggressive disease and a worse prognosis. Furthermore, a positive HER2 status may predict the likelihood of resistance to some conventional therapies, as well as probably being predictive of sensitivity to anthracycline dose intensification. In addition to this prognostic/predictive value, HER2 is a target for specific therapy, with anti-HER2 monoclonal antibody therapy available in the USA. This article reviews the different assays used to determine HER2 status, discussing their relative advantages/disadvantages and the need for their standardisation before integration alongside other pathological indices into the clinical management of breast cancer.",
        "Doc_title":"Assessment of HER2 status in breast cancer: why, when and how?",
        "Journal":"European journal of cancer (Oxford, England : 1990)",
        "Do_id":"10741274",
        "Doc_ChemicalList":"Biomarkers, Tumor;Neoplasm Proteins;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Biomarkers, Tumor;Breast Neoplasms;Female;Humans;Immunohistochemistry;Neoplasm Proteins;Receptor, ErbB-2",
        "Doc_meshqualifiers":"analysis;drug therapy;pathology;analysis;analysis",
        "_version_":1605763343135539200},
      {
        "Doc_abstract":"Genome-wide miRNA expression may be useful for predicting breast cancer risk and/or for the early detection of breast cancer.;A 41-miRNA model distinguished breast cancer risk in the discovery study (accuracy of 83.3%), which was replicated in the independent study (accuracy = 63.4%, P=0.09). Among the 41 miRNA, 20 miRNAs were detectable in serum, and predicted breast cancer occurrence within 18 months of blood draw (accuracy 53%, P=0.06). These risk-related miRNAs were enriched for HER-2 and estrogen-dependent breast cancer signaling.;MiRNAs were assessed in two cross-sectional studies of women without breast cancer and a nested case-control study of breast cancer. Using breast tissues, a multivariate analysis was used to model women with high and low breast cancer risk (based upon Gail risk model) in a discovery study of women without breast cancer (n=90), and applied to an independent replication study (n=71). The model was then assessed using serum samples from the nested case-control study (n=410).;Studying breast tissues of women without breast cancer revealed miRNAs correlated with breast cancer risk, which were then found to be altered in the serum of women who later developed breast cancer. These results serve as proof-of-principle that miRNAs in women without breast cancer may be useful for predicting breast cancer risk and/or as an adjunct for breast cancer early detection. The miRNAs identified herein may be involved in breast carcinogenic pathways because they were first identified in the breast tissues of healthy women.",
        "Doc_title":"Discovery and replication of microRNAs for breast cancer risk using genome-wide profiling.",
        "Journal":"Oncotarget",
        "Do_id":"27833082",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605799126501425152},
      {
        "Doc_abstract":"Triple negative breast cancers, which are defined by lack of expression of estrogen, progesterone, or HER2 receptors, represent approximately 15% of all breast cancers, although they account for a much higher proportional of breast cancer mortality. This is due both to their innate aggressive biological characteristics, but also to lack of effective therapies. Conventional chemotherapy is currently the only treatment option, thus there is a critical need to find new and effective targeted therapies in this disease. While investigation of agents such as poly (ADP-ribose) polymerase (PARP) inhibitors and EGFR inhibitors continues, results from recent clinical trials indicate that these therapies are not as active in sporadic triple negative breast cancers as initially hoped. It is important therefore to consider other emerging therapeutic agents. Mutation in p53 is found in the vast majority of triple negative breast cancers, and as such is a target of particular interest. Within this review, several agents with potential activity against aberrant p53 signaling have been considered, as a novel approach to finding an effective targeted therapy for this aggressive breast cancer subtype.",
        "Doc_title":"Targeting triple negative breast cancer: is p53 the answer?",
        "Journal":"Cancer treatment reviews",
        "Do_id":"23321033",
        "Doc_ChemicalList":"Receptors, Estrogen;Receptors, Progesterone;TP53 protein, human;Tumor Suppressor Protein p53;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Breast Neoplasms;Female;Humans;Receptor, ErbB-2;Receptors, Estrogen;Receptors, Progesterone;Tumor Suppressor Protein p53",
        "Doc_meshqualifiers":"genetics;metabolism;metabolism;metabolism;metabolism;genetics;metabolism",
        "_version_":1605893411911499776},
      {
        "Doc_abstract":"Integrin alpha6beta4 signaling interactions have been implicated in tumor progression, and beta4 expression has been linked to poor prognosis in certain breast cancer subtypes. We generated human antibodies to alpha6beta4 to further evaluate its role in tumor cell signaling. Biochemical characterization indicated these antibodies are specific for alpha6beta4, recognize distinct epitopes and have low nanomolar affinities for both human and murine protein. The antibodies demonstrated differing effects on alpha6beta4-mediated cellular adhesion, highlighting the existence of different functional epitopes on alpha6beta4. Interestingly however both antibodies blocked adhesion-independent growth in a panel of breast cancer cell lines. Antibody induced apoptosis and inhibition of phosphoinositide 3-kinase (PI3K) signaling were also observed within the context of matrix adhesion. Enhanced inhibitory effects were observed when the alpha6beta4 antibodies were used in combination with antibodies to epidermal growth factor receptor (EGFR) or erythoblastic leukemia viral oncogene homolog 2 (ErbB2). These findings illustrate a role for both the adhesive and signaling functions of alpha6beta4 in breast cancer cell survival. The antibodies and data generated herein advance our understanding of alpha6beta4 in regulating tumorigenic processes, and suggest that combination therapies involving alpha6beta4 may be therapeutically effective in breast cancer.",
        "Doc_title":"Antibodies directed to alpha6beta4 highlight the adhesive and signaling functions of the integrin in breast cancer cell lines.",
        "Journal":"Cancer biology & therapy",
        "Do_id":"20061819",
        "Doc_ChemicalList":"Antibodies;Integrin alpha6beta4;Integrins;Receptor, Epidermal Growth Factor",
        "Doc_meshdescriptors":"Antibodies;Apoptosis;Breast Neoplasms;Cell Adhesion;Cell Line;Female;Humans;Integrin alpha6beta4;Integrins;Neoplasms;Receptor, Epidermal Growth Factor;Signal Transduction",
        "Doc_meshqualifiers":"metabolism;drug effects;metabolism;pathology;physiology;metabolism;physiology;metabolism;metabolism;metabolism",
        "_version_":1605830887068401664},
      {
        "Doc_abstract":"The clinical significance of bilateral breast cancer is unclear and its influence on prognosis is controversial. We compared the characteristics and prognosis of bilateral breast cancer and unilateral breast cancer.;Our study included 4,183 patients with breast cancer who were treated at Sun Yat-sen University Cancer Center between January 1, 2000, and December 31, 2007. Bilateral breast cancer was categorized as synchronous (within 3 months) or metachronous (diagnosed after 3 months of first cancer). SPSS was used for data analysis.;106 (2.5%) and 31 (0.7%) patients were diagnosed with metachronous and synchronous bilateral cancer. Women with bilateral cancer had more frequent postmenopause, HER-2 negativity, and advanced disease than in patients with unilateral cancer. Young age at diagnosis, invasive lobular carcinoma, ER/PR negativity, HER-2 positivity, radiation, large tumor size (T > 5 cm), and stage III disease of the first cancer were risk factors for contralateral cancer. The 5-year disease-free survival and overall survival rates were 76 and 83% for unilateral cancer, while 32 and 72% for bilateral cancer (P = 0.000 for both).;Bilateral cancer was associated with shorter disease-free survival and overall survival than unilateral cancer. The prognosis of metachronous bilateral cancer, especially those diagnosed within 2 years after the first cancer was significantly worse than synchronous bilateral cancer.",
        "Doc_title":"Comparison of clinicopathological characteristics and prognoses between bilateral and unilateral breast cancer.",
        "Journal":"Journal of cancer research and clinical oncology",
        "Do_id":"22237454",
        "Doc_ChemicalList":"Receptor, ErbB-2",
        "Doc_meshdescriptors":"Adult;Asian Continental Ancestry Group;Breast Neoplasms;China;Cohort Studies;Disease Progression;Disease-Free Survival;Female;Humans;Kaplan-Meier Estimate;Middle Aged;Neoplasm Staging;Postmenopause;Prognosis;Receptor, ErbB-2;Risk Factors;Time Factors",
        "Doc_meshqualifiers":"statistics & numerical data;ethnology;metabolism;pathology;metabolism",
        "_version_":1605820470045704192},
      {
        "Doc_abstract":"Previous studies showed the prognostic and predictive impact of human epidermal growth factor receptor 2 (HER-2) gene alterations analyzed separately and jointly with topoisomerase II Î± (TOP2A) gene alterations; however, the role of TOP2A gene abnormalities alone has not been thoroughly investigated. Additionally, TOP2A aberrations were typically studied in HER-2-positive (HER-2(+)) tumors because these genes are frequently coamplified. Therefore, the knowledge concerning the impact of TOP2A abnormalities in HER-2-negative (HER-2(-)) patients is scarce. This study aimed to investigate the clinical significance of TOP2A anomalies in breast cancer patients with HER-2(-) and HER-2(+) tumors.;Snap-frozen tumor samples from 322 consecutive stage I-III breast cancer patients were analyzed for TOP2A gene dosage using quantitative real-time PCR (qPCR).;A high TOP2A gene dosage was found in 94 tumors (29%)-32% and 27% of HER-2(+) and HER-2(-) tumors, respectively. The mean TOP2A gene dosages in the HER-2(+) and HER-2(-) groups were 1.49 Â± 1.03 and 1.09 Â± 0.35, respectively. High TOP2A gene dosage had an inverse prognostic impact in terms of shorter disease-free survival (DFS) and overall survival (OS) times in the entire group and in both the HER-2(-) and HER-2(+) subgroups. The unfavorable prognostic impact of TOP2A gene dosage was maintained in the multivariate Cox regression analysis in the entire group and in HER-2(-) patients.;A high gene dosage of TOP2A determined using qPCR occurs frequently both in HER-2(+) and HER-2(-) tumors and has a strong adverse prognostic impact.",
        "Doc_title":"Prognostic significance of TOP2A gene dosage in HER-2-negative breast cancer.",
        "Journal":"The oncologist",
        "Do_id":"22871798",
        "Doc_ChemicalList":"Antigens, Neoplasm;DNA-Binding Proteins;Receptor, ErbB-2;DNA Topoisomerases, Type II;DNA topoisomerase II alpha",
        "Doc_meshdescriptors":"Aged;Antigens, Neoplasm;Breast Neoplasms;Cell Line, Tumor;DNA Topoisomerases, Type II;DNA-Binding Proteins;Female;Gene Dosage;Humans;Immunohistochemistry;In Situ Hybridization, Fluorescence;Middle Aged;Neoplasm Staging;Prognosis;Real-Time Polymerase Chain Reaction;Receptor, ErbB-2",
        "Doc_meshqualifiers":"genetics;enzymology;genetics;pathology;genetics;genetics;deficiency;metabolism",
        "_version_":1605747074492530688},
      {
        "Doc_abstract":"Gadd45a is a member of the Gadd45 family of genes that are known stress sensors. Gadd45a has been shown to serve as an effector in oncogenic stress in breast carcinogenesis in murine models. The present study was aimed at clarifying the expression of Gadd45a in human breast cancer and its correlation with clinicopathologic features.;The expression levels of Gadd45a in breast tissue samples of female breast surgery cases were examined by immunohistochemistry (IHC) using a Gadd45a antibody. Percent staining was determined and statistical analyses were applied to determine prognostic correlations.;56 female breast surgery cases were studied: Normal (11), Luminal A (9), Luminal B (11), HER2+ (10), Triple Negative (15). There was a highly significant difference in percent Gadd45a staining between groups [Mean]: Normal 16.3%; Luminal A 65.3%; Luminal B 80.7%; HER2+ 40.5%; TN 32%, Pâ€‰<â€‰0.001, ANOVA. Gadd45a IHC levels for Normal cases found 82% negative/low. Luminal A breast cancer cases were found to be 67% high. Luminal B breast cancers were 100% high. Her2+ cases were 50% negative/low. Triple Negative cases were 67% negative/low. This difference in distribution of Gadd45a levels across breast cancer receptor subtypes was significant, Pâ€‰=â€‰0.0009.;Gadd45a levels are significantly associated with hormone receptor status in human breast cancer. Normal breast tissue displays low Gadd45a levels. High Gadd45a levels are associated with Luminal A and Luminal B subtypes. Absence of hormone receptors in Triple Negative subtype is associated with Negative/Low levels of Gadd45a. Further studies are indicated to elucidate the role of Gadd45a in breast cancer as a potential prognosticator or target for treatment.",
        "Doc_title":"Gadd45a levels in human breast cancer are hormone receptor dependent.",
        "Journal":"Journal of translational medicine",
        "Do_id":"23706118",
        "Doc_ChemicalList":"Biomarkers, Tumor;Cell Cycle Proteins;GADD45A protein, human;Nuclear Proteins;ERBB2 protein, human;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Adult;Biomarkers, Tumor;Breast;Breast Neoplasms;Cell Cycle Proteins;Female;Gene Expression Profiling;Gene Expression Regulation, Neoplastic;Humans;Immunohistochemistry;Middle Aged;Nuclear Proteins;Prognosis;Receptor, ErbB-2;Triple Negative Breast Neoplasms",
        "Doc_meshqualifiers":"metabolism;metabolism;metabolism;metabolism;metabolism;metabolism;metabolism",
        "_version_":1605804469420818432}]
  }}
